data_2k9u_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2k9u _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.512 ' O ' ' N ' ' A' ' 18' ' ' ALA . . . . . . . . 0 N--CA 1.491 2.356 0 N-CA-C 110.809 -0.916 . . . . 2.4399999999999999 110.809 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.536 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -46.59 -11.5 0.05 OUTLIER Glycine 0 N--CA 1.492 2.402 0 O-C-N 121.635 -0.921 . . . . 2.0499999999999998 111.068 -178.956 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.512 ' N ' ' O ' ' A' ' 16' ' ' GLY . . . -45.93 -15.87 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.991 -1.299 . . . . 2.54 109.661 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' HIS . . . . . 0.536 ' N ' ' O ' ' A' ' 17' ' ' GLY . 10.7 t60 -94.48 -48.88 5.92 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.443 -0.786 . . . . 3.3700000000000001 109.779 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.51 -14.4 62.1 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.891 -1.13 . . . . 2.3700000000000001 109.435 -179.872 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 37.9 t -68.43 108.82 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.134 -0.979 . . . . 2.5800000000000001 108.629 179.387 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.407 HH11 ' CG ' ' A' ' 22' ' ' ARG . 0.0 OUTLIER -113.83 138.49 50.21 Favored 'General case' 0 N--CA 1.491 1.609 0 N-CA-C 109.131 -0.692 . . . . 3.8900000000000001 109.131 -179.515 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -147.72 113.36 5.68 Favored 'General case' 0 N--CA 1.491 1.603 0 N-CA-C 108.776 -0.824 . . . . 2.0099999999999998 108.776 179.553 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -151.96 131.68 3.51 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.461 -1.456 . . . . 2.0099999999999998 109.461 -179.597 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.0 -177.1 46.51 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.502 -1.439 . . . . 1.9299999999999999 109.502 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.515 ' C ' ' H ' ' A' ' 28' ' ' LEU . 13.5 t -79.59 -38.58 33.66 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.252 -1.146 . . . . 2.6899999999999999 109.16 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -60.28 -6.94 6.37 Favored Glycine 0 N--CA 1.483 1.811 0 N-CA-C 107.864 -2.094 . . . . 1.6399999999999999 107.864 179.222 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.515 ' H ' ' C ' ' A' ' 26' ' ' THR . 12.3 mt -99.3 24.29 8.2 Favored 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 108.247 -1.02 . . . . 2.0299999999999998 108.247 179.38 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 18.2 mt-10 -136.81 -37.66 0.66 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.515 -0.741 . . . . 2.3399999999999999 109.152 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . 0.48 HH11 ' HG2' ' A' ' 30' ' ' ARG . 2.5 ptt-85 -174.78 168.7 3.61 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.098 -1.001 . . . . 4.25 110.204 179.843 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -148.59 177.44 26.83 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 107.643 -2.183 . . . . 1.5900000000000001 107.643 179.558 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 44.1 t -134.41 151.0 31.2 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.12 0 O-C-N 121.056 -1.261 . . . . 2.21 111.043 -179.528 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -40.05 111.35 0.19 Allowed 'General case' 0 N--CA 1.498 1.937 0 CA-C-O 121.501 0.667 . . . . 2.0699999999999998 112.418 -179.233 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 55.63 50.21 61.63 Favored Glycine 0 N--CA 1.492 2.395 0 O-C-N 121.589 -0.694 . . . . 1.73 111.427 176.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 31.5 t -127.35 124.19 23.55 Favored Pre-proline 0 N--CA 1.496 1.851 0 N-CA-C 108.312 -0.996 . . . . 2.6499999999999999 108.312 178.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -57.3 131.98 48.23 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 N-CA-C 110.034 -0.795 . . . . 2.1400000000000001 110.034 -179.527 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -136.04 160.31 39.04 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.46 -0.775 . . . . 2.0299999999999998 109.004 179.81 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -155.32 171.47 19.8 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.012 -1.055 . . . . 2.23 111.213 -179.486 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 5.9 p90 -156.58 164.6 38.0 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 107.259 -1.386 . . . . 1.72 107.259 178.372 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 80.5 p -96.52 155.1 16.91 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.208 -0.933 . . . . 2.5800000000000001 111.279 -177.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 46.6 mt -146.42 97.71 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 N-CA-C 107.516 -1.29 . . . . 1.8600000000000001 107.516 178.767 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.4 ' CD1' ' C ' ' A' ' 42' ' ' TRP . 0.7 OUTLIER -84.88 146.96 27.03 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.113 -0.992 . . . . 4.4699999999999998 109.125 -179.407 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' THR . . . . . 0.556 ' OG1' ' N ' ' A' ' 44' ' ' ARG . 1.4 t -154.31 -130.35 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.525 0 N-CA-C 109.138 -0.689 . . . . 3.27 109.138 -179.414 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' ARG . . . . . 0.556 ' N ' ' OG1' ' A' ' 43' ' ' THR . 39.6 ttp180 54.18 73.98 0.36 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.172 -0.955 . . . . 5.2300000000000004 109.985 179.842 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 15.7 tt0 -165.14 -60.86 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.31 -0.869 . . . . 2.8900000000000001 108.875 179.357 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.63 -54.56 44.64 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.059 -1.026 . . . . 1.99 108.71 179.286 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 145.58 179.63 21.97 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.292 -1.523 . . . . 1.6499999999999999 109.292 179.848 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.73 162.74 0.82 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.134 -1.216 . . . . 1.77 109.598 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 168.89 -151.98 19.11 Favored Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.537 -1.425 . . . . 1.1200000000000001 109.537 -179.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.538 ' O ' ' N ' ' A' ' 92' ' ' ASN . . . -133.87 159.12 23.61 Favored Glycine 0 N--CA 1.497 2.743 0 N-CA-C 109.413 -1.475 . . . . 1.1799999999999999 109.413 -179.855 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.401 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 9.8 tp -134.14 100.5 4.73 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.529 -0.983 . . . . 1.5900000000000001 108.424 179.767 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 3.8 m -83.93 144.13 29.38 Favored 'General case' 0 N--CA 1.491 1.58 0 N-CA-C 108.527 -0.916 . . . . 1.9399999999999999 108.527 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.517 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 7.5 mt -135.71 100.94 2.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.354 -0.841 . . . . 1.3 109.203 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -98.19 106.22 18.48 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.306 -0.871 . . . . 1.27 108.986 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.44 ' O ' ' O ' ' B' ' 11' ' ' SER . 0.2 OUTLIER -97.64 144.42 11.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.499 -0.751 . . . . 1.55 109.403 -179.87 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 3.1 tt0 -141.11 142.09 34.14 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 107.909 -1.145 . . . . 1.8 107.909 179.059 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.432 ' O ' ' O ' ' B' ' 9' ' ' VAL . . . 169.03 176.89 39.44 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.173 -1.571 . . . . 0.56000000000000005 109.173 -178.811 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -56.48 -17.99 23.76 Favored 'Trans proline' 0 C--N 1.317 -1.123 0 C-N-CA 121.94 1.76 . . . . 0.76000000000000001 111.274 -179.482 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' SER . . . . . 0.53 ' HG ' ' HH ' ' A' ' 85' ' ' TYR . 1.4 p -150.22 159.93 44.07 Favored 'General case' 0 C--N 1.292 -1.922 0 O-C-N 121.284 -0.885 . . . . 2.02 110.154 179.87 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 68.2 mttt -78.86 108.2 12.14 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.498 -0.752 . . . . 3.02 109.558 -179.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -74.18 148.43 41.68 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.232 -0.918 . . . . 1.3600000000000001 109.481 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 5.0 tp10 -85.14 172.3 11.33 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.322 -0.861 . . . . 2.2999999999999998 108.786 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 3.7 mp -142.79 144.98 23.65 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.926 0 N-CA-C 108.259 -1.015 . . . . 2.0 108.259 179.809 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.521 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -150.53 114.47 5.04 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 120.6 -1.312 . . . . 1.73 109.923 -179.779 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 54.7 p90 -86.74 138.86 31.27 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.327 -0.858 . . . . 1.6000000000000001 109.572 179.73 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 . . . . . 0 N--CA 1.496 1.871 0 O-C-N 121.22 -0.925 . . . . 2.5099999999999998 109.711 -179.992 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 37.5 m . . . . . 0 N--CA 1.499 2.009 0 CA-C-O 121.418 0.628 . . . . 2.5600000000000001 109.788 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 5.9 t -83.97 125.81 32.41 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.2 -0.938 . . . . 2.3599999999999999 109.108 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -97.65 109.87 3.91 Favored Glycine 0 N--CA 1.495 2.616 0 N-CA-C 110.139 -1.184 . . . . 1.46 110.139 -179.572 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 32.1 t -99.23 100.86 11.26 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.929 0 O-C-N 121.583 -0.951 . . . . 2.1600000000000001 108.757 179.13 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.521 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.1 OUTLIER -89.53 126.14 35.48 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.675 -0.64 . . . . 2.1600000000000001 109.353 -179.551 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 52.0 p90 -123.52 173.89 7.75 Favored 'General case' 0 N--CA 1.495 1.811 0 N-CA-C 108.591 -0.892 . . . . 1.7 108.591 179.619 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 15.4 t -142.18 120.51 8.6 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.936 0 O-C-N 121.321 -0.862 . . . . 2.4500000000000002 109.769 -179.628 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 8.1 m -90.82 154.98 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.435 -0.791 . . . . 1.8200000000000001 109.314 179.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . 0.429 ' O ' ' OE2' ' A' ' 81' ' ' GLU . 33.5 tt0 -100.43 -45.85 5.43 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.192 -0.942 . . . . 3.1699999999999999 110.746 -179.18 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.429 ' OE2' ' O ' ' A' ' 80' ' ' GLN . 79.6 mm-40 -152.39 149.12 22.11 Favored Pre-proline 0 N--CA 1.504 2.251 0 O-C-N 120.458 -1.401 . . . . 2.02 111.399 -179.151 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.613 ' HG3' ' N ' ' A' ' 107' ' ' SER . 84.6 Cg_exo -36.86 162.19 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 123.117 2.544 . . . . 1.3999999999999999 113.637 178.232 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 143.42 -163.82 27.44 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 108.673 -1.771 . . . . 1.0800000000000001 108.673 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . 0.422 ' O ' ' OE1' ' A' ' 86' ' ' GLU . 3.0 m-20 -111.82 93.77 4.62 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.502 -0.999 . . . . 2.1299999999999999 108.353 179.354 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . 0.53 ' HH ' ' HG ' ' A' ' 59' ' ' SER . 3.1 m-85 -78.59 146.19 34.32 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 108.206 -1.035 . . . . 1.1399999999999999 108.206 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . 0.422 ' OE1' ' O ' ' A' ' 84' ' ' ASP . 0.0 OUTLIER -134.64 129.75 35.35 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.682 -0.636 . . . . 1.53 109.298 -178.98 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.8 p -124.99 146.79 30.05 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.554 -0.716 . . . . 1.6399999999999999 109.762 -179.807 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 53.6 p -128.59 101.61 6.23 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.442 -0.786 . . . . 1.99 109.106 179.642 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.2 pt -102.4 130.64 51.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.615 -0.678 . . . . 1.77 109.577 -179.573 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' LYS . . . . . 0.425 ' O ' ' CG ' ' A' ' 90' ' ' LYS . 0.5 OUTLIER -138.62 124.85 20.29 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.244 -0.91 . . . . 2.0600000000000001 109.238 179.721 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 36.5 t80 -83.13 95.16 8.0 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 120.992 -1.067 . . . . 1.45 108.599 179.391 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . 0.538 ' N ' ' O ' ' A' ' 50' ' ' GLY . 2.3 t-20 70.15 38.71 1.44 Allowed 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 107.925 -1.139 . . . . 2.7200000000000002 107.925 -178.69 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . 0.456 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 3.2 m-20 82.78 12.79 0.48 Allowed 'General case' 0 N--CA 1.498 1.943 0 CA-C-O 121.26 0.553 . . . . 1.9199999999999999 110.005 -179.222 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 4.1 mt-10 -88.88 70.7 8.64 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 107.576 -1.268 . . . . 2.5499999999999998 107.576 178.192 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 11.4 p80 -67.5 113.44 5.35 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-O 121.309 0.576 . . . . 3.2000000000000002 109.953 -179.133 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 2.0 pt -62.64 153.78 76.73 Favored Pre-proline 0 N--CA 1.491 1.61 0 N-CA-C 108.295 -1.002 . . . . 2.8199999999999998 108.295 179.444 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_exo -50.86 -44.69 40.08 Favored 'Trans proline' 0 C--N 1.321 -0.914 0 C-N-CA 121.051 1.167 . . . . 2.6299999999999999 109.987 179.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.564 ' CB ' ' CE2' ' A' ' 101' ' ' PHE . 3.4 m-20 -51.33 -48.43 62.4 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.146 -0.972 . . . . 2.6499999999999999 109.85 179.67 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 2.4 t -56.45 126.13 68.46 Favored Pre-proline 0 C--N 1.298 -1.655 0 N-CA-C 107.752 -1.203 . . . . 2.3199999999999998 107.752 179.545 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 8.3 Cg_endo -72.24 117.55 3.94 Favored 'Cis proline' 0 CA--C 1.548 1.188 0 CA-C-N 119.317 0.792 . . . . 1.9399999999999999 111.48 0.328 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . 0.564 ' CE2' ' CB ' ' A' ' 98' ' ' ASP . 0.1 OUTLIER -73.3 170.97 13.92 Favored 'General case' 0 N--CA 1.494 1.757 0 N-CA-C 107.251 -1.389 . . . . 2.6299999999999999 107.251 178.273 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.6 p -126.77 133.27 68.91 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 121.358 -0.838 . . . . 1.8200000000000001 109.16 179.79 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 86.5 t -128.93 83.08 67.31 Favored Pre-proline 0 N--CA 1.502 2.161 0 O-C-N 121.454 -0.779 . . . . 1.73 109.63 -179.513 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -64.77 114.45 2.76 Favored 'Trans proline' 0 C--N 1.32 -0.932 0 C-N-CA 121.302 1.334 . . . . 1.6100000000000001 110.477 -179.506 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 53.1 t -93.91 146.15 6.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 N-CA-C 108.292 -1.003 . . . . 1.7 108.292 179.484 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -131.92 130.28 41.38 Favored 'General case' 0 N--CA 1.507 2.401 0 CA-C-O 121.932 0.872 . . . . 2.04 111.941 -177.291 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' SER . . . . . 0.613 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 76.2 p -98.65 98.3 9.46 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.733 -1.23 . . . . 2.2999999999999998 107.788 179.184 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' LEU . . . . . 0.45 ' CD1' ' N ' ' A' ' 108' ' ' LEU . 8.9 mp 54.62 9.3 0.26 Allowed 'General case' 0 C--N 1.293 -1.872 0 N-CA-C 108.278 -1.008 . . . . 3.6000000000000001 108.278 -178.585 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.521 ' H ' ' C ' ' A' ' 107' ' ' SER . 8.3 t -101.05 -28.57 12.64 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.604 -0.685 . . . . 2.4900000000000002 109.16 179.503 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 13.8 t70 . . . . . 0 N--CA 1.489 1.493 0 N-CA-C 107.776 -1.194 . . . . 2.8500000000000001 107.776 -179.528 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . 0.583 HH11 ' CG ' ' B' ' 8' ' ' ARG . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.769 0 N-CA-C 107.349 -1.352 . . . . 3.6699999999999999 107.349 . . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 9' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' A' ' 57' ' ' GLY . 34.8 t -71.94 160.0 5.47 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 120.75 -1.219 . . . . 1.3899999999999999 108.422 179.611 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -123.71 156.71 35.45 Favored 'General case' 0 N--CA 1.5 2.066 0 O-C-N 121.418 -0.801 . . . . 1.22 110.015 -179.26 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 11' ' ' SER . . . . . 0.44 ' O ' ' O ' ' A' ' 55' ' ' VAL . 3.2 t -149.56 144.03 25.97 Favored 'General case' 0 N--CA 1.492 1.641 0 N-CA-C 108.869 -0.789 . . . . 1.6299999999999999 108.869 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 47.2 t -143.48 120.12 11.12 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 120.976 -1.078 . . . . 1.8799999999999999 109.99 -179.666 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . 0.488 ' CG2' ' N ' ' B' ' 14' ' ' PHE . 3.1 p -157.92 165.77 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 N-CA-C 108.722 -0.844 . . . . 1.2 108.722 179.542 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 14' ' ' PHE . . . . . 0.517 ' HB3' ' H ' ' A' ' 53' ' ' ILE . 4.9 p90 -177.99 -170.35 0.24 Allowed 'General case' 0 N--CA 1.49 1.563 0 C-N-CA 119.38 -0.928 . . . . 2.3900000000000001 112.158 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 3.1 pt -149.87 -163.66 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.341 0 N-CA-C 108.273 -1.01 . . . . 1.8100000000000001 108.273 179.831 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -161.09 146.55 14.22 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 120.724 -1.235 . . . . 2.04 109.911 179.769 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 13.4 mt . . . . . 0 N--CA 1.495 1.785 0 O-C-N 121.219 -0.926 . . . . 1.8700000000000001 109.376 179.696 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.407 ' O ' ' CB ' ' A' ' 94' ' ' GLU . . . . . . . . 0 N--CA 1.49 2.24 0 N-CA-C 111.635 -0.586 . . . . 2.4399999999999999 111.635 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.568 ' C ' ' H ' ' A' ' 19' ' ' HIS . . . 72.36 -52.34 1.45 Allowed Glycine 0 N--CA 1.493 2.487 0 O-C-N 121.458 -1.024 . . . . 2.0499999999999998 111.127 178.296 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.472 ' N ' ' CD ' ' A' ' 94' ' ' GLU . . . -49.45 -6.95 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.098 -1.236 . . . . 2.54 110.169 -179.308 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' HIS . . . . . 0.568 ' H ' ' C ' ' A' ' 17' ' ' GLY . 29.2 t-80 -94.97 -12.09 27.34 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.067 -1.021 . . . . 3.3700000000000001 110.295 -179.801 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 2.3 pptp? -132.6 11.64 4.44 Favored 'General case' 0 N--CA 1.504 2.235 0 O-C-N 121.031 -1.043 . . . . 2.3700000000000001 110.457 -179.759 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 53.2 t -94.29 113.19 28.38 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 120.976 -1.078 . . . . 2.5800000000000001 109.257 179.491 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 20.3 tpt180 -113.08 121.33 44.24 Favored 'General case' 0 N--CA 1.496 1.846 0 N-CA-C 108.98 -0.748 . . . . 3.8900000000000001 108.98 179.843 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -128.16 114.07 16.53 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 108.878 -0.786 . . . . 2.0099999999999998 108.878 179.735 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -151.24 130.6 3.22 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 109.509 -1.436 . . . . 2.0099999999999998 109.509 -179.616 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.29 171.08 43.42 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.739 -1.344 . . . . 1.9299999999999999 109.739 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 13.2 p -78.51 -27.13 46.06 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.343 -1.092 . . . . 2.6899999999999999 109.373 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.68 -12.55 70.57 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 109.11 -1.596 . . . . 1.6399999999999999 109.11 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 12.1 mt -87.68 -15.53 36.9 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.437 -1.037 . . . . 2.0299999999999998 108.852 179.679 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 42.2 mt-10 -87.66 -62.07 1.58 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.412 -0.805 . . . . 2.3399999999999999 109.726 -179.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 72.5 mtt180 -148.14 178.48 8.51 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.114 -0.991 . . . . 4.25 110.058 -179.678 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -150.11 175.21 29.3 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 107.786 -2.125 . . . . 1.5900000000000001 107.786 179.317 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 40.7 t -133.54 151.7 33.82 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.15 0 O-C-N 121.084 -1.245 . . . . 2.21 110.744 -179.57 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -43.56 111.01 0.23 Allowed 'General case' 0 N--CA 1.5 2.04 0 CA-C-O 121.57 0.7 . . . . 2.0699999999999998 112.428 -178.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 55.87 52.8 46.37 Favored Glycine 0 N--CA 1.491 2.315 0 O-C-N 121.515 -0.741 . . . . 1.73 111.52 176.884 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 8.5 t -127.83 126.97 23.99 Favored Pre-proline 0 N--CA 1.497 1.911 0 O-C-N 121.502 -0.999 . . . . 2.6499999999999999 108.373 178.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -57.77 117.8 4.57 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 N-CA-C 109.33 -1.065 . . . . 2.1400000000000001 109.33 179.711 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -127.43 149.99 49.84 Favored 'General case' 0 N--CA 1.501 2.089 0 N-CA-C 108.873 -0.788 . . . . 2.0299999999999998 108.873 -179.827 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -155.33 162.41 40.85 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.937 -1.102 . . . . 2.23 111.172 -179.448 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . 0.58 ' N ' ' CD1' ' A' ' 39' ' ' PHE . 0.5 OUTLIER -137.98 -176.77 4.55 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 106.831 -1.544 . . . . 1.72 106.831 178.163 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 72.6 p -121.04 145.49 47.71 Favored 'General case' 0 N--CA 1.499 1.981 0 CA-C-O 121.5 0.667 . . . . 2.5800000000000001 110.121 -179.222 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.444 ' O ' ' N ' ' A' ' 73' ' ' CYS . 48.5 mt -142.2 117.02 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 N-CA-C 108.515 -0.921 . . . . 1.8600000000000001 108.515 179.32 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.434 ' CD1' ' C ' ' A' ' 42' ' ' TRP . 0.2 OUTLIER -113.74 129.62 56.55 Favored 'General case' 0 N--CA 1.497 1.878 0 N-CA-C 108.432 -0.951 . . . . 4.4699999999999998 108.432 179.923 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' THR . . . . . 0.569 ' HG1' ' H ' ' A' ' 44' ' ' ARG . 9.2 p -144.73 -127.51 0.08 Allowed 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.343 -0.848 . . . . 3.27 109.16 -179.667 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' ARG . . . . . 0.569 ' H ' ' HG1' ' A' ' 43' ' ' THR . 1.6 ttt-85 56.89 79.85 0.17 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.363 -0.836 . . . . 5.2300000000000004 110.059 179.646 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -156.27 -52.26 0.08 Allowed 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 108.543 -0.91 . . . . 2.8900000000000001 108.543 179.146 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -60.78 -48.14 83.15 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.214 -0.929 . . . . 1.99 108.779 179.326 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 151.98 -174.48 30.99 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 109.514 -1.435 . . . . 1.6499999999999999 109.514 179.809 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.33 161.44 0.94 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.252 -1.146 . . . . 1.77 109.047 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 176.17 -158.32 24.8 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.69 -1.364 . . . . 1.1200000000000001 109.69 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -145.86 124.75 2.13 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 109.826 -1.31 . . . . 1.1799999999999999 109.826 -179.806 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.433 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 10.4 tp -100.2 100.89 11.79 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.456 -1.026 . . . . 1.5900000000000001 108.557 179.461 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 25.0 p -86.19 141.34 29.4 Favored 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 108.567 -0.901 . . . . 1.9399999999999999 108.567 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.479 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 72.7 mt -130.44 114.25 27.96 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 O-C-N 121.235 -0.915 . . . . 1.3 109.552 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -105.36 107.94 19.2 Favored 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 108.777 -0.823 . . . . 1.27 108.777 179.677 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -101.37 142.95 15.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 O-C-N 121.528 -0.733 . . . . 1.55 109.25 -179.857 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 8.7 tt0 -141.88 145.39 34.56 Favored 'General case' 0 N--CA 1.49 1.575 0 N-CA-C 107.685 -1.228 . . . . 1.8 107.685 178.755 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.43 ' O ' ' O ' ' B' ' 9' ' ' VAL . . . 164.58 -172.97 40.47 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.79 -1.324 . . . . 0.56000000000000005 109.79 -179.296 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -67.71 -30.6 34.16 Favored 'Trans proline' 0 C--N 1.318 -1.06 0 C-N-CA 122.139 1.893 . . . . 0.76000000000000001 112.09 -179.361 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' SER . . . . . 0.644 ' HG ' ' HH ' ' A' ' 85' ' ' TYR . 0.3 OUTLIER -128.55 179.7 5.53 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 121.162 -0.962 . . . . 2.02 110.226 -179.126 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.466 ' NZ ' ' O ' ' B' ' 10' ' ' ALA . 62.7 mmtt -92.0 114.53 27.09 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.607 -0.683 . . . . 3.02 109.241 -179.817 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.481 ' O ' ' N ' ' A' ' 63' ' ' ILE . . . -66.15 103.74 1.03 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.023 -1.048 . . . . 1.3600000000000001 109.231 179.701 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 30.3 mt-10 -65.19 72.17 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.141 -0.974 . . . . 2.2999999999999998 109.635 -179.738 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . 0.481 ' N ' ' O ' ' A' ' 61' ' ' ALA . 3.4 mp -58.14 149.35 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.613 -0.68 . . . . 2.0 109.295 179.852 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.54 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -150.4 127.6 11.29 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.996 -1.065 . . . . 1.73 109.453 -179.859 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . 0.458 ' CD2' ' O ' ' A' ' 65' ' ' PHE . 50.3 p90 -87.01 130.85 34.28 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.179 -0.951 . . . . 1.6000000000000001 109.488 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 . . . . . 0 N--CA 1.497 1.891 0 O-C-N 121.286 -0.884 . . . . 2.5099999999999998 109.338 179.821 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 16.1 t . . . . . 0 N--CA 1.495 1.785 0 N-CA-C 109.011 -0.736 . . . . 2.5600000000000001 109.011 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' CYS . . . . . 0.444 ' N ' ' O ' ' A' ' 41' ' ' ILE . 33.7 m -83.31 105.17 14.05 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.202 -0.937 . . . . 2.3599999999999999 109.825 -179.515 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -85.28 116.25 4.29 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.168 -1.573 . . . . 1.46 109.168 179.594 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 49.8 t -107.09 99.64 9.0 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.072 0 O-C-N 121.58 -0.953 . . . . 2.1600000000000001 109.597 -179.674 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.54 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.5 OUTLIER -89.71 131.39 35.71 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.396 -0.815 . . . . 2.1600000000000001 109.258 179.775 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 0.426 ' O ' ' CG ' ' A' ' 77' ' ' TYR . 2.3 p90 -133.07 126.81 32.65 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.379 -0.826 . . . . 1.7 109.825 -179.837 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 3.0 t -107.74 103.8 16.05 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 O-C-N 121.674 -0.641 . . . . 2.4500000000000002 109.876 -179.665 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 2.4 m -80.23 167.66 2.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.296 -0.877 . . . . 1.8200000000000001 108.72 179.423 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 41.7 tp60 -102.26 -46.33 4.85 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.213 -0.929 . . . . 3.1699999999999999 110.732 -179.298 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.432 ' O ' ' O ' ' A' ' 82' ' ' PRO . 71.8 mm-40 -147.61 151.02 38.4 Favored Pre-proline 0 N--CA 1.506 2.37 0 O-C-N 120.754 -1.216 . . . . 2.02 112.161 -178.254 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.581 ' HG3' ' N ' ' A' ' 107' ' ' SER . 86.0 Cg_exo -36.5 168.12 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 123.389 2.726 . . . . 1.3999999999999999 113.734 178.113 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 140.9 -176.11 21.75 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.678 -1.369 . . . . 1.0800000000000001 109.678 179.374 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . 0.528 ' OD2' ' NE ' ' B' ' 8' ' ' ARG . 2.4 p-10 -99.8 86.55 3.32 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.512 -0.993 . . . . 2.1299999999999999 108.349 179.419 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . 0.644 ' HH ' ' HG ' ' A' ' 59' ' ' SER . 2.7 m-85 -72.87 130.72 41.05 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 108.044 -1.095 . . . . 1.1399999999999999 108.044 -179.789 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -107.24 129.12 54.91 Favored 'General case' 0 N--CA 1.496 1.87 0 N-CA-C 108.474 -0.936 . . . . 1.53 108.474 -179.196 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.446 ' CG1' ' CZ ' ' A' ' 101' ' ' PHE . 5.7 p -126.18 141.99 44.14 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 N-CA-C 109.17 -0.678 . . . . 1.6399999999999999 109.17 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 13.5 p -138.65 107.15 5.84 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.264 -0.898 . . . . 1.99 109.795 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.8 pt -112.57 136.46 48.75 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.92 0 CA-C-O 121.414 0.626 . . . . 1.77 110.097 -179.738 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' LYS . . . . . 0.457 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.2 OUTLIER -143.05 122.41 13.08 Favored 'General case' 0 N--CA 1.486 1.333 0 O-C-N 121.383 -0.823 . . . . 2.0600000000000001 108.785 179.447 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 55.3 t80 -79.67 99.74 7.53 Favored 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 107.716 -1.216 . . . . 1.45 107.716 178.458 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . 0.416 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 13.9 t-20 69.56 39.9 1.49 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.492 -0.755 . . . . 2.7200000000000002 109.404 -178.885 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . 0.416 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 0.9 OUTLIER 76.7 13.27 2.32 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.665 -0.647 . . . . 1.9199999999999999 111.585 179.442 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . 0.472 ' CD ' ' N ' ' A' ' 18' ' ' ALA . 0.6 OUTLIER -98.27 94.9 7.03 Favored 'General case' 0 N--CA 1.499 1.978 0 N-CA-C 106.919 -1.511 . . . . 2.5499999999999998 106.919 177.649 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' HIS . . . . . 0.578 ' CD2' ' H ' ' A' ' 95' ' ' HIS . 0.1 OUTLIER -71.12 106.99 3.94 Favored 'General case' 0 N--CA 1.488 1.431 0 CA-C-O 121.586 0.707 . . . . 3.2000000000000002 109.839 -178.16 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' ILE . . . . . 0.574 ' O ' ' N ' ' A' ' 98' ' ' ASP . 10.6 pt -52.8 150.4 9.86 Favored Pre-proline 0 C--N 1.299 -1.6 0 N-CA-C 108.579 -0.897 . . . . 2.8199999999999998 108.579 179.634 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . 0.413 ' O ' ' CG ' ' A' ' 98' ' ' ASP . 1.0 OUTLIER -57.48 75.56 0.04 OUTLIER 'Trans proline' 0 C--O 1.214 -0.7 0 C-N-CA 121.146 1.231 . . . . 2.6299999999999999 109.195 179.362 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.574 ' N ' ' O ' ' A' ' 96' ' ' ILE . 1.9 m-20 -177.62 -59.82 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.485 0 N-CA-C 108.278 -1.008 . . . . 2.6499999999999999 108.278 -178.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 9.5 m -57.44 138.79 81.13 Favored Pre-proline 0 C--N 1.299 -1.627 0 O-C-N 121.414 -0.804 . . . . 2.3199999999999998 110.031 -178.216 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_endo -89.78 114.28 2.41 Favored 'Cis proline' 0 N--CA 1.493 1.458 0 N-CA-C 109.707 -0.92 . . . . 1.9399999999999999 109.707 -2.724 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . 0.446 ' CZ ' ' CG1' ' A' ' 87' ' ' VAL . 15.3 p90 -104.9 170.86 7.63 Favored 'General case' 0 N--CA 1.515 2.79 0 O-C-N 120.425 -1.422 . . . . 2.6299999999999999 110.01 178.87 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.5 p -95.49 153.79 3.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.602 -0.686 . . . . 1.8200000000000001 110.095 -179.467 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.498 ' N ' ' O ' ' A' ' 85' ' ' TYR . 69.2 t -128.66 86.37 57.78 Favored Pre-proline 0 N--CA 1.498 1.948 0 N-CA-C 107.868 -1.16 . . . . 1.73 107.868 179.316 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -60.99 113.85 1.91 Allowed 'Trans proline' 0 C--N 1.323 -0.792 0 C-N-CA 121.497 1.465 . . . . 1.6100000000000001 112.256 -177.56 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 55.3 t -96.1 138.12 22.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 N-CA-C 106.784 -1.561 . . . . 1.7 106.784 177.724 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -119.0 126.56 52.02 Favored 'General case' 0 N--CA 1.511 2.582 0 N-CA-C 113.161 0.801 . . . . 2.04 113.161 -175.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' SER . . . . . 0.602 ' C ' ' H ' ' A' ' 109' ' ' SER . 23.8 t -94.84 97.89 10.35 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 120.3 -1.5 . . . . 2.2999999999999998 107.586 178.09 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 13.7 mt 66.35 -21.04 0.1 Allowed 'General case' 0 C--N 1.289 -2.058 0 N-CA-C 109.22 -0.659 . . . . 3.6000000000000001 109.22 -178.767 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.602 ' H ' ' C ' ' A' ' 107' ' ' SER . 9.6 t -70.93 -29.17 65.12 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.084 -1.01 . . . . 2.4900000000000002 108.908 179.027 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 . . . . . 0 N--CA 1.491 1.583 0 N-CA-C 107.874 -1.158 . . . . 2.8500000000000001 107.874 179.83 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . 0.56 HH11 ' CG ' ' B' ' 8' ' ' ARG . 2.5 mtt-85 . . . . . 0 N--CA 1.489 1.511 0 N-CA-C 108.286 -1.005 . . . . 3.6699999999999999 108.286 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 9' ' ' VAL . . . . . 0.43 ' O ' ' O ' ' A' ' 57' ' ' GLY . 24.6 t -50.81 158.72 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 N-CA-C 107.785 -1.191 . . . . 1.3899999999999999 107.785 179.137 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . 0.466 ' O ' ' NZ ' ' A' ' 60' ' ' LYS . . . -128.98 149.14 50.94 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.227 -0.921 . . . . 1.22 110.563 -178.585 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 4.1 t -139.58 146.35 39.73 Favored 'General case' 0 N--CA 1.495 1.789 0 N-CA-C 108.763 -0.829 . . . . 1.6299999999999999 108.763 179.498 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 42.9 m -147.41 121.91 9.74 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.07 -1.019 . . . . 1.8799999999999999 109.927 -179.589 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . 0.482 ' CG2' ' N ' ' B' ' 14' ' ' PHE . 7.7 p -169.85 170.52 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 N-CA-C 108.883 -0.784 . . . . 1.2 108.883 179.759 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 14' ' ' PHE . . . . . 0.482 ' N ' ' CG2' ' B' ' 13' ' ' VAL . 9.1 p90 -176.6 -163.47 0.1 Allowed 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 119.226 -0.99 . . . . 2.3900000000000001 112.084 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.3 pt -147.49 160.95 8.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 N-CA-C 108.518 -0.919 . . . . 1.8100000000000001 108.518 179.82 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 17.9 m -131.18 141.73 50.11 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.273 -0.892 . . . . 2.04 109.892 -179.734 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.0 mt . . . . . 0 N--CA 1.498 1.926 0 O-C-N 121.418 -0.802 . . . . 1.8700000000000001 109.36 179.712 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.988 0 N-CA-C 110.003 -1.239 . . . . 2.4399999999999999 110.003 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.514 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 95.02 -57.99 1.76 Allowed Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.761 -1.336 . . . . 2.0499999999999998 109.761 179.707 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -47.86 -12.32 0.03 OUTLIER 'General case' 0 C--N 1.297 -1.68 0 O-C-N 121.64 -0.917 . . . . 2.54 110.067 -179.121 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' HIS . . . . . 0.514 ' N ' ' O ' ' A' ' 17' ' ' GLY . 29.1 t-80 -98.46 -7.11 29.1 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.245 -0.909 . . . . 3.3700000000000001 110.684 -178.745 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.498 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.4 OUTLIER -145.98 5.58 1.0 Allowed 'General case' 0 N--CA 1.496 1.851 0 O-C-N 120.854 -1.153 . . . . 2.3700000000000001 110.252 -179.491 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.429 ' O ' ' CG1' ' A' ' 21' ' ' VAL . 7.4 p -77.35 115.56 19.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.022 -1.049 . . . . 2.5800000000000001 108.51 179.116 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 12.7 tpp180 -109.92 139.27 45.2 Favored 'General case' 0 N--CA 1.49 1.574 0 CA-C-O 121.509 0.671 . . . . 3.8900000000000001 109.566 -178.745 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -148.18 113.27 5.51 Favored 'General case' 0 N--CA 1.491 1.599 0 N-CA-C 108.609 -0.885 . . . . 2.0099999999999998 108.609 179.424 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -147.85 132.1 4.11 Favored Glycine 0 N--CA 1.495 2.614 0 N-CA-C 109.523 -1.431 . . . . 2.0099999999999998 109.523 -179.624 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.27 174.13 46.08 Favored Glycine 0 N--CA 1.488 2.115 0 C-N-CA 119.598 -1.287 . . . . 1.9299999999999999 110.013 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 8.5 p -79.85 -22.04 43.42 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.338 -1.095 . . . . 2.6899999999999999 108.985 179.479 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -68.67 -16.47 69.94 Favored Glycine 0 N--CA 1.487 2.034 0 N-CA-C 108.62 -1.792 . . . . 1.6399999999999999 108.62 179.637 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.0 mt -93.04 30.28 1.66 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.625 -0.927 . . . . 2.0299999999999998 108.799 179.783 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 13.5 mt-10 -141.91 -43.44 0.35 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.396 -0.815 . . . . 2.3399999999999999 109.62 -179.375 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 11.8 ptm180 -175.65 172.11 2.63 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.007 -1.058 . . . . 4.25 109.991 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -150.77 176.51 29.3 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 108.335 -1.906 . . . . 1.5900000000000001 108.335 179.665 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 39.2 t -134.23 151.54 32.41 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.031 0 O-C-N 121.186 -1.185 . . . . 2.21 110.529 -179.733 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -44.91 115.47 0.89 Allowed 'General case' 0 N--CA 1.497 1.88 0 CA-C-O 121.869 0.842 . . . . 2.0699999999999998 112.477 -179.195 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 54.03 50.81 53.7 Favored Glycine 0 N--CA 1.488 2.143 0 N-CA-C 111.245 -0.742 . . . . 1.73 111.245 177.264 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 5.0 t -127.03 127.11 24.41 Favored Pre-proline 0 N--CA 1.496 1.871 0 N-CA-C 108.232 -1.025 . . . . 2.6499999999999999 108.232 179.14 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -55.51 121.17 9.47 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 N-CA-C 109.918 -0.839 . . . . 2.1400000000000001 109.918 -179.845 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -128.78 145.42 51.19 Favored 'General case' 0 N--CA 1.497 1.922 0 N-CA-C 108.488 -0.93 . . . . 2.0299999999999998 108.488 179.736 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -152.16 164.05 38.11 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.995 -1.066 . . . . 2.23 110.765 -179.512 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . 0.549 ' N ' ' CD1' ' A' ' 39' ' ' PHE . 0.7 OUTLIER -139.71 178.43 7.24 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 107.007 -1.479 . . . . 1.72 107.007 177.907 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 58.7 m -121.32 141.27 51.08 Favored 'General case' 0 N--CA 1.496 1.857 0 CA-C-O 121.573 0.702 . . . . 2.5800000000000001 110.382 -178.83 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.508 ' O ' ' N ' ' A' ' 73' ' ' CYS . 68.3 mt -138.14 124.08 25.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 N-CA-C 108.307 -0.997 . . . . 1.8600000000000001 108.307 179.106 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.523 ' HE1' ' CG ' ' A' ' 44' ' ' ARG . 3.1 t90 -128.08 125.46 39.31 Favored 'General case' 0 N--CA 1.496 1.858 0 N-CA-C 108.615 -0.884 . . . . 4.4699999999999998 108.615 -179.549 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' THR . . . . . 0.498 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -151.21 118.23 5.89 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.321 -0.862 . . . . 3.27 109.269 -179.672 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' ARG . . . . . 0.523 ' CG ' ' HE1' ' A' ' 42' ' ' TRP . 10.6 ptm180 -171.09 72.19 0.05 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.172 -0.955 . . . . 5.2300000000000004 109.72 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 21.3 tt0 -154.32 -45.19 0.09 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.306 -0.871 . . . . 2.8900000000000001 109.083 179.579 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.99 -55.66 13.5 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.117 -0.989 . . . . 1.99 109.196 179.686 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 154.96 156.36 7.71 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.608 -1.397 . . . . 1.6499999999999999 109.608 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.49 156.92 2.29 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.232 -1.158 . . . . 1.77 109.511 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -170.48 -111.34 0.25 Allowed Glycine 0 N--CA 1.488 2.16 0 N-CA-C 108.965 -1.654 . . . . 1.1200000000000001 108.965 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.544 ' O ' ' N ' ' A' ' 92' ' ' ASN . . . -157.7 161.87 31.68 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.463 -1.455 . . . . 1.1799999999999999 109.463 179.684 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.425 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 10.2 tp -140.55 97.0 3.12 Favored 'General case' 0 N--CA 1.493 1.703 0 N-CA-C 107.839 -1.171 . . . . 1.5900000000000001 107.839 179.513 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 13.7 m -87.69 142.81 27.54 Favored 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 108.846 -0.798 . . . . 1.9399999999999999 108.846 -179.586 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.508 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 6.7 mt -136.71 100.42 2.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.366 -0.834 . . . . 1.3 108.859 179.721 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -98.8 106.42 18.69 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.258 -0.902 . . . . 1.27 108.907 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -97.87 146.14 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 O-C-N 121.434 -0.791 . . . . 1.55 109.33 -179.814 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 35.4 tp10 -141.13 138.04 33.18 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 107.385 -1.339 . . . . 1.8 107.385 178.531 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.532 ' O ' ' N ' ' B' ' 9' ' ' VAL . . . 173.37 -173.0 45.58 Favored Glycine 0 N--CA 1.493 2.44 0 C-N-CA 119.271 -1.442 . . . . 0.56000000000000005 110.033 -178.72 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -62.76 -35.1 70.54 Favored 'Trans proline' 0 C--N 1.318 -1.038 0 C-N-CA 122.127 1.885 . . . . 0.76000000000000001 111.568 -179.596 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' SER . . . . . 0.43 ' O ' ' OH ' ' A' ' 85' ' ' TYR . 10.7 m -139.57 162.34 35.31 Favored 'General case' 0 N--CA 1.5 2.025 0 O-C-N 121.072 -1.017 . . . . 2.02 110.057 -179.036 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 23.0 mttp -85.29 95.57 9.24 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.435 -0.791 . . . . 3.02 109.495 -179.844 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -50.59 135.32 23.15 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.336 -0.853 . . . . 1.3600000000000001 109.315 179.83 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.47 ' CD ' ' N ' ' A' ' 62' ' ' GLU . 15.9 mp0 -71.09 85.38 0.73 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.247 -0.908 . . . . 2.2999999999999998 109.582 -179.873 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 19.2 tt -58.88 150.21 5.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 N-CA-C 108.963 -0.755 . . . . 2.0 108.963 179.611 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.547 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -150.61 114.51 5.02 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 120.691 -1.255 . . . . 1.73 109.744 -179.715 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . 0.417 ' CD1' ' N ' ' A' ' 65' ' ' PHE . 17.7 p90 -90.33 125.08 35.41 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.284 -0.885 . . . . 1.6000000000000001 109.388 179.612 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 . . . . . 0 N--CA 1.496 1.841 0 O-C-N 121.256 -0.902 . . . . 2.5099999999999998 109.545 -179.893 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 10.6 t . . . . . 0 N--CA 1.494 1.765 0 N-CA-C 108.88 -0.785 . . . . 2.5600000000000001 108.88 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' CYS . . . . . 0.508 ' N ' ' O ' ' A' ' 41' ' ' ILE . 49.8 t -80.05 104.81 10.87 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.222 -0.924 . . . . 2.3599999999999999 109.845 -179.451 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -91.82 116.33 4.97 Favored Glycine 0 N--CA 1.493 2.5 0 N-CA-C 109.123 -1.591 . . . . 1.46 109.123 179.65 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 96.4 t -105.82 102.16 13.46 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.135 0 O-C-N 121.486 -1.008 . . . . 2.1600000000000001 109.684 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.547 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.1 OUTLIER -88.42 130.08 35.26 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.376 -0.828 . . . . 2.1600000000000001 108.936 179.649 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 0.426 ' O ' ' CG ' ' A' ' 77' ' ' TYR . 2.8 p90 -132.42 125.48 30.88 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.479 -0.763 . . . . 1.7 109.053 -179.824 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 5.9 t -99.86 103.72 15.14 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.392 -0.817 . . . . 2.4500000000000002 109.37 -179.478 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 25.9 m -69.77 160.32 5.03 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 O-C-N 121.22 -0.925 . . . . 1.8200000000000001 109.31 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 24.0 tp60 -100.72 -48.62 4.44 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.235 -0.915 . . . . 3.1699999999999999 110.586 -179.416 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -155.25 152.77 25.66 Favored Pre-proline 0 N--CA 1.501 2.106 0 O-C-N 120.806 -1.184 . . . . 2.02 110.995 -178.915 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.562 ' HG3' ' N ' ' A' ' 107' ' ' SER . 75.1 Cg_exo -38.31 163.2 0.02 OUTLIER 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 123.176 2.584 . . . . 1.3999999999999999 113.659 179.36 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 147.13 -162.36 28.59 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.156 -1.578 . . . . 1.0800000000000001 109.156 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 33.5 m-20 -111.39 89.78 3.15 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.653 -0.91 . . . . 2.1299999999999999 108.937 179.761 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . 0.45 ' O ' ' N ' ' A' ' 103' ' ' VAL . 3.3 m-85 -77.64 128.94 34.93 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 108.004 -1.11 . . . . 1.1399999999999999 108.004 179.687 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -112.63 129.74 56.28 Favored 'General case' 0 N--CA 1.5 2.042 0 N-CA-C 108.406 -0.961 . . . . 1.53 108.406 -179.088 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 8.6 p -124.84 137.63 56.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 CA-C-O 121.486 0.66 . . . . 1.6399999999999999 110.002 -179.522 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 29.5 t -126.12 103.25 7.61 Favored 'General case' 0 N--CA 1.497 1.907 0 N-CA-C 109.405 -0.591 . . . . 1.99 109.405 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -111.18 132.78 58.76 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.023 0 O-C-N 121.519 -0.738 . . . . 1.77 110.226 -179.39 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' LYS . . . . . 0.401 ' O ' ' CG ' ' A' ' 90' ' ' LYS . 0.4 OUTLIER -140.91 127.06 19.56 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.369 -0.832 . . . . 2.0600000000000001 109.909 179.658 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 54.5 t80 -82.3 94.39 7.33 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.12 -0.987 . . . . 1.45 108.457 178.855 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . 0.544 ' N ' ' O ' ' A' ' 50' ' ' GLY . 6.7 t30 69.22 37.08 2.19 Favored 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 108.074 -1.084 . . . . 2.7200000000000002 108.074 -179.017 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . 0.463 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 2.6 m-20 83.4 14.7 0.34 Allowed 'General case' 0 N--CA 1.499 1.981 0 CA-C-N 116.485 -0.325 . . . . 1.9199999999999999 110.905 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . 0.526 ' CG ' ' O ' ' A' ' 94' ' ' GLU . 0.0 OUTLIER -91.17 90.83 7.97 Favored 'General case' 0 N--CA 1.496 1.827 0 N-CA-C 106.862 -1.533 . . . . 2.5499999999999998 106.862 178.119 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' HIS . . . . . 0.509 ' CG ' ' O ' ' A' ' 95' ' ' HIS . 9.0 p80 -68.15 88.8 0.3 Allowed 'General case' 0 C--N 1.299 -1.615 0 O-C-N 119.94 -1.725 . . . . 3.2000000000000002 110.359 -177.816 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 2.3 tt -48.3 137.13 11.73 Favored Pre-proline 0 N--CA 1.496 1.846 0 N-CA-C 107.635 -1.246 . . . . 2.8199999999999998 107.635 178.675 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -40.51 -39.55 2.89 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 121.307 1.338 . . . . 2.6299999999999999 111.747 -178.42 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 18.8 m-20 -49.18 -66.49 0.39 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 120.689 -1.257 . . . . 2.6499999999999999 109.237 179.356 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -69.31 147.94 97.26 Favored Pre-proline 0 C--N 1.293 -1.875 0 O-C-N 121.151 -0.968 . . . . 2.3199999999999998 110.067 -178.917 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -84.44 112.02 2.36 Favored 'Cis proline' 0 N--CA 1.491 1.343 0 N-CA-C 109.538 -0.986 . . . . 1.9399999999999999 109.538 -2.238 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 43.1 p90 -116.21 166.86 11.55 Favored 'General case' 0 N--CA 1.522 3.162 0 O-C-N 120.509 -1.37 . . . . 2.6299999999999999 110.445 178.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.2 p -95.49 148.19 5.35 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.903 0 CA-C-O 121.752 0.787 . . . . 1.8200000000000001 111.549 -177.703 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.45 ' N ' ' O ' ' A' ' 85' ' ' TYR . 79.4 t -121.8 86.38 45.59 Favored Pre-proline 0 N--CA 1.498 1.926 0 N-CA-C 108.279 -1.008 . . . . 1.73 108.279 179.238 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_exo -62.81 114.14 2.28 Favored 'Trans proline' 0 C--N 1.319 -1.021 0 C-N-CA 121.351 1.367 . . . . 1.6100000000000001 112.09 -178.011 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 55.2 t -95.27 144.34 10.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 N-CA-C 106.938 -1.504 . . . . 1.7 106.938 177.865 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -134.76 136.24 42.47 Favored 'General case' 0 N--CA 1.51 2.536 0 CA-C-O 122.079 0.942 . . . . 2.04 111.748 -177.457 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' SER . . . . . 0.562 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 80.6 p -92.17 76.41 5.35 Favored 'General case' 0 N--CA 1.492 1.674 0 N-CA-C 107.472 -1.307 . . . . 2.2999999999999998 107.472 179.278 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 23.6 mt 61.72 6.36 1.57 Allowed 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 107.103 -1.443 . . . . 3.6000000000000001 107.103 -177.735 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.537 ' H ' ' C ' ' A' ' 107' ' ' SER . 14.0 t -92.27 -20.83 20.73 Favored 'General case' 0 N--CA 1.486 1.338 0 N-CA-C 109.205 -0.665 . . . . 2.4900000000000002 109.205 179.588 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . 0.41 ' CG ' ' O ' ' A' ' 109' ' ' SER . 2.6 p30 . . . . . 0 N--CA 1.498 1.939 0 N-CA-C 108.417 -0.957 . . . . 2.8500000000000001 108.417 -179.052 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . 0.407 ' NH1' ' HG3' ' B' ' 8' ' ' ARG . 23.4 mtm-85 . . . . . 0 N--CA 1.489 1.503 0 N-CA-C 108.287 -1.005 . . . . 3.6699999999999999 108.287 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 9' ' ' VAL . . . . . 0.532 ' N ' ' O ' ' A' ' 57' ' ' GLY . 0.4 OUTLIER -122.48 170.85 12.22 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.069 0 N-CA-C 108.139 -1.06 . . . . 1.3899999999999999 108.139 178.989 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -114.81 136.24 53.31 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.717 -0.615 . . . . 1.22 110.07 -179.41 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 9.4 m -149.28 82.88 1.43 Allowed 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.376 -0.828 . . . . 1.6299999999999999 109.44 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 12.8 t -101.04 116.72 33.52 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.363 -0.836 . . . . 1.8799999999999999 109.434 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . 0.477 ' CG2' ' N ' ' B' ' 14' ' ' PHE . 3.2 p -156.66 164.45 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.265 -0.897 . . . . 1.2 109.177 179.823 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 14' ' ' PHE . . . . . 0.508 ' HB3' ' H ' ' A' ' 53' ' ' ILE . 6.5 p90 -178.99 -164.7 0.07 Allowed 'General case' 0 N--CA 1.49 1.555 0 CA-C-O 122.1 0.953 . . . . 2.3900000000000001 111.924 179.575 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.615 ' N ' ' CD1' ' B' ' 15' ' ' ILE . 0.1 OUTLIER -145.72 155.49 13.0 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.094 0 N-CA-C 108.635 -0.876 . . . . 1.8100000000000001 108.635 179.811 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 97.0 m -109.11 158.9 17.33 Favored 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.214 -0.929 . . . . 2.04 109.781 -179.799 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 34.3 mt . . . . . 0 N--CA 1.499 2.019 0 O-C-N 121.475 -0.766 . . . . 1.8700000000000001 109.167 179.821 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.214 0 N-CA-C 110.735 -0.946 . . . . 2.4399999999999999 110.735 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.559 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -67.71 -6.18 41.9 Favored Glycine 0 N--CA 1.491 2.338 0 O-C-N 121.42 -1.047 . . . . 2.0499999999999998 111.063 -178.855 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -47.94 -11.99 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.465 -1.609 . . . . 2.54 109.452 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' HIS . . . . . 0.559 ' N ' ' O ' ' A' ' 17' ' ' GLY . 39.7 t-80 -96.92 -41.73 8.27 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.203 -0.935 . . . . 3.3700000000000001 109.729 179.577 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.528 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.0 OUTLIER -79.77 -24.43 41.52 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 120.92 -1.112 . . . . 2.3700000000000001 109.95 -179.64 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.464 ' O ' ' CG1' ' A' ' 21' ' ' VAL . 4.1 p -68.07 115.27 5.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 120.924 -1.11 . . . . 2.5800000000000001 108.927 179.87 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 12.0 tpp180 -98.07 136.05 38.88 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.625 -0.672 . . . . 3.8900000000000001 109.445 -179.155 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -147.55 113.42 5.76 Favored 'General case' 0 N--CA 1.492 1.639 0 N-CA-C 108.69 -0.855 . . . . 2.0099999999999998 108.69 179.486 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -162.62 136.5 4.36 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.584 -1.406 . . . . 2.0099999999999998 109.584 -179.579 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.1 173.7 46.16 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.667 -1.373 . . . . 1.9299999999999999 109.667 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 19.1 m -77.19 -18.43 57.77 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.352 -1.087 . . . . 2.6899999999999999 109.604 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -73.34 -20.26 79.85 Favored Glycine 0 N--CA 1.487 2.05 0 N-CA-C 109.304 -1.518 . . . . 1.6399999999999999 109.304 -179.884 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 55.7 mt -88.8 -13.97 38.14 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.433 -1.039 . . . . 2.0299999999999998 109.341 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 56.9 mt-10 -84.06 -62.74 1.49 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.292 -0.88 . . . . 2.3399999999999999 110.053 -179.519 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 79.3 mtt180 -149.0 165.2 32.34 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.014 -1.054 . . . . 4.25 110.342 -179.589 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -142.5 169.6 25.43 Favored Glycine 0 N--CA 1.495 2.591 0 N-CA-C 107.708 -2.157 . . . . 1.5900000000000001 107.708 179.019 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 40.9 t -134.04 150.57 31.4 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.202 0 O-C-N 121.051 -1.264 . . . . 2.21 110.971 -179.326 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -37.5 113.1 0.24 Allowed 'General case' 0 N--CA 1.501 2.08 0 CA-C-O 121.809 0.814 . . . . 2.0699999999999998 112.242 -179.533 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 52.29 50.54 46.36 Favored Glycine 0 N--CA 1.488 2.124 0 N-CA-C 111.244 -0.743 . . . . 1.73 111.244 177.162 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 24.1 t -126.6 103.3 25.05 Favored Pre-proline 0 N--CA 1.494 1.757 0 N-CA-C 108.061 -1.088 . . . . 2.6499999999999999 108.061 178.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -55.69 139.83 83.66 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 120.749 0.966 . . . . 2.1400000000000001 110.574 -178.713 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -146.97 175.04 10.97 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.449 -0.782 . . . . 2.0299999999999998 109.458 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -154.52 165.37 36.67 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.958 -1.089 . . . . 2.23 111.297 -179.378 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . 0.515 ' N ' ' CD1' ' A' ' 39' ' ' PHE . 0.7 OUTLIER -143.43 -174.25 4.17 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 107.066 -1.457 . . . . 1.72 107.066 177.464 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 44.7 m -120.63 151.58 39.28 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 121.238 -0.914 . . . . 2.5800000000000001 111.512 -177.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.441 HG23 HD11 ' A' ' 41' ' ' ILE . 85.5 mt -141.97 91.68 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 N-CA-C 108.332 -0.988 . . . . 1.8600000000000001 108.332 178.531 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.414 ' CD1' ' N ' ' A' ' 43' ' ' THR . 9.6 t90 -96.02 141.03 29.91 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.165 -0.959 . . . . 4.4699999999999998 108.69 179.887 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' THR . . . . . 0.528 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -161.83 130.26 4.26 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.247 -0.908 . . . . 3.27 109.748 -179.577 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' ARG . . . . . . . . . . . . . 66.6 ttt180 -172.02 77.33 0.05 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.324 -0.86 . . . . 5.2300000000000004 109.728 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 6.8 tp10 -165.18 -55.26 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.099 -1.001 . . . . 2.8900000000000001 109.735 179.631 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -58.33 -58.66 7.49 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.125 -0.984 . . . . 1.99 109.018 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 142.27 -160.53 27.24 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.231 -1.548 . . . . 1.6499999999999999 109.231 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -64.28 163.79 12.28 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.288 -1.125 . . . . 1.77 109.38 179.717 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 174.29 178.79 44.46 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.724 -1.351 . . . . 1.1200000000000001 109.724 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -117.12 125.47 6.54 Favored Glycine 0 N--CA 1.499 2.856 0 N-CA-C 109.682 -1.367 . . . . 1.1799999999999999 109.682 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.422 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 11.8 tp -99.53 101.17 12.31 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.283 -1.128 . . . . 1.5900000000000001 108.642 179.63 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 19.1 m -88.79 140.51 29.37 Favored 'General case' 0 N--CA 1.493 1.694 0 N-CA-C 108.696 -0.854 . . . . 1.9399999999999999 108.696 179.854 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.493 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 90.8 mt -132.28 108.03 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 O-C-N 121.288 -0.883 . . . . 1.3 109.347 -179.819 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -98.63 106.35 18.61 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.304 -0.872 . . . . 1.27 108.928 179.706 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -99.34 141.94 15.89 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.53 -0.731 . . . . 1.55 109.408 -179.826 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 10.1 tt0 -141.97 143.92 33.45 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.279 -1.008 . . . . 1.8 108.279 178.793 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 165.55 -174.12 41.29 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.614 -1.394 . . . . 0.56000000000000005 109.614 -179.289 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -58.18 -26.34 75.76 Favored 'Trans proline' 0 C--N 1.317 -1.122 0 C-N-CA 121.998 1.799 . . . . 0.76000000000000001 111.971 -179.513 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 2.1 m -143.61 170.62 15.49 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.063 -1.023 . . . . 2.02 110.291 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 29.1 mtpt -90.31 100.28 13.14 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.387 -0.82 . . . . 3.02 109.373 -179.878 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -63.38 142.82 58.25 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.182 -0.949 . . . . 1.3600000000000001 109.603 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 24.9 tt0 -80.66 172.0 14.31 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.283 -0.886 . . . . 2.2999999999999998 109.281 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 14.0 mt -149.65 141.31 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.906 0 N-CA-C 108.006 -1.109 . . . . 2.0 108.006 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -150.67 112.47 4.51 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 120.449 -1.407 . . . . 1.73 110.251 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . 0.519 ' CD2' ' O ' ' A' ' 65' ' ' PHE . 51.3 p90 -85.92 123.51 31.35 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.562 -0.711 . . . . 1.6000000000000001 110.205 179.795 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 42.8 tt0 . . . . . 0 N--CA 1.494 1.763 0 O-C-N 121.488 -0.757 . . . . 2.5099999999999998 109.056 179.555 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 14.0 m . . . . . 0 N--CA 1.495 1.775 0 N-CA-C 109.271 -0.641 . . . . 2.5600000000000001 109.271 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 11.3 t -82.48 120.29 25.3 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.217 -0.927 . . . . 2.3599999999999999 109.463 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -99.51 117.22 5.8 Favored Glycine 0 N--CA 1.496 2.694 0 N-CA-C 109.657 -1.377 . . . . 1.46 109.657 -179.832 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -105.32 105.11 18.04 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.075 0 O-C-N 121.54 -0.977 . . . . 2.1600000000000001 109.647 179.85 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 3.9 t -84.14 124.8 31.53 Favored 'General case' 0 N--CA 1.485 1.31 0 N-CA-C 108.148 -1.056 . . . . 2.1600000000000001 108.148 178.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 1.9 p90 -123.0 171.84 8.95 Favored 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 108.57 -0.9 . . . . 1.7 108.57 -179.078 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 41.4 t -141.79 141.67 29.28 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.929 0 O-C-N 121.169 -0.957 . . . . 2.4500000000000002 109.804 -179.581 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 30.7 m -109.53 150.69 12.07 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.095 0 O-C-N 121.439 -0.788 . . . . 1.8200000000000001 109.254 179.646 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 6.6 tp-100 -96.7 -45.27 6.75 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.219 -0.925 . . . . 3.1699999999999999 110.305 -179.717 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -159.28 152.33 18.39 Favored Pre-proline 0 N--CA 1.502 2.161 0 O-C-N 120.768 -1.208 . . . . 2.02 110.857 -179.26 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.622 ' HG3' ' N ' ' A' ' 107' ' ' SER . 85.5 Cg_exo -37.54 158.55 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 123.248 2.632 . . . . 1.3999999999999999 113.369 179.032 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 147.92 166.99 13.08 Favored Glycine 0 N--CA 1.488 2.109 0 N-CA-C 109.477 -1.449 . . . . 1.0800000000000001 109.477 179.823 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . 0.824 ' H ' HH12 ' B' ' 8' ' ' ARG . 66.9 m-20 -87.65 84.55 7.08 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 107.666 -1.235 . . . . 2.1299999999999999 107.666 179.117 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -69.93 134.16 48.09 Favored 'General case' 0 C--N 1.297 -1.709 0 N-CA-C 107.966 -1.124 . . . . 1.1399999999999999 107.966 -179.526 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . 0.419 ' OE1' ' O ' ' A' ' 84' ' ' ASP . 0.0 OUTLIER -112.27 127.63 56.03 Favored 'General case' 0 N--CA 1.501 2.105 0 N-CA-C 108.667 -0.864 . . . . 1.53 108.667 -179.413 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 9.6 p -123.88 141.06 45.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.712 -0.618 . . . . 1.6399999999999999 109.794 -179.633 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 3.8 m -130.29 97.82 4.53 Favored 'General case' 0 N--CA 1.498 1.952 0 CA-C-O 121.539 0.685 . . . . 1.99 109.38 179.781 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.6 pt -104.88 133.32 49.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 CA-C-O 121.471 0.653 . . . . 1.77 109.846 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' LYS . . . . . 0.458 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -144.42 127.39 16.45 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 108.027 -1.101 . . . . 2.0600000000000001 108.027 179.946 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.421 ' O ' ' CB ' ' A' ' 92' ' ' ASN . 76.5 t80 -85.47 102.22 13.29 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.63 -1.294 . . . . 1.45 108.462 179.16 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . 0.431 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 13.0 t30 72.38 33.87 1.41 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.068 -1.02 . . . . 2.7200000000000002 108.748 -178.679 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . 0.431 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 0.8 OUTLIER 80.21 14.04 0.87 Allowed 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.891 -0.505 . . . . 1.9199999999999999 111.698 179.509 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . 0.462 ' CG ' ' O ' ' A' ' 94' ' ' GLU . 5.0 pt-20 -99.84 94.44 6.32 Favored 'General case' 0 N--CA 1.495 1.806 0 N-CA-C 107.029 -1.471 . . . . 2.5499999999999998 107.029 177.573 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' HIS . . . . . 0.544 ' CD2' ' H ' ' A' ' 95' ' ' HIS . 7.0 p80 -74.7 112.41 10.87 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-O 121.542 0.687 . . . . 3.2000000000000002 110.281 -178.071 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' ILE . . . . . 0.624 ' CD1' ' H ' ' A' ' 96' ' ' ILE . 0.0 OUTLIER -60.49 155.76 46.83 Favored Pre-proline 0 N--CA 1.497 1.918 0 N-CA-C 107.257 -1.386 . . . . 2.8199999999999998 107.257 178.994 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -49.47 -25.78 11.12 Favored 'Trans proline' 0 C--N 1.321 -0.879 0 N-CA-C 108.968 -1.204 . . . . 2.6299999999999999 108.968 179.847 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.471 ' N ' ' OD1' ' A' ' 98' ' ' ASP . 0.9 OUTLIER -59.52 -64.69 0.85 Allowed 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 108.873 -0.788 . . . . 2.6499999999999999 108.873 178.852 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 2.4 p -66.83 141.01 96.52 Favored Pre-proline 0 C--N 1.297 -1.7 0 O-C-N 121.308 -0.87 . . . . 2.3199999999999998 110.04 -178.42 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -85.91 116.99 4.11 Favored 'Cis proline' 0 N--CA 1.492 1.405 0 N-CA-C 109.563 -0.976 . . . . 1.9399999999999999 109.563 -2.389 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 53.3 p90 -117.03 163.62 15.96 Favored 'General case' 0 N--CA 1.518 2.945 0 O-C-N 120.532 -1.355 . . . . 2.6299999999999999 110.003 178.687 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.5 p -93.23 152.89 3.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 CA-C-O 121.666 0.746 . . . . 1.8200000000000001 111.008 -178.144 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 65.1 t -125.92 86.84 57.04 Favored Pre-proline 0 N--CA 1.497 1.888 0 N-CA-C 107.917 -1.142 . . . . 1.73 107.917 179.024 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -63.71 113.29 2.08 Favored 'Trans proline' 0 C--N 1.319 -0.999 0 C-N-CA 121.418 1.412 . . . . 1.6100000000000001 112.264 -177.743 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 54.3 t -97.72 142.18 14.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 N-CA-C 106.302 -1.74 . . . . 1.7 106.302 177.496 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -130.23 132.84 46.15 Favored 'General case' 0 N--CA 1.511 2.606 0 CA-C-O 122.109 0.956 . . . . 2.04 111.82 -177.18 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' SER . . . . . 0.622 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 36.3 p -94.98 90.91 6.14 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.759 -1.213 . . . . 2.2999999999999998 107.748 179.577 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' LEU . . . . . 0.499 ' CD1' ' N ' ' A' ' 108' ' ' LEU . 8.0 mp 54.65 10.49 0.36 Allowed 'General case' 0 C--N 1.294 -1.816 0 N-CA-C 107.848 -1.167 . . . . 3.6000000000000001 107.848 -178.2 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.513 ' H ' ' C ' ' A' ' 107' ' ' SER . 9.0 t -98.88 -27.09 14.06 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 109.255 -0.646 . . . . 2.4900000000000002 109.255 179.712 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . 0.477 ' OD1' ' N ' ' A' ' 110' ' ' ASP . 1.8 m-20 . . . . . 0 N--CA 1.489 1.483 0 N-CA-C 107.941 -1.133 . . . . 2.8500000000000001 107.941 -179.275 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . 0.824 HH12 ' H ' ' A' ' 84' ' ' ASP . 5.8 mtt180 . . . . . 0 N--CA 1.494 1.767 0 N-CA-C 108.638 -0.875 . . . . 3.6699999999999999 108.638 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 9' ' ' VAL . . . . . . . . . . . . . 17.1 t -53.8 159.55 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 108.017 -1.105 . . . . 1.3899999999999999 108.017 179.307 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -123.18 150.28 43.55 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.464 -0.773 . . . . 1.22 110.002 -179.115 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 4.2 t -144.57 139.54 28.21 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.454 -0.779 . . . . 1.6299999999999999 109.017 179.695 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 16.7 m -140.4 116.03 10.17 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.328 -0.857 . . . . 1.8799999999999999 109.465 -179.714 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . 0.494 ' CG2' ' N ' ' B' ' 14' ' ' PHE . 2.9 p -160.15 166.29 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 O-C-N 121.34 -0.85 . . . . 1.2 109.234 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 14' ' ' PHE . . . . . 0.494 ' N ' ' CG2' ' B' ' 13' ' ' VAL . 7.4 p90 -177.54 -165.85 0.12 Allowed 'General case' 0 N--CA 1.487 1.425 0 CA-C-O 122.108 0.956 . . . . 2.3900000000000001 112.083 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.7 pt -149.51 169.92 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.318 0 N-CA-C 108.387 -0.968 . . . . 1.8100000000000001 108.387 179.851 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 65.9 p -135.54 128.64 31.68 Favored 'General case' 0 N--CA 1.5 2.049 0 O-C-N 121.184 -0.947 . . . . 2.04 109.784 -179.803 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.6 mt . . . . . 0 N--CA 1.492 1.671 0 O-C-N 121.349 -0.844 . . . . 1.8700000000000001 109.167 179.651 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.404 ' O ' ' CB ' ' A' ' 94' ' ' GLU . . . . . . . . 0 N--CA 1.489 2.224 0 N-CA-C 110.912 -0.875 . . . . 2.4399999999999999 110.912 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.531 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 71.35 -53.94 1.14 Allowed Glycine 0 N--CA 1.491 2.351 0 N-CA-C 110.416 -1.073 . . . . 2.0499999999999998 110.416 179.066 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.43 ' N ' ' CD ' ' A' ' 94' ' ' GLU . . . -46.79 -12.53 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.543 -0.975 . . . . 2.54 110.14 -179.439 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' HIS . . . . . 0.531 ' N ' ' O ' ' A' ' 17' ' ' GLY . 10.0 t-80 -89.77 -42.79 11.09 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.123 -0.985 . . . . 3.3700000000000001 110.299 -179.168 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.444 ' HZ1' ' H ' ' A' ' 46' ' ' ALA . 0.0 OUTLIER -93.84 -9.08 38.57 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 120.928 -1.108 . . . . 2.3700000000000001 110.682 -179.006 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 74.2 t -83.4 112.14 20.54 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 120.865 -1.147 . . . . 2.5800000000000001 110.3 -179.383 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 20.9 tpt180 -103.07 139.91 38.0 Favored 'General case' 0 N--CA 1.491 1.615 0 N-CA-C 108.06 -1.089 . . . . 3.8900000000000001 108.06 179.042 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -140.02 113.3 8.39 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.263 -0.898 . . . . 2.0099999999999998 109.648 -179.599 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -155.78 130.59 2.8 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 109.352 -1.499 . . . . 2.0099999999999998 109.352 179.71 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.3 167.14 37.57 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.816 -1.314 . . . . 1.9299999999999999 109.816 -179.856 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 17.6 m -74.1 -28.16 61.23 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.297 -1.119 . . . . 2.6899999999999999 109.486 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.6 -22.9 78.02 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 109.085 -1.606 . . . . 1.6399999999999999 109.085 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 20.8 mt -77.0 -10.21 59.21 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.446 -1.032 . . . . 2.0299999999999998 108.963 179.689 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 59.4 mt-10 -90.15 -51.91 5.22 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.372 -0.83 . . . . 2.3399999999999999 109.478 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . 0.405 ' NH1' ' HG2' ' A' ' 30' ' ' ARG . 0.0 OUTLIER -169.05 -168.69 0.87 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.035 -1.04 . . . . 4.25 109.993 -179.992 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -153.92 178.76 30.65 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 108.508 -1.837 . . . . 1.5900000000000001 108.508 179.876 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 42.0 t -134.37 151.09 31.42 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.041 0 O-C-N 121.165 -1.197 . . . . 2.21 110.635 -179.618 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -38.79 111.68 0.19 Allowed 'General case' 0 N--CA 1.5 2.062 0 CA-C-O 121.544 0.688 . . . . 2.0699999999999998 112.39 -179.154 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 53.43 51.42 47.8 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 111.302 -0.719 . . . . 1.73 111.302 176.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 31.4 t -127.59 103.04 22.32 Favored Pre-proline 0 N--CA 1.495 1.78 0 O-C-N 121.513 -0.993 . . . . 2.6499999999999999 109.016 179.203 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -58.55 133.07 52.03 Favored 'Trans proline' 0 C--O 1.215 -0.636 0 N-CA-C 109.51 -0.996 . . . . 2.1400000000000001 109.51 -179.88 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -142.18 -169.62 2.98 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.338 -0.851 . . . . 2.0299999999999998 108.803 -179.825 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -169.45 165.23 10.54 Favored 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 118.931 -1.107 . . . . 2.23 111.228 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . 0.57 ' N ' ' CD1' ' A' ' 39' ' ' PHE . 0.7 OUTLIER -138.32 -176.28 4.4 Favored 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 106.758 -1.571 . . . . 1.72 106.758 178.033 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 43.8 t -122.28 147.12 46.62 Favored 'General case' 0 N--CA 1.498 1.969 0 CA-C-O 121.596 0.712 . . . . 2.5800000000000001 110.298 -179.103 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 49.6 mt -142.73 97.24 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 N-CA-C 107.986 -1.116 . . . . 1.8600000000000001 107.986 179.033 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.46 ' CD1' ' C ' ' A' ' 42' ' ' TRP . 0.4 OUTLIER -86.68 144.96 26.88 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.355 -0.841 . . . . 4.4699999999999998 108.864 -179.493 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' THR . . . . . 0.534 ' OG1' ' N ' ' A' ' 44' ' ' ARG . 1.7 t -168.16 -124.85 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.322 -0.861 . . . . 3.27 109.355 -179.898 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' ARG . . . . . 0.534 ' N ' ' OG1' ' A' ' 43' ' ' THR . 61.2 ttt180 57.62 77.67 0.27 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.277 -0.889 . . . . 5.2300000000000004 109.754 179.804 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 26.1 tt0 -160.62 -45.93 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.289 -0.882 . . . . 2.8900000000000001 109.127 179.642 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.444 ' H ' ' HZ1' ' A' ' 20' ' ' LYS . . . -61.82 -56.16 22.33 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.257 -0.902 . . . . 1.99 109.1 179.658 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 155.64 178.27 29.69 Favored Glycine 0 N--CA 1.489 2.167 0 N-CA-C 109.459 -1.457 . . . . 1.6499999999999999 109.459 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.7 145.01 16.46 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.173 -1.192 . . . . 1.77 109.152 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -164.33 -164.24 19.13 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.667 -1.373 . . . . 1.1200000000000001 109.667 -179.828 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -137.97 116.57 1.34 Allowed Glycine 0 N--CA 1.496 2.69 0 N-CA-C 109.546 -1.422 . . . . 1.1799999999999999 109.546 -179.828 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.417 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 64.3 tp -91.57 109.39 20.69 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.274 -1.133 . . . . 1.5900000000000001 108.422 179.383 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 28.3 m -92.96 141.61 28.22 Favored 'General case' 0 N--CA 1.498 1.969 0 N-CA-C 108.598 -0.89 . . . . 1.9399999999999999 108.598 179.616 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.544 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 93.9 mt -134.34 116.99 23.35 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.945 0 O-C-N 121.165 -0.959 . . . . 1.3 110.148 -179.304 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -107.47 109.66 21.41 Favored 'General case' 0 N--CA 1.495 1.799 0 N-CA-C 108.133 -1.062 . . . . 1.27 108.133 178.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -101.41 143.19 14.8 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.43 -0.794 . . . . 1.55 110.228 -178.862 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 23.4 tp10 -139.02 143.12 38.31 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 106.765 -1.569 . . . . 1.8 106.765 178.396 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.433 ' O ' ' N ' ' B' ' 9' ' ' VAL . . . 171.68 -173.98 45.07 Favored Glycine 0 N--CA 1.491 2.301 0 C-N-CA 119.131 -1.509 . . . . 0.56000000000000005 109.654 -178.667 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -64.96 -32.68 53.92 Favored 'Trans proline' 0 C--N 1.316 -1.183 0 C-N-CA 121.748 1.632 . . . . 0.76000000000000001 110.317 179.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' SER . . . . . 0.413 ' O ' ' OH ' ' A' ' 85' ' ' TYR . 58.4 m -137.86 158.89 43.42 Favored 'General case' 0 N--CA 1.5 2.035 0 O-C-N 121.319 -0.863 . . . . 2.02 109.931 -179.323 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 34.5 mttp -76.03 93.14 3.24 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.363 -0.836 . . . . 3.02 109.483 -179.842 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -63.89 136.42 57.36 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.278 -0.888 . . . . 1.3600000000000001 109.426 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 55.1 mm-40 -79.49 172.54 13.65 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.126 -0.984 . . . . 2.2999999999999998 109.539 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 4.4 mp -140.22 151.01 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 N-CA-C 108.325 -0.991 . . . . 2.0 108.325 -179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -151.04 120.02 6.67 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 120.603 -1.31 . . . . 1.73 109.468 -179.712 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 54.4 p90 -86.19 139.13 31.34 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.276 -0.89 . . . . 1.6000000000000001 109.764 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.487 ' N ' ' O ' ' A' ' 74' ' ' GLY . 43.7 tt0 . . . . . 0 N--CA 1.496 1.846 0 O-C-N 121.395 -0.816 . . . . 2.5099999999999998 109.149 179.886 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 9.6 t . . . . . 0 N--CA 1.496 1.834 0 N-CA-C 109.107 -0.701 . . . . 2.5600000000000001 109.107 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 10.4 t -78.06 153.12 32.56 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.248 -0.908 . . . . 2.3599999999999999 109.438 -179.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.487 ' O ' ' N ' ' A' ' 66' ' ' GLU . . . -126.45 111.95 1.51 Allowed Glycine 0 N--CA 1.498 2.793 0 N-CA-C 109.352 -1.499 . . . . 1.46 109.352 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 27.4 t -100.52 99.93 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.011 0 O-C-N 121.56 -0.965 . . . . 2.1600000000000001 109.399 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -84.79 165.3 17.89 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 108.293 -1.003 . . . . 2.1600000000000001 108.293 179.399 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 0.404 ' CD1' ' N ' ' A' ' 77' ' ' TYR . 12.5 p90 -165.36 169.9 15.24 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.275 -0.891 . . . . 1.7 109.238 -179.329 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.47 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 5.0 p -142.18 116.32 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.215 0 O-C-N 121.122 -0.986 . . . . 2.4500000000000002 110.211 179.35 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 6.5 m -89.97 153.3 3.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.276 -0.89 . . . . 1.8200000000000001 108.863 179.708 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . 0.407 ' O ' ' OE2' ' A' ' 81' ' ' GLU . 20.6 tt0 -94.57 -48.02 6.28 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.994 -1.066 . . . . 3.1699999999999999 110.84 -178.892 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.407 ' OE2' ' O ' ' A' ' 80' ' ' GLN . 78.3 mm-40 -153.88 150.05 22.09 Favored Pre-proline 0 N--CA 1.503 2.198 0 O-C-N 120.613 -1.304 . . . . 2.02 111.218 -178.455 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.608 ' HG3' ' N ' ' A' ' 107' ' ' SER . 87.8 Cg_exo -36.76 157.9 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.944 2.429 . . . . 1.3999999999999999 113.368 178.24 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 150.07 -156.92 26.98 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 108.893 -1.683 . . . . 1.0800000000000001 108.893 -179.911 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 37.5 m-20 -116.38 92.4 3.87 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.52 -0.988 . . . . 2.1299999999999999 109.408 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . 0.451 ' O ' ' N ' ' A' ' 103' ' ' VAL . 2.7 m-85 -78.98 129.76 34.82 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 107.977 -1.12 . . . . 1.1399999999999999 107.977 179.343 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.37 128.41 56.45 Favored 'General case' 0 N--CA 1.502 2.131 0 N-CA-C 108.675 -0.861 . . . . 1.53 108.675 -178.847 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 6.3 p -126.6 138.53 54.46 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.681 -0.637 . . . . 1.6399999999999999 109.928 -179.667 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' SER . . . . . 0.414 ' O ' ' OG ' ' A' ' 88' ' ' SER . 44.7 p -127.83 96.69 4.58 Favored 'General case' 0 N--CA 1.499 1.987 0 N-CA-C 109.358 -0.608 . . . . 1.99 109.358 179.792 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -106.3 134.78 46.91 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 CA-C-O 121.479 0.657 . . . . 1.77 109.938 -179.469 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' LYS . . . . . 0.459 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -142.97 123.72 14.18 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.454 -0.779 . . . . 2.0600000000000001 109.073 -179.882 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 57.2 t80 -80.05 101.11 8.51 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.011 -1.056 . . . . 1.45 108.199 178.661 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . 0.411 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 16.8 t-20 69.2 37.68 2.07 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.13 -0.982 . . . . 2.7200000000000002 109.149 -179.014 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . 0.411 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 1.5 m-20 77.87 14.87 1.57 Allowed 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.836 -0.54 . . . . 1.9199999999999999 111.928 179.337 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . 0.493 ' OE1' ' O ' ' A' ' 94' ' ' GLU . 0.3 OUTLIER -100.6 99.81 10.44 Favored 'General case' 0 N--CA 1.501 2.106 0 N-CA-C 107.462 -1.31 . . . . 2.5499999999999998 107.462 177.707 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 29.9 m-70 -70.16 105.12 2.82 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.553 -0.717 . . . . 3.2000000000000002 109.779 -178.613 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' ILE . . . . . 0.639 ' O ' ' N ' ' A' ' 98' ' ' ASP . 9.9 pt -51.21 152.9 3.75 Favored Pre-proline 0 N--CA 1.493 1.681 0 N-CA-C 108.587 -0.894 . . . . 2.8199999999999998 108.587 179.667 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -59.1 61.74 0.06 OUTLIER 'Trans proline' 0 N--CA 1.484 0.945 0 C-N-CA 121.457 1.438 . . . . 2.6299999999999999 109.582 179.255 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.639 ' N ' ' O ' ' A' ' 96' ' ' ILE . 31.4 m-20 -162.17 -58.42 0.05 OUTLIER 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 108.386 -0.968 . . . . 2.6499999999999999 108.386 -179.536 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 1.1 t -65.43 141.31 97.98 Favored Pre-proline 0 C--N 1.297 -1.705 0 C-N-CA 119.868 -0.733 . . . . 2.3199999999999998 110.085 -177.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -85.99 114.56 3.03 Favored 'Cis proline' 0 N--CA 1.492 1.396 0 N-CA-C 109.585 -0.967 . . . . 1.9399999999999999 109.585 -2.103 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 46.4 p90 -110.32 160.27 16.7 Favored 'General case' 0 N--CA 1.517 2.896 0 O-C-N 120.501 -1.375 . . . . 2.6299999999999999 110.261 178.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.3 p -92.62 148.98 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 CA-C-O 121.517 0.675 . . . . 1.8200000000000001 110.206 -179.152 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.451 ' N ' ' O ' ' A' ' 85' ' ' TYR . 70.8 t -124.11 85.6 54.62 Favored Pre-proline 0 N--CA 1.498 1.946 0 N-CA-C 107.858 -1.164 . . . . 1.73 107.858 179.511 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -63.45 113.08 1.94 Allowed 'Trans proline' 0 C--N 1.32 -0.968 0 C-N-CA 121.339 1.359 . . . . 1.6100000000000001 112.021 -177.605 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 54.1 t -90.22 143.97 10.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 N-CA-C 106.682 -1.599 . . . . 1.7 106.682 177.71 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -131.78 130.29 41.65 Favored 'General case' 0 N--CA 1.508 2.462 0 O-C-N 121.217 -0.927 . . . . 2.04 111.629 -177.167 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' SER . . . . . 0.608 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 60.3 p -95.45 90.61 5.84 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.71 -1.244 . . . . 2.2999999999999998 107.873 179.36 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' LEU . . . . . 0.459 ' CD1' ' N ' ' A' ' 108' ' ' LEU . 9.2 mp 54.83 10.38 0.37 Allowed 'General case' 0 C--N 1.295 -1.774 0 N-CA-C 107.949 -1.13 . . . . 3.6000000000000001 107.949 -178.434 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.518 ' H ' ' C ' ' A' ' 107' ' ' SER . 50.4 p -100.24 -24.97 14.41 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 109.32 -0.622 . . . . 2.4900000000000002 109.32 179.563 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 15.9 t70 . . . . . 0 N--CA 1.493 1.684 0 O-C-N 121.079 -1.013 . . . . 2.8500000000000001 108.392 -179.604 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . 0.597 HH11 ' CG ' ' B' ' 8' ' ' ARG . 0.3 OUTLIER . . . . . 0 N--CA 1.494 1.766 0 N-CA-C 107.833 -1.173 . . . . 3.6699999999999999 107.833 . . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 9' ' ' VAL . . . . . 0.433 ' N ' ' O ' ' A' ' 57' ' ' GLY . 0.5 OUTLIER -176.23 168.83 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 N-CA-C 107.612 -1.255 . . . . 1.3899999999999999 107.612 177.936 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -120.81 136.01 55.01 Favored 'General case' 0 N--CA 1.502 2.133 0 CA-C-O 121.487 0.66 . . . . 1.22 110.514 -178.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 18.4 m -149.65 138.45 21.0 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.468 -0.77 . . . . 1.6299999999999999 109.265 179.395 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 27.8 p -145.94 126.08 13.79 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.089 -1.007 . . . . 1.8799999999999999 109.984 -179.682 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . 0.484 ' CG2' ' N ' ' B' ' 14' ' ' PHE . 6.8 p -167.11 170.81 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 N-CA-C 108.678 -0.86 . . . . 1.2 108.678 179.735 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 14' ' ' PHE . . . . . 0.544 ' HB3' ' H ' ' A' ' 53' ' ' ILE . 6.4 p90 -177.03 -171.45 0.36 Allowed 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 119.046 -1.061 . . . . 2.3900000000000001 112.458 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 4.0 mm -142.96 172.45 7.77 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 N-CA-C 108.213 -1.032 . . . . 1.8100000000000001 108.213 179.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -144.05 144.58 31.7 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 120.89 -1.131 . . . . 2.04 109.567 179.645 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 21.7 mt . . . . . 0 N--CA 1.498 1.964 0 O-C-N 121.26 -0.9 . . . . 1.8700000000000001 109.589 -179.886 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.232 0 N-CA-C 111.095 -0.802 . . . . 2.4399999999999999 111.095 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.562 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 68.73 -53.63 0.51 Allowed Glycine 0 N--CA 1.492 2.405 0 O-C-N 121.499 -1.0 . . . . 2.0499999999999998 110.668 178.733 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.443 ' N ' ' HG2' ' A' ' 94' ' ' GLU . . . -42.66 -16.3 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.882 -0.775 . . . . 2.54 110.673 -178.598 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' HIS . . . . . 0.562 ' N ' ' O ' ' A' ' 17' ' ' GLY . 10.8 t-80 -93.82 -43.51 8.56 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.174 -0.954 . . . . 3.3700000000000001 110.879 -178.409 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -91.29 -35.99 14.14 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 120.966 -1.084 . . . . 2.3700000000000001 111.022 -178.486 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.478 ' O ' ' CG1' ' A' ' 21' ' ' VAL . 6.6 p -46.66 111.28 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 120.989 -1.069 . . . . 2.5800000000000001 110.061 -178.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 19.5 tpt180 -118.43 124.84 48.63 Favored 'General case' 0 N--CA 1.497 1.878 0 N-CA-C 108.89 -0.781 . . . . 3.8900000000000001 108.89 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -128.05 116.48 20.08 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.489 -0.757 . . . . 2.0099999999999998 109.26 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -148.2 128.78 2.95 Favored Glycine 0 N--CA 1.495 2.571 0 N-CA-C 109.403 -1.479 . . . . 2.0099999999999998 109.403 -179.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.11 169.19 40.38 Favored Glycine 0 N--CA 1.489 2.206 0 C-N-CA 119.574 -1.298 . . . . 1.9299999999999999 110.062 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 43.3 p -74.06 -11.94 60.47 Favored 'General case' 0 N--CA 1.486 1.34 0 O-C-N 121.349 -1.089 . . . . 2.6899999999999999 109.771 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -67.37 -17.06 68.03 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 108.205 -1.958 . . . . 1.6399999999999999 108.205 179.46 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 28.2 mt -89.86 -11.65 41.32 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 108.467 -0.938 . . . . 2.0299999999999998 108.467 179.437 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 19.9 mm-40 -82.68 -60.35 2.21 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.596 -0.69 . . . . 2.3399999999999999 109.858 -179.47 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 26.6 ptt180 -172.96 178.79 2.45 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.032 -1.043 . . . . 4.25 109.992 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -148.85 178.0 26.71 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 108.446 -1.861 . . . . 1.5900000000000001 108.446 179.765 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 27.3 t -134.8 148.33 29.31 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.015 0 O-C-N 121.205 -1.174 . . . . 2.21 110.145 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -41.56 113.95 0.47 Allowed 'General case' 0 N--CA 1.495 1.792 0 CA-C-O 121.567 0.699 . . . . 2.0699999999999998 112.388 -179.155 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 59.87 46.44 94.1 Favored Glycine 0 N--CA 1.492 2.424 0 O-C-N 121.658 -0.651 . . . . 1.73 111.687 177.113 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 13.9 t -127.36 126.03 24.06 Favored Pre-proline 0 N--CA 1.499 2.009 0 N-CA-C 108.019 -1.104 . . . . 2.6499999999999999 108.019 178.827 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -55.12 121.38 9.81 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 120.487 0.791 . . . . 2.1400000000000001 110.441 -179.362 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -119.92 151.5 38.81 Favored 'General case' 0 N--CA 1.499 1.992 0 N-CA-C 108.235 -1.024 . . . . 2.0299999999999998 108.235 179.319 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 8.6 pt-20 -160.16 166.24 30.1 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.727 -1.233 . . . . 2.23 111.334 -179.445 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . 0.55 ' N ' ' CD1' ' A' ' 39' ' ' PHE . 0.9 OUTLIER -140.48 -178.08 5.34 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 107.046 -1.464 . . . . 1.72 107.046 177.428 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 15.5 m -128.31 134.83 48.98 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.678 -0.639 . . . . 2.5800000000000001 110.084 -179.161 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.532 ' O ' ' N ' ' A' ' 73' ' ' CYS . 73.0 mt -124.61 145.79 31.26 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 N-CA-C 107.683 -1.228 . . . . 1.8600000000000001 107.683 179.13 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.522 ' CD2' ' OG1' ' A' ' 43' ' ' THR . 14.5 p-90 -154.82 -176.99 6.2 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.678 -1.264 . . . . 4.4699999999999998 110.445 -179.653 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' THR . . . . . 0.522 ' OG1' ' CD2' ' A' ' 42' ' ' TRP . 0.2 OUTLIER 81.85 109.9 0.07 Allowed 'General case' 0 N--CA 1.495 1.806 0 N-CA-C 109.356 -0.609 . . . . 3.27 109.356 -179.883 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' ARG . . . . . 0.575 ' CG ' HH11 ' A' ' 44' ' ' ARG . 0.0 OUTLIER -132.16 56.94 1.8 Allowed 'General case' 0 N--CA 1.499 1.976 0 N-CA-C 108.982 -0.747 . . . . 5.2300000000000004 108.982 -179.864 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 27.3 tt0 -90.3 -15.91 30.29 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.264 -0.897 . . . . 2.8900000000000001 109.976 -179.583 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.39 -66.88 0.5 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.04 -1.038 . . . . 1.99 109.179 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 138.21 -162.83 25.71 Favored Glycine 0 N--CA 1.495 2.633 0 N-CA-C 109.672 -1.371 . . . . 1.6499999999999999 109.672 179.812 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.86 147.37 12.14 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.278 -1.131 . . . . 1.77 109.33 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -173.19 -168.96 35.1 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.538 -1.425 . . . . 1.1200000000000001 109.538 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -137.49 114.29 1.09 Allowed Glycine 0 N--CA 1.496 2.663 0 N-CA-C 109.114 -1.594 . . . . 1.1799999999999999 109.114 179.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.402 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 10.1 tp -93.74 97.58 10.53 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.251 -1.146 . . . . 1.5900000000000001 108.582 179.79 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 4.2 m -83.78 142.16 30.87 Favored 'General case' 0 N--CA 1.494 1.738 0 N-CA-C 108.485 -0.932 . . . . 1.9399999999999999 108.485 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.53 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 61.0 mt -133.65 123.22 45.29 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.083 -1.011 . . . . 1.3 109.674 -179.688 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -116.07 111.71 20.69 Favored 'General case' 0 N--CA 1.497 1.89 0 N-CA-C 108.325 -0.991 . . . . 1.27 108.325 179.236 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 1.1 t -102.94 149.14 7.32 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.977 0 O-C-N 121.449 -0.782 . . . . 1.55 110.052 -179.277 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . 0.42 ' OE2' ' O ' ' B' ' 9' ' ' VAL . 50.9 tp10 -140.65 138.39 34.3 Favored 'General case' 0 N--CA 1.486 1.374 0 N-CA-C 108.441 -0.948 . . . . 1.8 108.441 178.285 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 174.3 -177.51 46.47 Favored Glycine 0 N--CA 1.487 2.075 0 N-CA-C 108.719 -1.752 . . . . 0.56000000000000005 108.719 -179.607 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_exo -62.74 -18.54 64.81 Favored 'Trans proline' 0 C--N 1.313 -1.32 0 C-N-CA 121.802 1.668 . . . . 0.76000000000000001 110.957 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' SER . . . . . 0.5 ' H ' ' HH ' ' A' ' 85' ' ' TYR . 1.1 p -149.77 166.36 29.68 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.349 -0.844 . . . . 2.02 110.411 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 46.1 mttt -89.92 125.74 35.47 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.607 -0.683 . . . . 3.02 109.502 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -81.8 142.86 32.21 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.278 -0.889 . . . . 1.3600000000000001 109.325 179.766 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 10.0 tp10 -86.61 90.55 8.29 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.24 -0.913 . . . . 2.2999999999999998 109.766 -179.808 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 6.3 mm -58.5 155.62 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 121.574 -0.704 . . . . 2.0 109.133 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.487 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -149.68 114.43 5.33 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.804 -1.185 . . . . 1.73 109.503 179.577 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . 0.463 ' CD2' ' O ' ' A' ' 65' ' ' PHE . 16.5 p90 -88.85 119.11 29.05 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.164 -0.96 . . . . 1.6000000000000001 109.041 179.476 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 . . . . . 0 N--CA 1.496 1.864 0 O-C-N 121.252 -0.905 . . . . 2.5099999999999998 109.902 -179.633 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 74.8 m . . . . . 0 N--CA 1.493 1.703 0 N-CA-C 109.395 -0.594 . . . . 2.5600000000000001 109.395 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' CYS . . . . . 0.532 ' N ' ' O ' ' A' ' 41' ' ' ILE . 28.2 m -80.18 119.89 23.55 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.225 -0.922 . . . . 2.3599999999999999 109.295 179.801 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -98.26 123.58 7.9 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.42 -1.472 . . . . 1.46 109.42 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 40.2 t -114.85 102.68 14.19 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.089 0 O-C-N 121.632 -0.923 . . . . 2.1600000000000001 109.05 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.487 ' O ' ' N ' ' A' ' 64' ' ' ALA . 3.3 t -94.01 130.4 40.16 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.34 -0.85 . . . . 2.1600000000000001 110.136 -179.598 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 8.5 p90 -126.46 129.85 49.51 Favored 'General case' 0 N--CA 1.492 1.646 0 N-CA-C 108.158 -1.052 . . . . 1.7 108.158 179.455 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 11.3 t -100.56 111.29 29.78 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.181 -0.949 . . . . 2.4500000000000002 109.453 -179.155 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 13.2 m -77.94 157.71 5.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 O-C-N 121.287 -0.883 . . . . 1.8200000000000001 109.329 -179.866 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 30.1 tt0 -101.87 -47.92 4.43 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.173 -0.955 . . . . 3.1699999999999999 110.303 -179.499 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.404 ' O ' ' O ' ' A' ' 82' ' ' PRO . 75.5 mm-40 -149.98 150.03 29.01 Favored Pre-proline 0 N--CA 1.502 2.143 0 O-C-N 120.829 -1.169 . . . . 2.02 111.253 -178.623 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.498 ' HG3' ' N ' ' A' ' 107' ' ' SER . 77.8 Cg_exo -37.43 165.49 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.679 0 C-N-CA 122.825 2.35 . . . . 1.3999999999999999 113.296 178.551 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 142.37 -178.89 20.61 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 108.989 -1.644 . . . . 1.0800000000000001 108.989 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . 0.552 ' O ' ' NH1' ' B' ' 8' ' ' ARG . 29.6 m-20 -98.69 89.74 4.47 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 107.835 -1.172 . . . . 2.1299999999999999 107.835 179.224 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . 0.5 ' HH ' ' H ' ' A' ' 59' ' ' SER . 2.9 m-85 -74.7 133.67 42.04 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 108.347 -0.983 . . . . 1.1399999999999999 108.347 -179.366 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . 0.488 ' OE2' ' NH1' ' B' ' 8' ' ' ARG . 0.0 OUTLIER -117.65 125.05 50.04 Favored 'General case' 0 N--CA 1.498 1.949 0 N-CA-C 108.305 -0.998 . . . . 1.53 108.305 -179.098 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.556 ' CG1' ' CE2' ' A' ' 101' ' ' PHE . 7.5 p -122.94 137.38 56.6 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.986 0 O-C-N 121.624 -0.673 . . . . 1.6399999999999999 109.401 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 99.8 p -131.55 113.87 14.18 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.596 -0.69 . . . . 1.99 109.797 -179.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 2.9 pt -111.83 143.13 22.24 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.735 -0.603 . . . . 1.77 109.917 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -140.4 123.52 16.67 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.236 -0.915 . . . . 2.0600000000000001 109.273 178.971 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 25.1 t80 -78.67 92.99 4.82 Favored 'General case' 0 N--CA 1.494 1.744 0 C-N-CA 119.026 -1.069 . . . . 1.45 108.325 179.449 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . 0.486 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 5.8 t-20 65.82 37.62 5.52 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 108.236 -1.024 . . . . 2.7200000000000002 108.236 -178.809 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . 0.486 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 2.2 m-20 88.76 10.97 0.09 Allowed 'General case' 0 N--CA 1.503 2.192 0 CA-C-N 116.605 -0.27 . . . . 1.9199999999999999 111.381 179.658 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . 0.522 ' CG ' ' O ' ' A' ' 94' ' ' GLU . 0.0 OUTLIER -86.33 86.97 7.35 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 106.091 -1.818 . . . . 2.5499999999999998 106.091 177.687 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' HIS . . . . . 0.445 ' O ' ' C ' ' A' ' 96' ' ' ILE . 2.3 t-80 -68.12 94.36 0.5 Allowed 'General case' 0 C--N 1.296 -1.735 0 O-C-N 120.4 -1.437 . . . . 3.2000000000000002 110.948 -177.845 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' ILE . . . . . 0.506 ' C ' ' H ' ' A' ' 98' ' ' ASP . 4.7 mm -38.38 135.81 0.88 Allowed Pre-proline 0 N--CA 1.504 2.271 0 O-C-N 121.497 -0.752 . . . . 2.8199999999999998 109.281 179.084 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -54.52 -7.36 0.8 Allowed 'Trans proline' 0 C--N 1.325 -0.7 0 N-CA-C 109.239 -1.1 . . . . 2.6299999999999999 109.239 179.131 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.506 ' H ' ' C ' ' A' ' 96' ' ' ILE . 55.0 m-20 -86.87 -47.32 9.12 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.481 -0.762 . . . . 2.6499999999999999 109.729 179.765 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 6.4 p -54.71 136.32 64.16 Favored Pre-proline 0 C--N 1.298 -1.661 0 O-C-N 121.191 -0.943 . . . . 2.3199999999999998 109.835 -177.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -89.3 113.81 2.34 Favored 'Cis proline' 0 N--CA 1.494 1.554 0 CA-C-N 118.935 0.655 . . . . 1.9399999999999999 110.44 -1.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . 0.609 ' CD1' ' N ' ' A' ' 101' ' ' PHE . 0.1 OUTLIER -81.42 158.58 24.55 Favored 'General case' 0 N--CA 1.509 2.522 0 O-C-N 119.674 -1.891 . . . . 2.6299999999999999 108.785 178.476 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 10.4 p -97.93 138.04 23.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.404 -0.81 . . . . 1.8200000000000001 109.388 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 60.6 t -121.03 85.53 40.95 Favored Pre-proline 0 N--CA 1.499 2.019 0 N-CA-C 108.623 -0.88 . . . . 1.73 108.623 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -65.63 111.32 1.85 Allowed 'Trans proline' 0 C--N 1.321 -0.899 0 C-N-CA 121.443 1.428 . . . . 1.6100000000000001 111.467 -178.336 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 54.6 t -95.49 146.32 7.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.775 0 N-CA-C 107.1 -1.444 . . . . 1.7 107.1 178.34 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -138.71 135.65 34.98 Favored 'General case' 0 N--CA 1.509 2.523 0 O-C-N 121.092 -1.005 . . . . 2.04 111.799 -177.541 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' SER . . . . . 0.508 ' O ' ' CB ' ' A' ' 108' ' ' LEU . 9.9 m -86.71 58.73 5.23 Favored 'General case' 0 N--CA 1.494 1.752 0 N-CA-C 107.42 -1.326 . . . . 2.2999999999999998 107.42 178.808 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' LEU . . . . . 0.508 ' CB ' ' O ' ' A' ' 107' ' ' SER . 3.4 tp 83.8 -11.35 0.89 Allowed 'General case' 0 N--CA 1.495 1.814 0 N-CA-C 106.972 -1.492 . . . . 3.6000000000000001 106.972 -177.843 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.409 ' O ' ' CG ' ' A' ' 110' ' ' ASP . 24.1 t -71.18 -19.28 62.42 Favored 'General case' 0 C--N 1.305 -1.333 0 N-CA-C 108.878 -0.786 . . . . 2.4900000000000002 108.878 178.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . 0.409 ' CG ' ' O ' ' A' ' 109' ' ' SER . 1.1 p30 . . . . . 0 N--CA 1.496 1.833 0 N-CA-C 108.285 -1.006 . . . . 2.8500000000000001 108.285 -178.822 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . 0.552 ' NH1' ' O ' ' A' ' 84' ' ' ASP . 68.3 mtt180 . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 108.429 -0.952 . . . . 3.6699999999999999 108.429 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 9' ' ' VAL . . . . . 0.42 ' O ' ' OE2' ' A' ' 56' ' ' GLU . 21.0 t -53.99 158.71 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 N-CA-C 108.162 -1.051 . . . . 1.3899999999999999 108.162 178.971 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -117.83 141.72 48.11 Favored 'General case' 0 N--CA 1.502 2.166 0 O-C-N 121.489 -0.757 . . . . 1.22 109.981 -179.337 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 18.4 t -143.0 137.68 29.49 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.368 -0.832 . . . . 1.6299999999999999 109.319 179.581 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 8.7 t -141.13 128.31 20.9 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.308 -0.87 . . . . 1.8799999999999999 109.584 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . 0.48 ' CG2' ' N ' ' B' ' 14' ' ' PHE . 6.1 p -169.44 167.89 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.484 -0.76 . . . . 1.2 109.205 -179.874 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 14' ' ' PHE . . . . . 0.53 ' HB3' ' H ' ' A' ' 53' ' ' ILE . 6.7 p90 -177.61 -167.67 0.16 Allowed 'General case' 0 N--CA 1.49 1.552 0 CA-C-O 122.202 1.001 . . . . 2.3900000000000001 112.537 179.65 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.4 pt -150.71 172.07 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.31 0 N-CA-C 108.322 -0.992 . . . . 1.8100000000000001 108.322 179.818 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 31.7 p -144.96 147.12 32.33 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 120.865 -1.147 . . . . 2.04 109.9 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.4 mt . . . . . 0 N--CA 1.494 1.774 0 O-C-N 121.349 -0.845 . . . . 1.8700000000000001 109.178 179.715 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.899 0 N-CA-C 109.447 -1.461 . . . . 2.4399999999999999 109.447 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.534 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -69.58 -5.93 52.67 Favored Glycine 0 N--CA 1.487 2.083 0 N-CA-C 110.054 -1.219 . . . . 2.0499999999999998 110.054 -179.664 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -48.3 -13.39 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.675 0 O-C-N 120.663 -1.492 . . . . 2.54 109.228 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' HIS . . . . . 0.534 ' N ' ' O ' ' A' ' 17' ' ' GLY . 1.6 t60 -95.48 -45.17 7.2 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.384 -0.823 . . . . 3.3700000000000001 109.181 179.38 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.52 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.0 OUTLIER -79.83 -26.08 40.59 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.112 -0.993 . . . . 2.3700000000000001 109.332 179.894 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 69.2 t -62.98 112.66 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.115 -0.991 . . . . 2.5800000000000001 109.051 179.497 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 12.9 tpp180 -100.93 137.52 39.19 Favored 'General case' 0 C--N 1.301 -1.535 0 CA-C-O 121.475 0.655 . . . . 3.8900000000000001 109.263 -179.72 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -148.37 113.28 5.45 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.604 -0.887 . . . . 2.0099999999999998 108.604 179.415 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -150.76 133.23 4.21 Favored Glycine 0 N--CA 1.496 2.68 0 N-CA-C 109.74 -1.344 . . . . 2.0099999999999998 109.74 -179.616 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.46 175.36 47.37 Favored Glycine 0 N--CA 1.487 2.067 0 C-N-CA 119.628 -1.272 . . . . 1.9299999999999999 110.268 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 18.0 m -77.44 -17.95 57.62 Favored 'General case' 0 N--CA 1.486 1.363 0 O-C-N 121.457 -1.025 . . . . 2.6899999999999999 109.77 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -68.34 -22.75 74.87 Favored Glycine 0 N--CA 1.487 2.036 0 N-CA-C 108.761 -1.736 . . . . 1.6399999999999999 108.761 179.757 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.5 mt -84.39 -7.15 59.39 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.623 -0.927 . . . . 2.0299999999999998 108.963 179.853 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 27.0 mm-40 -88.45 -56.69 3.21 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.47 -0.769 . . . . 2.3399999999999999 109.993 -179.341 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 26.1 ptt180 -175.05 -176.74 0.99 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.126 -0.984 . . . . 4.25 109.666 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -149.27 177.47 27.45 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 108.917 -1.673 . . . . 1.5900000000000001 108.917 179.857 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.432 ' H ' HG12 ' A' ' 35' ' ' VAL . 25.8 t -134.91 148.03 29.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.425 -1.044 . . . . 2.21 109.803 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -37.84 106.65 0.05 Allowed 'General case' 0 N--CA 1.496 1.866 0 CA-C-O 121.341 0.591 . . . . 2.0699999999999998 112.085 -179.142 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 62.49 57.51 16.23 Favored Glycine 0 N--CA 1.49 2.268 0 O-C-N 121.249 -0.907 . . . . 1.73 111.541 177.558 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.448 ' O ' ' CG1' ' A' ' 35' ' ' VAL . 2.8 p -126.09 129.2 24.31 Favored Pre-proline 0 N--CA 1.502 2.167 0 O-C-N 121.311 -1.111 . . . . 2.6499999999999999 109.133 178.84 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -63.5 125.64 16.0 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 N-CA-C 108.24 -1.485 . . . . 2.1400000000000001 108.24 178.473 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -134.47 160.91 36.55 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.212 -0.93 . . . . 2.0299999999999998 109.294 -179.367 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -162.36 167.22 24.08 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 121.161 -0.962 . . . . 2.23 110.758 -179.634 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . 0.527 ' N ' ' CD1' ' A' ' 39' ' ' PHE . 0.7 OUTLIER -141.61 -179.98 6.48 Favored 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 107.059 -1.46 . . . . 1.72 107.059 177.627 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 6.1 m -124.12 138.05 54.48 Favored 'General case' 0 N--CA 1.498 1.941 0 CA-C-O 121.405 0.622 . . . . 2.5800000000000001 110.178 -178.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.527 ' O ' ' N ' ' A' ' 73' ' ' CYS . 74.3 mt -136.7 119.38 20.99 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.556 -0.715 . . . . 1.8600000000000001 109.269 179.645 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 6.2 p-90 -119.52 137.35 53.87 Favored 'General case' 0 N--CA 1.503 2.2 0 N-CA-C 108.905 -0.776 . . . . 4.4699999999999998 108.905 179.201 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' THR . . . . . 0.52 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.1 OUTLIER -148.83 137.77 21.46 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.199 -0.938 . . . . 3.27 109.694 -179.581 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' ARG . . . . . . . . . . . . . 59.7 ttt180 -171.87 66.3 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.344 -0.848 . . . . 5.2300000000000004 109.743 179.665 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 6.4 tp10 -157.84 -53.81 0.07 Allowed 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.078 -1.014 . . . . 2.8900000000000001 109.43 179.553 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -58.46 -58.75 7.16 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.2 -0.937 . . . . 1.99 109.148 179.769 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 138.62 176.49 14.62 Favored Glycine 0 N--CA 1.494 2.502 0 N-CA-C 108.928 -1.669 . . . . 1.6499999999999999 108.928 -179.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.39 163.51 0.6 Allowed 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.088 -1.243 . . . . 1.77 109.386 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 179.8 -148.78 8.2 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.868 -1.293 . . . . 1.1200000000000001 109.868 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.479 ' O ' ' N ' ' A' ' 92' ' ' ASN . . . -144.13 126.98 2.85 Favored Glycine 0 N--CA 1.495 2.606 0 N-CA-C 109.618 -1.393 . . . . 1.1799999999999999 109.618 -179.838 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 10.8 tp -102.93 102.15 12.21 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.399 -1.059 . . . . 1.5900000000000001 109.027 179.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 3.2 t -85.97 142.11 29.03 Favored 'General case' 0 N--CA 1.494 1.767 0 N-CA-C 108.221 -1.029 . . . . 1.9399999999999999 108.221 179.295 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.531 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 89.5 mt -133.54 120.14 36.85 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.987 0 O-C-N 121.087 -1.008 . . . . 1.3 109.896 -179.709 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -109.44 106.86 16.8 Favored 'General case' 0 N--CA 1.496 1.874 0 N-CA-C 108.772 -0.825 . . . . 1.27 108.772 179.376 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -97.84 143.19 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 O-C-N 121.245 -0.91 . . . . 1.55 109.25 -179.844 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 12.5 tt0 -141.61 142.87 33.44 Favored 'General case' 0 N--CA 1.491 1.624 0 N-CA-C 107.882 -1.155 . . . . 1.8 107.882 179.336 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 166.04 -172.88 41.54 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.502 -1.439 . . . . 0.56000000000000005 109.502 -179.239 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -64.21 -30.18 64.54 Favored 'Trans proline' 0 C--N 1.318 -1.056 0 C-N-CA 121.993 1.795 . . . . 0.76000000000000001 111.412 -179.218 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' SER . . . . . 0.516 ' H ' ' HH ' ' A' ' 85' ' ' TYR . 6.0 m -141.4 152.26 44.16 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.075 -1.016 . . . . 2.02 109.827 -179.801 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 16.1 ptmt -74.56 107.68 6.84 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.261 -0.899 . . . . 3.02 109.024 179.829 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -72.67 136.43 45.63 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.014 -1.054 . . . . 1.3600000000000001 109.401 -179.602 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -71.92 173.35 8.45 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.099 -1.0 . . . . 2.2999999999999998 109.236 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . 0.405 HG21 HD13 ' A' ' 63' ' ' ILE . 42.9 mt -142.52 152.52 17.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 N-CA-C 107.799 -1.185 . . . . 2.0 107.799 -179.847 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.55 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -150.13 114.64 5.23 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 120.653 -1.279 . . . . 1.73 110.202 -179.45 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 45.1 p90 -86.76 129.07 35.02 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.248 -0.907 . . . . 1.6000000000000001 109.157 179.393 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 54.0 tt0 . . . . . 0 N--CA 1.496 1.863 0 O-C-N 121.238 -0.914 . . . . 2.5099999999999998 109.602 -179.756 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 94.0 p . . . . . 0 N--CA 1.495 1.812 0 N-CA-C 109.466 -0.568 . . . . 2.5600000000000001 109.466 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' CYS . . . . . 0.527 ' N ' ' O ' ' A' ' 41' ' ' ILE . 32.3 m -85.31 117.27 24.14 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.232 -0.917 . . . . 2.3599999999999999 109.633 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -99.95 119.8 6.64 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 109.294 -1.522 . . . . 1.46 109.294 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 17.9 t -109.74 103.09 14.94 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.153 0 O-C-N 121.524 -0.986 . . . . 2.1600000000000001 109.818 -179.756 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.55 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.0 OUTLIER -91.76 142.94 27.04 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.326 -0.859 . . . . 2.1600000000000001 108.851 179.687 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 0.411 ' CD1' ' N ' ' A' ' 77' ' ' TYR . 11.6 p90 -142.82 171.92 13.4 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.281 -0.887 . . . . 1.7 109.189 -179.421 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.464 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 4.4 p -142.2 119.98 7.92 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.211 0 O-C-N 121.105 -0.997 . . . . 2.4500000000000002 110.288 179.529 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.5 m -87.15 153.97 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.309 -0.87 . . . . 1.8200000000000001 108.677 179.251 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . 0.432 ' OE1' ' OG ' ' A' ' 59' ' ' SER . 38.3 tt0 -96.6 -47.0 6.1 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.008 -1.057 . . . . 3.1699999999999999 110.657 -179.156 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 80.2 mm-40 -152.16 150.48 25.66 Favored Pre-proline 0 N--CA 1.502 2.129 0 O-C-N 120.646 -1.284 . . . . 2.02 111.056 -178.625 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.526 ' HG3' ' N ' ' A' ' 107' ' ' SER . 75.7 Cg_exo -37.68 164.72 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.67 0 C-N-CA 122.8 2.333 . . . . 1.3999999999999999 113.099 178.398 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 144.24 -163.88 27.71 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.122 -1.591 . . . . 1.0800000000000001 109.122 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 20.0 m-20 -108.97 91.13 3.52 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.639 -0.918 . . . . 2.1299999999999999 108.797 179.652 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . 0.516 ' HH ' ' H ' ' A' ' 59' ' ' SER . 3.1 m-85 -78.81 130.69 36.0 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 108.091 -1.077 . . . . 1.1399999999999999 108.091 179.896 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . 0.409 ' OE2' ' NH2' ' B' ' 8' ' ' ARG . 0.0 OUTLIER -115.62 129.23 56.43 Favored 'General case' 0 N--CA 1.501 2.1 0 N-CA-C 108.89 -0.781 . . . . 1.53 108.89 -179.041 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 9.9 p -124.12 140.19 48.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.712 -0.617 . . . . 1.6399999999999999 109.361 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' SER . . . . . 0.423 ' O ' ' OG ' ' A' ' 88' ' ' SER . 22.2 p -131.98 101.9 5.61 Favored 'General case' 0 N--CA 1.498 1.944 0 N-CA-C 109.184 -0.673 . . . . 1.99 109.184 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.5 pt -111.84 136.11 49.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 CA-C-O 121.599 0.714 . . . . 1.77 110.479 -179.084 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' LYS . . . . . 0.459 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.2 OUTLIER -140.95 122.77 15.35 Favored 'General case' 0 N--CA 1.486 1.329 0 N-CA-C 108.001 -1.111 . . . . 2.0600000000000001 108.001 179.449 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.413 ' O ' ' OE1' ' A' ' 94' ' ' GLU . 84.7 t80 -82.15 100.29 9.73 Favored 'General case' 0 C--N 1.3 -1.569 0 C-N-CA 118.347 -1.341 . . . . 1.45 107.927 179.041 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . 0.479 ' N ' ' O ' ' A' ' 50' ' ' GLY . 0.3 OUTLIER 71.42 36.48 1.31 Allowed 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.25 -0.906 . . . . 2.7200000000000002 109.158 -178.665 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . 0.438 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 1.8 m-20 79.6 12.9 1.11 Allowed 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.703 -0.623 . . . . 1.9199999999999999 111.903 179.232 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . 0.483 ' OE2' ' CA ' ' A' ' 17' ' ' GLY . 5.2 pt-20 -99.98 96.59 7.64 Favored 'General case' 0 N--CA 1.498 1.97 0 N-CA-C 106.958 -1.497 . . . . 2.5499999999999998 106.958 177.617 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' HIS . . . . . 0.513 ' ND1' ' O ' ' A' ' 95' ' ' HIS . 0.0 OUTLIER -70.44 111.37 5.94 Favored 'General case' 0 N--CA 1.488 1.452 0 CA-C-O 121.595 0.712 . . . . 3.2000000000000002 110.884 -177.577 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' ILE . . . . . 0.479 ' O ' ' N ' ' A' ' 98' ' ' ASP . 32.4 mt -57.66 137.39 82.54 Favored Pre-proline 0 C--N 1.3 -1.557 0 N-CA-C 107.826 -1.176 . . . . 2.8199999999999998 107.826 178.651 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_exo -42.91 -21.75 0.23 Allowed 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 120.823 1.015 . . . . 2.6299999999999999 110.184 -179.694 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.479 ' N ' ' O ' ' A' ' 96' ' ' ILE . 87.2 m-20 -67.58 -68.08 0.41 Allowed 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 108.478 -0.934 . . . . 2.6499999999999999 108.478 178.266 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' SER . . . . . 0.49 ' H ' ' HG ' ' A' ' 99' ' ' SER . 0.3 OUTLIER -60.65 143.65 90.3 Favored Pre-proline 0 C--N 1.295 -1.762 0 O-C-N 121.595 -0.69 . . . . 2.3199999999999998 109.901 -178.389 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -84.41 112.62 2.6 Favored 'Cis proline' 0 N--CA 1.491 1.337 0 N-CA-C 109.456 -1.017 . . . . 1.9399999999999999 109.456 -2.318 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 53.6 p90 -112.11 161.96 15.95 Favored 'General case' 0 N--CA 1.517 2.887 0 O-C-N 120.543 -1.348 . . . . 2.6299999999999999 110.196 179.107 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.2 p -93.66 154.42 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.528 -0.732 . . . . 1.8200000000000001 110.928 -178.421 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.473 ' N ' ' O ' ' A' ' 85' ' ' TYR . 64.4 t -128.65 86.96 56.23 Favored Pre-proline 0 N--CA 1.498 1.934 0 N-CA-C 108.233 -1.025 . . . . 1.73 108.233 179.41 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 4.1 Cg_exo -63.54 113.12 1.97 Allowed 'Trans proline' 0 C--N 1.319 -1.008 0 C-N-CA 121.333 1.355 . . . . 1.6100000000000001 111.963 -178.081 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 53.4 t -96.17 143.76 11.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 N-CA-C 106.713 -1.588 . . . . 1.7 106.713 177.862 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -136.65 133.63 36.43 Favored 'General case' 0 N--CA 1.51 2.539 0 O-C-N 121.14 -0.975 . . . . 2.04 111.863 -177.3 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' SER . . . . . 0.526 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 38.7 p -85.27 63.73 8.26 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.796 -1.19 . . . . 2.2999999999999998 107.819 179.12 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' LEU . . . . . 0.485 ' CB ' ' O ' ' A' ' 107' ' ' SER . 2.8 tp 79.9 -14.89 0.8 Allowed 'General case' 0 C--N 1.298 -1.648 0 N-CA-C 106.927 -1.509 . . . . 3.6000000000000001 106.927 -177.991 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.497 ' H ' ' C ' ' A' ' 107' ' ' SER . 21.7 t -66.89 -23.46 66.0 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 108.762 -0.829 . . . . 2.4900000000000002 108.762 178.769 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 42.9 m-20 . . . . . 0 N--CA 1.493 1.685 0 N-CA-C 108.079 -1.082 . . . . 2.8500000000000001 108.079 -179.46 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . 0.409 ' NH2' ' OE2' ' A' ' 86' ' ' GLU . 18.2 mtm-85 . . . . . 0 N--CA 1.491 1.594 0 N-CA-C 108.129 -1.063 . . . . 3.6699999999999999 108.129 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 9' ' ' VAL . . . . . . . . . . . . . 20.4 t -52.96 159.54 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 120.916 -1.115 . . . . 1.3899999999999999 108.21 179.617 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -120.64 149.11 42.99 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.404 -0.81 . . . . 1.22 110.422 -178.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 7.4 t -143.2 142.69 31.5 Favored 'General case' 0 N--CA 1.495 1.785 0 N-CA-C 108.814 -0.81 . . . . 1.6299999999999999 108.814 179.365 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 23.6 p -145.38 127.92 16.05 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.987 -1.07 . . . . 1.8799999999999999 110.121 -179.639 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . 0.466 ' CG2' ' N ' ' B' ' 14' ' ' PHE . 7.2 p -172.44 171.46 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 N-CA-C 108.826 -0.805 . . . . 1.2 108.826 179.69 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 14' ' ' PHE . . . . . 0.531 ' HB3' ' H ' ' A' ' 53' ' ' ILE . 6.8 p90 -177.48 -167.95 0.17 Allowed 'General case' 0 N--CA 1.489 1.522 0 CA-C-O 122.234 1.016 . . . . 2.3900000000000001 112.282 179.793 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.8 pt -148.95 172.64 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.29 0 N-CA-C 107.897 -1.149 . . . . 1.8100000000000001 107.897 179.709 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 2.4 t -146.6 148.44 32.12 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 120.756 -1.215 . . . . 2.04 110.195 -179.842 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.2 mt . . . . . 0 N--CA 1.495 1.823 0 O-C-N 121.51 -0.744 . . . . 1.8700000000000001 109.146 179.785 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.217 0 N-CA-C 111.605 -0.598 . . . . 2.4399999999999999 111.605 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.523 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 74.05 -56.06 2.27 Favored Glycine 0 N--CA 1.493 2.451 0 N-CA-C 110.487 -1.045 . . . . 2.0499999999999998 110.487 178.614 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.484 ' CB ' ' OE1' ' A' ' 94' ' ' GLU . . . -49.82 -9.22 0.04 OUTLIER 'General case' 0 C--N 1.294 -1.828 0 O-C-N 121.243 -1.151 . . . . 2.54 109.6 -179.624 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' HIS . . . . . 0.523 ' N ' ' O ' ' A' ' 17' ' ' GLY . 15.2 t-80 -94.91 -8.9 35.79 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.085 -1.009 . . . . 3.3700000000000001 110.475 -179.456 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.544 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.0 OUTLIER -134.24 1.79 3.24 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.078 -1.014 . . . . 2.3700000000000001 110.2 -179.685 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 68.7 t -88.07 113.43 25.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 120.92 -1.113 . . . . 2.5800000000000001 109.637 179.767 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 6.2 tpt180 -97.8 132.9 42.99 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.577 -0.702 . . . . 3.8900000000000001 109.126 179.808 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -139.28 113.92 9.18 Favored 'General case' 0 N--CA 1.494 1.751 0 N-CA-C 108.582 -0.896 . . . . 2.0099999999999998 108.582 179.771 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -156.64 129.22 2.37 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.849 -1.3 . . . . 2.0099999999999998 109.849 -179.448 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.94 -179.82 48.73 Favored Glycine 0 N--CA 1.488 2.127 0 C-N-CA 119.512 -1.328 . . . . 1.9299999999999999 110.052 179.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 10.9 p -80.61 -15.96 55.29 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.397 -1.061 . . . . 2.6899999999999999 109.451 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -76.89 -8.42 86.64 Favored Glycine 0 N--CA 1.487 2.074 0 N-CA-C 109.532 -1.427 . . . . 1.6399999999999999 109.532 -179.733 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 28.5 mt -100.26 -0.67 38.12 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.373 -1.075 . . . . 2.0299999999999998 109.076 179.692 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -102.18 -44.56 5.4 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.519 -0.738 . . . . 2.3399999999999999 109.565 -179.681 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 18.1 ptt180 -176.81 172.58 2.05 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.006 -1.059 . . . . 4.25 110.119 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -143.45 174.72 23.84 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 107.842 -2.103 . . . . 1.5900000000000001 107.842 179.272 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 35.2 t -134.05 149.79 30.7 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.092 0 O-C-N 121.1 -1.235 . . . . 2.21 110.375 -179.842 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -41.47 114.17 0.48 Allowed 'General case' 0 N--CA 1.498 1.933 0 CA-C-O 121.804 0.812 . . . . 2.0699999999999998 112.593 -179.128 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 57.18 47.3 88.74 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 111.552 -0.619 . . . . 1.73 111.552 176.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 25.5 t -127.23 113.53 21.54 Favored Pre-proline 0 N--CA 1.498 1.966 0 O-C-N 121.458 -1.024 . . . . 2.6499999999999999 108.756 179.116 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -59.93 126.51 20.57 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 N-CA-C 109.944 -0.829 . . . . 2.1400000000000001 109.944 -179.756 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -127.58 174.56 8.96 Favored 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 108.182 -1.044 . . . . 2.0299999999999998 108.182 179.597 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -163.09 171.28 16.63 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.838 -1.164 . . . . 2.23 110.961 -179.789 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . 0.41 ' N ' ' CD1' ' A' ' 39' ' ' PHE . 5.8 p90 -155.9 167.75 29.4 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 107.707 -1.22 . . . . 1.72 107.707 178.568 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 14.6 m -101.67 150.14 23.42 Favored 'General case' 0 N--CA 1.495 1.821 0 CA-C-O 121.803 0.811 . . . . 2.5800000000000001 111.147 -178.1 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 11.8 mt -141.12 88.55 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 N-CA-C 108.436 -0.95 . . . . 1.8600000000000001 108.436 178.774 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.422 ' HE1' ' CG ' ' A' ' 44' ' ' ARG . 5.6 t90 -90.77 132.99 35.52 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.105 -0.997 . . . . 4.4699999999999998 108.788 -179.804 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' THR . . . . . 0.544 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.8 OUTLIER -160.94 128.53 4.28 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.22 -0.925 . . . . 3.27 109.949 -179.436 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' ARG . . . . . 0.422 ' CG ' ' HE1' ' A' ' 42' ' ' TRP . 1.8 ptp180 -178.39 77.27 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.278 -0.889 . . . . 5.2300000000000004 109.612 179.6 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 26.0 tt0 -158.6 -52.32 0.06 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.187 -0.946 . . . . 2.8900000000000001 109.498 179.796 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -60.79 -49.99 75.24 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.04 -1.038 . . . . 1.99 109.008 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 148.85 160.92 9.36 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.448 -1.461 . . . . 1.6499999999999999 109.448 179.807 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.79 161.23 1.18 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.196 -1.179 . . . . 1.77 109.386 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -174.42 -128.88 1.12 Allowed Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.827 -1.309 . . . . 1.1200000000000001 109.827 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -157.69 126.22 1.69 Allowed Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.58 -1.408 . . . . 1.1799999999999999 109.58 -179.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 11.7 tp -97.97 100.53 11.87 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.294 -1.121 . . . . 1.5900000000000001 109.078 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 2.0 t -88.36 142.72 27.5 Favored 'General case' 0 C--O 1.211 -0.947 0 N-CA-C 108.667 -0.864 . . . . 1.9399999999999999 108.667 179.89 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.506 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 93.5 mt -134.08 106.97 9.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 O-C-N 121.025 -1.047 . . . . 1.3 109.764 -179.568 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -96.34 106.06 18.23 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.315 -0.995 . . . . 1.27 108.315 179.183 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -94.52 144.57 9.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.421 -0.799 . . . . 1.55 109.676 -179.445 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 16.6 tt0 -141.1 145.16 35.44 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 107.529 -1.286 . . . . 1.8 107.529 178.738 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.428 ' O ' ' O ' ' B' ' 9' ' ' VAL . . . 163.14 -171.08 38.81 Favored Glycine 0 N--CA 1.489 2.196 0 C-N-CA 119.554 -1.308 . . . . 0.56000000000000005 109.854 -179.065 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -62.68 -29.85 77.96 Favored 'Trans proline' 0 C--N 1.318 -1.063 0 C-N-CA 122.224 1.949 . . . . 0.76000000000000001 112.386 -179.289 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 8.7 t -142.36 160.0 41.12 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 120.891 -1.131 . . . . 2.02 110.138 -179.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 80.5 mttt -78.33 109.53 12.55 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.498 -0.751 . . . . 3.02 109.204 179.796 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -76.46 142.37 41.01 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.258 -0.902 . . . . 1.3600000000000001 109.588 -179.829 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.402 ' H ' HG12 ' A' ' 78' ' ' VAL . 20.6 tt0 -81.39 172.62 13.33 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.319 -0.863 . . . . 2.2999999999999998 108.78 179.778 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 3.2 mp -140.17 154.4 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 N-CA-C 108.309 -0.997 . . . . 2.0 108.309 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.55 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -151.07 114.88 4.95 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.758 -1.214 . . . . 1.73 109.538 -179.845 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . 0.528 ' CD2' ' O ' ' A' ' 65' ' ' PHE . 44.0 p90 -93.55 120.21 33.55 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.19 -0.944 . . . . 1.6000000000000001 109.469 179.724 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 54.2 tt0 . . . . . 0 N--CA 1.497 1.91 0 O-C-N 121.234 -0.916 . . . . 2.5099999999999998 109.611 -179.883 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.8 m . . . . . 0 N--CA 1.495 1.781 0 N-CA-C 108.85 -0.796 . . . . 2.5600000000000001 108.85 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 15.1 t -88.02 126.63 35.18 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.151 -0.968 . . . . 2.3599999999999999 109.773 -179.521 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -105.13 118.34 5.84 Favored Glycine 0 N--CA 1.498 2.831 0 N-CA-C 109.576 -1.41 . . . . 1.46 109.576 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 21.9 t -105.88 106.08 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.141 0 O-C-N 121.476 -1.014 . . . . 2.1600000000000001 109.423 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.55 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.3 OUTLIER -96.17 139.21 32.66 Favored 'General case' 0 N--CA 1.493 1.676 0 N-CA-C 108.988 -0.745 . . . . 2.1600000000000001 108.988 179.828 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 41.9 p90 -138.07 173.3 11.77 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.294 -0.879 . . . . 1.7 109.262 -179.636 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.437 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 8.9 p -138.69 120.01 16.53 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.246 0 O-C-N 121.372 -0.83 . . . . 2.4500000000000002 109.969 179.56 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 5.7 m -89.57 163.08 2.43 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.387 -0.82 . . . . 1.8200000000000001 108.984 179.72 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 7.0 tp-100 -104.4 -47.6 4.06 Favored 'General case' 0 N--CA 1.501 2.077 0 O-C-N 121.199 -0.938 . . . . 3.1699999999999999 111.103 -178.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -156.52 153.27 24.49 Favored Pre-proline 0 N--CA 1.503 2.194 0 O-C-N 120.641 -1.287 . . . . 2.02 111.106 -178.799 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.588 ' HG3' ' N ' ' A' ' 107' ' ' SER . 73.0 Cg_exo -37.63 158.68 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 123.267 2.644 . . . . 1.3999999999999999 113.609 179.268 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 148.15 -163.45 28.9 Favored Glycine 0 N--CA 1.493 2.441 0 N-CA-C 109.662 -1.375 . . . . 1.0800000000000001 109.662 179.606 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 46.6 m-20 -110.66 88.63 2.82 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.615 -0.932 . . . . 2.1299999999999999 108.984 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . 0.508 ' O ' ' N ' ' A' ' 103' ' ' VAL . 2.8 m-85 -76.16 129.69 37.14 Favored 'General case' 0 C--N 1.303 -1.414 0 N-CA-C 107.998 -1.112 . . . . 1.1399999999999999 107.998 179.708 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -109.23 128.01 54.71 Favored 'General case' 0 N--CA 1.5 2.069 0 N-CA-C 108.35 -0.981 . . . . 1.53 108.35 -179.52 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 9.9 p -123.91 133.56 68.93 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.713 -0.617 . . . . 1.6399999999999999 109.767 -179.295 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 6.6 m -123.84 95.05 4.42 Favored 'General case' 0 N--CA 1.497 1.886 0 CA-C-O 121.393 0.616 . . . . 1.99 109.54 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.2 pt -101.26 134.48 41.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.643 -0.661 . . . . 1.77 109.797 -179.775 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' LYS . . . . . 0.468 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.1 OUTLIER -140.32 121.98 15.28 Favored 'General case' 0 N--CA 1.485 1.296 0 N-CA-C 108.712 -0.847 . . . . 2.0600000000000001 108.712 179.746 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 79.9 t80 -81.09 100.03 8.81 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 107.665 -1.235 . . . . 1.45 107.665 178.514 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . 0.438 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 26.8 t30 69.81 36.42 2.07 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.448 -0.782 . . . . 2.7200000000000002 109.362 -178.809 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . 0.438 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 0.7 OUTLIER 79.92 14.32 0.92 Allowed 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.688 -0.633 . . . . 1.9199999999999999 111.554 179.42 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . 0.484 ' OE1' ' CB ' ' A' ' 18' ' ' ALA . 0.5 OUTLIER -100.94 95.53 6.66 Favored 'General case' 0 N--CA 1.499 1.98 0 N-CA-C 107.239 -1.393 . . . . 2.5499999999999998 107.239 177.892 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' HIS . . . . . 0.53 ' O ' ' CD2' ' A' ' 95' ' ' HIS . 0.4 OUTLIER -66.58 110.55 3.22 Favored 'General case' 0 N--CA 1.488 1.466 0 CA-C-O 121.697 0.76 . . . . 3.2000000000000002 111.177 -177.773 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' ILE . . . . . 0.536 ' O ' ' N ' ' A' ' 98' ' ' ASP . 5.5 mm -50.61 137.22 24.34 Favored Pre-proline 0 N--CA 1.492 1.671 0 N-CA-C 107.621 -1.251 . . . . 2.8199999999999998 107.621 178.576 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -44.39 -16.75 0.12 Allowed 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 120.68 0.92 . . . . 2.6299999999999999 109.844 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 96' ' ' ILE . 42.9 m-20 -76.92 -66.56 0.8 Allowed 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 108.517 -0.92 . . . . 2.6499999999999999 108.517 178.277 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -57.34 144.02 72.09 Favored Pre-proline 0 C--N 1.297 -1.702 0 O-C-N 121.622 -0.674 . . . . 2.3199999999999998 109.801 -178.106 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -83.82 110.36 1.79 Allowed 'Cis proline' 0 N--CA 1.491 1.339 0 N-CA-C 109.71 -0.919 . . . . 1.9399999999999999 109.71 -2.129 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 47.3 p90 -108.87 166.98 10.41 Favored 'General case' 0 N--CA 1.515 2.794 0 O-C-N 120.51 -1.369 . . . . 2.6299999999999999 110.035 179.109 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.3 p -94.39 153.13 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.518 -0.739 . . . . 1.8200000000000001 110.758 -178.777 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.508 ' N ' ' O ' ' A' ' 85' ' ' TYR . 70.3 t -127.62 86.21 58.96 Favored Pre-proline 0 N--CA 1.499 1.986 0 N-CA-C 107.863 -1.162 . . . . 1.73 107.863 179.395 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -62.4 113.45 1.93 Allowed 'Trans proline' 0 C--N 1.318 -1.036 0 C-N-CA 121.288 1.325 . . . . 1.6100000000000001 111.979 -177.82 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 42.7 t -90.4 141.68 14.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 N-CA-C 106.88 -1.526 . . . . 1.7 106.88 177.766 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.405 ' CB ' ' N ' ' A' ' 110' ' ' ASP . . . -121.65 127.67 51.06 Favored 'General case' 0 N--CA 1.505 2.322 0 CA-C-O 121.664 0.745 . . . . 2.04 111.607 -177.033 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' SER . . . . . 0.588 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 7.8 t -88.69 77.76 7.84 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 120.365 -1.459 . . . . 2.2999999999999998 107.484 178.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' LEU . . . . . 0.442 ' CB ' ' O ' ' A' ' 107' ' ' SER . 0.9 OUTLIER 72.66 -7.81 1.35 Allowed 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 107.307 -1.368 . . . . 3.6000000000000001 107.307 -178.288 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.547 ' H ' ' C ' ' A' ' 107' ' ' SER . 3.0 m -78.11 -21.59 50.18 Favored 'General case' 0 N--CA 1.486 1.335 0 N-CA-C 108.602 -0.888 . . . . 2.4900000000000002 108.602 178.993 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . 0.405 ' N ' ' CB ' ' A' ' 106' ' ' ALA . 1.4 m-20 . . . . . 0 N--CA 1.491 1.586 0 O-C-N 121.359 -0.838 . . . . 2.8500000000000001 109.23 179.353 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . 0.516 HH11 ' CG ' ' B' ' 8' ' ' ARG . 2.2 mtt-85 . . . . . 0 N--CA 1.489 1.487 0 N-CA-C 108.003 -1.11 . . . . 3.6699999999999999 108.003 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 9' ' ' VAL . . . . . 0.428 ' O ' ' O ' ' A' ' 57' ' ' GLY . 22.9 t -48.3 159.3 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.021 -1.049 . . . . 1.3899999999999999 108.671 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -123.89 153.74 40.69 Favored 'General case' 0 N--CA 1.501 2.111 0 O-C-N 121.369 -0.832 . . . . 1.22 110.257 -178.89 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 2.7 t -148.66 147.12 28.56 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.498 -0.751 . . . . 1.6299999999999999 109.235 179.773 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 28.5 p -145.89 126.77 14.47 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.164 -0.96 . . . . 1.8799999999999999 110.064 -179.628 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . 0.489 ' C ' ' CG ' ' B' ' 14' ' ' PHE . 7.2 p -172.18 174.8 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 N-CA-C 108.497 -0.927 . . . . 1.2 108.497 179.731 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 14' ' ' PHE . . . . . 0.506 ' HB3' ' H ' ' A' ' 53' ' ' ILE . 0.1 OUTLIER 174.41 -166.23 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.563 0 C-N-CA 118.779 -1.168 . . . . 2.3900000000000001 111.864 -179.979 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 5.8 pt -137.58 139.49 43.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 N-CA-C 108.981 -0.748 . . . . 1.8100000000000001 108.981 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 80.7 p -94.26 131.19 40.12 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.101 -0.999 . . . . 2.04 109.785 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . 0.516 ' CD2' ' N ' ' B' ' 17' ' ' LEU . 3.5 mm? . . . . . 0 N--CA 1.494 1.756 0 O-C-N 121.294 -0.879 . . . . 1.8700000000000001 108.891 179.615 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.047 0 N-CA-C 110.082 -1.207 . . . . 2.4399999999999999 110.082 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.567 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 91.88 -53.38 2.95 Favored Glycine 0 N--CA 1.494 2.542 0 N-CA-C 110.213 -1.155 . . . . 2.0499999999999998 110.213 179.444 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.45 ' N ' ' HG2' ' A' ' 94' ' ' GLU . . . -41.49 -18.22 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.84 -0.8 . . . . 2.54 110.463 -178.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' HIS . . . . . 0.567 ' N ' ' O ' ' A' ' 17' ' ' GLY . 11.0 t60 -85.39 -40.69 16.19 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.281 -0.887 . . . . 3.3700000000000001 109.99 -179.456 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.78 -29.04 12.85 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.099 -1.001 . . . . 2.3700000000000001 110.584 -179.173 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 84.0 t -51.58 112.1 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.004 -1.06 . . . . 2.5800000000000001 109.869 -179.608 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 3.9 tpt180 -119.15 136.43 54.18 Favored 'General case' 0 N--CA 1.495 1.792 0 N-CA-C 109.284 -0.635 . . . . 3.8900000000000001 109.284 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -144.58 113.87 7.01 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.461 -0.775 . . . . 2.0099999999999998 108.933 179.677 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -149.25 123.83 1.69 Allowed Glycine 0 N--CA 1.495 2.586 0 N-CA-C 110.137 -1.185 . . . . 2.0099999999999998 110.137 -179.424 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.81 177.77 48.27 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.904 -1.279 . . . . 1.9299999999999999 109.904 179.567 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 11.0 m -76.81 -12.62 60.0 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.291 -1.123 . . . . 2.6899999999999999 109.958 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -67.68 -16.68 68.16 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 108.417 -1.873 . . . . 1.6399999999999999 108.417 179.599 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 18.1 mt -92.92 -10.31 36.96 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.783 -0.833 . . . . 2.0299999999999998 109.022 179.722 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 47.3 mm-40 -83.61 -55.23 4.4 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.491 -0.755 . . . . 2.3399999999999999 110.056 -179.264 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 4.9 ptp180 -176.36 -177.59 0.87 Allowed 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.036 -1.04 . . . . 4.25 109.879 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -145.13 174.53 25.14 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 108.649 -1.78 . . . . 1.5900000000000001 108.649 179.664 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 30.3 t -134.39 149.73 30.18 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.947 0 O-C-N 121.285 -1.126 . . . . 2.21 110.159 -179.779 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -40.5 112.19 0.26 Allowed 'General case' 0 N--CA 1.496 1.83 0 CA-C-O 121.499 0.666 . . . . 2.0699999999999998 112.515 -178.887 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 58.82 47.16 91.9 Favored Glycine 0 N--CA 1.492 2.391 0 O-C-N 121.514 -0.741 . . . . 1.73 111.569 177.117 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 23.6 t -127.45 124.84 23.74 Favored Pre-proline 0 N--CA 1.499 1.988 0 O-C-N 121.417 -1.049 . . . . 2.6499999999999999 108.417 179.031 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_exo -58.39 114.77 2.13 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 N-CA-C 109.99 -0.811 . . . . 2.1400000000000001 109.99 -179.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -107.64 155.45 20.14 Favored 'General case' 0 N--CA 1.495 1.789 0 N-CA-C 107.803 -1.184 . . . . 2.0299999999999998 107.803 179.176 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -164.51 169.85 16.63 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 118.431 -1.308 . . . . 2.23 111.41 -179.405 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . 0.45 ' N ' ' CD1' ' A' ' 39' ' ' PHE . 4.6 p90 -154.66 171.03 20.16 Favored 'General case' 0 C--N 1.298 -1.669 0 N-CA-C 107.705 -1.22 . . . . 1.72 107.705 178.008 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 83.6 p -100.59 150.99 22.13 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.575 -0.703 . . . . 2.5800000000000001 110.599 -178.389 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 11.6 mt -143.6 104.71 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 N-CA-C 108.712 -0.847 . . . . 1.8600000000000001 108.712 178.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.526 ' CG ' ' N ' ' A' ' 43' ' ' THR . 0.7 OUTLIER -102.62 166.45 10.5 Favored 'General case' 0 N--CA 1.497 1.911 0 N-CA-C 108.33 -0.989 . . . . 4.4699999999999998 108.33 179.854 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' THR . . . . . 0.526 ' N ' ' CG ' ' A' ' 42' ' ' TRP . 35.0 p -153.6 131.49 11.68 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.146 -0.971 . . . . 3.27 109.827 -179.616 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' ARG . . . . . . . . . . . . . 32.5 ttm180 -72.58 -86.3 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.243 -0.91 . . . . 5.2300000000000004 109.43 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 24.9 tt0 -172.17 63.35 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.809 -1.182 . . . . 2.8900000000000001 110.935 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -71.24 -52.0 21.45 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 120.73 -1.231 . . . . 1.99 108.584 178.823 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 155.39 169.62 20.02 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.487 -1.445 . . . . 1.6499999999999999 109.487 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.8 143.98 19.53 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.215 -1.168 . . . . 1.77 109.371 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -163.72 -168.35 25.6 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.522 -1.431 . . . . 1.1200000000000001 109.522 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -137.68 117.37 1.48 Allowed Glycine 0 N--CA 1.496 2.666 0 N-CA-C 109.261 -1.536 . . . . 1.1799999999999999 109.261 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.423 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 9.7 tp -87.53 99.23 11.88 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.283 -1.128 . . . . 1.5900000000000001 108.597 179.758 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 12.8 m -84.01 141.13 31.42 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 108.834 -0.802 . . . . 1.9399999999999999 108.834 -179.887 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.492 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 72.6 mt -130.37 111.5 21.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.357 -0.839 . . . . 1.3 109.36 -179.891 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -100.85 106.98 18.41 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.374 -0.829 . . . . 1.27 108.938 179.724 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.428 ' O ' ' O ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -103.93 135.44 41.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 121.573 -0.704 . . . . 1.55 109.323 -179.771 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 27.3 tt0 -137.96 140.53 40.28 Favored 'General case' 0 N--CA 1.494 1.736 0 N-CA-C 108.024 -1.102 . . . . 1.8 108.024 179.092 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 168.47 -172.15 42.88 Favored Glycine 0 N--CA 1.487 2.092 0 N-CA-C 109.407 -1.477 . . . . 0.56000000000000005 109.407 -179.271 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -62.87 -30.9 77.8 Favored 'Trans proline' 0 C--N 1.316 -1.16 0 C-N-CA 121.873 1.715 . . . . 0.76000000000000001 111.584 -179.621 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.8 t -137.64 157.24 46.93 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.153 -0.967 . . . . 2.02 110.278 -179.488 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.436 ' O ' ' OE2' ' A' ' 62' ' ' GLU . 31.5 mtpt -80.65 123.37 28.11 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 109.09 -0.707 . . . . 3.02 109.09 179.728 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -85.79 144.29 27.82 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.162 -0.961 . . . . 1.3600000000000001 109.318 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.482 ' CD ' ' N ' ' A' ' 62' ' ' GLU . 9.0 mp0 -96.76 100.52 12.07 Favored 'General case' 0 N--CA 1.502 2.137 0 O-C-N 121.048 -1.032 . . . . 2.2999999999999998 110.619 -179.476 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 1.7 mp -62.51 156.12 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 N-CA-C 108.673 -0.862 . . . . 2.0 108.673 178.721 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.466 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -140.97 175.01 9.97 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.122 -0.987 . . . . 1.73 109.237 179.782 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . 0.513 ' CD2' ' O ' ' A' ' 65' ' ' PHE . 32.3 p90 -147.08 116.25 6.94 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.317 -0.864 . . . . 1.6000000000000001 109.407 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 69.8 tt0 . . . . . 0 N--CA 1.495 1.821 0 O-C-N 121.287 -0.883 . . . . 2.5099999999999998 109.515 -179.977 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 28.9 t . . . . . 0 N--CA 1.494 1.754 0 N-CA-C 108.782 -0.821 . . . . 2.5600000000000001 108.782 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 37.9 t -93.39 126.42 38.52 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.148 -0.97 . . . . 2.3599999999999999 109.644 -179.708 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -102.35 120.48 6.84 Favored Glycine 0 N--CA 1.497 2.755 0 N-CA-C 109.855 -1.298 . . . . 1.46 109.855 -179.795 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 41.3 t -104.59 119.34 53.35 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.959 0 O-C-N 121.464 -1.021 . . . . 2.1600000000000001 108.814 179.603 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.466 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.4 OUTLIER -113.39 124.35 52.23 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.69 -0.631 . . . . 2.1600000000000001 109.387 -179.836 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 51.7 p90 -122.97 131.62 53.79 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 108.358 -0.979 . . . . 1.7 108.358 179.316 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.471 ' CG1' ' OE1' ' A' ' 62' ' ' GLU . 8.9 p -106.63 117.54 52.61 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.243 0 O-C-N 121.293 -0.879 . . . . 2.4500000000000002 109.603 -179.378 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 1.2 m -90.07 161.8 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 O-C-N 121.282 -0.887 . . . . 1.8200000000000001 108.978 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 1.2 tp-100 -97.62 -51.33 4.15 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.122 -0.986 . . . . 3.1699999999999999 110.787 -179.158 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.429 ' O ' ' O ' ' A' ' 82' ' ' PRO . 77.2 mm-40 -145.47 150.31 43.66 Favored Pre-proline 0 N--CA 1.504 2.259 0 O-C-N 120.872 -1.142 . . . . 2.02 111.718 -178.125 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.545 ' HG3' ' N ' ' A' ' 107' ' ' SER . 88.7 Cg_exo -36.73 166.38 0.01 OUTLIER 'Trans proline' 0 C--O 1.216 -0.616 0 C-N-CA 123.142 2.561 . . . . 1.3999999999999999 113.381 178.391 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 142.7 -178.53 21.04 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.183 -1.567 . . . . 1.0800000000000001 109.183 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . 0.713 ' H ' ' NH1' ' B' ' 8' ' ' ARG . 31.7 m-20 -97.22 85.9 3.8 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 107.79 -1.189 . . . . 2.1299999999999999 107.79 179.213 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -70.16 132.54 45.96 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 108.128 -1.064 . . . . 1.1399999999999999 108.128 -179.502 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -105.36 115.67 30.65 Favored 'General case' 0 N--CA 1.496 1.872 0 N-CA-C 108.255 -1.017 . . . . 1.53 108.255 -179.067 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.4 p -115.83 143.03 26.73 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 O-C-N 121.604 -0.685 . . . . 1.6399999999999999 110.12 -179.29 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 2.9 m -138.87 97.06 3.24 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.507 -0.745 . . . . 1.99 109.588 179.661 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.1 pt -104.38 132.84 50.04 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 N-CA-C 109.332 -0.618 . . . . 1.77 109.332 -179.888 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.09 132.76 17.85 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.106 -0.996 . . . . 2.0600000000000001 109.855 -179.481 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 43.5 t80 -83.05 94.62 7.83 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.642 -1.286 . . . . 1.45 108.591 178.721 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . 0.479 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 38.7 t30 67.22 38.13 3.45 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.492 -0.929 . . . . 2.7200000000000002 108.492 -179.088 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . 0.479 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 0.6 OUTLIER 86.45 12.31 0.16 Allowed 'General case' 0 N--CA 1.503 2.181 0 CA-C-N 116.399 -0.364 . . . . 1.9199999999999999 111.467 179.629 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . 0.525 ' CG ' ' O ' ' A' ' 94' ' ' GLU . 0.0 OUTLIER -90.51 90.14 7.88 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 107.191 -1.411 . . . . 2.5499999999999998 107.191 177.984 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' HIS . . . . . 0.421 ' CD2' ' H ' ' A' ' 95' ' ' HIS . 9.7 p80 -72.19 98.13 2.09 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 119.759 -1.838 . . . . 3.2000000000000002 109.848 -179.142 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' ILE . . . . . 0.678 ' CD1' ' H ' ' A' ' 96' ' ' ILE . 0.0 OUTLIER -48.74 158.93 0.59 Allowed Pre-proline 0 N--CA 1.504 2.269 0 N-CA-C 107.31 -1.367 . . . . 2.8199999999999998 107.31 179.218 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -60.42 65.5 0.08 OUTLIER 'Trans proline' 0 N--CA 1.481 0.736 0 C-N-CA 121.504 1.469 . . . . 2.6299999999999999 109.469 -179.87 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.593 ' N ' ' O ' ' A' ' 96' ' ' ILE . 8.8 m-20 -164.9 -57.56 0.03 OUTLIER 'General case' 0 C--N 1.298 -1.634 0 N-CA-C 108.167 -1.049 . . . . 2.6499999999999999 108.167 -179.514 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' SER . . . . . 0.445 ' H ' ' HG ' ' A' ' 99' ' ' SER . 3.3 p -68.8 137.29 90.16 Favored Pre-proline 0 C--N 1.296 -1.755 0 C-N-CA 119.489 -0.884 . . . . 2.3199999999999998 109.754 -179.179 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 27.2 Cg_endo -89.54 119.87 4.28 Favored 'Cis proline' 0 N--CA 1.493 1.462 0 N-CA-C 110.017 -0.801 . . . . 1.9399999999999999 110.017 -2.644 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 30.4 p90 -124.55 166.42 16.09 Favored 'General case' 0 N--CA 1.516 2.844 0 O-C-N 120.571 -1.33 . . . . 2.6299999999999999 109.74 178.153 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.3 p -88.44 146.49 6.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.551 -0.718 . . . . 1.8200000000000001 110.521 -178.532 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 71.4 t -119.63 86.66 35.34 Favored Pre-proline 0 N--CA 1.495 1.803 0 N-CA-C 107.82 -1.178 . . . . 1.73 107.82 179.157 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -61.96 112.92 1.65 Allowed 'Trans proline' 0 C--N 1.322 -0.866 0 C-N-CA 121.423 1.416 . . . . 1.6100000000000001 112.121 -177.724 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 60.3 t -98.93 143.19 13.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 N-CA-C 106.15 -1.796 . . . . 1.7 106.15 177.719 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -136.48 135.15 38.36 Favored 'General case' 0 N--CA 1.51 2.56 0 O-C-N 120.972 -1.08 . . . . 2.04 112.089 -176.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' SER . . . . . 0.545 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 9.2 t -86.39 73.02 10.22 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 107.713 -1.218 . . . . 2.2999999999999998 107.713 179.158 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER 68.11 -1.26 1.83 Allowed 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 107.363 -1.347 . . . . 3.6000000000000001 107.363 -178.505 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.528 ' H ' ' C ' ' A' ' 107' ' ' SER . 22.9 t -83.54 -21.96 32.55 Favored 'General case' 0 N--CA 1.486 1.344 0 N-CA-C 108.864 -0.791 . . . . 2.4900000000000002 108.864 179.249 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . 0.401 ' N ' ' OD1' ' A' ' 110' ' ' ASP . 1.8 m-20 . . . . . 0 N--CA 1.492 1.673 0 N-CA-C 108.135 -1.061 . . . . 2.8500000000000001 108.135 -179.344 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . 0.713 ' NH1' ' H ' ' A' ' 84' ' ' ASP . 5.6 mtt180 . . . . . 0 N--CA 1.493 1.699 0 N-CA-C 109.393 -0.595 . . . . 3.6699999999999999 109.393 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 9' ' ' VAL . . . . . 0.408 ' CG1' ' N ' ' B' ' 10' ' ' ALA . 5.2 t -51.08 160.48 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 N-CA-C 108.226 -1.027 . . . . 1.3899999999999999 108.226 179.375 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . 0.408 ' N ' ' CG1' ' B' ' 9' ' ' VAL . . . -114.59 148.3 38.26 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.47 -0.768 . . . . 1.22 110.053 -179.158 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 11' ' ' SER . . . . . 0.428 ' O ' ' O ' ' A' ' 55' ' ' VAL . 31.3 t -150.02 133.06 16.2 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.517 -0.74 . . . . 1.6299999999999999 109.2 179.634 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 34.1 p -144.55 120.54 10.69 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.117 -0.989 . . . . 1.8799999999999999 109.809 -179.695 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . 0.484 ' CG2' ' N ' ' B' ' 14' ' ' PHE . 4.1 p -164.04 168.4 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.436 -0.79 . . . . 1.2 109.07 179.858 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 14' ' ' PHE . . . . . 0.492 ' HB3' ' H ' ' A' ' 53' ' ' ILE . 10.7 p90 -176.38 -165.58 0.14 Allowed 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 119.172 -1.011 . . . . 2.3900000000000001 112.265 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.7 pt -150.93 168.63 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.291 0 N-CA-C 108.598 -0.89 . . . . 1.8100000000000001 108.598 179.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 3.8 t -145.17 157.41 44.09 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 120.965 -1.084 . . . . 2.04 109.367 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.5 2.062 0 O-C-N 121.397 -0.815 . . . . 1.8700000000000001 109.533 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.099 0 N-CA-C 110.772 -0.931 . . . . 2.4399999999999999 110.772 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.547 ' C ' ' H ' ' A' ' 19' ' ' HIS . . . 78.7 -52.6 3.91 Favored Glycine 0 N--CA 1.492 2.43 0 O-C-N 121.47 -1.018 . . . . 2.0499999999999998 111.089 178.69 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.476 ' N ' ' CD ' ' A' ' 94' ' ' GLU . . . -50.27 -6.68 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.081 -1.247 . . . . 2.54 110.162 -179.29 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' HIS . . . . . 0.547 ' H ' ' C ' ' A' ' 17' ' ' GLY . 29.5 t-80 -98.97 -6.31 28.91 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.092 -1.005 . . . . 3.3700000000000001 110.717 -179.171 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.543 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.0 OUTLIER -137.7 2.38 2.42 Favored 'General case' 0 N--CA 1.502 2.164 0 O-C-N 120.959 -1.088 . . . . 2.3700000000000001 110.258 -179.664 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 71.3 t -87.85 114.22 26.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 120.982 -1.074 . . . . 2.5800000000000001 109.25 179.489 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 13.3 tpp180 -113.61 138.54 50.03 Favored 'General case' 0 N--CA 1.492 1.635 0 N-CA-C 108.83 -0.804 . . . . 3.8900000000000001 108.83 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -147.13 113.57 5.95 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.434 -0.791 . . . . 2.0099999999999998 108.987 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -152.0 130.33 3.07 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.677 -1.369 . . . . 2.0099999999999998 109.677 -179.759 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.98 -178.79 48.47 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.603 -1.399 . . . . 1.9299999999999999 109.603 179.87 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 6.6 p -78.93 -26.59 43.67 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.183 -1.186 . . . . 2.6899999999999999 108.99 179.648 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -66.88 -18.25 68.36 Favored Glycine 0 N--CA 1.486 2.015 0 N-CA-C 108.283 -1.927 . . . . 1.6399999999999999 108.283 179.482 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 57.1 mt -89.64 29.55 1.13 Allowed 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.527 -0.916 . . . . 2.0299999999999998 108.527 179.395 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 27.5 mt-10 -140.09 -63.84 0.49 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.528 -0.733 . . . . 2.3399999999999999 109.623 -179.557 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 41.2 mtt180 -148.45 168.57 22.34 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.168 -0.958 . . . . 4.25 110.293 -179.573 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -144.38 173.33 25.09 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 107.415 -2.274 . . . . 1.5900000000000001 107.415 178.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 39.7 t -133.79 150.99 32.18 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.15 0 O-C-N 120.999 -1.295 . . . . 2.21 110.884 -179.365 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -42.34 114.81 0.61 Allowed 'General case' 0 N--CA 1.497 1.887 0 CA-C-O 121.893 0.854 . . . . 2.0699999999999998 112.314 -179.299 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 55.8 48.2 73.69 Favored Glycine 0 N--CA 1.488 2.159 0 N-CA-C 111.497 -0.641 . . . . 1.73 111.497 177.119 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 t -127.45 123.8 23.32 Favored Pre-proline 0 N--CA 1.499 1.986 0 O-C-N 121.451 -1.029 . . . . 2.6499999999999999 108.866 179.075 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -60.64 112.21 1.27 Allowed 'Trans proline' 0 C--O 1.215 -0.652 0 N-CA-C 109.949 -0.827 . . . . 2.1400000000000001 109.949 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -110.87 158.96 18.13 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 108.401 -0.963 . . . . 2.0299999999999998 108.401 179.445 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -160.64 170.46 20.79 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.767 -1.208 . . . . 2.23 111.496 -179.768 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . 0.458 ' N ' ' CD1' ' A' ' 39' ' ' PHE . 6.2 p90 -155.62 177.37 11.45 Favored 'General case' 0 C--N 1.296 -1.729 0 N-CA-C 107.217 -1.401 . . . . 1.72 107.217 178.473 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 27.5 m -105.17 152.32 22.97 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.344 -0.848 . . . . 2.5800000000000001 110.619 -178.502 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 10.0 mt -143.64 89.53 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 N-CA-C 108.714 -0.847 . . . . 1.8600000000000001 108.714 178.854 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.529 ' CD1' ' N ' ' A' ' 43' ' ' THR . 7.4 t90 -91.33 141.29 28.93 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.172 -0.955 . . . . 4.4699999999999998 108.924 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' THR . . . . . 0.543 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 1.7 t -162.34 -124.2 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.177 -0.952 . . . . 3.27 109.486 -179.845 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' ARG . . . . . 0.531 ' N ' ' OG1' ' A' ' 43' ' ' THR . 5.3 ttt-85 54.49 91.81 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.347 -0.845 . . . . 5.2300000000000004 110.074 179.748 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -170.97 -50.23 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.285 -0.884 . . . . 2.8900000000000001 109.304 179.457 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -61.14 -50.29 73.8 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.09 -1.006 . . . . 1.99 108.937 179.665 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 155.2 -178.81 31.65 Favored Glycine 0 N--CA 1.487 2.044 0 N-CA-C 109.536 -1.426 . . . . 1.6499999999999999 109.536 179.813 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.68 156.92 2.45 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.169 -1.195 . . . . 1.77 109.263 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -179.65 -160.51 25.38 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.712 -1.355 . . . . 1.1200000000000001 109.712 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -144.05 123.38 2.01 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 109.663 -1.375 . . . . 1.1799999999999999 109.663 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 60.2 tp -96.82 104.99 17.04 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.34 -1.094 . . . . 1.5900000000000001 108.651 179.571 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 2.0 t -93.23 144.66 25.08 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 108.93 -0.767 . . . . 1.9399999999999999 108.93 179.736 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.504 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 80.0 mt -132.97 105.74 8.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 O-C-N 121.305 -0.872 . . . . 1.3 109.79 -179.378 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -95.76 107.86 20.13 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 107.726 -1.213 . . . . 1.27 107.726 178.841 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.41 ' O ' ' O ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -105.33 146.73 11.99 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 CA-C-O 121.772 0.796 . . . . 1.55 110.693 -178.421 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . 0.408 ' OE2' ' O ' ' B' ' 9' ' ' VAL . 39.9 tp10 -139.23 129.41 25.31 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 107.248 -1.39 . . . . 1.8 107.248 177.954 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -175.82 163.59 33.3 Favored Glycine 0 N--CA 1.487 2.068 0 N-CA-C 108.386 -1.886 . . . . 0.56000000000000005 108.386 -179.702 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_exo -46.37 -23.44 2.08 Favored 'Trans proline' 0 C--N 1.317 -1.13 0 C-N-CA 121.91 1.74 . . . . 0.76000000000000001 111.714 -178.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 30.3 t -141.74 167.49 22.01 Favored 'General case' 0 N--CA 1.501 2.101 0 O-C-N 121.473 -0.767 . . . . 2.02 110.681 -179.274 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 29.3 tttm -91.4 92.05 8.4 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.666 -0.646 . . . . 3.02 109.535 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -52.05 145.13 10.78 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.341 -0.85 . . . . 1.3600000000000001 109.308 179.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.426 ' OE2' ' O ' ' A' ' 63' ' ' ILE . 0.2 OUTLIER -93.78 87.63 5.5 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.234 -0.916 . . . . 2.2999999999999998 109.561 -179.843 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . 0.426 ' O ' ' OE2' ' A' ' 62' ' ' GLU . 25.0 mt -60.23 150.17 6.69 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 N-CA-C 109.263 -0.643 . . . . 2.0 109.263 179.574 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -151.09 114.83 4.93 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 120.725 -1.234 . . . . 1.73 109.939 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . 0.492 ' CD2' ' O ' ' A' ' 65' ' ' PHE . 40.1 p90 -86.85 124.17 32.79 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.222 -0.924 . . . . 1.6000000000000001 109.198 179.531 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 62.9 tt0 . . . . . 0 N--CA 1.497 1.915 0 O-C-N 121.254 -0.904 . . . . 2.5099999999999998 109.43 179.971 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 4.3 t . . . . . 0 N--CA 1.492 1.671 0 N-CA-C 108.983 -0.747 . . . . 2.5600000000000001 108.983 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 24.5 m -78.23 129.33 34.96 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.19 -0.944 . . . . 2.3599999999999999 109.356 -179.844 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -101.14 116.5 5.59 Favored Glycine 0 N--CA 1.497 2.747 0 N-CA-C 110.111 -1.196 . . . . 1.46 110.111 -179.637 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 71.8 t -105.36 106.85 21.28 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.098 0 O-C-N 121.537 -0.978 . . . . 2.1600000000000001 109.284 179.571 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 4.0 t -100.11 126.39 46.34 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.549 -0.719 . . . . 2.1600000000000001 109.474 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 0.401 ' N ' ' CD1' ' A' ' 77' ' ' TYR . 12.0 p90 -125.36 131.69 52.94 Favored 'General case' 0 N--CA 1.497 1.882 0 N-CA-C 108.758 -0.831 . . . . 1.7 108.758 179.746 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.481 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 9.9 p -98.73 114.35 36.17 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.294 -0.879 . . . . 2.4500000000000002 109.255 -179.501 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 15.5 m -81.79 161.83 3.57 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 O-C-N 121.041 -1.037 . . . . 1.8200000000000001 109.027 -179.707 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . 0.531 ' O ' ' NE2' ' A' ' 80' ' ' GLN . 0.0 OUTLIER -101.44 -48.54 4.32 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.227 -0.92 . . . . 3.1699999999999999 110.781 -178.825 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -156.67 153.13 23.91 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 120.554 -1.341 . . . . 2.02 111.108 -179.506 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.592 ' HG3' ' N ' ' A' ' 107' ' ' SER . 76.4 Cg_exo -37.08 158.08 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.646 0 C-N-CA 123.363 2.709 . . . . 1.3999999999999999 113.875 179.231 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 150.77 -167.49 30.46 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.359 -1.496 . . . . 1.0800000000000001 109.359 179.765 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . 0.521 ' OD2' ' NH2' ' B' ' 8' ' ' ARG . 10.7 m-20 -109.3 91.58 3.7 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.532 -0.981 . . . . 2.1299999999999999 108.756 179.64 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 3.0 m-85 -78.25 136.19 37.72 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 108.049 -1.093 . . . . 1.1399999999999999 108.049 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . 0.402 ' OE2' ' O ' ' A' ' 84' ' ' ASP . 0.0 OUTLIER -119.18 117.36 28.44 Favored 'General case' 0 N--CA 1.501 2.086 0 N-CA-C 108.121 -1.066 . . . . 1.53 108.121 -179.033 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.415 ' CG1' ' CE2' ' A' ' 101' ' ' PHE . 14.6 p -117.11 133.91 62.36 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 121.622 -0.674 . . . . 1.6399999999999999 110.408 -178.842 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 3.5 p -128.65 105.77 8.49 Favored 'General case' 0 N--CA 1.501 2.092 0 O-C-N 121.61 -0.682 . . . . 1.99 109.459 179.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.4 pt -107.95 138.22 35.53 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.897 0 CA-C-O 121.415 0.626 . . . . 1.77 109.839 -179.732 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' LYS . . . . . 0.458 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -145.08 122.63 11.74 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 108.659 -0.867 . . . . 2.0600000000000001 108.659 179.928 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 78.7 t80 -80.33 100.95 8.66 Favored 'General case' 0 N--CA 1.491 1.588 0 C-N-CA 118.764 -1.174 . . . . 1.45 107.891 178.492 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . 0.407 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 2.0 t30 69.59 39.86 1.49 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.343 -0.848 . . . . 2.7200000000000002 109.177 -178.908 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . 0.407 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 1.5 m-20 75.61 13.93 2.88 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.678 -0.639 . . . . 1.9199999999999999 111.62 179.483 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . 0.476 ' CD ' ' N ' ' A' ' 18' ' ' ALA . 0.5 OUTLIER -98.44 94.44 6.72 Favored 'General case' 0 N--CA 1.498 1.97 0 N-CA-C 106.964 -1.495 . . . . 2.5499999999999998 106.964 177.58 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' HIS . . . . . 0.508 ' CG ' ' O ' ' A' ' 95' ' ' HIS . 6.5 p80 -71.57 112.69 7.9 Favored 'General case' 0 N--CA 1.487 1.384 0 CA-C-O 121.485 0.66 . . . . 3.2000000000000002 109.748 -178.219 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' ILE . . . . . 0.557 ' O ' ' N ' ' A' ' 98' ' ' ASP . 6.3 pt -57.06 152.02 31.4 Favored Pre-proline 0 C--N 1.3 -1.579 0 N-CA-C 108.319 -0.993 . . . . 2.8199999999999998 108.319 179.594 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -59.05 73.96 0.05 OUTLIER 'Trans proline' 0 CA--C 1.54 0.789 0 N-CA-C 109.234 -1.102 . . . . 2.6299999999999999 109.234 179.364 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.557 ' N ' ' O ' ' A' ' 96' ' ' ILE . 0.9 OUTLIER -174.93 -51.87 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.077 -1.014 . . . . 2.6499999999999999 109.38 -179.339 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 5.3 t -54.25 134.31 60.57 Favored Pre-proline 0 C--N 1.299 -1.626 0 O-C-N 121.321 -0.862 . . . . 2.3199999999999998 109.926 -177.64 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_endo -89.94 116.25 2.91 Favored 'Cis proline' 0 N--CA 1.495 1.606 0 CA-C-N 118.995 0.677 . . . . 1.9399999999999999 110.521 -1.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . 0.574 ' CD1' ' N ' ' A' ' 101' ' ' PHE . 0.1 OUTLIER -89.49 149.59 22.84 Favored 'General case' 0 N--CA 1.512 2.639 0 O-C-N 119.979 -1.701 . . . . 2.6299999999999999 108.76 178.029 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 8.6 p -86.45 138.43 19.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.5 -0.75 . . . . 1.8200000000000001 109.133 179.681 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 76.7 t -120.15 85.37 35.6 Favored Pre-proline 0 N--CA 1.498 1.936 0 N-CA-C 108.312 -0.996 . . . . 1.73 108.312 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -65.3 112.97 2.25 Favored 'Trans proline' 0 C--N 1.32 -0.953 0 C-N-CA 121.276 1.317 . . . . 1.6100000000000001 111.556 -178.012 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 47.2 t -89.73 143.06 11.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 N-CA-C 106.667 -1.605 . . . . 1.7 106.667 177.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -127.92 131.28 49.37 Favored 'General case' 0 N--CA 1.507 2.406 0 CA-C-O 121.956 0.884 . . . . 2.04 111.788 -177.016 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' SER . . . . . 0.592 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 66.4 p -99.8 84.77 2.96 Favored 'General case' 0 N--CA 1.493 1.693 0 N-CA-C 107.229 -1.397 . . . . 2.2999999999999998 107.229 178.783 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 13.3 mt 65.12 -0.69 1.02 Allowed 'General case' 0 C--N 1.292 -1.917 0 N-CA-C 108.081 -1.081 . . . . 3.6000000000000001 108.081 -178.103 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.511 ' H ' ' C ' ' A' ' 107' ' ' SER . 53.8 p -89.1 -22.89 22.66 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.982 -0.747 . . . . 2.4900000000000002 108.982 179.068 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 32.9 t70 . . . . . 0 N--CA 1.493 1.676 0 O-C-N 121.139 -0.975 . . . . 2.8500000000000001 108.586 -179.924 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . 0.521 ' NH2' ' OD2' ' A' ' 84' ' ' ASP . 3.8 mmt-85 . . . . . 0 N--CA 1.492 1.67 0 CA-C-O 121.472 0.654 . . . . 3.6699999999999999 109.358 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 9' ' ' VAL . . . . . 0.408 ' O ' ' OE2' ' A' ' 56' ' ' GLU . 2.6 t -68.47 161.23 4.22 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 N-CA-C 107.505 -1.294 . . . . 1.3899999999999999 107.505 178.549 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -97.77 138.94 34.38 Favored 'General case' 0 N--CA 1.5 2.034 0 O-C-N 121.186 -0.947 . . . . 1.22 110.809 -178.636 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 11' ' ' SER . . . . . 0.41 ' O ' ' O ' ' A' ' 55' ' ' VAL . 35.7 t -143.07 130.73 21.34 Favored 'General case' 0 N--CA 1.493 1.72 0 N-CA-C 108.444 -0.947 . . . . 1.6299999999999999 108.444 179.092 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 11.1 t -150.69 125.37 9.67 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.069 -1.019 . . . . 1.8799999999999999 110.072 -179.369 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . 0.541 ' CG2' ' H ' ' B' ' 14' ' ' PHE . 12.3 p -173.26 179.81 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 N-CA-C 108.263 -1.014 . . . . 1.2 108.263 179.649 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 14' ' ' PHE . . . . . 0.541 ' H ' ' CG2' ' B' ' 13' ' ' VAL . 0.1 OUTLIER 174.59 -167.65 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.504 0 C-N-CA 118.548 -1.261 . . . . 2.3900000000000001 112.237 179.629 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -141.34 159.66 22.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 N-CA-C 108.097 -1.075 . . . . 1.8100000000000001 108.097 -179.841 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 16' ' ' THR . . . . . 0.498 ' HG1' ' N ' ' B' ' 17' ' ' LEU . 1.7 t -132.11 151.07 51.98 Favored 'General case' 0 N--CA 1.499 2.017 0 O-C-N 121.303 -0.873 . . . . 2.04 109.474 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . 0.498 ' N ' ' HG1' ' B' ' 16' ' ' THR . 28.4 mt . . . . . 0 N--CA 1.5 2.047 0 O-C-N 121.487 -0.758 . . . . 1.8700000000000001 109.576 -179.899 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 2.003 0 N-CA-C 109.886 -1.286 . . . . 2.4399999999999999 109.886 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.544 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -68.24 -15.55 67.89 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.881 -1.288 . . . . 2.0499999999999998 109.881 -179.68 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.51 ' N ' ' OE1' ' A' ' 94' ' ' GLU . . . -43.8 -17.67 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.525 -0.985 . . . . 2.54 109.823 -179.679 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' HIS . . . . . 0.544 ' N ' ' O ' ' A' ' 17' ' ' GLY . 11.7 t-80 -100.25 -52.56 3.35 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.447 -0.783 . . . . 3.3700000000000001 110.388 -179.146 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.423 ' HZ3' ' CB ' ' A' ' 43' ' ' THR . 0.0 OUTLIER -64.49 -17.89 64.29 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.962 -1.086 . . . . 2.3700000000000001 109.874 -179.288 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.475 ' O ' ' CG1' ' A' ' 21' ' ' VAL . 9.7 p -72.22 114.31 10.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.046 -1.034 . . . . 2.5800000000000001 108.829 179.503 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 5.9 tpp180 -109.84 134.61 51.86 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.452 -0.78 . . . . 3.8900000000000001 110.108 -178.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -141.79 113.59 7.89 Favored 'General case' 0 N--CA 1.493 1.691 0 N-CA-C 108.392 -0.966 . . . . 2.0099999999999998 108.392 179.15 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -150.93 132.07 3.76 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 109.94 -1.264 . . . . 2.0099999999999998 109.94 -179.294 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.38 179.11 48.9 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 110.055 -1.218 . . . . 1.9299999999999999 110.055 179.721 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 7.2 m -75.9 -19.9 58.46 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.47 -1.018 . . . . 2.6899999999999999 109.674 179.922 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.449 ' O ' ' OH ' ' A' ' 77' ' ' TYR . . . -70.97 -24.76 76.8 Favored Glycine 0 N--CA 1.488 2.138 0 N-CA-C 108.767 -1.733 . . . . 1.6399999999999999 108.767 179.844 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 29.6 mt -81.51 -11.21 59.27 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.555 -0.968 . . . . 2.0299999999999998 108.946 179.633 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 33.2 mm-40 -84.67 -49.03 8.88 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.512 -0.743 . . . . 2.3399999999999999 109.762 -179.494 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . 0.504 ' NH1' ' OD1' ' A' ' 110' ' ' ASP . 9.4 ptp180 -174.92 173.69 2.66 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.221 -0.925 . . . . 4.25 109.407 179.809 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -138.71 170.91 23.78 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 108.196 -1.962 . . . . 1.5900000000000001 108.196 179.475 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 25.6 t -134.64 149.36 29.56 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 O-C-N 121.23 -1.159 . . . . 2.21 109.944 -179.526 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -38.51 113.03 0.26 Allowed 'General case' 0 N--CA 1.496 1.832 0 CA-C-O 121.712 0.767 . . . . 2.0699999999999998 112.098 -179.306 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 63.48 40.67 99.04 Favored Glycine 0 N--CA 1.491 2.337 0 O-C-N 121.685 -0.635 . . . . 1.73 111.814 177.424 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 46.4 t -127.32 119.95 22.07 Favored Pre-proline 0 N--CA 1.502 2.146 0 O-C-N 121.289 -1.124 . . . . 2.6499999999999999 108.536 178.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -59.37 113.89 1.8 Allowed 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 120.589 0.86 . . . . 2.1400000000000001 110.541 -179.488 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -86.39 90.67 8.27 Favored 'General case' 0 N--CA 1.492 1.665 0 N-CA-C 108.281 -1.007 . . . . 2.0299999999999998 108.281 179.032 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -85.78 148.28 25.92 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.244 -0.91 . . . . 2.23 110.884 -178.513 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . 0.531 ' CD1' ' O ' ' A' ' 75' ' ' VAL . 5.2 p90 -153.25 159.03 42.52 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 107.148 -1.427 . . . . 1.72 107.148 177.825 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' SER . . . . . 0.426 ' OG ' ' OG ' ' A' ' 72' ' ' SER . 3.6 t -98.26 156.2 16.82 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.223 -0.923 . . . . 2.5800000000000001 111.904 -177.093 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.524 ' O ' ' N ' ' A' ' 73' ' ' CYS . 13.3 mt -149.18 117.16 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 N-CA-C 108.368 -0.975 . . . . 1.8600000000000001 108.368 178.713 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.519 ' O ' ' CD2' ' A' ' 42' ' ' TRP . 7.3 p-90 -122.07 129.12 52.12 Favored 'General case' 0 N--CA 1.503 2.182 0 O-C-N 121.256 -0.903 . . . . 4.4699999999999998 109.031 179.718 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' THR . . . . . 0.423 ' CB ' ' HZ3' ' A' ' 20' ' ' LYS . 0.6 OUTLIER -149.02 142.11 24.9 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.229 -0.919 . . . . 3.27 109.605 -179.103 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -178.1 68.16 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.352 -0.842 . . . . 5.2300000000000004 109.308 179.501 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 28.6 tt0 -153.47 -51.33 0.1 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.176 -0.953 . . . . 2.8900000000000001 109.501 -179.919 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -61.57 -57.16 13.16 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.146 -0.971 . . . . 1.99 109.439 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 136.13 -177.56 19.46 Favored Glycine 0 N--CA 1.495 2.586 0 N-CA-C 108.683 -1.767 . . . . 1.6499999999999999 108.683 -179.621 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.78 142.36 23.98 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.048 -1.266 . . . . 1.77 109.306 179.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -159.2 176.95 35.94 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.422 -1.471 . . . . 1.1200000000000001 109.422 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -109.82 114.35 3.87 Favored Glycine 0 N--CA 1.498 2.785 0 N-CA-C 109.439 -1.464 . . . . 1.1799999999999999 109.439 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.437 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 10.5 tp -94.43 96.75 9.71 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.216 -1.167 . . . . 1.5900000000000001 108.353 179.386 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' SER . . . . . 0.492 ' HG ' ' CD ' ' A' ' 90' ' ' LYS . 22.3 p -84.68 141.16 30.8 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.627 -0.879 . . . . 1.9399999999999999 108.627 -179.953 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.514 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 87.3 mt -134.01 113.96 18.72 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.342 -0.848 . . . . 1.3 109.489 -179.838 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -105.28 108.52 20.08 Favored 'General case' 0 N--CA 1.495 1.784 0 N-CA-C 108.808 -0.812 . . . . 1.27 108.808 179.611 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.417 ' O ' ' O ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -100.27 142.58 15.27 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.494 -0.753 . . . . 1.55 109.412 -179.795 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 12.5 tt0 -141.89 144.12 33.65 Favored 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 108.046 -1.094 . . . . 1.8 108.046 178.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.429 ' O ' ' O ' ' B' ' 9' ' ' VAL . . . 163.79 -172.4 39.66 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.836 -1.306 . . . . 0.56000000000000005 109.836 -179.498 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -63.34 -28.73 72.03 Favored 'Trans proline' 0 C--N 1.318 -1.053 0 C-N-CA 122.133 1.889 . . . . 0.76000000000000001 112.136 -179.412 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -131.73 175.99 8.72 Favored 'General case' 0 N--CA 1.502 2.152 0 O-C-N 121.225 -0.922 . . . . 2.02 110.165 -179.575 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 47.0 mttp -93.09 120.21 33.14 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.518 -0.739 . . . . 3.02 109.523 -179.712 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -80.94 108.63 14.78 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.331 -0.856 . . . . 1.3600000000000001 108.825 179.82 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 23.4 mt-10 -83.51 103.17 12.65 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.072 -1.018 . . . . 2.2999999999999998 109.87 -179.592 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . 0.422 HG23 HD11 ' A' ' 63' ' ' ILE . 7.6 mm -58.73 156.96 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.886 -0.509 . . . . 2.0 109.751 179.781 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.469 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -139.66 174.5 10.45 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.122 -0.986 . . . . 1.73 109.015 179.649 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . 0.441 ' CD1' ' N ' ' A' ' 65' ' ' PHE . 13.9 p90 -139.64 117.18 11.43 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.412 -0.805 . . . . 1.6000000000000001 109.536 -179.896 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 . . . . . 0 N--CA 1.495 1.818 0 O-C-N 121.31 -0.869 . . . . 2.5099999999999998 109.453 179.93 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.426 ' OG ' ' OG ' ' A' ' 40' ' ' SER . 24.2 t . . . . . 0 N--CA 1.49 1.561 0 N-CA-C 109.131 -0.692 . . . . 2.5600000000000001 109.131 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' CYS . . . . . 0.524 ' N ' ' O ' ' A' ' 41' ' ' ILE . 20.5 m -77.26 110.89 12.36 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.233 -0.917 . . . . 2.3599999999999999 109.582 -179.849 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -83.79 115.15 4.0 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.408 -1.477 . . . . 1.46 109.408 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.531 ' O ' ' CD1' ' A' ' 39' ' ' PHE . 10.1 t -115.42 133.86 60.41 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.052 0 O-C-N 121.649 -0.912 . . . . 2.1600000000000001 108.964 179.897 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.469 ' O ' ' N ' ' A' ' 64' ' ' ALA . 6.0 t -136.73 139.82 42.16 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.447 -0.783 . . . . 2.1600000000000001 109.944 -179.827 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 0.492 ' CD1' ' N ' ' A' ' 77' ' ' TYR . 6.9 p90 -120.16 139.2 52.97 Favored 'General case' 0 N--CA 1.495 1.79 0 N-CA-C 108.201 -1.037 . . . . 1.7 108.201 179.224 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.464 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 9.7 p -108.87 120.78 60.88 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 O-C-N 121.332 -0.855 . . . . 2.4500000000000002 109.741 -179.078 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 3.6 m -101.12 168.4 1.93 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 N-CA-C 108.439 -0.949 . . . . 1.8200000000000001 108.439 179.448 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 34.2 tp60 -101.5 -40.56 6.99 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.08 -1.013 . . . . 3.1699999999999999 110.758 -179.486 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.429 ' O ' ' O ' ' A' ' 82' ' ' PRO . 0.0 OUTLIER -153.32 156.51 32.54 Favored Pre-proline 0 N--CA 1.504 2.248 0 O-C-N 120.539 -1.351 . . . . 2.02 111.209 -179.276 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.511 ' HG3' ' N ' ' A' ' 107' ' ' SER . 78.7 Cg_exo -37.73 169.12 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.654 0 C-N-CA 123.444 2.763 . . . . 1.3999999999999999 113.239 179.016 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 142.82 179.02 19.25 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.659 -1.376 . . . . 1.0800000000000001 109.659 179.559 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . 0.716 ' H ' HH12 ' B' ' 8' ' ' ARG . 3.0 m-20 -96.97 87.2 4.18 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 107.929 -1.137 . . . . 2.1299999999999999 107.929 179.301 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 2.9 m-85 -74.13 134.76 42.87 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 108.351 -0.981 . . . . 1.1399999999999999 108.351 -179.345 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -111.22 121.58 45.65 Favored 'General case' 0 N--CA 1.497 1.91 0 N-CA-C 108.682 -0.858 . . . . 1.53 108.682 -179.058 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.1 p -119.65 140.58 43.16 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.891 0 O-C-N 121.552 -0.717 . . . . 1.6399999999999999 109.546 -179.798 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 12.2 t -133.18 101.39 5.18 Favored 'General case' 0 N--CA 1.5 2.026 0 O-C-N 121.515 -0.741 . . . . 1.99 109.308 179.772 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.9 pt -108.51 137.51 39.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.721 -0.612 . . . . 1.77 110.37 -179.285 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' LYS . . . . . 0.492 ' CD ' ' HG ' ' A' ' 52' ' ' SER . 0.2 OUTLIER -146.91 125.87 12.79 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.857 -0.794 . . . . 2.0600000000000001 108.857 179.367 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 48.4 t80 -81.69 93.89 6.86 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 120.785 -1.197 . . . . 1.45 108.492 179.42 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . 0.409 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 5.4 t30 69.93 43.24 0.94 Allowed 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 107.913 -1.143 . . . . 2.7200000000000002 107.913 -178.591 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . 0.409 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 3.4 m-20 78.3 11.76 1.75 Allowed 'General case' 0 N--CA 1.495 1.789 0 CA-C-O 121.253 0.549 . . . . 1.9199999999999999 109.96 -179.241 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . 0.51 ' OE1' ' N ' ' A' ' 18' ' ' ALA . 50.0 mt-10 -85.43 77.34 9.94 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 107.805 -1.183 . . . . 2.5499999999999998 107.805 178.454 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' HIS . . . . . 0.546 ' O ' ' CD2' ' A' ' 95' ' ' HIS . 0.4 OUTLIER -67.97 106.41 2.33 Favored 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 120.03 -0.668 . . . . 3.2000000000000002 109.752 -179.513 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' ILE . . . . . 0.633 ' CD1' ' H ' ' A' ' 96' ' ' ILE . 0.0 OUTLIER -68.96 156.1 92.15 Favored Pre-proline 0 N--CA 1.495 1.787 0 N-CA-C 107.709 -1.219 . . . . 2.8199999999999998 107.709 179.606 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -48.9 -29.28 14.86 Favored 'Trans proline' 0 C--N 1.323 -0.806 0 C-N-CA 121.059 1.173 . . . . 2.6299999999999999 109.144 -179.797 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 57.0 m-20 -58.83 -64.16 1.04 Allowed 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 108.963 -0.755 . . . . 2.6499999999999999 108.963 178.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 3.1 m -70.78 139.7 86.06 Favored Pre-proline 0 C--N 1.296 -1.739 0 O-C-N 121.05 -1.031 . . . . 2.3199999999999998 110.073 -178.681 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -87.08 119.46 5.07 Favored 'Cis proline' 0 N--CA 1.493 1.49 0 N-CA-C 110.025 -0.798 . . . . 1.9399999999999999 110.025 -2.342 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 40.5 p90 -121.14 166.97 13.17 Favored 'General case' 0 N--CA 1.519 2.996 0 O-C-N 120.499 -1.376 . . . . 2.6299999999999999 109.882 178.195 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.4 p -92.35 146.23 6.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 CA-C-O 121.642 0.734 . . . . 1.8200000000000001 110.918 -178.28 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 79.8 t -119.83 86.46 35.94 Favored Pre-proline 0 N--CA 1.496 1.842 0 N-CA-C 107.799 -1.185 . . . . 1.73 107.799 178.888 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -63.96 114.28 2.54 Favored 'Trans proline' 0 C--N 1.32 -0.95 0 C-N-CA 121.36 1.373 . . . . 1.6100000000000001 111.683 -178.028 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 75.2 t -98.88 144.09 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 N-CA-C 106.569 -1.641 . . . . 1.7 106.569 178.11 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -134.94 138.28 43.91 Favored 'General case' 0 N--CA 1.51 2.556 0 CA-C-O 122.055 0.931 . . . . 2.04 112.08 -177.174 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' SER . . . . . 0.512 ' C ' ' H ' ' A' ' 109' ' ' SER . 20.3 m -92.2 63.77 4.37 Favored 'General case' 0 N--CA 1.496 1.856 0 N-CA-C 107.152 -1.425 . . . . 2.2999999999999998 107.152 178.652 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' LEU . . . . . 0.49 ' CB ' ' O ' ' A' ' 107' ' ' SER . 3.2 tp 80.45 -13.56 0.92 Allowed 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 106.456 -1.683 . . . . 3.6000000000000001 106.456 -177.416 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.512 ' H ' ' C ' ' A' ' 107' ' ' SER . 5.2 m -68.54 -21.9 64.53 Favored 'General case' 0 C--N 1.306 -1.305 0 N-CA-C 108.732 -0.84 . . . . 2.4900000000000002 108.732 178.785 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . 0.504 ' OD1' ' NH1' ' A' ' 30' ' ' ARG . 21.5 t70 . . . . . 0 N--CA 1.494 1.736 0 CA-C-O 121.937 0.875 . . . . 2.8500000000000001 108.666 179.876 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . 0.716 HH12 ' H ' ' A' ' 84' ' ' ASP . 10.7 mtt180 . . . . . 0 N--CA 1.489 1.497 0 N-CA-C 108.087 -1.079 . . . . 3.6699999999999999 108.087 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 9' ' ' VAL . . . . . 0.429 ' O ' ' O ' ' A' ' 57' ' ' GLY . 38.6 t -51.74 155.79 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 120.921 -1.112 . . . . 1.3899999999999999 108.215 179.404 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -119.66 149.87 41.28 Favored 'General case' 0 N--CA 1.501 2.078 0 O-C-N 121.402 -0.811 . . . . 1.22 110.142 -178.914 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 11' ' ' SER . . . . . 0.417 ' O ' ' O ' ' A' ' 55' ' ' VAL . 6.9 t -147.36 141.84 26.46 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.506 -0.746 . . . . 1.6299999999999999 109.301 179.688 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 12' ' ' SER . . . . . 0.41 ' HG ' ' C ' ' B' ' 11' ' ' SER . 6.7 m -143.88 121.14 11.56 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.176 -0.952 . . . . 1.8799999999999999 109.439 -179.846 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . 0.47 ' CG2' ' N ' ' B' ' 14' ' ' PHE . 7.7 p -163.62 168.76 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.39 -0.819 . . . . 1.2 109.183 179.91 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 14' ' ' PHE . . . . . 0.514 ' HB3' ' H ' ' A' ' 53' ' ' ILE . 7.9 p90 -176.91 -168.05 0.2 Allowed 'General case' 0 N--CA 1.488 1.437 0 C-N-CA 119.402 -0.919 . . . . 2.3900000000000001 111.928 179.7 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.6 pt -151.29 167.47 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.344 0 N-CA-C 109.091 -0.707 . . . . 1.8100000000000001 109.091 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 7.3 t -122.53 128.92 51.38 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 121.463 -0.773 . . . . 2.04 109.009 179.661 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 12.1 mt . . . . . 0 N--CA 1.497 1.901 0 O-C-N 121.204 -0.935 . . . . 1.8700000000000001 109.866 -179.617 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.509 ' O ' ' N ' ' A' ' 18' ' ' ALA . . . . . . . . 0 N--CA 1.488 2.107 0 N-CA-C 111.157 -0.777 . . . . 2.4399999999999999 111.157 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.55 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -38.83 -23.39 0.02 OUTLIER Glycine 0 N--CA 1.497 2.702 0 O-C-N 121.819 -0.813 . . . . 2.0499999999999998 111.59 -178.704 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.509 ' N ' ' O ' ' A' ' 16' ' ' GLY . . . -47.25 -11.57 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.861 0 O-C-N 120.857 -1.378 . . . . 2.54 110.145 -179.467 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' HIS . . . . . 0.55 ' N ' ' O ' ' A' ' 17' ' ' GLY . 1.8 t60 -97.24 -37.73 9.96 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.249 -0.907 . . . . 3.3700000000000001 110.242 -179.372 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.666 ' NZ ' ' HG1' ' A' ' 43' ' ' THR . 0.0 OUTLIER -91.03 -14.48 31.29 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.008 -1.057 . . . . 2.3700000000000001 110.497 -179.145 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.476 ' O ' ' CG1' ' A' ' 21' ' ' VAL . 4.7 p -78.96 114.4 19.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 120.838 -1.164 . . . . 2.5800000000000001 109.712 -179.763 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 12.5 tpp180 -109.75 139.27 45.0 Favored 'General case' 0 N--CA 1.492 1.646 0 N-CA-C 108.92 -0.771 . . . . 3.8900000000000001 108.92 -179.877 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -147.32 113.57 5.89 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.535 -0.728 . . . . 2.0099999999999998 109.2 179.584 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -147.6 128.38 2.9 Favored Glycine 0 N--CA 1.496 2.662 0 N-CA-C 109.472 -1.451 . . . . 2.0099999999999998 109.472 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.07 171.24 43.69 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.842 -1.303 . . . . 1.9299999999999999 109.842 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 34.1 m -74.89 -23.6 58.4 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.329 -1.101 . . . . 2.6899999999999999 109.266 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.465 ' C ' ' H ' ' A' ' 29' ' ' GLU . . . -68.61 -27.92 73.51 Favored Glycine 0 N--CA 1.485 1.925 0 N-CA-C 108.444 -1.862 . . . . 1.6399999999999999 108.444 179.641 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 24.9 mt -81.06 26.92 0.41 Allowed 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 108.416 -0.957 . . . . 2.0299999999999998 108.416 179.397 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.465 ' H ' ' C ' ' A' ' 27' ' ' GLY . 42.5 mt-10 -132.21 -50.56 0.94 Allowed 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.687 -0.633 . . . . 2.3399999999999999 109.608 -179.621 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 29.0 ptt180 -168.17 177.8 5.32 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 120.89 -1.131 . . . . 4.25 110.602 -179.774 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -151.08 175.68 29.92 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 108.566 -1.814 . . . . 1.5900000000000001 108.566 179.686 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 39.9 t -134.56 151.93 32.58 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.087 0 O-C-N 121.22 -1.165 . . . . 2.21 110.748 -179.702 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -39.16 108.95 0.09 Allowed 'General case' 0 N--CA 1.5 2.029 0 CA-C-O 121.399 0.618 . . . . 2.0699999999999998 112.494 -179.388 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 54.57 53.71 37.15 Favored Glycine 0 N--CA 1.491 2.323 0 O-C-N 121.393 -0.817 . . . . 1.73 111.626 176.899 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 24.0 t -127.23 124.28 23.68 Favored Pre-proline 0 N--CA 1.496 1.826 0 N-CA-C 108.205 -1.035 . . . . 2.6499999999999999 108.205 178.663 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo -57.24 128.95 31.69 Favored 'Trans proline' 0 C--O 1.216 -0.615 0 N-CA-C 109.693 -0.926 . . . . 2.1400000000000001 109.693 -179.581 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -134.36 157.89 45.22 Favored 'General case' 0 N--CA 1.502 2.16 0 O-C-N 121.518 -0.739 . . . . 2.0299999999999998 109.507 -179.634 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -160.14 164.08 33.23 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.121 -0.987 . . . . 2.23 110.976 -179.663 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . 0.558 ' N ' ' CD1' ' A' ' 39' ' ' PHE . 0.7 OUTLIER -139.89 -179.03 5.71 Favored 'General case' 0 C--N 1.304 -1.391 0 N-CA-C 106.896 -1.52 . . . . 1.72 106.896 177.75 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 52.2 p -119.16 145.87 45.64 Favored 'General case' 0 N--CA 1.5 2.04 0 O-C-N 121.598 -0.688 . . . . 2.5800000000000001 110.609 -178.816 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.537 ' O ' ' N ' ' A' ' 73' ' ' CYS . 42.8 mt -143.63 128.68 15.1 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 N-CA-C 108.58 -0.896 . . . . 1.8600000000000001 108.58 179.213 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 5.5 p-90 -128.24 138.78 52.59 Favored 'General case' 0 N--CA 1.502 2.161 0 N-CA-C 108.853 -0.795 . . . . 4.4699999999999998 108.853 179.423 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' THR . . . . . 0.666 ' HG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -162.42 139.22 7.9 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.171 -0.956 . . . . 3.27 109.896 -179.534 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' ARG . . . . . . . . . . . . . 61.7 ttt180 -171.84 68.38 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.414 -0.804 . . . . 5.2300000000000004 109.226 179.732 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 11.1 tp10 -153.72 -51.79 0.1 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.244 -0.91 . . . . 2.8900000000000001 109.568 -179.87 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.76 -50.08 73.33 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.201 -0.937 . . . . 1.99 108.946 179.795 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 116.14 -162.4 12.62 Favored Glycine 0 N--CA 1.497 2.745 0 N-CA-C 109.639 -1.384 . . . . 1.6499999999999999 109.639 179.735 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.4 151.98 5.11 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.276 -1.132 . . . . 1.77 109.386 -179.841 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -176.49 -162.72 27.7 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.55 -1.42 . . . . 1.1200000000000001 109.55 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -140.47 119.71 1.63 Allowed Glycine 0 N--CA 1.496 2.663 0 N-CA-C 109.528 -1.429 . . . . 1.1799999999999999 109.528 -179.878 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.428 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 11.6 tp -99.43 99.04 9.9 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.357 -1.084 . . . . 1.5900000000000001 108.691 179.685 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 4.1 m -84.8 142.33 29.85 Favored 'General case' 0 N--CA 1.496 1.84 0 N-CA-C 108.741 -0.837 . . . . 1.9399999999999999 108.741 179.867 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.501 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 80.5 mt -132.36 116.6 29.21 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 O-C-N 121.01 -1.056 . . . . 1.3 109.889 -179.915 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -106.99 106.92 17.69 Favored 'General case' 0 N--CA 1.496 1.865 0 N-CA-C 108.562 -0.903 . . . . 1.27 108.562 179.328 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -106.23 137.55 35.96 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 121.388 -0.82 . . . . 1.55 109.941 -179.186 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . 0.433 ' OE2' ' O ' ' B' ' 9' ' ' VAL . 40.7 tp10 -131.97 142.78 49.72 Favored 'General case' 0 N--CA 1.495 1.785 0 N-CA-C 107.896 -1.15 . . . . 1.8 107.896 178.36 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 172.95 -179.51 44.34 Favored Glycine 0 N--CA 1.488 2.132 0 N-CA-C 108.784 -1.726 . . . . 0.56000000000000005 108.784 -179.635 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -63.43 -21.91 71.26 Favored 'Trans proline' 0 C--N 1.315 -1.231 0 C-N-CA 121.678 1.585 . . . . 0.76000000000000001 110.732 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' SER . . . . . 0.423 ' O ' ' OH ' ' A' ' 85' ' ' TYR . 36.6 m -143.24 165.47 27.36 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.453 -0.78 . . . . 2.02 110.114 -179.62 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 38.2 mttp -86.97 104.96 16.78 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.507 -0.746 . . . . 3.02 109.396 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -67.06 113.06 4.74 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.337 -0.852 . . . . 1.3600000000000001 109.535 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 24.5 mm-40 -53.72 171.76 0.09 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.282 -0.886 . . . . 2.2999999999999998 109.225 179.84 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 90.1 mt -142.32 155.59 18.83 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 N-CA-C 108.122 -1.066 . . . . 2.0 108.122 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.542 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -149.56 175.35 11.6 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 120.642 -1.286 . . . . 1.73 109.635 -179.802 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . 0.522 ' CD2' ' O ' ' A' ' 65' ' ' PHE . 54.6 p90 -138.88 124.77 19.84 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.448 -0.782 . . . . 1.6000000000000001 109.124 179.846 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 . . . . . 0 N--CA 1.495 1.821 0 O-C-N 121.273 -0.892 . . . . 2.5099999999999998 109.579 -179.825 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 40.3 t . . . . . 0 N--CA 1.494 1.762 0 N-CA-C 109.176 -0.675 . . . . 2.5600000000000001 109.176 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' CYS . . . . . 0.537 ' N ' ' O ' ' A' ' 41' ' ' ILE . 46.6 t -71.54 111.1 6.57 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.228 -0.92 . . . . 2.3599999999999999 109.48 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -91.96 115.14 4.71 Favored Glycine 0 N--CA 1.493 2.477 0 N-CA-C 109.692 -1.363 . . . . 1.46 109.692 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 45.3 t -99.38 102.0 12.84 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 O-C-N 121.467 -1.019 . . . . 2.1600000000000001 109.011 179.721 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.542 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.4 OUTLIER -92.0 137.09 32.65 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.338 -0.851 . . . . 2.1600000000000001 109.111 -179.837 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 8.5 p90 -136.34 166.04 24.38 Favored 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 108.674 -0.861 . . . . 1.7 108.674 -179.862 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 6.7 t -141.86 110.05 2.34 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.329 -0.857 . . . . 2.4500000000000002 109.585 -179.669 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 3.3 m -84.73 154.32 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.544 -0.723 . . . . 1.8200000000000001 109.429 -179.915 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 4.3 tp-100 -93.26 -48.93 6.21 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.065 -1.022 . . . . 3.1699999999999999 111.015 -178.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.431 ' O ' ' O ' ' A' ' 82' ' ' PRO . 81.5 mm-40 -148.57 149.92 32.39 Favored Pre-proline 0 N--CA 1.504 2.263 0 O-C-N 120.68 -1.262 . . . . 2.02 111.609 -178.427 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.573 ' HG3' ' N ' ' A' ' 107' ' ' SER . 83.1 Cg_exo -37.18 168.53 0.0 OUTLIER 'Trans proline' 0 C--O 1.216 -0.599 0 C-N-CA 123.15 2.567 . . . . 1.3999999999999999 113.787 178.37 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 141.8 -173.8 23.4 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 108.651 -1.779 . . . . 1.0800000000000001 108.651 -179.87 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . 0.668 ' N ' HH12 ' B' ' 8' ' ' ARG . 0.4 OUTLIER -103.18 90.41 3.72 Favored 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 107.866 -1.161 . . . . 2.1299999999999999 107.866 179.217 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . 0.423 ' OH ' ' O ' ' A' ' 59' ' ' SER . 3.0 m-85 -74.69 133.4 42.09 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 107.992 -1.114 . . . . 1.1399999999999999 107.992 -179.574 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.36 116.38 28.85 Favored 'General case' 0 N--CA 1.5 2.034 0 N-CA-C 108.503 -0.925 . . . . 1.53 108.503 -178.791 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 11.3 p -114.63 142.32 27.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 121.719 -0.613 . . . . 1.6399999999999999 109.865 -179.66 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 32.9 t -136.11 106.07 6.28 Favored 'General case' 0 N--CA 1.494 1.756 0 N-CA-C 109.289 -0.634 . . . . 1.99 109.289 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.8 pt -111.4 136.85 46.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 CA-C-O 121.374 0.607 . . . . 1.77 110.148 -179.429 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' LYS . . . . . 0.46 ' HZ2' ' CD2' ' A' ' 95' ' ' HIS . 0.3 OUTLIER -138.99 121.27 15.92 Favored 'General case' 0 N--CA 1.486 1.355 0 N-CA-C 108.518 -0.919 . . . . 2.0600000000000001 108.518 179.329 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.411 ' CE2' ' NZ ' ' A' ' 20' ' ' LYS . 52.6 t80 -80.1 99.02 7.52 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 107.699 -1.223 . . . . 1.45 107.699 178.563 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . 0.442 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 3.6 t-20 69.8 37.79 1.76 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.503 -0.748 . . . . 2.7200000000000002 109.284 -178.735 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . 0.442 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 1.8 m-20 79.06 13.49 1.2 Allowed 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.625 -0.672 . . . . 1.9199999999999999 111.629 179.313 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . 0.482 ' OE1' ' CB ' ' A' ' 18' ' ' ALA . 0.6 OUTLIER -99.29 97.88 8.9 Favored 'General case' 0 N--CA 1.5 2.059 0 N-CA-C 106.857 -1.534 . . . . 2.5499999999999998 106.857 177.732 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' HIS . . . . . 0.602 ' H ' ' HD1' ' A' ' 95' ' ' HIS . 5.9 m80 -67.88 101.86 1.16 Allowed 'General case' 0 N--CA 1.487 1.421 0 CA-C-O 121.411 0.624 . . . . 3.2000000000000002 110.924 -177.636 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' ILE . . . . . 0.408 ' CD1' ' OD1' ' A' ' 98' ' ' ASP . 2.1 tt -53.32 137.46 49.69 Favored Pre-proline 0 N--CA 1.49 1.566 0 N-CA-C 106.869 -1.53 . . . . 2.8199999999999998 106.869 178.26 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_exo -40.76 -39.06 2.95 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 121.077 1.184 . . . . 2.6299999999999999 111.194 -178.575 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.408 ' OD1' ' CD1' ' A' ' 96' ' ' ILE . 8.6 m-20 -50.12 -67.2 0.28 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.787 -1.196 . . . . 2.6499999999999999 109.092 178.843 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 2.8 p -57.53 142.03 77.77 Favored Pre-proline 0 C--N 1.296 -1.759 0 O-C-N 121.405 -0.81 . . . . 2.3199999999999998 110.086 -178.236 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -85.15 114.92 3.22 Favored 'Cis proline' 0 N--CA 1.49 1.288 0 N-CA-C 108.739 -1.293 . . . . 1.9399999999999999 108.739 -2.612 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 51.8 p90 -112.77 156.45 22.83 Favored 'General case' 0 N--CA 1.514 2.748 0 O-C-N 120.405 -1.434 . . . . 2.6299999999999999 110.217 179.286 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.4 p -88.94 146.1 6.58 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 CA-C-O 121.556 0.693 . . . . 1.8200000000000001 110.417 -178.595 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 47.3 t -120.97 86.55 42.09 Favored Pre-proline 0 N--CA 1.494 1.768 0 N-CA-C 107.753 -1.203 . . . . 1.73 107.753 179.236 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo -65.07 111.08 1.65 Allowed 'Trans proline' 0 C--N 1.32 -0.935 0 C-N-CA 121.393 1.395 . . . . 1.6100000000000001 111.74 -177.879 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 58.6 t -96.53 141.05 16.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 N-CA-C 106.148 -1.797 . . . . 1.7 106.148 177.828 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -133.89 133.72 41.83 Favored 'General case' 0 N--CA 1.51 2.53 0 CA-C-O 122.303 1.049 . . . . 2.04 112.131 -177.031 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' SER . . . . . 0.573 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 17.0 t -101.02 85.55 2.87 Favored 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 107.129 -1.434 . . . . 2.2999999999999998 107.129 178.685 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 12.9 mt 64.76 0.51 1.18 Allowed 'General case' 0 C--N 1.296 -1.729 0 N-CA-C 108.035 -1.098 . . . . 3.6000000000000001 108.035 -178.011 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.518 ' H ' ' C ' ' A' ' 107' ' ' SER . 8.2 t -89.88 -24.95 21.23 Favored 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 109.011 -0.737 . . . . 2.4900000000000002 109.011 179.061 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 25.2 t70 . . . . . 0 N--CA 1.488 1.436 0 N-CA-C 107.897 -1.149 . . . . 2.8500000000000001 107.897 -178.969 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . 0.668 HH12 ' N ' ' A' ' 84' ' ' ASP . 43.8 mtt180 . . . . . 0 N--CA 1.493 1.7 0 N-CA-C 109.325 -0.62 . . . . 3.6699999999999999 109.325 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 9' ' ' VAL . . . . . 0.433 ' O ' ' OE2' ' A' ' 56' ' ' GLU . 15.2 t -59.34 160.32 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 N-CA-C 107.718 -1.215 . . . . 1.3899999999999999 107.718 178.719 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -116.99 142.94 46.31 Favored 'General case' 0 N--CA 1.503 2.189 0 O-C-N 121.287 -0.883 . . . . 1.22 110.433 -179.073 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 30.2 t -143.72 131.36 21.25 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.471 -0.768 . . . . 1.6299999999999999 109.063 179.47 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 87.8 p -140.39 120.19 13.46 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.232 -0.918 . . . . 1.8799999999999999 109.587 -179.727 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . 0.501 ' CG2' ' N ' ' B' ' 14' ' ' PHE . 3.0 p -162.26 168.3 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.412 0 O-C-N 121.379 -0.826 . . . . 1.2 109.073 -179.948 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 14' ' ' PHE . . . . . 0.501 ' HB3' ' H ' ' A' ' 53' ' ' ILE . 6.6 p90 -177.1 -171.76 0.37 Allowed 'General case' 0 N--CA 1.487 1.4 0 C-N-CA 119.391 -0.923 . . . . 2.3900000000000001 112.008 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -142.64 173.78 6.38 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.322 0 N-CA-C 108.335 -0.987 . . . . 1.8100000000000001 108.335 179.597 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 32.3 p -146.65 139.82 25.54 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 120.929 -1.107 . . . . 2.04 109.817 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.4 mt . . . . . 0 N--CA 1.494 1.737 0 O-C-N 121.256 -0.902 . . . . 1.8700000000000001 109.074 179.582 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.497 ' O ' ' N ' ' A' ' 18' ' ' ALA . . . . . . . . 0 N--CA 1.49 2.255 0 N-CA-C 110.643 -0.983 . . . . 2.4399999999999999 110.643 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.583 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 64.21 -47.1 0.1 OUTLIER Glycine 0 N--CA 1.493 2.497 0 O-C-N 121.479 -1.012 . . . . 2.0499999999999998 111.055 178.823 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.497 ' N ' ' O ' ' A' ' 16' ' ' GLY . . . -46.24 -11.13 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.871 0 O-C-N 120.959 -1.318 . . . . 2.54 110.05 -179.578 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' HIS . . . . . 0.583 ' N ' ' O ' ' A' ' 17' ' ' GLY . 34.0 t60 -84.64 -48.42 9.51 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 120.994 -1.066 . . . . 3.3700000000000001 109.6 179.729 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.552 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.1 OUTLIER -83.18 -3.63 57.57 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.047 -1.033 . . . . 2.3700000000000001 110.192 -179.617 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 66.6 t -77.86 113.24 16.8 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 120.944 -1.098 . . . . 2.5800000000000001 109.537 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 20.9 tpt180 -100.14 138.93 36.53 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.633 -0.667 . . . . 3.8900000000000001 109.571 -179.858 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -147.42 113.37 5.79 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 108.402 -0.962 . . . . 2.0099999999999998 108.402 179.332 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -158.5 128.7 2.12 Favored Glycine 0 N--CA 1.491 2.339 0 C-N-CA 119.688 -1.244 . . . . 2.0099999999999998 110.234 -179.199 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.3 -179.7 48.77 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.641 -1.383 . . . . 1.9299999999999999 109.641 179.611 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 6.5 m -76.58 -21.86 55.03 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.168 -1.195 . . . . 2.6899999999999999 109.24 179.759 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.9 -23.83 77.64 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 108.818 -1.713 . . . . 1.6399999999999999 108.818 179.71 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 34.6 mt -85.1 28.79 0.69 Allowed 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.499 -1.001 . . . . 2.0299999999999998 108.689 179.572 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 15.0 mt-10 -138.71 -64.24 0.52 Allowed 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.503 -0.748 . . . . 2.3399999999999999 109.908 -179.655 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 80.8 mtm180 -150.64 165.42 33.44 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 120.895 -1.128 . . . . 4.25 110.222 -179.248 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -139.07 170.57 24.01 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 107.473 -2.251 . . . . 1.5900000000000001 107.473 178.887 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 40.5 t -133.85 151.31 32.63 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.109 0 O-C-N 121.088 -1.243 . . . . 2.21 110.948 -179.029 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -40.48 114.59 0.47 Allowed 'General case' 0 N--CA 1.497 1.902 0 CA-C-O 121.867 0.841 . . . . 2.0699999999999998 112.428 -179.313 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 52.99 49.71 54.19 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 111.225 -0.75 . . . . 1.73 111.225 177.13 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 22.5 t -127.02 124.98 24.1 Favored Pre-proline 0 N--CA 1.496 1.843 0 O-C-N 121.497 -1.002 . . . . 2.6499999999999999 108.46 179.143 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -58.41 109.86 0.57 Allowed 'Trans proline' 0 C--O 1.215 -0.637 0 N-CA-C 109.682 -0.93 . . . . 2.1400000000000001 109.682 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -108.03 142.07 38.74 Favored 'General case' 0 N--CA 1.495 1.825 0 N-CA-C 107.929 -1.138 . . . . 2.0299999999999998 107.929 179.408 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -150.92 169.52 21.53 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.871 -1.143 . . . . 2.23 111.244 -179.385 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . 0.45 ' N ' ' CD1' ' A' ' 39' ' ' PHE . 5.2 p90 -154.35 173.78 15.73 Favored 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 107.617 -1.253 . . . . 1.72 107.617 178.452 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 72.9 m -101.54 150.82 22.68 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.496 -0.753 . . . . 2.5800000000000001 110.469 -178.652 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 11.3 mt -142.95 90.64 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 N-CA-C 108.748 -0.834 . . . . 1.8600000000000001 108.748 178.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 31.1 t-105 -92.93 120.01 32.81 Favored 'General case' 0 N--CA 1.493 1.704 0 N-CA-C 108.251 -1.018 . . . . 4.4699999999999998 108.251 179.504 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' THR . . . . . 0.552 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -152.74 108.84 3.36 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.276 -0.89 . . . . 3.27 109.594 -179.148 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' ARG . . . . . 0.588 ' CG ' HH11 ' A' ' 44' ' ' ARG . 0.1 OUTLIER -171.57 82.12 0.07 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.225 -0.922 . . . . 5.2300000000000004 109.599 -179.984 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 74.2 tt0 -159.5 -46.24 0.05 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.016 -1.053 . . . . 2.8900000000000001 109.985 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.15 -45.62 87.68 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.03 -1.044 . . . . 1.99 109.195 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 160.78 -153.03 23.83 Favored Glycine 0 N--CA 1.485 1.903 0 C-N-CA 119.403 -1.379 . . . . 1.6499999999999999 110.175 179.786 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -96.66 158.57 15.37 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.558 -0.966 . . . . 1.77 109.174 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -179.09 173.0 45.2 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.392 -1.483 . . . . 1.1200000000000001 109.392 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -105.11 121.09 6.76 Favored Glycine 0 N--CA 1.495 2.624 0 N-CA-C 109.501 -1.439 . . . . 1.1799999999999999 109.501 -179.891 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.437 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 64.2 tp -91.01 108.79 20.09 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.222 -1.163 . . . . 1.5900000000000001 107.897 179.153 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.7 t -91.23 142.37 27.8 Favored 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 108.663 -0.865 . . . . 1.9399999999999999 108.663 179.89 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.515 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 22.5 mt -130.49 100.62 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 121.521 -0.737 . . . . 1.3 109.071 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -93.86 106.41 18.38 Favored 'General case' 0 N--CA 1.489 1.506 0 N-CA-C 108.621 -0.881 . . . . 1.27 108.621 179.711 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -101.48 143.28 14.7 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 CA-C-O 121.588 0.708 . . . . 1.55 109.582 -179.631 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 8.2 tt0 -141.52 145.57 35.33 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 107.479 -1.304 . . . . 1.8 107.479 178.868 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 165.56 -172.71 41.14 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.856 -1.298 . . . . 0.56000000000000005 109.856 -179.095 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -63.18 -33.99 70.14 Favored 'Trans proline' 0 C--N 1.319 -0.988 0 C-N-CA 122.315 2.01 . . . . 0.76000000000000001 112.514 -179.435 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' SER . . . . . 0.497 ' OG ' ' N ' ' A' ' 60' ' ' LYS . 5.9 t -132.36 177.76 7.34 Favored 'General case' 0 N--CA 1.504 2.239 0 O-C-N 120.944 -1.097 . . . . 2.02 110.49 -179.273 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . 0.497 ' N ' ' OG ' ' A' ' 59' ' ' SER . 45.8 tttm -93.82 96.18 9.59 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.689 -0.632 . . . . 3.02 109.713 -179.591 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -61.54 131.17 49.23 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.179 -0.951 . . . . 1.3600000000000001 109.017 179.696 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 16.2 tp10 -88.54 95.05 10.08 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 120.964 -1.085 . . . . 2.2999999999999998 110.174 -179.456 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . 0.448 ' N ' ' CD1' ' A' ' 63' ' ' ILE . 1.7 mp -60.61 156.04 3.43 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 N-CA-C 109.207 -0.664 . . . . 2.0 109.207 179.335 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.476 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -144.72 172.38 13.08 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.013 -1.054 . . . . 1.73 108.78 179.598 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . 0.524 ' CD2' ' O ' ' A' ' 65' ' ' PHE . 41.0 p90 -148.44 116.2 6.33 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.26 -0.9 . . . . 1.6000000000000001 109.188 179.845 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 78.6 tt0 . . . . . 0 N--CA 1.498 1.964 0 O-C-N 121.161 -0.962 . . . . 2.5099999999999998 109.821 -179.884 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 19.8 t . . . . . 0 N--CA 1.488 1.467 0 N-CA-C 108.827 -0.805 . . . . 2.5600000000000001 108.827 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 8.6 t -76.69 129.14 35.93 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.103 -0.998 . . . . 2.3599999999999999 109.103 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -103.68 114.68 4.87 Favored Glycine 0 N--CA 1.496 2.69 0 N-CA-C 110.064 -1.214 . . . . 1.46 110.064 -179.332 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 38.4 t -101.83 108.74 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.925 0 O-C-N 121.516 -0.99 . . . . 2.1600000000000001 108.771 179.426 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.476 ' O ' ' N ' ' A' ' 64' ' ' ALA . 4.1 t -103.46 127.69 50.79 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.531 -0.731 . . . . 2.1600000000000001 109.457 179.849 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 6.4 p90 -128.45 128.2 43.97 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 108.303 -0.999 . . . . 1.7 108.303 179.838 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -103.8 110.06 29.01 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.159 0 O-C-N 121.324 -0.86 . . . . 2.4500000000000002 109.404 -178.859 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 5.8 m -82.6 163.39 3.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.496 -0.753 . . . . 1.8200000000000001 109.42 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 20.1 tt0 -95.78 -50.39 4.93 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.005 -1.059 . . . . 3.1699999999999999 111.117 -179.163 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -152.29 155.55 33.17 Favored Pre-proline 0 N--CA 1.504 2.237 0 O-C-N 120.688 -1.257 . . . . 2.02 111.72 -178.594 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.525 ' HG3' ' N ' ' A' ' 107' ' ' SER . 75.9 Cg_exo -37.07 160.77 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 123.61 2.873 . . . . 1.3999999999999999 113.636 179.285 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 148.19 -164.16 28.94 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.223 -1.551 . . . . 1.0800000000000001 109.223 179.816 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 65.0 m-20 -108.82 88.85 2.83 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.601 -0.94 . . . . 2.1299999999999999 108.662 179.656 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . 0.499 ' O ' ' N ' ' A' ' 103' ' ' VAL . 2.9 m-85 -76.27 129.52 36.8 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 108.165 -1.05 . . . . 1.1399999999999999 108.165 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -107.85 128.33 54.51 Favored 'General case' 0 N--CA 1.497 1.914 0 N-CA-C 108.144 -1.058 . . . . 1.53 108.144 -179.446 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 9.4 p -126.12 140.27 49.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.525 -0.734 . . . . 1.6399999999999999 109.972 -179.401 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' SER . . . . . 0.425 ' O ' ' OG ' ' A' ' 88' ' ' SER . 11.1 p -134.4 104.39 6.11 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.585 -0.697 . . . . 1.99 109.52 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.422 ' H ' ' HG ' ' A' ' 99' ' ' SER . 0.8 OUTLIER -112.33 129.58 67.6 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 CA-C-O 121.585 0.707 . . . . 1.77 109.492 -179.847 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' LYS . . . . . 0.469 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -139.71 124.2 18.17 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 108.232 -1.025 . . . . 2.0600000000000001 108.232 179.661 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.408 ' O ' ' CB ' ' A' ' 92' ' ' ASN . 31.8 t80 -85.64 102.96 14.02 Favored 'General case' 0 N--CA 1.494 1.737 0 N-CA-C 107.546 -1.279 . . . . 1.45 107.546 178.783 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . 0.423 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 8.5 t30 72.48 35.84 1.09 Allowed 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.806 -0.813 . . . . 2.7200000000000002 108.806 -178.235 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . 0.423 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 1.7 m-20 76.4 15.24 2.25 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.676 -0.64 . . . . 1.9199999999999999 111.409 179.692 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . 0.498 ' CG ' ' O ' ' A' ' 94' ' ' GLU . 7.2 pt-20 -98.53 100.43 11.68 Favored 'General case' 0 N--CA 1.493 1.717 0 N-CA-C 107.201 -1.407 . . . . 2.5499999999999998 107.201 177.949 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' HIS . . . . . 0.539 ' CD2' ' H ' ' A' ' 95' ' ' HIS . 7.0 p80 -71.67 106.52 4.11 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.215 -0.928 . . . . 3.2000000000000002 109.534 -178.541 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' ILE . . . . . 0.561 ' O ' ' N ' ' A' ' 98' ' ' ASP . 10.1 pt -55.82 150.19 28.94 Favored Pre-proline 0 N--CA 1.491 1.611 0 C-N-CA 119.377 -0.929 . . . . 2.8199999999999998 108.507 179.795 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . 0.411 ' O ' ' CG ' ' A' ' 98' ' ' ASP . 4.6 Cg_exo -53.87 82.01 0.03 OUTLIER 'Trans proline' 0 C--O 1.213 -0.738 0 N-CA-C 109.202 -1.114 . . . . 2.6299999999999999 109.202 179.415 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.561 ' N ' ' O ' ' A' ' 96' ' ' ILE . 1.9 m-20 175.05 -63.36 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 108.037 -1.097 . . . . 2.6499999999999999 108.037 -178.949 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' SER . . . . . 0.422 ' HG ' ' H ' ' A' ' 89' ' ' ILE . 5.1 m -59.03 139.08 87.68 Favored Pre-proline 0 C--N 1.298 -1.671 0 O-C-N 121.539 -0.725 . . . . 2.3199999999999998 110.119 -178.134 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_endo -88.58 115.21 2.9 Favored 'Cis proline' 0 N--CA 1.493 1.474 0 N-CA-C 109.722 -0.915 . . . . 1.9399999999999999 109.722 -2.597 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 45.6 p90 -112.53 168.45 9.64 Favored 'General case' 0 N--CA 1.516 2.868 0 O-C-N 120.556 -1.34 . . . . 2.6299999999999999 110.027 178.828 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.4 p -94.38 152.28 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.474 -0.766 . . . . 1.8200000000000001 110.735 -178.901 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.499 ' N ' ' O ' ' A' ' 85' ' ' TYR . 61.3 t -126.69 87.01 57.4 Favored Pre-proline 0 N--CA 1.499 1.992 0 N-CA-C 107.919 -1.141 . . . . 1.73 107.919 179.193 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -61.25 113.09 1.61 Allowed 'Trans proline' 0 C--N 1.32 -0.951 0 C-N-CA 121.376 1.384 . . . . 1.6100000000000001 112.189 -177.787 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 53.8 t -94.16 145.08 8.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 N-CA-C 106.64 -1.615 . . . . 1.7 106.64 177.736 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -136.73 137.33 39.81 Favored 'General case' 0 N--CA 1.506 2.328 0 CA-C-O 122.268 1.032 . . . . 2.04 111.995 -177.507 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' SER . . . . . 0.525 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 9.5 t -110.53 68.47 0.67 Allowed 'General case' 0 N--CA 1.495 1.808 0 N-CA-C 107.229 -1.397 . . . . 2.2999999999999998 107.229 178.855 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' LEU . . . . . 0.496 ' CB ' ' O ' ' A' ' 107' ' ' SER . 2.6 tp 81.23 -3.53 1.7 Allowed 'General case' 0 N--CA 1.492 1.641 0 N-CA-C 106.603 -1.629 . . . . 3.6000000000000001 106.603 -177.574 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 2.0 m -80.08 -27.09 39.36 Favored 'General case' 0 N--CA 1.486 1.348 0 N-CA-C 108.853 -0.795 . . . . 2.4900000000000002 108.853 179.138 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 37.8 m-20 . . . . . 0 N--CA 1.492 1.659 0 O-C-N 121.283 -0.886 . . . . 2.8500000000000001 108.799 -179.71 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . 0.531 HH11 ' CG ' ' B' ' 8' ' ' ARG . 1.5 mtt-85 . . . . . 0 N--CA 1.491 1.605 0 N-CA-C 108.694 -0.854 . . . . 3.6699999999999999 108.694 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 9' ' ' VAL . . . . . . . . . . . . . 5.7 t -49.09 159.82 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.065 -1.022 . . . . 1.3899999999999999 108.263 179.547 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -117.67 162.16 18.5 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.524 -0.735 . . . . 1.22 110.222 -178.769 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 32.4 m -153.59 141.24 19.94 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.585 -0.697 . . . . 1.6299999999999999 109.13 179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 41.7 m -145.05 112.27 6.06 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.113 -0.992 . . . . 1.8799999999999999 110.021 -179.664 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . 0.484 ' CG2' ' N ' ' B' ' 14' ' ' PHE . 3.2 p -159.93 167.48 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 N-CA-C 108.689 -0.856 . . . . 1.2 108.689 179.661 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 14' ' ' PHE . . . . . 0.515 ' HB3' ' H ' ' A' ' 53' ' ' ILE . 9.1 p90 -176.77 -169.07 0.25 Allowed 'General case' 0 N--CA 1.49 1.565 0 C-N-CA 119.162 -1.015 . . . . 2.3900000000000001 112.179 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.4 ' CD1' ' O ' ' B' ' 14' ' ' PHE . 3.9 mm -142.12 165.14 17.68 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 N-CA-C 108.69 -0.856 . . . . 1.8100000000000001 108.69 179.759 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 75.7 p -120.0 136.72 54.45 Favored 'General case' 0 N--CA 1.503 2.2 0 O-C-N 121.283 -0.886 . . . . 2.04 109.681 179.876 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 11.0 mt . . . . . 0 N--CA 1.5 2.058 0 O-C-N 121.369 -0.832 . . . . 1.8700000000000001 109.975 -179.836 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.472 ' O ' ' CB ' ' A' ' 94' ' ' GLU . . . . . . . . 0 N--CA 1.488 2.115 0 N-CA-C 111.568 -0.613 . . . . 2.4399999999999999 111.568 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.558 ' C ' ' H ' ' A' ' 19' ' ' HIS . . . 67.71 -49.03 0.33 Allowed Glycine 0 N--CA 1.495 2.61 0 O-C-N 121.577 -0.955 . . . . 2.0499999999999998 111.662 178.092 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.437 ' N ' ' CD ' ' A' ' 94' ' ' GLU . . . -51.3 -5.29 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.853 0 O-C-N 120.963 -1.316 . . . . 2.54 109.975 -179.201 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' HIS . . . . . 0.558 ' H ' ' C ' ' A' ' 17' ' ' GLY . 6.1 t60 -98.75 -7.13 28.13 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.135 -0.978 . . . . 3.3700000000000001 110.503 -179.545 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.667 ' HZ1' ' HG1' ' A' ' 43' ' ' THR . 0.0 OUTLIER -137.8 6.0 2.65 Favored 'General case' 0 N--CA 1.501 2.106 0 O-C-N 120.968 -1.082 . . . . 2.3700000000000001 110.34 -179.581 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 71.3 t -91.05 113.43 26.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 120.95 -1.094 . . . . 2.5800000000000001 109.851 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 12.8 tpp180 -105.33 137.88 42.43 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 108.827 -0.805 . . . . 3.8900000000000001 108.827 179.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -147.12 113.64 5.98 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.418 -0.801 . . . . 2.0099999999999998 108.857 179.794 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -155.26 129.73 2.61 Favored Glycine 0 N--CA 1.493 2.471 0 N-CA-C 109.678 -1.369 . . . . 2.0099999999999998 109.678 -179.655 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.54 -176.88 46.8 Favored Glycine 0 N--CA 1.491 2.304 0 C-N-CA 119.741 -1.219 . . . . 1.9299999999999999 110.088 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 12.6 p -79.65 -25.53 41.34 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.353 -1.086 . . . . 2.6899999999999999 109.343 179.877 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -68.94 -15.99 69.94 Favored Glycine 0 N--CA 1.485 1.934 0 N-CA-C 108.304 -1.918 . . . . 1.6399999999999999 108.304 179.548 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 90.4 mt -93.35 30.41 1.71 Allowed 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 108.601 -0.889 . . . . 2.0299999999999998 108.601 179.49 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 15.3 mt-10 -139.11 -48.72 0.49 Allowed 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.504 -0.747 . . . . 2.3399999999999999 109.34 -179.834 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 5.4 ptp180 -174.69 177.12 2.15 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.153 -0.967 . . . . 4.25 110.192 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -149.43 174.58 28.93 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 108.495 -1.842 . . . . 1.5900000000000001 108.495 179.717 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 39.5 t -134.42 149.87 30.26 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.075 0 O-C-N 121.203 -1.175 . . . . 2.21 110.567 -179.702 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -37.38 113.98 0.3 Allowed 'General case' 0 N--CA 1.496 1.864 0 CA-C-O 121.745 0.783 . . . . 2.0699999999999998 112.471 -179.232 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 51.68 51.42 38.74 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 111.24 -0.744 . . . . 1.73 111.24 177.097 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 24.4 t -126.82 121.67 23.18 Favored Pre-proline 0 N--CA 1.495 1.821 0 N-CA-C 108.198 -1.038 . . . . 2.6499999999999999 108.198 178.834 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -57.87 140.22 93.04 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 120.483 0.789 . . . . 2.1400000000000001 110.142 -179.422 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -145.33 158.0 43.92 Favored 'General case' 0 N--CA 1.493 1.716 0 N-CA-C 108.275 -1.009 . . . . 2.0299999999999998 108.275 179.603 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -155.8 172.01 19.06 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.815 -1.178 . . . . 2.23 110.8 -179.543 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 5.9 p90 -156.27 166.64 32.85 Favored 'General case' 0 C--N 1.298 -1.646 0 N-CA-C 107.888 -1.153 . . . . 1.72 107.888 178.446 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 43.9 m -99.05 152.12 20.18 Favored 'General case' 0 N--CA 1.494 1.762 0 CA-C-O 121.782 0.801 . . . . 2.5800000000000001 111.129 -178.146 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 10.8 mt -143.48 85.79 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 N-CA-C 108.416 -0.957 . . . . 1.8600000000000001 108.416 178.91 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 31.5 t90 -91.61 147.36 23.06 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.053 -1.029 . . . . 4.4699999999999998 109.284 -179.489 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' THR . . . . . 0.667 ' HG1' ' HZ1' ' A' ' 20' ' ' LYS . 0.1 OUTLIER -161.76 -110.99 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.286 -0.883 . . . . 3.27 109.628 -179.731 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' ARG . . . . . 0.523 ' N ' ' OG1' ' A' ' 43' ' ' THR . 2.3 ttt-85 52.69 90.74 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.221 -0.924 . . . . 5.2300000000000004 109.862 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -172.2 -60.68 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.245 -0.909 . . . . 2.8900000000000001 109.365 179.265 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -57.04 -57.89 10.57 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.988 -1.07 . . . . 1.99 108.741 179.724 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 150.99 -160.46 28.64 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 110.029 -1.228 . . . . 1.6499999999999999 110.029 179.488 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.01 149.17 9.55 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.403 -1.057 . . . . 1.77 109.778 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -176.26 173.65 46.42 Favored Glycine 0 N--CA 1.489 2.168 0 N-CA-C 109.487 -1.445 . . . . 1.1200000000000001 109.487 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -126.76 122.63 4.4 Favored Glycine 0 N--CA 1.498 2.825 0 N-CA-C 109.143 -1.583 . . . . 1.1799999999999999 109.143 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.434 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 11.3 tp -93.85 99.37 11.75 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.221 -1.164 . . . . 1.5900000000000001 108.843 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 2.2 t -83.51 141.27 31.76 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 108.42 -0.956 . . . . 1.9399999999999999 108.42 179.687 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.531 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 92.3 mt -134.73 115.58 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.217 -0.927 . . . . 1.3 109.33 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -104.65 106.86 17.52 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.364 -0.835 . . . . 1.27 109.008 179.778 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -101.45 135.07 39.72 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.115 0 O-C-N 121.477 -0.765 . . . . 1.55 109.516 -179.771 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . 0.43 ' OE2' ' O ' ' B' ' 9' ' ' VAL . 30.9 tp10 -134.36 142.46 47.22 Favored 'General case' 0 N--CA 1.494 1.738 0 N-CA-C 107.399 -1.334 . . . . 1.8 107.399 178.324 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 171.51 -176.67 44.67 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.421 -1.472 . . . . 0.56000000000000005 109.421 -179.362 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -61.62 -28.35 82.6 Favored 'Trans proline' 0 C--N 1.318 -1.06 0 C-N-CA 121.992 1.795 . . . . 0.76000000000000001 111.856 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' SER . . . . . 0.407 ' OG ' ' OH ' ' A' ' 85' ' ' TYR . 10.6 p -142.39 163.24 33.37 Favored 'General case' 0 N--CA 1.501 2.095 0 O-C-N 121.063 -1.023 . . . . 2.02 110.349 -179.564 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 19.4 mtpp -81.09 115.71 20.66 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.532 -0.73 . . . . 3.02 109.28 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -80.67 129.54 34.58 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.284 -0.885 . . . . 1.3600000000000001 109.648 -179.817 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 18.2 tp10 -68.29 170.95 7.85 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.127 -0.983 . . . . 2.2999999999999998 108.535 179.722 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 3.8 mp -139.9 153.75 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 N-CA-C 108.417 -0.956 . . . . 2.0 108.417 -179.389 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.563 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -150.79 114.6 4.98 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 120.672 -1.267 . . . . 1.73 109.747 -179.565 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . 0.505 ' CD2' ' O ' ' A' ' 65' ' ' PHE . 43.0 p90 -92.77 122.56 35.28 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.27 -0.894 . . . . 1.6000000000000001 109.19 179.615 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 . . . . . 0 N--CA 1.496 1.858 0 O-C-N 121.266 -0.896 . . . . 2.5099999999999998 109.51 -179.835 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 89.9 p . . . . . 0 N--CA 1.495 1.78 0 N-CA-C 109.107 -0.701 . . . . 2.5600000000000001 109.107 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 29.7 t -89.72 136.47 33.02 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.199 -0.938 . . . . 2.3599999999999999 109.682 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -114.24 114.24 3.24 Favored Glycine 0 N--CA 1.5 2.937 0 N-CA-C 109.696 -1.362 . . . . 1.46 109.696 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 78.9 t -99.7 105.13 17.04 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.102 0 O-C-N 121.411 -1.052 . . . . 2.1600000000000001 109.629 179.722 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.563 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.1 OUTLIER -95.26 134.5 37.95 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 109.018 -0.734 . . . . 2.1600000000000001 109.018 179.84 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 45.7 p90 -135.32 172.73 12.59 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.205 -0.934 . . . . 1.7 109.079 -179.848 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.458 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 9.8 p -140.34 118.09 9.96 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.082 0 O-C-N 121.256 -0.902 . . . . 2.4500000000000002 110.033 179.758 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 13.4 m -86.64 151.97 3.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.391 -0.818 . . . . 1.8200000000000001 108.922 179.548 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 4.0 tp-100 -94.51 -47.24 6.64 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.042 -1.036 . . . . 3.1699999999999999 110.899 -179.039 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -153.37 152.37 27.48 Favored Pre-proline 0 N--CA 1.505 2.302 0 O-C-N 120.406 -1.434 . . . . 2.02 110.965 -179.497 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.58 ' HG3' ' N ' ' A' ' 107' ' ' SER . 78.4 Cg_exo -38.48 164.42 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 123.392 2.728 . . . . 1.3999999999999999 113.778 178.833 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 145.08 -164.97 27.84 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.004 -1.639 . . . . 1.0800000000000001 109.004 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 25.2 m-20 -109.01 90.88 3.43 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.61 -0.935 . . . . 2.1299999999999999 108.641 179.581 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . 0.411 ' O ' ' N ' ' A' ' 103' ' ' VAL . 3.7 m-85 -78.74 130.53 35.88 Favored 'General case' 0 N--CA 1.487 1.406 0 N-CA-C 108.003 -1.11 . . . . 1.1399999999999999 108.003 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -115.35 128.49 56.12 Favored 'General case' 0 N--CA 1.502 2.146 0 N-CA-C 108.946 -0.761 . . . . 1.53 108.946 -178.503 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 10.0 p -125.36 140.46 48.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.75 -0.593 . . . . 1.6399999999999999 109.925 -179.852 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 16.2 m -129.33 100.07 5.45 Favored 'General case' 0 N--CA 1.497 1.884 0 N-CA-C 108.922 -0.77 . . . . 1.99 108.922 179.477 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.6 pt -105.57 134.93 45.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 CA-C-O 121.482 0.658 . . . . 1.77 110.208 -179.301 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' LYS . . . . . 0.466 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -144.3 122.35 12.11 Favored 'General case' 0 C--N 1.305 -1.339 0 N-CA-C 108.271 -1.011 . . . . 2.0600000000000001 108.271 179.508 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 62.9 t80 -80.97 101.27 9.4 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.864 -1.147 . . . . 1.45 107.995 178.705 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 70.37 39.04 1.29 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.392 -0.817 . . . . 2.7200000000000002 108.982 -178.809 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 74.57 15.03 3.41 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.705 -0.622 . . . . 1.9199999999999999 111.293 179.653 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . 0.472 ' CB ' ' O ' ' A' ' 16' ' ' GLY . 0.5 OUTLIER -98.29 96.22 7.91 Favored 'General case' 0 N--CA 1.498 1.974 0 N-CA-C 106.813 -1.551 . . . . 2.5499999999999998 106.813 177.641 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' HIS . . . . . 0.555 ' CD2' ' H ' ' A' ' 95' ' ' HIS . 5.8 m-70 -73.07 111.66 8.39 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.615 -0.678 . . . . 3.2000000000000002 110.112 -177.926 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' ILE . . . . . 0.583 ' CD1' ' H ' ' A' ' 96' ' ' ILE . 0.0 OUTLIER -70.35 155.93 92.67 Favored Pre-proline 0 N--CA 1.494 1.734 0 N-CA-C 107.444 -1.317 . . . . 2.8199999999999998 107.444 179.148 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_exo -46.54 -35.6 16.93 Favored 'Trans proline' 0 C--N 1.322 -0.861 0 C-N-CA 121.336 1.357 . . . . 2.6299999999999999 109.942 -179.412 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -53.78 -63.65 1.08 Allowed 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.301 -0.875 . . . . 2.6499999999999999 109.383 179.267 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 3.6 m -70.45 141.21 87.92 Favored Pre-proline 0 C--N 1.295 -1.777 0 O-C-N 120.92 -1.112 . . . . 2.3199999999999998 110.19 -178.467 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -86.8 119.02 4.96 Favored 'Cis proline' 0 N--CA 1.493 1.474 0 N-CA-C 109.967 -0.82 . . . . 1.9399999999999999 109.967 -2.439 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 45.2 p90 -120.89 158.34 27.85 Favored 'General case' 0 N--CA 1.518 2.939 0 O-C-N 120.445 -1.41 . . . . 2.6299999999999999 109.506 178.273 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.3 p -92.17 157.26 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.429 -0.794 . . . . 1.8200000000000001 110.887 -178.426 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.411 ' N ' ' O ' ' A' ' 85' ' ' TYR . 56.9 t -128.26 86.25 58.41 Favored Pre-proline 0 N--CA 1.495 1.778 0 N-CA-C 107.85 -1.167 . . . . 1.73 107.85 179.341 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -64.04 112.71 1.93 Allowed 'Trans proline' 0 C--N 1.32 -0.966 0 C-N-CA 121.377 1.385 . . . . 1.6100000000000001 111.624 -177.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 54.8 t -95.54 141.01 15.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 N-CA-C 106.771 -1.566 . . . . 1.7 106.771 177.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -130.6 131.79 45.15 Favored 'General case' 0 N--CA 1.51 2.551 0 CA-C-O 121.925 0.869 . . . . 2.04 112.064 -177.041 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' SER . . . . . 0.58 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 35.4 t -101.36 92.99 5.19 Favored 'General case' 0 N--CA 1.494 1.75 0 N-CA-C 107.993 -1.114 . . . . 2.2999999999999998 107.993 179.274 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 20.5 mt 60.08 3.71 0.54 Allowed 'General case' 0 C--N 1.295 -1.774 0 N-CA-C 108.166 -1.05 . . . . 3.6000000000000001 108.166 -178.574 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.547 ' H ' ' C ' ' A' ' 107' ' ' SER . 8.3 t -94.83 -29.26 14.82 Favored 'General case' 0 N--CA 1.49 1.563 0 N-CA-C 109.03 -0.729 . . . . 2.4900000000000002 109.03 179.391 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 16.9 t70 . . . . . 0 N--CA 1.489 1.496 0 N-CA-C 107.754 -1.202 . . . . 2.8500000000000001 107.754 -178.843 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . 0.607 HH11 ' CG ' ' B' ' 8' ' ' ARG . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.769 0 N-CA-C 108.061 -1.088 . . . . 3.6699999999999999 108.061 . . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 9' ' ' VAL . . . . . 0.43 ' O ' ' OE2' ' A' ' 56' ' ' GLU . 36.3 t -51.61 155.48 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 O-C-N 120.963 -1.085 . . . . 1.3899999999999999 108.508 179.519 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -107.7 158.84 16.94 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 121.484 -0.76 . . . . 1.22 110.443 -178.763 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 25.6 t -159.34 112.91 2.29 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.487 -0.758 . . . . 1.6299999999999999 109.007 179.51 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 15.0 p -117.02 124.9 50.44 Favored 'General case' 0 N--CA 1.501 2.111 0 O-C-N 121.417 -0.802 . . . . 1.8799999999999999 109.413 -179.771 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . 0.468 ' CG2' ' N ' ' B' ' 14' ' ' PHE . 6.6 p -164.39 164.01 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.293 -0.879 . . . . 1.2 109.786 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 14' ' ' PHE . . . . . 0.531 ' HB3' ' H ' ' A' ' 53' ' ' ILE . 6.5 p90 -179.29 -175.21 0.35 Allowed 'General case' 0 N--CA 1.488 1.472 0 CA-C-O 121.784 0.802 . . . . 2.3900000000000001 111.427 179.102 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -144.01 168.8 10.77 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.295 0 N-CA-C 109.28 -0.637 . . . . 1.8100000000000001 109.28 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 74.1 p -133.81 156.13 48.59 Favored 'General case' 0 N--CA 1.499 2.021 0 N-CA-C 108.72 -0.844 . . . . 2.04 108.72 179.523 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.491 1.615 0 O-C-N 120.948 -1.095 . . . . 1.8700000000000001 110.643 -179.307 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.502 ' O ' ' N ' ' A' ' 18' ' ' ALA . . . . . . . . 0 N--CA 1.486 2.007 0 N-CA-C 110.009 -1.236 . . . . 2.4399999999999999 110.009 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.553 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -42.72 -19.8 0.07 OUTLIER Glycine 0 N--CA 1.49 2.282 0 O-C-N 121.417 -1.049 . . . . 2.0499999999999998 110.839 -179.325 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.502 ' N ' ' O ' ' A' ' 16' ' ' GLY . . . -47.26 -12.92 0.03 OUTLIER 'General case' 0 N--CA 1.495 1.8 0 O-C-N 120.448 -1.619 . . . . 2.54 109.297 179.413 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' HIS . . . . . 0.553 ' N ' ' O ' ' A' ' 17' ' ' GLY . 12.8 t-80 -93.36 -52.25 4.61 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.268 -0.895 . . . . 3.3700000000000001 109.906 179.882 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.535 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.1 OUTLIER -69.75 -23.6 63.4 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.869 -1.144 . . . . 2.3700000000000001 109.588 -179.69 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 76.1 t -63.33 112.62 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.161 -0.962 . . . . 2.5800000000000001 109.5 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 20.6 tpt180 -97.34 138.32 34.99 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 108.695 -0.854 . . . . 3.8900000000000001 108.695 179.666 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -142.64 113.46 7.5 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.287 -0.883 . . . . 2.0099999999999998 109.279 -179.88 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -154.08 130.85 3.03 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 109.518 -1.433 . . . . 2.0099999999999998 109.518 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -177.94 171.17 43.67 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.703 -1.359 . . . . 1.9299999999999999 109.703 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 10.9 p -77.97 -28.87 49.53 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.302 -1.117 . . . . 2.6899999999999999 109.405 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -67.72 -16.88 68.51 Favored Glycine 0 N--CA 1.487 2.038 0 N-CA-C 108.42 -1.872 . . . . 1.6399999999999999 108.42 179.606 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 49.0 mt -85.85 22.68 1.61 Allowed 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 108.506 -0.924 . . . . 2.0299999999999998 108.506 179.356 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 11.5 mt-10 -133.47 -50.38 0.85 Allowed 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.62 -0.675 . . . . 2.3399999999999999 109.398 -179.673 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 11.3 ptt180 -163.31 -176.71 4.92 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.069 -1.019 . . . . 4.25 109.936 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -157.18 -178.42 31.23 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 108.761 -1.735 . . . . 1.5900000000000001 108.761 -179.799 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 38.4 t -134.71 151.8 32.09 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.153 0 O-C-N 121.154 -1.203 . . . . 2.21 110.663 -179.777 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -45.77 115.22 0.91 Allowed 'General case' 0 N--CA 1.498 1.936 0 CA-C-O 121.815 0.817 . . . . 2.0699999999999998 112.443 -179.34 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 57.82 46.55 92.22 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 111.562 -0.615 . . . . 1.73 111.562 177.062 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 25.2 t -127.38 120.49 22.16 Favored Pre-proline 0 N--CA 1.499 1.98 0 O-C-N 121.37 -1.076 . . . . 2.6499999999999999 108.818 179.178 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -60.09 113.02 1.48 Allowed 'Trans proline' 0 C--O 1.215 -0.657 0 N-CA-C 109.676 -0.932 . . . . 2.1400000000000001 109.676 179.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -113.04 156.12 23.64 Favored 'General case' 0 N--CA 1.498 1.949 0 N-CA-C 108.268 -1.012 . . . . 2.0299999999999998 108.268 179.617 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -158.03 163.68 37.49 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.718 -1.239 . . . . 2.23 111.403 -179.779 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . 0.575 ' N ' ' CD1' ' A' ' 39' ' ' PHE . 0.8 OUTLIER -139.93 -173.17 3.57 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 107.228 -1.397 . . . . 1.72 107.228 178.513 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 24.4 m -121.83 149.11 43.82 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.535 -0.728 . . . . 2.5800000000000001 110.307 -179.234 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.416 HG23 HD13 ' A' ' 41' ' ' ILE . 34.9 mt -144.48 102.05 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 N-CA-C 107.962 -1.125 . . . . 1.8600000000000001 107.962 178.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.458 ' CD1' ' C ' ' A' ' 42' ' ' TRP . 0.1 OUTLIER -89.59 139.6 30.38 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.259 -0.901 . . . . 4.4699999999999998 108.927 -179.635 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' THR . . . . . 0.535 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.1 OUTLIER -152.79 120.03 5.89 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.42 -0.8 . . . . 3.27 109.214 -179.733 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' ARG . . . . . . . . . . . . . 28.9 ttt-85 -170.28 62.87 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.201 -0.937 . . . . 5.2300000000000004 109.848 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 25.4 tt0 -157.06 -56.6 0.08 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.14 -0.975 . . . . 2.8900000000000001 109.534 179.65 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -57.88 -57.4 12.93 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.092 -1.005 . . . . 1.99 108.88 179.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 142.03 -179.2 20.17 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.263 -1.535 . . . . 1.6499999999999999 109.263 179.845 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -55.9 159.14 3.35 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.127 -1.22 . . . . 1.77 109.345 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -176.83 176.12 47.88 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.595 -1.402 . . . . 1.1200000000000001 109.595 -179.877 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -106.94 123.26 7.24 Favored Glycine 0 N--CA 1.497 2.743 0 N-CA-C 109.427 -1.469 . . . . 1.1799999999999999 109.427 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.42 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 12.3 tp -99.8 100.55 11.51 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.295 -1.12 . . . . 1.5900000000000001 108.452 179.663 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 3.9 m -85.51 144.13 28.12 Favored 'General case' 0 N--CA 1.491 1.616 0 N-CA-C 108.662 -0.866 . . . . 1.9399999999999999 108.662 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.499 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 78.5 mt -134.71 106.69 7.68 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 O-C-N 121.224 -0.922 . . . . 1.3 109.614 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -95.65 106.26 18.34 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.377 -0.971 . . . . 1.27 108.377 179.272 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -97.45 145.29 9.47 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 121.421 -0.799 . . . . 1.55 109.933 -179.339 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 20.2 tt0 -141.56 145.06 34.65 Favored 'General case' 0 N--CA 1.491 1.61 0 N-CA-C 107.536 -1.283 . . . . 1.8 107.536 178.708 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 161.64 -171.04 37.52 Favored Glycine 0 N--CA 1.488 2.13 0 N-CA-C 109.644 -1.382 . . . . 0.56000000000000005 109.644 -179.069 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -64.32 -30.31 63.46 Favored 'Trans proline' 0 C--N 1.316 -1.142 0 C-N-CA 122.047 1.831 . . . . 0.76000000000000001 111.652 -179.598 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 24.3 t -142.1 164.96 28.76 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.039 -1.038 . . . . 2.02 110.129 -179.877 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 58.4 mttt -84.44 107.48 16.72 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.527 -0.733 . . . . 3.02 109.56 -179.8 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -67.08 143.39 56.71 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.222 -0.924 . . . . 1.3600000000000001 109.4 179.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . 0.4 ' H ' HG11 ' A' ' 78' ' ' VAL . 23.3 tt0 -93.2 91.36 7.24 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.225 -0.922 . . . . 2.2999999999999998 109.537 -179.93 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . 0.411 ' N ' ' CD1' ' A' ' 63' ' ' ILE . 2.2 mp -60.54 156.61 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 N-CA-C 109.138 -0.689 . . . . 2.0 109.138 179.602 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.527 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -145.99 174.85 10.91 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.981 -1.074 . . . . 1.73 108.595 179.621 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . 0.487 ' O ' ' CG ' ' A' ' 65' ' ' PHE . 28.8 p90 -147.87 115.87 6.47 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.093 -1.005 . . . . 1.6000000000000001 109.647 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 . . . . . 0 N--CA 1.497 1.883 0 O-C-N 121.209 -0.932 . . . . 2.5099999999999998 109.485 179.791 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.5 p . . . . . 0 N--CA 1.495 1.791 0 N-CA-C 109.085 -0.709 . . . . 2.5600000000000001 109.085 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 7.7 t -75.42 146.58 40.64 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.214 -0.929 . . . . 2.3599999999999999 109.622 -179.814 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -120.25 111.58 2.01 Favored Glycine 0 N--CA 1.499 2.851 0 N-CA-C 109.32 -1.512 . . . . 1.46 109.32 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 22.5 t -99.32 106.22 18.64 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 O-C-N 121.542 -0.975 . . . . 2.1600000000000001 109.109 179.807 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.527 ' O ' ' N ' ' A' ' 64' ' ' ALA . 5.9 t -100.04 135.67 41.11 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.537 -0.727 . . . . 2.1600000000000001 109.895 -179.687 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 4.9 p90 -133.59 131.4 39.61 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 108.801 -0.815 . . . . 1.7 108.801 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.471 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 8.0 p -100.37 115.79 42.42 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.955 0 O-C-N 121.276 -0.89 . . . . 2.4500000000000002 109.183 -179.668 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 26.9 m -84.73 164.5 2.53 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 121.187 -0.946 . . . . 1.8200000000000001 109.142 -179.681 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 36.3 tt0 -102.54 -49.08 3.94 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.276 -0.89 . . . . 3.1699999999999999 110.324 -179.689 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -157.15 153.99 25.04 Favored Pre-proline 0 N--CA 1.502 2.132 0 O-C-N 120.907 -1.121 . . . . 2.02 111.161 -179.147 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.535 ' HG3' ' N ' ' A' ' 107' ' ' SER . 89.1 Cg_exo -35.55 156.99 0.02 OUTLIER 'Trans proline' 0 C--O 1.214 -0.683 0 C-N-CA 123.394 2.729 . . . . 1.3999999999999999 113.745 179.354 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 148.51 -170.3 29.02 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 108.556 -1.818 . . . . 1.0800000000000001 108.556 -179.675 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . 0.527 ' OD2' ' NH2' ' B' ' 8' ' ' ARG . 4.5 p-10 -107.24 93.71 4.7 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.378 -1.072 . . . . 2.1299999999999999 108.452 179.368 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . 0.426 ' O ' ' N ' ' A' ' 103' ' ' VAL . 2.4 m-85 -77.38 131.63 38.15 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 108.398 -0.964 . . . . 1.1399999999999999 108.398 -179.784 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -112.82 126.82 55.85 Favored 'General case' 0 N--CA 1.501 2.081 0 N-CA-C 108.465 -0.939 . . . . 1.53 108.465 -179.292 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.466 ' CG1' ' CE2' ' A' ' 101' ' ' PHE . 5.5 p -126.29 133.96 67.55 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 O-C-N 121.525 -0.734 . . . . 1.6399999999999999 109.782 -179.703 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' SER . . . . . 0.407 ' O ' ' OG ' ' A' ' 88' ' ' SER . 19.0 p -124.58 104.82 8.92 Favored 'General case' 0 N--CA 1.499 1.986 0 N-CA-C 109.171 -0.678 . . . . 1.99 109.171 179.835 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.405 ' N ' ' OG ' ' A' ' 99' ' ' SER . 1.5 pt -108.37 133.18 54.13 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 CA-C-O 121.54 0.686 . . . . 1.77 110.37 -179.245 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' LYS . . . . . 0.456 ' O ' ' CG ' ' A' ' 90' ' ' LYS . 0.3 OUTLIER -138.08 122.51 18.36 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 107.927 -1.138 . . . . 2.0600000000000001 107.927 179.257 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.412 ' O ' ' CB ' ' A' ' 92' ' ' ASN . 81.4 t80 -82.84 99.99 10.06 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 120.443 -1.411 . . . . 1.45 107.924 179.21 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . 0.446 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 3.2 t-20 72.28 34.85 1.3 Allowed 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.266 -0.896 . . . . 2.7200000000000002 108.983 -178.627 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . 0.446 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 1.6 m-20 80.47 13.81 0.83 Allowed 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.725 -0.609 . . . . 1.9199999999999999 111.662 179.336 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . 0.467 ' CG ' ' O ' ' A' ' 94' ' ' GLU . 5.4 pt-20 -100.71 98.84 9.34 Favored 'General case' 0 N--CA 1.499 2.023 0 N-CA-C 107.459 -1.312 . . . . 2.5499999999999998 107.459 177.843 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 26.6 p-80 -65.3 99.59 0.41 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.686 -0.634 . . . . 3.2000000000000002 110.243 -178.251 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' ILE . . . . . 0.523 ' O ' ' N ' ' A' ' 98' ' ' ASP . 4.0 tt -50.82 136.09 26.77 Favored Pre-proline 0 N--CA 1.489 1.524 0 N-CA-C 107.988 -1.116 . . . . 2.8199999999999998 107.988 179.089 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . 0.433 ' O ' ' CB ' ' A' ' 98' ' ' ASP . 9.4 Cg_exo -47.88 90.35 0.02 OUTLIER 'Trans proline' 0 C--O 1.213 -0.727 0 C-N-CA 120.547 0.832 . . . . 2.6299999999999999 110.006 -179.627 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.523 ' N ' ' O ' ' A' ' 96' ' ' ILE . 0.9 OUTLIER 166.5 -57.87 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.749 0 N-CA-C 108.445 -0.946 . . . . 2.6499999999999999 108.445 -179.569 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' SER . . . . . 0.405 ' OG ' ' N ' ' A' ' 89' ' ' ILE . 3.3 m -55.55 137.75 69.7 Favored Pre-proline 0 C--N 1.296 -1.72 0 O-C-N 121.246 -0.909 . . . . 2.3199999999999998 109.6 -178.185 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo -90.0 114.96 2.59 Favored 'Cis proline' 0 N--CA 1.494 1.513 0 N-CA-C 110.249 -0.712 . . . . 1.9399999999999999 110.249 -2.33 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . 0.466 ' CE2' ' CG1' ' A' ' 87' ' ' VAL . 1.6 p90 -97.18 163.26 12.99 Favored 'General case' 0 N--CA 1.515 2.802 0 O-C-N 120.217 -1.552 . . . . 2.6299999999999999 109.568 178.456 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.9 p -95.31 148.96 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.594 -0.691 . . . . 1.8200000000000001 109.822 -179.703 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.426 ' N ' ' O ' ' A' ' 85' ' ' TYR . 64.5 t -128.53 86.41 57.79 Favored Pre-proline 0 N--CA 1.499 2.002 0 N-CA-C 108.432 -0.951 . . . . 1.73 108.432 179.89 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -63.92 112.16 1.76 Allowed 'Trans proline' 0 C--N 1.321 -0.88 0 C-N-CA 121.429 1.419 . . . . 1.6100000000000001 111.821 -178.133 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 52.5 t -91.39 147.36 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.514 -1.291 . . . . 1.7 107.514 178.268 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -135.77 134.3 38.85 Favored 'General case' 0 N--CA 1.508 2.467 0 O-C-N 121.373 -0.829 . . . . 2.04 110.911 -178.074 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' SER . . . . . 0.535 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 16.5 t -87.69 67.75 9.29 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.571 -1.331 . . . . 2.2999999999999998 108.095 179.799 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' LEU . . . . . 0.434 ' CB ' ' O ' ' A' ' 107' ' ' SER . 1.0 OUTLIER 71.53 -2.6 2.38 Favored 'General case' 0 C--N 1.295 -1.79 0 N-CA-C 106.921 -1.511 . . . . 3.6000000000000001 106.921 -178.439 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.521 ' H ' ' C ' ' A' ' 107' ' ' SER . 82.6 p -82.73 -21.63 34.7 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 109.165 -0.679 . . . . 2.4900000000000002 109.165 179.422 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 62.2 t0 . . . . . 0 N--CA 1.494 1.753 0 N-CA-C 108.312 -0.996 . . . . 2.8500000000000001 108.312 -179.456 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . 0.527 ' NH2' ' OD2' ' A' ' 84' ' ' ASP . 2.2 mtt-85 . . . . . 0 N--CA 1.494 1.742 0 N-CA-C 108.715 -0.846 . . . . 3.6699999999999999 108.715 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 9' ' ' VAL . . . . . . . . . . . . . 19.4 t -51.41 158.2 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.141 -0.975 . . . . 1.3899999999999999 108.61 179.717 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -121.54 146.88 46.5 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.627 -0.67 . . . . 1.22 109.645 -179.339 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 4.9 t -140.62 143.77 35.39 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.387 -0.821 . . . . 1.6299999999999999 109.436 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 46.8 t -141.39 116.54 9.98 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.319 -0.863 . . . . 1.8799999999999999 109.689 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . 0.489 ' CG2' ' N ' ' B' ' 14' ' ' PHE . 6.6 p -165.04 170.41 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.342 -0.849 . . . . 1.2 109.029 179.899 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 14' ' ' PHE . . . . . 0.499 ' HB3' ' H ' ' A' ' 53' ' ' ILE . 9.6 p90 -175.92 -163.14 0.1 Allowed 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 119.285 -0.966 . . . . 2.3900000000000001 112.144 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.9 pt -150.47 165.55 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.339 0 N-CA-C 108.965 -0.754 . . . . 1.8100000000000001 108.965 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 17.9 m -125.27 128.82 48.87 Favored 'General case' 0 N--CA 1.502 2.132 0 O-C-N 121.385 -0.822 . . . . 2.04 109.437 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 9.3 mt . . . . . 0 N--CA 1.497 1.898 0 O-C-N 121.267 -0.896 . . . . 1.8700000000000001 109.922 -179.715 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.122 0 N-CA-C 111.204 -0.758 . . . . 2.4399999999999999 111.204 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.558 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -43.2 -23.65 0.26 Allowed Glycine 0 N--CA 1.49 2.271 0 O-C-N 121.715 -0.874 . . . . 2.0499999999999998 111.489 -178.265 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.493 ' N ' ' OE1' ' A' ' 94' ' ' GLU . . . -43.01 -17.94 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.042 -1.27 . . . . 2.54 110.047 -179.715 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' HIS . . . . . 0.558 ' N ' ' O ' ' A' ' 17' ' ' GLY . 8.9 t-80 -95.3 -52.06 4.33 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.33 -0.856 . . . . 3.3700000000000001 109.731 179.884 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.646 ' HZ2' ' HG1' ' A' ' 43' ' ' THR . 0.0 OUTLIER -67.21 -14.71 63.17 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.996 -1.065 . . . . 2.3700000000000001 109.551 -179.602 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 71.2 t -76.93 113.4 15.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.181 -0.95 . . . . 2.5800000000000001 108.813 179.308 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 20.7 tpt180 -110.4 136.31 49.76 Favored 'General case' 0 N--CA 1.494 1.774 0 CA-C-O 121.567 0.698 . . . . 3.8900000000000001 110.18 -179.015 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -140.05 113.61 8.61 Favored 'General case' 0 N--CA 1.491 1.603 0 N-CA-C 108.645 -0.872 . . . . 2.0099999999999998 108.645 179.569 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -146.38 126.51 2.5 Favored Glycine 0 N--CA 1.496 2.638 0 N-CA-C 109.625 -1.39 . . . . 2.0099999999999998 109.625 -179.647 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.32 177.93 48.5 Favored Glycine 0 N--CA 1.488 2.139 0 N-CA-C 109.743 -1.343 . . . . 1.9299999999999999 109.743 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 41.7 p -79.63 -24.62 41.79 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.249 -1.148 . . . . 2.6899999999999999 109.461 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -68.56 -14.1 66.6 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 108.387 -1.885 . . . . 1.6399999999999999 108.387 179.492 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 33.6 mt -100.35 35.25 2.15 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.688 -0.856 . . . . 2.0299999999999998 108.688 179.76 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 -144.32 -46.01 0.25 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.377 -0.827 . . . . 2.3399999999999999 109.516 -179.742 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 29.2 ptt180 -172.36 171.95 4.58 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 120.98 -1.075 . . . . 4.25 110.093 -179.874 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -147.76 174.4 27.51 Favored Glycine 0 N--CA 1.493 2.439 0 N-CA-C 108.598 -1.801 . . . . 1.5900000000000001 108.598 179.622 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 37.6 t -134.68 152.52 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.088 0 O-C-N 121.136 -1.214 . . . . 2.21 110.576 -179.635 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -40.78 112.29 0.28 Allowed 'General case' 0 N--CA 1.499 1.999 0 CA-C-O 121.586 0.708 . . . . 2.0699999999999998 112.321 -179.268 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 53.72 51.82 46.32 Favored Glycine 0 N--CA 1.49 2.253 0 O-C-N 121.57 -0.706 . . . . 1.73 111.377 177.049 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 24.7 t -127.29 98.38 29.68 Favored Pre-proline 0 N--CA 1.495 1.787 0 O-C-N 121.451 -1.029 . . . . 2.6499999999999999 108.453 178.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_exo -57.85 138.71 87.37 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 120.67 0.913 . . . . 2.1400000000000001 109.854 -179.25 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -146.79 -167.76 2.85 Favored 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 108.491 -0.929 . . . . 2.0299999999999998 108.491 -179.839 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -169.26 170.75 8.38 Favored 'General case' 0 C--N 1.303 -1.415 0 C-N-CA 118.745 -1.182 . . . . 2.23 111.04 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . 0.53 ' N ' ' CD1' ' A' ' 39' ' ' PHE . 1.2 p90 -142.3 -178.26 5.65 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 107.49 -1.3 . . . . 1.72 107.49 178.274 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 88.9 p -124.43 138.37 54.36 Favored 'General case' 0 N--CA 1.501 2.088 0 CA-C-O 122.118 0.961 . . . . 2.5800000000000001 111.219 -178.515 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.476 ' O ' ' N ' ' A' ' 73' ' ' CYS . 33.3 mm -130.58 126.59 60.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 N-CA-C 108.238 -1.023 . . . . 1.8600000000000001 108.238 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.504 ' C ' ' CD1' ' A' ' 42' ' ' TRP . 0.6 OUTLIER -138.28 142.13 39.83 Favored 'General case' 0 N--CA 1.503 2.221 0 O-C-N 120.898 -1.126 . . . . 4.4699999999999998 109.539 179.357 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' THR . . . . . 0.646 ' HG1' ' HZ2' ' A' ' 20' ' ' LYS . 0.2 OUTLIER -156.44 151.94 26.83 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.553 -0.717 . . . . 3.27 109.605 -179.076 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' ARG . . . . . 0.479 ' CG ' ' NH1' ' A' ' 44' ' ' ARG . 0.0 OUTLIER -168.38 62.47 0.06 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.481 -0.762 . . . . 5.2300000000000004 109.069 179.596 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -155.43 -60.09 0.11 Allowed 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.106 -0.996 . . . . 2.8900000000000001 110.016 -179.748 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -59.7 -32.75 70.8 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.886 -1.134 . . . . 1.99 109.333 -179.734 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 94.94 -157.36 22.14 Favored Glycine 0 N--CA 1.495 2.603 0 N-CA-C 109.996 -1.242 . . . . 1.6499999999999999 109.996 179.72 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.65 163.19 0.71 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.398 -1.06 . . . . 1.77 110.101 -179.605 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 175.56 -165.85 36.91 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.264 -1.534 . . . . 1.1200000000000001 109.264 179.844 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.404 ' O ' ' N ' ' A' ' 92' ' ' ASN . . . -132.6 119.62 2.49 Favored Glycine 0 N--CA 1.498 2.816 0 N-CA-C 108.985 -1.646 . . . . 1.1799999999999999 108.985 179.867 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.429 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 31.6 tp -100.44 104.53 15.94 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.328 -1.101 . . . . 1.5900000000000001 109.014 -179.873 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 13.8 t -91.14 142.73 27.43 Favored 'General case' 0 N--CA 1.495 1.824 0 N-CA-C 108.703 -0.851 . . . . 1.9399999999999999 108.703 179.575 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.503 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 66.0 mt -132.47 103.58 6.54 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.986 0 O-C-N 121.119 -0.988 . . . . 1.3 109.571 -179.922 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -93.76 106.23 18.21 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.641 -0.874 . . . . 1.27 108.641 179.479 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.429 ' O ' ' O ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -98.91 141.7 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.564 -0.71 . . . . 1.55 109.478 -179.622 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 21.0 tt0 -141.28 144.2 34.52 Favored 'General case' 0 N--CA 1.492 1.639 0 N-CA-C 107.535 -1.283 . . . . 1.8 107.535 178.678 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 164.07 -173.3 40.08 Favored Glycine 0 N--CA 1.488 2.134 0 N-CA-C 109.489 -1.444 . . . . 0.56000000000000005 109.489 -178.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -64.01 -33.46 62.54 Favored 'Trans proline' 0 C--N 1.319 -1.015 0 C-N-CA 122.114 1.876 . . . . 0.76000000000000001 112.154 -179.567 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 33.0 m -135.22 155.77 50.1 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.072 -1.017 . . . . 2.02 109.947 -179.307 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 77.3 tttt -73.7 96.35 2.49 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.621 -0.674 . . . . 3.02 109.609 -179.834 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -61.05 123.9 18.98 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.342 -0.849 . . . . 1.3600000000000001 109.341 179.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 19.6 tt0 -70.94 171.03 11.48 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.238 -0.914 . . . . 2.2999999999999998 109.214 -179.82 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 72.4 mt -140.92 152.08 20.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 N-CA-C 107.663 -1.236 . . . . 2.0 107.663 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.518 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -150.09 113.45 4.93 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.537 -1.352 . . . . 1.73 109.356 179.816 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . 0.461 ' CD2' ' O ' ' A' ' 65' ' ' PHE . 47.0 p90 -87.24 125.14 34.01 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.35 -0.844 . . . . 1.6000000000000001 109.71 179.874 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 59.5 tt0 . . . . . 0 N--CA 1.496 1.837 0 O-C-N 121.386 -0.821 . . . . 2.5099999999999998 109.233 179.808 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 45.5 t . . . . . 0 N--CA 1.496 1.871 0 CA-C-O 121.242 0.544 . . . . 2.5600000000000001 109.612 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' CYS . . . . . 0.476 ' N ' ' O ' ' A' ' 41' ' ' ILE . 42.6 m -87.91 114.15 24.24 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.293 -0.879 . . . . 2.3599999999999999 109.548 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -93.9 118.21 5.68 Favored Glycine 0 N--CA 1.494 2.524 0 N-CA-C 109.15 -1.58 . . . . 1.46 109.15 179.815 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -106.92 106.14 20.08 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.298 0 O-C-N 121.53 -0.982 . . . . 2.1600000000000001 109.011 -179.868 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.518 ' O ' ' N ' ' A' ' 64' ' ' ALA . 1.4 m -89.73 150.81 22.14 Favored 'General case' 0 N--CA 1.49 1.568 0 N-CA-C 108.523 -0.917 . . . . 2.1600000000000001 108.523 179.273 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 11.7 p90 -145.89 174.27 11.4 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.212 -0.93 . . . . 1.7 109.348 -179.106 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.472 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 4.8 p -145.79 116.71 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.503 2.192 0 O-C-N 120.991 -1.068 . . . . 2.4500000000000002 110.66 179.47 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 10.3 m -90.96 151.41 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 O-C-N 121.144 -0.972 . . . . 1.8200000000000001 108.745 179.295 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . 0.42 ' O ' ' OE2' ' A' ' 81' ' ' GLU . 7.2 tp-100 -94.76 -46.91 6.7 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.011 -1.056 . . . . 3.1699999999999999 110.819 -179.06 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.42 ' OE2' ' O ' ' A' ' 80' ' ' GLN . 78.1 mm-40 -153.8 150.06 22.23 Favored Pre-proline 0 N--CA 1.503 2.185 0 O-C-N 120.68 -1.262 . . . . 2.02 111.02 -178.651 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.576 ' HG3' ' N ' ' A' ' 107' ' ' SER . 84.9 Cg_exo -36.76 163.45 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.645 0 C-N-CA 122.918 2.412 . . . . 1.3999999999999999 113.529 178.177 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 148.16 -165.29 28.97 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.28 -1.528 . . . . 1.0800000000000001 109.28 179.838 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -106.95 88.25 2.7 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.599 -0.942 . . . . 2.1299999999999999 108.665 179.697 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . 0.457 ' O ' ' N ' ' A' ' 103' ' ' VAL . 3.4 m-85 -76.64 129.55 36.55 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.283 -1.006 . . . . 1.1399999999999999 108.283 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -110.21 121.49 45.41 Favored 'General case' 0 N--CA 1.498 1.933 0 N-CA-C 108.372 -0.973 . . . . 1.53 108.372 -179.101 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 8.4 p -120.28 133.41 67.09 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.593 -0.692 . . . . 1.6399999999999999 109.705 -179.607 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 11.6 t -128.24 101.64 6.33 Favored 'General case' 0 N--CA 1.498 1.958 0 N-CA-C 109.609 -0.515 . . . . 1.99 109.609 -179.831 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.449 ' H ' ' CB ' ' A' ' 99' ' ' SER . 0.8 OUTLIER -108.0 130.85 59.78 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.875 0 O-C-N 121.567 -0.708 . . . . 1.77 109.6 -179.806 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -139.9 128.77 23.38 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.413 -0.804 . . . . 2.0600000000000001 109.05 -179.979 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 44.7 t80 -84.69 95.63 8.98 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 120.527 -1.358 . . . . 1.45 108.387 179.296 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . 0.457 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 0.2 OUTLIER 68.58 39.72 2.03 Favored 'General case' 0 N--CA 1.488 1.435 0 N-CA-C 107.893 -1.151 . . . . 2.7200000000000002 107.893 -178.532 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . 0.457 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 3.4 m-20 82.6 14.07 0.45 Allowed 'General case' 0 N--CA 1.499 1.992 0 CA-C-O 121.188 0.518 . . . . 1.9199999999999999 110.23 -179.434 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . 0.493 ' OE1' ' N ' ' A' ' 18' ' ' ALA . 55.2 mt-10 -87.91 78.73 8.24 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.431 -0.951 . . . . 2.5499999999999998 108.431 178.916 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 44.2 m-70 -55.75 109.67 0.6 Allowed 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.529 -0.732 . . . . 3.2000000000000002 110.602 -179.17 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' ILE . . . . . 0.426 ' O ' ' O ' ' A' ' 99' ' ' SER . 1.5 mp -66.55 136.48 94.88 Favored Pre-proline 0 N--CA 1.492 1.637 0 N-CA-C 107.476 -1.305 . . . . 2.8199999999999998 107.476 179.034 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_exo -41.17 -41.21 4.51 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 120.997 1.131 . . . . 2.6299999999999999 110.575 -179.633 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.506 ' N ' ' OD1' ' A' ' 98' ' ' ASP . 1.3 m-20 -56.9 -65.61 0.59 Allowed 'General case' 0 N--CA 1.488 1.434 0 O-C-N 120.83 -1.169 . . . . 2.6499999999999999 108.026 178.191 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' SER . . . . . 0.449 ' CB ' ' H ' ' A' ' 89' ' ' ILE . 0.1 OUTLIER -68.71 145.02 96.68 Favored Pre-proline 0 C--N 1.293 -1.882 0 O-C-N 121.173 -0.955 . . . . 2.3199999999999998 109.564 -179.448 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -85.22 113.01 2.71 Favored 'Cis proline' 0 CA--C 1.549 1.271 0 O-C-N 122.636 0.808 . . . . 1.9399999999999999 110.154 -1.864 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 31.3 p90 -121.82 164.23 17.84 Favored 'General case' 0 N--CA 1.521 3.088 0 O-C-N 120.497 -1.377 . . . . 2.6299999999999999 109.921 178.402 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.3 p -87.43 144.41 9.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.462 -0.774 . . . . 1.8200000000000001 110.643 -178.129 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.457 ' N ' ' O ' ' A' ' 85' ' ' TYR . 71.7 t -117.24 89.54 31.26 Favored Pre-proline 0 N--CA 1.498 1.949 0 N-CA-C 108.503 -0.925 . . . . 1.73 108.503 179.354 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -62.93 113.99 2.24 Favored 'Trans proline' 0 C--N 1.319 -0.989 0 C-N-CA 121.142 1.228 . . . . 1.6100000000000001 111.916 -178.266 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 55.4 t -96.41 140.4 17.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 N-CA-C 105.926 -1.879 . . . . 1.7 105.926 177.446 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -131.89 133.53 44.7 Favored 'General case' 0 N--CA 1.512 2.671 0 CA-C-O 122.067 0.937 . . . . 2.04 112.059 -176.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' SER . . . . . 0.576 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 23.2 t -101.06 86.77 3.11 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 107.928 -1.138 . . . . 2.2999999999999998 107.928 179.177 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 13.3 mt 60.24 6.07 0.94 Allowed 'General case' 0 C--N 1.297 -1.708 0 N-CA-C 107.718 -1.216 . . . . 3.6000000000000001 107.718 -178.323 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.532 ' H ' ' C ' ' A' ' 107' ' ' SER . 52.0 p -97.77 -23.39 15.92 Favored 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 109.206 -0.664 . . . . 2.4900000000000002 109.206 179.657 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 34.4 t70 . . . . . 0 N--CA 1.489 1.484 0 O-C-N 121.131 -0.981 . . . . 2.8500000000000001 108.436 -179.587 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . 0.434 ' HG2' HH11 ' B' ' 8' ' ' ARG . 11.7 mtt-85 . . . . . 0 N--CA 1.492 1.641 0 N-CA-C 109.078 -0.712 . . . . 3.6699999999999999 109.078 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 9' ' ' VAL . . . . . 0.403 ' CG1' ' N ' ' B' ' 10' ' ' ALA . 3.1 t -48.72 159.69 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.135 -0.978 . . . . 1.3899999999999999 108.515 179.747 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . 0.403 ' N ' ' CG1' ' B' ' 9' ' ' VAL . . . -116.44 150.84 37.18 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.655 -0.653 . . . . 1.22 109.482 -179.344 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 11' ' ' SER . . . . . 0.429 ' O ' ' O ' ' A' ' 55' ' ' VAL . 58.2 m -153.19 139.88 18.92 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.283 -0.886 . . . . 1.6299999999999999 109.865 -179.832 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 51.6 p -148.36 112.51 5.21 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.197 -0.939 . . . . 1.8799999999999999 109.562 -179.697 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . 0.501 ' CG2' ' N ' ' B' ' 14' ' ' PHE . 2.5 p -154.61 167.58 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 N-CA-C 108.624 -0.88 . . . . 1.2 108.624 179.811 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 14' ' ' PHE . . . . . 0.503 ' HB3' ' H ' ' A' ' 53' ' ' ILE . 7.8 p90 -176.55 -167.18 0.18 Allowed 'General case' 0 N--CA 1.488 1.435 0 C-N-CA 119.132 -1.027 . . . . 2.3900000000000001 112.069 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -143.45 146.26 21.49 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.226 0 N-CA-C 108.883 -0.784 . . . . 1.8100000000000001 108.883 179.871 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 46.1 m -113.03 128.3 56.46 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.353 -0.842 . . . . 2.04 109.293 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 16.8 mt . . . . . 0 N--CA 1.497 1.913 0 O-C-N 121.174 -0.954 . . . . 1.8700000000000001 109.562 179.939 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.482 ' O ' ' N ' ' A' ' 18' ' ' ALA . . . . . . . . 0 N--CA 1.485 1.92 0 N-CA-C 109.48 -1.448 . . . . 2.4399999999999999 109.48 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.511 ' C ' ' H ' ' A' ' 19' ' ' HIS . . . -43.97 -19.76 0.13 Allowed Glycine 0 N--CA 1.488 2.159 0 O-C-N 121.387 -1.067 . . . . 2.0499999999999998 110.579 -179.457 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.522 ' N ' ' CD ' ' A' ' 94' ' ' GLU . . . -51.07 -9.9 0.06 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.826 -1.397 . . . . 2.54 109.204 -179.829 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' HIS . . . . . 0.511 ' H ' ' C ' ' A' ' 17' ' ' GLY . 22.0 t60 -103.01 -4.59 24.42 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.404 -0.81 . . . . 3.3700000000000001 110.175 -179.738 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.524 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 1.9 pptp? -135.81 0.6 2.69 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.1 -1.0 . . . . 2.3700000000000001 110.261 -179.559 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.401 ' CG2' ' NZ ' ' A' ' 20' ' ' LYS . 55.3 t -88.8 113.47 25.55 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.003 -1.06 . . . . 2.5800000000000001 109.751 179.665 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 21.0 tpt180 -108.97 135.85 49.47 Favored 'General case' 0 N--CA 1.495 1.79 0 N-CA-C 109.308 -0.627 . . . . 3.8900000000000001 109.308 179.647 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -143.31 113.81 7.46 Favored 'General case' 0 N--CA 1.492 1.674 0 N-CA-C 108.566 -0.902 . . . . 2.0099999999999998 108.566 179.467 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -152.6 130.95 3.2 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.671 -1.371 . . . . 2.0099999999999998 109.671 -179.367 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -177.55 167.58 38.67 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.801 -1.32 . . . . 1.9299999999999999 109.801 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.538 ' C ' ' H ' ' A' ' 28' ' ' LEU . 0.5 OUTLIER -80.5 -27.53 37.72 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.318 -1.107 . . . . 2.6899999999999999 109.864 -179.698 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -64.21 -1.36 5.46 Favored Glycine 0 N--CA 1.483 1.78 0 N-CA-C 107.938 -2.065 . . . . 1.6399999999999999 107.938 179.193 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.538 ' H ' ' C ' ' A' ' 26' ' ' THR . 60.9 mt -108.45 -10.56 15.27 Favored 'General case' 0 N--CA 1.493 1.712 0 N-CA-C 108.643 -0.873 . . . . 2.0299999999999998 108.643 179.748 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 20.3 mm-40 -85.74 -54.16 4.7 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.568 -0.708 . . . . 2.3399999999999999 109.561 -179.586 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . 0.572 ' CG ' HH11 ' A' ' 30' ' ' ARG . 3.2 mtt-85 -156.83 161.94 39.72 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.125 -0.984 . . . . 4.25 109.76 179.918 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -140.73 172.17 23.74 Favored Glycine 0 N--CA 1.493 2.499 0 N-CA-C 108.102 -1.999 . . . . 1.5900000000000001 108.102 179.205 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 36.0 t -134.37 150.93 31.2 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.03 0 O-C-N 121.189 -1.183 . . . . 2.21 110.398 -179.338 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -38.83 113.89 0.34 Allowed 'General case' 0 N--CA 1.495 1.784 0 CA-C-O 121.862 0.839 . . . . 2.0699999999999998 112.844 -179.184 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 53.99 49.77 57.64 Favored Glycine 0 N--CA 1.489 2.167 0 N-CA-C 111.238 -0.745 . . . . 1.73 111.238 177.378 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 25.3 t -126.98 99.41 28.88 Favored Pre-proline 0 N--CA 1.497 1.9 0 O-C-N 121.531 -0.982 . . . . 2.6499999999999999 108.396 179.052 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -56.75 143.44 90.27 Favored 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 120.946 1.097 . . . . 2.1400000000000001 110.588 -178.906 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -150.23 -169.06 3.28 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.563 -0.903 . . . . 2.0299999999999998 108.563 179.869 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -169.38 162.23 10.22 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.958 -1.089 . . . . 2.23 111.03 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . 0.575 ' N ' ' CD1' ' A' ' 39' ' ' PHE . 0.2 OUTLIER -134.8 -176.37 4.21 Favored 'General case' 0 N--CA 1.485 1.303 0 N-CA-C 106.638 -1.615 . . . . 1.72 106.638 178.355 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 18.3 t -121.35 145.97 47.34 Favored 'General case' 0 N--CA 1.501 2.1 0 CA-C-O 121.72 0.771 . . . . 2.5800000000000001 111.07 -178.633 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.523 ' O ' ' N ' ' A' ' 73' ' ' CYS . 62.6 mt -143.19 118.69 4.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 N-CA-C 108.547 -0.908 . . . . 1.8600000000000001 108.547 179.222 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.533 ' O ' ' CD2' ' A' ' 42' ' ' TRP . 5.9 p-90 -118.1 127.19 53.54 Favored 'General case' 0 N--CA 1.502 2.135 0 O-C-N 121.219 -0.926 . . . . 4.4699999999999998 108.549 179.109 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' THR . . . . . 0.524 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -150.92 128.4 11.41 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.224 -0.923 . . . . 3.27 109.926 -178.828 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' ARG . . . . . . . . . . . . . 24.8 ttm180 -172.48 79.35 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.442 -0.786 . . . . 5.2300000000000004 109.092 179.663 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 2.3 tm-20 -159.69 -55.04 0.06 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.188 -0.945 . . . . 2.8900000000000001 109.881 -179.676 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -53.43 -55.29 26.38 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 120.911 -1.118 . . . . 1.99 108.672 -179.821 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 140.58 -170.37 24.47 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.163 -1.575 . . . . 1.6499999999999999 109.163 179.678 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.67 148.28 10.05 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.14 -1.212 . . . . 1.77 109.202 179.832 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -171.66 -170.06 35.23 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.762 -1.335 . . . . 1.1200000000000001 109.762 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -133.05 122.71 3.24 Favored Glycine 0 N--CA 1.497 2.727 0 N-CA-C 109.403 -1.479 . . . . 1.1799999999999999 109.403 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 11.3 tp -97.65 97.98 9.49 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.303 -1.116 . . . . 1.5900000000000001 108.69 179.651 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' SER . . . . . 0.546 ' H ' ' HG ' ' A' ' 52' ' ' SER . 0.3 OUTLIER -84.52 145.63 27.99 Favored 'General case' 0 C--N 1.312 -1.035 0 N-CA-C 108.026 -1.102 . . . . 1.9399999999999999 108.026 179.695 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.459 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 65.4 mt -134.98 118.68 25.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.217 -0.927 . . . . 1.3 110.048 -179.315 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -106.63 106.85 17.57 Favored 'General case' 0 N--CA 1.495 1.824 0 N-CA-C 108.431 -0.952 . . . . 1.27 108.431 179.072 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 2.4 t -97.59 146.36 7.88 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.266 -0.897 . . . . 1.55 109.639 -179.436 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 22.8 tt0 -139.5 131.21 27.38 Favored 'General case' 0 N--CA 1.488 1.448 0 N-CA-C 107.616 -1.253 . . . . 1.8 107.616 178.835 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -178.41 172.31 44.71 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.159 -1.576 . . . . 0.56000000000000005 109.159 -179.498 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_exo -52.06 -28.61 33.25 Favored 'Trans proline' 0 C--N 1.318 -1.076 0 C-N-CA 121.808 1.672 . . . . 0.76000000000000001 110.859 -179.501 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.2 t -140.79 157.18 45.77 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.439 -0.788 . . . . 2.02 109.839 -179.527 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 49.3 mttp -77.78 104.75 8.52 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.421 -0.799 . . . . 3.02 109.169 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -74.15 136.95 42.89 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.272 -0.892 . . . . 1.3600000000000001 109.549 -179.728 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -75.33 175.54 8.29 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.141 -0.974 . . . . 2.2999999999999998 109.629 -179.829 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 4.8 mm -140.51 156.46 23.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 N-CA-C 108.033 -1.099 . . . . 2.0 108.033 -179.656 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -144.45 174.63 10.77 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 120.551 -1.343 . . . . 1.73 108.999 179.749 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . 0.51 ' CD2' ' O ' ' A' ' 65' ' ' PHE . 37.7 p90 -147.25 116.36 6.9 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.308 -0.87 . . . . 1.6000000000000001 109.46 -179.919 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 76.2 tt0 . . . . . 0 N--CA 1.496 1.849 0 O-C-N 121.317 -0.864 . . . . 2.5099999999999998 109.241 179.989 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 60.6 p . . . . . 0 N--CA 1.495 1.807 0 CA-C-O 121.313 0.578 . . . . 2.5600000000000001 109.666 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' CYS . . . . . 0.523 ' N ' ' O ' ' A' ' 41' ' ' ILE . 17.0 t -75.77 112.23 11.93 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.306 -0.871 . . . . 2.3599999999999999 109.361 179.789 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -91.77 117.99 5.37 Favored Glycine 0 N--CA 1.493 2.439 0 N-CA-C 109.394 -1.482 . . . . 1.46 109.394 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 1.9 m -109.28 114.68 47.57 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.097 0 O-C-N 121.611 -0.935 . . . . 2.1600000000000001 109.502 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -92.55 167.84 11.66 Favored 'General case' 0 N--CA 1.491 1.62 0 N-CA-C 108.341 -0.985 . . . . 2.1600000000000001 108.341 179.537 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 5.9 p90 -163.77 168.15 20.03 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.356 -0.84 . . . . 1.7 109.095 -179.338 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.471 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 5.0 p -143.11 115.31 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.369 0 O-C-N 121.0 -1.062 . . . . 2.4500000000000002 110.448 179.418 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 14.3 m -88.82 152.38 3.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.244 -0.91 . . . . 1.8200000000000001 109.233 179.741 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 6.8 tt0 -88.92 -50.33 6.26 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.092 -1.005 . . . . 3.1699999999999999 110.764 -179.043 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -153.31 156.92 32.85 Favored Pre-proline 0 N--CA 1.504 2.271 0 O-C-N 120.722 -1.236 . . . . 2.02 110.766 -179.015 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.56 ' HG3' ' N ' ' A' ' 107' ' ' SER . 71.0 Cg_exo -37.67 163.55 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 123.293 2.662 . . . . 1.3999999999999999 113.452 179.17 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 145.35 -177.37 23.82 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.138 -1.585 . . . . 1.0800000000000001 109.138 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . 0.528 ' OD1' ' NH2' ' B' ' 8' ' ' ARG . 0.4 OUTLIER -99.81 90.93 4.61 Favored 'General case' 0 N--CA 1.493 1.715 0 N-CA-C 107.962 -1.125 . . . . 2.1299999999999999 107.962 179.289 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -76.25 132.05 39.64 Favored 'General case' 0 C--N 1.296 -1.721 0 N-CA-C 108.245 -1.02 . . . . 1.1399999999999999 108.245 -179.747 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.66 115.56 27.31 Favored 'General case' 0 N--CA 1.501 2.082 0 N-CA-C 108.337 -0.986 . . . . 1.53 108.337 -179.351 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.556 ' CG1' ' CE2' ' A' ' 101' ' ' PHE . 4.5 p -112.85 132.78 60.69 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.676 -0.64 . . . . 1.6399999999999999 109.421 -179.779 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 3.0 m -121.85 139.53 53.51 Favored 'General case' 0 N--CA 1.497 1.886 0 N-CA-C 108.536 -0.912 . . . . 1.99 108.536 179.635 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.3 pt -141.1 130.68 25.34 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.181 0 O-C-N 121.076 -1.015 . . . . 1.77 109.845 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -136.89 123.61 21.14 Favored 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 107.72 -1.215 . . . . 2.0600000000000001 107.72 178.191 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 83.5 t80 -83.7 102.2 12.09 Favored 'General case' 0 C--N 1.295 -1.77 0 N-CA-C 107.985 -1.117 . . . . 1.45 107.985 179.326 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . 0.442 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 1.3 t30 69.33 34.83 2.79 Favored 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 108.788 -0.819 . . . . 2.7200000000000002 108.788 -178.651 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . 0.442 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 2.7 m-20 79.34 16.66 0.89 Allowed 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.827 -0.546 . . . . 1.9199999999999999 111.505 179.473 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . 0.522 ' CD ' ' N ' ' A' ' 18' ' ' ALA . 0.6 OUTLIER -101.1 100.23 10.77 Favored 'General case' 0 N--CA 1.499 2.005 0 N-CA-C 107.407 -1.331 . . . . 2.5499999999999998 107.407 178.188 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 11.9 m-70 -73.97 110.92 8.64 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.117 -0.99 . . . . 3.2000000000000002 110.632 -177.844 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' ILE . . . . . 0.465 ' O ' ' N ' ' A' ' 98' ' ' ASP . 3.4 tp -63.95 134.62 95.99 Favored Pre-proline 0 N--CA 1.488 1.455 0 N-CA-C 107.554 -1.276 . . . . 2.8199999999999998 107.554 178.868 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . 0.401 ' O ' ' CG ' ' A' ' 98' ' ' ASP . 7.2 Cg_exo -49.56 92.5 0.03 OUTLIER 'Trans proline' 0 C--O 1.214 -0.721 0 N-CA-C 109.839 -0.87 . . . . 2.6299999999999999 109.839 -179.824 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.465 ' N ' ' O ' ' A' ' 96' ' ' ILE . 0.9 OUTLIER 169.76 -54.05 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 108.756 -0.831 . . . . 2.6499999999999999 108.756 -179.574 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 6.2 m -55.3 136.95 68.73 Favored Pre-proline 0 C--N 1.298 -1.636 0 O-C-N 121.231 -0.918 . . . . 2.3199999999999998 109.588 -178.261 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_endo -88.36 113.58 2.43 Favored 'Cis proline' 0 N--CA 1.494 1.539 0 N-CA-C 110.328 -0.681 . . . . 1.9399999999999999 110.328 -1.862 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . 0.598 ' CD1' ' N ' ' A' ' 101' ' ' PHE . 0.0 OUTLIER -80.71 155.08 26.93 Favored 'General case' 0 N--CA 1.509 2.522 0 O-C-N 119.727 -1.858 . . . . 2.6299999999999999 108.66 178.346 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 10.5 p -89.21 144.5 8.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.483 -0.761 . . . . 1.8200000000000001 109.158 179.653 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 76.9 t -128.04 85.87 59.52 Favored Pre-proline 0 N--CA 1.499 1.997 0 N-CA-C 108.133 -1.062 . . . . 1.73 108.133 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -64.91 112.53 2.04 Favored 'Trans proline' 0 C--N 1.321 -0.878 0 C-N-CA 121.433 1.422 . . . . 1.6100000000000001 111.851 -177.867 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 54.5 t -96.36 143.89 11.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 N-CA-C 106.172 -1.788 . . . . 1.7 106.172 177.667 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -136.36 135.23 38.65 Favored 'General case' 0 N--CA 1.509 2.489 0 O-C-N 121.151 -0.968 . . . . 2.04 112.133 -176.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' SER . . . . . 0.56 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 11.0 t -89.67 76.27 7.31 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 107.413 -1.329 . . . . 2.2999999999999998 107.413 178.982 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 13.6 mt 65.87 -0.06 1.42 Allowed 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 107.748 -1.204 . . . . 3.6000000000000001 107.748 -177.861 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.519 ' H ' ' C ' ' A' ' 107' ' ' SER . 22.9 t -84.67 -22.14 29.94 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.74 -0.837 . . . . 2.4900000000000002 108.74 178.873 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 . . . . . 0 N--CA 1.487 1.423 0 N-CA-C 107.984 -1.117 . . . . 2.8500000000000001 107.984 -179.141 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . 0.528 ' NH2' ' OD1' ' A' ' 84' ' ' ASP . 16.5 mmt-85 . . . . . 0 N--CA 1.491 1.606 0 N-CA-C 108.435 -0.95 . . . . 3.6699999999999999 108.435 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 9' ' ' VAL . . . . . . . . . . . . . 3.0 t -57.66 161.48 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 N-CA-C 106.924 -1.51 . . . . 1.3899999999999999 106.924 178.746 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -115.07 148.52 38.8 Favored 'General case' 0 N--CA 1.504 2.267 0 O-C-N 121.267 -0.896 . . . . 1.22 111.151 -178.06 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 1.3 t -141.11 150.86 43.42 Favored 'General case' 0 N--CA 1.497 1.906 0 N-CA-C 109.232 -0.655 . . . . 1.6299999999999999 109.232 179.39 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 28.5 p -149.09 131.47 15.64 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.053 -1.029 . . . . 1.8799999999999999 110.224 -179.836 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . 0.483 ' C ' ' CG ' ' B' ' 14' ' ' PHE . 7.5 p -173.6 174.39 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 N-CA-C 108.345 -0.983 . . . . 1.2 108.345 179.777 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 14' ' ' PHE . . . . . 0.483 ' CG ' ' C ' ' B' ' 13' ' ' VAL . 0.1 OUTLIER 173.05 -171.97 0.04 OUTLIER 'General case' 0 N--CA 1.493 1.702 0 C-N-CA 118.797 -1.161 . . . . 2.3900000000000001 112.201 179.483 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -143.85 -179.4 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.339 0 N-CA-C 108.898 -0.779 . . . . 1.8100000000000001 108.898 179.903 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 9.0 t -141.31 142.91 33.82 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.154 -0.966 . . . . 2.04 109.291 179.59 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.3 mt . . . . . 0 N--CA 1.499 2.019 0 O-C-N 121.261 -0.9 . . . . 1.8700000000000001 110.108 -179.55 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.766 0 N-CA-C 108.52 -1.832 . . . . 2.4399999999999999 108.52 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.518 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -72.65 -4.81 62.42 Favored Glycine 0 N--CA 1.486 2.025 0 N-CA-C 109.717 -1.353 . . . . 2.0499999999999998 109.717 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -49.03 -12.39 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.729 -1.453 . . . . 2.54 109.236 179.832 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' HIS . . . . . 0.518 ' N ' ' O ' ' A' ' 17' ' ' GLY . 10.6 t-160 -97.15 -41.15 8.46 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.39 -0.819 . . . . 3.3700000000000001 109.445 179.651 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.656 ' HZ1' ' N ' ' A' ' 44' ' ' ARG . 0.0 OUTLIER -82.32 -25.37 33.99 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.141 -0.974 . . . . 2.3700000000000001 109.722 -179.879 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 77.9 t -60.93 112.32 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.045 -1.034 . . . . 2.5800000000000001 109.081 179.635 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 5.9 tpp180 -104.11 131.14 51.69 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.629 -0.669 . . . . 3.8900000000000001 109.628 -179.648 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -136.7 113.64 10.47 Favored 'General case' 0 N--CA 1.493 1.723 0 N-CA-C 108.577 -0.898 . . . . 2.0099999999999998 108.577 179.519 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -155.89 134.66 4.21 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.73 -1.348 . . . . 2.0099999999999998 109.73 -179.463 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.1 -176.44 46.07 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.99 -1.244 . . . . 1.9299999999999999 109.99 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 8.6 p -79.49 -25.82 41.74 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.335 -1.097 . . . . 2.6899999999999999 109.538 -179.862 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.428 ' CA ' ' OH ' ' A' ' 77' ' ' TYR . . . -69.46 -15.44 70.54 Favored Glycine 0 N--CA 1.486 1.992 0 N-CA-C 108.506 -1.838 . . . . 1.6399999999999999 108.506 179.676 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 65.8 mt -93.36 33.02 1.26 Allowed 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 108.487 -0.931 . . . . 2.0299999999999998 108.487 179.454 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -144.3 -55.41 0.35 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.373 -0.829 . . . . 2.3399999999999999 109.796 -179.545 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . 0.528 ' NH1' ' OD1' ' A' ' 110' ' ' ASP . 31.9 mtm180 -156.53 153.69 29.1 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 120.984 -1.073 . . . . 4.25 110.345 -179.441 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -140.42 171.76 23.84 Favored Glycine 0 N--CA 1.495 2.61 0 N-CA-C 108.244 -1.942 . . . . 1.5900000000000001 108.244 179.003 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.428 ' H ' HG11 ' A' ' 35' ' ' VAL . 28.1 t -135.54 148.32 28.4 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.008 0 O-C-N 121.173 -1.192 . . . . 2.21 110.448 -179.553 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -38.73 105.79 0.04 OUTLIER 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.916 -0.49 . . . . 2.0699999999999998 111.688 -179.859 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 64.34 57.0 14.45 Favored Glycine 0 N--CA 1.489 2.23 0 O-C-N 121.089 -1.007 . . . . 1.73 111.864 177.353 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.428 HG11 ' H ' ' A' ' 32' ' ' VAL . 4.5 p -125.82 133.92 25.38 Favored Pre-proline 0 N--CA 1.503 2.208 0 O-C-N 121.279 -1.13 . . . . 2.6499999999999999 108.949 178.72 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_endo -58.47 114.69 2.09 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 N-CA-C 108.547 -1.366 . . . . 2.1400000000000001 108.547 178.739 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -127.0 148.61 50.1 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.344 -0.847 . . . . 2.0299999999999998 109.494 -179.352 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.3 pt-20 -157.13 174.01 16.12 Favored 'General case' 0 N--CA 1.488 1.474 0 CA-C-O 122.22 1.01 . . . . 2.23 110.759 -179.886 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . 0.417 ' N ' ' CD1' ' A' ' 39' ' ' PHE . 5.0 p90 -159.52 167.07 29.49 Favored 'General case' 0 C--N 1.296 -1.753 0 N-CA-C 107.819 -1.178 . . . . 1.72 107.819 178.67 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 6.4 t -98.04 150.96 20.84 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.462 -0.774 . . . . 2.5800000000000001 110.715 -178.409 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 10.7 mt -142.09 89.72 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 N-CA-C 108.757 -0.831 . . . . 1.8600000000000001 108.757 179.117 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.458 ' CD1' ' C ' ' A' ' 42' ' ' TRP . 0.8 OUTLIER -85.28 142.35 29.44 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.115 -0.991 . . . . 4.4699999999999998 108.815 -179.907 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' THR . . . . . 0.487 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -171.98 117.51 0.39 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.39 -0.818 . . . . 3.27 109.298 -179.688 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' ARG . . . . . 0.656 ' N ' ' HZ1' ' A' ' 20' ' ' LYS . 1.5 tpt180 -164.99 -12.24 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.171 -0.956 . . . . 5.2300000000000004 109.696 -179.832 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -68.55 -47.53 66.63 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.0 -1.062 . . . . 2.8900000000000001 109.763 -179.621 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -60.23 -59.76 4.89 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.098 -1.001 . . . . 1.99 109.299 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 142.94 -151.76 23.42 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.585 -1.406 . . . . 1.6499999999999999 109.585 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -80.64 163.11 23.86 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.479 -1.012 . . . . 1.77 109.531 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 174.02 -143.49 7.05 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.666 -1.373 . . . . 1.1200000000000001 109.666 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.433 ' O ' ' N ' ' A' ' 92' ' ' ASN . . . -148.48 127.64 2.6 Favored Glycine 0 N--CA 1.495 2.586 0 N-CA-C 109.554 -1.418 . . . . 1.1799999999999999 109.554 -179.913 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.43 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 46.8 tp -102.65 107.03 17.79 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.367 -1.078 . . . . 1.5900000000000001 108.843 179.833 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.4 t -90.62 141.44 28.77 Favored 'General case' 0 N--CA 1.494 1.75 0 N-CA-C 108.616 -0.883 . . . . 1.9399999999999999 108.616 179.504 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.493 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 63.3 mt -132.06 102.35 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.923 0 O-C-N 121.214 -0.929 . . . . 1.3 109.469 -179.843 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -93.31 105.85 17.88 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 108.497 -0.927 . . . . 1.27 108.497 179.395 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -95.42 145.07 8.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.521 -0.737 . . . . 1.55 109.254 -179.738 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -141.47 144.17 34.25 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 108.026 -1.101 . . . . 1.8 108.026 179.22 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.415 ' O ' ' O ' ' B' ' 9' ' ' VAL . . . 162.13 -172.95 38.37 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.768 -1.333 . . . . 0.56000000000000005 109.768 -179.215 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -61.77 -31.88 85.87 Favored 'Trans proline' 0 C--N 1.319 -0.979 0 C-N-CA 122.302 2.001 . . . . 0.76000000000000001 112.046 -179.666 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 8.0 t -139.0 169.95 16.86 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 120.949 -1.094 . . . . 2.02 110.549 -179.169 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 38.5 mtpt -87.1 106.86 18.16 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 109.003 -0.74 . . . . 3.02 109.003 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -73.48 127.42 32.67 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.165 -0.959 . . . . 1.3600000000000001 109.776 -179.711 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 24.4 tt0 -65.42 170.44 4.87 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.288 -0.882 . . . . 2.2999999999999998 109.028 179.732 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 20.1 mt -143.52 155.11 16.37 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 N-CA-C 108.345 -0.983 . . . . 2.0 108.345 -179.9 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.532 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -143.12 174.91 10.28 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 120.685 -1.259 . . . . 1.73 109.21 -179.775 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . 0.449 ' CD2' ' O ' ' A' ' 65' ' ' PHE . 51.7 p90 -142.29 128.49 19.82 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.363 -0.835 . . . . 1.6000000000000001 109.172 179.9 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 . . . . . 0 N--CA 1.497 1.892 0 O-C-N 121.296 -0.878 . . . . 2.5099999999999998 109.987 -179.782 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.0 t . . . . . 0 N--CA 1.497 1.88 0 CA-C-O 121.428 0.632 . . . . 2.5600000000000001 109.764 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 36.9 t -88.04 139.47 30.48 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.329 -0.857 . . . . 2.3599999999999999 109.347 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -112.4 114.02 3.4 Favored Glycine 0 N--CA 1.5 2.948 0 N-CA-C 109.985 -1.246 . . . . 1.46 109.985 -179.761 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 77.9 t -100.97 116.15 43.97 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.948 0 O-C-N 121.467 -1.019 . . . . 2.1600000000000001 108.912 179.291 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.532 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.6 OUTLIER -103.81 136.75 42.91 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.579 -0.7 . . . . 2.1600000000000001 109.196 -179.846 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 0.428 ' OH ' ' CA ' ' A' ' 27' ' ' GLY . 11.3 p90 -134.65 166.69 22.34 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.508 -0.745 . . . . 1.7 109.671 -179.769 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 8.4 t -139.86 113.54 6.3 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 N-CA-C 108.887 -0.783 . . . . 2.4500000000000002 108.887 -179.729 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.594 ' CG1' ' CE2' ' A' ' 85' ' ' TYR . 0.2 OUTLIER -79.75 168.57 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 N-CA-C 108.499 -0.926 . . . . 1.8200000000000001 108.499 179.552 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 10.5 tt0 -109.3 -36.79 5.93 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.441 -0.787 . . . . 3.1699999999999999 109.417 179.323 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.428 ' O ' ' O ' ' A' ' 82' ' ' PRO . 75.2 mm-40 -158.85 149.6 16.01 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.278 -0.888 . . . . 2.02 110.679 -179.308 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.561 ' HG3' ' N ' ' A' ' 107' ' ' SER . 82.1 Cg_exo -39.08 169.38 0.01 OUTLIER 'Trans proline' 0 C--O 1.213 -0.727 0 C-N-CA 122.761 2.307 . . . . 1.3999999999999999 112.756 177.696 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 141.69 177.33 16.74 Favored Glycine 0 N--CA 1.493 2.451 0 N-CA-C 109.726 -1.35 . . . . 1.0800000000000001 109.726 179.226 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -93.16 89.57 6.5 Favored 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 107.741 -1.207 . . . . 2.1299999999999999 107.741 179.149 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . 0.594 ' CE2' ' CG1' ' A' ' 79' ' ' VAL . 3.7 m-85 -78.04 132.15 37.64 Favored 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.458 -0.776 . . . . 1.1399999999999999 108.912 -179.014 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -112.81 128.79 56.54 Favored 'General case' 0 N--CA 1.498 1.947 0 N-CA-C 108.588 -0.893 . . . . 1.53 108.588 -179.079 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.411 ' CG1' ' CE2' ' A' ' 101' ' ' PHE . 5.8 p -126.13 133.64 68.4 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 121.568 -0.708 . . . . 1.6399999999999999 109.471 -179.865 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.1 t -123.64 103.96 8.73 Favored 'General case' 0 N--CA 1.498 1.933 0 N-CA-C 109.445 -0.576 . . . . 1.99 109.445 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.2 pt -107.7 130.29 60.29 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 CA-C-O 121.64 0.734 . . . . 1.77 110.045 -179.573 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' LYS . . . . . 0.47 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.98 122.68 17.52 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 107.9 -1.148 . . . . 2.0600000000000001 107.9 179.593 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.412 ' O ' ' CB ' ' A' ' 92' ' ' ASN . 71.2 t80 -83.08 100.57 10.59 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 120.515 -1.365 . . . . 1.45 108.029 179.351 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . 0.433 ' N ' ' O ' ' A' ' 50' ' ' GLY . 2.2 t30 72.31 35.48 1.19 Allowed 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.196 -0.94 . . . . 2.7200000000000002 108.809 -178.646 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . 0.429 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 0.9 OUTLIER 78.2 14.77 1.44 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.879 -0.513 . . . . 1.9199999999999999 111.609 179.53 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . 0.489 ' OE2' ' CA ' ' A' ' 17' ' ' GLY . 5.7 pt-20 -100.54 99.22 9.78 Favored 'General case' 0 N--CA 1.496 1.843 0 N-CA-C 107.145 -1.428 . . . . 2.5499999999999998 107.145 177.964 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' HIS . . . . . 0.462 ' CG ' ' O ' ' A' ' 95' ' ' HIS . 46.2 p-80 -66.96 105.46 1.63 Allowed 'General case' 0 N--CA 1.487 1.389 0 CA-C-O 121.472 0.653 . . . . 3.2000000000000002 110.453 -177.928 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' ILE . . . . . 0.523 ' O ' ' N ' ' A' ' 98' ' ' ASP . 4.0 tt -56.56 136.33 77.23 Favored Pre-proline 0 C--N 1.3 -1.548 0 N-CA-C 107.81 -1.182 . . . . 2.8199999999999998 107.81 178.983 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . 0.44 ' O ' ' CB ' ' A' ' 98' ' ' ASP . 11.6 Cg_exo -47.15 90.98 0.02 OUTLIER 'Trans proline' 0 C--O 1.213 -0.729 0 N-CA-C 109.886 -0.852 . . . . 2.6299999999999999 109.886 -179.755 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.523 ' N ' ' O ' ' A' ' 96' ' ' ILE . 0.9 OUTLIER 165.61 -60.43 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 108.235 -1.024 . . . . 2.6499999999999999 108.235 -179.418 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 1.3 t -55.8 139.08 70.18 Favored Pre-proline 0 C--N 1.296 -1.727 0 O-C-N 121.299 -0.875 . . . . 2.3199999999999998 109.796 -178.306 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_endo -88.36 113.72 2.47 Favored 'Cis proline' 0 N--CA 1.494 1.521 0 N-CA-C 110.024 -0.798 . . . . 1.9399999999999999 110.024 -2.393 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . 0.411 ' CE2' ' CG1' ' A' ' 87' ' ' VAL . 2.6 p90 -97.74 169.15 9.88 Favored 'General case' 0 N--CA 1.518 2.944 0 O-C-N 120.236 -1.54 . . . . 2.6299999999999999 109.779 178.625 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.3 p -96.78 150.45 4.44 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.643 -0.66 . . . . 1.8200000000000001 109.982 -179.635 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.446 ' N ' ' O ' ' A' ' 85' ' ' TYR . 87.0 t -128.3 87.03 56.36 Favored Pre-proline 0 N--CA 1.498 1.965 0 N-CA-C 108.379 -0.971 . . . . 1.73 108.379 179.675 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo -65.11 114.9 3.01 Favored 'Trans proline' 0 C--N 1.322 -0.856 0 C-N-CA 121.571 1.514 . . . . 1.6100000000000001 111.8 -178.27 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 84.3 t -106.59 143.54 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 N-CA-C 106.342 -1.725 . . . . 1.7 106.342 178.365 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -133.24 138.51 46.53 Favored 'General case' 0 N--CA 1.512 2.666 0 CA-C-O 122.272 1.034 . . . . 2.04 112.516 -176.719 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' SER . . . . . 0.561 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 59.8 p -94.29 78.21 3.95 Favored 'General case' 0 N--CA 1.494 1.725 0 N-CA-C 107.608 -1.256 . . . . 2.2999999999999998 107.608 179.097 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 16.8 mt 63.15 3.33 1.27 Allowed 'General case' 0 C--N 1.295 -1.766 0 N-CA-C 107.438 -1.319 . . . . 3.6000000000000001 107.438 -177.835 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.524 ' H ' ' C ' ' A' ' 107' ' ' SER . 18.5 t -89.84 -23.18 21.74 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 108.813 -0.81 . . . . 2.4900000000000002 108.813 179.328 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . 0.528 ' OD1' ' NH1' ' A' ' 30' ' ' ARG . 50.5 t0 . . . . . 0 N--CA 1.487 1.382 0 N-CA-C 107.822 -1.177 . . . . 2.8500000000000001 107.822 -179.196 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . 0.549 HH11 ' CG ' ' B' ' 8' ' ' ARG . 1.4 mtt-85 . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 108.542 -0.91 . . . . 3.6699999999999999 108.542 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 9' ' ' VAL . . . . . 0.415 ' O ' ' O ' ' A' ' 57' ' ' GLY . 11.2 t -49.89 159.85 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 120.973 -1.079 . . . . 1.3899999999999999 108.311 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . 0.4 ' N ' ' CG1' ' B' ' 9' ' ' VAL . . . -124.67 144.13 50.37 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.526 -0.734 . . . . 1.22 110.173 -178.887 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 2.8 t -134.7 145.88 48.93 Favored 'General case' 0 N--CA 1.495 1.817 0 N-CA-C 108.636 -0.876 . . . . 1.6299999999999999 108.636 179.446 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 17.7 m -142.46 114.66 8.31 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.223 -0.923 . . . . 1.8799999999999999 109.69 -179.491 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . 0.494 ' CG2' ' N ' ' B' ' 14' ' ' PHE . 2.7 p -160.03 166.67 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 O-C-N 121.367 -0.833 . . . . 1.2 109.014 179.83 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 14' ' ' PHE . . . . . 0.494 ' N ' ' CG2' ' B' ' 13' ' ' VAL . 8.3 p90 -177.16 -166.88 0.15 Allowed 'General case' 0 N--CA 1.488 1.429 0 CA-C-O 122.077 0.941 . . . . 2.3900000000000001 111.926 179.85 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -140.02 152.98 22.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 N-CA-C 108.271 -1.011 . . . . 1.8100000000000001 108.271 179.721 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 7.2 m -123.66 131.14 53.54 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.317 -0.865 . . . . 2.04 109.921 -179.666 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 13.8 mt . . . . . 0 N--CA 1.496 1.843 0 O-C-N 121.327 -0.858 . . . . 1.8700000000000001 109.01 179.609 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.519 ' O ' ' N ' ' A' ' 18' ' ' ALA . . . . . . . . 0 N--CA 1.49 2.284 0 N-CA-C 110.851 -0.899 . . . . 2.4399999999999999 110.851 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.55 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -46.28 -12.33 0.05 OUTLIER Glycine 0 N--CA 1.491 2.333 0 N-CA-C 110.603 -0.999 . . . . 2.0499999999999998 110.603 -179.2 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.519 ' N ' ' O ' ' A' ' 16' ' ' GLY . . . -47.64 -10.41 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.145 -1.209 . . . . 2.54 110.093 -179.924 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' HIS . . . . . 0.55 ' N ' ' O ' ' A' ' 17' ' ' GLY . 80.2 t60 -104.81 -31.36 9.34 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.188 -0.945 . . . . 3.3700000000000001 110.444 -179.38 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -101.6 -14.72 17.32 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 120.997 -1.064 . . . . 2.3700000000000001 110.848 -178.979 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.43 ' O ' ' CG1' ' A' ' 21' ' ' VAL . 9.0 p -70.85 114.39 8.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 120.819 -1.175 . . . . 2.5800000000000001 109.818 -179.606 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 20.6 tpt180 -104.08 140.38 37.85 Favored 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 109.008 -0.738 . . . . 3.8900000000000001 109.008 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -144.45 113.28 6.75 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.247 -0.908 . . . . 2.0099999999999998 109.37 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -156.49 129.05 2.33 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.788 -1.325 . . . . 2.0099999999999998 109.788 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.11 -177.59 47.72 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.666 -1.374 . . . . 1.9299999999999999 109.666 179.805 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 12.3 p -78.36 -26.12 46.56 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.25 -1.147 . . . . 2.6899999999999999 109.396 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -71.06 -12.13 71.23 Favored Glycine 0 N--CA 1.488 2.132 0 N-CA-C 109.301 -1.52 . . . . 1.6399999999999999 109.301 -179.831 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 12.8 mt -91.36 -6.13 53.46 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.364 -1.08 . . . . 2.0299999999999998 108.914 179.875 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -96.27 -51.03 4.55 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.336 -0.853 . . . . 2.3399999999999999 109.748 -179.708 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 23.0 ptt180 -175.28 -173.65 0.67 Allowed 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.017 -1.052 . . . . 4.25 110.16 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -152.4 177.58 30.08 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 108.358 -1.897 . . . . 1.5900000000000001 108.358 179.583 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 41.5 t -134.84 151.05 30.6 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.045 0 O-C-N 121.143 -1.21 . . . . 2.21 110.481 -179.683 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -37.05 112.2 0.19 Allowed 'General case' 0 N--CA 1.5 2.072 0 CA-C-O 121.737 0.78 . . . . 2.0699999999999998 112.406 -179.293 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 54.59 49.88 59.42 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 111.371 -0.692 . . . . 1.73 111.371 177.249 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 40.5 t -127.38 98.22 29.71 Favored Pre-proline 0 N--CA 1.496 1.826 0 O-C-N 121.511 -0.994 . . . . 2.6499999999999999 108.512 178.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -56.89 149.05 63.43 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 120.955 1.103 . . . . 2.1400000000000001 110.445 -178.86 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -157.49 -167.73 2.37 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.4 -0.813 . . . . 2.0299999999999998 109.018 -179.812 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -170.54 168.48 7.68 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.148 -0.97 . . . . 2.23 110.873 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . 0.504 ' N ' ' CD1' ' A' ' 39' ' ' PHE . 1.1 p90 -144.95 -178.68 6.16 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 107.161 -1.422 . . . . 1.72 107.161 178.345 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 12.0 m -109.42 150.99 27.27 Favored 'General case' 0 N--CA 1.5 2.049 0 O-C-N 121.359 -0.838 . . . . 2.5800000000000001 110.99 -178.345 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 11.3 mt -147.8 94.55 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 N-CA-C 108.749 -0.834 . . . . 1.8600000000000001 108.749 179.048 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.49 ' C ' ' CD1' ' A' ' 42' ' ' TRP . 0.6 OUTLIER -86.99 138.07 31.82 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 120.946 -1.096 . . . . 4.4699999999999998 108.563 179.837 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -167.61 114.85 0.75 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.282 -0.886 . . . . 3.27 109.523 -179.678 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' ARG . . . . . 0.436 ' C ' ' CD ' ' A' ' 44' ' ' ARG . 1.7 ppt_? -169.47 -12.33 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.19 -0.944 . . . . 5.2300000000000004 109.7 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -65.04 -46.15 82.46 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.213 -0.929 . . . . 2.8900000000000001 109.469 -179.735 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.58 -50.4 72.07 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.153 -0.967 . . . . 1.99 108.856 179.695 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 139.76 -153.58 23.24 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.249 -1.54 . . . . 1.6499999999999999 109.249 179.777 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -86.11 155.97 20.56 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.446 -1.032 . . . . 1.77 108.924 179.547 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 179.35 -140.28 4.28 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.563 -1.415 . . . . 1.1200000000000001 109.563 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.47 ' O ' ' N ' ' A' ' 92' ' ' ASN . . . -138.88 167.64 25.04 Favored Glycine 0 N--CA 1.495 2.611 0 N-CA-C 109.283 -1.527 . . . . 1.1799999999999999 109.283 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.413 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 46.4 tp -142.56 106.48 4.7 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.381 -1.07 . . . . 1.5900000000000001 108.434 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.4 m -90.43 143.54 26.65 Favored 'General case' 0 N--CA 1.495 1.787 0 N-CA-C 108.557 -0.905 . . . . 1.9399999999999999 108.557 179.863 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.52 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 53.6 mt -135.36 105.1 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.266 -0.897 . . . . 1.3 109.176 179.84 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -97.97 106.62 18.94 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.283 -0.886 . . . . 1.27 108.786 179.755 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.437 ' O ' ' O ' ' B' ' 11' ' ' SER . 0.2 OUTLIER -96.79 142.34 14.17 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.501 -0.749 . . . . 1.55 109.555 -179.745 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -141.78 142.7 33.22 Favored 'General case' 0 N--CA 1.491 1.61 0 N-CA-C 108.21 -1.033 . . . . 1.8 108.21 178.846 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 164.92 -173.9 40.83 Favored Glycine 0 N--CA 1.489 2.167 0 N-CA-C 109.448 -1.461 . . . . 0.56000000000000005 109.448 -179.104 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -59.46 -26.0 80.51 Favored 'Trans proline' 0 C--N 1.315 -1.199 0 C-N-CA 121.93 1.753 . . . . 0.76000000000000001 112.103 -179.299 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' SER . . . . . 0.581 ' H ' ' HH ' ' A' ' 85' ' ' TYR . 22.9 t -142.54 169.24 17.95 Favored 'General case' 0 N--CA 1.502 2.168 0 O-C-N 121.015 -1.053 . . . . 2.02 110.364 179.947 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 60.7 mttt -81.09 95.31 6.81 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.497 -0.752 . . . . 3.02 109.763 -179.608 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -63.54 117.29 6.55 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.173 -0.954 . . . . 1.3600000000000001 109.511 179.854 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 26.0 tt0 -66.27 168.39 8.79 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.154 -0.966 . . . . 2.2999999999999998 109.148 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 28.1 mt -141.0 155.61 21.76 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 N-CA-C 108.642 -0.873 . . . . 2.0 108.642 -179.79 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -144.87 170.75 15.52 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 120.627 -1.295 . . . . 1.73 109.156 179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . 0.46 ' CD2' ' O ' ' A' ' 65' ' ' PHE . 31.3 p90 -147.16 117.88 7.57 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.28 -0.887 . . . . 1.6000000000000001 109.472 -179.962 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 . . . . . 0 N--CA 1.495 1.81 0 O-C-N 121.364 -0.835 . . . . 2.5099999999999998 109.546 -179.998 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 14.0 p . . . . . 0 N--CA 1.495 1.779 0 N-CA-C 108.76 -0.83 . . . . 2.5600000000000001 108.76 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 3.3 m -78.81 115.22 18.36 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.15 -0.969 . . . . 2.3599999999999999 109.521 -179.585 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -93.72 114.68 4.78 Favored Glycine 0 N--CA 1.494 2.543 0 N-CA-C 109.919 -1.273 . . . . 1.46 109.919 -179.716 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 94.0 t -98.39 108.5 22.15 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 121.409 -1.053 . . . . 2.1600000000000001 109.465 179.695 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -89.55 166.64 13.53 Favored 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 108.268 -1.012 . . . . 2.1600000000000001 108.268 179.331 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 0.406 ' CD1' ' N ' ' A' ' 77' ' ' TYR . 14.1 p90 -164.14 172.36 13.81 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.216 -0.928 . . . . 1.7 109.659 -179.36 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.463 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 3.7 p -142.17 119.25 7.11 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.254 0 O-C-N 121.104 -0.998 . . . . 2.4500000000000002 110.391 179.61 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 8.5 m -94.98 147.06 6.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.186 -0.946 . . . . 1.8200000000000001 109.164 179.674 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . 0.426 ' OE1' ' OG ' ' A' ' 59' ' ' SER . 29.5 tt0 -90.16 -47.44 7.8 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.082 -1.011 . . . . 3.1699999999999999 110.582 -179.254 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -155.9 155.59 29.52 Favored Pre-proline 0 N--CA 1.504 2.231 0 O-C-N 120.695 -1.253 . . . . 2.02 110.902 -179.347 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.605 ' HG3' ' N ' ' A' ' 107' ' ' SER . 87.2 Cg_exo -36.19 152.77 0.03 OUTLIER 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 123.279 2.653 . . . . 1.3999999999999999 113.287 179.03 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 152.31 158.04 8.26 Favored Glycine 0 N--CA 1.487 2.052 0 N-CA-C 109.251 -1.54 . . . . 1.0800000000000001 109.251 -179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . 0.761 ' N ' HH12 ' B' ' 8' ' ' ARG . 0.3 OUTLIER -83.39 90.38 7.16 Favored 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 107.648 -1.242 . . . . 2.1299999999999999 107.648 179.077 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . 0.581 ' HH ' ' H ' ' A' ' 59' ' ' SER . 1.4 m-85 -73.28 156.11 38.8 Favored 'General case' 0 C--N 1.294 -1.843 0 N-CA-C 108.266 -1.012 . . . . 1.1399999999999999 108.266 -179.267 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . 0.42 ' OE1' ' O ' ' A' ' 84' ' ' ASP . 0.0 OUTLIER -138.48 120.83 15.95 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.461 -0.774 . . . . 1.53 109.287 -179.369 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.7 p -120.89 147.17 24.87 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.532 -0.73 . . . . 1.6399999999999999 109.54 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 82.6 p -129.98 107.25 9.21 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.437 -0.79 . . . . 1.99 109.328 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.566 ' H ' ' HG ' ' A' ' 99' ' ' SER . 1.6 pt -106.29 130.75 57.48 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.658 -0.651 . . . . 1.77 109.946 -179.568 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' LYS . . . . . 0.466 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.6 OUTLIER -136.55 122.63 20.29 Favored 'General case' 0 N--CA 1.492 1.627 0 N-CA-C 108.837 -0.801 . . . . 2.0600000000000001 108.837 179.341 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.56 ' O ' ' ND2' ' A' ' 92' ' ' ASN . 60.0 t80 -80.16 107.0 12.61 Favored 'General case' 0 C--N 1.299 -1.603 0 C-N-CA 118.716 -1.193 . . . . 1.45 107.819 178.37 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . 0.56 ' ND2' ' O ' ' A' ' 91' ' ' PHE . 2.9 p30 61.71 32.79 18.26 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.448 -0.783 . . . . 2.7200000000000002 109.94 -178.584 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . 0.472 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 2.5 m-20 86.21 16.97 0.11 Allowed 'General case' 0 N--CA 1.506 2.363 0 O-C-N 121.593 -0.692 . . . . 1.9199999999999999 112.24 178.171 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . 0.489 ' OE1' ' O ' ' A' ' 94' ' ' GLU . 0.3 OUTLIER -102.4 98.64 8.71 Favored 'General case' 0 N--CA 1.499 1.98 0 N-CA-C 107.039 -1.467 . . . . 2.5499999999999998 107.039 177.503 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' HIS . . . . . 0.502 ' CG ' ' O ' ' A' ' 95' ' ' HIS . 52.1 p-80 -68.64 106.48 2.63 Favored 'General case' 0 N--CA 1.487 1.417 0 N-CA-C 109.14 -0.689 . . . . 3.2000000000000002 109.14 -178.838 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' ILE . . . . . 0.421 ' O ' ' CD1' ' A' ' 96' ' ' ILE . 0.0 OUTLIER -58.91 155.07 34.28 Favored Pre-proline 0 N--CA 1.491 1.602 0 N-CA-C 108.557 -0.905 . . . . 2.8199999999999998 108.557 -179.614 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_endo -63.47 77.24 0.13 Allowed 'Trans proline' 0 CA--C 1.539 0.768 0 C-N-CA 121.23 1.287 . . . . 2.6299999999999999 109.892 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.507 ' CG ' ' CE2' ' A' ' 101' ' ' PHE . 0.4 OUTLIER 179.81 -28.72 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.857 0 O-C-N 120.968 -1.082 . . . . 2.6499999999999999 109.054 -179.649 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' SER . . . . . 0.566 ' HG ' ' H ' ' A' ' 89' ' ' ILE . 29.4 m -78.02 136.69 61.77 Favored Pre-proline 0 C--N 1.298 -1.674 0 N-CA-C 107.313 -1.366 . . . . 2.3199999999999998 107.313 178.448 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -76.64 116.95 4.66 Favored 'Cis proline' 0 CA--C 1.547 1.174 0 C-N-CA 125.165 -0.765 . . . . 1.9399999999999999 111.09 -0.099 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . 0.507 ' CE2' ' CG ' ' A' ' 98' ' ' ASP . 0.1 OUTLIER -70.54 164.77 24.11 Favored 'General case' 0 N--CA 1.494 1.736 0 N-CA-C 107.793 -1.188 . . . . 2.6299999999999999 107.793 178.566 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 8.6 p -123.4 127.93 74.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 N-CA-C 108.43 -0.952 . . . . 1.8200000000000001 108.43 179.068 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 94.9 t -121.47 83.56 40.96 Favored Pre-proline 0 N--CA 1.503 2.18 0 O-C-N 121.406 -0.809 . . . . 1.73 109.535 -179.223 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -66.85 110.64 1.97 Allowed 'Trans proline' 0 C--N 1.32 -0.967 0 C-N-CA 121.252 1.301 . . . . 1.6100000000000001 110.742 -179.131 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 54.2 t -89.06 146.15 6.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 N-CA-C 107.28 -1.378 . . . . 1.7 107.28 178.54 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -133.64 130.43 38.27 Favored 'General case' 0 N--CA 1.508 2.46 0 O-C-N 121.289 -0.882 . . . . 2.04 111.746 -177.085 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' SER . . . . . 0.605 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 94.6 p -106.05 93.4 4.6 Favored 'General case' 0 N--CA 1.494 1.752 0 N-CA-C 106.854 -1.536 . . . . 2.2999999999999998 106.854 178.578 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 11.1 mp 57.38 7.47 0.49 Allowed 'General case' 0 C--N 1.293 -1.858 0 N-CA-C 107.839 -1.171 . . . . 3.6000000000000001 107.839 -177.696 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.545 ' H ' ' C ' ' A' ' 107' ' ' SER . 6.1 t -92.99 -29.42 15.85 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 108.506 -0.924 . . . . 2.4900000000000002 108.506 178.989 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 26.8 m-20 . . . . . 0 N--CA 1.488 1.432 0 N-CA-C 108.061 -1.089 . . . . 2.8500000000000001 108.061 -178.994 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . 0.761 HH12 ' N ' ' A' ' 84' ' ' ASP . 3.9 mtt180 . . . . . 0 N--CA 1.496 1.862 0 N-CA-C 108.562 -0.903 . . . . 3.6699999999999999 108.562 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 9' ' ' VAL . . . . . . . . . . . . . 20.8 t -56.82 159.34 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 N-CA-C 107.632 -1.247 . . . . 1.3899999999999999 107.632 179.041 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -125.84 150.1 48.12 Favored 'General case' 0 N--CA 1.502 2.133 0 O-C-N 121.328 -0.857 . . . . 1.22 109.968 -179.136 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 11' ' ' SER . . . . . 0.437 ' O ' ' O ' ' A' ' 55' ' ' VAL . 6.2 m -148.77 145.14 27.46 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.389 -0.819 . . . . 1.6299999999999999 109.44 179.911 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 14.8 t -142.08 118.57 10.93 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.205 -0.934 . . . . 1.8799999999999999 109.553 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . 0.494 ' CG2' ' N ' ' B' ' 14' ' ' PHE . 2.4 p -157.61 167.04 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 121.365 -0.834 . . . . 1.2 108.804 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 14' ' ' PHE . . . . . 0.52 ' HB3' ' H ' ' A' ' 53' ' ' ILE . 5.4 p90 -176.69 -167.13 0.18 Allowed 'General case' 0 N--CA 1.488 1.47 0 C-N-CA 119.298 -0.961 . . . . 2.3900000000000001 112.082 -179.859 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.9 pt -146.63 176.94 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 N-CA-C 108.419 -0.956 . . . . 1.8100000000000001 108.419 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 16.1 m -140.2 142.09 35.91 Favored 'General case' 0 N--CA 1.5 2.041 0 O-C-N 120.921 -1.112 . . . . 2.04 110.096 -179.703 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 18.5 mt . . . . . 0 N--CA 1.497 1.917 0 O-C-N 121.532 -0.73 . . . . 1.8700000000000001 109.084 179.531 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.477 ' O ' ' N ' ' A' ' 18' ' ' ALA . . . . . . . . 0 N--CA 1.49 2.291 0 N-CA-C 111.779 -0.529 . . . . 2.4399999999999999 111.779 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.588 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 63.79 -49.83 0.08 OUTLIER Glycine 0 N--CA 1.493 2.475 0 O-C-N 121.759 -0.848 . . . . 2.0499999999999998 111.669 177.968 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.512 ' N ' ' OE2' ' A' ' 94' ' ' GLU . . . -45.33 -12.08 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.111 -1.229 . . . . 2.54 109.935 -179.276 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' HIS . . . . . 0.588 ' N ' ' O ' ' A' ' 17' ' ' GLY . 1.5 t60 -83.65 -40.64 18.72 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.142 -0.974 . . . . 3.3700000000000001 109.557 179.207 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.528 ' NZ ' ' HG1' ' A' ' 43' ' ' THR . 0.9 OUTLIER -93.93 4.17 54.3 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 120.874 -1.141 . . . . 2.3700000000000001 110.5 -179.508 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.44 ' CG2' ' HZ3' ' A' ' 20' ' ' LYS . 64.6 t -83.06 113.51 22.36 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 120.811 -1.18 . . . . 2.5800000000000001 109.25 179.721 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 20.3 tpt180 -111.03 137.27 48.87 Favored 'General case' 0 N--CA 1.496 1.83 0 CA-C-O 121.408 0.623 . . . . 3.8900000000000001 109.63 -179.634 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -144.21 113.55 6.98 Favored 'General case' 0 N--CA 1.493 1.701 0 N-CA-C 108.744 -0.836 . . . . 2.0099999999999998 108.744 179.417 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -153.17 128.53 2.47 Favored Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.924 -1.27 . . . . 2.0099999999999998 109.924 -179.465 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 179.84 -173.92 45.5 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.926 -1.269 . . . . 1.9299999999999999 109.926 179.721 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 16.7 p -78.92 -25.76 43.7 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.358 -1.083 . . . . 2.6899999999999999 109.235 179.554 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.485 ' N ' ' O ' ' A' ' 38' ' ' GLU . . . -65.9 -17.78 65.7 Favored Glycine 0 N--CA 1.488 2.131 0 N-CA-C 108.388 -1.885 . . . . 1.6399999999999999 108.388 179.58 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 14.1 mt -94.12 32.46 1.5 Allowed 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 108.477 -0.935 . . . . 2.0299999999999998 108.477 179.439 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -140.33 -50.91 0.47 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.445 -0.784 . . . . 2.3399999999999999 109.615 -179.58 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . 0.519 ' NH1' ' OD1' ' A' ' 110' ' ' ASP . 30.8 ptt180 -172.27 173.75 4.13 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.953 -1.092 . . . . 4.25 110.573 -179.79 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -150.24 176.4 28.88 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 107.878 -2.089 . . . . 1.5900000000000001 107.878 179.437 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 37.5 t -134.09 153.13 35.44 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.137 0 O-C-N 120.992 -1.299 . . . . 2.21 110.755 -179.629 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -40.37 114.1 0.42 Allowed 'General case' 0 N--CA 1.497 1.891 0 CA-C-O 121.587 0.708 . . . . 2.0699999999999998 112.092 -179.334 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 56.46 46.04 88.38 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 111.397 -0.681 . . . . 1.73 111.397 177.05 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 37.1 t -126.92 122.54 23.33 Favored Pre-proline 0 N--CA 1.497 1.909 0 O-C-N 121.443 -1.033 . . . . 2.6499999999999999 108.23 178.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 2.3 Cg_endo -59.47 120.52 8.41 Favored 'Trans proline' 0 C--O 1.216 -0.622 0 C-N-CA 120.474 0.783 . . . . 2.1400000000000001 110.27 -179.38 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -116.81 161.21 19.65 Favored 'General case' 0 N--CA 1.497 1.904 0 N-CA-C 107.814 -1.18 . . . . 2.0299999999999998 107.814 179.167 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . 0.485 ' O ' ' N ' ' A' ' 27' ' ' GLY . 7.0 pt-20 -163.8 173.01 13.31 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 120.642 -1.286 . . . . 2.23 111.519 -179.455 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . 0.405 ' CD1' ' N ' ' A' ' 39' ' ' PHE . 5.6 p90 -157.99 165.24 35.63 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 107.647 -1.242 . . . . 1.72 107.647 178.504 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 58.0 m -99.96 148.96 23.93 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.404 -0.81 . . . . 2.5800000000000001 110.843 -178.099 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 95.5 mt -137.84 102.64 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 N-CA-C 108.353 -0.98 . . . . 1.8600000000000001 108.353 178.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 3.0 t-105 -100.04 132.77 45.21 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.314 -0.866 . . . . 4.4699999999999998 108.683 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' THR . . . . . 0.547 ' OG1' ' N ' ' A' ' 44' ' ' ARG . 1.6 t -162.25 -126.16 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.405 -0.809 . . . . 3.27 109.503 -179.641 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' ARG . . . . . 0.547 ' N ' ' OG1' ' A' ' 43' ' ' THR . 25.9 mtm180 60.61 80.22 0.22 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.285 -0.885 . . . . 5.2300000000000004 109.954 179.885 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 12.5 tp10 -159.45 -46.82 0.05 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.282 -0.886 . . . . 2.8900000000000001 109.134 179.383 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -60.34 -59.96 4.58 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.086 -1.009 . . . . 1.99 109.066 179.715 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 163.59 -175.88 39.76 Favored Glycine 0 N--CA 1.484 1.856 0 C-N-CA 119.385 -1.388 . . . . 1.6499999999999999 110.464 179.62 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.6 163.47 0.65 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.535 -0.98 . . . . 1.77 109.853 -179.686 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 172.72 -163.2 35.04 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.68 -1.368 . . . . 1.1200000000000001 109.68 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -142.77 130.45 4.2 Favored Glycine 0 N--CA 1.496 2.634 0 N-CA-C 109.245 -1.542 . . . . 1.1799999999999999 109.245 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.434 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 12.2 tp -103.07 100.62 10.56 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.425 -1.044 . . . . 1.5900000000000001 109.042 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 3.9 m -88.77 139.76 30.14 Favored 'General case' 0 N--CA 1.497 1.92 0 N-CA-C 108.723 -0.843 . . . . 1.9399999999999999 108.723 179.476 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.486 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 82.6 mt -128.15 113.28 29.78 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.111 0 O-C-N 121.088 -1.008 . . . . 1.3 109.916 -179.811 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -102.48 106.04 16.7 Favored 'General case' 0 N--CA 1.494 1.736 0 N-CA-C 108.718 -0.845 . . . . 1.27 108.718 179.251 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -102.84 143.7 14.78 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 O-C-N 121.471 -0.768 . . . . 1.55 109.326 -179.697 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 -141.95 144.03 33.54 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 108.181 -1.044 . . . . 1.8 108.181 178.743 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 168.71 -172.59 43.17 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 109.179 -1.569 . . . . 0.56000000000000005 109.179 -179.031 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -63.73 -27.6 68.37 Favored 'Trans proline' 0 C--N 1.316 -1.133 0 C-N-CA 121.888 1.725 . . . . 0.76000000000000001 111.461 -179.696 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' SER . . . . . 0.421 ' O ' ' OH ' ' A' ' 85' ' ' TYR . 16.0 m -140.4 168.12 20.55 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.257 -0.902 . . . . 2.02 109.754 -179.77 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 37.1 mtpt -91.13 126.44 36.22 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.376 -0.828 . . . . 3.02 109.517 -179.713 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -86.83 135.12 33.45 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.242 -0.911 . . . . 1.3600000000000001 109.358 179.861 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 20.0 tt0 -90.19 94.53 9.8 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.129 -0.982 . . . . 2.2999999999999998 109.97 -179.658 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . 0.423 ' N ' ' CD1' ' A' ' 63' ' ' ILE . 1.8 mp -60.34 153.74 4.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 N-CA-C 109.118 -0.697 . . . . 2.0 109.118 179.415 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.547 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -151.3 123.8 8.41 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.037 -1.039 . . . . 1.73 109.24 179.778 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . 0.47 ' CD2' ' O ' ' A' ' 65' ' ' PHE . 47.5 p90 -89.0 124.59 34.42 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.204 -0.935 . . . . 1.6000000000000001 109.376 179.787 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 75.9 tt0 . . . . . 0 N--CA 1.497 1.887 0 O-C-N 121.222 -0.924 . . . . 2.5099999999999998 109.772 -179.96 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 3.3 t . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 109.092 -0.707 . . . . 2.5600000000000001 109.092 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 76.4 m -86.23 113.39 22.21 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.126 -0.984 . . . . 2.3599999999999999 109.428 -179.927 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -87.62 115.46 4.34 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.703 -1.359 . . . . 1.46 109.703 -179.717 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 22.0 t -107.03 104.46 17.1 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.995 0 O-C-N 121.605 -0.938 . . . . 2.1600000000000001 109.012 179.79 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.547 ' O ' ' N ' ' A' ' 64' ' ' ALA . 37.3 m -99.4 131.84 45.14 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.558 -0.714 . . . . 2.1600000000000001 110.06 -179.45 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 0.511 ' O ' ' CD1' ' A' ' 77' ' ' TYR . 44.3 p90 -128.01 134.96 49.29 Favored 'General case' 0 N--CA 1.497 1.915 0 N-CA-C 108.875 -0.787 . . . . 1.7 108.875 179.882 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.481 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 9.7 p -104.52 114.2 43.51 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.099 0 O-C-N 121.324 -0.86 . . . . 2.4500000000000002 109.582 -179.576 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 2.0 m -88.64 158.96 2.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.096 -1.002 . . . . 1.8200000000000001 109.031 -179.865 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . 0.403 ' OE1' ' OG ' ' A' ' 59' ' ' SER . 35.1 tt0 -97.28 -49.47 4.93 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.079 -1.013 . . . . 3.1699999999999999 110.758 -179.133 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 76.5 mm-40 -147.15 150.74 39.15 Favored Pre-proline 0 N--CA 1.504 2.242 0 O-C-N 120.794 -1.191 . . . . 2.02 111.661 -178.314 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.594 ' HG3' ' N ' ' A' ' 107' ' ' SER . 77.3 Cg_exo -36.85 164.27 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 123.248 2.632 . . . . 1.3999999999999999 113.346 178.409 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 145.03 175.21 17.99 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.543 -1.423 . . . . 1.0800000000000001 109.543 179.676 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . 0.737 ' H ' HH12 ' B' ' 8' ' ' ARG . 0.9 OUTLIER -94.26 83.97 4.33 Favored 'General case' 0 N--CA 1.49 1.549 0 N-CA-C 107.959 -1.126 . . . . 2.1299999999999999 107.959 179.277 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' TYR . . . . . 0.421 ' OH ' ' O ' ' A' ' 59' ' ' SER . 2.7 m-85 -68.89 135.25 50.76 Favored 'General case' 0 C--N 1.299 -1.606 0 N-CA-C 107.84 -1.171 . . . . 1.1399999999999999 107.84 -179.712 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . 0.442 ' OE2' ' O ' ' A' ' 84' ' ' ASP . 0.8 OUTLIER -116.31 121.04 40.8 Favored 'General case' 0 N--CA 1.499 1.996 0 N-CA-C 108.768 -0.827 . . . . 1.53 108.768 -179.37 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 10.6 p -116.46 145.35 22.33 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 121.592 -0.693 . . . . 1.6399999999999999 110.194 -179.375 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 9.4 p -136.47 110.35 8.19 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 108.699 -0.852 . . . . 1.99 108.699 179.596 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.8 pt -116.89 135.75 56.23 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.949 0 O-C-N 121.577 -0.702 . . . . 1.77 110.632 -178.886 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' LYS . . . . . 0.589 ' HZ2' ' CD2' ' A' ' 95' ' ' HIS . 0.3 OUTLIER -136.03 121.31 19.14 Favored 'General case' 0 N--CA 1.486 1.339 0 N-CA-C 107.923 -1.14 . . . . 2.0600000000000001 107.923 178.625 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.409 ' O ' ' OE1' ' A' ' 94' ' ' GLU . 52.7 t80 -85.15 101.65 12.64 Favored 'General case' 0 N--CA 1.491 1.621 0 N-CA-C 107.196 -1.409 . . . . 1.45 107.196 178.632 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' ASN . . . . . 0.454 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 21.3 t30 72.09 34.36 1.45 Allowed 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 109.214 -0.661 . . . . 2.7200000000000002 109.214 -178.266 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . 0.454 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 1.4 m-20 80.22 14.4 0.84 Allowed 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.614 -0.679 . . . . 1.9199999999999999 111.437 179.393 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . 0.512 ' OE2' ' N ' ' A' ' 18' ' ' ALA . 6.5 pt-20 -99.39 98.68 9.58 Favored 'General case' 0 N--CA 1.497 1.908 0 N-CA-C 107.09 -1.448 . . . . 2.5499999999999998 107.09 177.898 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' HIS . . . . . 0.589 ' CD2' ' HZ2' ' A' ' 90' ' ' LYS . 0.2 OUTLIER -67.19 98.54 0.61 Allowed 'General case' 0 N--CA 1.491 1.578 0 CA-C-O 121.586 0.708 . . . . 3.2000000000000002 110.022 -177.845 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -54.86 137.29 64.99 Favored Pre-proline 0 N--CA 1.489 1.503 0 N-CA-C 107.429 -1.322 . . . . 2.8199999999999998 107.429 179.351 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_exo -39.37 -44.78 3.03 Favored 'Trans proline' 0 CA--C 1.537 0.657 0 C-N-CA 121.234 1.289 . . . . 2.6299999999999999 111.791 -178.809 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.455 ' N ' ' OD1' ' A' ' 98' ' ' ASP . 1.2 m-20 -47.05 -65.72 0.52 Allowed 'General case' 0 N--CA 1.498 1.949 0 O-C-N 120.747 -1.221 . . . . 2.6499999999999999 109.174 179.325 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 3.8 m -57.06 138.89 79.54 Favored Pre-proline 0 C--N 1.297 -1.705 0 O-C-N 121.26 -0.9 . . . . 2.3199999999999998 109.204 -178.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -88.31 115.32 2.97 Favored 'Cis proline' 0 N--CA 1.49 1.271 0 N-CA-C 109.055 -1.171 . . . . 1.9399999999999999 109.055 -1.669 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 52.5 p90 -114.5 162.96 16.03 Favored 'General case' 0 N--CA 1.517 2.918 0 O-C-N 120.546 -1.347 . . . . 2.6299999999999999 110.335 179.117 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.1 p -91.79 151.92 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 CA-C-O 121.713 0.768 . . . . 1.8200000000000001 110.749 -178.34 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 55.8 t -128.24 86.42 58.0 Favored Pre-proline 0 N--CA 1.494 1.766 0 N-CA-C 107.679 -1.23 . . . . 1.73 107.679 179.158 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -66.47 110.59 1.87 Allowed 'Trans proline' 0 C--N 1.321 -0.89 0 C-N-CA 121.623 1.549 . . . . 1.6100000000000001 112.194 -177.563 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 55.5 t -94.51 142.52 13.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 N-CA-C 106.488 -1.671 . . . . 1.7 106.488 177.465 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -129.55 132.32 46.8 Favored 'General case' 0 N--CA 1.512 2.652 0 CA-C-O 122.173 0.987 . . . . 2.04 112.516 -176.59 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' SER . . . . . 0.594 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 35.7 m -94.53 81.33 3.91 Favored 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 107.117 -1.438 . . . . 2.2999999999999998 107.117 178.515 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 23.9 mt 62.63 1.02 0.72 Allowed 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 107.795 -1.187 . . . . 3.6000000000000001 107.795 -177.723 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 109' ' ' SER . . . . . 0.566 ' H ' ' C ' ' A' ' 107' ' ' SER . 60.8 p -87.72 -21.39 25.22 Favored 'General case' 0 N--CA 1.488 1.444 0 N-CA-C 108.471 -0.937 . . . . 2.4900000000000002 108.471 178.859 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . 0.519 ' OD1' ' NH1' ' A' ' 30' ' ' ARG . 36.0 t0 . . . . . 0 N--CA 1.489 1.511 0 N-CA-C 108.512 -0.922 . . . . 2.8500000000000001 108.512 -179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 8' ' ' ARG . . . . . 0.737 HH12 ' H ' ' A' ' 84' ' ' ASP . 39.0 mtt180 . . . . . 0 N--CA 1.494 1.757 0 N-CA-C 108.847 -0.797 . . . . 3.6699999999999999 108.847 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 9' ' ' VAL . . . . . . . . . . . . . 14.7 t -50.9 159.72 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 N-CA-C 108.059 -1.089 . . . . 1.3899999999999999 108.059 179.24 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -122.66 144.26 49.25 Favored 'General case' 0 N--CA 1.501 2.092 0 O-C-N 121.372 -0.83 . . . . 1.22 110.092 -178.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 4.1 t -137.17 145.15 43.4 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.59 -0.693 . . . . 1.6299999999999999 109.246 179.712 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 17.7 m -148.64 115.48 6.02 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.28 -0.888 . . . . 1.8799999999999999 109.752 -179.797 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . 0.48 ' CG2' ' N ' ' B' ' 14' ' ' PHE . 2.9 p -157.86 166.81 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 N-CA-C 108.694 -0.854 . . . . 1.2 108.694 179.624 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 14' ' ' PHE . . . . . 0.486 ' HB3' ' H ' ' A' ' 53' ' ' ILE . 6.9 p90 -177.33 -167.02 0.15 Allowed 'General case' 0 N--CA 1.489 1.509 0 C-N-CA 119.168 -1.013 . . . . 2.3900000000000001 112.403 -179.811 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 3.2 pt -146.62 168.73 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 N-CA-C 108.437 -0.949 . . . . 1.8100000000000001 108.437 179.819 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 49.5 m -138.69 142.08 38.97 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 120.999 -1.063 . . . . 2.04 110.178 -179.599 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 16.5 mt . . . . . 0 N--CA 1.497 1.899 0 O-C-N 121.52 -0.738 . . . . 1.8700000000000001 109.162 179.545 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.955 0 N-CA-C 119.786 2.674 . . . . 6.7300000000000004 119.786 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.559 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 14.5 tt -172.18 50.63 0.12 Allowed Pre-proline 0 C--N 1.306 -1.32 0 N-CA-C 107.8 -1.185 . . . . 7.3799999999999999 107.8 179.421 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.763 ' C ' ' H ' ' A' ' 5' ' ' PHE . 5.5 Cg_endo -58.13 -82.22 0.01 OUTLIER 'Trans proline' 0 C--N 1.32 -0.962 0 N-CA-C 108.534 -1.372 . . . . 5.5 108.534 179.713 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 66.68 -3.83 0.84 Allowed 'General case' 0 N--CA 1.5 2.065 0 N-CA-C 105.101 -2.185 . . . . 6.8399999999999999 105.101 -176.206 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . 0.763 ' H ' ' C ' ' A' ' 3' ' ' PRO . 5.4 m-85 -105.11 18.55 22.15 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 102.705 -3.072 . . . . 6.4400000000000004 102.705 176.876 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.522 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 35.0 p90 46.16 -152.13 0.07 Allowed 'General case' 0 C--N 1.309 -1.169 0 CA-C-N 113.588 -1.642 . . . . 5.0599999999999996 109.204 -177.176 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.506 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 5.1 tt0 82.99 -8.9 1.13 Allowed 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 104.819 -2.289 . . . . 4.8099999999999996 104.819 -177.028 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.502 ' H ' ' C ' ' A' ' 6' ' ' PHE . 79.9 m-85 -146.98 -39.0 0.2 Allowed 'General case' 0 N--CA 1.484 1.268 0 N-CA-C 107.932 -1.136 . . . . 5.7300000000000004 107.932 178.339 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 43.5 m -93.06 3.28 56.01 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 105.652 -1.981 . . . . 5.3499999999999996 105.652 177.249 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 9.7 p -46.76 -42.36 5.73 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 CA-C-N 115.278 -0.874 . . . . 4.3799999999999999 109.544 -179.504 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.63 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 141.25 -83.18 0.22 Allowed Glycine 0 N--CA 1.499 2.889 0 N-CA-C 108.154 -1.978 . . . . 4.4800000000000004 108.154 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.515 ' O ' ' N ' ' A' ' 14' ' ' GLY . 12.2 Cg_endo -66.35 40.57 0.15 Allowed 'Trans proline' 0 C--N 1.321 -0.901 0 C-N-CA 121.866 1.71 . . . . 4.0499999999999998 108.779 177.463 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.63 ' H ' ' C ' ' A' ' 11' ' ' GLY . 0.2 OUTLIER 28.65 37.39 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.276 0 CA-C-O 121.265 0.555 . . . . 4.0599999999999996 110.997 -179.634 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.649 ' C ' ' H ' ' A' ' 16' ' ' GLY . . . 66.91 -35.08 0.18 Allowed Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.556 -1.418 . . . . 3.1400000000000001 109.556 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.623 ' H ' ' C ' ' A' ' 13' ' ' LEU . 6.8 tp10 62.99 -9.31 0.11 Allowed 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.552 -0.969 . . . . 3.1699999999999999 108.897 -178.856 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.649 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 102.87 -151.34 18.03 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 110.809 -0.916 . . . . 2.4399999999999999 110.809 178.429 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.536 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -46.59 -11.5 0.05 OUTLIER Glycine 0 N--CA 1.492 2.402 0 O-C-N 121.635 -0.921 . . . . 2.0499999999999998 111.068 -178.956 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.512 ' N ' ' O ' ' A' ' 16' ' ' GLY . . . -45.93 -15.87 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.991 -1.299 . . . . 2.54 109.661 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . 0.536 ' N ' ' O ' ' A' ' 17' ' ' GLY . 10.7 t60 -94.48 -48.88 5.92 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.443 -0.786 . . . . 3.3700000000000001 109.779 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.51 -14.4 62.1 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.891 -1.13 . . . . 2.3700000000000001 109.435 -179.872 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 37.9 t -68.43 108.82 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.134 -0.979 . . . . 2.5800000000000001 108.629 179.387 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.407 HH11 ' CG ' ' A' ' 22' ' ' ARG . 0.0 OUTLIER -113.83 138.49 50.21 Favored 'General case' 0 N--CA 1.491 1.609 0 N-CA-C 109.131 -0.692 . . . . 3.8900000000000001 109.131 -179.515 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -147.72 113.36 5.68 Favored 'General case' 0 N--CA 1.491 1.603 0 N-CA-C 108.776 -0.824 . . . . 2.0099999999999998 108.776 179.553 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -151.96 131.68 3.51 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.461 -1.456 . . . . 2.0099999999999998 109.461 -179.597 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.0 -177.1 46.51 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.502 -1.439 . . . . 1.9299999999999999 109.502 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.515 ' C ' ' H ' ' A' ' 28' ' ' LEU . 13.5 t -79.59 -38.58 33.66 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.252 -1.146 . . . . 2.6899999999999999 109.16 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -60.28 -6.94 6.37 Favored Glycine 0 N--CA 1.483 1.811 0 N-CA-C 107.864 -2.094 . . . . 1.6399999999999999 107.864 179.222 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.515 ' H ' ' C ' ' A' ' 26' ' ' THR . 12.3 mt -99.3 24.29 8.2 Favored 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 108.247 -1.02 . . . . 2.0299999999999998 108.247 179.38 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 18.2 mt-10 -136.81 -37.66 0.66 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.515 -0.741 . . . . 2.3399999999999999 109.152 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . 0.48 HH11 ' HG2' ' A' ' 30' ' ' ARG . 2.5 ptt-85 -174.78 168.7 3.61 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.098 -1.001 . . . . 4.25 110.204 179.843 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -148.59 177.44 26.83 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 107.643 -2.183 . . . . 1.5900000000000001 107.643 179.558 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 44.1 t -134.41 151.0 31.2 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.12 0 O-C-N 121.056 -1.261 . . . . 2.21 111.043 -179.528 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -40.05 111.35 0.19 Allowed 'General case' 0 N--CA 1.498 1.937 0 CA-C-O 121.501 0.667 . . . . 2.0699999999999998 112.418 -179.233 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 55.63 50.21 61.63 Favored Glycine 0 N--CA 1.492 2.395 0 O-C-N 121.589 -0.694 . . . . 1.73 111.427 176.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 31.5 t -127.35 124.19 23.55 Favored Pre-proline 0 N--CA 1.496 1.851 0 N-CA-C 108.312 -0.996 . . . . 2.6499999999999999 108.312 178.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -57.3 131.98 48.23 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 N-CA-C 110.034 -0.795 . . . . 2.1400000000000001 110.034 -179.527 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -136.04 160.31 39.04 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.46 -0.775 . . . . 2.0299999999999998 109.004 179.81 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -155.32 171.47 19.8 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.012 -1.055 . . . . 2.23 111.213 -179.486 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 5.9 p90 -156.58 164.6 38.0 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 107.259 -1.386 . . . . 1.72 107.259 178.372 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 80.5 p -96.52 155.1 16.91 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.208 -0.933 . . . . 2.5800000000000001 111.279 -177.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 46.6 mt -146.42 97.71 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 N-CA-C 107.516 -1.29 . . . . 1.8600000000000001 107.516 178.767 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.4 ' CD1' ' C ' ' A' ' 42' ' ' TRP . 0.7 OUTLIER -84.88 146.96 27.03 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.113 -0.992 . . . . 4.4699999999999998 109.125 -179.407 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' THR . . . . . 0.556 ' OG1' ' N ' ' A' ' 44' ' ' ARG . 1.4 t -154.31 -130.35 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.525 0 N-CA-C 109.138 -0.689 . . . . 3.27 109.138 -179.414 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ARG . . . . . 0.556 ' N ' ' OG1' ' A' ' 43' ' ' THR . 39.6 ttp180 54.18 73.98 0.36 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.172 -0.955 . . . . 5.2300000000000004 109.985 179.842 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 15.7 tt0 -165.14 -60.86 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.31 -0.869 . . . . 2.8900000000000001 108.875 179.357 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.63 -54.56 44.64 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.059 -1.026 . . . . 1.99 108.71 179.286 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 145.58 179.63 21.97 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.292 -1.523 . . . . 1.6499999999999999 109.292 179.848 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.73 162.74 0.82 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.134 -1.216 . . . . 1.77 109.598 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 168.89 -151.98 19.11 Favored Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.537 -1.425 . . . . 1.1200000000000001 109.537 -179.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.538 ' O ' ' N ' ' A' ' 92' ' ' ASN . . . -133.87 159.12 23.61 Favored Glycine 0 N--CA 1.497 2.743 0 N-CA-C 109.413 -1.475 . . . . 1.1799999999999999 109.413 -179.855 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.401 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 9.8 tp -134.14 100.5 4.73 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.529 -0.983 . . . . 1.5900000000000001 108.424 179.767 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 3.8 m -83.93 144.13 29.38 Favored 'General case' 0 N--CA 1.491 1.58 0 N-CA-C 108.527 -0.916 . . . . 1.9399999999999999 108.527 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.517 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 7.5 mt -135.71 100.94 2.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.354 -0.841 . . . . 1.3 109.203 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -98.19 106.22 18.48 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.306 -0.871 . . . . 1.27 108.986 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.44 ' O ' ' O ' ' B' ' 11' ' ' SER . 0.2 OUTLIER -97.64 144.42 11.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.499 -0.751 . . . . 1.55 109.403 -179.87 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 3.1 tt0 -141.11 142.09 34.14 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 107.909 -1.145 . . . . 1.8 107.909 179.059 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.432 ' O ' ' O ' ' B' ' 9' ' ' VAL . . . 169.03 176.89 39.44 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.173 -1.571 . . . . 0.56000000000000005 109.173 -178.811 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -56.48 -17.99 23.76 Favored 'Trans proline' 0 C--N 1.317 -1.123 0 C-N-CA 121.94 1.76 . . . . 0.76000000000000001 111.274 -179.482 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' SER . . . . . 0.53 ' HG ' ' HH ' ' A' ' 85' ' ' TYR . 1.4 p -150.22 159.93 44.07 Favored 'General case' 0 C--N 1.292 -1.922 0 O-C-N 121.284 -0.885 . . . . 2.02 110.154 179.87 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 68.2 mttt -78.86 108.2 12.14 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.498 -0.752 . . . . 3.02 109.558 -179.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -74.18 148.43 41.68 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.232 -0.918 . . . . 1.3600000000000001 109.481 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 5.0 tp10 -85.14 172.3 11.33 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.322 -0.861 . . . . 2.2999999999999998 108.786 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 3.7 mp -142.79 144.98 23.65 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.926 0 N-CA-C 108.259 -1.015 . . . . 2.0 108.259 179.809 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.521 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -150.53 114.47 5.04 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 120.6 -1.312 . . . . 1.73 109.923 -179.779 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 54.7 p90 -86.74 138.86 31.27 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.327 -0.858 . . . . 1.6000000000000001 109.572 179.73 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 -141.4 105.61 4.81 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.22 -0.925 . . . . 2.5099999999999998 109.711 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . 0.427 ' O ' ' OD1' ' A' ' 67' ' ' ASP . 7.2 p30 -79.18 76.65 5.71 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 108.315 -0.995 . . . . 2.0699999999999998 108.315 178.834 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.409 ' HG2' HH11 ' A' ' 68' ' ' ARG . 25.3 ttt-85 -137.55 59.62 1.66 Allowed 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.433 -0.792 . . . . 5.29 109.366 -179.39 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.467 ' O ' ' CB ' ' A' ' 70' ' ' ASP . 26.8 mttp -146.12 3.25 0.91 Allowed 'General case' 0 C--N 1.305 -1.338 0 O-C-N 121.217 -0.927 . . . . 3.8599999999999999 108.732 179.837 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.467 ' CB ' ' O ' ' A' ' 69' ' ' LYS . 2.5 t70 77.15 4.11 3.25 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.833 -0.542 . . . . 3.0600000000000001 109.66 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 166.7 -25.52 0.15 Allowed Glycine 0 N--CA 1.49 2.245 0 C-N-CA 118.719 -1.705 . . . . 2.1600000000000001 111.472 179.703 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 37.5 m -95.11 135.15 37.01 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 120.844 -1.386 . . . . 2.5600000000000001 109.788 -179.464 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 5.9 t -83.97 125.81 32.41 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.2 -0.938 . . . . 2.3599999999999999 109.108 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -97.65 109.87 3.91 Favored Glycine 0 N--CA 1.495 2.616 0 N-CA-C 110.139 -1.184 . . . . 1.46 110.139 -179.572 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 32.1 t -99.23 100.86 11.26 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.929 0 O-C-N 121.583 -0.951 . . . . 2.1600000000000001 108.757 179.13 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.521 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.1 OUTLIER -89.53 126.14 35.48 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.675 -0.64 . . . . 2.1600000000000001 109.353 -179.551 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 52.0 p90 -123.52 173.89 7.75 Favored 'General case' 0 N--CA 1.495 1.811 0 N-CA-C 108.591 -0.892 . . . . 1.7 108.591 179.619 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 15.4 t -142.18 120.51 8.6 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.936 0 O-C-N 121.321 -0.862 . . . . 2.4500000000000002 109.769 -179.628 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 8.1 m -90.82 154.98 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.435 -0.791 . . . . 1.8200000000000001 109.314 179.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . 0.429 ' O ' ' OE2' ' A' ' 81' ' ' GLU . 33.5 tt0 -100.43 -45.85 5.43 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.192 -0.942 . . . . 3.1699999999999999 110.746 -179.18 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.429 ' OE2' ' O ' ' A' ' 80' ' ' GLN . 79.6 mm-40 -152.39 149.12 22.11 Favored Pre-proline 0 N--CA 1.504 2.251 0 O-C-N 120.458 -1.401 . . . . 2.02 111.399 -179.151 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.613 ' HG3' ' N ' ' A' ' 107' ' ' SER . 84.6 Cg_exo -36.86 162.19 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 123.117 2.544 . . . . 1.3999999999999999 113.637 178.232 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 143.42 -163.82 27.44 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 108.673 -1.771 . . . . 1.0800000000000001 108.673 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . 0.422 ' O ' ' OE1' ' A' ' 86' ' ' GLU . 3.0 m-20 -111.82 93.77 4.62 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.502 -0.999 . . . . 2.1299999999999999 108.353 179.354 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . 0.53 ' HH ' ' HG ' ' A' ' 59' ' ' SER . 3.1 m-85 -78.59 146.19 34.32 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 108.206 -1.035 . . . . 1.1399999999999999 108.206 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . 0.422 ' OE1' ' O ' ' A' ' 84' ' ' ASP . 0.0 OUTLIER -134.64 129.75 35.35 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.682 -0.636 . . . . 1.53 109.298 -178.98 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.8 p -124.99 146.79 30.05 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.554 -0.716 . . . . 1.6399999999999999 109.762 -179.807 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 53.6 p -128.59 101.61 6.23 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.442 -0.786 . . . . 1.99 109.106 179.642 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.2 pt -102.4 130.64 51.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.615 -0.678 . . . . 1.77 109.577 -179.573 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . 0.425 ' O ' ' CG ' ' A' ' 90' ' ' LYS . 0.5 OUTLIER -138.62 124.85 20.29 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.244 -0.91 . . . . 2.0600000000000001 109.238 179.721 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 36.5 t80 -83.13 95.16 8.0 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 120.992 -1.067 . . . . 1.45 108.599 179.391 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . 0.538 ' N ' ' O ' ' A' ' 50' ' ' GLY . 2.3 t-20 70.15 38.71 1.44 Allowed 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 107.925 -1.139 . . . . 2.7200000000000002 107.925 -178.69 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . 0.456 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 3.2 m-20 82.78 12.79 0.48 Allowed 'General case' 0 N--CA 1.498 1.943 0 CA-C-O 121.26 0.553 . . . . 1.9199999999999999 110.005 -179.222 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 4.1 mt-10 -88.88 70.7 8.64 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 107.576 -1.268 . . . . 2.5499999999999998 107.576 178.192 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 11.4 p80 -67.5 113.44 5.35 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-O 121.309 0.576 . . . . 3.2000000000000002 109.953 -179.133 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 2.0 pt -62.64 153.78 76.73 Favored Pre-proline 0 N--CA 1.491 1.61 0 N-CA-C 108.295 -1.002 . . . . 2.8199999999999998 108.295 179.444 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_exo -50.86 -44.69 40.08 Favored 'Trans proline' 0 C--N 1.321 -0.914 0 C-N-CA 121.051 1.167 . . . . 2.6299999999999999 109.987 179.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.564 ' CB ' ' CE2' ' A' ' 101' ' ' PHE . 3.4 m-20 -51.33 -48.43 62.4 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.146 -0.972 . . . . 2.6499999999999999 109.85 179.67 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 2.4 t -56.45 126.13 68.46 Favored Pre-proline 0 C--N 1.298 -1.655 0 N-CA-C 107.752 -1.203 . . . . 2.3199999999999998 107.752 179.545 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 8.3 Cg_endo -72.24 117.55 3.94 Favored 'Cis proline' 0 CA--C 1.548 1.188 0 CA-C-N 119.317 0.792 . . . . 1.9399999999999999 111.48 0.328 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . 0.564 ' CE2' ' CB ' ' A' ' 98' ' ' ASP . 0.1 OUTLIER -73.3 170.97 13.92 Favored 'General case' 0 N--CA 1.494 1.757 0 N-CA-C 107.251 -1.389 . . . . 2.6299999999999999 107.251 178.273 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.6 p -126.77 133.27 68.91 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 121.358 -0.838 . . . . 1.8200000000000001 109.16 179.79 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 86.5 t -128.93 83.08 67.31 Favored Pre-proline 0 N--CA 1.502 2.161 0 O-C-N 121.454 -0.779 . . . . 1.73 109.63 -179.513 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -64.77 114.45 2.76 Favored 'Trans proline' 0 C--N 1.32 -0.932 0 C-N-CA 121.302 1.334 . . . . 1.6100000000000001 110.477 -179.506 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 53.1 t -93.91 146.15 6.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 N-CA-C 108.292 -1.003 . . . . 1.7 108.292 179.484 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -131.92 130.28 41.38 Favored 'General case' 0 N--CA 1.507 2.401 0 CA-C-O 121.932 0.872 . . . . 2.04 111.941 -177.291 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' SER . . . . . 0.613 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 76.2 p -98.65 98.3 9.46 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.733 -1.23 . . . . 2.2999999999999998 107.788 179.184 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . 0.45 ' CD1' ' N ' ' A' ' 108' ' ' LEU . 8.9 mp 54.62 9.3 0.26 Allowed 'General case' 0 C--N 1.293 -1.872 0 N-CA-C 108.278 -1.008 . . . . 3.6000000000000001 108.278 -178.585 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.588 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 8.3 t -101.05 -28.57 12.64 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.604 -0.685 . . . . 2.4900000000000002 109.16 179.503 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 13.8 t70 55.04 11.12 0.46 Allowed 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 107.776 -1.194 . . . . 2.8500000000000001 107.776 -179.528 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.513 ' H ' ' C ' ' A' ' 109' ' ' SER . 1.8 p30 -168.28 -30.53 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 109.484 -0.561 . . . . 2.46 109.484 -179.602 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.588 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 49.25 75.24 0.16 Allowed 'General case' 0 N--CA 1.497 1.883 0 O-C-N 120.79 -1.193 . . . . 2.0800000000000001 108.821 -179.576 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.532 ' C ' ' H ' ' A' ' 115' ' ' LEU . 0.0 OUTLIER -82.82 149.54 27.12 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.323 -0.861 . . . . 6.54 110.292 -178.785 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 22.6 ttp180 -73.9 12.49 0.67 Allowed 'General case' 0 N--CA 1.494 1.733 0 N-CA-C 108.664 -0.865 . . . . 6.2400000000000002 108.664 179.239 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.532 ' H ' ' C ' ' A' ' 113' ' ' ARG . 31.0 mt -127.83 -29.83 2.56 Favored 'General case' 0 N--CA 1.503 2.183 0 N-CA-C 109.116 -0.698 . . . . 4.71 109.116 -179.906 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.529 ' C ' ' H ' ' A' ' 118' ' ' THR . 33.9 m -91.48 -80.01 0.36 Allowed 'General case' 0 N--CA 1.494 1.755 0 N-CA-C 106.893 -1.521 . . . . 4.3499999999999996 106.893 178.847 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 32.0 t -61.36 -10.04 3.34 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 N-CA-C 105.579 -2.008 . . . . 3.3100000000000001 105.579 176.384 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' THR . . . . . 0.529 ' H ' ' C ' ' A' ' 116' ' ' THR . 5.1 t 36.6 58.22 1.08 Allowed 'General case' 0 N--CA 1.484 1.267 0 CA-C-N 114.851 -1.068 . . . . 3.73 110.742 179.88 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' SER . . . . . 0.463 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.7 p . . . . . 0 C--N 1.304 -1.404 0 CA-C-O 118.021 -0.99 . . . . 3.8300000000000001 109.569 179.384 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 19.3 mmt . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.463 -0.569 . . . . 8.8699999999999992 109.463 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . 50.97 90.41 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.213 -0.93 . . . . 5.9299999999999997 109.435 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 3' ' ' SER . . . . . . . . . . . . . 36.4 t -53.31 107.66 0.26 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.26 -0.9 . . . . 5.5700000000000003 109.454 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 4' ' ' LYS . . . . . 0.541 ' N ' ' CD ' ' B' ' 5' ' ' PRO . 6.3 tttp -60.9 -47.28 96.06 Favored Pre-proline 0 N--CA 1.488 1.465 0 O-C-N 121.346 -0.846 . . . . 7.25 110.296 -179.991 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 5' ' ' PRO . . . . . 0.541 ' CD ' ' N ' ' B' ' 4' ' ' LYS . 6.1 Cg_exo -63.48 129.99 26.92 Favored 'Trans proline' 0 C--N 1.321 -0.872 0 C-N-CA 120.879 1.052 . . . . 5.8899999999999997 109.852 -179.345 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 6' ' ' GLU . . . . . . . . . . . . . 3.0 pt-20 -63.97 115.87 5.31 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.369 -0.832 . . . . 4.7800000000000002 109.59 -179.766 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 67.2 mttt 48.64 -165.43 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.234 -0.916 . . . . 4.5599999999999996 109.471 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . 0.583 HH11 ' CG ' ' B' ' 8' ' ' ARG . 0.0 OUTLIER -101.53 -163.28 1.0 Allowed 'General case' 0 N--CA 1.494 1.769 0 N-CA-C 107.349 -1.352 . . . . 3.6699999999999999 107.349 179.559 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 9' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' A' ' 57' ' ' GLY . 34.8 t -71.94 160.0 5.47 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 120.75 -1.219 . . . . 1.3899999999999999 108.422 179.611 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -123.71 156.71 35.45 Favored 'General case' 0 N--CA 1.5 2.066 0 O-C-N 121.418 -0.801 . . . . 1.22 110.015 -179.26 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 11' ' ' SER . . . . . 0.44 ' O ' ' O ' ' A' ' 55' ' ' VAL . 3.2 t -149.56 144.03 25.97 Favored 'General case' 0 N--CA 1.492 1.641 0 N-CA-C 108.869 -0.789 . . . . 1.6299999999999999 108.869 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 47.2 t -143.48 120.12 11.12 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 120.976 -1.078 . . . . 1.8799999999999999 109.99 -179.666 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . 0.488 ' CG2' ' N ' ' B' ' 14' ' ' PHE . 3.1 p -157.92 165.77 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 N-CA-C 108.722 -0.844 . . . . 1.2 108.722 179.542 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 14' ' ' PHE . . . . . 0.517 ' HB3' ' H ' ' A' ' 53' ' ' ILE . 4.9 p90 -177.99 -170.35 0.24 Allowed 'General case' 0 N--CA 1.49 1.563 0 C-N-CA 119.38 -0.928 . . . . 2.3900000000000001 112.158 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 3.1 pt -149.87 -163.66 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.341 0 N-CA-C 108.273 -1.01 . . . . 1.8100000000000001 108.273 179.831 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -161.09 146.55 14.22 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 120.724 -1.235 . . . . 2.04 109.911 179.769 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 13.4 mt -91.66 108.6 20.02 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.219 -0.926 . . . . 1.8700000000000001 109.376 179.696 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -138.7 82.37 21.53 Favored Pre-proline 0 N--CA 1.495 1.776 0 N-CA-C 108.741 -0.837 . . . . 1.47 108.741 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_exo -59.58 166.43 8.03 Favored 'Trans proline' 0 C--N 1.32 -0.93 0 C-N-CA 121.046 1.164 . . . . 1.96 109.808 -178.846 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 20' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -54.11 -173.57 0.02 OUTLIER 'Trans proline' 0 C--N 1.319 -1.024 0 C-N-CA 121.457 1.438 . . . . 3.3799999999999999 109.998 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 78.9 mtm180 -58.34 129.61 42.84 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.286 -0.884 . . . . 6.7400000000000002 109.72 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 22' ' ' ARG . . . . . . . . . . . . . 66.8 mtm180 -59.32 137.46 57.98 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.239 -0.913 . . . . 6.9400000000000004 109.33 179.756 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 42.8 t0 -160.93 12.7 0.1 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.125 -0.985 . . . . 5.6200000000000001 109.751 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 33.7 m . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 118.033 -0.985 . . . . 6.75 109.405 -179.99 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.922 0 N-CA-C 119.671 2.628 . . . . 6.7300000000000004 119.671 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.568 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 15.0 tt -172.27 50.28 0.12 Allowed Pre-proline 0 C--N 1.307 -1.255 0 N-CA-C 107.807 -1.182 . . . . 7.3799999999999999 107.807 179.573 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.782 ' C ' ' H ' ' A' ' 5' ' ' PHE . 6.1 Cg_endo -57.94 -82.71 0.01 OUTLIER 'Trans proline' 0 C--N 1.318 -1.076 0 N-CA-C 108.583 -1.353 . . . . 5.5 108.583 179.827 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.523 ' C ' ' H ' ' A' ' 6' ' ' PHE . 0.5 OUTLIER 74.11 -18.76 0.39 Allowed 'General case' 0 N--CA 1.496 1.831 0 N-CA-C 104.209 -2.515 . . . . 6.8399999999999999 104.209 -175.851 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . 0.782 ' H ' ' C ' ' A' ' 3' ' ' PRO . 5.5 m-85 -90.03 19.48 4.91 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 103.966 -2.605 . . . . 6.4400000000000004 103.966 176.718 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.542 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 39.5 p90 46.17 -152.49 0.06 Allowed 'General case' 0 C--N 1.307 -1.27 0 CA-C-N 114.421 -1.263 . . . . 5.0599999999999996 109.38 -177.436 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.53 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 8.6 tt0 83.6 -8.12 1.08 Allowed 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 105.023 -2.214 . . . . 4.8099999999999996 105.023 -177.205 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.471 ' H ' ' C ' ' A' ' 6' ' ' PHE . 48.0 m-85 -148.34 -39.42 0.17 Allowed 'General case' 0 C--N 1.307 -1.27 0 N-CA-C 107.66 -1.237 . . . . 5.7300000000000004 107.66 178.383 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 25.6 m -91.07 2.45 56.31 Favored 'General case' 0 C--N 1.295 -1.762 0 N-CA-C 105.874 -1.899 . . . . 5.3499999999999996 105.874 177.199 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 8.7 p -45.51 -44.16 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.327 0 CA-C-N 115.513 -0.767 . . . . 4.3799999999999999 109.439 -179.568 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.592 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 143.86 -84.86 0.19 Allowed Glycine 0 N--CA 1.497 2.735 0 N-CA-C 108.411 -1.876 . . . . 4.4800000000000004 108.411 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.529 ' O ' ' N ' ' A' ' 14' ' ' GLY . 12.3 Cg_endo -68.57 35.84 0.18 Allowed 'Trans proline' 0 C--N 1.322 -0.859 0 C-N-CA 121.468 1.445 . . . . 4.0499999999999998 109.074 177.964 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.592 ' H ' ' C ' ' A' ' 11' ' ' GLY . 0.1 OUTLIER 40.46 23.91 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.261 0 N-CA-C 108.877 -0.786 . . . . 4.0599999999999996 108.877 -179.152 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.557 ' C ' ' H ' ' A' ' 16' ' ' GLY . . . 69.99 -45.67 0.57 Allowed Glycine 0 N--CA 1.486 1.995 0 N-CA-C 107.42 -2.272 . . . . 3.1400000000000001 107.42 -178.243 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.576 ' H ' ' C ' ' A' ' 13' ' ' LEU . 7.1 tp10 49.13 10.93 0.03 OUTLIER 'General case' 0 C--N 1.305 -1.359 0 CA-C-O 121.948 0.88 . . . . 3.1699999999999999 109.01 179.73 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.557 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 55.16 121.21 0.01 OUTLIER Glycine 0 N--CA 1.49 2.24 0 O-C-N 121.513 -0.742 . . . . 2.4399999999999999 111.635 178.835 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.568 ' C ' ' H ' ' A' ' 19' ' ' HIS . . . 72.36 -52.34 1.45 Allowed Glycine 0 N--CA 1.493 2.487 0 O-C-N 121.458 -1.024 . . . . 2.0499999999999998 111.127 178.296 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.472 ' N ' ' CD ' ' A' ' 94' ' ' GLU . . . -49.45 -6.95 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.098 -1.236 . . . . 2.54 110.169 -179.308 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . 0.568 ' H ' ' C ' ' A' ' 17' ' ' GLY . 29.2 t-80 -94.97 -12.09 27.34 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.067 -1.021 . . . . 3.3700000000000001 110.295 -179.801 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 2.3 pptp? -132.6 11.64 4.44 Favored 'General case' 0 N--CA 1.504 2.235 0 O-C-N 121.031 -1.043 . . . . 2.3700000000000001 110.457 -179.759 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 53.2 t -94.29 113.19 28.38 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 120.976 -1.078 . . . . 2.5800000000000001 109.257 179.491 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 20.3 tpt180 -113.08 121.33 44.24 Favored 'General case' 0 N--CA 1.496 1.846 0 N-CA-C 108.98 -0.748 . . . . 3.8900000000000001 108.98 179.843 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -128.16 114.07 16.53 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 108.878 -0.786 . . . . 2.0099999999999998 108.878 179.735 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -151.24 130.6 3.22 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 109.509 -1.436 . . . . 2.0099999999999998 109.509 -179.616 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.29 171.08 43.42 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.739 -1.344 . . . . 1.9299999999999999 109.739 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 13.2 p -78.51 -27.13 46.06 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.343 -1.092 . . . . 2.6899999999999999 109.373 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.68 -12.55 70.57 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 109.11 -1.596 . . . . 1.6399999999999999 109.11 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 12.1 mt -87.68 -15.53 36.9 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.437 -1.037 . . . . 2.0299999999999998 108.852 179.679 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 42.2 mt-10 -87.66 -62.07 1.58 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.412 -0.805 . . . . 2.3399999999999999 109.726 -179.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 72.5 mtt180 -148.14 178.48 8.51 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.114 -0.991 . . . . 4.25 110.058 -179.678 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -150.11 175.21 29.3 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 107.786 -2.125 . . . . 1.5900000000000001 107.786 179.317 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 40.7 t -133.54 151.7 33.82 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.15 0 O-C-N 121.084 -1.245 . . . . 2.21 110.744 -179.57 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -43.56 111.01 0.23 Allowed 'General case' 0 N--CA 1.5 2.04 0 CA-C-O 121.57 0.7 . . . . 2.0699999999999998 112.428 -178.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 55.87 52.8 46.37 Favored Glycine 0 N--CA 1.491 2.315 0 O-C-N 121.515 -0.741 . . . . 1.73 111.52 176.884 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 8.5 t -127.83 126.97 23.99 Favored Pre-proline 0 N--CA 1.497 1.911 0 O-C-N 121.502 -0.999 . . . . 2.6499999999999999 108.373 178.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -57.77 117.8 4.57 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 N-CA-C 109.33 -1.065 . . . . 2.1400000000000001 109.33 179.711 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -127.43 149.99 49.84 Favored 'General case' 0 N--CA 1.501 2.089 0 N-CA-C 108.873 -0.788 . . . . 2.0299999999999998 108.873 -179.827 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -155.33 162.41 40.85 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.937 -1.102 . . . . 2.23 111.172 -179.448 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.58 ' N ' ' CD1' ' A' ' 39' ' ' PHE . 0.5 OUTLIER -137.98 -176.77 4.55 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 106.831 -1.544 . . . . 1.72 106.831 178.163 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 72.6 p -121.04 145.49 47.71 Favored 'General case' 0 N--CA 1.499 1.981 0 CA-C-O 121.5 0.667 . . . . 2.5800000000000001 110.121 -179.222 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.444 ' O ' ' N ' ' A' ' 73' ' ' CYS . 48.5 mt -142.2 117.02 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 N-CA-C 108.515 -0.921 . . . . 1.8600000000000001 108.515 179.32 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.434 ' CD1' ' C ' ' A' ' 42' ' ' TRP . 0.2 OUTLIER -113.74 129.62 56.55 Favored 'General case' 0 N--CA 1.497 1.878 0 N-CA-C 108.432 -0.951 . . . . 4.4699999999999998 108.432 179.923 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' THR . . . . . 0.569 ' HG1' ' H ' ' A' ' 44' ' ' ARG . 9.2 p -144.73 -127.51 0.08 Allowed 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.343 -0.848 . . . . 3.27 109.16 -179.667 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' ARG . . . . . 0.569 ' H ' ' HG1' ' A' ' 43' ' ' THR . 1.6 ttt-85 56.89 79.85 0.17 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.363 -0.836 . . . . 5.2300000000000004 110.059 179.646 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -156.27 -52.26 0.08 Allowed 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 108.543 -0.91 . . . . 2.8900000000000001 108.543 179.146 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -60.78 -48.14 83.15 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.214 -0.929 . . . . 1.99 108.779 179.326 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 151.98 -174.48 30.99 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 109.514 -1.435 . . . . 1.6499999999999999 109.514 179.809 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.33 161.44 0.94 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.252 -1.146 . . . . 1.77 109.047 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 176.17 -158.32 24.8 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.69 -1.364 . . . . 1.1200000000000001 109.69 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -145.86 124.75 2.13 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 109.826 -1.31 . . . . 1.1799999999999999 109.826 -179.806 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.433 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 10.4 tp -100.2 100.89 11.79 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.456 -1.026 . . . . 1.5900000000000001 108.557 179.461 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 25.0 p -86.19 141.34 29.4 Favored 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 108.567 -0.901 . . . . 1.9399999999999999 108.567 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.479 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 72.7 mt -130.44 114.25 27.96 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 O-C-N 121.235 -0.915 . . . . 1.3 109.552 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -105.36 107.94 19.2 Favored 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 108.777 -0.823 . . . . 1.27 108.777 179.677 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -101.37 142.95 15.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 O-C-N 121.528 -0.733 . . . . 1.55 109.25 -179.857 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 8.7 tt0 -141.88 145.39 34.56 Favored 'General case' 0 N--CA 1.49 1.575 0 N-CA-C 107.685 -1.228 . . . . 1.8 107.685 178.755 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.43 ' O ' ' O ' ' B' ' 9' ' ' VAL . . . 164.58 -172.97 40.47 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.79 -1.324 . . . . 0.56000000000000005 109.79 -179.296 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -67.71 -30.6 34.16 Favored 'Trans proline' 0 C--N 1.318 -1.06 0 C-N-CA 122.139 1.893 . . . . 0.76000000000000001 112.09 -179.361 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' SER . . . . . 0.644 ' HG ' ' HH ' ' A' ' 85' ' ' TYR . 0.3 OUTLIER -128.55 179.7 5.53 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 121.162 -0.962 . . . . 2.02 110.226 -179.126 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.466 ' NZ ' ' O ' ' B' ' 10' ' ' ALA . 62.7 mmtt -92.0 114.53 27.09 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.607 -0.683 . . . . 3.02 109.241 -179.817 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.481 ' O ' ' N ' ' A' ' 63' ' ' ILE . . . -66.15 103.74 1.03 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.023 -1.048 . . . . 1.3600000000000001 109.231 179.701 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 30.3 mt-10 -65.19 72.17 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.141 -0.974 . . . . 2.2999999999999998 109.635 -179.738 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . 0.481 ' N ' ' O ' ' A' ' 61' ' ' ALA . 3.4 mp -58.14 149.35 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.613 -0.68 . . . . 2.0 109.295 179.852 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.54 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -150.4 127.6 11.29 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.996 -1.065 . . . . 1.73 109.453 -179.859 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.458 ' CD2' ' O ' ' A' ' 65' ' ' PHE . 50.3 p90 -87.01 130.85 34.28 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.179 -0.951 . . . . 1.6000000000000001 109.488 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -141.19 109.49 5.87 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.286 -0.884 . . . . 2.5099999999999998 109.338 179.821 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . 0.473 ' OD1' ' N ' ' A' ' 67' ' ' ASP . 18.2 p-10 -90.13 107.2 18.99 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.243 -0.911 . . . . 2.0699999999999998 109.32 179.77 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 79.8 mtm180 -99.03 -17.38 18.3 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.305 -0.872 . . . . 5.29 109.272 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.543 ' C ' ' H ' ' A' ' 71' ' ' GLY . 78.9 mttt -122.09 -0.77 9.39 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.6 -0.687 . . . . 3.8599999999999999 109.16 179.935 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.461 ' CB ' ' O ' ' A' ' 69' ' ' LYS . 3.0 t0 73.51 -21.28 0.27 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.375 -0.828 . . . . 3.0600000000000001 109.06 -179.683 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . 0.543 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -115.31 -24.98 3.95 Favored Glycine 0 N--CA 1.495 2.609 0 N-CA-C 109.434 -1.466 . . . . 2.1600000000000001 109.434 -179.545 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 16.1 t -95.43 121.16 36.81 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.318 -1.107 . . . . 2.5600000000000001 109.011 179.696 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' CYS . . . . . 0.444 ' N ' ' O ' ' A' ' 41' ' ' ILE . 33.7 m -83.31 105.17 14.05 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.202 -0.937 . . . . 2.3599999999999999 109.825 -179.515 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -85.28 116.25 4.29 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.168 -1.573 . . . . 1.46 109.168 179.594 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 49.8 t -107.09 99.64 9.0 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.072 0 O-C-N 121.58 -0.953 . . . . 2.1600000000000001 109.597 -179.674 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.54 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.5 OUTLIER -89.71 131.39 35.71 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.396 -0.815 . . . . 2.1600000000000001 109.258 179.775 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 0.426 ' O ' ' CG ' ' A' ' 77' ' ' TYR . 2.3 p90 -133.07 126.81 32.65 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.379 -0.826 . . . . 1.7 109.825 -179.837 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 3.0 t -107.74 103.8 16.05 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 O-C-N 121.674 -0.641 . . . . 2.4500000000000002 109.876 -179.665 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 2.4 m -80.23 167.66 2.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.296 -0.877 . . . . 1.8200000000000001 108.72 179.423 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 41.7 tp60 -102.26 -46.33 4.85 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.213 -0.929 . . . . 3.1699999999999999 110.732 -179.298 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.432 ' O ' ' O ' ' A' ' 82' ' ' PRO . 71.8 mm-40 -147.61 151.02 38.4 Favored Pre-proline 0 N--CA 1.506 2.37 0 O-C-N 120.754 -1.216 . . . . 2.02 112.161 -178.254 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.581 ' HG3' ' N ' ' A' ' 107' ' ' SER . 86.0 Cg_exo -36.5 168.12 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 123.389 2.726 . . . . 1.3999999999999999 113.734 178.113 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 140.9 -176.11 21.75 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.678 -1.369 . . . . 1.0800000000000001 109.678 179.374 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . 0.528 ' OD2' ' NE ' ' B' ' 8' ' ' ARG . 2.4 p-10 -99.8 86.55 3.32 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.512 -0.993 . . . . 2.1299999999999999 108.349 179.419 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . 0.644 ' HH ' ' HG ' ' A' ' 59' ' ' SER . 2.7 m-85 -72.87 130.72 41.05 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 108.044 -1.095 . . . . 1.1399999999999999 108.044 -179.789 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -107.24 129.12 54.91 Favored 'General case' 0 N--CA 1.496 1.87 0 N-CA-C 108.474 -0.936 . . . . 1.53 108.474 -179.196 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.446 ' CG1' ' CZ ' ' A' ' 101' ' ' PHE . 5.7 p -126.18 141.99 44.14 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 N-CA-C 109.17 -0.678 . . . . 1.6399999999999999 109.17 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 13.5 p -138.65 107.15 5.84 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.264 -0.898 . . . . 1.99 109.795 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.8 pt -112.57 136.46 48.75 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.92 0 CA-C-O 121.414 0.626 . . . . 1.77 110.097 -179.738 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . 0.457 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.2 OUTLIER -143.05 122.41 13.08 Favored 'General case' 0 N--CA 1.486 1.333 0 O-C-N 121.383 -0.823 . . . . 2.0600000000000001 108.785 179.447 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 55.3 t80 -79.67 99.74 7.53 Favored 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 107.716 -1.216 . . . . 1.45 107.716 178.458 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . 0.416 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 13.9 t-20 69.56 39.9 1.49 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.492 -0.755 . . . . 2.7200000000000002 109.404 -178.885 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . 0.416 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 0.9 OUTLIER 76.7 13.27 2.32 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.665 -0.647 . . . . 1.9199999999999999 111.585 179.442 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . 0.472 ' CD ' ' N ' ' A' ' 18' ' ' ALA . 0.6 OUTLIER -98.27 94.9 7.03 Favored 'General case' 0 N--CA 1.499 1.978 0 N-CA-C 106.919 -1.511 . . . . 2.5499999999999998 106.919 177.649 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . 0.578 ' CD2' ' H ' ' A' ' 95' ' ' HIS . 0.1 OUTLIER -71.12 106.99 3.94 Favored 'General case' 0 N--CA 1.488 1.431 0 CA-C-O 121.586 0.707 . . . . 3.2000000000000002 109.839 -178.16 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . 0.574 ' O ' ' N ' ' A' ' 98' ' ' ASP . 10.6 pt -52.8 150.4 9.86 Favored Pre-proline 0 C--N 1.299 -1.6 0 N-CA-C 108.579 -0.897 . . . . 2.8199999999999998 108.579 179.634 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.413 ' O ' ' CG ' ' A' ' 98' ' ' ASP . 1.0 OUTLIER -57.48 75.56 0.04 OUTLIER 'Trans proline' 0 C--O 1.214 -0.7 0 C-N-CA 121.146 1.231 . . . . 2.6299999999999999 109.195 179.362 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.574 ' N ' ' O ' ' A' ' 96' ' ' ILE . 1.9 m-20 -177.62 -59.82 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.485 0 N-CA-C 108.278 -1.008 . . . . 2.6499999999999999 108.278 -178.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 9.5 m -57.44 138.79 81.13 Favored Pre-proline 0 C--N 1.299 -1.627 0 O-C-N 121.414 -0.804 . . . . 2.3199999999999998 110.031 -178.216 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_endo -89.78 114.28 2.41 Favored 'Cis proline' 0 N--CA 1.493 1.458 0 N-CA-C 109.707 -0.92 . . . . 1.9399999999999999 109.707 -2.724 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . 0.446 ' CZ ' ' CG1' ' A' ' 87' ' ' VAL . 15.3 p90 -104.9 170.86 7.63 Favored 'General case' 0 N--CA 1.515 2.79 0 O-C-N 120.425 -1.422 . . . . 2.6299999999999999 110.01 178.87 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.5 p -95.49 153.79 3.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.602 -0.686 . . . . 1.8200000000000001 110.095 -179.467 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.498 ' N ' ' O ' ' A' ' 85' ' ' TYR . 69.2 t -128.66 86.37 57.78 Favored Pre-proline 0 N--CA 1.498 1.948 0 N-CA-C 107.868 -1.16 . . . . 1.73 107.868 179.316 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -60.99 113.85 1.91 Allowed 'Trans proline' 0 C--N 1.323 -0.792 0 C-N-CA 121.497 1.465 . . . . 1.6100000000000001 112.256 -177.56 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 55.3 t -96.1 138.12 22.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 N-CA-C 106.784 -1.561 . . . . 1.7 106.784 177.724 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -119.0 126.56 52.02 Favored 'General case' 0 N--CA 1.511 2.582 0 N-CA-C 113.161 0.801 . . . . 2.04 113.161 -175.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' SER . . . . . 0.602 ' C ' ' H ' ' A' ' 109' ' ' SER . 23.8 t -94.84 97.89 10.35 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 120.3 -1.5 . . . . 2.2999999999999998 107.586 178.09 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 13.7 mt 66.35 -21.04 0.1 Allowed 'General case' 0 C--N 1.289 -2.058 0 N-CA-C 109.22 -0.659 . . . . 3.6000000000000001 109.22 -178.767 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.602 ' H ' ' C ' ' A' ' 107' ' ' SER . 9.6 t -70.93 -29.17 65.12 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.084 -1.01 . . . . 2.4900000000000002 108.908 179.027 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 54.31 13.23 0.59 Allowed 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 107.874 -1.158 . . . . 2.8500000000000001 107.874 179.83 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.486 ' H ' ' C ' ' A' ' 109' ' ' SER . 28.6 t0 -172.55 -24.92 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.574 0 CA-C-N 116.107 -0.497 . . . . 2.46 109.738 -179.54 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.574 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 56.08 170.86 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.6 -1.312 . . . . 2.0800000000000001 108.624 -179.515 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.411 ' C ' ' H ' ' A' ' 115' ' ' LEU . 56.4 mtm180 -83.14 111.22 18.72 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.105 -0.997 . . . . 6.54 109.671 -179.564 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.433 ' HG3' HH11 ' A' ' 114' ' ' ARG . 8.0 ttm-85 -76.17 8.46 3.27 Favored 'General case' 0 N--CA 1.493 1.721 0 CA-C-O 121.751 0.786 . . . . 6.2400000000000002 109.178 179.879 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.411 ' H ' ' C ' ' A' ' 113' ' ' ARG . 37.6 mt -124.48 -28.71 3.58 Favored 'General case' 0 N--CA 1.503 2.22 0 O-C-N 121.734 -0.604 . . . . 4.71 109.477 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.528 ' C ' ' H ' ' A' ' 118' ' ' THR . 14.2 m -103.84 -76.29 0.6 Allowed 'General case' 0 N--CA 1.499 2.007 0 N-CA-C 107.327 -1.36 . . . . 4.3499999999999996 107.327 179.071 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.432 ' O ' ' OXT' ' A' ' 119' ' ' SER . 51.7 t -62.9 -9.07 3.86 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.69 0 N-CA-C 105.726 -1.953 . . . . 3.3100000000000001 105.726 176.887 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' THR . . . . . 0.528 ' H ' ' C ' ' A' ' 116' ' ' THR . 4.9 t 35.67 59.21 0.85 Allowed 'General case' 0 N--CA 1.485 1.305 0 CA-C-N 114.883 -1.053 . . . . 3.73 111.121 179.572 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' SER . . . . . 0.432 ' OXT' ' O ' ' A' ' 117' ' ' VAL . 1.7 p . . . . . 0 C--N 1.303 -1.45 0 CA-C-O 118.023 -0.989 . . . . 3.8300000000000001 109.635 179.162 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 1' ' ' MET . . . . . 0.562 ' C ' ' H ' ' B' ' 3' ' ' SER . 72.8 mtm . . . . . 0 N--CA 1.49 1.574 0 N-CA-C 109.495 -0.557 . . . . 8.8699999999999992 109.495 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . 63.09 -7.42 0.15 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.43 -0.794 . . . . 5.9299999999999997 109.774 -179.779 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 3' ' ' SER . . . . . 0.562 ' H ' ' C ' ' B' ' 1' ' ' MET . 8.0 m 45.45 -147.36 0.12 Allowed 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.208 -0.933 . . . . 5.5700000000000003 110.066 179.699 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 4' ' ' LYS . . . . . . . . . . . . . 59.3 mttp -152.51 95.91 3.05 Favored Pre-proline 0 N--CA 1.493 1.676 0 O-C-N 121.473 -0.767 . . . . 7.25 108.942 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 5' ' ' PRO . . . . . . . . . . . . . 3.8 Cg_exo -59.54 97.59 0.1 Allowed 'Trans proline' 0 C--N 1.325 -0.701 0 C-N-CA 120.845 1.03 . . . . 5.8899999999999997 110.177 -179.16 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 6' ' ' GLU . . . . . . . . . . . . . 14.6 pt-20 -115.58 32.39 6.1 Favored 'General case' 0 N--CA 1.498 1.95 0 N-CA-C 109.141 -0.689 . . . . 4.7800000000000002 109.141 179.71 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 28.9 mmtp 57.26 107.62 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.595 -0.69 . . . . 4.5599999999999996 110.09 179.825 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . 0.56 HH11 ' CG ' ' B' ' 8' ' ' ARG . 2.5 mtt-85 -67.76 170.23 8.29 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.286 -1.005 . . . . 3.6699999999999999 108.286 179.008 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 9' ' ' VAL . . . . . 0.43 ' O ' ' O ' ' A' ' 57' ' ' GLY . 24.6 t -50.81 158.72 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 N-CA-C 107.785 -1.191 . . . . 1.3899999999999999 107.785 179.137 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . 0.466 ' O ' ' NZ ' ' A' ' 60' ' ' LYS . . . -128.98 149.14 50.94 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.227 -0.921 . . . . 1.22 110.563 -178.585 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 4.1 t -139.58 146.35 39.73 Favored 'General case' 0 N--CA 1.495 1.789 0 N-CA-C 108.763 -0.829 . . . . 1.6299999999999999 108.763 179.498 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 42.9 m -147.41 121.91 9.74 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.07 -1.019 . . . . 1.8799999999999999 109.927 -179.589 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . 0.482 ' CG2' ' N ' ' B' ' 14' ' ' PHE . 7.7 p -169.85 170.52 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 N-CA-C 108.883 -0.784 . . . . 1.2 108.883 179.759 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 14' ' ' PHE . . . . . 0.482 ' N ' ' CG2' ' B' ' 13' ' ' VAL . 9.1 p90 -176.6 -163.47 0.1 Allowed 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 119.226 -0.99 . . . . 2.3900000000000001 112.084 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.3 pt -147.49 160.95 8.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 N-CA-C 108.518 -0.919 . . . . 1.8100000000000001 108.518 179.82 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 17.9 m -131.18 141.73 50.11 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.273 -0.892 . . . . 2.04 109.892 -179.734 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.0 mt -100.3 127.17 46.66 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.418 -0.802 . . . . 1.8700000000000001 109.36 179.712 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -156.59 90.55 2.6 Favored Pre-proline 0 N--CA 1.493 1.689 0 N-CA-C 109.108 -0.701 . . . . 1.47 109.108 -179.719 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_exo -60.06 167.14 7.77 Favored 'Trans proline' 0 CA--C 1.546 1.088 0 C-N-CA 121.136 1.224 . . . . 1.96 110.117 -178.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 20' ' ' PRO . . . . . 0.429 ' O ' ' O ' ' B' ' 21' ' ' ARG . 1.8 Cg_endo -58.06 -18.71 37.41 Favored 'Trans proline' 0 C--N 1.321 -0.874 0 C-N-CA 121.692 1.594 . . . . 3.3799999999999999 110.703 -179.675 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . 0.429 ' O ' ' O ' ' B' ' 20' ' ' PRO . 38.3 mtp180 -63.25 -129.87 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.954 -1.091 . . . . 6.7400000000000002 109.451 -179.792 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 22' ' ' ARG . . . . . . . . . . . . . 44.1 ttt180 58.44 42.5 21.11 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.235 -0.916 . . . . 6.9400000000000004 109.435 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . 0.445 ' CG ' ' H ' ' B' ' 24' ' ' VAL . 2.8 p-10 -84.04 -65.18 1.04 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.271 -0.893 . . . . 5.6200000000000001 109.345 -179.94 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . 0.445 ' H ' ' CG ' ' B' ' 23' ' ' ASP . 13.9 p . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 118.014 -0.993 . . . . 6.75 109.448 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.906 0 N-CA-C 119.658 2.623 . . . . 6.7300000000000004 119.658 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.617 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 1.0 OUTLIER -162.23 46.09 0.17 Allowed Pre-proline 0 C--N 1.305 -1.331 0 N-CA-C 107.658 -1.238 . . . . 7.3799999999999999 107.658 179.222 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.839 ' C ' ' H ' ' A' ' 5' ' ' PHE . 2.1 Cg_endo -54.46 -80.86 0.02 OUTLIER 'Trans proline' 0 C--N 1.318 -1.042 0 N-CA-C 108.777 -1.278 . . . . 5.5 108.777 179.78 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.535 ' C ' ' H ' ' A' ' 6' ' ' PHE . 4.2 tp10 73.01 -17.84 0.39 Allowed 'General case' 0 N--CA 1.496 1.827 0 N-CA-C 104.359 -2.46 . . . . 6.8399999999999999 104.359 -175.834 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . 0.839 ' H ' ' C ' ' A' ' 3' ' ' PRO . 2.3 m-85 -90.71 19.73 5.23 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 103.778 -2.675 . . . . 6.4400000000000004 103.778 176.751 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.547 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 37.6 p90 45.85 -154.29 0.04 OUTLIER 'General case' 0 C--N 1.307 -1.249 0 CA-C-N 114.298 -1.319 . . . . 5.0599999999999996 109.359 -177.435 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.524 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 17.3 tt0 86.31 -9.87 0.69 Allowed 'General case' 0 N--CA 1.492 1.646 0 N-CA-C 105.169 -2.16 . . . . 4.8099999999999996 105.169 -177.389 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.435 ' H ' ' C ' ' A' ' 6' ' ' PHE . 45.1 t80 -152.49 -37.48 0.11 Allowed 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 107.925 -1.139 . . . . 5.7300000000000004 107.925 178.39 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 89.5 m -93.15 3.96 54.81 Favored 'General case' 0 C--N 1.295 -1.77 0 N-CA-C 105.97 -1.863 . . . . 5.3499999999999996 105.97 177.479 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.439 ' CG1' ' N ' ' A' ' 11' ' ' GLY . 12.5 p -44.38 -45.52 2.39 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.317 0 CA-C-N 115.555 -0.748 . . . . 4.3799999999999999 109.25 -179.668 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.618 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 134.27 -83.04 0.29 Allowed Glycine 0 N--CA 1.501 2.983 0 N-CA-C 109.098 -1.601 . . . . 4.4800000000000004 109.098 179.148 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.437 ' O ' ' N ' ' A' ' 14' ' ' GLY . 11.4 Cg_endo -67.21 35.13 0.14 Allowed 'Trans proline' 0 C--N 1.319 -1.019 0 C-N-CA 121.566 1.51 . . . . 4.0499999999999998 109.212 178.691 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.618 ' H ' ' C ' ' A' ' 11' ' ' GLY . 0.1 OUTLIER 38.65 32.02 0.05 OUTLIER 'General case' 0 N--CA 1.506 2.327 0 CA-C-O 122.016 0.912 . . . . 4.0599999999999996 108.791 -178.613 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.524 ' C ' ' H ' ' A' ' 16' ' ' GLY . . . 72.41 -40.52 0.75 Allowed Glycine 0 N--CA 1.488 2.155 0 N-CA-C 108.595 -1.802 . . . . 3.1400000000000001 108.595 -179.241 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.535 ' H ' ' C ' ' A' ' 13' ' ' LEU . 8.9 tp10 52.87 8.85 0.1 Allowed 'General case' 0 C--N 1.304 -1.396 0 O-C-N 121.486 -1.008 . . . . 3.1699999999999999 108.924 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.524 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 59.1 118.33 0.01 OUTLIER Glycine 0 N--CA 1.486 1.988 0 N-CA-C 110.003 -1.239 . . . . 2.4399999999999999 110.003 179.823 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.514 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 95.02 -57.99 1.76 Allowed Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.761 -1.336 . . . . 2.0499999999999998 109.761 179.707 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -47.86 -12.32 0.03 OUTLIER 'General case' 0 C--N 1.297 -1.68 0 O-C-N 121.64 -0.917 . . . . 2.54 110.067 -179.121 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . 0.514 ' N ' ' O ' ' A' ' 17' ' ' GLY . 29.1 t-80 -98.46 -7.11 29.1 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.245 -0.909 . . . . 3.3700000000000001 110.684 -178.745 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.498 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.4 OUTLIER -145.98 5.58 1.0 Allowed 'General case' 0 N--CA 1.496 1.851 0 O-C-N 120.854 -1.153 . . . . 2.3700000000000001 110.252 -179.491 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.429 ' O ' ' CG1' ' A' ' 21' ' ' VAL . 7.4 p -77.35 115.56 19.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.022 -1.049 . . . . 2.5800000000000001 108.51 179.116 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 12.7 tpp180 -109.92 139.27 45.2 Favored 'General case' 0 N--CA 1.49 1.574 0 CA-C-O 121.509 0.671 . . . . 3.8900000000000001 109.566 -178.745 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -148.18 113.27 5.51 Favored 'General case' 0 N--CA 1.491 1.599 0 N-CA-C 108.609 -0.885 . . . . 2.0099999999999998 108.609 179.424 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -147.85 132.1 4.11 Favored Glycine 0 N--CA 1.495 2.614 0 N-CA-C 109.523 -1.431 . . . . 2.0099999999999998 109.523 -179.624 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.27 174.13 46.08 Favored Glycine 0 N--CA 1.488 2.115 0 C-N-CA 119.598 -1.287 . . . . 1.9299999999999999 110.013 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 8.5 p -79.85 -22.04 43.42 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.338 -1.095 . . . . 2.6899999999999999 108.985 179.479 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -68.67 -16.47 69.94 Favored Glycine 0 N--CA 1.487 2.034 0 N-CA-C 108.62 -1.792 . . . . 1.6399999999999999 108.62 179.637 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.0 mt -93.04 30.28 1.66 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.625 -0.927 . . . . 2.0299999999999998 108.799 179.783 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 13.5 mt-10 -141.91 -43.44 0.35 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.396 -0.815 . . . . 2.3399999999999999 109.62 -179.375 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 11.8 ptm180 -175.65 172.11 2.63 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.007 -1.058 . . . . 4.25 109.991 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -150.77 176.51 29.3 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 108.335 -1.906 . . . . 1.5900000000000001 108.335 179.665 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 39.2 t -134.23 151.54 32.41 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.031 0 O-C-N 121.186 -1.185 . . . . 2.21 110.529 -179.733 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -44.91 115.47 0.89 Allowed 'General case' 0 N--CA 1.497 1.88 0 CA-C-O 121.869 0.842 . . . . 2.0699999999999998 112.477 -179.195 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 54.03 50.81 53.7 Favored Glycine 0 N--CA 1.488 2.143 0 N-CA-C 111.245 -0.742 . . . . 1.73 111.245 177.264 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 5.0 t -127.03 127.11 24.41 Favored Pre-proline 0 N--CA 1.496 1.871 0 N-CA-C 108.232 -1.025 . . . . 2.6499999999999999 108.232 179.14 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -55.51 121.17 9.47 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 N-CA-C 109.918 -0.839 . . . . 2.1400000000000001 109.918 -179.845 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -128.78 145.42 51.19 Favored 'General case' 0 N--CA 1.497 1.922 0 N-CA-C 108.488 -0.93 . . . . 2.0299999999999998 108.488 179.736 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -152.16 164.05 38.11 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.995 -1.066 . . . . 2.23 110.765 -179.512 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.549 ' N ' ' CD1' ' A' ' 39' ' ' PHE . 0.7 OUTLIER -139.71 178.43 7.24 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 107.007 -1.479 . . . . 1.72 107.007 177.907 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 58.7 m -121.32 141.27 51.08 Favored 'General case' 0 N--CA 1.496 1.857 0 CA-C-O 121.573 0.702 . . . . 2.5800000000000001 110.382 -178.83 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.508 ' O ' ' N ' ' A' ' 73' ' ' CYS . 68.3 mt -138.14 124.08 25.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 N-CA-C 108.307 -0.997 . . . . 1.8600000000000001 108.307 179.106 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.523 ' HE1' ' CG ' ' A' ' 44' ' ' ARG . 3.1 t90 -128.08 125.46 39.31 Favored 'General case' 0 N--CA 1.496 1.858 0 N-CA-C 108.615 -0.884 . . . . 4.4699999999999998 108.615 -179.549 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' THR . . . . . 0.498 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -151.21 118.23 5.89 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.321 -0.862 . . . . 3.27 109.269 -179.672 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' ARG . . . . . 0.523 ' CG ' ' HE1' ' A' ' 42' ' ' TRP . 10.6 ptm180 -171.09 72.19 0.05 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.172 -0.955 . . . . 5.2300000000000004 109.72 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 21.3 tt0 -154.32 -45.19 0.09 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.306 -0.871 . . . . 2.8900000000000001 109.083 179.579 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.99 -55.66 13.5 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.117 -0.989 . . . . 1.99 109.196 179.686 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 154.96 156.36 7.71 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.608 -1.397 . . . . 1.6499999999999999 109.608 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.49 156.92 2.29 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.232 -1.158 . . . . 1.77 109.511 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -170.48 -111.34 0.25 Allowed Glycine 0 N--CA 1.488 2.16 0 N-CA-C 108.965 -1.654 . . . . 1.1200000000000001 108.965 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.544 ' O ' ' N ' ' A' ' 92' ' ' ASN . . . -157.7 161.87 31.68 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.463 -1.455 . . . . 1.1799999999999999 109.463 179.684 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.425 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 10.2 tp -140.55 97.0 3.12 Favored 'General case' 0 N--CA 1.493 1.703 0 N-CA-C 107.839 -1.171 . . . . 1.5900000000000001 107.839 179.513 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 13.7 m -87.69 142.81 27.54 Favored 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 108.846 -0.798 . . . . 1.9399999999999999 108.846 -179.586 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.508 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 6.7 mt -136.71 100.42 2.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.366 -0.834 . . . . 1.3 108.859 179.721 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -98.8 106.42 18.69 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.258 -0.902 . . . . 1.27 108.907 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -97.87 146.14 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 O-C-N 121.434 -0.791 . . . . 1.55 109.33 -179.814 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 35.4 tp10 -141.13 138.04 33.18 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 107.385 -1.339 . . . . 1.8 107.385 178.531 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.532 ' O ' ' N ' ' B' ' 9' ' ' VAL . . . 173.37 -173.0 45.58 Favored Glycine 0 N--CA 1.493 2.44 0 C-N-CA 119.271 -1.442 . . . . 0.56000000000000005 110.033 -178.72 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -62.76 -35.1 70.54 Favored 'Trans proline' 0 C--N 1.318 -1.038 0 C-N-CA 122.127 1.885 . . . . 0.76000000000000001 111.568 -179.596 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' SER . . . . . 0.43 ' O ' ' OH ' ' A' ' 85' ' ' TYR . 10.7 m -139.57 162.34 35.31 Favored 'General case' 0 N--CA 1.5 2.025 0 O-C-N 121.072 -1.017 . . . . 2.02 110.057 -179.036 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 23.0 mttp -85.29 95.57 9.24 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.435 -0.791 . . . . 3.02 109.495 -179.844 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -50.59 135.32 23.15 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.336 -0.853 . . . . 1.3600000000000001 109.315 179.83 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.47 ' CD ' ' N ' ' A' ' 62' ' ' GLU . 15.9 mp0 -71.09 85.38 0.73 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.247 -0.908 . . . . 2.2999999999999998 109.582 -179.873 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 19.2 tt -58.88 150.21 5.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 N-CA-C 108.963 -0.755 . . . . 2.0 108.963 179.611 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.547 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -150.61 114.51 5.02 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 120.691 -1.255 . . . . 1.73 109.744 -179.715 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.417 ' CD1' ' N ' ' A' ' 65' ' ' PHE . 17.7 p90 -90.33 125.08 35.41 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.284 -0.885 . . . . 1.6000000000000001 109.388 179.612 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 -141.48 105.79 4.82 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.256 -0.902 . . . . 2.5099999999999998 109.545 -179.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -83.92 100.39 10.98 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.273 -0.892 . . . . 2.0699999999999998 109.243 179.804 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.592 ' CG ' HH11 ' A' ' 68' ' ' ARG . 0.0 OUTLIER -90.98 -9.54 45.65 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.186 -0.946 . . . . 5.29 109.504 -179.752 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.53 ' C ' ' H ' ' A' ' 71' ' ' GLY . 20.5 mmmt -124.93 -0.17 7.93 Favored 'General case' 0 N--CA 1.5 2.035 0 O-C-N 121.48 -0.762 . . . . 3.8599999999999999 109.439 -179.768 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.446 ' CB ' ' O ' ' A' ' 69' ' ' LYS . 2.4 t70 70.97 -11.48 0.66 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.2 -0.938 . . . . 3.0600000000000001 108.899 -179.603 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . 0.53 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -129.71 -25.63 0.91 Allowed Glycine 0 N--CA 1.493 2.489 0 N-CA-C 109.559 -1.416 . . . . 2.1600000000000001 109.559 -179.303 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 10.6 t -95.5 109.36 21.58 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.235 -1.156 . . . . 2.5600000000000001 108.88 179.532 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' CYS . . . . . 0.508 ' N ' ' O ' ' A' ' 41' ' ' ILE . 49.8 t -80.05 104.81 10.87 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.222 -0.924 . . . . 2.3599999999999999 109.845 -179.451 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -91.82 116.33 4.97 Favored Glycine 0 N--CA 1.493 2.5 0 N-CA-C 109.123 -1.591 . . . . 1.46 109.123 179.65 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 96.4 t -105.82 102.16 13.46 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.135 0 O-C-N 121.486 -1.008 . . . . 2.1600000000000001 109.684 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.547 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.1 OUTLIER -88.42 130.08 35.26 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.376 -0.828 . . . . 2.1600000000000001 108.936 179.649 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 0.426 ' O ' ' CG ' ' A' ' 77' ' ' TYR . 2.8 p90 -132.42 125.48 30.88 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.479 -0.763 . . . . 1.7 109.053 -179.824 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 5.9 t -99.86 103.72 15.14 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.392 -0.817 . . . . 2.4500000000000002 109.37 -179.478 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 25.9 m -69.77 160.32 5.03 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 O-C-N 121.22 -0.925 . . . . 1.8200000000000001 109.31 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 24.0 tp60 -100.72 -48.62 4.44 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.235 -0.915 . . . . 3.1699999999999999 110.586 -179.416 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -155.25 152.77 25.66 Favored Pre-proline 0 N--CA 1.501 2.106 0 O-C-N 120.806 -1.184 . . . . 2.02 110.995 -178.915 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.562 ' HG3' ' N ' ' A' ' 107' ' ' SER . 75.1 Cg_exo -38.31 163.2 0.02 OUTLIER 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 123.176 2.584 . . . . 1.3999999999999999 113.659 179.36 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 147.13 -162.36 28.59 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.156 -1.578 . . . . 1.0800000000000001 109.156 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 33.5 m-20 -111.39 89.78 3.15 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.653 -0.91 . . . . 2.1299999999999999 108.937 179.761 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . 0.45 ' O ' ' N ' ' A' ' 103' ' ' VAL . 3.3 m-85 -77.64 128.94 34.93 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 108.004 -1.11 . . . . 1.1399999999999999 108.004 179.687 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -112.63 129.74 56.28 Favored 'General case' 0 N--CA 1.5 2.042 0 N-CA-C 108.406 -0.961 . . . . 1.53 108.406 -179.088 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 8.6 p -124.84 137.63 56.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 CA-C-O 121.486 0.66 . . . . 1.6399999999999999 110.002 -179.522 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 29.5 t -126.12 103.25 7.61 Favored 'General case' 0 N--CA 1.497 1.907 0 N-CA-C 109.405 -0.591 . . . . 1.99 109.405 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -111.18 132.78 58.76 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.023 0 O-C-N 121.519 -0.738 . . . . 1.77 110.226 -179.39 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . 0.401 ' O ' ' CG ' ' A' ' 90' ' ' LYS . 0.4 OUTLIER -140.91 127.06 19.56 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.369 -0.832 . . . . 2.0600000000000001 109.909 179.658 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 54.5 t80 -82.3 94.39 7.33 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.12 -0.987 . . . . 1.45 108.457 178.855 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . 0.544 ' N ' ' O ' ' A' ' 50' ' ' GLY . 6.7 t30 69.22 37.08 2.19 Favored 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 108.074 -1.084 . . . . 2.7200000000000002 108.074 -179.017 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . 0.463 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 2.6 m-20 83.4 14.7 0.34 Allowed 'General case' 0 N--CA 1.499 1.981 0 CA-C-N 116.485 -0.325 . . . . 1.9199999999999999 110.905 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . 0.526 ' CG ' ' O ' ' A' ' 94' ' ' GLU . 0.0 OUTLIER -91.17 90.83 7.97 Favored 'General case' 0 N--CA 1.496 1.827 0 N-CA-C 106.862 -1.533 . . . . 2.5499999999999998 106.862 178.119 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . 0.509 ' CG ' ' O ' ' A' ' 95' ' ' HIS . 9.0 p80 -68.15 88.8 0.3 Allowed 'General case' 0 C--N 1.299 -1.615 0 O-C-N 119.94 -1.725 . . . . 3.2000000000000002 110.359 -177.816 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 2.3 tt -48.3 137.13 11.73 Favored Pre-proline 0 N--CA 1.496 1.846 0 N-CA-C 107.635 -1.246 . . . . 2.8199999999999998 107.635 178.675 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -40.51 -39.55 2.89 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 121.307 1.338 . . . . 2.6299999999999999 111.747 -178.42 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 18.8 m-20 -49.18 -66.49 0.39 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 120.689 -1.257 . . . . 2.6499999999999999 109.237 179.356 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -69.31 147.94 97.26 Favored Pre-proline 0 C--N 1.293 -1.875 0 O-C-N 121.151 -0.968 . . . . 2.3199999999999998 110.067 -178.917 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -84.44 112.02 2.36 Favored 'Cis proline' 0 N--CA 1.491 1.343 0 N-CA-C 109.538 -0.986 . . . . 1.9399999999999999 109.538 -2.238 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 43.1 p90 -116.21 166.86 11.55 Favored 'General case' 0 N--CA 1.522 3.162 0 O-C-N 120.509 -1.37 . . . . 2.6299999999999999 110.445 178.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.2 p -95.49 148.19 5.35 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.903 0 CA-C-O 121.752 0.787 . . . . 1.8200000000000001 111.549 -177.703 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.45 ' N ' ' O ' ' A' ' 85' ' ' TYR . 79.4 t -121.8 86.38 45.59 Favored Pre-proline 0 N--CA 1.498 1.926 0 N-CA-C 108.279 -1.008 . . . . 1.73 108.279 179.238 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_exo -62.81 114.14 2.28 Favored 'Trans proline' 0 C--N 1.319 -1.021 0 C-N-CA 121.351 1.367 . . . . 1.6100000000000001 112.09 -178.011 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 55.2 t -95.27 144.34 10.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 N-CA-C 106.938 -1.504 . . . . 1.7 106.938 177.865 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -134.76 136.24 42.47 Favored 'General case' 0 N--CA 1.51 2.536 0 CA-C-O 122.079 0.942 . . . . 2.04 111.748 -177.457 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' SER . . . . . 0.562 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 80.6 p -92.17 76.41 5.35 Favored 'General case' 0 N--CA 1.492 1.674 0 N-CA-C 107.472 -1.307 . . . . 2.2999999999999998 107.472 179.278 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 23.6 mt 61.72 6.36 1.57 Allowed 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 107.103 -1.443 . . . . 3.6000000000000001 107.103 -177.735 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.578 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 14.0 t -92.27 -20.83 20.73 Favored 'General case' 0 N--CA 1.486 1.338 0 N-CA-C 109.205 -0.665 . . . . 2.4900000000000002 109.205 179.588 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . 0.41 ' CG ' ' O ' ' A' ' 109' ' ' SER . 2.6 p30 45.31 19.6 0.04 OUTLIER 'General case' 0 N--CA 1.498 1.939 0 N-CA-C 108.417 -0.957 . . . . 2.8500000000000001 108.417 -179.052 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.513 ' N ' ' O ' ' A' ' 109' ' ' SER . 23.8 t0 -173.34 -29.07 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 109.003 -0.74 . . . . 2.46 109.003 -179.584 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.578 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 59.03 -173.29 0.1 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.974 -1.079 . . . . 2.0800000000000001 109.198 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 1.7 tpt180 -159.53 -157.8 0.61 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.156 -0.965 . . . . 6.54 109.467 179.816 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.412 HH11 ' HG3' ' A' ' 114' ' ' ARG . 24.3 ttm-85 -144.27 1.39 1.08 Allowed 'General case' 0 N--CA 1.492 1.664 0 N-CA-C 107.856 -1.164 . . . . 6.2400000000000002 107.856 179.638 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -127.95 -26.81 2.85 Favored 'General case' 0 N--CA 1.501 2.079 0 N-CA-C 108.758 -0.83 . . . . 4.71 108.758 179.483 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.543 ' C ' ' H ' ' A' ' 118' ' ' THR . 77.9 m -105.29 -79.14 0.56 Allowed 'General case' 0 N--CA 1.495 1.815 0 N-CA-C 107.209 -1.404 . . . . 4.3499999999999996 107.209 179.142 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 53.3 t -62.11 -8.53 2.78 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.698 0 N-CA-C 106.014 -1.847 . . . . 3.3100000000000001 106.014 176.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' THR . . . . . 0.543 ' H ' ' C ' ' A' ' 116' ' ' THR . 4.2 t 36.07 60.62 0.82 Allowed 'General case' 0 N--CA 1.487 1.413 0 CA-C-N 115.2 -0.909 . . . . 3.73 110.723 179.855 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' SER . . . . . 0.446 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.6 p . . . . . 0 C--N 1.303 -1.455 0 CA-C-O 117.971 -1.014 . . . . 3.8300000000000001 109.562 179.409 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 19.3 mtt . . . . . 0 N--CA 1.49 1.564 0 N-CA-C 109.468 -0.567 . . . . 8.8699999999999992 109.468 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -67.0 -149.21 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.251 -0.906 . . . . 5.9299999999999997 109.512 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 3' ' ' SER . . . . . . . . . . . . . 22.8 t -75.02 150.13 39.03 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.31 -0.869 . . . . 5.5700000000000003 109.515 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 4' ' ' LYS . . . . . . . . . . . . . 59.3 tttm -160.51 68.03 2.67 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.299 -0.876 . . . . 7.25 109.572 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 5' ' ' PRO . . . . . 0.428 ' O ' ' O ' ' B' ' 6' ' ' GLU . 2.0 Cg_endo -63.15 101.18 0.28 Allowed 'Trans proline' 0 C--N 1.318 -1.048 0 C-N-CA 121.527 1.485 . . . . 5.8899999999999997 110.198 -179.612 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 6' ' ' GLU . . . . . 0.428 ' O ' ' O ' ' B' ' 5' ' ' PRO . 23.1 tp10 58.72 156.53 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.274 -0.891 . . . . 4.7800000000000002 109.721 179.544 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 7' ' ' LYS . . . . . 0.4 ' O ' ' O ' ' B' ' 6' ' ' GLU . 36.9 mttp -63.83 -130.38 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.216 -0.927 . . . . 4.5599999999999996 109.38 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . 0.407 ' NH1' ' HG3' ' B' ' 8' ' ' ARG . 23.4 mtm-85 -98.51 -117.75 0.14 Allowed 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.287 -1.005 . . . . 3.6699999999999999 108.287 179.841 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 9' ' ' VAL . . . . . 0.532 ' N ' ' O ' ' A' ' 57' ' ' GLY . 0.4 OUTLIER -122.48 170.85 12.22 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.069 0 N-CA-C 108.139 -1.06 . . . . 1.3899999999999999 108.139 178.989 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -114.81 136.24 53.31 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.717 -0.615 . . . . 1.22 110.07 -179.41 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 9.4 m -149.28 82.88 1.43 Allowed 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.376 -0.828 . . . . 1.6299999999999999 109.44 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 12.8 t -101.04 116.72 33.52 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.363 -0.836 . . . . 1.8799999999999999 109.434 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . 0.477 ' CG2' ' N ' ' B' ' 14' ' ' PHE . 3.2 p -156.66 164.45 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.265 -0.897 . . . . 1.2 109.177 179.823 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 14' ' ' PHE . . . . . 0.508 ' HB3' ' H ' ' A' ' 53' ' ' ILE . 6.5 p90 -178.99 -164.7 0.07 Allowed 'General case' 0 N--CA 1.49 1.555 0 CA-C-O 122.1 0.953 . . . . 2.3900000000000001 111.924 179.575 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.615 ' N ' ' CD1' ' B' ' 15' ' ' ILE . 0.1 OUTLIER -145.72 155.49 13.0 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.094 0 N-CA-C 108.635 -0.876 . . . . 1.8100000000000001 108.635 179.811 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 97.0 m -109.11 158.9 17.33 Favored 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.214 -0.929 . . . . 2.04 109.781 -179.799 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 34.3 mt -132.8 104.99 6.88 Favored 'General case' 0 N--CA 1.499 2.019 0 O-C-N 121.475 -0.766 . . . . 1.8700000000000001 109.167 179.821 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -158.81 76.86 3.26 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.295 -0.878 . . . . 1.47 109.342 -179.828 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -65.79 166.15 21.17 Favored 'Trans proline' 0 CA--C 1.544 1.006 0 C-N-CA 121.303 1.335 . . . . 1.96 109.733 -179.36 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 20' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_endo -62.47 84.26 0.1 Allowed 'Trans proline' 0 C--N 1.319 -1.023 0 C-N-CA 121.509 1.472 . . . . 3.3799999999999999 109.77 179.611 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 34.8 ttp180 -100.11 90.62 4.44 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.146 -0.971 . . . . 6.7400000000000002 109.401 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 22' ' ' ARG . . . . . 0.57 HH11 ' CG ' ' B' ' 22' ' ' ARG . 3.4 mtt-85 -64.73 -106.5 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.233 -0.917 . . . . 6.9400000000000004 109.392 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . 0.49 ' OD1' ' N ' ' B' ' 24' ' ' VAL . 37.8 t0 -170.65 146.75 2.74 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.196 -0.94 . . . . 5.6200000000000001 109.436 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . 0.49 ' N ' ' OD1' ' B' ' 23' ' ' ASP . 15.4 m . . . . . 0 N--CA 1.49 1.557 0 CA-C-O 118.006 -0.997 . . . . 6.75 109.384 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.531 4.968 0 N-CA-C 119.773 2.669 . . . . 6.7300000000000004 119.773 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.571 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 12.7 tt -171.75 50.66 0.13 Allowed Pre-proline 0 C--N 1.306 -1.32 0 N-CA-C 107.949 -1.13 . . . . 7.3799999999999999 107.949 179.523 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.689 ' C ' ' H ' ' A' ' 5' ' ' PHE . 4.3 Cg_endo -57.08 -79.19 0.02 OUTLIER 'Trans proline' 0 C--N 1.318 -1.047 0 C-N-CA 121.279 1.32 . . . . 5.5 109.3 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.434 ' CB ' ' O ' ' A' ' 3' ' ' PRO . 0.0 OUTLIER 72.54 -48.94 0.69 Allowed 'General case' 0 N--CA 1.493 1.684 0 N-CA-C 103.227 -2.879 . . . . 6.8399999999999999 103.227 -175.684 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . 0.689 ' H ' ' C ' ' A' ' 3' ' ' PRO . 7.3 m-85 -51.4 -27.28 9.59 Favored 'General case' 0 C--N 1.305 -1.356 0 N-CA-C 106.552 -1.647 . . . . 6.4400000000000004 106.552 175.167 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.541 ' CD1' ' O ' ' A' ' 5' ' ' PHE . 0.0 OUTLIER 112.35 -151.4 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.262 0 C-N-CA 124.675 1.19 . . . . 5.0599999999999996 111.353 179.378 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.533 ' N ' ' CG ' ' A' ' 6' ' ' PHE . 21.2 tt0 82.78 -4.61 1.32 Allowed 'General case' 0 N--CA 1.494 1.728 0 N-CA-C 105.442 -2.059 . . . . 4.8099999999999996 105.442 -177.562 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.425 ' H ' ' C ' ' A' ' 6' ' ' PHE . 25.1 t80 -153.06 -40.12 0.1 Allowed 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 107.233 -1.395 . . . . 5.7300000000000004 107.233 178.801 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.45 ' O ' ' N ' ' A' ' 11' ' ' GLY . 8.6 m -83.5 1.68 40.61 Favored 'General case' 0 C--N 1.296 -1.745 0 N-CA-C 105.937 -1.875 . . . . 5.3499999999999996 105.937 177.011 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.412 ' C ' ' O ' ' A' ' 9' ' ' THR . 8.0 p -38.46 -30.24 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 CA-C-N 115.257 -0.883 . . . . 4.3799999999999999 109.897 -179.827 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.583 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 137.02 -72.83 0.45 Allowed Glycine 0 N--CA 1.499 2.872 0 N-CA-C 108.709 -1.756 . . . . 4.4800000000000004 108.709 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.526 ' O ' ' N ' ' A' ' 14' ' ' GLY . 15.5 Cg_endo -68.71 39.92 0.24 Allowed 'Trans proline' 0 C--N 1.318 -1.051 0 C-N-CA 122.026 1.817 . . . . 4.0499999999999998 108.68 178.352 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.6 ' C ' ' H ' ' A' ' 15' ' ' GLU . 0.2 OUTLIER 28.36 38.66 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.248 0 CA-C-O 121.452 0.644 . . . . 4.0599999999999996 110.903 -179.595 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.635 ' C ' ' H ' ' A' ' 16' ' ' GLY . . . 68.84 -37.46 0.29 Allowed Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.108 -1.597 . . . . 3.1400000000000001 109.108 -179.606 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.6 ' H ' ' C ' ' A' ' 13' ' ' LEU . 41.1 tt0 63.24 -10.58 0.1 Allowed 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.742 -0.857 . . . . 3.1699999999999999 109.239 -179.099 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.635 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 89.88 -147.24 19.22 Favored Glycine 0 N--CA 1.489 2.214 0 O-C-N 121.181 -0.949 . . . . 2.4399999999999999 110.735 178.725 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.559 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -67.71 -6.18 41.9 Favored Glycine 0 N--CA 1.491 2.338 0 O-C-N 121.42 -1.047 . . . . 2.0499999999999998 111.063 -178.855 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -47.94 -11.99 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.465 -1.609 . . . . 2.54 109.452 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . 0.559 ' N ' ' O ' ' A' ' 17' ' ' GLY . 39.7 t-80 -96.92 -41.73 8.27 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.203 -0.935 . . . . 3.3700000000000001 109.729 179.577 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.528 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.0 OUTLIER -79.77 -24.43 41.52 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 120.92 -1.112 . . . . 2.3700000000000001 109.95 -179.64 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.464 ' O ' ' CG1' ' A' ' 21' ' ' VAL . 4.1 p -68.07 115.27 5.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 120.924 -1.11 . . . . 2.5800000000000001 108.927 179.87 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 12.0 tpp180 -98.07 136.05 38.88 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.625 -0.672 . . . . 3.8900000000000001 109.445 -179.155 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -147.55 113.42 5.76 Favored 'General case' 0 N--CA 1.492 1.639 0 N-CA-C 108.69 -0.855 . . . . 2.0099999999999998 108.69 179.486 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -162.62 136.5 4.36 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.584 -1.406 . . . . 2.0099999999999998 109.584 -179.579 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.1 173.7 46.16 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.667 -1.373 . . . . 1.9299999999999999 109.667 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 19.1 m -77.19 -18.43 57.77 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.352 -1.087 . . . . 2.6899999999999999 109.604 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -73.34 -20.26 79.85 Favored Glycine 0 N--CA 1.487 2.05 0 N-CA-C 109.304 -1.518 . . . . 1.6399999999999999 109.304 -179.884 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 55.7 mt -88.8 -13.97 38.14 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.433 -1.039 . . . . 2.0299999999999998 109.341 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 56.9 mt-10 -84.06 -62.74 1.49 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.292 -0.88 . . . . 2.3399999999999999 110.053 -179.519 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 79.3 mtt180 -149.0 165.2 32.34 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.014 -1.054 . . . . 4.25 110.342 -179.589 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -142.5 169.6 25.43 Favored Glycine 0 N--CA 1.495 2.591 0 N-CA-C 107.708 -2.157 . . . . 1.5900000000000001 107.708 179.019 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 40.9 t -134.04 150.57 31.4 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.202 0 O-C-N 121.051 -1.264 . . . . 2.21 110.971 -179.326 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -37.5 113.1 0.24 Allowed 'General case' 0 N--CA 1.501 2.08 0 CA-C-O 121.809 0.814 . . . . 2.0699999999999998 112.242 -179.533 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 52.29 50.54 46.36 Favored Glycine 0 N--CA 1.488 2.124 0 N-CA-C 111.244 -0.743 . . . . 1.73 111.244 177.162 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 24.1 t -126.6 103.3 25.05 Favored Pre-proline 0 N--CA 1.494 1.757 0 N-CA-C 108.061 -1.088 . . . . 2.6499999999999999 108.061 178.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -55.69 139.83 83.66 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 120.749 0.966 . . . . 2.1400000000000001 110.574 -178.713 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -146.97 175.04 10.97 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.449 -0.782 . . . . 2.0299999999999998 109.458 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -154.52 165.37 36.67 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.958 -1.089 . . . . 2.23 111.297 -179.378 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.515 ' N ' ' CD1' ' A' ' 39' ' ' PHE . 0.7 OUTLIER -143.43 -174.25 4.17 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 107.066 -1.457 . . . . 1.72 107.066 177.464 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 44.7 m -120.63 151.58 39.28 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 121.238 -0.914 . . . . 2.5800000000000001 111.512 -177.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.441 HG23 HD11 ' A' ' 41' ' ' ILE . 85.5 mt -141.97 91.68 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 N-CA-C 108.332 -0.988 . . . . 1.8600000000000001 108.332 178.531 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.414 ' CD1' ' N ' ' A' ' 43' ' ' THR . 9.6 t90 -96.02 141.03 29.91 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.165 -0.959 . . . . 4.4699999999999998 108.69 179.887 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' THR . . . . . 0.528 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -161.83 130.26 4.26 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.247 -0.908 . . . . 3.27 109.748 -179.577 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' ARG . . . . . . . . . . . . . 66.6 ttt180 -172.02 77.33 0.05 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.324 -0.86 . . . . 5.2300000000000004 109.728 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 6.8 tp10 -165.18 -55.26 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.099 -1.001 . . . . 2.8900000000000001 109.735 179.631 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -58.33 -58.66 7.49 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.125 -0.984 . . . . 1.99 109.018 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 142.27 -160.53 27.24 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.231 -1.548 . . . . 1.6499999999999999 109.231 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -64.28 163.79 12.28 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.288 -1.125 . . . . 1.77 109.38 179.717 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 174.29 178.79 44.46 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.724 -1.351 . . . . 1.1200000000000001 109.724 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -117.12 125.47 6.54 Favored Glycine 0 N--CA 1.499 2.856 0 N-CA-C 109.682 -1.367 . . . . 1.1799999999999999 109.682 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.422 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 11.8 tp -99.53 101.17 12.31 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.283 -1.128 . . . . 1.5900000000000001 108.642 179.63 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 19.1 m -88.79 140.51 29.37 Favored 'General case' 0 N--CA 1.493 1.694 0 N-CA-C 108.696 -0.854 . . . . 1.9399999999999999 108.696 179.854 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.493 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 90.8 mt -132.28 108.03 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 O-C-N 121.288 -0.883 . . . . 1.3 109.347 -179.819 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -98.63 106.35 18.61 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.304 -0.872 . . . . 1.27 108.928 179.706 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -99.34 141.94 15.89 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.53 -0.731 . . . . 1.55 109.408 -179.826 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 10.1 tt0 -141.97 143.92 33.45 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.279 -1.008 . . . . 1.8 108.279 178.793 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 165.55 -174.12 41.29 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.614 -1.394 . . . . 0.56000000000000005 109.614 -179.289 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -58.18 -26.34 75.76 Favored 'Trans proline' 0 C--N 1.317 -1.122 0 C-N-CA 121.998 1.799 . . . . 0.76000000000000001 111.971 -179.513 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 2.1 m -143.61 170.62 15.49 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.063 -1.023 . . . . 2.02 110.291 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 29.1 mtpt -90.31 100.28 13.14 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.387 -0.82 . . . . 3.02 109.373 -179.878 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -63.38 142.82 58.25 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.182 -0.949 . . . . 1.3600000000000001 109.603 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 24.9 tt0 -80.66 172.0 14.31 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.283 -0.886 . . . . 2.2999999999999998 109.281 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 14.0 mt -149.65 141.31 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.906 0 N-CA-C 108.006 -1.109 . . . . 2.0 108.006 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -150.67 112.47 4.51 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 120.449 -1.407 . . . . 1.73 110.251 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.519 ' CD2' ' O ' ' A' ' 65' ' ' PHE . 51.3 p90 -85.92 123.51 31.35 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.562 -0.711 . . . . 1.6000000000000001 110.205 179.795 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 42.8 tt0 -141.48 119.75 12.21 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.488 -0.757 . . . . 2.5099999999999998 109.056 179.555 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -73.73 114.0 11.51 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.181 -0.949 . . . . 2.0699999999999998 109.613 -179.733 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 38.6 ttp180 -108.67 -13.37 14.81 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.454 -0.779 . . . . 5.29 109.473 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.526 ' C ' ' H ' ' A' ' 71' ' ' GLY . 16.7 mtpp -122.62 -3.39 8.79 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.467 -0.77 . . . . 3.8599999999999999 109.389 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.466 ' CB ' ' O ' ' A' ' 69' ' ' LYS . 1.4 t70 73.48 -19.18 0.34 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.391 -0.818 . . . . 3.0600000000000001 109.214 -179.757 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . 0.526 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -119.39 -41.04 0.59 Allowed Glycine 0 N--CA 1.495 2.589 0 N-CA-C 109.725 -1.35 . . . . 2.1600000000000001 109.725 -179.416 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 14.0 m -95.37 126.28 40.57 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.175 -1.191 . . . . 2.5600000000000001 109.271 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 11.3 t -82.48 120.29 25.3 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.217 -0.927 . . . . 2.3599999999999999 109.463 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -99.51 117.22 5.8 Favored Glycine 0 N--CA 1.496 2.694 0 N-CA-C 109.657 -1.377 . . . . 1.46 109.657 -179.832 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -105.32 105.11 18.04 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.075 0 O-C-N 121.54 -0.977 . . . . 2.1600000000000001 109.647 179.85 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 3.9 t -84.14 124.8 31.53 Favored 'General case' 0 N--CA 1.485 1.31 0 N-CA-C 108.148 -1.056 . . . . 2.1600000000000001 108.148 178.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 1.9 p90 -123.0 171.84 8.95 Favored 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 108.57 -0.9 . . . . 1.7 108.57 -179.078 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 41.4 t -141.79 141.67 29.28 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.929 0 O-C-N 121.169 -0.957 . . . . 2.4500000000000002 109.804 -179.581 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 30.7 m -109.53 150.69 12.07 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.095 0 O-C-N 121.439 -0.788 . . . . 1.8200000000000001 109.254 179.646 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 6.6 tp-100 -96.7 -45.27 6.75 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.219 -0.925 . . . . 3.1699999999999999 110.305 -179.717 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -159.28 152.33 18.39 Favored Pre-proline 0 N--CA 1.502 2.161 0 O-C-N 120.768 -1.208 . . . . 2.02 110.857 -179.26 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.622 ' HG3' ' N ' ' A' ' 107' ' ' SER . 85.5 Cg_exo -37.54 158.55 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 123.248 2.632 . . . . 1.3999999999999999 113.369 179.032 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 147.92 166.99 13.08 Favored Glycine 0 N--CA 1.488 2.109 0 N-CA-C 109.477 -1.449 . . . . 1.0800000000000001 109.477 179.823 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . 0.824 ' H ' HH12 ' B' ' 8' ' ' ARG . 66.9 m-20 -87.65 84.55 7.08 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 107.666 -1.235 . . . . 2.1299999999999999 107.666 179.117 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -69.93 134.16 48.09 Favored 'General case' 0 C--N 1.297 -1.709 0 N-CA-C 107.966 -1.124 . . . . 1.1399999999999999 107.966 -179.526 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . 0.419 ' OE1' ' O ' ' A' ' 84' ' ' ASP . 0.0 OUTLIER -112.27 127.63 56.03 Favored 'General case' 0 N--CA 1.501 2.105 0 N-CA-C 108.667 -0.864 . . . . 1.53 108.667 -179.413 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 9.6 p -123.88 141.06 45.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.712 -0.618 . . . . 1.6399999999999999 109.794 -179.633 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 3.8 m -130.29 97.82 4.53 Favored 'General case' 0 N--CA 1.498 1.952 0 CA-C-O 121.539 0.685 . . . . 1.99 109.38 179.781 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.6 pt -104.88 133.32 49.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 CA-C-O 121.471 0.653 . . . . 1.77 109.846 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . 0.458 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -144.42 127.39 16.45 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 108.027 -1.101 . . . . 2.0600000000000001 108.027 179.946 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.421 ' O ' ' CB ' ' A' ' 92' ' ' ASN . 76.5 t80 -85.47 102.22 13.29 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.63 -1.294 . . . . 1.45 108.462 179.16 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . 0.431 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 13.0 t30 72.38 33.87 1.41 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.068 -1.02 . . . . 2.7200000000000002 108.748 -178.679 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . 0.431 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 0.8 OUTLIER 80.21 14.04 0.87 Allowed 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.891 -0.505 . . . . 1.9199999999999999 111.698 179.509 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . 0.462 ' CG ' ' O ' ' A' ' 94' ' ' GLU . 5.0 pt-20 -99.84 94.44 6.32 Favored 'General case' 0 N--CA 1.495 1.806 0 N-CA-C 107.029 -1.471 . . . . 2.5499999999999998 107.029 177.573 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . 0.544 ' CD2' ' H ' ' A' ' 95' ' ' HIS . 7.0 p80 -74.7 112.41 10.87 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-O 121.542 0.687 . . . . 3.2000000000000002 110.281 -178.071 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . 0.624 ' CD1' ' H ' ' A' ' 96' ' ' ILE . 0.0 OUTLIER -60.49 155.76 46.83 Favored Pre-proline 0 N--CA 1.497 1.918 0 N-CA-C 107.257 -1.386 . . . . 2.8199999999999998 107.257 178.994 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -49.47 -25.78 11.12 Favored 'Trans proline' 0 C--N 1.321 -0.879 0 N-CA-C 108.968 -1.204 . . . . 2.6299999999999999 108.968 179.847 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.471 ' N ' ' OD1' ' A' ' 98' ' ' ASP . 0.9 OUTLIER -59.52 -64.69 0.85 Allowed 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 108.873 -0.788 . . . . 2.6499999999999999 108.873 178.852 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 2.4 p -66.83 141.01 96.52 Favored Pre-proline 0 C--N 1.297 -1.7 0 O-C-N 121.308 -0.87 . . . . 2.3199999999999998 110.04 -178.42 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -85.91 116.99 4.11 Favored 'Cis proline' 0 N--CA 1.492 1.405 0 N-CA-C 109.563 -0.976 . . . . 1.9399999999999999 109.563 -2.389 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 53.3 p90 -117.03 163.62 15.96 Favored 'General case' 0 N--CA 1.518 2.945 0 O-C-N 120.532 -1.355 . . . . 2.6299999999999999 110.003 178.687 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.5 p -93.23 152.89 3.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 CA-C-O 121.666 0.746 . . . . 1.8200000000000001 111.008 -178.144 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 65.1 t -125.92 86.84 57.04 Favored Pre-proline 0 N--CA 1.497 1.888 0 N-CA-C 107.917 -1.142 . . . . 1.73 107.917 179.024 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -63.71 113.29 2.08 Favored 'Trans proline' 0 C--N 1.319 -0.999 0 C-N-CA 121.418 1.412 . . . . 1.6100000000000001 112.264 -177.743 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 54.3 t -97.72 142.18 14.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 N-CA-C 106.302 -1.74 . . . . 1.7 106.302 177.496 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -130.23 132.84 46.15 Favored 'General case' 0 N--CA 1.511 2.606 0 CA-C-O 122.109 0.956 . . . . 2.04 111.82 -177.18 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' SER . . . . . 0.622 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 36.3 p -94.98 90.91 6.14 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.759 -1.213 . . . . 2.2999999999999998 107.748 179.577 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . 0.499 ' CD1' ' N ' ' A' ' 108' ' ' LEU . 8.0 mp 54.65 10.49 0.36 Allowed 'General case' 0 C--N 1.294 -1.816 0 N-CA-C 107.848 -1.167 . . . . 3.6000000000000001 107.848 -178.2 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.598 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 9.0 t -98.88 -27.09 14.06 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 109.255 -0.646 . . . . 2.4900000000000002 109.255 179.712 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . 0.477 ' OD1' ' N ' ' A' ' 110' ' ' ASP . 1.8 m-20 53.93 12.23 0.42 Allowed 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 107.941 -1.133 . . . . 2.8500000000000001 107.941 -179.275 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.503 ' H ' ' C ' ' A' ' 109' ' ' SER . 2.6 p30 -168.99 -30.13 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 109.348 -0.612 . . . . 2.46 109.348 -179.615 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.598 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 49.26 -171.3 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.81 0 O-C-N 120.825 -1.172 . . . . 2.0800000000000001 109.198 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 15.7 ttt180 -159.2 -161.09 0.9 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.061 -1.025 . . . . 6.54 109.547 179.696 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 37.9 ttp180 -143.56 2.32 1.24 Allowed 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 107.578 -1.268 . . . . 6.2400000000000002 107.578 179.442 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 32.1 mt -129.8 -26.93 2.38 Favored 'General case' 0 N--CA 1.499 2.022 0 N-CA-C 109.016 -0.735 . . . . 4.71 109.016 179.632 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.536 ' C ' ' H ' ' A' ' 118' ' ' THR . 98.5 m -102.13 -79.55 0.52 Allowed 'General case' 0 N--CA 1.495 1.793 0 N-CA-C 106.999 -1.482 . . . . 4.3499999999999996 106.999 178.92 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 50.7 t -61.88 -8.9 2.82 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 N-CA-C 105.967 -1.864 . . . . 3.3100000000000001 105.967 176.715 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' THR . . . . . 0.536 ' H ' ' C ' ' A' ' 116' ' ' THR . 4.4 t 36.29 60.66 0.85 Allowed 'General case' 0 N--CA 1.487 1.422 0 CA-C-N 115.148 -0.933 . . . . 3.73 110.735 179.847 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' SER . . . . . 0.457 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.7 p . . . . . 0 C--N 1.303 -1.453 0 CA-C-O 117.973 -1.013 . . . . 3.8300000000000001 109.569 179.363 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.595 0 N-CA-C 108.911 -0.774 . . . . 8.8699999999999992 108.911 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -76.21 110.31 10.6 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.218 -0.926 . . . . 5.9299999999999997 109.376 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 3' ' ' SER . . . . . . . . . . . . . 90.0 p -95.05 -137.05 0.22 Allowed 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.291 -0.881 . . . . 5.5700000000000003 109.651 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 4' ' ' LYS . . . . . . . . . . . . . 19.8 tptp -172.4 70.17 0.42 Allowed Pre-proline 0 N--CA 1.491 1.619 0 O-C-N 121.317 -0.864 . . . . 7.25 109.287 -179.78 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 5' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_exo -60.8 -78.24 0.01 OUTLIER 'Trans proline' 0 C--N 1.317 -1.106 0 C-N-CA 121.458 1.438 . . . . 5.8899999999999997 110.086 -179.497 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 6' ' ' GLU . . . . . . . . . . . . . 68.3 mt-10 -152.97 169.76 22.07 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.079 -1.013 . . . . 4.7800000000000002 109.499 -179.858 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 78.0 mttt -77.9 179.61 6.62 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.334 -0.854 . . . . 4.5599999999999996 109.35 179.864 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . 0.824 HH12 ' H ' ' A' ' 84' ' ' ASP . 5.8 mtt180 -98.73 170.29 8.88 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.289 -0.882 . . . . 3.6699999999999999 108.638 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 9' ' ' VAL . . . . . . . . . . . . . 17.1 t -53.8 159.55 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 108.017 -1.105 . . . . 1.3899999999999999 108.017 179.307 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -123.18 150.28 43.55 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.464 -0.773 . . . . 1.22 110.002 -179.115 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 4.2 t -144.57 139.54 28.21 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.454 -0.779 . . . . 1.6299999999999999 109.017 179.695 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 16.7 m -140.4 116.03 10.17 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.328 -0.857 . . . . 1.8799999999999999 109.465 -179.714 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . 0.494 ' CG2' ' N ' ' B' ' 14' ' ' PHE . 2.9 p -160.15 166.29 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 O-C-N 121.34 -0.85 . . . . 1.2 109.234 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 14' ' ' PHE . . . . . 0.494 ' N ' ' CG2' ' B' ' 13' ' ' VAL . 7.4 p90 -177.54 -165.85 0.12 Allowed 'General case' 0 N--CA 1.487 1.425 0 CA-C-O 122.108 0.956 . . . . 2.3900000000000001 112.083 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.7 pt -149.51 169.92 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.318 0 N-CA-C 108.387 -0.968 . . . . 1.8100000000000001 108.387 179.851 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 65.9 p -135.54 128.64 31.68 Favored 'General case' 0 N--CA 1.5 2.049 0 O-C-N 121.184 -0.947 . . . . 2.04 109.784 -179.803 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.6 mt -90.92 136.58 32.98 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.349 -0.844 . . . . 1.8700000000000001 109.167 179.651 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -143.86 68.54 16.31 Favored Pre-proline 0 N--CA 1.495 1.796 0 O-C-N 121.302 -0.874 . . . . 1.47 109.49 -179.847 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -60.46 168.47 6.54 Favored 'Trans proline' 0 C--N 1.317 -1.098 0 C-N-CA 121.36 1.373 . . . . 1.96 109.504 -179.867 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 20' ' ' PRO . . . . . 0.497 ' C ' ' H ' ' B' ' 22' ' ' ARG . 3.1 Cg_exo -56.36 114.24 1.82 Allowed 'Trans proline' 0 C--N 1.319 -1.018 0 C-N-CA 121.346 1.364 . . . . 3.3799999999999999 110.003 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 85.2 mtt180 -50.67 -11.23 0.08 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.307 -0.87 . . . . 6.7400000000000002 109.399 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 22' ' ' ARG . . . . . 0.497 ' H ' ' C ' ' B' ' 20' ' ' PRO . 36.1 ttp180 52.39 -125.87 2.39 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.303 -0.873 . . . . 6.9400000000000004 109.459 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 33.5 m-20 -91.42 175.86 6.77 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.089 -1.007 . . . . 5.6200000000000001 109.614 -179.742 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 7.4 p . . . . . 0 N--CA 1.49 1.55 0 CA-C-O 117.988 -1.006 . . . . 6.75 109.399 179.938 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.954 0 N-CA-C 119.835 2.694 . . . . 6.7300000000000004 119.835 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.57 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 3.7 tp -172.62 50.61 0.12 Allowed Pre-proline 0 C--N 1.306 -1.292 0 N-CA-C 107.842 -1.17 . . . . 7.3799999999999999 107.842 179.483 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.816 ' C ' ' H ' ' A' ' 5' ' ' PHE . 3.2 Cg_endo -56.18 -80.82 0.01 OUTLIER 'Trans proline' 0 C--N 1.318 -1.035 0 C-N-CA 121.13 1.22 . . . . 5.5 109.04 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.536 ' C ' ' H ' ' A' ' 6' ' ' PHE . 11.3 tt0 73.43 -18.34 0.38 Allowed 'General case' 0 N--CA 1.496 1.853 0 N-CA-C 104.349 -2.463 . . . . 6.8399999999999999 104.349 -175.615 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . 0.816 ' H ' ' C ' ' A' ' 3' ' ' PRO . 10.4 t80 -89.83 18.66 5.41 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 103.892 -2.633 . . . . 6.4400000000000004 103.892 176.841 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.539 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 41.5 p90 46.69 -154.73 0.05 Allowed 'General case' 0 C--N 1.307 -1.251 0 CA-C-N 114.159 -1.382 . . . . 5.0599999999999996 109.53 -177.797 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.526 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 0.2 OUTLIER 85.42 -9.23 0.81 Allowed 'General case' 0 N--CA 1.492 1.644 0 N-CA-C 105.037 -2.209 . . . . 4.8099999999999996 105.037 -177.143 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.427 ' H ' ' C ' ' A' ' 6' ' ' PHE . 52.0 t80 -153.2 -37.62 0.1 Allowed 'General case' 0 C--N 1.304 -1.383 0 N-CA-C 107.816 -1.179 . . . . 5.7300000000000004 107.816 178.321 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 22.2 m -91.84 2.61 56.4 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 105.965 -1.865 . . . . 5.3499999999999996 105.965 177.382 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.5 p -43.25 -38.65 1.04 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 CA-C-N 115.481 -0.781 . . . . 4.3799999999999999 109.618 -179.737 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.634 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 141.45 -84.8 0.21 Allowed Glycine 0 N--CA 1.498 2.786 0 N-CA-C 108.238 -1.945 . . . . 4.4800000000000004 108.238 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.527 ' O ' ' N ' ' A' ' 14' ' ' GLY . 12.8 Cg_endo -67.35 39.57 0.18 Allowed 'Trans proline' 0 C--N 1.32 -0.964 0 C-N-CA 121.597 1.531 . . . . 4.0499999999999998 108.496 177.541 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.634 ' H ' ' C ' ' A' ' 11' ' ' GLY . 0.2 OUTLIER 29.99 36.51 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.173 0 CA-C-O 121.607 0.718 . . . . 4.0599999999999996 110.628 -179.168 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.551 ' C ' ' H ' ' A' ' 16' ' ' GLY . . . 68.49 -37.73 0.27 Allowed Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.586 -1.406 . . . . 3.1400000000000001 109.586 179.812 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.558 ' H ' ' C ' ' A' ' 13' ' ' LEU . 31.2 tt0 56.24 4.46 0.14 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.359 -1.083 . . . . 3.1699999999999999 109.136 -179.637 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.551 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 60.24 131.15 0.01 OUTLIER Glycine 0 N--CA 1.489 2.224 0 N-CA-C 110.912 -0.875 . . . . 2.4399999999999999 110.912 179.084 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.531 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 71.35 -53.94 1.14 Allowed Glycine 0 N--CA 1.491 2.351 0 N-CA-C 110.416 -1.073 . . . . 2.0499999999999998 110.416 179.066 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.43 ' N ' ' CD ' ' A' ' 94' ' ' GLU . . . -46.79 -12.53 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.543 -0.975 . . . . 2.54 110.14 -179.439 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . 0.531 ' N ' ' O ' ' A' ' 17' ' ' GLY . 10.0 t-80 -89.77 -42.79 11.09 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.123 -0.985 . . . . 3.3700000000000001 110.299 -179.168 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.444 ' HZ1' ' H ' ' A' ' 46' ' ' ALA . 0.0 OUTLIER -93.84 -9.08 38.57 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 120.928 -1.108 . . . . 2.3700000000000001 110.682 -179.006 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 74.2 t -83.4 112.14 20.54 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 120.865 -1.147 . . . . 2.5800000000000001 110.3 -179.383 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 20.9 tpt180 -103.07 139.91 38.0 Favored 'General case' 0 N--CA 1.491 1.615 0 N-CA-C 108.06 -1.089 . . . . 3.8900000000000001 108.06 179.042 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -140.02 113.3 8.39 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.263 -0.898 . . . . 2.0099999999999998 109.648 -179.599 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -155.78 130.59 2.8 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 109.352 -1.499 . . . . 2.0099999999999998 109.352 179.71 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.3 167.14 37.57 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.816 -1.314 . . . . 1.9299999999999999 109.816 -179.856 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 17.6 m -74.1 -28.16 61.23 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.297 -1.119 . . . . 2.6899999999999999 109.486 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.6 -22.9 78.02 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 109.085 -1.606 . . . . 1.6399999999999999 109.085 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 20.8 mt -77.0 -10.21 59.21 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.446 -1.032 . . . . 2.0299999999999998 108.963 179.689 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 59.4 mt-10 -90.15 -51.91 5.22 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.372 -0.83 . . . . 2.3399999999999999 109.478 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . 0.405 ' NH1' ' HG2' ' A' ' 30' ' ' ARG . 0.0 OUTLIER -169.05 -168.69 0.87 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.035 -1.04 . . . . 4.25 109.993 -179.992 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -153.92 178.76 30.65 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 108.508 -1.837 . . . . 1.5900000000000001 108.508 179.876 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 42.0 t -134.37 151.09 31.42 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.041 0 O-C-N 121.165 -1.197 . . . . 2.21 110.635 -179.618 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -38.79 111.68 0.19 Allowed 'General case' 0 N--CA 1.5 2.062 0 CA-C-O 121.544 0.688 . . . . 2.0699999999999998 112.39 -179.154 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 53.43 51.42 47.8 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 111.302 -0.719 . . . . 1.73 111.302 176.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 31.4 t -127.59 103.04 22.32 Favored Pre-proline 0 N--CA 1.495 1.78 0 O-C-N 121.513 -0.993 . . . . 2.6499999999999999 109.016 179.203 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -58.55 133.07 52.03 Favored 'Trans proline' 0 C--O 1.215 -0.636 0 N-CA-C 109.51 -0.996 . . . . 2.1400000000000001 109.51 -179.88 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -142.18 -169.62 2.98 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.338 -0.851 . . . . 2.0299999999999998 108.803 -179.825 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -169.45 165.23 10.54 Favored 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 118.931 -1.107 . . . . 2.23 111.228 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.57 ' N ' ' CD1' ' A' ' 39' ' ' PHE . 0.7 OUTLIER -138.32 -176.28 4.4 Favored 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 106.758 -1.571 . . . . 1.72 106.758 178.033 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 43.8 t -122.28 147.12 46.62 Favored 'General case' 0 N--CA 1.498 1.969 0 CA-C-O 121.596 0.712 . . . . 2.5800000000000001 110.298 -179.103 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 49.6 mt -142.73 97.24 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 N-CA-C 107.986 -1.116 . . . . 1.8600000000000001 107.986 179.033 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.46 ' CD1' ' C ' ' A' ' 42' ' ' TRP . 0.4 OUTLIER -86.68 144.96 26.88 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.355 -0.841 . . . . 4.4699999999999998 108.864 -179.493 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' THR . . . . . 0.534 ' OG1' ' N ' ' A' ' 44' ' ' ARG . 1.7 t -168.16 -124.85 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.322 -0.861 . . . . 3.27 109.355 -179.898 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' ARG . . . . . 0.534 ' N ' ' OG1' ' A' ' 43' ' ' THR . 61.2 ttt180 57.62 77.67 0.27 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.277 -0.889 . . . . 5.2300000000000004 109.754 179.804 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 26.1 tt0 -160.62 -45.93 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.289 -0.882 . . . . 2.8900000000000001 109.127 179.642 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.444 ' H ' ' HZ1' ' A' ' 20' ' ' LYS . . . -61.82 -56.16 22.33 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.257 -0.902 . . . . 1.99 109.1 179.658 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 155.64 178.27 29.69 Favored Glycine 0 N--CA 1.489 2.167 0 N-CA-C 109.459 -1.457 . . . . 1.6499999999999999 109.459 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.7 145.01 16.46 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.173 -1.192 . . . . 1.77 109.152 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -164.33 -164.24 19.13 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.667 -1.373 . . . . 1.1200000000000001 109.667 -179.828 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -137.97 116.57 1.34 Allowed Glycine 0 N--CA 1.496 2.69 0 N-CA-C 109.546 -1.422 . . . . 1.1799999999999999 109.546 -179.828 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.417 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 64.3 tp -91.57 109.39 20.69 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.274 -1.133 . . . . 1.5900000000000001 108.422 179.383 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 28.3 m -92.96 141.61 28.22 Favored 'General case' 0 N--CA 1.498 1.969 0 N-CA-C 108.598 -0.89 . . . . 1.9399999999999999 108.598 179.616 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.544 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 93.9 mt -134.34 116.99 23.35 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.945 0 O-C-N 121.165 -0.959 . . . . 1.3 110.148 -179.304 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -107.47 109.66 21.41 Favored 'General case' 0 N--CA 1.495 1.799 0 N-CA-C 108.133 -1.062 . . . . 1.27 108.133 178.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -101.41 143.19 14.8 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.43 -0.794 . . . . 1.55 110.228 -178.862 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 23.4 tp10 -139.02 143.12 38.31 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 106.765 -1.569 . . . . 1.8 106.765 178.396 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.433 ' O ' ' N ' ' B' ' 9' ' ' VAL . . . 171.68 -173.98 45.07 Favored Glycine 0 N--CA 1.491 2.301 0 C-N-CA 119.131 -1.509 . . . . 0.56000000000000005 109.654 -178.667 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -64.96 -32.68 53.92 Favored 'Trans proline' 0 C--N 1.316 -1.183 0 C-N-CA 121.748 1.632 . . . . 0.76000000000000001 110.317 179.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' SER . . . . . 0.413 ' O ' ' OH ' ' A' ' 85' ' ' TYR . 58.4 m -137.86 158.89 43.42 Favored 'General case' 0 N--CA 1.5 2.035 0 O-C-N 121.319 -0.863 . . . . 2.02 109.931 -179.323 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 34.5 mttp -76.03 93.14 3.24 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.363 -0.836 . . . . 3.02 109.483 -179.842 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -63.89 136.42 57.36 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.278 -0.888 . . . . 1.3600000000000001 109.426 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 55.1 mm-40 -79.49 172.54 13.65 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.126 -0.984 . . . . 2.2999999999999998 109.539 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 4.4 mp -140.22 151.01 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 N-CA-C 108.325 -0.991 . . . . 2.0 108.325 -179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -151.04 120.02 6.67 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 120.603 -1.31 . . . . 1.73 109.468 -179.712 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 54.4 p90 -86.19 139.13 31.34 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.276 -0.89 . . . . 1.6000000000000001 109.764 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.487 ' N ' ' O ' ' A' ' 74' ' ' GLY . 43.7 tt0 -141.22 122.45 14.79 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.395 -0.816 . . . . 2.5099999999999998 109.149 179.886 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . 0.412 ' OD1' ' N ' ' A' ' 67' ' ' ASP . 15.1 p-10 -81.25 88.18 6.07 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.222 -0.924 . . . . 2.0699999999999998 109.713 -179.812 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.424 ' C ' ' H ' ' A' ' 70' ' ' ASP . 16.6 mtm180 -98.81 162.4 13.12 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.286 -0.884 . . . . 5.29 108.965 179.606 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.531 ' C ' ' H ' ' A' ' 71' ' ' GLY . 19.5 mttm 60.77 7.09 1.32 Allowed 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.135 -0.978 . . . . 3.8599999999999999 108.864 -179.884 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.424 ' H ' ' C ' ' A' ' 68' ' ' ARG . 7.5 t70 56.71 4.12 0.15 Allowed 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 119.928 -0.709 . . . . 3.0600000000000001 110.063 178.514 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . 0.531 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -147.14 -30.73 0.07 OUTLIER Glycine 0 N--CA 1.485 1.933 0 N-CA-C 110.085 -1.206 . . . . 2.1600000000000001 110.085 -178.522 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 9.6 t -95.73 129.23 43.01 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.105 -1.233 . . . . 2.5600000000000001 109.107 179.677 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 10.4 t -78.06 153.12 32.56 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.248 -0.908 . . . . 2.3599999999999999 109.438 -179.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.487 ' O ' ' N ' ' A' ' 66' ' ' GLU . . . -126.45 111.95 1.51 Allowed Glycine 0 N--CA 1.498 2.793 0 N-CA-C 109.352 -1.499 . . . . 1.46 109.352 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 27.4 t -100.52 99.93 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.011 0 O-C-N 121.56 -0.965 . . . . 2.1600000000000001 109.399 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -84.79 165.3 17.89 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 108.293 -1.003 . . . . 2.1600000000000001 108.293 179.399 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 0.404 ' CD1' ' N ' ' A' ' 77' ' ' TYR . 12.5 p90 -165.36 169.9 15.24 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.275 -0.891 . . . . 1.7 109.238 -179.329 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.47 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 5.0 p -142.18 116.32 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.215 0 O-C-N 121.122 -0.986 . . . . 2.4500000000000002 110.211 179.35 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 6.5 m -89.97 153.3 3.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.276 -0.89 . . . . 1.8200000000000001 108.863 179.708 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . 0.407 ' O ' ' OE2' ' A' ' 81' ' ' GLU . 20.6 tt0 -94.57 -48.02 6.28 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.994 -1.066 . . . . 3.1699999999999999 110.84 -178.892 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.407 ' OE2' ' O ' ' A' ' 80' ' ' GLN . 78.3 mm-40 -153.88 150.05 22.09 Favored Pre-proline 0 N--CA 1.503 2.198 0 O-C-N 120.613 -1.304 . . . . 2.02 111.218 -178.455 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.608 ' HG3' ' N ' ' A' ' 107' ' ' SER . 87.8 Cg_exo -36.76 157.9 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.944 2.429 . . . . 1.3999999999999999 113.368 178.24 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 150.07 -156.92 26.98 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 108.893 -1.683 . . . . 1.0800000000000001 108.893 -179.911 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 37.5 m-20 -116.38 92.4 3.87 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.52 -0.988 . . . . 2.1299999999999999 109.408 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . 0.451 ' O ' ' N ' ' A' ' 103' ' ' VAL . 2.7 m-85 -78.98 129.76 34.82 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 107.977 -1.12 . . . . 1.1399999999999999 107.977 179.343 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.37 128.41 56.45 Favored 'General case' 0 N--CA 1.502 2.131 0 N-CA-C 108.675 -0.861 . . . . 1.53 108.675 -178.847 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 6.3 p -126.6 138.53 54.46 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.681 -0.637 . . . . 1.6399999999999999 109.928 -179.667 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' SER . . . . . 0.414 ' O ' ' OG ' ' A' ' 88' ' ' SER . 44.7 p -127.83 96.69 4.58 Favored 'General case' 0 N--CA 1.499 1.987 0 N-CA-C 109.358 -0.608 . . . . 1.99 109.358 179.792 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -106.3 134.78 46.91 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 CA-C-O 121.479 0.657 . . . . 1.77 109.938 -179.469 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . 0.459 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -142.97 123.72 14.18 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.454 -0.779 . . . . 2.0600000000000001 109.073 -179.882 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 57.2 t80 -80.05 101.11 8.51 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.011 -1.056 . . . . 1.45 108.199 178.661 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . 0.411 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 16.8 t-20 69.2 37.68 2.07 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.13 -0.982 . . . . 2.7200000000000002 109.149 -179.014 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . 0.411 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 1.5 m-20 77.87 14.87 1.57 Allowed 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.836 -0.54 . . . . 1.9199999999999999 111.928 179.337 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . 0.493 ' OE1' ' O ' ' A' ' 94' ' ' GLU . 0.3 OUTLIER -100.6 99.81 10.44 Favored 'General case' 0 N--CA 1.501 2.106 0 N-CA-C 107.462 -1.31 . . . . 2.5499999999999998 107.462 177.707 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 29.9 m-70 -70.16 105.12 2.82 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.553 -0.717 . . . . 3.2000000000000002 109.779 -178.613 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . 0.639 ' O ' ' N ' ' A' ' 98' ' ' ASP . 9.9 pt -51.21 152.9 3.75 Favored Pre-proline 0 N--CA 1.493 1.681 0 N-CA-C 108.587 -0.894 . . . . 2.8199999999999998 108.587 179.667 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -59.1 61.74 0.06 OUTLIER 'Trans proline' 0 N--CA 1.484 0.945 0 C-N-CA 121.457 1.438 . . . . 2.6299999999999999 109.582 179.255 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.639 ' N ' ' O ' ' A' ' 96' ' ' ILE . 31.4 m-20 -162.17 -58.42 0.05 OUTLIER 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 108.386 -0.968 . . . . 2.6499999999999999 108.386 -179.536 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 1.1 t -65.43 141.31 97.98 Favored Pre-proline 0 C--N 1.297 -1.705 0 C-N-CA 119.868 -0.733 . . . . 2.3199999999999998 110.085 -177.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -85.99 114.56 3.03 Favored 'Cis proline' 0 N--CA 1.492 1.396 0 N-CA-C 109.585 -0.967 . . . . 1.9399999999999999 109.585 -2.103 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 46.4 p90 -110.32 160.27 16.7 Favored 'General case' 0 N--CA 1.517 2.896 0 O-C-N 120.501 -1.375 . . . . 2.6299999999999999 110.261 178.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.3 p -92.62 148.98 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 CA-C-O 121.517 0.675 . . . . 1.8200000000000001 110.206 -179.152 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.451 ' N ' ' O ' ' A' ' 85' ' ' TYR . 70.8 t -124.11 85.6 54.62 Favored Pre-proline 0 N--CA 1.498 1.946 0 N-CA-C 107.858 -1.164 . . . . 1.73 107.858 179.511 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -63.45 113.08 1.94 Allowed 'Trans proline' 0 C--N 1.32 -0.968 0 C-N-CA 121.339 1.359 . . . . 1.6100000000000001 112.021 -177.605 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 54.1 t -90.22 143.97 10.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 N-CA-C 106.682 -1.599 . . . . 1.7 106.682 177.71 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -131.78 130.29 41.65 Favored 'General case' 0 N--CA 1.508 2.462 0 O-C-N 121.217 -0.927 . . . . 2.04 111.629 -177.167 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' SER . . . . . 0.608 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 60.3 p -95.45 90.61 5.84 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.71 -1.244 . . . . 2.2999999999999998 107.873 179.36 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . 0.459 ' CD1' ' N ' ' A' ' 108' ' ' LEU . 9.2 mp 54.83 10.38 0.37 Allowed 'General case' 0 C--N 1.295 -1.774 0 N-CA-C 107.949 -1.13 . . . . 3.6000000000000001 107.949 -178.434 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.565 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 50.4 p -100.24 -24.97 14.41 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 109.32 -0.622 . . . . 2.4900000000000002 109.32 179.563 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 15.9 t70 49.62 15.95 0.17 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.079 -1.013 . . . . 2.8500000000000001 108.392 -179.604 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.482 ' N ' ' C ' ' A' ' 109' ' ' SER . 13.8 t0 -174.68 -25.07 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.896 -0.503 . . . . 2.46 109.724 -179.48 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.565 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 56.4 93.84 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.704 -1.248 . . . . 2.0800000000000001 109.126 -179.742 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.402 ' NH1' ' HG2' ' A' ' 113' ' ' ARG . 0.3 OUTLIER -57.18 -170.08 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.266 -0.896 . . . . 6.54 109.54 -179.743 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.437 ' HG3' HH11 ' A' ' 114' ' ' ARG . 7.5 ttm-85 -133.9 1.66 3.32 Favored 'General case' 0 N--CA 1.495 1.807 0 N-CA-C 108.511 -0.922 . . . . 6.2400000000000002 108.511 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 30.3 mt -127.21 -25.47 3.24 Favored 'General case' 0 N--CA 1.502 2.139 0 N-CA-C 109.081 -0.711 . . . . 4.71 109.081 179.831 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.542 ' C ' ' H ' ' A' ' 118' ' ' THR . 97.9 m -107.88 -79.65 0.58 Allowed 'General case' 0 N--CA 1.497 1.903 0 N-CA-C 107.118 -1.438 . . . . 4.3499999999999996 107.118 179.197 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 50.9 t -61.29 -8.66 2.2 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.63 0 N-CA-C 106.032 -1.84 . . . . 3.3100000000000001 106.032 176.842 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' THR . . . . . 0.542 ' H ' ' C ' ' A' ' 116' ' ' THR . 3.9 t 36.63 61.97 0.79 Allowed 'General case' 0 N--CA 1.487 1.417 0 CA-C-N 115.193 -0.912 . . . . 3.73 110.704 179.902 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' SER . . . . . 0.421 ' OG ' ' O ' ' A' ' 118' ' ' THR . 1.7 p . . . . . 0 C--N 1.302 -1.476 0 CA-C-O 118.034 -0.984 . . . . 3.8300000000000001 109.624 179.299 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 67.7 mtm . . . . . 0 N--CA 1.49 1.572 0 N-CA-C 109.564 -0.532 . . . . 8.8699999999999992 109.564 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -73.04 5.05 3.63 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.264 -0.897 . . . . 5.9299999999999997 109.232 179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 3' ' ' SER . . . . . . . . . . . . . 61.6 p -163.77 -168.5 1.64 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.283 -0.886 . . . . 5.5700000000000003 109.343 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 4' ' ' LYS . . . . . . . . . . . . . 37.5 mmtm 49.96 69.36 2.7 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.205 -0.934 . . . . 7.25 109.535 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 5' ' ' PRO . . . . . . . . . . . . . 2.1 Cg_endo -63.75 -154.33 0.02 OUTLIER 'Trans proline' 0 C--N 1.317 -1.112 0 C-N-CA 121.474 1.45 . . . . 5.8899999999999997 109.672 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 6' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -131.5 79.64 1.89 Allowed 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.368 -0.833 . . . . 4.7800000000000002 109.198 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 6.1 ptpp? -158.79 138.46 11.83 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.3 -0.875 . . . . 4.5599999999999996 109.352 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . 0.597 HH11 ' CG ' ' B' ' 8' ' ' ARG . 0.3 OUTLIER -114.46 -76.32 0.58 Allowed 'General case' 0 N--CA 1.494 1.766 0 N-CA-C 107.833 -1.173 . . . . 3.6699999999999999 107.833 -179.904 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 9' ' ' VAL . . . . . 0.433 ' N ' ' O ' ' A' ' 57' ' ' GLY . 0.5 OUTLIER -176.23 168.83 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 N-CA-C 107.612 -1.255 . . . . 1.3899999999999999 107.612 177.936 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -120.81 136.01 55.01 Favored 'General case' 0 N--CA 1.502 2.133 0 CA-C-O 121.487 0.66 . . . . 1.22 110.514 -178.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 18.4 m -149.65 138.45 21.0 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.468 -0.77 . . . . 1.6299999999999999 109.265 179.395 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 27.8 p -145.94 126.08 13.79 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.089 -1.007 . . . . 1.8799999999999999 109.984 -179.682 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . 0.484 ' CG2' ' N ' ' B' ' 14' ' ' PHE . 6.8 p -167.11 170.81 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 N-CA-C 108.678 -0.86 . . . . 1.2 108.678 179.735 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 14' ' ' PHE . . . . . 0.544 ' HB3' ' H ' ' A' ' 53' ' ' ILE . 6.4 p90 -177.03 -171.45 0.36 Allowed 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 119.046 -1.061 . . . . 2.3900000000000001 112.458 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 4.0 mm -142.96 172.45 7.77 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 N-CA-C 108.213 -1.032 . . . . 1.8100000000000001 108.213 179.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -144.05 144.58 31.7 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 120.89 -1.131 . . . . 2.04 109.567 179.645 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 21.7 mt -97.66 138.26 35.32 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.26 -0.9 . . . . 1.8700000000000001 109.589 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -166.09 79.65 1.12 Allowed Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.478 -0.764 . . . . 1.47 109.056 -179.776 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -60.07 167.28 7.6 Favored 'Trans proline' 0 CA--C 1.544 1.001 0 C-N-CA 121.241 1.294 . . . . 1.96 109.972 -179.104 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 20' ' ' PRO . . . . . . . . . . . . . 1.1 Cg_endo -58.99 -58.78 0.57 Allowed 'Trans proline' 0 C--N 1.319 -0.996 0 C-N-CA 121.556 1.504 . . . . 3.3799999999999999 110.281 -179.778 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . 0.432 ' O ' ' O ' ' B' ' 22' ' ' ARG . 25.0 ttm-85 -137.03 161.61 35.59 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.377 -0.827 . . . . 6.7400000000000002 109.421 -179.533 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 22' ' ' ARG . . . . . 0.432 ' O ' ' O ' ' B' ' 21' ' ' ARG . 51.4 mtp180 -57.16 -163.53 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.379 -0.826 . . . . 6.9400000000000004 109.461 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . 0.527 ' OD2' ' N ' ' B' ' 24' ' ' VAL . 5.6 p-10 41.58 -136.19 0.24 Allowed 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.667 -0.646 . . . . 5.6200000000000001 110.059 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . 0.527 ' N ' ' OD2' ' B' ' 23' ' ' ASP . 63.3 t . . . . . 0 N--CA 1.494 1.731 0 CA-C-O 118.009 -0.996 . . . . 6.75 109.361 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.963 0 N-CA-C 119.62 2.608 . . . . 6.7300000000000004 119.62 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.571 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 14.1 tt -172.08 50.0 0.12 Allowed Pre-proline 0 C--N 1.307 -1.282 0 N-CA-C 107.94 -1.134 . . . . 7.3799999999999999 107.94 179.594 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.809 ' C ' ' H ' ' A' ' 5' ' ' PHE . 5.2 Cg_endo -57.41 -82.75 0.01 OUTLIER 'Trans proline' 0 C--N 1.318 -1.072 0 N-CA-C 108.512 -1.38 . . . . 5.5 108.512 179.632 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.536 ' C ' ' H ' ' A' ' 6' ' ' PHE . 11.9 tt0 73.52 -19.25 0.34 Allowed 'General case' 0 N--CA 1.496 1.839 0 N-CA-C 104.395 -2.446 . . . . 6.8399999999999999 104.395 -176.029 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . 0.809 ' H ' ' C ' ' A' ' 3' ' ' PRO . 2.5 m-85 -88.68 17.5 5.46 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 104.055 -2.572 . . . . 6.4400000000000004 104.055 176.777 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.536 ' H ' ' C ' ' A' ' 4' ' ' GLU . 38.6 p90 45.35 -153.24 0.04 OUTLIER 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 114.389 -1.278 . . . . 5.0599999999999996 109.428 -177.616 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.505 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 2.1 tm0? 83.14 -9.76 1.05 Allowed 'General case' 0 N--CA 1.489 1.506 0 N-CA-C 105.007 -2.22 . . . . 4.8099999999999996 105.007 -177.222 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.51 ' H ' ' C ' ' A' ' 6' ' ' PHE . 87.6 t80 -149.95 -37.57 0.15 Allowed 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 107.955 -1.128 . . . . 5.7300000000000004 107.955 178.296 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 61.1 m -94.07 4.2 54.23 Favored 'General case' 0 C--N 1.297 -1.713 0 N-CA-C 105.922 -1.881 . . . . 5.3499999999999996 105.922 177.349 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.444 ' CG1' ' N ' ' A' ' 11' ' ' GLY . 11.6 p -45.38 -46.2 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.324 0 CA-C-N 115.529 -0.759 . . . . 4.3799999999999999 109.196 -179.507 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.613 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 132.07 -81.64 0.32 Allowed Glycine 0 N--CA 1.501 2.967 0 N-CA-C 108.64 -1.784 . . . . 4.4800000000000004 108.64 179.413 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.498 ' O ' ' N ' ' A' ' 14' ' ' GLY . 13.6 Cg_endo -68.36 38.4 0.2 Allowed 'Trans proline' 0 C--N 1.319 -1.019 0 C-N-CA 121.562 1.508 . . . . 4.0499999999999998 108.567 178.147 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.613 ' H ' ' C ' ' A' ' 11' ' ' GLY . 0.2 OUTLIER 32.55 36.0 0.01 OUTLIER 'General case' 0 N--CA 1.505 2.323 0 CA-C-O 121.972 0.891 . . . . 4.0599999999999996 109.781 -178.7 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.564 ' C ' ' H ' ' A' ' 16' ' ' GLY . . . 69.94 -39.37 0.42 Allowed Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.382 -1.487 . . . . 3.1400000000000001 109.382 -179.806 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.543 ' H ' ' C ' ' A' ' 13' ' ' LEU . 21.6 tt0 52.2 6.58 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.478 -1.013 . . . . 3.1699999999999999 109.386 -179.544 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.564 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 59.34 130.69 0.01 OUTLIER Glycine 0 N--CA 1.489 2.232 0 O-C-N 121.329 -0.857 . . . . 2.4399999999999999 111.095 178.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.562 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 68.73 -53.63 0.51 Allowed Glycine 0 N--CA 1.492 2.405 0 O-C-N 121.499 -1.0 . . . . 2.0499999999999998 110.668 178.733 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.443 ' N ' ' HG2' ' A' ' 94' ' ' GLU . . . -42.66 -16.3 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.882 -0.775 . . . . 2.54 110.673 -178.598 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . 0.562 ' N ' ' O ' ' A' ' 17' ' ' GLY . 10.8 t-80 -93.82 -43.51 8.56 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.174 -0.954 . . . . 3.3700000000000001 110.879 -178.409 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -91.29 -35.99 14.14 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 120.966 -1.084 . . . . 2.3700000000000001 111.022 -178.486 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.478 ' O ' ' CG1' ' A' ' 21' ' ' VAL . 6.6 p -46.66 111.28 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 120.989 -1.069 . . . . 2.5800000000000001 110.061 -178.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 19.5 tpt180 -118.43 124.84 48.63 Favored 'General case' 0 N--CA 1.497 1.878 0 N-CA-C 108.89 -0.781 . . . . 3.8900000000000001 108.89 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -128.05 116.48 20.08 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.489 -0.757 . . . . 2.0099999999999998 109.26 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -148.2 128.78 2.95 Favored Glycine 0 N--CA 1.495 2.571 0 N-CA-C 109.403 -1.479 . . . . 2.0099999999999998 109.403 -179.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.11 169.19 40.38 Favored Glycine 0 N--CA 1.489 2.206 0 C-N-CA 119.574 -1.298 . . . . 1.9299999999999999 110.062 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 43.3 p -74.06 -11.94 60.47 Favored 'General case' 0 N--CA 1.486 1.34 0 O-C-N 121.349 -1.089 . . . . 2.6899999999999999 109.771 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -67.37 -17.06 68.03 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 108.205 -1.958 . . . . 1.6399999999999999 108.205 179.46 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 28.2 mt -89.86 -11.65 41.32 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 108.467 -0.938 . . . . 2.0299999999999998 108.467 179.437 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 19.9 mm-40 -82.68 -60.35 2.21 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.596 -0.69 . . . . 2.3399999999999999 109.858 -179.47 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 26.6 ptt180 -172.96 178.79 2.45 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.032 -1.043 . . . . 4.25 109.992 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -148.85 178.0 26.71 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 108.446 -1.861 . . . . 1.5900000000000001 108.446 179.765 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 27.3 t -134.8 148.33 29.31 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.015 0 O-C-N 121.205 -1.174 . . . . 2.21 110.145 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -41.56 113.95 0.47 Allowed 'General case' 0 N--CA 1.495 1.792 0 CA-C-O 121.567 0.699 . . . . 2.0699999999999998 112.388 -179.155 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 59.87 46.44 94.1 Favored Glycine 0 N--CA 1.492 2.424 0 O-C-N 121.658 -0.651 . . . . 1.73 111.687 177.113 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 13.9 t -127.36 126.03 24.06 Favored Pre-proline 0 N--CA 1.499 2.009 0 N-CA-C 108.019 -1.104 . . . . 2.6499999999999999 108.019 178.827 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -55.12 121.38 9.81 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 120.487 0.791 . . . . 2.1400000000000001 110.441 -179.362 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -119.92 151.5 38.81 Favored 'General case' 0 N--CA 1.499 1.992 0 N-CA-C 108.235 -1.024 . . . . 2.0299999999999998 108.235 179.319 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 8.6 pt-20 -160.16 166.24 30.1 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.727 -1.233 . . . . 2.23 111.334 -179.445 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.55 ' N ' ' CD1' ' A' ' 39' ' ' PHE . 0.9 OUTLIER -140.48 -178.08 5.34 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 107.046 -1.464 . . . . 1.72 107.046 177.428 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 15.5 m -128.31 134.83 48.98 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.678 -0.639 . . . . 2.5800000000000001 110.084 -179.161 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.532 ' O ' ' N ' ' A' ' 73' ' ' CYS . 73.0 mt -124.61 145.79 31.26 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 N-CA-C 107.683 -1.228 . . . . 1.8600000000000001 107.683 179.13 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.522 ' CD2' ' OG1' ' A' ' 43' ' ' THR . 14.5 p-90 -154.82 -176.99 6.2 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.678 -1.264 . . . . 4.4699999999999998 110.445 -179.653 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' THR . . . . . 0.522 ' OG1' ' CD2' ' A' ' 42' ' ' TRP . 0.2 OUTLIER 81.85 109.9 0.07 Allowed 'General case' 0 N--CA 1.495 1.806 0 N-CA-C 109.356 -0.609 . . . . 3.27 109.356 -179.883 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' ARG . . . . . 0.575 ' CG ' HH11 ' A' ' 44' ' ' ARG . 0.0 OUTLIER -132.16 56.94 1.8 Allowed 'General case' 0 N--CA 1.499 1.976 0 N-CA-C 108.982 -0.747 . . . . 5.2300000000000004 108.982 -179.864 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 27.3 tt0 -90.3 -15.91 30.29 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.264 -0.897 . . . . 2.8900000000000001 109.976 -179.583 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.39 -66.88 0.5 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.04 -1.038 . . . . 1.99 109.179 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 138.21 -162.83 25.71 Favored Glycine 0 N--CA 1.495 2.633 0 N-CA-C 109.672 -1.371 . . . . 1.6499999999999999 109.672 179.812 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.86 147.37 12.14 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.278 -1.131 . . . . 1.77 109.33 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -173.19 -168.96 35.1 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.538 -1.425 . . . . 1.1200000000000001 109.538 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -137.49 114.29 1.09 Allowed Glycine 0 N--CA 1.496 2.663 0 N-CA-C 109.114 -1.594 . . . . 1.1799999999999999 109.114 179.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.402 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 10.1 tp -93.74 97.58 10.53 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.251 -1.146 . . . . 1.5900000000000001 108.582 179.79 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 4.2 m -83.78 142.16 30.87 Favored 'General case' 0 N--CA 1.494 1.738 0 N-CA-C 108.485 -0.932 . . . . 1.9399999999999999 108.485 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.53 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 61.0 mt -133.65 123.22 45.29 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.083 -1.011 . . . . 1.3 109.674 -179.688 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -116.07 111.71 20.69 Favored 'General case' 0 N--CA 1.497 1.89 0 N-CA-C 108.325 -0.991 . . . . 1.27 108.325 179.236 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 1.1 t -102.94 149.14 7.32 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.977 0 O-C-N 121.449 -0.782 . . . . 1.55 110.052 -179.277 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . 0.42 ' OE2' ' O ' ' B' ' 9' ' ' VAL . 50.9 tp10 -140.65 138.39 34.3 Favored 'General case' 0 N--CA 1.486 1.374 0 N-CA-C 108.441 -0.948 . . . . 1.8 108.441 178.285 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 174.3 -177.51 46.47 Favored Glycine 0 N--CA 1.487 2.075 0 N-CA-C 108.719 -1.752 . . . . 0.56000000000000005 108.719 -179.607 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_exo -62.74 -18.54 64.81 Favored 'Trans proline' 0 C--N 1.313 -1.32 0 C-N-CA 121.802 1.668 . . . . 0.76000000000000001 110.957 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' SER . . . . . 0.5 ' H ' ' HH ' ' A' ' 85' ' ' TYR . 1.1 p -149.77 166.36 29.68 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.349 -0.844 . . . . 2.02 110.411 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 46.1 mttt -89.92 125.74 35.47 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.607 -0.683 . . . . 3.02 109.502 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -81.8 142.86 32.21 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.278 -0.889 . . . . 1.3600000000000001 109.325 179.766 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 10.0 tp10 -86.61 90.55 8.29 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.24 -0.913 . . . . 2.2999999999999998 109.766 -179.808 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 6.3 mm -58.5 155.62 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 121.574 -0.704 . . . . 2.0 109.133 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.487 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -149.68 114.43 5.33 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.804 -1.185 . . . . 1.73 109.503 179.577 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.463 ' CD2' ' O ' ' A' ' 65' ' ' PHE . 16.5 p90 -88.85 119.11 29.05 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.164 -0.96 . . . . 1.6000000000000001 109.041 179.476 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -141.29 106.91 5.08 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.252 -0.905 . . . . 2.5099999999999998 109.902 -179.633 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 11.2 p-10 -79.94 127.13 31.9 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.247 -0.908 . . . . 2.0699999999999998 108.9 179.354 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 84.1 mtm180 -110.96 -34.11 6.31 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.407 -0.808 . . . . 5.29 109.574 -179.607 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.568 ' C ' ' H ' ' A' ' 71' ' ' GLY . 28.5 mmtp -117.41 3.49 12.51 Favored 'General case' 0 N--CA 1.496 1.843 0 N-CA-C 108.631 -0.878 . . . . 3.8599999999999999 108.631 179.8 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.437 ' CB ' ' O ' ' A' ' 69' ' ' LYS . 1.3 t70 72.99 -34.64 0.3 Allowed 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 108.684 -0.858 . . . . 3.0600000000000001 108.684 -179.2 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . 0.568 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -93.76 -35.17 6.23 Favored Glycine 0 N--CA 1.489 2.171 0 N-CA-C 109.443 -1.463 . . . . 2.1600000000000001 109.443 -179.864 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 74.8 m -95.76 107.56 19.8 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.317 -1.108 . . . . 2.5600000000000001 109.395 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' CYS . . . . . 0.532 ' N ' ' O ' ' A' ' 41' ' ' ILE . 28.2 m -80.18 119.89 23.55 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.225 -0.922 . . . . 2.3599999999999999 109.295 179.801 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -98.26 123.58 7.9 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.42 -1.472 . . . . 1.46 109.42 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 40.2 t -114.85 102.68 14.19 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.089 0 O-C-N 121.632 -0.923 . . . . 2.1600000000000001 109.05 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.487 ' O ' ' N ' ' A' ' 64' ' ' ALA . 3.3 t -94.01 130.4 40.16 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.34 -0.85 . . . . 2.1600000000000001 110.136 -179.598 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 8.5 p90 -126.46 129.85 49.51 Favored 'General case' 0 N--CA 1.492 1.646 0 N-CA-C 108.158 -1.052 . . . . 1.7 108.158 179.455 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 11.3 t -100.56 111.29 29.78 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.181 -0.949 . . . . 2.4500000000000002 109.453 -179.155 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 13.2 m -77.94 157.71 5.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 O-C-N 121.287 -0.883 . . . . 1.8200000000000001 109.329 -179.866 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 30.1 tt0 -101.87 -47.92 4.43 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.173 -0.955 . . . . 3.1699999999999999 110.303 -179.499 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.404 ' O ' ' O ' ' A' ' 82' ' ' PRO . 75.5 mm-40 -149.98 150.03 29.01 Favored Pre-proline 0 N--CA 1.502 2.143 0 O-C-N 120.829 -1.169 . . . . 2.02 111.253 -178.623 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.498 ' HG3' ' N ' ' A' ' 107' ' ' SER . 77.8 Cg_exo -37.43 165.49 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.679 0 C-N-CA 122.825 2.35 . . . . 1.3999999999999999 113.296 178.551 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 142.37 -178.89 20.61 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 108.989 -1.644 . . . . 1.0800000000000001 108.989 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . 0.552 ' O ' ' NH1' ' B' ' 8' ' ' ARG . 29.6 m-20 -98.69 89.74 4.47 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 107.835 -1.172 . . . . 2.1299999999999999 107.835 179.224 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . 0.5 ' HH ' ' H ' ' A' ' 59' ' ' SER . 2.9 m-85 -74.7 133.67 42.04 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 108.347 -0.983 . . . . 1.1399999999999999 108.347 -179.366 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . 0.488 ' OE2' ' NH1' ' B' ' 8' ' ' ARG . 0.0 OUTLIER -117.65 125.05 50.04 Favored 'General case' 0 N--CA 1.498 1.949 0 N-CA-C 108.305 -0.998 . . . . 1.53 108.305 -179.098 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.556 ' CG1' ' CE2' ' A' ' 101' ' ' PHE . 7.5 p -122.94 137.38 56.6 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.986 0 O-C-N 121.624 -0.673 . . . . 1.6399999999999999 109.401 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 99.8 p -131.55 113.87 14.18 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.596 -0.69 . . . . 1.99 109.797 -179.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 2.9 pt -111.83 143.13 22.24 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.735 -0.603 . . . . 1.77 109.917 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -140.4 123.52 16.67 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.236 -0.915 . . . . 2.0600000000000001 109.273 178.971 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 25.1 t80 -78.67 92.99 4.82 Favored 'General case' 0 N--CA 1.494 1.744 0 C-N-CA 119.026 -1.069 . . . . 1.45 108.325 179.449 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . 0.486 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 5.8 t-20 65.82 37.62 5.52 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 108.236 -1.024 . . . . 2.7200000000000002 108.236 -178.809 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . 0.486 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 2.2 m-20 88.76 10.97 0.09 Allowed 'General case' 0 N--CA 1.503 2.192 0 CA-C-N 116.605 -0.27 . . . . 1.9199999999999999 111.381 179.658 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . 0.522 ' CG ' ' O ' ' A' ' 94' ' ' GLU . 0.0 OUTLIER -86.33 86.97 7.35 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 106.091 -1.818 . . . . 2.5499999999999998 106.091 177.687 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . 0.445 ' O ' ' C ' ' A' ' 96' ' ' ILE . 2.3 t-80 -68.12 94.36 0.5 Allowed 'General case' 0 C--N 1.296 -1.735 0 O-C-N 120.4 -1.437 . . . . 3.2000000000000002 110.948 -177.845 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . 0.506 ' C ' ' H ' ' A' ' 98' ' ' ASP . 4.7 mm -38.38 135.81 0.88 Allowed Pre-proline 0 N--CA 1.504 2.271 0 O-C-N 121.497 -0.752 . . . . 2.8199999999999998 109.281 179.084 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -54.52 -7.36 0.8 Allowed 'Trans proline' 0 C--N 1.325 -0.7 0 N-CA-C 109.239 -1.1 . . . . 2.6299999999999999 109.239 179.131 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.506 ' H ' ' C ' ' A' ' 96' ' ' ILE . 55.0 m-20 -86.87 -47.32 9.12 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.481 -0.762 . . . . 2.6499999999999999 109.729 179.765 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 6.4 p -54.71 136.32 64.16 Favored Pre-proline 0 C--N 1.298 -1.661 0 O-C-N 121.191 -0.943 . . . . 2.3199999999999998 109.835 -177.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -89.3 113.81 2.34 Favored 'Cis proline' 0 N--CA 1.494 1.554 0 CA-C-N 118.935 0.655 . . . . 1.9399999999999999 110.44 -1.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . 0.609 ' CD1' ' N ' ' A' ' 101' ' ' PHE . 0.1 OUTLIER -81.42 158.58 24.55 Favored 'General case' 0 N--CA 1.509 2.522 0 O-C-N 119.674 -1.891 . . . . 2.6299999999999999 108.785 178.476 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 10.4 p -97.93 138.04 23.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.404 -0.81 . . . . 1.8200000000000001 109.388 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 60.6 t -121.03 85.53 40.95 Favored Pre-proline 0 N--CA 1.499 2.019 0 N-CA-C 108.623 -0.88 . . . . 1.73 108.623 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -65.63 111.32 1.85 Allowed 'Trans proline' 0 C--N 1.321 -0.899 0 C-N-CA 121.443 1.428 . . . . 1.6100000000000001 111.467 -178.336 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 54.6 t -95.49 146.32 7.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.775 0 N-CA-C 107.1 -1.444 . . . . 1.7 107.1 178.34 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -138.71 135.65 34.98 Favored 'General case' 0 N--CA 1.509 2.523 0 O-C-N 121.092 -1.005 . . . . 2.04 111.799 -177.541 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' SER . . . . . 0.508 ' O ' ' CB ' ' A' ' 108' ' ' LEU . 9.9 m -86.71 58.73 5.23 Favored 'General case' 0 N--CA 1.494 1.752 0 N-CA-C 107.42 -1.326 . . . . 2.2999999999999998 107.42 178.808 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . 0.508 ' CB ' ' O ' ' A' ' 107' ' ' SER . 3.4 tp 83.8 -11.35 0.89 Allowed 'General case' 0 N--CA 1.495 1.814 0 N-CA-C 106.972 -1.492 . . . . 3.6000000000000001 106.972 -177.843 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.614 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 24.1 t -71.18 -19.28 62.42 Favored 'General case' 0 C--N 1.305 -1.333 0 N-CA-C 108.878 -0.786 . . . . 2.4900000000000002 108.878 178.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . 0.409 ' CG ' ' O ' ' A' ' 109' ' ' SER . 1.1 p30 48.44 15.06 0.07 Allowed 'General case' 0 N--CA 1.496 1.833 0 N-CA-C 108.285 -1.006 . . . . 2.8500000000000001 108.285 -178.822 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.528 ' H ' ' C ' ' A' ' 109' ' ' SER . 29.9 m-20 -166.64 -34.16 0.03 OUTLIER 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 108.173 -1.047 . . . . 2.46 108.173 -179.759 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.614 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 39.16 83.41 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.604 -0.685 . . . . 2.0800000000000001 110.585 179.765 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.429 ' O ' ' N ' ' A' ' 118' ' ' THR . 82.5 mtt180 -76.77 138.77 40.1 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.164 -0.96 . . . . 6.54 109.222 179.875 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 57.8 ttt180 -90.18 5.64 46.09 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.438 -0.789 . . . . 6.2400000000000002 109.121 -179.794 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 2.2 mp -125.84 -25.49 3.62 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.577 -0.702 . . . . 4.71 110.061 -179.401 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.544 ' C ' ' H ' ' A' ' 118' ' ' THR . 61.5 m -110.75 -77.83 0.59 Allowed 'General case' 0 N--CA 1.499 1.997 0 N-CA-C 107.252 -1.388 . . . . 4.3499999999999996 107.252 179.177 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 42.5 t -62.32 -7.61 2.32 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.656 0 N-CA-C 105.994 -1.854 . . . . 3.3100000000000001 105.994 176.72 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' THR . . . . . 0.544 ' H ' ' C ' ' A' ' 116' ' ' THR . 4.2 t 36.19 59.39 0.93 Allowed 'General case' 0 N--CA 1.487 1.391 0 CA-C-N 115.12 -0.945 . . . . 3.73 110.687 179.743 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' SER . . . . . 0.452 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.5 p . . . . . 0 C--N 1.304 -1.398 0 CA-C-O 118.021 -0.99 . . . . 3.8300000000000001 109.673 179.43 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 11.8 ptt? . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 109.468 -0.567 . . . . 8.8699999999999992 109.468 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -172.74 145.79 1.54 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.216 -0.927 . . . . 5.9299999999999997 109.405 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 3' ' ' SER . . . . . . . . . . . . . 60.7 p 49.79 75.29 0.17 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.257 -0.902 . . . . 5.5700000000000003 109.361 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 4' ' ' LYS . . . . . 0.429 ' O ' ' O ' ' B' ' 5' ' ' PRO . 43.5 mttm -63.83 148.17 95.07 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.254 -0.904 . . . . 7.25 108.941 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 5' ' ' PRO . . . . . 0.429 ' O ' ' O ' ' B' ' 4' ' ' LYS . 1.9 Cg_endo -57.2 -158.02 0.01 OUTLIER 'Trans proline' 0 C--N 1.324 -0.727 0 C-N-CA 120.914 1.076 . . . . 5.8899999999999997 109.766 179.544 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 6' ' ' GLU . . . . . . . . . . . . . 15.5 tt0 67.55 179.69 0.23 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.244 -0.91 . . . . 4.7800000000000002 108.973 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 53.53 62.82 2.45 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.218 -0.926 . . . . 4.5599999999999996 109.592 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . 0.552 ' NH1' ' O ' ' A' ' 84' ' ' ASP . 68.3 mtt180 -98.82 176.63 5.54 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 108.429 -0.952 . . . . 3.6699999999999999 108.429 179.606 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 9' ' ' VAL . . . . . 0.42 ' O ' ' OE2' ' A' ' 56' ' ' GLU . 21.0 t -53.99 158.71 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 N-CA-C 108.162 -1.051 . . . . 1.3899999999999999 108.162 178.971 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -117.83 141.72 48.11 Favored 'General case' 0 N--CA 1.502 2.166 0 O-C-N 121.489 -0.757 . . . . 1.22 109.981 -179.337 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 18.4 t -143.0 137.68 29.49 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.368 -0.832 . . . . 1.6299999999999999 109.319 179.581 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 8.7 t -141.13 128.31 20.9 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.308 -0.87 . . . . 1.8799999999999999 109.584 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . 0.48 ' CG2' ' N ' ' B' ' 14' ' ' PHE . 6.1 p -169.44 167.89 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.484 -0.76 . . . . 1.2 109.205 -179.874 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 14' ' ' PHE . . . . . 0.53 ' HB3' ' H ' ' A' ' 53' ' ' ILE . 6.7 p90 -177.61 -167.67 0.16 Allowed 'General case' 0 N--CA 1.49 1.552 0 CA-C-O 122.202 1.001 . . . . 2.3900000000000001 112.537 179.65 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.4 pt -150.71 172.07 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.31 0 N-CA-C 108.322 -0.992 . . . . 1.8100000000000001 108.322 179.818 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 31.7 p -144.96 147.12 32.33 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 120.865 -1.147 . . . . 2.04 109.9 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.4 mt -97.58 132.63 43.08 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.349 -0.845 . . . . 1.8700000000000001 109.178 179.715 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -150.91 68.63 8.23 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.227 -0.921 . . . . 1.47 109.652 -179.862 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . 0.427 ' O ' ' O ' ' B' ' 20' ' ' PRO . 6.3 Cg_exo -60.45 170.4 4.29 Favored 'Trans proline' 0 C--N 1.317 -1.096 0 C-N-CA 121.3 1.334 . . . . 1.96 109.307 -179.911 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 20' ' ' PRO . . . . . 0.427 ' O ' ' O ' ' B' ' 19' ' ' PRO . 4.7 Cg_exo -56.6 -158.05 0.01 OUTLIER 'Trans proline' 0 C--N 1.318 -1.066 0 C-N-CA 121.259 1.306 . . . . 3.3799999999999999 109.862 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -144.0 -163.53 1.69 Allowed 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.188 -0.945 . . . . 6.7400000000000002 109.312 -179.934 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 22' ' ' ARG . . . . . . . . . . . . . 8.4 ptm180 -152.24 121.58 6.78 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.204 -0.935 . . . . 6.9400000000000004 109.368 -179.866 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . 0.513 ' OD1' ' N ' ' B' ' 23' ' ' ASP . 8.5 p-10 -175.22 122.87 0.22 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.206 -0.934 . . . . 5.6200000000000001 109.455 -179.895 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 15.0 p . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 117.959 -1.019 . . . . 6.75 109.443 179.978 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.531 4.997 0 N-CA-C 119.799 2.68 . . . . 6.7300000000000004 119.799 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.562 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 11.4 tt -172.88 50.77 0.11 Allowed Pre-proline 0 C--N 1.308 -1.231 0 N-CA-C 107.784 -1.191 . . . . 7.3799999999999999 107.784 179.53 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.777 ' C ' ' H ' ' A' ' 5' ' ' PHE . 6.5 Cg_endo -58.76 -82.79 0.01 OUTLIER 'Trans proline' 0 C--N 1.318 -1.042 0 N-CA-C 108.73 -1.296 . . . . 5.5 108.73 179.829 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.526 ' C ' ' H ' ' A' ' 6' ' ' PHE . 11.6 tt0 73.83 -19.13 0.36 Allowed 'General case' 0 N--CA 1.495 1.796 0 N-CA-C 104.373 -2.454 . . . . 6.8399999999999999 104.373 -175.819 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . 0.777 ' H ' ' C ' ' A' ' 3' ' ' PRO . 6.4 m-85 -89.68 20.21 4.18 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 103.996 -2.594 . . . . 6.4400000000000004 103.996 176.732 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.549 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 37.2 p90 46.33 -153.69 0.06 Allowed 'General case' 0 C--N 1.307 -1.275 0 CA-C-N 114.314 -1.312 . . . . 5.0599999999999996 109.394 -177.466 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.537 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 22.0 tt0 86.8 -10.27 0.63 Allowed 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 105.282 -2.118 . . . . 4.8099999999999996 105.282 -177.318 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.453 ' H ' ' C ' ' A' ' 6' ' ' PHE . 35.5 t80 -151.77 -37.25 0.12 Allowed 'General case' 0 C--N 1.305 -1.347 0 N-CA-C 107.955 -1.128 . . . . 5.7300000000000004 107.955 178.485 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 39.9 m -93.58 3.74 55.04 Favored 'General case' 0 C--N 1.296 -1.72 0 N-CA-C 105.96 -1.867 . . . . 5.3499999999999996 105.96 177.363 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.487 ' CG1' ' N ' ' A' ' 11' ' ' GLY . 9.8 p -44.35 -42.91 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 CA-C-N 115.457 -0.792 . . . . 4.3799999999999999 109.867 -179.474 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.51 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . -114.64 -172.06 17.34 Favored Glycine 0 N--CA 1.494 2.54 0 N-CA-C 109.705 -1.358 . . . . 4.4800000000000004 109.705 -179.039 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.441 ' C ' ' HG ' ' A' ' 13' ' ' LEU . 10.1 Cg_endo -69.46 -0.16 6.26 Favored 'Trans proline' 0 C--N 1.316 -1.171 0 C-N-CA 121.847 1.698 . . . . 4.0499999999999998 109.514 -179.702 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.51 ' H ' ' C ' ' A' ' 11' ' ' GLY . 0.3 OUTLIER 168.54 24.74 0.0 OUTLIER 'General case' 0 C--N 1.278 -2.523 0 CA-C-N 114.453 -1.249 . . . . 4.0599999999999996 108.256 -177.698 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.458 ' C ' ' N ' ' A' ' 16' ' ' GLY . . . 77.45 -42.19 1.93 Allowed Glycine 0 N--CA 1.49 2.277 0 N-CA-C 108.732 -1.747 . . . . 3.1400000000000001 108.732 -179.654 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.448 ' H ' ' C ' ' A' ' 13' ' ' LEU . 25.3 tt0 53.24 13.89 0.46 Allowed 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 108.137 -1.06 . . . . 3.1699999999999999 108.137 -179.685 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.458 ' N ' ' C ' ' A' ' 14' ' ' GLY . . . 73.67 -164.09 54.77 Favored Glycine 0 N--CA 1.484 1.899 0 N-CA-C 109.447 -1.461 . . . . 2.4399999999999999 109.447 -179.892 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.534 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -69.58 -5.93 52.67 Favored Glycine 0 N--CA 1.487 2.083 0 N-CA-C 110.054 -1.219 . . . . 2.0499999999999998 110.054 -179.664 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -48.3 -13.39 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.675 0 O-C-N 120.663 -1.492 . . . . 2.54 109.228 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . 0.534 ' N ' ' O ' ' A' ' 17' ' ' GLY . 1.6 t60 -95.48 -45.17 7.2 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.384 -0.823 . . . . 3.3700000000000001 109.181 179.38 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.52 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.0 OUTLIER -79.83 -26.08 40.59 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.112 -0.993 . . . . 2.3700000000000001 109.332 179.894 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 69.2 t -62.98 112.66 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.115 -0.991 . . . . 2.5800000000000001 109.051 179.497 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 12.9 tpp180 -100.93 137.52 39.19 Favored 'General case' 0 C--N 1.301 -1.535 0 CA-C-O 121.475 0.655 . . . . 3.8900000000000001 109.263 -179.72 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -148.37 113.28 5.45 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.604 -0.887 . . . . 2.0099999999999998 108.604 179.415 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -150.76 133.23 4.21 Favored Glycine 0 N--CA 1.496 2.68 0 N-CA-C 109.74 -1.344 . . . . 2.0099999999999998 109.74 -179.616 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.46 175.36 47.37 Favored Glycine 0 N--CA 1.487 2.067 0 C-N-CA 119.628 -1.272 . . . . 1.9299999999999999 110.268 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 18.0 m -77.44 -17.95 57.62 Favored 'General case' 0 N--CA 1.486 1.363 0 O-C-N 121.457 -1.025 . . . . 2.6899999999999999 109.77 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -68.34 -22.75 74.87 Favored Glycine 0 N--CA 1.487 2.036 0 N-CA-C 108.761 -1.736 . . . . 1.6399999999999999 108.761 179.757 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.5 mt -84.39 -7.15 59.39 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.623 -0.927 . . . . 2.0299999999999998 108.963 179.853 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 27.0 mm-40 -88.45 -56.69 3.21 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.47 -0.769 . . . . 2.3399999999999999 109.993 -179.341 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 26.1 ptt180 -175.05 -176.74 0.99 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.126 -0.984 . . . . 4.25 109.666 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -149.27 177.47 27.45 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 108.917 -1.673 . . . . 1.5900000000000001 108.917 179.857 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.432 ' H ' HG12 ' A' ' 35' ' ' VAL . 25.8 t -134.91 148.03 29.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.425 -1.044 . . . . 2.21 109.803 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -37.84 106.65 0.05 Allowed 'General case' 0 N--CA 1.496 1.866 0 CA-C-O 121.341 0.591 . . . . 2.0699999999999998 112.085 -179.142 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 62.49 57.51 16.23 Favored Glycine 0 N--CA 1.49 2.268 0 O-C-N 121.249 -0.907 . . . . 1.73 111.541 177.558 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.448 ' O ' ' CG1' ' A' ' 35' ' ' VAL . 2.8 p -126.09 129.2 24.31 Favored Pre-proline 0 N--CA 1.502 2.167 0 O-C-N 121.311 -1.111 . . . . 2.6499999999999999 109.133 178.84 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -63.5 125.64 16.0 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 N-CA-C 108.24 -1.485 . . . . 2.1400000000000001 108.24 178.473 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -134.47 160.91 36.55 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.212 -0.93 . . . . 2.0299999999999998 109.294 -179.367 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -162.36 167.22 24.08 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 121.161 -0.962 . . . . 2.23 110.758 -179.634 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.527 ' N ' ' CD1' ' A' ' 39' ' ' PHE . 0.7 OUTLIER -141.61 -179.98 6.48 Favored 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 107.059 -1.46 . . . . 1.72 107.059 177.627 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 6.1 m -124.12 138.05 54.48 Favored 'General case' 0 N--CA 1.498 1.941 0 CA-C-O 121.405 0.622 . . . . 2.5800000000000001 110.178 -178.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.527 ' O ' ' N ' ' A' ' 73' ' ' CYS . 74.3 mt -136.7 119.38 20.99 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.556 -0.715 . . . . 1.8600000000000001 109.269 179.645 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 6.2 p-90 -119.52 137.35 53.87 Favored 'General case' 0 N--CA 1.503 2.2 0 N-CA-C 108.905 -0.776 . . . . 4.4699999999999998 108.905 179.201 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' THR . . . . . 0.52 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.1 OUTLIER -148.83 137.77 21.46 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.199 -0.938 . . . . 3.27 109.694 -179.581 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' ARG . . . . . . . . . . . . . 59.7 ttt180 -171.87 66.3 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.344 -0.848 . . . . 5.2300000000000004 109.743 179.665 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 6.4 tp10 -157.84 -53.81 0.07 Allowed 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.078 -1.014 . . . . 2.8900000000000001 109.43 179.553 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -58.46 -58.75 7.16 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.2 -0.937 . . . . 1.99 109.148 179.769 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 138.62 176.49 14.62 Favored Glycine 0 N--CA 1.494 2.502 0 N-CA-C 108.928 -1.669 . . . . 1.6499999999999999 108.928 -179.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.39 163.51 0.6 Allowed 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.088 -1.243 . . . . 1.77 109.386 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 179.8 -148.78 8.2 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.868 -1.293 . . . . 1.1200000000000001 109.868 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.479 ' O ' ' N ' ' A' ' 92' ' ' ASN . . . -144.13 126.98 2.85 Favored Glycine 0 N--CA 1.495 2.606 0 N-CA-C 109.618 -1.393 . . . . 1.1799999999999999 109.618 -179.838 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 10.8 tp -102.93 102.15 12.21 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.399 -1.059 . . . . 1.5900000000000001 109.027 179.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 3.2 t -85.97 142.11 29.03 Favored 'General case' 0 N--CA 1.494 1.767 0 N-CA-C 108.221 -1.029 . . . . 1.9399999999999999 108.221 179.295 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.531 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 89.5 mt -133.54 120.14 36.85 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.987 0 O-C-N 121.087 -1.008 . . . . 1.3 109.896 -179.709 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -109.44 106.86 16.8 Favored 'General case' 0 N--CA 1.496 1.874 0 N-CA-C 108.772 -0.825 . . . . 1.27 108.772 179.376 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -97.84 143.19 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 O-C-N 121.245 -0.91 . . . . 1.55 109.25 -179.844 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 12.5 tt0 -141.61 142.87 33.44 Favored 'General case' 0 N--CA 1.491 1.624 0 N-CA-C 107.882 -1.155 . . . . 1.8 107.882 179.336 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 166.04 -172.88 41.54 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.502 -1.439 . . . . 0.56000000000000005 109.502 -179.239 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -64.21 -30.18 64.54 Favored 'Trans proline' 0 C--N 1.318 -1.056 0 C-N-CA 121.993 1.795 . . . . 0.76000000000000001 111.412 -179.218 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' SER . . . . . 0.516 ' H ' ' HH ' ' A' ' 85' ' ' TYR . 6.0 m -141.4 152.26 44.16 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.075 -1.016 . . . . 2.02 109.827 -179.801 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 16.1 ptmt -74.56 107.68 6.84 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.261 -0.899 . . . . 3.02 109.024 179.829 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -72.67 136.43 45.63 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.014 -1.054 . . . . 1.3600000000000001 109.401 -179.602 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -71.92 173.35 8.45 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.099 -1.0 . . . . 2.2999999999999998 109.236 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . 0.405 HG21 HD13 ' A' ' 63' ' ' ILE . 42.9 mt -142.52 152.52 17.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 N-CA-C 107.799 -1.185 . . . . 2.0 107.799 -179.847 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.55 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -150.13 114.64 5.23 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 120.653 -1.279 . . . . 1.73 110.202 -179.45 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 45.1 p90 -86.76 129.07 35.02 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.248 -0.907 . . . . 1.6000000000000001 109.157 179.393 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 54.0 tt0 -141.26 123.78 15.91 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.238 -0.914 . . . . 2.5099999999999998 109.602 -179.756 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . 0.437 ' OD1' ' N ' ' A' ' 67' ' ' ASP . 2.3 p-10 -84.76 119.24 25.06 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.35 -0.844 . . . . 2.0699999999999998 109.371 179.833 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.584 ' CG ' HH11 ' A' ' 68' ' ' ARG . 0.3 OUTLIER -96.06 -39.99 9.46 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.221 -0.924 . . . . 5.29 109.638 -179.926 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.563 ' C ' ' H ' ' A' ' 71' ' ' GLY . 20.4 mtpp -122.35 13.11 10.25 Favored 'General case' 0 N--CA 1.496 1.826 0 N-CA-C 108.663 -0.866 . . . . 3.8599999999999999 108.663 179.853 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.473 ' CB ' ' O ' ' A' ' 69' ' ' LYS . 4.4 t0 74.04 -29.52 0.2 Allowed 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 108.476 -0.935 . . . . 3.0600000000000001 108.476 -178.99 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . 0.563 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -103.63 -24.92 7.53 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.613 -1.395 . . . . 2.1600000000000001 109.613 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 94.0 p -95.81 115.66 27.76 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.17 -1.194 . . . . 2.5600000000000001 109.466 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' CYS . . . . . 0.527 ' N ' ' O ' ' A' ' 41' ' ' ILE . 32.3 m -85.31 117.27 24.14 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.232 -0.917 . . . . 2.3599999999999999 109.633 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -99.95 119.8 6.64 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 109.294 -1.522 . . . . 1.46 109.294 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 17.9 t -109.74 103.09 14.94 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.153 0 O-C-N 121.524 -0.986 . . . . 2.1600000000000001 109.818 -179.756 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.55 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.0 OUTLIER -91.76 142.94 27.04 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.326 -0.859 . . . . 2.1600000000000001 108.851 179.687 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 0.411 ' CD1' ' N ' ' A' ' 77' ' ' TYR . 11.6 p90 -142.82 171.92 13.4 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.281 -0.887 . . . . 1.7 109.189 -179.421 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.464 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 4.4 p -142.2 119.98 7.92 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.211 0 O-C-N 121.105 -0.997 . . . . 2.4500000000000002 110.288 179.529 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 11.5 m -87.15 153.97 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.309 -0.87 . . . . 1.8200000000000001 108.677 179.251 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . 0.432 ' OE1' ' OG ' ' A' ' 59' ' ' SER . 38.3 tt0 -96.6 -47.0 6.1 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.008 -1.057 . . . . 3.1699999999999999 110.657 -179.156 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 80.2 mm-40 -152.16 150.48 25.66 Favored Pre-proline 0 N--CA 1.502 2.129 0 O-C-N 120.646 -1.284 . . . . 2.02 111.056 -178.625 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.526 ' HG3' ' N ' ' A' ' 107' ' ' SER . 75.7 Cg_exo -37.68 164.72 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.67 0 C-N-CA 122.8 2.333 . . . . 1.3999999999999999 113.099 178.398 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 144.24 -163.88 27.71 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.122 -1.591 . . . . 1.0800000000000001 109.122 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 20.0 m-20 -108.97 91.13 3.52 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.639 -0.918 . . . . 2.1299999999999999 108.797 179.652 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . 0.516 ' HH ' ' H ' ' A' ' 59' ' ' SER . 3.1 m-85 -78.81 130.69 36.0 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 108.091 -1.077 . . . . 1.1399999999999999 108.091 179.896 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . 0.409 ' OE2' ' NH2' ' B' ' 8' ' ' ARG . 0.0 OUTLIER -115.62 129.23 56.43 Favored 'General case' 0 N--CA 1.501 2.1 0 N-CA-C 108.89 -0.781 . . . . 1.53 108.89 -179.041 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 9.9 p -124.12 140.19 48.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.712 -0.617 . . . . 1.6399999999999999 109.361 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' SER . . . . . 0.423 ' O ' ' OG ' ' A' ' 88' ' ' SER . 22.2 p -131.98 101.9 5.61 Favored 'General case' 0 N--CA 1.498 1.944 0 N-CA-C 109.184 -0.673 . . . . 1.99 109.184 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.5 pt -111.84 136.11 49.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 CA-C-O 121.599 0.714 . . . . 1.77 110.479 -179.084 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . 0.459 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.2 OUTLIER -140.95 122.77 15.35 Favored 'General case' 0 N--CA 1.486 1.329 0 N-CA-C 108.001 -1.111 . . . . 2.0600000000000001 108.001 179.449 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.413 ' O ' ' OE1' ' A' ' 94' ' ' GLU . 84.7 t80 -82.15 100.29 9.73 Favored 'General case' 0 C--N 1.3 -1.569 0 C-N-CA 118.347 -1.341 . . . . 1.45 107.927 179.041 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . 0.479 ' N ' ' O ' ' A' ' 50' ' ' GLY . 0.3 OUTLIER 71.42 36.48 1.31 Allowed 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.25 -0.906 . . . . 2.7200000000000002 109.158 -178.665 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . 0.438 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 1.8 m-20 79.6 12.9 1.11 Allowed 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.703 -0.623 . . . . 1.9199999999999999 111.903 179.232 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . 0.483 ' OE2' ' CA ' ' A' ' 17' ' ' GLY . 5.2 pt-20 -99.98 96.59 7.64 Favored 'General case' 0 N--CA 1.498 1.97 0 N-CA-C 106.958 -1.497 . . . . 2.5499999999999998 106.958 177.617 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . 0.513 ' ND1' ' O ' ' A' ' 95' ' ' HIS . 0.0 OUTLIER -70.44 111.37 5.94 Favored 'General case' 0 N--CA 1.488 1.452 0 CA-C-O 121.595 0.712 . . . . 3.2000000000000002 110.884 -177.577 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . 0.479 ' O ' ' N ' ' A' ' 98' ' ' ASP . 32.4 mt -57.66 137.39 82.54 Favored Pre-proline 0 C--N 1.3 -1.557 0 N-CA-C 107.826 -1.176 . . . . 2.8199999999999998 107.826 178.651 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_exo -42.91 -21.75 0.23 Allowed 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 120.823 1.015 . . . . 2.6299999999999999 110.184 -179.694 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.479 ' N ' ' O ' ' A' ' 96' ' ' ILE . 87.2 m-20 -67.58 -68.08 0.41 Allowed 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 108.478 -0.934 . . . . 2.6499999999999999 108.478 178.266 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' SER . . . . . 0.49 ' H ' ' HG ' ' A' ' 99' ' ' SER . 0.3 OUTLIER -60.65 143.65 90.3 Favored Pre-proline 0 C--N 1.295 -1.762 0 O-C-N 121.595 -0.69 . . . . 2.3199999999999998 109.901 -178.389 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -84.41 112.62 2.6 Favored 'Cis proline' 0 N--CA 1.491 1.337 0 N-CA-C 109.456 -1.017 . . . . 1.9399999999999999 109.456 -2.318 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 53.6 p90 -112.11 161.96 15.95 Favored 'General case' 0 N--CA 1.517 2.887 0 O-C-N 120.543 -1.348 . . . . 2.6299999999999999 110.196 179.107 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.2 p -93.66 154.42 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.528 -0.732 . . . . 1.8200000000000001 110.928 -178.421 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.473 ' N ' ' O ' ' A' ' 85' ' ' TYR . 64.4 t -128.65 86.96 56.23 Favored Pre-proline 0 N--CA 1.498 1.934 0 N-CA-C 108.233 -1.025 . . . . 1.73 108.233 179.41 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 4.1 Cg_exo -63.54 113.12 1.97 Allowed 'Trans proline' 0 C--N 1.319 -1.008 0 C-N-CA 121.333 1.355 . . . . 1.6100000000000001 111.963 -178.081 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 53.4 t -96.17 143.76 11.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 N-CA-C 106.713 -1.588 . . . . 1.7 106.713 177.862 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -136.65 133.63 36.43 Favored 'General case' 0 N--CA 1.51 2.539 0 O-C-N 121.14 -0.975 . . . . 2.04 111.863 -177.3 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' SER . . . . . 0.526 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 38.7 p -85.27 63.73 8.26 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.796 -1.19 . . . . 2.2999999999999998 107.819 179.12 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . 0.485 ' CB ' ' O ' ' A' ' 107' ' ' SER . 2.8 tp 79.9 -14.89 0.8 Allowed 'General case' 0 C--N 1.298 -1.648 0 N-CA-C 106.927 -1.509 . . . . 3.6000000000000001 106.927 -177.991 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.611 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 21.7 t -66.89 -23.46 66.0 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 108.762 -0.829 . . . . 2.4900000000000002 108.762 178.769 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . 0.418 ' O ' ' OD2' ' A' ' 111' ' ' ASP . 42.9 m-20 52.71 12.04 0.23 Allowed 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 108.079 -1.082 . . . . 2.8500000000000001 108.079 -179.46 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.526 ' H ' ' C ' ' A' ' 109' ' ' SER . 4.5 m-20 -167.04 -30.43 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 108.663 -0.865 . . . . 2.46 108.663 -179.671 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.611 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 54.89 81.09 0.11 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.005 -1.059 . . . . 2.0800000000000001 109.415 -179.898 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.481 ' HG2' HH11 ' A' ' 113' ' ' ARG . 5.1 mtt-85 -65.17 -167.94 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.218 -0.927 . . . . 6.54 109.23 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 33.8 ttm180 -139.62 4.39 2.14 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.4 -0.813 . . . . 6.2400000000000002 108.89 -179.597 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 32.3 mt -126.56 -27.57 3.12 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.607 -0.683 . . . . 4.71 109.216 179.799 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.565 ' C ' ' H ' ' A' ' 118' ' ' THR . 58.8 m -106.85 -75.62 0.63 Allowed 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 107.347 -1.353 . . . . 4.3499999999999996 107.347 179.152 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.43 ' O ' ' C ' ' A' ' 118' ' ' THR . 47.9 t -65.11 -3.64 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 N-CA-C 106.201 -1.777 . . . . 3.3100000000000001 106.201 176.981 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' THR . . . . . 0.565 ' H ' ' C ' ' A' ' 116' ' ' THR . 6.7 t 29.54 69.39 0.08 Allowed 'General case' 0 N--CA 1.489 1.489 0 CA-C-O 122.277 1.037 . . . . 3.73 111.064 -179.698 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' SER . . . . . 0.405 ' O ' ' O ' ' A' ' 118' ' ' THR . 0.5 OUTLIER . . . . . 0 C--N 1.302 -1.462 0 CA-C-O 117.996 -1.002 . . . . 3.8300000000000001 109.502 179.564 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 19.2 ttt . . . . . 0 N--CA 1.489 1.51 0 CA-C-O 121.244 0.545 . . . . 8.8699999999999992 109.606 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -158.27 143.22 16.39 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.224 -0.923 . . . . 5.9299999999999997 109.625 -179.821 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 3' ' ' SER . . . . . . . . . . . . . 9.5 p -66.19 81.25 0.08 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.268 -0.895 . . . . 5.5700000000000003 109.211 179.84 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 4' ' ' LYS . . . . . . . . . . . . . 14.0 pttt -75.45 154.26 85.83 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.263 -0.898 . . . . 7.25 109.051 -179.745 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 5' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_exo -54.6 -175.38 0.03 OUTLIER 'Trans proline' 0 C--N 1.323 -0.8 0 C-N-CA 121.111 1.207 . . . . 5.8899999999999997 109.745 179.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 6' ' ' GLU . . . . . . . . . . . . . 30.7 tt0 -151.34 129.56 11.95 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.275 -0.89 . . . . 4.7800000000000002 109.355 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 9.2 ptmm? -57.87 139.93 53.08 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.292 -0.88 . . . . 4.5599999999999996 109.425 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . 0.409 ' NH2' ' OE2' ' A' ' 86' ' ' GLU . 18.2 mtm-85 -96.43 167.59 11.07 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 108.129 -1.063 . . . . 3.6699999999999999 108.129 179.547 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 9' ' ' VAL . . . . . . . . . . . . . 20.4 t -52.96 159.54 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 120.916 -1.115 . . . . 1.3899999999999999 108.21 179.617 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -120.64 149.11 42.99 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.404 -0.81 . . . . 1.22 110.422 -178.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 7.4 t -143.2 142.69 31.5 Favored 'General case' 0 N--CA 1.495 1.785 0 N-CA-C 108.814 -0.81 . . . . 1.6299999999999999 108.814 179.365 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 23.6 p -145.38 127.92 16.05 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.987 -1.07 . . . . 1.8799999999999999 110.121 -179.639 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . 0.466 ' CG2' ' N ' ' B' ' 14' ' ' PHE . 7.2 p -172.44 171.46 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 N-CA-C 108.826 -0.805 . . . . 1.2 108.826 179.69 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 14' ' ' PHE . . . . . 0.531 ' HB3' ' H ' ' A' ' 53' ' ' ILE . 6.8 p90 -177.48 -167.95 0.17 Allowed 'General case' 0 N--CA 1.489 1.522 0 CA-C-O 122.234 1.016 . . . . 2.3900000000000001 112.282 179.793 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.8 pt -148.95 172.64 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.29 0 N-CA-C 107.897 -1.149 . . . . 1.8100000000000001 107.897 179.709 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 2.4 t -146.6 148.44 32.12 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 120.756 -1.215 . . . . 2.04 110.195 -179.842 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.2 mt -101.17 127.28 47.8 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.51 -0.744 . . . . 1.8700000000000001 109.146 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -156.96 74.54 4.47 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.317 -0.864 . . . . 1.47 109.224 -179.685 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -62.44 166.93 12.19 Favored 'Trans proline' 0 C--N 1.318 -1.049 0 C-N-CA 121.269 1.313 . . . . 1.96 109.747 -179.264 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 20' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -58.46 150.21 69.78 Favored 'Trans proline' 0 C--N 1.318 -1.053 0 C-N-CA 121.517 1.478 . . . . 3.3799999999999999 109.917 179.834 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . 0.4 ' HG2' HH11 ' B' ' 21' ' ' ARG . 0.3 OUTLIER -82.21 84.88 6.93 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.27 -0.894 . . . . 6.7400000000000002 108.693 179.782 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 22' ' ' ARG . . . . . 0.406 HH11 ' CG ' ' B' ' 22' ' ' ARG . 0.5 OUTLIER -46.88 -51.89 15.67 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.302 -0.874 . . . . 6.9400000000000004 109.707 -179.859 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 48.4 t0 52.61 -115.91 0.98 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.213 -0.929 . . . . 5.6200000000000001 109.471 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 35.9 m . . . . . 0 N--CA 1.49 1.552 0 CA-C-O 118.025 -0.988 . . . . 6.75 109.435 179.993 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.928 0 N-CA-C 119.763 2.665 . . . . 6.7300000000000004 119.763 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.679 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 1.5 mp -149.45 41.33 0.23 Allowed Pre-proline 0 C--N 1.311 -1.105 0 N-CA-C 107.751 -1.203 . . . . 7.3799999999999999 107.751 178.382 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.847 ' C ' ' H ' ' A' ' 5' ' ' PHE . 1.3 Cg_endo -54.63 -79.54 0.02 OUTLIER 'Trans proline' 0 C--N 1.32 -0.956 0 N-CA-C 108.449 -1.404 . . . . 5.5 108.449 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.544 ' C ' ' H ' ' A' ' 6' ' ' PHE . 6.6 tt0 73.56 -20.65 0.29 Allowed 'General case' 0 N--CA 1.496 1.832 0 N-CA-C 104.379 -2.452 . . . . 6.8399999999999999 104.379 -176.106 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . 0.847 ' H ' ' C ' ' A' ' 3' ' ' PRO . 5.7 m-85 -87.54 17.66 4.44 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 104.298 -2.482 . . . . 6.4400000000000004 104.298 176.718 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.544 ' H ' ' C ' ' A' ' 4' ' ' GLU . 38.7 p90 45.6 -153.15 0.05 OUTLIER 'General case' 0 C--N 1.308 -1.218 0 CA-C-N 114.513 -1.221 . . . . 5.0599999999999996 109.478 -177.684 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.443 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 0.1 OUTLIER 82.97 -9.8 1.07 Allowed 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 104.973 -2.232 . . . . 4.8099999999999996 104.973 -177.221 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.524 ' H ' ' C ' ' A' ' 6' ' ' PHE . 68.8 t80 -150.24 -37.59 0.15 Allowed 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 107.858 -1.164 . . . . 5.7300000000000004 107.858 178.226 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 38.2 m -93.63 3.26 55.78 Favored 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 105.731 -1.951 . . . . 5.3499999999999996 105.731 177.256 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.438 ' CG1' ' N ' ' A' ' 11' ' ' GLY . 13.0 p -46.44 -45.34 6.57 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.31 0 CA-C-N 115.508 -0.769 . . . . 4.3799999999999999 109.32 -179.555 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.589 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 135.7 -84.65 0.26 Allowed Glycine 0 N--CA 1.497 2.746 0 N-CA-C 108.92 -1.672 . . . . 4.4800000000000004 108.92 179.616 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.431 ' O ' ' N ' ' A' ' 14' ' ' GLY . 13.3 Cg_endo -69.05 35.8 0.2 Allowed 'Trans proline' 0 C--N 1.321 -0.883 0 C-N-CA 121.587 1.525 . . . . 4.0499999999999998 109.178 178.538 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.603 ' CD2' ' N ' ' A' ' 13' ' ' LEU . 0.0 OUTLIER 42.36 27.48 0.08 Allowed 'General case' 0 N--CA 1.501 2.109 0 N-CA-C 108.596 -0.89 . . . . 4.0599999999999996 108.596 -178.731 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.565 ' C ' ' H ' ' A' ' 16' ' ' GLY . . . 71.95 -42.6 0.76 Allowed Glycine 0 N--CA 1.488 2.157 0 N-CA-C 108.622 -1.791 . . . . 3.1400000000000001 108.622 -179.386 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.522 ' H ' ' C ' ' A' ' 13' ' ' LEU . 18.6 tp10 52.2 7.49 0.06 Allowed 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.579 -0.954 . . . . 3.1699999999999999 109.237 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.565 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 55.99 118.29 0.01 OUTLIER Glycine 0 N--CA 1.489 2.217 0 O-C-N 121.3 -0.875 . . . . 2.4399999999999999 111.605 178.899 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.523 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 74.05 -56.06 2.27 Favored Glycine 0 N--CA 1.493 2.451 0 N-CA-C 110.487 -1.045 . . . . 2.0499999999999998 110.487 178.614 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.484 ' CB ' ' OE1' ' A' ' 94' ' ' GLU . . . -49.82 -9.22 0.04 OUTLIER 'General case' 0 C--N 1.294 -1.828 0 O-C-N 121.243 -1.151 . . . . 2.54 109.6 -179.624 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . 0.523 ' N ' ' O ' ' A' ' 17' ' ' GLY . 15.2 t-80 -94.91 -8.9 35.79 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.085 -1.009 . . . . 3.3700000000000001 110.475 -179.456 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.544 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.0 OUTLIER -134.24 1.79 3.24 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.078 -1.014 . . . . 2.3700000000000001 110.2 -179.685 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 68.7 t -88.07 113.43 25.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 120.92 -1.113 . . . . 2.5800000000000001 109.637 179.767 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 6.2 tpt180 -97.8 132.9 42.99 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.577 -0.702 . . . . 3.8900000000000001 109.126 179.808 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -139.28 113.92 9.18 Favored 'General case' 0 N--CA 1.494 1.751 0 N-CA-C 108.582 -0.896 . . . . 2.0099999999999998 108.582 179.771 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -156.64 129.22 2.37 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.849 -1.3 . . . . 2.0099999999999998 109.849 -179.448 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.94 -179.82 48.73 Favored Glycine 0 N--CA 1.488 2.127 0 C-N-CA 119.512 -1.328 . . . . 1.9299999999999999 110.052 179.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 10.9 p -80.61 -15.96 55.29 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.397 -1.061 . . . . 2.6899999999999999 109.451 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -76.89 -8.42 86.64 Favored Glycine 0 N--CA 1.487 2.074 0 N-CA-C 109.532 -1.427 . . . . 1.6399999999999999 109.532 -179.733 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 28.5 mt -100.26 -0.67 38.12 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.373 -1.075 . . . . 2.0299999999999998 109.076 179.692 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -102.18 -44.56 5.4 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.519 -0.738 . . . . 2.3399999999999999 109.565 -179.681 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 18.1 ptt180 -176.81 172.58 2.05 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.006 -1.059 . . . . 4.25 110.119 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -143.45 174.72 23.84 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 107.842 -2.103 . . . . 1.5900000000000001 107.842 179.272 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 35.2 t -134.05 149.79 30.7 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.092 0 O-C-N 121.1 -1.235 . . . . 2.21 110.375 -179.842 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -41.47 114.17 0.48 Allowed 'General case' 0 N--CA 1.498 1.933 0 CA-C-O 121.804 0.812 . . . . 2.0699999999999998 112.593 -179.128 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 57.18 47.3 88.74 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 111.552 -0.619 . . . . 1.73 111.552 176.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 25.5 t -127.23 113.53 21.54 Favored Pre-proline 0 N--CA 1.498 1.966 0 O-C-N 121.458 -1.024 . . . . 2.6499999999999999 108.756 179.116 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -59.93 126.51 20.57 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 N-CA-C 109.944 -0.829 . . . . 2.1400000000000001 109.944 -179.756 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -127.58 174.56 8.96 Favored 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 108.182 -1.044 . . . . 2.0299999999999998 108.182 179.597 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -163.09 171.28 16.63 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.838 -1.164 . . . . 2.23 110.961 -179.789 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.41 ' N ' ' CD1' ' A' ' 39' ' ' PHE . 5.8 p90 -155.9 167.75 29.4 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 107.707 -1.22 . . . . 1.72 107.707 178.568 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 14.6 m -101.67 150.14 23.42 Favored 'General case' 0 N--CA 1.495 1.821 0 CA-C-O 121.803 0.811 . . . . 2.5800000000000001 111.147 -178.1 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 11.8 mt -141.12 88.55 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 N-CA-C 108.436 -0.95 . . . . 1.8600000000000001 108.436 178.774 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.422 ' HE1' ' CG ' ' A' ' 44' ' ' ARG . 5.6 t90 -90.77 132.99 35.52 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.105 -0.997 . . . . 4.4699999999999998 108.788 -179.804 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' THR . . . . . 0.544 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.8 OUTLIER -160.94 128.53 4.28 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.22 -0.925 . . . . 3.27 109.949 -179.436 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' ARG . . . . . 0.422 ' CG ' ' HE1' ' A' ' 42' ' ' TRP . 1.8 ptp180 -178.39 77.27 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.278 -0.889 . . . . 5.2300000000000004 109.612 179.6 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 26.0 tt0 -158.6 -52.32 0.06 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.187 -0.946 . . . . 2.8900000000000001 109.498 179.796 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -60.79 -49.99 75.24 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.04 -1.038 . . . . 1.99 109.008 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 148.85 160.92 9.36 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.448 -1.461 . . . . 1.6499999999999999 109.448 179.807 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.79 161.23 1.18 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.196 -1.179 . . . . 1.77 109.386 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -174.42 -128.88 1.12 Allowed Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.827 -1.309 . . . . 1.1200000000000001 109.827 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -157.69 126.22 1.69 Allowed Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.58 -1.408 . . . . 1.1799999999999999 109.58 -179.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 11.7 tp -97.97 100.53 11.87 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.294 -1.121 . . . . 1.5900000000000001 109.078 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 2.0 t -88.36 142.72 27.5 Favored 'General case' 0 C--O 1.211 -0.947 0 N-CA-C 108.667 -0.864 . . . . 1.9399999999999999 108.667 179.89 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.506 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 93.5 mt -134.08 106.97 9.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 O-C-N 121.025 -1.047 . . . . 1.3 109.764 -179.568 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -96.34 106.06 18.23 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.315 -0.995 . . . . 1.27 108.315 179.183 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -94.52 144.57 9.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.421 -0.799 . . . . 1.55 109.676 -179.445 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 16.6 tt0 -141.1 145.16 35.44 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 107.529 -1.286 . . . . 1.8 107.529 178.738 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.428 ' O ' ' O ' ' B' ' 9' ' ' VAL . . . 163.14 -171.08 38.81 Favored Glycine 0 N--CA 1.489 2.196 0 C-N-CA 119.554 -1.308 . . . . 0.56000000000000005 109.854 -179.065 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -62.68 -29.85 77.96 Favored 'Trans proline' 0 C--N 1.318 -1.063 0 C-N-CA 122.224 1.949 . . . . 0.76000000000000001 112.386 -179.289 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 8.7 t -142.36 160.0 41.12 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 120.891 -1.131 . . . . 2.02 110.138 -179.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 80.5 mttt -78.33 109.53 12.55 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.498 -0.751 . . . . 3.02 109.204 179.796 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -76.46 142.37 41.01 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.258 -0.902 . . . . 1.3600000000000001 109.588 -179.829 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.402 ' H ' HG12 ' A' ' 78' ' ' VAL . 20.6 tt0 -81.39 172.62 13.33 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.319 -0.863 . . . . 2.2999999999999998 108.78 179.778 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 3.2 mp -140.17 154.4 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 N-CA-C 108.309 -0.997 . . . . 2.0 108.309 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.55 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -151.07 114.88 4.95 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.758 -1.214 . . . . 1.73 109.538 -179.845 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.528 ' CD2' ' O ' ' A' ' 65' ' ' PHE . 44.0 p90 -93.55 120.21 33.55 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.19 -0.944 . . . . 1.6000000000000001 109.469 179.724 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 54.2 tt0 -141.51 103.22 4.35 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.234 -0.916 . . . . 2.5099999999999998 109.611 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . 0.431 ' N ' ' OD1' ' A' ' 67' ' ' ASP . 20.6 p-10 -85.39 102.61 13.57 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.238 -0.914 . . . . 2.0699999999999998 109.149 179.696 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 2.5 ptp180 -101.46 5.96 42.21 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.335 -0.853 . . . . 5.29 109.537 -179.725 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 64.5 mmtt -118.25 -3.24 11.04 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.42 -0.8 . . . . 3.8599999999999999 109.095 179.581 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 4.7 t70 68.56 3.3 3.77 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.351 -0.843 . . . . 3.0600000000000001 109.406 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -150.61 -34.34 0.04 OUTLIER Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.919 -1.272 . . . . 2.1600000000000001 109.919 -178.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.8 m -95.39 125.36 39.95 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.235 -1.156 . . . . 2.5600000000000001 108.85 179.58 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 15.1 t -88.02 126.63 35.18 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.151 -0.968 . . . . 2.3599999999999999 109.773 -179.521 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -105.13 118.34 5.84 Favored Glycine 0 N--CA 1.498 2.831 0 N-CA-C 109.576 -1.41 . . . . 1.46 109.576 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 21.9 t -105.88 106.08 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.141 0 O-C-N 121.476 -1.014 . . . . 2.1600000000000001 109.423 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.55 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.3 OUTLIER -96.17 139.21 32.66 Favored 'General case' 0 N--CA 1.493 1.676 0 N-CA-C 108.988 -0.745 . . . . 2.1600000000000001 108.988 179.828 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 41.9 p90 -138.07 173.3 11.77 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.294 -0.879 . . . . 1.7 109.262 -179.636 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.437 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 8.9 p -138.69 120.01 16.53 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.246 0 O-C-N 121.372 -0.83 . . . . 2.4500000000000002 109.969 179.56 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 5.7 m -89.57 163.08 2.43 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.387 -0.82 . . . . 1.8200000000000001 108.984 179.72 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 7.0 tp-100 -104.4 -47.6 4.06 Favored 'General case' 0 N--CA 1.501 2.077 0 O-C-N 121.199 -0.938 . . . . 3.1699999999999999 111.103 -178.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -156.52 153.27 24.49 Favored Pre-proline 0 N--CA 1.503 2.194 0 O-C-N 120.641 -1.287 . . . . 2.02 111.106 -178.799 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.588 ' HG3' ' N ' ' A' ' 107' ' ' SER . 73.0 Cg_exo -37.63 158.68 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 123.267 2.644 . . . . 1.3999999999999999 113.609 179.268 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 148.15 -163.45 28.9 Favored Glycine 0 N--CA 1.493 2.441 0 N-CA-C 109.662 -1.375 . . . . 1.0800000000000001 109.662 179.606 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 46.6 m-20 -110.66 88.63 2.82 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.615 -0.932 . . . . 2.1299999999999999 108.984 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . 0.508 ' O ' ' N ' ' A' ' 103' ' ' VAL . 2.8 m-85 -76.16 129.69 37.14 Favored 'General case' 0 C--N 1.303 -1.414 0 N-CA-C 107.998 -1.112 . . . . 1.1399999999999999 107.998 179.708 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -109.23 128.01 54.71 Favored 'General case' 0 N--CA 1.5 2.069 0 N-CA-C 108.35 -0.981 . . . . 1.53 108.35 -179.52 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 9.9 p -123.91 133.56 68.93 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.713 -0.617 . . . . 1.6399999999999999 109.767 -179.295 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 6.6 m -123.84 95.05 4.42 Favored 'General case' 0 N--CA 1.497 1.886 0 CA-C-O 121.393 0.616 . . . . 1.99 109.54 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.2 pt -101.26 134.48 41.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.643 -0.661 . . . . 1.77 109.797 -179.775 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . 0.468 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.1 OUTLIER -140.32 121.98 15.28 Favored 'General case' 0 N--CA 1.485 1.296 0 N-CA-C 108.712 -0.847 . . . . 2.0600000000000001 108.712 179.746 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 79.9 t80 -81.09 100.03 8.81 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 107.665 -1.235 . . . . 1.45 107.665 178.514 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . 0.438 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 26.8 t30 69.81 36.42 2.07 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.448 -0.782 . . . . 2.7200000000000002 109.362 -178.809 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . 0.438 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 0.7 OUTLIER 79.92 14.32 0.92 Allowed 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.688 -0.633 . . . . 1.9199999999999999 111.554 179.42 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . 0.484 ' OE1' ' CB ' ' A' ' 18' ' ' ALA . 0.5 OUTLIER -100.94 95.53 6.66 Favored 'General case' 0 N--CA 1.499 1.98 0 N-CA-C 107.239 -1.393 . . . . 2.5499999999999998 107.239 177.892 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . 0.53 ' O ' ' CD2' ' A' ' 95' ' ' HIS . 0.4 OUTLIER -66.58 110.55 3.22 Favored 'General case' 0 N--CA 1.488 1.466 0 CA-C-O 121.697 0.76 . . . . 3.2000000000000002 111.177 -177.773 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . 0.536 ' O ' ' N ' ' A' ' 98' ' ' ASP . 5.5 mm -50.61 137.22 24.34 Favored Pre-proline 0 N--CA 1.492 1.671 0 N-CA-C 107.621 -1.251 . . . . 2.8199999999999998 107.621 178.576 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -44.39 -16.75 0.12 Allowed 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 120.68 0.92 . . . . 2.6299999999999999 109.844 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 96' ' ' ILE . 42.9 m-20 -76.92 -66.56 0.8 Allowed 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 108.517 -0.92 . . . . 2.6499999999999999 108.517 178.277 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -57.34 144.02 72.09 Favored Pre-proline 0 C--N 1.297 -1.702 0 O-C-N 121.622 -0.674 . . . . 2.3199999999999998 109.801 -178.106 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -83.82 110.36 1.79 Allowed 'Cis proline' 0 N--CA 1.491 1.339 0 N-CA-C 109.71 -0.919 . . . . 1.9399999999999999 109.71 -2.129 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 47.3 p90 -108.87 166.98 10.41 Favored 'General case' 0 N--CA 1.515 2.794 0 O-C-N 120.51 -1.369 . . . . 2.6299999999999999 110.035 179.109 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.3 p -94.39 153.13 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.518 -0.739 . . . . 1.8200000000000001 110.758 -178.777 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.508 ' N ' ' O ' ' A' ' 85' ' ' TYR . 70.3 t -127.62 86.21 58.96 Favored Pre-proline 0 N--CA 1.499 1.986 0 N-CA-C 107.863 -1.162 . . . . 1.73 107.863 179.395 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -62.4 113.45 1.93 Allowed 'Trans proline' 0 C--N 1.318 -1.036 0 C-N-CA 121.288 1.325 . . . . 1.6100000000000001 111.979 -177.82 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 42.7 t -90.4 141.68 14.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 N-CA-C 106.88 -1.526 . . . . 1.7 106.88 177.766 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.405 ' CB ' ' N ' ' A' ' 110' ' ' ASP . . . -121.65 127.67 51.06 Favored 'General case' 0 N--CA 1.505 2.322 0 CA-C-O 121.664 0.745 . . . . 2.04 111.607 -177.033 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' SER . . . . . 0.588 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 7.8 t -88.69 77.76 7.84 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 120.365 -1.459 . . . . 2.2999999999999998 107.484 178.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . 0.442 ' CB ' ' O ' ' A' ' 107' ' ' SER . 0.9 OUTLIER 72.66 -7.81 1.35 Allowed 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 107.307 -1.368 . . . . 3.6000000000000001 107.307 -178.288 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.547 ' H ' ' C ' ' A' ' 107' ' ' SER . 3.0 m -78.11 -21.59 50.18 Favored 'General case' 0 N--CA 1.486 1.335 0 N-CA-C 108.602 -0.888 . . . . 2.4900000000000002 108.602 178.993 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . 0.405 ' N ' ' CB ' ' A' ' 106' ' ' ALA . 1.4 m-20 50.93 10.42 0.07 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.359 -0.838 . . . . 2.8500000000000001 109.23 179.353 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.508 ' H ' ' C ' ' A' ' 109' ' ' SER . 0.8 OUTLIER -177.99 -21.47 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.482 -0.761 . . . . 2.46 110.438 -179.85 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.433 ' O ' ' O ' ' A' ' 113' ' ' ARG . . . 51.56 75.23 0.21 Allowed 'General case' 0 N--CA 1.496 1.871 0 O-C-N 120.373 -1.454 . . . . 2.0800000000000001 108.631 -179.311 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.433 ' O ' ' O ' ' A' ' 112' ' ' ALA . 1.0 OUTLIER -53.26 -170.72 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.374 -0.829 . . . . 6.54 110.04 -178.909 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.486 ' HG2' HH11 ' A' ' 114' ' ' ARG . 2.4 ttt-85 -132.36 2.52 3.87 Favored 'General case' 0 N--CA 1.492 1.659 0 N-CA-C 107.86 -1.163 . . . . 6.2400000000000002 107.86 179.514 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 34.8 mt -128.49 -27.71 2.61 Favored 'General case' 0 N--CA 1.501 2.082 0 N-CA-C 109.188 -0.671 . . . . 4.71 109.188 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.545 ' C ' ' H ' ' A' ' 118' ' ' THR . 1.1 p -103.27 -80.37 0.52 Allowed 'General case' 0 N--CA 1.492 1.636 0 N-CA-C 106.859 -1.534 . . . . 4.3499999999999996 106.859 179.082 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 56.0 t -61.19 -8.81 2.19 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.718 0 N-CA-C 106.156 -1.794 . . . . 3.3100000000000001 106.156 176.858 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' THR . . . . . 0.545 ' H ' ' C ' ' A' ' 116' ' ' THR . 4.5 t 36.54 61.01 0.87 Allowed 'General case' 0 N--CA 1.487 1.387 0 CA-C-O 122.019 0.914 . . . . 3.73 110.775 179.656 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' SER . . . . . 0.443 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.6 p . . . . . 0 C--N 1.303 -1.436 0 CA-C-O 117.954 -1.022 . . . . 3.8300000000000001 109.577 179.349 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 21.7 mmt . . . . . 0 N--CA 1.49 1.57 0 N-CA-C 109.523 -0.547 . . . . 8.8699999999999992 109.523 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -58.37 120.96 9.69 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.315 -0.866 . . . . 5.9299999999999997 109.52 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 3' ' ' SER . . . . . . . . . . . . . 51.3 m -160.59 -52.17 0.05 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.233 -0.917 . . . . 5.5700000000000003 109.412 179.858 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 4' ' ' LYS . . . . . . . . . . . . . 16.7 pttm -173.83 66.71 0.32 Allowed Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.21 -0.931 . . . . 7.25 109.756 179.885 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 5' ' ' PRO . . . . . . . . . . . . . 2.3 Cg_endo -61.99 100.12 0.2 Allowed 'Trans proline' 0 C--N 1.318 -1.041 0 C-N-CA 121.315 1.344 . . . . 5.8899999999999997 109.658 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 6' ' ' GLU . . . . . 0.443 ' O ' ' C ' ' B' ' 7' ' ' LYS . 19.1 mt-10 -84.31 -153.46 0.15 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.307 -0.871 . . . . 4.7800000000000002 109.935 -179.685 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 7' ' ' LYS . . . . . 0.443 ' C ' ' O ' ' B' ' 6' ' ' GLU . 13.4 pttm 31.86 79.36 0.03 OUTLIER 'General case' 0 N--CA 1.501 2.087 0 CA-C-O 121.268 0.556 . . . . 4.5599999999999996 111.433 179.836 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . 0.516 HH11 ' CG ' ' B' ' 8' ' ' ARG . 2.2 mtt-85 -86.78 157.95 19.49 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.003 -1.11 . . . . 3.6699999999999999 108.003 178.897 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 9' ' ' VAL . . . . . 0.428 ' O ' ' O ' ' A' ' 57' ' ' GLY . 22.9 t -48.3 159.3 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.021 -1.049 . . . . 1.3899999999999999 108.671 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -123.89 153.74 40.69 Favored 'General case' 0 N--CA 1.501 2.111 0 O-C-N 121.369 -0.832 . . . . 1.22 110.257 -178.89 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 2.7 t -148.66 147.12 28.56 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.498 -0.751 . . . . 1.6299999999999999 109.235 179.773 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 28.5 p -145.89 126.77 14.47 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.164 -0.96 . . . . 1.8799999999999999 110.064 -179.628 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . 0.489 ' C ' ' CG ' ' B' ' 14' ' ' PHE . 7.2 p -172.18 174.8 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 N-CA-C 108.497 -0.927 . . . . 1.2 108.497 179.731 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 14' ' ' PHE . . . . . 0.506 ' HB3' ' H ' ' A' ' 53' ' ' ILE . 0.1 OUTLIER 174.41 -166.23 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.563 0 C-N-CA 118.779 -1.168 . . . . 2.3900000000000001 111.864 -179.979 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 5.8 pt -137.58 139.49 43.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 N-CA-C 108.981 -0.748 . . . . 1.8100000000000001 108.981 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 80.7 p -94.26 131.19 40.12 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.101 -0.999 . . . . 2.04 109.785 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . 0.516 ' CD2' ' N ' ' B' ' 17' ' ' LEU . 3.5 mm? -92.98 107.31 19.12 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.294 -0.879 . . . . 1.8700000000000001 108.891 179.615 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -155.45 89.1 3.01 Favored Pre-proline 0 N--CA 1.492 1.667 0 O-C-N 121.34 -0.85 . . . . 1.47 109.227 -179.49 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -59.38 166.49 7.56 Favored 'Trans proline' 0 CA--C 1.543 0.974 0 C-N-CA 120.954 1.103 . . . . 1.96 109.83 -179.176 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 20' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -59.67 -80.49 0.01 OUTLIER 'Trans proline' 0 C--N 1.319 -0.975 0 C-N-CA 121.56 1.506 . . . . 3.3799999999999999 110.303 -179.72 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -59.28 166.95 1.99 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.194 -0.941 . . . . 6.7400000000000002 109.846 -179.439 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 22' ' ' ARG . . . . . 0.421 HH11 ' HG3' ' B' ' 22' ' ' ARG . 15.2 mmm-85 -69.79 -122.51 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.416 -0.803 . . . . 6.9400000000000004 109.15 179.87 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . 0.521 ' CG ' ' H ' ' B' ' 24' ' ' VAL . 1.2 p-10 -144.74 -89.31 0.11 Allowed 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.02 -1.05 . . . . 5.6200000000000001 109.397 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . 0.521 ' H ' ' CG ' ' B' ' 23' ' ' ASP . 13.3 t . . . . . 0 N--CA 1.489 1.516 0 CA-C-O 118.002 -0.999 . . . . 6.75 109.485 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.531 4.99 0 N-CA-C 119.758 2.663 . . . . 6.7300000000000004 119.758 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.57 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 3.6 tp -171.36 49.98 0.13 Allowed Pre-proline 0 C--N 1.306 -1.314 0 O-C-N 121.336 -1.097 . . . . 7.3799999999999999 108.249 179.537 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.795 ' C ' ' H ' ' A' ' 5' ' ' PHE . 2.7 Cg_endo -51.74 -77.8 0.02 OUTLIER 'Trans proline' 0 C--N 1.319 -1.021 0 N-CA-C 109.02 -1.185 . . . . 5.5 109.02 179.488 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.54 ' C ' ' H ' ' A' ' 6' ' ' PHE . 0.3 OUTLIER 73.7 -16.23 0.52 Allowed 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 104.234 -2.506 . . . . 6.8399999999999999 104.234 -175.732 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . 0.795 ' H ' ' C ' ' A' ' 3' ' ' PRO . 3.3 m-85 -89.78 17.74 6.3 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 103.822 -2.659 . . . . 6.4400000000000004 103.822 176.817 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.54 ' H ' ' C ' ' A' ' 4' ' ' GLU . 42.8 p90 45.88 -155.76 0.04 OUTLIER 'General case' 0 C--N 1.306 -1.288 0 CA-C-N 114.17 -1.377 . . . . 5.0599999999999996 109.686 -177.677 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.522 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 5.1 tp-100 84.02 -8.74 1.0 Allowed 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 104.927 -2.249 . . . . 4.8099999999999996 104.927 -177.09 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.461 ' H ' ' C ' ' A' ' 6' ' ' PHE . 66.8 t80 -154.83 -37.01 0.09 Allowed 'General case' 0 C--N 1.304 -1.376 0 CA-C-N 114.512 -1.222 . . . . 5.7300000000000004 107.912 178.439 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.404 ' O ' ' C ' ' A' ' 10' ' ' VAL . 15.0 m -91.11 2.28 56.46 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 106.009 -1.849 . . . . 5.3499999999999996 106.009 177.355 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.404 ' C ' ' O ' ' A' ' 9' ' ' THR . 7.2 p -41.11 -37.6 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 CA-C-O 121.773 0.796 . . . . 4.3799999999999999 109.507 -179.828 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.58 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 144.93 -86.58 0.18 Allowed Glycine 0 N--CA 1.496 2.685 0 N-CA-C 109.0 -1.64 . . . . 4.4800000000000004 109.0 179.511 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.467 ' O ' ' N ' ' A' ' 14' ' ' GLY . 13.3 Cg_endo -68.93 36.18 0.2 Allowed 'Trans proline' 0 N--CA 1.482 0.82 0 C-N-CA 121.546 1.497 . . . . 4.0499999999999998 109.225 178.666 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.626 ' CD2' ' N ' ' A' ' 13' ' ' LEU . 0.0 OUTLIER 43.1 24.17 0.04 OUTLIER 'General case' 0 N--CA 1.5 2.028 0 CA-C-O 121.846 0.831 . . . . 4.0599999999999996 108.836 -178.823 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.507 ' O ' ' N ' ' A' ' 16' ' ' GLY . . . 69.94 -39.08 0.41 Allowed Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.273 -1.531 . . . . 3.1400000000000001 109.273 -179.831 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.561 ' H ' ' C ' ' A' ' 13' ' ' LEU . 24.7 tt0 47.77 15.08 0.05 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.352 -1.087 . . . . 3.1699999999999999 108.83 -179.394 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.507 ' N ' ' O ' ' A' ' 14' ' ' GLY . . . 65.76 115.19 0.01 OUTLIER Glycine 0 N--CA 1.487 2.047 0 N-CA-C 110.082 -1.207 . . . . 2.4399999999999999 110.082 179.695 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.567 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 91.88 -53.38 2.95 Favored Glycine 0 N--CA 1.494 2.542 0 N-CA-C 110.213 -1.155 . . . . 2.0499999999999998 110.213 179.444 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.45 ' N ' ' HG2' ' A' ' 94' ' ' GLU . . . -41.49 -18.22 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.84 -0.8 . . . . 2.54 110.463 -178.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . 0.567 ' N ' ' O ' ' A' ' 17' ' ' GLY . 11.0 t60 -85.39 -40.69 16.19 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.281 -0.887 . . . . 3.3700000000000001 109.99 -179.456 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.78 -29.04 12.85 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.099 -1.001 . . . . 2.3700000000000001 110.584 -179.173 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 84.0 t -51.58 112.1 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.004 -1.06 . . . . 2.5800000000000001 109.869 -179.608 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 3.9 tpt180 -119.15 136.43 54.18 Favored 'General case' 0 N--CA 1.495 1.792 0 N-CA-C 109.284 -0.635 . . . . 3.8900000000000001 109.284 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -144.58 113.87 7.01 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.461 -0.775 . . . . 2.0099999999999998 108.933 179.677 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -149.25 123.83 1.69 Allowed Glycine 0 N--CA 1.495 2.586 0 N-CA-C 110.137 -1.185 . . . . 2.0099999999999998 110.137 -179.424 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.81 177.77 48.27 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.904 -1.279 . . . . 1.9299999999999999 109.904 179.567 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 11.0 m -76.81 -12.62 60.0 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.291 -1.123 . . . . 2.6899999999999999 109.958 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -67.68 -16.68 68.16 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 108.417 -1.873 . . . . 1.6399999999999999 108.417 179.599 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 18.1 mt -92.92 -10.31 36.96 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.783 -0.833 . . . . 2.0299999999999998 109.022 179.722 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 47.3 mm-40 -83.61 -55.23 4.4 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.491 -0.755 . . . . 2.3399999999999999 110.056 -179.264 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 4.9 ptp180 -176.36 -177.59 0.87 Allowed 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.036 -1.04 . . . . 4.25 109.879 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -145.13 174.53 25.14 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 108.649 -1.78 . . . . 1.5900000000000001 108.649 179.664 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 30.3 t -134.39 149.73 30.18 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.947 0 O-C-N 121.285 -1.126 . . . . 2.21 110.159 -179.779 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -40.5 112.19 0.26 Allowed 'General case' 0 N--CA 1.496 1.83 0 CA-C-O 121.499 0.666 . . . . 2.0699999999999998 112.515 -178.887 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 58.82 47.16 91.9 Favored Glycine 0 N--CA 1.492 2.391 0 O-C-N 121.514 -0.741 . . . . 1.73 111.569 177.117 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 23.6 t -127.45 124.84 23.74 Favored Pre-proline 0 N--CA 1.499 1.988 0 O-C-N 121.417 -1.049 . . . . 2.6499999999999999 108.417 179.031 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_exo -58.39 114.77 2.13 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 N-CA-C 109.99 -0.811 . . . . 2.1400000000000001 109.99 -179.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -107.64 155.45 20.14 Favored 'General case' 0 N--CA 1.495 1.789 0 N-CA-C 107.803 -1.184 . . . . 2.0299999999999998 107.803 179.176 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -164.51 169.85 16.63 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 118.431 -1.308 . . . . 2.23 111.41 -179.405 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.45 ' N ' ' CD1' ' A' ' 39' ' ' PHE . 4.6 p90 -154.66 171.03 20.16 Favored 'General case' 0 C--N 1.298 -1.669 0 N-CA-C 107.705 -1.22 . . . . 1.72 107.705 178.008 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 83.6 p -100.59 150.99 22.13 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.575 -0.703 . . . . 2.5800000000000001 110.599 -178.389 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 11.6 mt -143.6 104.71 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 N-CA-C 108.712 -0.847 . . . . 1.8600000000000001 108.712 178.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.526 ' CG ' ' N ' ' A' ' 43' ' ' THR . 0.7 OUTLIER -102.62 166.45 10.5 Favored 'General case' 0 N--CA 1.497 1.911 0 N-CA-C 108.33 -0.989 . . . . 4.4699999999999998 108.33 179.854 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' THR . . . . . 0.526 ' N ' ' CG ' ' A' ' 42' ' ' TRP . 35.0 p -153.6 131.49 11.68 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.146 -0.971 . . . . 3.27 109.827 -179.616 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' ARG . . . . . . . . . . . . . 32.5 ttm180 -72.58 -86.3 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.243 -0.91 . . . . 5.2300000000000004 109.43 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 24.9 tt0 -172.17 63.35 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.809 -1.182 . . . . 2.8900000000000001 110.935 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -71.24 -52.0 21.45 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 120.73 -1.231 . . . . 1.99 108.584 178.823 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 155.39 169.62 20.02 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.487 -1.445 . . . . 1.6499999999999999 109.487 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.8 143.98 19.53 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.215 -1.168 . . . . 1.77 109.371 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -163.72 -168.35 25.6 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.522 -1.431 . . . . 1.1200000000000001 109.522 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -137.68 117.37 1.48 Allowed Glycine 0 N--CA 1.496 2.666 0 N-CA-C 109.261 -1.536 . . . . 1.1799999999999999 109.261 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.423 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 9.7 tp -87.53 99.23 11.88 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.283 -1.128 . . . . 1.5900000000000001 108.597 179.758 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 12.8 m -84.01 141.13 31.42 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 108.834 -0.802 . . . . 1.9399999999999999 108.834 -179.887 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.492 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 72.6 mt -130.37 111.5 21.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.357 -0.839 . . . . 1.3 109.36 -179.891 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -100.85 106.98 18.41 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.374 -0.829 . . . . 1.27 108.938 179.724 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.428 ' O ' ' O ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -103.93 135.44 41.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 121.573 -0.704 . . . . 1.55 109.323 -179.771 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 27.3 tt0 -137.96 140.53 40.28 Favored 'General case' 0 N--CA 1.494 1.736 0 N-CA-C 108.024 -1.102 . . . . 1.8 108.024 179.092 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 168.47 -172.15 42.88 Favored Glycine 0 N--CA 1.487 2.092 0 N-CA-C 109.407 -1.477 . . . . 0.56000000000000005 109.407 -179.271 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -62.87 -30.9 77.8 Favored 'Trans proline' 0 C--N 1.316 -1.16 0 C-N-CA 121.873 1.715 . . . . 0.76000000000000001 111.584 -179.621 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.8 t -137.64 157.24 46.93 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.153 -0.967 . . . . 2.02 110.278 -179.488 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.436 ' O ' ' OE2' ' A' ' 62' ' ' GLU . 31.5 mtpt -80.65 123.37 28.11 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 109.09 -0.707 . . . . 3.02 109.09 179.728 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -85.79 144.29 27.82 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.162 -0.961 . . . . 1.3600000000000001 109.318 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.482 ' CD ' ' N ' ' A' ' 62' ' ' GLU . 9.0 mp0 -96.76 100.52 12.07 Favored 'General case' 0 N--CA 1.502 2.137 0 O-C-N 121.048 -1.032 . . . . 2.2999999999999998 110.619 -179.476 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 1.7 mp -62.51 156.12 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 N-CA-C 108.673 -0.862 . . . . 2.0 108.673 178.721 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.466 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -140.97 175.01 9.97 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.122 -0.987 . . . . 1.73 109.237 179.782 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.513 ' CD2' ' O ' ' A' ' 65' ' ' PHE . 32.3 p90 -147.08 116.25 6.94 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.317 -0.864 . . . . 1.6000000000000001 109.407 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 69.8 tt0 -141.38 127.6 19.72 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.287 -0.883 . . . . 2.5099999999999998 109.515 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . 0.468 ' N ' ' OD1' ' A' ' 67' ' ' ASP . 22.2 p-10 -81.69 120.1 24.67 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.263 -0.898 . . . . 2.0699999999999998 109.402 179.903 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.586 ' CG ' HH11 ' A' ' 68' ' ' ARG . 0.1 OUTLIER -100.09 -23.24 14.92 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.303 -0.873 . . . . 5.29 109.748 -179.828 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.55 ' C ' ' H ' ' A' ' 71' ' ' GLY . 23.3 mmtp -125.15 7.9 7.91 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.511 -0.743 . . . . 3.8599999999999999 109.283 -179.669 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.428 ' CB ' ' O ' ' A' ' 69' ' ' LYS . 1.5 t70 70.83 -12.68 0.54 Allowed 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.371 -0.831 . . . . 3.0600000000000001 108.797 -179.439 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . 0.55 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -127.01 -26.79 1.07 Allowed Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.406 -1.478 . . . . 2.1600000000000001 109.406 -179.341 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 28.9 t -95.58 134.37 38.53 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.237 -1.155 . . . . 2.5600000000000001 108.782 179.465 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 37.9 t -93.39 126.42 38.52 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.148 -0.97 . . . . 2.3599999999999999 109.644 -179.708 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -102.35 120.48 6.84 Favored Glycine 0 N--CA 1.497 2.755 0 N-CA-C 109.855 -1.298 . . . . 1.46 109.855 -179.795 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 41.3 t -104.59 119.34 53.35 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.959 0 O-C-N 121.464 -1.021 . . . . 2.1600000000000001 108.814 179.603 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.466 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.4 OUTLIER -113.39 124.35 52.23 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.69 -0.631 . . . . 2.1600000000000001 109.387 -179.836 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 51.7 p90 -122.97 131.62 53.79 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 108.358 -0.979 . . . . 1.7 108.358 179.316 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.471 ' CG1' ' OE1' ' A' ' 62' ' ' GLU . 8.9 p -106.63 117.54 52.61 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.243 0 O-C-N 121.293 -0.879 . . . . 2.4500000000000002 109.603 -179.378 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 1.2 m -90.07 161.8 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 O-C-N 121.282 -0.887 . . . . 1.8200000000000001 108.978 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 1.2 tp-100 -97.62 -51.33 4.15 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.122 -0.986 . . . . 3.1699999999999999 110.787 -179.158 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.429 ' O ' ' O ' ' A' ' 82' ' ' PRO . 77.2 mm-40 -145.47 150.31 43.66 Favored Pre-proline 0 N--CA 1.504 2.259 0 O-C-N 120.872 -1.142 . . . . 2.02 111.718 -178.125 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.545 ' HG3' ' N ' ' A' ' 107' ' ' SER . 88.7 Cg_exo -36.73 166.38 0.01 OUTLIER 'Trans proline' 0 C--O 1.216 -0.616 0 C-N-CA 123.142 2.561 . . . . 1.3999999999999999 113.381 178.391 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 142.7 -178.53 21.04 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.183 -1.567 . . . . 1.0800000000000001 109.183 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . 0.713 ' H ' ' NH1' ' B' ' 8' ' ' ARG . 31.7 m-20 -97.22 85.9 3.8 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 107.79 -1.189 . . . . 2.1299999999999999 107.79 179.213 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -70.16 132.54 45.96 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 108.128 -1.064 . . . . 1.1399999999999999 108.128 -179.502 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -105.36 115.67 30.65 Favored 'General case' 0 N--CA 1.496 1.872 0 N-CA-C 108.255 -1.017 . . . . 1.53 108.255 -179.067 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.4 p -115.83 143.03 26.73 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 O-C-N 121.604 -0.685 . . . . 1.6399999999999999 110.12 -179.29 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 2.9 m -138.87 97.06 3.24 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.507 -0.745 . . . . 1.99 109.588 179.661 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.1 pt -104.38 132.84 50.04 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 N-CA-C 109.332 -0.618 . . . . 1.77 109.332 -179.888 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.09 132.76 17.85 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.106 -0.996 . . . . 2.0600000000000001 109.855 -179.481 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 43.5 t80 -83.05 94.62 7.83 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.642 -1.286 . . . . 1.45 108.591 178.721 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . 0.479 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 38.7 t30 67.22 38.13 3.45 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.492 -0.929 . . . . 2.7200000000000002 108.492 -179.088 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . 0.479 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 0.6 OUTLIER 86.45 12.31 0.16 Allowed 'General case' 0 N--CA 1.503 2.181 0 CA-C-N 116.399 -0.364 . . . . 1.9199999999999999 111.467 179.629 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . 0.525 ' CG ' ' O ' ' A' ' 94' ' ' GLU . 0.0 OUTLIER -90.51 90.14 7.88 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 107.191 -1.411 . . . . 2.5499999999999998 107.191 177.984 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . 0.421 ' CD2' ' H ' ' A' ' 95' ' ' HIS . 9.7 p80 -72.19 98.13 2.09 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 119.759 -1.838 . . . . 3.2000000000000002 109.848 -179.142 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . 0.678 ' CD1' ' H ' ' A' ' 96' ' ' ILE . 0.0 OUTLIER -48.74 158.93 0.59 Allowed Pre-proline 0 N--CA 1.504 2.269 0 N-CA-C 107.31 -1.367 . . . . 2.8199999999999998 107.31 179.218 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -60.42 65.5 0.08 OUTLIER 'Trans proline' 0 N--CA 1.481 0.736 0 C-N-CA 121.504 1.469 . . . . 2.6299999999999999 109.469 -179.87 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.593 ' N ' ' O ' ' A' ' 96' ' ' ILE . 8.8 m-20 -164.9 -57.56 0.03 OUTLIER 'General case' 0 C--N 1.298 -1.634 0 N-CA-C 108.167 -1.049 . . . . 2.6499999999999999 108.167 -179.514 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' SER . . . . . 0.445 ' H ' ' HG ' ' A' ' 99' ' ' SER . 3.3 p -68.8 137.29 90.16 Favored Pre-proline 0 C--N 1.296 -1.755 0 C-N-CA 119.489 -0.884 . . . . 2.3199999999999998 109.754 -179.179 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 27.2 Cg_endo -89.54 119.87 4.28 Favored 'Cis proline' 0 N--CA 1.493 1.462 0 N-CA-C 110.017 -0.801 . . . . 1.9399999999999999 110.017 -2.644 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 30.4 p90 -124.55 166.42 16.09 Favored 'General case' 0 N--CA 1.516 2.844 0 O-C-N 120.571 -1.33 . . . . 2.6299999999999999 109.74 178.153 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.3 p -88.44 146.49 6.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.551 -0.718 . . . . 1.8200000000000001 110.521 -178.532 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 71.4 t -119.63 86.66 35.34 Favored Pre-proline 0 N--CA 1.495 1.803 0 N-CA-C 107.82 -1.178 . . . . 1.73 107.82 179.157 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -61.96 112.92 1.65 Allowed 'Trans proline' 0 C--N 1.322 -0.866 0 C-N-CA 121.423 1.416 . . . . 1.6100000000000001 112.121 -177.724 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 60.3 t -98.93 143.19 13.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 N-CA-C 106.15 -1.796 . . . . 1.7 106.15 177.719 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -136.48 135.15 38.36 Favored 'General case' 0 N--CA 1.51 2.56 0 O-C-N 120.972 -1.08 . . . . 2.04 112.089 -176.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' SER . . . . . 0.545 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 9.2 t -86.39 73.02 10.22 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 107.713 -1.218 . . . . 2.2999999999999998 107.713 179.158 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER 68.11 -1.26 1.83 Allowed 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 107.363 -1.347 . . . . 3.6000000000000001 107.363 -178.505 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.608 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 22.9 t -83.54 -21.96 32.55 Favored 'General case' 0 N--CA 1.486 1.344 0 N-CA-C 108.864 -0.791 . . . . 2.4900000000000002 108.864 179.249 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . 0.403 ' O ' ' CG ' ' A' ' 111' ' ' ASP . 1.8 m-20 52.34 12.23 0.22 Allowed 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 108.135 -1.061 . . . . 2.8500000000000001 108.135 -179.344 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.533 ' H ' ' C ' ' A' ' 109' ' ' SER . 5.0 m-20 -169.02 -29.26 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 108.877 -0.786 . . . . 2.46 108.877 -179.702 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.608 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 53.92 84.92 0.06 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.823 -1.173 . . . . 2.0800000000000001 109.429 -179.779 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.415 ' O ' ' O ' ' A' ' 112' ' ' ALA . 10.5 mpt_? -55.48 -169.36 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.208 -0.932 . . . . 6.54 109.19 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 9.8 tpt180 -138.34 2.0 2.24 Favored 'General case' 0 N--CA 1.495 1.78 0 N-CA-C 108.749 -0.834 . . . . 6.2400000000000002 108.749 -179.832 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 39.9 mt -129.36 -26.41 2.55 Favored 'General case' 0 N--CA 1.503 2.198 0 O-C-N 121.542 -0.723 . . . . 4.71 109.244 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.521 ' C ' ' H ' ' A' ' 118' ' ' THR . 1.3 p -103.89 -81.08 0.52 Allowed 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 106.857 -1.534 . . . . 4.3499999999999996 106.857 179.066 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 54.9 t -61.06 -8.87 2.1 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.63 0 N-CA-C 106.144 -1.798 . . . . 3.3100000000000001 106.144 176.826 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' THR . . . . . 0.521 ' H ' ' C ' ' A' ' 116' ' ' THR . 4.2 t 36.84 61.45 0.87 Allowed 'General case' 0 N--CA 1.486 1.375 0 CA-C-O 121.999 0.904 . . . . 3.73 110.742 179.913 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' SER . . . . . 0.468 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.6 p . . . . . 0 C--N 1.305 -1.365 0 CA-C-O 117.998 -1.001 . . . . 3.8300000000000001 109.635 179.291 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 28.1 ttt . . . . . 0 N--CA 1.49 1.554 0 N-CA-C 109.45 -0.574 . . . . 8.8699999999999992 109.45 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -56.69 -37.33 70.72 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.227 -0.921 . . . . 5.9299999999999997 109.432 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 3' ' ' SER . . . . . . . . . . . . . 40.5 m -160.69 28.96 0.15 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.226 -0.921 . . . . 5.5700000000000003 109.378 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 4' ' ' LYS . . . . . . . . . . . . . 27.3 tttp 56.28 67.32 2.86 Favored Pre-proline 0 N--CA 1.489 1.507 0 O-C-N 121.329 -0.857 . . . . 7.25 109.35 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 5' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_endo -61.77 -162.1 0.03 OUTLIER 'Trans proline' 0 C--N 1.318 -1.027 0 C-N-CA 121.475 1.45 . . . . 5.8899999999999997 110.1 -179.384 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 6' ' ' GLU . . . . . . . . . . . . . 53.9 mt-10 -150.84 56.57 0.91 Allowed 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.287 -0.883 . . . . 4.7800000000000002 109.326 -179.908 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 38.7 mttm 55.05 174.68 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.267 -0.896 . . . . 4.5599999999999996 109.695 179.806 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . 0.713 ' NH1' ' H ' ' A' ' 84' ' ' ASP . 5.6 mtt180 -88.37 173.63 8.62 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.277 -0.889 . . . . 3.6699999999999999 109.393 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 9' ' ' VAL . . . . . 0.408 ' CG1' ' N ' ' B' ' 10' ' ' ALA . 5.2 t -51.08 160.48 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 N-CA-C 108.226 -1.027 . . . . 1.3899999999999999 108.226 179.375 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . 0.408 ' N ' ' CG1' ' B' ' 9' ' ' VAL . . . -114.59 148.3 38.26 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.47 -0.768 . . . . 1.22 110.053 -179.158 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 11' ' ' SER . . . . . 0.428 ' O ' ' O ' ' A' ' 55' ' ' VAL . 31.3 t -150.02 133.06 16.2 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.517 -0.74 . . . . 1.6299999999999999 109.2 179.634 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 34.1 p -144.55 120.54 10.69 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.117 -0.989 . . . . 1.8799999999999999 109.809 -179.695 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . 0.484 ' CG2' ' N ' ' B' ' 14' ' ' PHE . 4.1 p -164.04 168.4 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.436 -0.79 . . . . 1.2 109.07 179.858 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 14' ' ' PHE . . . . . 0.492 ' HB3' ' H ' ' A' ' 53' ' ' ILE . 10.7 p90 -176.38 -165.58 0.14 Allowed 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 119.172 -1.011 . . . . 2.3900000000000001 112.265 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.7 pt -150.93 168.63 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.291 0 N-CA-C 108.598 -0.89 . . . . 1.8100000000000001 108.598 179.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 3.8 t -145.17 157.41 44.09 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 120.965 -1.084 . . . . 2.04 109.367 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -131.47 150.63 52.08 Favored 'General case' 0 N--CA 1.5 2.062 0 O-C-N 121.397 -0.815 . . . . 1.8700000000000001 109.533 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -150.89 81.13 6.43 Favored Pre-proline 0 N--CA 1.492 1.674 0 N-CA-C 108.726 -0.842 . . . . 1.47 108.726 -179.804 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . 0.439 ' O ' ' O ' ' B' ' 20' ' ' PRO . 5.5 Cg_exo -59.82 169.4 4.56 Favored 'Trans proline' 0 CA--C 1.545 1.042 0 C-N-CA 121.206 1.271 . . . . 1.96 109.977 -178.73 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 20' ' ' PRO . . . . . 0.439 ' O ' ' O ' ' B' ' 19' ' ' PRO . 3.9 Cg_exo -57.11 -146.81 0.0 OUTLIER 'Trans proline' 0 CA--C 1.542 0.91 0 C-N-CA 121.623 1.549 . . . . 3.3799999999999999 110.239 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 35.3 mtp180 61.91 65.95 0.87 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.211 -0.931 . . . . 6.7400000000000002 109.476 -179.813 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 22' ' ' ARG . . . . . 0.595 HH11 ' CG ' ' B' ' 22' ' ' ARG . 0.0 OUTLIER -169.89 -134.96 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.381 -0.824 . . . . 6.9400000000000004 109.323 179.837 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . 0.409 ' H ' ' CG ' ' B' ' 22' ' ' ARG . 62.5 m-20 -88.4 129.02 35.52 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.157 -0.964 . . . . 5.6200000000000001 109.447 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 39.3 t . . . . . 0 N--CA 1.49 1.533 0 CA-C-O 117.973 -1.013 . . . . 6.75 109.517 179.913 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.904 0 N-CA-C 119.879 2.712 . . . . 6.7300000000000004 119.879 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.627 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 1.1 pp -160.74 45.69 0.19 Allowed Pre-proline 0 C--N 1.308 -1.234 0 N-CA-C 107.767 -1.198 . . . . 7.3799999999999999 107.767 179.038 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.804 ' C ' ' H ' ' A' ' 5' ' ' PHE . 1.2 Cg_endo -53.81 -79.33 0.02 OUTLIER 'Trans proline' 0 C--N 1.32 -0.942 0 N-CA-C 108.904 -1.229 . . . . 5.5 108.904 179.774 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.53 ' C ' ' H ' ' A' ' 6' ' ' PHE . 9.4 tt0 73.18 -18.15 0.38 Allowed 'General case' 0 N--CA 1.495 1.783 0 N-CA-C 104.373 -2.454 . . . . 6.8399999999999999 104.373 -175.729 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . 0.804 ' H ' ' C ' ' A' ' 3' ' ' PRO . 4.6 m-85 -88.83 17.41 5.66 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 103.912 -2.625 . . . . 6.4400000000000004 103.912 176.654 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.535 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 39.6 p90 46.08 -153.49 0.05 Allowed 'General case' 0 C--N 1.308 -1.233 0 CA-C-N 114.308 -1.314 . . . . 5.0599999999999996 109.366 -177.553 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.523 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 16.8 tt0 82.89 -8.67 1.15 Allowed 'General case' 0 N--CA 1.49 1.543 0 N-CA-C 104.929 -2.248 . . . . 4.8099999999999996 104.929 -177.112 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.515 ' H ' ' C ' ' A' ' 6' ' ' PHE . 35.1 t80 -150.53 -38.19 0.14 Allowed 'General case' 0 C--N 1.307 -1.252 0 N-CA-C 107.761 -1.199 . . . . 5.7300000000000004 107.761 178.409 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 45.3 m -91.98 2.36 56.6 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 105.662 -1.977 . . . . 5.3499999999999996 105.662 177.147 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.1 p -46.37 -38.04 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.27 0 CA-C-N 115.268 -0.878 . . . . 4.3799999999999999 109.479 -179.641 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.609 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 140.23 -83.25 0.23 Allowed Glycine 0 N--CA 1.5 2.915 0 N-CA-C 108.58 -1.808 . . . . 4.4800000000000004 108.58 179.704 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.542 ' O ' ' N ' ' A' ' 14' ' ' GLY . 13.6 Cg_endo -66.6 40.95 0.16 Allowed 'Trans proline' 0 C--N 1.32 -0.964 0 C-N-CA 121.911 1.74 . . . . 4.0499999999999998 108.798 177.954 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.609 ' H ' ' C ' ' A' ' 11' ' ' GLY . 0.2 OUTLIER 30.52 34.27 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.22 0 CA-C-O 121.518 0.675 . . . . 4.0599999999999996 110.835 -179.277 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.562 ' C ' ' H ' ' A' ' 16' ' ' GLY . . . 67.25 -35.47 0.2 Allowed Glycine 0 N--CA 1.49 2.244 0 N-CA-C 110.159 -1.176 . . . . 3.1400000000000001 110.159 179.427 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.57 ' H ' ' C ' ' A' ' 13' ' ' LEU . 6.4 tp10 58.47 1.58 0.18 Allowed 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.313 -1.11 . . . . 3.1699999999999999 108.921 -179.332 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.562 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 70.22 112.34 0.03 OUTLIER Glycine 0 N--CA 1.487 2.099 0 C-N-CA 120.34 -0.933 . . . . 2.4399999999999999 110.772 179.197 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.547 ' C ' ' H ' ' A' ' 19' ' ' HIS . . . 78.7 -52.6 3.91 Favored Glycine 0 N--CA 1.492 2.43 0 O-C-N 121.47 -1.018 . . . . 2.0499999999999998 111.089 178.69 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.476 ' N ' ' CD ' ' A' ' 94' ' ' GLU . . . -50.27 -6.68 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.081 -1.247 . . . . 2.54 110.162 -179.29 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . 0.547 ' H ' ' C ' ' A' ' 17' ' ' GLY . 29.5 t-80 -98.97 -6.31 28.91 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.092 -1.005 . . . . 3.3700000000000001 110.717 -179.171 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.543 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.0 OUTLIER -137.7 2.38 2.42 Favored 'General case' 0 N--CA 1.502 2.164 0 O-C-N 120.959 -1.088 . . . . 2.3700000000000001 110.258 -179.664 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 71.3 t -87.85 114.22 26.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 120.982 -1.074 . . . . 2.5800000000000001 109.25 179.489 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 13.3 tpp180 -113.61 138.54 50.03 Favored 'General case' 0 N--CA 1.492 1.635 0 N-CA-C 108.83 -0.804 . . . . 3.8900000000000001 108.83 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -147.13 113.57 5.95 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.434 -0.791 . . . . 2.0099999999999998 108.987 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -152.0 130.33 3.07 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.677 -1.369 . . . . 2.0099999999999998 109.677 -179.759 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.98 -178.79 48.47 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.603 -1.399 . . . . 1.9299999999999999 109.603 179.87 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 6.6 p -78.93 -26.59 43.67 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.183 -1.186 . . . . 2.6899999999999999 108.99 179.648 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -66.88 -18.25 68.36 Favored Glycine 0 N--CA 1.486 2.015 0 N-CA-C 108.283 -1.927 . . . . 1.6399999999999999 108.283 179.482 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 57.1 mt -89.64 29.55 1.13 Allowed 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.527 -0.916 . . . . 2.0299999999999998 108.527 179.395 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 27.5 mt-10 -140.09 -63.84 0.49 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.528 -0.733 . . . . 2.3399999999999999 109.623 -179.557 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 41.2 mtt180 -148.45 168.57 22.34 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.168 -0.958 . . . . 4.25 110.293 -179.573 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -144.38 173.33 25.09 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 107.415 -2.274 . . . . 1.5900000000000001 107.415 178.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 39.7 t -133.79 150.99 32.18 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.15 0 O-C-N 120.999 -1.295 . . . . 2.21 110.884 -179.365 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -42.34 114.81 0.61 Allowed 'General case' 0 N--CA 1.497 1.887 0 CA-C-O 121.893 0.854 . . . . 2.0699999999999998 112.314 -179.299 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 55.8 48.2 73.69 Favored Glycine 0 N--CA 1.488 2.159 0 N-CA-C 111.497 -0.641 . . . . 1.73 111.497 177.119 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 t -127.45 123.8 23.32 Favored Pre-proline 0 N--CA 1.499 1.986 0 O-C-N 121.451 -1.029 . . . . 2.6499999999999999 108.866 179.075 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -60.64 112.21 1.27 Allowed 'Trans proline' 0 C--O 1.215 -0.652 0 N-CA-C 109.949 -0.827 . . . . 2.1400000000000001 109.949 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -110.87 158.96 18.13 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 108.401 -0.963 . . . . 2.0299999999999998 108.401 179.445 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -160.64 170.46 20.79 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.767 -1.208 . . . . 2.23 111.496 -179.768 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.458 ' N ' ' CD1' ' A' ' 39' ' ' PHE . 6.2 p90 -155.62 177.37 11.45 Favored 'General case' 0 C--N 1.296 -1.729 0 N-CA-C 107.217 -1.401 . . . . 1.72 107.217 178.473 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 27.5 m -105.17 152.32 22.97 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.344 -0.848 . . . . 2.5800000000000001 110.619 -178.502 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 10.0 mt -143.64 89.53 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 N-CA-C 108.714 -0.847 . . . . 1.8600000000000001 108.714 178.854 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.529 ' CD1' ' N ' ' A' ' 43' ' ' THR . 7.4 t90 -91.33 141.29 28.93 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.172 -0.955 . . . . 4.4699999999999998 108.924 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' THR . . . . . 0.543 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 1.7 t -162.34 -124.2 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.177 -0.952 . . . . 3.27 109.486 -179.845 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' ARG . . . . . 0.531 ' N ' ' OG1' ' A' ' 43' ' ' THR . 5.3 ttt-85 54.49 91.81 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.347 -0.845 . . . . 5.2300000000000004 110.074 179.748 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -170.97 -50.23 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.285 -0.884 . . . . 2.8900000000000001 109.304 179.457 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -61.14 -50.29 73.8 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.09 -1.006 . . . . 1.99 108.937 179.665 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 155.2 -178.81 31.65 Favored Glycine 0 N--CA 1.487 2.044 0 N-CA-C 109.536 -1.426 . . . . 1.6499999999999999 109.536 179.813 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.68 156.92 2.45 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.169 -1.195 . . . . 1.77 109.263 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -179.65 -160.51 25.38 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.712 -1.355 . . . . 1.1200000000000001 109.712 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -144.05 123.38 2.01 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 109.663 -1.375 . . . . 1.1799999999999999 109.663 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 60.2 tp -96.82 104.99 17.04 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.34 -1.094 . . . . 1.5900000000000001 108.651 179.571 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 2.0 t -93.23 144.66 25.08 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 108.93 -0.767 . . . . 1.9399999999999999 108.93 179.736 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.504 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 80.0 mt -132.97 105.74 8.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 O-C-N 121.305 -0.872 . . . . 1.3 109.79 -179.378 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -95.76 107.86 20.13 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 107.726 -1.213 . . . . 1.27 107.726 178.841 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.41 ' O ' ' O ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -105.33 146.73 11.99 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 CA-C-O 121.772 0.796 . . . . 1.55 110.693 -178.421 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . 0.408 ' OE2' ' O ' ' B' ' 9' ' ' VAL . 39.9 tp10 -139.23 129.41 25.31 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 107.248 -1.39 . . . . 1.8 107.248 177.954 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -175.82 163.59 33.3 Favored Glycine 0 N--CA 1.487 2.068 0 N-CA-C 108.386 -1.886 . . . . 0.56000000000000005 108.386 -179.702 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_exo -46.37 -23.44 2.08 Favored 'Trans proline' 0 C--N 1.317 -1.13 0 C-N-CA 121.91 1.74 . . . . 0.76000000000000001 111.714 -178.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 30.3 t -141.74 167.49 22.01 Favored 'General case' 0 N--CA 1.501 2.101 0 O-C-N 121.473 -0.767 . . . . 2.02 110.681 -179.274 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 29.3 tttm -91.4 92.05 8.4 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.666 -0.646 . . . . 3.02 109.535 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -52.05 145.13 10.78 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.341 -0.85 . . . . 1.3600000000000001 109.308 179.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.426 ' OE2' ' O ' ' A' ' 63' ' ' ILE . 0.2 OUTLIER -93.78 87.63 5.5 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.234 -0.916 . . . . 2.2999999999999998 109.561 -179.843 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . 0.426 ' O ' ' OE2' ' A' ' 62' ' ' GLU . 25.0 mt -60.23 150.17 6.69 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 N-CA-C 109.263 -0.643 . . . . 2.0 109.263 179.574 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -151.09 114.83 4.93 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 120.725 -1.234 . . . . 1.73 109.939 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.492 ' CD2' ' O ' ' A' ' 65' ' ' PHE . 40.1 p90 -86.85 124.17 32.79 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.222 -0.924 . . . . 1.6000000000000001 109.198 179.531 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 62.9 tt0 -141.2 125.1 17.07 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.254 -0.904 . . . . 2.5099999999999998 109.43 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -88.69 93.93 9.73 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.351 -0.843 . . . . 2.0699999999999998 109.695 -179.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.603 ' CG ' HH11 ' A' ' 68' ' ' ARG . 0.0 OUTLIER -115.92 10.68 15.27 Favored 'General case' 0 N--CA 1.499 2.019 0 N-CA-C 108.3 -1.0 . . . . 5.29 108.3 179.53 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 28.3 mmtp -115.19 -8.71 12.34 Favored 'General case' 0 N--CA 1.496 1.845 0 N-CA-C 109.141 -0.689 . . . . 3.8599999999999999 109.141 -179.492 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 3.0 t70 67.85 6.03 4.86 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.46 -0.775 . . . . 3.0600000000000001 109.769 179.529 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -163.43 -41.92 0.02 OUTLIER Glycine 0 N--CA 1.487 2.048 0 C-N-CA 119.489 -1.338 . . . . 2.1600000000000001 109.785 -179.428 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 4.3 t -95.28 130.92 41.87 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.32 -1.106 . . . . 2.5600000000000001 108.983 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 24.5 m -78.23 129.33 34.96 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.19 -0.944 . . . . 2.3599999999999999 109.356 -179.844 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -101.14 116.5 5.59 Favored Glycine 0 N--CA 1.497 2.747 0 N-CA-C 110.111 -1.196 . . . . 1.46 110.111 -179.637 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 71.8 t -105.36 106.85 21.28 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.098 0 O-C-N 121.537 -0.978 . . . . 2.1600000000000001 109.284 179.571 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 4.0 t -100.11 126.39 46.34 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.549 -0.719 . . . . 2.1600000000000001 109.474 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 0.401 ' N ' ' CD1' ' A' ' 77' ' ' TYR . 12.0 p90 -125.36 131.69 52.94 Favored 'General case' 0 N--CA 1.497 1.882 0 N-CA-C 108.758 -0.831 . . . . 1.7 108.758 179.746 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.481 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 9.9 p -98.73 114.35 36.17 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.294 -0.879 . . . . 2.4500000000000002 109.255 -179.501 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 15.5 m -81.79 161.83 3.57 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 O-C-N 121.041 -1.037 . . . . 1.8200000000000001 109.027 -179.707 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . 0.531 ' O ' ' NE2' ' A' ' 80' ' ' GLN . 0.0 OUTLIER -101.44 -48.54 4.32 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.227 -0.92 . . . . 3.1699999999999999 110.781 -178.825 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -156.67 153.13 23.91 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 120.554 -1.341 . . . . 2.02 111.108 -179.506 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.592 ' HG3' ' N ' ' A' ' 107' ' ' SER . 76.4 Cg_exo -37.08 158.08 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.646 0 C-N-CA 123.363 2.709 . . . . 1.3999999999999999 113.875 179.231 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 150.77 -167.49 30.46 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.359 -1.496 . . . . 1.0800000000000001 109.359 179.765 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . 0.521 ' OD2' ' NH2' ' B' ' 8' ' ' ARG . 10.7 m-20 -109.3 91.58 3.7 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.532 -0.981 . . . . 2.1299999999999999 108.756 179.64 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 3.0 m-85 -78.25 136.19 37.72 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 108.049 -1.093 . . . . 1.1399999999999999 108.049 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . 0.402 ' OE2' ' O ' ' A' ' 84' ' ' ASP . 0.0 OUTLIER -119.18 117.36 28.44 Favored 'General case' 0 N--CA 1.501 2.086 0 N-CA-C 108.121 -1.066 . . . . 1.53 108.121 -179.033 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.415 ' CG1' ' CE2' ' A' ' 101' ' ' PHE . 14.6 p -117.11 133.91 62.36 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 121.622 -0.674 . . . . 1.6399999999999999 110.408 -178.842 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 3.5 p -128.65 105.77 8.49 Favored 'General case' 0 N--CA 1.501 2.092 0 O-C-N 121.61 -0.682 . . . . 1.99 109.459 179.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.4 pt -107.95 138.22 35.53 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.897 0 CA-C-O 121.415 0.626 . . . . 1.77 109.839 -179.732 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . 0.458 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -145.08 122.63 11.74 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 108.659 -0.867 . . . . 2.0600000000000001 108.659 179.928 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 78.7 t80 -80.33 100.95 8.66 Favored 'General case' 0 N--CA 1.491 1.588 0 C-N-CA 118.764 -1.174 . . . . 1.45 107.891 178.492 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . 0.407 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 2.0 t30 69.59 39.86 1.49 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.343 -0.848 . . . . 2.7200000000000002 109.177 -178.908 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . 0.407 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 1.5 m-20 75.61 13.93 2.88 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.678 -0.639 . . . . 1.9199999999999999 111.62 179.483 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . 0.476 ' CD ' ' N ' ' A' ' 18' ' ' ALA . 0.5 OUTLIER -98.44 94.44 6.72 Favored 'General case' 0 N--CA 1.498 1.97 0 N-CA-C 106.964 -1.495 . . . . 2.5499999999999998 106.964 177.58 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . 0.508 ' CG ' ' O ' ' A' ' 95' ' ' HIS . 6.5 p80 -71.57 112.69 7.9 Favored 'General case' 0 N--CA 1.487 1.384 0 CA-C-O 121.485 0.66 . . . . 3.2000000000000002 109.748 -178.219 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . 0.557 ' O ' ' N ' ' A' ' 98' ' ' ASP . 6.3 pt -57.06 152.02 31.4 Favored Pre-proline 0 C--N 1.3 -1.579 0 N-CA-C 108.319 -0.993 . . . . 2.8199999999999998 108.319 179.594 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -59.05 73.96 0.05 OUTLIER 'Trans proline' 0 CA--C 1.54 0.789 0 N-CA-C 109.234 -1.102 . . . . 2.6299999999999999 109.234 179.364 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.557 ' N ' ' O ' ' A' ' 96' ' ' ILE . 0.9 OUTLIER -174.93 -51.87 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.077 -1.014 . . . . 2.6499999999999999 109.38 -179.339 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 5.3 t -54.25 134.31 60.57 Favored Pre-proline 0 C--N 1.299 -1.626 0 O-C-N 121.321 -0.862 . . . . 2.3199999999999998 109.926 -177.64 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_endo -89.94 116.25 2.91 Favored 'Cis proline' 0 N--CA 1.495 1.606 0 CA-C-N 118.995 0.677 . . . . 1.9399999999999999 110.521 -1.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . 0.574 ' CD1' ' N ' ' A' ' 101' ' ' PHE . 0.1 OUTLIER -89.49 149.59 22.84 Favored 'General case' 0 N--CA 1.512 2.639 0 O-C-N 119.979 -1.701 . . . . 2.6299999999999999 108.76 178.029 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 8.6 p -86.45 138.43 19.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.5 -0.75 . . . . 1.8200000000000001 109.133 179.681 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 76.7 t -120.15 85.37 35.6 Favored Pre-proline 0 N--CA 1.498 1.936 0 N-CA-C 108.312 -0.996 . . . . 1.73 108.312 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -65.3 112.97 2.25 Favored 'Trans proline' 0 C--N 1.32 -0.953 0 C-N-CA 121.276 1.317 . . . . 1.6100000000000001 111.556 -178.012 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 47.2 t -89.73 143.06 11.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 N-CA-C 106.667 -1.605 . . . . 1.7 106.667 177.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -127.92 131.28 49.37 Favored 'General case' 0 N--CA 1.507 2.406 0 CA-C-O 121.956 0.884 . . . . 2.04 111.788 -177.016 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' SER . . . . . 0.592 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 66.4 p -99.8 84.77 2.96 Favored 'General case' 0 N--CA 1.493 1.693 0 N-CA-C 107.229 -1.397 . . . . 2.2999999999999998 107.229 178.783 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 13.3 mt 65.12 -0.69 1.02 Allowed 'General case' 0 C--N 1.292 -1.917 0 N-CA-C 108.081 -1.081 . . . . 3.6000000000000001 108.081 -178.103 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.542 ' OG ' ' N ' ' A' ' 112' ' ' ALA . 53.8 p -89.1 -22.89 22.66 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.982 -0.747 . . . . 2.4900000000000002 108.982 179.068 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 32.9 t70 50.24 13.4 0.11 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.139 -0.975 . . . . 2.8500000000000001 108.586 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.521 ' H ' ' C ' ' A' ' 109' ' ' SER . 65.3 t0 -171.93 -28.74 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 109.375 -0.602 . . . . 2.46 109.375 -179.605 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.542 ' N ' ' OG ' ' A' ' 109' ' ' SER . . . 49.5 78.93 0.09 Allowed 'General case' 0 N--CA 1.494 1.752 0 O-C-N 120.784 -1.197 . . . . 2.0800000000000001 109.189 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 61.9 mtm180 -50.16 160.75 0.33 Allowed 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.412 -0.805 . . . . 6.54 109.82 -179.55 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 18.3 ttm180 -103.22 5.74 37.81 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.568 -0.707 . . . . 6.2400000000000002 109.382 -179.512 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 28.6 mt -123.2 -30.81 3.67 Favored 'General case' 0 N--CA 1.506 2.326 0 O-C-N 121.526 -0.733 . . . . 4.71 110.003 -179.391 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.515 ' C ' ' H ' ' A' ' 118' ' ' THR . 0.8 OUTLIER -105.26 -79.23 0.56 Allowed 'General case' 0 N--CA 1.493 1.721 0 N-CA-C 107.241 -1.392 . . . . 4.3499999999999996 107.241 179.527 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 55.0 t -60.21 -9.85 2.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 N-CA-C 106.215 -1.772 . . . . 3.3100000000000001 106.215 177.043 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' THR . . . . . 0.515 ' H ' ' C ' ' A' ' 116' ' ' THR . 5.0 t 36.98 60.86 0.95 Allowed 'General case' 0 N--CA 1.485 1.287 0 CA-C-O 122.109 0.957 . . . . 3.73 110.88 179.718 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' SER . . . . . 0.452 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.5 p . . . . . 0 C--N 1.304 -1.408 0 CA-C-O 118.025 -0.988 . . . . 3.8300000000000001 109.548 179.207 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 34.1 ttp . . . . . 0 N--CA 1.491 1.582 0 N-CA-C 109.467 -0.568 . . . . 8.8699999999999992 109.467 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -73.79 -73.7 0.21 Allowed 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.241 -0.912 . . . . 5.9299999999999997 109.185 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 3' ' ' SER . . . . . . . . . . . . . 13.0 p -175.32 -40.76 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.313 -0.867 . . . . 5.5700000000000003 109.726 179.824 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 4' ' ' LYS . . . . . . . . . . . . . 59.4 tttm -170.96 76.99 0.55 Allowed Pre-proline 0 N--CA 1.489 1.493 0 O-C-N 121.201 -0.937 . . . . 7.25 109.626 -179.537 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 5' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -59.99 156.92 36.37 Favored 'Trans proline' 0 C--N 1.318 -1.071 0 C-N-CA 121.291 1.327 . . . . 5.8899999999999997 110.055 -179.612 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 6' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -47.61 171.86 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.27 -0.894 . . . . 4.7800000000000002 109.902 -179.724 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 49.0 mtpt -78.78 -154.99 0.08 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.398 -0.814 . . . . 4.5599999999999996 109.385 179.822 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . 0.521 ' NH2' ' OD2' ' A' ' 84' ' ' ASP . 3.8 mmt-85 -89.55 -170.87 2.99 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.148 -0.97 . . . . 3.6699999999999999 109.358 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 9' ' ' VAL . . . . . 0.408 ' O ' ' OE2' ' A' ' 56' ' ' GLU . 2.6 t -68.47 161.23 4.22 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 N-CA-C 107.505 -1.294 . . . . 1.3899999999999999 107.505 178.549 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -97.77 138.94 34.38 Favored 'General case' 0 N--CA 1.5 2.034 0 O-C-N 121.186 -0.947 . . . . 1.22 110.809 -178.636 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 11' ' ' SER . . . . . 0.41 ' O ' ' O ' ' A' ' 55' ' ' VAL . 35.7 t -143.07 130.73 21.34 Favored 'General case' 0 N--CA 1.493 1.72 0 N-CA-C 108.444 -0.947 . . . . 1.6299999999999999 108.444 179.092 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 11.1 t -150.69 125.37 9.67 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.069 -1.019 . . . . 1.8799999999999999 110.072 -179.369 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . 0.541 ' CG2' ' H ' ' B' ' 14' ' ' PHE . 12.3 p -173.26 179.81 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 N-CA-C 108.263 -1.014 . . . . 1.2 108.263 179.649 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 14' ' ' PHE . . . . . 0.541 ' H ' ' CG2' ' B' ' 13' ' ' VAL . 0.1 OUTLIER 174.59 -167.65 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.504 0 C-N-CA 118.548 -1.261 . . . . 2.3900000000000001 112.237 179.629 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -141.34 159.66 22.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 N-CA-C 108.097 -1.075 . . . . 1.8100000000000001 108.097 -179.841 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 16' ' ' THR . . . . . 0.498 ' HG1' ' N ' ' B' ' 17' ' ' LEU . 1.7 t -132.11 151.07 51.98 Favored 'General case' 0 N--CA 1.499 2.017 0 O-C-N 121.303 -0.873 . . . . 2.04 109.474 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . 0.498 ' N ' ' HG1' ' B' ' 16' ' ' THR . 28.4 mt -112.13 141.39 45.86 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.487 -0.758 . . . . 1.8700000000000001 109.576 -179.899 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -158.89 117.23 1.7 Allowed Pre-proline 0 N--CA 1.492 1.654 0 N-CA-C 108.73 -0.841 . . . . 1.47 108.73 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_exo -59.74 164.63 11.28 Favored 'Trans proline' 0 CA--C 1.545 1.068 0 N-CA-C 109.992 -0.811 . . . . 1.96 109.992 -179.493 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 20' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_endo -63.15 124.14 13.4 Favored 'Trans proline' 0 C--N 1.321 -0.894 0 C-N-CA 121.626 1.551 . . . . 3.3799999999999999 110.089 179.72 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . 0.543 HH11 ' CG ' ' B' ' 21' ' ' ARG . 0.3 OUTLIER 46.55 -127.25 1.49 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.241 -0.912 . . . . 6.7400000000000002 109.708 179.304 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 22' ' ' ARG . . . . . 0.439 ' O ' ' O ' ' B' ' 23' ' ' ASP . 9.9 tpt180 -122.5 25.15 8.96 Favored 'General case' 0 N--CA 1.499 1.984 0 N-CA-C 108.932 -0.766 . . . . 6.9400000000000004 108.932 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . 0.439 ' O ' ' O ' ' B' ' 22' ' ' ARG . 0.8 OUTLIER 60.45 142.55 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.42 -0.8 . . . . 5.6200000000000001 109.736 -179.93 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 11.0 m . . . . . 0 N--CA 1.491 1.587 0 O-C-N 121.118 -0.988 . . . . 6.75 109.483 -179.937 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.531 4.972 0 N-CA-C 119.763 2.665 . . . . 6.7300000000000004 119.763 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.659 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 1.7 mp -149.11 43.99 0.31 Allowed Pre-proline 0 C--N 1.31 -1.143 0 N-CA-C 107.51 -1.293 . . . . 7.3799999999999999 107.51 178.512 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.746 ' C ' ' H ' ' A' ' 5' ' ' PHE . 1.8 Cg_endo -51.97 -75.59 0.03 OUTLIER 'Trans proline' 0 C--N 1.319 -0.998 0 N-CA-C 109.016 -1.186 . . . . 5.5 109.016 -179.722 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.427 ' CB ' ' O ' ' A' ' 3' ' ' PRO . 13.9 tp10 70.32 -6.14 1.21 Allowed 'General case' 0 N--CA 1.495 1.801 0 N-CA-C 104.319 -2.474 . . . . 6.8399999999999999 104.319 -175.705 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . 0.746 ' H ' ' C ' ' A' ' 3' ' ' PRO . 3.0 m-85 -102.06 15.21 29.77 Favored 'General case' 0 C--N 1.3 -1.558 0 N-CA-C 103.434 -2.802 . . . . 6.4400000000000004 103.434 177.542 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.551 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 47.3 p90 50.83 -153.34 0.17 Allowed 'General case' 0 C--N 1.308 -1.235 0 CA-C-N 113.838 -1.528 . . . . 5.0599999999999996 110.346 -177.886 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.421 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 13.4 mt-30 82.7 -9.22 1.14 Allowed 'General case' 0 N--CA 1.495 1.822 0 N-CA-C 105.233 -2.136 . . . . 4.8099999999999996 105.233 -176.465 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.501 ' H ' ' C ' ' A' ' 6' ' ' PHE . 88.4 m-85 -149.46 -37.93 0.16 Allowed 'General case' 0 C--N 1.306 -1.307 0 N-CA-C 107.828 -1.175 . . . . 5.7300000000000004 107.828 178.178 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 23.0 m -93.31 3.59 55.38 Favored 'General case' 0 C--N 1.295 -1.799 0 N-CA-C 105.679 -1.971 . . . . 5.3499999999999996 105.679 177.21 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 1.1 p -46.59 -30.33 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.249 0 CA-C-N 115.34 -0.845 . . . . 4.3799999999999999 109.639 -179.131 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.598 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 164.01 -83.75 0.11 Allowed Glycine 0 N--CA 1.499 2.868 0 C-N-CA 119.81 -1.186 . . . . 4.4800000000000004 110.377 179.039 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -64.57 37.95 0.11 Allowed 'Trans proline' 0 N--CA 1.484 0.934 0 C-N-CA 122.137 1.891 . . . . 4.0499999999999998 109.677 179.561 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.603 ' CD2' ' N ' ' A' ' 13' ' ' LEU . 0.0 OUTLIER 45.59 27.46 0.42 Allowed 'General case' 0 N--CA 1.498 1.932 0 N-CA-C 108.474 -0.936 . . . . 4.0599999999999996 108.474 -179.412 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.496 ' C ' ' H ' ' A' ' 16' ' ' GLY . . . 72.55 -41.71 0.82 Allowed Glycine 0 N--CA 1.487 2.052 0 N-CA-C 108.192 -1.963 . . . . 3.1400000000000001 108.192 -179.088 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.547 ' H ' ' C ' ' A' ' 13' ' ' LEU . 22.9 tp10 50.0 14.3 0.13 Allowed 'General case' 0 N--CA 1.486 1.353 0 O-C-N 121.532 -0.981 . . . . 3.1699999999999999 108.452 -179.841 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.496 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 70.81 -155.85 53.03 Favored Glycine 0 N--CA 1.486 2.003 0 N-CA-C 109.886 -1.286 . . . . 2.4399999999999999 109.886 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.544 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -68.24 -15.55 67.89 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.881 -1.288 . . . . 2.0499999999999998 109.881 -179.68 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.51 ' N ' ' OE1' ' A' ' 94' ' ' GLU . . . -43.8 -17.67 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.525 -0.985 . . . . 2.54 109.823 -179.679 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . 0.544 ' N ' ' O ' ' A' ' 17' ' ' GLY . 11.7 t-80 -100.25 -52.56 3.35 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.447 -0.783 . . . . 3.3700000000000001 110.388 -179.146 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.423 ' HZ3' ' CB ' ' A' ' 43' ' ' THR . 0.0 OUTLIER -64.49 -17.89 64.29 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.962 -1.086 . . . . 2.3700000000000001 109.874 -179.288 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.475 ' O ' ' CG1' ' A' ' 21' ' ' VAL . 9.7 p -72.22 114.31 10.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.046 -1.034 . . . . 2.5800000000000001 108.829 179.503 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 5.9 tpp180 -109.84 134.61 51.86 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.452 -0.78 . . . . 3.8900000000000001 110.108 -178.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -141.79 113.59 7.89 Favored 'General case' 0 N--CA 1.493 1.691 0 N-CA-C 108.392 -0.966 . . . . 2.0099999999999998 108.392 179.15 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -150.93 132.07 3.76 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 109.94 -1.264 . . . . 2.0099999999999998 109.94 -179.294 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.38 179.11 48.9 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 110.055 -1.218 . . . . 1.9299999999999999 110.055 179.721 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 7.2 m -75.9 -19.9 58.46 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.47 -1.018 . . . . 2.6899999999999999 109.674 179.922 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.449 ' O ' ' OH ' ' A' ' 77' ' ' TYR . . . -70.97 -24.76 76.8 Favored Glycine 0 N--CA 1.488 2.138 0 N-CA-C 108.767 -1.733 . . . . 1.6399999999999999 108.767 179.844 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 29.6 mt -81.51 -11.21 59.27 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.555 -0.968 . . . . 2.0299999999999998 108.946 179.633 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 33.2 mm-40 -84.67 -49.03 8.88 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.512 -0.743 . . . . 2.3399999999999999 109.762 -179.494 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . 0.504 ' NH1' ' OD1' ' A' ' 110' ' ' ASP . 9.4 ptp180 -174.92 173.69 2.66 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.221 -0.925 . . . . 4.25 109.407 179.809 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -138.71 170.91 23.78 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 108.196 -1.962 . . . . 1.5900000000000001 108.196 179.475 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 25.6 t -134.64 149.36 29.56 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 O-C-N 121.23 -1.159 . . . . 2.21 109.944 -179.526 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -38.51 113.03 0.26 Allowed 'General case' 0 N--CA 1.496 1.832 0 CA-C-O 121.712 0.767 . . . . 2.0699999999999998 112.098 -179.306 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 63.48 40.67 99.04 Favored Glycine 0 N--CA 1.491 2.337 0 O-C-N 121.685 -0.635 . . . . 1.73 111.814 177.424 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 46.4 t -127.32 119.95 22.07 Favored Pre-proline 0 N--CA 1.502 2.146 0 O-C-N 121.289 -1.124 . . . . 2.6499999999999999 108.536 178.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -59.37 113.89 1.8 Allowed 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 120.589 0.86 . . . . 2.1400000000000001 110.541 -179.488 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -86.39 90.67 8.27 Favored 'General case' 0 N--CA 1.492 1.665 0 N-CA-C 108.281 -1.007 . . . . 2.0299999999999998 108.281 179.032 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -85.78 148.28 25.92 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.244 -0.91 . . . . 2.23 110.884 -178.513 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.531 ' CD1' ' O ' ' A' ' 75' ' ' VAL . 5.2 p90 -153.25 159.03 42.52 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 107.148 -1.427 . . . . 1.72 107.148 177.825 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' SER . . . . . 0.426 ' OG ' ' OG ' ' A' ' 72' ' ' SER . 3.6 t -98.26 156.2 16.82 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.223 -0.923 . . . . 2.5800000000000001 111.904 -177.093 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.524 ' O ' ' N ' ' A' ' 73' ' ' CYS . 13.3 mt -149.18 117.16 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 N-CA-C 108.368 -0.975 . . . . 1.8600000000000001 108.368 178.713 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.519 ' O ' ' CD2' ' A' ' 42' ' ' TRP . 7.3 p-90 -122.07 129.12 52.12 Favored 'General case' 0 N--CA 1.503 2.182 0 O-C-N 121.256 -0.903 . . . . 4.4699999999999998 109.031 179.718 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' THR . . . . . 0.423 ' CB ' ' HZ3' ' A' ' 20' ' ' LYS . 0.6 OUTLIER -149.02 142.11 24.9 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.229 -0.919 . . . . 3.27 109.605 -179.103 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -178.1 68.16 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.352 -0.842 . . . . 5.2300000000000004 109.308 179.501 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 28.6 tt0 -153.47 -51.33 0.1 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.176 -0.953 . . . . 2.8900000000000001 109.501 -179.919 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -61.57 -57.16 13.16 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.146 -0.971 . . . . 1.99 109.439 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 136.13 -177.56 19.46 Favored Glycine 0 N--CA 1.495 2.586 0 N-CA-C 108.683 -1.767 . . . . 1.6499999999999999 108.683 -179.621 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.78 142.36 23.98 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.048 -1.266 . . . . 1.77 109.306 179.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -159.2 176.95 35.94 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.422 -1.471 . . . . 1.1200000000000001 109.422 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -109.82 114.35 3.87 Favored Glycine 0 N--CA 1.498 2.785 0 N-CA-C 109.439 -1.464 . . . . 1.1799999999999999 109.439 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.437 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 10.5 tp -94.43 96.75 9.71 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.216 -1.167 . . . . 1.5900000000000001 108.353 179.386 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' SER . . . . . 0.492 ' HG ' ' CD ' ' A' ' 90' ' ' LYS . 22.3 p -84.68 141.16 30.8 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.627 -0.879 . . . . 1.9399999999999999 108.627 -179.953 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.514 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 87.3 mt -134.01 113.96 18.72 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.342 -0.848 . . . . 1.3 109.489 -179.838 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -105.28 108.52 20.08 Favored 'General case' 0 N--CA 1.495 1.784 0 N-CA-C 108.808 -0.812 . . . . 1.27 108.808 179.611 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.417 ' O ' ' O ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -100.27 142.58 15.27 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.494 -0.753 . . . . 1.55 109.412 -179.795 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 12.5 tt0 -141.89 144.12 33.65 Favored 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 108.046 -1.094 . . . . 1.8 108.046 178.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.429 ' O ' ' O ' ' B' ' 9' ' ' VAL . . . 163.79 -172.4 39.66 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.836 -1.306 . . . . 0.56000000000000005 109.836 -179.498 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -63.34 -28.73 72.03 Favored 'Trans proline' 0 C--N 1.318 -1.053 0 C-N-CA 122.133 1.889 . . . . 0.76000000000000001 112.136 -179.412 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -131.73 175.99 8.72 Favored 'General case' 0 N--CA 1.502 2.152 0 O-C-N 121.225 -0.922 . . . . 2.02 110.165 -179.575 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 47.0 mttp -93.09 120.21 33.14 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.518 -0.739 . . . . 3.02 109.523 -179.712 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -80.94 108.63 14.78 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.331 -0.856 . . . . 1.3600000000000001 108.825 179.82 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 23.4 mt-10 -83.51 103.17 12.65 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.072 -1.018 . . . . 2.2999999999999998 109.87 -179.592 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . 0.422 HG23 HD11 ' A' ' 63' ' ' ILE . 7.6 mm -58.73 156.96 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.886 -0.509 . . . . 2.0 109.751 179.781 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.469 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -139.66 174.5 10.45 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.122 -0.986 . . . . 1.73 109.015 179.649 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.441 ' CD1' ' N ' ' A' ' 65' ' ' PHE . 13.9 p90 -139.64 117.18 11.43 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.412 -0.805 . . . . 1.6000000000000001 109.536 -179.896 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -141.36 113.53 8.0 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.31 -0.869 . . . . 2.5099999999999998 109.453 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -74.38 138.83 43.66 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.207 -0.933 . . . . 2.0699999999999998 109.148 179.719 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 66.2 ttt180 -118.96 -47.74 2.48 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.475 -0.766 . . . . 5.29 109.505 -179.787 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.553 ' C ' ' H ' ' A' ' 71' ' ' GLY . 33.0 mttm -115.86 7.22 14.46 Favored 'General case' 0 N--CA 1.495 1.803 0 N-CA-C 108.379 -0.971 . . . . 3.8599999999999999 108.379 179.645 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.409 ' CB ' ' O ' ' A' ' 69' ' ' LYS . 6.0 t70 70.73 -40.73 0.48 Allowed 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 108.432 -0.951 . . . . 3.0600000000000001 108.432 -179.054 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . 0.553 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -91.35 27.84 8.95 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.363 -1.495 . . . . 2.1600000000000001 109.363 179.766 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.426 ' OG ' ' OG ' ' A' ' 40' ' ' SER . 24.2 t -156.16 119.59 4.31 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.425 -1.044 . . . . 2.5600000000000001 109.131 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' CYS . . . . . 0.524 ' N ' ' O ' ' A' ' 41' ' ' ILE . 20.5 m -77.26 110.89 12.36 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.233 -0.917 . . . . 2.3599999999999999 109.582 -179.849 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -83.79 115.15 4.0 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.408 -1.477 . . . . 1.46 109.408 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.531 ' O ' ' CD1' ' A' ' 39' ' ' PHE . 10.1 t -115.42 133.86 60.41 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.052 0 O-C-N 121.649 -0.912 . . . . 2.1600000000000001 108.964 179.897 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.469 ' O ' ' N ' ' A' ' 64' ' ' ALA . 6.0 t -136.73 139.82 42.16 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.447 -0.783 . . . . 2.1600000000000001 109.944 -179.827 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 0.492 ' CD1' ' N ' ' A' ' 77' ' ' TYR . 6.9 p90 -120.16 139.2 52.97 Favored 'General case' 0 N--CA 1.495 1.79 0 N-CA-C 108.201 -1.037 . . . . 1.7 108.201 179.224 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.464 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 9.7 p -108.87 120.78 60.88 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 O-C-N 121.332 -0.855 . . . . 2.4500000000000002 109.741 -179.078 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 3.6 m -101.12 168.4 1.93 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 N-CA-C 108.439 -0.949 . . . . 1.8200000000000001 108.439 179.448 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 34.2 tp60 -101.5 -40.56 6.99 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.08 -1.013 . . . . 3.1699999999999999 110.758 -179.486 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.429 ' O ' ' O ' ' A' ' 82' ' ' PRO . 0.0 OUTLIER -153.32 156.51 32.54 Favored Pre-proline 0 N--CA 1.504 2.248 0 O-C-N 120.539 -1.351 . . . . 2.02 111.209 -179.276 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.511 ' HG3' ' N ' ' A' ' 107' ' ' SER . 78.7 Cg_exo -37.73 169.12 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.654 0 C-N-CA 123.444 2.763 . . . . 1.3999999999999999 113.239 179.016 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 142.82 179.02 19.25 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.659 -1.376 . . . . 1.0800000000000001 109.659 179.559 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . 0.716 ' H ' HH12 ' B' ' 8' ' ' ARG . 3.0 m-20 -96.97 87.2 4.18 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 107.929 -1.137 . . . . 2.1299999999999999 107.929 179.301 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 2.9 m-85 -74.13 134.76 42.87 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 108.351 -0.981 . . . . 1.1399999999999999 108.351 -179.345 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -111.22 121.58 45.65 Favored 'General case' 0 N--CA 1.497 1.91 0 N-CA-C 108.682 -0.858 . . . . 1.53 108.682 -179.058 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.1 p -119.65 140.58 43.16 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.891 0 O-C-N 121.552 -0.717 . . . . 1.6399999999999999 109.546 -179.798 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 12.2 t -133.18 101.39 5.18 Favored 'General case' 0 N--CA 1.5 2.026 0 O-C-N 121.515 -0.741 . . . . 1.99 109.308 179.772 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.9 pt -108.51 137.51 39.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.721 -0.612 . . . . 1.77 110.37 -179.285 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . 0.492 ' CD ' ' HG ' ' A' ' 52' ' ' SER . 0.2 OUTLIER -146.91 125.87 12.79 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.857 -0.794 . . . . 2.0600000000000001 108.857 179.367 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 48.4 t80 -81.69 93.89 6.86 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 120.785 -1.197 . . . . 1.45 108.492 179.42 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . 0.409 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 5.4 t30 69.93 43.24 0.94 Allowed 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 107.913 -1.143 . . . . 2.7200000000000002 107.913 -178.591 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . 0.409 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 3.4 m-20 78.3 11.76 1.75 Allowed 'General case' 0 N--CA 1.495 1.789 0 CA-C-O 121.253 0.549 . . . . 1.9199999999999999 109.96 -179.241 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . 0.51 ' OE1' ' N ' ' A' ' 18' ' ' ALA . 50.0 mt-10 -85.43 77.34 9.94 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 107.805 -1.183 . . . . 2.5499999999999998 107.805 178.454 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . 0.546 ' O ' ' CD2' ' A' ' 95' ' ' HIS . 0.4 OUTLIER -67.97 106.41 2.33 Favored 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 120.03 -0.668 . . . . 3.2000000000000002 109.752 -179.513 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . 0.633 ' CD1' ' H ' ' A' ' 96' ' ' ILE . 0.0 OUTLIER -68.96 156.1 92.15 Favored Pre-proline 0 N--CA 1.495 1.787 0 N-CA-C 107.709 -1.219 . . . . 2.8199999999999998 107.709 179.606 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -48.9 -29.28 14.86 Favored 'Trans proline' 0 C--N 1.323 -0.806 0 C-N-CA 121.059 1.173 . . . . 2.6299999999999999 109.144 -179.797 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 57.0 m-20 -58.83 -64.16 1.04 Allowed 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 108.963 -0.755 . . . . 2.6499999999999999 108.963 178.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 3.1 m -70.78 139.7 86.06 Favored Pre-proline 0 C--N 1.296 -1.739 0 O-C-N 121.05 -1.031 . . . . 2.3199999999999998 110.073 -178.681 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -87.08 119.46 5.07 Favored 'Cis proline' 0 N--CA 1.493 1.49 0 N-CA-C 110.025 -0.798 . . . . 1.9399999999999999 110.025 -2.342 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 40.5 p90 -121.14 166.97 13.17 Favored 'General case' 0 N--CA 1.519 2.996 0 O-C-N 120.499 -1.376 . . . . 2.6299999999999999 109.882 178.195 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.4 p -92.35 146.23 6.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 CA-C-O 121.642 0.734 . . . . 1.8200000000000001 110.918 -178.28 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 79.8 t -119.83 86.46 35.94 Favored Pre-proline 0 N--CA 1.496 1.842 0 N-CA-C 107.799 -1.185 . . . . 1.73 107.799 178.888 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -63.96 114.28 2.54 Favored 'Trans proline' 0 C--N 1.32 -0.95 0 C-N-CA 121.36 1.373 . . . . 1.6100000000000001 111.683 -178.028 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 75.2 t -98.88 144.09 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 N-CA-C 106.569 -1.641 . . . . 1.7 106.569 178.11 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -134.94 138.28 43.91 Favored 'General case' 0 N--CA 1.51 2.556 0 CA-C-O 122.055 0.931 . . . . 2.04 112.08 -177.174 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' SER . . . . . 0.512 ' C ' ' H ' ' A' ' 109' ' ' SER . 20.3 m -92.2 63.77 4.37 Favored 'General case' 0 N--CA 1.496 1.856 0 N-CA-C 107.152 -1.425 . . . . 2.2999999999999998 107.152 178.652 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . 0.49 ' CB ' ' O ' ' A' ' 107' ' ' SER . 3.2 tp 80.45 -13.56 0.92 Allowed 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 106.456 -1.683 . . . . 3.6000000000000001 106.456 -177.416 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.512 ' H ' ' C ' ' A' ' 107' ' ' SER . 5.2 m -68.54 -21.9 64.53 Favored 'General case' 0 C--N 1.306 -1.305 0 N-CA-C 108.732 -0.84 . . . . 2.4900000000000002 108.732 178.785 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . 0.504 ' OD1' ' NH1' ' A' ' 30' ' ' ARG . 21.5 t70 47.57 18.82 0.12 Allowed 'General case' 0 N--CA 1.494 1.736 0 CA-C-O 121.937 0.875 . . . . 2.8500000000000001 108.666 179.876 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.462 ' N ' ' O ' ' A' ' 109' ' ' SER . 12.6 t70 -173.88 -30.84 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 108.567 -0.901 . . . . 2.46 108.567 -179.643 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.47 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 48.29 92.81 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.123 -0.986 . . . . 2.0800000000000001 109.509 179.661 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.556 ' CG ' HH11 ' A' ' 113' ' ' ARG . 0.0 OUTLIER -62.44 -154.16 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.222 -0.924 . . . . 6.54 109.16 -179.797 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 57.5 ttt180 -145.28 2.4 0.99 Allowed 'General case' 0 N--CA 1.492 1.636 0 N-CA-C 107.883 -1.155 . . . . 6.2400000000000002 107.883 179.456 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 36.2 mt -130.62 -27.64 2.12 Favored 'General case' 0 N--CA 1.5 2.039 0 N-CA-C 108.968 -0.752 . . . . 4.71 108.968 179.497 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.529 ' C ' ' H ' ' A' ' 118' ' ' THR . 1.6 p -98.77 -81.0 0.45 Allowed 'General case' 0 N--CA 1.489 1.52 0 N-CA-C 106.82 -1.548 . . . . 4.3499999999999996 106.82 178.907 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 51.6 t -60.94 -9.46 2.43 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.602 0 N-CA-C 105.967 -1.864 . . . . 3.3100000000000001 105.967 176.684 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' THR . . . . . 0.529 ' H ' ' C ' ' A' ' 116' ' ' THR . 4.9 t 36.91 60.79 0.94 Allowed 'General case' 0 N--CA 1.487 1.384 0 CA-C-N 115.136 -0.938 . . . . 3.73 110.685 179.736 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' SER . . . . . 0.45 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.6 p . . . . . 0 C--N 1.303 -1.43 0 CA-C-O 117.952 -1.023 . . . . 3.8300000000000001 109.607 179.303 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 1' ' ' MET . . . . . 0.419 ' H3 ' ' H ' ' B' ' 2' ' ' ALA . 82.7 mtp . . . . . 0 N--CA 1.491 1.599 0 N-CA-C 109.414 -0.587 . . . . 8.8699999999999992 109.414 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 2' ' ' ALA . . . . . 0.419 ' H ' ' H3 ' ' B' ' 1' ' ' MET . . . 50.9 -160.24 0.08 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.293 -0.879 . . . . 5.9299999999999997 109.506 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 3' ' ' SER . . . . . . . . . . . . . 10.2 t 50.35 73.43 0.27 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.354 -0.841 . . . . 5.5700000000000003 109.654 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 4' ' ' LYS . . . . . 0.634 ' N ' ' CD ' ' B' ' 5' ' ' PRO . 29.7 tttm -77.26 -35.97 1.43 Allowed Pre-proline 0 N--CA 1.489 1.487 0 O-C-N 121.164 -0.96 . . . . 7.25 111.313 179.831 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 5' ' ' PRO . . . . . 0.634 ' CD ' ' N ' ' B' ' 4' ' ' LYS . 4.1 Cg_endo -74.08 116.8 4.77 Favored 'Trans proline' 0 C--N 1.324 -0.757 0 C-N-CA 120.764 0.976 . . . . 5.8899999999999997 109.633 -179.584 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 6' ' ' GLU . . . . . 0.541 ' OE1' ' N ' ' B' ' 6' ' ' GLU . 0.0 OUTLIER -158.13 135.17 9.96 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.032 -1.043 . . . . 4.7800000000000002 109.928 179.627 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 7' ' ' LYS . . . . . 0.448 ' O ' ' O ' ' B' ' 6' ' ' GLU . 30.9 mmtp 54.4 108.03 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.405 -0.809 . . . . 4.5599999999999996 110.044 179.696 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . 0.716 HH12 ' H ' ' A' ' 84' ' ' ASP . 10.7 mtt180 -78.07 171.07 15.57 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.087 -1.079 . . . . 3.6699999999999999 108.087 179.19 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 9' ' ' VAL . . . . . 0.429 ' O ' ' O ' ' A' ' 57' ' ' GLY . 38.6 t -51.74 155.79 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 120.921 -1.112 . . . . 1.3899999999999999 108.215 179.404 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -119.66 149.87 41.28 Favored 'General case' 0 N--CA 1.501 2.078 0 O-C-N 121.402 -0.811 . . . . 1.22 110.142 -178.914 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 11' ' ' SER . . . . . 0.417 ' O ' ' O ' ' A' ' 55' ' ' VAL . 6.9 t -147.36 141.84 26.46 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.506 -0.746 . . . . 1.6299999999999999 109.301 179.688 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 12' ' ' SER . . . . . 0.41 ' HG ' ' C ' ' B' ' 11' ' ' SER . 6.7 m -143.88 121.14 11.56 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.176 -0.952 . . . . 1.8799999999999999 109.439 -179.846 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . 0.47 ' CG2' ' N ' ' B' ' 14' ' ' PHE . 7.7 p -163.62 168.76 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.39 -0.819 . . . . 1.2 109.183 179.91 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 14' ' ' PHE . . . . . 0.514 ' HB3' ' H ' ' A' ' 53' ' ' ILE . 7.9 p90 -176.91 -168.05 0.2 Allowed 'General case' 0 N--CA 1.488 1.437 0 C-N-CA 119.402 -0.919 . . . . 2.3900000000000001 111.928 179.7 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.6 pt -151.29 167.47 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.344 0 N-CA-C 109.091 -0.707 . . . . 1.8100000000000001 109.091 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 7.3 t -122.53 128.92 51.38 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 121.463 -0.773 . . . . 2.04 109.009 179.661 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 12.1 mt -97.63 150.94 20.61 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.204 -0.935 . . . . 1.8700000000000001 109.866 -179.617 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -168.41 151.72 5.51 Favored Pre-proline 0 N--CA 1.49 1.545 0 N-CA-C 108.606 -0.887 . . . . 1.47 108.606 179.584 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -60.62 140.78 92.83 Favored 'Trans proline' 0 CA--C 1.551 1.35 0 C-N-CA 120.911 1.074 . . . . 1.96 109.431 179.84 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 20' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_endo -62.16 -36.46 69.25 Favored 'Trans proline' 0 C--N 1.324 -0.719 0 N-CA-C 109.359 -1.054 . . . . 3.3799999999999999 109.359 179.159 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 79.4 mtm180 -66.8 -163.28 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.469 -0.769 . . . . 6.7400000000000002 109.718 -179.717 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 22' ' ' ARG . . . . . . . . . . . . . 21.1 mmm180 -130.95 -78.14 0.53 Allowed 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.532 -0.73 . . . . 6.9400000000000004 109.098 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 -64.97 -132.68 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.295 -0.878 . . . . 5.6200000000000001 109.454 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 97.6 t . . . . . 0 N--CA 1.493 1.716 0 CA-C-O 117.974 -1.013 . . . . 6.75 109.336 179.977 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.91 0 N-CA-C 119.722 2.649 . . . . 6.7300000000000004 119.722 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.556 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 3.8 tp -172.42 50.69 0.12 Allowed Pre-proline 0 C--N 1.307 -1.258 0 N-CA-C 108.194 -1.039 . . . . 7.3799999999999999 108.194 179.647 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.737 ' C ' ' H ' ' A' ' 5' ' ' PHE . 4.1 Cg_exo -50.53 -76.23 0.03 OUTLIER 'Trans proline' 0 C--N 1.319 -0.989 0 C-N-CA 121.194 1.263 . . . . 5.5 109.218 179.601 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.441 ' CB ' ' O ' ' A' ' 3' ' ' PRO . 8.7 tt0 70.97 -5.63 1.46 Allowed 'General case' 0 N--CA 1.494 1.745 0 N-CA-C 104.215 -2.513 . . . . 6.8399999999999999 104.215 -175.717 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . 0.737 ' H ' ' C ' ' A' ' 3' ' ' PRO . 4.3 m-85 -103.56 17.43 24.11 Favored 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 103.392 -2.818 . . . . 6.4400000000000004 103.392 177.648 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.542 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 44.1 p90 46.23 -159.01 0.03 OUTLIER 'General case' 0 C--N 1.308 -1.212 0 CA-C-N 113.774 -1.557 . . . . 5.0599999999999996 109.852 -177.665 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.529 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 32.3 tp60 87.0 -9.81 0.62 Allowed 'General case' 0 N--CA 1.493 1.717 0 N-CA-C 104.911 -2.255 . . . . 4.8099999999999996 104.911 -177.016 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.456 ' H ' ' C ' ' A' ' 6' ' ' PHE . 45.3 m-85 -158.06 -35.81 0.07 Allowed 'General case' 0 C--N 1.304 -1.412 0 CA-C-N 114.537 -1.211 . . . . 5.7300000000000004 107.915 178.179 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.418 ' O ' ' CG2' ' A' ' 9' ' ' THR . 17.8 m -92.39 2.57 56.58 Favored 'General case' 0 C--N 1.298 -1.638 0 N-CA-C 106.008 -1.849 . . . . 5.3499999999999996 106.008 177.373 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.403 ' C ' ' O ' ' A' ' 9' ' ' THR . 7.5 p -40.74 -38.29 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 CA-C-O 121.792 0.806 . . . . 4.3799999999999999 109.401 179.838 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.602 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 143.97 -86.87 0.18 Allowed Glycine 0 N--CA 1.496 2.691 0 N-CA-C 108.564 -1.814 . . . . 4.4800000000000004 108.564 179.566 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.452 ' O ' ' N ' ' A' ' 14' ' ' GLY . 12.5 Cg_endo -69.34 34.98 0.2 Allowed 'Trans proline' 0 C--N 1.321 -0.915 0 C-N-CA 121.321 1.347 . . . . 4.0499999999999998 108.974 178.243 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.604 ' CD2' ' N ' ' A' ' 13' ' ' LEU . 0.0 OUTLIER 40.56 28.51 0.05 OUTLIER 'General case' 0 N--CA 1.503 2.206 0 CA-C-O 121.925 0.869 . . . . 4.0599999999999996 108.731 -178.734 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.605 ' C ' ' H ' ' A' ' 16' ' ' GLY . . . 72.37 -42.21 0.81 Allowed Glycine 0 N--CA 1.487 2.071 0 N-CA-C 108.375 -1.89 . . . . 3.1400000000000001 108.375 -179.226 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.534 ' H ' ' C ' ' A' ' 13' ' ' LEU . 28.4 tt0 55.13 2.22 0.05 OUTLIER 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.669 -0.901 . . . . 3.1699999999999999 108.978 -179.257 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.605 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 87.24 -149.21 21.85 Favored Glycine 0 N--CA 1.488 2.107 0 O-C-N 121.292 -0.88 . . . . 2.4399999999999999 111.157 178.78 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.55 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -38.83 -23.39 0.02 OUTLIER Glycine 0 N--CA 1.497 2.702 0 O-C-N 121.819 -0.813 . . . . 2.0499999999999998 111.59 -178.704 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.509 ' N ' ' O ' ' A' ' 16' ' ' GLY . . . -47.25 -11.57 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.861 0 O-C-N 120.857 -1.378 . . . . 2.54 110.145 -179.467 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . 0.55 ' N ' ' O ' ' A' ' 17' ' ' GLY . 1.8 t60 -97.24 -37.73 9.96 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.249 -0.907 . . . . 3.3700000000000001 110.242 -179.372 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.666 ' NZ ' ' HG1' ' A' ' 43' ' ' THR . 0.0 OUTLIER -91.03 -14.48 31.29 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.008 -1.057 . . . . 2.3700000000000001 110.497 -179.145 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.476 ' O ' ' CG1' ' A' ' 21' ' ' VAL . 4.7 p -78.96 114.4 19.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 120.838 -1.164 . . . . 2.5800000000000001 109.712 -179.763 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 12.5 tpp180 -109.75 139.27 45.0 Favored 'General case' 0 N--CA 1.492 1.646 0 N-CA-C 108.92 -0.771 . . . . 3.8900000000000001 108.92 -179.877 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -147.32 113.57 5.89 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.535 -0.728 . . . . 2.0099999999999998 109.2 179.584 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -147.6 128.38 2.9 Favored Glycine 0 N--CA 1.496 2.662 0 N-CA-C 109.472 -1.451 . . . . 2.0099999999999998 109.472 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.07 171.24 43.69 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.842 -1.303 . . . . 1.9299999999999999 109.842 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 34.1 m -74.89 -23.6 58.4 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.329 -1.101 . . . . 2.6899999999999999 109.266 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.465 ' C ' ' H ' ' A' ' 29' ' ' GLU . . . -68.61 -27.92 73.51 Favored Glycine 0 N--CA 1.485 1.925 0 N-CA-C 108.444 -1.862 . . . . 1.6399999999999999 108.444 179.641 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 24.9 mt -81.06 26.92 0.41 Allowed 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 108.416 -0.957 . . . . 2.0299999999999998 108.416 179.397 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.465 ' H ' ' C ' ' A' ' 27' ' ' GLY . 42.5 mt-10 -132.21 -50.56 0.94 Allowed 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.687 -0.633 . . . . 2.3399999999999999 109.608 -179.621 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 29.0 ptt180 -168.17 177.8 5.32 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 120.89 -1.131 . . . . 4.25 110.602 -179.774 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -151.08 175.68 29.92 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 108.566 -1.814 . . . . 1.5900000000000001 108.566 179.686 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 39.9 t -134.56 151.93 32.58 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.087 0 O-C-N 121.22 -1.165 . . . . 2.21 110.748 -179.702 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -39.16 108.95 0.09 Allowed 'General case' 0 N--CA 1.5 2.029 0 CA-C-O 121.399 0.618 . . . . 2.0699999999999998 112.494 -179.388 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 54.57 53.71 37.15 Favored Glycine 0 N--CA 1.491 2.323 0 O-C-N 121.393 -0.817 . . . . 1.73 111.626 176.899 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 24.0 t -127.23 124.28 23.68 Favored Pre-proline 0 N--CA 1.496 1.826 0 N-CA-C 108.205 -1.035 . . . . 2.6499999999999999 108.205 178.663 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo -57.24 128.95 31.69 Favored 'Trans proline' 0 C--O 1.216 -0.615 0 N-CA-C 109.693 -0.926 . . . . 2.1400000000000001 109.693 -179.581 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -134.36 157.89 45.22 Favored 'General case' 0 N--CA 1.502 2.16 0 O-C-N 121.518 -0.739 . . . . 2.0299999999999998 109.507 -179.634 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -160.14 164.08 33.23 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.121 -0.987 . . . . 2.23 110.976 -179.663 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.558 ' N ' ' CD1' ' A' ' 39' ' ' PHE . 0.7 OUTLIER -139.89 -179.03 5.71 Favored 'General case' 0 C--N 1.304 -1.391 0 N-CA-C 106.896 -1.52 . . . . 1.72 106.896 177.75 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 52.2 p -119.16 145.87 45.64 Favored 'General case' 0 N--CA 1.5 2.04 0 O-C-N 121.598 -0.688 . . . . 2.5800000000000001 110.609 -178.816 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.537 ' O ' ' N ' ' A' ' 73' ' ' CYS . 42.8 mt -143.63 128.68 15.1 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 N-CA-C 108.58 -0.896 . . . . 1.8600000000000001 108.58 179.213 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 5.5 p-90 -128.24 138.78 52.59 Favored 'General case' 0 N--CA 1.502 2.161 0 N-CA-C 108.853 -0.795 . . . . 4.4699999999999998 108.853 179.423 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' THR . . . . . 0.666 ' HG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -162.42 139.22 7.9 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.171 -0.956 . . . . 3.27 109.896 -179.534 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' ARG . . . . . . . . . . . . . 61.7 ttt180 -171.84 68.38 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.414 -0.804 . . . . 5.2300000000000004 109.226 179.732 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 11.1 tp10 -153.72 -51.79 0.1 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.244 -0.91 . . . . 2.8900000000000001 109.568 -179.87 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.76 -50.08 73.33 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.201 -0.937 . . . . 1.99 108.946 179.795 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 116.14 -162.4 12.62 Favored Glycine 0 N--CA 1.497 2.745 0 N-CA-C 109.639 -1.384 . . . . 1.6499999999999999 109.639 179.735 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.4 151.98 5.11 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.276 -1.132 . . . . 1.77 109.386 -179.841 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -176.49 -162.72 27.7 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.55 -1.42 . . . . 1.1200000000000001 109.55 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -140.47 119.71 1.63 Allowed Glycine 0 N--CA 1.496 2.663 0 N-CA-C 109.528 -1.429 . . . . 1.1799999999999999 109.528 -179.878 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.428 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 11.6 tp -99.43 99.04 9.9 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.357 -1.084 . . . . 1.5900000000000001 108.691 179.685 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 4.1 m -84.8 142.33 29.85 Favored 'General case' 0 N--CA 1.496 1.84 0 N-CA-C 108.741 -0.837 . . . . 1.9399999999999999 108.741 179.867 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.501 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 80.5 mt -132.36 116.6 29.21 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 O-C-N 121.01 -1.056 . . . . 1.3 109.889 -179.915 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -106.99 106.92 17.69 Favored 'General case' 0 N--CA 1.496 1.865 0 N-CA-C 108.562 -0.903 . . . . 1.27 108.562 179.328 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -106.23 137.55 35.96 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 121.388 -0.82 . . . . 1.55 109.941 -179.186 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . 0.433 ' OE2' ' O ' ' B' ' 9' ' ' VAL . 40.7 tp10 -131.97 142.78 49.72 Favored 'General case' 0 N--CA 1.495 1.785 0 N-CA-C 107.896 -1.15 . . . . 1.8 107.896 178.36 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 172.95 -179.51 44.34 Favored Glycine 0 N--CA 1.488 2.132 0 N-CA-C 108.784 -1.726 . . . . 0.56000000000000005 108.784 -179.635 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -63.43 -21.91 71.26 Favored 'Trans proline' 0 C--N 1.315 -1.231 0 C-N-CA 121.678 1.585 . . . . 0.76000000000000001 110.732 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' SER . . . . . 0.423 ' O ' ' OH ' ' A' ' 85' ' ' TYR . 36.6 m -143.24 165.47 27.36 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.453 -0.78 . . . . 2.02 110.114 -179.62 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 38.2 mttp -86.97 104.96 16.78 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.507 -0.746 . . . . 3.02 109.396 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -67.06 113.06 4.74 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.337 -0.852 . . . . 1.3600000000000001 109.535 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 24.5 mm-40 -53.72 171.76 0.09 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.282 -0.886 . . . . 2.2999999999999998 109.225 179.84 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 90.1 mt -142.32 155.59 18.83 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 N-CA-C 108.122 -1.066 . . . . 2.0 108.122 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.542 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -149.56 175.35 11.6 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 120.642 -1.286 . . . . 1.73 109.635 -179.802 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.522 ' CD2' ' O ' ' A' ' 65' ' ' PHE . 54.6 p90 -138.88 124.77 19.84 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.448 -0.782 . . . . 1.6000000000000001 109.124 179.846 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -141.46 123.63 15.58 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.273 -0.892 . . . . 2.5099999999999998 109.579 -179.825 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -99.77 101.97 13.28 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.364 -0.835 . . . . 2.0699999999999998 109.267 179.807 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 39.4 ttm180 -90.14 -15.55 31.34 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.198 -0.939 . . . . 5.29 109.763 -179.771 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.539 ' C ' ' H ' ' A' ' 71' ' ' GLY . 4.5 mmmm -127.56 5.12 6.18 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 121.442 -0.786 . . . . 3.8599999999999999 109.44 -179.681 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.464 ' CB ' ' O ' ' A' ' 69' ' ' LYS . 4.5 t0 73.14 -17.21 0.43 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.198 -0.939 . . . . 3.0600000000000001 108.739 -179.437 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . 0.539 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -124.97 -17.02 2.84 Favored Glycine 0 N--CA 1.495 2.593 0 N-CA-C 109.367 -1.493 . . . . 2.1600000000000001 109.367 -179.671 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 40.3 t -95.85 100.37 12.08 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.258 -1.142 . . . . 2.5600000000000001 109.176 179.785 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' CYS . . . . . 0.537 ' N ' ' O ' ' A' ' 41' ' ' ILE . 46.6 t -71.54 111.1 6.57 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.228 -0.92 . . . . 2.3599999999999999 109.48 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -91.96 115.14 4.71 Favored Glycine 0 N--CA 1.493 2.477 0 N-CA-C 109.692 -1.363 . . . . 1.46 109.692 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 45.3 t -99.38 102.0 12.84 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 O-C-N 121.467 -1.019 . . . . 2.1600000000000001 109.011 179.721 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.542 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.4 OUTLIER -92.0 137.09 32.65 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.338 -0.851 . . . . 2.1600000000000001 109.111 -179.837 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 8.5 p90 -136.34 166.04 24.38 Favored 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 108.674 -0.861 . . . . 1.7 108.674 -179.862 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 6.7 t -141.86 110.05 2.34 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.329 -0.857 . . . . 2.4500000000000002 109.585 -179.669 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 3.3 m -84.73 154.32 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.544 -0.723 . . . . 1.8200000000000001 109.429 -179.915 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 4.3 tp-100 -93.26 -48.93 6.21 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.065 -1.022 . . . . 3.1699999999999999 111.015 -178.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.431 ' O ' ' O ' ' A' ' 82' ' ' PRO . 81.5 mm-40 -148.57 149.92 32.39 Favored Pre-proline 0 N--CA 1.504 2.263 0 O-C-N 120.68 -1.262 . . . . 2.02 111.609 -178.427 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.573 ' HG3' ' N ' ' A' ' 107' ' ' SER . 83.1 Cg_exo -37.18 168.53 0.0 OUTLIER 'Trans proline' 0 C--O 1.216 -0.599 0 C-N-CA 123.15 2.567 . . . . 1.3999999999999999 113.787 178.37 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 141.8 -173.8 23.4 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 108.651 -1.779 . . . . 1.0800000000000001 108.651 -179.87 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . 0.668 ' N ' HH12 ' B' ' 8' ' ' ARG . 0.4 OUTLIER -103.18 90.41 3.72 Favored 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 107.866 -1.161 . . . . 2.1299999999999999 107.866 179.217 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . 0.423 ' OH ' ' O ' ' A' ' 59' ' ' SER . 3.0 m-85 -74.69 133.4 42.09 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 107.992 -1.114 . . . . 1.1399999999999999 107.992 -179.574 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.36 116.38 28.85 Favored 'General case' 0 N--CA 1.5 2.034 0 N-CA-C 108.503 -0.925 . . . . 1.53 108.503 -178.791 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 11.3 p -114.63 142.32 27.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 121.719 -0.613 . . . . 1.6399999999999999 109.865 -179.66 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 32.9 t -136.11 106.07 6.28 Favored 'General case' 0 N--CA 1.494 1.756 0 N-CA-C 109.289 -0.634 . . . . 1.99 109.289 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.8 pt -111.4 136.85 46.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 CA-C-O 121.374 0.607 . . . . 1.77 110.148 -179.429 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . 0.46 ' HZ2' ' CD2' ' A' ' 95' ' ' HIS . 0.3 OUTLIER -138.99 121.27 15.92 Favored 'General case' 0 N--CA 1.486 1.355 0 N-CA-C 108.518 -0.919 . . . . 2.0600000000000001 108.518 179.329 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.411 ' CE2' ' NZ ' ' A' ' 20' ' ' LYS . 52.6 t80 -80.1 99.02 7.52 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 107.699 -1.223 . . . . 1.45 107.699 178.563 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . 0.442 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 3.6 t-20 69.8 37.79 1.76 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.503 -0.748 . . . . 2.7200000000000002 109.284 -178.735 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . 0.442 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 1.8 m-20 79.06 13.49 1.2 Allowed 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.625 -0.672 . . . . 1.9199999999999999 111.629 179.313 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . 0.482 ' OE1' ' CB ' ' A' ' 18' ' ' ALA . 0.6 OUTLIER -99.29 97.88 8.9 Favored 'General case' 0 N--CA 1.5 2.059 0 N-CA-C 106.857 -1.534 . . . . 2.5499999999999998 106.857 177.732 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . 0.602 ' H ' ' HD1' ' A' ' 95' ' ' HIS . 5.9 m80 -67.88 101.86 1.16 Allowed 'General case' 0 N--CA 1.487 1.421 0 CA-C-O 121.411 0.624 . . . . 3.2000000000000002 110.924 -177.636 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . 0.408 ' CD1' ' OD1' ' A' ' 98' ' ' ASP . 2.1 tt -53.32 137.46 49.69 Favored Pre-proline 0 N--CA 1.49 1.566 0 N-CA-C 106.869 -1.53 . . . . 2.8199999999999998 106.869 178.26 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_exo -40.76 -39.06 2.95 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 121.077 1.184 . . . . 2.6299999999999999 111.194 -178.575 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.408 ' OD1' ' CD1' ' A' ' 96' ' ' ILE . 8.6 m-20 -50.12 -67.2 0.28 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.787 -1.196 . . . . 2.6499999999999999 109.092 178.843 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 2.8 p -57.53 142.03 77.77 Favored Pre-proline 0 C--N 1.296 -1.759 0 O-C-N 121.405 -0.81 . . . . 2.3199999999999998 110.086 -178.236 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -85.15 114.92 3.22 Favored 'Cis proline' 0 N--CA 1.49 1.288 0 N-CA-C 108.739 -1.293 . . . . 1.9399999999999999 108.739 -2.612 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 51.8 p90 -112.77 156.45 22.83 Favored 'General case' 0 N--CA 1.514 2.748 0 O-C-N 120.405 -1.434 . . . . 2.6299999999999999 110.217 179.286 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.4 p -88.94 146.1 6.58 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 CA-C-O 121.556 0.693 . . . . 1.8200000000000001 110.417 -178.595 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 47.3 t -120.97 86.55 42.09 Favored Pre-proline 0 N--CA 1.494 1.768 0 N-CA-C 107.753 -1.203 . . . . 1.73 107.753 179.236 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo -65.07 111.08 1.65 Allowed 'Trans proline' 0 C--N 1.32 -0.935 0 C-N-CA 121.393 1.395 . . . . 1.6100000000000001 111.74 -177.879 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 58.6 t -96.53 141.05 16.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 N-CA-C 106.148 -1.797 . . . . 1.7 106.148 177.828 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -133.89 133.72 41.83 Favored 'General case' 0 N--CA 1.51 2.53 0 CA-C-O 122.303 1.049 . . . . 2.04 112.131 -177.031 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' SER . . . . . 0.573 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 17.0 t -101.02 85.55 2.87 Favored 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 107.129 -1.434 . . . . 2.2999999999999998 107.129 178.685 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 12.9 mt 64.76 0.51 1.18 Allowed 'General case' 0 C--N 1.296 -1.729 0 N-CA-C 108.035 -1.098 . . . . 3.6000000000000001 108.035 -178.011 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.568 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 8.2 t -89.88 -24.95 21.23 Favored 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 109.011 -0.737 . . . . 2.4900000000000002 109.011 179.061 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 25.2 t70 54.32 10.65 0.33 Allowed 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 107.897 -1.149 . . . . 2.8500000000000001 107.897 -178.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.521 ' H ' ' C ' ' A' ' 109' ' ' SER . 42.3 t0 -168.81 -34.01 0.02 OUTLIER 'General case' 0 C--N 1.305 -1.341 0 O-C-N 121.756 -0.59 . . . . 2.46 109.556 -179.73 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.568 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 34.66 78.02 0.03 OUTLIER 'General case' 0 N--CA 1.508 2.433 0 O-C-N 121.479 -0.763 . . . . 2.0800000000000001 110.894 179.883 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 72.6 mtt180 -82.91 167.15 18.28 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.127 -0.983 . . . . 6.54 109.756 -179.475 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 28.2 ttp180 -110.52 5.4 21.2 Favored 'General case' 0 N--CA 1.498 1.929 0 N-CA-C 108.649 -0.871 . . . . 6.2400000000000002 108.649 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 27.9 mt -125.65 -26.59 3.5 Favored 'General case' 0 N--CA 1.503 2.221 0 N-CA-C 109.157 -0.682 . . . . 4.71 109.157 -179.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.553 ' C ' ' H ' ' A' ' 118' ' ' THR . 99.8 m -107.93 -79.19 0.58 Allowed 'General case' 0 N--CA 1.497 1.914 0 N-CA-C 107.244 -1.391 . . . . 4.3499999999999996 107.244 179.165 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 46.1 t -60.8 -8.94 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.644 0 N-CA-C 106.053 -1.832 . . . . 3.3100000000000001 106.053 176.803 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' THR . . . . . 0.553 ' H ' ' C ' ' A' ' 116' ' ' THR . 4.9 t 36.59 59.07 1.03 Allowed 'General case' 0 N--CA 1.486 1.35 0 CA-C-N 115.181 -0.918 . . . . 3.73 110.835 179.632 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' SER . . . . . 0.456 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.6 p . . . . . 0 C--N 1.303 -1.44 0 CA-C-O 117.984 -1.008 . . . . 3.8300000000000001 109.492 179.383 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 1' ' ' MET . . . . . 0.59 ' SD ' ' N ' ' B' ' 1' ' ' MET . 1.8 mpp? . . . . . 0 N--CA 1.491 1.602 0 N-CA-C 109.421 -0.585 . . . . 8.8699999999999992 109.421 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 2' ' ' ALA . . . . . 0.448 ' O ' ' O ' ' B' ' 3' ' ' SER . . . 59.02 113.25 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.396 -0.815 . . . . 5.9299999999999997 109.652 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 3' ' ' SER . . . . . 0.448 ' O ' ' O ' ' B' ' 2' ' ' ALA . 17.1 p 47.96 98.45 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.441 -0.787 . . . . 5.5700000000000003 109.857 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 4' ' ' LYS . . . . . 0.479 ' O ' ' O ' ' B' ' 5' ' ' PRO . 37.2 mtmt -46.77 155.01 0.64 Allowed Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.272 -0.892 . . . . 7.25 109.095 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 5' ' ' PRO . . . . . 0.49 ' O ' ' CB ' ' B' ' 6' ' ' GLU . 3.2 Cg_exo -55.8 -148.31 0.0 OUTLIER 'Trans proline' 0 CA--C 1.544 1.002 0 C-N-CA 121.479 1.453 . . . . 5.8899999999999997 110.357 179.411 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 6' ' ' GLU . . . . . 0.49 ' CB ' ' O ' ' B' ' 5' ' ' PRO . 20.0 tt0 82.18 150.59 0.09 Allowed 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.41 -0.806 . . . . 4.7800000000000002 109.25 -179.682 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 44.1 mtmt -78.38 -156.51 0.1 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.299 -0.875 . . . . 4.5599999999999996 109.869 -179.597 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . 0.668 HH12 ' N ' ' A' ' 84' ' ' ASP . 43.8 mtt180 -101.02 -176.47 3.17 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.395 -0.816 . . . . 3.6699999999999999 109.325 -179.781 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 9' ' ' VAL . . . . . 0.433 ' O ' ' OE2' ' A' ' 56' ' ' GLU . 15.2 t -59.34 160.32 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 N-CA-C 107.718 -1.215 . . . . 1.3899999999999999 107.718 178.719 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -116.99 142.94 46.31 Favored 'General case' 0 N--CA 1.503 2.189 0 O-C-N 121.287 -0.883 . . . . 1.22 110.433 -179.073 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 30.2 t -143.72 131.36 21.25 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.471 -0.768 . . . . 1.6299999999999999 109.063 179.47 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 87.8 p -140.39 120.19 13.46 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.232 -0.918 . . . . 1.8799999999999999 109.587 -179.727 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . 0.501 ' CG2' ' N ' ' B' ' 14' ' ' PHE . 3.0 p -162.26 168.3 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.412 0 O-C-N 121.379 -0.826 . . . . 1.2 109.073 -179.948 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 14' ' ' PHE . . . . . 0.501 ' HB3' ' H ' ' A' ' 53' ' ' ILE . 6.6 p90 -177.1 -171.76 0.37 Allowed 'General case' 0 N--CA 1.487 1.4 0 C-N-CA 119.391 -0.923 . . . . 2.3900000000000001 112.008 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -142.64 173.78 6.38 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.322 0 N-CA-C 108.335 -0.987 . . . . 1.8100000000000001 108.335 179.597 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 32.3 p -146.65 139.82 25.54 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 120.929 -1.107 . . . . 2.04 109.817 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.4 mt -90.34 133.62 34.85 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.256 -0.902 . . . . 1.8700000000000001 109.074 179.582 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -169.56 80.74 0.66 Allowed Pre-proline 0 N--CA 1.489 1.489 0 O-C-N 121.278 -0.889 . . . . 1.47 109.516 -179.436 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_exo -57.34 112.15 1.04 Allowed 'Trans proline' 0 CA--C 1.554 1.505 0 C-N-CA 121.357 1.371 . . . . 1.96 109.82 -179.385 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 20' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -66.3 -65.61 0.04 OUTLIER 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 120.761 0.974 . . . . 3.3799999999999999 110.101 -179.661 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 7.0 tpt180 -48.51 145.53 3.46 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.295 -0.878 . . . . 6.7400000000000002 109.54 -179.423 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 22' ' ' ARG . . . . . 0.41 HH11 ' CG ' ' B' ' 22' ' ' ARG . 0.2 OUTLIER -147.96 64.97 1.1 Allowed 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.274 -0.891 . . . . 6.9400000000000004 109.251 179.941 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -71.43 161.04 31.68 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.237 -0.914 . . . . 5.6200000000000001 109.297 179.828 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 16.7 m . . . . . 0 N--CA 1.49 1.571 0 CA-C-O 117.938 -1.03 . . . . 6.75 109.483 -179.869 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.531 4.97 0 N-CA-C 119.75 2.66 . . . . 6.7300000000000004 119.75 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.562 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 11.0 tp -171.86 50.16 0.12 Allowed Pre-proline 0 C--N 1.307 -1.268 0 N-CA-C 108.131 -1.063 . . . . 7.3799999999999999 108.131 179.559 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.79 ' C ' ' H ' ' A' ' 5' ' ' PHE . 1.0 OUTLIER -53.96 -79.53 0.02 OUTLIER 'Trans proline' 0 C--N 1.319 -1.013 0 C-N-CA 121.133 1.222 . . . . 5.5 109.073 179.737 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.526 ' C ' ' H ' ' A' ' 6' ' ' PHE . 9.4 tt0 73.35 -16.78 0.46 Allowed 'General case' 0 N--CA 1.494 1.73 0 N-CA-C 104.39 -2.448 . . . . 6.8399999999999999 104.39 -175.703 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . 0.79 ' H ' ' C ' ' A' ' 3' ' ' PRO . 3.7 m-85 -89.73 17.92 6.07 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 103.909 -2.626 . . . . 6.4400000000000004 103.909 176.708 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.531 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 41.3 p90 45.58 -155.0 0.04 OUTLIER 'General case' 0 C--N 1.307 -1.246 0 CA-C-N 114.23 -1.35 . . . . 5.0599999999999996 109.432 -177.642 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.531 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 18.8 tt0 83.67 -9.26 1.02 Allowed 'General case' 0 N--CA 1.492 1.638 0 N-CA-C 105.019 -2.215 . . . . 4.8099999999999996 105.019 -177.226 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.49 ' H ' ' C ' ' A' ' 6' ' ' PHE . 85.1 t80 -154.19 -36.56 0.1 Allowed 'General case' 0 C--N 1.305 -1.361 0 CA-C-N 114.66 -1.155 . . . . 5.7300000000000004 108.111 178.484 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 94.2 m -93.79 2.99 56.09 Favored 'General case' 0 C--N 1.298 -1.673 0 N-CA-C 105.815 -1.921 . . . . 5.3499999999999996 105.815 177.25 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.3 p -43.18 -36.3 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 CA-C-N 115.433 -0.803 . . . . 4.3799999999999999 109.399 -179.918 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.627 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 141.22 -84.86 0.21 Allowed Glycine 0 N--CA 1.497 2.757 0 N-CA-C 108.311 -1.916 . . . . 4.4800000000000004 108.311 179.802 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.492 ' O ' ' N ' ' A' ' 14' ' ' GLY . 14.0 Cg_endo -67.84 40.33 0.21 Allowed 'Trans proline' 0 C--N 1.319 -0.996 0 C-N-CA 121.619 1.546 . . . . 4.0499999999999998 108.412 177.633 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.627 ' H ' ' C ' ' A' ' 11' ' ' GLY . 0.2 OUTLIER 29.08 39.51 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.238 0 CA-C-O 121.508 0.671 . . . . 4.0599999999999996 110.73 -179.295 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.527 ' C ' ' H ' ' A' ' 16' ' ' GLY . . . 69.61 -37.26 0.36 Allowed Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.423 -1.471 . . . . 3.1400000000000001 109.423 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.564 ' H ' ' C ' ' A' ' 13' ' ' LEU . 7.2 tp10 57.66 4.43 0.25 Allowed 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.352 -1.087 . . . . 3.1699999999999999 108.888 -179.833 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.527 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 65.9 90.73 0.04 OUTLIER Glycine 0 N--CA 1.49 2.255 0 N-CA-C 110.643 -0.983 . . . . 2.4399999999999999 110.643 179.213 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.583 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 64.21 -47.1 0.1 OUTLIER Glycine 0 N--CA 1.493 2.497 0 O-C-N 121.479 -1.012 . . . . 2.0499999999999998 111.055 178.823 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.497 ' N ' ' O ' ' A' ' 16' ' ' GLY . . . -46.24 -11.13 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.871 0 O-C-N 120.959 -1.318 . . . . 2.54 110.05 -179.578 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . 0.583 ' N ' ' O ' ' A' ' 17' ' ' GLY . 34.0 t60 -84.64 -48.42 9.51 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 120.994 -1.066 . . . . 3.3700000000000001 109.6 179.729 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.552 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.1 OUTLIER -83.18 -3.63 57.57 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.047 -1.033 . . . . 2.3700000000000001 110.192 -179.617 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 66.6 t -77.86 113.24 16.8 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 120.944 -1.098 . . . . 2.5800000000000001 109.537 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 20.9 tpt180 -100.14 138.93 36.53 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.633 -0.667 . . . . 3.8900000000000001 109.571 -179.858 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -147.42 113.37 5.79 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 108.402 -0.962 . . . . 2.0099999999999998 108.402 179.332 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -158.5 128.7 2.12 Favored Glycine 0 N--CA 1.491 2.339 0 C-N-CA 119.688 -1.244 . . . . 2.0099999999999998 110.234 -179.199 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.3 -179.7 48.77 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.641 -1.383 . . . . 1.9299999999999999 109.641 179.611 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 6.5 m -76.58 -21.86 55.03 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.168 -1.195 . . . . 2.6899999999999999 109.24 179.759 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.9 -23.83 77.64 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 108.818 -1.713 . . . . 1.6399999999999999 108.818 179.71 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 34.6 mt -85.1 28.79 0.69 Allowed 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.499 -1.001 . . . . 2.0299999999999998 108.689 179.572 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 15.0 mt-10 -138.71 -64.24 0.52 Allowed 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.503 -0.748 . . . . 2.3399999999999999 109.908 -179.655 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 80.8 mtm180 -150.64 165.42 33.44 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 120.895 -1.128 . . . . 4.25 110.222 -179.248 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -139.07 170.57 24.01 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 107.473 -2.251 . . . . 1.5900000000000001 107.473 178.887 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 40.5 t -133.85 151.31 32.63 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.109 0 O-C-N 121.088 -1.243 . . . . 2.21 110.948 -179.029 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -40.48 114.59 0.47 Allowed 'General case' 0 N--CA 1.497 1.902 0 CA-C-O 121.867 0.841 . . . . 2.0699999999999998 112.428 -179.313 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 52.99 49.71 54.19 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 111.225 -0.75 . . . . 1.73 111.225 177.13 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 22.5 t -127.02 124.98 24.1 Favored Pre-proline 0 N--CA 1.496 1.843 0 O-C-N 121.497 -1.002 . . . . 2.6499999999999999 108.46 179.143 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -58.41 109.86 0.57 Allowed 'Trans proline' 0 C--O 1.215 -0.637 0 N-CA-C 109.682 -0.93 . . . . 2.1400000000000001 109.682 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -108.03 142.07 38.74 Favored 'General case' 0 N--CA 1.495 1.825 0 N-CA-C 107.929 -1.138 . . . . 2.0299999999999998 107.929 179.408 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -150.92 169.52 21.53 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.871 -1.143 . . . . 2.23 111.244 -179.385 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.45 ' N ' ' CD1' ' A' ' 39' ' ' PHE . 5.2 p90 -154.35 173.78 15.73 Favored 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 107.617 -1.253 . . . . 1.72 107.617 178.452 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 72.9 m -101.54 150.82 22.68 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.496 -0.753 . . . . 2.5800000000000001 110.469 -178.652 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 11.3 mt -142.95 90.64 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 N-CA-C 108.748 -0.834 . . . . 1.8600000000000001 108.748 178.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.517 ' CE3' ' O ' ' A' ' 71' ' ' GLY . 31.1 t-105 -92.93 120.01 32.81 Favored 'General case' 0 N--CA 1.493 1.704 0 N-CA-C 108.251 -1.018 . . . . 4.4699999999999998 108.251 179.504 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' THR . . . . . 0.552 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -152.74 108.84 3.36 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.276 -0.89 . . . . 3.27 109.594 -179.148 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' ARG . . . . . 0.588 ' CG ' HH11 ' A' ' 44' ' ' ARG . 0.1 OUTLIER -171.57 82.12 0.07 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.225 -0.922 . . . . 5.2300000000000004 109.599 -179.984 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 74.2 tt0 -159.5 -46.24 0.05 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.016 -1.053 . . . . 2.8900000000000001 109.985 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.15 -45.62 87.68 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.03 -1.044 . . . . 1.99 109.195 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 160.78 -153.03 23.83 Favored Glycine 0 N--CA 1.485 1.903 0 C-N-CA 119.403 -1.379 . . . . 1.6499999999999999 110.175 179.786 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -96.66 158.57 15.37 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.558 -0.966 . . . . 1.77 109.174 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -179.09 173.0 45.2 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.392 -1.483 . . . . 1.1200000000000001 109.392 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -105.11 121.09 6.76 Favored Glycine 0 N--CA 1.495 2.624 0 N-CA-C 109.501 -1.439 . . . . 1.1799999999999999 109.501 -179.891 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.437 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 64.2 tp -91.01 108.79 20.09 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.222 -1.163 . . . . 1.5900000000000001 107.897 179.153 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.7 t -91.23 142.37 27.8 Favored 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 108.663 -0.865 . . . . 1.9399999999999999 108.663 179.89 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.515 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 22.5 mt -130.49 100.62 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 121.521 -0.737 . . . . 1.3 109.071 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -93.86 106.41 18.38 Favored 'General case' 0 N--CA 1.489 1.506 0 N-CA-C 108.621 -0.881 . . . . 1.27 108.621 179.711 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -101.48 143.28 14.7 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 CA-C-O 121.588 0.708 . . . . 1.55 109.582 -179.631 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 8.2 tt0 -141.52 145.57 35.33 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 107.479 -1.304 . . . . 1.8 107.479 178.868 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 165.56 -172.71 41.14 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.856 -1.298 . . . . 0.56000000000000005 109.856 -179.095 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -63.18 -33.99 70.14 Favored 'Trans proline' 0 C--N 1.319 -0.988 0 C-N-CA 122.315 2.01 . . . . 0.76000000000000001 112.514 -179.435 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' SER . . . . . 0.497 ' OG ' ' N ' ' A' ' 60' ' ' LYS . 5.9 t -132.36 177.76 7.34 Favored 'General case' 0 N--CA 1.504 2.239 0 O-C-N 120.944 -1.097 . . . . 2.02 110.49 -179.273 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . 0.497 ' N ' ' OG ' ' A' ' 59' ' ' SER . 45.8 tttm -93.82 96.18 9.59 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.689 -0.632 . . . . 3.02 109.713 -179.591 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -61.54 131.17 49.23 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.179 -0.951 . . . . 1.3600000000000001 109.017 179.696 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 16.2 tp10 -88.54 95.05 10.08 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 120.964 -1.085 . . . . 2.2999999999999998 110.174 -179.456 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . 0.448 ' N ' ' CD1' ' A' ' 63' ' ' ILE . 1.7 mp -60.61 156.04 3.43 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 N-CA-C 109.207 -0.664 . . . . 2.0 109.207 179.335 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.476 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -144.72 172.38 13.08 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.013 -1.054 . . . . 1.73 108.78 179.598 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.524 ' CD2' ' O ' ' A' ' 65' ' ' PHE . 41.0 p90 -148.44 116.2 6.33 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.26 -0.9 . . . . 1.6000000000000001 109.188 179.845 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 78.6 tt0 -141.78 105.05 4.63 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.161 -0.962 . . . . 2.5099999999999998 109.821 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -81.91 107.17 14.41 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.232 -0.918 . . . . 2.0699999999999998 108.935 179.452 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.526 ' CG ' HH11 ' A' ' 68' ' ' ARG . 0.0 OUTLIER -110.98 -9.43 14.42 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.532 -0.73 . . . . 5.29 109.096 -179.477 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.528 ' C ' ' H ' ' A' ' 71' ' ' GLY . 58.1 mmtt -109.73 -9.37 14.84 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.355 -0.841 . . . . 3.8599999999999999 109.104 179.894 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 4.8 t70 64.79 -3.12 0.6 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.378 -0.826 . . . . 3.0600000000000001 109.394 179.656 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . 0.528 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -141.34 17.18 2.69 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.423 -1.471 . . . . 2.1600000000000001 109.423 -179.009 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 19.8 t -156.36 114.96 3.38 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.457 -1.025 . . . . 2.5600000000000001 108.827 179.673 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 8.6 t -76.69 129.14 35.93 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.103 -0.998 . . . . 2.3599999999999999 109.103 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -103.68 114.68 4.87 Favored Glycine 0 N--CA 1.496 2.69 0 N-CA-C 110.064 -1.214 . . . . 1.46 110.064 -179.332 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 38.4 t -101.83 108.74 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.925 0 O-C-N 121.516 -0.99 . . . . 2.1600000000000001 108.771 179.426 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.476 ' O ' ' N ' ' A' ' 64' ' ' ALA . 4.1 t -103.46 127.69 50.79 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.531 -0.731 . . . . 2.1600000000000001 109.457 179.849 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 6.4 p90 -128.45 128.2 43.97 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 108.303 -0.999 . . . . 1.7 108.303 179.838 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -103.8 110.06 29.01 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.159 0 O-C-N 121.324 -0.86 . . . . 2.4500000000000002 109.404 -178.859 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 5.8 m -82.6 163.39 3.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.496 -0.753 . . . . 1.8200000000000001 109.42 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 20.1 tt0 -95.78 -50.39 4.93 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.005 -1.059 . . . . 3.1699999999999999 111.117 -179.163 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -152.29 155.55 33.17 Favored Pre-proline 0 N--CA 1.504 2.237 0 O-C-N 120.688 -1.257 . . . . 2.02 111.72 -178.594 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.525 ' HG3' ' N ' ' A' ' 107' ' ' SER . 75.9 Cg_exo -37.07 160.77 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 123.61 2.873 . . . . 1.3999999999999999 113.636 179.285 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 148.19 -164.16 28.94 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.223 -1.551 . . . . 1.0800000000000001 109.223 179.816 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 65.0 m-20 -108.82 88.85 2.83 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.601 -0.94 . . . . 2.1299999999999999 108.662 179.656 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . 0.499 ' O ' ' N ' ' A' ' 103' ' ' VAL . 2.9 m-85 -76.27 129.52 36.8 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 108.165 -1.05 . . . . 1.1399999999999999 108.165 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -107.85 128.33 54.51 Favored 'General case' 0 N--CA 1.497 1.914 0 N-CA-C 108.144 -1.058 . . . . 1.53 108.144 -179.446 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 9.4 p -126.12 140.27 49.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.525 -0.734 . . . . 1.6399999999999999 109.972 -179.401 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' SER . . . . . 0.425 ' O ' ' OG ' ' A' ' 88' ' ' SER . 11.1 p -134.4 104.39 6.11 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.585 -0.697 . . . . 1.99 109.52 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.422 ' H ' ' HG ' ' A' ' 99' ' ' SER . 0.8 OUTLIER -112.33 129.58 67.6 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 CA-C-O 121.585 0.707 . . . . 1.77 109.492 -179.847 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . 0.469 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -139.71 124.2 18.17 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 108.232 -1.025 . . . . 2.0600000000000001 108.232 179.661 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.408 ' O ' ' CB ' ' A' ' 92' ' ' ASN . 31.8 t80 -85.64 102.96 14.02 Favored 'General case' 0 N--CA 1.494 1.737 0 N-CA-C 107.546 -1.279 . . . . 1.45 107.546 178.783 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . 0.423 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 8.5 t30 72.48 35.84 1.09 Allowed 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.806 -0.813 . . . . 2.7200000000000002 108.806 -178.235 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . 0.423 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 1.7 m-20 76.4 15.24 2.25 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.676 -0.64 . . . . 1.9199999999999999 111.409 179.692 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . 0.498 ' CG ' ' O ' ' A' ' 94' ' ' GLU . 7.2 pt-20 -98.53 100.43 11.68 Favored 'General case' 0 N--CA 1.493 1.717 0 N-CA-C 107.201 -1.407 . . . . 2.5499999999999998 107.201 177.949 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . 0.539 ' CD2' ' H ' ' A' ' 95' ' ' HIS . 7.0 p80 -71.67 106.52 4.11 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.215 -0.928 . . . . 3.2000000000000002 109.534 -178.541 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . 0.561 ' O ' ' N ' ' A' ' 98' ' ' ASP . 10.1 pt -55.82 150.19 28.94 Favored Pre-proline 0 N--CA 1.491 1.611 0 C-N-CA 119.377 -0.929 . . . . 2.8199999999999998 108.507 179.795 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.411 ' O ' ' CG ' ' A' ' 98' ' ' ASP . 4.6 Cg_exo -53.87 82.01 0.03 OUTLIER 'Trans proline' 0 C--O 1.213 -0.738 0 N-CA-C 109.202 -1.114 . . . . 2.6299999999999999 109.202 179.415 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.561 ' N ' ' O ' ' A' ' 96' ' ' ILE . 1.9 m-20 175.05 -63.36 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 108.037 -1.097 . . . . 2.6499999999999999 108.037 -178.949 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' SER . . . . . 0.422 ' HG ' ' H ' ' A' ' 89' ' ' ILE . 5.1 m -59.03 139.08 87.68 Favored Pre-proline 0 C--N 1.298 -1.671 0 O-C-N 121.539 -0.725 . . . . 2.3199999999999998 110.119 -178.134 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_endo -88.58 115.21 2.9 Favored 'Cis proline' 0 N--CA 1.493 1.474 0 N-CA-C 109.722 -0.915 . . . . 1.9399999999999999 109.722 -2.597 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 45.6 p90 -112.53 168.45 9.64 Favored 'General case' 0 N--CA 1.516 2.868 0 O-C-N 120.556 -1.34 . . . . 2.6299999999999999 110.027 178.828 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.4 p -94.38 152.28 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.474 -0.766 . . . . 1.8200000000000001 110.735 -178.901 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.499 ' N ' ' O ' ' A' ' 85' ' ' TYR . 61.3 t -126.69 87.01 57.4 Favored Pre-proline 0 N--CA 1.499 1.992 0 N-CA-C 107.919 -1.141 . . . . 1.73 107.919 179.193 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -61.25 113.09 1.61 Allowed 'Trans proline' 0 C--N 1.32 -0.951 0 C-N-CA 121.376 1.384 . . . . 1.6100000000000001 112.189 -177.787 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 53.8 t -94.16 145.08 8.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 N-CA-C 106.64 -1.615 . . . . 1.7 106.64 177.736 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -136.73 137.33 39.81 Favored 'General case' 0 N--CA 1.506 2.328 0 CA-C-O 122.268 1.032 . . . . 2.04 111.995 -177.507 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' SER . . . . . 0.525 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 9.5 t -110.53 68.47 0.67 Allowed 'General case' 0 N--CA 1.495 1.808 0 N-CA-C 107.229 -1.397 . . . . 2.2999999999999998 107.229 178.855 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . 0.496 ' CB ' ' O ' ' A' ' 107' ' ' SER . 2.6 tp 81.23 -3.53 1.7 Allowed 'General case' 0 N--CA 1.492 1.641 0 N-CA-C 106.603 -1.629 . . . . 3.6000000000000001 106.603 -177.574 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.487 ' C ' ' H ' ' A' ' 111' ' ' ASP . 2.0 m -80.08 -27.09 39.36 Favored 'General case' 0 N--CA 1.486 1.348 0 N-CA-C 108.853 -0.795 . . . . 2.4900000000000002 108.853 179.138 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 37.8 m-20 47.71 16.21 0.07 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.283 -0.886 . . . . 2.8500000000000001 108.799 -179.71 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.487 ' H ' ' C ' ' A' ' 109' ' ' SER . 9.8 t70 -171.55 -29.14 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.695 -0.628 . . . . 2.46 109.401 -179.757 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.437 ' O ' ' O ' ' A' ' 111' ' ' ASP . . . 51.88 97.62 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.812 0 O-C-N 120.973 -1.079 . . . . 2.0800000000000001 109.572 179.851 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 10.8 mmt180 -72.16 -159.12 0.05 OUTLIER 'General case' 0 N--CA 1.485 1.305 0 O-C-N 121.192 -0.942 . . . . 6.54 110.25 -179.601 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.45 ' HG3' HH11 ' A' ' 114' ' ' ARG . 2.4 ttm-85 -142.01 3.39 1.59 Allowed 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.368 -0.832 . . . . 6.2400000000000002 109.124 -179.578 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -126.78 -26.01 3.27 Favored 'General case' 0 N--CA 1.504 2.233 0 O-C-N 121.49 -0.756 . . . . 4.71 109.108 -179.672 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.541 ' C ' ' H ' ' A' ' 118' ' ' THR . 57.5 m -108.58 -78.96 0.58 Allowed 'General case' 0 N--CA 1.497 1.9 0 N-CA-C 107.227 -1.397 . . . . 4.3499999999999996 107.227 179.239 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 53.5 t -61.74 -8.16 2.28 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.672 0 N-CA-C 106.096 -1.816 . . . . 3.3100000000000001 106.096 176.865 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' THR . . . . . 0.541 ' H ' ' C ' ' A' ' 116' ' ' THR . 4.0 t 36.16 61.4 0.78 Allowed 'General case' 0 N--CA 1.486 1.366 0 CA-C-N 115.135 -0.939 . . . . 3.73 110.896 179.699 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' SER . . . . . 0.43 ' OG ' ' O ' ' A' ' 118' ' ' THR . 1.7 p . . . . . 0 C--N 1.303 -1.431 0 CA-C-O 118.015 -0.993 . . . . 3.8300000000000001 109.632 179.236 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 66.9 mtm . . . . . 0 N--CA 1.49 1.557 0 N-CA-C 109.444 -0.576 . . . . 8.8699999999999992 109.444 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' B' B ' 2' ' ' ALA . . . . . 0.431 ' O ' ' O ' ' B' ' 3' ' ' SER . . . -79.0 129.6 34.63 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.165 -0.96 . . . . 5.9299999999999997 109.435 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 3' ' ' SER . . . . . 0.431 ' O ' ' O ' ' B' ' 2' ' ' ALA . 32.7 p 51.99 178.49 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.213 -0.93 . . . . 5.5700000000000003 109.301 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 4' ' ' LYS . . . . . . . . . . . . . 21.7 mtpp -81.39 147.7 60.86 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.218 -0.926 . . . . 7.25 108.707 179.851 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 5' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -55.34 105.92 0.17 Allowed 'Trans proline' 0 C--N 1.323 -0.777 0 C-N-CA 120.887 1.058 . . . . 5.8899999999999997 109.69 179.553 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 6' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.41 157.29 27.6 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.25 -0.906 . . . . 4.7800000000000002 109.32 -179.907 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 30.7 mmtp -109.12 167.36 10.16 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.522 -0.737 . . . . 4.5599999999999996 109.164 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . 0.531 HH11 ' CG ' ' B' ' 8' ' ' ARG . 1.5 mtt-85 -89.95 162.31 15.47 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.23 -0.919 . . . . 3.6699999999999999 108.694 179.643 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 9' ' ' VAL . . . . . . . . . . . . . 5.7 t -49.09 159.82 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.065 -1.022 . . . . 1.3899999999999999 108.263 179.547 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -117.67 162.16 18.5 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.524 -0.735 . . . . 1.22 110.222 -178.769 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 32.4 m -153.59 141.24 19.94 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.585 -0.697 . . . . 1.6299999999999999 109.13 179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 41.7 m -145.05 112.27 6.06 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.113 -0.992 . . . . 1.8799999999999999 110.021 -179.664 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . 0.484 ' CG2' ' N ' ' B' ' 14' ' ' PHE . 3.2 p -159.93 167.48 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 N-CA-C 108.689 -0.856 . . . . 1.2 108.689 179.661 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 14' ' ' PHE . . . . . 0.515 ' HB3' ' H ' ' A' ' 53' ' ' ILE . 9.1 p90 -176.77 -169.07 0.25 Allowed 'General case' 0 N--CA 1.49 1.565 0 C-N-CA 119.162 -1.015 . . . . 2.3900000000000001 112.179 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.4 ' CD1' ' O ' ' B' ' 14' ' ' PHE . 3.9 mm -142.12 165.14 17.68 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 N-CA-C 108.69 -0.856 . . . . 1.8100000000000001 108.69 179.759 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 75.7 p -120.0 136.72 54.45 Favored 'General case' 0 N--CA 1.503 2.2 0 O-C-N 121.283 -0.886 . . . . 2.04 109.681 179.876 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 11.0 mt -103.67 141.78 35.47 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.369 -0.832 . . . . 1.8700000000000001 109.975 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -166.79 139.03 2.89 Favored Pre-proline 0 N--CA 1.49 1.549 0 N-CA-C 108.765 -0.828 . . . . 1.47 108.765 179.2 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_endo -62.73 142.54 89.59 Favored 'Trans proline' 0 CA--C 1.55 1.285 0 N-CA-C 109.553 -0.98 . . . . 1.96 109.553 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 20' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_endo -62.68 -52.5 2.33 Favored 'Trans proline' 0 C--O 1.214 -0.686 0 N-CA-C 109.047 -1.174 . . . . 3.3799999999999999 109.047 178.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . 0.42 HH11 ' HG3' ' B' ' 21' ' ' ARG . 25.9 mtm-85 -149.07 106.12 3.59 Favored 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 108.846 -0.798 . . . . 6.7400000000000002 108.846 179.816 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 22' ' ' ARG . . . . . 0.455 ' NH1' ' O ' ' B' ' 23' ' ' ASP . 0.2 OUTLIER -78.33 6.99 7.13 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.162 -0.961 . . . . 6.9400000000000004 109.622 -179.666 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . 0.455 ' O ' ' NH1' ' B' ' 22' ' ' ARG . 26.4 t0 53.47 -130.44 2.19 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.205 -0.935 . . . . 5.6200000000000001 109.556 179.755 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . 0.427 ' H ' ' CG ' ' B' ' 23' ' ' ASP . 14.9 p . . . . . 0 N--CA 1.49 1.54 0 CA-C-O 118.002 -0.999 . . . . 6.75 109.507 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.945 0 N-CA-C 119.718 2.647 . . . . 6.7300000000000004 119.718 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.631 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 1.1 pp -160.83 45.44 0.18 Allowed Pre-proline 0 C--N 1.307 -1.25 0 N-CA-C 107.933 -1.136 . . . . 7.3799999999999999 107.933 179.057 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.835 ' C ' ' H ' ' A' ' 5' ' ' PHE . 1.4 Cg_endo -52.54 -79.3 0.02 OUTLIER 'Trans proline' 0 C--N 1.32 -0.939 0 N-CA-C 108.856 -1.248 . . . . 5.5 108.856 179.729 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.542 ' C ' ' H ' ' A' ' 6' ' ' PHE . 4.5 tp10 73.56 -18.53 0.38 Allowed 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 104.365 -2.457 . . . . 6.8399999999999999 104.365 -175.844 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . 0.835 ' H ' ' C ' ' A' ' 3' ' ' PRO . 2.0 m-85 -87.96 16.44 5.96 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 104.02 -2.585 . . . . 6.4400000000000004 104.02 176.741 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.542 ' H ' ' C ' ' A' ' 4' ' ' GLU . 40.6 p90 45.56 -154.02 0.04 OUTLIER 'General case' 0 C--N 1.307 -1.252 0 CA-C-N 114.344 -1.298 . . . . 5.0599999999999996 109.44 -177.612 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.526 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 6.7 tt0 83.19 -9.59 1.06 Allowed 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 105.008 -2.219 . . . . 4.8099999999999996 105.008 -177.339 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.509 ' H ' ' C ' ' A' ' 6' ' ' PHE . 26.7 t80 -152.12 -36.61 0.12 Allowed 'General case' 0 C--N 1.306 -1.301 0 CA-C-N 114.794 -1.094 . . . . 5.7300000000000004 108.076 178.475 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 92.4 m -96.05 4.49 52.56 Favored 'General case' 0 C--N 1.296 -1.753 0 N-CA-C 105.759 -1.941 . . . . 5.3499999999999996 105.759 177.288 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.447 ' CG1' ' N ' ' A' ' 11' ' ' GLY . 8.4 p -45.9 -45.95 5.32 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.357 0 CA-C-N 115.473 -0.785 . . . . 4.3799999999999999 109.211 -179.572 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.603 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 127.18 -80.56 0.36 Allowed Glycine 0 N--CA 1.502 3.063 0 N-CA-C 109.394 -1.483 . . . . 4.4800000000000004 109.394 179.111 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.509 ' O ' ' N ' ' A' ' 14' ' ' GLY . 12.3 Cg_endo -66.97 37.56 0.15 Allowed 'Trans proline' 0 C--N 1.318 -1.043 0 C-N-CA 121.753 1.636 . . . . 4.0499999999999998 109.099 178.854 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.603 ' H ' ' C ' ' A' ' 11' ' ' GLY . 0.0 OUTLIER 40.67 26.04 0.02 OUTLIER 'General case' 0 N--CA 1.505 2.289 0 N-CA-C 108.333 -0.988 . . . . 4.0599999999999996 108.333 -178.955 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.541 ' C ' ' H ' ' A' ' 16' ' ' GLY . . . 70.19 -44.57 0.57 Allowed Glycine 0 N--CA 1.486 2.028 0 N-CA-C 107.88 -2.088 . . . . 3.1400000000000001 107.88 -178.137 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.57 ' H ' ' C ' ' A' ' 13' ' ' LEU . 7.1 tp10 48.4 12.33 0.04 OUTLIER 'General case' 0 N--CA 1.488 1.462 0 CA-C-O 121.978 0.894 . . . . 3.1699999999999999 108.914 179.866 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.541 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 58.21 114.51 0.01 OUTLIER Glycine 0 N--CA 1.488 2.115 0 O-C-N 121.38 -0.825 . . . . 2.4399999999999999 111.568 178.996 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.558 ' C ' ' H ' ' A' ' 19' ' ' HIS . . . 67.71 -49.03 0.33 Allowed Glycine 0 N--CA 1.495 2.61 0 O-C-N 121.577 -0.955 . . . . 2.0499999999999998 111.662 178.092 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.437 ' N ' ' CD ' ' A' ' 94' ' ' GLU . . . -51.3 -5.29 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.853 0 O-C-N 120.963 -1.316 . . . . 2.54 109.975 -179.201 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . 0.558 ' H ' ' C ' ' A' ' 17' ' ' GLY . 6.1 t60 -98.75 -7.13 28.13 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.135 -0.978 . . . . 3.3700000000000001 110.503 -179.545 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.667 ' HZ1' ' HG1' ' A' ' 43' ' ' THR . 0.0 OUTLIER -137.8 6.0 2.65 Favored 'General case' 0 N--CA 1.501 2.106 0 O-C-N 120.968 -1.082 . . . . 2.3700000000000001 110.34 -179.581 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 71.3 t -91.05 113.43 26.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 120.95 -1.094 . . . . 2.5800000000000001 109.851 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 12.8 tpp180 -105.33 137.88 42.43 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 108.827 -0.805 . . . . 3.8900000000000001 108.827 179.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -147.12 113.64 5.98 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.418 -0.801 . . . . 2.0099999999999998 108.857 179.794 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -155.26 129.73 2.61 Favored Glycine 0 N--CA 1.493 2.471 0 N-CA-C 109.678 -1.369 . . . . 2.0099999999999998 109.678 -179.655 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.54 -176.88 46.8 Favored Glycine 0 N--CA 1.491 2.304 0 C-N-CA 119.741 -1.219 . . . . 1.9299999999999999 110.088 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 12.6 p -79.65 -25.53 41.34 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.353 -1.086 . . . . 2.6899999999999999 109.343 179.877 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -68.94 -15.99 69.94 Favored Glycine 0 N--CA 1.485 1.934 0 N-CA-C 108.304 -1.918 . . . . 1.6399999999999999 108.304 179.548 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 90.4 mt -93.35 30.41 1.71 Allowed 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 108.601 -0.889 . . . . 2.0299999999999998 108.601 179.49 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 15.3 mt-10 -139.11 -48.72 0.49 Allowed 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.504 -0.747 . . . . 2.3399999999999999 109.34 -179.834 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 5.4 ptp180 -174.69 177.12 2.15 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.153 -0.967 . . . . 4.25 110.192 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -149.43 174.58 28.93 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 108.495 -1.842 . . . . 1.5900000000000001 108.495 179.717 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 39.5 t -134.42 149.87 30.26 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.075 0 O-C-N 121.203 -1.175 . . . . 2.21 110.567 -179.702 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -37.38 113.98 0.3 Allowed 'General case' 0 N--CA 1.496 1.864 0 CA-C-O 121.745 0.783 . . . . 2.0699999999999998 112.471 -179.232 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 51.68 51.42 38.74 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 111.24 -0.744 . . . . 1.73 111.24 177.097 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 24.4 t -126.82 121.67 23.18 Favored Pre-proline 0 N--CA 1.495 1.821 0 N-CA-C 108.198 -1.038 . . . . 2.6499999999999999 108.198 178.834 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -57.87 140.22 93.04 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 120.483 0.789 . . . . 2.1400000000000001 110.142 -179.422 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -145.33 158.0 43.92 Favored 'General case' 0 N--CA 1.493 1.716 0 N-CA-C 108.275 -1.009 . . . . 2.0299999999999998 108.275 179.603 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -155.8 172.01 19.06 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.815 -1.178 . . . . 2.23 110.8 -179.543 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . . . . . . . . . 5.9 p90 -156.27 166.64 32.85 Favored 'General case' 0 C--N 1.298 -1.646 0 N-CA-C 107.888 -1.153 . . . . 1.72 107.888 178.446 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 43.9 m -99.05 152.12 20.18 Favored 'General case' 0 N--CA 1.494 1.762 0 CA-C-O 121.782 0.801 . . . . 2.5800000000000001 111.129 -178.146 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 10.8 mt -143.48 85.79 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 N-CA-C 108.416 -0.957 . . . . 1.8600000000000001 108.416 178.91 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 31.5 t90 -91.61 147.36 23.06 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.053 -1.029 . . . . 4.4699999999999998 109.284 -179.489 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' THR . . . . . 0.667 ' HG1' ' HZ1' ' A' ' 20' ' ' LYS . 0.1 OUTLIER -161.76 -110.99 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.286 -0.883 . . . . 3.27 109.628 -179.731 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' ARG . . . . . 0.523 ' N ' ' OG1' ' A' ' 43' ' ' THR . 2.3 ttt-85 52.69 90.74 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.221 -0.924 . . . . 5.2300000000000004 109.862 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -172.2 -60.68 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.245 -0.909 . . . . 2.8900000000000001 109.365 179.265 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -57.04 -57.89 10.57 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.988 -1.07 . . . . 1.99 108.741 179.724 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 150.99 -160.46 28.64 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 110.029 -1.228 . . . . 1.6499999999999999 110.029 179.488 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.01 149.17 9.55 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.403 -1.057 . . . . 1.77 109.778 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -176.26 173.65 46.42 Favored Glycine 0 N--CA 1.489 2.168 0 N-CA-C 109.487 -1.445 . . . . 1.1200000000000001 109.487 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -126.76 122.63 4.4 Favored Glycine 0 N--CA 1.498 2.825 0 N-CA-C 109.143 -1.583 . . . . 1.1799999999999999 109.143 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.434 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 11.3 tp -93.85 99.37 11.75 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.221 -1.164 . . . . 1.5900000000000001 108.843 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 2.2 t -83.51 141.27 31.76 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 108.42 -0.956 . . . . 1.9399999999999999 108.42 179.687 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.531 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 92.3 mt -134.73 115.58 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.217 -0.927 . . . . 1.3 109.33 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -104.65 106.86 17.52 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.364 -0.835 . . . . 1.27 109.008 179.778 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -101.45 135.07 39.72 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.115 0 O-C-N 121.477 -0.765 . . . . 1.55 109.516 -179.771 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . 0.43 ' OE2' ' O ' ' B' ' 9' ' ' VAL . 30.9 tp10 -134.36 142.46 47.22 Favored 'General case' 0 N--CA 1.494 1.738 0 N-CA-C 107.399 -1.334 . . . . 1.8 107.399 178.324 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 171.51 -176.67 44.67 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.421 -1.472 . . . . 0.56000000000000005 109.421 -179.362 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -61.62 -28.35 82.6 Favored 'Trans proline' 0 C--N 1.318 -1.06 0 C-N-CA 121.992 1.795 . . . . 0.76000000000000001 111.856 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' SER . . . . . 0.407 ' OG ' ' OH ' ' A' ' 85' ' ' TYR . 10.6 p -142.39 163.24 33.37 Favored 'General case' 0 N--CA 1.501 2.095 0 O-C-N 121.063 -1.023 . . . . 2.02 110.349 -179.564 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 19.4 mtpp -81.09 115.71 20.66 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.532 -0.73 . . . . 3.02 109.28 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -80.67 129.54 34.58 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.284 -0.885 . . . . 1.3600000000000001 109.648 -179.817 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 18.2 tp10 -68.29 170.95 7.85 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.127 -0.983 . . . . 2.2999999999999998 108.535 179.722 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 3.8 mp -139.9 153.75 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 N-CA-C 108.417 -0.956 . . . . 2.0 108.417 -179.389 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.563 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -150.79 114.6 4.98 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 120.672 -1.267 . . . . 1.73 109.747 -179.565 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.505 ' CD2' ' O ' ' A' ' 65' ' ' PHE . 43.0 p90 -92.77 122.56 35.28 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.27 -0.894 . . . . 1.6000000000000001 109.19 179.615 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -141.19 120.54 13.09 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.266 -0.896 . . . . 2.5099999999999998 109.51 -179.835 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 9.7 p-10 -86.91 118.62 26.41 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.307 -0.871 . . . . 2.0699999999999998 109.328 179.884 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 41.0 ttm180 -99.52 -21.96 15.7 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.256 -0.902 . . . . 5.29 109.646 -179.846 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.565 ' C ' ' H ' ' A' ' 71' ' ' GLY . 14.3 mmmt -124.56 3.45 8.31 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.467 -0.771 . . . . 3.8599999999999999 109.067 -179.779 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.462 ' CB ' ' O ' ' A' ' 69' ' ' LYS . 0.8 OUTLIER 73.96 -26.43 0.19 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.33 -0.856 . . . . 3.0600000000000001 108.712 -179.146 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . 0.565 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -107.13 -34.59 2.92 Favored Glycine 0 N--CA 1.494 2.535 0 N-CA-C 109.446 -1.462 . . . . 2.1600000000000001 109.446 -179.801 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 89.9 p -95.44 121.59 37.28 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.271 -1.134 . . . . 2.5600000000000001 109.107 179.834 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 29.7 t -89.72 136.47 33.02 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.199 -0.938 . . . . 2.3599999999999999 109.682 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -114.24 114.24 3.24 Favored Glycine 0 N--CA 1.5 2.937 0 N-CA-C 109.696 -1.362 . . . . 1.46 109.696 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 78.9 t -99.7 105.13 17.04 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.102 0 O-C-N 121.411 -1.052 . . . . 2.1600000000000001 109.629 179.722 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.563 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.1 OUTLIER -95.26 134.5 37.95 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 109.018 -0.734 . . . . 2.1600000000000001 109.018 179.84 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 45.7 p90 -135.32 172.73 12.59 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.205 -0.934 . . . . 1.7 109.079 -179.848 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.458 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 9.8 p -140.34 118.09 9.96 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.082 0 O-C-N 121.256 -0.902 . . . . 2.4500000000000002 110.033 179.758 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 13.4 m -86.64 151.97 3.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.391 -0.818 . . . . 1.8200000000000001 108.922 179.548 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 4.0 tp-100 -94.51 -47.24 6.64 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.042 -1.036 . . . . 3.1699999999999999 110.899 -179.039 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -153.37 152.37 27.48 Favored Pre-proline 0 N--CA 1.505 2.302 0 O-C-N 120.406 -1.434 . . . . 2.02 110.965 -179.497 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.58 ' HG3' ' N ' ' A' ' 107' ' ' SER . 78.4 Cg_exo -38.48 164.42 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 123.392 2.728 . . . . 1.3999999999999999 113.778 178.833 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 145.08 -164.97 27.84 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.004 -1.639 . . . . 1.0800000000000001 109.004 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 25.2 m-20 -109.01 90.88 3.43 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.61 -0.935 . . . . 2.1299999999999999 108.641 179.581 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . 0.411 ' O ' ' N ' ' A' ' 103' ' ' VAL . 3.7 m-85 -78.74 130.53 35.88 Favored 'General case' 0 N--CA 1.487 1.406 0 N-CA-C 108.003 -1.11 . . . . 1.1399999999999999 108.003 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -115.35 128.49 56.12 Favored 'General case' 0 N--CA 1.502 2.146 0 N-CA-C 108.946 -0.761 . . . . 1.53 108.946 -178.503 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 10.0 p -125.36 140.46 48.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.75 -0.593 . . . . 1.6399999999999999 109.925 -179.852 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 16.2 m -129.33 100.07 5.45 Favored 'General case' 0 N--CA 1.497 1.884 0 N-CA-C 108.922 -0.77 . . . . 1.99 108.922 179.477 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.6 pt -105.57 134.93 45.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 CA-C-O 121.482 0.658 . . . . 1.77 110.208 -179.301 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . 0.466 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -144.3 122.35 12.11 Favored 'General case' 0 C--N 1.305 -1.339 0 N-CA-C 108.271 -1.011 . . . . 2.0600000000000001 108.271 179.508 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 62.9 t80 -80.97 101.27 9.4 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.864 -1.147 . . . . 1.45 107.995 178.705 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 70.37 39.04 1.29 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.392 -0.817 . . . . 2.7200000000000002 108.982 -178.809 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 74.57 15.03 3.41 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.705 -0.622 . . . . 1.9199999999999999 111.293 179.653 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . 0.472 ' CB ' ' O ' ' A' ' 16' ' ' GLY . 0.5 OUTLIER -98.29 96.22 7.91 Favored 'General case' 0 N--CA 1.498 1.974 0 N-CA-C 106.813 -1.551 . . . . 2.5499999999999998 106.813 177.641 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . 0.555 ' CD2' ' H ' ' A' ' 95' ' ' HIS . 5.8 m-70 -73.07 111.66 8.39 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.615 -0.678 . . . . 3.2000000000000002 110.112 -177.926 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . 0.583 ' CD1' ' H ' ' A' ' 96' ' ' ILE . 0.0 OUTLIER -70.35 155.93 92.67 Favored Pre-proline 0 N--CA 1.494 1.734 0 N-CA-C 107.444 -1.317 . . . . 2.8199999999999998 107.444 179.148 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_exo -46.54 -35.6 16.93 Favored 'Trans proline' 0 C--N 1.322 -0.861 0 C-N-CA 121.336 1.357 . . . . 2.6299999999999999 109.942 -179.412 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -53.78 -63.65 1.08 Allowed 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.301 -0.875 . . . . 2.6499999999999999 109.383 179.267 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 3.6 m -70.45 141.21 87.92 Favored Pre-proline 0 C--N 1.295 -1.777 0 O-C-N 120.92 -1.112 . . . . 2.3199999999999998 110.19 -178.467 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -86.8 119.02 4.96 Favored 'Cis proline' 0 N--CA 1.493 1.474 0 N-CA-C 109.967 -0.82 . . . . 1.9399999999999999 109.967 -2.439 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 45.2 p90 -120.89 158.34 27.85 Favored 'General case' 0 N--CA 1.518 2.939 0 O-C-N 120.445 -1.41 . . . . 2.6299999999999999 109.506 178.273 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.3 p -92.17 157.26 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.429 -0.794 . . . . 1.8200000000000001 110.887 -178.426 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.411 ' N ' ' O ' ' A' ' 85' ' ' TYR . 56.9 t -128.26 86.25 58.41 Favored Pre-proline 0 N--CA 1.495 1.778 0 N-CA-C 107.85 -1.167 . . . . 1.73 107.85 179.341 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -64.04 112.71 1.93 Allowed 'Trans proline' 0 C--N 1.32 -0.966 0 C-N-CA 121.377 1.385 . . . . 1.6100000000000001 111.624 -177.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 54.8 t -95.54 141.01 15.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 N-CA-C 106.771 -1.566 . . . . 1.7 106.771 177.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -130.6 131.79 45.15 Favored 'General case' 0 N--CA 1.51 2.551 0 CA-C-O 121.925 0.869 . . . . 2.04 112.064 -177.041 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' SER . . . . . 0.58 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 35.4 t -101.36 92.99 5.19 Favored 'General case' 0 N--CA 1.494 1.75 0 N-CA-C 107.993 -1.114 . . . . 2.2999999999999998 107.993 179.274 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 20.5 mt 60.08 3.71 0.54 Allowed 'General case' 0 C--N 1.295 -1.774 0 N-CA-C 108.166 -1.05 . . . . 3.6000000000000001 108.166 -178.574 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.582 ' C ' ' H ' ' A' ' 111' ' ' ASP . 8.3 t -94.83 -29.26 14.82 Favored 'General case' 0 N--CA 1.49 1.563 0 N-CA-C 109.03 -0.729 . . . . 2.4900000000000002 109.03 179.391 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 16.9 t70 57.52 6.28 0.39 Allowed 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 107.754 -1.202 . . . . 2.8500000000000001 107.754 -178.843 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.582 ' H ' ' C ' ' A' ' 109' ' ' SER . 17.8 m-20 -159.92 -35.47 0.06 Allowed 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 108.697 -0.853 . . . . 2.46 108.697 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.581 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 40.29 65.82 0.7 Allowed 'General case' 0 N--CA 1.501 2.077 0 O-C-N 121.491 -0.756 . . . . 2.0800000000000001 110.251 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.461 ' HG2' HH11 ' A' ' 113' ' ' ARG . 6.3 mtt-85 -54.1 -172.15 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.148 -0.97 . . . . 6.54 109.506 -179.562 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.567 ' CG ' HH11 ' A' ' 114' ' ' ARG . 0.1 OUTLIER -132.03 4.29 4.11 Favored 'General case' 0 N--CA 1.497 1.897 0 N-CA-C 108.711 -0.848 . . . . 6.2400000000000002 108.711 -179.621 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 30.0 mt -127.27 -24.02 3.45 Favored 'General case' 0 N--CA 1.503 2.218 0 O-C-N 121.645 -0.659 . . . . 4.71 109.405 -179.709 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.539 ' C ' ' H ' ' A' ' 118' ' ' THR . 85.3 m -110.73 -78.67 0.59 Allowed 'General case' 0 N--CA 1.498 1.94 0 N-CA-C 107.106 -1.442 . . . . 4.3499999999999996 107.106 179.079 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 45.9 t -62.13 -7.83 2.35 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.672 0 N-CA-C 106.016 -1.846 . . . . 3.3100000000000001 106.016 176.783 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' THR . . . . . 0.539 ' H ' ' C ' ' A' ' 116' ' ' THR . 4.4 t 36.48 59.8 0.95 Allowed 'General case' 0 N--CA 1.488 1.445 0 CA-C-N 115.253 -0.885 . . . . 3.73 110.728 179.823 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' SER . . . . . 0.457 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.5 p . . . . . 0 C--N 1.303 -1.417 0 CA-C-O 118.023 -0.989 . . . . 3.8300000000000001 109.574 179.401 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 1' ' ' MET . . . . . 0.569 ' SD ' ' N ' ' B' ' 1' ' ' MET . 4.3 mpp? . . . . . 0 N--CA 1.49 1.545 0 CA-C-O 121.312 0.577 . . . . 8.8699999999999992 109.455 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -167.33 -100.63 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.249 -0.907 . . . . 5.9299999999999997 109.331 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 3' ' ' SER . . . . . . . . . . . . . 54.6 p -72.45 60.1 0.45 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.252 -0.905 . . . . 5.5700000000000003 109.382 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 4' ' ' LYS . . . . . . . . . . . . . 6.8 ttpm? -168.44 69.3 0.78 Allowed Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.247 -0.908 . . . . 7.25 109.518 -179.892 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 5' ' ' PRO . . . . . 0.431 ' O ' ' O ' ' B' ' 6' ' ' GLU . 6.0 Cg_exo -60.59 -29.34 88.3 Favored 'Trans proline' 0 C--N 1.317 -1.103 0 C-N-CA 121.442 1.428 . . . . 5.8899999999999997 109.811 -179.785 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 6' ' ' GLU . . . . . 0.431 ' O ' ' O ' ' B' ' 5' ' ' PRO . 31.2 tt0 57.32 160.5 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.412 -0.805 . . . . 4.7800000000000002 109.855 179.815 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 46.3 mtpt -63.2 159.98 16.51 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.248 -0.908 . . . . 4.5599999999999996 109.298 179.904 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . 0.607 HH11 ' CG ' ' B' ' 8' ' ' ARG . 0.0 OUTLIER -101.58 163.68 12.14 Favored 'General case' 0 N--CA 1.494 1.769 0 N-CA-C 108.061 -1.088 . . . . 3.6699999999999999 108.061 179.798 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 9' ' ' VAL . . . . . 0.43 ' O ' ' OE2' ' A' ' 56' ' ' GLU . 36.3 t -51.61 155.48 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 O-C-N 120.963 -1.085 . . . . 1.3899999999999999 108.508 179.519 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -107.7 158.84 16.94 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 121.484 -0.76 . . . . 1.22 110.443 -178.763 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 25.6 t -159.34 112.91 2.29 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.487 -0.758 . . . . 1.6299999999999999 109.007 179.51 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 15.0 p -117.02 124.9 50.44 Favored 'General case' 0 N--CA 1.501 2.111 0 O-C-N 121.417 -0.802 . . . . 1.8799999999999999 109.413 -179.771 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . 0.468 ' CG2' ' N ' ' B' ' 14' ' ' PHE . 6.6 p -164.39 164.01 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.293 -0.879 . . . . 1.2 109.786 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 14' ' ' PHE . . . . . 0.531 ' HB3' ' H ' ' A' ' 53' ' ' ILE . 6.5 p90 -179.29 -175.21 0.35 Allowed 'General case' 0 N--CA 1.488 1.472 0 CA-C-O 121.784 0.802 . . . . 2.3900000000000001 111.427 179.102 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -144.01 168.8 10.77 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.295 0 N-CA-C 109.28 -0.637 . . . . 1.8100000000000001 109.28 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 74.1 p -133.81 156.13 48.59 Favored 'General case' 0 N--CA 1.499 2.021 0 N-CA-C 108.72 -0.844 . . . . 2.04 108.72 179.523 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -159.18 159.55 34.44 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.948 -1.095 . . . . 1.8700000000000001 110.643 -179.307 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -174.39 149.29 1.36 Allowed Pre-proline 0 N--CA 1.488 1.454 0 N-CA-C 108.843 -0.799 . . . . 1.47 108.843 179.751 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -57.65 166.83 4.52 Favored 'Trans proline' 0 CA--C 1.543 0.966 0 C-N-CA 120.933 1.089 . . . . 1.96 109.748 179.712 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 20' ' ' PRO . . . . . . . . . . . . . 2.3 Cg_endo -61.11 169.3 6.29 Favored 'Trans proline' 0 C--N 1.319 -0.985 0 C-N-CA 121.538 1.492 . . . . 3.3799999999999999 109.448 179.366 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . 0.413 HH11 ' HG3' ' B' ' 21' ' ' ARG . 3.8 ptm180 -79.81 137.55 37.0 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.171 -0.955 . . . . 6.7400000000000002 109.246 179.677 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 22' ' ' ARG . . . . . 0.561 HH11 ' CG ' ' B' ' 22' ' ' ARG . 0.1 OUTLIER -90.66 147.18 23.46 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.183 -0.948 . . . . 6.9400000000000004 109.349 -179.923 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 66.9 m-20 -66.01 135.83 55.2 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.217 -0.927 . . . . 5.6200000000000001 109.442 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 21.2 t . . . . . 0 N--CA 1.49 1.537 0 CA-C-O 118.046 -0.978 . . . . 6.75 109.624 -179.889 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.929 0 N-CA-C 119.8 2.68 . . . . 6.7300000000000004 119.8 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.646 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 7.3 mt -153.39 44.31 0.25 Allowed Pre-proline 0 C--N 1.311 -1.094 0 N-CA-C 107.8 -1.185 . . . . 7.3799999999999999 107.8 178.711 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.688 ' C ' ' H ' ' A' ' 5' ' ' PHE . 0.9 OUTLIER -53.79 -76.32 0.02 OUTLIER 'Trans proline' 0 C--N 1.32 -0.969 0 N-CA-C 109.149 -1.135 . . . . 5.5 109.149 -179.799 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.423 ' CB ' ' O ' ' A' ' 3' ' ' PRO . 8.9 tp10 72.14 -50.1 0.69 Allowed 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 103.13 -2.915 . . . . 6.8399999999999999 103.13 -175.861 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . 0.688 ' H ' ' C ' ' A' ' 3' ' ' PRO . 7.3 m-85 -49.62 -27.38 4.53 Favored 'General case' 0 C--N 1.303 -1.423 0 N-CA-C 106.485 -1.672 . . . . 6.4400000000000004 106.485 174.967 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.604 ' CG ' ' N ' ' A' ' 7' ' ' GLN . 0.0 OUTLIER 109.75 -150.93 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.217 0 CA-C-N 114.458 -1.246 . . . . 5.0599999999999996 111.144 179.47 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.604 ' N ' ' CG ' ' A' ' 6' ' ' PHE . 4.3 tt0 83.48 -4.06 1.19 Allowed 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 105.418 -2.068 . . . . 4.8099999999999996 105.418 -177.714 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.407 ' H ' ' C ' ' A' ' 6' ' ' PHE . 80.1 t80 -152.19 -40.14 0.11 Allowed 'General case' 0 C--N 1.303 -1.436 0 N-CA-C 107.395 -1.335 . . . . 5.7300000000000004 107.395 178.632 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 30.0 m -88.98 2.97 53.12 Favored 'General case' 0 C--N 1.296 -1.741 0 N-CA-C 106.201 -1.777 . . . . 5.3499999999999996 106.201 177.533 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.7 p -42.7 -41.72 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 CA-C-O 121.765 0.793 . . . . 4.3799999999999999 109.408 -179.804 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.601 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 144.06 -86.49 0.18 Allowed Glycine 0 N--CA 1.496 2.689 0 N-CA-C 108.658 -1.777 . . . . 4.4800000000000004 108.658 179.691 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.44 ' O ' ' N ' ' A' ' 14' ' ' GLY . 12.0 Cg_endo -68.19 34.89 0.17 Allowed 'Trans proline' 0 C--N 1.321 -0.875 0 C-N-CA 121.425 1.417 . . . . 4.0499999999999998 109.263 178.275 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.601 ' H ' ' C ' ' A' ' 11' ' ' GLY . 0.0 OUTLIER 39.68 29.88 0.05 OUTLIER 'General case' 0 N--CA 1.504 2.238 0 CA-C-O 121.855 0.836 . . . . 4.0599999999999996 109.001 -178.877 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.534 ' C ' ' H ' ' A' ' 16' ' ' GLY . . . 72.37 -41.46 0.78 Allowed Glycine 0 N--CA 1.488 2.161 0 N-CA-C 108.613 -1.795 . . . . 3.1400000000000001 108.613 -179.283 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.537 ' H ' ' C ' ' A' ' 13' ' ' LEU . 26.2 tt0 51.95 10.33 0.11 Allowed 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.552 -0.97 . . . . 3.1699999999999999 108.618 -179.491 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.534 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 78.19 -165.6 52.08 Favored Glycine 0 N--CA 1.486 2.007 0 N-CA-C 110.009 -1.236 . . . . 2.4399999999999999 110.009 179.841 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.553 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -42.72 -19.8 0.07 OUTLIER Glycine 0 N--CA 1.49 2.282 0 O-C-N 121.417 -1.049 . . . . 2.0499999999999998 110.839 -179.325 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.502 ' N ' ' O ' ' A' ' 16' ' ' GLY . . . -47.26 -12.92 0.03 OUTLIER 'General case' 0 N--CA 1.495 1.8 0 O-C-N 120.448 -1.619 . . . . 2.54 109.297 179.413 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . 0.553 ' N ' ' O ' ' A' ' 17' ' ' GLY . 12.8 t-80 -93.36 -52.25 4.61 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.268 -0.895 . . . . 3.3700000000000001 109.906 179.882 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.535 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.1 OUTLIER -69.75 -23.6 63.4 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.869 -1.144 . . . . 2.3700000000000001 109.588 -179.69 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 76.1 t -63.33 112.62 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.161 -0.962 . . . . 2.5800000000000001 109.5 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 20.6 tpt180 -97.34 138.32 34.99 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 108.695 -0.854 . . . . 3.8900000000000001 108.695 179.666 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -142.64 113.46 7.5 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.287 -0.883 . . . . 2.0099999999999998 109.279 -179.88 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -154.08 130.85 3.03 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 109.518 -1.433 . . . . 2.0099999999999998 109.518 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -177.94 171.17 43.67 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.703 -1.359 . . . . 1.9299999999999999 109.703 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 10.9 p -77.97 -28.87 49.53 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.302 -1.117 . . . . 2.6899999999999999 109.405 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -67.72 -16.88 68.51 Favored Glycine 0 N--CA 1.487 2.038 0 N-CA-C 108.42 -1.872 . . . . 1.6399999999999999 108.42 179.606 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 49.0 mt -85.85 22.68 1.61 Allowed 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 108.506 -0.924 . . . . 2.0299999999999998 108.506 179.356 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 11.5 mt-10 -133.47 -50.38 0.85 Allowed 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.62 -0.675 . . . . 2.3399999999999999 109.398 -179.673 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 11.3 ptt180 -163.31 -176.71 4.92 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.069 -1.019 . . . . 4.25 109.936 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -157.18 -178.42 31.23 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 108.761 -1.735 . . . . 1.5900000000000001 108.761 -179.799 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 38.4 t -134.71 151.8 32.09 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.153 0 O-C-N 121.154 -1.203 . . . . 2.21 110.663 -179.777 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -45.77 115.22 0.91 Allowed 'General case' 0 N--CA 1.498 1.936 0 CA-C-O 121.815 0.817 . . . . 2.0699999999999998 112.443 -179.34 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 57.82 46.55 92.22 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 111.562 -0.615 . . . . 1.73 111.562 177.062 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 25.2 t -127.38 120.49 22.16 Favored Pre-proline 0 N--CA 1.499 1.98 0 O-C-N 121.37 -1.076 . . . . 2.6499999999999999 108.818 179.178 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -60.09 113.02 1.48 Allowed 'Trans proline' 0 C--O 1.215 -0.657 0 N-CA-C 109.676 -0.932 . . . . 2.1400000000000001 109.676 179.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -113.04 156.12 23.64 Favored 'General case' 0 N--CA 1.498 1.949 0 N-CA-C 108.268 -1.012 . . . . 2.0299999999999998 108.268 179.617 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -158.03 163.68 37.49 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.718 -1.239 . . . . 2.23 111.403 -179.779 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.575 ' N ' ' CD1' ' A' ' 39' ' ' PHE . 0.8 OUTLIER -139.93 -173.17 3.57 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 107.228 -1.397 . . . . 1.72 107.228 178.513 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 24.4 m -121.83 149.11 43.82 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.535 -0.728 . . . . 2.5800000000000001 110.307 -179.234 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.416 HG23 HD13 ' A' ' 41' ' ' ILE . 34.9 mt -144.48 102.05 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 N-CA-C 107.962 -1.125 . . . . 1.8600000000000001 107.962 178.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.458 ' CD1' ' C ' ' A' ' 42' ' ' TRP . 0.1 OUTLIER -89.59 139.6 30.38 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.259 -0.901 . . . . 4.4699999999999998 108.927 -179.635 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' THR . . . . . 0.535 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.1 OUTLIER -152.79 120.03 5.89 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.42 -0.8 . . . . 3.27 109.214 -179.733 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' ARG . . . . . . . . . . . . . 28.9 ttt-85 -170.28 62.87 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.201 -0.937 . . . . 5.2300000000000004 109.848 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 25.4 tt0 -157.06 -56.6 0.08 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.14 -0.975 . . . . 2.8900000000000001 109.534 179.65 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -57.88 -57.4 12.93 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.092 -1.005 . . . . 1.99 108.88 179.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 142.03 -179.2 20.17 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.263 -1.535 . . . . 1.6499999999999999 109.263 179.845 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -55.9 159.14 3.35 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.127 -1.22 . . . . 1.77 109.345 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -176.83 176.12 47.88 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.595 -1.402 . . . . 1.1200000000000001 109.595 -179.877 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -106.94 123.26 7.24 Favored Glycine 0 N--CA 1.497 2.743 0 N-CA-C 109.427 -1.469 . . . . 1.1799999999999999 109.427 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.42 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 12.3 tp -99.8 100.55 11.51 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.295 -1.12 . . . . 1.5900000000000001 108.452 179.663 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 3.9 m -85.51 144.13 28.12 Favored 'General case' 0 N--CA 1.491 1.616 0 N-CA-C 108.662 -0.866 . . . . 1.9399999999999999 108.662 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.499 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 78.5 mt -134.71 106.69 7.68 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 O-C-N 121.224 -0.922 . . . . 1.3 109.614 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -95.65 106.26 18.34 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.377 -0.971 . . . . 1.27 108.377 179.272 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -97.45 145.29 9.47 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 121.421 -0.799 . . . . 1.55 109.933 -179.339 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 20.2 tt0 -141.56 145.06 34.65 Favored 'General case' 0 N--CA 1.491 1.61 0 N-CA-C 107.536 -1.283 . . . . 1.8 107.536 178.708 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 161.64 -171.04 37.52 Favored Glycine 0 N--CA 1.488 2.13 0 N-CA-C 109.644 -1.382 . . . . 0.56000000000000005 109.644 -179.069 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -64.32 -30.31 63.46 Favored 'Trans proline' 0 C--N 1.316 -1.142 0 C-N-CA 122.047 1.831 . . . . 0.76000000000000001 111.652 -179.598 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 24.3 t -142.1 164.96 28.76 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.039 -1.038 . . . . 2.02 110.129 -179.877 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 58.4 mttt -84.44 107.48 16.72 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.527 -0.733 . . . . 3.02 109.56 -179.8 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -67.08 143.39 56.71 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.222 -0.924 . . . . 1.3600000000000001 109.4 179.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.4 ' H ' HG11 ' A' ' 78' ' ' VAL . 23.3 tt0 -93.2 91.36 7.24 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.225 -0.922 . . . . 2.2999999999999998 109.537 -179.93 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . 0.411 ' N ' ' CD1' ' A' ' 63' ' ' ILE . 2.2 mp -60.54 156.61 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 N-CA-C 109.138 -0.689 . . . . 2.0 109.138 179.602 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.527 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -145.99 174.85 10.91 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.981 -1.074 . . . . 1.73 108.595 179.621 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.487 ' O ' ' CG ' ' A' ' 65' ' ' PHE . 28.8 p90 -147.87 115.87 6.47 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.093 -1.005 . . . . 1.6000000000000001 109.647 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -141.96 118.74 11.12 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.209 -0.932 . . . . 2.5099999999999998 109.485 179.791 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -84.93 119.77 25.74 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.143 -0.973 . . . . 2.0699999999999998 109.415 179.865 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 8.0 mmm180 -110.49 -5.7 15.08 Favored 'General case' 0 N--CA 1.5 2.062 0 O-C-N 121.545 -0.722 . . . . 5.29 109.298 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.511 ' C ' ' H ' ' A' ' 71' ' ' GLY . 20.4 mmmt -125.19 2.4 7.87 Favored 'General case' 0 N--CA 1.5 2.051 0 O-C-N 121.416 -0.803 . . . . 3.8599999999999999 109.379 -179.781 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.7 t70 67.3 -4.86 0.8 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.247 -0.908 . . . . 3.0600000000000001 109.105 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . 0.511 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -139.7 -32.16 0.17 Allowed Glycine 0 N--CA 1.493 2.478 0 N-CA-C 109.924 -1.27 . . . . 2.1600000000000001 109.924 -179.077 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.403 ' H ' ' HB2' ' A' ' 69' ' ' LYS . 5.5 p -95.84 116.14 28.46 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.195 -1.179 . . . . 2.5600000000000001 109.085 179.829 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 7.7 t -75.42 146.58 40.64 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.214 -0.929 . . . . 2.3599999999999999 109.622 -179.814 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -120.25 111.58 2.01 Favored Glycine 0 N--CA 1.499 2.851 0 N-CA-C 109.32 -1.512 . . . . 1.46 109.32 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 22.5 t -99.32 106.22 18.64 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 O-C-N 121.542 -0.975 . . . . 2.1600000000000001 109.109 179.807 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.527 ' O ' ' N ' ' A' ' 64' ' ' ALA . 5.9 t -100.04 135.67 41.11 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.537 -0.727 . . . . 2.1600000000000001 109.895 -179.687 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 4.9 p90 -133.59 131.4 39.61 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 108.801 -0.815 . . . . 1.7 108.801 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.471 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 8.0 p -100.37 115.79 42.42 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.955 0 O-C-N 121.276 -0.89 . . . . 2.4500000000000002 109.183 -179.668 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 26.9 m -84.73 164.5 2.53 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 121.187 -0.946 . . . . 1.8200000000000001 109.142 -179.681 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 36.3 tt0 -102.54 -49.08 3.94 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.276 -0.89 . . . . 3.1699999999999999 110.324 -179.689 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -157.15 153.99 25.04 Favored Pre-proline 0 N--CA 1.502 2.132 0 O-C-N 120.907 -1.121 . . . . 2.02 111.161 -179.147 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.535 ' HG3' ' N ' ' A' ' 107' ' ' SER . 89.1 Cg_exo -35.55 156.99 0.02 OUTLIER 'Trans proline' 0 C--O 1.214 -0.683 0 C-N-CA 123.394 2.729 . . . . 1.3999999999999999 113.745 179.354 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 148.51 -170.3 29.02 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 108.556 -1.818 . . . . 1.0800000000000001 108.556 -179.675 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . 0.527 ' OD2' ' NH2' ' B' ' 8' ' ' ARG . 4.5 p-10 -107.24 93.71 4.7 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.378 -1.072 . . . . 2.1299999999999999 108.452 179.368 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . 0.426 ' O ' ' N ' ' A' ' 103' ' ' VAL . 2.4 m-85 -77.38 131.63 38.15 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 108.398 -0.964 . . . . 1.1399999999999999 108.398 -179.784 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -112.82 126.82 55.85 Favored 'General case' 0 N--CA 1.501 2.081 0 N-CA-C 108.465 -0.939 . . . . 1.53 108.465 -179.292 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.466 ' CG1' ' CE2' ' A' ' 101' ' ' PHE . 5.5 p -126.29 133.96 67.55 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 O-C-N 121.525 -0.734 . . . . 1.6399999999999999 109.782 -179.703 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' SER . . . . . 0.407 ' O ' ' OG ' ' A' ' 88' ' ' SER . 19.0 p -124.58 104.82 8.92 Favored 'General case' 0 N--CA 1.499 1.986 0 N-CA-C 109.171 -0.678 . . . . 1.99 109.171 179.835 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.405 ' N ' ' OG ' ' A' ' 99' ' ' SER . 1.5 pt -108.37 133.18 54.13 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 CA-C-O 121.54 0.686 . . . . 1.77 110.37 -179.245 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . 0.456 ' O ' ' CG ' ' A' ' 90' ' ' LYS . 0.3 OUTLIER -138.08 122.51 18.36 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 107.927 -1.138 . . . . 2.0600000000000001 107.927 179.257 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.412 ' O ' ' CB ' ' A' ' 92' ' ' ASN . 81.4 t80 -82.84 99.99 10.06 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 120.443 -1.411 . . . . 1.45 107.924 179.21 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . 0.446 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 3.2 t-20 72.28 34.85 1.3 Allowed 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.266 -0.896 . . . . 2.7200000000000002 108.983 -178.627 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . 0.446 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 1.6 m-20 80.47 13.81 0.83 Allowed 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.725 -0.609 . . . . 1.9199999999999999 111.662 179.336 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . 0.467 ' CG ' ' O ' ' A' ' 94' ' ' GLU . 5.4 pt-20 -100.71 98.84 9.34 Favored 'General case' 0 N--CA 1.499 2.023 0 N-CA-C 107.459 -1.312 . . . . 2.5499999999999998 107.459 177.843 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . 0.416 ' O ' ' OE2' ' A' ' 15' ' ' GLU . 26.6 p-80 -65.3 99.59 0.41 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.686 -0.634 . . . . 3.2000000000000002 110.243 -178.251 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . 0.523 ' O ' ' N ' ' A' ' 98' ' ' ASP . 4.0 tt -50.82 136.09 26.77 Favored Pre-proline 0 N--CA 1.489 1.524 0 N-CA-C 107.988 -1.116 . . . . 2.8199999999999998 107.988 179.089 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.433 ' O ' ' CB ' ' A' ' 98' ' ' ASP . 9.4 Cg_exo -47.88 90.35 0.02 OUTLIER 'Trans proline' 0 C--O 1.213 -0.727 0 C-N-CA 120.547 0.832 . . . . 2.6299999999999999 110.006 -179.627 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.523 ' N ' ' O ' ' A' ' 96' ' ' ILE . 0.9 OUTLIER 166.5 -57.87 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.749 0 N-CA-C 108.445 -0.946 . . . . 2.6499999999999999 108.445 -179.569 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' SER . . . . . 0.405 ' OG ' ' N ' ' A' ' 89' ' ' ILE . 3.3 m -55.55 137.75 69.7 Favored Pre-proline 0 C--N 1.296 -1.72 0 O-C-N 121.246 -0.909 . . . . 2.3199999999999998 109.6 -178.185 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo -90.0 114.96 2.59 Favored 'Cis proline' 0 N--CA 1.494 1.513 0 N-CA-C 110.249 -0.712 . . . . 1.9399999999999999 110.249 -2.33 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . 0.466 ' CE2' ' CG1' ' A' ' 87' ' ' VAL . 1.6 p90 -97.18 163.26 12.99 Favored 'General case' 0 N--CA 1.515 2.802 0 O-C-N 120.217 -1.552 . . . . 2.6299999999999999 109.568 178.456 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.9 p -95.31 148.96 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.594 -0.691 . . . . 1.8200000000000001 109.822 -179.703 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.426 ' N ' ' O ' ' A' ' 85' ' ' TYR . 64.5 t -128.53 86.41 57.79 Favored Pre-proline 0 N--CA 1.499 2.002 0 N-CA-C 108.432 -0.951 . . . . 1.73 108.432 179.89 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -63.92 112.16 1.76 Allowed 'Trans proline' 0 C--N 1.321 -0.88 0 C-N-CA 121.429 1.419 . . . . 1.6100000000000001 111.821 -178.133 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 52.5 t -91.39 147.36 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.514 -1.291 . . . . 1.7 107.514 178.268 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -135.77 134.3 38.85 Favored 'General case' 0 N--CA 1.508 2.467 0 O-C-N 121.373 -0.829 . . . . 2.04 110.911 -178.074 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' SER . . . . . 0.535 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 16.5 t -87.69 67.75 9.29 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.571 -1.331 . . . . 2.2999999999999998 108.095 179.799 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . 0.434 ' CB ' ' O ' ' A' ' 107' ' ' SER . 1.0 OUTLIER 71.53 -2.6 2.38 Favored 'General case' 0 C--N 1.295 -1.79 0 N-CA-C 106.921 -1.511 . . . . 3.6000000000000001 106.921 -178.439 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.617 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 82.6 p -82.73 -21.63 34.7 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 109.165 -0.679 . . . . 2.4900000000000002 109.165 179.422 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 62.2 t0 48.62 17.35 0.14 Allowed 'General case' 0 N--CA 1.494 1.753 0 N-CA-C 108.312 -0.996 . . . . 2.8500000000000001 108.312 -179.456 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.493 ' N ' ' C ' ' A' ' 109' ' ' SER . 58.3 t0 -175.41 -23.8 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.523 0 CA-C-N 115.819 -0.628 . . . . 2.46 109.469 -179.321 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.617 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 61.16 96.7 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.887 -1.133 . . . . 2.0800000000000001 109.491 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.571 ' CG ' HH11 ' A' ' 113' ' ' ARG . 2.1 mtt-85 -60.52 -165.15 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.314 0 O-C-N 121.282 -0.886 . . . . 6.54 109.49 -179.923 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.412 ' CG ' HH11 ' A' ' 114' ' ' ARG . 0.0 OUTLIER -149.63 4.88 0.59 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.036 -1.04 . . . . 6.2400000000000002 109.914 -178.628 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -124.63 -29.26 3.47 Favored 'General case' 0 N--CA 1.507 2.424 0 O-C-N 121.236 -0.915 . . . . 4.71 109.876 -179.412 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.551 ' C ' ' H ' ' A' ' 118' ' ' THR . 0.6 OUTLIER -108.2 -79.1 0.58 Allowed 'General case' 0 N--CA 1.497 1.882 0 N-CA-C 107.093 -1.447 . . . . 4.3499999999999996 107.093 179.558 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 54.7 t -60.22 -9.18 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.703 0 N-CA-C 106.157 -1.794 . . . . 3.3100000000000001 106.157 176.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' THR . . . . . 0.551 ' H ' ' C ' ' A' ' 116' ' ' THR . 4.9 t 36.88 60.68 0.94 Allowed 'General case' 0 N--CA 1.486 1.362 0 CA-C-O 122.071 0.939 . . . . 3.73 110.744 179.687 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' SER . . . . . 0.477 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.5 p . . . . . 0 C--N 1.304 -1.378 0 CA-C-O 117.982 -1.009 . . . . 3.8300000000000001 109.634 179.299 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 44.7 mtm . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.543 -0.54 . . . . 8.8699999999999992 109.543 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -67.09 141.17 57.55 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.212 -0.93 . . . . 5.9299999999999997 109.526 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 3' ' ' SER . . . . . . . . . . . . . 34.3 t -89.95 -98.69 0.1 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.282 -0.886 . . . . 5.5700000000000003 109.668 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 4' ' ' LYS . . . . . . . . . . . . . 83.8 tttt -171.83 85.46 0.46 Allowed Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.306 -0.872 . . . . 7.25 109.69 -179.577 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 5' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_exo -55.1 142.81 76.56 Favored 'Trans proline' 0 C--N 1.321 -0.902 0 C-N-CA 120.9 1.067 . . . . 5.8899999999999997 109.714 -179.71 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 6' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -91.06 119.81 31.52 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.303 -0.873 . . . . 4.7800000000000002 110.331 -178.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 7.0 mtpm? 41.77 -160.91 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.725 0 CA-C-O 121.622 0.725 . . . . 4.5599999999999996 110.763 179.18 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . 0.527 ' NH2' ' OD2' ' A' ' 84' ' ' ASP . 2.2 mtt-85 -138.55 164.05 30.44 Favored 'General case' 0 N--CA 1.494 1.742 0 N-CA-C 108.715 -0.846 . . . . 3.6699999999999999 108.715 -179.728 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 9' ' ' VAL . . . . . . . . . . . . . 19.4 t -51.41 158.2 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.141 -0.975 . . . . 1.3899999999999999 108.61 179.717 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -121.54 146.88 46.5 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.627 -0.67 . . . . 1.22 109.645 -179.339 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 4.9 t -140.62 143.77 35.39 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.387 -0.821 . . . . 1.6299999999999999 109.436 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 46.8 t -141.39 116.54 9.98 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.319 -0.863 . . . . 1.8799999999999999 109.689 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . 0.489 ' CG2' ' N ' ' B' ' 14' ' ' PHE . 6.6 p -165.04 170.41 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.342 -0.849 . . . . 1.2 109.029 179.899 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 14' ' ' PHE . . . . . 0.499 ' HB3' ' H ' ' A' ' 53' ' ' ILE . 9.6 p90 -175.92 -163.14 0.1 Allowed 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 119.285 -0.966 . . . . 2.3900000000000001 112.144 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.9 pt -150.47 165.55 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.339 0 N-CA-C 108.965 -0.754 . . . . 1.8100000000000001 108.965 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 17.9 m -125.27 128.82 48.87 Favored 'General case' 0 N--CA 1.502 2.132 0 O-C-N 121.385 -0.822 . . . . 2.04 109.437 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 9.3 mt -99.07 138.72 35.76 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.267 -0.896 . . . . 1.8700000000000001 109.922 -179.715 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -169.17 150.57 4.35 Favored Pre-proline 0 N--CA 1.49 1.538 0 N-CA-C 108.765 -0.828 . . . . 1.47 108.765 179.259 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -59.15 167.8 5.43 Favored 'Trans proline' 0 CA--C 1.542 0.89 0 C-N-CA 121.051 1.167 . . . . 1.96 109.507 179.836 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 20' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_endo -61.95 -61.45 0.16 Allowed 'Trans proline' 0 C--N 1.317 -1.085 0 C-N-CA 121.371 1.381 . . . . 3.3799999999999999 109.455 179.348 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 11.6 ptp180 -72.36 162.89 28.86 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.427 -0.796 . . . . 6.7400000000000002 109.619 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 22' ' ' ARG . . . . . 0.485 ' CD ' ' N ' ' B' ' 22' ' ' ARG . 11.0 mpt_? -83.24 -164.71 0.93 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.298 -0.876 . . . . 6.9400000000000004 109.107 179.865 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -159.82 124.11 3.82 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.129 -0.982 . . . . 5.6200000000000001 109.622 179.891 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 11.8 t . . . . . 0 N--CA 1.491 1.586 0 CA-C-O 117.921 -1.038 . . . . 6.75 109.478 179.947 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.43 ' O ' ' CG2' ' A' ' 2' ' ' ILE . . . . . . . . 1 N--CA 1.531 4.988 0 N-CA-C 119.72 2.648 . . . . 6.7300000000000004 119.72 . . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.604 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 13.7 pt -162.6 47.06 0.2 Allowed Pre-proline 0 C--N 1.307 -1.282 0 N-CA-C 107.946 -1.131 . . . . 7.3799999999999999 107.946 179.004 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.821 ' C ' ' H ' ' A' ' 5' ' ' PHE . 3.4 Cg_endo -56.51 -80.45 0.01 OUTLIER 'Trans proline' 0 C--N 1.318 -1.037 0 N-CA-C 109.042 -1.176 . . . . 5.5 109.042 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.53 ' C ' ' H ' ' A' ' 6' ' ' PHE . 1.8 tm-20 73.76 -18.04 0.41 Allowed 'General case' 0 N--CA 1.494 1.769 0 N-CA-C 104.217 -2.512 . . . . 6.8399999999999999 104.217 -175.487 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . 0.821 ' H ' ' C ' ' A' ' 3' ' ' PRO . 3.8 m-85 -90.24 19.51 5.04 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 103.855 -2.646 . . . . 6.4400000000000004 103.855 176.733 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.534 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 38.4 p90 47.59 -150.61 0.12 Allowed 'General case' 0 C--N 1.307 -1.267 0 CA-C-N 114.366 -1.288 . . . . 5.0599999999999996 109.585 -177.581 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 7.0 mm-40 81.16 -8.28 1.42 Allowed 'General case' 0 N--CA 1.5 2.027 0 N-CA-C 105.241 -2.133 . . . . 4.8099999999999996 105.241 -176.723 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.507 ' H ' ' C ' ' A' ' 6' ' ' PHE . 47.6 t80 -151.59 -37.22 0.12 Allowed 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 107.864 -1.162 . . . . 5.7300000000000004 107.864 178.454 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 12.6 m -91.54 2.62 56.31 Favored 'General case' 0 C--N 1.297 -1.681 0 N-CA-C 105.867 -1.901 . . . . 5.3499999999999996 105.867 177.326 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 10.0 p -41.58 -36.88 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.381 0 CA-C-N 115.255 -0.884 . . . . 4.3799999999999999 109.518 -179.74 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.589 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 134.11 -81.46 0.31 Allowed Glycine 0 N--CA 1.505 3.242 0 N-CA-C 109.344 -1.502 . . . . 4.4800000000000004 109.344 179.187 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.464 ' O ' ' C ' ' A' ' 13' ' ' LEU . 16.6 Cg_endo -66.49 42.15 0.17 Allowed 'Trans proline' 0 C--N 1.319 -0.994 0 C-N-CA 122.033 1.822 . . . . 4.0499999999999998 108.533 178.462 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.589 ' H ' ' C ' ' A' ' 11' ' ' GLY . 0.2 OUTLIER 30.36 94.03 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.148 0 CA-C-O 121.355 0.598 . . . . 4.0599999999999996 110.412 -178.806 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.514 ' C ' ' H ' ' A' ' 16' ' ' GLY . . . -35.69 -30.64 0.02 OUTLIER Glycine 0 N--CA 1.499 2.854 0 N-CA-C 110.02 -1.232 . . . . 3.1400000000000001 110.02 -179.654 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.517 ' N ' ' O ' ' A' ' 13' ' ' LEU . 48.6 tt0 57.42 8.14 0.58 Allowed 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 108.287 -1.005 . . . . 3.1699999999999999 108.287 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.514 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 95.02 -144.95 17.49 Favored Glycine 0 N--CA 1.488 2.122 0 N-CA-C 111.204 -0.758 . . . . 2.4399999999999999 111.204 178.462 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.558 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -43.2 -23.65 0.26 Allowed Glycine 0 N--CA 1.49 2.271 0 O-C-N 121.715 -0.874 . . . . 2.0499999999999998 111.489 -178.265 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.493 ' N ' ' OE1' ' A' ' 94' ' ' GLU . . . -43.01 -17.94 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.042 -1.27 . . . . 2.54 110.047 -179.715 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . 0.558 ' N ' ' O ' ' A' ' 17' ' ' GLY . 8.9 t-80 -95.3 -52.06 4.33 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.33 -0.856 . . . . 3.3700000000000001 109.731 179.884 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.646 ' HZ2' ' HG1' ' A' ' 43' ' ' THR . 0.0 OUTLIER -67.21 -14.71 63.17 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.996 -1.065 . . . . 2.3700000000000001 109.551 -179.602 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 71.2 t -76.93 113.4 15.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.181 -0.95 . . . . 2.5800000000000001 108.813 179.308 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 20.7 tpt180 -110.4 136.31 49.76 Favored 'General case' 0 N--CA 1.494 1.774 0 CA-C-O 121.567 0.698 . . . . 3.8900000000000001 110.18 -179.015 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -140.05 113.61 8.61 Favored 'General case' 0 N--CA 1.491 1.603 0 N-CA-C 108.645 -0.872 . . . . 2.0099999999999998 108.645 179.569 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -146.38 126.51 2.5 Favored Glycine 0 N--CA 1.496 2.638 0 N-CA-C 109.625 -1.39 . . . . 2.0099999999999998 109.625 -179.647 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.32 177.93 48.5 Favored Glycine 0 N--CA 1.488 2.139 0 N-CA-C 109.743 -1.343 . . . . 1.9299999999999999 109.743 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 41.7 p -79.63 -24.62 41.79 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.249 -1.148 . . . . 2.6899999999999999 109.461 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -68.56 -14.1 66.6 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 108.387 -1.885 . . . . 1.6399999999999999 108.387 179.492 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 33.6 mt -100.35 35.25 2.15 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.688 -0.856 . . . . 2.0299999999999998 108.688 179.76 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 -144.32 -46.01 0.25 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.377 -0.827 . . . . 2.3399999999999999 109.516 -179.742 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 29.2 ptt180 -172.36 171.95 4.58 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 120.98 -1.075 . . . . 4.25 110.093 -179.874 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -147.76 174.4 27.51 Favored Glycine 0 N--CA 1.493 2.439 0 N-CA-C 108.598 -1.801 . . . . 1.5900000000000001 108.598 179.622 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 37.6 t -134.68 152.52 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.088 0 O-C-N 121.136 -1.214 . . . . 2.21 110.576 -179.635 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -40.78 112.29 0.28 Allowed 'General case' 0 N--CA 1.499 1.999 0 CA-C-O 121.586 0.708 . . . . 2.0699999999999998 112.321 -179.268 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 53.72 51.82 46.32 Favored Glycine 0 N--CA 1.49 2.253 0 O-C-N 121.57 -0.706 . . . . 1.73 111.377 177.049 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 24.7 t -127.29 98.38 29.68 Favored Pre-proline 0 N--CA 1.495 1.787 0 O-C-N 121.451 -1.029 . . . . 2.6499999999999999 108.453 178.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_exo -57.85 138.71 87.37 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 120.67 0.913 . . . . 2.1400000000000001 109.854 -179.25 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -146.79 -167.76 2.85 Favored 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 108.491 -0.929 . . . . 2.0299999999999998 108.491 -179.839 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -169.26 170.75 8.38 Favored 'General case' 0 C--N 1.303 -1.415 0 C-N-CA 118.745 -1.182 . . . . 2.23 111.04 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.53 ' N ' ' CD1' ' A' ' 39' ' ' PHE . 1.2 p90 -142.3 -178.26 5.65 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 107.49 -1.3 . . . . 1.72 107.49 178.274 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 88.9 p -124.43 138.37 54.36 Favored 'General case' 0 N--CA 1.501 2.088 0 CA-C-O 122.118 0.961 . . . . 2.5800000000000001 111.219 -178.515 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.476 ' O ' ' N ' ' A' ' 73' ' ' CYS . 33.3 mm -130.58 126.59 60.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 N-CA-C 108.238 -1.023 . . . . 1.8600000000000001 108.238 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.504 ' C ' ' CD1' ' A' ' 42' ' ' TRP . 0.6 OUTLIER -138.28 142.13 39.83 Favored 'General case' 0 N--CA 1.503 2.221 0 O-C-N 120.898 -1.126 . . . . 4.4699999999999998 109.539 179.357 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' THR . . . . . 0.646 ' HG1' ' HZ2' ' A' ' 20' ' ' LYS . 0.2 OUTLIER -156.44 151.94 26.83 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.553 -0.717 . . . . 3.27 109.605 -179.076 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' ARG . . . . . 0.479 ' CG ' ' NH1' ' A' ' 44' ' ' ARG . 0.0 OUTLIER -168.38 62.47 0.06 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.481 -0.762 . . . . 5.2300000000000004 109.069 179.596 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -155.43 -60.09 0.11 Allowed 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.106 -0.996 . . . . 2.8900000000000001 110.016 -179.748 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -59.7 -32.75 70.8 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.886 -1.134 . . . . 1.99 109.333 -179.734 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 94.94 -157.36 22.14 Favored Glycine 0 N--CA 1.495 2.603 0 N-CA-C 109.996 -1.242 . . . . 1.6499999999999999 109.996 179.72 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.65 163.19 0.71 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.398 -1.06 . . . . 1.77 110.101 -179.605 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 175.56 -165.85 36.91 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.264 -1.534 . . . . 1.1200000000000001 109.264 179.844 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.404 ' O ' ' N ' ' A' ' 92' ' ' ASN . . . -132.6 119.62 2.49 Favored Glycine 0 N--CA 1.498 2.816 0 N-CA-C 108.985 -1.646 . . . . 1.1799999999999999 108.985 179.867 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.429 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 31.6 tp -100.44 104.53 15.94 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.328 -1.101 . . . . 1.5900000000000001 109.014 -179.873 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 13.8 t -91.14 142.73 27.43 Favored 'General case' 0 N--CA 1.495 1.824 0 N-CA-C 108.703 -0.851 . . . . 1.9399999999999999 108.703 179.575 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.503 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 66.0 mt -132.47 103.58 6.54 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.986 0 O-C-N 121.119 -0.988 . . . . 1.3 109.571 -179.922 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -93.76 106.23 18.21 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.641 -0.874 . . . . 1.27 108.641 179.479 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.429 ' O ' ' O ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -98.91 141.7 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.564 -0.71 . . . . 1.55 109.478 -179.622 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 21.0 tt0 -141.28 144.2 34.52 Favored 'General case' 0 N--CA 1.492 1.639 0 N-CA-C 107.535 -1.283 . . . . 1.8 107.535 178.678 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 164.07 -173.3 40.08 Favored Glycine 0 N--CA 1.488 2.134 0 N-CA-C 109.489 -1.444 . . . . 0.56000000000000005 109.489 -178.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -64.01 -33.46 62.54 Favored 'Trans proline' 0 C--N 1.319 -1.015 0 C-N-CA 122.114 1.876 . . . . 0.76000000000000001 112.154 -179.567 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 33.0 m -135.22 155.77 50.1 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.072 -1.017 . . . . 2.02 109.947 -179.307 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 77.3 tttt -73.7 96.35 2.49 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.621 -0.674 . . . . 3.02 109.609 -179.834 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -61.05 123.9 18.98 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.342 -0.849 . . . . 1.3600000000000001 109.341 179.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 19.6 tt0 -70.94 171.03 11.48 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.238 -0.914 . . . . 2.2999999999999998 109.214 -179.82 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 72.4 mt -140.92 152.08 20.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 N-CA-C 107.663 -1.236 . . . . 2.0 107.663 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.518 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -150.09 113.45 4.93 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.537 -1.352 . . . . 1.73 109.356 179.816 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.461 ' CD2' ' O ' ' A' ' 65' ' ' PHE . 47.0 p90 -87.24 125.14 34.01 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.35 -0.844 . . . . 1.6000000000000001 109.71 179.874 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 59.5 tt0 -141.31 100.07 3.71 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.386 -0.821 . . . . 2.5099999999999998 109.233 179.808 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . 0.421 ' O ' ' OD1' ' A' ' 67' ' ' ASP . 1.3 p30 -74.16 128.54 35.81 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.251 -0.906 . . . . 2.0699999999999998 109.53 -179.86 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 84.6 mtm180 -101.81 -33.85 9.65 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.401 -0.812 . . . . 5.29 109.699 -179.885 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.575 ' C ' ' H ' ' A' ' 71' ' ' GLY . 29.6 mtmt -122.66 11.23 9.78 Favored 'General case' 0 N--CA 1.495 1.813 0 N-CA-C 109.006 -0.739 . . . . 3.8599999999999999 109.006 -179.937 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.457 ' CB ' ' O ' ' A' ' 69' ' ' LYS . 1.0 OUTLIER 72.92 -34.98 0.31 Allowed 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 108.577 -0.897 . . . . 3.0600000000000001 108.577 -179.206 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . 0.575 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -89.6 -37.34 7.0 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.941 -1.264 . . . . 2.1600000000000001 109.941 -179.76 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 45.5 t -95.54 113.45 25.11 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.22 -1.165 . . . . 2.5600000000000001 109.612 -179.769 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' CYS . . . . . 0.476 ' N ' ' O ' ' A' ' 41' ' ' ILE . 42.6 m -87.91 114.15 24.24 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.293 -0.879 . . . . 2.3599999999999999 109.548 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -93.9 118.21 5.68 Favored Glycine 0 N--CA 1.494 2.524 0 N-CA-C 109.15 -1.58 . . . . 1.46 109.15 179.815 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -106.92 106.14 20.08 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.298 0 O-C-N 121.53 -0.982 . . . . 2.1600000000000001 109.011 -179.868 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.518 ' O ' ' N ' ' A' ' 64' ' ' ALA . 1.4 m -89.73 150.81 22.14 Favored 'General case' 0 N--CA 1.49 1.568 0 N-CA-C 108.523 -0.917 . . . . 2.1600000000000001 108.523 179.273 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 11.7 p90 -145.89 174.27 11.4 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.212 -0.93 . . . . 1.7 109.348 -179.106 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.472 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 4.8 p -145.79 116.71 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.503 2.192 0 O-C-N 120.991 -1.068 . . . . 2.4500000000000002 110.66 179.47 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 10.3 m -90.96 151.41 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 O-C-N 121.144 -0.972 . . . . 1.8200000000000001 108.745 179.295 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . 0.42 ' O ' ' OE2' ' A' ' 81' ' ' GLU . 7.2 tp-100 -94.76 -46.91 6.7 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.011 -1.056 . . . . 3.1699999999999999 110.819 -179.06 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.42 ' OE2' ' O ' ' A' ' 80' ' ' GLN . 78.1 mm-40 -153.8 150.06 22.23 Favored Pre-proline 0 N--CA 1.503 2.185 0 O-C-N 120.68 -1.262 . . . . 2.02 111.02 -178.651 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.576 ' HG3' ' N ' ' A' ' 107' ' ' SER . 84.9 Cg_exo -36.76 163.45 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.645 0 C-N-CA 122.918 2.412 . . . . 1.3999999999999999 113.529 178.177 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 148.16 -165.29 28.97 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.28 -1.528 . . . . 1.0800000000000001 109.28 179.838 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -106.95 88.25 2.7 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.599 -0.942 . . . . 2.1299999999999999 108.665 179.697 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . 0.457 ' O ' ' N ' ' A' ' 103' ' ' VAL . 3.4 m-85 -76.64 129.55 36.55 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.283 -1.006 . . . . 1.1399999999999999 108.283 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -110.21 121.49 45.41 Favored 'General case' 0 N--CA 1.498 1.933 0 N-CA-C 108.372 -0.973 . . . . 1.53 108.372 -179.101 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 8.4 p -120.28 133.41 67.09 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.593 -0.692 . . . . 1.6399999999999999 109.705 -179.607 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 11.6 t -128.24 101.64 6.33 Favored 'General case' 0 N--CA 1.498 1.958 0 N-CA-C 109.609 -0.515 . . . . 1.99 109.609 -179.831 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.449 ' H ' ' CB ' ' A' ' 99' ' ' SER . 0.8 OUTLIER -108.0 130.85 59.78 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.875 0 O-C-N 121.567 -0.708 . . . . 1.77 109.6 -179.806 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -139.9 128.77 23.38 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.413 -0.804 . . . . 2.0600000000000001 109.05 -179.979 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 44.7 t80 -84.69 95.63 8.98 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 120.527 -1.358 . . . . 1.45 108.387 179.296 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . 0.457 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 0.2 OUTLIER 68.58 39.72 2.03 Favored 'General case' 0 N--CA 1.488 1.435 0 N-CA-C 107.893 -1.151 . . . . 2.7200000000000002 107.893 -178.532 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . 0.457 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 3.4 m-20 82.6 14.07 0.45 Allowed 'General case' 0 N--CA 1.499 1.992 0 CA-C-O 121.188 0.518 . . . . 1.9199999999999999 110.23 -179.434 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . 0.493 ' OE1' ' N ' ' A' ' 18' ' ' ALA . 55.2 mt-10 -87.91 78.73 8.24 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.431 -0.951 . . . . 2.5499999999999998 108.431 178.916 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 44.2 m-70 -55.75 109.67 0.6 Allowed 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.529 -0.732 . . . . 3.2000000000000002 110.602 -179.17 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . 0.426 ' O ' ' O ' ' A' ' 99' ' ' SER . 1.5 mp -66.55 136.48 94.88 Favored Pre-proline 0 N--CA 1.492 1.637 0 N-CA-C 107.476 -1.305 . . . . 2.8199999999999998 107.476 179.034 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_exo -41.17 -41.21 4.51 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 120.997 1.131 . . . . 2.6299999999999999 110.575 -179.633 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.506 ' N ' ' OD1' ' A' ' 98' ' ' ASP . 1.3 m-20 -56.9 -65.61 0.59 Allowed 'General case' 0 N--CA 1.488 1.434 0 O-C-N 120.83 -1.169 . . . . 2.6499999999999999 108.026 178.191 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' SER . . . . . 0.449 ' CB ' ' H ' ' A' ' 89' ' ' ILE . 0.1 OUTLIER -68.71 145.02 96.68 Favored Pre-proline 0 C--N 1.293 -1.882 0 O-C-N 121.173 -0.955 . . . . 2.3199999999999998 109.564 -179.448 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -85.22 113.01 2.71 Favored 'Cis proline' 0 CA--C 1.549 1.271 0 O-C-N 122.636 0.808 . . . . 1.9399999999999999 110.154 -1.864 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 31.3 p90 -121.82 164.23 17.84 Favored 'General case' 0 N--CA 1.521 3.088 0 O-C-N 120.497 -1.377 . . . . 2.6299999999999999 109.921 178.402 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.3 p -87.43 144.41 9.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.462 -0.774 . . . . 1.8200000000000001 110.643 -178.129 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.457 ' N ' ' O ' ' A' ' 85' ' ' TYR . 71.7 t -117.24 89.54 31.26 Favored Pre-proline 0 N--CA 1.498 1.949 0 N-CA-C 108.503 -0.925 . . . . 1.73 108.503 179.354 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -62.93 113.99 2.24 Favored 'Trans proline' 0 C--N 1.319 -0.989 0 C-N-CA 121.142 1.228 . . . . 1.6100000000000001 111.916 -178.266 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 55.4 t -96.41 140.4 17.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 N-CA-C 105.926 -1.879 . . . . 1.7 105.926 177.446 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -131.89 133.53 44.7 Favored 'General case' 0 N--CA 1.512 2.671 0 CA-C-O 122.067 0.937 . . . . 2.04 112.059 -176.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' SER . . . . . 0.576 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 23.2 t -101.06 86.77 3.11 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 107.928 -1.138 . . . . 2.2999999999999998 107.928 179.177 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 13.3 mt 60.24 6.07 0.94 Allowed 'General case' 0 C--N 1.297 -1.708 0 N-CA-C 107.718 -1.216 . . . . 3.6000000000000001 107.718 -178.323 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.727 ' HG ' ' H ' ' A' ' 111' ' ' ASP . 52.0 p -97.77 -23.39 15.92 Favored 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 109.206 -0.664 . . . . 2.4900000000000002 109.206 179.657 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 34.4 t70 52.78 11.41 0.2 Allowed 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.131 -0.981 . . . . 2.8500000000000001 108.436 -179.587 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.727 ' H ' ' HG ' ' A' ' 109' ' ' SER . 30.8 t70 -171.57 -30.13 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.711 -0.618 . . . . 2.46 109.567 -179.736 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.694 ' H ' ' HG ' ' A' ' 109' ' ' SER . . . 41.88 83.9 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.074 0 O-C-N 121.25 -0.906 . . . . 2.0800000000000001 110.1 179.884 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.509 ' CG ' HH11 ' A' ' 113' ' ' ARG . 0.0 OUTLIER -71.46 149.19 46.1 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.167 -0.958 . . . . 6.54 109.268 -179.677 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.569 ' CG ' HH11 ' A' ' 114' ' ' ARG . 0.2 OUTLIER -93.59 6.26 48.87 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.513 -0.742 . . . . 6.2400000000000002 109.156 -179.933 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 34.2 mt -128.0 -21.77 3.59 Favored 'General case' 0 N--CA 1.505 2.305 0 O-C-N 121.649 -0.657 . . . . 4.71 109.677 -179.507 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.527 ' C ' ' H ' ' A' ' 118' ' ' THR . 91.6 m -112.03 -77.22 0.59 Allowed 'General case' 0 N--CA 1.498 1.95 0 N-CA-C 107.087 -1.449 . . . . 4.3499999999999996 107.087 179.049 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 44.7 t -64.74 -6.2 2.87 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.749 0 N-CA-C 105.911 -1.885 . . . . 3.3100000000000001 105.911 176.799 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' THR . . . . . 0.527 ' H ' ' C ' ' A' ' 116' ' ' THR . 4.5 t 35.99 59.07 0.92 Allowed 'General case' 0 N--CA 1.488 1.455 0 CA-C-N 115.026 -0.988 . . . . 3.73 110.797 179.902 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' SER . . . . . 0.46 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.5 p . . . . . 0 N--CA 1.488 1.434 0 CA-C-O 117.977 -1.011 . . . . 3.8300000000000001 109.582 179.345 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 1' ' ' MET . . . . . 0.443 ' H3 ' ' H ' ' B' ' 2' ' ' ALA . 27.2 ttt . . . . . 0 N--CA 1.49 1.533 0 CA-C-O 121.277 0.561 . . . . 8.8699999999999992 109.525 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 2' ' ' ALA . . . . . 0.443 ' H ' ' H3 ' ' B' ' 1' ' ' MET . . . -80.31 149.35 30.34 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.217 -0.927 . . . . 5.9299999999999997 109.779 -179.818 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 3' ' ' SER . . . . . . . . . . . . . 21.6 p -171.34 -6.8 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.281 -0.887 . . . . 5.5700000000000003 109.086 179.85 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 4' ' ' LYS . . . . . 0.651 ' N ' ' CD ' ' B' ' 5' ' ' PRO . 25.7 ttpt -81.19 -33.55 0.69 Allowed Pre-proline 0 N--CA 1.488 1.451 0 O-C-N 121.418 -0.801 . . . . 7.25 111.826 179.964 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 5' ' ' PRO . . . . . 0.651 ' CD ' ' N ' ' B' ' 4' ' ' LYS . 6.2 Cg_exo -65.08 -169.77 0.14 Allowed 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 120.606 0.871 . . . . 5.8899999999999997 110.002 -178.977 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 6' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -77.54 35.18 0.18 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.234 -0.916 . . . . 4.7800000000000002 109.764 -179.711 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 7' ' ' LYS . . . . . 0.444 ' H ' ' C ' ' B' ' 5' ' ' PRO . 91.4 mttt 45.6 -114.04 0.43 Allowed 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.317 -0.864 . . . . 4.5599999999999996 109.847 179.89 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . 0.434 ' HG2' HH11 ' B' ' 8' ' ' ARG . 11.7 mtt-85 -91.1 168.2 11.8 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.19 -0.944 . . . . 3.6699999999999999 109.078 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 9' ' ' VAL . . . . . 0.403 ' CG1' ' N ' ' B' ' 10' ' ' ALA . 3.1 t -48.72 159.69 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.135 -0.978 . . . . 1.3899999999999999 108.515 179.747 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . 0.403 ' N ' ' CG1' ' B' ' 9' ' ' VAL . . . -116.44 150.84 37.18 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.655 -0.653 . . . . 1.22 109.482 -179.344 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 11' ' ' SER . . . . . 0.429 ' O ' ' O ' ' A' ' 55' ' ' VAL . 58.2 m -153.19 139.88 18.92 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.283 -0.886 . . . . 1.6299999999999999 109.865 -179.832 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 51.6 p -148.36 112.51 5.21 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.197 -0.939 . . . . 1.8799999999999999 109.562 -179.697 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . 0.501 ' CG2' ' N ' ' B' ' 14' ' ' PHE . 2.5 p -154.61 167.58 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 N-CA-C 108.624 -0.88 . . . . 1.2 108.624 179.811 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 14' ' ' PHE . . . . . 0.503 ' HB3' ' H ' ' A' ' 53' ' ' ILE . 7.8 p90 -176.55 -167.18 0.18 Allowed 'General case' 0 N--CA 1.488 1.435 0 C-N-CA 119.132 -1.027 . . . . 2.3900000000000001 112.069 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -143.45 146.26 21.49 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.226 0 N-CA-C 108.883 -0.784 . . . . 1.8100000000000001 108.883 179.871 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 46.1 m -113.03 128.3 56.46 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.353 -0.842 . . . . 2.04 109.293 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 16.8 mt -97.95 142.51 29.59 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.174 -0.954 . . . . 1.8700000000000001 109.562 179.939 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -171.75 66.97 0.42 Allowed Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.256 -0.903 . . . . 1.47 109.527 179.696 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -65.42 141.12 66.48 Favored 'Trans proline' 0 CA--C 1.551 1.363 0 C-N-CA 121.36 1.373 . . . . 1.96 109.32 -179.776 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 20' ' ' PRO . . . . . 0.426 ' O ' ' O ' ' B' ' 21' ' ' ARG . 4.6 Cg_endo -62.38 -36.2 68.32 Favored 'Trans proline' 0 CA--C 1.538 0.691 0 C-N-CA 120.872 1.048 . . . . 3.3799999999999999 109.699 179.394 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . 0.426 ' O ' ' O ' ' B' ' 20' ' ' PRO . 50.9 mtp180 -55.79 -164.96 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.442 -0.786 . . . . 6.7400000000000002 110.013 -179.579 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 22' ' ' ARG . . . . . . . . . . . . . 1.5 tmm_? 54.95 92.2 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.314 -0.866 . . . . 6.9400000000000004 109.158 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 -157.78 -13.4 0.08 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.331 -0.856 . . . . 5.6200000000000001 109.442 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 14.2 t . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 118.022 -0.989 . . . . 6.75 109.573 -179.834 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.964 0 N-CA-C 119.799 2.68 . . . . 6.7300000000000004 119.799 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.525 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 2.8 tt -174.98 52.22 0.1 Allowed Pre-proline 0 C--N 1.309 -1.174 0 N-CA-C 107.972 -1.121 . . . . 7.3799999999999999 107.972 179.578 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.712 ' C ' ' H ' ' A' ' 5' ' ' PHE . 1.3 Cg_endo -56.7 -80.92 0.01 OUTLIER 'Trans proline' 0 C--N 1.319 -0.996 0 N-CA-C 108.217 -1.494 . . . . 5.5 108.217 179.852 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 64.32 2.68 1.58 Allowed 'General case' 0 N--CA 1.499 2.024 0 N-CA-C 105.003 -2.221 . . . . 6.8399999999999999 105.003 -176.61 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . 0.712 ' H ' ' C ' ' A' ' 3' ' ' PRO . 5.2 m-85 -114.6 18.42 16.71 Favored 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 102.46 -3.163 . . . . 6.4400000000000004 102.46 177.58 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.541 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 36.0 p90 48.14 -151.09 0.13 Allowed 'General case' 0 C--N 1.308 -1.209 0 CA-C-N 113.302 -1.772 . . . . 5.0599999999999996 109.532 -177.315 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 66.4 mt-30 81.61 -9.53 1.25 Allowed 'General case' 0 N--CA 1.497 1.88 0 N-CA-C 105.139 -2.171 . . . . 4.8099999999999996 105.139 -176.697 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.527 ' H ' ' C ' ' A' ' 6' ' ' PHE . 28.4 t80 -150.37 -36.66 0.15 Allowed 'General case' 0 N--CA 1.486 1.333 0 N-CA-C 107.983 -1.117 . . . . 5.7300000000000004 107.983 178.24 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 39.1 m -94.91 4.57 53.66 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 105.704 -1.961 . . . . 5.3499999999999996 105.704 177.456 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.422 ' CG1' ' N ' ' A' ' 11' ' ' GLY . 13.0 p -45.69 -46.23 4.81 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.296 0 CA-C-N 115.272 -0.876 . . . . 4.3799999999999999 109.398 -179.535 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.612 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 131.03 -78.58 0.37 Allowed Glycine 0 N--CA 1.503 3.142 0 N-CA-C 109.132 -1.587 . . . . 4.4800000000000004 109.132 179.393 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.446 ' O ' ' C ' ' A' ' 13' ' ' LEU . 11.8 Cg_endo -65.24 40.22 0.12 Allowed 'Trans proline' 0 C--N 1.32 -0.958 0 C-N-CA 122.186 1.924 . . . . 4.0499999999999998 109.176 178.409 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.612 ' H ' ' C ' ' A' ' 11' ' ' GLY . 0.2 OUTLIER 28.17 46.05 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.157 0 CA-C-O 121.504 0.669 . . . . 4.0599999999999996 111.062 -179.848 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.483 ' C ' ' N ' ' A' ' 16' ' ' GLY . . . 69.06 -36.89 0.3 Allowed Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.567 -1.413 . . . . 3.1400000000000001 109.567 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.558 ' H ' ' C ' ' A' ' 13' ' ' LEU . 6.9 tp10 51.76 16.81 0.53 Allowed 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.115 -1.226 . . . . 3.1699999999999999 107.798 -179.132 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.483 ' N ' ' C ' ' A' ' 14' ' ' GLY . . . 82.09 -166.08 45.99 Favored Glycine 0 N--CA 1.485 1.92 0 N-CA-C 109.48 -1.448 . . . . 2.4399999999999999 109.48 -179.854 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.511 ' C ' ' H ' ' A' ' 19' ' ' HIS . . . -43.97 -19.76 0.13 Allowed Glycine 0 N--CA 1.488 2.159 0 O-C-N 121.387 -1.067 . . . . 2.0499999999999998 110.579 -179.457 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.522 ' N ' ' CD ' ' A' ' 94' ' ' GLU . . . -51.07 -9.9 0.06 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.826 -1.397 . . . . 2.54 109.204 -179.829 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . 0.511 ' H ' ' C ' ' A' ' 17' ' ' GLY . 22.0 t60 -103.01 -4.59 24.42 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.404 -0.81 . . . . 3.3700000000000001 110.175 -179.738 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.524 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 1.9 pptp? -135.81 0.6 2.69 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.1 -1.0 . . . . 2.3700000000000001 110.261 -179.559 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.401 ' CG2' ' NZ ' ' A' ' 20' ' ' LYS . 55.3 t -88.8 113.47 25.55 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.003 -1.06 . . . . 2.5800000000000001 109.751 179.665 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 21.0 tpt180 -108.97 135.85 49.47 Favored 'General case' 0 N--CA 1.495 1.79 0 N-CA-C 109.308 -0.627 . . . . 3.8900000000000001 109.308 179.647 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -143.31 113.81 7.46 Favored 'General case' 0 N--CA 1.492 1.674 0 N-CA-C 108.566 -0.902 . . . . 2.0099999999999998 108.566 179.467 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -152.6 130.95 3.2 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.671 -1.371 . . . . 2.0099999999999998 109.671 -179.367 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -177.55 167.58 38.67 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.801 -1.32 . . . . 1.9299999999999999 109.801 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.538 ' C ' ' H ' ' A' ' 28' ' ' LEU . 0.5 OUTLIER -80.5 -27.53 37.72 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.318 -1.107 . . . . 2.6899999999999999 109.864 -179.698 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -64.21 -1.36 5.46 Favored Glycine 0 N--CA 1.483 1.78 0 N-CA-C 107.938 -2.065 . . . . 1.6399999999999999 107.938 179.193 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.538 ' H ' ' C ' ' A' ' 26' ' ' THR . 60.9 mt -108.45 -10.56 15.27 Favored 'General case' 0 N--CA 1.493 1.712 0 N-CA-C 108.643 -0.873 . . . . 2.0299999999999998 108.643 179.748 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 20.3 mm-40 -85.74 -54.16 4.7 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.568 -0.708 . . . . 2.3399999999999999 109.561 -179.586 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . 0.572 ' CG ' HH11 ' A' ' 30' ' ' ARG . 3.2 mtt-85 -156.83 161.94 39.72 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.125 -0.984 . . . . 4.25 109.76 179.918 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -140.73 172.17 23.74 Favored Glycine 0 N--CA 1.493 2.499 0 N-CA-C 108.102 -1.999 . . . . 1.5900000000000001 108.102 179.205 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 36.0 t -134.37 150.93 31.2 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.03 0 O-C-N 121.189 -1.183 . . . . 2.21 110.398 -179.338 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -38.83 113.89 0.34 Allowed 'General case' 0 N--CA 1.495 1.784 0 CA-C-O 121.862 0.839 . . . . 2.0699999999999998 112.844 -179.184 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 53.99 49.77 57.64 Favored Glycine 0 N--CA 1.489 2.167 0 N-CA-C 111.238 -0.745 . . . . 1.73 111.238 177.378 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 25.3 t -126.98 99.41 28.88 Favored Pre-proline 0 N--CA 1.497 1.9 0 O-C-N 121.531 -0.982 . . . . 2.6499999999999999 108.396 179.052 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -56.75 143.44 90.27 Favored 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 120.946 1.097 . . . . 2.1400000000000001 110.588 -178.906 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -150.23 -169.06 3.28 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.563 -0.903 . . . . 2.0299999999999998 108.563 179.869 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -169.38 162.23 10.22 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.958 -1.089 . . . . 2.23 111.03 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.575 ' N ' ' CD1' ' A' ' 39' ' ' PHE . 0.2 OUTLIER -134.8 -176.37 4.21 Favored 'General case' 0 N--CA 1.485 1.303 0 N-CA-C 106.638 -1.615 . . . . 1.72 106.638 178.355 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 18.3 t -121.35 145.97 47.34 Favored 'General case' 0 N--CA 1.501 2.1 0 CA-C-O 121.72 0.771 . . . . 2.5800000000000001 111.07 -178.633 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.523 ' O ' ' N ' ' A' ' 73' ' ' CYS . 62.6 mt -143.19 118.69 4.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 N-CA-C 108.547 -0.908 . . . . 1.8600000000000001 108.547 179.222 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.533 ' O ' ' CD2' ' A' ' 42' ' ' TRP . 5.9 p-90 -118.1 127.19 53.54 Favored 'General case' 0 N--CA 1.502 2.135 0 O-C-N 121.219 -0.926 . . . . 4.4699999999999998 108.549 179.109 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' THR . . . . . 0.524 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -150.92 128.4 11.41 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.224 -0.923 . . . . 3.27 109.926 -178.828 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' ARG . . . . . . . . . . . . . 24.8 ttm180 -172.48 79.35 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.442 -0.786 . . . . 5.2300000000000004 109.092 179.663 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 2.3 tm-20 -159.69 -55.04 0.06 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.188 -0.945 . . . . 2.8900000000000001 109.881 -179.676 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -53.43 -55.29 26.38 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 120.911 -1.118 . . . . 1.99 108.672 -179.821 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 140.58 -170.37 24.47 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.163 -1.575 . . . . 1.6499999999999999 109.163 179.678 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.67 148.28 10.05 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.14 -1.212 . . . . 1.77 109.202 179.832 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -171.66 -170.06 35.23 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.762 -1.335 . . . . 1.1200000000000001 109.762 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -133.05 122.71 3.24 Favored Glycine 0 N--CA 1.497 2.727 0 N-CA-C 109.403 -1.479 . . . . 1.1799999999999999 109.403 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 11.3 tp -97.65 97.98 9.49 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.303 -1.116 . . . . 1.5900000000000001 108.69 179.651 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' SER . . . . . 0.546 ' H ' ' HG ' ' A' ' 52' ' ' SER . 0.3 OUTLIER -84.52 145.63 27.99 Favored 'General case' 0 C--N 1.312 -1.035 0 N-CA-C 108.026 -1.102 . . . . 1.9399999999999999 108.026 179.695 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.459 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 65.4 mt -134.98 118.68 25.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.217 -0.927 . . . . 1.3 110.048 -179.315 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -106.63 106.85 17.57 Favored 'General case' 0 N--CA 1.495 1.824 0 N-CA-C 108.431 -0.952 . . . . 1.27 108.431 179.072 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 2.4 t -97.59 146.36 7.88 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.266 -0.897 . . . . 1.55 109.639 -179.436 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 22.8 tt0 -139.5 131.21 27.38 Favored 'General case' 0 N--CA 1.488 1.448 0 N-CA-C 107.616 -1.253 . . . . 1.8 107.616 178.835 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -178.41 172.31 44.71 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.159 -1.576 . . . . 0.56000000000000005 109.159 -179.498 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_exo -52.06 -28.61 33.25 Favored 'Trans proline' 0 C--N 1.318 -1.076 0 C-N-CA 121.808 1.672 . . . . 0.76000000000000001 110.859 -179.501 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.2 t -140.79 157.18 45.77 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.439 -0.788 . . . . 2.02 109.839 -179.527 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 49.3 mttp -77.78 104.75 8.52 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.421 -0.799 . . . . 3.02 109.169 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -74.15 136.95 42.89 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.272 -0.892 . . . . 1.3600000000000001 109.549 -179.728 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -75.33 175.54 8.29 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.141 -0.974 . . . . 2.2999999999999998 109.629 -179.829 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 4.8 mm -140.51 156.46 23.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 N-CA-C 108.033 -1.099 . . . . 2.0 108.033 -179.656 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -144.45 174.63 10.77 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 120.551 -1.343 . . . . 1.73 108.999 179.749 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.51 ' CD2' ' O ' ' A' ' 65' ' ' PHE . 37.7 p90 -147.25 116.36 6.9 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.308 -0.87 . . . . 1.6000000000000001 109.46 -179.919 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 76.2 tt0 -141.57 111.0 6.4 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.317 -0.864 . . . . 2.5099999999999998 109.241 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . 0.428 ' O ' ' OD1' ' A' ' 67' ' ' ASP . 1.2 p30 -74.71 117.84 16.99 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.2 -0.938 . . . . 2.0699999999999998 109.541 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 29.9 ttp180 -102.15 -24.12 13.97 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.371 -0.831 . . . . 5.29 109.46 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.546 ' C ' ' H ' ' A' ' 71' ' ' GLY . 40.1 mttp -121.29 1.56 10.23 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.55 -0.719 . . . . 3.8599999999999999 109.079 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.463 ' CB ' ' O ' ' A' ' 69' ' ' LYS . 1.5 t70 74.0 -26.11 0.19 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.498 -0.751 . . . . 3.0600000000000001 109.11 -179.628 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . 0.546 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -108.54 -30.34 3.84 Favored Glycine 0 N--CA 1.495 2.58 0 N-CA-C 109.894 -1.282 . . . . 2.1600000000000001 109.894 -179.484 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 60.6 p -95.7 113.58 25.23 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.157 -1.202 . . . . 2.5600000000000001 109.666 -179.783 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' CYS . . . . . 0.523 ' N ' ' O ' ' A' ' 41' ' ' ILE . 17.0 t -75.77 112.23 11.93 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.306 -0.871 . . . . 2.3599999999999999 109.361 179.789 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -91.77 117.99 5.37 Favored Glycine 0 N--CA 1.493 2.439 0 N-CA-C 109.394 -1.482 . . . . 1.46 109.394 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 1.9 m -109.28 114.68 47.57 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.097 0 O-C-N 121.611 -0.935 . . . . 2.1600000000000001 109.502 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -92.55 167.84 11.66 Favored 'General case' 0 N--CA 1.491 1.62 0 N-CA-C 108.341 -0.985 . . . . 2.1600000000000001 108.341 179.537 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 5.9 p90 -163.77 168.15 20.03 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.356 -0.84 . . . . 1.7 109.095 -179.338 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.471 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 5.0 p -143.11 115.31 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.369 0 O-C-N 121.0 -1.062 . . . . 2.4500000000000002 110.448 179.418 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 14.3 m -88.82 152.38 3.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.244 -0.91 . . . . 1.8200000000000001 109.233 179.741 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 6.8 tt0 -88.92 -50.33 6.26 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.092 -1.005 . . . . 3.1699999999999999 110.764 -179.043 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -153.31 156.92 32.85 Favored Pre-proline 0 N--CA 1.504 2.271 0 O-C-N 120.722 -1.236 . . . . 2.02 110.766 -179.015 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.56 ' HG3' ' N ' ' A' ' 107' ' ' SER . 71.0 Cg_exo -37.67 163.55 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 123.293 2.662 . . . . 1.3999999999999999 113.452 179.17 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 145.35 -177.37 23.82 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.138 -1.585 . . . . 1.0800000000000001 109.138 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . 0.528 ' OD1' ' NH2' ' B' ' 8' ' ' ARG . 0.4 OUTLIER -99.81 90.93 4.61 Favored 'General case' 0 N--CA 1.493 1.715 0 N-CA-C 107.962 -1.125 . . . . 2.1299999999999999 107.962 179.289 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -76.25 132.05 39.64 Favored 'General case' 0 C--N 1.296 -1.721 0 N-CA-C 108.245 -1.02 . . . . 1.1399999999999999 108.245 -179.747 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.66 115.56 27.31 Favored 'General case' 0 N--CA 1.501 2.082 0 N-CA-C 108.337 -0.986 . . . . 1.53 108.337 -179.351 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.556 ' CG1' ' CE2' ' A' ' 101' ' ' PHE . 4.5 p -112.85 132.78 60.69 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.676 -0.64 . . . . 1.6399999999999999 109.421 -179.779 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 3.0 m -121.85 139.53 53.51 Favored 'General case' 0 N--CA 1.497 1.886 0 N-CA-C 108.536 -0.912 . . . . 1.99 108.536 179.635 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.3 pt -141.1 130.68 25.34 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.181 0 O-C-N 121.076 -1.015 . . . . 1.77 109.845 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -136.89 123.61 21.14 Favored 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 107.72 -1.215 . . . . 2.0600000000000001 107.72 178.191 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 83.5 t80 -83.7 102.2 12.09 Favored 'General case' 0 C--N 1.295 -1.77 0 N-CA-C 107.985 -1.117 . . . . 1.45 107.985 179.326 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . 0.442 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 1.3 t30 69.33 34.83 2.79 Favored 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 108.788 -0.819 . . . . 2.7200000000000002 108.788 -178.651 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . 0.442 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 2.7 m-20 79.34 16.66 0.89 Allowed 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.827 -0.546 . . . . 1.9199999999999999 111.505 179.473 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . 0.522 ' CD ' ' N ' ' A' ' 18' ' ' ALA . 0.6 OUTLIER -101.1 100.23 10.77 Favored 'General case' 0 N--CA 1.499 2.005 0 N-CA-C 107.407 -1.331 . . . . 2.5499999999999998 107.407 178.188 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 11.9 m-70 -73.97 110.92 8.64 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.117 -0.99 . . . . 3.2000000000000002 110.632 -177.844 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . 0.465 ' O ' ' N ' ' A' ' 98' ' ' ASP . 3.4 tp -63.95 134.62 95.99 Favored Pre-proline 0 N--CA 1.488 1.455 0 N-CA-C 107.554 -1.276 . . . . 2.8199999999999998 107.554 178.868 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.401 ' O ' ' CG ' ' A' ' 98' ' ' ASP . 7.2 Cg_exo -49.56 92.5 0.03 OUTLIER 'Trans proline' 0 C--O 1.214 -0.721 0 N-CA-C 109.839 -0.87 . . . . 2.6299999999999999 109.839 -179.824 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.465 ' N ' ' O ' ' A' ' 96' ' ' ILE . 0.9 OUTLIER 169.76 -54.05 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 108.756 -0.831 . . . . 2.6499999999999999 108.756 -179.574 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 6.2 m -55.3 136.95 68.73 Favored Pre-proline 0 C--N 1.298 -1.636 0 O-C-N 121.231 -0.918 . . . . 2.3199999999999998 109.588 -178.261 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_endo -88.36 113.58 2.43 Favored 'Cis proline' 0 N--CA 1.494 1.539 0 N-CA-C 110.328 -0.681 . . . . 1.9399999999999999 110.328 -1.862 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . 0.598 ' CD1' ' N ' ' A' ' 101' ' ' PHE . 0.0 OUTLIER -80.71 155.08 26.93 Favored 'General case' 0 N--CA 1.509 2.522 0 O-C-N 119.727 -1.858 . . . . 2.6299999999999999 108.66 178.346 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 10.5 p -89.21 144.5 8.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.483 -0.761 . . . . 1.8200000000000001 109.158 179.653 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 76.9 t -128.04 85.87 59.52 Favored Pre-proline 0 N--CA 1.499 1.997 0 N-CA-C 108.133 -1.062 . . . . 1.73 108.133 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -64.91 112.53 2.04 Favored 'Trans proline' 0 C--N 1.321 -0.878 0 C-N-CA 121.433 1.422 . . . . 1.6100000000000001 111.851 -177.867 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 54.5 t -96.36 143.89 11.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 N-CA-C 106.172 -1.788 . . . . 1.7 106.172 177.667 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -136.36 135.23 38.65 Favored 'General case' 0 N--CA 1.509 2.489 0 O-C-N 121.151 -0.968 . . . . 2.04 112.133 -176.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' SER . . . . . 0.56 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 11.0 t -89.67 76.27 7.31 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 107.413 -1.329 . . . . 2.2999999999999998 107.413 178.982 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 13.6 mt 65.87 -0.06 1.42 Allowed 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 107.748 -1.204 . . . . 3.6000000000000001 107.748 -177.861 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.61 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 22.9 t -84.67 -22.14 29.94 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.74 -0.837 . . . . 2.4900000000000002 108.74 178.873 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 57.17 6.93 0.4 Allowed 'General case' 0 N--CA 1.487 1.423 0 N-CA-C 107.984 -1.117 . . . . 2.8500000000000001 107.984 -179.141 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.551 ' H ' ' C ' ' A' ' 109' ' ' SER . 22.4 m-20 -164.79 -33.5 0.03 OUTLIER 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 108.714 -0.847 . . . . 2.46 108.714 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.61 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 41.56 84.49 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.332 -0.855 . . . . 2.0800000000000001 110.569 179.711 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.446 ' NH1' ' CB ' ' A' ' 111' ' ' ASP . 10.3 mpt_? -61.63 -169.54 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.906 -1.121 . . . . 6.54 108.574 179.681 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.666 HH12 ' NE ' ' B' ' 8' ' ' ARG . 50.3 ttt180 -147.39 4.1 0.79 Allowed 'General case' 0 N--CA 1.493 1.721 0 N-CA-C 108.548 -0.908 . . . . 6.2400000000000002 108.548 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 2.5 mp -129.8 -24.47 2.69 Favored 'General case' 0 N--CA 1.502 2.146 0 N-CA-C 109.458 -0.571 . . . . 4.71 109.458 179.778 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.526 ' C ' ' H ' ' A' ' 118' ' ' THR . 54.9 m -105.33 -79.44 0.56 Allowed 'General case' 0 N--CA 1.496 1.836 0 N-CA-C 106.955 -1.498 . . . . 4.3499999999999996 106.955 178.8 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 49.5 t -62.56 -8.2 2.88 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.702 0 N-CA-C 105.955 -1.869 . . . . 3.3100000000000001 105.955 176.724 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' THR . . . . . 0.526 ' H ' ' C ' ' A' ' 116' ' ' THR . 4.4 t 36.47 60.2 0.92 Allowed 'General case' 0 N--CA 1.488 1.437 0 CA-C-N 115.2 -0.909 . . . . 3.73 110.729 179.967 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' SER . . . . . 0.463 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.6 p . . . . . 0 C--N 1.304 -1.404 0 CA-C-O 118.0 -1.0 . . . . 3.8300000000000001 109.611 179.364 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 1' ' ' MET . . . . . 0.538 ' O ' ' N ' ' B' ' 3' ' ' SER . 6.5 ptm . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.467 -0.568 . . . . 8.8699999999999992 109.467 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . 59.89 -76.95 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.461 -0.774 . . . . 5.9299999999999997 109.75 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 3' ' ' SER . . . . . 0.538 ' N ' ' O ' ' B' ' 1' ' ' MET . 41.2 t -73.61 -144.71 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.131 -0.98 . . . . 5.5700000000000003 109.503 -179.952 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 4' ' ' LYS . . . . . 0.488 ' N ' ' OG ' ' B' ' 3' ' ' SER . 79.8 tttt -164.37 68.3 1.47 Allowed Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.278 -0.888 . . . . 7.25 109.648 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 5' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_exo -61.24 169.82 5.86 Favored 'Trans proline' 0 C--N 1.318 -1.071 0 C-N-CA 121.392 1.394 . . . . 5.8899999999999997 109.828 -179.819 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 6' ' ' GLU . . . . . . . . . . . . . 26.0 mt-10 -77.23 45.4 0.45 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.279 -0.888 . . . . 4.7800000000000002 109.569 -179.912 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 68.9 mttm 48.85 -115.66 0.77 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.161 -0.962 . . . . 4.5599999999999996 109.37 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . 0.666 ' NE ' HH12 ' A' ' 114' ' ' ARG . 16.5 mmt-85 -90.41 173.79 7.91 Favored 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 108.435 -0.95 . . . . 3.6699999999999999 108.435 179.561 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 9' ' ' VAL . . . . . . . . . . . . . 3.0 t -57.66 161.48 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 N-CA-C 106.924 -1.51 . . . . 1.3899999999999999 106.924 178.746 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -115.07 148.52 38.8 Favored 'General case' 0 N--CA 1.504 2.267 0 O-C-N 121.267 -0.896 . . . . 1.22 111.151 -178.06 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 1.3 t -141.11 150.86 43.42 Favored 'General case' 0 N--CA 1.497 1.906 0 N-CA-C 109.232 -0.655 . . . . 1.6299999999999999 109.232 179.39 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 28.5 p -149.09 131.47 15.64 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.053 -1.029 . . . . 1.8799999999999999 110.224 -179.836 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . 0.483 ' C ' ' CG ' ' B' ' 14' ' ' PHE . 7.5 p -173.6 174.39 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 N-CA-C 108.345 -0.983 . . . . 1.2 108.345 179.777 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 14' ' ' PHE . . . . . 0.483 ' CG ' ' C ' ' B' ' 13' ' ' VAL . 0.1 OUTLIER 173.05 -171.97 0.04 OUTLIER 'General case' 0 N--CA 1.493 1.702 0 C-N-CA 118.797 -1.161 . . . . 2.3900000000000001 112.201 179.483 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -143.85 -179.4 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.339 0 N-CA-C 108.898 -0.779 . . . . 1.8100000000000001 108.898 179.903 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 9.0 t -141.31 142.91 33.82 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.154 -0.966 . . . . 2.04 109.291 179.59 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.3 mt -101.86 147.26 26.72 Favored 'General case' 0 N--CA 1.499 2.019 0 O-C-N 121.261 -0.9 . . . . 1.8700000000000001 110.108 -179.55 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -155.14 152.92 26.2 Favored Pre-proline 0 N--CA 1.492 1.649 0 N-CA-C 108.111 -1.07 . . . . 1.47 108.111 179.396 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -58.82 165.7 7.83 Favored 'Trans proline' 0 CA--C 1.544 0.992 0 C-N-CA 120.862 1.041 . . . . 1.96 109.625 -179.956 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 20' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_endo -63.3 -159.33 0.03 OUTLIER 'Trans proline' 0 C--N 1.319 -0.989 0 C-N-CA 121.497 1.465 . . . . 3.3799999999999999 109.534 179.528 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 30.4 ptt180 -71.3 143.76 50.2 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.293 -0.879 . . . . 6.7400000000000002 109.016 179.426 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 22' ' ' ARG . . . . . . . . . . . . . 42.4 mtp180 -67.87 109.44 3.41 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.151 -0.968 . . . . 6.9400000000000004 109.511 -179.868 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . 0.431 ' O ' ' OXT' ' B' ' 24' ' ' VAL . 22.8 t0 -124.26 -34.77 2.88 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.583 -0.698 . . . . 5.6200000000000001 109.225 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . 0.431 ' OXT' ' O ' ' B' ' 23' ' ' ASP . 3.9 t . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 117.973 -1.013 . . . . 6.75 109.62 179.884 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.531 5.016 0 N-CA-C 119.75 2.66 . . . . 6.7300000000000004 119.75 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.577 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER -170.46 49.85 0.14 Allowed Pre-proline 0 C--N 1.307 -1.257 0 N-CA-C 107.56 -1.274 . . . . 7.3799999999999999 107.56 179.513 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.781 ' C ' ' H ' ' A' ' 5' ' ' PHE . 3.2 Cg_endo -56.42 -80.75 0.01 OUTLIER 'Trans proline' 0 C--N 1.32 -0.935 0 N-CA-C 108.996 -1.194 . . . . 5.5 108.996 179.559 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.514 ' C ' ' H ' ' A' ' 6' ' ' PHE . 7.3 tp10 73.62 -16.06 0.52 Allowed 'General case' 0 N--CA 1.495 1.788 0 N-CA-C 104.376 -2.454 . . . . 6.8399999999999999 104.376 -175.746 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . 0.781 ' H ' ' C ' ' A' ' 3' ' ' PRO . 2.2 m-85 -91.45 18.65 6.98 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 103.84 -2.652 . . . . 6.4400000000000004 103.84 176.906 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.531 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 37.2 p90 45.45 -153.84 0.04 OUTLIER 'General case' 0 C--N 1.306 -1.301 0 CA-C-N 114.174 -1.375 . . . . 5.0599999999999996 109.496 -177.56 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.524 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 3.4 tt0 83.63 -9.13 1.03 Allowed 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 104.975 -2.232 . . . . 4.8099999999999996 104.975 -177.131 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.488 ' H ' ' C ' ' A' ' 6' ' ' PHE . 49.6 t80 -151.6 -37.92 0.12 Allowed 'General case' 0 C--N 1.305 -1.353 0 N-CA-C 107.794 -1.188 . . . . 5.7300000000000004 107.794 178.506 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 22.1 m -91.38 2.84 56.11 Favored 'General case' 0 C--N 1.297 -1.679 0 N-CA-C 105.895 -1.891 . . . . 5.3499999999999996 105.895 177.386 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.9 p -43.29 -38.15 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.337 0 CA-C-N 115.311 -0.859 . . . . 4.3799999999999999 109.62 -179.654 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.613 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 138.88 -83.16 0.24 Allowed Glycine 0 N--CA 1.502 3.034 0 N-CA-C 109.157 -1.577 . . . . 4.4800000000000004 109.157 179.493 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.456 ' O ' ' C ' ' A' ' 13' ' ' LEU . 12.2 Cg_endo -65.85 40.18 0.14 Allowed 'Trans proline' 0 C--N 1.321 -0.914 0 C-N-CA 121.926 1.75 . . . . 4.0499999999999998 109.159 178.535 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.613 ' H ' ' C ' ' A' ' 11' ' ' GLY . 0.2 OUTLIER 29.04 44.45 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.219 0 CA-C-O 121.607 0.718 . . . . 4.0599999999999996 110.983 -179.655 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.475 ' C ' ' N ' ' A' ' 16' ' ' GLY . . . 70.36 -37.96 0.45 Allowed Glycine 0 N--CA 1.486 2.032 0 N-CA-C 109.671 -1.371 . . . . 3.1400000000000001 109.671 179.604 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.519 ' H ' ' C ' ' A' ' 13' ' ' LEU . 15.8 tp10 50.27 19.0 0.46 Allowed 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 107.776 -1.194 . . . . 3.1699999999999999 107.776 -179.033 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.475 ' N ' ' C ' ' A' ' 14' ' ' GLY . . . 76.89 -162.5 51.84 Favored Glycine 0 N--CA 1.482 1.766 0 N-CA-C 108.52 -1.832 . . . . 2.4399999999999999 108.52 -178.94 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.518 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -72.65 -4.81 62.42 Favored Glycine 0 N--CA 1.486 2.025 0 N-CA-C 109.717 -1.353 . . . . 2.0499999999999998 109.717 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -49.03 -12.39 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.729 -1.453 . . . . 2.54 109.236 179.832 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . 0.518 ' N ' ' O ' ' A' ' 17' ' ' GLY . 10.6 t-160 -97.15 -41.15 8.46 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.39 -0.819 . . . . 3.3700000000000001 109.445 179.651 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.656 ' HZ1' ' N ' ' A' ' 44' ' ' ARG . 0.0 OUTLIER -82.32 -25.37 33.99 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.141 -0.974 . . . . 2.3700000000000001 109.722 -179.879 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 77.9 t -60.93 112.32 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.045 -1.034 . . . . 2.5800000000000001 109.081 179.635 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 5.9 tpp180 -104.11 131.14 51.69 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.629 -0.669 . . . . 3.8900000000000001 109.628 -179.648 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -136.7 113.64 10.47 Favored 'General case' 0 N--CA 1.493 1.723 0 N-CA-C 108.577 -0.898 . . . . 2.0099999999999998 108.577 179.519 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -155.89 134.66 4.21 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.73 -1.348 . . . . 2.0099999999999998 109.73 -179.463 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.1 -176.44 46.07 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.99 -1.244 . . . . 1.9299999999999999 109.99 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 8.6 p -79.49 -25.82 41.74 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.335 -1.097 . . . . 2.6899999999999999 109.538 -179.862 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.428 ' CA ' ' OH ' ' A' ' 77' ' ' TYR . . . -69.46 -15.44 70.54 Favored Glycine 0 N--CA 1.486 1.992 0 N-CA-C 108.506 -1.838 . . . . 1.6399999999999999 108.506 179.676 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 65.8 mt -93.36 33.02 1.26 Allowed 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 108.487 -0.931 . . . . 2.0299999999999998 108.487 179.454 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -144.3 -55.41 0.35 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.373 -0.829 . . . . 2.3399999999999999 109.796 -179.545 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . 0.528 ' NH1' ' OD1' ' A' ' 110' ' ' ASP . 31.9 mtm180 -156.53 153.69 29.1 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 120.984 -1.073 . . . . 4.25 110.345 -179.441 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -140.42 171.76 23.84 Favored Glycine 0 N--CA 1.495 2.61 0 N-CA-C 108.244 -1.942 . . . . 1.5900000000000001 108.244 179.003 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.428 ' H ' HG11 ' A' ' 35' ' ' VAL . 28.1 t -135.54 148.32 28.4 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.008 0 O-C-N 121.173 -1.192 . . . . 2.21 110.448 -179.553 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -38.73 105.79 0.04 OUTLIER 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.916 -0.49 . . . . 2.0699999999999998 111.688 -179.859 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 64.34 57.0 14.45 Favored Glycine 0 N--CA 1.489 2.23 0 O-C-N 121.089 -1.007 . . . . 1.73 111.864 177.353 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.428 HG11 ' H ' ' A' ' 32' ' ' VAL . 4.5 p -125.82 133.92 25.38 Favored Pre-proline 0 N--CA 1.503 2.208 0 O-C-N 121.279 -1.13 . . . . 2.6499999999999999 108.949 178.72 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_endo -58.47 114.69 2.09 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 N-CA-C 108.547 -1.366 . . . . 2.1400000000000001 108.547 178.739 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -127.0 148.61 50.1 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.344 -0.847 . . . . 2.0299999999999998 109.494 -179.352 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.3 pt-20 -157.13 174.01 16.12 Favored 'General case' 0 N--CA 1.488 1.474 0 CA-C-O 122.22 1.01 . . . . 2.23 110.759 -179.886 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.417 ' N ' ' CD1' ' A' ' 39' ' ' PHE . 5.0 p90 -159.52 167.07 29.49 Favored 'General case' 0 C--N 1.296 -1.753 0 N-CA-C 107.819 -1.178 . . . . 1.72 107.819 178.67 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 6.4 t -98.04 150.96 20.84 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.462 -0.774 . . . . 2.5800000000000001 110.715 -178.409 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 10.7 mt -142.09 89.72 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 N-CA-C 108.757 -0.831 . . . . 1.8600000000000001 108.757 179.117 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.458 ' CD1' ' C ' ' A' ' 42' ' ' TRP . 0.8 OUTLIER -85.28 142.35 29.44 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.115 -0.991 . . . . 4.4699999999999998 108.815 -179.907 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' THR . . . . . 0.487 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -171.98 117.51 0.39 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.39 -0.818 . . . . 3.27 109.298 -179.688 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' ARG . . . . . 0.656 ' N ' ' HZ1' ' A' ' 20' ' ' LYS . 1.5 tpt180 -164.99 -12.24 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.171 -0.956 . . . . 5.2300000000000004 109.696 -179.832 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -68.55 -47.53 66.63 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.0 -1.062 . . . . 2.8900000000000001 109.763 -179.621 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -60.23 -59.76 4.89 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.098 -1.001 . . . . 1.99 109.299 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 142.94 -151.76 23.42 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.585 -1.406 . . . . 1.6499999999999999 109.585 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -80.64 163.11 23.86 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.479 -1.012 . . . . 1.77 109.531 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 174.02 -143.49 7.05 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.666 -1.373 . . . . 1.1200000000000001 109.666 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.433 ' O ' ' N ' ' A' ' 92' ' ' ASN . . . -148.48 127.64 2.6 Favored Glycine 0 N--CA 1.495 2.586 0 N-CA-C 109.554 -1.418 . . . . 1.1799999999999999 109.554 -179.913 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.43 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 46.8 tp -102.65 107.03 17.79 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.367 -1.078 . . . . 1.5900000000000001 108.843 179.833 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.4 t -90.62 141.44 28.77 Favored 'General case' 0 N--CA 1.494 1.75 0 N-CA-C 108.616 -0.883 . . . . 1.9399999999999999 108.616 179.504 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.493 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 63.3 mt -132.06 102.35 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.923 0 O-C-N 121.214 -0.929 . . . . 1.3 109.469 -179.843 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -93.31 105.85 17.88 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 108.497 -0.927 . . . . 1.27 108.497 179.395 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -95.42 145.07 8.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.521 -0.737 . . . . 1.55 109.254 -179.738 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -141.47 144.17 34.25 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 108.026 -1.101 . . . . 1.8 108.026 179.22 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.415 ' O ' ' O ' ' B' ' 9' ' ' VAL . . . 162.13 -172.95 38.37 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.768 -1.333 . . . . 0.56000000000000005 109.768 -179.215 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -61.77 -31.88 85.87 Favored 'Trans proline' 0 C--N 1.319 -0.979 0 C-N-CA 122.302 2.001 . . . . 0.76000000000000001 112.046 -179.666 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 8.0 t -139.0 169.95 16.86 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 120.949 -1.094 . . . . 2.02 110.549 -179.169 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 38.5 mtpt -87.1 106.86 18.16 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 109.003 -0.74 . . . . 3.02 109.003 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -73.48 127.42 32.67 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.165 -0.959 . . . . 1.3600000000000001 109.776 -179.711 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 24.4 tt0 -65.42 170.44 4.87 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.288 -0.882 . . . . 2.2999999999999998 109.028 179.732 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 20.1 mt -143.52 155.11 16.37 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 N-CA-C 108.345 -0.983 . . . . 2.0 108.345 -179.9 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.532 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -143.12 174.91 10.28 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 120.685 -1.259 . . . . 1.73 109.21 -179.775 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.449 ' CD2' ' O ' ' A' ' 65' ' ' PHE . 51.7 p90 -142.29 128.49 19.82 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.363 -0.835 . . . . 1.6000000000000001 109.172 179.9 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -141.38 113.08 7.7 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.296 -0.878 . . . . 2.5099999999999998 109.987 -179.782 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . 0.441 ' OD1' ' N ' ' A' ' 67' ' ' ASP . 4.2 p-10 -95.52 67.69 2.89 Favored 'General case' 0 N--CA 1.491 1.602 0 N-CA-C 108.155 -1.054 . . . . 2.0699999999999998 108.155 178.493 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 50.4 mtp180 -121.96 29.46 7.07 Favored 'General case' 0 N--CA 1.5 2.042 0 N-CA-C 109.231 -0.655 . . . . 5.29 109.231 -179.55 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.427 ' O ' ' CB ' ' A' ' 70' ' ' ASP . 66.3 mmtt -108.21 3.32 23.54 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 107.882 -1.155 . . . . 3.8599999999999999 107.882 179.405 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.427 ' CB ' ' O ' ' A' ' 69' ' ' LYS . 4.0 t0 72.49 12.79 5.52 Favored 'General case' 0 N--CA 1.487 1.388 0 N-CA-C 109.586 -0.524 . . . . 3.0600000000000001 109.586 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 163.32 -30.84 0.27 Allowed Glycine 0 N--CA 1.49 2.247 0 C-N-CA 119.017 -1.564 . . . . 2.1600000000000001 110.787 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.0 t -95.11 143.15 26.78 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 120.964 -1.315 . . . . 2.5600000000000001 109.764 -179.498 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 36.9 t -88.04 139.47 30.48 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.329 -0.857 . . . . 2.3599999999999999 109.347 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -112.4 114.02 3.4 Favored Glycine 0 N--CA 1.5 2.948 0 N-CA-C 109.985 -1.246 . . . . 1.46 109.985 -179.761 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 77.9 t -100.97 116.15 43.97 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.948 0 O-C-N 121.467 -1.019 . . . . 2.1600000000000001 108.912 179.291 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.532 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.6 OUTLIER -103.81 136.75 42.91 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.579 -0.7 . . . . 2.1600000000000001 109.196 -179.846 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 0.428 ' OH ' ' CA ' ' A' ' 27' ' ' GLY . 11.3 p90 -134.65 166.69 22.34 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.508 -0.745 . . . . 1.7 109.671 -179.769 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 8.4 t -139.86 113.54 6.3 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 N-CA-C 108.887 -0.783 . . . . 2.4500000000000002 108.887 -179.729 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.594 ' CG1' ' CE2' ' A' ' 85' ' ' TYR . 0.2 OUTLIER -79.75 168.57 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 N-CA-C 108.499 -0.926 . . . . 1.8200000000000001 108.499 179.552 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 10.5 tt0 -109.3 -36.79 5.93 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.441 -0.787 . . . . 3.1699999999999999 109.417 179.323 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.428 ' O ' ' O ' ' A' ' 82' ' ' PRO . 75.2 mm-40 -158.85 149.6 16.01 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.278 -0.888 . . . . 2.02 110.679 -179.308 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.561 ' HG3' ' N ' ' A' ' 107' ' ' SER . 82.1 Cg_exo -39.08 169.38 0.01 OUTLIER 'Trans proline' 0 C--O 1.213 -0.727 0 C-N-CA 122.761 2.307 . . . . 1.3999999999999999 112.756 177.696 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 141.69 177.33 16.74 Favored Glycine 0 N--CA 1.493 2.451 0 N-CA-C 109.726 -1.35 . . . . 1.0800000000000001 109.726 179.226 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -93.16 89.57 6.5 Favored 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 107.741 -1.207 . . . . 2.1299999999999999 107.741 179.149 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . 0.594 ' CE2' ' CG1' ' A' ' 79' ' ' VAL . 3.7 m-85 -78.04 132.15 37.64 Favored 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.458 -0.776 . . . . 1.1399999999999999 108.912 -179.014 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -112.81 128.79 56.54 Favored 'General case' 0 N--CA 1.498 1.947 0 N-CA-C 108.588 -0.893 . . . . 1.53 108.588 -179.079 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.411 ' CG1' ' CE2' ' A' ' 101' ' ' PHE . 5.8 p -126.13 133.64 68.4 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 121.568 -0.708 . . . . 1.6399999999999999 109.471 -179.865 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.1 t -123.64 103.96 8.73 Favored 'General case' 0 N--CA 1.498 1.933 0 N-CA-C 109.445 -0.576 . . . . 1.99 109.445 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.2 pt -107.7 130.29 60.29 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 CA-C-O 121.64 0.734 . . . . 1.77 110.045 -179.573 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . 0.47 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.98 122.68 17.52 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 107.9 -1.148 . . . . 2.0600000000000001 107.9 179.593 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.412 ' O ' ' CB ' ' A' ' 92' ' ' ASN . 71.2 t80 -83.08 100.57 10.59 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 120.515 -1.365 . . . . 1.45 108.029 179.351 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . 0.433 ' N ' ' O ' ' A' ' 50' ' ' GLY . 2.2 t30 72.31 35.48 1.19 Allowed 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.196 -0.94 . . . . 2.7200000000000002 108.809 -178.646 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . 0.429 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 0.9 OUTLIER 78.2 14.77 1.44 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.879 -0.513 . . . . 1.9199999999999999 111.609 179.53 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . 0.489 ' OE2' ' CA ' ' A' ' 17' ' ' GLY . 5.7 pt-20 -100.54 99.22 9.78 Favored 'General case' 0 N--CA 1.496 1.843 0 N-CA-C 107.145 -1.428 . . . . 2.5499999999999998 107.145 177.964 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . 0.462 ' CG ' ' O ' ' A' ' 95' ' ' HIS . 46.2 p-80 -66.96 105.46 1.63 Allowed 'General case' 0 N--CA 1.487 1.389 0 CA-C-O 121.472 0.653 . . . . 3.2000000000000002 110.453 -177.928 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . 0.523 ' O ' ' N ' ' A' ' 98' ' ' ASP . 4.0 tt -56.56 136.33 77.23 Favored Pre-proline 0 C--N 1.3 -1.548 0 N-CA-C 107.81 -1.182 . . . . 2.8199999999999998 107.81 178.983 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.44 ' O ' ' CB ' ' A' ' 98' ' ' ASP . 11.6 Cg_exo -47.15 90.98 0.02 OUTLIER 'Trans proline' 0 C--O 1.213 -0.729 0 N-CA-C 109.886 -0.852 . . . . 2.6299999999999999 109.886 -179.755 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.523 ' N ' ' O ' ' A' ' 96' ' ' ILE . 0.9 OUTLIER 165.61 -60.43 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 108.235 -1.024 . . . . 2.6499999999999999 108.235 -179.418 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 1.3 t -55.8 139.08 70.18 Favored Pre-proline 0 C--N 1.296 -1.727 0 O-C-N 121.299 -0.875 . . . . 2.3199999999999998 109.796 -178.306 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_endo -88.36 113.72 2.47 Favored 'Cis proline' 0 N--CA 1.494 1.521 0 N-CA-C 110.024 -0.798 . . . . 1.9399999999999999 110.024 -2.393 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . 0.411 ' CE2' ' CG1' ' A' ' 87' ' ' VAL . 2.6 p90 -97.74 169.15 9.88 Favored 'General case' 0 N--CA 1.518 2.944 0 O-C-N 120.236 -1.54 . . . . 2.6299999999999999 109.779 178.625 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.3 p -96.78 150.45 4.44 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.643 -0.66 . . . . 1.8200000000000001 109.982 -179.635 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.446 ' N ' ' O ' ' A' ' 85' ' ' TYR . 87.0 t -128.3 87.03 56.36 Favored Pre-proline 0 N--CA 1.498 1.965 0 N-CA-C 108.379 -0.971 . . . . 1.73 108.379 179.675 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo -65.11 114.9 3.01 Favored 'Trans proline' 0 C--N 1.322 -0.856 0 C-N-CA 121.571 1.514 . . . . 1.6100000000000001 111.8 -178.27 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 84.3 t -106.59 143.54 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 N-CA-C 106.342 -1.725 . . . . 1.7 106.342 178.365 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -133.24 138.51 46.53 Favored 'General case' 0 N--CA 1.512 2.666 0 CA-C-O 122.272 1.034 . . . . 2.04 112.516 -176.719 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' SER . . . . . 0.561 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 59.8 p -94.29 78.21 3.95 Favored 'General case' 0 N--CA 1.494 1.725 0 N-CA-C 107.608 -1.256 . . . . 2.2999999999999998 107.608 179.097 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 16.8 mt 63.15 3.33 1.27 Allowed 'General case' 0 C--N 1.295 -1.766 0 N-CA-C 107.438 -1.319 . . . . 3.6000000000000001 107.438 -177.835 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.618 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 18.5 t -89.84 -23.18 21.74 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 108.813 -0.81 . . . . 2.4900000000000002 108.813 179.328 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . 0.528 ' OD1' ' NH1' ' A' ' 30' ' ' ARG . 50.5 t0 54.83 11.33 0.46 Allowed 'General case' 0 N--CA 1.487 1.382 0 N-CA-C 107.822 -1.177 . . . . 2.8500000000000001 107.822 -179.196 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.521 ' H ' ' C ' ' A' ' 109' ' ' SER . 2.8 p30 -169.33 -31.85 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 109.185 -0.672 . . . . 2.46 109.185 -179.7 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.618 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 43.75 88.75 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.208 -0.932 . . . . 2.0800000000000001 109.783 179.915 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 13.9 ttt180 -58.03 -163.95 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.217 -0.927 . . . . 6.54 109.652 -179.436 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 44.9 ttt180 -136.03 0.16 2.59 Favored 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 108.002 -1.11 . . . . 6.2400000000000002 108.002 179.684 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 2.5 mp -132.31 -23.71 2.12 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.709 -0.62 . . . . 4.71 109.616 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.532 ' C ' ' H ' ' A' ' 118' ' ' THR . 90.3 m -104.1 -78.13 0.56 Allowed 'General case' 0 N--CA 1.495 1.818 0 N-CA-C 106.691 -1.596 . . . . 4.3499999999999996 106.691 178.768 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 48.9 t -64.03 -7.66 3.65 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.742 0 N-CA-C 105.807 -1.923 . . . . 3.3100000000000001 105.807 176.631 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' THR . . . . . 0.532 ' H ' ' C ' ' A' ' 116' ' ' THR . 4.4 t 36.2 60.33 0.87 Allowed 'General case' 0 N--CA 1.488 1.468 0 CA-C-N 115.164 -0.925 . . . . 3.73 110.638 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' SER . . . . . 0.474 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.5 p . . . . . 0 N--CA 1.487 1.38 0 CA-C-O 118.043 -0.979 . . . . 3.8300000000000001 109.549 179.503 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 1' ' ' MET . . . . . 0.611 ' SD ' ' N ' ' B' ' 2' ' ' ALA . 14.6 tmm? . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.36 -0.607 . . . . 8.8699999999999992 109.36 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 2' ' ' ALA . . . . . 0.611 ' N ' ' SD ' ' B' ' 1' ' ' MET . . . 45.67 91.85 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.188 -0.945 . . . . 5.9299999999999997 109.766 -179.95 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 3' ' ' SER . . . . . . . . . . . . . 35.1 t -155.26 126.62 7.27 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.197 -0.939 . . . . 5.5700000000000003 109.466 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 4' ' ' LYS . . . . . . . . . . . . . 22.4 mtpp -60.35 131.26 90.19 Favored Pre-proline 0 N--CA 1.487 1.422 0 O-C-N 121.187 -0.946 . . . . 7.25 108.794 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 5' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -59.75 -172.27 0.06 OUTLIER 'Trans proline' 0 C--O 1.216 -0.618 0 N-CA-C 109.837 -0.87 . . . . 5.8899999999999997 109.837 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 6' ' ' GLU . . . . . 0.441 ' O ' ' O ' ' B' ' 7' ' ' LYS . 34.6 mt-10 -155.28 39.71 0.41 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.313 -0.867 . . . . 4.7800000000000002 108.872 179.745 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 7' ' ' LYS . . . . . 0.441 ' O ' ' O ' ' B' ' 6' ' ' GLU . 32.9 mtmm 55.02 165.46 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.657 -0.652 . . . . 4.5599999999999996 109.645 -179.868 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . 0.549 HH11 ' CG ' ' B' ' 8' ' ' ARG . 1.4 mtt-85 -89.83 159.14 17.15 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.113 -0.992 . . . . 3.6699999999999999 108.542 179.877 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 9' ' ' VAL . . . . . 0.415 ' O ' ' O ' ' A' ' 57' ' ' GLY . 11.2 t -49.89 159.85 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 120.973 -1.079 . . . . 1.3899999999999999 108.311 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . 0.4 ' N ' ' CG1' ' B' ' 9' ' ' VAL . . . -124.67 144.13 50.37 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.526 -0.734 . . . . 1.22 110.173 -178.887 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 2.8 t -134.7 145.88 48.93 Favored 'General case' 0 N--CA 1.495 1.817 0 N-CA-C 108.636 -0.876 . . . . 1.6299999999999999 108.636 179.446 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 17.7 m -142.46 114.66 8.31 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.223 -0.923 . . . . 1.8799999999999999 109.69 -179.491 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . 0.494 ' CG2' ' N ' ' B' ' 14' ' ' PHE . 2.7 p -160.03 166.67 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 O-C-N 121.367 -0.833 . . . . 1.2 109.014 179.83 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 14' ' ' PHE . . . . . 0.494 ' N ' ' CG2' ' B' ' 13' ' ' VAL . 8.3 p90 -177.16 -166.88 0.15 Allowed 'General case' 0 N--CA 1.488 1.429 0 CA-C-O 122.077 0.941 . . . . 2.3900000000000001 111.926 179.85 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -140.02 152.98 22.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 N-CA-C 108.271 -1.011 . . . . 1.8100000000000001 108.271 179.721 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 7.2 m -123.66 131.14 53.54 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.317 -0.865 . . . . 2.04 109.921 -179.666 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 13.8 mt -99.3 117.93 34.85 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.327 -0.858 . . . . 1.8700000000000001 109.01 179.609 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -146.33 78.52 11.11 Favored Pre-proline 0 N--CA 1.494 1.768 0 O-C-N 121.259 -0.901 . . . . 1.47 109.636 -179.566 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo -60.2 169.67 4.75 Favored 'Trans proline' 0 C--N 1.319 -1.012 0 C-N-CA 121.218 1.279 . . . . 1.96 109.417 -179.78 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 20' ' ' PRO . . . . . . . . . . . . . 4.1 Cg_exo -53.82 133.46 54.57 Favored 'Trans proline' 0 C--N 1.319 -1.007 0 C-N-CA 121.344 1.363 . . . . 3.3799999999999999 110.281 -179.605 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . 0.471 ' HG2' HH11 ' B' ' 21' ' ' ARG . 0.0 OUTLIER -96.56 136.06 37.61 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.354 -0.841 . . . . 6.7400000000000002 109.352 -179.927 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' B' B ' 22' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -158.7 52.66 0.41 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.245 -0.909 . . . . 6.9400000000000004 109.454 179.756 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 18.6 m-20 -158.7 48.44 0.35 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.242 -0.911 . . . . 5.6200000000000001 109.458 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 12.1 p . . . . . 0 N--CA 1.491 1.596 0 CA-C-O 118.034 -0.984 . . . . 6.75 109.462 -179.985 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.446 ' O ' ' CD1' ' A' ' 2' ' ' ILE . . . . . . . . 1 N--CA 1.531 4.976 0 N-CA-C 119.88 2.712 . . . . 6.7300000000000004 119.88 . . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.644 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 6.8 mm -149.28 43.7 0.3 Allowed Pre-proline 0 C--N 1.311 -1.081 0 N-CA-C 107.546 -1.279 . . . . 7.3799999999999999 107.546 178.533 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.684 ' C ' ' H ' ' A' ' 5' ' ' PHE . 1.8 Cg_endo -52.12 -74.45 0.03 OUTLIER 'Trans proline' 0 C--N 1.319 -0.978 0 N-CA-C 109.343 -1.06 . . . . 5.5 109.343 -179.804 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.436 ' CB ' ' O ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER 71.96 -49.83 0.69 Allowed 'General case' 0 N--CA 1.494 1.727 0 N-CA-C 103.11 -2.922 . . . . 6.8399999999999999 103.11 -175.615 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . 0.684 ' H ' ' C ' ' A' ' 3' ' ' PRO . 5.3 m-85 -50.15 -28.09 6.84 Favored 'General case' 0 C--N 1.303 -1.414 0 N-CA-C 106.481 -1.674 . . . . 6.4400000000000004 106.481 174.954 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.599 ' CG ' ' N ' ' A' ' 7' ' ' GLN . 0.0 OUTLIER 110.8 -150.84 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.217 0 CA-C-N 114.511 -1.222 . . . . 5.0599999999999996 111.221 179.445 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.599 ' N ' ' CG ' ' A' ' 6' ' ' PHE . 18.5 tt0 81.74 -3.64 1.58 Allowed 'General case' 0 N--CA 1.493 1.702 0 N-CA-C 105.306 -2.109 . . . . 4.8099999999999996 105.306 -177.469 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.41 ' H ' ' C ' ' A' ' 6' ' ' PHE . 38.3 t80 -152.96 -40.4 0.1 Allowed 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 107.202 -1.407 . . . . 5.7300000000000004 107.202 178.623 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 12.1 m -86.19 1.44 50.7 Favored 'General case' 0 C--N 1.296 -1.722 0 N-CA-C 106.086 -1.82 . . . . 5.3499999999999996 106.086 177.287 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.8 p -40.51 -33.57 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 CA-C-N 115.47 -0.786 . . . . 4.3799999999999999 109.839 -179.77 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.597 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 146.71 -79.12 0.23 Allowed Glycine 0 N--CA 1.5 2.947 0 N-CA-C 109.172 -1.571 . . . . 4.4800000000000004 109.172 179.626 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.452 ' O ' ' C ' ' A' ' 13' ' ' LEU . 14.5 Cg_endo -66.35 43.79 0.19 Allowed 'Trans proline' 0 C--N 1.321 -0.917 0 C-N-CA 122.148 1.899 . . . . 4.0499999999999998 108.849 178.339 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.601 ' C ' ' H ' ' A' ' 15' ' ' GLU . 0.2 OUTLIER 29.17 46.78 0.02 OUTLIER 'General case' 0 N--CA 1.501 2.103 0 CA-C-N 115.692 -0.686 . . . . 4.0599999999999996 111.094 -179.746 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.556 ' C ' ' H ' ' A' ' 16' ' ' GLY . . . 68.17 -36.43 0.25 Allowed Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.325 -1.51 . . . . 3.1400000000000001 109.325 -179.884 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.601 ' H ' ' C ' ' A' ' 13' ' ' LEU . 24.6 tt0 55.31 6.59 0.17 Allowed 'General case' 0 N--CA 1.486 1.337 0 O-C-N 121.426 -1.043 . . . . 3.1699999999999999 108.518 -179.159 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.556 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 87.45 -164.72 34.93 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 110.851 -0.899 . . . . 2.4399999999999999 110.851 178.743 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.55 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -46.28 -12.33 0.05 OUTLIER Glycine 0 N--CA 1.491 2.333 0 N-CA-C 110.603 -0.999 . . . . 2.0499999999999998 110.603 -179.2 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.519 ' N ' ' O ' ' A' ' 16' ' ' GLY . . . -47.64 -10.41 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.145 -1.209 . . . . 2.54 110.093 -179.924 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . 0.55 ' N ' ' O ' ' A' ' 17' ' ' GLY . 80.2 t60 -104.81 -31.36 9.34 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.188 -0.945 . . . . 3.3700000000000001 110.444 -179.38 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -101.6 -14.72 17.32 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 120.997 -1.064 . . . . 2.3700000000000001 110.848 -178.979 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.43 ' O ' ' CG1' ' A' ' 21' ' ' VAL . 9.0 p -70.85 114.39 8.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 120.819 -1.175 . . . . 2.5800000000000001 109.818 -179.606 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 20.6 tpt180 -104.08 140.38 37.85 Favored 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 109.008 -0.738 . . . . 3.8900000000000001 109.008 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -144.45 113.28 6.75 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.247 -0.908 . . . . 2.0099999999999998 109.37 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -156.49 129.05 2.33 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.788 -1.325 . . . . 2.0099999999999998 109.788 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.11 -177.59 47.72 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.666 -1.374 . . . . 1.9299999999999999 109.666 179.805 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 12.3 p -78.36 -26.12 46.56 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.25 -1.147 . . . . 2.6899999999999999 109.396 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -71.06 -12.13 71.23 Favored Glycine 0 N--CA 1.488 2.132 0 N-CA-C 109.301 -1.52 . . . . 1.6399999999999999 109.301 -179.831 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 12.8 mt -91.36 -6.13 53.46 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.364 -1.08 . . . . 2.0299999999999998 108.914 179.875 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -96.27 -51.03 4.55 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.336 -0.853 . . . . 2.3399999999999999 109.748 -179.708 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 23.0 ptt180 -175.28 -173.65 0.67 Allowed 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.017 -1.052 . . . . 4.25 110.16 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -152.4 177.58 30.08 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 108.358 -1.897 . . . . 1.5900000000000001 108.358 179.583 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 41.5 t -134.84 151.05 30.6 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.045 0 O-C-N 121.143 -1.21 . . . . 2.21 110.481 -179.683 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -37.05 112.2 0.19 Allowed 'General case' 0 N--CA 1.5 2.072 0 CA-C-O 121.737 0.78 . . . . 2.0699999999999998 112.406 -179.293 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 54.59 49.88 59.42 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 111.371 -0.692 . . . . 1.73 111.371 177.249 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 40.5 t -127.38 98.22 29.71 Favored Pre-proline 0 N--CA 1.496 1.826 0 O-C-N 121.511 -0.994 . . . . 2.6499999999999999 108.512 178.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -56.89 149.05 63.43 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 120.955 1.103 . . . . 2.1400000000000001 110.445 -178.86 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -157.49 -167.73 2.37 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.4 -0.813 . . . . 2.0299999999999998 109.018 -179.812 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -170.54 168.48 7.68 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.148 -0.97 . . . . 2.23 110.873 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.504 ' N ' ' CD1' ' A' ' 39' ' ' PHE . 1.1 p90 -144.95 -178.68 6.16 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 107.161 -1.422 . . . . 1.72 107.161 178.345 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 12.0 m -109.42 150.99 27.27 Favored 'General case' 0 N--CA 1.5 2.049 0 O-C-N 121.359 -0.838 . . . . 2.5800000000000001 110.99 -178.345 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 11.3 mt -147.8 94.55 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 N-CA-C 108.749 -0.834 . . . . 1.8600000000000001 108.749 179.048 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.49 ' C ' ' CD1' ' A' ' 42' ' ' TRP . 0.6 OUTLIER -86.99 138.07 31.82 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 120.946 -1.096 . . . . 4.4699999999999998 108.563 179.837 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -167.61 114.85 0.75 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.282 -0.886 . . . . 3.27 109.523 -179.678 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' ARG . . . . . 0.436 ' C ' ' CD ' ' A' ' 44' ' ' ARG . 1.7 ppt_? -169.47 -12.33 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.19 -0.944 . . . . 5.2300000000000004 109.7 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -65.04 -46.15 82.46 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.213 -0.929 . . . . 2.8900000000000001 109.469 -179.735 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.58 -50.4 72.07 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.153 -0.967 . . . . 1.99 108.856 179.695 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 139.76 -153.58 23.24 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.249 -1.54 . . . . 1.6499999999999999 109.249 179.777 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -86.11 155.97 20.56 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.446 -1.032 . . . . 1.77 108.924 179.547 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 179.35 -140.28 4.28 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.563 -1.415 . . . . 1.1200000000000001 109.563 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.47 ' O ' ' N ' ' A' ' 92' ' ' ASN . . . -138.88 167.64 25.04 Favored Glycine 0 N--CA 1.495 2.611 0 N-CA-C 109.283 -1.527 . . . . 1.1799999999999999 109.283 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.413 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 46.4 tp -142.56 106.48 4.7 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.381 -1.07 . . . . 1.5900000000000001 108.434 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.4 m -90.43 143.54 26.65 Favored 'General case' 0 N--CA 1.495 1.787 0 N-CA-C 108.557 -0.905 . . . . 1.9399999999999999 108.557 179.863 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.52 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 53.6 mt -135.36 105.1 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.266 -0.897 . . . . 1.3 109.176 179.84 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -97.97 106.62 18.94 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.283 -0.886 . . . . 1.27 108.786 179.755 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.437 ' O ' ' O ' ' B' ' 11' ' ' SER . 0.2 OUTLIER -96.79 142.34 14.17 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.501 -0.749 . . . . 1.55 109.555 -179.745 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -141.78 142.7 33.22 Favored 'General case' 0 N--CA 1.491 1.61 0 N-CA-C 108.21 -1.033 . . . . 1.8 108.21 178.846 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 164.92 -173.9 40.83 Favored Glycine 0 N--CA 1.489 2.167 0 N-CA-C 109.448 -1.461 . . . . 0.56000000000000005 109.448 -179.104 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -59.46 -26.0 80.51 Favored 'Trans proline' 0 C--N 1.315 -1.199 0 C-N-CA 121.93 1.753 . . . . 0.76000000000000001 112.103 -179.299 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' SER . . . . . 0.581 ' H ' ' HH ' ' A' ' 85' ' ' TYR . 22.9 t -142.54 169.24 17.95 Favored 'General case' 0 N--CA 1.502 2.168 0 O-C-N 121.015 -1.053 . . . . 2.02 110.364 179.947 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 60.7 mttt -81.09 95.31 6.81 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.497 -0.752 . . . . 3.02 109.763 -179.608 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -63.54 117.29 6.55 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.173 -0.954 . . . . 1.3600000000000001 109.511 179.854 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 26.0 tt0 -66.27 168.39 8.79 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.154 -0.966 . . . . 2.2999999999999998 109.148 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 28.1 mt -141.0 155.61 21.76 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 N-CA-C 108.642 -0.873 . . . . 2.0 108.642 -179.79 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -144.87 170.75 15.52 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 120.627 -1.295 . . . . 1.73 109.156 179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.46 ' CD2' ' O ' ' A' ' 65' ' ' PHE . 31.3 p90 -147.16 117.88 7.57 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.28 -0.887 . . . . 1.6000000000000001 109.472 -179.962 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -141.44 102.6 4.24 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.364 -0.835 . . . . 2.5099999999999998 109.546 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . 0.519 ' N ' ' OD1' ' A' ' 67' ' ' ASP . 17.5 p-10 -73.85 95.43 2.43 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.213 -0.929 . . . . 2.0699999999999998 109.18 179.848 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 54.6 ttt180 -90.08 -7.6 53.41 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.274 -0.891 . . . . 5.29 109.732 -179.662 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.519 ' C ' ' H ' ' A' ' 71' ' ' GLY . 31.3 mmtp -122.42 1.66 9.6 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.504 -0.747 . . . . 3.8599999999999999 109.451 -179.839 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 4.1 t70 65.78 -4.01 0.66 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.258 -0.902 . . . . 3.0600000000000001 109.272 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . 0.519 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -138.98 -33.36 0.18 Allowed Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.874 -1.29 . . . . 2.1600000000000001 109.874 -178.907 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 14.0 p -95.52 109.61 21.8 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.23 -1.159 . . . . 2.5600000000000001 108.76 179.487 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 3.3 m -78.81 115.22 18.36 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.15 -0.969 . . . . 2.3599999999999999 109.521 -179.585 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -93.72 114.68 4.78 Favored Glycine 0 N--CA 1.494 2.543 0 N-CA-C 109.919 -1.273 . . . . 1.46 109.919 -179.716 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 94.0 t -98.39 108.5 22.15 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 121.409 -1.053 . . . . 2.1600000000000001 109.465 179.695 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -89.55 166.64 13.53 Favored 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 108.268 -1.012 . . . . 2.1600000000000001 108.268 179.331 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 0.406 ' CD1' ' N ' ' A' ' 77' ' ' TYR . 14.1 p90 -164.14 172.36 13.81 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.216 -0.928 . . . . 1.7 109.659 -179.36 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.463 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 3.7 p -142.17 119.25 7.11 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.254 0 O-C-N 121.104 -0.998 . . . . 2.4500000000000002 110.391 179.61 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 8.5 m -94.98 147.06 6.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.186 -0.946 . . . . 1.8200000000000001 109.164 179.674 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . 0.426 ' OE1' ' OG ' ' A' ' 59' ' ' SER . 29.5 tt0 -90.16 -47.44 7.8 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.082 -1.011 . . . . 3.1699999999999999 110.582 -179.254 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -155.9 155.59 29.52 Favored Pre-proline 0 N--CA 1.504 2.231 0 O-C-N 120.695 -1.253 . . . . 2.02 110.902 -179.347 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.605 ' HG3' ' N ' ' A' ' 107' ' ' SER . 87.2 Cg_exo -36.19 152.77 0.03 OUTLIER 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 123.279 2.653 . . . . 1.3999999999999999 113.287 179.03 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 152.31 158.04 8.26 Favored Glycine 0 N--CA 1.487 2.052 0 N-CA-C 109.251 -1.54 . . . . 1.0800000000000001 109.251 -179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . 0.761 ' N ' HH12 ' B' ' 8' ' ' ARG . 0.3 OUTLIER -83.39 90.38 7.16 Favored 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 107.648 -1.242 . . . . 2.1299999999999999 107.648 179.077 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . 0.581 ' HH ' ' H ' ' A' ' 59' ' ' SER . 1.4 m-85 -73.28 156.11 38.8 Favored 'General case' 0 C--N 1.294 -1.843 0 N-CA-C 108.266 -1.012 . . . . 1.1399999999999999 108.266 -179.267 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . 0.42 ' OE1' ' O ' ' A' ' 84' ' ' ASP . 0.0 OUTLIER -138.48 120.83 15.95 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.461 -0.774 . . . . 1.53 109.287 -179.369 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.7 p -120.89 147.17 24.87 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.532 -0.73 . . . . 1.6399999999999999 109.54 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 82.6 p -129.98 107.25 9.21 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.437 -0.79 . . . . 1.99 109.328 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.566 ' H ' ' HG ' ' A' ' 99' ' ' SER . 1.6 pt -106.29 130.75 57.48 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.658 -0.651 . . . . 1.77 109.946 -179.568 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . 0.466 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.6 OUTLIER -136.55 122.63 20.29 Favored 'General case' 0 N--CA 1.492 1.627 0 N-CA-C 108.837 -0.801 . . . . 2.0600000000000001 108.837 179.341 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.56 ' O ' ' ND2' ' A' ' 92' ' ' ASN . 60.0 t80 -80.16 107.0 12.61 Favored 'General case' 0 C--N 1.299 -1.603 0 C-N-CA 118.716 -1.193 . . . . 1.45 107.819 178.37 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . 0.56 ' ND2' ' O ' ' A' ' 91' ' ' PHE . 2.9 p30 61.71 32.79 18.26 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.448 -0.783 . . . . 2.7200000000000002 109.94 -178.584 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . 0.472 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 2.5 m-20 86.21 16.97 0.11 Allowed 'General case' 0 N--CA 1.506 2.363 0 O-C-N 121.593 -0.692 . . . . 1.9199999999999999 112.24 178.171 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . 0.489 ' OE1' ' O ' ' A' ' 94' ' ' GLU . 0.3 OUTLIER -102.4 98.64 8.71 Favored 'General case' 0 N--CA 1.499 1.98 0 N-CA-C 107.039 -1.467 . . . . 2.5499999999999998 107.039 177.503 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . 0.502 ' CG ' ' O ' ' A' ' 95' ' ' HIS . 52.1 p-80 -68.64 106.48 2.63 Favored 'General case' 0 N--CA 1.487 1.417 0 N-CA-C 109.14 -0.689 . . . . 3.2000000000000002 109.14 -178.838 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . 0.421 ' O ' ' CD1' ' A' ' 96' ' ' ILE . 0.0 OUTLIER -58.91 155.07 34.28 Favored Pre-proline 0 N--CA 1.491 1.602 0 N-CA-C 108.557 -0.905 . . . . 2.8199999999999998 108.557 -179.614 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_endo -63.47 77.24 0.13 Allowed 'Trans proline' 0 CA--C 1.539 0.768 0 C-N-CA 121.23 1.287 . . . . 2.6299999999999999 109.892 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.507 ' CG ' ' CE2' ' A' ' 101' ' ' PHE . 0.4 OUTLIER 179.81 -28.72 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.857 0 O-C-N 120.968 -1.082 . . . . 2.6499999999999999 109.054 -179.649 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' SER . . . . . 0.566 ' HG ' ' H ' ' A' ' 89' ' ' ILE . 29.4 m -78.02 136.69 61.77 Favored Pre-proline 0 C--N 1.298 -1.674 0 N-CA-C 107.313 -1.366 . . . . 2.3199999999999998 107.313 178.448 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -76.64 116.95 4.66 Favored 'Cis proline' 0 CA--C 1.547 1.174 0 C-N-CA 125.165 -0.765 . . . . 1.9399999999999999 111.09 -0.099 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . 0.507 ' CE2' ' CG ' ' A' ' 98' ' ' ASP . 0.1 OUTLIER -70.54 164.77 24.11 Favored 'General case' 0 N--CA 1.494 1.736 0 N-CA-C 107.793 -1.188 . . . . 2.6299999999999999 107.793 178.566 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 8.6 p -123.4 127.93 74.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 N-CA-C 108.43 -0.952 . . . . 1.8200000000000001 108.43 179.068 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 94.9 t -121.47 83.56 40.96 Favored Pre-proline 0 N--CA 1.503 2.18 0 O-C-N 121.406 -0.809 . . . . 1.73 109.535 -179.223 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -66.85 110.64 1.97 Allowed 'Trans proline' 0 C--N 1.32 -0.967 0 C-N-CA 121.252 1.301 . . . . 1.6100000000000001 110.742 -179.131 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 54.2 t -89.06 146.15 6.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 N-CA-C 107.28 -1.378 . . . . 1.7 107.28 178.54 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -133.64 130.43 38.27 Favored 'General case' 0 N--CA 1.508 2.46 0 O-C-N 121.289 -0.882 . . . . 2.04 111.746 -177.085 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' SER . . . . . 0.605 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 94.6 p -106.05 93.4 4.6 Favored 'General case' 0 N--CA 1.494 1.752 0 N-CA-C 106.854 -1.536 . . . . 2.2999999999999998 106.854 178.578 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 11.1 mp 57.38 7.47 0.49 Allowed 'General case' 0 C--N 1.293 -1.858 0 N-CA-C 107.839 -1.171 . . . . 3.6000000000000001 107.839 -177.696 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.545 ' H ' ' C ' ' A' ' 107' ' ' SER . 6.1 t -92.99 -29.42 15.85 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 108.506 -0.924 . . . . 2.4900000000000002 108.506 178.989 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 26.8 m-20 52.39 12.28 0.22 Allowed 'General case' 0 N--CA 1.488 1.432 0 N-CA-C 108.061 -1.089 . . . . 2.8500000000000001 108.061 -178.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.537 ' O ' ' C ' ' A' ' 112' ' ' ALA . 17.5 t0 -167.22 -35.13 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.311 0 O-C-N 121.72 -0.613 . . . . 2.46 109.748 -179.704 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.537 ' C ' ' O ' ' A' ' 111' ' ' ASP . . . 22.07 66.84 0.03 OUTLIER 'General case' 0 N--CA 1.515 2.816 0 CA-C-O 121.067 0.46 . . . . 2.0800000000000001 111.53 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.574 ' CG ' HH11 ' A' ' 113' ' ' ARG . 0.0 OUTLIER -71.91 -165.53 0.17 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.096 -1.003 . . . . 6.54 109.891 -179.206 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 7.6 ttm180 -134.08 1.1 3.22 Favored 'General case' 0 N--CA 1.494 1.764 0 N-CA-C 108.045 -1.095 . . . . 6.2400000000000002 108.045 179.535 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 2.4 mp -131.32 -23.67 2.37 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.808 -0.558 . . . . 4.71 109.495 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.53 ' C ' ' H ' ' A' ' 118' ' ' THR . 0.8 OUTLIER -105.41 -78.23 0.57 Allowed 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 106.558 -1.645 . . . . 4.3499999999999996 106.558 178.768 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 42.7 t -63.89 -7.12 2.97 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.702 0 N-CA-C 105.859 -1.904 . . . . 3.3100000000000001 105.859 176.726 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' THR . . . . . 0.53 ' H ' ' C ' ' A' ' 116' ' ' THR . 3.0 t 36.16 68.64 0.23 Allowed 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.058 -0.974 . . . . 3.73 110.831 179.798 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' SER . . . . . 0.403 ' OXT' ' O ' ' A' ' 118' ' ' THR . 0.9 OUTLIER . . . . . 0 C--N 1.303 -1.449 0 CA-C-O 117.978 -1.01 . . . . 3.8300000000000001 109.49 179.242 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 5.0 ptt? . . . . . 0 N--CA 1.491 1.617 0 N-CA-C 109.402 -0.592 . . . . 8.8699999999999992 109.402 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' B' B ' 2' ' ' ALA . . . . . 0.415 ' O ' ' OG ' ' B' ' 3' ' ' SER . . . -165.9 131.76 2.52 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.108 -0.995 . . . . 5.9299999999999997 109.74 -179.852 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 3' ' ' SER . . . . . 0.499 ' OG ' ' N ' ' B' ' 4' ' ' LYS . 19.5 p 54.98 -136.46 1.28 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.385 -0.822 . . . . 5.5700000000000003 109.86 179.869 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 4' ' ' LYS . . . . . 0.499 ' N ' ' OG ' ' B' ' 3' ' ' SER . 13.8 pttp -169.12 74.6 0.74 Allowed Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.363 -0.836 . . . . 7.25 109.27 -179.666 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 5' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -59.69 128.53 27.3 Favored 'Trans proline' 0 C--N 1.317 -1.086 0 C-N-CA 121.28 1.32 . . . . 5.8899999999999997 109.797 -179.548 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 6' ' ' GLU . . . . . . . . . . . . . 41.6 tp10 -78.22 83.76 4.47 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.274 -0.891 . . . . 4.7800000000000002 109.881 -179.591 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 86.6 mttt 46.9 -163.54 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.248 -0.908 . . . . 4.5599999999999996 109.691 179.647 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . 0.761 HH12 ' N ' ' A' ' 84' ' ' ASP . 3.9 mtt180 -100.51 175.3 5.73 Favored 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 108.562 -0.903 . . . . 3.6699999999999999 108.562 -179.78 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 9' ' ' VAL . . . . . . . . . . . . . 20.8 t -56.82 159.34 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 N-CA-C 107.632 -1.247 . . . . 1.3899999999999999 107.632 179.041 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -125.84 150.1 48.12 Favored 'General case' 0 N--CA 1.502 2.133 0 O-C-N 121.328 -0.857 . . . . 1.22 109.968 -179.136 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 11' ' ' SER . . . . . 0.437 ' O ' ' O ' ' A' ' 55' ' ' VAL . 6.2 m -148.77 145.14 27.46 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.389 -0.819 . . . . 1.6299999999999999 109.44 179.911 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 14.8 t -142.08 118.57 10.93 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.205 -0.934 . . . . 1.8799999999999999 109.553 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . 0.494 ' CG2' ' N ' ' B' ' 14' ' ' PHE . 2.4 p -157.61 167.04 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 121.365 -0.834 . . . . 1.2 108.804 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 14' ' ' PHE . . . . . 0.52 ' HB3' ' H ' ' A' ' 53' ' ' ILE . 5.4 p90 -176.69 -167.13 0.18 Allowed 'General case' 0 N--CA 1.488 1.47 0 C-N-CA 119.298 -0.961 . . . . 2.3900000000000001 112.082 -179.859 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.9 pt -146.63 176.94 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 N-CA-C 108.419 -0.956 . . . . 1.8100000000000001 108.419 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 16.1 m -140.2 142.09 35.91 Favored 'General case' 0 N--CA 1.5 2.041 0 O-C-N 120.921 -1.112 . . . . 2.04 110.096 -179.703 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 18.5 mt -104.86 120.27 41.02 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.532 -0.73 . . . . 1.8700000000000001 109.084 179.531 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -159.23 107.06 1.53 Allowed Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.256 -0.903 . . . . 1.47 109.272 -179.661 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . 0.485 ' C ' ' H ' ' B' ' 21' ' ' ARG . 5.4 Cg_exo -60.12 114.31 2.04 Favored 'Trans proline' 0 CA--C 1.553 1.472 0 N-CA-C 109.394 -1.041 . . . . 1.96 109.394 -179.677 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 20' ' ' PRO . . . . . . . . . . . . . 1.6 Cg_endo -62.8 0.76 1.36 Allowed 'Trans proline' 0 C--O 1.215 -0.64 0 N-CA-C 109.782 -0.891 . . . . 3.3799999999999999 109.782 -179.588 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . 0.485 ' H ' ' C ' ' B' ' 19' ' ' PRO . 77.2 mtt180 -65.93 -67.66 0.43 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.235 -0.916 . . . . 6.7400000000000002 109.455 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 22' ' ' ARG . . . . . . . . . . . . . 97.5 mtt180 50.67 -146.23 0.44 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.175 -0.953 . . . . 6.9400000000000004 109.512 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 26.4 t70 50.5 42.16 26.17 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.337 -0.852 . . . . 5.6200000000000001 109.343 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 14.0 m . . . . . 0 N--CA 1.49 1.538 0 CA-C-O 118.038 -0.982 . . . . 6.75 109.495 179.986 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.531 5.013 0 N-CA-C 119.762 2.665 . . . . 6.7300000000000004 119.762 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.567 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 12.3 tt -171.34 50.18 0.13 Allowed Pre-proline 0 C--N 1.307 -1.264 0 O-C-N 121.311 -1.111 . . . . 7.3799999999999999 108.137 179.438 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.8 ' C ' ' H ' ' A' ' 5' ' ' PHE . 1.6 Cg_endo -52.81 -78.52 0.02 OUTLIER 'Trans proline' 0 C--N 1.319 -0.987 0 C-N-CA 121.117 1.212 . . . . 5.5 109.063 179.504 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.505 ' C ' ' H ' ' A' ' 6' ' ' PHE . 8.9 tt0 73.5 -16.48 0.49 Allowed 'General case' 0 N--CA 1.495 1.789 0 N-CA-C 104.237 -2.505 . . . . 6.8399999999999999 104.237 -175.612 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . 0.8 ' H ' ' C ' ' A' ' 3' ' ' PRO . 4.2 t80 -90.03 17.11 7.23 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 103.788 -2.671 . . . . 6.4400000000000004 103.788 176.82 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.545 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 42.3 p90 46.6 -155.94 0.04 OUTLIER 'General case' 0 C--N 1.307 -1.254 0 CA-C-N 114.08 -1.418 . . . . 5.0599999999999996 109.759 -177.988 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.539 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 16.1 tt0 86.43 -10.56 0.66 Allowed 'General case' 0 N--CA 1.493 1.72 0 N-CA-C 105.081 -2.192 . . . . 4.8099999999999996 105.081 -177.112 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . 0.478 ' H ' ' C ' ' A' ' 6' ' ' PHE . 70.2 t80 -154.27 -36.31 0.1 Allowed 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 114.717 -1.129 . . . . 5.7300000000000004 108.029 178.358 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 88.1 m -94.3 4.16 54.25 Favored 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 105.941 -1.874 . . . . 5.3499999999999996 105.941 177.383 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.424 ' CG1' ' N ' ' A' ' 11' ' ' GLY . 12.7 p -44.29 -45.22 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.388 0 CA-C-N 115.374 -0.83 . . . . 4.3799999999999999 109.281 -179.693 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.642 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 130.83 -79.17 0.36 Allowed Glycine 0 N--CA 1.503 3.112 0 N-CA-C 108.791 -1.724 . . . . 4.4800000000000004 108.791 179.343 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.459 ' O ' ' C ' ' A' ' 13' ' ' LEU . 11.6 Cg_endo -65.74 39.05 0.13 Allowed 'Trans proline' 0 C--N 1.318 -1.044 0 C-N-CA 121.91 1.74 . . . . 4.0499999999999998 108.884 178.007 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.642 ' H ' ' C ' ' A' ' 11' ' ' GLY . 0.2 OUTLIER 28.08 46.1 0.01 OUTLIER 'General case' 0 N--CA 1.505 2.28 0 CA-C-O 121.477 0.656 . . . . 4.0599999999999996 110.78 -179.611 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.531 ' C ' ' H ' ' A' ' 16' ' ' GLY . . . 67.77 -35.57 0.23 Allowed Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.399 -1.48 . . . . 3.1400000000000001 109.399 -179.622 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.589 ' H ' ' C ' ' A' ' 13' ' ' LEU . 60.1 tt0 57.19 4.04 0.18 Allowed 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.316 -1.108 . . . . 3.1699999999999999 109.235 -179.862 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.531 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 64.94 112.05 0.01 OUTLIER Glycine 0 N--CA 1.49 2.291 0 O-C-N 121.503 -0.748 . . . . 2.4399999999999999 111.779 178.165 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.588 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 63.79 -49.83 0.08 OUTLIER Glycine 0 N--CA 1.493 2.475 0 O-C-N 121.759 -0.848 . . . . 2.0499999999999998 111.669 177.968 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.512 ' N ' ' OE2' ' A' ' 94' ' ' GLU . . . -45.33 -12.08 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.111 -1.229 . . . . 2.54 109.935 -179.276 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . 0.588 ' N ' ' O ' ' A' ' 17' ' ' GLY . 1.5 t60 -83.65 -40.64 18.72 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.142 -0.974 . . . . 3.3700000000000001 109.557 179.207 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.528 ' NZ ' ' HG1' ' A' ' 43' ' ' THR . 0.9 OUTLIER -93.93 4.17 54.3 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 120.874 -1.141 . . . . 2.3700000000000001 110.5 -179.508 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.44 ' CG2' ' HZ3' ' A' ' 20' ' ' LYS . 64.6 t -83.06 113.51 22.36 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 120.811 -1.18 . . . . 2.5800000000000001 109.25 179.721 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 20.3 tpt180 -111.03 137.27 48.87 Favored 'General case' 0 N--CA 1.496 1.83 0 CA-C-O 121.408 0.623 . . . . 3.8900000000000001 109.63 -179.634 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -144.21 113.55 6.98 Favored 'General case' 0 N--CA 1.493 1.701 0 N-CA-C 108.744 -0.836 . . . . 2.0099999999999998 108.744 179.417 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -153.17 128.53 2.47 Favored Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.924 -1.27 . . . . 2.0099999999999998 109.924 -179.465 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 179.84 -173.92 45.5 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.926 -1.269 . . . . 1.9299999999999999 109.926 179.721 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 16.7 p -78.92 -25.76 43.7 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.358 -1.083 . . . . 2.6899999999999999 109.235 179.554 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.485 ' N ' ' O ' ' A' ' 38' ' ' GLU . . . -65.9 -17.78 65.7 Favored Glycine 0 N--CA 1.488 2.131 0 N-CA-C 108.388 -1.885 . . . . 1.6399999999999999 108.388 179.58 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 14.1 mt -94.12 32.46 1.5 Allowed 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 108.477 -0.935 . . . . 2.0299999999999998 108.477 179.439 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -140.33 -50.91 0.47 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.445 -0.784 . . . . 2.3399999999999999 109.615 -179.58 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . 0.519 ' NH1' ' OD1' ' A' ' 110' ' ' ASP . 30.8 ptt180 -172.27 173.75 4.13 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.953 -1.092 . . . . 4.25 110.573 -179.79 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -150.24 176.4 28.88 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 107.878 -2.089 . . . . 1.5900000000000001 107.878 179.437 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 37.5 t -134.09 153.13 35.44 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.137 0 O-C-N 120.992 -1.299 . . . . 2.21 110.755 -179.629 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -40.37 114.1 0.42 Allowed 'General case' 0 N--CA 1.497 1.891 0 CA-C-O 121.587 0.708 . . . . 2.0699999999999998 112.092 -179.334 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 56.46 46.04 88.38 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 111.397 -0.681 . . . . 1.73 111.397 177.05 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 37.1 t -126.92 122.54 23.33 Favored Pre-proline 0 N--CA 1.497 1.909 0 O-C-N 121.443 -1.033 . . . . 2.6499999999999999 108.23 178.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 2.3 Cg_endo -59.47 120.52 8.41 Favored 'Trans proline' 0 C--O 1.216 -0.622 0 C-N-CA 120.474 0.783 . . . . 2.1400000000000001 110.27 -179.38 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -116.81 161.21 19.65 Favored 'General case' 0 N--CA 1.497 1.904 0 N-CA-C 107.814 -1.18 . . . . 2.0299999999999998 107.814 179.167 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . 0.485 ' O ' ' N ' ' A' ' 27' ' ' GLY . 7.0 pt-20 -163.8 173.01 13.31 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 120.642 -1.286 . . . . 2.23 111.519 -179.455 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.405 ' CD1' ' N ' ' A' ' 39' ' ' PHE . 5.6 p90 -157.99 165.24 35.63 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 107.647 -1.242 . . . . 1.72 107.647 178.504 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 58.0 m -99.96 148.96 23.93 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.404 -0.81 . . . . 2.5800000000000001 110.843 -178.099 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 95.5 mt -137.84 102.64 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 N-CA-C 108.353 -0.98 . . . . 1.8600000000000001 108.353 178.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 3.0 t-105 -100.04 132.77 45.21 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.314 -0.866 . . . . 4.4699999999999998 108.683 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' THR . . . . . 0.547 ' OG1' ' N ' ' A' ' 44' ' ' ARG . 1.6 t -162.25 -126.16 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.405 -0.809 . . . . 3.27 109.503 -179.641 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' ARG . . . . . 0.547 ' N ' ' OG1' ' A' ' 43' ' ' THR . 25.9 mtm180 60.61 80.22 0.22 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.285 -0.885 . . . . 5.2300000000000004 109.954 179.885 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 12.5 tp10 -159.45 -46.82 0.05 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.282 -0.886 . . . . 2.8900000000000001 109.134 179.383 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -60.34 -59.96 4.58 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.086 -1.009 . . . . 1.99 109.066 179.715 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 163.59 -175.88 39.76 Favored Glycine 0 N--CA 1.484 1.856 0 C-N-CA 119.385 -1.388 . . . . 1.6499999999999999 110.464 179.62 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.6 163.47 0.65 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.535 -0.98 . . . . 1.77 109.853 -179.686 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 172.72 -163.2 35.04 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.68 -1.368 . . . . 1.1200000000000001 109.68 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -142.77 130.45 4.2 Favored Glycine 0 N--CA 1.496 2.634 0 N-CA-C 109.245 -1.542 . . . . 1.1799999999999999 109.245 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.434 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 12.2 tp -103.07 100.62 10.56 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.425 -1.044 . . . . 1.5900000000000001 109.042 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 3.9 m -88.77 139.76 30.14 Favored 'General case' 0 N--CA 1.497 1.92 0 N-CA-C 108.723 -0.843 . . . . 1.9399999999999999 108.723 179.476 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.486 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 82.6 mt -128.15 113.28 29.78 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.111 0 O-C-N 121.088 -1.008 . . . . 1.3 109.916 -179.811 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -102.48 106.04 16.7 Favored 'General case' 0 N--CA 1.494 1.736 0 N-CA-C 108.718 -0.845 . . . . 1.27 108.718 179.251 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -102.84 143.7 14.78 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 O-C-N 121.471 -0.768 . . . . 1.55 109.326 -179.697 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 -141.95 144.03 33.54 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 108.181 -1.044 . . . . 1.8 108.181 178.743 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 168.71 -172.59 43.17 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 109.179 -1.569 . . . . 0.56000000000000005 109.179 -179.031 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -63.73 -27.6 68.37 Favored 'Trans proline' 0 C--N 1.316 -1.133 0 C-N-CA 121.888 1.725 . . . . 0.76000000000000001 111.461 -179.696 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' SER . . . . . 0.421 ' O ' ' OH ' ' A' ' 85' ' ' TYR . 16.0 m -140.4 168.12 20.55 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.257 -0.902 . . . . 2.02 109.754 -179.77 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 37.1 mtpt -91.13 126.44 36.22 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.376 -0.828 . . . . 3.02 109.517 -179.713 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -86.83 135.12 33.45 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.242 -0.911 . . . . 1.3600000000000001 109.358 179.861 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 20.0 tt0 -90.19 94.53 9.8 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.129 -0.982 . . . . 2.2999999999999998 109.97 -179.658 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . 0.423 ' N ' ' CD1' ' A' ' 63' ' ' ILE . 1.8 mp -60.34 153.74 4.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 N-CA-C 109.118 -0.697 . . . . 2.0 109.118 179.415 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.547 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -151.3 123.8 8.41 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.037 -1.039 . . . . 1.73 109.24 179.778 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.47 ' CD2' ' O ' ' A' ' 65' ' ' PHE . 47.5 p90 -89.0 124.59 34.42 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.204 -0.935 . . . . 1.6000000000000001 109.376 179.787 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 75.9 tt0 -141.58 111.16 6.49 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.222 -0.924 . . . . 2.5099999999999998 109.772 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -79.78 127.81 32.67 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.202 -0.936 . . . . 2.0699999999999998 108.687 179.273 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 56.0 ttt180 -118.16 -27.1 6.16 Favored 'General case' 0 N--CA 1.501 2.08 0 O-C-N 121.466 -0.771 . . . . 5.29 109.487 -179.583 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . 0.562 ' C ' ' H ' ' A' ' 71' ' ' GLY . 39.5 mttp -116.66 -3.19 11.79 Favored 'General case' 0 N--CA 1.496 1.858 0 N-CA-C 108.691 -0.855 . . . . 3.8599999999999999 108.691 179.829 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.444 ' CB ' ' O ' ' A' ' 69' ' ' LYS . 1.6 t70 72.15 -30.08 0.21 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.571 -0.706 . . . . 3.0600000000000001 109.111 -179.56 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . 0.562 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -103.17 19.4 46.21 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.436 -1.466 . . . . 2.1600000000000001 109.436 -179.765 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 3.3 t -153.85 129.65 10.13 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.351 -1.087 . . . . 2.5600000000000001 109.092 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 76.4 m -86.23 113.39 22.21 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.126 -0.984 . . . . 2.3599999999999999 109.428 -179.927 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -87.62 115.46 4.34 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.703 -1.359 . . . . 1.46 109.703 -179.717 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 22.0 t -107.03 104.46 17.1 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.995 0 O-C-N 121.605 -0.938 . . . . 2.1600000000000001 109.012 179.79 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.547 ' O ' ' N ' ' A' ' 64' ' ' ALA . 37.3 m -99.4 131.84 45.14 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.558 -0.714 . . . . 2.1600000000000001 110.06 -179.45 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 0.511 ' O ' ' CD1' ' A' ' 77' ' ' TYR . 44.3 p90 -128.01 134.96 49.29 Favored 'General case' 0 N--CA 1.497 1.915 0 N-CA-C 108.875 -0.787 . . . . 1.7 108.875 179.882 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.481 ' O ' ' CG1' ' A' ' 78' ' ' VAL . 9.7 p -104.52 114.2 43.51 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.099 0 O-C-N 121.324 -0.86 . . . . 2.4500000000000002 109.582 -179.576 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 2.0 m -88.64 158.96 2.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.096 -1.002 . . . . 1.8200000000000001 109.031 -179.865 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . 0.403 ' OE1' ' OG ' ' A' ' 59' ' ' SER . 35.1 tt0 -97.28 -49.47 4.93 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.079 -1.013 . . . . 3.1699999999999999 110.758 -179.133 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 76.5 mm-40 -147.15 150.74 39.15 Favored Pre-proline 0 N--CA 1.504 2.242 0 O-C-N 120.794 -1.191 . . . . 2.02 111.661 -178.314 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.594 ' HG3' ' N ' ' A' ' 107' ' ' SER . 77.3 Cg_exo -36.85 164.27 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 123.248 2.632 . . . . 1.3999999999999999 113.346 178.409 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 145.03 175.21 17.99 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.543 -1.423 . . . . 1.0800000000000001 109.543 179.676 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . 0.737 ' H ' HH12 ' B' ' 8' ' ' ARG . 0.9 OUTLIER -94.26 83.97 4.33 Favored 'General case' 0 N--CA 1.49 1.549 0 N-CA-C 107.959 -1.126 . . . . 2.1299999999999999 107.959 179.277 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' TYR . . . . . 0.421 ' OH ' ' O ' ' A' ' 59' ' ' SER . 2.7 m-85 -68.89 135.25 50.76 Favored 'General case' 0 C--N 1.299 -1.606 0 N-CA-C 107.84 -1.171 . . . . 1.1399999999999999 107.84 -179.712 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . 0.442 ' OE2' ' O ' ' A' ' 84' ' ' ASP . 0.8 OUTLIER -116.31 121.04 40.8 Favored 'General case' 0 N--CA 1.499 1.996 0 N-CA-C 108.768 -0.827 . . . . 1.53 108.768 -179.37 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 10.6 p -116.46 145.35 22.33 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 121.592 -0.693 . . . . 1.6399999999999999 110.194 -179.375 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 9.4 p -136.47 110.35 8.19 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 108.699 -0.852 . . . . 1.99 108.699 179.596 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.8 pt -116.89 135.75 56.23 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.949 0 O-C-N 121.577 -0.702 . . . . 1.77 110.632 -178.886 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . 0.589 ' HZ2' ' CD2' ' A' ' 95' ' ' HIS . 0.3 OUTLIER -136.03 121.31 19.14 Favored 'General case' 0 N--CA 1.486 1.339 0 N-CA-C 107.923 -1.14 . . . . 2.0600000000000001 107.923 178.625 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.409 ' O ' ' OE1' ' A' ' 94' ' ' GLU . 52.7 t80 -85.15 101.65 12.64 Favored 'General case' 0 N--CA 1.491 1.621 0 N-CA-C 107.196 -1.409 . . . . 1.45 107.196 178.632 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' ASN . . . . . 0.454 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 21.3 t30 72.09 34.36 1.45 Allowed 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 109.214 -0.661 . . . . 2.7200000000000002 109.214 -178.266 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . 0.454 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 1.4 m-20 80.22 14.4 0.84 Allowed 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.614 -0.679 . . . . 1.9199999999999999 111.437 179.393 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . 0.512 ' OE2' ' N ' ' A' ' 18' ' ' ALA . 6.5 pt-20 -99.39 98.68 9.58 Favored 'General case' 0 N--CA 1.497 1.908 0 N-CA-C 107.09 -1.448 . . . . 2.5499999999999998 107.09 177.898 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . 0.589 ' CD2' ' HZ2' ' A' ' 90' ' ' LYS . 0.2 OUTLIER -67.19 98.54 0.61 Allowed 'General case' 0 N--CA 1.491 1.578 0 CA-C-O 121.586 0.708 . . . . 3.2000000000000002 110.022 -177.845 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -54.86 137.29 64.99 Favored Pre-proline 0 N--CA 1.489 1.503 0 N-CA-C 107.429 -1.322 . . . . 2.8199999999999998 107.429 179.351 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_exo -39.37 -44.78 3.03 Favored 'Trans proline' 0 CA--C 1.537 0.657 0 C-N-CA 121.234 1.289 . . . . 2.6299999999999999 111.791 -178.809 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.455 ' N ' ' OD1' ' A' ' 98' ' ' ASP . 1.2 m-20 -47.05 -65.72 0.52 Allowed 'General case' 0 N--CA 1.498 1.949 0 O-C-N 120.747 -1.221 . . . . 2.6499999999999999 109.174 179.325 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 3.8 m -57.06 138.89 79.54 Favored Pre-proline 0 C--N 1.297 -1.705 0 O-C-N 121.26 -0.9 . . . . 2.3199999999999998 109.204 -178.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -88.31 115.32 2.97 Favored 'Cis proline' 0 N--CA 1.49 1.271 0 N-CA-C 109.055 -1.171 . . . . 1.9399999999999999 109.055 -1.669 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 52.5 p90 -114.5 162.96 16.03 Favored 'General case' 0 N--CA 1.517 2.918 0 O-C-N 120.546 -1.347 . . . . 2.6299999999999999 110.335 179.117 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.1 p -91.79 151.92 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 CA-C-O 121.713 0.768 . . . . 1.8200000000000001 110.749 -178.34 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 55.8 t -128.24 86.42 58.0 Favored Pre-proline 0 N--CA 1.494 1.766 0 N-CA-C 107.679 -1.23 . . . . 1.73 107.679 179.158 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -66.47 110.59 1.87 Allowed 'Trans proline' 0 C--N 1.321 -0.89 0 C-N-CA 121.623 1.549 . . . . 1.6100000000000001 112.194 -177.563 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 55.5 t -94.51 142.52 13.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 N-CA-C 106.488 -1.671 . . . . 1.7 106.488 177.465 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . . . . . . . . . . . -129.55 132.32 46.8 Favored 'General case' 0 N--CA 1.512 2.652 0 CA-C-O 122.173 0.987 . . . . 2.04 112.516 -176.59 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' SER . . . . . 0.594 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 35.7 m -94.53 81.33 3.91 Favored 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 107.117 -1.438 . . . . 2.2999999999999998 107.117 178.515 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 23.9 mt 62.63 1.02 0.72 Allowed 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 107.795 -1.187 . . . . 3.6000000000000001 107.795 -177.723 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.566 ' H ' ' C ' ' A' ' 107' ' ' SER . 60.8 p -87.72 -21.39 25.22 Favored 'General case' 0 N--CA 1.488 1.444 0 N-CA-C 108.471 -0.937 . . . . 2.4900000000000002 108.471 178.859 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . 0.519 ' OD1' ' NH1' ' A' ' 30' ' ' ARG . 36.0 t0 52.03 11.91 0.18 Allowed 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.512 -0.922 . . . . 2.8500000000000001 108.512 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.517 ' OD1' ' N ' ' A' ' 112' ' ' ALA . 4.0 p30 -172.39 -30.16 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.693 -0.629 . . . . 2.46 109.482 -179.773 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.536 ' N ' ' OG ' ' A' ' 109' ' ' SER . . . 42.86 57.07 3.74 Favored 'General case' 0 N--CA 1.502 2.129 0 O-C-N 121.162 -0.961 . . . . 2.0800000000000001 109.71 179.95 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.6 ' CG ' HH11 ' A' ' 113' ' ' ARG . 0.0 OUTLIER -44.21 146.26 0.68 Allowed 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.343 -0.848 . . . . 6.54 110.028 -179.101 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 46.3 ttt180 -103.86 4.04 34.45 Favored 'General case' 0 N--CA 1.496 1.826 0 N-CA-C 108.848 -0.797 . . . . 6.2400000000000002 108.848 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 33.9 mt -127.85 -25.0 3.14 Favored 'General case' 0 N--CA 1.504 2.235 0 O-C-N 121.712 -0.618 . . . . 4.71 109.386 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.545 ' C ' ' H ' ' A' ' 118' ' ' THR . 55.2 m -108.17 -78.21 0.59 Allowed 'General case' 0 N--CA 1.498 1.956 0 N-CA-C 107.172 -1.418 . . . . 4.3499999999999996 107.172 179.056 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.406 ' O ' ' C ' ' A' ' 118' ' ' THR . 51.3 t -62.84 -8.04 2.96 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.715 0 N-CA-C 105.911 -1.885 . . . . 3.3100000000000001 105.911 176.801 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' THR . . . . . 0.545 ' H ' ' C ' ' A' ' 116' ' ' THR . 4.1 t 36.13 60.58 0.83 Allowed 'General case' 0 N--CA 1.488 1.446 0 CA-C-N 115.221 -0.9 . . . . 3.73 110.636 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' SER . . . . . 0.472 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.6 p . . . . . 0 N--CA 1.487 1.38 0 CA-C-O 117.988 -1.006 . . . . 3.8300000000000001 109.59 179.461 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 25.9 ttt . . . . . 0 N--CA 1.491 1.599 0 N-CA-C 109.364 -0.606 . . . . 8.8699999999999992 109.364 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -164.04 176.51 9.27 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.271 -0.893 . . . . 5.9299999999999997 109.442 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 3' ' ' SER . . . . . 0.477 ' O ' ' C ' ' B' ' 4' ' ' LYS . 18.0 m -160.01 107.44 1.65 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.253 -0.904 . . . . 5.5700000000000003 109.292 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 4' ' ' LYS . . . . . 0.477 ' C ' ' O ' ' B' ' 3' ' ' SER . 66.5 mmtt -26.68 92.6 0.05 OUTLIER Pre-proline 0 N--CA 1.506 2.362 0 CA-C-O 119.523 -0.275 . . . . 7.25 111.317 -179.786 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 5' ' ' PRO . . . . . 0.417 ' N ' ' O ' ' B' ' 3' ' ' SER . 2.2 Cg_endo -69.39 -81.06 0.01 OUTLIER 'Trans proline' 0 C--N 1.324 -0.756 0 C-N-CA 121.135 1.223 . . . . 5.8899999999999997 109.793 -179.437 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 6' ' ' GLU . . . . . 0.462 ' N ' ' CD ' ' B' ' 6' ' ' GLU . 0.6 OUTLIER 51.82 50.6 18.3 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.241 -0.912 . . . . 4.7800000000000002 109.618 -179.8 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 7.1 ptmm? -159.96 146.49 16.01 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.225 -0.922 . . . . 4.5599999999999996 109.482 179.768 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 8' ' ' ARG . . . . . 0.737 HH12 ' H ' ' A' ' 84' ' ' ASP . 39.0 mtt180 -140.53 168.13 20.53 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.301 -0.874 . . . . 3.6699999999999999 108.847 179.903 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 9' ' ' VAL . . . . . . . . . . . . . 14.7 t -50.9 159.72 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 N-CA-C 108.059 -1.089 . . . . 1.3899999999999999 108.059 179.24 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -122.66 144.26 49.25 Favored 'General case' 0 N--CA 1.501 2.092 0 O-C-N 121.372 -0.83 . . . . 1.22 110.092 -178.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 4.1 t -137.17 145.15 43.4 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.59 -0.693 . . . . 1.6299999999999999 109.246 179.712 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 17.7 m -148.64 115.48 6.02 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.28 -0.888 . . . . 1.8799999999999999 109.752 -179.797 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . 0.48 ' CG2' ' N ' ' B' ' 14' ' ' PHE . 2.9 p -157.86 166.81 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 N-CA-C 108.694 -0.854 . . . . 1.2 108.694 179.624 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 14' ' ' PHE . . . . . 0.486 ' HB3' ' H ' ' A' ' 53' ' ' ILE . 6.9 p90 -177.33 -167.02 0.15 Allowed 'General case' 0 N--CA 1.489 1.509 0 C-N-CA 119.168 -1.013 . . . . 2.3900000000000001 112.403 -179.811 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 3.2 pt -146.62 168.73 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 N-CA-C 108.437 -0.949 . . . . 1.8100000000000001 108.437 179.819 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 49.5 m -138.69 142.08 38.97 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 120.999 -1.063 . . . . 2.04 110.178 -179.599 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 16.5 mt -103.32 129.86 50.44 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.52 -0.738 . . . . 1.8700000000000001 109.162 179.545 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -141.94 77.9 18.04 Favored Pre-proline 0 N--CA 1.497 1.879 0 O-C-N 121.351 -0.843 . . . . 1.47 109.635 -179.658 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -60.15 169.13 5.23 Favored 'Trans proline' 0 CA--C 1.545 1.056 0 C-N-CA 121.321 1.347 . . . . 1.96 109.593 -179.754 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 20' ' ' PRO . . . . . 0.437 ' O ' ' O ' ' B' ' 21' ' ' ARG . 2.5 Cg_endo -57.42 88.95 0.05 OUTLIER 'Trans proline' 0 C--N 1.32 -0.957 0 C-N-CA 121.416 1.41 . . . . 3.3799999999999999 110.367 -179.582 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . 0.437 ' O ' ' O ' ' B' ' 20' ' ' PRO . 2.6 tpm_? 58.16 158.03 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.231 -0.918 . . . . 6.7400000000000002 109.796 179.536 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 22' ' ' ARG . . . . . 0.454 ' O ' ' N ' ' B' ' 24' ' ' VAL . 72.7 mtm180 -79.63 101.91 8.62 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.193 -0.942 . . . . 6.9400000000000004 109.368 179.824 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -49.69 95.19 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.202 -0.936 . . . . 5.6200000000000001 109.511 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . 0.454 ' N ' ' O ' ' B' ' 22' ' ' ARG . 12.4 t . . . . . 0 N--CA 1.49 1.543 0 CA-C-O 117.993 -1.003 . . . . 6.75 109.529 179.903 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.512 ' O ' ' N ' ' A' ' 18' ' ' ALA . . . . . . . . 0 N--CA 1.491 2.356 0 N-CA-C 110.809 -0.916 . . . . 2.44 110.809 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.536 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -46.59 -11.5 0.05 OUTLIER Glycine 0 N--CA 1.492 2.402 0 O-C-N 121.635 -0.921 . . . . 1.81 111.068 -178.956 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.512 ' N ' ' O ' ' A' ' 16' ' ' GLY . . . -45.93 -15.87 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.991 -1.299 . . . . 2.21 109.661 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' HIS . . . . . 0.536 ' N ' ' O ' ' A' ' 17' ' ' GLY . 10.7 t60 -94.48 -48.88 5.92 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.443 -0.786 . . . . 2.87 109.779 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.51 -14.4 62.1 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.891 -1.13 . . . . 2.02 109.435 -179.872 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 37.9 t -68.43 108.82 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.134 -0.979 . . . . 2.07 108.629 179.387 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.416 ' CG ' HH11 ' A' ' 22' ' ' ARG . 0.0 OUTLIER -113.83 138.49 50.21 Favored 'General case' 0 N--CA 1.491 1.609 0 N-CA-C 109.131 -0.692 . . . . 3.5 109.131 -179.515 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -147.72 113.36 5.68 Favored 'General case' 0 N--CA 1.491 1.603 0 N-CA-C 108.776 -0.824 . . . . 1.83 108.776 179.553 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -151.96 131.68 3.51 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.461 -1.456 . . . . 1.9 109.461 -179.597 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.0 -177.1 46.51 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.502 -1.439 . . . . 1.85 109.502 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.471 HG23 ' N ' ' A' ' 27' ' ' GLY . 13.5 t -79.59 -38.58 33.66 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.252 -1.146 . . . . 2.31 109.16 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.471 ' N ' HG23 ' A' ' 26' ' ' THR . . . -60.28 -6.94 6.37 Favored Glycine 0 N--CA 1.483 1.811 0 N-CA-C 107.864 -2.094 . . . . 1.64 107.864 179.222 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.451 ' H ' ' C ' ' A' ' 26' ' ' THR . 12.3 mt -99.3 24.29 8.2 Favored 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 108.247 -1.02 . . . . 1.83 108.247 179.38 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 18.2 mt-10 -136.81 -37.66 0.66 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.515 -0.741 . . . . 2.34 109.152 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ARG . . . . . 0.514 HH11 ' HG2' ' A' ' 30' ' ' ARG . 2.5 ptt-85 -174.78 168.7 3.61 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.098 -1.001 . . . . 3.77 110.204 179.843 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -148.59 177.44 26.83 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 107.643 -2.183 . . . . 1.57 107.643 179.558 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 44.1 t -134.41 151.0 31.2 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.12 0 O-C-N 121.056 -1.261 . . . . 1.83 111.043 -179.528 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.515 ' HB2' ' HB3' ' A' ' 107' ' ' SER . . . -40.05 111.35 0.19 Allowed 'General case' 0 N--CA 1.498 1.937 0 CA-C-O 121.501 0.667 . . . . 1.64 112.418 -179.233 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 55.63 50.21 61.63 Favored Glycine 0 N--CA 1.492 2.395 0 O-C-N 121.589 -0.694 . . . . 1.73 111.427 176.983 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 31.5 t -127.35 124.19 23.55 Favored Pre-proline 0 N--CA 1.496 1.851 0 N-CA-C 108.312 -0.996 . . . . 2.19 108.312 178.827 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -57.3 131.98 48.23 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 N-CA-C 110.034 -0.795 . . . . 1.96 110.034 -179.527 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.527 ' HB3' ' CE1' ' A' ' 77' ' ' TYR . . . -136.04 160.31 39.04 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.46 -0.775 . . . . 1.69 109.004 179.81 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -155.32 171.47 19.8 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.012 -1.055 . . . . 2.23 111.213 -179.486 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 0.627 ' CE2' HD11 ' A' ' 41' ' ' ILE . 5.9 p90 -156.58 164.6 38.0 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 107.259 -1.386 . . . . 1.54 107.259 178.372 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 80.5 p -96.52 155.1 16.91 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.208 -0.933 . . . . 2.37 111.279 -177.806 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.878 HD12 HG21 ' A' ' 75' ' ' VAL . 46.6 mt -146.42 97.71 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 N-CA-C 107.516 -1.29 . . . . 1.65 107.516 178.767 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.4 ' CD1' ' C ' ' A' ' 42' ' ' TRP . 0.7 OUTLIER -84.88 146.96 27.03 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.113 -0.992 . . . . 3.68 109.125 -179.407 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.556 ' OG1' ' N ' ' A' ' 44' ' ' ARG . 1.4 t -154.31 -130.35 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.525 0 N-CA-C 109.138 -0.689 . . . . 2.89 109.138 -179.414 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' ARG . . . . . 0.556 ' N ' ' OG1' ' A' ' 43' ' ' THR . 39.6 ttp180 54.18 73.98 0.36 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.172 -0.955 . . . . 4.63 109.985 179.842 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 15.7 tt0 -165.14 -60.86 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.31 -0.869 . . . . 2.89 108.875 179.357 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.63 -54.56 44.64 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.059 -1.026 . . . . 1.74 108.71 179.286 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 145.58 179.63 21.97 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.292 -1.523 . . . . 1.6 109.292 179.848 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.73 162.74 0.82 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.134 -1.216 . . . . 1.4 109.598 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 168.89 -151.98 19.11 Favored Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.537 -1.425 . . . . 1.04 109.537 -179.881 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.538 ' O ' ' N ' ' A' ' 92' ' ' ASN . . . -133.87 159.12 23.61 Favored Glycine 0 N--CA 1.497 2.743 0 N-CA-C 109.413 -1.475 . . . . 1.06 109.413 -179.855 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.436 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 9.8 tp -134.14 100.5 4.73 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.529 -0.983 . . . . 1.1 108.424 179.767 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 3.8 m -83.93 144.13 29.38 Favored 'General case' 0 N--CA 1.491 1.58 0 N-CA-C 108.527 -0.916 . . . . 1.56 108.527 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.542 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 7.5 mt -135.71 100.94 2.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.354 -0.841 . . . . 0.65 109.203 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -98.19 106.22 18.48 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.306 -0.871 . . . . 0.69 108.986 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.44 ' O ' ' O ' ' B' ' 11' ' ' SER . 0.2 OUTLIER -97.64 144.42 11.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.499 -0.751 . . . . 0.91 109.403 -179.87 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 3.1 tt0 -141.11 142.09 34.14 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 107.909 -1.145 . . . . 1.8 107.909 179.059 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.432 ' O ' ' O ' ' B' ' 9' ' ' VAL . . . 169.03 176.89 39.44 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.173 -1.571 . . . . 0.49 109.173 -178.811 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -56.48 -17.99 23.76 Favored 'Trans proline' 0 C--N 1.317 -1.123 0 C-N-CA 121.94 1.76 . . . . 0.66 111.274 -179.482 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.4 p -150.22 159.93 44.07 Favored 'General case' 0 C--N 1.292 -1.922 0 O-C-N 121.284 -0.885 . . . . 1.55 110.154 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 68.2 mttt -78.86 108.2 12.14 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.498 -0.752 . . . . 2.53 109.558 -179.868 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -74.18 148.43 41.68 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.232 -0.918 . . . . 0.82 109.481 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.834 ' C ' HD12 ' A' ' 63' ' ' ILE . 5.0 tp10 -85.14 172.3 11.33 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.322 -0.861 . . . . 2.3 108.786 179.889 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.834 HD12 ' C ' ' A' ' 62' ' ' GLU . 3.7 mp -142.79 144.98 23.65 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.926 0 N-CA-C 108.259 -1.015 . . . . 1.4 108.259 179.809 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.521 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -150.53 114.47 5.04 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 120.6 -1.312 . . . . 1.36 109.923 -179.779 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 54.7 p90 -86.74 138.86 31.27 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.327 -0.858 . . . . 1.47 109.572 179.73 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 . . . . . 0 N--CA 1.496 1.871 0 O-C-N 121.22 -0.925 . . . . 2.51 109.711 -179.992 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 37.5 m . . . . . 0 N--CA 1.499 2.009 0 CA-C-O 121.418 0.628 . . . . 2.2 109.788 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 5.9 t -83.97 125.81 32.41 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.2 -0.938 . . . . 2.05 109.108 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -97.65 109.87 3.91 Favored Glycine 0 N--CA 1.495 2.616 0 N-CA-C 110.139 -1.184 . . . . 1.39 110.139 -179.572 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.878 HG21 HD12 ' A' ' 41' ' ' ILE . 32.1 t -99.23 100.86 11.26 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.929 0 O-C-N 121.583 -0.951 . . . . 1.57 108.757 179.13 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.521 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.1 OUTLIER -89.53 126.14 35.48 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.675 -0.64 . . . . 1.85 109.353 -179.551 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.527 ' CE1' ' HB3' ' A' ' 37' ' ' ALA . 52.0 p90 -123.52 173.89 7.75 Favored 'General case' 0 N--CA 1.495 1.811 0 N-CA-C 108.591 -0.892 . . . . 1.54 108.591 179.619 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 15.4 t -142.18 120.51 8.6 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.936 0 O-C-N 121.321 -0.862 . . . . 1.9 109.769 -179.628 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.526 HG11 HG21 ' A' ' 105' ' ' VAL . 8.1 m -90.82 154.98 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.435 -0.791 . . . . 1.27 109.314 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 80' ' ' GLN . . . . . 0.429 ' O ' ' OE2' ' A' ' 81' ' ' GLU . 33.5 tt0 -100.43 -45.85 5.43 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.192 -0.942 . . . . 2.48 110.746 -179.18 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.429 ' OE2' ' O ' ' A' ' 80' ' ' GLN . 79.6 mm-40 -152.39 149.12 22.11 Favored Pre-proline 0 N--CA 1.504 2.251 0 O-C-N 120.458 -1.401 . . . . 1.92 111.399 -179.151 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.678 ' HG3' ' N ' ' A' ' 107' ' ' SER . 84.6 Cg_exo -36.86 162.19 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 123.117 2.544 . . . . 1.3 113.637 178.232 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 143.42 -163.82 27.44 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 108.673 -1.771 . . . . 1.02 108.673 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 84' ' ' ASP . . . . . 0.422 ' O ' ' OE1' ' A' ' 86' ' ' GLU . 3.0 m-20 -111.82 93.77 4.62 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.502 -0.999 . . . . 2.13 108.353 179.354 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -78.59 146.19 34.32 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 108.206 -1.035 . . . . 0.92 108.206 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' GLU . . . . . 0.422 ' OE1' ' O ' ' A' ' 84' ' ' ASP . 0.0 OUTLIER -134.64 129.75 35.35 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.682 -0.636 . . . . 1.53 109.298 -178.98 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.8 p -124.99 146.79 30.05 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.554 -0.716 . . . . 1.0 109.762 -179.807 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 53.6 p -128.59 101.61 6.23 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.442 -0.786 . . . . 1.59 109.106 179.642 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.2 pt -102.4 130.64 51.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.615 -0.678 . . . . 1.29 109.577 -179.573 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' LYS . . . . . 0.435 ' HG3' ' H ' ' A' ' 93' ' ' ASP . 0.5 OUTLIER -138.62 124.85 20.29 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.244 -0.91 . . . . 1.58 109.238 179.721 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 36.5 t80 -83.13 95.16 8.0 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 120.992 -1.067 . . . . 1.34 108.599 179.391 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 92' ' ' ASN . . . . . 0.538 ' N ' ' O ' ' A' ' 50' ' ' GLY . 2.3 t-20 70.15 38.71 1.44 Allowed 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 107.925 -1.139 . . . . 2.32 107.925 -178.69 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.456 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 3.2 m-20 82.78 12.79 0.48 Allowed 'General case' 0 N--CA 1.498 1.943 0 CA-C-O 121.26 0.553 . . . . 1.92 110.005 -179.222 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 94' ' ' GLU . . . . . 0.405 ' HG2' ' H ' ' A' ' 18' ' ' ALA . 4.1 mt-10 -88.88 70.7 8.64 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 107.576 -1.268 . . . . 2.25 107.576 178.192 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 95' ' ' HIS . . . . . 0.462 ' H ' ' CD2' ' A' ' 95' ' ' HIS . 11.4 p80 -67.5 113.44 5.35 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-O 121.309 0.576 . . . . 2.88 109.953 -179.133 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 96' ' ' ILE . . . . . 0.406 HG12 ' H ' ' A' ' 96' ' ' ILE . 2.0 pt -62.64 153.78 76.73 Favored Pre-proline 0 N--CA 1.491 1.61 0 N-CA-C 108.295 -1.002 . . . . 2.35 108.295 179.444 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_exo -50.86 -44.69 40.08 Favored 'Trans proline' 0 C--N 1.321 -0.914 0 C-N-CA 121.051 1.167 . . . . 2.48 109.987 179.819 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.564 ' CB ' ' CE2' ' A' ' 101' ' ' PHE . 3.4 m-20 -51.33 -48.43 62.4 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.146 -0.972 . . . . 2.65 109.85 179.67 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 2.4 t -56.45 126.13 68.46 Favored Pre-proline 0 C--N 1.298 -1.655 0 N-CA-C 107.752 -1.203 . . . . 2.0 107.752 179.545 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 8.3 Cg_endo -72.24 117.55 3.94 Favored 'Cis proline' 0 CA--C 1.548 1.188 0 CA-C-N 119.317 0.792 . . . . 1.79 111.48 0.328 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 101' ' ' PHE . . . . . 0.564 ' CE2' ' CB ' ' A' ' 98' ' ' ASP . 0.1 OUTLIER -73.3 170.97 13.92 Favored 'General case' 0 N--CA 1.494 1.757 0 N-CA-C 107.251 -1.389 . . . . 2.19 107.251 178.273 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.403 ' O ' HG13 ' A' ' 102' ' ' VAL . 7.6 p -126.77 133.27 68.91 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 121.358 -0.838 . . . . 1.44 109.16 179.79 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 86.5 t -128.93 83.08 67.31 Favored Pre-proline 0 N--CA 1.502 2.161 0 O-C-N 121.454 -0.779 . . . . 1.19 109.63 -179.513 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -64.77 114.45 2.76 Favored 'Trans proline' 0 C--N 1.32 -0.932 0 C-N-CA 121.302 1.334 . . . . 1.49 110.477 -179.506 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.526 HG21 HG11 ' A' ' 79' ' ' VAL . 53.1 t -93.91 146.15 6.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 N-CA-C 108.292 -1.003 . . . . 1.35 108.292 179.484 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.65 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -131.92 130.28 41.38 Favored 'General case' 0 N--CA 1.507 2.401 0 CA-C-O 121.932 0.872 . . . . 1.67 111.941 -177.291 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 107' ' ' SER . . . . . 0.678 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 76.2 p -98.65 98.3 9.46 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.733 -1.23 . . . . 2.04 107.788 179.184 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 108' ' ' LEU . . . . . 0.514 HD12 ' N ' ' A' ' 108' ' ' LEU . 8.9 mp 54.62 9.3 0.26 Allowed 'General case' 0 C--N 1.293 -1.872 0 N-CA-C 108.278 -1.008 . . . . 3.2 108.278 -178.585 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.48 ' H ' ' C ' ' A' ' 107' ' ' SER . 8.3 t -101.05 -28.57 12.64 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.604 -0.685 . . . . 2.09 109.16 179.503 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 110' ' ' ASP . . . . . 0.65 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 13.8 t70 . . . . . 0 N--CA 1.489 1.493 0 N-CA-C 107.776 -1.194 . . . . 2.85 107.776 -179.528 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 8' ' ' ARG . . . . . 0.592 ' CG ' HH11 ' B' ' 8' ' ' ARG . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.769 0 N-CA-C 107.349 -1.352 . . . . 3.04 107.349 . . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 9' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' A' ' 57' ' ' GLY . 34.8 t -71.94 160.0 5.47 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 120.75 -1.219 . . . . 0.67 108.422 179.611 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 0.4 ' N ' HG12 ' B' ' 9' ' ' VAL . . . -123.71 156.71 35.45 Favored 'General case' 0 N--CA 1.5 2.066 0 O-C-N 121.418 -0.801 . . . . 0.58 110.015 -179.26 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 11' ' ' SER . . . . . 0.44 ' O ' ' O ' ' A' ' 55' ' ' VAL . 3.2 t -149.56 144.03 25.97 Favored 'General case' 0 N--CA 1.492 1.641 0 N-CA-C 108.869 -0.789 . . . . 1.19 108.869 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 47.2 t -143.48 120.12 11.12 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 120.976 -1.078 . . . . 1.38 109.99 -179.666 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 0.582 HG22 ' N ' ' B' ' 14' ' ' PHE . 3.1 p -157.92 165.77 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 N-CA-C 108.722 -0.844 . . . . 0.42 108.722 179.542 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 14' ' ' PHE . . . . . 0.582 ' N ' HG22 ' B' ' 13' ' ' VAL . 4.9 p90 -177.99 -170.35 0.24 Allowed 'General case' 0 N--CA 1.49 1.563 0 C-N-CA 119.38 -0.928 . . . . 1.79 112.158 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 3.1 pt -149.87 -163.66 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.341 0 N-CA-C 108.273 -1.01 . . . . 1.25 108.273 179.831 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -161.09 146.55 14.22 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 120.724 -1.235 . . . . 1.61 109.911 179.769 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 13.4 mt . . . . . 0 N--CA 1.495 1.785 0 O-C-N 121.219 -0.926 . . . . 1.32 109.376 179.696 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.407 ' O ' ' CB ' ' A' ' 94' ' ' GLU . . . . . . . . 0 N--CA 1.49 2.24 0 N-CA-C 111.635 -0.586 . . . . 2.44 111.635 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.558 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 72.36 -52.34 1.45 Allowed Glycine 0 N--CA 1.493 2.487 0 O-C-N 121.458 -1.024 . . . . 1.81 111.127 178.296 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.749 ' HB2' ' OE1' ' A' ' 94' ' ' GLU . . . -49.45 -6.95 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.098 -1.236 . . . . 2.21 110.169 -179.308 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' HIS . . . . . 0.558 ' N ' ' O ' ' A' ' 17' ' ' GLY . 29.2 t-80 -94.97 -12.09 27.34 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.067 -1.021 . . . . 2.87 110.295 -179.801 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.424 ' NZ ' HG23 ' A' ' 21' ' ' VAL . 2.3 pptp? -132.6 11.64 4.44 Favored 'General case' 0 N--CA 1.504 2.235 0 O-C-N 121.031 -1.043 . . . . 2.02 110.457 -179.759 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.424 HG23 ' NZ ' ' A' ' 20' ' ' LYS . 53.2 t -94.29 113.19 28.38 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 120.976 -1.078 . . . . 2.07 109.257 179.491 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 20.3 tpt180 -113.08 121.33 44.24 Favored 'General case' 0 N--CA 1.496 1.846 0 N-CA-C 108.98 -0.748 . . . . 3.5 108.98 179.843 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -128.16 114.07 16.53 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 108.878 -0.786 . . . . 1.83 108.878 179.735 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -151.24 130.6 3.22 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 109.509 -1.436 . . . . 1.9 109.509 -179.616 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.29 171.08 43.42 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.739 -1.344 . . . . 1.85 109.739 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 13.2 p -78.51 -27.13 46.06 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.343 -1.092 . . . . 2.31 109.373 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.68 -12.55 70.57 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 109.11 -1.596 . . . . 1.64 109.11 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 12.1 mt -87.68 -15.53 36.9 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.437 -1.037 . . . . 1.83 108.852 179.679 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 42.2 mt-10 -87.66 -62.07 1.58 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.412 -0.805 . . . . 2.34 109.726 -179.793 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 72.5 mtt180 -148.14 178.48 8.51 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.114 -0.991 . . . . 3.77 110.058 -179.678 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -150.11 175.21 29.3 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 107.786 -2.125 . . . . 1.57 107.786 179.317 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 40.7 t -133.54 151.7 33.82 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.15 0 O-C-N 121.084 -1.245 . . . . 1.83 110.744 -179.57 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.457 ' HB2' ' HD3' ' A' ' 82' ' ' PRO . . . -43.56 111.01 0.23 Allowed 'General case' 0 N--CA 1.5 2.04 0 CA-C-O 121.57 0.7 . . . . 1.64 112.428 -178.952 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 55.87 52.8 46.37 Favored Glycine 0 N--CA 1.491 2.315 0 O-C-N 121.515 -0.741 . . . . 1.73 111.52 176.884 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 8.5 t -127.83 126.97 23.99 Favored Pre-proline 0 N--CA 1.497 1.911 0 O-C-N 121.502 -0.999 . . . . 2.19 108.373 178.994 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -57.77 117.8 4.57 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 N-CA-C 109.33 -1.065 . . . . 1.96 109.33 179.711 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -127.43 149.99 49.84 Favored 'General case' 0 N--CA 1.501 2.089 0 N-CA-C 108.873 -0.788 . . . . 1.69 108.873 -179.827 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -155.33 162.41 40.85 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.937 -1.102 . . . . 2.23 111.172 -179.448 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 0.58 ' CD1' ' N ' ' A' ' 39' ' ' PHE . 0.5 OUTLIER -137.98 -176.77 4.55 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 106.831 -1.544 . . . . 1.54 106.831 178.163 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 72.6 p -121.04 145.49 47.71 Favored 'General case' 0 N--CA 1.499 1.981 0 CA-C-O 121.5 0.667 . . . . 2.37 110.121 -179.222 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.444 ' O ' ' N ' ' A' ' 73' ' ' CYS . 48.5 mt -142.2 117.02 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 N-CA-C 108.515 -0.921 . . . . 1.65 108.515 179.32 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.434 ' CD1' ' C ' ' A' ' 42' ' ' TRP . 0.2 OUTLIER -113.74 129.62 56.55 Favored 'General case' 0 N--CA 1.497 1.878 0 N-CA-C 108.432 -0.951 . . . . 3.68 108.432 179.923 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.524 ' OG1' ' N ' ' A' ' 44' ' ' ARG . 9.2 p -144.73 -127.51 0.08 Allowed 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.343 -0.848 . . . . 2.89 109.16 -179.667 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' ARG . . . . . 0.524 ' N ' ' OG1' ' A' ' 43' ' ' THR . 1.6 ttt-85 56.89 79.85 0.17 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.363 -0.836 . . . . 4.63 110.059 179.646 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -156.27 -52.26 0.08 Allowed 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 108.543 -0.91 . . . . 2.89 108.543 179.146 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -60.78 -48.14 83.15 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.214 -0.929 . . . . 1.74 108.779 179.326 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 151.98 -174.48 30.99 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 109.514 -1.435 . . . . 1.6 109.514 179.809 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.33 161.44 0.94 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.252 -1.146 . . . . 1.4 109.047 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 176.17 -158.32 24.8 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.69 -1.364 . . . . 1.04 109.69 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -145.86 124.75 2.13 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 109.826 -1.31 . . . . 1.06 109.826 -179.806 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.468 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 10.4 tp -100.2 100.89 11.79 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.456 -1.026 . . . . 1.1 108.557 179.461 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 25.0 p -86.19 141.34 29.4 Favored 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 108.567 -0.901 . . . . 1.56 108.567 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.515 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 72.7 mt -130.44 114.25 27.96 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 O-C-N 121.235 -0.915 . . . . 0.65 109.552 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -105.36 107.94 19.2 Favored 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 108.777 -0.823 . . . . 0.69 108.777 179.677 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.412 HG23 ' CB ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -101.37 142.95 15.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 O-C-N 121.528 -0.733 . . . . 0.91 109.25 -179.857 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 8.7 tt0 -141.88 145.39 34.56 Favored 'General case' 0 N--CA 1.49 1.575 0 N-CA-C 107.685 -1.228 . . . . 1.8 107.685 178.755 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.43 ' O ' ' O ' ' B' ' 9' ' ' VAL . . . 164.58 -172.97 40.47 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.79 -1.324 . . . . 0.49 109.79 -179.296 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -67.71 -30.6 34.16 Favored 'Trans proline' 0 C--N 1.318 -1.06 0 C-N-CA 122.139 1.893 . . . . 0.66 112.09 -179.361 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' SER . . . . . 0.424 ' CB ' ' OH ' ' A' ' 85' ' ' TYR . 0.3 OUTLIER -128.55 179.7 5.53 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 121.162 -0.962 . . . . 1.55 110.226 -179.126 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 62.7 mmtt -92.0 114.53 27.09 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.607 -0.683 . . . . 2.53 109.241 -179.817 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.598 ' O ' HD12 ' A' ' 63' ' ' ILE . . . -66.15 103.74 1.03 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.023 -1.048 . . . . 0.82 109.231 179.701 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 30.3 mt-10 -65.19 72.17 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.141 -0.974 . . . . 2.3 109.635 -179.738 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.598 HD12 ' O ' ' A' ' 61' ' ' ALA . 3.4 mp -58.14 149.35 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.613 -0.68 . . . . 1.4 109.295 179.852 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.54 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -150.4 127.6 11.29 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.996 -1.065 . . . . 1.36 109.453 -179.859 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.458 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 50.3 p90 -87.01 130.85 34.28 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.179 -0.951 . . . . 1.47 109.488 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 . . . . . 0 N--CA 1.497 1.891 0 O-C-N 121.286 -0.884 . . . . 2.51 109.338 179.821 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 16.1 t . . . . . 0 N--CA 1.495 1.785 0 N-CA-C 109.011 -0.736 . . . . 2.2 109.011 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 73' ' ' CYS . . . . . 0.444 ' N ' ' O ' ' A' ' 41' ' ' ILE . 33.7 m -83.31 105.17 14.05 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.202 -0.937 . . . . 2.05 109.825 -179.515 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -85.28 116.25 4.29 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.168 -1.573 . . . . 1.39 109.168 179.594 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 49.8 t -107.09 99.64 9.0 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.072 0 O-C-N 121.58 -0.953 . . . . 1.57 109.597 -179.674 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.54 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.5 OUTLIER -89.71 131.39 35.71 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.396 -0.815 . . . . 1.85 109.258 179.775 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.426 ' O ' ' CG ' ' A' ' 77' ' ' TYR . 2.3 p90 -133.07 126.81 32.65 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.379 -0.826 . . . . 1.54 109.825 -179.837 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 3.0 t -107.74 103.8 16.05 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 O-C-N 121.674 -0.641 . . . . 1.9 109.876 -179.665 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.463 ' H ' HG22 ' A' ' 79' ' ' VAL . 2.4 m -80.23 167.66 2.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.296 -0.877 . . . . 1.27 108.72 179.423 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 41.7 tp60 -102.26 -46.33 4.85 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.213 -0.929 . . . . 2.48 110.732 -179.298 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.448 ' OE2' ' HB1' ' A' ' 33' ' ' ALA . 71.8 mm-40 -147.61 151.02 38.4 Favored Pre-proline 0 N--CA 1.506 2.37 0 O-C-N 120.754 -1.216 . . . . 1.92 112.161 -178.254 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.638 ' HG3' ' N ' ' A' ' 107' ' ' SER . 86.0 Cg_exo -36.5 168.12 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 123.389 2.726 . . . . 1.3 113.734 178.113 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 140.9 -176.11 21.75 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.678 -1.369 . . . . 1.02 109.678 179.374 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 84' ' ' ASP . . . . . 0.528 ' OD2' ' NE ' ' B' ' 8' ' ' ARG . 2.4 p-10 -99.8 86.55 3.32 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.512 -0.993 . . . . 2.13 108.349 179.419 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.498 ' O ' ' N ' ' A' ' 103' ' ' VAL . 2.7 m-85 -72.87 130.72 41.05 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 108.044 -1.095 . . . . 0.92 108.044 -179.789 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 86' ' ' GLU . . . . . 0.428 ' H ' ' HG2' ' A' ' 86' ' ' GLU . 0.0 OUTLIER -107.24 129.12 54.91 Favored 'General case' 0 N--CA 1.496 1.87 0 N-CA-C 108.474 -0.936 . . . . 1.53 108.474 -179.196 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.446 ' CG1' ' CZ ' ' A' ' 101' ' ' PHE . 5.7 p -126.18 141.99 44.14 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 N-CA-C 109.17 -0.678 . . . . 1.0 109.17 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 13.5 p -138.65 107.15 5.84 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.264 -0.898 . . . . 1.59 109.795 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.8 pt -112.57 136.46 48.75 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.92 0 CA-C-O 121.414 0.626 . . . . 1.29 110.097 -179.738 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' LYS . . . . . 0.457 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.2 OUTLIER -143.05 122.41 13.08 Favored 'General case' 0 N--CA 1.486 1.333 0 O-C-N 121.383 -0.823 . . . . 1.58 108.785 179.447 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 55.3 t80 -79.67 99.74 7.53 Favored 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 107.716 -1.216 . . . . 1.34 107.716 178.458 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 92' ' ' ASN . . . . . 0.416 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 13.9 t-20 69.56 39.9 1.49 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.492 -0.755 . . . . 2.32 109.404 -178.885 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.422 ' H ' ' HG3' ' A' ' 90' ' ' LYS . 0.9 OUTLIER 76.7 13.27 2.32 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.665 -0.647 . . . . 1.92 111.585 179.442 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 94' ' ' GLU . . . . . 0.749 ' OE1' ' HB2' ' A' ' 18' ' ' ALA . 0.6 OUTLIER -98.27 94.9 7.03 Favored 'General case' 0 N--CA 1.499 1.978 0 N-CA-C 106.919 -1.511 . . . . 2.25 106.919 177.649 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -71.12 106.99 3.94 Favored 'General case' 0 N--CA 1.488 1.431 0 CA-C-O 121.586 0.707 . . . . 2.88 109.839 -178.16 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 96' ' ' ILE . . . . . 0.574 ' O ' ' N ' ' A' ' 98' ' ' ASP . 10.6 pt -52.8 150.4 9.86 Favored Pre-proline 0 C--N 1.299 -1.6 0 N-CA-C 108.579 -0.897 . . . . 2.35 108.579 179.634 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.413 ' O ' ' CG ' ' A' ' 98' ' ' ASP . 1.0 OUTLIER -57.48 75.56 0.04 OUTLIER 'Trans proline' 0 C--O 1.214 -0.7 0 C-N-CA 121.146 1.231 . . . . 2.48 109.195 179.362 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.574 ' N ' ' O ' ' A' ' 96' ' ' ILE . 1.9 m-20 -177.62 -59.82 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.485 0 N-CA-C 108.278 -1.008 . . . . 2.65 108.278 -178.995 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 9.5 m -57.44 138.79 81.13 Favored Pre-proline 0 C--N 1.299 -1.627 0 O-C-N 121.414 -0.804 . . . . 2.0 110.031 -178.216 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_endo -89.78 114.28 2.41 Favored 'Cis proline' 0 N--CA 1.493 1.458 0 N-CA-C 109.707 -0.92 . . . . 1.79 109.707 -2.724 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 101' ' ' PHE . . . . . 0.446 ' CZ ' ' CG1' ' A' ' 87' ' ' VAL . 15.3 p90 -104.9 170.86 7.63 Favored 'General case' 0 N--CA 1.515 2.79 0 O-C-N 120.425 -1.422 . . . . 2.19 110.01 178.87 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.5 p -95.49 153.79 3.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.602 -0.686 . . . . 1.44 110.095 -179.467 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.498 ' N ' ' O ' ' A' ' 85' ' ' TYR . 69.2 t -128.66 86.37 57.78 Favored Pre-proline 0 N--CA 1.498 1.948 0 N-CA-C 107.868 -1.16 . . . . 1.19 107.868 179.316 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -60.99 113.85 1.91 Allowed 'Trans proline' 0 C--N 1.323 -0.792 0 C-N-CA 121.497 1.465 . . . . 1.49 112.256 -177.56 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 55.3 t -96.1 138.12 22.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 N-CA-C 106.784 -1.561 . . . . 1.35 106.784 177.724 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.549 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -119.0 126.56 52.02 Favored 'General case' 0 N--CA 1.511 2.582 0 N-CA-C 113.161 0.801 . . . . 1.67 113.161 -175.921 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 107' ' ' SER . . . . . 0.638 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 23.8 t -94.84 97.89 10.35 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 120.3 -1.5 . . . . 2.04 107.586 178.09 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 13.7 mt 66.35 -21.04 0.1 Allowed 'General case' 0 C--N 1.289 -2.058 0 N-CA-C 109.22 -0.659 . . . . 3.2 109.22 -178.767 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.596 ' H ' ' C ' ' A' ' 107' ' ' SER . 9.6 t -70.93 -29.17 65.12 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.084 -1.01 . . . . 2.09 108.908 179.027 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 110' ' ' ASP . . . . . 0.549 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 9.1 m-20 . . . . . 0 N--CA 1.491 1.583 0 N-CA-C 107.874 -1.158 . . . . 2.85 107.874 179.83 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 8' ' ' ARG . . . . . 0.576 ' CG ' HH11 ' B' ' 8' ' ' ARG . 2.5 mtt-85 . . . . . 0 N--CA 1.489 1.511 0 N-CA-C 108.286 -1.005 . . . . 3.04 108.286 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 9' ' ' VAL . . . . . 0.43 ' O ' ' O ' ' A' ' 57' ' ' GLY . 24.6 t -50.81 158.72 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 N-CA-C 107.785 -1.191 . . . . 0.67 107.785 179.137 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -128.98 149.14 50.94 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.227 -0.921 . . . . 0.58 110.563 -178.585 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 11' ' ' SER . . . . . 0.412 ' CB ' HG23 ' A' ' 55' ' ' VAL . 4.1 t -139.58 146.35 39.73 Favored 'General case' 0 N--CA 1.495 1.789 0 N-CA-C 108.763 -0.829 . . . . 1.19 108.763 179.498 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 42.9 m -147.41 121.91 9.74 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.07 -1.019 . . . . 1.38 109.927 -179.589 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 0.645 HG22 ' N ' ' B' ' 14' ' ' PHE . 7.7 p -169.85 170.52 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 N-CA-C 108.883 -0.784 . . . . 0.42 108.883 179.759 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 14' ' ' PHE . . . . . 0.645 ' N ' HG22 ' B' ' 13' ' ' VAL . 9.1 p90 -176.6 -163.47 0.1 Allowed 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 119.226 -0.99 . . . . 1.79 112.084 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.3 pt -147.49 160.95 8.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 N-CA-C 108.518 -0.919 . . . . 1.25 108.518 179.82 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 17.9 m -131.18 141.73 50.11 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.273 -0.892 . . . . 1.61 109.892 -179.734 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.0 mt . . . . . 0 N--CA 1.498 1.926 0 O-C-N 121.418 -0.802 . . . . 1.32 109.36 179.712 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.988 0 N-CA-C 110.003 -1.239 . . . . 2.44 110.003 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.514 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 95.02 -57.99 1.76 Allowed Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.761 -1.336 . . . . 1.81 109.761 179.707 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.693 ' HB2' ' OE1' ' A' ' 94' ' ' GLU . . . -47.86 -12.32 0.03 OUTLIER 'General case' 0 C--N 1.297 -1.68 0 O-C-N 121.64 -0.917 . . . . 2.21 110.067 -179.121 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' HIS . . . . . 0.514 ' N ' ' O ' ' A' ' 17' ' ' GLY . 29.1 t-80 -98.46 -7.11 29.1 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.245 -0.909 . . . . 2.87 110.684 -178.745 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.498 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.4 OUTLIER -145.98 5.58 1.0 Allowed 'General case' 0 N--CA 1.496 1.851 0 O-C-N 120.854 -1.153 . . . . 2.02 110.252 -179.491 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.577 ' O ' HG13 ' A' ' 21' ' ' VAL . 7.4 p -77.35 115.56 19.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.022 -1.049 . . . . 2.07 108.51 179.116 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 12.7 tpp180 -109.92 139.27 45.2 Favored 'General case' 0 N--CA 1.49 1.574 0 CA-C-O 121.509 0.671 . . . . 3.5 109.566 -178.745 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -148.18 113.27 5.51 Favored 'General case' 0 N--CA 1.491 1.599 0 N-CA-C 108.609 -0.885 . . . . 1.83 108.609 179.424 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -147.85 132.1 4.11 Favored Glycine 0 N--CA 1.495 2.614 0 N-CA-C 109.523 -1.431 . . . . 1.9 109.523 -179.624 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.27 174.13 46.08 Favored Glycine 0 N--CA 1.488 2.115 0 C-N-CA 119.598 -1.287 . . . . 1.85 110.013 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 8.5 p -79.85 -22.04 43.42 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.338 -1.095 . . . . 2.31 108.985 179.479 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -68.67 -16.47 69.94 Favored Glycine 0 N--CA 1.487 2.034 0 N-CA-C 108.62 -1.792 . . . . 1.64 108.62 179.637 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.53 HD21 ' CG ' ' A' ' 39' ' ' PHE . 7.0 mt -93.04 30.28 1.66 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.625 -0.927 . . . . 1.83 108.799 179.783 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 13.5 mt-10 -141.91 -43.44 0.35 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.396 -0.815 . . . . 2.34 109.62 -179.375 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 11.8 ptm180 -175.65 172.11 2.63 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.007 -1.058 . . . . 3.77 109.991 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -150.77 176.51 29.3 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 108.335 -1.906 . . . . 1.57 108.335 179.665 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 39.2 t -134.23 151.54 32.41 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.031 0 O-C-N 121.186 -1.185 . . . . 1.83 110.529 -179.733 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.566 ' HB2' ' HD3' ' A' ' 82' ' ' PRO . . . -44.91 115.47 0.89 Allowed 'General case' 0 N--CA 1.497 1.88 0 CA-C-O 121.869 0.842 . . . . 1.64 112.477 -179.195 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 54.03 50.81 53.7 Favored Glycine 0 N--CA 1.488 2.143 0 N-CA-C 111.245 -0.742 . . . . 1.73 111.245 177.264 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 5.0 t -127.03 127.11 24.41 Favored Pre-proline 0 N--CA 1.496 1.871 0 N-CA-C 108.232 -1.025 . . . . 2.19 108.232 179.14 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -55.51 121.17 9.47 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 N-CA-C 109.918 -0.839 . . . . 1.96 109.918 -179.845 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -128.78 145.42 51.19 Favored 'General case' 0 N--CA 1.497 1.922 0 N-CA-C 108.488 -0.93 . . . . 1.69 108.488 179.736 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -152.16 164.05 38.11 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.995 -1.066 . . . . 2.23 110.765 -179.512 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 0.549 ' CD1' ' N ' ' A' ' 39' ' ' PHE . 0.7 OUTLIER -139.71 178.43 7.24 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 107.007 -1.479 . . . . 1.54 107.007 177.907 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 58.7 m -121.32 141.27 51.08 Favored 'General case' 0 N--CA 1.496 1.857 0 CA-C-O 121.573 0.702 . . . . 2.37 110.382 -178.83 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.508 ' O ' ' N ' ' A' ' 73' ' ' CYS . 68.3 mt -138.14 124.08 25.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 N-CA-C 108.307 -0.997 . . . . 1.65 108.307 179.106 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.556 ' HE1' ' CG ' ' A' ' 44' ' ' ARG . 3.1 t90 -128.08 125.46 39.31 Favored 'General case' 0 N--CA 1.496 1.858 0 N-CA-C 108.615 -0.884 . . . . 3.68 108.615 -179.549 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.498 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -151.21 118.23 5.89 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.321 -0.862 . . . . 2.89 109.269 -179.672 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 44' ' ' ARG . . . . . 0.556 ' CG ' ' HE1' ' A' ' 42' ' ' TRP . 10.6 ptm180 -171.09 72.19 0.05 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.172 -0.955 . . . . 4.63 109.72 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 21.3 tt0 -154.32 -45.19 0.09 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.306 -0.871 . . . . 2.89 109.083 179.579 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.99 -55.66 13.5 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.117 -0.989 . . . . 1.74 109.196 179.686 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 154.96 156.36 7.71 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.608 -1.397 . . . . 1.6 109.608 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.49 156.92 2.29 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.232 -1.158 . . . . 1.4 109.511 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -170.48 -111.34 0.25 Allowed Glycine 0 N--CA 1.488 2.16 0 N-CA-C 108.965 -1.654 . . . . 1.04 108.965 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.544 ' O ' ' N ' ' A' ' 92' ' ' ASN . . . -157.7 161.87 31.68 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.463 -1.455 . . . . 1.06 109.463 179.684 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.458 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 10.2 tp -140.55 97.0 3.12 Favored 'General case' 0 N--CA 1.493 1.703 0 N-CA-C 107.839 -1.171 . . . . 1.1 107.839 179.513 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 13.7 m -87.69 142.81 27.54 Favored 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 108.846 -0.798 . . . . 1.56 108.846 -179.586 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.54 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 6.7 mt -136.71 100.42 2.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.366 -0.834 . . . . 0.65 108.859 179.721 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -98.8 106.42 18.69 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.258 -0.902 . . . . 0.69 108.907 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -97.87 146.14 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 O-C-N 121.434 -0.791 . . . . 0.91 109.33 -179.814 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 35.4 tp10 -141.13 138.04 33.18 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 107.385 -1.339 . . . . 1.8 107.385 178.531 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.532 ' O ' ' N ' ' B' ' 9' ' ' VAL . . . 173.37 -173.0 45.58 Favored Glycine 0 N--CA 1.493 2.44 0 C-N-CA 119.271 -1.442 . . . . 0.49 110.033 -178.72 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -62.76 -35.1 70.54 Favored 'Trans proline' 0 C--N 1.318 -1.038 0 C-N-CA 122.127 1.885 . . . . 0.66 111.568 -179.596 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' SER . . . . . 0.421 ' O ' ' OH ' ' A' ' 85' ' ' TYR . 10.7 m -139.57 162.34 35.31 Favored 'General case' 0 N--CA 1.5 2.025 0 O-C-N 121.072 -1.017 . . . . 1.55 110.057 -179.036 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 23.0 mttp -85.29 95.57 9.24 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.435 -0.791 . . . . 2.53 109.495 -179.844 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -50.59 135.32 23.15 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.336 -0.853 . . . . 0.82 109.315 179.83 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.47 ' CD ' ' N ' ' A' ' 62' ' ' GLU . 15.9 mp0 -71.09 85.38 0.73 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.247 -0.908 . . . . 2.3 109.582 -179.873 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 19.2 tt -58.88 150.21 5.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 N-CA-C 108.963 -0.755 . . . . 1.4 108.963 179.611 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.547 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -150.61 114.51 5.02 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 120.691 -1.255 . . . . 1.36 109.744 -179.715 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 17.7 p90 -90.33 125.08 35.41 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.284 -0.885 . . . . 1.47 109.388 179.612 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 . . . . . 0 N--CA 1.496 1.841 0 O-C-N 121.256 -0.902 . . . . 2.51 109.545 -179.893 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 10.6 t . . . . . 0 N--CA 1.494 1.765 0 N-CA-C 108.88 -0.785 . . . . 2.2 108.88 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 73' ' ' CYS . . . . . 0.508 ' N ' ' O ' ' A' ' 41' ' ' ILE . 49.8 t -80.05 104.81 10.87 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.222 -0.924 . . . . 2.05 109.845 -179.451 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -91.82 116.33 4.97 Favored Glycine 0 N--CA 1.493 2.5 0 N-CA-C 109.123 -1.591 . . . . 1.39 109.123 179.65 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 96.4 t -105.82 102.16 13.46 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.135 0 O-C-N 121.486 -1.008 . . . . 1.57 109.684 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.547 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.1 OUTLIER -88.42 130.08 35.26 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.376 -0.828 . . . . 1.85 108.936 179.649 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.426 ' O ' ' CG ' ' A' ' 77' ' ' TYR . 2.8 p90 -132.42 125.48 30.88 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.479 -0.763 . . . . 1.54 109.053 -179.824 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 5.9 t -99.86 103.72 15.14 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.392 -0.817 . . . . 1.9 109.37 -179.478 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 25.9 m -69.77 160.32 5.03 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 O-C-N 121.22 -0.925 . . . . 1.27 109.31 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 24.0 tp60 -100.72 -48.62 4.44 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.235 -0.915 . . . . 2.48 110.586 -179.416 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -155.25 152.77 25.66 Favored Pre-proline 0 N--CA 1.501 2.106 0 O-C-N 120.806 -1.184 . . . . 1.92 110.995 -178.915 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.617 ' HG3' ' N ' ' A' ' 107' ' ' SER . 75.1 Cg_exo -38.31 163.2 0.02 OUTLIER 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 123.176 2.584 . . . . 1.3 113.659 179.36 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 147.13 -162.36 28.59 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.156 -1.578 . . . . 1.02 109.156 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 33.5 m-20 -111.39 89.78 3.15 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.653 -0.91 . . . . 2.13 108.937 179.761 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.45 ' O ' ' N ' ' A' ' 103' ' ' VAL . 3.3 m-85 -77.64 128.94 34.93 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 108.004 -1.11 . . . . 0.92 108.004 179.687 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -112.63 129.74 56.28 Favored 'General case' 0 N--CA 1.5 2.042 0 N-CA-C 108.406 -0.961 . . . . 1.53 108.406 -179.088 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 8.6 p -124.84 137.63 56.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 CA-C-O 121.486 0.66 . . . . 1.0 110.002 -179.522 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 29.5 t -126.12 103.25 7.61 Favored 'General case' 0 N--CA 1.497 1.907 0 N-CA-C 109.405 -0.591 . . . . 1.59 109.405 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.413 ' H ' ' CB ' ' A' ' 99' ' ' SER . 0.8 OUTLIER -111.18 132.78 58.76 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.023 0 O-C-N 121.519 -0.738 . . . . 1.29 110.226 -179.39 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 90' ' ' LYS . . . . . 0.446 ' HG3' ' H ' ' A' ' 93' ' ' ASP . 0.4 OUTLIER -140.91 127.06 19.56 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.369 -0.832 . . . . 1.58 109.909 179.658 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.443 ' H ' ' HG3' ' A' ' 94' ' ' GLU . 54.5 t80 -82.3 94.39 7.33 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.12 -0.987 . . . . 1.34 108.457 178.855 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 92' ' ' ASN . . . . . 0.544 ' N ' ' O ' ' A' ' 50' ' ' GLY . 6.7 t30 69.22 37.08 2.19 Favored 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 108.074 -1.084 . . . . 2.32 108.074 -179.017 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.463 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 2.6 m-20 83.4 14.7 0.34 Allowed 'General case' 0 N--CA 1.499 1.981 0 CA-C-N 116.485 -0.325 . . . . 1.92 110.905 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 94' ' ' GLU . . . . . 0.693 ' OE1' ' HB2' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -91.17 90.83 7.97 Favored 'General case' 0 N--CA 1.496 1.827 0 N-CA-C 106.862 -1.533 . . . . 2.25 106.862 178.119 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 95' ' ' HIS . . . . . 0.517 ' CD2' ' O ' ' A' ' 95' ' ' HIS . 41.9 p-80 -68.15 88.8 0.3 Allowed 'General case' 0 C--N 1.299 -1.615 0 O-C-N 119.94 -1.725 . . . . 2.88 110.359 -177.816 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 2.3 tt -48.3 137.13 11.73 Favored Pre-proline 0 N--CA 1.496 1.846 0 N-CA-C 107.635 -1.246 . . . . 2.35 107.635 178.675 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -40.51 -39.55 2.89 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 121.307 1.338 . . . . 2.48 111.747 -178.42 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 18.8 m-20 -49.18 -66.49 0.39 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 120.689 -1.257 . . . . 2.65 109.237 179.356 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.413 ' CB ' ' H ' ' A' ' 89' ' ' ILE . 0.1 OUTLIER -69.31 147.94 97.26 Favored Pre-proline 0 C--N 1.293 -1.875 0 O-C-N 121.151 -0.968 . . . . 2.0 110.067 -178.917 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -84.44 112.02 2.36 Favored 'Cis proline' 0 N--CA 1.491 1.343 0 N-CA-C 109.538 -0.986 . . . . 1.79 109.538 -2.238 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 43.1 p90 -116.21 166.86 11.55 Favored 'General case' 0 N--CA 1.522 3.162 0 O-C-N 120.509 -1.37 . . . . 2.19 110.445 178.964 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.2 p -95.49 148.19 5.35 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.903 0 CA-C-O 121.752 0.787 . . . . 1.44 111.549 -177.703 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.45 ' N ' ' O ' ' A' ' 85' ' ' TYR . 79.4 t -121.8 86.38 45.59 Favored Pre-proline 0 N--CA 1.498 1.926 0 N-CA-C 108.279 -1.008 . . . . 1.19 108.279 179.238 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_exo -62.81 114.14 2.28 Favored 'Trans proline' 0 C--N 1.319 -1.021 0 C-N-CA 121.351 1.367 . . . . 1.49 112.09 -178.011 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 55.2 t -95.27 144.34 10.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 N-CA-C 106.938 -1.504 . . . . 1.35 106.938 177.865 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.691 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -134.76 136.24 42.47 Favored 'General case' 0 N--CA 1.51 2.536 0 CA-C-O 122.079 0.942 . . . . 1.67 111.748 -177.457 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 107' ' ' SER . . . . . 0.617 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 80.6 p -92.17 76.41 5.35 Favored 'General case' 0 N--CA 1.492 1.674 0 N-CA-C 107.472 -1.307 . . . . 2.04 107.472 179.278 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 23.6 mt 61.72 6.36 1.57 Allowed 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 107.103 -1.443 . . . . 3.2 107.103 -177.735 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.497 ' H ' ' C ' ' A' ' 107' ' ' SER . 14.0 t -92.27 -20.83 20.73 Favored 'General case' 0 N--CA 1.486 1.338 0 N-CA-C 109.205 -0.665 . . . . 2.09 109.205 179.588 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 110' ' ' ASP . . . . . 0.691 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 2.6 p30 . . . . . 0 N--CA 1.498 1.939 0 N-CA-C 108.417 -0.957 . . . . 2.85 108.417 -179.052 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 8' ' ' ARG . . . . . 0.412 ' NH1' ' HG3' ' B' ' 8' ' ' ARG . 23.4 mtm-85 . . . . . 0 N--CA 1.489 1.503 0 N-CA-C 108.287 -1.005 . . . . 3.04 108.287 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 9' ' ' VAL . . . . . 0.532 ' N ' ' O ' ' A' ' 57' ' ' GLY . 0.4 OUTLIER -122.48 170.85 12.22 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.069 0 N-CA-C 108.139 -1.06 . . . . 0.67 108.139 178.989 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 0.436 ' N ' HG13 ' B' ' 9' ' ' VAL . . . -114.81 136.24 53.31 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.717 -0.615 . . . . 0.58 110.07 -179.41 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 9.4 m -149.28 82.88 1.43 Allowed 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.376 -0.828 . . . . 1.19 109.44 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 12.8 t -101.04 116.72 33.52 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.363 -0.836 . . . . 1.38 109.434 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 0.579 HG22 ' N ' ' B' ' 14' ' ' PHE . 3.2 p -156.66 164.45 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.265 -0.897 . . . . 0.42 109.177 179.823 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 14' ' ' PHE . . . . . 0.579 ' N ' HG22 ' B' ' 13' ' ' VAL . 6.5 p90 -178.99 -164.7 0.07 Allowed 'General case' 0 N--CA 1.49 1.555 0 CA-C-O 122.1 0.953 . . . . 1.79 111.924 179.575 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.875 ' N ' HD13 ' B' ' 15' ' ' ILE . 0.1 OUTLIER -145.72 155.49 13.0 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.094 0 N-CA-C 108.635 -0.876 . . . . 1.25 108.635 179.811 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 16' ' ' THR . . . . . 0.478 HG22 ' N ' ' B' ' 17' ' ' LEU . 97.0 m -109.11 158.9 17.33 Favored 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.214 -0.929 . . . . 1.61 109.781 -179.799 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.478 ' N ' HG22 ' B' ' 16' ' ' THR . 34.3 mt . . . . . 0 N--CA 1.499 2.019 0 O-C-N 121.475 -0.766 . . . . 1.32 109.167 179.821 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.214 0 N-CA-C 110.735 -0.946 . . . . 2.44 110.735 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.559 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -67.71 -6.18 41.9 Favored Glycine 0 N--CA 1.491 2.338 0 O-C-N 121.42 -1.047 . . . . 1.81 111.063 -178.855 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.426 ' HB2' ' HB2' ' A' ' 94' ' ' GLU . . . -47.94 -11.99 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.465 -1.609 . . . . 2.21 109.452 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' HIS . . . . . 0.559 ' N ' ' O ' ' A' ' 17' ' ' GLY . 39.7 t-80 -96.92 -41.73 8.27 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.203 -0.935 . . . . 2.87 109.729 179.577 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.77 -24.43 41.52 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 120.92 -1.112 . . . . 2.02 109.95 -179.64 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.533 ' O ' HG13 ' A' ' 21' ' ' VAL . 4.1 p -68.07 115.27 5.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 120.924 -1.11 . . . . 2.07 108.927 179.87 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 12.0 tpp180 -98.07 136.05 38.88 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.625 -0.672 . . . . 3.5 109.445 -179.155 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -147.55 113.42 5.76 Favored 'General case' 0 N--CA 1.492 1.639 0 N-CA-C 108.69 -0.855 . . . . 1.83 108.69 179.486 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -162.62 136.5 4.36 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.584 -1.406 . . . . 1.9 109.584 -179.579 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.1 173.7 46.16 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.667 -1.373 . . . . 1.85 109.667 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 19.1 m -77.19 -18.43 57.77 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.352 -1.087 . . . . 2.31 109.604 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -73.34 -20.26 79.85 Favored Glycine 0 N--CA 1.487 2.05 0 N-CA-C 109.304 -1.518 . . . . 1.64 109.304 -179.884 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.572 HD21 ' CD2' ' A' ' 39' ' ' PHE . 55.7 mt -88.8 -13.97 38.14 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.433 -1.039 . . . . 1.83 109.341 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 56.9 mt-10 -84.06 -62.74 1.49 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.292 -0.88 . . . . 2.34 110.053 -179.519 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 79.3 mtt180 -149.0 165.2 32.34 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.014 -1.054 . . . . 3.77 110.342 -179.589 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -142.5 169.6 25.43 Favored Glycine 0 N--CA 1.495 2.591 0 N-CA-C 107.708 -2.157 . . . . 1.57 107.708 179.019 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 40.9 t -134.04 150.57 31.4 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.202 0 O-C-N 121.051 -1.264 . . . . 1.83 110.971 -179.326 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -37.5 113.1 0.24 Allowed 'General case' 0 N--CA 1.501 2.08 0 CA-C-O 121.809 0.814 . . . . 1.64 112.242 -179.533 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 52.29 50.54 46.36 Favored Glycine 0 N--CA 1.488 2.124 0 N-CA-C 111.244 -0.743 . . . . 1.73 111.244 177.162 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 24.1 t -126.6 103.3 25.05 Favored Pre-proline 0 N--CA 1.494 1.757 0 N-CA-C 108.061 -1.088 . . . . 2.19 108.061 178.844 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -55.69 139.83 83.66 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 120.749 0.966 . . . . 1.96 110.574 -178.713 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.479 ' HB3' ' CE1' ' A' ' 77' ' ' TYR . . . -146.97 175.04 10.97 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.449 -0.782 . . . . 1.69 109.458 -179.923 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -154.52 165.37 36.67 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.958 -1.089 . . . . 2.23 111.297 -179.378 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 0.572 ' CD2' HD21 ' A' ' 28' ' ' LEU . 0.7 OUTLIER -143.43 -174.25 4.17 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 107.066 -1.457 . . . . 1.54 107.066 177.464 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 44.7 m -120.63 151.58 39.28 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 121.238 -0.914 . . . . 2.37 111.512 -177.937 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 85.5 mt -141.97 91.68 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 N-CA-C 108.332 -0.988 . . . . 1.65 108.332 178.531 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.414 ' CD1' ' N ' ' A' ' 43' ' ' THR . 9.6 t90 -96.02 141.03 29.91 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.165 -0.959 . . . . 3.68 108.69 179.887 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.414 ' N ' ' CD1' ' A' ' 42' ' ' TRP . 0.0 OUTLIER -161.83 130.26 4.26 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.247 -0.908 . . . . 2.89 109.748 -179.577 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 44' ' ' ARG . . . . . . . . . . . . . 66.6 ttt180 -172.02 77.33 0.05 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.324 -0.86 . . . . 4.63 109.728 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 6.8 tp10 -165.18 -55.26 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.099 -1.001 . . . . 2.89 109.735 179.631 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -58.33 -58.66 7.49 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.125 -0.984 . . . . 1.74 109.018 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 142.27 -160.53 27.24 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.231 -1.548 . . . . 1.6 109.231 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -64.28 163.79 12.28 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.288 -1.125 . . . . 1.4 109.38 179.717 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 174.29 178.79 44.46 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.724 -1.351 . . . . 1.04 109.724 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -117.12 125.47 6.54 Favored Glycine 0 N--CA 1.499 2.856 0 N-CA-C 109.682 -1.367 . . . . 1.06 109.682 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.458 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 11.8 tp -99.53 101.17 12.31 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.283 -1.128 . . . . 1.1 108.642 179.63 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 19.1 m -88.79 140.51 29.37 Favored 'General case' 0 N--CA 1.493 1.694 0 N-CA-C 108.696 -0.854 . . . . 1.56 108.696 179.854 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.514 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 90.8 mt -132.28 108.03 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 O-C-N 121.288 -0.883 . . . . 0.65 109.347 -179.819 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -98.63 106.35 18.61 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.304 -0.872 . . . . 0.69 108.928 179.706 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.429 HG23 ' OG ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -99.34 141.94 15.89 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.53 -0.731 . . . . 0.91 109.408 -179.826 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 10.1 tt0 -141.97 143.92 33.45 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.279 -1.008 . . . . 1.8 108.279 178.793 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 165.55 -174.12 41.29 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.614 -1.394 . . . . 0.49 109.614 -179.289 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -58.18 -26.34 75.76 Favored 'Trans proline' 0 C--N 1.317 -1.122 0 C-N-CA 121.998 1.799 . . . . 0.66 111.971 -179.513 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 2.1 m -143.61 170.62 15.49 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.063 -1.023 . . . . 1.55 110.291 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 29.1 mtpt -90.31 100.28 13.14 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.387 -0.82 . . . . 2.53 109.373 -179.878 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -63.38 142.82 58.25 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.182 -0.949 . . . . 0.82 109.603 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 24.9 tt0 -80.66 172.0 14.31 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.283 -0.886 . . . . 2.3 109.281 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 14.0 mt -149.65 141.31 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.906 0 N-CA-C 108.006 -1.109 . . . . 1.4 108.006 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -150.67 112.47 4.51 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 120.449 -1.407 . . . . 1.36 110.251 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.519 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 51.3 p90 -85.92 123.51 31.35 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.562 -0.711 . . . . 1.47 110.205 179.795 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 42.8 tt0 . . . . . 0 N--CA 1.494 1.763 0 O-C-N 121.488 -0.757 . . . . 2.51 109.056 179.555 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 14.0 m . . . . . 0 N--CA 1.495 1.775 0 N-CA-C 109.271 -0.641 . . . . 2.2 109.271 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 11.3 t -82.48 120.29 25.3 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.217 -0.927 . . . . 2.05 109.463 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -99.51 117.22 5.8 Favored Glycine 0 N--CA 1.496 2.694 0 N-CA-C 109.657 -1.377 . . . . 1.39 109.657 -179.832 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -105.32 105.11 18.04 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.075 0 O-C-N 121.54 -0.977 . . . . 1.57 109.647 179.85 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 3.9 t -84.14 124.8 31.53 Favored 'General case' 0 N--CA 1.485 1.31 0 N-CA-C 108.148 -1.056 . . . . 1.85 108.148 178.973 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.479 ' CE1' ' HB3' ' A' ' 37' ' ' ALA . 1.9 p90 -123.0 171.84 8.95 Favored 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 108.57 -0.9 . . . . 1.54 108.57 -179.078 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 41.4 t -141.79 141.67 29.28 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.929 0 O-C-N 121.169 -0.957 . . . . 1.9 109.804 -179.581 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 30.7 m -109.53 150.69 12.07 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.095 0 O-C-N 121.439 -0.788 . . . . 1.27 109.254 179.646 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 6.6 tp-100 -96.7 -45.27 6.75 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.219 -0.925 . . . . 2.48 110.305 -179.717 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -159.28 152.33 18.39 Favored Pre-proline 0 N--CA 1.502 2.161 0 O-C-N 120.768 -1.208 . . . . 1.92 110.857 -179.26 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.686 ' HG3' ' N ' ' A' ' 107' ' ' SER . 85.5 Cg_exo -37.54 158.55 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 123.248 2.632 . . . . 1.3 113.369 179.032 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 147.92 166.99 13.08 Favored Glycine 0 N--CA 1.488 2.109 0 N-CA-C 109.477 -1.449 . . . . 1.02 109.477 179.823 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 84' ' ' ASP . . . . . 0.887 ' H ' HH12 ' B' ' 8' ' ' ARG . 66.9 m-20 -87.65 84.55 7.08 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 107.666 -1.235 . . . . 2.13 107.666 179.117 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -69.93 134.16 48.09 Favored 'General case' 0 C--N 1.297 -1.709 0 N-CA-C 107.966 -1.124 . . . . 0.92 107.966 -179.526 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 86' ' ' GLU . . . . . 0.419 ' OE1' ' O ' ' A' ' 84' ' ' ASP . 0.0 OUTLIER -112.27 127.63 56.03 Favored 'General case' 0 N--CA 1.501 2.105 0 N-CA-C 108.667 -0.864 . . . . 1.53 108.667 -179.413 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 9.6 p -123.88 141.06 45.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.712 -0.618 . . . . 1.0 109.794 -179.633 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 3.8 m -130.29 97.82 4.53 Favored 'General case' 0 N--CA 1.498 1.952 0 CA-C-O 121.539 0.685 . . . . 1.59 109.38 179.781 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.413 ' H ' ' HB3' ' A' ' 99' ' ' SER . 1.6 pt -104.88 133.32 49.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 CA-C-O 121.471 0.653 . . . . 1.29 109.846 -179.741 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 90' ' ' LYS . . . . . 0.458 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -144.42 127.39 16.45 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 108.027 -1.101 . . . . 1.58 108.027 179.946 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.421 ' O ' ' CB ' ' A' ' 92' ' ' ASN . 76.5 t80 -85.47 102.22 13.29 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.63 -1.294 . . . . 1.34 108.462 179.16 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 92' ' ' ASN . . . . . 0.431 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 13.0 t30 72.38 33.87 1.41 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.068 -1.02 . . . . 2.32 108.748 -178.679 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.431 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 0.8 OUTLIER 80.21 14.04 0.87 Allowed 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.891 -0.505 . . . . 1.92 111.698 179.509 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 94' ' ' GLU . . . . . 0.462 ' CG ' ' O ' ' A' ' 94' ' ' GLU . 5.0 pt-20 -99.84 94.44 6.32 Favored 'General case' 0 N--CA 1.495 1.806 0 N-CA-C 107.029 -1.471 . . . . 2.25 107.029 177.573 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 19.5 p-80 -74.7 112.41 10.87 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-O 121.542 0.687 . . . . 2.88 110.281 -178.071 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 96' ' ' ILE . . . . . 0.796 ' H ' HD13 ' A' ' 96' ' ' ILE . 0.0 OUTLIER -60.49 155.76 46.83 Favored Pre-proline 0 N--CA 1.497 1.918 0 N-CA-C 107.257 -1.386 . . . . 2.35 107.257 178.994 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -49.47 -25.78 11.12 Favored 'Trans proline' 0 C--N 1.321 -0.879 0 N-CA-C 108.968 -1.204 . . . . 2.48 108.968 179.847 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.471 ' N ' ' OD1' ' A' ' 98' ' ' ASP . 0.9 OUTLIER -59.52 -64.69 0.85 Allowed 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 108.873 -0.788 . . . . 2.65 108.873 178.852 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.413 ' HB3' ' H ' ' A' ' 89' ' ' ILE . 2.4 p -66.83 141.01 96.52 Favored Pre-proline 0 C--N 1.297 -1.7 0 O-C-N 121.308 -0.87 . . . . 2.0 110.04 -178.42 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -85.91 116.99 4.11 Favored 'Cis proline' 0 N--CA 1.492 1.405 0 N-CA-C 109.563 -0.976 . . . . 1.79 109.563 -2.389 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 53.3 p90 -117.03 163.62 15.96 Favored 'General case' 0 N--CA 1.518 2.945 0 O-C-N 120.532 -1.355 . . . . 2.19 110.003 178.687 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.5 p -93.23 152.89 3.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 CA-C-O 121.666 0.746 . . . . 1.44 111.008 -178.144 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 65.1 t -125.92 86.84 57.04 Favored Pre-proline 0 N--CA 1.497 1.888 0 N-CA-C 107.917 -1.142 . . . . 1.19 107.917 179.024 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -63.71 113.29 2.08 Favored 'Trans proline' 0 C--N 1.319 -0.999 0 C-N-CA 121.418 1.412 . . . . 1.49 112.264 -177.743 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 54.3 t -97.72 142.18 14.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 N-CA-C 106.302 -1.74 . . . . 1.35 106.302 177.496 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.661 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -130.23 132.84 46.15 Favored 'General case' 0 N--CA 1.511 2.606 0 CA-C-O 122.109 0.956 . . . . 1.67 111.82 -177.18 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 107' ' ' SER . . . . . 0.686 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 36.3 p -94.98 90.91 6.14 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.759 -1.213 . . . . 2.04 107.748 179.577 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 108' ' ' LEU . . . . . 0.569 HD12 ' N ' ' A' ' 108' ' ' LEU . 8.0 mp 54.65 10.49 0.36 Allowed 'General case' 0 C--N 1.294 -1.816 0 N-CA-C 107.848 -1.167 . . . . 3.2 107.848 -178.2 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.482 ' N ' ' C ' ' A' ' 107' ' ' SER . 9.0 t -98.88 -27.09 14.06 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 109.255 -0.646 . . . . 2.09 109.255 179.712 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 110' ' ' ASP . . . . . 0.661 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 1.8 m-20 . . . . . 0 N--CA 1.489 1.483 0 N-CA-C 107.941 -1.133 . . . . 2.85 107.941 -179.275 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 8' ' ' ARG . . . . . 0.887 HH12 ' H ' ' A' ' 84' ' ' ASP . 5.8 mtt180 . . . . . 0 N--CA 1.494 1.767 0 N-CA-C 108.638 -0.875 . . . . 3.04 108.638 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 9' ' ' VAL . . . . . . . . . . . . . 17.1 t -53.8 159.55 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 108.017 -1.105 . . . . 0.67 108.017 179.307 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -123.18 150.28 43.55 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.464 -0.773 . . . . 0.58 110.002 -179.115 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 11' ' ' SER . . . . . 0.429 ' OG ' HG23 ' A' ' 55' ' ' VAL . 4.2 t -144.57 139.54 28.21 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.454 -0.779 . . . . 1.19 109.017 179.695 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 16.7 m -140.4 116.03 10.17 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.328 -0.857 . . . . 1.38 109.465 -179.714 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 0.579 HG22 ' N ' ' B' ' 14' ' ' PHE . 2.9 p -160.15 166.29 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 O-C-N 121.34 -0.85 . . . . 0.42 109.234 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 14' ' ' PHE . . . . . 0.579 ' N ' HG22 ' B' ' 13' ' ' VAL . 7.4 p90 -177.54 -165.85 0.12 Allowed 'General case' 0 N--CA 1.487 1.425 0 CA-C-O 122.108 0.956 . . . . 1.79 112.083 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.7 pt -149.51 169.92 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.318 0 N-CA-C 108.387 -0.968 . . . . 1.25 108.387 179.851 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 65.9 p -135.54 128.64 31.68 Favored 'General case' 0 N--CA 1.5 2.049 0 O-C-N 121.184 -0.947 . . . . 1.61 109.784 -179.803 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.6 mt . . . . . 0 N--CA 1.492 1.671 0 O-C-N 121.349 -0.844 . . . . 1.32 109.167 179.651 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.404 ' O ' ' CB ' ' A' ' 94' ' ' GLU . . . . . . . . 0 N--CA 1.489 2.224 0 N-CA-C 110.912 -0.875 . . . . 2.44 110.912 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.531 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 71.35 -53.94 1.14 Allowed Glycine 0 N--CA 1.491 2.351 0 N-CA-C 110.416 -1.073 . . . . 1.81 110.416 179.066 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.461 ' HB2' ' OE1' ' A' ' 94' ' ' GLU . . . -46.79 -12.53 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.543 -0.975 . . . . 2.21 110.14 -179.439 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' HIS . . . . . 0.531 ' N ' ' O ' ' A' ' 17' ' ' GLY . 10.0 t-80 -89.77 -42.79 11.09 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.123 -0.985 . . . . 2.87 110.299 -179.168 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.84 -9.08 38.57 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 120.928 -1.108 . . . . 2.02 110.682 -179.006 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 74.2 t -83.4 112.14 20.54 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 120.865 -1.147 . . . . 2.07 110.3 -179.383 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 20.9 tpt180 -103.07 139.91 38.0 Favored 'General case' 0 N--CA 1.491 1.615 0 N-CA-C 108.06 -1.089 . . . . 3.5 108.06 179.042 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -140.02 113.3 8.39 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.263 -0.898 . . . . 1.83 109.648 -179.599 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -155.78 130.59 2.8 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 109.352 -1.499 . . . . 1.9 109.352 179.71 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.3 167.14 37.57 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.816 -1.314 . . . . 1.85 109.816 -179.856 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 17.6 m -74.1 -28.16 61.23 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.297 -1.119 . . . . 2.31 109.486 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.6 -22.9 78.02 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 109.085 -1.606 . . . . 1.64 109.085 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 20.8 mt -77.0 -10.21 59.21 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.446 -1.032 . . . . 1.83 108.963 179.689 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 59.4 mt-10 -90.15 -51.91 5.22 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.372 -0.83 . . . . 2.34 109.478 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ARG . . . . . 0.411 ' NH1' ' HG2' ' A' ' 30' ' ' ARG . 0.0 OUTLIER -169.05 -168.69 0.87 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.035 -1.04 . . . . 3.77 109.993 -179.992 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -153.92 178.76 30.65 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 108.508 -1.837 . . . . 1.57 108.508 179.876 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 42.0 t -134.37 151.09 31.42 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.041 0 O-C-N 121.165 -1.197 . . . . 1.83 110.635 -179.618 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.522 ' HB2' ' HB3' ' A' ' 107' ' ' SER . . . -38.79 111.68 0.19 Allowed 'General case' 0 N--CA 1.5 2.062 0 CA-C-O 121.544 0.688 . . . . 1.64 112.39 -179.154 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 53.43 51.42 47.8 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 111.302 -0.719 . . . . 1.73 111.302 176.976 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 31.4 t -127.59 103.04 22.32 Favored Pre-proline 0 N--CA 1.495 1.78 0 O-C-N 121.513 -0.993 . . . . 2.19 109.016 179.203 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -58.55 133.07 52.03 Favored 'Trans proline' 0 C--O 1.215 -0.636 0 N-CA-C 109.51 -0.996 . . . . 1.96 109.51 -179.88 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.405 ' HB3' ' CZ ' ' A' ' 77' ' ' TYR . . . -142.18 -169.62 2.98 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.338 -0.851 . . . . 1.69 108.803 -179.825 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -169.45 165.23 10.54 Favored 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 118.931 -1.107 . . . . 2.23 111.228 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 0.57 ' CD1' ' N ' ' A' ' 39' ' ' PHE . 0.7 OUTLIER -138.32 -176.28 4.4 Favored 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 106.758 -1.571 . . . . 1.54 106.758 178.033 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 43.8 t -122.28 147.12 46.62 Favored 'General case' 0 N--CA 1.498 1.969 0 CA-C-O 121.596 0.712 . . . . 2.37 110.298 -179.103 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 49.6 mt -142.73 97.24 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 N-CA-C 107.986 -1.116 . . . . 1.65 107.986 179.033 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.46 ' CD1' ' C ' ' A' ' 42' ' ' TRP . 0.4 OUTLIER -86.68 144.96 26.88 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.355 -0.841 . . . . 3.68 108.864 -179.493 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.534 ' OG1' ' N ' ' A' ' 44' ' ' ARG . 1.7 t -168.16 -124.85 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.322 -0.861 . . . . 2.89 109.355 -179.898 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' ARG . . . . . 0.534 ' N ' ' OG1' ' A' ' 43' ' ' THR . 61.2 ttt180 57.62 77.67 0.27 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.277 -0.889 . . . . 4.63 109.754 179.804 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 26.1 tt0 -160.62 -45.93 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.289 -0.882 . . . . 2.89 109.127 179.642 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -61.82 -56.16 22.33 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.257 -0.902 . . . . 1.74 109.1 179.658 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 155.64 178.27 29.69 Favored Glycine 0 N--CA 1.489 2.167 0 N-CA-C 109.459 -1.457 . . . . 1.6 109.459 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.7 145.01 16.46 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.173 -1.192 . . . . 1.4 109.152 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -164.33 -164.24 19.13 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.667 -1.373 . . . . 1.04 109.667 -179.828 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -137.97 116.57 1.34 Allowed Glycine 0 N--CA 1.496 2.69 0 N-CA-C 109.546 -1.422 . . . . 1.06 109.546 -179.828 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.464 HD12 ' O ' ' A' ' 90' ' ' LYS . 64.3 tp -91.57 109.39 20.69 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.274 -1.133 . . . . 1.1 108.422 179.383 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 28.3 m -92.96 141.61 28.22 Favored 'General case' 0 N--CA 1.498 1.969 0 N-CA-C 108.598 -0.89 . . . . 1.56 108.598 179.616 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.581 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 93.9 mt -134.34 116.99 23.35 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.945 0 O-C-N 121.165 -0.959 . . . . 0.65 110.148 -179.304 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -107.47 109.66 21.41 Favored 'General case' 0 N--CA 1.495 1.799 0 N-CA-C 108.133 -1.062 . . . . 0.69 108.133 178.957 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -101.41 143.19 14.8 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.43 -0.794 . . . . 0.91 110.228 -178.862 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 23.4 tp10 -139.02 143.12 38.31 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 106.765 -1.569 . . . . 1.8 106.765 178.396 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.433 ' O ' ' N ' ' B' ' 9' ' ' VAL . . . 171.68 -173.98 45.07 Favored Glycine 0 N--CA 1.491 2.301 0 C-N-CA 119.131 -1.509 . . . . 0.49 109.654 -178.667 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -64.96 -32.68 53.92 Favored 'Trans proline' 0 C--N 1.316 -1.183 0 C-N-CA 121.748 1.632 . . . . 0.66 110.317 179.811 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' SER . . . . . 0.413 ' O ' ' OH ' ' A' ' 85' ' ' TYR . 58.4 m -137.86 158.89 43.42 Favored 'General case' 0 N--CA 1.5 2.035 0 O-C-N 121.319 -0.863 . . . . 1.55 109.931 -179.323 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 34.5 mttp -76.03 93.14 3.24 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.363 -0.836 . . . . 2.53 109.483 -179.842 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -63.89 136.42 57.36 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.278 -0.888 . . . . 0.82 109.426 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.537 ' C ' HD12 ' A' ' 63' ' ' ILE . 55.1 mm-40 -79.49 172.54 13.65 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.126 -0.984 . . . . 2.3 109.539 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.537 HD12 ' C ' ' A' ' 62' ' ' GLU . 4.4 mp -140.22 151.01 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 N-CA-C 108.325 -0.991 . . . . 1.4 108.325 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -151.04 120.02 6.67 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 120.603 -1.31 . . . . 1.36 109.468 -179.712 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 54.4 p90 -86.19 139.13 31.34 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.276 -0.89 . . . . 1.47 109.764 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.487 ' N ' ' O ' ' A' ' 74' ' ' GLY . 43.7 tt0 . . . . . 0 N--CA 1.496 1.846 0 O-C-N 121.395 -0.816 . . . . 2.51 109.149 179.886 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 9.6 t . . . . . 0 N--CA 1.496 1.834 0 N-CA-C 109.107 -0.701 . . . . 2.2 109.107 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 10.4 t -78.06 153.12 32.56 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.248 -0.908 . . . . 2.05 109.438 -179.858 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.487 ' O ' ' N ' ' A' ' 66' ' ' GLU . . . -126.45 111.95 1.51 Allowed Glycine 0 N--CA 1.498 2.793 0 N-CA-C 109.352 -1.499 . . . . 1.39 109.352 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 27.4 t -100.52 99.93 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.011 0 O-C-N 121.56 -0.965 . . . . 1.57 109.399 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -84.79 165.3 17.89 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 108.293 -1.003 . . . . 1.85 108.293 179.399 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.405 ' CZ ' ' HB3' ' A' ' 37' ' ' ALA . 12.5 p90 -165.36 169.9 15.24 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.275 -0.891 . . . . 1.54 109.238 -179.329 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.577 ' O ' HG13 ' A' ' 78' ' ' VAL . 5.0 p -142.18 116.32 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.215 0 O-C-N 121.122 -0.986 . . . . 1.9 110.211 179.35 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.511 HG11 HG21 ' A' ' 105' ' ' VAL . 6.5 m -89.97 153.3 3.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.276 -0.89 . . . . 1.27 108.863 179.708 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' GLN . . . . . 0.407 ' O ' ' OE2' ' A' ' 81' ' ' GLU . 20.6 tt0 -94.57 -48.02 6.28 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.994 -1.066 . . . . 2.48 110.84 -178.892 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.407 ' OE2' ' O ' ' A' ' 80' ' ' GLN . 78.3 mm-40 -153.88 150.05 22.09 Favored Pre-proline 0 N--CA 1.503 2.198 0 O-C-N 120.613 -1.304 . . . . 1.92 111.218 -178.455 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.669 ' HG3' ' N ' ' A' ' 107' ' ' SER . 87.8 Cg_exo -36.76 157.9 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.944 2.429 . . . . 1.3 113.368 178.24 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 150.07 -156.92 26.98 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 108.893 -1.683 . . . . 1.02 108.893 -179.911 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 37.5 m-20 -116.38 92.4 3.87 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.52 -0.988 . . . . 2.13 109.408 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.53 ' O ' ' N ' ' A' ' 103' ' ' VAL . 2.7 m-85 -78.98 129.76 34.82 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 107.977 -1.12 . . . . 0.92 107.977 179.343 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.37 128.41 56.45 Favored 'General case' 0 N--CA 1.502 2.131 0 N-CA-C 108.675 -0.861 . . . . 1.53 108.675 -178.847 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 6.3 p -126.6 138.53 54.46 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.681 -0.637 . . . . 1.0 109.928 -179.667 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' SER . . . . . 0.407 ' O ' ' OG ' ' A' ' 88' ' ' SER . 44.7 p -127.83 96.69 4.58 Favored 'General case' 0 N--CA 1.499 1.987 0 N-CA-C 109.358 -0.608 . . . . 1.59 109.358 179.792 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.421 HD11 ' CD1' ' A' ' 96' ' ' ILE . 1.0 OUTLIER -106.3 134.78 46.91 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 CA-C-O 121.479 0.657 . . . . 1.29 109.938 -179.469 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 90' ' ' LYS . . . . . 0.464 ' O ' HD12 ' A' ' 51' ' ' LEU . 0.0 OUTLIER -142.97 123.72 14.18 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.454 -0.779 . . . . 1.58 109.073 -179.882 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 57.2 t80 -80.05 101.11 8.51 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.011 -1.056 . . . . 1.34 108.199 178.661 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' ASN . . . . . 0.411 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 16.8 t-20 69.2 37.68 2.07 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.13 -0.982 . . . . 2.32 109.149 -179.014 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.411 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 1.5 m-20 77.87 14.87 1.57 Allowed 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.836 -0.54 . . . . 1.92 111.928 179.337 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 94' ' ' GLU . . . . . 0.493 ' O ' ' OE1' ' A' ' 94' ' ' GLU . 0.3 OUTLIER -100.6 99.81 10.44 Favored 'General case' 0 N--CA 1.501 2.106 0 N-CA-C 107.462 -1.31 . . . . 2.25 107.462 177.707 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 29.9 m-70 -70.16 105.12 2.82 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.553 -0.717 . . . . 2.88 109.779 -178.613 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 96' ' ' ILE . . . . . 0.639 ' O ' ' N ' ' A' ' 98' ' ' ASP . 9.9 pt -51.21 152.9 3.75 Favored Pre-proline 0 N--CA 1.493 1.681 0 N-CA-C 108.587 -0.894 . . . . 2.35 108.587 179.667 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -59.1 61.74 0.06 OUTLIER 'Trans proline' 0 N--CA 1.484 0.945 0 C-N-CA 121.457 1.438 . . . . 2.48 109.582 179.255 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.639 ' N ' ' O ' ' A' ' 96' ' ' ILE . 31.4 m-20 -162.17 -58.42 0.05 OUTLIER 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 108.386 -0.968 . . . . 2.65 108.386 -179.536 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 1.1 t -65.43 141.31 97.98 Favored Pre-proline 0 C--N 1.297 -1.705 0 C-N-CA 119.868 -0.733 . . . . 2.0 110.085 -177.895 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -85.99 114.56 3.03 Favored 'Cis proline' 0 N--CA 1.492 1.396 0 N-CA-C 109.585 -0.967 . . . . 1.79 109.585 -2.103 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 46.4 p90 -110.32 160.27 16.7 Favored 'General case' 0 N--CA 1.517 2.896 0 O-C-N 120.501 -1.375 . . . . 2.19 110.261 178.927 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.3 p -92.62 148.98 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 CA-C-O 121.517 0.675 . . . . 1.44 110.206 -179.152 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.53 ' N ' ' O ' ' A' ' 85' ' ' TYR . 70.8 t -124.11 85.6 54.62 Favored Pre-proline 0 N--CA 1.498 1.946 0 N-CA-C 107.858 -1.164 . . . . 1.19 107.858 179.511 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -63.45 113.08 1.94 Allowed 'Trans proline' 0 C--N 1.32 -0.968 0 C-N-CA 121.339 1.359 . . . . 1.49 112.021 -177.605 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.511 HG21 HG11 ' A' ' 79' ' ' VAL . 54.1 t -90.22 143.97 10.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 N-CA-C 106.682 -1.599 . . . . 1.35 106.682 177.71 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.686 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -131.78 130.29 41.65 Favored 'General case' 0 N--CA 1.508 2.462 0 O-C-N 121.217 -0.927 . . . . 1.67 111.629 -177.167 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 107' ' ' SER . . . . . 0.669 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 60.3 p -95.45 90.61 5.84 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.71 -1.244 . . . . 2.04 107.873 179.36 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 108' ' ' LEU . . . . . 0.553 HD12 ' N ' ' A' ' 108' ' ' LEU . 9.2 mp 54.83 10.38 0.37 Allowed 'General case' 0 C--N 1.295 -1.774 0 N-CA-C 107.949 -1.13 . . . . 3.2 107.949 -178.434 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.483 ' H ' ' C ' ' A' ' 107' ' ' SER . 50.4 p -100.24 -24.97 14.41 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 109.32 -0.622 . . . . 2.09 109.32 179.563 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 110' ' ' ASP . . . . . 0.686 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 15.9 t70 . . . . . 0 N--CA 1.493 1.684 0 O-C-N 121.079 -1.013 . . . . 2.85 108.392 -179.604 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 8' ' ' ARG . . . . . 0.609 ' CG ' HH11 ' B' ' 8' ' ' ARG . 0.3 OUTLIER . . . . . 0 N--CA 1.494 1.766 0 N-CA-C 107.833 -1.173 . . . . 3.04 107.833 . . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 9' ' ' VAL . . . . . 0.433 ' N ' ' O ' ' A' ' 57' ' ' GLY . 0.5 OUTLIER -176.23 168.83 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 N-CA-C 107.612 -1.255 . . . . 0.67 107.612 177.936 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 0.422 ' N ' HG13 ' B' ' 9' ' ' VAL . . . -120.81 136.01 55.01 Favored 'General case' 0 N--CA 1.502 2.133 0 CA-C-O 121.487 0.66 . . . . 0.58 110.514 -178.971 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 18.4 m -149.65 138.45 21.0 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.468 -0.77 . . . . 1.19 109.265 179.395 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 27.8 p -145.94 126.08 13.79 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.089 -1.007 . . . . 1.38 109.984 -179.682 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 0.645 HG22 ' N ' ' B' ' 14' ' ' PHE . 6.8 p -167.11 170.81 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 N-CA-C 108.678 -0.86 . . . . 0.42 108.678 179.735 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 14' ' ' PHE . . . . . 0.883 ' O ' HD13 ' B' ' 15' ' ' ILE . 6.4 p90 -177.03 -171.45 0.36 Allowed 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 119.046 -1.061 . . . . 1.79 112.458 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.883 HD13 ' O ' ' B' ' 14' ' ' PHE . 4.0 mm -142.96 172.45 7.77 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 N-CA-C 108.213 -1.032 . . . . 1.25 108.213 179.85 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 16' ' ' THR . . . . . 0.419 ' H ' HG22 ' B' ' 15' ' ' ILE . 0.1 OUTLIER -144.05 144.58 31.7 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 120.89 -1.131 . . . . 1.61 109.567 179.645 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 21.7 mt . . . . . 0 N--CA 1.498 1.964 0 O-C-N 121.26 -0.9 . . . . 1.32 109.589 -179.886 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.438 ' O ' ' N ' ' A' ' 18' ' ' ALA . . . . . . . . 0 N--CA 1.489 2.232 0 N-CA-C 111.095 -0.802 . . . . 2.44 111.095 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.562 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 68.73 -53.63 0.51 Allowed Glycine 0 N--CA 1.492 2.405 0 O-C-N 121.499 -1.0 . . . . 1.81 110.668 178.733 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.67 ' HB2' ' OE1' ' A' ' 94' ' ' GLU . . . -42.66 -16.3 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.882 -0.775 . . . . 2.21 110.673 -178.598 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' HIS . . . . . 0.562 ' N ' ' O ' ' A' ' 17' ' ' GLY . 10.8 t-80 -93.82 -43.51 8.56 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.174 -0.954 . . . . 2.87 110.879 -178.409 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -91.29 -35.99 14.14 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 120.966 -1.084 . . . . 2.02 111.022 -178.486 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.609 ' O ' HG13 ' A' ' 21' ' ' VAL . 6.6 p -46.66 111.28 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 120.989 -1.069 . . . . 2.07 110.061 -178.987 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.414 ' HG2' ' HE1' ' A' ' 42' ' ' TRP . 19.5 tpt180 -118.43 124.84 48.63 Favored 'General case' 0 N--CA 1.497 1.878 0 N-CA-C 108.89 -0.781 . . . . 3.5 108.89 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -128.05 116.48 20.08 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.489 -0.757 . . . . 1.83 109.26 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -148.2 128.78 2.95 Favored Glycine 0 N--CA 1.495 2.571 0 N-CA-C 109.403 -1.479 . . . . 1.9 109.403 -179.879 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.11 169.19 40.38 Favored Glycine 0 N--CA 1.489 2.206 0 C-N-CA 119.574 -1.298 . . . . 1.85 110.062 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 43.3 p -74.06 -11.94 60.47 Favored 'General case' 0 N--CA 1.486 1.34 0 O-C-N 121.349 -1.089 . . . . 2.31 109.771 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -67.37 -17.06 68.03 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 108.205 -1.958 . . . . 1.64 108.205 179.46 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 28.2 mt -89.86 -11.65 41.32 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 108.467 -0.938 . . . . 1.83 108.467 179.437 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 19.9 mm-40 -82.68 -60.35 2.21 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.596 -0.69 . . . . 2.34 109.858 -179.47 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 26.6 ptt180 -172.96 178.79 2.45 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.032 -1.043 . . . . 3.77 109.992 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -148.85 178.0 26.71 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 108.446 -1.861 . . . . 1.57 108.446 179.765 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 27.3 t -134.8 148.33 29.31 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.015 0 O-C-N 121.205 -1.174 . . . . 1.83 110.145 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.641 ' HB2' ' HD3' ' A' ' 82' ' ' PRO . . . -41.56 113.95 0.47 Allowed 'General case' 0 N--CA 1.495 1.792 0 CA-C-O 121.567 0.699 . . . . 1.64 112.388 -179.155 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 59.87 46.44 94.1 Favored Glycine 0 N--CA 1.492 2.424 0 O-C-N 121.658 -0.651 . . . . 1.73 111.687 177.113 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 13.9 t -127.36 126.03 24.06 Favored Pre-proline 0 N--CA 1.499 2.009 0 N-CA-C 108.019 -1.104 . . . . 2.19 108.019 178.827 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -55.12 121.38 9.81 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 120.487 0.791 . . . . 1.96 110.441 -179.362 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -119.92 151.5 38.81 Favored 'General case' 0 N--CA 1.499 1.992 0 N-CA-C 108.235 -1.024 . . . . 1.69 108.235 179.319 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 8.6 pt-20 -160.16 166.24 30.1 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.727 -1.233 . . . . 2.23 111.334 -179.445 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 0.55 ' CD1' ' N ' ' A' ' 39' ' ' PHE . 0.9 OUTLIER -140.48 -178.08 5.34 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 107.046 -1.464 . . . . 1.54 107.046 177.428 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 15.5 m -128.31 134.83 48.98 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.678 -0.639 . . . . 2.37 110.084 -179.161 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.532 ' O ' ' N ' ' A' ' 73' ' ' CYS . 73.0 mt -124.61 145.79 31.26 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 N-CA-C 107.683 -1.228 . . . . 1.65 107.683 179.13 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.522 ' CD2' ' OG1' ' A' ' 43' ' ' THR . 14.5 p-90 -154.82 -176.99 6.2 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.678 -1.264 . . . . 3.68 110.445 -179.653 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.522 ' OG1' ' CD2' ' A' ' 42' ' ' TRP . 0.2 OUTLIER 81.85 109.9 0.07 Allowed 'General case' 0 N--CA 1.495 1.806 0 N-CA-C 109.356 -0.609 . . . . 2.89 109.356 -179.883 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 44' ' ' ARG . . . . . 0.59 ' CG ' HH11 ' A' ' 44' ' ' ARG . 0.0 OUTLIER -132.16 56.94 1.8 Allowed 'General case' 0 N--CA 1.499 1.976 0 N-CA-C 108.982 -0.747 . . . . 4.63 108.982 -179.864 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 27.3 tt0 -90.3 -15.91 30.29 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.264 -0.897 . . . . 2.89 109.976 -179.583 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.39 -66.88 0.5 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.04 -1.038 . . . . 1.74 109.179 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 138.21 -162.83 25.71 Favored Glycine 0 N--CA 1.495 2.633 0 N-CA-C 109.672 -1.371 . . . . 1.6 109.672 179.812 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.86 147.37 12.14 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.278 -1.131 . . . . 1.4 109.33 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -173.19 -168.96 35.1 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.538 -1.425 . . . . 1.04 109.538 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -137.49 114.29 1.09 Allowed Glycine 0 N--CA 1.496 2.663 0 N-CA-C 109.114 -1.594 . . . . 1.06 109.114 179.848 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.431 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 10.1 tp -93.74 97.58 10.53 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.251 -1.146 . . . . 1.1 108.582 179.79 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 4.2 m -83.78 142.16 30.87 Favored 'General case' 0 N--CA 1.494 1.738 0 N-CA-C 108.485 -0.932 . . . . 1.56 108.485 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.555 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 61.0 mt -133.65 123.22 45.29 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.083 -1.011 . . . . 0.65 109.674 -179.688 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -116.07 111.71 20.69 Favored 'General case' 0 N--CA 1.497 1.89 0 N-CA-C 108.325 -0.991 . . . . 0.69 108.325 179.236 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 1.1 t -102.94 149.14 7.32 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.977 0 O-C-N 121.449 -0.782 . . . . 0.91 110.052 -179.277 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' GLU . . . . . 0.42 ' OE2' ' O ' ' B' ' 9' ' ' VAL . 50.9 tp10 -140.65 138.39 34.3 Favored 'General case' 0 N--CA 1.486 1.374 0 N-CA-C 108.441 -0.948 . . . . 1.8 108.441 178.285 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 174.3 -177.51 46.47 Favored Glycine 0 N--CA 1.487 2.075 0 N-CA-C 108.719 -1.752 . . . . 0.49 108.719 -179.607 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_exo -62.74 -18.54 64.81 Favored 'Trans proline' 0 C--N 1.313 -1.32 0 C-N-CA 121.802 1.668 . . . . 0.66 110.957 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' SER . . . . . 0.402 ' O ' ' OH ' ' A' ' 85' ' ' TYR . 1.1 p -149.77 166.36 29.68 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.349 -0.844 . . . . 1.55 110.411 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 46.1 mttt -89.92 125.74 35.47 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.607 -0.683 . . . . 2.53 109.502 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -81.8 142.86 32.21 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.278 -0.889 . . . . 0.82 109.325 179.766 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 10.0 tp10 -86.61 90.55 8.29 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.24 -0.913 . . . . 2.3 109.766 -179.808 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 6.3 mm -58.5 155.62 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 121.574 -0.704 . . . . 1.4 109.133 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.552 ' HB3' ' HB3' ' A' ' 76' ' ' SER . . . -149.68 114.43 5.33 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.804 -1.185 . . . . 1.36 109.503 179.577 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.463 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 16.5 p90 -88.85 119.11 29.05 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.164 -0.96 . . . . 1.47 109.041 179.476 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 . . . . . 0 N--CA 1.496 1.864 0 O-C-N 121.252 -0.905 . . . . 2.51 109.902 -179.633 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 74.8 m . . . . . 0 N--CA 1.493 1.703 0 N-CA-C 109.395 -0.594 . . . . 2.2 109.395 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 73' ' ' CYS . . . . . 0.532 ' N ' ' O ' ' A' ' 41' ' ' ILE . 28.2 m -80.18 119.89 23.55 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.225 -0.922 . . . . 2.05 109.295 179.801 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -98.26 123.58 7.9 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.42 -1.472 . . . . 1.39 109.42 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 40.2 t -114.85 102.68 14.19 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.089 0 O-C-N 121.632 -0.923 . . . . 1.57 109.05 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.552 ' HB3' ' HB3' ' A' ' 64' ' ' ALA . 3.3 t -94.01 130.4 40.16 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.34 -0.85 . . . . 1.85 110.136 -179.598 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 8.5 p90 -126.46 129.85 49.51 Favored 'General case' 0 N--CA 1.492 1.646 0 N-CA-C 108.158 -1.052 . . . . 1.54 108.158 179.455 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 11.3 t -100.56 111.29 29.78 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.181 -0.949 . . . . 1.9 109.453 -179.155 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.542 HG11 HG21 ' A' ' 105' ' ' VAL . 13.2 m -77.94 157.71 5.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 O-C-N 121.287 -0.883 . . . . 1.27 109.329 -179.866 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 30.1 tt0 -101.87 -47.92 4.43 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.173 -0.955 . . . . 2.48 110.303 -179.499 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.404 ' O ' ' O ' ' A' ' 82' ' ' PRO . 75.5 mm-40 -149.98 150.03 29.01 Favored Pre-proline 0 N--CA 1.502 2.143 0 O-C-N 120.829 -1.169 . . . . 1.92 111.253 -178.623 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.641 ' HD3' ' HB2' ' A' ' 33' ' ' ALA . 77.8 Cg_exo -37.43 165.49 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.679 0 C-N-CA 122.825 2.35 . . . . 1.3 113.296 178.551 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 142.37 -178.89 20.61 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 108.989 -1.644 . . . . 1.02 108.989 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 84' ' ' ASP . . . . . 0.552 ' O ' ' NH1' ' B' ' 8' ' ' ARG . 29.6 m-20 -98.69 89.74 4.47 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 107.835 -1.172 . . . . 2.13 107.835 179.224 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.402 ' OH ' ' O ' ' A' ' 59' ' ' SER . 2.9 m-85 -74.7 133.67 42.04 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 108.347 -0.983 . . . . 0.92 108.347 -179.366 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 86' ' ' GLU . . . . . 0.488 ' OE2' ' NH1' ' B' ' 8' ' ' ARG . 0.0 OUTLIER -117.65 125.05 50.04 Favored 'General case' 0 N--CA 1.498 1.949 0 N-CA-C 108.305 -0.998 . . . . 1.53 108.305 -179.098 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.556 ' CG1' ' CE2' ' A' ' 101' ' ' PHE . 7.5 p -122.94 137.38 56.6 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.986 0 O-C-N 121.624 -0.673 . . . . 1.0 109.401 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 99.8 p -131.55 113.87 14.18 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.596 -0.69 . . . . 1.59 109.797 -179.876 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 2.9 pt -111.83 143.13 22.24 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.735 -0.603 . . . . 1.29 109.917 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -140.4 123.52 16.67 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.236 -0.915 . . . . 1.58 109.273 178.971 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 25.1 t80 -78.67 92.99 4.82 Favored 'General case' 0 N--CA 1.494 1.744 0 C-N-CA 119.026 -1.069 . . . . 1.34 108.325 179.449 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 92' ' ' ASN . . . . . 0.486 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 0.5 OUTLIER 65.82 37.62 5.52 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 108.236 -1.024 . . . . 2.32 108.236 -178.809 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.486 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 2.2 m-20 88.76 10.97 0.09 Allowed 'General case' 0 N--CA 1.503 2.192 0 CA-C-N 116.605 -0.27 . . . . 1.92 111.381 179.658 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 94' ' ' GLU . . . . . 0.711 ' OE2' HD13 ' A' ' 96' ' ' ILE . 0.0 OUTLIER -86.33 86.97 7.35 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 106.091 -1.818 . . . . 2.25 106.091 177.687 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 95' ' ' HIS . . . . . 0.445 ' O ' ' C ' ' A' ' 96' ' ' ILE . 2.3 t-80 -68.12 94.36 0.5 Allowed 'General case' 0 C--N 1.296 -1.735 0 O-C-N 120.4 -1.437 . . . . 2.88 110.948 -177.845 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 96' ' ' ILE . . . . . 0.711 HD13 ' OE2' ' A' ' 94' ' ' GLU . 4.7 mm -38.38 135.81 0.88 Allowed Pre-proline 0 N--CA 1.504 2.271 0 O-C-N 121.497 -0.752 . . . . 2.35 109.281 179.084 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -54.52 -7.36 0.8 Allowed 'Trans proline' 0 C--N 1.325 -0.7 0 N-CA-C 109.239 -1.1 . . . . 2.48 109.239 179.131 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.48 ' H ' ' C ' ' A' ' 96' ' ' ILE . 55.0 m-20 -86.87 -47.32 9.12 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.481 -0.762 . . . . 2.65 109.729 179.765 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 6.4 p -54.71 136.32 64.16 Favored Pre-proline 0 C--N 1.298 -1.661 0 O-C-N 121.191 -0.943 . . . . 2.0 109.835 -177.941 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -89.3 113.81 2.34 Favored 'Cis proline' 0 N--CA 1.494 1.554 0 CA-C-N 118.935 0.655 . . . . 1.79 110.44 -1.902 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 101' ' ' PHE . . . . . 0.609 ' CD1' ' N ' ' A' ' 101' ' ' PHE . 0.1 OUTLIER -81.42 158.58 24.55 Favored 'General case' 0 N--CA 1.509 2.522 0 O-C-N 119.674 -1.891 . . . . 2.19 108.785 178.476 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 10.4 p -97.93 138.04 23.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.404 -0.81 . . . . 1.44 109.388 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 60.6 t -121.03 85.53 40.95 Favored Pre-proline 0 N--CA 1.499 2.019 0 N-CA-C 108.623 -0.88 . . . . 1.19 108.623 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -65.63 111.32 1.85 Allowed 'Trans proline' 0 C--N 1.321 -0.899 0 C-N-CA 121.443 1.428 . . . . 1.49 111.467 -178.336 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.542 HG21 HG11 ' A' ' 79' ' ' VAL . 54.6 t -95.49 146.32 7.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.775 0 N-CA-C 107.1 -1.444 . . . . 1.35 107.1 178.34 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.656 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -138.71 135.65 34.98 Favored 'General case' 0 N--CA 1.509 2.523 0 O-C-N 121.092 -1.005 . . . . 1.67 111.799 -177.541 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 107' ' ' SER . . . . . 0.542 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 9.9 m -86.71 58.73 5.23 Favored 'General case' 0 N--CA 1.494 1.752 0 N-CA-C 107.42 -1.326 . . . . 2.04 107.42 178.808 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 108' ' ' LEU . . . . . 0.508 ' CB ' ' O ' ' A' ' 107' ' ' SER . 3.4 tp 83.8 -11.35 0.89 Allowed 'General case' 0 N--CA 1.495 1.814 0 N-CA-C 106.972 -1.492 . . . . 3.2 106.972 -177.843 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.409 ' O ' ' CG ' ' A' ' 110' ' ' ASP . 24.1 t -71.18 -19.28 62.42 Favored 'General case' 0 C--N 1.305 -1.333 0 N-CA-C 108.878 -0.786 . . . . 2.09 108.878 178.967 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 110' ' ' ASP . . . . . 0.656 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 1.1 p30 . . . . . 0 N--CA 1.496 1.833 0 N-CA-C 108.285 -1.006 . . . . 2.85 108.285 -178.822 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 8' ' ' ARG . . . . . 0.552 ' NH1' ' O ' ' A' ' 84' ' ' ASP . 68.3 mtt180 . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 108.429 -0.952 . . . . 3.04 108.429 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 9' ' ' VAL . . . . . 0.42 ' O ' ' OE2' ' A' ' 56' ' ' GLU . 21.0 t -53.99 158.71 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 N-CA-C 108.162 -1.051 . . . . 0.67 108.162 178.971 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -117.83 141.72 48.11 Favored 'General case' 0 N--CA 1.502 2.166 0 O-C-N 121.489 -0.757 . . . . 0.58 109.981 -179.337 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 18.4 t -143.0 137.68 29.49 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.368 -0.832 . . . . 1.19 109.319 179.581 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 8.7 t -141.13 128.31 20.9 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.308 -0.87 . . . . 1.38 109.584 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 0.622 HG22 ' N ' ' B' ' 14' ' ' PHE . 6.1 p -169.44 167.89 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.484 -0.76 . . . . 0.42 109.205 -179.874 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 14' ' ' PHE . . . . . 0.622 ' N ' HG22 ' B' ' 13' ' ' VAL . 6.7 p90 -177.61 -167.67 0.16 Allowed 'General case' 0 N--CA 1.49 1.552 0 CA-C-O 122.202 1.001 . . . . 1.79 112.537 179.65 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.4 pt -150.71 172.07 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.31 0 N-CA-C 108.322 -0.992 . . . . 1.25 108.322 179.818 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 31.7 p -144.96 147.12 32.33 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 120.865 -1.147 . . . . 1.61 109.9 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.4 mt . . . . . 0 N--CA 1.494 1.774 0 O-C-N 121.349 -0.845 . . . . 1.32 109.178 179.715 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.899 0 N-CA-C 109.447 -1.461 . . . . 2.44 109.447 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.534 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -69.58 -5.93 52.67 Favored Glycine 0 N--CA 1.487 2.083 0 N-CA-C 110.054 -1.219 . . . . 1.81 110.054 -179.664 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -48.3 -13.39 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.675 0 O-C-N 120.663 -1.492 . . . . 2.21 109.228 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' HIS . . . . . 0.534 ' N ' ' O ' ' A' ' 17' ' ' GLY . 1.6 t60 -95.48 -45.17 7.2 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.384 -0.823 . . . . 2.87 109.181 179.38 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.52 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.0 OUTLIER -79.83 -26.08 40.59 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.112 -0.993 . . . . 2.02 109.332 179.894 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.417 HG11 HD11 ' A' ' 96' ' ' ILE . 69.2 t -62.98 112.66 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.115 -0.991 . . . . 2.07 109.051 179.497 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 12.9 tpp180 -100.93 137.52 39.19 Favored 'General case' 0 C--N 1.301 -1.535 0 CA-C-O 121.475 0.655 . . . . 3.5 109.263 -179.72 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -148.37 113.28 5.45 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.604 -0.887 . . . . 1.83 108.604 179.415 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -150.76 133.23 4.21 Favored Glycine 0 N--CA 1.496 2.68 0 N-CA-C 109.74 -1.344 . . . . 1.9 109.74 -179.616 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.46 175.36 47.37 Favored Glycine 0 N--CA 1.487 2.067 0 C-N-CA 119.628 -1.272 . . . . 1.85 110.268 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 18.0 m -77.44 -17.95 57.62 Favored 'General case' 0 N--CA 1.486 1.363 0 O-C-N 121.457 -1.025 . . . . 2.31 109.77 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -68.34 -22.75 74.87 Favored Glycine 0 N--CA 1.487 2.036 0 N-CA-C 108.761 -1.736 . . . . 1.64 108.761 179.757 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.5 mt -84.39 -7.15 59.39 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.623 -0.927 . . . . 1.83 108.963 179.853 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 27.0 mm-40 -88.45 -56.69 3.21 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.47 -0.769 . . . . 2.34 109.993 -179.341 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 26.1 ptt180 -175.05 -176.74 0.99 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.126 -0.984 . . . . 3.77 109.666 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -149.27 177.47 27.45 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 108.917 -1.673 . . . . 1.57 108.917 179.857 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.465 ' H ' ' CG1' ' A' ' 35' ' ' VAL . 25.8 t -134.91 148.03 29.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.425 -1.044 . . . . 1.83 109.803 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.464 ' HB2' ' HD3' ' A' ' 82' ' ' PRO . . . -37.84 106.65 0.05 Allowed 'General case' 0 N--CA 1.496 1.866 0 CA-C-O 121.341 0.591 . . . . 1.64 112.085 -179.142 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 62.49 57.51 16.23 Favored Glycine 0 N--CA 1.49 2.268 0 O-C-N 121.249 -0.907 . . . . 1.73 111.541 177.558 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.465 ' CG1' ' H ' ' A' ' 32' ' ' VAL . 2.8 p -126.09 129.2 24.31 Favored Pre-proline 0 N--CA 1.502 2.167 0 O-C-N 121.311 -1.111 . . . . 2.19 109.133 178.84 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -63.5 125.64 16.0 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 N-CA-C 108.24 -1.485 . . . . 1.96 108.24 178.473 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.598 ' HB3' ' CZ ' ' A' ' 77' ' ' TYR . . . -134.47 160.91 36.55 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.212 -0.93 . . . . 1.69 109.294 -179.367 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -162.36 167.22 24.08 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 121.161 -0.962 . . . . 2.23 110.758 -179.634 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 0.527 ' CD1' ' N ' ' A' ' 39' ' ' PHE . 0.7 OUTLIER -141.61 -179.98 6.48 Favored 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 107.059 -1.46 . . . . 1.54 107.059 177.627 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 6.1 m -124.12 138.05 54.48 Favored 'General case' 0 N--CA 1.498 1.941 0 CA-C-O 121.405 0.622 . . . . 2.37 110.178 -178.937 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.479 ' O ' ' N ' ' A' ' 73' ' ' CYS . 74.3 mt -136.7 119.38 20.99 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.556 -0.715 . . . . 1.65 109.269 179.645 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 6.2 p-90 -119.52 137.35 53.87 Favored 'General case' 0 N--CA 1.503 2.2 0 N-CA-C 108.905 -0.776 . . . . 3.68 108.905 179.201 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.52 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.1 OUTLIER -148.83 137.77 21.46 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.199 -0.938 . . . . 2.89 109.694 -179.581 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 44' ' ' ARG . . . . . . . . . . . . . 59.7 ttt180 -171.87 66.3 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.344 -0.848 . . . . 4.63 109.743 179.665 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.485 ' H ' ' HZ3' ' A' ' 20' ' ' LYS . 6.4 tp10 -157.84 -53.81 0.07 Allowed 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.078 -1.014 . . . . 2.89 109.43 179.553 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -58.46 -58.75 7.16 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.2 -0.937 . . . . 1.74 109.148 179.769 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 138.62 176.49 14.62 Favored Glycine 0 N--CA 1.494 2.502 0 N-CA-C 108.928 -1.669 . . . . 1.6 108.928 -179.938 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.39 163.51 0.6 Allowed 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.088 -1.243 . . . . 1.4 109.386 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 179.8 -148.78 8.2 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.868 -1.293 . . . . 1.04 109.868 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -144.13 126.98 2.85 Favored Glycine 0 N--CA 1.495 2.606 0 N-CA-C 109.618 -1.393 . . . . 1.06 109.618 -179.838 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.423 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 10.8 tp -102.93 102.15 12.21 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.399 -1.059 . . . . 1.1 109.027 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 3.2 t -85.97 142.11 29.03 Favored 'General case' 0 N--CA 1.494 1.767 0 N-CA-C 108.221 -1.029 . . . . 1.56 108.221 179.295 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.555 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 89.5 mt -133.54 120.14 36.85 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.987 0 O-C-N 121.087 -1.008 . . . . 0.65 109.896 -179.709 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.435 ' HB3' ' OG ' ' A' ' 88' ' ' SER . . . -109.44 106.86 16.8 Favored 'General case' 0 N--CA 1.496 1.874 0 N-CA-C 108.772 -0.825 . . . . 0.69 108.772 179.376 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.43 HG23 ' OG ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -97.84 143.19 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 O-C-N 121.245 -0.91 . . . . 0.91 109.25 -179.844 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 12.5 tt0 -141.61 142.87 33.44 Favored 'General case' 0 N--CA 1.491 1.624 0 N-CA-C 107.882 -1.155 . . . . 1.8 107.882 179.336 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 166.04 -172.88 41.54 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.502 -1.439 . . . . 0.49 109.502 -179.239 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -64.21 -30.18 64.54 Favored 'Trans proline' 0 C--N 1.318 -1.056 0 C-N-CA 121.993 1.795 . . . . 0.66 111.412 -179.218 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' SER . . . . . 0.403 ' O ' ' OH ' ' A' ' 85' ' ' TYR . 6.0 m -141.4 152.26 44.16 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.075 -1.016 . . . . 1.55 109.827 -179.801 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 16.1 ptmt -74.56 107.68 6.84 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.261 -0.899 . . . . 2.53 109.024 179.829 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -72.67 136.43 45.63 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.014 -1.054 . . . . 0.82 109.401 -179.602 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -71.92 173.35 8.45 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.099 -1.0 . . . . 2.3 109.236 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 42.9 mt -142.52 152.52 17.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 N-CA-C 107.799 -1.185 . . . . 1.4 107.799 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.55 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -150.13 114.64 5.23 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 120.653 -1.279 . . . . 1.36 110.202 -179.45 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 45.1 p90 -86.76 129.07 35.02 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.248 -0.907 . . . . 1.47 109.157 179.393 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 54.0 tt0 . . . . . 0 N--CA 1.496 1.863 0 O-C-N 121.238 -0.914 . . . . 2.51 109.602 -179.756 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 94.0 p . . . . . 0 N--CA 1.495 1.812 0 N-CA-C 109.466 -0.568 . . . . 2.2 109.466 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 73' ' ' CYS . . . . . 0.479 ' N ' ' O ' ' A' ' 41' ' ' ILE . 32.3 m -85.31 117.27 24.14 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.232 -0.917 . . . . 2.05 109.633 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -99.95 119.8 6.64 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 109.294 -1.522 . . . . 1.39 109.294 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 17.9 t -109.74 103.09 14.94 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.153 0 O-C-N 121.524 -0.986 . . . . 1.57 109.818 -179.756 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.55 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.0 OUTLIER -91.76 142.94 27.04 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.326 -0.859 . . . . 1.85 108.851 179.687 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.598 ' CZ ' ' HB3' ' A' ' 37' ' ' ALA . 11.6 p90 -142.82 171.92 13.4 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.281 -0.887 . . . . 1.54 109.189 -179.421 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.556 ' O ' HG13 ' A' ' 78' ' ' VAL . 4.4 p -142.2 119.98 7.92 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.211 0 O-C-N 121.105 -0.997 . . . . 1.9 110.288 179.529 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.515 HG11 HG21 ' A' ' 105' ' ' VAL . 11.5 m -87.15 153.97 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.309 -0.87 . . . . 1.27 108.677 179.251 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 38.3 tt0 -96.6 -47.0 6.1 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.008 -1.057 . . . . 2.48 110.657 -179.156 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 80.2 mm-40 -152.16 150.48 25.66 Favored Pre-proline 0 N--CA 1.502 2.129 0 O-C-N 120.646 -1.284 . . . . 1.92 111.056 -178.625 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.576 ' HG3' ' N ' ' A' ' 107' ' ' SER . 75.7 Cg_exo -37.68 164.72 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.67 0 C-N-CA 122.8 2.333 . . . . 1.3 113.099 178.398 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 144.24 -163.88 27.71 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.122 -1.591 . . . . 1.02 109.122 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 20.0 m-20 -108.97 91.13 3.52 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.639 -0.918 . . . . 2.13 108.797 179.652 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.473 ' O ' ' N ' ' A' ' 103' ' ' VAL . 3.1 m-85 -78.81 130.69 36.0 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 108.091 -1.077 . . . . 0.92 108.091 179.896 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 86' ' ' GLU . . . . . 0.409 ' OE2' ' NH2' ' B' ' 8' ' ' ARG . 0.0 OUTLIER -115.62 129.23 56.43 Favored 'General case' 0 N--CA 1.501 2.1 0 N-CA-C 108.89 -0.781 . . . . 1.53 108.89 -179.041 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 9.9 p -124.12 140.19 48.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.712 -0.617 . . . . 1.0 109.361 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 88' ' ' SER . . . . . 0.435 ' OG ' ' HB3' ' A' ' 54' ' ' ALA . 22.2 p -131.98 101.9 5.61 Favored 'General case' 0 N--CA 1.498 1.944 0 N-CA-C 109.184 -0.673 . . . . 1.59 109.184 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.418 ' H ' ' HB3' ' A' ' 99' ' ' SER . 1.5 pt -111.84 136.11 49.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 CA-C-O 121.599 0.714 . . . . 1.29 110.479 -179.084 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 90' ' ' LYS . . . . . 0.459 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.2 OUTLIER -140.95 122.77 15.35 Favored 'General case' 0 N--CA 1.486 1.329 0 N-CA-C 108.001 -1.111 . . . . 1.58 108.001 179.449 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.413 ' O ' ' OE1' ' A' ' 94' ' ' GLU . 84.7 t80 -82.15 100.29 9.73 Favored 'General case' 0 C--N 1.3 -1.569 0 C-N-CA 118.347 -1.341 . . . . 1.34 107.927 179.041 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 92' ' ' ASN . . . . . 0.438 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 12.7 t-20 71.42 36.48 1.31 Allowed 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.25 -0.906 . . . . 2.32 109.158 -178.665 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.438 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 1.8 m-20 79.6 12.9 1.11 Allowed 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.703 -0.623 . . . . 1.92 111.903 179.232 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 94' ' ' GLU . . . . . 0.483 ' OE2' ' CA ' ' A' ' 17' ' ' GLY . 5.2 pt-20 -99.98 96.59 7.64 Favored 'General case' 0 N--CA 1.498 1.97 0 N-CA-C 106.958 -1.497 . . . . 2.25 106.958 177.617 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 95' ' ' HIS . . . . . 0.513 ' O ' ' ND1' ' A' ' 95' ' ' HIS . 0.0 OUTLIER -70.44 111.37 5.94 Favored 'General case' 0 N--CA 1.488 1.452 0 CA-C-O 121.595 0.712 . . . . 2.88 110.884 -177.577 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 96' ' ' ILE . . . . . 0.479 ' O ' ' N ' ' A' ' 98' ' ' ASP . 32.4 mt -57.66 137.39 82.54 Favored Pre-proline 0 C--N 1.3 -1.557 0 N-CA-C 107.826 -1.176 . . . . 2.35 107.826 178.651 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_exo -42.91 -21.75 0.23 Allowed 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 120.823 1.015 . . . . 2.48 110.184 -179.694 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.479 ' N ' ' O ' ' A' ' 96' ' ' ILE . 87.2 m-20 -67.58 -68.08 0.41 Allowed 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 108.478 -0.934 . . . . 2.65 108.478 178.266 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.418 ' HB3' ' H ' ' A' ' 89' ' ' ILE . 0.3 OUTLIER -60.65 143.65 90.3 Favored Pre-proline 0 C--N 1.295 -1.762 0 O-C-N 121.595 -0.69 . . . . 2.0 109.901 -178.389 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -84.41 112.62 2.6 Favored 'Cis proline' 0 N--CA 1.491 1.337 0 N-CA-C 109.456 -1.017 . . . . 1.79 109.456 -2.318 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 53.6 p90 -112.11 161.96 15.95 Favored 'General case' 0 N--CA 1.517 2.887 0 O-C-N 120.543 -1.348 . . . . 2.19 110.196 179.107 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.414 HG22 ' N ' ' A' ' 103' ' ' VAL . 7.2 p -93.66 154.42 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.528 -0.732 . . . . 1.44 110.928 -178.421 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.473 ' N ' ' O ' ' A' ' 85' ' ' TYR . 64.4 t -128.65 86.96 56.23 Favored Pre-proline 0 N--CA 1.498 1.934 0 N-CA-C 108.233 -1.025 . . . . 1.19 108.233 179.41 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 4.1 Cg_exo -63.54 113.12 1.97 Allowed 'Trans proline' 0 C--N 1.319 -1.008 0 C-N-CA 121.333 1.355 . . . . 1.49 111.963 -178.081 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.515 HG21 HG11 ' A' ' 79' ' ' VAL . 53.4 t -96.17 143.76 11.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 N-CA-C 106.713 -1.588 . . . . 1.35 106.713 177.862 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.649 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -136.65 133.63 36.43 Favored 'General case' 0 N--CA 1.51 2.539 0 O-C-N 121.14 -0.975 . . . . 1.67 111.863 -177.3 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 107' ' ' SER . . . . . 0.576 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 38.7 p -85.27 63.73 8.26 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.796 -1.19 . . . . 2.04 107.819 179.12 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 108' ' ' LEU . . . . . 0.485 ' CB ' ' O ' ' A' ' 107' ' ' SER . 2.8 tp 79.9 -14.89 0.8 Allowed 'General case' 0 C--N 1.298 -1.648 0 N-CA-C 106.927 -1.509 . . . . 3.2 106.927 -177.991 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.481 ' H ' ' C ' ' A' ' 107' ' ' SER . 21.7 t -66.89 -23.46 66.0 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 108.762 -0.829 . . . . 2.09 108.762 178.769 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 110' ' ' ASP . . . . . 0.649 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 42.9 m-20 . . . . . 0 N--CA 1.493 1.685 0 N-CA-C 108.079 -1.082 . . . . 2.85 108.079 -179.46 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 8' ' ' ARG . . . . . 0.409 ' NH2' ' OE2' ' A' ' 86' ' ' GLU . 18.2 mtm-85 . . . . . 0 N--CA 1.491 1.594 0 N-CA-C 108.129 -1.063 . . . . 3.04 108.129 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 9' ' ' VAL . . . . . . . . . . . . . 20.4 t -52.96 159.54 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 120.916 -1.115 . . . . 0.67 108.21 179.617 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -120.64 149.11 42.99 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.404 -0.81 . . . . 0.58 110.422 -178.957 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 11' ' ' SER . . . . . 0.43 ' OG ' HG23 ' A' ' 55' ' ' VAL . 7.4 t -143.2 142.69 31.5 Favored 'General case' 0 N--CA 1.495 1.785 0 N-CA-C 108.814 -0.81 . . . . 1.19 108.814 179.365 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 23.6 p -145.38 127.92 16.05 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.987 -1.07 . . . . 1.38 110.121 -179.639 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 0.655 HG22 ' N ' ' B' ' 14' ' ' PHE . 7.2 p -172.44 171.46 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 N-CA-C 108.826 -0.805 . . . . 0.42 108.826 179.69 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 14' ' ' PHE . . . . . 0.655 ' N ' HG22 ' B' ' 13' ' ' VAL . 6.8 p90 -177.48 -167.95 0.17 Allowed 'General case' 0 N--CA 1.489 1.522 0 CA-C-O 122.234 1.016 . . . . 1.79 112.282 179.793 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.8 pt -148.95 172.64 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.29 0 N-CA-C 107.897 -1.149 . . . . 1.25 107.897 179.709 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 2.4 t -146.6 148.44 32.12 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 120.756 -1.215 . . . . 1.61 110.195 -179.842 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.2 mt . . . . . 0 N--CA 1.495 1.823 0 O-C-N 121.51 -0.744 . . . . 1.32 109.146 179.785 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.217 0 N-CA-C 111.605 -0.598 . . . . 2.44 111.605 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.523 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 74.05 -56.06 2.27 Favored Glycine 0 N--CA 1.493 2.451 0 N-CA-C 110.487 -1.045 . . . . 1.81 110.487 178.614 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.871 ' HB2' ' OE1' ' A' ' 94' ' ' GLU . . . -49.82 -9.22 0.04 OUTLIER 'General case' 0 C--N 1.294 -1.828 0 O-C-N 121.243 -1.151 . . . . 2.21 109.6 -179.624 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' HIS . . . . . 0.523 ' N ' ' O ' ' A' ' 17' ' ' GLY . 15.2 t-80 -94.91 -8.9 35.79 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.085 -1.009 . . . . 2.87 110.475 -179.456 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.502 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.0 OUTLIER -134.24 1.79 3.24 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.078 -1.014 . . . . 2.02 110.2 -179.685 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 68.7 t -88.07 113.43 25.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 120.92 -1.113 . . . . 2.07 109.637 179.767 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 6.2 tpt180 -97.8 132.9 42.99 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.577 -0.702 . . . . 3.5 109.126 179.808 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -139.28 113.92 9.18 Favored 'General case' 0 N--CA 1.494 1.751 0 N-CA-C 108.582 -0.896 . . . . 1.83 108.582 179.771 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -156.64 129.22 2.37 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.849 -1.3 . . . . 1.9 109.849 -179.448 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.94 -179.82 48.73 Favored Glycine 0 N--CA 1.488 2.127 0 C-N-CA 119.512 -1.328 . . . . 1.85 110.052 179.876 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 10.9 p -80.61 -15.96 55.29 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.397 -1.061 . . . . 2.31 109.451 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -76.89 -8.42 86.64 Favored Glycine 0 N--CA 1.487 2.074 0 N-CA-C 109.532 -1.427 . . . . 1.64 109.532 -179.733 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.48 HD21 ' CD2' ' A' ' 39' ' ' PHE . 28.5 mt -100.26 -0.67 38.12 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.373 -1.075 . . . . 1.83 109.076 179.692 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -102.18 -44.56 5.4 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.519 -0.738 . . . . 2.34 109.565 -179.681 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 18.1 ptt180 -176.81 172.58 2.05 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.006 -1.059 . . . . 3.77 110.119 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -143.45 174.72 23.84 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 107.842 -2.103 . . . . 1.57 107.842 179.272 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 35.2 t -134.05 149.79 30.7 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.092 0 O-C-N 121.1 -1.235 . . . . 1.83 110.375 -179.842 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.544 ' HB2' ' HD3' ' A' ' 82' ' ' PRO . . . -41.47 114.17 0.48 Allowed 'General case' 0 N--CA 1.498 1.933 0 CA-C-O 121.804 0.812 . . . . 1.64 112.593 -179.128 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 57.18 47.3 88.74 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 111.552 -0.619 . . . . 1.73 111.552 176.986 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 25.5 t -127.23 113.53 21.54 Favored Pre-proline 0 N--CA 1.498 1.966 0 O-C-N 121.458 -1.024 . . . . 2.19 108.756 179.116 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -59.93 126.51 20.57 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 N-CA-C 109.944 -0.829 . . . . 1.96 109.944 -179.756 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.409 ' HB3' ' CZ ' ' A' ' 77' ' ' TYR . . . -127.58 174.56 8.96 Favored 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 108.182 -1.044 . . . . 1.69 108.182 179.597 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -163.09 171.28 16.63 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.838 -1.164 . . . . 2.23 110.961 -179.789 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 0.63 ' CE2' HD11 ' A' ' 41' ' ' ILE . 5.8 p90 -155.9 167.75 29.4 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 107.707 -1.22 . . . . 1.54 107.707 178.568 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 14.6 m -101.67 150.14 23.42 Favored 'General case' 0 N--CA 1.495 1.821 0 CA-C-O 121.803 0.811 . . . . 2.37 111.147 -178.1 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.657 HD12 HG21 ' A' ' 75' ' ' VAL . 11.8 mt -141.12 88.55 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 N-CA-C 108.436 -0.95 . . . . 1.65 108.436 178.774 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.459 ' HE1' ' CG ' ' A' ' 44' ' ' ARG . 5.6 t90 -90.77 132.99 35.52 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.105 -0.997 . . . . 3.68 108.788 -179.804 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.502 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.8 OUTLIER -160.94 128.53 4.28 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.22 -0.925 . . . . 2.89 109.949 -179.436 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 44' ' ' ARG . . . . . 0.459 ' CG ' ' HE1' ' A' ' 42' ' ' TRP . 1.8 ptp180 -178.39 77.27 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.278 -0.889 . . . . 4.63 109.612 179.6 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.469 ' H ' ' HZ3' ' A' ' 20' ' ' LYS . 26.0 tt0 -158.6 -52.32 0.06 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.187 -0.946 . . . . 2.89 109.498 179.796 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -60.79 -49.99 75.24 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.04 -1.038 . . . . 1.74 109.008 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 148.85 160.92 9.36 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.448 -1.461 . . . . 1.6 109.448 179.807 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.79 161.23 1.18 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.196 -1.179 . . . . 1.4 109.386 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -174.42 -128.88 1.12 Allowed Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.827 -1.309 . . . . 1.04 109.827 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -157.69 126.22 1.69 Allowed Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.58 -1.408 . . . . 1.06 109.58 -179.828 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 11.7 tp -97.97 100.53 11.87 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.294 -1.121 . . . . 1.1 109.078 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' SER . . . . . 0.403 ' HA ' ' CD2' ' B' ' 14' ' ' PHE . 2.0 t -88.36 142.72 27.5 Favored 'General case' 0 C--O 1.211 -0.947 0 N-CA-C 108.667 -0.864 . . . . 1.56 108.667 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.522 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 93.5 mt -134.08 106.97 9.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 O-C-N 121.025 -1.047 . . . . 0.65 109.764 -179.568 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -96.34 106.06 18.23 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.315 -0.995 . . . . 0.69 108.315 179.183 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.429 HG23 ' CB ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -94.52 144.57 9.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.421 -0.799 . . . . 0.91 109.676 -179.445 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 16.6 tt0 -141.1 145.16 35.44 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 107.529 -1.286 . . . . 1.8 107.529 178.738 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.428 ' O ' ' O ' ' B' ' 9' ' ' VAL . . . 163.14 -171.08 38.81 Favored Glycine 0 N--CA 1.489 2.196 0 C-N-CA 119.554 -1.308 . . . . 0.49 109.854 -179.065 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -62.68 -29.85 77.96 Favored 'Trans proline' 0 C--N 1.318 -1.063 0 C-N-CA 122.224 1.949 . . . . 0.66 112.386 -179.289 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 8.7 t -142.36 160.0 41.12 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 120.891 -1.131 . . . . 1.55 110.138 -179.643 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 80.5 mttt -78.33 109.53 12.55 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.498 -0.751 . . . . 2.53 109.204 179.796 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -76.46 142.37 41.01 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.258 -0.902 . . . . 0.82 109.588 -179.829 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.847 ' C ' HD12 ' A' ' 63' ' ' ILE . 20.6 tt0 -81.39 172.62 13.33 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.319 -0.863 . . . . 2.3 108.78 179.778 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.847 HD12 ' C ' ' A' ' 62' ' ' GLU . 3.2 mp -140.17 154.4 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 N-CA-C 108.309 -0.997 . . . . 1.4 108.309 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.55 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -151.07 114.88 4.95 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.758 -1.214 . . . . 1.36 109.538 -179.845 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.528 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 44.0 p90 -93.55 120.21 33.55 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.19 -0.944 . . . . 1.47 109.469 179.724 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 54.2 tt0 . . . . . 0 N--CA 1.497 1.91 0 O-C-N 121.234 -0.916 . . . . 2.51 109.611 -179.883 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.8 m . . . . . 0 N--CA 1.495 1.781 0 N-CA-C 108.85 -0.796 . . . . 2.2 108.85 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 15.1 t -88.02 126.63 35.18 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.151 -0.968 . . . . 2.05 109.773 -179.521 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -105.13 118.34 5.84 Favored Glycine 0 N--CA 1.498 2.831 0 N-CA-C 109.576 -1.41 . . . . 1.39 109.576 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.657 HG21 HD12 ' A' ' 41' ' ' ILE . 21.9 t -105.88 106.08 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.141 0 O-C-N 121.476 -1.014 . . . . 1.57 109.423 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.55 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.3 OUTLIER -96.17 139.21 32.66 Favored 'General case' 0 N--CA 1.493 1.676 0 N-CA-C 108.988 -0.745 . . . . 1.85 108.988 179.828 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.409 ' CZ ' ' HB3' ' A' ' 37' ' ' ALA . 41.9 p90 -138.07 173.3 11.77 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.294 -0.879 . . . . 1.54 109.262 -179.636 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.552 ' O ' HG13 ' A' ' 78' ' ' VAL . 8.9 p -138.69 120.01 16.53 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.246 0 O-C-N 121.372 -0.83 . . . . 1.9 109.969 179.56 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.441 HG22 ' H ' ' A' ' 79' ' ' VAL . 5.7 m -89.57 163.08 2.43 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.387 -0.82 . . . . 1.27 108.984 179.72 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 7.0 tp-100 -104.4 -47.6 4.06 Favored 'General case' 0 N--CA 1.501 2.077 0 O-C-N 121.199 -0.938 . . . . 2.48 111.103 -178.929 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -156.52 153.27 24.49 Favored Pre-proline 0 N--CA 1.503 2.194 0 O-C-N 120.641 -1.287 . . . . 1.92 111.106 -178.799 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.641 ' HG3' ' N ' ' A' ' 107' ' ' SER . 73.0 Cg_exo -37.63 158.68 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 123.267 2.644 . . . . 1.3 113.609 179.268 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 148.15 -163.45 28.9 Favored Glycine 0 N--CA 1.493 2.441 0 N-CA-C 109.662 -1.375 . . . . 1.02 109.662 179.606 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 46.6 m-20 -110.66 88.63 2.82 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.615 -0.932 . . . . 2.13 108.984 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.508 ' O ' ' N ' ' A' ' 103' ' ' VAL . 2.8 m-85 -76.16 129.69 37.14 Favored 'General case' 0 C--N 1.303 -1.414 0 N-CA-C 107.998 -1.112 . . . . 0.92 107.998 179.708 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -109.23 128.01 54.71 Favored 'General case' 0 N--CA 1.5 2.069 0 N-CA-C 108.35 -0.981 . . . . 1.53 108.35 -179.52 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 9.9 p -123.91 133.56 68.93 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.713 -0.617 . . . . 1.0 109.767 -179.295 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 6.6 m -123.84 95.05 4.42 Favored 'General case' 0 N--CA 1.497 1.886 0 CA-C-O 121.393 0.616 . . . . 1.59 109.54 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.415 ' H ' ' HB3' ' A' ' 99' ' ' SER . 1.2 pt -101.26 134.48 41.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.643 -0.661 . . . . 1.29 109.797 -179.775 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 90' ' ' LYS . . . . . 0.468 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.1 OUTLIER -140.32 121.98 15.28 Favored 'General case' 0 N--CA 1.485 1.296 0 N-CA-C 108.712 -0.847 . . . . 1.58 108.712 179.746 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 79.9 t80 -81.09 100.03 8.81 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 107.665 -1.235 . . . . 1.34 107.665 178.514 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 92' ' ' ASN . . . . . 0.438 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 26.8 t30 69.81 36.42 2.07 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.448 -0.782 . . . . 2.32 109.362 -178.809 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.438 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 0.7 OUTLIER 79.92 14.32 0.92 Allowed 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.688 -0.633 . . . . 1.92 111.554 179.42 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 94' ' ' GLU . . . . . 0.871 ' OE1' ' HB2' ' A' ' 18' ' ' ALA . 0.5 OUTLIER -100.94 95.53 6.66 Favored 'General case' 0 N--CA 1.499 1.98 0 N-CA-C 107.239 -1.393 . . . . 2.25 107.239 177.892 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 95' ' ' HIS . . . . . 0.461 ' O ' ' CG ' ' A' ' 95' ' ' HIS . 0.0 OUTLIER -66.58 110.55 3.22 Favored 'General case' 0 N--CA 1.488 1.466 0 CA-C-O 121.697 0.76 . . . . 2.88 111.177 -177.773 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 96' ' ' ILE . . . . . 0.536 ' O ' ' N ' ' A' ' 98' ' ' ASP . 5.5 mm -50.61 137.22 24.34 Favored Pre-proline 0 N--CA 1.492 1.671 0 N-CA-C 107.621 -1.251 . . . . 2.35 107.621 178.576 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -44.39 -16.75 0.12 Allowed 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 120.68 0.92 . . . . 2.48 109.844 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 96' ' ' ILE . 42.9 m-20 -76.92 -66.56 0.8 Allowed 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 108.517 -0.92 . . . . 2.65 108.517 178.277 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.415 ' HB3' ' H ' ' A' ' 89' ' ' ILE . 0.2 OUTLIER -57.34 144.02 72.09 Favored Pre-proline 0 C--N 1.297 -1.702 0 O-C-N 121.622 -0.674 . . . . 2.0 109.801 -178.106 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -83.82 110.36 1.79 Allowed 'Cis proline' 0 N--CA 1.491 1.339 0 N-CA-C 109.71 -0.919 . . . . 1.79 109.71 -2.129 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 47.3 p90 -108.87 166.98 10.41 Favored 'General case' 0 N--CA 1.515 2.794 0 O-C-N 120.51 -1.369 . . . . 2.19 110.035 179.109 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.3 p -94.39 153.13 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.518 -0.739 . . . . 1.44 110.758 -178.777 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.508 ' N ' ' O ' ' A' ' 85' ' ' TYR . 70.3 t -127.62 86.21 58.96 Favored Pre-proline 0 N--CA 1.499 1.986 0 N-CA-C 107.863 -1.162 . . . . 1.19 107.863 179.395 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -62.4 113.45 1.93 Allowed 'Trans proline' 0 C--N 1.318 -1.036 0 C-N-CA 121.288 1.325 . . . . 1.49 111.979 -177.82 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 42.7 t -90.4 141.68 14.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 N-CA-C 106.88 -1.526 . . . . 1.35 106.88 177.766 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.726 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -121.65 127.67 51.06 Favored 'General case' 0 N--CA 1.505 2.322 0 CA-C-O 121.664 0.745 . . . . 1.67 111.607 -177.033 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 107' ' ' SER . . . . . 0.641 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 7.8 t -88.69 77.76 7.84 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 120.365 -1.459 . . . . 2.04 107.484 178.97 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 108' ' ' LEU . . . . . 0.442 ' CB ' ' O ' ' A' ' 107' ' ' SER . 0.9 OUTLIER 72.66 -7.81 1.35 Allowed 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 107.307 -1.368 . . . . 3.2 107.307 -178.288 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.503 ' H ' ' C ' ' A' ' 107' ' ' SER . 3.0 m -78.11 -21.59 50.18 Favored 'General case' 0 N--CA 1.486 1.335 0 N-CA-C 108.602 -0.888 . . . . 2.09 108.602 178.993 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 110' ' ' ASP . . . . . 0.726 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 1.4 m-20 . . . . . 0 N--CA 1.491 1.586 0 O-C-N 121.359 -0.838 . . . . 2.85 109.23 179.353 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 8' ' ' ARG . . . . . 0.531 ' CG ' HH11 ' B' ' 8' ' ' ARG . 2.2 mtt-85 . . . . . 0 N--CA 1.489 1.487 0 N-CA-C 108.003 -1.11 . . . . 3.04 108.003 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 9' ' ' VAL . . . . . 0.428 ' O ' ' O ' ' A' ' 57' ' ' GLY . 22.9 t -48.3 159.3 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.021 -1.049 . . . . 0.67 108.671 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -123.89 153.74 40.69 Favored 'General case' 0 N--CA 1.501 2.111 0 O-C-N 121.369 -0.832 . . . . 0.58 110.257 -178.89 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 11' ' ' SER . . . . . 0.429 ' CB ' HG23 ' A' ' 55' ' ' VAL . 2.7 t -148.66 147.12 28.56 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.498 -0.751 . . . . 1.19 109.235 179.773 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 28.5 p -145.89 126.77 14.47 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.164 -0.96 . . . . 1.38 110.064 -179.628 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 0.656 HG22 ' N ' ' B' ' 14' ' ' PHE . 7.2 p -172.18 174.8 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 N-CA-C 108.497 -0.927 . . . . 0.42 108.497 179.731 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 14' ' ' PHE . . . . . 0.656 ' N ' HG22 ' B' ' 13' ' ' VAL . 0.1 OUTLIER 174.41 -166.23 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.563 0 C-N-CA 118.779 -1.168 . . . . 1.79 111.864 -179.979 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 5.8 pt -137.58 139.49 43.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 N-CA-C 108.981 -0.748 . . . . 1.25 108.981 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 80.7 p -94.26 131.19 40.12 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.101 -0.999 . . . . 1.61 109.785 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.597 HD22 ' N ' ' B' ' 17' ' ' LEU . 3.5 mm? . . . . . 0 N--CA 1.494 1.756 0 O-C-N 121.294 -0.879 . . . . 1.32 108.891 179.615 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.047 0 N-CA-C 110.082 -1.207 . . . . 2.44 110.082 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.567 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 91.88 -53.38 2.95 Favored Glycine 0 N--CA 1.494 2.542 0 N-CA-C 110.213 -1.155 . . . . 1.81 110.213 179.444 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.632 ' HB2' ' OE1' ' A' ' 94' ' ' GLU . . . -41.49 -18.22 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.84 -0.8 . . . . 2.21 110.463 -178.993 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' HIS . . . . . 0.567 ' N ' ' O ' ' A' ' 17' ' ' GLY . 11.0 t60 -85.39 -40.69 16.19 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.281 -0.887 . . . . 2.87 109.99 -179.456 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.599 ' HG2' ' HB2' ' A' ' 46' ' ' ALA . 0.0 OUTLIER -99.78 -29.04 12.85 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.099 -1.001 . . . . 2.02 110.584 -179.173 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 84.0 t -51.58 112.1 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.004 -1.06 . . . . 2.07 109.869 -179.608 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 3.9 tpt180 -119.15 136.43 54.18 Favored 'General case' 0 N--CA 1.495 1.792 0 N-CA-C 109.284 -0.635 . . . . 3.5 109.284 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -144.58 113.87 7.01 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.461 -0.775 . . . . 1.83 108.933 179.677 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -149.25 123.83 1.69 Allowed Glycine 0 N--CA 1.495 2.586 0 N-CA-C 110.137 -1.185 . . . . 1.9 110.137 -179.424 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.81 177.77 48.27 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.904 -1.279 . . . . 1.85 109.904 179.567 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 11.0 m -76.81 -12.62 60.0 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.291 -1.123 . . . . 2.31 109.958 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -67.68 -16.68 68.16 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 108.417 -1.873 . . . . 1.64 108.417 179.599 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.434 HD21 ' CD2' ' A' ' 39' ' ' PHE . 18.1 mt -92.92 -10.31 36.96 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.783 -0.833 . . . . 1.83 109.022 179.722 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 47.3 mm-40 -83.61 -55.23 4.4 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.491 -0.755 . . . . 2.34 110.056 -179.264 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 4.9 ptp180 -176.36 -177.59 0.87 Allowed 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.036 -1.04 . . . . 3.77 109.879 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -145.13 174.53 25.14 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 108.649 -1.78 . . . . 1.57 108.649 179.664 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 30.3 t -134.39 149.73 30.18 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.947 0 O-C-N 121.285 -1.126 . . . . 1.83 110.159 -179.779 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.516 ' HB2' ' HD3' ' A' ' 82' ' ' PRO . . . -40.5 112.19 0.26 Allowed 'General case' 0 N--CA 1.496 1.83 0 CA-C-O 121.499 0.666 . . . . 1.64 112.515 -178.887 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 58.82 47.16 91.9 Favored Glycine 0 N--CA 1.492 2.391 0 O-C-N 121.514 -0.741 . . . . 1.73 111.569 177.117 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 23.6 t -127.45 124.84 23.74 Favored Pre-proline 0 N--CA 1.499 1.988 0 O-C-N 121.417 -1.049 . . . . 2.19 108.417 179.031 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_exo -58.39 114.77 2.13 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 N-CA-C 109.99 -0.811 . . . . 1.96 109.99 -179.828 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.423 ' HB3' ' CE2' ' A' ' 77' ' ' TYR . . . -107.64 155.45 20.14 Favored 'General case' 0 N--CA 1.495 1.789 0 N-CA-C 107.803 -1.184 . . . . 1.69 107.803 179.176 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -164.51 169.85 16.63 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 118.431 -1.308 . . . . 2.23 111.41 -179.405 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 0.61 ' CE2' HD11 ' A' ' 41' ' ' ILE . 4.6 p90 -154.66 171.03 20.16 Favored 'General case' 0 C--N 1.298 -1.669 0 N-CA-C 107.705 -1.22 . . . . 1.54 107.705 178.008 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 83.6 p -100.59 150.99 22.13 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.575 -0.703 . . . . 2.37 110.599 -178.389 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.61 HD11 ' CE2' ' A' ' 39' ' ' PHE . 11.6 mt -143.6 104.71 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 N-CA-C 108.712 -0.847 . . . . 1.65 108.712 178.937 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.526 ' CG ' ' N ' ' A' ' 43' ' ' THR . 0.7 OUTLIER -102.62 166.45 10.5 Favored 'General case' 0 N--CA 1.497 1.911 0 N-CA-C 108.33 -0.989 . . . . 3.68 108.33 179.854 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.526 ' N ' ' CG ' ' A' ' 42' ' ' TRP . 35.0 p -153.6 131.49 11.68 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.146 -0.971 . . . . 2.89 109.827 -179.616 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' ARG . . . . . 0.475 ' H ' ' HB2' ' A' ' 20' ' ' LYS . 32.5 ttm180 -72.58 -86.3 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.243 -0.91 . . . . 4.63 109.43 179.847 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 24.9 tt0 -172.17 63.35 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.809 -1.182 . . . . 2.89 110.935 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.599 ' HB2' ' HG2' ' A' ' 20' ' ' LYS . . . -71.24 -52.0 21.45 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 120.73 -1.231 . . . . 1.74 108.584 178.823 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 155.39 169.62 20.02 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.487 -1.445 . . . . 1.6 109.487 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.8 143.98 19.53 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.215 -1.168 . . . . 1.4 109.371 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -163.72 -168.35 25.6 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.522 -1.431 . . . . 1.04 109.522 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -137.68 117.37 1.48 Allowed Glycine 0 N--CA 1.496 2.666 0 N-CA-C 109.261 -1.536 . . . . 1.06 109.261 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.463 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 9.7 tp -87.53 99.23 11.88 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.283 -1.128 . . . . 1.1 108.597 179.758 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 12.8 m -84.01 141.13 31.42 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 108.834 -0.802 . . . . 1.56 108.834 -179.887 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.512 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 72.6 mt -130.37 111.5 21.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.357 -0.839 . . . . 0.65 109.36 -179.891 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -100.85 106.98 18.41 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.374 -0.829 . . . . 0.69 108.938 179.724 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.428 ' O ' ' O ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -103.93 135.44 41.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 121.573 -0.704 . . . . 0.91 109.323 -179.771 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 27.3 tt0 -137.96 140.53 40.28 Favored 'General case' 0 N--CA 1.494 1.736 0 N-CA-C 108.024 -1.102 . . . . 1.8 108.024 179.092 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 168.47 -172.15 42.88 Favored Glycine 0 N--CA 1.487 2.092 0 N-CA-C 109.407 -1.477 . . . . 0.49 109.407 -179.271 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -62.87 -30.9 77.8 Favored 'Trans proline' 0 C--N 1.316 -1.16 0 C-N-CA 121.873 1.715 . . . . 0.66 111.584 -179.621 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.8 t -137.64 157.24 46.93 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.153 -0.967 . . . . 1.55 110.278 -179.488 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.436 ' O ' ' OE2' ' A' ' 62' ' ' GLU . 31.5 mtpt -80.65 123.37 28.11 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 109.09 -0.707 . . . . 2.53 109.09 179.728 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -85.79 144.29 27.82 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.162 -0.961 . . . . 0.82 109.318 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.482 ' CD ' ' N ' ' A' ' 62' ' ' GLU . 9.0 mp0 -96.76 100.52 12.07 Favored 'General case' 0 N--CA 1.502 2.137 0 O-C-N 121.048 -1.032 . . . . 2.3 110.619 -179.476 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.47 HD12 ' N ' ' A' ' 63' ' ' ILE . 1.7 mp -62.51 156.12 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 N-CA-C 108.673 -0.862 . . . . 1.4 108.673 178.721 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.524 ' HB3' ' OG ' ' A' ' 76' ' ' SER . . . -140.97 175.01 9.97 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.122 -0.987 . . . . 1.36 109.237 179.782 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.513 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 32.3 p90 -147.08 116.25 6.94 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.317 -0.864 . . . . 1.47 109.407 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 69.8 tt0 . . . . . 0 N--CA 1.495 1.821 0 O-C-N 121.287 -0.883 . . . . 2.51 109.515 -179.977 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 28.9 t . . . . . 0 N--CA 1.494 1.754 0 N-CA-C 108.782 -0.821 . . . . 2.2 108.782 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 37.9 t -93.39 126.42 38.52 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.148 -0.97 . . . . 2.05 109.644 -179.708 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -102.35 120.48 6.84 Favored Glycine 0 N--CA 1.497 2.755 0 N-CA-C 109.855 -1.298 . . . . 1.39 109.855 -179.795 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.414 ' CG2' HD12 ' A' ' 41' ' ' ILE . 41.3 t -104.59 119.34 53.35 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.959 0 O-C-N 121.464 -1.021 . . . . 1.57 108.814 179.603 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.524 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 0.4 OUTLIER -113.39 124.35 52.23 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.69 -0.631 . . . . 1.85 109.387 -179.836 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.423 ' CE2' ' HB3' ' A' ' 37' ' ' ALA . 51.7 p90 -122.97 131.62 53.79 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 108.358 -0.979 . . . . 1.54 108.358 179.316 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.625 ' O ' HG13 ' A' ' 78' ' ' VAL . 8.9 p -106.63 117.54 52.61 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.243 0 O-C-N 121.293 -0.879 . . . . 1.9 109.603 -179.378 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 1.2 m -90.07 161.8 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 O-C-N 121.282 -0.887 . . . . 1.27 108.978 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 12.6 tp60 -97.62 -51.33 4.15 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.122 -0.986 . . . . 2.48 110.787 -179.158 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.429 ' O ' ' O ' ' A' ' 82' ' ' PRO . 77.2 mm-40 -145.47 150.31 43.66 Favored Pre-proline 0 N--CA 1.504 2.259 0 O-C-N 120.872 -1.142 . . . . 1.92 111.718 -178.125 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.599 ' HG3' ' N ' ' A' ' 107' ' ' SER . 88.7 Cg_exo -36.73 166.38 0.01 OUTLIER 'Trans proline' 0 C--O 1.216 -0.616 0 C-N-CA 123.142 2.561 . . . . 1.3 113.381 178.391 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 142.7 -178.53 21.04 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.183 -1.567 . . . . 1.02 109.183 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' ASP . . . . . 0.717 ' H ' ' NH1' ' B' ' 8' ' ' ARG . 31.7 m-20 -97.22 85.9 3.8 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 107.79 -1.189 . . . . 2.13 107.79 179.213 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -70.16 132.54 45.96 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 108.128 -1.064 . . . . 0.92 108.128 -179.502 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -105.36 115.67 30.65 Favored 'General case' 0 N--CA 1.496 1.872 0 N-CA-C 108.255 -1.017 . . . . 1.53 108.255 -179.067 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.4 p -115.83 143.03 26.73 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 O-C-N 121.604 -0.685 . . . . 1.0 110.12 -179.29 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 2.9 m -138.87 97.06 3.24 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.507 -0.745 . . . . 1.59 109.588 179.661 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.539 HG13 HD11 ' A' ' 96' ' ' ILE . 1.1 pt -104.38 132.84 50.04 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 N-CA-C 109.332 -0.618 . . . . 1.29 109.332 -179.888 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 90' ' ' LYS . . . . . 0.435 ' HG3' ' H ' ' A' ' 93' ' ' ASP . 0.0 OUTLIER -148.09 132.76 17.85 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.106 -0.996 . . . . 1.58 109.855 -179.481 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 43.5 t80 -83.05 94.62 7.83 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.642 -1.286 . . . . 1.34 108.591 178.721 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 92' ' ' ASN . . . . . 0.479 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 38.7 t30 67.22 38.13 3.45 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.492 -0.929 . . . . 2.32 108.492 -179.088 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.479 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 0.6 OUTLIER 86.45 12.31 0.16 Allowed 'General case' 0 N--CA 1.503 2.181 0 CA-C-N 116.399 -0.364 . . . . 1.92 111.467 179.629 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 94' ' ' GLU . . . . . 0.632 ' OE1' ' HB2' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -90.51 90.14 7.88 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 107.191 -1.411 . . . . 2.25 107.191 177.984 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 95' ' ' HIS . . . . . 0.507 ' H ' ' CD2' ' A' ' 95' ' ' HIS . 9.7 p80 -72.19 98.13 2.09 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 119.759 -1.838 . . . . 2.88 109.848 -179.142 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 96' ' ' ILE . . . . . 0.906 ' H ' HD13 ' A' ' 96' ' ' ILE . 0.0 OUTLIER -48.74 158.93 0.59 Allowed Pre-proline 0 N--CA 1.504 2.269 0 N-CA-C 107.31 -1.367 . . . . 2.35 107.31 179.218 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -60.42 65.5 0.08 OUTLIER 'Trans proline' 0 N--CA 1.481 0.736 0 C-N-CA 121.504 1.469 . . . . 2.48 109.469 -179.87 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.593 ' N ' ' O ' ' A' ' 96' ' ' ILE . 8.8 m-20 -164.9 -57.56 0.03 OUTLIER 'General case' 0 C--N 1.298 -1.634 0 N-CA-C 108.167 -1.049 . . . . 2.65 108.167 -179.514 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.423 ' HB3' ' H ' ' A' ' 89' ' ' ILE . 3.3 p -68.8 137.29 90.16 Favored Pre-proline 0 C--N 1.296 -1.755 0 C-N-CA 119.489 -0.884 . . . . 2.0 109.754 -179.179 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 27.2 Cg_endo -89.54 119.87 4.28 Favored 'Cis proline' 0 N--CA 1.493 1.462 0 N-CA-C 110.017 -0.801 . . . . 1.79 110.017 -2.644 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 30.4 p90 -124.55 166.42 16.09 Favored 'General case' 0 N--CA 1.516 2.844 0 O-C-N 120.571 -1.33 . . . . 2.19 109.74 178.153 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.3 p -88.44 146.49 6.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.551 -0.718 . . . . 1.44 110.521 -178.532 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 71.4 t -119.63 86.66 35.34 Favored Pre-proline 0 N--CA 1.495 1.803 0 N-CA-C 107.82 -1.178 . . . . 1.19 107.82 179.157 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -61.96 112.92 1.65 Allowed 'Trans proline' 0 C--N 1.322 -0.866 0 C-N-CA 121.423 1.416 . . . . 1.49 112.121 -177.724 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 60.3 t -98.93 143.19 13.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 N-CA-C 106.15 -1.796 . . . . 1.35 106.15 177.719 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.658 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -136.48 135.15 38.36 Favored 'General case' 0 N--CA 1.51 2.56 0 O-C-N 120.972 -1.08 . . . . 1.67 112.089 -176.932 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 107' ' ' SER . . . . . 0.599 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 9.2 t -86.39 73.02 10.22 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 107.713 -1.218 . . . . 2.04 107.713 179.158 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER 68.11 -1.26 1.83 Allowed 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 107.363 -1.347 . . . . 3.2 107.363 -178.505 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.493 ' H ' ' C ' ' A' ' 107' ' ' SER . 22.9 t -83.54 -21.96 32.55 Favored 'General case' 0 N--CA 1.486 1.344 0 N-CA-C 108.864 -0.791 . . . . 2.09 108.864 179.249 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 110' ' ' ASP . . . . . 0.658 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 1.8 m-20 . . . . . 0 N--CA 1.492 1.673 0 N-CA-C 108.135 -1.061 . . . . 2.85 108.135 -179.344 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 8' ' ' ARG . . . . . 0.717 ' NH1' ' H ' ' A' ' 84' ' ' ASP . 5.6 mtt180 . . . . . 0 N--CA 1.493 1.699 0 N-CA-C 109.393 -0.595 . . . . 3.04 109.393 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 9' ' ' VAL . . . . . 0.408 ' CG1' ' N ' ' B' ' 10' ' ' ALA . 5.2 t -51.08 160.48 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 N-CA-C 108.226 -1.027 . . . . 0.67 108.226 179.375 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 0.408 ' N ' ' CG1' ' B' ' 9' ' ' VAL . . . -114.59 148.3 38.26 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.47 -0.768 . . . . 0.58 110.053 -179.158 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 11' ' ' SER . . . . . 0.428 ' O ' ' O ' ' A' ' 55' ' ' VAL . 31.3 t -150.02 133.06 16.2 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.517 -0.74 . . . . 1.19 109.2 179.634 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 34.1 p -144.55 120.54 10.69 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.117 -0.989 . . . . 1.38 109.809 -179.695 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 0.613 HG22 ' N ' ' B' ' 14' ' ' PHE . 4.1 p -164.04 168.4 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.436 -0.79 . . . . 0.42 109.07 179.858 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 14' ' ' PHE . . . . . 0.613 ' N ' HG22 ' B' ' 13' ' ' VAL . 10.7 p90 -176.38 -165.58 0.14 Allowed 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 119.172 -1.011 . . . . 1.79 112.265 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.7 pt -150.93 168.63 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.291 0 N-CA-C 108.598 -0.89 . . . . 1.25 108.598 179.873 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 3.8 t -145.17 157.41 44.09 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 120.965 -1.084 . . . . 1.61 109.367 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.5 2.062 0 O-C-N 121.397 -0.815 . . . . 1.32 109.533 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.099 0 N-CA-C 110.772 -0.931 . . . . 2.44 110.772 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.539 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 78.7 -52.6 3.91 Favored Glycine 0 N--CA 1.492 2.43 0 O-C-N 121.47 -1.018 . . . . 1.81 111.089 178.69 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.599 ' HB2' ' OE1' ' A' ' 94' ' ' GLU . . . -50.27 -6.68 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.081 -1.247 . . . . 2.21 110.162 -179.29 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' HIS . . . . . 0.539 ' N ' ' O ' ' A' ' 17' ' ' GLY . 29.5 t-80 -98.97 -6.31 28.91 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.092 -1.005 . . . . 2.87 110.717 -179.171 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.502 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.0 OUTLIER -137.7 2.38 2.42 Favored 'General case' 0 N--CA 1.502 2.164 0 O-C-N 120.959 -1.088 . . . . 2.02 110.258 -179.664 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 71.3 t -87.85 114.22 26.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 120.982 -1.074 . . . . 2.07 109.25 179.489 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 13.3 tpp180 -113.61 138.54 50.03 Favored 'General case' 0 N--CA 1.492 1.635 0 N-CA-C 108.83 -0.804 . . . . 3.5 108.83 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -147.13 113.57 5.95 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.434 -0.791 . . . . 1.83 108.987 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -152.0 130.33 3.07 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.677 -1.369 . . . . 1.9 109.677 -179.759 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.98 -178.79 48.47 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.603 -1.399 . . . . 1.85 109.603 179.87 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 6.6 p -78.93 -26.59 43.67 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.183 -1.186 . . . . 2.31 108.99 179.648 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -66.88 -18.25 68.36 Favored Glycine 0 N--CA 1.486 2.015 0 N-CA-C 108.283 -1.927 . . . . 1.64 108.283 179.482 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 57.1 mt -89.64 29.55 1.13 Allowed 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.527 -0.916 . . . . 1.83 108.527 179.395 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 27.5 mt-10 -140.09 -63.84 0.49 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.528 -0.733 . . . . 2.34 109.623 -179.557 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 41.2 mtt180 -148.45 168.57 22.34 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.168 -0.958 . . . . 3.77 110.293 -179.573 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -144.38 173.33 25.09 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 107.415 -2.274 . . . . 1.57 107.415 178.73 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 39.7 t -133.79 150.99 32.18 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.15 0 O-C-N 120.999 -1.295 . . . . 1.83 110.884 -179.365 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.434 ' HB2' ' HD3' ' A' ' 82' ' ' PRO . . . -42.34 114.81 0.61 Allowed 'General case' 0 N--CA 1.497 1.887 0 CA-C-O 121.893 0.854 . . . . 1.64 112.314 -179.299 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 55.8 48.2 73.69 Favored Glycine 0 N--CA 1.488 2.159 0 N-CA-C 111.497 -0.641 . . . . 1.73 111.497 177.119 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 t -127.45 123.8 23.32 Favored Pre-proline 0 N--CA 1.499 1.986 0 O-C-N 121.451 -1.029 . . . . 2.19 108.866 179.075 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -60.64 112.21 1.27 Allowed 'Trans proline' 0 C--O 1.215 -0.652 0 N-CA-C 109.949 -0.827 . . . . 1.96 109.949 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -110.87 158.96 18.13 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 108.401 -0.963 . . . . 1.69 108.401 179.445 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -160.64 170.46 20.79 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.767 -1.208 . . . . 2.23 111.496 -179.768 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 0.602 ' CE2' HD11 ' A' ' 41' ' ' ILE . 6.2 p90 -155.62 177.37 11.45 Favored 'General case' 0 C--N 1.296 -1.729 0 N-CA-C 107.217 -1.401 . . . . 1.54 107.217 178.473 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 27.5 m -105.17 152.32 22.97 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.344 -0.848 . . . . 2.37 110.619 -178.502 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.649 HD12 HG21 ' A' ' 75' ' ' VAL . 10.0 mt -143.64 89.53 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 N-CA-C 108.714 -0.847 . . . . 1.65 108.714 178.854 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.529 ' CD1' ' N ' ' A' ' 43' ' ' THR . 7.4 t90 -91.33 141.29 28.93 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.172 -0.955 . . . . 3.68 108.924 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.531 ' OG1' ' N ' ' A' ' 44' ' ' ARG . 1.7 t -162.34 -124.2 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.177 -0.952 . . . . 2.89 109.486 -179.845 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' ARG . . . . . 0.531 ' N ' ' OG1' ' A' ' 43' ' ' THR . 5.3 ttt-85 54.49 91.81 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.347 -0.845 . . . . 4.63 110.074 179.748 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -170.97 -50.23 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.285 -0.884 . . . . 2.89 109.304 179.457 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -61.14 -50.29 73.8 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.09 -1.006 . . . . 1.74 108.937 179.665 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 155.2 -178.81 31.65 Favored Glycine 0 N--CA 1.487 2.044 0 N-CA-C 109.536 -1.426 . . . . 1.6 109.536 179.813 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.68 156.92 2.45 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.169 -1.195 . . . . 1.4 109.263 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -179.65 -160.51 25.38 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.712 -1.355 . . . . 1.04 109.712 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -144.05 123.38 2.01 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 109.663 -1.375 . . . . 1.06 109.663 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 60.2 tp -96.82 104.99 17.04 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.34 -1.094 . . . . 1.1 108.651 179.571 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' SER . . . . . 0.406 ' HA ' ' CD2' ' B' ' 14' ' ' PHE . 2.0 t -93.23 144.66 25.08 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 108.93 -0.767 . . . . 1.56 108.93 179.736 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.507 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 80.0 mt -132.97 105.74 8.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 O-C-N 121.305 -0.872 . . . . 0.65 109.79 -179.378 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -95.76 107.86 20.13 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 107.726 -1.213 . . . . 0.69 107.726 178.841 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.41 ' O ' ' O ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -105.33 146.73 11.99 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 CA-C-O 121.772 0.796 . . . . 0.91 110.693 -178.421 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 56' ' ' GLU . . . . . 0.408 ' OE2' ' O ' ' B' ' 9' ' ' VAL . 39.9 tp10 -139.23 129.41 25.31 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 107.248 -1.39 . . . . 1.8 107.248 177.954 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -175.82 163.59 33.3 Favored Glycine 0 N--CA 1.487 2.068 0 N-CA-C 108.386 -1.886 . . . . 0.49 108.386 -179.702 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_exo -46.37 -23.44 2.08 Favored 'Trans proline' 0 C--N 1.317 -1.13 0 C-N-CA 121.91 1.74 . . . . 0.66 111.714 -178.989 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 30.3 t -141.74 167.49 22.01 Favored 'General case' 0 N--CA 1.501 2.101 0 O-C-N 121.473 -0.767 . . . . 1.55 110.681 -179.274 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 29.3 tttm -91.4 92.05 8.4 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.666 -0.646 . . . . 2.53 109.535 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -52.05 145.13 10.78 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.341 -0.85 . . . . 0.82 109.308 179.889 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.426 ' OE2' ' O ' ' A' ' 63' ' ' ILE . 0.2 OUTLIER -93.78 87.63 5.5 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.234 -0.916 . . . . 2.3 109.561 -179.843 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.426 ' O ' ' OE2' ' A' ' 62' ' ' GLU . 25.0 mt -60.23 150.17 6.69 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 N-CA-C 109.263 -0.643 . . . . 1.4 109.263 179.574 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -151.09 114.83 4.93 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 120.725 -1.234 . . . . 1.36 109.939 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.492 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 40.1 p90 -86.85 124.17 32.79 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.222 -0.924 . . . . 1.47 109.198 179.531 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 62.9 tt0 . . . . . 0 N--CA 1.497 1.915 0 O-C-N 121.254 -0.904 . . . . 2.51 109.43 179.971 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 4.3 t . . . . . 0 N--CA 1.492 1.671 0 N-CA-C 108.983 -0.747 . . . . 2.2 108.983 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 24.5 m -78.23 129.33 34.96 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.19 -0.944 . . . . 2.05 109.356 -179.844 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -101.14 116.5 5.59 Favored Glycine 0 N--CA 1.497 2.747 0 N-CA-C 110.111 -1.196 . . . . 1.39 110.111 -179.637 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.649 HG21 HD12 ' A' ' 41' ' ' ILE . 71.8 t -105.36 106.85 21.28 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.098 0 O-C-N 121.537 -0.978 . . . . 1.57 109.284 179.571 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 4.0 t -100.11 126.39 46.34 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.549 -0.719 . . . . 1.85 109.474 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.401 ' N ' ' CD1' ' A' ' 77' ' ' TYR . 12.0 p90 -125.36 131.69 52.94 Favored 'General case' 0 N--CA 1.497 1.882 0 N-CA-C 108.758 -0.831 . . . . 1.54 108.758 179.746 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.627 ' O ' HG13 ' A' ' 78' ' ' VAL . 9.9 p -98.73 114.35 36.17 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.294 -0.879 . . . . 1.9 109.255 -179.501 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.406 HG22 ' H ' ' A' ' 79' ' ' VAL . 15.5 m -81.79 161.83 3.57 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 O-C-N 121.041 -1.037 . . . . 1.27 109.027 -179.707 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -101.44 -48.54 4.32 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.227 -0.92 . . . . 2.48 110.781 -178.825 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -156.67 153.13 23.91 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 120.554 -1.341 . . . . 1.92 111.108 -179.506 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.648 ' HG3' ' N ' ' A' ' 107' ' ' SER . 76.4 Cg_exo -37.08 158.08 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.646 0 C-N-CA 123.363 2.709 . . . . 1.3 113.875 179.231 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 150.77 -167.49 30.46 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.359 -1.496 . . . . 1.02 109.359 179.765 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 84' ' ' ASP . . . . . 0.521 ' OD2' ' NH2' ' B' ' 8' ' ' ARG . 10.7 m-20 -109.3 91.58 3.7 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.532 -0.981 . . . . 2.13 108.756 179.64 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 3.0 m-85 -78.25 136.19 37.72 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 108.049 -1.093 . . . . 0.92 108.049 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 86' ' ' GLU . . . . . 0.402 ' OE2' ' O ' ' A' ' 84' ' ' ASP . 0.0 OUTLIER -119.18 117.36 28.44 Favored 'General case' 0 N--CA 1.501 2.086 0 N-CA-C 108.121 -1.066 . . . . 1.53 108.121 -179.033 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.437 ' O ' HG13 ' A' ' 87' ' ' VAL . 14.6 p -117.11 133.91 62.36 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 121.622 -0.674 . . . . 1.0 110.408 -178.842 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 3.5 p -128.65 105.77 8.49 Favored 'General case' 0 N--CA 1.501 2.092 0 O-C-N 121.61 -0.682 . . . . 1.59 109.459 179.715 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.4 pt -107.95 138.22 35.53 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.897 0 CA-C-O 121.415 0.626 . . . . 1.29 109.839 -179.732 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 90' ' ' LYS . . . . . 0.458 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -145.08 122.63 11.74 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 108.659 -0.867 . . . . 1.58 108.659 179.928 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 78.7 t80 -80.33 100.95 8.66 Favored 'General case' 0 N--CA 1.491 1.588 0 C-N-CA 118.764 -1.174 . . . . 1.34 107.891 178.492 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' ASN . . . . . 0.407 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 2.0 t30 69.59 39.86 1.49 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.343 -0.848 . . . . 2.32 109.177 -178.908 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.407 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 1.5 m-20 75.61 13.93 2.88 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.678 -0.639 . . . . 1.92 111.62 179.483 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 94' ' ' GLU . . . . . 0.599 ' OE1' ' HB2' ' A' ' 18' ' ' ALA . 0.5 OUTLIER -98.44 94.44 6.72 Favored 'General case' 0 N--CA 1.498 1.97 0 N-CA-C 106.964 -1.495 . . . . 2.25 106.964 177.58 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 95' ' ' HIS . . . . . 0.508 ' O ' ' CG ' ' A' ' 95' ' ' HIS . 29.5 p-80 -71.57 112.69 7.9 Favored 'General case' 0 N--CA 1.487 1.384 0 CA-C-O 121.485 0.66 . . . . 2.88 109.748 -178.219 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 96' ' ' ILE . . . . . 0.557 ' O ' ' N ' ' A' ' 98' ' ' ASP . 6.3 pt -57.06 152.02 31.4 Favored Pre-proline 0 C--N 1.3 -1.579 0 N-CA-C 108.319 -0.993 . . . . 2.35 108.319 179.594 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -59.05 73.96 0.05 OUTLIER 'Trans proline' 0 CA--C 1.54 0.789 0 N-CA-C 109.234 -1.102 . . . . 2.48 109.234 179.364 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.557 ' N ' ' O ' ' A' ' 96' ' ' ILE . 0.9 OUTLIER -174.93 -51.87 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.077 -1.014 . . . . 2.65 109.38 -179.339 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 5.3 t -54.25 134.31 60.57 Favored Pre-proline 0 C--N 1.299 -1.626 0 O-C-N 121.321 -0.862 . . . . 2.0 109.926 -177.64 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_endo -89.94 116.25 2.91 Favored 'Cis proline' 0 N--CA 1.495 1.606 0 CA-C-N 118.995 0.677 . . . . 1.79 110.521 -1.98 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 101' ' ' PHE . . . . . 0.574 ' CD1' ' N ' ' A' ' 101' ' ' PHE . 0.1 OUTLIER -89.49 149.59 22.84 Favored 'General case' 0 N--CA 1.512 2.639 0 O-C-N 119.979 -1.701 . . . . 2.19 108.76 178.029 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 8.6 p -86.45 138.43 19.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.5 -0.75 . . . . 1.44 109.133 179.681 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 76.7 t -120.15 85.37 35.6 Favored Pre-proline 0 N--CA 1.498 1.936 0 N-CA-C 108.312 -0.996 . . . . 1.19 108.312 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -65.3 112.97 2.25 Favored 'Trans proline' 0 C--N 1.32 -0.953 0 C-N-CA 121.276 1.317 . . . . 1.49 111.556 -178.012 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 47.2 t -89.73 143.06 11.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 N-CA-C 106.667 -1.605 . . . . 1.35 106.667 177.853 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.702 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -127.92 131.28 49.37 Favored 'General case' 0 N--CA 1.507 2.406 0 CA-C-O 121.956 0.884 . . . . 1.67 111.788 -177.016 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 107' ' ' SER . . . . . 0.648 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 66.4 p -99.8 84.77 2.96 Favored 'General case' 0 N--CA 1.493 1.693 0 N-CA-C 107.229 -1.397 . . . . 2.04 107.229 178.783 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 13.3 mt 65.12 -0.69 1.02 Allowed 'General case' 0 C--N 1.292 -1.917 0 N-CA-C 108.081 -1.081 . . . . 3.2 108.081 -178.103 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.484 ' H ' ' C ' ' A' ' 107' ' ' SER . 53.8 p -89.1 -22.89 22.66 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.982 -0.747 . . . . 2.09 108.982 179.068 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 110' ' ' ASP . . . . . 0.702 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 32.9 t70 . . . . . 0 N--CA 1.493 1.676 0 O-C-N 121.139 -0.975 . . . . 2.85 108.586 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 8' ' ' ARG . . . . . 0.521 ' NH2' ' OD2' ' A' ' 84' ' ' ASP . 3.8 mmt-85 . . . . . 0 N--CA 1.492 1.67 0 CA-C-O 121.472 0.654 . . . . 3.04 109.358 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 9' ' ' VAL . . . . . 0.408 ' O ' ' OE2' ' A' ' 56' ' ' GLU . 2.6 t -68.47 161.23 4.22 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 N-CA-C 107.505 -1.294 . . . . 0.67 107.505 178.549 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -97.77 138.94 34.38 Favored 'General case' 0 N--CA 1.5 2.034 0 O-C-N 121.186 -0.947 . . . . 0.58 110.809 -178.636 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 11' ' ' SER . . . . . 0.41 ' O ' ' O ' ' A' ' 55' ' ' VAL . 35.7 t -143.07 130.73 21.34 Favored 'General case' 0 N--CA 1.493 1.72 0 N-CA-C 108.444 -0.947 . . . . 1.19 108.444 179.092 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 11.1 t -150.69 125.37 9.67 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.069 -1.019 . . . . 1.38 110.072 -179.369 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 0.731 HG22 ' H ' ' B' ' 14' ' ' PHE . 12.3 p -173.26 179.81 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 N-CA-C 108.263 -1.014 . . . . 0.42 108.263 179.649 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 14' ' ' PHE . . . . . 0.731 ' H ' HG22 ' B' ' 13' ' ' VAL . 0.1 OUTLIER 174.59 -167.65 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.504 0 C-N-CA 118.548 -1.261 . . . . 1.79 112.237 179.629 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -141.34 159.66 22.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 N-CA-C 108.097 -1.075 . . . . 1.25 108.097 -179.841 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 1.7 t -132.11 151.07 51.98 Favored 'General case' 0 N--CA 1.499 2.017 0 O-C-N 121.303 -0.873 . . . . 1.61 109.474 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 28.4 mt . . . . . 0 N--CA 1.5 2.047 0 O-C-N 121.487 -0.758 . . . . 1.32 109.576 -179.899 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 2.003 0 N-CA-C 109.886 -1.286 . . . . 2.44 109.886 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.544 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -68.24 -15.55 67.89 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.881 -1.288 . . . . 1.81 109.881 -179.68 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.51 ' N ' ' OE1' ' A' ' 94' ' ' GLU . . . -43.8 -17.67 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.525 -0.985 . . . . 2.21 109.823 -179.679 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' HIS . . . . . 0.544 ' N ' ' O ' ' A' ' 17' ' ' GLY . 11.7 t-80 -100.25 -52.56 3.35 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.447 -0.783 . . . . 2.87 110.388 -179.146 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.545 ' HZ1' ' CB ' ' A' ' 43' ' ' THR . 0.0 OUTLIER -64.49 -17.89 64.29 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.962 -1.086 . . . . 2.02 109.874 -179.288 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.592 ' O ' HG13 ' A' ' 21' ' ' VAL . 9.7 p -72.22 114.31 10.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.046 -1.034 . . . . 2.07 108.829 179.503 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.405 ' HG2' ' HE1' ' A' ' 42' ' ' TRP . 5.9 tpp180 -109.84 134.61 51.86 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.452 -0.78 . . . . 3.5 110.108 -178.944 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -141.79 113.59 7.89 Favored 'General case' 0 N--CA 1.493 1.691 0 N-CA-C 108.392 -0.966 . . . . 1.83 108.392 179.15 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -150.93 132.07 3.76 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 109.94 -1.264 . . . . 1.9 109.94 -179.294 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.38 179.11 48.9 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 110.055 -1.218 . . . . 1.85 110.055 179.721 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 7.2 m -75.9 -19.9 58.46 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.47 -1.018 . . . . 2.31 109.674 179.922 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.449 ' O ' ' OH ' ' A' ' 77' ' ' TYR . . . -70.97 -24.76 76.8 Favored Glycine 0 N--CA 1.488 2.138 0 N-CA-C 108.767 -1.733 . . . . 1.64 108.767 179.844 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 29.6 mt -81.51 -11.21 59.27 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.555 -0.968 . . . . 1.83 108.946 179.633 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 33.2 mm-40 -84.67 -49.03 8.88 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.512 -0.743 . . . . 2.34 109.762 -179.494 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' ARG . . . . . 0.504 ' NH1' ' OD1' ' A' ' 110' ' ' ASP . 9.4 ptp180 -174.92 173.69 2.66 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.221 -0.925 . . . . 3.77 109.407 179.809 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -138.71 170.91 23.78 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 108.196 -1.962 . . . . 1.57 108.196 179.475 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.4 ' HA ' ' O ' ' A' ' 106' ' ' ALA . 25.6 t -134.64 149.36 29.56 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 O-C-N 121.23 -1.159 . . . . 1.83 109.944 -179.526 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.44 ' HB2' ' HD3' ' A' ' 82' ' ' PRO . . . -38.51 113.03 0.26 Allowed 'General case' 0 N--CA 1.496 1.832 0 CA-C-O 121.712 0.767 . . . . 1.64 112.098 -179.306 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 63.48 40.67 99.04 Favored Glycine 0 N--CA 1.491 2.337 0 O-C-N 121.685 -0.635 . . . . 1.73 111.814 177.424 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 46.4 t -127.32 119.95 22.07 Favored Pre-proline 0 N--CA 1.502 2.146 0 O-C-N 121.289 -1.124 . . . . 2.19 108.536 178.924 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -59.37 113.89 1.8 Allowed 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 120.589 0.86 . . . . 1.96 110.541 -179.488 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.517 ' HB3' ' CZ ' ' A' ' 77' ' ' TYR . . . -86.39 90.67 8.27 Favored 'General case' 0 N--CA 1.492 1.665 0 N-CA-C 108.281 -1.007 . . . . 1.69 108.281 179.032 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -85.78 148.28 25.92 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.244 -0.91 . . . . 2.23 110.884 -178.513 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 0.674 ' CE2' HD11 ' A' ' 41' ' ' ILE . 5.2 p90 -153.25 159.03 42.52 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 107.148 -1.427 . . . . 1.54 107.148 177.825 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 40' ' ' SER . . . . . 0.426 ' OG ' ' OG ' ' A' ' 72' ' ' SER . 3.6 t -98.26 156.2 16.82 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.223 -0.923 . . . . 2.37 111.904 -177.093 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.674 HD11 ' CE2' ' A' ' 39' ' ' PHE . 13.3 mt -149.18 117.16 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 N-CA-C 108.368 -0.975 . . . . 1.65 108.368 178.713 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.519 ' O ' ' CD2' ' A' ' 42' ' ' TRP . 7.3 p-90 -122.07 129.12 52.12 Favored 'General case' 0 N--CA 1.503 2.182 0 O-C-N 121.256 -0.903 . . . . 3.68 109.031 179.718 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.545 ' CB ' ' HZ1' ' A' ' 20' ' ' LYS . 0.6 OUTLIER -149.02 142.11 24.9 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.229 -0.919 . . . . 2.89 109.605 -179.103 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 44' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -178.1 68.16 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.352 -0.842 . . . . 4.63 109.308 179.501 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 28.6 tt0 -153.47 -51.33 0.1 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.176 -0.953 . . . . 2.89 109.501 -179.919 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -61.57 -57.16 13.16 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.146 -0.971 . . . . 1.74 109.439 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 136.13 -177.56 19.46 Favored Glycine 0 N--CA 1.495 2.586 0 N-CA-C 108.683 -1.767 . . . . 1.6 108.683 -179.621 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.78 142.36 23.98 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.048 -1.266 . . . . 1.4 109.306 179.907 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -159.2 176.95 35.94 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.422 -1.471 . . . . 1.04 109.422 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -109.82 114.35 3.87 Favored Glycine 0 N--CA 1.498 2.785 0 N-CA-C 109.439 -1.464 . . . . 1.06 109.439 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.474 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 10.5 tp -94.43 96.75 9.71 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.216 -1.167 . . . . 1.1 108.353 179.386 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 22.3 p -84.68 141.16 30.8 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.627 -0.879 . . . . 1.56 108.627 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.537 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 87.3 mt -134.01 113.96 18.72 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.342 -0.848 . . . . 0.65 109.489 -179.838 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -105.28 108.52 20.08 Favored 'General case' 0 N--CA 1.495 1.784 0 N-CA-C 108.808 -0.812 . . . . 0.69 108.808 179.611 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.433 HG23 ' OG ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -100.27 142.58 15.27 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.494 -0.753 . . . . 0.91 109.412 -179.795 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 12.5 tt0 -141.89 144.12 33.65 Favored 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 108.046 -1.094 . . . . 1.8 108.046 178.999 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.429 ' O ' ' O ' ' B' ' 9' ' ' VAL . . . 163.79 -172.4 39.66 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.836 -1.306 . . . . 0.49 109.836 -179.498 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -63.34 -28.73 72.03 Favored 'Trans proline' 0 C--N 1.318 -1.053 0 C-N-CA 122.133 1.889 . . . . 0.66 112.136 -179.412 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -131.73 175.99 8.72 Favored 'General case' 0 N--CA 1.502 2.152 0 O-C-N 121.225 -0.922 . . . . 1.55 110.165 -179.575 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 47.0 mttp -93.09 120.21 33.14 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.518 -0.739 . . . . 2.53 109.523 -179.712 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.673 ' HB1' ' HB2' ' A' ' 77' ' ' TYR . . . -80.94 108.63 14.78 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.331 -0.856 . . . . 0.82 108.825 179.82 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 23.4 mt-10 -83.51 103.17 12.65 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.072 -1.018 . . . . 2.3 109.87 -179.592 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 7.6 mm -58.73 156.96 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.886 -0.509 . . . . 1.4 109.751 179.781 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.469 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -139.66 174.5 10.45 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.122 -0.986 . . . . 1.36 109.015 179.649 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.441 ' CD1' ' N ' ' A' ' 65' ' ' PHE . 13.9 p90 -139.64 117.18 11.43 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.412 -0.805 . . . . 1.47 109.536 -179.896 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 . . . . . 0 N--CA 1.495 1.818 0 O-C-N 121.31 -0.869 . . . . 2.51 109.453 179.93 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.426 ' OG ' ' OG ' ' A' ' 40' ' ' SER . 24.2 t . . . . . 0 N--CA 1.49 1.561 0 N-CA-C 109.131 -0.692 . . . . 2.2 109.131 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' CYS . . . . . 0.51 ' N ' ' O ' ' A' ' 41' ' ' ILE . 20.5 m -77.26 110.89 12.36 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.233 -0.917 . . . . 2.05 109.582 -179.849 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -83.79 115.15 4.0 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.408 -1.477 . . . . 1.39 109.408 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.552 HG21 HD12 ' A' ' 41' ' ' ILE . 10.1 t -115.42 133.86 60.41 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.052 0 O-C-N 121.649 -0.912 . . . . 1.57 108.964 179.897 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.469 ' O ' ' N ' ' A' ' 64' ' ' ALA . 6.0 t -136.73 139.82 42.16 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.447 -0.783 . . . . 1.85 109.944 -179.827 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.673 ' HB2' ' HB1' ' A' ' 61' ' ' ALA . 6.9 p90 -120.16 139.2 52.97 Favored 'General case' 0 N--CA 1.495 1.79 0 N-CA-C 108.201 -1.037 . . . . 1.54 108.201 179.224 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.576 ' O ' HG13 ' A' ' 78' ' ' VAL . 9.7 p -108.87 120.78 60.88 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 O-C-N 121.332 -0.855 . . . . 1.9 109.741 -179.078 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.415 HG12 ' CZ ' ' A' ' 85' ' ' TYR . 3.6 m -101.12 168.4 1.93 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 N-CA-C 108.439 -0.949 . . . . 1.27 108.439 179.448 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 34.2 tp60 -101.5 -40.56 6.99 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.08 -1.013 . . . . 2.48 110.758 -179.486 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.429 ' O ' ' O ' ' A' ' 82' ' ' PRO . 0.0 OUTLIER -153.32 156.51 32.54 Favored Pre-proline 0 N--CA 1.504 2.248 0 O-C-N 120.539 -1.351 . . . . 1.92 111.209 -179.276 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.558 ' HG3' ' N ' ' A' ' 107' ' ' SER . 78.7 Cg_exo -37.73 169.12 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.654 0 C-N-CA 123.444 2.763 . . . . 1.3 113.239 179.016 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 142.82 179.02 19.25 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.659 -1.376 . . . . 1.02 109.659 179.559 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 84' ' ' ASP . . . . . 0.814 ' H ' HH12 ' B' ' 8' ' ' ARG . 3.0 m-20 -96.97 87.2 4.18 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 107.929 -1.137 . . . . 2.13 107.929 179.301 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.415 ' CZ ' HG12 ' A' ' 79' ' ' VAL . 2.9 m-85 -74.13 134.76 42.87 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 108.351 -0.981 . . . . 0.92 108.351 -179.345 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -111.22 121.58 45.65 Favored 'General case' 0 N--CA 1.497 1.91 0 N-CA-C 108.682 -0.858 . . . . 1.53 108.682 -179.058 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.1 p -119.65 140.58 43.16 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.891 0 O-C-N 121.552 -0.717 . . . . 1.0 109.546 -179.798 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 12.2 t -133.18 101.39 5.18 Favored 'General case' 0 N--CA 1.5 2.026 0 O-C-N 121.515 -0.741 . . . . 1.59 109.308 179.772 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.42 HG13 HD11 ' A' ' 96' ' ' ILE . 1.9 pt -108.51 137.51 39.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.721 -0.612 . . . . 1.29 110.37 -179.285 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 90' ' ' LYS . . . . . 0.44 ' HG3' ' H ' ' A' ' 93' ' ' ASP . 0.2 OUTLIER -146.91 125.87 12.79 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.857 -0.794 . . . . 1.58 108.857 179.367 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 48.4 t80 -81.69 93.89 6.86 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 120.785 -1.197 . . . . 1.34 108.492 179.42 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 92' ' ' ASN . . . . . 0.409 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 5.4 t30 69.93 43.24 0.94 Allowed 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 107.913 -1.143 . . . . 2.32 107.913 -178.591 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.44 ' H ' ' HG3' ' A' ' 90' ' ' LYS . 3.4 m-20 78.3 11.76 1.75 Allowed 'General case' 0 N--CA 1.495 1.789 0 CA-C-O 121.253 0.549 . . . . 1.92 109.96 -179.241 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 94' ' ' GLU . . . . . 0.51 ' OE1' ' N ' ' A' ' 18' ' ' ALA . 50.0 mt-10 -85.43 77.34 9.94 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 107.805 -1.183 . . . . 2.25 107.805 178.454 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 95' ' ' HIS . . . . . 0.401 ' O ' ' CG ' ' A' ' 95' ' ' HIS . 0.0 OUTLIER -67.97 106.41 2.33 Favored 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 120.03 -0.668 . . . . 2.88 109.752 -179.513 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 96' ' ' ILE . . . . . 0.775 ' H ' HD13 ' A' ' 96' ' ' ILE . 0.0 OUTLIER -68.96 156.1 92.15 Favored Pre-proline 0 N--CA 1.495 1.787 0 N-CA-C 107.709 -1.219 . . . . 2.35 107.709 179.606 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -48.9 -29.28 14.86 Favored 'Trans proline' 0 C--N 1.323 -0.806 0 C-N-CA 121.059 1.173 . . . . 2.48 109.144 -179.797 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 57.0 m-20 -58.83 -64.16 1.04 Allowed 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 108.963 -0.755 . . . . 2.65 108.963 178.952 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 3.1 m -70.78 139.7 86.06 Favored Pre-proline 0 C--N 1.296 -1.739 0 O-C-N 121.05 -1.031 . . . . 2.0 110.073 -178.681 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -87.08 119.46 5.07 Favored 'Cis proline' 0 N--CA 1.493 1.49 0 N-CA-C 110.025 -0.798 . . . . 1.79 110.025 -2.342 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 40.5 p90 -121.14 166.97 13.17 Favored 'General case' 0 N--CA 1.519 2.996 0 O-C-N 120.499 -1.376 . . . . 2.19 109.882 178.195 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.4 p -92.35 146.23 6.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 CA-C-O 121.642 0.734 . . . . 1.44 110.918 -178.28 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 79.8 t -119.83 86.46 35.94 Favored Pre-proline 0 N--CA 1.496 1.842 0 N-CA-C 107.799 -1.185 . . . . 1.19 107.799 178.888 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -63.96 114.28 2.54 Favored 'Trans proline' 0 C--N 1.32 -0.95 0 C-N-CA 121.36 1.373 . . . . 1.49 111.683 -178.028 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 75.2 t -98.88 144.09 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 N-CA-C 106.569 -1.641 . . . . 1.35 106.569 178.11 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.681 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -134.94 138.28 43.91 Favored 'General case' 0 N--CA 1.51 2.556 0 CA-C-O 122.055 0.931 . . . . 1.67 112.08 -177.174 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 107' ' ' SER . . . . . 0.558 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 20.3 m -92.2 63.77 4.37 Favored 'General case' 0 N--CA 1.496 1.856 0 N-CA-C 107.152 -1.425 . . . . 2.04 107.152 178.652 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 108' ' ' LEU . . . . . 0.49 ' CB ' ' O ' ' A' ' 107' ' ' SER . 3.2 tp 80.45 -13.56 0.92 Allowed 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 106.456 -1.683 . . . . 3.2 106.456 -177.416 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.478 ' H ' ' C ' ' A' ' 107' ' ' SER . 5.2 m -68.54 -21.9 64.53 Favored 'General case' 0 C--N 1.306 -1.305 0 N-CA-C 108.732 -0.84 . . . . 2.09 108.732 178.785 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 110' ' ' ASP . . . . . 0.681 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 21.5 t70 . . . . . 0 N--CA 1.494 1.736 0 CA-C-O 121.937 0.875 . . . . 2.85 108.666 179.876 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 8' ' ' ARG . . . . . 0.814 HH12 ' H ' ' A' ' 84' ' ' ASP . 10.7 mtt180 . . . . . 0 N--CA 1.489 1.497 0 N-CA-C 108.087 -1.079 . . . . 3.04 108.087 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 9' ' ' VAL . . . . . 0.429 ' O ' ' O ' ' A' ' 57' ' ' GLY . 38.6 t -51.74 155.79 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 120.921 -1.112 . . . . 0.67 108.215 179.404 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -119.66 149.87 41.28 Favored 'General case' 0 N--CA 1.501 2.078 0 O-C-N 121.402 -0.811 . . . . 0.58 110.142 -178.914 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 11' ' ' SER . . . . . 0.433 ' OG ' HG23 ' A' ' 55' ' ' VAL . 6.9 t -147.36 141.84 26.46 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.506 -0.746 . . . . 1.19 109.301 179.688 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 6.7 m -143.88 121.14 11.56 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.176 -0.952 . . . . 1.38 109.439 -179.846 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 0.631 HG22 ' N ' ' B' ' 14' ' ' PHE . 7.7 p -163.62 168.76 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.39 -0.819 . . . . 0.42 109.183 179.91 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 14' ' ' PHE . . . . . 0.631 ' N ' HG22 ' B' ' 13' ' ' VAL . 7.9 p90 -176.91 -168.05 0.2 Allowed 'General case' 0 N--CA 1.488 1.437 0 C-N-CA 119.402 -0.919 . . . . 1.79 111.928 179.7 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.6 pt -151.29 167.47 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.344 0 N-CA-C 109.091 -0.707 . . . . 1.25 109.091 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 16' ' ' THR . . . . . 0.428 ' O ' HG23 ' B' ' 16' ' ' THR . 7.3 t -122.53 128.92 51.38 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 121.463 -0.773 . . . . 1.61 109.009 179.661 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 12.1 mt . . . . . 0 N--CA 1.497 1.901 0 O-C-N 121.204 -0.935 . . . . 1.32 109.866 -179.617 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.509 ' O ' ' N ' ' A' ' 18' ' ' ALA . . . . . . . . 0 N--CA 1.488 2.107 0 N-CA-C 111.157 -0.777 . . . . 2.44 111.157 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.55 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -38.83 -23.39 0.02 OUTLIER Glycine 0 N--CA 1.497 2.702 0 O-C-N 121.819 -0.813 . . . . 1.81 111.59 -178.704 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.709 ' HB2' ' OE1' ' A' ' 94' ' ' GLU . . . -47.25 -11.57 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.861 0 O-C-N 120.857 -1.378 . . . . 2.21 110.145 -179.467 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' HIS . . . . . 0.55 ' N ' ' O ' ' A' ' 17' ' ' GLY . 1.8 t60 -97.24 -37.73 9.96 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.249 -0.907 . . . . 2.87 110.242 -179.372 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.515 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.0 OUTLIER -91.03 -14.48 31.29 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.008 -1.057 . . . . 2.02 110.497 -179.145 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.566 ' O ' HG13 ' A' ' 21' ' ' VAL . 4.7 p -78.96 114.4 19.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 120.838 -1.164 . . . . 2.07 109.712 -179.763 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 12.5 tpp180 -109.75 139.27 45.0 Favored 'General case' 0 N--CA 1.492 1.646 0 N-CA-C 108.92 -0.771 . . . . 3.5 108.92 -179.877 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -147.32 113.57 5.89 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.535 -0.728 . . . . 1.83 109.2 179.584 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -147.6 128.38 2.9 Favored Glycine 0 N--CA 1.496 2.662 0 N-CA-C 109.472 -1.451 . . . . 1.9 109.472 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.07 171.24 43.69 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.842 -1.303 . . . . 1.85 109.842 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 34.1 m -74.89 -23.6 58.4 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.329 -1.101 . . . . 2.31 109.266 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.426 ' C ' ' H ' ' A' ' 29' ' ' GLU . . . -68.61 -27.92 73.51 Favored Glycine 0 N--CA 1.485 1.925 0 N-CA-C 108.444 -1.862 . . . . 1.64 108.444 179.641 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 24.9 mt -81.06 26.92 0.41 Allowed 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 108.416 -0.957 . . . . 1.83 108.416 179.397 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.426 ' H ' ' C ' ' A' ' 27' ' ' GLY . 42.5 mt-10 -132.21 -50.56 0.94 Allowed 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.687 -0.633 . . . . 2.34 109.608 -179.621 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 29.0 ptt180 -168.17 177.8 5.32 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 120.89 -1.131 . . . . 3.77 110.602 -179.774 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -151.08 175.68 29.92 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 108.566 -1.814 . . . . 1.57 108.566 179.686 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 39.9 t -134.56 151.93 32.58 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.087 0 O-C-N 121.22 -1.165 . . . . 1.83 110.748 -179.702 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.574 ' HB2' ' HB2' ' A' ' 107' ' ' SER . . . -39.16 108.95 0.09 Allowed 'General case' 0 N--CA 1.5 2.029 0 CA-C-O 121.399 0.618 . . . . 1.64 112.494 -179.388 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 54.57 53.71 37.15 Favored Glycine 0 N--CA 1.491 2.323 0 O-C-N 121.393 -0.817 . . . . 1.73 111.626 176.899 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 24.0 t -127.23 124.28 23.68 Favored Pre-proline 0 N--CA 1.496 1.826 0 N-CA-C 108.205 -1.035 . . . . 2.19 108.205 178.663 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo -57.24 128.95 31.69 Favored 'Trans proline' 0 C--O 1.216 -0.615 0 N-CA-C 109.693 -0.926 . . . . 1.96 109.693 -179.581 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.554 ' HB3' ' CZ ' ' A' ' 77' ' ' TYR . . . -134.36 157.89 45.22 Favored 'General case' 0 N--CA 1.502 2.16 0 O-C-N 121.518 -0.739 . . . . 1.69 109.507 -179.634 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -160.14 164.08 33.23 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.121 -0.987 . . . . 2.23 110.976 -179.663 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 0.558 ' CD1' ' N ' ' A' ' 39' ' ' PHE . 0.7 OUTLIER -139.89 -179.03 5.71 Favored 'General case' 0 C--N 1.304 -1.391 0 N-CA-C 106.896 -1.52 . . . . 1.54 106.896 177.75 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 52.2 p -119.16 145.87 45.64 Favored 'General case' 0 N--CA 1.5 2.04 0 O-C-N 121.598 -0.688 . . . . 2.37 110.609 -178.816 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.537 ' O ' ' N ' ' A' ' 73' ' ' CYS . 42.8 mt -143.63 128.68 15.1 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 N-CA-C 108.58 -0.896 . . . . 1.65 108.58 179.213 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 5.5 p-90 -128.24 138.78 52.59 Favored 'General case' 0 N--CA 1.502 2.161 0 N-CA-C 108.853 -0.795 . . . . 3.68 108.853 179.423 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.515 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -162.42 139.22 7.9 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.171 -0.956 . . . . 2.89 109.896 -179.534 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 44' ' ' ARG . . . . . . . . . . . . . 61.7 ttt180 -171.84 68.38 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.414 -0.804 . . . . 4.63 109.226 179.732 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 11.1 tp10 -153.72 -51.79 0.1 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.244 -0.91 . . . . 2.89 109.568 -179.87 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.76 -50.08 73.33 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.201 -0.937 . . . . 1.74 108.946 179.795 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 116.14 -162.4 12.62 Favored Glycine 0 N--CA 1.497 2.745 0 N-CA-C 109.639 -1.384 . . . . 1.6 109.639 179.735 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.4 151.98 5.11 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.276 -1.132 . . . . 1.4 109.386 -179.841 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -176.49 -162.72 27.7 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.55 -1.42 . . . . 1.04 109.55 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -140.47 119.71 1.63 Allowed Glycine 0 N--CA 1.496 2.663 0 N-CA-C 109.528 -1.429 . . . . 1.06 109.528 -179.878 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.466 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 11.6 tp -99.43 99.04 9.9 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.357 -1.084 . . . . 1.1 108.691 179.685 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 4.1 m -84.8 142.33 29.85 Favored 'General case' 0 N--CA 1.496 1.84 0 N-CA-C 108.741 -0.837 . . . . 1.56 108.741 179.867 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.52 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 80.5 mt -132.36 116.6 29.21 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 O-C-N 121.01 -1.056 . . . . 0.65 109.889 -179.915 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -106.99 106.92 17.69 Favored 'General case' 0 N--CA 1.496 1.865 0 N-CA-C 108.562 -0.903 . . . . 0.69 108.562 179.328 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -106.23 137.55 35.96 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 121.388 -0.82 . . . . 0.91 109.941 -179.186 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' GLU . . . . . 0.433 ' OE2' ' O ' ' B' ' 9' ' ' VAL . 40.7 tp10 -131.97 142.78 49.72 Favored 'General case' 0 N--CA 1.495 1.785 0 N-CA-C 107.896 -1.15 . . . . 1.8 107.896 178.36 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 172.95 -179.51 44.34 Favored Glycine 0 N--CA 1.488 2.132 0 N-CA-C 108.784 -1.726 . . . . 0.49 108.784 -179.635 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -63.43 -21.91 71.26 Favored 'Trans proline' 0 C--N 1.315 -1.231 0 C-N-CA 121.678 1.585 . . . . 0.66 110.732 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' SER . . . . . 0.423 ' O ' ' OH ' ' A' ' 85' ' ' TYR . 36.6 m -143.24 165.47 27.36 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.453 -0.78 . . . . 1.55 110.114 -179.62 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 38.2 mttp -86.97 104.96 16.78 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.507 -0.746 . . . . 2.53 109.396 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -67.06 113.06 4.74 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.337 -0.852 . . . . 0.82 109.535 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 24.5 mm-40 -53.72 171.76 0.09 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.282 -0.886 . . . . 2.3 109.225 179.84 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.4 HG22 ' N ' ' A' ' 64' ' ' ALA . 90.1 mt -142.32 155.59 18.83 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 N-CA-C 108.122 -1.066 . . . . 1.4 108.122 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.542 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -149.56 175.35 11.6 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 120.642 -1.286 . . . . 1.36 109.635 -179.802 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.522 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 54.6 p90 -138.88 124.77 19.84 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.448 -0.782 . . . . 1.47 109.124 179.846 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 . . . . . 0 N--CA 1.495 1.821 0 O-C-N 121.273 -0.892 . . . . 2.51 109.579 -179.825 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 40.3 t . . . . . 0 N--CA 1.494 1.762 0 N-CA-C 109.176 -0.675 . . . . 2.2 109.176 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 73' ' ' CYS . . . . . 0.537 ' N ' ' O ' ' A' ' 41' ' ' ILE . 46.6 t -71.54 111.1 6.57 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.228 -0.92 . . . . 2.05 109.48 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -91.96 115.14 4.71 Favored Glycine 0 N--CA 1.493 2.477 0 N-CA-C 109.692 -1.363 . . . . 1.39 109.692 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 45.3 t -99.38 102.0 12.84 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 O-C-N 121.467 -1.019 . . . . 1.57 109.011 179.721 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.542 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.4 OUTLIER -92.0 137.09 32.65 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.338 -0.851 . . . . 1.85 109.111 -179.837 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.554 ' CZ ' ' HB3' ' A' ' 37' ' ' ALA . 8.5 p90 -136.34 166.04 24.38 Favored 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 108.674 -0.861 . . . . 1.54 108.674 -179.862 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 6.7 t -141.86 110.05 2.34 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.329 -0.857 . . . . 1.9 109.585 -179.669 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.464 ' H ' HG22 ' A' ' 79' ' ' VAL . 3.3 m -84.73 154.32 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.544 -0.723 . . . . 1.27 109.429 -179.915 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 4.3 tp-100 -93.26 -48.93 6.21 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.065 -1.022 . . . . 2.48 111.015 -178.96 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.431 ' O ' ' O ' ' A' ' 82' ' ' PRO . 81.5 mm-40 -148.57 149.92 32.39 Favored Pre-proline 0 N--CA 1.504 2.263 0 O-C-N 120.68 -1.262 . . . . 1.92 111.609 -178.427 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.637 ' HG3' ' N ' ' A' ' 107' ' ' SER . 83.1 Cg_exo -37.18 168.53 0.0 OUTLIER 'Trans proline' 0 C--O 1.216 -0.599 0 C-N-CA 123.15 2.567 . . . . 1.3 113.787 178.37 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 141.8 -173.8 23.4 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 108.651 -1.779 . . . . 1.02 108.651 -179.87 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 84' ' ' ASP . . . . . 0.717 ' H ' ' NH1' ' B' ' 8' ' ' ARG . 0.4 OUTLIER -103.18 90.41 3.72 Favored 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 107.866 -1.161 . . . . 2.13 107.866 179.217 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.423 ' OH ' ' O ' ' A' ' 59' ' ' SER . 3.0 m-85 -74.69 133.4 42.09 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 107.992 -1.114 . . . . 0.92 107.992 -179.574 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.36 116.38 28.85 Favored 'General case' 0 N--CA 1.5 2.034 0 N-CA-C 108.503 -0.925 . . . . 1.53 108.503 -178.791 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.429 HG11 ' CZ ' ' A' ' 101' ' ' PHE . 11.3 p -114.63 142.32 27.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 121.719 -0.613 . . . . 1.0 109.865 -179.66 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 32.9 t -136.11 106.07 6.28 Favored 'General case' 0 N--CA 1.494 1.756 0 N-CA-C 109.289 -0.634 . . . . 1.59 109.289 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.413 ' H ' ' HB3' ' A' ' 99' ' ' SER . 1.8 pt -111.4 136.85 46.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 CA-C-O 121.374 0.607 . . . . 1.29 110.148 -179.429 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 90' ' ' LYS . . . . . 0.458 ' HZ2' ' CD2' ' A' ' 95' ' ' HIS . 0.3 OUTLIER -138.99 121.27 15.92 Favored 'General case' 0 N--CA 1.486 1.355 0 N-CA-C 108.518 -0.919 . . . . 1.58 108.518 179.329 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 52.6 t80 -80.1 99.02 7.52 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 107.699 -1.223 . . . . 1.34 107.699 178.563 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 92' ' ' ASN . . . . . 0.442 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 3.6 t-20 69.8 37.79 1.76 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.503 -0.748 . . . . 2.32 109.284 -178.735 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.442 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 1.8 m-20 79.06 13.49 1.2 Allowed 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.625 -0.672 . . . . 1.92 111.629 179.313 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 94' ' ' GLU . . . . . 0.709 ' OE1' ' HB2' ' A' ' 18' ' ' ALA . 0.6 OUTLIER -99.29 97.88 8.9 Favored 'General case' 0 N--CA 1.5 2.059 0 N-CA-C 106.857 -1.534 . . . . 2.25 106.857 177.732 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 95' ' ' HIS . . . . . 0.458 ' CD2' ' HZ2' ' A' ' 90' ' ' LYS . 5.9 m80 -67.88 101.86 1.16 Allowed 'General case' 0 N--CA 1.487 1.421 0 CA-C-O 121.411 0.624 . . . . 2.88 110.924 -177.636 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 96' ' ' ILE . . . . . 0.428 HG23 ' H ' ' A' ' 99' ' ' SER . 2.1 tt -53.32 137.46 49.69 Favored Pre-proline 0 N--CA 1.49 1.566 0 N-CA-C 106.869 -1.53 . . . . 2.35 106.869 178.26 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_exo -40.76 -39.06 2.95 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 121.077 1.184 . . . . 2.48 111.194 -178.575 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.408 ' OD1' ' CD1' ' A' ' 96' ' ' ILE . 8.6 m-20 -50.12 -67.2 0.28 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.787 -1.196 . . . . 2.65 109.092 178.843 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.428 ' H ' HG23 ' A' ' 96' ' ' ILE . 2.8 p -57.53 142.03 77.77 Favored Pre-proline 0 C--N 1.296 -1.759 0 O-C-N 121.405 -0.81 . . . . 2.0 110.086 -178.236 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -85.15 114.92 3.22 Favored 'Cis proline' 0 N--CA 1.49 1.288 0 N-CA-C 108.739 -1.293 . . . . 1.79 108.739 -2.612 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 101' ' ' PHE . . . . . 0.429 ' CZ ' HG11 ' A' ' 87' ' ' VAL . 51.8 p90 -112.77 156.45 22.83 Favored 'General case' 0 N--CA 1.514 2.748 0 O-C-N 120.405 -1.434 . . . . 2.19 110.217 179.286 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.4 p -88.94 146.1 6.58 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 CA-C-O 121.556 0.693 . . . . 1.44 110.417 -178.595 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.414 ' O ' HG12 ' A' ' 103' ' ' VAL . 47.3 t -120.97 86.55 42.09 Favored Pre-proline 0 N--CA 1.494 1.768 0 N-CA-C 107.753 -1.203 . . . . 1.19 107.753 179.236 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo -65.07 111.08 1.65 Allowed 'Trans proline' 0 C--N 1.32 -0.935 0 C-N-CA 121.393 1.395 . . . . 1.49 111.74 -177.879 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.431 HG21 HG11 ' A' ' 79' ' ' VAL . 58.6 t -96.53 141.05 16.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 N-CA-C 106.148 -1.797 . . . . 1.35 106.148 177.828 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.69 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -133.89 133.72 41.83 Favored 'General case' 0 N--CA 1.51 2.53 0 CA-C-O 122.303 1.049 . . . . 1.67 112.131 -177.031 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 107' ' ' SER . . . . . 0.637 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 17.0 t -101.02 85.55 2.87 Favored 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 107.129 -1.434 . . . . 2.04 107.129 178.685 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 12.9 mt 64.76 0.51 1.18 Allowed 'General case' 0 C--N 1.296 -1.729 0 N-CA-C 108.035 -1.098 . . . . 3.2 108.035 -178.011 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.489 ' H ' ' C ' ' A' ' 107' ' ' SER . 8.2 t -89.88 -24.95 21.23 Favored 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 109.011 -0.737 . . . . 2.09 109.011 179.061 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 110' ' ' ASP . . . . . 0.69 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 25.2 t70 . . . . . 0 N--CA 1.488 1.436 0 N-CA-C 107.897 -1.149 . . . . 2.85 107.897 -178.969 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 8' ' ' ARG . . . . . 0.717 ' NH1' ' H ' ' A' ' 84' ' ' ASP . 43.8 mtt180 . . . . . 0 N--CA 1.493 1.7 0 N-CA-C 109.325 -0.62 . . . . 3.04 109.325 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 9' ' ' VAL . . . . . 0.433 ' O ' ' OE2' ' A' ' 56' ' ' GLU . 15.2 t -59.34 160.32 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 N-CA-C 107.718 -1.215 . . . . 0.67 107.718 178.719 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -116.99 142.94 46.31 Favored 'General case' 0 N--CA 1.503 2.189 0 O-C-N 121.287 -0.883 . . . . 0.58 110.433 -179.073 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 30.2 t -143.72 131.36 21.25 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.471 -0.768 . . . . 1.19 109.063 179.47 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 87.8 p -140.39 120.19 13.46 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.232 -0.918 . . . . 1.38 109.587 -179.727 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 0.603 HG22 ' N ' ' B' ' 14' ' ' PHE . 3.0 p -162.26 168.3 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.412 0 O-C-N 121.379 -0.826 . . . . 0.42 109.073 -179.948 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 14' ' ' PHE . . . . . 0.603 ' N ' HG22 ' B' ' 13' ' ' VAL . 6.6 p90 -177.1 -171.76 0.37 Allowed 'General case' 0 N--CA 1.487 1.4 0 C-N-CA 119.391 -0.923 . . . . 1.79 112.008 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -142.64 173.78 6.38 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.322 0 N-CA-C 108.335 -0.987 . . . . 1.25 108.335 179.597 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 32.3 p -146.65 139.82 25.54 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 120.929 -1.107 . . . . 1.61 109.817 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.4 mt . . . . . 0 N--CA 1.494 1.737 0 O-C-N 121.256 -0.902 . . . . 1.32 109.074 179.582 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.548 ' O ' ' N ' ' A' ' 18' ' ' ALA . . . . . . . . 0 N--CA 1.49 2.255 0 N-CA-C 110.643 -0.983 . . . . 2.44 110.643 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.583 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 64.21 -47.1 0.1 OUTLIER Glycine 0 N--CA 1.493 2.497 0 O-C-N 121.479 -1.012 . . . . 1.81 111.055 178.823 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.548 ' N ' ' O ' ' A' ' 16' ' ' GLY . . . -46.24 -11.13 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.871 0 O-C-N 120.959 -1.318 . . . . 2.21 110.05 -179.578 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' HIS . . . . . 0.583 ' N ' ' O ' ' A' ' 17' ' ' GLY . 34.0 t60 -84.64 -48.42 9.51 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 120.994 -1.066 . . . . 2.87 109.6 179.729 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.552 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.1 OUTLIER -83.18 -3.63 57.57 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.047 -1.033 . . . . 2.02 110.192 -179.617 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 66.6 t -77.86 113.24 16.8 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 120.944 -1.098 . . . . 2.07 109.537 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 20.9 tpt180 -100.14 138.93 36.53 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.633 -0.667 . . . . 3.5 109.571 -179.858 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -147.42 113.37 5.79 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 108.402 -0.962 . . . . 1.83 108.402 179.332 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -158.5 128.7 2.12 Favored Glycine 0 N--CA 1.491 2.339 0 C-N-CA 119.688 -1.244 . . . . 1.9 110.234 -179.199 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.3 -179.7 48.77 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.641 -1.383 . . . . 1.85 109.641 179.611 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 6.5 m -76.58 -21.86 55.03 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.168 -1.195 . . . . 2.31 109.24 179.759 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.9 -23.83 77.64 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 108.818 -1.713 . . . . 1.64 108.818 179.71 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 34.6 mt -85.1 28.79 0.69 Allowed 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.499 -1.001 . . . . 1.83 108.689 179.572 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 15.0 mt-10 -138.71 -64.24 0.52 Allowed 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.503 -0.748 . . . . 2.34 109.908 -179.655 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 80.8 mtm180 -150.64 165.42 33.44 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 120.895 -1.128 . . . . 3.77 110.222 -179.248 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -139.07 170.57 24.01 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 107.473 -2.251 . . . . 1.57 107.473 178.887 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 40.5 t -133.85 151.31 32.63 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.109 0 O-C-N 121.088 -1.243 . . . . 1.83 110.948 -179.029 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.499 ' HB2' ' HB2' ' A' ' 107' ' ' SER . . . -40.48 114.59 0.47 Allowed 'General case' 0 N--CA 1.497 1.902 0 CA-C-O 121.867 0.841 . . . . 1.64 112.428 -179.313 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 52.99 49.71 54.19 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 111.225 -0.75 . . . . 1.73 111.225 177.13 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 22.5 t -127.02 124.98 24.1 Favored Pre-proline 0 N--CA 1.496 1.843 0 O-C-N 121.497 -1.002 . . . . 2.19 108.46 179.143 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -58.41 109.86 0.57 Allowed 'Trans proline' 0 C--O 1.215 -0.637 0 N-CA-C 109.682 -0.93 . . . . 1.96 109.682 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -108.03 142.07 38.74 Favored 'General case' 0 N--CA 1.495 1.825 0 N-CA-C 107.929 -1.138 . . . . 1.69 107.929 179.408 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -150.92 169.52 21.53 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.871 -1.143 . . . . 2.23 111.244 -179.385 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 0.61 ' CE2' HD11 ' A' ' 41' ' ' ILE . 5.2 p90 -154.35 173.78 15.73 Favored 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 107.617 -1.253 . . . . 1.54 107.617 178.452 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 72.9 m -101.54 150.82 22.68 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.496 -0.753 . . . . 2.37 110.469 -178.652 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.61 HD11 ' CE2' ' A' ' 39' ' ' PHE . 11.3 mt -142.95 90.64 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 N-CA-C 108.748 -0.834 . . . . 1.65 108.748 178.981 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 31.1 t-105 -92.93 120.01 32.81 Favored 'General case' 0 N--CA 1.493 1.704 0 N-CA-C 108.251 -1.018 . . . . 3.68 108.251 179.504 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.552 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -152.74 108.84 3.36 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.276 -0.89 . . . . 2.89 109.594 -179.148 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 44' ' ' ARG . . . . . 0.598 ' CG ' HH11 ' A' ' 44' ' ' ARG . 0.1 OUTLIER -171.57 82.12 0.07 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.225 -0.922 . . . . 4.63 109.599 -179.984 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 74.2 tt0 -159.5 -46.24 0.05 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.016 -1.053 . . . . 2.89 109.985 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.456 ' H ' ' HE2' ' A' ' 20' ' ' LYS . . . -64.15 -45.62 87.68 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.03 -1.044 . . . . 1.74 109.195 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 160.78 -153.03 23.83 Favored Glycine 0 N--CA 1.485 1.903 0 C-N-CA 119.403 -1.379 . . . . 1.6 110.175 179.786 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -96.66 158.57 15.37 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.558 -0.966 . . . . 1.4 109.174 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -179.09 173.0 45.2 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.392 -1.483 . . . . 1.04 109.392 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -105.11 121.09 6.76 Favored Glycine 0 N--CA 1.495 2.624 0 N-CA-C 109.501 -1.439 . . . . 1.06 109.501 -179.891 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.465 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 64.2 tp -91.01 108.79 20.09 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.222 -1.163 . . . . 1.1 107.897 179.153 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.7 t -91.23 142.37 27.8 Favored 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 108.663 -0.865 . . . . 1.56 108.663 179.89 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.544 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 22.5 mt -130.49 100.62 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 121.521 -0.737 . . . . 0.65 109.071 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.438 ' HB3' ' OG ' ' A' ' 88' ' ' SER . . . -93.86 106.41 18.38 Favored 'General case' 0 N--CA 1.489 1.506 0 N-CA-C 108.621 -0.881 . . . . 0.69 108.621 179.711 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.408 HG23 ' CB ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -101.48 143.28 14.7 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 CA-C-O 121.588 0.708 . . . . 0.91 109.582 -179.631 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 8.2 tt0 -141.52 145.57 35.33 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 107.479 -1.304 . . . . 1.8 107.479 178.868 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 165.56 -172.71 41.14 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.856 -1.298 . . . . 0.49 109.856 -179.095 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -63.18 -33.99 70.14 Favored 'Trans proline' 0 C--N 1.319 -0.988 0 C-N-CA 122.315 2.01 . . . . 0.66 112.514 -179.435 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' SER . . . . . 0.497 ' OG ' ' N ' ' A' ' 60' ' ' LYS . 5.9 t -132.36 177.76 7.34 Favored 'General case' 0 N--CA 1.504 2.239 0 O-C-N 120.944 -1.097 . . . . 1.55 110.49 -179.273 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' LYS . . . . . 0.497 ' N ' ' OG ' ' A' ' 59' ' ' SER . 45.8 tttm -93.82 96.18 9.59 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.689 -0.632 . . . . 2.53 109.713 -179.591 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -61.54 131.17 49.23 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.179 -0.951 . . . . 0.82 109.017 179.696 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 16.2 tp10 -88.54 95.05 10.08 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 120.964 -1.085 . . . . 2.3 110.174 -179.456 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.563 HD12 ' N ' ' A' ' 63' ' ' ILE . 1.7 mp -60.61 156.04 3.43 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 N-CA-C 109.207 -0.664 . . . . 1.4 109.207 179.335 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.534 ' HB3' ' HB3' ' A' ' 76' ' ' SER . . . -144.72 172.38 13.08 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.013 -1.054 . . . . 1.36 108.78 179.598 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.524 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 41.0 p90 -148.44 116.2 6.33 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.26 -0.9 . . . . 1.47 109.188 179.845 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 78.6 tt0 . . . . . 0 N--CA 1.498 1.964 0 O-C-N 121.161 -0.962 . . . . 2.51 109.821 -179.884 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 19.8 t . . . . . 0 N--CA 1.488 1.467 0 N-CA-C 108.827 -0.805 . . . . 2.2 108.827 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 8.6 t -76.69 129.14 35.93 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.103 -0.998 . . . . 2.05 109.103 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -103.68 114.68 4.87 Favored Glycine 0 N--CA 1.496 2.69 0 N-CA-C 110.064 -1.214 . . . . 1.39 110.064 -179.332 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.588 HG21 HD12 ' A' ' 41' ' ' ILE . 38.4 t -101.83 108.74 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.925 0 O-C-N 121.516 -0.99 . . . . 1.57 108.771 179.426 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.534 ' HB3' ' HB3' ' A' ' 64' ' ' ALA . 4.1 t -103.46 127.69 50.79 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.531 -0.731 . . . . 1.85 109.457 179.849 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 6.4 p90 -128.45 128.2 43.97 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 108.303 -0.999 . . . . 1.54 108.303 179.838 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -103.8 110.06 29.01 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.159 0 O-C-N 121.324 -0.86 . . . . 1.9 109.404 -178.859 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.47 ' H ' HG22 ' A' ' 79' ' ' VAL . 5.8 m -82.6 163.39 3.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.496 -0.753 . . . . 1.27 109.42 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 20.1 tt0 -95.78 -50.39 4.93 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.005 -1.059 . . . . 2.48 111.117 -179.163 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -152.29 155.55 33.17 Favored Pre-proline 0 N--CA 1.504 2.237 0 O-C-N 120.688 -1.257 . . . . 1.92 111.72 -178.594 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.572 ' HG3' ' N ' ' A' ' 107' ' ' SER . 75.9 Cg_exo -37.07 160.77 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 123.61 2.873 . . . . 1.3 113.636 179.285 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 148.19 -164.16 28.94 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.223 -1.551 . . . . 1.02 109.223 179.816 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 84' ' ' ASP . . . . . 0.431 ' HB2' ' HE ' ' B' ' 8' ' ' ARG . 65.0 m-20 -108.82 88.85 2.83 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.601 -0.94 . . . . 2.13 108.662 179.656 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.499 ' O ' ' N ' ' A' ' 103' ' ' VAL . 2.9 m-85 -76.27 129.52 36.8 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 108.165 -1.05 . . . . 0.92 108.165 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -107.85 128.33 54.51 Favored 'General case' 0 N--CA 1.497 1.914 0 N-CA-C 108.144 -1.058 . . . . 1.53 108.144 -179.446 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 9.4 p -126.12 140.27 49.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.525 -0.734 . . . . 1.0 109.972 -179.401 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 88' ' ' SER . . . . . 0.438 ' OG ' ' HB3' ' A' ' 54' ' ' ALA . 11.1 p -134.4 104.39 6.11 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.585 -0.697 . . . . 1.59 109.52 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.414 HD11 ' CD1' ' A' ' 96' ' ' ILE . 0.8 OUTLIER -112.33 129.58 67.6 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 CA-C-O 121.585 0.707 . . . . 1.29 109.492 -179.847 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 90' ' ' LYS . . . . . 0.469 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -139.71 124.2 18.17 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 108.232 -1.025 . . . . 1.58 108.232 179.661 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.408 ' O ' ' CB ' ' A' ' 92' ' ' ASN . 31.8 t80 -85.64 102.96 14.02 Favored 'General case' 0 N--CA 1.494 1.737 0 N-CA-C 107.546 -1.279 . . . . 1.34 107.546 178.783 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 92' ' ' ASN . . . . . 0.423 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 8.5 t30 72.48 35.84 1.09 Allowed 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.806 -0.813 . . . . 2.32 108.806 -178.235 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.423 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 1.7 m-20 76.4 15.24 2.25 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.676 -0.64 . . . . 1.92 111.409 179.692 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 94' ' ' GLU . . . . . 0.498 ' CG ' ' O ' ' A' ' 94' ' ' GLU . 7.2 pt-20 -98.53 100.43 11.68 Favored 'General case' 0 N--CA 1.493 1.717 0 N-CA-C 107.201 -1.407 . . . . 2.25 107.201 177.949 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 95' ' ' HIS . . . . . 0.427 ' CD2' ' O ' ' A' ' 95' ' ' HIS . 17.7 p-80 -71.67 106.52 4.11 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.215 -0.928 . . . . 2.88 109.534 -178.541 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 96' ' ' ILE . . . . . 0.561 ' O ' ' N ' ' A' ' 98' ' ' ASP . 10.1 pt -55.82 150.19 28.94 Favored Pre-proline 0 N--CA 1.491 1.611 0 C-N-CA 119.377 -0.929 . . . . 2.35 108.507 179.795 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.411 ' O ' ' CG ' ' A' ' 98' ' ' ASP . 4.6 Cg_exo -53.87 82.01 0.03 OUTLIER 'Trans proline' 0 C--O 1.213 -0.738 0 N-CA-C 109.202 -1.114 . . . . 2.48 109.202 179.415 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.561 ' N ' ' O ' ' A' ' 96' ' ' ILE . 1.9 m-20 175.05 -63.36 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 108.037 -1.097 . . . . 2.65 108.037 -178.949 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 5.1 m -59.03 139.08 87.68 Favored Pre-proline 0 C--N 1.298 -1.671 0 O-C-N 121.539 -0.725 . . . . 2.0 110.119 -178.134 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_endo -88.58 115.21 2.9 Favored 'Cis proline' 0 N--CA 1.493 1.474 0 N-CA-C 109.722 -0.915 . . . . 1.79 109.722 -2.597 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 45.6 p90 -112.53 168.45 9.64 Favored 'General case' 0 N--CA 1.516 2.868 0 O-C-N 120.556 -1.34 . . . . 2.19 110.027 178.828 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.4 p -94.38 152.28 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.474 -0.766 . . . . 1.44 110.735 -178.901 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.499 ' N ' ' O ' ' A' ' 85' ' ' TYR . 61.3 t -126.69 87.01 57.4 Favored Pre-proline 0 N--CA 1.499 1.992 0 N-CA-C 107.919 -1.141 . . . . 1.19 107.919 179.193 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -61.25 113.09 1.61 Allowed 'Trans proline' 0 C--N 1.32 -0.951 0 C-N-CA 121.376 1.384 . . . . 1.49 112.189 -177.787 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 53.8 t -94.16 145.08 8.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 N-CA-C 106.64 -1.615 . . . . 1.35 106.64 177.736 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.543 ' HB1' ' H ' ' A' ' 110' ' ' ASP . . . -136.73 137.33 39.81 Favored 'General case' 0 N--CA 1.506 2.328 0 CA-C-O 122.268 1.032 . . . . 1.67 111.995 -177.507 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 107' ' ' SER . . . . . 0.572 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 9.5 t -110.53 68.47 0.67 Allowed 'General case' 0 N--CA 1.495 1.808 0 N-CA-C 107.229 -1.397 . . . . 2.04 107.229 178.855 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 108' ' ' LEU . . . . . 0.496 ' CB ' ' O ' ' A' ' 107' ' ' SER . 2.6 tp 81.23 -3.53 1.7 Allowed 'General case' 0 N--CA 1.492 1.641 0 N-CA-C 106.603 -1.629 . . . . 3.2 106.603 -177.574 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 2.0 m -80.08 -27.09 39.36 Favored 'General case' 0 N--CA 1.486 1.348 0 N-CA-C 108.853 -0.795 . . . . 2.09 108.853 179.138 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 110' ' ' ASP . . . . . 0.543 ' H ' ' HB1' ' A' ' 106' ' ' ALA . 37.8 m-20 . . . . . 0 N--CA 1.492 1.659 0 O-C-N 121.283 -0.886 . . . . 2.85 108.799 -179.71 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 8' ' ' ARG . . . . . 0.546 ' CG ' HH11 ' B' ' 8' ' ' ARG . 1.5 mtt-85 . . . . . 0 N--CA 1.491 1.605 0 N-CA-C 108.694 -0.854 . . . . 3.04 108.694 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 9' ' ' VAL . . . . . . . . . . . . . 5.7 t -49.09 159.82 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.065 -1.022 . . . . 0.67 108.263 179.547 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -117.67 162.16 18.5 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.524 -0.735 . . . . 0.58 110.222 -178.769 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 11' ' ' SER . . . . . 0.408 ' CB ' HG23 ' A' ' 55' ' ' VAL . 32.4 m -153.59 141.24 19.94 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.585 -0.697 . . . . 1.19 109.13 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 41.7 m -145.05 112.27 6.06 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.113 -0.992 . . . . 1.38 110.021 -179.664 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 0.595 HG22 ' N ' ' B' ' 14' ' ' PHE . 3.2 p -159.93 167.48 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 N-CA-C 108.689 -0.856 . . . . 0.42 108.689 179.661 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 14' ' ' PHE . . . . . 0.896 ' O ' HD13 ' B' ' 15' ' ' ILE . 9.1 p90 -176.77 -169.07 0.25 Allowed 'General case' 0 N--CA 1.49 1.565 0 C-N-CA 119.162 -1.015 . . . . 1.79 112.179 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.896 HD13 ' O ' ' B' ' 14' ' ' PHE . 3.9 mm -142.12 165.14 17.68 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 N-CA-C 108.69 -0.856 . . . . 1.25 108.69 179.759 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 75.7 p -120.0 136.72 54.45 Favored 'General case' 0 N--CA 1.503 2.2 0 O-C-N 121.283 -0.886 . . . . 1.61 109.681 179.876 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 11.0 mt . . . . . 0 N--CA 1.5 2.058 0 O-C-N 121.369 -0.832 . . . . 1.32 109.975 -179.836 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.472 ' O ' ' CB ' ' A' ' 94' ' ' GLU . . . . . . . . 0 N--CA 1.488 2.115 0 N-CA-C 111.568 -0.613 . . . . 2.44 111.568 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.541 ' C ' ' H ' ' A' ' 19' ' ' HIS . . . 67.71 -49.03 0.33 Allowed Glycine 0 N--CA 1.495 2.61 0 O-C-N 121.577 -0.955 . . . . 1.81 111.662 178.092 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.796 ' HB2' ' OE1' ' A' ' 94' ' ' GLU . . . -51.3 -5.29 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.853 0 O-C-N 120.963 -1.316 . . . . 2.21 109.975 -179.201 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' HIS . . . . . 0.541 ' H ' ' C ' ' A' ' 17' ' ' GLY . 6.1 t60 -98.75 -7.13 28.13 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.135 -0.978 . . . . 2.87 110.503 -179.545 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.551 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.0 OUTLIER -137.8 6.0 2.65 Favored 'General case' 0 N--CA 1.501 2.106 0 O-C-N 120.968 -1.082 . . . . 2.02 110.34 -179.581 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 71.3 t -91.05 113.43 26.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 120.95 -1.094 . . . . 2.07 109.851 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 12.8 tpp180 -105.33 137.88 42.43 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 108.827 -0.805 . . . . 3.5 108.827 179.844 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -147.12 113.64 5.98 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.418 -0.801 . . . . 1.83 108.857 179.794 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -155.26 129.73 2.61 Favored Glycine 0 N--CA 1.493 2.471 0 N-CA-C 109.678 -1.369 . . . . 1.9 109.678 -179.655 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.54 -176.88 46.8 Favored Glycine 0 N--CA 1.491 2.304 0 C-N-CA 119.741 -1.219 . . . . 1.85 110.088 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 12.6 p -79.65 -25.53 41.34 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.353 -1.086 . . . . 2.31 109.343 179.877 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -68.94 -15.99 69.94 Favored Glycine 0 N--CA 1.485 1.934 0 N-CA-C 108.304 -1.918 . . . . 1.64 108.304 179.548 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 90.4 mt -93.35 30.41 1.71 Allowed 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 108.601 -0.889 . . . . 1.83 108.601 179.49 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 15.3 mt-10 -139.11 -48.72 0.49 Allowed 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.504 -0.747 . . . . 2.34 109.34 -179.834 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 5.4 ptp180 -174.69 177.12 2.15 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.153 -0.967 . . . . 3.77 110.192 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -149.43 174.58 28.93 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 108.495 -1.842 . . . . 1.57 108.495 179.717 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 39.5 t -134.42 149.87 30.26 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.075 0 O-C-N 121.203 -1.175 . . . . 1.83 110.567 -179.702 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.575 ' HB2' ' HB2' ' A' ' 107' ' ' SER . . . -37.38 113.98 0.3 Allowed 'General case' 0 N--CA 1.496 1.864 0 CA-C-O 121.745 0.783 . . . . 1.64 112.471 -179.232 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 51.68 51.42 38.74 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 111.24 -0.744 . . . . 1.73 111.24 177.097 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 24.4 t -126.82 121.67 23.18 Favored Pre-proline 0 N--CA 1.495 1.821 0 N-CA-C 108.198 -1.038 . . . . 2.19 108.198 178.834 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -57.87 140.22 93.04 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 120.483 0.789 . . . . 1.96 110.142 -179.422 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.418 ' HB3' ' CE1' ' A' ' 77' ' ' TYR . . . -145.33 158.0 43.92 Favored 'General case' 0 N--CA 1.493 1.716 0 N-CA-C 108.275 -1.009 . . . . 1.69 108.275 179.603 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -155.8 172.01 19.06 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.815 -1.178 . . . . 2.23 110.8 -179.543 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 0.609 ' CE2' HD11 ' A' ' 41' ' ' ILE . 5.9 p90 -156.27 166.64 32.85 Favored 'General case' 0 C--N 1.298 -1.646 0 N-CA-C 107.888 -1.153 . . . . 1.54 107.888 178.446 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 43.9 m -99.05 152.12 20.18 Favored 'General case' 0 N--CA 1.494 1.762 0 CA-C-O 121.782 0.801 . . . . 2.37 111.129 -178.146 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.609 HD11 ' CE2' ' A' ' 39' ' ' PHE . 10.8 mt -143.48 85.79 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 N-CA-C 108.416 -0.957 . . . . 1.65 108.416 178.91 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 31.5 t90 -91.61 147.36 23.06 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.053 -1.029 . . . . 3.68 109.284 -179.489 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.551 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.1 OUTLIER -161.76 -110.99 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.286 -0.883 . . . . 2.89 109.628 -179.731 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 44' ' ' ARG . . . . . 0.526 HH11 ' HG2' ' A' ' 44' ' ' ARG . 2.3 ttt-85 52.69 90.74 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.221 -0.924 . . . . 4.63 109.862 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -172.2 -60.68 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.245 -0.909 . . . . 2.89 109.365 179.265 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -57.04 -57.89 10.57 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.988 -1.07 . . . . 1.74 108.741 179.724 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 150.99 -160.46 28.64 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 110.029 -1.228 . . . . 1.6 110.029 179.488 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.01 149.17 9.55 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.403 -1.057 . . . . 1.4 109.778 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -176.26 173.65 46.42 Favored Glycine 0 N--CA 1.489 2.168 0 N-CA-C 109.487 -1.445 . . . . 1.04 109.487 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -126.76 122.63 4.4 Favored Glycine 0 N--CA 1.498 2.825 0 N-CA-C 109.143 -1.583 . . . . 1.06 109.143 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.47 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 11.3 tp -93.85 99.37 11.75 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.221 -1.164 . . . . 1.1 108.843 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 2.2 t -83.51 141.27 31.76 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 108.42 -0.956 . . . . 1.56 108.42 179.687 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.559 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 92.3 mt -134.73 115.58 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.217 -0.927 . . . . 0.65 109.33 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -104.65 106.86 17.52 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.364 -0.835 . . . . 0.69 109.008 179.778 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -101.45 135.07 39.72 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.115 0 O-C-N 121.477 -0.765 . . . . 0.91 109.516 -179.771 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 56' ' ' GLU . . . . . 0.43 ' OE2' ' O ' ' B' ' 9' ' ' VAL . 30.9 tp10 -134.36 142.46 47.22 Favored 'General case' 0 N--CA 1.494 1.738 0 N-CA-C 107.399 -1.334 . . . . 1.8 107.399 178.324 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 171.51 -176.67 44.67 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.421 -1.472 . . . . 0.49 109.421 -179.362 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -61.62 -28.35 82.6 Favored 'Trans proline' 0 C--N 1.318 -1.06 0 C-N-CA 121.992 1.795 . . . . 0.66 111.856 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' SER . . . . . 0.413 ' O ' ' OH ' ' A' ' 85' ' ' TYR . 10.6 p -142.39 163.24 33.37 Favored 'General case' 0 N--CA 1.501 2.095 0 O-C-N 121.063 -1.023 . . . . 1.55 110.349 -179.564 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 19.4 mtpp -81.09 115.71 20.66 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.532 -0.73 . . . . 2.53 109.28 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -80.67 129.54 34.58 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.284 -0.885 . . . . 0.82 109.648 -179.817 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.455 ' CB ' HG12 ' A' ' 78' ' ' VAL . 18.2 tp10 -68.29 170.95 7.85 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.127 -0.983 . . . . 2.3 108.535 179.722 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.402 HD12 ' N ' ' A' ' 63' ' ' ILE . 3.8 mp -139.9 153.75 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 N-CA-C 108.417 -0.956 . . . . 1.4 108.417 -179.389 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.563 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -150.79 114.6 4.98 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 120.672 -1.267 . . . . 1.36 109.747 -179.565 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.505 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 43.0 p90 -92.77 122.56 35.28 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.27 -0.894 . . . . 1.47 109.19 179.615 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 . . . . . 0 N--CA 1.496 1.858 0 O-C-N 121.266 -0.896 . . . . 2.51 109.51 -179.835 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 89.9 p . . . . . 0 N--CA 1.495 1.78 0 N-CA-C 109.107 -0.701 . . . . 2.2 109.107 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 29.7 t -89.72 136.47 33.02 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.199 -0.938 . . . . 2.05 109.682 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -114.24 114.24 3.24 Favored Glycine 0 N--CA 1.5 2.937 0 N-CA-C 109.696 -1.362 . . . . 1.39 109.696 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.465 HG21 HD12 ' A' ' 41' ' ' ILE . 78.9 t -99.7 105.13 17.04 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.102 0 O-C-N 121.411 -1.052 . . . . 1.57 109.629 179.722 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.563 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.1 OUTLIER -95.26 134.5 37.95 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 109.018 -0.734 . . . . 1.85 109.018 179.84 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.418 ' CE1' ' HB3' ' A' ' 37' ' ' ALA . 45.7 p90 -135.32 172.73 12.59 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.205 -0.934 . . . . 1.54 109.079 -179.848 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.602 ' O ' HG13 ' A' ' 78' ' ' VAL . 9.8 p -140.34 118.09 9.96 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.082 0 O-C-N 121.256 -0.902 . . . . 1.9 110.033 179.758 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.456 HG11 HG21 ' A' ' 105' ' ' VAL . 13.4 m -86.64 151.97 3.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.391 -0.818 . . . . 1.27 108.922 179.548 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 4.0 tp-100 -94.51 -47.24 6.64 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.042 -1.036 . . . . 2.48 110.899 -179.039 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -153.37 152.37 27.48 Favored Pre-proline 0 N--CA 1.505 2.302 0 O-C-N 120.406 -1.434 . . . . 1.92 110.965 -179.497 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.64 ' HG3' ' N ' ' A' ' 107' ' ' SER . 78.4 Cg_exo -38.48 164.42 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 123.392 2.728 . . . . 1.3 113.778 178.833 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 145.08 -164.97 27.84 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.004 -1.639 . . . . 1.02 109.004 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 25.2 m-20 -109.01 90.88 3.43 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.61 -0.935 . . . . 2.13 108.641 179.581 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.413 ' OH ' ' O ' ' A' ' 59' ' ' SER . 3.7 m-85 -78.74 130.53 35.88 Favored 'General case' 0 N--CA 1.487 1.406 0 N-CA-C 108.003 -1.11 . . . . 0.92 108.003 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -115.35 128.49 56.12 Favored 'General case' 0 N--CA 1.502 2.146 0 N-CA-C 108.946 -0.761 . . . . 1.53 108.946 -178.503 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 10.0 p -125.36 140.46 48.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.75 -0.593 . . . . 1.0 109.925 -179.852 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 16.2 m -129.33 100.07 5.45 Favored 'General case' 0 N--CA 1.497 1.884 0 N-CA-C 108.922 -0.77 . . . . 1.59 108.922 179.477 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.447 ' N ' ' OG ' ' A' ' 99' ' ' SER . 1.6 pt -105.57 134.93 45.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 CA-C-O 121.482 0.658 . . . . 1.29 110.208 -179.301 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 90' ' ' LYS . . . . . 0.591 ' HB3' ' HZ2' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -144.3 122.35 12.11 Favored 'General case' 0 C--N 1.305 -1.339 0 N-CA-C 108.271 -1.011 . . . . 1.58 108.271 179.508 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 62.9 t80 -80.97 101.27 9.4 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.864 -1.147 . . . . 1.34 107.995 178.705 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 70.37 39.04 1.29 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.392 -0.817 . . . . 2.32 108.982 -178.809 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 74.57 15.03 3.41 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.705 -0.622 . . . . 1.92 111.293 179.653 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 94' ' ' GLU . . . . . 0.796 ' OE1' ' HB2' ' A' ' 18' ' ' ALA . 0.5 OUTLIER -98.29 96.22 7.91 Favored 'General case' 0 N--CA 1.498 1.974 0 N-CA-C 106.813 -1.551 . . . . 2.25 106.813 177.641 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 4.3 m80 -73.07 111.66 8.39 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.615 -0.678 . . . . 2.88 110.112 -177.926 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 96' ' ' ILE . . . . . 0.683 ' H ' HD13 ' A' ' 96' ' ' ILE . 0.0 OUTLIER -70.35 155.93 92.67 Favored Pre-proline 0 N--CA 1.494 1.734 0 N-CA-C 107.444 -1.317 . . . . 2.35 107.444 179.148 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_exo -46.54 -35.6 16.93 Favored 'Trans proline' 0 C--N 1.322 -0.861 0 C-N-CA 121.336 1.357 . . . . 2.48 109.942 -179.412 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -53.78 -63.65 1.08 Allowed 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.301 -0.875 . . . . 2.65 109.383 179.267 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.447 ' OG ' ' N ' ' A' ' 89' ' ' ILE . 3.6 m -70.45 141.21 87.92 Favored Pre-proline 0 C--N 1.295 -1.777 0 O-C-N 120.92 -1.112 . . . . 2.0 110.19 -178.467 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -86.8 119.02 4.96 Favored 'Cis proline' 0 N--CA 1.493 1.474 0 N-CA-C 109.967 -0.82 . . . . 1.79 109.967 -2.439 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 45.2 p90 -120.89 158.34 27.85 Favored 'General case' 0 N--CA 1.518 2.939 0 O-C-N 120.445 -1.41 . . . . 2.19 109.506 178.273 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.469 HG22 ' N ' ' A' ' 103' ' ' VAL . 7.3 p -92.17 157.26 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.429 -0.794 . . . . 1.44 110.887 -178.426 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.469 ' N ' HG22 ' A' ' 102' ' ' VAL . 56.9 t -128.26 86.25 58.41 Favored Pre-proline 0 N--CA 1.495 1.778 0 N-CA-C 107.85 -1.167 . . . . 1.19 107.85 179.341 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -64.04 112.71 1.93 Allowed 'Trans proline' 0 C--N 1.32 -0.966 0 C-N-CA 121.377 1.385 . . . . 1.49 111.624 -177.982 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.456 HG21 HG11 ' A' ' 79' ' ' VAL . 54.8 t -95.54 141.01 15.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 N-CA-C 106.771 -1.566 . . . . 1.35 106.771 177.978 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.635 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -130.6 131.79 45.15 Favored 'General case' 0 N--CA 1.51 2.551 0 CA-C-O 121.925 0.869 . . . . 1.67 112.064 -177.041 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 107' ' ' SER . . . . . 0.64 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 35.4 t -101.36 92.99 5.19 Favored 'General case' 0 N--CA 1.494 1.75 0 N-CA-C 107.993 -1.114 . . . . 2.04 107.993 179.274 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 20.5 mt 60.08 3.71 0.54 Allowed 'General case' 0 C--N 1.295 -1.774 0 N-CA-C 108.166 -1.05 . . . . 3.2 108.166 -178.574 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.501 ' H ' ' C ' ' A' ' 107' ' ' SER . 8.3 t -94.83 -29.26 14.82 Favored 'General case' 0 N--CA 1.49 1.563 0 N-CA-C 109.03 -0.729 . . . . 2.09 109.03 179.391 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 110' ' ' ASP . . . . . 0.635 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 16.9 t70 . . . . . 0 N--CA 1.489 1.496 0 N-CA-C 107.754 -1.202 . . . . 2.85 107.754 -178.843 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 8' ' ' ARG . . . . . 0.618 ' CG ' HH11 ' B' ' 8' ' ' ARG . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.769 0 N-CA-C 108.061 -1.088 . . . . 3.04 108.061 . . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 9' ' ' VAL . . . . . 0.43 ' O ' ' OE2' ' A' ' 56' ' ' GLU . 36.3 t -51.61 155.48 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 O-C-N 120.963 -1.085 . . . . 0.67 108.508 179.519 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -107.7 158.84 16.94 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 121.484 -0.76 . . . . 0.58 110.443 -178.763 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 25.6 t -159.34 112.91 2.29 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.487 -0.758 . . . . 1.19 109.007 179.51 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 15.0 p -117.02 124.9 50.44 Favored 'General case' 0 N--CA 1.501 2.111 0 O-C-N 121.417 -0.802 . . . . 1.38 109.413 -179.771 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 0.608 HG22 ' N ' ' B' ' 14' ' ' PHE . 6.6 p -164.39 164.01 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.293 -0.879 . . . . 0.42 109.786 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 14' ' ' PHE . . . . . 0.608 ' N ' HG22 ' B' ' 13' ' ' VAL . 6.5 p90 -179.29 -175.21 0.35 Allowed 'General case' 0 N--CA 1.488 1.472 0 CA-C-O 121.784 0.802 . . . . 1.79 111.427 179.102 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -144.01 168.8 10.77 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.295 0 N-CA-C 109.28 -0.637 . . . . 1.25 109.28 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 74.1 p -133.81 156.13 48.59 Favored 'General case' 0 N--CA 1.499 2.021 0 N-CA-C 108.72 -0.844 . . . . 1.61 108.72 179.523 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.491 1.615 0 O-C-N 120.948 -1.095 . . . . 1.32 110.643 -179.307 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.502 ' O ' ' N ' ' A' ' 18' ' ' ALA . . . . . . . . 0 N--CA 1.486 2.007 0 N-CA-C 110.009 -1.236 . . . . 2.44 110.009 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.553 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -42.72 -19.8 0.07 OUTLIER Glycine 0 N--CA 1.49 2.282 0 O-C-N 121.417 -1.049 . . . . 1.81 110.839 -179.325 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.502 ' N ' ' O ' ' A' ' 16' ' ' GLY . . . -47.26 -12.92 0.03 OUTLIER 'General case' 0 N--CA 1.495 1.8 0 O-C-N 120.448 -1.619 . . . . 2.21 109.297 179.413 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' HIS . . . . . 0.553 ' N ' ' O ' ' A' ' 17' ' ' GLY . 12.8 t-80 -93.36 -52.25 4.61 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.268 -0.895 . . . . 2.87 109.906 179.882 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.535 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.1 OUTLIER -69.75 -23.6 63.4 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.869 -1.144 . . . . 2.02 109.588 -179.69 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 76.1 t -63.33 112.62 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.161 -0.962 . . . . 2.07 109.5 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 20.6 tpt180 -97.34 138.32 34.99 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 108.695 -0.854 . . . . 3.5 108.695 179.666 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -142.64 113.46 7.5 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.287 -0.883 . . . . 1.83 109.279 -179.88 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -154.08 130.85 3.03 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 109.518 -1.433 . . . . 1.9 109.518 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -177.94 171.17 43.67 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.703 -1.359 . . . . 1.85 109.703 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 10.9 p -77.97 -28.87 49.53 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.302 -1.117 . . . . 2.31 109.405 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -67.72 -16.88 68.51 Favored Glycine 0 N--CA 1.487 2.038 0 N-CA-C 108.42 -1.872 . . . . 1.64 108.42 179.606 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 49.0 mt -85.85 22.68 1.61 Allowed 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 108.506 -0.924 . . . . 1.83 108.506 179.356 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 11.5 mt-10 -133.47 -50.38 0.85 Allowed 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.62 -0.675 . . . . 2.34 109.398 -179.673 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 11.3 ptt180 -163.31 -176.71 4.92 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.069 -1.019 . . . . 3.77 109.936 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -157.18 -178.42 31.23 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 108.761 -1.735 . . . . 1.57 108.761 -179.799 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 38.4 t -134.71 151.8 32.09 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.153 0 O-C-N 121.154 -1.203 . . . . 1.83 110.663 -179.777 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.556 ' HB2' ' HD3' ' A' ' 82' ' ' PRO . . . -45.77 115.22 0.91 Allowed 'General case' 0 N--CA 1.498 1.936 0 CA-C-O 121.815 0.817 . . . . 1.64 112.443 -179.34 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 57.82 46.55 92.22 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 111.562 -0.615 . . . . 1.73 111.562 177.062 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 25.2 t -127.38 120.49 22.16 Favored Pre-proline 0 N--CA 1.499 1.98 0 O-C-N 121.37 -1.076 . . . . 2.19 108.818 179.178 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -60.09 113.02 1.48 Allowed 'Trans proline' 0 C--O 1.215 -0.657 0 N-CA-C 109.676 -0.932 . . . . 1.96 109.676 179.871 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -113.04 156.12 23.64 Favored 'General case' 0 N--CA 1.498 1.949 0 N-CA-C 108.268 -1.012 . . . . 1.69 108.268 179.617 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -158.03 163.68 37.49 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.718 -1.239 . . . . 2.23 111.403 -179.779 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 0.575 ' CD1' ' N ' ' A' ' 39' ' ' PHE . 0.8 OUTLIER -139.93 -173.17 3.57 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 107.228 -1.397 . . . . 1.54 107.228 178.513 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 24.4 m -121.83 149.11 43.82 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.535 -0.728 . . . . 2.37 110.307 -179.234 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 34.9 mt -144.48 102.05 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 N-CA-C 107.962 -1.125 . . . . 1.65 107.962 178.982 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.458 ' CD1' ' C ' ' A' ' 42' ' ' TRP . 0.1 OUTLIER -89.59 139.6 30.38 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.259 -0.901 . . . . 3.68 108.927 -179.635 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.535 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.1 OUTLIER -152.79 120.03 5.89 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.42 -0.8 . . . . 2.89 109.214 -179.733 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 44' ' ' ARG . . . . . . . . . . . . . 28.9 ttt-85 -170.28 62.87 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.201 -0.937 . . . . 4.63 109.848 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 25.4 tt0 -157.06 -56.6 0.08 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.14 -0.975 . . . . 2.89 109.534 179.65 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.423 ' H ' ' HE2' ' A' ' 20' ' ' LYS . . . -57.88 -57.4 12.93 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.092 -1.005 . . . . 1.74 108.88 179.883 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 142.03 -179.2 20.17 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.263 -1.535 . . . . 1.6 109.263 179.845 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -55.9 159.14 3.35 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.127 -1.22 . . . . 1.4 109.345 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -176.83 176.12 47.88 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.595 -1.402 . . . . 1.04 109.595 -179.877 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -106.94 123.26 7.24 Favored Glycine 0 N--CA 1.497 2.743 0 N-CA-C 109.427 -1.469 . . . . 1.06 109.427 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.453 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 12.3 tp -99.8 100.55 11.51 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.295 -1.12 . . . . 1.1 108.452 179.663 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 3.9 m -85.51 144.13 28.12 Favored 'General case' 0 N--CA 1.491 1.616 0 N-CA-C 108.662 -0.866 . . . . 1.56 108.662 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.525 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 78.5 mt -134.71 106.69 7.68 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 O-C-N 121.224 -0.922 . . . . 0.65 109.614 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -95.65 106.26 18.34 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.377 -0.971 . . . . 0.69 108.377 179.272 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.437 HG23 ' OG ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -97.45 145.29 9.47 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 121.421 -0.799 . . . . 0.91 109.933 -179.339 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 20.2 tt0 -141.56 145.06 34.65 Favored 'General case' 0 N--CA 1.491 1.61 0 N-CA-C 107.536 -1.283 . . . . 1.8 107.536 178.708 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 161.64 -171.04 37.52 Favored Glycine 0 N--CA 1.488 2.13 0 N-CA-C 109.644 -1.382 . . . . 0.49 109.644 -179.069 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -64.32 -30.31 63.46 Favored 'Trans proline' 0 C--N 1.316 -1.142 0 C-N-CA 122.047 1.831 . . . . 0.66 111.652 -179.598 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 24.3 t -142.1 164.96 28.76 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.039 -1.038 . . . . 1.55 110.129 -179.877 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 58.4 mttt -84.44 107.48 16.72 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.527 -0.733 . . . . 2.53 109.56 -179.8 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -67.08 143.39 56.71 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.222 -0.924 . . . . 0.82 109.4 179.932 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 23.3 tt0 -93.2 91.36 7.24 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.225 -0.922 . . . . 2.3 109.537 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.621 HD12 ' N ' ' A' ' 63' ' ' ILE . 2.2 mp -60.54 156.61 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 N-CA-C 109.138 -0.689 . . . . 1.4 109.138 179.602 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.559 ' HB3' ' HB3' ' A' ' 76' ' ' SER . . . -145.99 174.85 10.91 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.981 -1.074 . . . . 1.36 108.595 179.621 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.487 ' CG ' ' O ' ' A' ' 65' ' ' PHE . 28.8 p90 -147.87 115.87 6.47 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.093 -1.005 . . . . 1.47 109.647 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 . . . . . 0 N--CA 1.497 1.883 0 O-C-N 121.209 -0.932 . . . . 2.51 109.485 179.791 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.5 p . . . . . 0 N--CA 1.495 1.791 0 N-CA-C 109.085 -0.709 . . . . 2.2 109.085 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 7.7 t -75.42 146.58 40.64 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.214 -0.929 . . . . 2.05 109.622 -179.814 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -120.25 111.58 2.01 Favored Glycine 0 N--CA 1.499 2.851 0 N-CA-C 109.32 -1.512 . . . . 1.39 109.32 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 22.5 t -99.32 106.22 18.64 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 O-C-N 121.542 -0.975 . . . . 1.57 109.109 179.807 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.559 ' HB3' ' HB3' ' A' ' 64' ' ' ALA . 5.9 t -100.04 135.67 41.11 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.537 -0.727 . . . . 1.85 109.895 -179.687 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 4.9 p90 -133.59 131.4 39.61 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 108.801 -0.815 . . . . 1.54 108.801 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.587 ' O ' HG13 ' A' ' 78' ' ' VAL . 8.0 p -100.37 115.79 42.42 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.955 0 O-C-N 121.276 -0.89 . . . . 1.9 109.183 -179.668 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 26.9 m -84.73 164.5 2.53 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 121.187 -0.946 . . . . 1.27 109.142 -179.681 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 36.3 tt0 -102.54 -49.08 3.94 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.276 -0.89 . . . . 2.48 110.324 -179.689 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -157.15 153.99 25.04 Favored Pre-proline 0 N--CA 1.502 2.132 0 O-C-N 120.907 -1.121 . . . . 1.92 111.161 -179.147 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.588 ' HG3' ' N ' ' A' ' 107' ' ' SER . 89.1 Cg_exo -35.55 156.99 0.02 OUTLIER 'Trans proline' 0 C--O 1.214 -0.683 0 C-N-CA 123.394 2.729 . . . . 1.3 113.745 179.354 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 148.51 -170.3 29.02 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 108.556 -1.818 . . . . 1.02 108.556 -179.675 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 84' ' ' ASP . . . . . 0.571 ' CG ' ' HE ' ' B' ' 8' ' ' ARG . 4.5 p-10 -107.24 93.71 4.7 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.378 -1.072 . . . . 2.13 108.452 179.368 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.426 ' O ' ' N ' ' A' ' 103' ' ' VAL . 2.4 m-85 -77.38 131.63 38.15 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 108.398 -0.964 . . . . 0.92 108.398 -179.784 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -112.82 126.82 55.85 Favored 'General case' 0 N--CA 1.501 2.081 0 N-CA-C 108.465 -0.939 . . . . 1.53 108.465 -179.292 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.466 ' CG1' ' CE2' ' A' ' 101' ' ' PHE . 5.5 p -126.29 133.96 67.55 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 O-C-N 121.525 -0.734 . . . . 1.0 109.782 -179.703 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 88' ' ' SER . . . . . 0.407 ' O ' ' OG ' ' A' ' 88' ' ' SER . 19.0 p -124.58 104.82 8.92 Favored 'General case' 0 N--CA 1.499 1.986 0 N-CA-C 109.171 -0.678 . . . . 1.59 109.171 179.835 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.405 ' N ' ' OG ' ' A' ' 99' ' ' SER . 1.5 pt -108.37 133.18 54.13 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 CA-C-O 121.54 0.686 . . . . 1.29 110.37 -179.245 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 90' ' ' LYS . . . . . 0.456 ' O ' ' CG ' ' A' ' 90' ' ' LYS . 0.3 OUTLIER -138.08 122.51 18.36 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 107.927 -1.138 . . . . 1.58 107.927 179.257 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.412 ' O ' ' CB ' ' A' ' 92' ' ' ASN . 81.4 t80 -82.84 99.99 10.06 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 120.443 -1.411 . . . . 1.34 107.924 179.21 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 92' ' ' ASN . . . . . 0.446 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 14.2 t30 72.28 34.85 1.3 Allowed 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.266 -0.896 . . . . 2.32 108.983 -178.627 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.446 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 1.6 m-20 80.47 13.81 0.83 Allowed 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.725 -0.609 . . . . 1.92 111.662 179.336 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 94' ' ' GLU . . . . . 0.494 ' HB2' ' HB2' ' A' ' 18' ' ' ALA . 5.4 pt-20 -100.71 98.84 9.34 Favored 'General case' 0 N--CA 1.499 2.023 0 N-CA-C 107.459 -1.312 . . . . 2.25 107.459 177.843 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 26.6 p-80 -65.3 99.59 0.41 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.686 -0.634 . . . . 2.88 110.243 -178.251 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 96' ' ' ILE . . . . . 0.523 ' O ' ' N ' ' A' ' 98' ' ' ASP . 4.0 tt -50.82 136.09 26.77 Favored Pre-proline 0 N--CA 1.489 1.524 0 N-CA-C 107.988 -1.116 . . . . 2.35 107.988 179.089 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.433 ' O ' ' CB ' ' A' ' 98' ' ' ASP . 9.4 Cg_exo -47.88 90.35 0.02 OUTLIER 'Trans proline' 0 C--O 1.213 -0.727 0 C-N-CA 120.547 0.832 . . . . 2.48 110.006 -179.627 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.523 ' N ' ' O ' ' A' ' 96' ' ' ILE . 0.9 OUTLIER 166.5 -57.87 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.749 0 N-CA-C 108.445 -0.946 . . . . 2.65 108.445 -179.569 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.405 ' OG ' ' N ' ' A' ' 89' ' ' ILE . 3.3 m -55.55 137.75 69.7 Favored Pre-proline 0 C--N 1.296 -1.72 0 O-C-N 121.246 -0.909 . . . . 2.0 109.6 -178.185 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo -90.0 114.96 2.59 Favored 'Cis proline' 0 N--CA 1.494 1.513 0 N-CA-C 110.249 -0.712 . . . . 1.79 110.249 -2.33 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 101' ' ' PHE . . . . . 0.466 ' CE2' ' CG1' ' A' ' 87' ' ' VAL . 1.6 p90 -97.18 163.26 12.99 Favored 'General case' 0 N--CA 1.515 2.802 0 O-C-N 120.217 -1.552 . . . . 2.19 109.568 178.456 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.9 p -95.31 148.96 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.594 -0.691 . . . . 1.44 109.822 -179.703 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.426 ' N ' ' O ' ' A' ' 85' ' ' TYR . 64.5 t -128.53 86.41 57.79 Favored Pre-proline 0 N--CA 1.499 2.002 0 N-CA-C 108.432 -0.951 . . . . 1.19 108.432 179.89 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -63.92 112.16 1.76 Allowed 'Trans proline' 0 C--N 1.321 -0.88 0 C-N-CA 121.429 1.419 . . . . 1.49 111.821 -178.133 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 52.5 t -91.39 147.36 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.514 -1.291 . . . . 1.35 107.514 178.268 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.677 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -135.77 134.3 38.85 Favored 'General case' 0 N--CA 1.508 2.467 0 O-C-N 121.373 -0.829 . . . . 1.67 110.911 -178.074 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 107' ' ' SER . . . . . 0.588 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 16.5 t -87.69 67.75 9.29 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.571 -1.331 . . . . 2.04 108.095 179.799 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 108' ' ' LEU . . . . . 0.434 ' CB ' ' O ' ' A' ' 107' ' ' SER . 1.0 OUTLIER 71.53 -2.6 2.38 Favored 'General case' 0 C--N 1.295 -1.79 0 N-CA-C 106.921 -1.511 . . . . 3.2 106.921 -178.439 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.501 ' H ' ' C ' ' A' ' 107' ' ' SER . 82.6 p -82.73 -21.63 34.7 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 109.165 -0.679 . . . . 2.09 109.165 179.422 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 110' ' ' ASP . . . . . 0.677 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 62.2 t0 . . . . . 0 N--CA 1.494 1.753 0 N-CA-C 108.312 -0.996 . . . . 2.85 108.312 -179.456 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 8' ' ' ARG . . . . . 0.571 ' HE ' ' CG ' ' A' ' 84' ' ' ASP . 2.2 mtt-85 . . . . . 0 N--CA 1.494 1.742 0 N-CA-C 108.715 -0.846 . . . . 3.04 108.715 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 9' ' ' VAL . . . . . . . . . . . . . 19.4 t -51.41 158.2 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.141 -0.975 . . . . 0.67 108.61 179.717 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -121.54 146.88 46.5 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.627 -0.67 . . . . 0.58 109.645 -179.339 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 11' ' ' SER . . . . . 0.437 ' OG ' HG23 ' A' ' 55' ' ' VAL . 4.9 t -140.62 143.77 35.39 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.387 -0.821 . . . . 1.19 109.436 179.878 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 46.8 t -141.39 116.54 9.98 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.319 -0.863 . . . . 1.38 109.689 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 0.645 HG22 ' N ' ' B' ' 14' ' ' PHE . 6.6 p -165.04 170.41 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.342 -0.849 . . . . 0.42 109.029 179.899 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 14' ' ' PHE . . . . . 0.645 ' N ' HG22 ' B' ' 13' ' ' VAL . 9.6 p90 -175.92 -163.14 0.1 Allowed 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 119.285 -0.966 . . . . 1.79 112.144 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.9 pt -150.47 165.55 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.339 0 N-CA-C 108.965 -0.754 . . . . 1.25 108.965 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 17.9 m -125.27 128.82 48.87 Favored 'General case' 0 N--CA 1.502 2.132 0 O-C-N 121.385 -0.822 . . . . 1.61 109.437 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 9.3 mt . . . . . 0 N--CA 1.497 1.898 0 O-C-N 121.267 -0.896 . . . . 1.32 109.922 -179.715 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.122 0 N-CA-C 111.204 -0.758 . . . . 2.44 111.204 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.558 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -43.2 -23.65 0.26 Allowed Glycine 0 N--CA 1.49 2.271 0 O-C-N 121.715 -0.874 . . . . 1.81 111.489 -178.265 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.493 ' N ' ' OE1' ' A' ' 94' ' ' GLU . . . -43.01 -17.94 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.042 -1.27 . . . . 2.21 110.047 -179.715 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' HIS . . . . . 0.558 ' N ' ' O ' ' A' ' 17' ' ' GLY . 8.9 t-80 -95.3 -52.06 4.33 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.33 -0.856 . . . . 2.87 109.731 179.884 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.536 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.0 OUTLIER -67.21 -14.71 63.17 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.996 -1.065 . . . . 2.02 109.551 -179.602 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.414 HG23 ' O ' ' A' ' 17' ' ' GLY . 71.2 t -76.93 113.4 15.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.181 -0.95 . . . . 2.07 108.813 179.308 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 20.7 tpt180 -110.4 136.31 49.76 Favored 'General case' 0 N--CA 1.494 1.774 0 CA-C-O 121.567 0.698 . . . . 3.5 110.18 -179.015 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.474 ' HA ' HD13 ' A' ' 41' ' ' ILE . . . -140.05 113.61 8.61 Favored 'General case' 0 N--CA 1.491 1.603 0 N-CA-C 108.645 -0.872 . . . . 1.83 108.645 179.569 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -146.38 126.51 2.5 Favored Glycine 0 N--CA 1.496 2.638 0 N-CA-C 109.625 -1.39 . . . . 1.9 109.625 -179.647 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.32 177.93 48.5 Favored Glycine 0 N--CA 1.488 2.139 0 N-CA-C 109.743 -1.343 . . . . 1.85 109.743 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 41.7 p -79.63 -24.62 41.79 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.249 -1.148 . . . . 2.31 109.461 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -68.56 -14.1 66.6 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 108.387 -1.885 . . . . 1.64 108.387 179.492 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 33.6 mt -100.35 35.25 2.15 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.688 -0.856 . . . . 1.83 108.688 179.76 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 -144.32 -46.01 0.25 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.377 -0.827 . . . . 2.34 109.516 -179.742 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 29.2 ptt180 -172.36 171.95 4.58 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 120.98 -1.075 . . . . 3.77 110.093 -179.874 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -147.76 174.4 27.51 Favored Glycine 0 N--CA 1.493 2.439 0 N-CA-C 108.598 -1.801 . . . . 1.57 108.598 179.622 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 37.6 t -134.68 152.52 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.088 0 O-C-N 121.136 -1.214 . . . . 1.83 110.576 -179.635 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.563 ' HB2' ' HB2' ' A' ' 107' ' ' SER . . . -40.78 112.29 0.28 Allowed 'General case' 0 N--CA 1.499 1.999 0 CA-C-O 121.586 0.708 . . . . 1.64 112.321 -179.268 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 53.72 51.82 46.32 Favored Glycine 0 N--CA 1.49 2.253 0 O-C-N 121.57 -0.706 . . . . 1.73 111.377 177.049 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 24.7 t -127.29 98.38 29.68 Favored Pre-proline 0 N--CA 1.495 1.787 0 O-C-N 121.451 -1.029 . . . . 2.19 108.453 178.895 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_exo -57.85 138.71 87.37 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 120.67 0.913 . . . . 1.96 109.854 -179.25 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -146.79 -167.76 2.85 Favored 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 108.491 -0.929 . . . . 1.69 108.491 -179.839 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -169.26 170.75 8.38 Favored 'General case' 0 C--N 1.303 -1.415 0 C-N-CA 118.745 -1.182 . . . . 2.23 111.04 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 0.53 ' CD1' ' N ' ' A' ' 39' ' ' PHE . 1.2 p90 -142.3 -178.26 5.65 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 107.49 -1.3 . . . . 1.54 107.49 178.274 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 88.9 p -124.43 138.37 54.36 Favored 'General case' 0 N--CA 1.501 2.088 0 CA-C-O 122.118 0.961 . . . . 2.37 111.219 -178.515 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.474 HD13 ' HA ' ' A' ' 23' ' ' ALA . 33.3 mm -130.58 126.59 60.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 N-CA-C 108.238 -1.023 . . . . 1.65 108.238 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.504 ' CD1' ' C ' ' A' ' 42' ' ' TRP . 0.6 OUTLIER -138.28 142.13 39.83 Favored 'General case' 0 N--CA 1.503 2.221 0 O-C-N 120.898 -1.126 . . . . 3.68 109.539 179.357 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.536 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.2 OUTLIER -156.44 151.94 26.83 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.553 -0.717 . . . . 2.89 109.605 -179.076 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 44' ' ' ARG . . . . . 0.508 HH11 ' HG2' ' A' ' 44' ' ' ARG . 0.0 OUTLIER -168.38 62.47 0.06 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.481 -0.762 . . . . 4.63 109.069 179.596 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -155.43 -60.09 0.11 Allowed 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.106 -0.996 . . . . 2.89 110.016 -179.748 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.449 ' HB3' ' NZ ' ' A' ' 20' ' ' LYS . . . -59.7 -32.75 70.8 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.886 -1.134 . . . . 1.74 109.333 -179.734 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 94.94 -157.36 22.14 Favored Glycine 0 N--CA 1.495 2.603 0 N-CA-C 109.996 -1.242 . . . . 1.6 109.996 179.72 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.65 163.19 0.71 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.398 -1.06 . . . . 1.4 110.101 -179.605 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 175.56 -165.85 36.91 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.264 -1.534 . . . . 1.04 109.264 179.844 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.4 ' O ' ' N ' ' A' ' 92' ' ' ASN . . . -132.6 119.62 2.49 Favored Glycine 0 N--CA 1.498 2.816 0 N-CA-C 108.985 -1.646 . . . . 1.06 108.985 179.867 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.461 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 31.6 tp -100.44 104.53 15.94 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.328 -1.101 . . . . 1.1 109.014 -179.873 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 13.8 t -91.14 142.73 27.43 Favored 'General case' 0 N--CA 1.495 1.824 0 N-CA-C 108.703 -0.851 . . . . 1.56 108.703 179.575 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.533 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 66.0 mt -132.47 103.58 6.54 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.986 0 O-C-N 121.119 -0.988 . . . . 0.65 109.571 -179.922 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -93.76 106.23 18.21 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.641 -0.874 . . . . 0.69 108.641 179.479 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.429 ' O ' ' O ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -98.91 141.7 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.564 -0.71 . . . . 0.91 109.478 -179.622 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 21.0 tt0 -141.28 144.2 34.52 Favored 'General case' 0 N--CA 1.492 1.639 0 N-CA-C 107.535 -1.283 . . . . 1.8 107.535 178.678 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 164.07 -173.3 40.08 Favored Glycine 0 N--CA 1.488 2.134 0 N-CA-C 109.489 -1.444 . . . . 0.49 109.489 -178.913 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -64.01 -33.46 62.54 Favored 'Trans proline' 0 C--N 1.319 -1.015 0 C-N-CA 122.114 1.876 . . . . 0.66 112.154 -179.567 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 33.0 m -135.22 155.77 50.1 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.072 -1.017 . . . . 1.55 109.947 -179.307 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 77.3 tttt -73.7 96.35 2.49 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.621 -0.674 . . . . 2.53 109.609 -179.834 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -61.05 123.9 18.98 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.342 -0.849 . . . . 0.82 109.341 179.894 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.456 ' CB ' HG12 ' A' ' 78' ' ' VAL . 19.6 tt0 -70.94 171.03 11.48 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.238 -0.914 . . . . 2.3 109.214 -179.82 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 72.4 mt -140.92 152.08 20.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 N-CA-C 107.663 -1.236 . . . . 1.4 107.663 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.54 ' HB3' ' HB2' ' A' ' 76' ' ' SER . . . -150.09 113.45 4.93 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.537 -1.352 . . . . 1.36 109.356 179.816 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.461 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 47.0 p90 -87.24 125.14 34.01 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.35 -0.844 . . . . 1.47 109.71 179.874 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 59.5 tt0 . . . . . 0 N--CA 1.496 1.837 0 O-C-N 121.386 -0.821 . . . . 2.51 109.233 179.808 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 45.5 t . . . . . 0 N--CA 1.496 1.871 0 CA-C-O 121.242 0.544 . . . . 2.2 109.612 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 73' ' ' CYS . . . . . 0.409 ' N ' ' O ' ' A' ' 41' ' ' ILE . 42.6 m -87.91 114.15 24.24 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.293 -0.879 . . . . 2.05 109.548 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -93.9 118.21 5.68 Favored Glycine 0 N--CA 1.494 2.524 0 N-CA-C 109.15 -1.58 . . . . 1.39 109.15 179.815 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -106.92 106.14 20.08 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.298 0 O-C-N 121.53 -0.982 . . . . 1.57 109.011 -179.868 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.54 ' HB2' ' HB3' ' A' ' 64' ' ' ALA . 1.4 m -89.73 150.81 22.14 Favored 'General case' 0 N--CA 1.49 1.568 0 N-CA-C 108.523 -0.917 . . . . 1.85 108.523 179.273 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 11.7 p90 -145.89 174.27 11.4 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.212 -0.93 . . . . 1.54 109.348 -179.106 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.592 ' O ' HG13 ' A' ' 78' ' ' VAL . 4.8 p -145.79 116.71 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.503 2.192 0 O-C-N 120.991 -1.068 . . . . 1.9 110.66 179.47 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.457 HG11 HG21 ' A' ' 105' ' ' VAL . 10.3 m -90.96 151.41 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 O-C-N 121.144 -0.972 . . . . 1.27 108.745 179.295 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 80' ' ' GLN . . . . . 0.42 ' O ' ' OE2' ' A' ' 81' ' ' GLU . 7.2 tp-100 -94.76 -46.91 6.7 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.011 -1.056 . . . . 2.48 110.819 -179.06 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.42 ' OE2' ' O ' ' A' ' 80' ' ' GLN . 78.1 mm-40 -153.8 150.06 22.23 Favored Pre-proline 0 N--CA 1.503 2.185 0 O-C-N 120.68 -1.262 . . . . 1.92 111.02 -178.651 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.635 ' HG3' ' N ' ' A' ' 107' ' ' SER . 84.9 Cg_exo -36.76 163.45 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.645 0 C-N-CA 122.918 2.412 . . . . 1.3 113.529 178.177 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 148.16 -165.29 28.97 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.28 -1.528 . . . . 1.02 109.28 179.838 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -106.95 88.25 2.7 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.599 -0.942 . . . . 2.13 108.665 179.697 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.457 ' O ' ' N ' ' A' ' 103' ' ' VAL . 3.4 m-85 -76.64 129.55 36.55 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.283 -1.006 . . . . 0.92 108.283 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -110.21 121.49 45.41 Favored 'General case' 0 N--CA 1.498 1.933 0 N-CA-C 108.372 -0.973 . . . . 1.53 108.372 -179.101 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.417 ' O ' HG13 ' A' ' 87' ' ' VAL . 8.4 p -120.28 133.41 67.09 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.593 -0.692 . . . . 1.0 109.705 -179.607 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 11.6 t -128.24 101.64 6.33 Favored 'General case' 0 N--CA 1.498 1.958 0 N-CA-C 109.609 -0.515 . . . . 1.59 109.609 -179.831 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.472 ' H ' ' CB ' ' A' ' 99' ' ' SER . 0.8 OUTLIER -108.0 130.85 59.78 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.875 0 O-C-N 121.567 -0.708 . . . . 1.29 109.6 -179.806 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 90' ' ' LYS . . . . . 0.426 ' HG3' ' H ' ' A' ' 93' ' ' ASP . 0.1 OUTLIER -139.9 128.77 23.38 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.413 -0.804 . . . . 1.58 109.05 -179.979 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 44.7 t80 -84.69 95.63 8.98 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 120.527 -1.358 . . . . 1.34 108.387 179.296 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 92' ' ' ASN . . . . . 0.457 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 12.5 t-20 68.58 39.72 2.03 Favored 'General case' 0 N--CA 1.488 1.435 0 N-CA-C 107.893 -1.151 . . . . 2.32 107.893 -178.532 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.457 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 3.4 m-20 82.6 14.07 0.45 Allowed 'General case' 0 N--CA 1.499 1.992 0 CA-C-O 121.188 0.518 . . . . 1.92 110.23 -179.434 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 94' ' ' GLU . . . . . 0.493 ' OE1' ' N ' ' A' ' 18' ' ' ALA . 55.2 mt-10 -87.91 78.73 8.24 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.431 -0.951 . . . . 2.25 108.431 178.916 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 42.2 m80 -55.75 109.67 0.6 Allowed 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.529 -0.732 . . . . 2.88 110.602 -179.17 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 96' ' ' ILE . . . . . 0.426 ' O ' ' O ' ' A' ' 99' ' ' SER . 1.5 mp -66.55 136.48 94.88 Favored Pre-proline 0 N--CA 1.492 1.637 0 N-CA-C 107.476 -1.305 . . . . 2.35 107.476 179.034 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_exo -41.17 -41.21 4.51 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 120.997 1.131 . . . . 2.48 110.575 -179.633 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.506 ' N ' ' OD1' ' A' ' 98' ' ' ASP . 1.3 m-20 -56.9 -65.61 0.59 Allowed 'General case' 0 N--CA 1.488 1.434 0 O-C-N 120.83 -1.169 . . . . 2.65 108.026 178.191 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.472 ' CB ' ' H ' ' A' ' 89' ' ' ILE . 0.1 OUTLIER -68.71 145.02 96.68 Favored Pre-proline 0 C--N 1.293 -1.882 0 O-C-N 121.173 -0.955 . . . . 2.0 109.564 -179.448 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -85.22 113.01 2.71 Favored 'Cis proline' 0 CA--C 1.549 1.271 0 O-C-N 122.636 0.808 . . . . 1.79 110.154 -1.864 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 31.3 p90 -121.82 164.23 17.84 Favored 'General case' 0 N--CA 1.521 3.088 0 O-C-N 120.497 -1.377 . . . . 2.19 109.921 178.402 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.3 p -87.43 144.41 9.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.462 -0.774 . . . . 1.44 110.643 -178.129 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.457 ' N ' ' O ' ' A' ' 85' ' ' TYR . 71.7 t -117.24 89.54 31.26 Favored Pre-proline 0 N--CA 1.498 1.949 0 N-CA-C 108.503 -0.925 . . . . 1.19 108.503 179.354 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -62.93 113.99 2.24 Favored 'Trans proline' 0 C--N 1.319 -0.989 0 C-N-CA 121.142 1.228 . . . . 1.49 111.916 -178.266 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.457 HG21 HG11 ' A' ' 79' ' ' VAL . 55.4 t -96.41 140.4 17.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 N-CA-C 105.926 -1.879 . . . . 1.35 105.926 177.446 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.684 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -131.89 133.53 44.7 Favored 'General case' 0 N--CA 1.512 2.671 0 CA-C-O 122.067 0.937 . . . . 1.67 112.059 -176.889 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 107' ' ' SER . . . . . 0.635 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 23.2 t -101.06 86.77 3.11 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 107.928 -1.138 . . . . 2.04 107.928 179.177 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 13.3 mt 60.24 6.07 0.94 Allowed 'General case' 0 C--N 1.297 -1.708 0 N-CA-C 107.718 -1.216 . . . . 3.2 107.718 -178.323 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.488 ' H ' ' C ' ' A' ' 107' ' ' SER . 52.0 p -97.77 -23.39 15.92 Favored 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 109.206 -0.664 . . . . 2.09 109.206 179.657 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 110' ' ' ASP . . . . . 0.684 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 34.4 t70 . . . . . 0 N--CA 1.489 1.484 0 O-C-N 121.131 -0.981 . . . . 2.85 108.436 -179.587 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 8' ' ' ARG . . . . . 0.456 HH11 ' HG2' ' B' ' 8' ' ' ARG . 11.7 mtt-85 . . . . . 0 N--CA 1.492 1.641 0 N-CA-C 109.078 -0.712 . . . . 3.04 109.078 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 9' ' ' VAL . . . . . 0.403 ' CG1' ' N ' ' B' ' 10' ' ' ALA . 3.1 t -48.72 159.69 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.135 -0.978 . . . . 0.67 108.515 179.747 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 0.403 ' N ' ' CG1' ' B' ' 9' ' ' VAL . . . -116.44 150.84 37.18 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.655 -0.653 . . . . 0.58 109.482 -179.344 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 11' ' ' SER . . . . . 0.429 ' O ' ' O ' ' A' ' 55' ' ' VAL . 58.2 m -153.19 139.88 18.92 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.283 -0.886 . . . . 1.19 109.865 -179.832 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 51.6 p -148.36 112.51 5.21 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.197 -0.939 . . . . 1.38 109.562 -179.697 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 0.58 HG22 ' N ' ' B' ' 14' ' ' PHE . 2.5 p -154.61 167.58 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 N-CA-C 108.624 -0.88 . . . . 0.42 108.624 179.811 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 14' ' ' PHE . . . . . 0.58 ' N ' HG22 ' B' ' 13' ' ' VAL . 7.8 p90 -176.55 -167.18 0.18 Allowed 'General case' 0 N--CA 1.488 1.435 0 C-N-CA 119.132 -1.027 . . . . 1.79 112.069 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -143.45 146.26 21.49 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.226 0 N-CA-C 108.883 -0.784 . . . . 1.25 108.883 179.871 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 46.1 m -113.03 128.3 56.46 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.353 -0.842 . . . . 1.61 109.293 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 16.8 mt . . . . . 0 N--CA 1.497 1.913 0 O-C-N 121.174 -0.954 . . . . 1.32 109.562 179.939 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.482 ' O ' ' N ' ' A' ' 18' ' ' ALA . . . . . . . . 0 N--CA 1.485 1.92 0 N-CA-C 109.48 -1.448 . . . . 2.44 109.48 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.503 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -43.97 -19.76 0.13 Allowed Glycine 0 N--CA 1.488 2.159 0 O-C-N 121.387 -1.067 . . . . 1.81 110.579 -179.457 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.774 ' HB2' ' OE1' ' A' ' 94' ' ' GLU . . . -51.07 -9.9 0.06 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.826 -1.397 . . . . 2.21 109.204 -179.829 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' HIS . . . . . 0.503 ' N ' ' O ' ' A' ' 17' ' ' GLY . 22.0 t60 -103.01 -4.59 24.42 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.404 -0.81 . . . . 2.87 110.175 -179.738 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.612 ' HZ2' HG23 ' A' ' 21' ' ' VAL . 1.9 pptp? -135.81 0.6 2.69 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.1 -1.0 . . . . 2.02 110.261 -179.559 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.612 HG23 ' HZ2' ' A' ' 20' ' ' LYS . 55.3 t -88.8 113.47 25.55 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.003 -1.06 . . . . 2.07 109.751 179.665 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 21.0 tpt180 -108.97 135.85 49.47 Favored 'General case' 0 N--CA 1.495 1.79 0 N-CA-C 109.308 -0.627 . . . . 3.5 109.308 179.647 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -143.31 113.81 7.46 Favored 'General case' 0 N--CA 1.492 1.674 0 N-CA-C 108.566 -0.902 . . . . 1.83 108.566 179.467 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -152.6 130.95 3.2 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.671 -1.371 . . . . 1.9 109.671 -179.367 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -177.55 167.58 38.67 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.801 -1.32 . . . . 1.85 109.801 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.49 ' C ' ' H ' ' A' ' 28' ' ' LEU . 0.5 OUTLIER -80.5 -27.53 37.72 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.318 -1.107 . . . . 2.31 109.864 -179.698 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -64.21 -1.36 5.46 Favored Glycine 0 N--CA 1.483 1.78 0 N-CA-C 107.938 -2.065 . . . . 1.64 107.938 179.193 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.49 ' H ' ' C ' ' A' ' 26' ' ' THR . 60.9 mt -108.45 -10.56 15.27 Favored 'General case' 0 N--CA 1.493 1.712 0 N-CA-C 108.643 -0.873 . . . . 1.83 108.643 179.748 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 20.3 mm-40 -85.74 -54.16 4.7 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.568 -0.708 . . . . 2.34 109.561 -179.586 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' ARG . . . . . 0.584 ' CG ' HH11 ' A' ' 30' ' ' ARG . 3.2 mtt-85 -156.83 161.94 39.72 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.125 -0.984 . . . . 3.77 109.76 179.918 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -140.73 172.17 23.74 Favored Glycine 0 N--CA 1.493 2.499 0 N-CA-C 108.102 -1.999 . . . . 1.57 108.102 179.205 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 36.0 t -134.37 150.93 31.2 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.03 0 O-C-N 121.189 -1.183 . . . . 1.83 110.398 -179.338 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -38.83 113.89 0.34 Allowed 'General case' 0 N--CA 1.495 1.784 0 CA-C-O 121.862 0.839 . . . . 1.64 112.844 -179.184 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 53.99 49.77 57.64 Favored Glycine 0 N--CA 1.489 2.167 0 N-CA-C 111.238 -0.745 . . . . 1.73 111.238 177.378 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 25.3 t -126.98 99.41 28.88 Favored Pre-proline 0 N--CA 1.497 1.9 0 O-C-N 121.531 -0.982 . . . . 2.19 108.396 179.052 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -56.75 143.44 90.27 Favored 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 120.946 1.097 . . . . 1.96 110.588 -178.906 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.473 ' HB3' ' CE1' ' A' ' 77' ' ' TYR . . . -150.23 -169.06 3.28 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.563 -0.903 . . . . 1.69 108.563 179.869 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -169.38 162.23 10.22 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.958 -1.089 . . . . 2.23 111.03 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 0.575 ' CD1' ' N ' ' A' ' 39' ' ' PHE . 0.2 OUTLIER -134.8 -176.37 4.21 Favored 'General case' 0 N--CA 1.485 1.303 0 N-CA-C 106.638 -1.615 . . . . 1.54 106.638 178.355 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 18.3 t -121.35 145.97 47.34 Favored 'General case' 0 N--CA 1.501 2.1 0 CA-C-O 121.72 0.771 . . . . 2.37 111.07 -178.633 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.523 ' O ' ' N ' ' A' ' 73' ' ' CYS . 62.6 mt -143.19 118.69 4.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 N-CA-C 108.547 -0.908 . . . . 1.65 108.547 179.222 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.533 ' O ' ' CD2' ' A' ' 42' ' ' TRP . 5.9 p-90 -118.1 127.19 53.54 Favored 'General case' 0 N--CA 1.502 2.135 0 O-C-N 121.219 -0.926 . . . . 3.68 108.549 179.109 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.52 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -150.92 128.4 11.41 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.224 -0.923 . . . . 2.89 109.926 -178.828 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 44' ' ' ARG . . . . . . . . . . . . . 24.8 ttm180 -172.48 79.35 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.442 -0.786 . . . . 4.63 109.092 179.663 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 2.3 tm-20 -159.69 -55.04 0.06 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.188 -0.945 . . . . 2.89 109.881 -179.676 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -53.43 -55.29 26.38 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 120.911 -1.118 . . . . 1.74 108.672 -179.821 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 140.58 -170.37 24.47 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.163 -1.575 . . . . 1.6 109.163 179.678 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.67 148.28 10.05 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.14 -1.212 . . . . 1.4 109.202 179.832 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -171.66 -170.06 35.23 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.762 -1.335 . . . . 1.04 109.762 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -133.05 122.71 3.24 Favored Glycine 0 N--CA 1.497 2.727 0 N-CA-C 109.403 -1.479 . . . . 1.06 109.403 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 11.3 tp -97.65 97.98 9.49 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.303 -1.116 . . . . 1.1 108.69 179.651 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 52' ' ' SER . . . . . 0.409 ' HA ' ' CD2' ' B' ' 14' ' ' PHE . 0.3 OUTLIER -84.52 145.63 27.99 Favored 'General case' 0 C--N 1.312 -1.035 0 N-CA-C 108.026 -1.102 . . . . 1.56 108.026 179.695 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.445 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 65.4 mt -134.98 118.68 25.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.217 -0.927 . . . . 0.65 110.048 -179.315 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -106.63 106.85 17.57 Favored 'General case' 0 N--CA 1.495 1.824 0 N-CA-C 108.431 -0.952 . . . . 0.69 108.431 179.072 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 2.4 t -97.59 146.36 7.88 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.266 -0.897 . . . . 0.91 109.639 -179.436 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 22.8 tt0 -139.5 131.21 27.38 Favored 'General case' 0 N--CA 1.488 1.448 0 N-CA-C 107.616 -1.253 . . . . 1.8 107.616 178.835 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -178.41 172.31 44.71 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.159 -1.576 . . . . 0.49 109.159 -179.498 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_exo -52.06 -28.61 33.25 Favored 'Trans proline' 0 C--N 1.318 -1.076 0 C-N-CA 121.808 1.672 . . . . 0.66 110.859 -179.501 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.2 t -140.79 157.18 45.77 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.439 -0.788 . . . . 1.55 109.839 -179.527 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 49.3 mttp -77.78 104.75 8.52 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.421 -0.799 . . . . 2.53 109.169 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -74.15 136.95 42.89 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.272 -0.892 . . . . 0.82 109.549 -179.728 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.679 ' O ' HD13 ' A' ' 63' ' ' ILE . 46.9 mt-10 -75.33 175.54 8.29 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.141 -0.974 . . . . 2.3 109.629 -179.829 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.679 HD13 ' O ' ' A' ' 62' ' ' GLU . 4.8 mm -140.51 156.46 23.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 N-CA-C 108.033 -1.099 . . . . 1.4 108.033 -179.656 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.433 ' HB3' ' CB ' ' A' ' 76' ' ' SER . . . -144.45 174.63 10.77 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 120.551 -1.343 . . . . 1.36 108.999 179.749 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.51 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 37.7 p90 -147.25 116.36 6.9 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.308 -0.87 . . . . 1.47 109.46 -179.919 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 76.2 tt0 . . . . . 0 N--CA 1.496 1.849 0 O-C-N 121.317 -0.864 . . . . 2.51 109.241 179.989 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 60.6 p . . . . . 0 N--CA 1.495 1.807 0 CA-C-O 121.313 0.578 . . . . 2.2 109.666 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 73' ' ' CYS . . . . . 0.523 ' N ' ' O ' ' A' ' 41' ' ' ILE . 17.0 t -75.77 112.23 11.93 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.306 -0.871 . . . . 2.05 109.361 179.789 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -91.77 117.99 5.37 Favored Glycine 0 N--CA 1.493 2.439 0 N-CA-C 109.394 -1.482 . . . . 1.39 109.394 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 1.9 m -109.28 114.68 47.57 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.097 0 O-C-N 121.611 -0.935 . . . . 1.57 109.502 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.433 ' CB ' ' HB3' ' A' ' 64' ' ' ALA . 0.9 OUTLIER -92.55 167.84 11.66 Favored 'General case' 0 N--CA 1.491 1.62 0 N-CA-C 108.341 -0.985 . . . . 1.85 108.341 179.537 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.473 ' CE1' ' HB3' ' A' ' 37' ' ' ALA . 5.9 p90 -163.77 168.15 20.03 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.356 -0.84 . . . . 1.54 109.095 -179.338 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.577 ' O ' HG13 ' A' ' 78' ' ' VAL . 5.0 p -143.11 115.31 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.369 0 O-C-N 121.0 -1.062 . . . . 1.9 110.448 179.418 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.418 HG22 ' H ' ' A' ' 79' ' ' VAL . 14.3 m -88.82 152.38 3.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.244 -0.91 . . . . 1.27 109.233 179.741 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 28.4 tt0 -88.92 -50.33 6.26 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.092 -1.005 . . . . 2.48 110.764 -179.043 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -153.31 156.92 32.85 Favored Pre-proline 0 N--CA 1.504 2.271 0 O-C-N 120.722 -1.236 . . . . 1.92 110.766 -179.015 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.615 ' HG3' ' N ' ' A' ' 107' ' ' SER . 71.0 Cg_exo -37.67 163.55 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 123.293 2.662 . . . . 1.3 113.452 179.17 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 145.35 -177.37 23.82 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.138 -1.585 . . . . 1.02 109.138 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 84' ' ' ASP . . . . . 0.528 ' OD1' ' NH2' ' B' ' 8' ' ' ARG . 0.4 OUTLIER -99.81 90.93 4.61 Favored 'General case' 0 N--CA 1.493 1.715 0 N-CA-C 107.962 -1.125 . . . . 2.13 107.962 179.289 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -76.25 132.05 39.64 Favored 'General case' 0 C--N 1.296 -1.721 0 N-CA-C 108.245 -1.02 . . . . 0.92 108.245 -179.747 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.66 115.56 27.31 Favored 'General case' 0 N--CA 1.501 2.082 0 N-CA-C 108.337 -0.986 . . . . 1.53 108.337 -179.351 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.556 ' CG1' ' CE2' ' A' ' 101' ' ' PHE . 4.5 p -112.85 132.78 60.69 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.676 -0.64 . . . . 1.0 109.421 -179.779 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 3.0 m -121.85 139.53 53.51 Favored 'General case' 0 N--CA 1.497 1.886 0 N-CA-C 108.536 -0.912 . . . . 1.59 108.536 179.635 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.3 pt -141.1 130.68 25.34 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.181 0 O-C-N 121.076 -1.015 . . . . 1.29 109.845 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -136.89 123.61 21.14 Favored 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 107.72 -1.215 . . . . 1.58 107.72 178.191 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 83.5 t80 -83.7 102.2 12.09 Favored 'General case' 0 C--N 1.295 -1.77 0 N-CA-C 107.985 -1.117 . . . . 1.34 107.985 179.326 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 92' ' ' ASN . . . . . 0.442 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 1.3 t30 69.33 34.83 2.79 Favored 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 108.788 -0.819 . . . . 2.32 108.788 -178.651 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.442 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 2.7 m-20 79.34 16.66 0.89 Allowed 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.827 -0.546 . . . . 1.92 111.505 179.473 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 94' ' ' GLU . . . . . 0.774 ' OE1' ' HB2' ' A' ' 18' ' ' ALA . 0.6 OUTLIER -101.1 100.23 10.77 Favored 'General case' 0 N--CA 1.499 2.005 0 N-CA-C 107.407 -1.331 . . . . 2.25 107.407 178.188 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 4.1 m80 -73.97 110.92 8.64 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.117 -0.99 . . . . 2.88 110.632 -177.844 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 96' ' ' ILE . . . . . 0.465 ' O ' ' N ' ' A' ' 98' ' ' ASP . 3.4 tp -63.95 134.62 95.99 Favored Pre-proline 0 N--CA 1.488 1.455 0 N-CA-C 107.554 -1.276 . . . . 2.35 107.554 178.868 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.417 ' HD2' HD12 ' A' ' 96' ' ' ILE . 7.2 Cg_exo -49.56 92.5 0.03 OUTLIER 'Trans proline' 0 C--O 1.214 -0.721 0 N-CA-C 109.839 -0.87 . . . . 2.48 109.839 -179.824 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.465 ' N ' ' O ' ' A' ' 96' ' ' ILE . 0.9 OUTLIER 169.76 -54.05 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 108.756 -0.831 . . . . 2.65 108.756 -179.574 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 6.2 m -55.3 136.95 68.73 Favored Pre-proline 0 C--N 1.298 -1.636 0 O-C-N 121.231 -0.918 . . . . 2.0 109.588 -178.261 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_endo -88.36 113.58 2.43 Favored 'Cis proline' 0 N--CA 1.494 1.539 0 N-CA-C 110.328 -0.681 . . . . 1.79 110.328 -1.862 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 101' ' ' PHE . . . . . 0.598 ' CD1' ' N ' ' A' ' 101' ' ' PHE . 0.0 OUTLIER -80.71 155.08 26.93 Favored 'General case' 0 N--CA 1.509 2.522 0 O-C-N 119.727 -1.858 . . . . 2.19 108.66 178.346 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 10.5 p -89.21 144.5 8.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.483 -0.761 . . . . 1.44 109.158 179.653 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 76.9 t -128.04 85.87 59.52 Favored Pre-proline 0 N--CA 1.499 1.997 0 N-CA-C 108.133 -1.062 . . . . 1.19 108.133 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -64.91 112.53 2.04 Favored 'Trans proline' 0 C--N 1.321 -0.878 0 C-N-CA 121.433 1.422 . . . . 1.49 111.851 -177.867 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 54.5 t -96.36 143.89 11.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 N-CA-C 106.172 -1.788 . . . . 1.35 106.172 177.667 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.673 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -136.36 135.23 38.65 Favored 'General case' 0 N--CA 1.509 2.489 0 O-C-N 121.151 -0.968 . . . . 1.67 112.133 -176.985 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 107' ' ' SER . . . . . 0.615 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 11.0 t -89.67 76.27 7.31 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 107.413 -1.329 . . . . 2.04 107.413 178.982 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 13.6 mt 65.87 -0.06 1.42 Allowed 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 107.748 -1.204 . . . . 3.2 107.748 -177.861 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.502 ' H ' ' C ' ' A' ' 107' ' ' SER . 22.9 t -84.67 -22.14 29.94 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.74 -0.837 . . . . 2.09 108.74 178.873 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 110' ' ' ASP . . . . . 0.673 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 5.5 m-20 . . . . . 0 N--CA 1.487 1.423 0 N-CA-C 107.984 -1.117 . . . . 2.85 107.984 -179.141 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 8' ' ' ARG . . . . . 0.528 ' NH2' ' OD1' ' A' ' 84' ' ' ASP . 16.5 mmt-85 . . . . . 0 N--CA 1.491 1.606 0 N-CA-C 108.435 -0.95 . . . . 3.04 108.435 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 9' ' ' VAL . . . . . . . . . . . . . 3.0 t -57.66 161.48 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 N-CA-C 106.924 -1.51 . . . . 0.67 106.924 178.746 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -115.07 148.52 38.8 Favored 'General case' 0 N--CA 1.504 2.267 0 O-C-N 121.267 -0.896 . . . . 0.58 111.151 -178.06 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 1.3 t -141.11 150.86 43.42 Favored 'General case' 0 N--CA 1.497 1.906 0 N-CA-C 109.232 -0.655 . . . . 1.19 109.232 179.39 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 28.5 p -149.09 131.47 15.64 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.053 -1.029 . . . . 1.38 110.224 -179.836 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 0.664 HG22 ' N ' ' B' ' 14' ' ' PHE . 7.5 p -173.6 174.39 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 N-CA-C 108.345 -0.983 . . . . 0.42 108.345 179.777 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 14' ' ' PHE . . . . . 0.664 ' N ' HG22 ' B' ' 13' ' ' VAL . 0.1 OUTLIER 173.05 -171.97 0.04 OUTLIER 'General case' 0 N--CA 1.493 1.702 0 C-N-CA 118.797 -1.161 . . . . 1.79 112.201 179.483 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -143.85 -179.4 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.339 0 N-CA-C 108.898 -0.779 . . . . 1.25 108.898 179.903 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 9.0 t -141.31 142.91 33.82 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.154 -0.966 . . . . 1.61 109.291 179.59 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.3 mt . . . . . 0 N--CA 1.499 2.019 0 O-C-N 121.261 -0.9 . . . . 1.32 110.108 -179.55 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.766 0 N-CA-C 108.52 -1.832 . . . . 2.44 108.52 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.518 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -72.65 -4.81 62.42 Favored Glycine 0 N--CA 1.486 2.025 0 N-CA-C 109.717 -1.353 . . . . 1.81 109.717 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -49.03 -12.39 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.729 -1.453 . . . . 2.21 109.236 179.832 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' HIS . . . . . 0.518 ' N ' ' O ' ' A' ' 17' ' ' GLY . 10.6 t-160 -97.15 -41.15 8.46 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.39 -0.819 . . . . 2.87 109.445 179.651 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.719 ' HZ2' ' N ' ' A' ' 44' ' ' ARG . 0.0 OUTLIER -82.32 -25.37 33.99 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.141 -0.974 . . . . 2.02 109.722 -179.879 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 77.9 t -60.93 112.32 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.045 -1.034 . . . . 2.07 109.081 179.635 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 5.9 tpp180 -104.11 131.14 51.69 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.629 -0.669 . . . . 3.5 109.628 -179.648 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -136.7 113.64 10.47 Favored 'General case' 0 N--CA 1.493 1.723 0 N-CA-C 108.577 -0.898 . . . . 1.83 108.577 179.519 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -155.89 134.66 4.21 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.73 -1.348 . . . . 1.9 109.73 -179.463 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.1 -176.44 46.07 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.99 -1.244 . . . . 1.85 109.99 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 8.6 p -79.49 -25.82 41.74 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.335 -1.097 . . . . 2.31 109.538 -179.862 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.428 ' CA ' ' OH ' ' A' ' 77' ' ' TYR . . . -69.46 -15.44 70.54 Favored Glycine 0 N--CA 1.486 1.992 0 N-CA-C 108.506 -1.838 . . . . 1.64 108.506 179.676 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 65.8 mt -93.36 33.02 1.26 Allowed 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 108.487 -0.931 . . . . 1.83 108.487 179.454 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -144.3 -55.41 0.35 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.373 -0.829 . . . . 2.34 109.796 -179.545 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' ARG . . . . . 0.528 ' NH1' ' OD1' ' A' ' 110' ' ' ASP . 31.9 mtm180 -156.53 153.69 29.1 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 120.984 -1.073 . . . . 3.77 110.345 -179.441 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.55 ' C ' HG13 ' A' ' 105' ' ' VAL . . . -140.42 171.76 23.84 Favored Glycine 0 N--CA 1.495 2.61 0 N-CA-C 108.244 -1.942 . . . . 1.57 108.244 179.003 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.468 ' H ' ' CG1' ' A' ' 35' ' ' VAL . 28.1 t -135.54 148.32 28.4 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.008 0 O-C-N 121.173 -1.192 . . . . 1.83 110.448 -179.553 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.625 ' HB2' ' HD3' ' A' ' 82' ' ' PRO . . . -38.73 105.79 0.04 OUTLIER 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.916 -0.49 . . . . 1.64 111.688 -179.859 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 64.34 57.0 14.45 Favored Glycine 0 N--CA 1.489 2.23 0 O-C-N 121.089 -1.007 . . . . 1.73 111.864 177.353 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.468 ' CG1' ' H ' ' A' ' 32' ' ' VAL . 4.5 p -125.82 133.92 25.38 Favored Pre-proline 0 N--CA 1.503 2.208 0 O-C-N 121.279 -1.13 . . . . 2.19 108.949 178.72 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_endo -58.47 114.69 2.09 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 N-CA-C 108.547 -1.366 . . . . 1.96 108.547 178.739 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -127.0 148.61 50.1 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.344 -0.847 . . . . 1.69 109.494 -179.352 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.3 pt-20 -157.13 174.01 16.12 Favored 'General case' 0 N--CA 1.488 1.474 0 CA-C-O 122.22 1.01 . . . . 2.23 110.759 -179.886 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 0.603 ' CE2' HD11 ' A' ' 41' ' ' ILE . 5.0 p90 -159.52 167.07 29.49 Favored 'General case' 0 C--N 1.296 -1.753 0 N-CA-C 107.819 -1.178 . . . . 1.54 107.819 178.67 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 6.4 t -98.04 150.96 20.84 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.462 -0.774 . . . . 2.37 110.715 -178.409 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.603 HD11 ' CE2' ' A' ' 39' ' ' PHE . 10.7 mt -142.09 89.72 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 N-CA-C 108.757 -0.831 . . . . 1.65 108.757 179.117 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.458 ' CD1' ' C ' ' A' ' 42' ' ' TRP . 0.8 OUTLIER -85.28 142.35 29.44 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.115 -0.991 . . . . 3.68 108.815 -179.907 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.487 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -171.98 117.51 0.39 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.39 -0.818 . . . . 2.89 109.298 -179.688 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 44' ' ' ARG . . . . . 0.719 ' N ' ' HZ2' ' A' ' 20' ' ' LYS . 1.5 tpt180 -164.99 -12.24 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.171 -0.956 . . . . 4.63 109.696 -179.832 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.409 ' H ' ' HD3' ' A' ' 20' ' ' LYS . 0.4 OUTLIER -68.55 -47.53 66.63 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.0 -1.062 . . . . 2.89 109.763 -179.621 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -60.23 -59.76 4.89 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.098 -1.001 . . . . 1.74 109.299 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 142.94 -151.76 23.42 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.585 -1.406 . . . . 1.6 109.585 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -80.64 163.11 23.86 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.479 -1.012 . . . . 1.4 109.531 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 174.02 -143.49 7.05 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.666 -1.373 . . . . 1.04 109.666 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -148.48 127.64 2.6 Favored Glycine 0 N--CA 1.495 2.586 0 N-CA-C 109.554 -1.418 . . . . 1.06 109.554 -179.913 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.465 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 46.8 tp -102.65 107.03 17.79 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.367 -1.078 . . . . 1.1 108.843 179.833 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.4 t -90.62 141.44 28.77 Favored 'General case' 0 N--CA 1.494 1.75 0 N-CA-C 108.616 -0.883 . . . . 1.56 108.616 179.504 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.515 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 63.3 mt -132.06 102.35 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.923 0 O-C-N 121.214 -0.929 . . . . 0.65 109.469 -179.843 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -93.31 105.85 17.88 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 108.497 -0.927 . . . . 0.69 108.497 179.395 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.44 HG23 ' CB ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -95.42 145.07 8.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.521 -0.737 . . . . 0.91 109.254 -179.738 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -141.47 144.17 34.25 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 108.026 -1.101 . . . . 1.8 108.026 179.22 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.415 ' O ' ' O ' ' B' ' 9' ' ' VAL . . . 162.13 -172.95 38.37 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.768 -1.333 . . . . 0.49 109.768 -179.215 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -61.77 -31.88 85.87 Favored 'Trans proline' 0 C--N 1.319 -0.979 0 C-N-CA 122.302 2.001 . . . . 0.66 112.046 -179.666 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 8.0 t -139.0 169.95 16.86 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 120.949 -1.094 . . . . 1.55 110.549 -179.169 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 38.5 mtpt -87.1 106.86 18.16 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 109.003 -0.74 . . . . 2.53 109.003 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -73.48 127.42 32.67 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.165 -0.959 . . . . 0.82 109.776 -179.711 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 24.4 tt0 -65.42 170.44 4.87 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.288 -0.882 . . . . 2.3 109.028 179.732 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.414 HD12 HG13 ' B' ' 13' ' ' VAL . 20.1 mt -143.52 155.11 16.37 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 N-CA-C 108.345 -0.983 . . . . 1.4 108.345 -179.9 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.532 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -143.12 174.91 10.28 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 120.685 -1.259 . . . . 1.36 109.21 -179.775 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.449 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 51.7 p90 -142.29 128.49 19.82 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.363 -0.835 . . . . 1.47 109.172 179.9 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 . . . . . 0 N--CA 1.497 1.892 0 O-C-N 121.296 -0.878 . . . . 2.51 109.987 -179.782 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.0 t . . . . . 0 N--CA 1.497 1.88 0 CA-C-O 121.428 0.632 . . . . 2.2 109.764 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 36.9 t -88.04 139.47 30.48 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.329 -0.857 . . . . 2.05 109.347 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -112.4 114.02 3.4 Favored Glycine 0 N--CA 1.5 2.948 0 N-CA-C 109.985 -1.246 . . . . 1.39 109.985 -179.761 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.502 HG21 HD12 ' A' ' 41' ' ' ILE . 77.9 t -100.97 116.15 43.97 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.948 0 O-C-N 121.467 -1.019 . . . . 1.57 108.912 179.291 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.532 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.6 OUTLIER -103.81 136.75 42.91 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.579 -0.7 . . . . 1.85 109.196 -179.846 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.428 ' OH ' ' CA ' ' A' ' 27' ' ' GLY . 11.3 p90 -134.65 166.69 22.34 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.508 -0.745 . . . . 1.54 109.671 -179.769 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 8.4 t -139.86 113.54 6.3 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 N-CA-C 108.887 -0.783 . . . . 1.9 108.887 -179.729 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.594 ' CG1' ' CE2' ' A' ' 85' ' ' TYR . 0.2 OUTLIER -79.75 168.57 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 N-CA-C 108.499 -0.926 . . . . 1.27 108.499 179.552 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 10.5 tt0 -109.3 -36.79 5.93 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.441 -0.787 . . . . 2.48 109.417 179.323 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.428 ' O ' ' O ' ' A' ' 82' ' ' PRO . 75.2 mm-40 -158.85 149.6 16.01 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.278 -0.888 . . . . 1.92 110.679 -179.308 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.625 ' HD3' ' HB2' ' A' ' 33' ' ' ALA . 82.1 Cg_exo -39.08 169.38 0.01 OUTLIER 'Trans proline' 0 C--O 1.213 -0.727 0 C-N-CA 122.761 2.307 . . . . 1.3 112.756 177.696 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 141.69 177.33 16.74 Favored Glycine 0 N--CA 1.493 2.451 0 N-CA-C 109.726 -1.35 . . . . 1.02 109.726 179.226 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -93.16 89.57 6.5 Favored 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 107.741 -1.207 . . . . 2.13 107.741 179.149 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.594 ' CE2' ' CG1' ' A' ' 79' ' ' VAL . 3.7 m-85 -78.04 132.15 37.64 Favored 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.458 -0.776 . . . . 0.92 108.912 -179.014 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -112.81 128.79 56.54 Favored 'General case' 0 N--CA 1.498 1.947 0 N-CA-C 108.588 -0.893 . . . . 1.53 108.588 -179.079 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.411 ' CG1' ' CE2' ' A' ' 101' ' ' PHE . 5.8 p -126.13 133.64 68.4 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 121.568 -0.708 . . . . 1.0 109.471 -179.865 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.1 t -123.64 103.96 8.73 Favored 'General case' 0 N--CA 1.498 1.933 0 N-CA-C 109.445 -0.576 . . . . 1.59 109.445 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.2 pt -107.7 130.29 60.29 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 CA-C-O 121.64 0.734 . . . . 1.29 110.045 -179.573 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 90' ' ' LYS . . . . . 0.47 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.98 122.68 17.52 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 107.9 -1.148 . . . . 1.58 107.9 179.593 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.412 ' O ' ' CB ' ' A' ' 92' ' ' ASN . 71.2 t80 -83.08 100.57 10.59 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 120.515 -1.365 . . . . 1.34 108.029 179.351 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 92' ' ' ASN . . . . . 0.429 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 2.2 t30 72.31 35.48 1.19 Allowed 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.196 -0.94 . . . . 2.32 108.809 -178.646 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.429 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 0.9 OUTLIER 78.2 14.77 1.44 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.879 -0.513 . . . . 1.92 111.609 179.53 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 94' ' ' GLU . . . . . 0.489 ' OE2' ' CA ' ' A' ' 17' ' ' GLY . 5.7 pt-20 -100.54 99.22 9.78 Favored 'General case' 0 N--CA 1.496 1.843 0 N-CA-C 107.145 -1.428 . . . . 2.25 107.145 177.964 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 95' ' ' HIS . . . . . 0.462 ' O ' ' CG ' ' A' ' 95' ' ' HIS . 46.2 p-80 -66.96 105.46 1.63 Allowed 'General case' 0 N--CA 1.487 1.389 0 CA-C-O 121.472 0.653 . . . . 2.88 110.453 -177.928 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 96' ' ' ILE . . . . . 0.523 ' O ' ' N ' ' A' ' 98' ' ' ASP . 4.0 tt -56.56 136.33 77.23 Favored Pre-proline 0 C--N 1.3 -1.548 0 N-CA-C 107.81 -1.182 . . . . 2.35 107.81 178.983 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.44 ' O ' ' CB ' ' A' ' 98' ' ' ASP . 11.6 Cg_exo -47.15 90.98 0.02 OUTLIER 'Trans proline' 0 C--O 1.213 -0.729 0 N-CA-C 109.886 -0.852 . . . . 2.48 109.886 -179.755 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.523 ' N ' ' O ' ' A' ' 96' ' ' ILE . 0.9 OUTLIER 165.61 -60.43 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 108.235 -1.024 . . . . 2.65 108.235 -179.418 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 1.3 t -55.8 139.08 70.18 Favored Pre-proline 0 C--N 1.296 -1.727 0 O-C-N 121.299 -0.875 . . . . 2.0 109.796 -178.306 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_endo -88.36 113.72 2.47 Favored 'Cis proline' 0 N--CA 1.494 1.521 0 N-CA-C 110.024 -0.798 . . . . 1.79 110.024 -2.393 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 101' ' ' PHE . . . . . 0.411 ' CE2' ' CG1' ' A' ' 87' ' ' VAL . 2.6 p90 -97.74 169.15 9.88 Favored 'General case' 0 N--CA 1.518 2.944 0 O-C-N 120.236 -1.54 . . . . 2.19 109.779 178.625 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.3 p -96.78 150.45 4.44 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.643 -0.66 . . . . 1.44 109.982 -179.635 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.446 ' N ' ' O ' ' A' ' 85' ' ' TYR . 87.0 t -128.3 87.03 56.36 Favored Pre-proline 0 N--CA 1.498 1.965 0 N-CA-C 108.379 -0.971 . . . . 1.19 108.379 179.675 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo -65.11 114.9 3.01 Favored 'Trans proline' 0 C--N 1.322 -0.856 0 C-N-CA 121.571 1.514 . . . . 1.49 111.8 -178.27 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.55 HG13 ' C ' ' A' ' 31' ' ' GLY . 84.3 t -106.59 143.54 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 N-CA-C 106.342 -1.725 . . . . 1.35 106.342 178.365 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.671 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -133.24 138.51 46.53 Favored 'General case' 0 N--CA 1.512 2.666 0 CA-C-O 122.272 1.034 . . . . 1.67 112.516 -176.719 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 107' ' ' SER . . . . . 0.623 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 59.8 p -94.29 78.21 3.95 Favored 'General case' 0 N--CA 1.494 1.725 0 N-CA-C 107.608 -1.256 . . . . 2.04 107.608 179.097 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 16.8 mt 63.15 3.33 1.27 Allowed 'General case' 0 C--N 1.295 -1.766 0 N-CA-C 107.438 -1.319 . . . . 3.2 107.438 -177.835 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.502 ' H ' ' C ' ' A' ' 107' ' ' SER . 18.5 t -89.84 -23.18 21.74 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 108.813 -0.81 . . . . 2.09 108.813 179.328 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 110' ' ' ASP . . . . . 0.671 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 50.5 t0 . . . . . 0 N--CA 1.487 1.382 0 N-CA-C 107.822 -1.177 . . . . 2.85 107.822 -179.196 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 8' ' ' ARG . . . . . 0.563 ' CG ' HH11 ' B' ' 8' ' ' ARG . 1.4 mtt-85 . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 108.542 -0.91 . . . . 3.04 108.542 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 9' ' ' VAL . . . . . 0.415 ' O ' ' O ' ' A' ' 57' ' ' GLY . 11.2 t -49.89 159.85 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 120.973 -1.079 . . . . 0.67 108.311 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 0.4 ' N ' ' CG1' ' B' ' 9' ' ' VAL . . . -124.67 144.13 50.37 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.526 -0.734 . . . . 0.58 110.173 -178.887 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 11' ' ' SER . . . . . 0.44 ' CB ' HG23 ' A' ' 55' ' ' VAL . 2.8 t -134.7 145.88 48.93 Favored 'General case' 0 N--CA 1.495 1.817 0 N-CA-C 108.636 -0.876 . . . . 1.19 108.636 179.446 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 17.7 m -142.46 114.66 8.31 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.223 -0.923 . . . . 1.38 109.69 -179.491 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 0.57 HG22 ' N ' ' B' ' 14' ' ' PHE . 2.7 p -160.03 166.67 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 O-C-N 121.367 -0.833 . . . . 0.42 109.014 179.83 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 14' ' ' PHE . . . . . 0.57 ' N ' HG22 ' B' ' 13' ' ' VAL . 8.3 p90 -177.16 -166.88 0.15 Allowed 'General case' 0 N--CA 1.488 1.429 0 CA-C-O 122.077 0.941 . . . . 1.79 111.926 179.85 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.413 ' N ' HD13 ' B' ' 15' ' ' ILE . 0.0 OUTLIER -140.02 152.98 22.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 N-CA-C 108.271 -1.011 . . . . 1.25 108.271 179.721 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 7.2 m -123.66 131.14 53.54 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.317 -0.865 . . . . 1.61 109.921 -179.666 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 13.8 mt . . . . . 0 N--CA 1.496 1.843 0 O-C-N 121.327 -0.858 . . . . 1.32 109.01 179.609 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.519 ' O ' ' N ' ' A' ' 18' ' ' ALA . . . . . . . . 0 N--CA 1.49 2.284 0 N-CA-C 110.851 -0.899 . . . . 2.44 110.851 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.55 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -46.28 -12.33 0.05 OUTLIER Glycine 0 N--CA 1.491 2.333 0 N-CA-C 110.603 -0.999 . . . . 1.81 110.603 -179.2 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.519 ' N ' ' O ' ' A' ' 16' ' ' GLY . . . -47.64 -10.41 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.145 -1.209 . . . . 2.21 110.093 -179.924 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' HIS . . . . . 0.55 ' N ' ' O ' ' A' ' 17' ' ' GLY . 80.2 t60 -104.81 -31.36 9.34 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.188 -0.945 . . . . 2.87 110.444 -179.38 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -101.6 -14.72 17.32 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 120.997 -1.064 . . . . 2.02 110.848 -178.979 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.614 ' O ' HG13 ' A' ' 21' ' ' VAL . 9.0 p -70.85 114.39 8.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 120.819 -1.175 . . . . 2.07 109.818 -179.606 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 20.6 tpt180 -104.08 140.38 37.85 Favored 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 109.008 -0.738 . . . . 3.5 109.008 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -144.45 113.28 6.75 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.247 -0.908 . . . . 1.83 109.37 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -156.49 129.05 2.33 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.788 -1.325 . . . . 1.9 109.788 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.11 -177.59 47.72 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.666 -1.374 . . . . 1.85 109.666 179.805 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 12.3 p -78.36 -26.12 46.56 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.25 -1.147 . . . . 2.31 109.396 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -71.06 -12.13 71.23 Favored Glycine 0 N--CA 1.488 2.132 0 N-CA-C 109.301 -1.52 . . . . 1.64 109.301 -179.831 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 12.8 mt -91.36 -6.13 53.46 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.364 -1.08 . . . . 1.83 108.914 179.875 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -96.27 -51.03 4.55 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.336 -0.853 . . . . 2.34 109.748 -179.708 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 23.0 ptt180 -175.28 -173.65 0.67 Allowed 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.017 -1.052 . . . . 3.77 110.16 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -152.4 177.58 30.08 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 108.358 -1.897 . . . . 1.57 108.358 179.583 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 41.5 t -134.84 151.05 30.6 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.045 0 O-C-N 121.143 -1.21 . . . . 1.83 110.481 -179.683 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.589 ' HB2' ' HB3' ' A' ' 107' ' ' SER . . . -37.05 112.2 0.19 Allowed 'General case' 0 N--CA 1.5 2.072 0 CA-C-O 121.737 0.78 . . . . 1.64 112.406 -179.293 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 54.59 49.88 59.42 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 111.371 -0.692 . . . . 1.73 111.371 177.249 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 40.5 t -127.38 98.22 29.71 Favored Pre-proline 0 N--CA 1.496 1.826 0 O-C-N 121.511 -0.994 . . . . 2.19 108.512 178.95 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -56.89 149.05 63.43 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 120.955 1.103 . . . . 1.96 110.445 -178.86 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.403 ' HB3' ' CZ ' ' A' ' 77' ' ' TYR . . . -157.49 -167.73 2.37 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.4 -0.813 . . . . 1.69 109.018 -179.812 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -170.54 168.48 7.68 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.148 -0.97 . . . . 2.23 110.873 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 0.568 ' CE2' HD11 ' A' ' 41' ' ' ILE . 1.1 p90 -144.95 -178.68 6.16 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 107.161 -1.422 . . . . 1.54 107.161 178.345 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 12.0 m -109.42 150.99 27.27 Favored 'General case' 0 N--CA 1.5 2.049 0 O-C-N 121.359 -0.838 . . . . 2.37 110.99 -178.345 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.686 HD12 HG21 ' A' ' 75' ' ' VAL . 11.3 mt -147.8 94.55 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 N-CA-C 108.749 -0.834 . . . . 1.65 108.749 179.048 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.49 ' CD1' ' C ' ' A' ' 42' ' ' TRP . 0.6 OUTLIER -86.99 138.07 31.82 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 120.946 -1.096 . . . . 3.68 108.563 179.837 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -167.61 114.85 0.75 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.282 -0.886 . . . . 2.89 109.523 -179.678 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 44' ' ' ARG . . . . . 0.436 ' C ' ' CD ' ' A' ' 44' ' ' ARG . 1.7 ppt_? -169.47 -12.33 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.19 -0.944 . . . . 4.63 109.7 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -65.04 -46.15 82.46 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.213 -0.929 . . . . 2.89 109.469 -179.735 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.58 -50.4 72.07 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.153 -0.967 . . . . 1.74 108.856 179.695 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 139.76 -153.58 23.24 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.249 -1.54 . . . . 1.6 109.249 179.777 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -86.11 155.97 20.56 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.446 -1.032 . . . . 1.4 108.924 179.547 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 179.35 -140.28 4.28 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.563 -1.415 . . . . 1.04 109.563 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.47 ' O ' ' N ' ' A' ' 92' ' ' ASN . . . -138.88 167.64 25.04 Favored Glycine 0 N--CA 1.495 2.611 0 N-CA-C 109.283 -1.527 . . . . 1.06 109.283 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.445 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 46.4 tp -142.56 106.48 4.7 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.381 -1.07 . . . . 1.1 108.434 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.4 m -90.43 143.54 26.65 Favored 'General case' 0 N--CA 1.495 1.787 0 N-CA-C 108.557 -0.905 . . . . 1.56 108.557 179.863 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.548 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 53.6 mt -135.36 105.1 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.266 -0.897 . . . . 0.65 109.176 179.84 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -97.97 106.62 18.94 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.283 -0.886 . . . . 0.69 108.786 179.755 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.437 ' O ' ' O ' ' B' ' 11' ' ' SER . 0.2 OUTLIER -96.79 142.34 14.17 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.501 -0.749 . . . . 0.91 109.555 -179.745 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -141.78 142.7 33.22 Favored 'General case' 0 N--CA 1.491 1.61 0 N-CA-C 108.21 -1.033 . . . . 1.8 108.21 178.846 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 164.92 -173.9 40.83 Favored Glycine 0 N--CA 1.489 2.167 0 N-CA-C 109.448 -1.461 . . . . 0.49 109.448 -179.104 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -59.46 -26.0 80.51 Favored 'Trans proline' 0 C--N 1.315 -1.199 0 C-N-CA 121.93 1.753 . . . . 0.66 112.103 -179.299 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' SER . . . . . 0.435 ' O ' ' OH ' ' A' ' 85' ' ' TYR . 22.9 t -142.54 169.24 17.95 Favored 'General case' 0 N--CA 1.502 2.168 0 O-C-N 121.015 -1.053 . . . . 1.55 110.364 179.947 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 60.7 mttt -81.09 95.31 6.81 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.497 -0.752 . . . . 2.53 109.763 -179.608 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -63.54 117.29 6.55 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.173 -0.954 . . . . 0.82 109.511 179.854 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 62' ' ' GLU . . . . . 0.453 ' CB ' HG12 ' A' ' 78' ' ' VAL . 26.0 tt0 -66.27 168.39 8.79 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.154 -0.966 . . . . 2.3 109.148 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.458 HD12 HG13 ' B' ' 13' ' ' VAL . 28.1 mt -141.0 155.61 21.76 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 N-CA-C 108.642 -0.873 . . . . 1.4 108.642 -179.79 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.542 ' HB3' ' OG ' ' A' ' 76' ' ' SER . . . -144.87 170.75 15.52 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 120.627 -1.295 . . . . 1.36 109.156 179.978 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.46 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 31.3 p90 -147.16 117.88 7.57 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.28 -0.887 . . . . 1.47 109.472 -179.962 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 . . . . . 0 N--CA 1.495 1.81 0 O-C-N 121.364 -0.835 . . . . 2.51 109.546 -179.998 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 14.0 p . . . . . 0 N--CA 1.495 1.779 0 N-CA-C 108.76 -0.83 . . . . 2.2 108.76 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 3.3 m -78.81 115.22 18.36 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.15 -0.969 . . . . 2.05 109.521 -179.585 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -93.72 114.68 4.78 Favored Glycine 0 N--CA 1.494 2.543 0 N-CA-C 109.919 -1.273 . . . . 1.39 109.919 -179.716 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.686 HG21 HD12 ' A' ' 41' ' ' ILE . 94.0 t -98.39 108.5 22.15 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 121.409 -1.053 . . . . 1.57 109.465 179.695 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.542 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 0.7 OUTLIER -89.55 166.64 13.53 Favored 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 108.268 -1.012 . . . . 1.85 108.268 179.331 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.406 ' CD1' ' N ' ' A' ' 77' ' ' TYR . 14.1 p90 -164.14 172.36 13.81 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.216 -0.928 . . . . 1.54 109.659 -179.36 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.533 ' O ' HG13 ' A' ' 78' ' ' VAL . 3.7 p -142.17 119.25 7.11 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.254 0 O-C-N 121.104 -0.998 . . . . 1.9 110.391 179.61 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.51 HG11 HG21 ' A' ' 105' ' ' VAL . 8.5 m -94.98 147.06 6.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.186 -0.946 . . . . 1.27 109.164 179.674 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 29.5 tt0 -90.16 -47.44 7.8 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.082 -1.011 . . . . 2.48 110.582 -179.254 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -155.9 155.59 29.52 Favored Pre-proline 0 N--CA 1.504 2.231 0 O-C-N 120.695 -1.253 . . . . 1.92 110.902 -179.347 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.663 ' HG3' ' N ' ' A' ' 107' ' ' SER . 87.2 Cg_exo -36.19 152.77 0.03 OUTLIER 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 123.279 2.653 . . . . 1.3 113.287 179.03 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 152.31 158.04 8.26 Favored Glycine 0 N--CA 1.487 2.052 0 N-CA-C 109.251 -1.54 . . . . 1.02 109.251 -179.926 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 84' ' ' ASP . . . . . 0.781 ' H ' HH12 ' B' ' 8' ' ' ARG . 0.3 OUTLIER -83.39 90.38 7.16 Favored 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 107.648 -1.242 . . . . 2.13 107.648 179.077 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.435 ' OH ' ' O ' ' A' ' 59' ' ' SER . 1.4 m-85 -73.28 156.11 38.8 Favored 'General case' 0 C--N 1.294 -1.843 0 N-CA-C 108.266 -1.012 . . . . 0.92 108.266 -179.267 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 86' ' ' GLU . . . . . 0.42 ' OE1' ' O ' ' A' ' 84' ' ' ASP . 0.0 OUTLIER -138.48 120.83 15.95 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.461 -0.774 . . . . 1.53 109.287 -179.369 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.7 p -120.89 147.17 24.87 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.532 -0.73 . . . . 1.0 109.54 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 82.6 p -129.98 107.25 9.21 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.437 -0.79 . . . . 1.59 109.328 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.6 pt -106.29 130.75 57.48 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.658 -0.651 . . . . 1.29 109.946 -179.568 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 90' ' ' LYS . . . . . 0.466 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.6 OUTLIER -136.55 122.63 20.29 Favored 'General case' 0 N--CA 1.492 1.627 0 N-CA-C 108.837 -0.801 . . . . 1.58 108.837 179.341 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.56 ' O ' ' ND2' ' A' ' 92' ' ' ASN . 60.0 t80 -80.16 107.0 12.61 Favored 'General case' 0 C--N 1.299 -1.603 0 C-N-CA 118.716 -1.193 . . . . 1.34 107.819 178.37 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 92' ' ' ASN . . . . . 0.56 ' ND2' ' O ' ' A' ' 91' ' ' PHE . 2.9 p30 61.71 32.79 18.26 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.448 -0.783 . . . . 2.32 109.94 -178.584 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.472 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 2.5 m-20 86.21 16.97 0.11 Allowed 'General case' 0 N--CA 1.506 2.363 0 O-C-N 121.593 -0.692 . . . . 1.92 112.24 178.171 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 94' ' ' GLU . . . . . 0.489 ' O ' ' OE1' ' A' ' 94' ' ' GLU . 0.3 OUTLIER -102.4 98.64 8.71 Favored 'General case' 0 N--CA 1.499 1.98 0 N-CA-C 107.039 -1.467 . . . . 2.25 107.039 177.503 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 95' ' ' HIS . . . . . 0.502 ' O ' ' CG ' ' A' ' 95' ' ' HIS . 52.1 p-80 -68.64 106.48 2.63 Favored 'General case' 0 N--CA 1.487 1.417 0 N-CA-C 109.14 -0.689 . . . . 2.88 109.14 -178.838 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 96' ' ' ILE . . . . . 0.897 ' O ' HD13 ' A' ' 96' ' ' ILE . 0.0 OUTLIER -58.91 155.07 34.28 Favored Pre-proline 0 N--CA 1.491 1.602 0 N-CA-C 108.557 -0.905 . . . . 2.35 108.557 -179.614 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_endo -63.47 77.24 0.13 Allowed 'Trans proline' 0 CA--C 1.539 0.768 0 C-N-CA 121.23 1.287 . . . . 2.48 109.892 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.507 ' CG ' ' CE2' ' A' ' 101' ' ' PHE . 0.4 OUTLIER 179.81 -28.72 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.857 0 O-C-N 120.968 -1.082 . . . . 2.65 109.054 -179.649 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 29.4 m -78.02 136.69 61.77 Favored Pre-proline 0 C--N 1.298 -1.674 0 N-CA-C 107.313 -1.366 . . . . 2.0 107.313 178.448 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -76.64 116.95 4.66 Favored 'Cis proline' 0 CA--C 1.547 1.174 0 C-N-CA 125.165 -0.765 . . . . 1.79 111.09 -0.099 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 101' ' ' PHE . . . . . 0.507 ' CE2' ' CG ' ' A' ' 98' ' ' ASP . 0.1 OUTLIER -70.54 164.77 24.11 Favored 'General case' 0 N--CA 1.494 1.736 0 N-CA-C 107.793 -1.188 . . . . 2.19 107.793 178.566 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.485 HG13 ' O ' ' A' ' 102' ' ' VAL . 8.6 p -123.4 127.93 74.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 N-CA-C 108.43 -0.952 . . . . 1.44 108.43 179.068 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 94.9 t -121.47 83.56 40.96 Favored Pre-proline 0 N--CA 1.503 2.18 0 O-C-N 121.406 -0.809 . . . . 1.19 109.535 -179.223 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -66.85 110.64 1.97 Allowed 'Trans proline' 0 C--N 1.32 -0.967 0 C-N-CA 121.252 1.301 . . . . 1.49 110.742 -179.131 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.51 HG21 HG11 ' A' ' 79' ' ' VAL . 54.2 t -89.06 146.15 6.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 N-CA-C 107.28 -1.378 . . . . 1.35 107.28 178.54 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.553 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -133.64 130.43 38.27 Favored 'General case' 0 N--CA 1.508 2.46 0 O-C-N 121.289 -0.882 . . . . 1.67 111.746 -177.085 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 107' ' ' SER . . . . . 0.663 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 94.6 p -106.05 93.4 4.6 Favored 'General case' 0 N--CA 1.494 1.752 0 N-CA-C 106.854 -1.536 . . . . 2.04 106.854 178.578 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 108' ' ' LEU . . . . . 0.491 HD12 ' N ' ' A' ' 108' ' ' LEU . 11.1 mp 57.38 7.47 0.49 Allowed 'General case' 0 C--N 1.293 -1.858 0 N-CA-C 107.839 -1.171 . . . . 3.2 107.839 -177.696 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.513 ' H ' ' C ' ' A' ' 107' ' ' SER . 6.1 t -92.99 -29.42 15.85 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 108.506 -0.924 . . . . 2.09 108.506 178.989 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 110' ' ' ASP . . . . . 0.553 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 26.8 m-20 . . . . . 0 N--CA 1.488 1.432 0 N-CA-C 108.061 -1.089 . . . . 2.85 108.061 -178.994 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 8' ' ' ARG . . . . . 0.781 HH12 ' H ' ' A' ' 84' ' ' ASP . 3.9 mtt180 . . . . . 0 N--CA 1.496 1.862 0 N-CA-C 108.562 -0.903 . . . . 3.04 108.562 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 9' ' ' VAL . . . . . . . . . . . . . 20.8 t -56.82 159.34 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 N-CA-C 107.632 -1.247 . . . . 0.67 107.632 179.041 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -125.84 150.1 48.12 Favored 'General case' 0 N--CA 1.502 2.133 0 O-C-N 121.328 -0.857 . . . . 0.58 109.968 -179.136 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 11' ' ' SER . . . . . 0.437 ' O ' ' O ' ' A' ' 55' ' ' VAL . 6.2 m -148.77 145.14 27.46 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.389 -0.819 . . . . 1.19 109.44 179.911 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 14.8 t -142.08 118.57 10.93 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.205 -0.934 . . . . 1.38 109.553 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 0.56 HG22 ' N ' ' B' ' 14' ' ' PHE . 2.4 p -157.61 167.04 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 121.365 -0.834 . . . . 0.42 108.804 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 14' ' ' PHE . . . . . 0.56 ' N ' HG22 ' B' ' 13' ' ' VAL . 5.4 p90 -176.69 -167.13 0.18 Allowed 'General case' 0 N--CA 1.488 1.47 0 C-N-CA 119.298 -0.961 . . . . 1.79 112.082 -179.859 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.9 pt -146.63 176.94 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 N-CA-C 108.419 -0.956 . . . . 1.25 108.419 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 16.1 m -140.2 142.09 35.91 Favored 'General case' 0 N--CA 1.5 2.041 0 O-C-N 120.921 -1.112 . . . . 1.61 110.096 -179.703 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 18.5 mt . . . . . 0 N--CA 1.497 1.917 0 O-C-N 121.532 -0.73 . . . . 1.32 109.084 179.531 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.477 ' O ' ' N ' ' A' ' 18' ' ' ALA . . . . . . . . 0 N--CA 1.49 2.291 0 N-CA-C 111.779 -0.529 . . . . 2.44 111.779 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.588 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 63.79 -49.83 0.08 OUTLIER Glycine 0 N--CA 1.493 2.475 0 O-C-N 121.759 -0.848 . . . . 1.81 111.669 177.968 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.512 ' N ' ' OE2' ' A' ' 94' ' ' GLU . . . -45.33 -12.08 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.111 -1.229 . . . . 2.21 109.935 -179.276 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' HIS . . . . . 0.588 ' N ' ' O ' ' A' ' 17' ' ' GLY . 1.5 t60 -83.65 -40.64 18.72 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.142 -0.974 . . . . 2.87 109.557 179.207 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.527 ' HZ2' HG23 ' A' ' 21' ' ' VAL . 0.9 OUTLIER -93.93 4.17 54.3 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 120.874 -1.141 . . . . 2.02 110.5 -179.508 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.527 HG23 ' HZ2' ' A' ' 20' ' ' LYS . 64.6 t -83.06 113.51 22.36 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 120.811 -1.18 . . . . 2.07 109.25 179.721 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 20.3 tpt180 -111.03 137.27 48.87 Favored 'General case' 0 N--CA 1.496 1.83 0 CA-C-O 121.408 0.623 . . . . 3.5 109.63 -179.634 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -144.21 113.55 6.98 Favored 'General case' 0 N--CA 1.493 1.701 0 N-CA-C 108.744 -0.836 . . . . 1.83 108.744 179.417 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -153.17 128.53 2.47 Favored Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.924 -1.27 . . . . 1.9 109.924 -179.465 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 179.84 -173.92 45.5 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.926 -1.269 . . . . 1.85 109.926 179.721 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 16.7 p -78.92 -25.76 43.7 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.358 -1.083 . . . . 2.31 109.235 179.554 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.485 ' N ' ' O ' ' A' ' 38' ' ' GLU . . . -65.9 -17.78 65.7 Favored Glycine 0 N--CA 1.488 2.131 0 N-CA-C 108.388 -1.885 . . . . 1.64 108.388 179.58 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 14.1 mt -94.12 32.46 1.5 Allowed 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 108.477 -0.935 . . . . 1.83 108.477 179.439 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -140.33 -50.91 0.47 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.445 -0.784 . . . . 2.34 109.615 -179.58 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' ARG . . . . . 0.519 ' NH1' ' OD1' ' A' ' 110' ' ' ASP . 30.8 ptt180 -172.27 173.75 4.13 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.953 -1.092 . . . . 3.77 110.573 -179.79 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -150.24 176.4 28.88 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 107.878 -2.089 . . . . 1.57 107.878 179.437 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 37.5 t -134.09 153.13 35.44 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.137 0 O-C-N 120.992 -1.299 . . . . 1.83 110.755 -179.629 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.813 ' HB2' ' OG ' ' A' ' 107' ' ' SER . . . -40.37 114.1 0.42 Allowed 'General case' 0 N--CA 1.497 1.891 0 CA-C-O 121.587 0.708 . . . . 1.64 112.092 -179.334 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 56.46 46.04 88.38 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 111.397 -0.681 . . . . 1.73 111.397 177.05 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 37.1 t -126.92 122.54 23.33 Favored Pre-proline 0 N--CA 1.497 1.909 0 O-C-N 121.443 -1.033 . . . . 2.19 108.23 178.933 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 2.3 Cg_endo -59.47 120.52 8.41 Favored 'Trans proline' 0 C--O 1.216 -0.622 0 C-N-CA 120.474 0.783 . . . . 1.96 110.27 -179.38 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.47 ' HB3' ' CE1' ' A' ' 77' ' ' TYR . . . -116.81 161.21 19.65 Favored 'General case' 0 N--CA 1.497 1.904 0 N-CA-C 107.814 -1.18 . . . . 1.69 107.814 179.167 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' GLU . . . . . 0.485 ' O ' ' N ' ' A' ' 27' ' ' GLY . 7.0 pt-20 -163.8 173.01 13.31 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 120.642 -1.286 . . . . 2.23 111.519 -179.455 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 0.675 ' CE2' HD11 ' A' ' 41' ' ' ILE . 5.6 p90 -157.99 165.24 35.63 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 107.647 -1.242 . . . . 1.54 107.647 178.504 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 58.0 m -99.96 148.96 23.93 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.404 -0.81 . . . . 2.37 110.843 -178.099 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.795 HD12 HG21 ' A' ' 75' ' ' VAL . 95.5 mt -137.84 102.64 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 N-CA-C 108.353 -0.98 . . . . 1.65 108.353 178.963 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 3.0 t-105 -100.04 132.77 45.21 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.314 -0.866 . . . . 3.68 108.683 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.547 ' OG1' ' N ' ' A' ' 44' ' ' ARG . 1.6 t -162.25 -126.16 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.405 -0.809 . . . . 2.89 109.503 -179.641 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 44' ' ' ARG . . . . . 0.547 ' N ' ' OG1' ' A' ' 43' ' ' THR . 25.9 mtm180 60.61 80.22 0.22 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.285 -0.885 . . . . 4.63 109.954 179.885 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 12.5 tp10 -159.45 -46.82 0.05 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.282 -0.886 . . . . 2.89 109.134 179.383 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -60.34 -59.96 4.58 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.086 -1.009 . . . . 1.74 109.066 179.715 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 163.59 -175.88 39.76 Favored Glycine 0 N--CA 1.484 1.856 0 C-N-CA 119.385 -1.388 . . . . 1.6 110.464 179.62 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.6 163.47 0.65 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.535 -0.98 . . . . 1.4 109.853 -179.686 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 172.72 -163.2 35.04 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.68 -1.368 . . . . 1.04 109.68 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -142.77 130.45 4.2 Favored Glycine 0 N--CA 1.496 2.634 0 N-CA-C 109.245 -1.542 . . . . 1.06 109.245 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.475 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 12.2 tp -103.07 100.62 10.56 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.425 -1.044 . . . . 1.1 109.042 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 3.9 m -88.77 139.76 30.14 Favored 'General case' 0 N--CA 1.497 1.92 0 N-CA-C 108.723 -0.843 . . . . 1.56 108.723 179.476 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.507 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 82.6 mt -128.15 113.28 29.78 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.111 0 O-C-N 121.088 -1.008 . . . . 0.65 109.916 -179.811 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -102.48 106.04 16.7 Favored 'General case' 0 N--CA 1.494 1.736 0 N-CA-C 108.718 -0.845 . . . . 0.69 108.718 179.251 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.44 HG23 ' OG ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -102.84 143.7 14.78 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 O-C-N 121.471 -0.768 . . . . 0.91 109.326 -179.697 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 -141.95 144.03 33.54 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 108.181 -1.044 . . . . 1.8 108.181 178.743 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 168.71 -172.59 43.17 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 109.179 -1.569 . . . . 0.49 109.179 -179.031 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -63.73 -27.6 68.37 Favored 'Trans proline' 0 C--N 1.316 -1.133 0 C-N-CA 121.888 1.725 . . . . 0.66 111.461 -179.696 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' SER . . . . . 0.421 ' O ' ' OH ' ' A' ' 85' ' ' TYR . 16.0 m -140.4 168.12 20.55 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.257 -0.902 . . . . 1.55 109.754 -179.77 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 37.1 mtpt -91.13 126.44 36.22 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.376 -0.828 . . . . 2.53 109.517 -179.713 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -86.83 135.12 33.45 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.242 -0.911 . . . . 0.82 109.358 179.861 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 20.0 tt0 -90.19 94.53 9.8 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.129 -0.982 . . . . 2.3 109.97 -179.658 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.602 HD12 ' N ' ' A' ' 63' ' ' ILE . 1.8 mp -60.34 153.74 4.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 N-CA-C 109.118 -0.697 . . . . 1.4 109.118 179.415 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.547 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -151.3 123.8 8.41 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.037 -1.039 . . . . 1.36 109.24 179.778 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.47 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 47.5 p90 -89.0 124.59 34.42 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.204 -0.935 . . . . 1.47 109.376 179.787 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 75.9 tt0 . . . . . 0 N--CA 1.497 1.887 0 O-C-N 121.222 -0.924 . . . . 2.51 109.772 -179.96 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 3.3 t . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 109.092 -0.707 . . . . 2.2 109.092 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 76.4 m -86.23 113.39 22.21 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.126 -0.984 . . . . 2.05 109.428 -179.927 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -87.62 115.46 4.34 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.703 -1.359 . . . . 1.39 109.703 -179.717 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.795 HG21 HD12 ' A' ' 41' ' ' ILE . 22.0 t -107.03 104.46 17.1 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.995 0 O-C-N 121.605 -0.938 . . . . 1.57 109.012 179.79 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.547 ' O ' ' N ' ' A' ' 64' ' ' ALA . 37.3 m -99.4 131.84 45.14 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.558 -0.714 . . . . 1.85 110.06 -179.45 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.511 ' CD1' ' O ' ' A' ' 77' ' ' TYR . 44.3 p90 -128.01 134.96 49.29 Favored 'General case' 0 N--CA 1.497 1.915 0 N-CA-C 108.875 -0.787 . . . . 1.54 108.875 179.882 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.64 ' O ' HG13 ' A' ' 78' ' ' VAL . 9.7 p -104.52 114.2 43.51 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.099 0 O-C-N 121.324 -0.86 . . . . 1.9 109.582 -179.576 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.476 HG11 HG21 ' A' ' 105' ' ' VAL . 2.0 m -88.64 158.96 2.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.096 -1.002 . . . . 1.27 109.031 -179.865 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 35.1 tt0 -97.28 -49.47 4.93 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.079 -1.013 . . . . 2.48 110.758 -179.133 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 76.5 mm-40 -147.15 150.74 39.15 Favored Pre-proline 0 N--CA 1.504 2.242 0 O-C-N 120.794 -1.191 . . . . 1.92 111.661 -178.314 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.653 ' HG3' ' N ' ' A' ' 107' ' ' SER . 77.3 Cg_exo -36.85 164.27 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 123.248 2.632 . . . . 1.3 113.346 178.409 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 145.03 175.21 17.99 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.543 -1.423 . . . . 1.02 109.543 179.676 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 84' ' ' ASP . . . . . 0.837 ' H ' HH12 ' B' ' 8' ' ' ARG . 0.9 OUTLIER -94.26 83.97 4.33 Favored 'General case' 0 N--CA 1.49 1.549 0 N-CA-C 107.959 -1.126 . . . . 2.13 107.959 179.277 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 85' ' ' TYR . . . . . 0.421 ' OH ' ' O ' ' A' ' 59' ' ' SER . 2.7 m-85 -68.89 135.25 50.76 Favored 'General case' 0 C--N 1.299 -1.606 0 N-CA-C 107.84 -1.171 . . . . 0.92 107.84 -179.712 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 86' ' ' GLU . . . . . 0.442 ' OE2' ' O ' ' A' ' 84' ' ' ASP . 0.8 OUTLIER -116.31 121.04 40.8 Favored 'General case' 0 N--CA 1.499 1.996 0 N-CA-C 108.768 -0.827 . . . . 1.53 108.768 -179.37 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 10.6 p -116.46 145.35 22.33 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 121.592 -0.693 . . . . 1.0 110.194 -179.375 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 88' ' ' SER . . . . . 0.783 ' HB2' ' HE1' ' A' ' 95' ' ' HIS . 9.4 p -136.47 110.35 8.19 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 108.699 -0.852 . . . . 1.59 108.699 179.596 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.8 pt -116.89 135.75 56.23 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.949 0 O-C-N 121.577 -0.702 . . . . 1.29 110.632 -178.886 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 90' ' ' LYS . . . . . 0.461 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.3 OUTLIER -136.03 121.31 19.14 Favored 'General case' 0 N--CA 1.486 1.339 0 N-CA-C 107.923 -1.14 . . . . 1.58 107.923 178.625 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.409 ' O ' ' OE1' ' A' ' 94' ' ' GLU . 52.7 t80 -85.15 101.65 12.64 Favored 'General case' 0 N--CA 1.491 1.621 0 N-CA-C 107.196 -1.409 . . . . 1.34 107.196 178.632 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 92' ' ' ASN . . . . . 0.454 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 21.3 t30 72.09 34.36 1.45 Allowed 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 109.214 -0.661 . . . . 2.32 109.214 -178.266 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.454 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 1.4 m-20 80.22 14.4 0.84 Allowed 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.614 -0.679 . . . . 1.92 111.437 179.393 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 94' ' ' GLU . . . . . 0.512 ' OE2' ' N ' ' A' ' 18' ' ' ALA . 6.5 pt-20 -99.39 98.68 9.58 Favored 'General case' 0 N--CA 1.497 1.908 0 N-CA-C 107.09 -1.448 . . . . 2.25 107.09 177.898 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 95' ' ' HIS . . . . . 0.783 ' HE1' ' HB2' ' A' ' 88' ' ' SER . 0.7 OUTLIER -67.19 98.54 0.61 Allowed 'General case' 0 N--CA 1.491 1.578 0 CA-C-O 121.586 0.708 . . . . 2.88 110.022 -177.845 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 96' ' ' ILE . . . . . 0.467 HD13 ' HD2' ' A' ' 97' ' ' PRO . 0.1 OUTLIER -54.86 137.29 64.99 Favored Pre-proline 0 N--CA 1.489 1.503 0 N-CA-C 107.429 -1.322 . . . . 2.35 107.429 179.351 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.467 ' HD2' HD13 ' A' ' 96' ' ' ILE . 24.6 Cg_exo -39.37 -44.78 3.03 Favored 'Trans proline' 0 CA--C 1.537 0.657 0 C-N-CA 121.234 1.289 . . . . 2.48 111.791 -178.809 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.455 ' N ' ' OD1' ' A' ' 98' ' ' ASP . 1.2 m-20 -47.05 -65.72 0.52 Allowed 'General case' 0 N--CA 1.498 1.949 0 O-C-N 120.747 -1.221 . . . . 2.65 109.174 179.325 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.507 ' HB3' ' CE1' ' A' ' 95' ' ' HIS . 3.8 m -57.06 138.89 79.54 Favored Pre-proline 0 C--N 1.297 -1.705 0 O-C-N 121.26 -0.9 . . . . 2.0 109.204 -178.912 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -88.31 115.32 2.97 Favored 'Cis proline' 0 N--CA 1.49 1.271 0 N-CA-C 109.055 -1.171 . . . . 1.79 109.055 -1.669 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 52.5 p90 -114.5 162.96 16.03 Favored 'General case' 0 N--CA 1.517 2.918 0 O-C-N 120.546 -1.347 . . . . 2.19 110.335 179.117 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.1 p -91.79 151.92 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 CA-C-O 121.713 0.768 . . . . 1.44 110.749 -178.34 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 55.8 t -128.24 86.42 58.0 Favored Pre-proline 0 N--CA 1.494 1.766 0 N-CA-C 107.679 -1.23 . . . . 1.19 107.679 179.158 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -66.47 110.59 1.87 Allowed 'Trans proline' 0 C--N 1.321 -0.89 0 C-N-CA 121.623 1.549 . . . . 1.49 112.194 -177.563 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.476 HG21 HG11 ' A' ' 79' ' ' VAL . 55.5 t -94.51 142.52 13.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 N-CA-C 106.488 -1.671 . . . . 1.35 106.488 177.465 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.712 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -129.55 132.32 46.8 Favored 'General case' 0 N--CA 1.512 2.652 0 CA-C-O 122.173 0.987 . . . . 1.67 112.516 -176.59 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 107' ' ' SER . . . . . 0.813 ' OG ' ' HB2' ' A' ' 33' ' ' ALA . 35.7 m -94.53 81.33 3.91 Favored 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 107.117 -1.438 . . . . 2.04 107.117 178.515 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 23.9 mt 62.63 1.02 0.72 Allowed 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 107.795 -1.187 . . . . 3.2 107.795 -177.723 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 109' ' ' SER . . . . . 0.544 ' H ' ' C ' ' A' ' 107' ' ' SER . 60.8 p -87.72 -21.39 25.22 Favored 'General case' 0 N--CA 1.488 1.444 0 N-CA-C 108.471 -0.937 . . . . 2.09 108.471 178.859 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 110' ' ' ASP . . . . . 0.712 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 36.0 t0 . . . . . 0 N--CA 1.489 1.511 0 N-CA-C 108.512 -0.922 . . . . 2.85 108.512 -179.977 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 8' ' ' ARG . . . . . 0.837 HH12 ' H ' ' A' ' 84' ' ' ASP . 39.0 mtt180 . . . . . 0 N--CA 1.494 1.757 0 N-CA-C 108.847 -0.797 . . . . 3.04 108.847 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 9' ' ' VAL . . . . . . . . . . . . . 14.7 t -50.9 159.72 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 N-CA-C 108.059 -1.089 . . . . 0.67 108.059 179.24 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -122.66 144.26 49.25 Favored 'General case' 0 N--CA 1.501 2.092 0 O-C-N 121.372 -0.83 . . . . 0.58 110.092 -178.961 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 11' ' ' SER . . . . . 0.44 ' OG ' HG23 ' A' ' 55' ' ' VAL . 4.1 t -137.17 145.15 43.4 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.59 -0.693 . . . . 1.19 109.246 179.712 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 17.7 m -148.64 115.48 6.02 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.28 -0.888 . . . . 1.38 109.752 -179.797 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 0.596 HG22 ' N ' ' B' ' 14' ' ' PHE . 2.9 p -157.86 166.81 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 N-CA-C 108.694 -0.854 . . . . 0.42 108.694 179.624 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 14' ' ' PHE . . . . . 0.596 ' N ' HG22 ' B' ' 13' ' ' VAL . 6.9 p90 -177.33 -167.02 0.15 Allowed 'General case' 0 N--CA 1.489 1.509 0 C-N-CA 119.168 -1.013 . . . . 1.79 112.403 -179.811 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 3.2 pt -146.62 168.73 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 N-CA-C 108.437 -0.949 . . . . 1.25 108.437 179.819 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 49.5 m -138.69 142.08 38.97 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 120.999 -1.063 . . . . 1.61 110.178 -179.599 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 16.5 mt . . . . . 0 N--CA 1.497 1.899 0 O-C-N 121.52 -0.738 . . . . 1.32 109.162 179.545 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.955 0 N-CA-C 119.786 2.674 . . . . 6.64 119.786 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.559 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 14.5 tt -172.18 50.63 0.12 Allowed Pre-proline 0 C--N 1.306 -1.32 0 N-CA-C 107.8 -1.185 . . . . 7.08 107.8 179.421 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.749 ' C ' ' H ' ' A' ' 5' ' ' PHE . 5.5 Cg_endo -58.13 -82.22 0.01 OUTLIER 'Trans proline' 0 C--N 1.32 -0.962 0 N-CA-C 108.534 -1.372 . . . . 5.5 108.534 179.713 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 66.68 -3.83 0.84 Allowed 'General case' 0 N--CA 1.5 2.065 0 N-CA-C 105.101 -2.185 . . . . 6.75 105.101 -176.206 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' PHE . . . . . 0.749 ' H ' ' C ' ' A' ' 3' ' ' PRO . 5.4 m-85 -105.11 18.55 22.15 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 102.705 -3.072 . . . . 6.07 102.705 176.876 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.522 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 35.0 p90 46.16 -152.13 0.07 Allowed 'General case' 0 C--N 1.309 -1.169 0 CA-C-N 113.588 -1.642 . . . . 4.72 109.204 -177.176 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.506 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 5.1 tt0 82.99 -8.9 1.13 Allowed 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 104.819 -2.289 . . . . 4.4 104.819 -177.028 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.469 ' H ' ' C ' ' A' ' 6' ' ' PHE . 79.9 m-85 -146.98 -39.0 0.2 Allowed 'General case' 0 N--CA 1.484 1.268 0 N-CA-C 107.932 -1.136 . . . . 5.15 107.932 178.339 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.421 HG22 ' O ' ' A' ' 9' ' ' THR . 43.5 m -93.06 3.28 56.01 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 105.652 -1.981 . . . . 5.13 105.652 177.249 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.483 HG13 ' N ' ' A' ' 11' ' ' GLY . 9.7 p -46.76 -42.36 5.73 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 CA-C-N 115.278 -0.874 . . . . 4.38 109.544 -179.504 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.596 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 141.25 -83.18 0.22 Allowed Glycine 0 N--CA 1.499 2.889 0 N-CA-C 108.154 -1.978 . . . . 4.22 108.154 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.515 ' O ' ' N ' ' A' ' 14' ' ' GLY . 12.2 Cg_endo -66.35 40.57 0.15 Allowed 'Trans proline' 0 C--N 1.321 -0.901 0 C-N-CA 121.866 1.71 . . . . 3.85 108.779 177.463 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.596 ' H ' ' C ' ' A' ' 11' ' ' GLY . 0.2 OUTLIER 28.65 37.39 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.276 0 CA-C-O 121.265 0.555 . . . . 3.67 110.997 -179.634 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.62 ' C ' ' H ' ' A' ' 16' ' ' GLY . . . 66.91 -35.08 0.18 Allowed Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.556 -1.418 . . . . 2.97 109.556 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.594 ' H ' ' C ' ' A' ' 13' ' ' LEU . 6.8 tp10 62.99 -9.31 0.11 Allowed 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.552 -0.969 . . . . 2.97 108.897 -178.856 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.62 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 102.87 -151.34 18.03 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 110.809 -0.916 . . . . 2.44 110.809 178.429 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.536 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -46.59 -11.5 0.05 OUTLIER Glycine 0 N--CA 1.492 2.402 0 O-C-N 121.635 -0.921 . . . . 1.81 111.068 -178.956 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.512 ' N ' ' O ' ' A' ' 16' ' ' GLY . . . -45.93 -15.87 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.991 -1.299 . . . . 2.21 109.661 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' HIS . . . . . 0.536 ' N ' ' O ' ' A' ' 17' ' ' GLY . 10.7 t60 -94.48 -48.88 5.92 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.443 -0.786 . . . . 2.87 109.779 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.51 -14.4 62.1 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.891 -1.13 . . . . 2.02 109.435 -179.872 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 37.9 t -68.43 108.82 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.134 -0.979 . . . . 2.07 108.629 179.387 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.416 ' CG ' HH11 ' A' ' 22' ' ' ARG . 0.0 OUTLIER -113.83 138.49 50.21 Favored 'General case' 0 N--CA 1.491 1.609 0 N-CA-C 109.131 -0.692 . . . . 3.5 109.131 -179.515 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -147.72 113.36 5.68 Favored 'General case' 0 N--CA 1.491 1.603 0 N-CA-C 108.776 -0.824 . . . . 1.83 108.776 179.553 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -151.96 131.68 3.51 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.461 -1.456 . . . . 1.9 109.461 -179.597 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.0 -177.1 46.51 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.502 -1.439 . . . . 1.85 109.502 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.471 HG23 ' N ' ' A' ' 27' ' ' GLY . 13.5 t -79.59 -38.58 33.66 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.252 -1.146 . . . . 2.31 109.16 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.471 ' N ' HG23 ' A' ' 26' ' ' THR . . . -60.28 -6.94 6.37 Favored Glycine 0 N--CA 1.483 1.811 0 N-CA-C 107.864 -2.094 . . . . 1.64 107.864 179.222 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.451 ' H ' ' C ' ' A' ' 26' ' ' THR . 12.3 mt -99.3 24.29 8.2 Favored 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 108.247 -1.02 . . . . 1.83 108.247 179.38 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 18.2 mt-10 -136.81 -37.66 0.66 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.515 -0.741 . . . . 2.34 109.152 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ARG . . . . . 0.514 HH11 ' HG2' ' A' ' 30' ' ' ARG . 2.5 ptt-85 -174.78 168.7 3.61 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.098 -1.001 . . . . 3.77 110.204 179.843 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -148.59 177.44 26.83 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 107.643 -2.183 . . . . 1.57 107.643 179.558 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 44.1 t -134.41 151.0 31.2 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.12 0 O-C-N 121.056 -1.261 . . . . 1.83 111.043 -179.528 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.515 ' HB2' ' HB3' ' A' ' 107' ' ' SER . . . -40.05 111.35 0.19 Allowed 'General case' 0 N--CA 1.498 1.937 0 CA-C-O 121.501 0.667 . . . . 1.64 112.418 -179.233 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 55.63 50.21 61.63 Favored Glycine 0 N--CA 1.492 2.395 0 O-C-N 121.589 -0.694 . . . . 1.73 111.427 176.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 31.5 t -127.35 124.19 23.55 Favored Pre-proline 0 N--CA 1.496 1.851 0 N-CA-C 108.312 -0.996 . . . . 2.19 108.312 178.827 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -57.3 131.98 48.23 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 N-CA-C 110.034 -0.795 . . . . 1.96 110.034 -179.527 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.527 ' HB3' ' CE1' ' A' ' 77' ' ' TYR . . . -136.04 160.31 39.04 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.46 -0.775 . . . . 1.69 109.004 179.81 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -155.32 171.47 19.8 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.012 -1.055 . . . . 2.23 111.213 -179.486 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.627 ' CE2' HD11 ' A' ' 41' ' ' ILE . 5.9 p90 -156.58 164.6 38.0 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 107.259 -1.386 . . . . 1.54 107.259 178.372 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 80.5 p -96.52 155.1 16.91 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.208 -0.933 . . . . 2.37 111.279 -177.806 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.878 HD12 HG21 ' A' ' 75' ' ' VAL . 46.6 mt -146.42 97.71 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 N-CA-C 107.516 -1.29 . . . . 1.65 107.516 178.767 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.4 ' CD1' ' C ' ' A' ' 42' ' ' TRP . 0.7 OUTLIER -84.88 146.96 27.03 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.113 -0.992 . . . . 3.68 109.125 -179.407 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.556 ' OG1' ' N ' ' A' ' 44' ' ' ARG . 1.4 t -154.31 -130.35 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.525 0 N-CA-C 109.138 -0.689 . . . . 2.89 109.138 -179.414 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ARG . . . . . 0.556 ' N ' ' OG1' ' A' ' 43' ' ' THR . 39.6 ttp180 54.18 73.98 0.36 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.172 -0.955 . . . . 4.63 109.985 179.842 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 15.7 tt0 -165.14 -60.86 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.31 -0.869 . . . . 2.89 108.875 179.357 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.63 -54.56 44.64 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.059 -1.026 . . . . 1.74 108.71 179.286 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 145.58 179.63 21.97 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.292 -1.523 . . . . 1.6 109.292 179.848 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.73 162.74 0.82 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.134 -1.216 . . . . 1.4 109.598 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 168.89 -151.98 19.11 Favored Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.537 -1.425 . . . . 1.04 109.537 -179.881 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.538 ' O ' ' N ' ' A' ' 92' ' ' ASN . . . -133.87 159.12 23.61 Favored Glycine 0 N--CA 1.497 2.743 0 N-CA-C 109.413 -1.475 . . . . 1.06 109.413 -179.855 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.436 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 9.8 tp -134.14 100.5 4.73 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.529 -0.983 . . . . 1.1 108.424 179.767 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 3.8 m -83.93 144.13 29.38 Favored 'General case' 0 N--CA 1.491 1.58 0 N-CA-C 108.527 -0.916 . . . . 1.56 108.527 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.542 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 7.5 mt -135.71 100.94 2.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.354 -0.841 . . . . 0.65 109.203 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -98.19 106.22 18.48 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.306 -0.871 . . . . 0.69 108.986 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.44 ' O ' ' O ' ' B' ' 11' ' ' SER . 0.2 OUTLIER -97.64 144.42 11.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.499 -0.751 . . . . 0.91 109.403 -179.87 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 3.1 tt0 -141.11 142.09 34.14 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 107.909 -1.145 . . . . 1.8 107.909 179.059 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.432 ' O ' ' O ' ' B' ' 9' ' ' VAL . . . 169.03 176.89 39.44 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.173 -1.571 . . . . 0.49 109.173 -178.811 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -56.48 -17.99 23.76 Favored 'Trans proline' 0 C--N 1.317 -1.123 0 C-N-CA 121.94 1.76 . . . . 0.66 111.274 -179.482 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.4 p -150.22 159.93 44.07 Favored 'General case' 0 C--N 1.292 -1.922 0 O-C-N 121.284 -0.885 . . . . 1.55 110.154 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 68.2 mttt -78.86 108.2 12.14 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.498 -0.752 . . . . 2.53 109.558 -179.868 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -74.18 148.43 41.68 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.232 -0.918 . . . . 0.82 109.481 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.834 ' C ' HD12 ' A' ' 63' ' ' ILE . 5.0 tp10 -85.14 172.3 11.33 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.322 -0.861 . . . . 2.3 108.786 179.889 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.834 HD12 ' C ' ' A' ' 62' ' ' GLU . 3.7 mp -142.79 144.98 23.65 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.926 0 N-CA-C 108.259 -1.015 . . . . 1.4 108.259 179.809 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.521 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -150.53 114.47 5.04 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 120.6 -1.312 . . . . 1.36 109.923 -179.779 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 54.7 p90 -86.74 138.86 31.27 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.327 -0.858 . . . . 1.47 109.572 179.73 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 -141.4 105.61 4.81 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.22 -0.925 . . . . 2.51 109.711 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.427 ' OD1' ' O ' ' A' ' 67' ' ' ASP . 7.2 p30 -79.18 76.65 5.71 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 108.315 -0.995 . . . . 2.07 108.315 178.834 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.424 HH11 ' HG2' ' A' ' 68' ' ' ARG . 25.3 ttt-85 -137.55 59.62 1.66 Allowed 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.433 -0.792 . . . . 4.63 109.366 -179.39 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.467 ' O ' ' CB ' ' A' ' 70' ' ' ASP . 26.8 mttp -146.12 3.25 0.91 Allowed 'General case' 0 C--N 1.305 -1.338 0 O-C-N 121.217 -0.927 . . . . 3.49 108.732 179.837 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.467 ' CB ' ' O ' ' A' ' 69' ' ' LYS . 2.5 t70 77.15 4.11 3.25 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.833 -0.542 . . . . 3.06 109.66 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 166.7 -25.52 0.15 Allowed Glycine 0 N--CA 1.49 2.245 0 C-N-CA 118.719 -1.705 . . . . 2.16 111.472 179.703 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 37.5 m -95.11 135.15 37.01 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 120.844 -1.386 . . . . 2.2 109.788 -179.464 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 5.9 t -83.97 125.81 32.41 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.2 -0.938 . . . . 2.05 109.108 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -97.65 109.87 3.91 Favored Glycine 0 N--CA 1.495 2.616 0 N-CA-C 110.139 -1.184 . . . . 1.39 110.139 -179.572 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.878 HG21 HD12 ' A' ' 41' ' ' ILE . 32.1 t -99.23 100.86 11.26 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.929 0 O-C-N 121.583 -0.951 . . . . 1.57 108.757 179.13 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.521 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.1 OUTLIER -89.53 126.14 35.48 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.675 -0.64 . . . . 1.85 109.353 -179.551 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.527 ' CE1' ' HB3' ' A' ' 37' ' ' ALA . 52.0 p90 -123.52 173.89 7.75 Favored 'General case' 0 N--CA 1.495 1.811 0 N-CA-C 108.591 -0.892 . . . . 1.54 108.591 179.619 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 15.4 t -142.18 120.51 8.6 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.936 0 O-C-N 121.321 -0.862 . . . . 1.9 109.769 -179.628 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.526 HG11 HG21 ' A' ' 105' ' ' VAL . 8.1 m -90.82 154.98 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.435 -0.791 . . . . 1.27 109.314 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' GLN . . . . . 0.429 ' O ' ' OE2' ' A' ' 81' ' ' GLU . 33.5 tt0 -100.43 -45.85 5.43 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.192 -0.942 . . . . 2.48 110.746 -179.18 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.429 ' OE2' ' O ' ' A' ' 80' ' ' GLN . 79.6 mm-40 -152.39 149.12 22.11 Favored Pre-proline 0 N--CA 1.504 2.251 0 O-C-N 120.458 -1.401 . . . . 1.92 111.399 -179.151 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.678 ' HG3' ' N ' ' A' ' 107' ' ' SER . 84.6 Cg_exo -36.86 162.19 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 123.117 2.544 . . . . 1.3 113.637 178.232 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 143.42 -163.82 27.44 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 108.673 -1.771 . . . . 1.02 108.673 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' ASP . . . . . 0.422 ' O ' ' OE1' ' A' ' 86' ' ' GLU . 3.0 m-20 -111.82 93.77 4.62 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.502 -0.999 . . . . 2.13 108.353 179.354 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -78.59 146.19 34.32 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 108.206 -1.035 . . . . 0.92 108.206 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' GLU . . . . . 0.422 ' OE1' ' O ' ' A' ' 84' ' ' ASP . 0.0 OUTLIER -134.64 129.75 35.35 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.682 -0.636 . . . . 1.53 109.298 -178.98 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.8 p -124.99 146.79 30.05 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.554 -0.716 . . . . 1.0 109.762 -179.807 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 53.6 p -128.59 101.61 6.23 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.442 -0.786 . . . . 1.59 109.106 179.642 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.2 pt -102.4 130.64 51.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.615 -0.678 . . . . 1.29 109.577 -179.573 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' LYS . . . . . 0.435 ' HG3' ' H ' ' A' ' 93' ' ' ASP . 0.5 OUTLIER -138.62 124.85 20.29 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.244 -0.91 . . . . 1.58 109.238 179.721 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 36.5 t80 -83.13 95.16 8.0 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 120.992 -1.067 . . . . 1.34 108.599 179.391 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' ASN . . . . . 0.538 ' N ' ' O ' ' A' ' 50' ' ' GLY . 2.3 t-20 70.15 38.71 1.44 Allowed 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 107.925 -1.139 . . . . 2.32 107.925 -178.69 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.456 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 3.2 m-20 82.78 12.79 0.48 Allowed 'General case' 0 N--CA 1.498 1.943 0 CA-C-O 121.26 0.553 . . . . 1.92 110.005 -179.222 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' GLU . . . . . 0.405 ' HG2' ' H ' ' A' ' 18' ' ' ALA . 4.1 mt-10 -88.88 70.7 8.64 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 107.576 -1.268 . . . . 2.25 107.576 178.192 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' HIS . . . . . 0.462 ' H ' ' CD2' ' A' ' 95' ' ' HIS . 11.4 p80 -67.5 113.44 5.35 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-O 121.309 0.576 . . . . 2.88 109.953 -179.133 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 96' ' ' ILE . . . . . 0.406 HG12 ' H ' ' A' ' 96' ' ' ILE . 2.0 pt -62.64 153.78 76.73 Favored Pre-proline 0 N--CA 1.491 1.61 0 N-CA-C 108.295 -1.002 . . . . 2.35 108.295 179.444 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_exo -50.86 -44.69 40.08 Favored 'Trans proline' 0 C--N 1.321 -0.914 0 C-N-CA 121.051 1.167 . . . . 2.48 109.987 179.819 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.564 ' CB ' ' CE2' ' A' ' 101' ' ' PHE . 3.4 m-20 -51.33 -48.43 62.4 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.146 -0.972 . . . . 2.65 109.85 179.67 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 2.4 t -56.45 126.13 68.46 Favored Pre-proline 0 C--N 1.298 -1.655 0 N-CA-C 107.752 -1.203 . . . . 2.0 107.752 179.545 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 8.3 Cg_endo -72.24 117.55 3.94 Favored 'Cis proline' 0 CA--C 1.548 1.188 0 CA-C-N 119.317 0.792 . . . . 1.79 111.48 0.328 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' PHE . . . . . 0.564 ' CE2' ' CB ' ' A' ' 98' ' ' ASP . 0.1 OUTLIER -73.3 170.97 13.92 Favored 'General case' 0 N--CA 1.494 1.757 0 N-CA-C 107.251 -1.389 . . . . 2.19 107.251 178.273 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.403 ' O ' HG13 ' A' ' 102' ' ' VAL . 7.6 p -126.77 133.27 68.91 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 121.358 -0.838 . . . . 1.44 109.16 179.79 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 86.5 t -128.93 83.08 67.31 Favored Pre-proline 0 N--CA 1.502 2.161 0 O-C-N 121.454 -0.779 . . . . 1.19 109.63 -179.513 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -64.77 114.45 2.76 Favored 'Trans proline' 0 C--N 1.32 -0.932 0 C-N-CA 121.302 1.334 . . . . 1.49 110.477 -179.506 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.526 HG21 HG11 ' A' ' 79' ' ' VAL . 53.1 t -93.91 146.15 6.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 N-CA-C 108.292 -1.003 . . . . 1.35 108.292 179.484 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.65 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -131.92 130.28 41.38 Favored 'General case' 0 N--CA 1.507 2.401 0 CA-C-O 121.932 0.872 . . . . 1.67 111.941 -177.291 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.678 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 76.2 p -98.65 98.3 9.46 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.733 -1.23 . . . . 2.04 107.788 179.184 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 108' ' ' LEU . . . . . 0.514 HD12 ' N ' ' A' ' 108' ' ' LEU . 8.9 mp 54.62 9.3 0.26 Allowed 'General case' 0 C--N 1.293 -1.872 0 N-CA-C 108.278 -1.008 . . . . 3.2 108.278 -178.585 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.656 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 8.3 t -101.05 -28.57 12.64 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.604 -0.685 . . . . 2.09 109.16 179.503 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 110' ' ' ASP . . . . . 0.65 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 13.8 t70 55.04 11.12 0.46 Allowed 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 107.776 -1.194 . . . . 2.85 107.776 -179.528 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.478 ' H ' ' C ' ' A' ' 109' ' ' SER . 1.8 p30 -168.28 -30.53 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 109.484 -0.561 . . . . 2.46 109.484 -179.602 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.656 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 49.25 75.24 0.16 Allowed 'General case' 0 N--CA 1.497 1.883 0 O-C-N 120.79 -1.193 . . . . 2.08 108.821 -179.576 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 113' ' ' ARG . . . . . 0.501 ' C ' ' H ' ' A' ' 115' ' ' LEU . 0.0 OUTLIER -82.82 149.54 27.12 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.323 -0.861 . . . . 5.93 110.292 -178.785 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 22.6 ttp180 -73.9 12.49 0.67 Allowed 'General case' 0 N--CA 1.494 1.733 0 N-CA-C 108.664 -0.865 . . . . 5.61 108.664 179.239 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.501 ' H ' ' C ' ' A' ' 113' ' ' ARG . 31.0 mt -127.83 -29.83 2.56 Favored 'General case' 0 N--CA 1.503 2.183 0 N-CA-C 109.116 -0.698 . . . . 4.39 109.116 -179.906 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.503 ' C ' ' N ' ' A' ' 118' ' ' THR . 33.9 m -91.48 -80.01 0.36 Allowed 'General case' 0 N--CA 1.494 1.755 0 N-CA-C 106.893 -1.521 . . . . 4.09 106.893 178.847 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.403 ' O ' HG12 ' A' ' 117' ' ' VAL . 32.0 t -61.36 -10.04 3.34 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 N-CA-C 105.579 -2.008 . . . . 2.9 105.579 176.384 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 118' ' ' THR . . . . . 0.503 ' N ' ' C ' ' A' ' 116' ' ' THR . 5.1 t 36.6 58.22 1.08 Allowed 'General case' 0 N--CA 1.484 1.267 0 CA-C-N 114.851 -1.068 . . . . 3.36 110.742 179.88 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 119' ' ' SER . . . . . 0.463 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.7 p . . . . . 0 C--N 1.304 -1.404 0 CA-C-O 118.021 -0.99 . . . . 3.39 109.569 179.384 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 19.3 mmt . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.463 -0.569 . . . . 8.49 109.463 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . 50.97 90.41 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.213 -0.93 . . . . 5.53 109.435 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 3' ' ' SER . . . . . . . . . . . . . 36.4 t -53.31 107.66 0.26 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.26 -0.9 . . . . 5.43 109.454 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 4' ' ' LYS . . . . . 0.541 ' N ' ' CD ' ' B' ' 5' ' ' PRO . 6.3 tttp -60.9 -47.28 96.06 Favored Pre-proline 0 N--CA 1.488 1.465 0 O-C-N 121.346 -0.846 . . . . 6.87 110.296 -179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 5' ' ' PRO . . . . . 0.541 ' CD ' ' N ' ' B' ' 4' ' ' LYS . 6.1 Cg_exo -63.48 129.99 26.92 Favored 'Trans proline' 0 C--N 1.321 -0.872 0 C-N-CA 120.879 1.052 . . . . 5.16 109.852 -179.345 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 6' ' ' GLU . . . . . 0.422 ' HG2' ' H ' ' B' ' 6' ' ' GLU . 3.0 pt-20 -63.97 115.87 5.31 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.369 -0.832 . . . . 4.78 109.59 -179.766 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 67.2 mttt 48.64 -165.43 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.234 -0.916 . . . . 4.09 109.471 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.592 ' CG ' HH11 ' B' ' 8' ' ' ARG . 0.0 OUTLIER -101.53 -163.28 1.0 Allowed 'General case' 0 N--CA 1.494 1.769 0 N-CA-C 107.349 -1.352 . . . . 3.04 107.349 179.559 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 9' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' A' ' 57' ' ' GLY . 34.8 t -71.94 160.0 5.47 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 120.75 -1.219 . . . . 0.67 108.422 179.611 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 0.4 ' N ' HG12 ' B' ' 9' ' ' VAL . . . -123.71 156.71 35.45 Favored 'General case' 0 N--CA 1.5 2.066 0 O-C-N 121.418 -0.801 . . . . 0.58 110.015 -179.26 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 11' ' ' SER . . . . . 0.44 ' O ' ' O ' ' A' ' 55' ' ' VAL . 3.2 t -149.56 144.03 25.97 Favored 'General case' 0 N--CA 1.492 1.641 0 N-CA-C 108.869 -0.789 . . . . 1.19 108.869 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 47.2 t -143.48 120.12 11.12 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 120.976 -1.078 . . . . 1.38 109.99 -179.666 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 0.582 HG22 ' N ' ' B' ' 14' ' ' PHE . 3.1 p -157.92 165.77 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 N-CA-C 108.722 -0.844 . . . . 0.42 108.722 179.542 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 14' ' ' PHE . . . . . 0.582 ' N ' HG22 ' B' ' 13' ' ' VAL . 4.9 p90 -177.99 -170.35 0.24 Allowed 'General case' 0 N--CA 1.49 1.563 0 C-N-CA 119.38 -0.928 . . . . 1.79 112.158 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 3.1 pt -149.87 -163.66 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.341 0 N-CA-C 108.273 -1.01 . . . . 1.25 108.273 179.831 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -161.09 146.55 14.22 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 120.724 -1.235 . . . . 1.61 109.911 179.769 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 13.4 mt -91.66 108.6 20.02 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.219 -0.926 . . . . 1.32 109.376 179.696 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -138.7 82.37 21.53 Favored Pre-proline 0 N--CA 1.495 1.776 0 N-CA-C 108.741 -0.837 . . . . 1.45 108.741 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_exo -59.58 166.43 8.03 Favored 'Trans proline' 0 C--N 1.32 -0.93 0 C-N-CA 121.046 1.164 . . . . 1.5 109.808 -178.846 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 20' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -54.11 -173.57 0.02 OUTLIER 'Trans proline' 0 C--N 1.319 -1.024 0 C-N-CA 121.457 1.438 . . . . 2.86 109.998 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 78.9 mtm180 -58.34 129.61 42.84 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.286 -0.884 . . . . 6.12 109.72 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 22' ' ' ARG . . . . . . . . . . . . . 66.8 mtm180 -59.32 137.46 57.98 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.239 -0.913 . . . . 6.29 109.33 179.756 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 42.8 t0 -160.93 12.7 0.1 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.125 -0.985 . . . . 5.62 109.751 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 33.7 m . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 118.033 -0.985 . . . . 6.48 109.405 -179.99 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.922 0 N-CA-C 119.671 2.628 . . . . 6.64 119.671 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.568 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 15.0 tt -172.27 50.28 0.12 Allowed Pre-proline 0 C--N 1.307 -1.255 0 N-CA-C 107.807 -1.182 . . . . 7.08 107.807 179.573 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.814 ' C ' ' H ' ' A' ' 5' ' ' PHE . 6.1 Cg_endo -57.94 -82.71 0.01 OUTLIER 'Trans proline' 0 C--N 1.318 -1.076 0 N-CA-C 108.583 -1.353 . . . . 5.5 108.583 179.827 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.483 ' CB ' ' O ' ' A' ' 3' ' ' PRO . 0.5 OUTLIER 74.11 -18.76 0.39 Allowed 'General case' 0 N--CA 1.496 1.831 0 N-CA-C 104.209 -2.515 . . . . 6.75 104.209 -175.851 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 5' ' ' PHE . . . . . 0.814 ' H ' ' C ' ' A' ' 3' ' ' PRO . 5.5 m-85 -90.03 19.48 4.91 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 103.966 -2.605 . . . . 6.07 103.966 176.718 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.542 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 39.5 p90 46.17 -152.49 0.06 Allowed 'General case' 0 C--N 1.307 -1.27 0 CA-C-N 114.421 -1.263 . . . . 4.72 109.38 -177.436 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.53 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 8.6 tt0 83.6 -8.12 1.08 Allowed 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 105.023 -2.214 . . . . 4.4 105.023 -177.205 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.458 ' H ' ' C ' ' A' ' 6' ' ' PHE . 48.0 m-85 -148.34 -39.42 0.17 Allowed 'General case' 0 C--N 1.307 -1.27 0 N-CA-C 107.66 -1.237 . . . . 5.15 107.66 178.383 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 25.6 m -91.07 2.45 56.31 Favored 'General case' 0 C--N 1.295 -1.762 0 N-CA-C 105.874 -1.899 . . . . 5.13 105.874 177.199 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.533 HG13 ' N ' ' A' ' 11' ' ' GLY . 8.7 p -45.51 -44.16 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.327 0 CA-C-N 115.513 -0.767 . . . . 4.38 109.439 -179.568 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.559 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 143.86 -84.86 0.19 Allowed Glycine 0 N--CA 1.497 2.735 0 N-CA-C 108.411 -1.876 . . . . 4.22 108.411 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.529 ' O ' ' N ' ' A' ' 14' ' ' GLY . 12.3 Cg_endo -68.57 35.84 0.18 Allowed 'Trans proline' 0 C--N 1.322 -0.859 0 C-N-CA 121.468 1.445 . . . . 3.85 109.074 177.964 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.559 ' H ' ' C ' ' A' ' 11' ' ' GLY . 0.1 OUTLIER 40.46 23.91 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.261 0 N-CA-C 108.877 -0.786 . . . . 3.67 108.877 -179.152 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.532 ' C ' ' H ' ' A' ' 16' ' ' GLY . . . 69.99 -45.67 0.57 Allowed Glycine 0 N--CA 1.486 1.995 0 N-CA-C 107.42 -2.272 . . . . 2.97 107.42 -178.243 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.534 ' H ' ' C ' ' A' ' 13' ' ' LEU . 7.1 tp10 49.13 10.93 0.03 OUTLIER 'General case' 0 C--N 1.305 -1.359 0 CA-C-O 121.948 0.88 . . . . 2.97 109.01 179.73 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.532 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 55.16 121.21 0.01 OUTLIER Glycine 0 N--CA 1.49 2.24 0 O-C-N 121.513 -0.742 . . . . 2.44 111.635 178.835 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.558 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 72.36 -52.34 1.45 Allowed Glycine 0 N--CA 1.493 2.487 0 O-C-N 121.458 -1.024 . . . . 1.81 111.127 178.296 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.749 ' HB2' ' OE1' ' A' ' 94' ' ' GLU . . . -49.45 -6.95 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.098 -1.236 . . . . 2.21 110.169 -179.308 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' HIS . . . . . 0.558 ' N ' ' O ' ' A' ' 17' ' ' GLY . 29.2 t-80 -94.97 -12.09 27.34 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.067 -1.021 . . . . 2.87 110.295 -179.801 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.424 ' NZ ' HG23 ' A' ' 21' ' ' VAL . 2.3 pptp? -132.6 11.64 4.44 Favored 'General case' 0 N--CA 1.504 2.235 0 O-C-N 121.031 -1.043 . . . . 2.02 110.457 -179.759 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.424 HG23 ' NZ ' ' A' ' 20' ' ' LYS . 53.2 t -94.29 113.19 28.38 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 120.976 -1.078 . . . . 2.07 109.257 179.491 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 20.3 tpt180 -113.08 121.33 44.24 Favored 'General case' 0 N--CA 1.496 1.846 0 N-CA-C 108.98 -0.748 . . . . 3.5 108.98 179.843 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -128.16 114.07 16.53 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 108.878 -0.786 . . . . 1.83 108.878 179.735 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -151.24 130.6 3.22 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 109.509 -1.436 . . . . 1.9 109.509 -179.616 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.29 171.08 43.42 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.739 -1.344 . . . . 1.85 109.739 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 13.2 p -78.51 -27.13 46.06 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.343 -1.092 . . . . 2.31 109.373 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.68 -12.55 70.57 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 109.11 -1.596 . . . . 1.64 109.11 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 12.1 mt -87.68 -15.53 36.9 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.437 -1.037 . . . . 1.83 108.852 179.679 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 42.2 mt-10 -87.66 -62.07 1.58 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.412 -0.805 . . . . 2.34 109.726 -179.793 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 72.5 mtt180 -148.14 178.48 8.51 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.114 -0.991 . . . . 3.77 110.058 -179.678 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -150.11 175.21 29.3 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 107.786 -2.125 . . . . 1.57 107.786 179.317 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 40.7 t -133.54 151.7 33.82 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.15 0 O-C-N 121.084 -1.245 . . . . 1.83 110.744 -179.57 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.457 ' HB2' ' HD3' ' A' ' 82' ' ' PRO . . . -43.56 111.01 0.23 Allowed 'General case' 0 N--CA 1.5 2.04 0 CA-C-O 121.57 0.7 . . . . 1.64 112.428 -178.952 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 55.87 52.8 46.37 Favored Glycine 0 N--CA 1.491 2.315 0 O-C-N 121.515 -0.741 . . . . 1.73 111.52 176.884 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 8.5 t -127.83 126.97 23.99 Favored Pre-proline 0 N--CA 1.497 1.911 0 O-C-N 121.502 -0.999 . . . . 2.19 108.373 178.994 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -57.77 117.8 4.57 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 N-CA-C 109.33 -1.065 . . . . 1.96 109.33 179.711 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -127.43 149.99 49.84 Favored 'General case' 0 N--CA 1.501 2.089 0 N-CA-C 108.873 -0.788 . . . . 1.69 108.873 -179.827 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -155.33 162.41 40.85 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.937 -1.102 . . . . 2.23 111.172 -179.448 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.58 ' CD1' ' N ' ' A' ' 39' ' ' PHE . 0.5 OUTLIER -137.98 -176.77 4.55 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 106.831 -1.544 . . . . 1.54 106.831 178.163 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 72.6 p -121.04 145.49 47.71 Favored 'General case' 0 N--CA 1.499 1.981 0 CA-C-O 121.5 0.667 . . . . 2.37 110.121 -179.222 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.444 ' O ' ' N ' ' A' ' 73' ' ' CYS . 48.5 mt -142.2 117.02 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 N-CA-C 108.515 -0.921 . . . . 1.65 108.515 179.32 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.434 ' CD1' ' C ' ' A' ' 42' ' ' TRP . 0.2 OUTLIER -113.74 129.62 56.55 Favored 'General case' 0 N--CA 1.497 1.878 0 N-CA-C 108.432 -0.951 . . . . 3.68 108.432 179.923 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.524 ' OG1' ' N ' ' A' ' 44' ' ' ARG . 9.2 p -144.73 -127.51 0.08 Allowed 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.343 -0.848 . . . . 2.89 109.16 -179.667 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' ARG . . . . . 0.524 ' N ' ' OG1' ' A' ' 43' ' ' THR . 1.6 ttt-85 56.89 79.85 0.17 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.363 -0.836 . . . . 4.63 110.059 179.646 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -156.27 -52.26 0.08 Allowed 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 108.543 -0.91 . . . . 2.89 108.543 179.146 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -60.78 -48.14 83.15 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.214 -0.929 . . . . 1.74 108.779 179.326 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 151.98 -174.48 30.99 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 109.514 -1.435 . . . . 1.6 109.514 179.809 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.33 161.44 0.94 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.252 -1.146 . . . . 1.4 109.047 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 176.17 -158.32 24.8 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.69 -1.364 . . . . 1.04 109.69 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -145.86 124.75 2.13 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 109.826 -1.31 . . . . 1.06 109.826 -179.806 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.468 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 10.4 tp -100.2 100.89 11.79 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.456 -1.026 . . . . 1.1 108.557 179.461 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 25.0 p -86.19 141.34 29.4 Favored 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 108.567 -0.901 . . . . 1.56 108.567 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.515 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 72.7 mt -130.44 114.25 27.96 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 O-C-N 121.235 -0.915 . . . . 0.65 109.552 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -105.36 107.94 19.2 Favored 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 108.777 -0.823 . . . . 0.69 108.777 179.677 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.412 HG23 ' CB ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -101.37 142.95 15.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 O-C-N 121.528 -0.733 . . . . 0.91 109.25 -179.857 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 8.7 tt0 -141.88 145.39 34.56 Favored 'General case' 0 N--CA 1.49 1.575 0 N-CA-C 107.685 -1.228 . . . . 1.8 107.685 178.755 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.43 ' O ' ' O ' ' B' ' 9' ' ' VAL . . . 164.58 -172.97 40.47 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.79 -1.324 . . . . 0.49 109.79 -179.296 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -67.71 -30.6 34.16 Favored 'Trans proline' 0 C--N 1.318 -1.06 0 C-N-CA 122.139 1.893 . . . . 0.66 112.09 -179.361 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' SER . . . . . 0.424 ' CB ' ' OH ' ' A' ' 85' ' ' TYR . 0.3 OUTLIER -128.55 179.7 5.53 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 121.162 -0.962 . . . . 1.55 110.226 -179.126 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 62.7 mmtt -92.0 114.53 27.09 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.607 -0.683 . . . . 2.53 109.241 -179.817 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.598 ' O ' HD12 ' A' ' 63' ' ' ILE . . . -66.15 103.74 1.03 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.023 -1.048 . . . . 0.82 109.231 179.701 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 30.3 mt-10 -65.19 72.17 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.141 -0.974 . . . . 2.3 109.635 -179.738 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.598 HD12 ' O ' ' A' ' 61' ' ' ALA . 3.4 mp -58.14 149.35 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.613 -0.68 . . . . 1.4 109.295 179.852 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.54 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -150.4 127.6 11.29 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.996 -1.065 . . . . 1.36 109.453 -179.859 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.458 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 50.3 p90 -87.01 130.85 34.28 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.179 -0.951 . . . . 1.47 109.488 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -141.19 109.49 5.87 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.286 -0.884 . . . . 2.51 109.338 179.821 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.473 ' OD1' ' N ' ' A' ' 67' ' ' ASP . 18.2 p-10 -90.13 107.2 18.99 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.243 -0.911 . . . . 2.07 109.32 179.77 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 79.8 mtm180 -99.03 -17.38 18.3 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.305 -0.872 . . . . 4.63 109.272 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.51 ' C ' ' H ' ' A' ' 71' ' ' GLY . 78.9 mttt -122.09 -0.77 9.39 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.6 -0.687 . . . . 3.49 109.16 179.935 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.461 ' CB ' ' O ' ' A' ' 69' ' ' LYS . 3.0 t0 73.51 -21.28 0.27 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.375 -0.828 . . . . 3.06 109.06 -179.683 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' GLY . . . . . 0.51 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -115.31 -24.98 3.95 Favored Glycine 0 N--CA 1.495 2.609 0 N-CA-C 109.434 -1.466 . . . . 2.16 109.434 -179.545 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 16.1 t -95.43 121.16 36.81 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.318 -1.107 . . . . 2.2 109.011 179.696 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' CYS . . . . . 0.444 ' N ' ' O ' ' A' ' 41' ' ' ILE . 33.7 m -83.31 105.17 14.05 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.202 -0.937 . . . . 2.05 109.825 -179.515 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -85.28 116.25 4.29 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.168 -1.573 . . . . 1.39 109.168 179.594 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 49.8 t -107.09 99.64 9.0 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.072 0 O-C-N 121.58 -0.953 . . . . 1.57 109.597 -179.674 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.54 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.5 OUTLIER -89.71 131.39 35.71 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.396 -0.815 . . . . 1.85 109.258 179.775 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.426 ' O ' ' CG ' ' A' ' 77' ' ' TYR . 2.3 p90 -133.07 126.81 32.65 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.379 -0.826 . . . . 1.54 109.825 -179.837 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 3.0 t -107.74 103.8 16.05 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 O-C-N 121.674 -0.641 . . . . 1.9 109.876 -179.665 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.463 ' H ' HG22 ' A' ' 79' ' ' VAL . 2.4 m -80.23 167.66 2.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.296 -0.877 . . . . 1.27 108.72 179.423 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 41.7 tp60 -102.26 -46.33 4.85 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.213 -0.929 . . . . 2.48 110.732 -179.298 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.448 ' OE2' ' HB1' ' A' ' 33' ' ' ALA . 71.8 mm-40 -147.61 151.02 38.4 Favored Pre-proline 0 N--CA 1.506 2.37 0 O-C-N 120.754 -1.216 . . . . 1.92 112.161 -178.254 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.638 ' HG3' ' N ' ' A' ' 107' ' ' SER . 86.0 Cg_exo -36.5 168.12 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 123.389 2.726 . . . . 1.3 113.734 178.113 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 140.9 -176.11 21.75 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.678 -1.369 . . . . 1.02 109.678 179.374 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' ASP . . . . . 0.528 ' OD2' ' NE ' ' B' ' 8' ' ' ARG . 2.4 p-10 -99.8 86.55 3.32 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.512 -0.993 . . . . 2.13 108.349 179.419 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.498 ' O ' ' N ' ' A' ' 103' ' ' VAL . 2.7 m-85 -72.87 130.72 41.05 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 108.044 -1.095 . . . . 0.92 108.044 -179.789 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' GLU . . . . . 0.428 ' H ' ' HG2' ' A' ' 86' ' ' GLU . 0.0 OUTLIER -107.24 129.12 54.91 Favored 'General case' 0 N--CA 1.496 1.87 0 N-CA-C 108.474 -0.936 . . . . 1.53 108.474 -179.196 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.446 ' CG1' ' CZ ' ' A' ' 101' ' ' PHE . 5.7 p -126.18 141.99 44.14 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 N-CA-C 109.17 -0.678 . . . . 1.0 109.17 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 13.5 p -138.65 107.15 5.84 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.264 -0.898 . . . . 1.59 109.795 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.8 pt -112.57 136.46 48.75 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.92 0 CA-C-O 121.414 0.626 . . . . 1.29 110.097 -179.738 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' LYS . . . . . 0.457 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.2 OUTLIER -143.05 122.41 13.08 Favored 'General case' 0 N--CA 1.486 1.333 0 O-C-N 121.383 -0.823 . . . . 1.58 108.785 179.447 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 55.3 t80 -79.67 99.74 7.53 Favored 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 107.716 -1.216 . . . . 1.34 107.716 178.458 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' ASN . . . . . 0.416 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 13.9 t-20 69.56 39.9 1.49 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.492 -0.755 . . . . 2.32 109.404 -178.885 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.422 ' H ' ' HG3' ' A' ' 90' ' ' LYS . 0.9 OUTLIER 76.7 13.27 2.32 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.665 -0.647 . . . . 1.92 111.585 179.442 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 94' ' ' GLU . . . . . 0.749 ' OE1' ' HB2' ' A' ' 18' ' ' ALA . 0.6 OUTLIER -98.27 94.9 7.03 Favored 'General case' 0 N--CA 1.499 1.978 0 N-CA-C 106.919 -1.511 . . . . 2.25 106.919 177.649 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -71.12 106.99 3.94 Favored 'General case' 0 N--CA 1.488 1.431 0 CA-C-O 121.586 0.707 . . . . 2.88 109.839 -178.16 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 96' ' ' ILE . . . . . 0.574 ' O ' ' N ' ' A' ' 98' ' ' ASP . 10.6 pt -52.8 150.4 9.86 Favored Pre-proline 0 C--N 1.299 -1.6 0 N-CA-C 108.579 -0.897 . . . . 2.35 108.579 179.634 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.413 ' O ' ' CG ' ' A' ' 98' ' ' ASP . 1.0 OUTLIER -57.48 75.56 0.04 OUTLIER 'Trans proline' 0 C--O 1.214 -0.7 0 C-N-CA 121.146 1.231 . . . . 2.48 109.195 179.362 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.574 ' N ' ' O ' ' A' ' 96' ' ' ILE . 1.9 m-20 -177.62 -59.82 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.485 0 N-CA-C 108.278 -1.008 . . . . 2.65 108.278 -178.995 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 9.5 m -57.44 138.79 81.13 Favored Pre-proline 0 C--N 1.299 -1.627 0 O-C-N 121.414 -0.804 . . . . 2.0 110.031 -178.216 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_endo -89.78 114.28 2.41 Favored 'Cis proline' 0 N--CA 1.493 1.458 0 N-CA-C 109.707 -0.92 . . . . 1.79 109.707 -2.724 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' PHE . . . . . 0.446 ' CZ ' ' CG1' ' A' ' 87' ' ' VAL . 15.3 p90 -104.9 170.86 7.63 Favored 'General case' 0 N--CA 1.515 2.79 0 O-C-N 120.425 -1.422 . . . . 2.19 110.01 178.87 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.5 p -95.49 153.79 3.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.602 -0.686 . . . . 1.44 110.095 -179.467 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.498 ' N ' ' O ' ' A' ' 85' ' ' TYR . 69.2 t -128.66 86.37 57.78 Favored Pre-proline 0 N--CA 1.498 1.948 0 N-CA-C 107.868 -1.16 . . . . 1.19 107.868 179.316 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -60.99 113.85 1.91 Allowed 'Trans proline' 0 C--N 1.323 -0.792 0 C-N-CA 121.497 1.465 . . . . 1.49 112.256 -177.56 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 55.3 t -96.1 138.12 22.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 N-CA-C 106.784 -1.561 . . . . 1.35 106.784 177.724 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.549 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -119.0 126.56 52.02 Favored 'General case' 0 N--CA 1.511 2.582 0 N-CA-C 113.161 0.801 . . . . 1.67 113.161 -175.921 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.638 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 23.8 t -94.84 97.89 10.35 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 120.3 -1.5 . . . . 2.04 107.586 178.09 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 13.7 mt 66.35 -21.04 0.1 Allowed 'General case' 0 C--N 1.289 -2.058 0 N-CA-C 109.22 -0.659 . . . . 3.2 109.22 -178.767 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.64 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 9.6 t -70.93 -29.17 65.12 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.084 -1.01 . . . . 2.09 108.908 179.027 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 110' ' ' ASP . . . . . 0.549 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 9.1 m-20 54.31 13.23 0.59 Allowed 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 107.874 -1.158 . . . . 2.85 107.874 179.83 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.472 ' N ' ' C ' ' A' ' 109' ' ' SER . 28.6 t0 -172.55 -24.92 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.574 0 CA-C-N 116.107 -0.497 . . . . 2.46 109.738 -179.54 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.64 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 56.08 170.86 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.6 -1.312 . . . . 2.08 108.624 -179.515 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 113' ' ' ARG . . . . . 0.434 ' HB3' ' H ' ' A' ' 116' ' ' THR . 56.4 mtm180 -83.14 111.22 18.72 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.105 -0.997 . . . . 5.93 109.671 -179.564 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.446 ' HG3' HH11 ' A' ' 114' ' ' ARG . 8.0 ttm-85 -76.17 8.46 3.27 Favored 'General case' 0 N--CA 1.493 1.721 0 CA-C-O 121.751 0.786 . . . . 5.61 109.178 179.879 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 37.6 mt -124.48 -28.71 3.58 Favored 'General case' 0 N--CA 1.503 2.22 0 O-C-N 121.734 -0.604 . . . . 4.39 109.477 -179.896 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.497 ' C ' ' H ' ' A' ' 118' ' ' THR . 14.2 m -103.84 -76.29 0.6 Allowed 'General case' 0 N--CA 1.499 2.007 0 N-CA-C 107.327 -1.36 . . . . 4.09 107.327 179.071 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.432 ' O ' ' OXT' ' A' ' 119' ' ' SER . 51.7 t -62.9 -9.07 3.86 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.69 0 N-CA-C 105.726 -1.953 . . . . 2.9 105.726 176.887 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 118' ' ' THR . . . . . 0.497 ' H ' ' C ' ' A' ' 116' ' ' THR . 4.9 t 35.67 59.21 0.85 Allowed 'General case' 0 N--CA 1.485 1.305 0 CA-C-N 114.883 -1.053 . . . . 3.36 111.121 179.572 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 119' ' ' SER . . . . . 0.432 ' OXT' ' O ' ' A' ' 117' ' ' VAL . 1.7 p . . . . . 0 C--N 1.303 -1.45 0 CA-C-O 118.023 -0.989 . . . . 3.39 109.635 179.162 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 1' ' ' MET . . . . . 0.544 ' C ' ' H ' ' B' ' 3' ' ' SER . 72.8 mtm . . . . . 0 N--CA 1.49 1.574 0 N-CA-C 109.495 -0.557 . . . . 8.49 109.495 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 2' ' ' ALA . . . . . 0.421 ' HB3' ' O ' ' B' ' 1' ' ' MET . . . 63.09 -7.42 0.15 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.43 -0.794 . . . . 5.53 109.774 -179.779 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 3' ' ' SER . . . . . 0.544 ' H ' ' C ' ' B' ' 1' ' ' MET . 8.0 m 45.45 -147.36 0.12 Allowed 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.208 -0.933 . . . . 5.43 110.066 179.699 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 4' ' ' LYS . . . . . . . . . . . . . 59.3 mttp -152.51 95.91 3.05 Favored Pre-proline 0 N--CA 1.493 1.676 0 O-C-N 121.473 -0.767 . . . . 6.87 108.942 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 5' ' ' PRO . . . . . . . . . . . . . 3.8 Cg_exo -59.54 97.59 0.1 Allowed 'Trans proline' 0 C--N 1.325 -0.701 0 C-N-CA 120.845 1.03 . . . . 5.16 110.177 -179.16 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 6' ' ' GLU . . . . . . . . . . . . . 14.6 pt-20 -115.58 32.39 6.1 Favored 'General case' 0 N--CA 1.498 1.95 0 N-CA-C 109.141 -0.689 . . . . 4.78 109.141 179.71 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 28.9 mmtp 57.26 107.62 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.595 -0.69 . . . . 4.09 110.09 179.825 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.576 ' CG ' HH11 ' B' ' 8' ' ' ARG . 2.5 mtt-85 -67.76 170.23 8.29 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.286 -1.005 . . . . 3.04 108.286 179.008 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 9' ' ' VAL . . . . . 0.43 ' O ' ' O ' ' A' ' 57' ' ' GLY . 24.6 t -50.81 158.72 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 N-CA-C 107.785 -1.191 . . . . 0.67 107.785 179.137 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -128.98 149.14 50.94 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.227 -0.921 . . . . 0.58 110.563 -178.585 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 11' ' ' SER . . . . . 0.412 ' CB ' HG23 ' A' ' 55' ' ' VAL . 4.1 t -139.58 146.35 39.73 Favored 'General case' 0 N--CA 1.495 1.789 0 N-CA-C 108.763 -0.829 . . . . 1.19 108.763 179.498 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 42.9 m -147.41 121.91 9.74 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.07 -1.019 . . . . 1.38 109.927 -179.589 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 0.645 HG22 ' N ' ' B' ' 14' ' ' PHE . 7.7 p -169.85 170.52 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 N-CA-C 108.883 -0.784 . . . . 0.42 108.883 179.759 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 14' ' ' PHE . . . . . 0.645 ' N ' HG22 ' B' ' 13' ' ' VAL . 9.1 p90 -176.6 -163.47 0.1 Allowed 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 119.226 -0.99 . . . . 1.79 112.084 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.3 pt -147.49 160.95 8.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 N-CA-C 108.518 -0.919 . . . . 1.25 108.518 179.82 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 17.9 m -131.18 141.73 50.11 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.273 -0.892 . . . . 1.61 109.892 -179.734 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.0 mt -100.3 127.17 46.66 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.418 -0.802 . . . . 1.32 109.36 179.712 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -156.59 90.55 2.6 Favored Pre-proline 0 N--CA 1.493 1.689 0 N-CA-C 109.108 -0.701 . . . . 1.45 109.108 -179.719 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_exo -60.06 167.14 7.77 Favored 'Trans proline' 0 CA--C 1.546 1.088 0 C-N-CA 121.136 1.224 . . . . 1.5 110.117 -178.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 20' ' ' PRO . . . . . 0.429 ' O ' ' O ' ' B' ' 21' ' ' ARG . 1.8 Cg_endo -58.06 -18.71 37.41 Favored 'Trans proline' 0 C--N 1.321 -0.874 0 C-N-CA 121.692 1.594 . . . . 2.86 110.703 -179.675 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 21' ' ' ARG . . . . . 0.429 ' O ' ' O ' ' B' ' 20' ' ' PRO . 38.3 mtp180 -63.25 -129.87 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.954 -1.091 . . . . 6.12 109.451 -179.792 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 22' ' ' ARG . . . . . . . . . . . . . 44.1 ttt180 58.44 42.5 21.11 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.235 -0.916 . . . . 6.29 109.435 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 23' ' ' ASP . . . . . 0.402 ' CG ' ' H ' ' B' ' 24' ' ' VAL . 2.8 p-10 -84.04 -65.18 1.04 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.271 -0.893 . . . . 5.62 109.345 -179.94 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 24' ' ' VAL . . . . . 0.402 ' H ' ' CG ' ' B' ' 23' ' ' ASP . 13.9 p . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 118.014 -0.993 . . . . 6.48 109.448 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.528 ' O ' HG23 ' A' ' 2' ' ' ILE . . . . . . . . 1 N--CA 1.53 4.906 0 N-CA-C 119.658 2.623 . . . . 6.64 119.658 . . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.617 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 1.0 OUTLIER -162.23 46.09 0.17 Allowed Pre-proline 0 C--N 1.305 -1.331 0 N-CA-C 107.658 -1.238 . . . . 7.08 107.658 179.222 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.838 ' C ' ' H ' ' A' ' 5' ' ' PHE . 2.1 Cg_endo -54.46 -80.86 0.02 OUTLIER 'Trans proline' 0 C--N 1.318 -1.042 0 N-CA-C 108.777 -1.278 . . . . 5.5 108.777 179.78 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.505 ' C ' ' H ' ' A' ' 6' ' ' PHE . 4.2 tp10 73.01 -17.84 0.39 Allowed 'General case' 0 N--CA 1.496 1.827 0 N-CA-C 104.359 -2.46 . . . . 6.75 104.359 -175.834 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' PHE . . . . . 0.838 ' H ' ' C ' ' A' ' 3' ' ' PRO . 2.3 m-85 -90.71 19.73 5.23 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 103.778 -2.675 . . . . 6.07 103.778 176.751 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.547 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 37.6 p90 45.85 -154.29 0.04 OUTLIER 'General case' 0 C--N 1.307 -1.249 0 CA-C-N 114.298 -1.319 . . . . 4.72 109.359 -177.435 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.524 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 17.3 tt0 86.31 -9.87 0.69 Allowed 'General case' 0 N--CA 1.492 1.646 0 N-CA-C 105.169 -2.16 . . . . 4.4 105.169 -177.389 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.418 ' H ' ' C ' ' A' ' 6' ' ' PHE . 45.1 t80 -152.49 -37.48 0.11 Allowed 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 107.925 -1.139 . . . . 5.15 107.925 178.39 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.49 HG22 ' O ' ' A' ' 9' ' ' THR . 89.5 m -93.15 3.96 54.81 Favored 'General case' 0 C--N 1.295 -1.77 0 N-CA-C 105.97 -1.863 . . . . 5.13 105.97 177.479 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.542 HG13 ' N ' ' A' ' 11' ' ' GLY . 12.5 p -44.38 -45.52 2.39 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.317 0 CA-C-N 115.555 -0.748 . . . . 4.38 109.25 -179.668 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.668 ' O ' HD23 ' A' ' 13' ' ' LEU . . . 134.27 -83.04 0.29 Allowed Glycine 0 N--CA 1.501 2.983 0 N-CA-C 109.098 -1.601 . . . . 4.22 109.098 179.148 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.437 ' O ' ' N ' ' A' ' 14' ' ' GLY . 11.4 Cg_endo -67.21 35.13 0.14 Allowed 'Trans proline' 0 C--N 1.319 -1.019 0 C-N-CA 121.566 1.51 . . . . 3.85 109.212 178.691 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.849 ' N ' HD23 ' A' ' 13' ' ' LEU . 0.1 OUTLIER 38.65 32.02 0.05 OUTLIER 'General case' 0 N--CA 1.506 2.327 0 CA-C-O 122.016 0.912 . . . . 3.67 108.791 -178.613 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.508 ' C ' ' H ' ' A' ' 16' ' ' GLY . . . 72.41 -40.52 0.75 Allowed Glycine 0 N--CA 1.488 2.155 0 N-CA-C 108.595 -1.802 . . . . 2.97 108.595 -179.241 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.489 ' H ' ' C ' ' A' ' 13' ' ' LEU . 8.9 tp10 52.87 8.85 0.1 Allowed 'General case' 0 C--N 1.304 -1.396 0 O-C-N 121.486 -1.008 . . . . 2.97 108.924 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.508 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 59.1 118.33 0.01 OUTLIER Glycine 0 N--CA 1.486 1.988 0 N-CA-C 110.003 -1.239 . . . . 2.44 110.003 179.823 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.514 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 95.02 -57.99 1.76 Allowed Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.761 -1.336 . . . . 1.81 109.761 179.707 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.693 ' HB2' ' OE1' ' A' ' 94' ' ' GLU . . . -47.86 -12.32 0.03 OUTLIER 'General case' 0 C--N 1.297 -1.68 0 O-C-N 121.64 -0.917 . . . . 2.21 110.067 -179.121 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' HIS . . . . . 0.514 ' N ' ' O ' ' A' ' 17' ' ' GLY . 29.1 t-80 -98.46 -7.11 29.1 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.245 -0.909 . . . . 2.87 110.684 -178.745 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.498 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.4 OUTLIER -145.98 5.58 1.0 Allowed 'General case' 0 N--CA 1.496 1.851 0 O-C-N 120.854 -1.153 . . . . 2.02 110.252 -179.491 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.577 ' O ' HG13 ' A' ' 21' ' ' VAL . 7.4 p -77.35 115.56 19.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.022 -1.049 . . . . 2.07 108.51 179.116 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 12.7 tpp180 -109.92 139.27 45.2 Favored 'General case' 0 N--CA 1.49 1.574 0 CA-C-O 121.509 0.671 . . . . 3.5 109.566 -178.745 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -148.18 113.27 5.51 Favored 'General case' 0 N--CA 1.491 1.599 0 N-CA-C 108.609 -0.885 . . . . 1.83 108.609 179.424 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -147.85 132.1 4.11 Favored Glycine 0 N--CA 1.495 2.614 0 N-CA-C 109.523 -1.431 . . . . 1.9 109.523 -179.624 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.27 174.13 46.08 Favored Glycine 0 N--CA 1.488 2.115 0 C-N-CA 119.598 -1.287 . . . . 1.85 110.013 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 8.5 p -79.85 -22.04 43.42 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.338 -1.095 . . . . 2.31 108.985 179.479 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -68.67 -16.47 69.94 Favored Glycine 0 N--CA 1.487 2.034 0 N-CA-C 108.62 -1.792 . . . . 1.64 108.62 179.637 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.53 HD21 ' CG ' ' A' ' 39' ' ' PHE . 7.0 mt -93.04 30.28 1.66 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.625 -0.927 . . . . 1.83 108.799 179.783 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 13.5 mt-10 -141.91 -43.44 0.35 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.396 -0.815 . . . . 2.34 109.62 -179.375 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 11.8 ptm180 -175.65 172.11 2.63 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.007 -1.058 . . . . 3.77 109.991 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -150.77 176.51 29.3 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 108.335 -1.906 . . . . 1.57 108.335 179.665 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 39.2 t -134.23 151.54 32.41 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.031 0 O-C-N 121.186 -1.185 . . . . 1.83 110.529 -179.733 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.566 ' HB2' ' HD3' ' A' ' 82' ' ' PRO . . . -44.91 115.47 0.89 Allowed 'General case' 0 N--CA 1.497 1.88 0 CA-C-O 121.869 0.842 . . . . 1.64 112.477 -179.195 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 54.03 50.81 53.7 Favored Glycine 0 N--CA 1.488 2.143 0 N-CA-C 111.245 -0.742 . . . . 1.73 111.245 177.264 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 5.0 t -127.03 127.11 24.41 Favored Pre-proline 0 N--CA 1.496 1.871 0 N-CA-C 108.232 -1.025 . . . . 2.19 108.232 179.14 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -55.51 121.17 9.47 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 N-CA-C 109.918 -0.839 . . . . 1.96 109.918 -179.845 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -128.78 145.42 51.19 Favored 'General case' 0 N--CA 1.497 1.922 0 N-CA-C 108.488 -0.93 . . . . 1.69 108.488 179.736 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -152.16 164.05 38.11 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.995 -1.066 . . . . 2.23 110.765 -179.512 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.549 ' CD1' ' N ' ' A' ' 39' ' ' PHE . 0.7 OUTLIER -139.71 178.43 7.24 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 107.007 -1.479 . . . . 1.54 107.007 177.907 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 58.7 m -121.32 141.27 51.08 Favored 'General case' 0 N--CA 1.496 1.857 0 CA-C-O 121.573 0.702 . . . . 2.37 110.382 -178.83 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.508 ' O ' ' N ' ' A' ' 73' ' ' CYS . 68.3 mt -138.14 124.08 25.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 N-CA-C 108.307 -0.997 . . . . 1.65 108.307 179.106 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.556 ' HE1' ' CG ' ' A' ' 44' ' ' ARG . 3.1 t90 -128.08 125.46 39.31 Favored 'General case' 0 N--CA 1.496 1.858 0 N-CA-C 108.615 -0.884 . . . . 3.68 108.615 -179.549 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.498 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -151.21 118.23 5.89 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.321 -0.862 . . . . 2.89 109.269 -179.672 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 44' ' ' ARG . . . . . 0.556 ' CG ' ' HE1' ' A' ' 42' ' ' TRP . 10.6 ptm180 -171.09 72.19 0.05 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.172 -0.955 . . . . 4.63 109.72 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 21.3 tt0 -154.32 -45.19 0.09 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.306 -0.871 . . . . 2.89 109.083 179.579 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.99 -55.66 13.5 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.117 -0.989 . . . . 1.74 109.196 179.686 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 154.96 156.36 7.71 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.608 -1.397 . . . . 1.6 109.608 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.49 156.92 2.29 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.232 -1.158 . . . . 1.4 109.511 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -170.48 -111.34 0.25 Allowed Glycine 0 N--CA 1.488 2.16 0 N-CA-C 108.965 -1.654 . . . . 1.04 108.965 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.544 ' O ' ' N ' ' A' ' 92' ' ' ASN . . . -157.7 161.87 31.68 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.463 -1.455 . . . . 1.06 109.463 179.684 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.458 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 10.2 tp -140.55 97.0 3.12 Favored 'General case' 0 N--CA 1.493 1.703 0 N-CA-C 107.839 -1.171 . . . . 1.1 107.839 179.513 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 13.7 m -87.69 142.81 27.54 Favored 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 108.846 -0.798 . . . . 1.56 108.846 -179.586 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.54 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 6.7 mt -136.71 100.42 2.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.366 -0.834 . . . . 0.65 108.859 179.721 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -98.8 106.42 18.69 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.258 -0.902 . . . . 0.69 108.907 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -97.87 146.14 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 O-C-N 121.434 -0.791 . . . . 0.91 109.33 -179.814 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 35.4 tp10 -141.13 138.04 33.18 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 107.385 -1.339 . . . . 1.8 107.385 178.531 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.532 ' O ' ' N ' ' B' ' 9' ' ' VAL . . . 173.37 -173.0 45.58 Favored Glycine 0 N--CA 1.493 2.44 0 C-N-CA 119.271 -1.442 . . . . 0.49 110.033 -178.72 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -62.76 -35.1 70.54 Favored 'Trans proline' 0 C--N 1.318 -1.038 0 C-N-CA 122.127 1.885 . . . . 0.66 111.568 -179.596 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' SER . . . . . 0.421 ' O ' ' OH ' ' A' ' 85' ' ' TYR . 10.7 m -139.57 162.34 35.31 Favored 'General case' 0 N--CA 1.5 2.025 0 O-C-N 121.072 -1.017 . . . . 1.55 110.057 -179.036 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 23.0 mttp -85.29 95.57 9.24 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.435 -0.791 . . . . 2.53 109.495 -179.844 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -50.59 135.32 23.15 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.336 -0.853 . . . . 0.82 109.315 179.83 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.47 ' CD ' ' N ' ' A' ' 62' ' ' GLU . 15.9 mp0 -71.09 85.38 0.73 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.247 -0.908 . . . . 2.3 109.582 -179.873 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 19.2 tt -58.88 150.21 5.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 N-CA-C 108.963 -0.755 . . . . 1.4 108.963 179.611 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.547 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -150.61 114.51 5.02 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 120.691 -1.255 . . . . 1.36 109.744 -179.715 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 17.7 p90 -90.33 125.08 35.41 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.284 -0.885 . . . . 1.47 109.388 179.612 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 -141.48 105.79 4.82 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.256 -0.902 . . . . 2.51 109.545 -179.893 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -83.92 100.39 10.98 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.273 -0.892 . . . . 2.07 109.243 179.804 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.606 ' CG ' HH11 ' A' ' 68' ' ' ARG . 0.0 OUTLIER -90.98 -9.54 45.65 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.186 -0.946 . . . . 4.63 109.504 -179.752 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.5 ' C ' ' H ' ' A' ' 71' ' ' GLY . 20.5 mmmt -124.93 -0.17 7.93 Favored 'General case' 0 N--CA 1.5 2.035 0 O-C-N 121.48 -0.762 . . . . 3.49 109.439 -179.768 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.446 ' CB ' ' O ' ' A' ' 69' ' ' LYS . 2.4 t70 70.97 -11.48 0.66 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.2 -0.938 . . . . 3.06 108.899 -179.603 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' GLY . . . . . 0.5 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -129.71 -25.63 0.91 Allowed Glycine 0 N--CA 1.493 2.489 0 N-CA-C 109.559 -1.416 . . . . 2.16 109.559 -179.303 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 10.6 t -95.5 109.36 21.58 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.235 -1.156 . . . . 2.2 108.88 179.532 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' CYS . . . . . 0.508 ' N ' ' O ' ' A' ' 41' ' ' ILE . 49.8 t -80.05 104.81 10.87 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.222 -0.924 . . . . 2.05 109.845 -179.451 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -91.82 116.33 4.97 Favored Glycine 0 N--CA 1.493 2.5 0 N-CA-C 109.123 -1.591 . . . . 1.39 109.123 179.65 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 96.4 t -105.82 102.16 13.46 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.135 0 O-C-N 121.486 -1.008 . . . . 1.57 109.684 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.547 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.1 OUTLIER -88.42 130.08 35.26 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.376 -0.828 . . . . 1.85 108.936 179.649 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.426 ' O ' ' CG ' ' A' ' 77' ' ' TYR . 2.8 p90 -132.42 125.48 30.88 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.479 -0.763 . . . . 1.54 109.053 -179.824 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 5.9 t -99.86 103.72 15.14 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.392 -0.817 . . . . 1.9 109.37 -179.478 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 25.9 m -69.77 160.32 5.03 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 O-C-N 121.22 -0.925 . . . . 1.27 109.31 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 24.0 tp60 -100.72 -48.62 4.44 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.235 -0.915 . . . . 2.48 110.586 -179.416 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -155.25 152.77 25.66 Favored Pre-proline 0 N--CA 1.501 2.106 0 O-C-N 120.806 -1.184 . . . . 1.92 110.995 -178.915 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.617 ' HG3' ' N ' ' A' ' 107' ' ' SER . 75.1 Cg_exo -38.31 163.2 0.02 OUTLIER 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 123.176 2.584 . . . . 1.3 113.659 179.36 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 147.13 -162.36 28.59 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.156 -1.578 . . . . 1.02 109.156 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 33.5 m-20 -111.39 89.78 3.15 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.653 -0.91 . . . . 2.13 108.937 179.761 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.45 ' O ' ' N ' ' A' ' 103' ' ' VAL . 3.3 m-85 -77.64 128.94 34.93 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 108.004 -1.11 . . . . 0.92 108.004 179.687 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -112.63 129.74 56.28 Favored 'General case' 0 N--CA 1.5 2.042 0 N-CA-C 108.406 -0.961 . . . . 1.53 108.406 -179.088 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 8.6 p -124.84 137.63 56.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 CA-C-O 121.486 0.66 . . . . 1.0 110.002 -179.522 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 29.5 t -126.12 103.25 7.61 Favored 'General case' 0 N--CA 1.497 1.907 0 N-CA-C 109.405 -0.591 . . . . 1.59 109.405 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.413 ' H ' ' CB ' ' A' ' 99' ' ' SER . 0.8 OUTLIER -111.18 132.78 58.76 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.023 0 O-C-N 121.519 -0.738 . . . . 1.29 110.226 -179.39 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 90' ' ' LYS . . . . . 0.446 ' HG3' ' H ' ' A' ' 93' ' ' ASP . 0.4 OUTLIER -140.91 127.06 19.56 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.369 -0.832 . . . . 1.58 109.909 179.658 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.443 ' H ' ' HG3' ' A' ' 94' ' ' GLU . 54.5 t80 -82.3 94.39 7.33 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.12 -0.987 . . . . 1.34 108.457 178.855 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 92' ' ' ASN . . . . . 0.544 ' N ' ' O ' ' A' ' 50' ' ' GLY . 6.7 t30 69.22 37.08 2.19 Favored 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 108.074 -1.084 . . . . 2.32 108.074 -179.017 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.463 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 2.6 m-20 83.4 14.7 0.34 Allowed 'General case' 0 N--CA 1.499 1.981 0 CA-C-N 116.485 -0.325 . . . . 1.92 110.905 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 94' ' ' GLU . . . . . 0.693 ' OE1' ' HB2' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -91.17 90.83 7.97 Favored 'General case' 0 N--CA 1.496 1.827 0 N-CA-C 106.862 -1.533 . . . . 2.25 106.862 178.119 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 95' ' ' HIS . . . . . 0.517 ' CD2' ' O ' ' A' ' 95' ' ' HIS . 41.9 p-80 -68.15 88.8 0.3 Allowed 'General case' 0 C--N 1.299 -1.615 0 O-C-N 119.94 -1.725 . . . . 2.88 110.359 -177.816 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 2.3 tt -48.3 137.13 11.73 Favored Pre-proline 0 N--CA 1.496 1.846 0 N-CA-C 107.635 -1.246 . . . . 2.35 107.635 178.675 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -40.51 -39.55 2.89 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 121.307 1.338 . . . . 2.48 111.747 -178.42 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 18.8 m-20 -49.18 -66.49 0.39 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 120.689 -1.257 . . . . 2.65 109.237 179.356 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.413 ' CB ' ' H ' ' A' ' 89' ' ' ILE . 0.1 OUTLIER -69.31 147.94 97.26 Favored Pre-proline 0 C--N 1.293 -1.875 0 O-C-N 121.151 -0.968 . . . . 2.0 110.067 -178.917 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -84.44 112.02 2.36 Favored 'Cis proline' 0 N--CA 1.491 1.343 0 N-CA-C 109.538 -0.986 . . . . 1.79 109.538 -2.238 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 43.1 p90 -116.21 166.86 11.55 Favored 'General case' 0 N--CA 1.522 3.162 0 O-C-N 120.509 -1.37 . . . . 2.19 110.445 178.964 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.2 p -95.49 148.19 5.35 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.903 0 CA-C-O 121.752 0.787 . . . . 1.44 111.549 -177.703 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.45 ' N ' ' O ' ' A' ' 85' ' ' TYR . 79.4 t -121.8 86.38 45.59 Favored Pre-proline 0 N--CA 1.498 1.926 0 N-CA-C 108.279 -1.008 . . . . 1.19 108.279 179.238 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_exo -62.81 114.14 2.28 Favored 'Trans proline' 0 C--N 1.319 -1.021 0 C-N-CA 121.351 1.367 . . . . 1.49 112.09 -178.011 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 55.2 t -95.27 144.34 10.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 N-CA-C 106.938 -1.504 . . . . 1.35 106.938 177.865 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.691 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -134.76 136.24 42.47 Favored 'General case' 0 N--CA 1.51 2.536 0 CA-C-O 122.079 0.942 . . . . 1.67 111.748 -177.457 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.617 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 80.6 p -92.17 76.41 5.35 Favored 'General case' 0 N--CA 1.492 1.674 0 N-CA-C 107.472 -1.307 . . . . 2.04 107.472 179.278 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 23.6 mt 61.72 6.36 1.57 Allowed 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 107.103 -1.443 . . . . 3.2 107.103 -177.735 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.647 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 14.0 t -92.27 -20.83 20.73 Favored 'General case' 0 N--CA 1.486 1.338 0 N-CA-C 109.205 -0.665 . . . . 2.09 109.205 179.588 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 110' ' ' ASP . . . . . 0.691 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 2.6 p30 45.31 19.6 0.04 OUTLIER 'General case' 0 N--CA 1.498 1.939 0 N-CA-C 108.417 -0.957 . . . . 2.85 108.417 -179.052 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.513 ' N ' ' O ' ' A' ' 109' ' ' SER . 23.8 t0 -173.34 -29.07 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 109.003 -0.74 . . . . 2.46 109.003 -179.584 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.647 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 59.03 -173.29 0.1 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.974 -1.079 . . . . 2.08 109.198 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 1.7 tpt180 -159.53 -157.8 0.61 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.156 -0.965 . . . . 5.93 109.467 179.816 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.428 ' HG3' HH11 ' A' ' 114' ' ' ARG . 24.3 ttm-85 -144.27 1.39 1.08 Allowed 'General case' 0 N--CA 1.492 1.664 0 N-CA-C 107.856 -1.164 . . . . 5.61 107.856 179.638 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.435 HD23 ' N ' ' A' ' 115' ' ' LEU . 0.1 OUTLIER -127.95 -26.81 2.85 Favored 'General case' 0 N--CA 1.501 2.079 0 N-CA-C 108.758 -0.83 . . . . 4.39 108.758 179.483 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.502 ' C ' ' H ' ' A' ' 118' ' ' THR . 77.9 m -105.29 -79.14 0.56 Allowed 'General case' 0 N--CA 1.495 1.815 0 N-CA-C 107.209 -1.404 . . . . 4.09 107.209 179.142 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.428 ' O ' HG12 ' A' ' 117' ' ' VAL . 53.3 t -62.11 -8.53 2.78 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.698 0 N-CA-C 106.014 -1.847 . . . . 2.9 106.014 176.928 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 118' ' ' THR . . . . . 0.502 ' H ' ' C ' ' A' ' 116' ' ' THR . 4.2 t 36.07 60.62 0.82 Allowed 'General case' 0 N--CA 1.487 1.413 0 CA-C-N 115.2 -0.909 . . . . 3.36 110.723 179.855 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 119' ' ' SER . . . . . 0.446 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.6 p . . . . . 0 C--N 1.303 -1.455 0 CA-C-O 117.971 -1.014 . . . . 3.39 109.562 179.409 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 19.3 mtt . . . . . 0 N--CA 1.49 1.564 0 N-CA-C 109.468 -0.567 . . . . 8.49 109.468 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -67.0 -149.21 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.251 -0.906 . . . . 5.53 109.512 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 3' ' ' SER . . . . . . . . . . . . . 22.8 t -75.02 150.13 39.03 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.31 -0.869 . . . . 5.43 109.515 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 4' ' ' LYS . . . . . . . . . . . . . 59.3 tttm -160.51 68.03 2.67 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.299 -0.876 . . . . 6.87 109.572 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 5' ' ' PRO . . . . . 0.428 ' O ' ' O ' ' B' ' 6' ' ' GLU . 2.0 Cg_endo -63.15 101.18 0.28 Allowed 'Trans proline' 0 C--N 1.318 -1.048 0 C-N-CA 121.527 1.485 . . . . 5.16 110.198 -179.612 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 6' ' ' GLU . . . . . 0.428 ' O ' ' O ' ' B' ' 5' ' ' PRO . 23.1 tp10 58.72 156.53 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.274 -0.891 . . . . 4.78 109.721 179.544 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 7' ' ' LYS . . . . . 0.4 ' O ' ' O ' ' B' ' 6' ' ' GLU . 36.9 mttp -63.83 -130.38 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.216 -0.927 . . . . 4.09 109.38 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.412 ' NH1' ' HG3' ' B' ' 8' ' ' ARG . 23.4 mtm-85 -98.51 -117.75 0.14 Allowed 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.287 -1.005 . . . . 3.04 108.287 179.841 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 9' ' ' VAL . . . . . 0.532 ' N ' ' O ' ' A' ' 57' ' ' GLY . 0.4 OUTLIER -122.48 170.85 12.22 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.069 0 N-CA-C 108.139 -1.06 . . . . 0.67 108.139 178.989 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 0.436 ' N ' HG13 ' B' ' 9' ' ' VAL . . . -114.81 136.24 53.31 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.717 -0.615 . . . . 0.58 110.07 -179.41 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 9.4 m -149.28 82.88 1.43 Allowed 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.376 -0.828 . . . . 1.19 109.44 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 12.8 t -101.04 116.72 33.52 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.363 -0.836 . . . . 1.38 109.434 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 0.579 HG22 ' N ' ' B' ' 14' ' ' PHE . 3.2 p -156.66 164.45 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.265 -0.897 . . . . 0.42 109.177 179.823 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 14' ' ' PHE . . . . . 0.579 ' N ' HG22 ' B' ' 13' ' ' VAL . 6.5 p90 -178.99 -164.7 0.07 Allowed 'General case' 0 N--CA 1.49 1.555 0 CA-C-O 122.1 0.953 . . . . 1.79 111.924 179.575 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.875 ' N ' HD13 ' B' ' 15' ' ' ILE . 0.1 OUTLIER -145.72 155.49 13.0 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.094 0 N-CA-C 108.635 -0.876 . . . . 1.25 108.635 179.811 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 16' ' ' THR . . . . . 0.478 HG22 ' N ' ' B' ' 17' ' ' LEU . 97.0 m -109.11 158.9 17.33 Favored 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.214 -0.929 . . . . 1.61 109.781 -179.799 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.478 ' N ' HG22 ' B' ' 16' ' ' THR . 34.3 mt -132.8 104.99 6.88 Favored 'General case' 0 N--CA 1.499 2.019 0 O-C-N 121.475 -0.766 . . . . 1.32 109.167 179.821 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -158.81 76.86 3.26 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.295 -0.878 . . . . 1.45 109.342 -179.828 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -65.79 166.15 21.17 Favored 'Trans proline' 0 CA--C 1.544 1.006 0 C-N-CA 121.303 1.335 . . . . 1.5 109.733 -179.36 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 20' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_endo -62.47 84.26 0.1 Allowed 'Trans proline' 0 C--N 1.319 -1.023 0 C-N-CA 121.509 1.472 . . . . 2.86 109.77 179.611 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 34.8 ttp180 -100.11 90.62 4.44 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.146 -0.971 . . . . 6.12 109.401 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 22' ' ' ARG . . . . . 0.586 HH11 ' CG ' ' B' ' 22' ' ' ARG . 3.4 mtt-85 -64.73 -106.5 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.233 -0.917 . . . . 6.29 109.392 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 23' ' ' ASP . . . . . 0.49 ' OD1' ' N ' ' B' ' 24' ' ' VAL . 37.8 t0 -170.65 146.75 2.74 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.196 -0.94 . . . . 5.62 109.436 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 24' ' ' VAL . . . . . 0.49 ' N ' ' OD1' ' B' ' 23' ' ' ASP . 15.4 m . . . . . 0 N--CA 1.49 1.557 0 CA-C-O 118.006 -0.997 . . . . 6.48 109.384 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.531 4.968 0 N-CA-C 119.773 2.669 . . . . 6.64 119.773 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.571 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 12.7 tt -171.75 50.66 0.13 Allowed Pre-proline 0 C--N 1.306 -1.32 0 N-CA-C 107.949 -1.13 . . . . 7.08 107.949 179.523 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.635 ' C ' ' H ' ' A' ' 5' ' ' PHE . 4.3 Cg_endo -57.08 -79.19 0.02 OUTLIER 'Trans proline' 0 C--N 1.318 -1.047 0 C-N-CA 121.279 1.32 . . . . 5.5 109.3 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.434 ' CB ' ' O ' ' A' ' 3' ' ' PRO . 0.0 OUTLIER 72.54 -48.94 0.69 Allowed 'General case' 0 N--CA 1.493 1.684 0 N-CA-C 103.227 -2.879 . . . . 6.75 103.227 -175.684 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 5' ' ' PHE . . . . . 0.635 ' H ' ' C ' ' A' ' 3' ' ' PRO . 7.3 m-85 -51.4 -27.28 9.59 Favored 'General case' 0 C--N 1.305 -1.356 0 N-CA-C 106.552 -1.647 . . . . 6.07 106.552 175.167 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.541 ' CD1' ' O ' ' A' ' 5' ' ' PHE . 0.0 OUTLIER 112.35 -151.4 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.262 0 C-N-CA 124.675 1.19 . . . . 4.72 111.353 179.378 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.533 ' N ' ' CG ' ' A' ' 6' ' ' PHE . 21.2 tt0 82.78 -4.61 1.32 Allowed 'General case' 0 N--CA 1.494 1.728 0 N-CA-C 105.442 -2.059 . . . . 4.4 105.442 -177.562 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.408 ' H ' ' C ' ' A' ' 6' ' ' PHE . 25.1 t80 -153.06 -40.12 0.1 Allowed 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 107.233 -1.395 . . . . 5.15 107.233 178.801 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.45 ' O ' ' N ' ' A' ' 11' ' ' GLY . 8.6 m -83.5 1.68 40.61 Favored 'General case' 0 C--N 1.296 -1.745 0 N-CA-C 105.937 -1.875 . . . . 5.13 105.937 177.011 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.654 HG13 ' HD2' ' A' ' 12' ' ' PRO . 8.0 p -38.46 -30.24 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 CA-C-N 115.257 -0.883 . . . . 4.38 109.897 -179.827 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.552 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 137.02 -72.83 0.45 Allowed Glycine 0 N--CA 1.499 2.872 0 N-CA-C 108.709 -1.756 . . . . 4.22 108.709 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.654 ' HD2' HG13 ' A' ' 10' ' ' VAL . 15.5 Cg_endo -68.71 39.92 0.24 Allowed 'Trans proline' 0 C--N 1.318 -1.051 0 C-N-CA 122.026 1.817 . . . . 3.85 108.68 178.352 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.571 ' C ' ' H ' ' A' ' 15' ' ' GLU . 0.2 OUTLIER 28.36 38.66 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.248 0 CA-C-O 121.452 0.644 . . . . 3.67 110.903 -179.595 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.61 ' C ' ' H ' ' A' ' 16' ' ' GLY . . . 68.84 -37.46 0.29 Allowed Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.108 -1.597 . . . . 2.97 109.108 -179.606 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.571 ' H ' ' C ' ' A' ' 13' ' ' LEU . 41.1 tt0 63.24 -10.58 0.1 Allowed 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.742 -0.857 . . . . 2.97 109.239 -179.099 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.61 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 89.88 -147.24 19.22 Favored Glycine 0 N--CA 1.489 2.214 0 O-C-N 121.181 -0.949 . . . . 2.44 110.735 178.725 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.559 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -67.71 -6.18 41.9 Favored Glycine 0 N--CA 1.491 2.338 0 O-C-N 121.42 -1.047 . . . . 1.81 111.063 -178.855 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.426 ' HB2' ' HB2' ' A' ' 94' ' ' GLU . . . -47.94 -11.99 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.465 -1.609 . . . . 2.21 109.452 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' HIS . . . . . 0.559 ' N ' ' O ' ' A' ' 17' ' ' GLY . 39.7 t-80 -96.92 -41.73 8.27 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.203 -0.935 . . . . 2.87 109.729 179.577 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.77 -24.43 41.52 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 120.92 -1.112 . . . . 2.02 109.95 -179.64 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.533 ' O ' HG13 ' A' ' 21' ' ' VAL . 4.1 p -68.07 115.27 5.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 120.924 -1.11 . . . . 2.07 108.927 179.87 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 12.0 tpp180 -98.07 136.05 38.88 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.625 -0.672 . . . . 3.5 109.445 -179.155 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -147.55 113.42 5.76 Favored 'General case' 0 N--CA 1.492 1.639 0 N-CA-C 108.69 -0.855 . . . . 1.83 108.69 179.486 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -162.62 136.5 4.36 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.584 -1.406 . . . . 1.9 109.584 -179.579 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.1 173.7 46.16 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.667 -1.373 . . . . 1.85 109.667 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 19.1 m -77.19 -18.43 57.77 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.352 -1.087 . . . . 2.31 109.604 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -73.34 -20.26 79.85 Favored Glycine 0 N--CA 1.487 2.05 0 N-CA-C 109.304 -1.518 . . . . 1.64 109.304 -179.884 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.572 HD21 ' CD2' ' A' ' 39' ' ' PHE . 55.7 mt -88.8 -13.97 38.14 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.433 -1.039 . . . . 1.83 109.341 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 56.9 mt-10 -84.06 -62.74 1.49 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.292 -0.88 . . . . 2.34 110.053 -179.519 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 79.3 mtt180 -149.0 165.2 32.34 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.014 -1.054 . . . . 3.77 110.342 -179.589 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -142.5 169.6 25.43 Favored Glycine 0 N--CA 1.495 2.591 0 N-CA-C 107.708 -2.157 . . . . 1.57 107.708 179.019 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 40.9 t -134.04 150.57 31.4 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.202 0 O-C-N 121.051 -1.264 . . . . 1.83 110.971 -179.326 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -37.5 113.1 0.24 Allowed 'General case' 0 N--CA 1.501 2.08 0 CA-C-O 121.809 0.814 . . . . 1.64 112.242 -179.533 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 52.29 50.54 46.36 Favored Glycine 0 N--CA 1.488 2.124 0 N-CA-C 111.244 -0.743 . . . . 1.73 111.244 177.162 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 24.1 t -126.6 103.3 25.05 Favored Pre-proline 0 N--CA 1.494 1.757 0 N-CA-C 108.061 -1.088 . . . . 2.19 108.061 178.844 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -55.69 139.83 83.66 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 120.749 0.966 . . . . 1.96 110.574 -178.713 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.479 ' HB3' ' CE1' ' A' ' 77' ' ' TYR . . . -146.97 175.04 10.97 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.449 -0.782 . . . . 1.69 109.458 -179.923 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -154.52 165.37 36.67 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.958 -1.089 . . . . 2.23 111.297 -179.378 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.572 ' CD2' HD21 ' A' ' 28' ' ' LEU . 0.7 OUTLIER -143.43 -174.25 4.17 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 107.066 -1.457 . . . . 1.54 107.066 177.464 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 44.7 m -120.63 151.58 39.28 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 121.238 -0.914 . . . . 2.37 111.512 -177.937 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 85.5 mt -141.97 91.68 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 N-CA-C 108.332 -0.988 . . . . 1.65 108.332 178.531 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.414 ' CD1' ' N ' ' A' ' 43' ' ' THR . 9.6 t90 -96.02 141.03 29.91 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.165 -0.959 . . . . 3.68 108.69 179.887 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.414 ' N ' ' CD1' ' A' ' 42' ' ' TRP . 0.0 OUTLIER -161.83 130.26 4.26 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.247 -0.908 . . . . 2.89 109.748 -179.577 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 44' ' ' ARG . . . . . . . . . . . . . 66.6 ttt180 -172.02 77.33 0.05 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.324 -0.86 . . . . 4.63 109.728 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 6.8 tp10 -165.18 -55.26 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.099 -1.001 . . . . 2.89 109.735 179.631 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -58.33 -58.66 7.49 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.125 -0.984 . . . . 1.74 109.018 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 142.27 -160.53 27.24 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.231 -1.548 . . . . 1.6 109.231 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -64.28 163.79 12.28 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.288 -1.125 . . . . 1.4 109.38 179.717 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 174.29 178.79 44.46 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.724 -1.351 . . . . 1.04 109.724 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -117.12 125.47 6.54 Favored Glycine 0 N--CA 1.499 2.856 0 N-CA-C 109.682 -1.367 . . . . 1.06 109.682 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.458 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 11.8 tp -99.53 101.17 12.31 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.283 -1.128 . . . . 1.1 108.642 179.63 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 19.1 m -88.79 140.51 29.37 Favored 'General case' 0 N--CA 1.493 1.694 0 N-CA-C 108.696 -0.854 . . . . 1.56 108.696 179.854 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.514 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 90.8 mt -132.28 108.03 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 O-C-N 121.288 -0.883 . . . . 0.65 109.347 -179.819 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -98.63 106.35 18.61 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.304 -0.872 . . . . 0.69 108.928 179.706 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.429 HG23 ' OG ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -99.34 141.94 15.89 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.53 -0.731 . . . . 0.91 109.408 -179.826 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 10.1 tt0 -141.97 143.92 33.45 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.279 -1.008 . . . . 1.8 108.279 178.793 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 165.55 -174.12 41.29 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.614 -1.394 . . . . 0.49 109.614 -179.289 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -58.18 -26.34 75.76 Favored 'Trans proline' 0 C--N 1.317 -1.122 0 C-N-CA 121.998 1.799 . . . . 0.66 111.971 -179.513 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 2.1 m -143.61 170.62 15.49 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.063 -1.023 . . . . 1.55 110.291 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 29.1 mtpt -90.31 100.28 13.14 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.387 -0.82 . . . . 2.53 109.373 -179.878 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -63.38 142.82 58.25 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.182 -0.949 . . . . 0.82 109.603 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 24.9 tt0 -80.66 172.0 14.31 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.283 -0.886 . . . . 2.3 109.281 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 14.0 mt -149.65 141.31 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.906 0 N-CA-C 108.006 -1.109 . . . . 1.4 108.006 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -150.67 112.47 4.51 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 120.449 -1.407 . . . . 1.36 110.251 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.519 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 51.3 p90 -85.92 123.51 31.35 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.562 -0.711 . . . . 1.47 110.205 179.795 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 42.8 tt0 -141.48 119.75 12.21 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.488 -0.757 . . . . 2.51 109.056 179.555 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -73.73 114.0 11.51 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.181 -0.949 . . . . 2.07 109.613 -179.733 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 38.6 ttp180 -108.67 -13.37 14.81 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.454 -0.779 . . . . 4.63 109.473 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.507 ' C ' ' H ' ' A' ' 71' ' ' GLY . 16.7 mtpp -122.62 -3.39 8.79 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.467 -0.77 . . . . 3.49 109.389 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.466 ' CB ' ' O ' ' A' ' 69' ' ' LYS . 1.4 t70 73.48 -19.18 0.34 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.391 -0.818 . . . . 3.06 109.214 -179.757 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' GLY . . . . . 0.507 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -119.39 -41.04 0.59 Allowed Glycine 0 N--CA 1.495 2.589 0 N-CA-C 109.725 -1.35 . . . . 2.16 109.725 -179.416 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.44 ' H ' ' HB2' ' A' ' 69' ' ' LYS . 14.0 m -95.37 126.28 40.57 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.175 -1.191 . . . . 2.2 109.271 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 11.3 t -82.48 120.29 25.3 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.217 -0.927 . . . . 2.05 109.463 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -99.51 117.22 5.8 Favored Glycine 0 N--CA 1.496 2.694 0 N-CA-C 109.657 -1.377 . . . . 1.39 109.657 -179.832 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -105.32 105.11 18.04 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.075 0 O-C-N 121.54 -0.977 . . . . 1.57 109.647 179.85 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 3.9 t -84.14 124.8 31.53 Favored 'General case' 0 N--CA 1.485 1.31 0 N-CA-C 108.148 -1.056 . . . . 1.85 108.148 178.973 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.479 ' CE1' ' HB3' ' A' ' 37' ' ' ALA . 1.9 p90 -123.0 171.84 8.95 Favored 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 108.57 -0.9 . . . . 1.54 108.57 -179.078 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 41.4 t -141.79 141.67 29.28 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.929 0 O-C-N 121.169 -0.957 . . . . 1.9 109.804 -179.581 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 30.7 m -109.53 150.69 12.07 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.095 0 O-C-N 121.439 -0.788 . . . . 1.27 109.254 179.646 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 6.6 tp-100 -96.7 -45.27 6.75 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.219 -0.925 . . . . 2.48 110.305 -179.717 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -159.28 152.33 18.39 Favored Pre-proline 0 N--CA 1.502 2.161 0 O-C-N 120.768 -1.208 . . . . 1.92 110.857 -179.26 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.686 ' HG3' ' N ' ' A' ' 107' ' ' SER . 85.5 Cg_exo -37.54 158.55 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 123.248 2.632 . . . . 1.3 113.369 179.032 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 147.92 166.99 13.08 Favored Glycine 0 N--CA 1.488 2.109 0 N-CA-C 109.477 -1.449 . . . . 1.02 109.477 179.823 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' ASP . . . . . 0.887 ' H ' HH12 ' B' ' 8' ' ' ARG . 66.9 m-20 -87.65 84.55 7.08 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 107.666 -1.235 . . . . 2.13 107.666 179.117 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -69.93 134.16 48.09 Favored 'General case' 0 C--N 1.297 -1.709 0 N-CA-C 107.966 -1.124 . . . . 0.92 107.966 -179.526 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' GLU . . . . . 0.419 ' OE1' ' O ' ' A' ' 84' ' ' ASP . 0.0 OUTLIER -112.27 127.63 56.03 Favored 'General case' 0 N--CA 1.501 2.105 0 N-CA-C 108.667 -0.864 . . . . 1.53 108.667 -179.413 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 9.6 p -123.88 141.06 45.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.712 -0.618 . . . . 1.0 109.794 -179.633 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 3.8 m -130.29 97.82 4.53 Favored 'General case' 0 N--CA 1.498 1.952 0 CA-C-O 121.539 0.685 . . . . 1.59 109.38 179.781 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.413 ' H ' ' HB3' ' A' ' 99' ' ' SER . 1.6 pt -104.88 133.32 49.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 CA-C-O 121.471 0.653 . . . . 1.29 109.846 -179.741 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 90' ' ' LYS . . . . . 0.458 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -144.42 127.39 16.45 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 108.027 -1.101 . . . . 1.58 108.027 179.946 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.421 ' O ' ' CB ' ' A' ' 92' ' ' ASN . 76.5 t80 -85.47 102.22 13.29 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.63 -1.294 . . . . 1.34 108.462 179.16 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 92' ' ' ASN . . . . . 0.431 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 13.0 t30 72.38 33.87 1.41 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.068 -1.02 . . . . 2.32 108.748 -178.679 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.431 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 0.8 OUTLIER 80.21 14.04 0.87 Allowed 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.891 -0.505 . . . . 1.92 111.698 179.509 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 94' ' ' GLU . . . . . 0.462 ' CG ' ' O ' ' A' ' 94' ' ' GLU . 5.0 pt-20 -99.84 94.44 6.32 Favored 'General case' 0 N--CA 1.495 1.806 0 N-CA-C 107.029 -1.471 . . . . 2.25 107.029 177.573 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 95' ' ' HIS . . . . . 0.422 ' O ' ' OE2' ' A' ' 15' ' ' GLU . 19.5 p-80 -74.7 112.41 10.87 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-O 121.542 0.687 . . . . 2.88 110.281 -178.071 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 96' ' ' ILE . . . . . 0.796 ' H ' HD13 ' A' ' 96' ' ' ILE . 0.0 OUTLIER -60.49 155.76 46.83 Favored Pre-proline 0 N--CA 1.497 1.918 0 N-CA-C 107.257 -1.386 . . . . 2.35 107.257 178.994 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -49.47 -25.78 11.12 Favored 'Trans proline' 0 C--N 1.321 -0.879 0 N-CA-C 108.968 -1.204 . . . . 2.48 108.968 179.847 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.471 ' N ' ' OD1' ' A' ' 98' ' ' ASP . 0.9 OUTLIER -59.52 -64.69 0.85 Allowed 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 108.873 -0.788 . . . . 2.65 108.873 178.852 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.413 ' HB3' ' H ' ' A' ' 89' ' ' ILE . 2.4 p -66.83 141.01 96.52 Favored Pre-proline 0 C--N 1.297 -1.7 0 O-C-N 121.308 -0.87 . . . . 2.0 110.04 -178.42 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -85.91 116.99 4.11 Favored 'Cis proline' 0 N--CA 1.492 1.405 0 N-CA-C 109.563 -0.976 . . . . 1.79 109.563 -2.389 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 53.3 p90 -117.03 163.62 15.96 Favored 'General case' 0 N--CA 1.518 2.945 0 O-C-N 120.532 -1.355 . . . . 2.19 110.003 178.687 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.5 p -93.23 152.89 3.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 CA-C-O 121.666 0.746 . . . . 1.44 111.008 -178.144 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 65.1 t -125.92 86.84 57.04 Favored Pre-proline 0 N--CA 1.497 1.888 0 N-CA-C 107.917 -1.142 . . . . 1.19 107.917 179.024 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -63.71 113.29 2.08 Favored 'Trans proline' 0 C--N 1.319 -0.999 0 C-N-CA 121.418 1.412 . . . . 1.49 112.264 -177.743 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 54.3 t -97.72 142.18 14.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 N-CA-C 106.302 -1.74 . . . . 1.35 106.302 177.496 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.661 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -130.23 132.84 46.15 Favored 'General case' 0 N--CA 1.511 2.606 0 CA-C-O 122.109 0.956 . . . . 1.67 111.82 -177.18 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.686 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 36.3 p -94.98 90.91 6.14 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.759 -1.213 . . . . 2.04 107.748 179.577 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 108' ' ' LEU . . . . . 0.569 HD12 ' N ' ' A' ' 108' ' ' LEU . 8.0 mp 54.65 10.49 0.36 Allowed 'General case' 0 C--N 1.294 -1.816 0 N-CA-C 107.848 -1.167 . . . . 3.2 107.848 -178.2 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.664 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 9.0 t -98.88 -27.09 14.06 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 109.255 -0.646 . . . . 2.09 109.255 179.712 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 110' ' ' ASP . . . . . 0.661 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 1.8 m-20 53.93 12.23 0.42 Allowed 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 107.941 -1.133 . . . . 2.85 107.941 -179.275 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.492 ' N ' ' C ' ' A' ' 109' ' ' SER . 2.6 p30 -168.99 -30.13 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 109.348 -0.612 . . . . 2.46 109.348 -179.615 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.664 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 49.26 -171.3 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.81 0 O-C-N 120.825 -1.172 . . . . 2.08 109.198 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 15.7 ttt180 -159.2 -161.09 0.9 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.061 -1.025 . . . . 5.93 109.547 179.696 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 37.9 ttp180 -143.56 2.32 1.24 Allowed 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 107.578 -1.268 . . . . 5.61 107.578 179.442 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 32.1 mt -129.8 -26.93 2.38 Favored 'General case' 0 N--CA 1.499 2.022 0 N-CA-C 109.016 -0.735 . . . . 4.39 109.016 179.632 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.496 ' C ' ' H ' ' A' ' 118' ' ' THR . 98.5 m -102.13 -79.55 0.52 Allowed 'General case' 0 N--CA 1.495 1.793 0 N-CA-C 106.999 -1.482 . . . . 4.09 106.999 178.92 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.439 ' O ' HG12 ' A' ' 117' ' ' VAL . 50.7 t -61.88 -8.9 2.82 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 N-CA-C 105.967 -1.864 . . . . 2.9 105.967 176.715 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 118' ' ' THR . . . . . 0.496 ' H ' ' C ' ' A' ' 116' ' ' THR . 4.4 t 36.29 60.66 0.85 Allowed 'General case' 0 N--CA 1.487 1.422 0 CA-C-N 115.148 -0.933 . . . . 3.36 110.735 179.847 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 119' ' ' SER . . . . . 0.457 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.7 p . . . . . 0 C--N 1.303 -1.453 0 CA-C-O 117.973 -1.013 . . . . 3.39 109.569 179.363 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.595 0 N-CA-C 108.911 -0.774 . . . . 8.49 108.911 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -76.21 110.31 10.6 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.218 -0.926 . . . . 5.53 109.376 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 3' ' ' SER . . . . . . . . . . . . . 90.0 p -95.05 -137.05 0.22 Allowed 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.291 -0.881 . . . . 5.43 109.651 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 4' ' ' LYS . . . . . . . . . . . . . 19.8 tptp -172.4 70.17 0.42 Allowed Pre-proline 0 N--CA 1.491 1.619 0 O-C-N 121.317 -0.864 . . . . 6.87 109.287 -179.78 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 5' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_exo -60.8 -78.24 0.01 OUTLIER 'Trans proline' 0 C--N 1.317 -1.106 0 C-N-CA 121.458 1.438 . . . . 5.16 110.086 -179.497 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 6' ' ' GLU . . . . . . . . . . . . . 68.3 mt-10 -152.97 169.76 22.07 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.079 -1.013 . . . . 4.78 109.499 -179.858 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 78.0 mttt -77.9 179.61 6.62 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.334 -0.854 . . . . 4.09 109.35 179.864 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.887 HH12 ' H ' ' A' ' 84' ' ' ASP . 5.8 mtt180 -98.73 170.29 8.88 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.289 -0.882 . . . . 3.04 108.638 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 9' ' ' VAL . . . . . . . . . . . . . 17.1 t -53.8 159.55 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 108.017 -1.105 . . . . 0.67 108.017 179.307 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -123.18 150.28 43.55 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.464 -0.773 . . . . 0.58 110.002 -179.115 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 11' ' ' SER . . . . . 0.429 ' OG ' HG23 ' A' ' 55' ' ' VAL . 4.2 t -144.57 139.54 28.21 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.454 -0.779 . . . . 1.19 109.017 179.695 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 16.7 m -140.4 116.03 10.17 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.328 -0.857 . . . . 1.38 109.465 -179.714 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 0.579 HG22 ' N ' ' B' ' 14' ' ' PHE . 2.9 p -160.15 166.29 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 O-C-N 121.34 -0.85 . . . . 0.42 109.234 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 14' ' ' PHE . . . . . 0.579 ' N ' HG22 ' B' ' 13' ' ' VAL . 7.4 p90 -177.54 -165.85 0.12 Allowed 'General case' 0 N--CA 1.487 1.425 0 CA-C-O 122.108 0.956 . . . . 1.79 112.083 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.7 pt -149.51 169.92 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.318 0 N-CA-C 108.387 -0.968 . . . . 1.25 108.387 179.851 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 65.9 p -135.54 128.64 31.68 Favored 'General case' 0 N--CA 1.5 2.049 0 O-C-N 121.184 -0.947 . . . . 1.61 109.784 -179.803 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.6 mt -90.92 136.58 32.98 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.349 -0.844 . . . . 1.32 109.167 179.651 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -143.86 68.54 16.31 Favored Pre-proline 0 N--CA 1.495 1.796 0 O-C-N 121.302 -0.874 . . . . 1.45 109.49 -179.847 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -60.46 168.47 6.54 Favored 'Trans proline' 0 C--N 1.317 -1.098 0 C-N-CA 121.36 1.373 . . . . 1.5 109.504 -179.867 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 20' ' ' PRO . . . . . 0.471 ' O ' ' N ' ' B' ' 22' ' ' ARG . 3.1 Cg_exo -56.36 114.24 1.82 Allowed 'Trans proline' 0 C--N 1.319 -1.018 0 C-N-CA 121.346 1.364 . . . . 2.86 110.003 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 85.2 mtt180 -50.67 -11.23 0.08 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.307 -0.87 . . . . 6.12 109.399 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 22' ' ' ARG . . . . . 0.471 ' N ' ' O ' ' B' ' 20' ' ' PRO . 36.1 ttp180 52.39 -125.87 2.39 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.303 -0.873 . . . . 6.29 109.459 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 33.5 m-20 -91.42 175.86 6.77 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.089 -1.007 . . . . 5.62 109.614 -179.742 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 7.4 p . . . . . 0 N--CA 1.49 1.55 0 CA-C-O 117.988 -1.006 . . . . 6.48 109.399 179.938 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.954 0 N-CA-C 119.835 2.694 . . . . 6.64 119.835 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.647 HG23 ' O ' ' A' ' 2' ' ' ILE . 3.7 tp -172.62 50.61 0.12 Allowed Pre-proline 0 C--N 1.306 -1.292 0 N-CA-C 107.842 -1.17 . . . . 7.08 107.842 179.483 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.814 ' C ' ' H ' ' A' ' 5' ' ' PHE . 3.2 Cg_endo -56.18 -80.82 0.01 OUTLIER 'Trans proline' 0 C--N 1.318 -1.035 0 C-N-CA 121.13 1.22 . . . . 5.5 109.04 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.515 ' C ' ' H ' ' A' ' 6' ' ' PHE . 11.3 tt0 73.43 -18.34 0.38 Allowed 'General case' 0 N--CA 1.496 1.853 0 N-CA-C 104.349 -2.463 . . . . 6.75 104.349 -175.615 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' PHE . . . . . 0.814 ' H ' ' C ' ' A' ' 3' ' ' PRO . 10.4 t80 -89.83 18.66 5.41 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 103.892 -2.633 . . . . 6.07 103.892 176.841 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.539 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 41.5 p90 46.69 -154.73 0.05 Allowed 'General case' 0 C--N 1.307 -1.251 0 CA-C-N 114.159 -1.382 . . . . 4.72 109.53 -177.797 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.526 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 0.2 OUTLIER 85.42 -9.23 0.81 Allowed 'General case' 0 N--CA 1.492 1.644 0 N-CA-C 105.037 -2.209 . . . . 4.4 105.037 -177.143 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.404 ' H ' ' C ' ' A' ' 6' ' ' PHE . 52.0 t80 -153.2 -37.62 0.1 Allowed 'General case' 0 C--N 1.304 -1.383 0 N-CA-C 107.816 -1.179 . . . . 5.15 107.816 178.321 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 22.2 m -91.84 2.61 56.4 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 105.965 -1.865 . . . . 5.13 105.965 177.382 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.424 HG13 ' N ' ' A' ' 11' ' ' GLY . 7.5 p -43.25 -38.65 1.04 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 CA-C-N 115.481 -0.781 . . . . 4.38 109.618 -179.737 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.594 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 141.45 -84.8 0.21 Allowed Glycine 0 N--CA 1.498 2.786 0 N-CA-C 108.238 -1.945 . . . . 4.22 108.238 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.527 ' O ' ' N ' ' A' ' 14' ' ' GLY . 12.8 Cg_endo -67.35 39.57 0.18 Allowed 'Trans proline' 0 C--N 1.32 -0.964 0 C-N-CA 121.597 1.531 . . . . 3.85 108.496 177.541 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.594 ' H ' ' C ' ' A' ' 11' ' ' GLY . 0.2 OUTLIER 29.99 36.51 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.173 0 CA-C-O 121.607 0.718 . . . . 3.67 110.628 -179.168 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.533 ' C ' ' H ' ' A' ' 16' ' ' GLY . . . 68.49 -37.73 0.27 Allowed Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.586 -1.406 . . . . 2.97 109.586 179.812 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.532 ' H ' ' C ' ' A' ' 13' ' ' LEU . 31.2 tt0 56.24 4.46 0.14 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.359 -1.083 . . . . 2.97 109.136 -179.637 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.533 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 60.24 131.15 0.01 OUTLIER Glycine 0 N--CA 1.489 2.224 0 N-CA-C 110.912 -0.875 . . . . 2.44 110.912 179.084 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.531 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 71.35 -53.94 1.14 Allowed Glycine 0 N--CA 1.491 2.351 0 N-CA-C 110.416 -1.073 . . . . 1.81 110.416 179.066 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.461 ' HB2' ' OE1' ' A' ' 94' ' ' GLU . . . -46.79 -12.53 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.543 -0.975 . . . . 2.21 110.14 -179.439 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' HIS . . . . . 0.531 ' N ' ' O ' ' A' ' 17' ' ' GLY . 10.0 t-80 -89.77 -42.79 11.09 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.123 -0.985 . . . . 2.87 110.299 -179.168 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.84 -9.08 38.57 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 120.928 -1.108 . . . . 2.02 110.682 -179.006 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 74.2 t -83.4 112.14 20.54 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 120.865 -1.147 . . . . 2.07 110.3 -179.383 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 20.9 tpt180 -103.07 139.91 38.0 Favored 'General case' 0 N--CA 1.491 1.615 0 N-CA-C 108.06 -1.089 . . . . 3.5 108.06 179.042 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -140.02 113.3 8.39 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.263 -0.898 . . . . 1.83 109.648 -179.599 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -155.78 130.59 2.8 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 109.352 -1.499 . . . . 1.9 109.352 179.71 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.3 167.14 37.57 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.816 -1.314 . . . . 1.85 109.816 -179.856 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 17.6 m -74.1 -28.16 61.23 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.297 -1.119 . . . . 2.31 109.486 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.6 -22.9 78.02 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 109.085 -1.606 . . . . 1.64 109.085 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 20.8 mt -77.0 -10.21 59.21 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.446 -1.032 . . . . 1.83 108.963 179.689 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 59.4 mt-10 -90.15 -51.91 5.22 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.372 -0.83 . . . . 2.34 109.478 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ARG . . . . . 0.411 ' NH1' ' HG2' ' A' ' 30' ' ' ARG . 0.0 OUTLIER -169.05 -168.69 0.87 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.035 -1.04 . . . . 3.77 109.993 -179.992 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -153.92 178.76 30.65 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 108.508 -1.837 . . . . 1.57 108.508 179.876 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 42.0 t -134.37 151.09 31.42 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.041 0 O-C-N 121.165 -1.197 . . . . 1.83 110.635 -179.618 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.522 ' HB2' ' HB3' ' A' ' 107' ' ' SER . . . -38.79 111.68 0.19 Allowed 'General case' 0 N--CA 1.5 2.062 0 CA-C-O 121.544 0.688 . . . . 1.64 112.39 -179.154 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 53.43 51.42 47.8 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 111.302 -0.719 . . . . 1.73 111.302 176.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 31.4 t -127.59 103.04 22.32 Favored Pre-proline 0 N--CA 1.495 1.78 0 O-C-N 121.513 -0.993 . . . . 2.19 109.016 179.203 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -58.55 133.07 52.03 Favored 'Trans proline' 0 C--O 1.215 -0.636 0 N-CA-C 109.51 -0.996 . . . . 1.96 109.51 -179.88 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.405 ' HB3' ' CZ ' ' A' ' 77' ' ' TYR . . . -142.18 -169.62 2.98 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.338 -0.851 . . . . 1.69 108.803 -179.825 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -169.45 165.23 10.54 Favored 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 118.931 -1.107 . . . . 2.23 111.228 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.57 ' CD1' ' N ' ' A' ' 39' ' ' PHE . 0.7 OUTLIER -138.32 -176.28 4.4 Favored 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 106.758 -1.571 . . . . 1.54 106.758 178.033 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 43.8 t -122.28 147.12 46.62 Favored 'General case' 0 N--CA 1.498 1.969 0 CA-C-O 121.596 0.712 . . . . 2.37 110.298 -179.103 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 49.6 mt -142.73 97.24 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 N-CA-C 107.986 -1.116 . . . . 1.65 107.986 179.033 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.46 ' CD1' ' C ' ' A' ' 42' ' ' TRP . 0.4 OUTLIER -86.68 144.96 26.88 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.355 -0.841 . . . . 3.68 108.864 -179.493 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.534 ' OG1' ' N ' ' A' ' 44' ' ' ARG . 1.7 t -168.16 -124.85 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.322 -0.861 . . . . 2.89 109.355 -179.898 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' ARG . . . . . 0.534 ' N ' ' OG1' ' A' ' 43' ' ' THR . 61.2 ttt180 57.62 77.67 0.27 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.277 -0.889 . . . . 4.63 109.754 179.804 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 26.1 tt0 -160.62 -45.93 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.289 -0.882 . . . . 2.89 109.127 179.642 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -61.82 -56.16 22.33 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.257 -0.902 . . . . 1.74 109.1 179.658 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 155.64 178.27 29.69 Favored Glycine 0 N--CA 1.489 2.167 0 N-CA-C 109.459 -1.457 . . . . 1.6 109.459 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.7 145.01 16.46 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.173 -1.192 . . . . 1.4 109.152 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -164.33 -164.24 19.13 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.667 -1.373 . . . . 1.04 109.667 -179.828 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -137.97 116.57 1.34 Allowed Glycine 0 N--CA 1.496 2.69 0 N-CA-C 109.546 -1.422 . . . . 1.06 109.546 -179.828 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.464 HD12 ' O ' ' A' ' 90' ' ' LYS . 64.3 tp -91.57 109.39 20.69 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.274 -1.133 . . . . 1.1 108.422 179.383 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 28.3 m -92.96 141.61 28.22 Favored 'General case' 0 N--CA 1.498 1.969 0 N-CA-C 108.598 -0.89 . . . . 1.56 108.598 179.616 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.581 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 93.9 mt -134.34 116.99 23.35 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.945 0 O-C-N 121.165 -0.959 . . . . 0.65 110.148 -179.304 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -107.47 109.66 21.41 Favored 'General case' 0 N--CA 1.495 1.799 0 N-CA-C 108.133 -1.062 . . . . 0.69 108.133 178.957 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -101.41 143.19 14.8 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.43 -0.794 . . . . 0.91 110.228 -178.862 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 23.4 tp10 -139.02 143.12 38.31 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 106.765 -1.569 . . . . 1.8 106.765 178.396 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.433 ' O ' ' N ' ' B' ' 9' ' ' VAL . . . 171.68 -173.98 45.07 Favored Glycine 0 N--CA 1.491 2.301 0 C-N-CA 119.131 -1.509 . . . . 0.49 109.654 -178.667 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -64.96 -32.68 53.92 Favored 'Trans proline' 0 C--N 1.316 -1.183 0 C-N-CA 121.748 1.632 . . . . 0.66 110.317 179.811 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' SER . . . . . 0.413 ' O ' ' OH ' ' A' ' 85' ' ' TYR . 58.4 m -137.86 158.89 43.42 Favored 'General case' 0 N--CA 1.5 2.035 0 O-C-N 121.319 -0.863 . . . . 1.55 109.931 -179.323 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 34.5 mttp -76.03 93.14 3.24 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.363 -0.836 . . . . 2.53 109.483 -179.842 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -63.89 136.42 57.36 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.278 -0.888 . . . . 0.82 109.426 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.537 ' C ' HD12 ' A' ' 63' ' ' ILE . 55.1 mm-40 -79.49 172.54 13.65 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.126 -0.984 . . . . 2.3 109.539 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.537 HD12 ' C ' ' A' ' 62' ' ' GLU . 4.4 mp -140.22 151.01 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 N-CA-C 108.325 -0.991 . . . . 1.4 108.325 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -151.04 120.02 6.67 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 120.603 -1.31 . . . . 1.36 109.468 -179.712 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 54.4 p90 -86.19 139.13 31.34 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.276 -0.89 . . . . 1.47 109.764 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.487 ' N ' ' O ' ' A' ' 74' ' ' GLY . 43.7 tt0 -141.22 122.45 14.79 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.395 -0.816 . . . . 2.51 109.149 179.886 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.412 ' OD1' ' N ' ' A' ' 67' ' ' ASP . 15.1 p-10 -81.25 88.18 6.07 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.222 -0.924 . . . . 2.07 109.713 -179.812 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.408 ' C ' ' H ' ' A' ' 70' ' ' ASP . 16.6 mtm180 -98.81 162.4 13.12 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.286 -0.884 . . . . 4.63 108.965 179.606 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.478 ' C ' ' H ' ' A' ' 71' ' ' GLY . 19.5 mttm 60.77 7.09 1.32 Allowed 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.135 -0.978 . . . . 3.49 108.864 -179.884 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.408 ' H ' ' C ' ' A' ' 68' ' ' ARG . 7.5 t70 56.71 4.12 0.15 Allowed 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 119.928 -0.709 . . . . 3.06 110.063 178.514 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' GLY . . . . . 0.478 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -147.14 -30.73 0.07 OUTLIER Glycine 0 N--CA 1.485 1.933 0 N-CA-C 110.085 -1.206 . . . . 2.16 110.085 -178.522 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.435 ' H ' ' HB2' ' A' ' 69' ' ' LYS . 9.6 t -95.73 129.23 43.01 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.105 -1.233 . . . . 2.2 109.107 179.677 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 10.4 t -78.06 153.12 32.56 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.248 -0.908 . . . . 2.05 109.438 -179.858 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.487 ' O ' ' N ' ' A' ' 66' ' ' GLU . . . -126.45 111.95 1.51 Allowed Glycine 0 N--CA 1.498 2.793 0 N-CA-C 109.352 -1.499 . . . . 1.39 109.352 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 27.4 t -100.52 99.93 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.011 0 O-C-N 121.56 -0.965 . . . . 1.57 109.399 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -84.79 165.3 17.89 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 108.293 -1.003 . . . . 1.85 108.293 179.399 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.405 ' CZ ' ' HB3' ' A' ' 37' ' ' ALA . 12.5 p90 -165.36 169.9 15.24 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.275 -0.891 . . . . 1.54 109.238 -179.329 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.577 ' O ' HG13 ' A' ' 78' ' ' VAL . 5.0 p -142.18 116.32 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.215 0 O-C-N 121.122 -0.986 . . . . 1.9 110.211 179.35 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.511 HG11 HG21 ' A' ' 105' ' ' VAL . 6.5 m -89.97 153.3 3.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.276 -0.89 . . . . 1.27 108.863 179.708 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' GLN . . . . . 0.407 ' O ' ' OE2' ' A' ' 81' ' ' GLU . 20.6 tt0 -94.57 -48.02 6.28 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.994 -1.066 . . . . 2.48 110.84 -178.892 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.407 ' OE2' ' O ' ' A' ' 80' ' ' GLN . 78.3 mm-40 -153.88 150.05 22.09 Favored Pre-proline 0 N--CA 1.503 2.198 0 O-C-N 120.613 -1.304 . . . . 1.92 111.218 -178.455 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.669 ' HG3' ' N ' ' A' ' 107' ' ' SER . 87.8 Cg_exo -36.76 157.9 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.944 2.429 . . . . 1.3 113.368 178.24 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 150.07 -156.92 26.98 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 108.893 -1.683 . . . . 1.02 108.893 -179.911 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 37.5 m-20 -116.38 92.4 3.87 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.52 -0.988 . . . . 2.13 109.408 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.53 ' O ' ' N ' ' A' ' 103' ' ' VAL . 2.7 m-85 -78.98 129.76 34.82 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 107.977 -1.12 . . . . 0.92 107.977 179.343 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.37 128.41 56.45 Favored 'General case' 0 N--CA 1.502 2.131 0 N-CA-C 108.675 -0.861 . . . . 1.53 108.675 -178.847 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 6.3 p -126.6 138.53 54.46 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.681 -0.637 . . . . 1.0 109.928 -179.667 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' SER . . . . . 0.407 ' O ' ' OG ' ' A' ' 88' ' ' SER . 44.7 p -127.83 96.69 4.58 Favored 'General case' 0 N--CA 1.499 1.987 0 N-CA-C 109.358 -0.608 . . . . 1.59 109.358 179.792 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.421 HD11 ' CD1' ' A' ' 96' ' ' ILE . 1.0 OUTLIER -106.3 134.78 46.91 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 CA-C-O 121.479 0.657 . . . . 1.29 109.938 -179.469 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 90' ' ' LYS . . . . . 0.464 ' O ' HD12 ' A' ' 51' ' ' LEU . 0.0 OUTLIER -142.97 123.72 14.18 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.454 -0.779 . . . . 1.58 109.073 -179.882 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 57.2 t80 -80.05 101.11 8.51 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.011 -1.056 . . . . 1.34 108.199 178.661 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' ASN . . . . . 0.411 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 16.8 t-20 69.2 37.68 2.07 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.13 -0.982 . . . . 2.32 109.149 -179.014 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.411 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 1.5 m-20 77.87 14.87 1.57 Allowed 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.836 -0.54 . . . . 1.92 111.928 179.337 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' GLU . . . . . 0.493 ' O ' ' OE1' ' A' ' 94' ' ' GLU . 0.3 OUTLIER -100.6 99.81 10.44 Favored 'General case' 0 N--CA 1.501 2.106 0 N-CA-C 107.462 -1.31 . . . . 2.25 107.462 177.707 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 29.9 m-70 -70.16 105.12 2.82 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.553 -0.717 . . . . 2.88 109.779 -178.613 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' ILE . . . . . 0.639 ' O ' ' N ' ' A' ' 98' ' ' ASP . 9.9 pt -51.21 152.9 3.75 Favored Pre-proline 0 N--CA 1.493 1.681 0 N-CA-C 108.587 -0.894 . . . . 2.35 108.587 179.667 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -59.1 61.74 0.06 OUTLIER 'Trans proline' 0 N--CA 1.484 0.945 0 C-N-CA 121.457 1.438 . . . . 2.48 109.582 179.255 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.639 ' N ' ' O ' ' A' ' 96' ' ' ILE . 31.4 m-20 -162.17 -58.42 0.05 OUTLIER 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 108.386 -0.968 . . . . 2.65 108.386 -179.536 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 1.1 t -65.43 141.31 97.98 Favored Pre-proline 0 C--N 1.297 -1.705 0 C-N-CA 119.868 -0.733 . . . . 2.0 110.085 -177.895 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -85.99 114.56 3.03 Favored 'Cis proline' 0 N--CA 1.492 1.396 0 N-CA-C 109.585 -0.967 . . . . 1.79 109.585 -2.103 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 46.4 p90 -110.32 160.27 16.7 Favored 'General case' 0 N--CA 1.517 2.896 0 O-C-N 120.501 -1.375 . . . . 2.19 110.261 178.927 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.3 p -92.62 148.98 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 CA-C-O 121.517 0.675 . . . . 1.44 110.206 -179.152 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.53 ' N ' ' O ' ' A' ' 85' ' ' TYR . 70.8 t -124.11 85.6 54.62 Favored Pre-proline 0 N--CA 1.498 1.946 0 N-CA-C 107.858 -1.164 . . . . 1.19 107.858 179.511 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -63.45 113.08 1.94 Allowed 'Trans proline' 0 C--N 1.32 -0.968 0 C-N-CA 121.339 1.359 . . . . 1.49 112.021 -177.605 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.511 HG21 HG11 ' A' ' 79' ' ' VAL . 54.1 t -90.22 143.97 10.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 N-CA-C 106.682 -1.599 . . . . 1.35 106.682 177.71 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.686 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -131.78 130.29 41.65 Favored 'General case' 0 N--CA 1.508 2.462 0 O-C-N 121.217 -0.927 . . . . 1.67 111.629 -177.167 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.669 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 60.3 p -95.45 90.61 5.84 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.71 -1.244 . . . . 2.04 107.873 179.36 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 108' ' ' LEU . . . . . 0.553 HD12 ' N ' ' A' ' 108' ' ' LEU . 9.2 mp 54.83 10.38 0.37 Allowed 'General case' 0 C--N 1.295 -1.774 0 N-CA-C 107.949 -1.13 . . . . 3.2 107.949 -178.434 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.638 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 50.4 p -100.24 -24.97 14.41 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 109.32 -0.622 . . . . 2.09 109.32 179.563 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 110' ' ' ASP . . . . . 0.686 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 15.9 t70 49.62 15.95 0.17 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.079 -1.013 . . . . 2.85 108.392 -179.604 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.482 ' N ' ' C ' ' A' ' 109' ' ' SER . 13.8 t0 -174.68 -25.07 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.896 -0.503 . . . . 2.46 109.724 -179.48 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.638 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 56.4 93.84 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.704 -1.248 . . . . 2.08 109.126 -179.742 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 113' ' ' ARG . . . . . 0.409 ' NH1' ' HG2' ' A' ' 113' ' ' ARG . 0.3 OUTLIER -57.18 -170.08 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.266 -0.896 . . . . 5.93 109.54 -179.743 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.45 ' HG3' HH11 ' A' ' 114' ' ' ARG . 7.5 ttm-85 -133.9 1.66 3.32 Favored 'General case' 0 N--CA 1.495 1.807 0 N-CA-C 108.511 -0.922 . . . . 5.61 108.511 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 30.3 mt -127.21 -25.47 3.24 Favored 'General case' 0 N--CA 1.502 2.139 0 N-CA-C 109.081 -0.711 . . . . 4.39 109.081 179.831 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.507 ' C ' ' H ' ' A' ' 118' ' ' THR . 97.9 m -107.88 -79.65 0.58 Allowed 'General case' 0 N--CA 1.497 1.903 0 N-CA-C 107.118 -1.438 . . . . 4.09 107.118 179.197 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.431 ' O ' HG12 ' A' ' 117' ' ' VAL . 50.9 t -61.29 -8.66 2.2 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.63 0 N-CA-C 106.032 -1.84 . . . . 2.9 106.032 176.842 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 118' ' ' THR . . . . . 0.507 ' H ' ' C ' ' A' ' 116' ' ' THR . 3.9 t 36.63 61.97 0.79 Allowed 'General case' 0 N--CA 1.487 1.417 0 CA-C-N 115.193 -0.912 . . . . 3.36 110.704 179.902 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 119' ' ' SER . . . . . 0.415 ' OG ' ' O ' ' A' ' 118' ' ' THR . 1.7 p . . . . . 0 C--N 1.302 -1.476 0 CA-C-O 118.034 -0.984 . . . . 3.39 109.624 179.299 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 67.7 mtm . . . . . 0 N--CA 1.49 1.572 0 N-CA-C 109.564 -0.532 . . . . 8.49 109.564 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -73.04 5.05 3.63 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.264 -0.897 . . . . 5.53 109.232 179.927 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 3' ' ' SER . . . . . . . . . . . . . 61.6 p -163.77 -168.5 1.64 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.283 -0.886 . . . . 5.43 109.343 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 4' ' ' LYS . . . . . . . . . . . . . 37.5 mmtm 49.96 69.36 2.7 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.205 -0.934 . . . . 6.87 109.535 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 5' ' ' PRO . . . . . . . . . . . . . 2.1 Cg_endo -63.75 -154.33 0.02 OUTLIER 'Trans proline' 0 C--N 1.317 -1.112 0 C-N-CA 121.474 1.45 . . . . 5.16 109.672 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 6' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -131.5 79.64 1.89 Allowed 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.368 -0.833 . . . . 4.78 109.198 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 6.1 ptpp? -158.79 138.46 11.83 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.3 -0.875 . . . . 4.09 109.352 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.609 ' CG ' HH11 ' B' ' 8' ' ' ARG . 0.3 OUTLIER -114.46 -76.32 0.58 Allowed 'General case' 0 N--CA 1.494 1.766 0 N-CA-C 107.833 -1.173 . . . . 3.04 107.833 -179.904 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 9' ' ' VAL . . . . . 0.433 ' N ' ' O ' ' A' ' 57' ' ' GLY . 0.5 OUTLIER -176.23 168.83 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 N-CA-C 107.612 -1.255 . . . . 0.67 107.612 177.936 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 0.422 ' N ' HG13 ' B' ' 9' ' ' VAL . . . -120.81 136.01 55.01 Favored 'General case' 0 N--CA 1.502 2.133 0 CA-C-O 121.487 0.66 . . . . 0.58 110.514 -178.971 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 18.4 m -149.65 138.45 21.0 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.468 -0.77 . . . . 1.19 109.265 179.395 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 27.8 p -145.94 126.08 13.79 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.089 -1.007 . . . . 1.38 109.984 -179.682 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 0.645 HG22 ' N ' ' B' ' 14' ' ' PHE . 6.8 p -167.11 170.81 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 N-CA-C 108.678 -0.86 . . . . 0.42 108.678 179.735 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 14' ' ' PHE . . . . . 0.883 ' O ' HD13 ' B' ' 15' ' ' ILE . 6.4 p90 -177.03 -171.45 0.36 Allowed 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 119.046 -1.061 . . . . 1.79 112.458 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.883 HD13 ' O ' ' B' ' 14' ' ' PHE . 4.0 mm -142.96 172.45 7.77 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 N-CA-C 108.213 -1.032 . . . . 1.25 108.213 179.85 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 16' ' ' THR . . . . . 0.419 ' H ' HG22 ' B' ' 15' ' ' ILE . 0.1 OUTLIER -144.05 144.58 31.7 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 120.89 -1.131 . . . . 1.61 109.567 179.645 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 21.7 mt -97.66 138.26 35.32 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.26 -0.9 . . . . 1.32 109.589 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -166.09 79.65 1.12 Allowed Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.478 -0.764 . . . . 1.45 109.056 -179.776 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -60.07 167.28 7.6 Favored 'Trans proline' 0 CA--C 1.544 1.001 0 C-N-CA 121.241 1.294 . . . . 1.5 109.972 -179.104 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 20' ' ' PRO . . . . . . . . . . . . . 1.1 Cg_endo -58.99 -58.78 0.57 Allowed 'Trans proline' 0 C--N 1.319 -0.996 0 C-N-CA 121.556 1.504 . . . . 2.86 110.281 -179.778 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 21' ' ' ARG . . . . . 0.432 ' O ' ' O ' ' B' ' 22' ' ' ARG . 25.0 ttm-85 -137.03 161.61 35.59 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.377 -0.827 . . . . 6.12 109.421 -179.533 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 22' ' ' ARG . . . . . 0.432 ' O ' ' O ' ' B' ' 21' ' ' ARG . 51.4 mtp180 -57.16 -163.53 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.379 -0.826 . . . . 6.29 109.461 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 23' ' ' ASP . . . . . 0.527 ' OD2' ' N ' ' B' ' 24' ' ' VAL . 5.6 p-10 41.58 -136.19 0.24 Allowed 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.667 -0.646 . . . . 5.62 110.059 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 24' ' ' VAL . . . . . 0.527 ' N ' ' OD2' ' B' ' 23' ' ' ASP . 63.3 t . . . . . 0 N--CA 1.494 1.731 0 CA-C-O 118.009 -0.996 . . . . 6.48 109.361 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.963 0 N-CA-C 119.62 2.608 . . . . 6.64 119.62 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.571 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 14.1 tt -172.08 50.0 0.12 Allowed Pre-proline 0 C--N 1.307 -1.282 0 N-CA-C 107.94 -1.134 . . . . 7.08 107.94 179.594 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.798 ' C ' ' H ' ' A' ' 5' ' ' PHE . 5.2 Cg_endo -57.41 -82.75 0.01 OUTLIER 'Trans proline' 0 C--N 1.318 -1.072 0 N-CA-C 108.512 -1.38 . . . . 5.5 108.512 179.632 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.516 ' C ' ' H ' ' A' ' 6' ' ' PHE . 11.9 tt0 73.52 -19.25 0.34 Allowed 'General case' 0 N--CA 1.496 1.839 0 N-CA-C 104.395 -2.446 . . . . 6.75 104.395 -176.029 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' PHE . . . . . 0.798 ' H ' ' C ' ' A' ' 3' ' ' PRO . 2.5 m-85 -88.68 17.5 5.46 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 104.055 -2.572 . . . . 6.07 104.055 176.777 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.526 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 38.6 p90 45.35 -153.24 0.04 OUTLIER 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 114.389 -1.278 . . . . 4.72 109.428 -177.616 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.505 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 2.1 tm0? 83.14 -9.76 1.05 Allowed 'General case' 0 N--CA 1.489 1.506 0 N-CA-C 105.007 -2.22 . . . . 4.4 105.007 -177.222 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.493 ' H ' ' C ' ' A' ' 6' ' ' PHE . 87.6 t80 -149.95 -37.57 0.15 Allowed 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 107.955 -1.128 . . . . 5.15 107.955 178.296 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.464 HG22 ' O ' ' A' ' 9' ' ' THR . 61.1 m -94.07 4.2 54.23 Favored 'General case' 0 C--N 1.297 -1.713 0 N-CA-C 105.922 -1.881 . . . . 5.13 105.922 177.349 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.553 HG13 ' N ' ' A' ' 11' ' ' GLY . 11.6 p -45.38 -46.2 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.324 0 CA-C-N 115.529 -0.759 . . . . 4.38 109.196 -179.507 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.576 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 132.07 -81.64 0.32 Allowed Glycine 0 N--CA 1.501 2.967 0 N-CA-C 108.64 -1.784 . . . . 4.22 108.64 179.413 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.498 ' O ' ' N ' ' A' ' 14' ' ' GLY . 13.6 Cg_endo -68.36 38.4 0.2 Allowed 'Trans proline' 0 C--N 1.319 -1.019 0 C-N-CA 121.562 1.508 . . . . 3.85 108.567 178.147 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.714 ' N ' HD23 ' A' ' 13' ' ' LEU . 0.2 OUTLIER 32.55 36.0 0.01 OUTLIER 'General case' 0 N--CA 1.505 2.323 0 CA-C-O 121.972 0.891 . . . . 3.67 109.781 -178.7 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.552 ' C ' ' H ' ' A' ' 16' ' ' GLY . . . 69.94 -39.37 0.42 Allowed Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.382 -1.487 . . . . 2.97 109.382 -179.806 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.51 ' H ' ' C ' ' A' ' 13' ' ' LEU . 21.6 tt0 52.2 6.58 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.478 -1.013 . . . . 2.97 109.386 -179.544 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.552 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 59.34 130.69 0.01 OUTLIER Glycine 0 N--CA 1.489 2.232 0 O-C-N 121.329 -0.857 . . . . 2.44 111.095 178.954 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.562 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 68.73 -53.63 0.51 Allowed Glycine 0 N--CA 1.492 2.405 0 O-C-N 121.499 -1.0 . . . . 1.81 110.668 178.733 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.67 ' HB2' ' OE1' ' A' ' 94' ' ' GLU . . . -42.66 -16.3 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.882 -0.775 . . . . 2.21 110.673 -178.598 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' HIS . . . . . 0.562 ' N ' ' O ' ' A' ' 17' ' ' GLY . 10.8 t-80 -93.82 -43.51 8.56 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.174 -0.954 . . . . 2.87 110.879 -178.409 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -91.29 -35.99 14.14 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 120.966 -1.084 . . . . 2.02 111.022 -178.486 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.609 ' O ' HG13 ' A' ' 21' ' ' VAL . 6.6 p -46.66 111.28 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 120.989 -1.069 . . . . 2.07 110.061 -178.987 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.414 ' HG2' ' HE1' ' A' ' 42' ' ' TRP . 19.5 tpt180 -118.43 124.84 48.63 Favored 'General case' 0 N--CA 1.497 1.878 0 N-CA-C 108.89 -0.781 . . . . 3.5 108.89 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -128.05 116.48 20.08 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.489 -0.757 . . . . 1.83 109.26 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -148.2 128.78 2.95 Favored Glycine 0 N--CA 1.495 2.571 0 N-CA-C 109.403 -1.479 . . . . 1.9 109.403 -179.879 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.11 169.19 40.38 Favored Glycine 0 N--CA 1.489 2.206 0 C-N-CA 119.574 -1.298 . . . . 1.85 110.062 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 43.3 p -74.06 -11.94 60.47 Favored 'General case' 0 N--CA 1.486 1.34 0 O-C-N 121.349 -1.089 . . . . 2.31 109.771 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -67.37 -17.06 68.03 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 108.205 -1.958 . . . . 1.64 108.205 179.46 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 28.2 mt -89.86 -11.65 41.32 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 108.467 -0.938 . . . . 1.83 108.467 179.437 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 19.9 mm-40 -82.68 -60.35 2.21 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.596 -0.69 . . . . 2.34 109.858 -179.47 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 26.6 ptt180 -172.96 178.79 2.45 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.032 -1.043 . . . . 3.77 109.992 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -148.85 178.0 26.71 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 108.446 -1.861 . . . . 1.57 108.446 179.765 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 27.3 t -134.8 148.33 29.31 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.015 0 O-C-N 121.205 -1.174 . . . . 1.83 110.145 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.641 ' HB2' ' HD3' ' A' ' 82' ' ' PRO . . . -41.56 113.95 0.47 Allowed 'General case' 0 N--CA 1.495 1.792 0 CA-C-O 121.567 0.699 . . . . 1.64 112.388 -179.155 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 59.87 46.44 94.1 Favored Glycine 0 N--CA 1.492 2.424 0 O-C-N 121.658 -0.651 . . . . 1.73 111.687 177.113 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 13.9 t -127.36 126.03 24.06 Favored Pre-proline 0 N--CA 1.499 2.009 0 N-CA-C 108.019 -1.104 . . . . 2.19 108.019 178.827 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -55.12 121.38 9.81 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 120.487 0.791 . . . . 1.96 110.441 -179.362 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -119.92 151.5 38.81 Favored 'General case' 0 N--CA 1.499 1.992 0 N-CA-C 108.235 -1.024 . . . . 1.69 108.235 179.319 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 8.6 pt-20 -160.16 166.24 30.1 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.727 -1.233 . . . . 2.23 111.334 -179.445 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.55 ' CD1' ' N ' ' A' ' 39' ' ' PHE . 0.9 OUTLIER -140.48 -178.08 5.34 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 107.046 -1.464 . . . . 1.54 107.046 177.428 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 15.5 m -128.31 134.83 48.98 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.678 -0.639 . . . . 2.37 110.084 -179.161 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.532 ' O ' ' N ' ' A' ' 73' ' ' CYS . 73.0 mt -124.61 145.79 31.26 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 N-CA-C 107.683 -1.228 . . . . 1.65 107.683 179.13 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.522 ' CD2' ' OG1' ' A' ' 43' ' ' THR . 14.5 p-90 -154.82 -176.99 6.2 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.678 -1.264 . . . . 3.68 110.445 -179.653 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.522 ' OG1' ' CD2' ' A' ' 42' ' ' TRP . 0.2 OUTLIER 81.85 109.9 0.07 Allowed 'General case' 0 N--CA 1.495 1.806 0 N-CA-C 109.356 -0.609 . . . . 2.89 109.356 -179.883 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 44' ' ' ARG . . . . . 0.59 ' CG ' HH11 ' A' ' 44' ' ' ARG . 0.0 OUTLIER -132.16 56.94 1.8 Allowed 'General case' 0 N--CA 1.499 1.976 0 N-CA-C 108.982 -0.747 . . . . 4.63 108.982 -179.864 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 27.3 tt0 -90.3 -15.91 30.29 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.264 -0.897 . . . . 2.89 109.976 -179.583 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.39 -66.88 0.5 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.04 -1.038 . . . . 1.74 109.179 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 138.21 -162.83 25.71 Favored Glycine 0 N--CA 1.495 2.633 0 N-CA-C 109.672 -1.371 . . . . 1.6 109.672 179.812 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.86 147.37 12.14 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.278 -1.131 . . . . 1.4 109.33 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -173.19 -168.96 35.1 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.538 -1.425 . . . . 1.04 109.538 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -137.49 114.29 1.09 Allowed Glycine 0 N--CA 1.496 2.663 0 N-CA-C 109.114 -1.594 . . . . 1.06 109.114 179.848 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.431 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 10.1 tp -93.74 97.58 10.53 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.251 -1.146 . . . . 1.1 108.582 179.79 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 4.2 m -83.78 142.16 30.87 Favored 'General case' 0 N--CA 1.494 1.738 0 N-CA-C 108.485 -0.932 . . . . 1.56 108.485 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.555 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 61.0 mt -133.65 123.22 45.29 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.083 -1.011 . . . . 0.65 109.674 -179.688 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -116.07 111.71 20.69 Favored 'General case' 0 N--CA 1.497 1.89 0 N-CA-C 108.325 -0.991 . . . . 0.69 108.325 179.236 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 1.1 t -102.94 149.14 7.32 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.977 0 O-C-N 121.449 -0.782 . . . . 0.91 110.052 -179.277 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.42 ' OE2' ' O ' ' B' ' 9' ' ' VAL . 50.9 tp10 -140.65 138.39 34.3 Favored 'General case' 0 N--CA 1.486 1.374 0 N-CA-C 108.441 -0.948 . . . . 1.8 108.441 178.285 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 174.3 -177.51 46.47 Favored Glycine 0 N--CA 1.487 2.075 0 N-CA-C 108.719 -1.752 . . . . 0.49 108.719 -179.607 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_exo -62.74 -18.54 64.81 Favored 'Trans proline' 0 C--N 1.313 -1.32 0 C-N-CA 121.802 1.668 . . . . 0.66 110.957 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' SER . . . . . 0.402 ' O ' ' OH ' ' A' ' 85' ' ' TYR . 1.1 p -149.77 166.36 29.68 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.349 -0.844 . . . . 1.55 110.411 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 46.1 mttt -89.92 125.74 35.47 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.607 -0.683 . . . . 2.53 109.502 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -81.8 142.86 32.21 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.278 -0.889 . . . . 0.82 109.325 179.766 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 10.0 tp10 -86.61 90.55 8.29 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.24 -0.913 . . . . 2.3 109.766 -179.808 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 6.3 mm -58.5 155.62 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 121.574 -0.704 . . . . 1.4 109.133 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.552 ' HB3' ' HB3' ' A' ' 76' ' ' SER . . . -149.68 114.43 5.33 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.804 -1.185 . . . . 1.36 109.503 179.577 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.463 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 16.5 p90 -88.85 119.11 29.05 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.164 -0.96 . . . . 1.47 109.041 179.476 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -141.29 106.91 5.08 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.252 -0.905 . . . . 2.51 109.902 -179.633 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 11.2 p-10 -79.94 127.13 31.9 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.247 -0.908 . . . . 2.07 108.9 179.354 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 84.1 mtm180 -110.96 -34.11 6.31 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.407 -0.808 . . . . 4.63 109.574 -179.607 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.537 ' C ' ' H ' ' A' ' 71' ' ' GLY . 28.5 mmtp -117.41 3.49 12.51 Favored 'General case' 0 N--CA 1.496 1.843 0 N-CA-C 108.631 -0.878 . . . . 3.49 108.631 179.8 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.437 ' CB ' ' O ' ' A' ' 69' ' ' LYS . 1.3 t70 72.99 -34.64 0.3 Allowed 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 108.684 -0.858 . . . . 3.06 108.684 -179.2 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' GLY . . . . . 0.537 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -93.76 -35.17 6.23 Favored Glycine 0 N--CA 1.489 2.171 0 N-CA-C 109.443 -1.463 . . . . 2.16 109.443 -179.864 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 74.8 m -95.76 107.56 19.8 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.317 -1.108 . . . . 2.2 109.395 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' CYS . . . . . 0.532 ' N ' ' O ' ' A' ' 41' ' ' ILE . 28.2 m -80.18 119.89 23.55 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.225 -0.922 . . . . 2.05 109.295 179.801 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -98.26 123.58 7.9 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.42 -1.472 . . . . 1.39 109.42 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 40.2 t -114.85 102.68 14.19 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.089 0 O-C-N 121.632 -0.923 . . . . 1.57 109.05 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.552 ' HB3' ' HB3' ' A' ' 64' ' ' ALA . 3.3 t -94.01 130.4 40.16 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.34 -0.85 . . . . 1.85 110.136 -179.598 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 8.5 p90 -126.46 129.85 49.51 Favored 'General case' 0 N--CA 1.492 1.646 0 N-CA-C 108.158 -1.052 . . . . 1.54 108.158 179.455 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 11.3 t -100.56 111.29 29.78 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.181 -0.949 . . . . 1.9 109.453 -179.155 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.542 HG11 HG21 ' A' ' 105' ' ' VAL . 13.2 m -77.94 157.71 5.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 O-C-N 121.287 -0.883 . . . . 1.27 109.329 -179.866 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 30.1 tt0 -101.87 -47.92 4.43 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.173 -0.955 . . . . 2.48 110.303 -179.499 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.404 ' O ' ' O ' ' A' ' 82' ' ' PRO . 75.5 mm-40 -149.98 150.03 29.01 Favored Pre-proline 0 N--CA 1.502 2.143 0 O-C-N 120.829 -1.169 . . . . 1.92 111.253 -178.623 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.641 ' HD3' ' HB2' ' A' ' 33' ' ' ALA . 77.8 Cg_exo -37.43 165.49 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.679 0 C-N-CA 122.825 2.35 . . . . 1.3 113.296 178.551 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 142.37 -178.89 20.61 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 108.989 -1.644 . . . . 1.02 108.989 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' ASP . . . . . 0.552 ' O ' ' NH1' ' B' ' 8' ' ' ARG . 29.6 m-20 -98.69 89.74 4.47 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 107.835 -1.172 . . . . 2.13 107.835 179.224 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.402 ' OH ' ' O ' ' A' ' 59' ' ' SER . 2.9 m-85 -74.7 133.67 42.04 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 108.347 -0.983 . . . . 0.92 108.347 -179.366 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 86' ' ' GLU . . . . . 0.488 ' OE2' ' NH1' ' B' ' 8' ' ' ARG . 0.0 OUTLIER -117.65 125.05 50.04 Favored 'General case' 0 N--CA 1.498 1.949 0 N-CA-C 108.305 -0.998 . . . . 1.53 108.305 -179.098 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.556 ' CG1' ' CE2' ' A' ' 101' ' ' PHE . 7.5 p -122.94 137.38 56.6 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.986 0 O-C-N 121.624 -0.673 . . . . 1.0 109.401 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 99.8 p -131.55 113.87 14.18 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.596 -0.69 . . . . 1.59 109.797 -179.876 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 2.9 pt -111.83 143.13 22.24 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.735 -0.603 . . . . 1.29 109.917 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -140.4 123.52 16.67 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.236 -0.915 . . . . 1.58 109.273 178.971 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 25.1 t80 -78.67 92.99 4.82 Favored 'General case' 0 N--CA 1.494 1.744 0 C-N-CA 119.026 -1.069 . . . . 1.34 108.325 179.449 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' ASN . . . . . 0.486 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 0.5 OUTLIER 65.82 37.62 5.52 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 108.236 -1.024 . . . . 2.32 108.236 -178.809 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.486 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 2.2 m-20 88.76 10.97 0.09 Allowed 'General case' 0 N--CA 1.503 2.192 0 CA-C-N 116.605 -0.27 . . . . 1.92 111.381 179.658 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 94' ' ' GLU . . . . . 0.711 ' OE2' HD13 ' A' ' 96' ' ' ILE . 0.0 OUTLIER -86.33 86.97 7.35 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 106.091 -1.818 . . . . 2.25 106.091 177.687 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 95' ' ' HIS . . . . . 0.445 ' O ' ' C ' ' A' ' 96' ' ' ILE . 2.3 t-80 -68.12 94.36 0.5 Allowed 'General case' 0 C--N 1.296 -1.735 0 O-C-N 120.4 -1.437 . . . . 2.88 110.948 -177.845 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 96' ' ' ILE . . . . . 0.711 HD13 ' OE2' ' A' ' 94' ' ' GLU . 4.7 mm -38.38 135.81 0.88 Allowed Pre-proline 0 N--CA 1.504 2.271 0 O-C-N 121.497 -0.752 . . . . 2.35 109.281 179.084 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -54.52 -7.36 0.8 Allowed 'Trans proline' 0 C--N 1.325 -0.7 0 N-CA-C 109.239 -1.1 . . . . 2.48 109.239 179.131 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.48 ' H ' ' C ' ' A' ' 96' ' ' ILE . 55.0 m-20 -86.87 -47.32 9.12 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.481 -0.762 . . . . 2.65 109.729 179.765 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 6.4 p -54.71 136.32 64.16 Favored Pre-proline 0 C--N 1.298 -1.661 0 O-C-N 121.191 -0.943 . . . . 2.0 109.835 -177.941 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -89.3 113.81 2.34 Favored 'Cis proline' 0 N--CA 1.494 1.554 0 CA-C-N 118.935 0.655 . . . . 1.79 110.44 -1.902 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' PHE . . . . . 0.609 ' CD1' ' N ' ' A' ' 101' ' ' PHE . 0.1 OUTLIER -81.42 158.58 24.55 Favored 'General case' 0 N--CA 1.509 2.522 0 O-C-N 119.674 -1.891 . . . . 2.19 108.785 178.476 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 10.4 p -97.93 138.04 23.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.404 -0.81 . . . . 1.44 109.388 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 60.6 t -121.03 85.53 40.95 Favored Pre-proline 0 N--CA 1.499 2.019 0 N-CA-C 108.623 -0.88 . . . . 1.19 108.623 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -65.63 111.32 1.85 Allowed 'Trans proline' 0 C--N 1.321 -0.899 0 C-N-CA 121.443 1.428 . . . . 1.49 111.467 -178.336 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.542 HG21 HG11 ' A' ' 79' ' ' VAL . 54.6 t -95.49 146.32 7.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.775 0 N-CA-C 107.1 -1.444 . . . . 1.35 107.1 178.34 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.656 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -138.71 135.65 34.98 Favored 'General case' 0 N--CA 1.509 2.523 0 O-C-N 121.092 -1.005 . . . . 1.67 111.799 -177.541 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.542 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 9.9 m -86.71 58.73 5.23 Favored 'General case' 0 N--CA 1.494 1.752 0 N-CA-C 107.42 -1.326 . . . . 2.04 107.42 178.808 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 108' ' ' LEU . . . . . 0.508 ' CB ' ' O ' ' A' ' 107' ' ' SER . 3.4 tp 83.8 -11.35 0.89 Allowed 'General case' 0 N--CA 1.495 1.814 0 N-CA-C 106.972 -1.492 . . . . 3.2 106.972 -177.843 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.681 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 24.1 t -71.18 -19.28 62.42 Favored 'General case' 0 C--N 1.305 -1.333 0 N-CA-C 108.878 -0.786 . . . . 2.09 108.878 178.967 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 110' ' ' ASP . . . . . 0.656 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 1.1 p30 48.44 15.06 0.07 Allowed 'General case' 0 N--CA 1.496 1.833 0 N-CA-C 108.285 -1.006 . . . . 2.85 108.285 -178.822 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.515 ' N ' ' C ' ' A' ' 109' ' ' SER . 29.9 m-20 -166.64 -34.16 0.03 OUTLIER 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 108.173 -1.047 . . . . 2.46 108.173 -179.759 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.681 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 39.16 83.41 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.604 -0.685 . . . . 2.08 110.585 179.765 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 113' ' ' ARG . . . . . 0.429 ' O ' ' N ' ' A' ' 118' ' ' THR . 82.5 mtt180 -76.77 138.77 40.1 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.164 -0.96 . . . . 5.93 109.222 179.875 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 57.8 ttt180 -90.18 5.64 46.09 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.438 -0.789 . . . . 5.61 109.121 -179.794 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 2.2 mp -125.84 -25.49 3.62 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.577 -0.702 . . . . 4.39 110.061 -179.401 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.511 ' C ' ' H ' ' A' ' 118' ' ' THR . 61.5 m -110.75 -77.83 0.59 Allowed 'General case' 0 N--CA 1.499 1.997 0 N-CA-C 107.252 -1.388 . . . . 4.09 107.252 179.177 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.439 ' O ' HG12 ' A' ' 117' ' ' VAL . 42.5 t -62.32 -7.61 2.32 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.656 0 N-CA-C 105.994 -1.854 . . . . 2.9 105.994 176.72 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 118' ' ' THR . . . . . 0.511 ' H ' ' C ' ' A' ' 116' ' ' THR . 4.2 t 36.19 59.39 0.93 Allowed 'General case' 0 N--CA 1.487 1.391 0 CA-C-N 115.12 -0.945 . . . . 3.36 110.687 179.743 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 119' ' ' SER . . . . . 0.452 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.5 p . . . . . 0 C--N 1.304 -1.398 0 CA-C-O 118.021 -0.99 . . . . 3.39 109.673 179.43 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 11.8 ptt? . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 109.468 -0.567 . . . . 8.49 109.468 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -172.74 145.79 1.54 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.216 -0.927 . . . . 5.53 109.405 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 3' ' ' SER . . . . . . . . . . . . . 60.7 p 49.79 75.29 0.17 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.257 -0.902 . . . . 5.43 109.361 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 4' ' ' LYS . . . . . 0.429 ' O ' ' O ' ' B' ' 5' ' ' PRO . 43.5 mttm -63.83 148.17 95.07 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.254 -0.904 . . . . 6.87 108.941 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 5' ' ' PRO . . . . . 0.429 ' O ' ' O ' ' B' ' 4' ' ' LYS . 1.9 Cg_endo -57.2 -158.02 0.01 OUTLIER 'Trans proline' 0 C--N 1.324 -0.727 0 C-N-CA 120.914 1.076 . . . . 5.16 109.766 179.544 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 6' ' ' GLU . . . . . . . . . . . . . 15.5 tt0 67.55 179.69 0.23 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.244 -0.91 . . . . 4.78 108.973 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 53.53 62.82 2.45 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.218 -0.926 . . . . 4.09 109.592 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.552 ' NH1' ' O ' ' A' ' 84' ' ' ASP . 68.3 mtt180 -98.82 176.63 5.54 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 108.429 -0.952 . . . . 3.04 108.429 179.606 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 9' ' ' VAL . . . . . 0.42 ' O ' ' OE2' ' A' ' 56' ' ' GLU . 21.0 t -53.99 158.71 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 N-CA-C 108.162 -1.051 . . . . 0.67 108.162 178.971 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -117.83 141.72 48.11 Favored 'General case' 0 N--CA 1.502 2.166 0 O-C-N 121.489 -0.757 . . . . 0.58 109.981 -179.337 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 18.4 t -143.0 137.68 29.49 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.368 -0.832 . . . . 1.19 109.319 179.581 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 8.7 t -141.13 128.31 20.9 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.308 -0.87 . . . . 1.38 109.584 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 0.622 HG22 ' N ' ' B' ' 14' ' ' PHE . 6.1 p -169.44 167.89 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.484 -0.76 . . . . 0.42 109.205 -179.874 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 14' ' ' PHE . . . . . 0.622 ' N ' HG22 ' B' ' 13' ' ' VAL . 6.7 p90 -177.61 -167.67 0.16 Allowed 'General case' 0 N--CA 1.49 1.552 0 CA-C-O 122.202 1.001 . . . . 1.79 112.537 179.65 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.4 pt -150.71 172.07 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.31 0 N-CA-C 108.322 -0.992 . . . . 1.25 108.322 179.818 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 31.7 p -144.96 147.12 32.33 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 120.865 -1.147 . . . . 1.61 109.9 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.4 mt -97.58 132.63 43.08 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.349 -0.845 . . . . 1.32 109.178 179.715 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -150.91 68.63 8.23 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.227 -0.921 . . . . 1.45 109.652 -179.862 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 19' ' ' PRO . . . . . 0.427 ' O ' ' O ' ' B' ' 20' ' ' PRO . 6.3 Cg_exo -60.45 170.4 4.29 Favored 'Trans proline' 0 C--N 1.317 -1.096 0 C-N-CA 121.3 1.334 . . . . 1.5 109.307 -179.911 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 20' ' ' PRO . . . . . 0.427 ' O ' ' O ' ' B' ' 19' ' ' PRO . 4.7 Cg_exo -56.6 -158.05 0.01 OUTLIER 'Trans proline' 0 C--N 1.318 -1.066 0 C-N-CA 121.259 1.306 . . . . 2.86 109.862 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -144.0 -163.53 1.69 Allowed 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.188 -0.945 . . . . 6.12 109.312 -179.934 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 22' ' ' ARG . . . . . . . . . . . . . 8.4 ptm180 -152.24 121.58 6.78 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.204 -0.935 . . . . 6.29 109.368 -179.866 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 23' ' ' ASP . . . . . 0.513 ' N ' ' OD1' ' B' ' 23' ' ' ASP . 8.5 p-10 -175.22 122.87 0.22 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.206 -0.934 . . . . 5.62 109.455 -179.895 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 15.0 p . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 117.959 -1.019 . . . . 6.48 109.443 179.978 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.531 4.997 0 N-CA-C 119.799 2.68 . . . . 6.64 119.799 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.562 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 11.4 tt -172.88 50.77 0.11 Allowed Pre-proline 0 C--N 1.308 -1.231 0 N-CA-C 107.784 -1.191 . . . . 7.08 107.784 179.53 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.803 ' C ' ' H ' ' A' ' 5' ' ' PHE . 6.5 Cg_endo -58.76 -82.79 0.01 OUTLIER 'Trans proline' 0 C--N 1.318 -1.042 0 N-CA-C 108.73 -1.296 . . . . 5.5 108.73 179.829 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.506 ' C ' ' H ' ' A' ' 6' ' ' PHE . 11.6 tt0 73.83 -19.13 0.36 Allowed 'General case' 0 N--CA 1.495 1.796 0 N-CA-C 104.373 -2.454 . . . . 6.75 104.373 -175.819 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' PHE . . . . . 0.803 ' H ' ' C ' ' A' ' 3' ' ' PRO . 6.4 m-85 -89.68 20.21 4.18 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 103.996 -2.594 . . . . 6.07 103.996 176.732 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.549 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 37.2 p90 46.33 -153.69 0.06 Allowed 'General case' 0 C--N 1.307 -1.275 0 CA-C-N 114.314 -1.312 . . . . 4.72 109.394 -177.466 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.537 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 22.0 tt0 86.8 -10.27 0.63 Allowed 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 105.282 -2.118 . . . . 4.4 105.282 -177.318 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.412 ' H ' ' C ' ' A' ' 6' ' ' PHE . 35.5 t80 -151.77 -37.25 0.12 Allowed 'General case' 0 C--N 1.305 -1.347 0 N-CA-C 107.955 -1.128 . . . . 5.15 107.955 178.485 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.415 HG22 ' O ' ' A' ' 9' ' ' THR . 39.9 m -93.58 3.74 55.04 Favored 'General case' 0 C--N 1.296 -1.72 0 N-CA-C 105.96 -1.867 . . . . 5.13 105.96 177.363 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.519 HG13 ' N ' ' A' ' 11' ' ' GLY . 9.8 p -44.35 -42.91 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 CA-C-N 115.457 -0.792 . . . . 4.38 109.867 -179.474 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.519 ' N ' HG13 ' A' ' 10' ' ' VAL . . . -114.64 -172.06 17.34 Favored Glycine 0 N--CA 1.494 2.54 0 N-CA-C 109.705 -1.358 . . . . 4.22 109.705 -179.039 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.48 ' C ' ' HG ' ' A' ' 13' ' ' LEU . 10.1 Cg_endo -69.46 -0.16 6.26 Favored 'Trans proline' 0 C--N 1.316 -1.171 0 C-N-CA 121.847 1.698 . . . . 3.85 109.514 -179.702 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.521 HD12 ' H ' ' A' ' 15' ' ' GLU . 0.3 OUTLIER 168.54 24.74 0.0 OUTLIER 'General case' 0 C--N 1.278 -2.523 0 CA-C-N 114.453 -1.249 . . . . 3.67 108.256 -177.698 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.458 ' C ' ' N ' ' A' ' 16' ' ' GLY . . . 77.45 -42.19 1.93 Allowed Glycine 0 N--CA 1.49 2.277 0 N-CA-C 108.732 -1.747 . . . . 2.97 108.732 -179.654 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.521 ' H ' HD12 ' A' ' 13' ' ' LEU . 25.3 tt0 53.24 13.89 0.46 Allowed 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 108.137 -1.06 . . . . 2.97 108.137 -179.685 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.458 ' N ' ' C ' ' A' ' 14' ' ' GLY . . . 73.67 -164.09 54.77 Favored Glycine 0 N--CA 1.484 1.899 0 N-CA-C 109.447 -1.461 . . . . 2.44 109.447 -179.892 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.534 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -69.58 -5.93 52.67 Favored Glycine 0 N--CA 1.487 2.083 0 N-CA-C 110.054 -1.219 . . . . 1.81 110.054 -179.664 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -48.3 -13.39 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.675 0 O-C-N 120.663 -1.492 . . . . 2.21 109.228 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' HIS . . . . . 0.534 ' N ' ' O ' ' A' ' 17' ' ' GLY . 1.6 t60 -95.48 -45.17 7.2 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.384 -0.823 . . . . 2.87 109.181 179.38 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.52 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.0 OUTLIER -79.83 -26.08 40.59 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.112 -0.993 . . . . 2.02 109.332 179.894 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.417 HG11 HD11 ' A' ' 96' ' ' ILE . 69.2 t -62.98 112.66 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.115 -0.991 . . . . 2.07 109.051 179.497 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 12.9 tpp180 -100.93 137.52 39.19 Favored 'General case' 0 C--N 1.301 -1.535 0 CA-C-O 121.475 0.655 . . . . 3.5 109.263 -179.72 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -148.37 113.28 5.45 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.604 -0.887 . . . . 1.83 108.604 179.415 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -150.76 133.23 4.21 Favored Glycine 0 N--CA 1.496 2.68 0 N-CA-C 109.74 -1.344 . . . . 1.9 109.74 -179.616 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.46 175.36 47.37 Favored Glycine 0 N--CA 1.487 2.067 0 C-N-CA 119.628 -1.272 . . . . 1.85 110.268 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 18.0 m -77.44 -17.95 57.62 Favored 'General case' 0 N--CA 1.486 1.363 0 O-C-N 121.457 -1.025 . . . . 2.31 109.77 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -68.34 -22.75 74.87 Favored Glycine 0 N--CA 1.487 2.036 0 N-CA-C 108.761 -1.736 . . . . 1.64 108.761 179.757 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.5 mt -84.39 -7.15 59.39 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.623 -0.927 . . . . 1.83 108.963 179.853 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 27.0 mm-40 -88.45 -56.69 3.21 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.47 -0.769 . . . . 2.34 109.993 -179.341 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 26.1 ptt180 -175.05 -176.74 0.99 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.126 -0.984 . . . . 3.77 109.666 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -149.27 177.47 27.45 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 108.917 -1.673 . . . . 1.57 108.917 179.857 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.465 ' H ' ' CG1' ' A' ' 35' ' ' VAL . 25.8 t -134.91 148.03 29.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.425 -1.044 . . . . 1.83 109.803 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.464 ' HB2' ' HD3' ' A' ' 82' ' ' PRO . . . -37.84 106.65 0.05 Allowed 'General case' 0 N--CA 1.496 1.866 0 CA-C-O 121.341 0.591 . . . . 1.64 112.085 -179.142 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 62.49 57.51 16.23 Favored Glycine 0 N--CA 1.49 2.268 0 O-C-N 121.249 -0.907 . . . . 1.73 111.541 177.558 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.465 ' CG1' ' H ' ' A' ' 32' ' ' VAL . 2.8 p -126.09 129.2 24.31 Favored Pre-proline 0 N--CA 1.502 2.167 0 O-C-N 121.311 -1.111 . . . . 2.19 109.133 178.84 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -63.5 125.64 16.0 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 N-CA-C 108.24 -1.485 . . . . 1.96 108.24 178.473 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.598 ' HB3' ' CZ ' ' A' ' 77' ' ' TYR . . . -134.47 160.91 36.55 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.212 -0.93 . . . . 1.69 109.294 -179.367 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -162.36 167.22 24.08 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 121.161 -0.962 . . . . 2.23 110.758 -179.634 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.527 ' CD1' ' N ' ' A' ' 39' ' ' PHE . 0.7 OUTLIER -141.61 -179.98 6.48 Favored 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 107.059 -1.46 . . . . 1.54 107.059 177.627 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 6.1 m -124.12 138.05 54.48 Favored 'General case' 0 N--CA 1.498 1.941 0 CA-C-O 121.405 0.622 . . . . 2.37 110.178 -178.937 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.479 ' O ' ' N ' ' A' ' 73' ' ' CYS . 74.3 mt -136.7 119.38 20.99 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.556 -0.715 . . . . 1.65 109.269 179.645 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 6.2 p-90 -119.52 137.35 53.87 Favored 'General case' 0 N--CA 1.503 2.2 0 N-CA-C 108.905 -0.776 . . . . 3.68 108.905 179.201 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.52 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.1 OUTLIER -148.83 137.77 21.46 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.199 -0.938 . . . . 2.89 109.694 -179.581 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 44' ' ' ARG . . . . . . . . . . . . . 59.7 ttt180 -171.87 66.3 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.344 -0.848 . . . . 4.63 109.743 179.665 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.485 ' H ' ' HZ3' ' A' ' 20' ' ' LYS . 6.4 tp10 -157.84 -53.81 0.07 Allowed 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.078 -1.014 . . . . 2.89 109.43 179.553 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -58.46 -58.75 7.16 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.2 -0.937 . . . . 1.74 109.148 179.769 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 138.62 176.49 14.62 Favored Glycine 0 N--CA 1.494 2.502 0 N-CA-C 108.928 -1.669 . . . . 1.6 108.928 -179.938 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.39 163.51 0.6 Allowed 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.088 -1.243 . . . . 1.4 109.386 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 179.8 -148.78 8.2 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.868 -1.293 . . . . 1.04 109.868 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -144.13 126.98 2.85 Favored Glycine 0 N--CA 1.495 2.606 0 N-CA-C 109.618 -1.393 . . . . 1.06 109.618 -179.838 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.423 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 10.8 tp -102.93 102.15 12.21 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.399 -1.059 . . . . 1.1 109.027 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 3.2 t -85.97 142.11 29.03 Favored 'General case' 0 N--CA 1.494 1.767 0 N-CA-C 108.221 -1.029 . . . . 1.56 108.221 179.295 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.555 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 89.5 mt -133.54 120.14 36.85 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.987 0 O-C-N 121.087 -1.008 . . . . 0.65 109.896 -179.709 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.435 ' HB3' ' OG ' ' A' ' 88' ' ' SER . . . -109.44 106.86 16.8 Favored 'General case' 0 N--CA 1.496 1.874 0 N-CA-C 108.772 -0.825 . . . . 0.69 108.772 179.376 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.43 HG23 ' OG ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -97.84 143.19 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 O-C-N 121.245 -0.91 . . . . 0.91 109.25 -179.844 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 12.5 tt0 -141.61 142.87 33.44 Favored 'General case' 0 N--CA 1.491 1.624 0 N-CA-C 107.882 -1.155 . . . . 1.8 107.882 179.336 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 166.04 -172.88 41.54 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.502 -1.439 . . . . 0.49 109.502 -179.239 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -64.21 -30.18 64.54 Favored 'Trans proline' 0 C--N 1.318 -1.056 0 C-N-CA 121.993 1.795 . . . . 0.66 111.412 -179.218 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' SER . . . . . 0.403 ' O ' ' OH ' ' A' ' 85' ' ' TYR . 6.0 m -141.4 152.26 44.16 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.075 -1.016 . . . . 1.55 109.827 -179.801 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 16.1 ptmt -74.56 107.68 6.84 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.261 -0.899 . . . . 2.53 109.024 179.829 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -72.67 136.43 45.63 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.014 -1.054 . . . . 0.82 109.401 -179.602 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -71.92 173.35 8.45 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.099 -1.0 . . . . 2.3 109.236 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 42.9 mt -142.52 152.52 17.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 N-CA-C 107.799 -1.185 . . . . 1.4 107.799 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.55 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -150.13 114.64 5.23 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 120.653 -1.279 . . . . 1.36 110.202 -179.45 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 45.1 p90 -86.76 129.07 35.02 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.248 -0.907 . . . . 1.47 109.157 179.393 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 54.0 tt0 -141.26 123.78 15.91 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.238 -0.914 . . . . 2.51 109.602 -179.756 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.415 ' OD1' ' N ' ' A' ' 67' ' ' ASP . 2.3 p-10 -84.76 119.24 25.06 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.35 -0.844 . . . . 2.07 109.371 179.833 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.597 ' CG ' HH11 ' A' ' 68' ' ' ARG . 0.3 OUTLIER -96.06 -39.99 9.46 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.221 -0.924 . . . . 4.63 109.638 -179.926 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.528 ' C ' ' H ' ' A' ' 71' ' ' GLY . 20.4 mtpp -122.35 13.11 10.25 Favored 'General case' 0 N--CA 1.496 1.826 0 N-CA-C 108.663 -0.866 . . . . 3.49 108.663 179.853 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.473 ' CB ' ' O ' ' A' ' 69' ' ' LYS . 4.4 t0 74.04 -29.52 0.2 Allowed 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 108.476 -0.935 . . . . 3.06 108.476 -178.99 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' GLY . . . . . 0.528 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -103.63 -24.92 7.53 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.613 -1.395 . . . . 2.16 109.613 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 94.0 p -95.81 115.66 27.76 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.17 -1.194 . . . . 2.2 109.466 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' CYS . . . . . 0.479 ' N ' ' O ' ' A' ' 41' ' ' ILE . 32.3 m -85.31 117.27 24.14 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.232 -0.917 . . . . 2.05 109.633 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -99.95 119.8 6.64 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 109.294 -1.522 . . . . 1.39 109.294 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 17.9 t -109.74 103.09 14.94 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.153 0 O-C-N 121.524 -0.986 . . . . 1.57 109.818 -179.756 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.55 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.0 OUTLIER -91.76 142.94 27.04 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.326 -0.859 . . . . 1.85 108.851 179.687 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.598 ' CZ ' ' HB3' ' A' ' 37' ' ' ALA . 11.6 p90 -142.82 171.92 13.4 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.281 -0.887 . . . . 1.54 109.189 -179.421 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.556 ' O ' HG13 ' A' ' 78' ' ' VAL . 4.4 p -142.2 119.98 7.92 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.211 0 O-C-N 121.105 -0.997 . . . . 1.9 110.288 179.529 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.515 HG11 HG21 ' A' ' 105' ' ' VAL . 11.5 m -87.15 153.97 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.309 -0.87 . . . . 1.27 108.677 179.251 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 38.3 tt0 -96.6 -47.0 6.1 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.008 -1.057 . . . . 2.48 110.657 -179.156 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 80.2 mm-40 -152.16 150.48 25.66 Favored Pre-proline 0 N--CA 1.502 2.129 0 O-C-N 120.646 -1.284 . . . . 1.92 111.056 -178.625 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.576 ' HG3' ' N ' ' A' ' 107' ' ' SER . 75.7 Cg_exo -37.68 164.72 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.67 0 C-N-CA 122.8 2.333 . . . . 1.3 113.099 178.398 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 144.24 -163.88 27.71 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.122 -1.591 . . . . 1.02 109.122 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 20.0 m-20 -108.97 91.13 3.52 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.639 -0.918 . . . . 2.13 108.797 179.652 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.473 ' O ' ' N ' ' A' ' 103' ' ' VAL . 3.1 m-85 -78.81 130.69 36.0 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 108.091 -1.077 . . . . 0.92 108.091 179.896 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 86' ' ' GLU . . . . . 0.409 ' OE2' ' NH2' ' B' ' 8' ' ' ARG . 0.0 OUTLIER -115.62 129.23 56.43 Favored 'General case' 0 N--CA 1.501 2.1 0 N-CA-C 108.89 -0.781 . . . . 1.53 108.89 -179.041 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 9.9 p -124.12 140.19 48.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.712 -0.617 . . . . 1.0 109.361 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' SER . . . . . 0.435 ' OG ' ' HB3' ' A' ' 54' ' ' ALA . 22.2 p -131.98 101.9 5.61 Favored 'General case' 0 N--CA 1.498 1.944 0 N-CA-C 109.184 -0.673 . . . . 1.59 109.184 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.418 ' H ' ' HB3' ' A' ' 99' ' ' SER . 1.5 pt -111.84 136.11 49.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 CA-C-O 121.599 0.714 . . . . 1.29 110.479 -179.084 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 90' ' ' LYS . . . . . 0.459 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.2 OUTLIER -140.95 122.77 15.35 Favored 'General case' 0 N--CA 1.486 1.329 0 N-CA-C 108.001 -1.111 . . . . 1.58 108.001 179.449 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.413 ' O ' ' OE1' ' A' ' 94' ' ' GLU . 84.7 t80 -82.15 100.29 9.73 Favored 'General case' 0 C--N 1.3 -1.569 0 C-N-CA 118.347 -1.341 . . . . 1.34 107.927 179.041 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 92' ' ' ASN . . . . . 0.438 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 12.7 t-20 71.42 36.48 1.31 Allowed 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.25 -0.906 . . . . 2.32 109.158 -178.665 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.438 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 1.8 m-20 79.6 12.9 1.11 Allowed 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.703 -0.623 . . . . 1.92 111.903 179.232 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 94' ' ' GLU . . . . . 0.483 ' OE2' ' CA ' ' A' ' 17' ' ' GLY . 5.2 pt-20 -99.98 96.59 7.64 Favored 'General case' 0 N--CA 1.498 1.97 0 N-CA-C 106.958 -1.497 . . . . 2.25 106.958 177.617 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 95' ' ' HIS . . . . . 0.513 ' O ' ' ND1' ' A' ' 95' ' ' HIS . 0.0 OUTLIER -70.44 111.37 5.94 Favored 'General case' 0 N--CA 1.488 1.452 0 CA-C-O 121.595 0.712 . . . . 2.88 110.884 -177.577 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 96' ' ' ILE . . . . . 0.479 ' O ' ' N ' ' A' ' 98' ' ' ASP . 32.4 mt -57.66 137.39 82.54 Favored Pre-proline 0 C--N 1.3 -1.557 0 N-CA-C 107.826 -1.176 . . . . 2.35 107.826 178.651 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_exo -42.91 -21.75 0.23 Allowed 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 120.823 1.015 . . . . 2.48 110.184 -179.694 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.479 ' N ' ' O ' ' A' ' 96' ' ' ILE . 87.2 m-20 -67.58 -68.08 0.41 Allowed 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 108.478 -0.934 . . . . 2.65 108.478 178.266 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.418 ' HB3' ' H ' ' A' ' 89' ' ' ILE . 0.3 OUTLIER -60.65 143.65 90.3 Favored Pre-proline 0 C--N 1.295 -1.762 0 O-C-N 121.595 -0.69 . . . . 2.0 109.901 -178.389 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -84.41 112.62 2.6 Favored 'Cis proline' 0 N--CA 1.491 1.337 0 N-CA-C 109.456 -1.017 . . . . 1.79 109.456 -2.318 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 53.6 p90 -112.11 161.96 15.95 Favored 'General case' 0 N--CA 1.517 2.887 0 O-C-N 120.543 -1.348 . . . . 2.19 110.196 179.107 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.414 HG22 ' N ' ' A' ' 103' ' ' VAL . 7.2 p -93.66 154.42 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.528 -0.732 . . . . 1.44 110.928 -178.421 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.473 ' N ' ' O ' ' A' ' 85' ' ' TYR . 64.4 t -128.65 86.96 56.23 Favored Pre-proline 0 N--CA 1.498 1.934 0 N-CA-C 108.233 -1.025 . . . . 1.19 108.233 179.41 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 4.1 Cg_exo -63.54 113.12 1.97 Allowed 'Trans proline' 0 C--N 1.319 -1.008 0 C-N-CA 121.333 1.355 . . . . 1.49 111.963 -178.081 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.515 HG21 HG11 ' A' ' 79' ' ' VAL . 53.4 t -96.17 143.76 11.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 N-CA-C 106.713 -1.588 . . . . 1.35 106.713 177.862 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.649 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -136.65 133.63 36.43 Favored 'General case' 0 N--CA 1.51 2.539 0 O-C-N 121.14 -0.975 . . . . 1.67 111.863 -177.3 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.576 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 38.7 p -85.27 63.73 8.26 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.796 -1.19 . . . . 2.04 107.819 179.12 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 108' ' ' LEU . . . . . 0.485 ' CB ' ' O ' ' A' ' 107' ' ' SER . 2.8 tp 79.9 -14.89 0.8 Allowed 'General case' 0 C--N 1.298 -1.648 0 N-CA-C 106.927 -1.509 . . . . 3.2 106.927 -177.991 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.676 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 21.7 t -66.89 -23.46 66.0 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 108.762 -0.829 . . . . 2.09 108.762 178.769 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 110' ' ' ASP . . . . . 0.649 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 42.9 m-20 52.71 12.04 0.23 Allowed 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 108.079 -1.082 . . . . 2.85 108.079 -179.46 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.503 ' H ' ' C ' ' A' ' 109' ' ' SER . 4.5 m-20 -167.04 -30.43 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 108.663 -0.865 . . . . 2.46 108.663 -179.671 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.676 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 54.89 81.09 0.11 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.005 -1.059 . . . . 2.08 109.415 -179.898 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 113' ' ' ARG . . . . . 0.517 HH11 ' HG2' ' A' ' 113' ' ' ARG . 5.1 mtt-85 -65.17 -167.94 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.218 -0.927 . . . . 5.93 109.23 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 33.8 ttm180 -139.62 4.39 2.14 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.4 -0.813 . . . . 5.61 108.89 -179.597 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 32.3 mt -126.56 -27.57 3.12 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.607 -0.683 . . . . 4.39 109.216 179.799 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.541 ' C ' ' H ' ' A' ' 118' ' ' THR . 58.8 m -106.85 -75.62 0.63 Allowed 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 107.347 -1.353 . . . . 4.09 107.347 179.152 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.51 ' O ' HG12 ' A' ' 117' ' ' VAL . 47.9 t -65.11 -3.64 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 N-CA-C 106.201 -1.777 . . . . 2.9 106.201 176.981 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 118' ' ' THR . . . . . 0.677 ' O ' HG23 ' A' ' 118' ' ' THR . 6.7 t 29.54 69.39 0.08 Allowed 'General case' 0 N--CA 1.489 1.489 0 CA-C-O 122.277 1.037 . . . . 3.36 111.064 -179.698 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 119' ' ' SER . . . . . 0.405 ' O ' ' O ' ' A' ' 118' ' ' THR . 0.5 OUTLIER . . . . . 0 C--N 1.302 -1.462 0 CA-C-O 117.996 -1.002 . . . . 3.39 109.502 179.564 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 19.2 ttt . . . . . 0 N--CA 1.489 1.51 0 CA-C-O 121.244 0.545 . . . . 8.49 109.606 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -158.27 143.22 16.39 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.224 -0.923 . . . . 5.53 109.625 -179.821 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 3' ' ' SER . . . . . . . . . . . . . 9.5 p -66.19 81.25 0.08 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.268 -0.895 . . . . 5.43 109.211 179.84 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 4' ' ' LYS . . . . . . . . . . . . . 14.0 pttt -75.45 154.26 85.83 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.263 -0.898 . . . . 6.87 109.051 -179.745 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 5' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_exo -54.6 -175.38 0.03 OUTLIER 'Trans proline' 0 C--N 1.323 -0.8 0 C-N-CA 121.111 1.207 . . . . 5.16 109.745 179.386 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 6' ' ' GLU . . . . . . . . . . . . . 30.7 tt0 -151.34 129.56 11.95 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.275 -0.89 . . . . 4.78 109.355 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 9.2 ptmm? -57.87 139.93 53.08 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.292 -0.88 . . . . 4.09 109.425 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.409 ' NH2' ' OE2' ' A' ' 86' ' ' GLU . 18.2 mtm-85 -96.43 167.59 11.07 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 108.129 -1.063 . . . . 3.04 108.129 179.547 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 9' ' ' VAL . . . . . . . . . . . . . 20.4 t -52.96 159.54 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 120.916 -1.115 . . . . 0.67 108.21 179.617 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -120.64 149.11 42.99 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.404 -0.81 . . . . 0.58 110.422 -178.957 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 11' ' ' SER . . . . . 0.43 ' OG ' HG23 ' A' ' 55' ' ' VAL . 7.4 t -143.2 142.69 31.5 Favored 'General case' 0 N--CA 1.495 1.785 0 N-CA-C 108.814 -0.81 . . . . 1.19 108.814 179.365 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 23.6 p -145.38 127.92 16.05 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.987 -1.07 . . . . 1.38 110.121 -179.639 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 0.655 HG22 ' N ' ' B' ' 14' ' ' PHE . 7.2 p -172.44 171.46 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 N-CA-C 108.826 -0.805 . . . . 0.42 108.826 179.69 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 14' ' ' PHE . . . . . 0.655 ' N ' HG22 ' B' ' 13' ' ' VAL . 6.8 p90 -177.48 -167.95 0.17 Allowed 'General case' 0 N--CA 1.489 1.522 0 CA-C-O 122.234 1.016 . . . . 1.79 112.282 179.793 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.8 pt -148.95 172.64 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.29 0 N-CA-C 107.897 -1.149 . . . . 1.25 107.897 179.709 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 2.4 t -146.6 148.44 32.12 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 120.756 -1.215 . . . . 1.61 110.195 -179.842 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.2 mt -101.17 127.28 47.8 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.51 -0.744 . . . . 1.32 109.146 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -156.96 74.54 4.47 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.317 -0.864 . . . . 1.45 109.224 -179.685 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -62.44 166.93 12.19 Favored 'Trans proline' 0 C--N 1.318 -1.049 0 C-N-CA 121.269 1.313 . . . . 1.5 109.747 -179.264 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 20' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -58.46 150.21 69.78 Favored 'Trans proline' 0 C--N 1.318 -1.053 0 C-N-CA 121.517 1.478 . . . . 2.86 109.917 179.834 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 21' ' ' ARG . . . . . 0.417 ' HG2' HH11 ' B' ' 21' ' ' ARG . 0.3 OUTLIER -82.21 84.88 6.93 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.27 -0.894 . . . . 6.12 108.693 179.782 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 22' ' ' ARG . . . . . 0.417 HH11 ' CG ' ' B' ' 22' ' ' ARG . 0.5 OUTLIER -46.88 -51.89 15.67 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.302 -0.874 . . . . 6.29 109.707 -179.859 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 48.4 t0 52.61 -115.91 0.98 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.213 -0.929 . . . . 5.62 109.471 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 35.9 m . . . . . 0 N--CA 1.49 1.552 0 CA-C-O 118.025 -0.988 . . . . 6.48 109.435 179.993 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.595 ' C ' HD12 ' A' ' 2' ' ' ILE . . . . . . . . 1 N--CA 1.53 4.928 0 N-CA-C 119.763 2.665 . . . . 6.64 119.763 . . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.679 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 1.5 mp -149.45 41.33 0.23 Allowed Pre-proline 0 C--N 1.311 -1.105 0 N-CA-C 107.751 -1.203 . . . . 7.08 107.751 178.382 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.847 ' C ' ' H ' ' A' ' 5' ' ' PHE . 1.3 Cg_endo -54.63 -79.54 0.02 OUTLIER 'Trans proline' 0 C--N 1.32 -0.956 0 N-CA-C 108.449 -1.404 . . . . 5.5 108.449 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.527 ' C ' ' H ' ' A' ' 6' ' ' PHE . 6.6 tt0 73.56 -20.65 0.29 Allowed 'General case' 0 N--CA 1.496 1.832 0 N-CA-C 104.379 -2.452 . . . . 6.75 104.379 -176.106 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' PHE . . . . . 0.847 ' H ' ' C ' ' A' ' 3' ' ' PRO . 5.7 m-85 -87.54 17.66 4.44 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 104.298 -2.482 . . . . 6.07 104.298 176.718 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.534 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 38.7 p90 45.6 -153.15 0.05 OUTLIER 'General case' 0 C--N 1.308 -1.218 0 CA-C-N 114.513 -1.221 . . . . 4.72 109.478 -177.684 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.443 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 0.1 OUTLIER 82.97 -9.8 1.07 Allowed 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 104.973 -2.232 . . . . 4.4 104.973 -177.221 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.496 ' H ' ' C ' ' A' ' 6' ' ' PHE . 68.8 t80 -150.24 -37.59 0.15 Allowed 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 107.858 -1.164 . . . . 5.15 107.858 178.226 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.402 HG22 ' O ' ' A' ' 9' ' ' THR . 38.2 m -93.63 3.26 55.78 Favored 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 105.731 -1.951 . . . . 5.13 105.731 177.256 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.556 HG13 ' N ' ' A' ' 11' ' ' GLY . 13.0 p -46.44 -45.34 6.57 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.31 0 CA-C-N 115.508 -0.769 . . . . 4.38 109.32 -179.555 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.654 ' O ' HD23 ' A' ' 13' ' ' LEU . . . 135.7 -84.65 0.26 Allowed Glycine 0 N--CA 1.497 2.746 0 N-CA-C 108.92 -1.672 . . . . 4.22 108.92 179.616 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.431 ' O ' ' N ' ' A' ' 14' ' ' GLY . 13.3 Cg_endo -69.05 35.8 0.2 Allowed 'Trans proline' 0 C--N 1.321 -0.883 0 C-N-CA 121.587 1.525 . . . . 3.85 109.178 178.538 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.886 ' N ' HD23 ' A' ' 13' ' ' LEU . 0.0 OUTLIER 42.36 27.48 0.08 Allowed 'General case' 0 N--CA 1.501 2.109 0 N-CA-C 108.596 -0.89 . . . . 3.67 108.596 -178.731 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.536 ' C ' ' H ' ' A' ' 16' ' ' GLY . . . 71.95 -42.6 0.76 Allowed Glycine 0 N--CA 1.488 2.157 0 N-CA-C 108.622 -1.791 . . . . 2.97 108.622 -179.386 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.596 ' HB3' ' HB3' ' A' ' 18' ' ' ALA . 18.6 tp10 52.2 7.49 0.06 Allowed 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.579 -0.954 . . . . 2.97 109.237 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.536 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 55.99 118.29 0.01 OUTLIER Glycine 0 N--CA 1.489 2.217 0 O-C-N 121.3 -0.875 . . . . 2.44 111.605 178.899 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.523 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 74.05 -56.06 2.27 Favored Glycine 0 N--CA 1.493 2.451 0 N-CA-C 110.487 -1.045 . . . . 1.81 110.487 178.614 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.871 ' HB2' ' OE1' ' A' ' 94' ' ' GLU . . . -49.82 -9.22 0.04 OUTLIER 'General case' 0 C--N 1.294 -1.828 0 O-C-N 121.243 -1.151 . . . . 2.21 109.6 -179.624 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' HIS . . . . . 0.523 ' N ' ' O ' ' A' ' 17' ' ' GLY . 15.2 t-80 -94.91 -8.9 35.79 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.085 -1.009 . . . . 2.87 110.475 -179.456 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.502 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.0 OUTLIER -134.24 1.79 3.24 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.078 -1.014 . . . . 2.02 110.2 -179.685 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 68.7 t -88.07 113.43 25.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 120.92 -1.113 . . . . 2.07 109.637 179.767 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 6.2 tpt180 -97.8 132.9 42.99 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.577 -0.702 . . . . 3.5 109.126 179.808 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -139.28 113.92 9.18 Favored 'General case' 0 N--CA 1.494 1.751 0 N-CA-C 108.582 -0.896 . . . . 1.83 108.582 179.771 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -156.64 129.22 2.37 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.849 -1.3 . . . . 1.9 109.849 -179.448 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.94 -179.82 48.73 Favored Glycine 0 N--CA 1.488 2.127 0 C-N-CA 119.512 -1.328 . . . . 1.85 110.052 179.876 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 10.9 p -80.61 -15.96 55.29 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.397 -1.061 . . . . 2.31 109.451 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -76.89 -8.42 86.64 Favored Glycine 0 N--CA 1.487 2.074 0 N-CA-C 109.532 -1.427 . . . . 1.64 109.532 -179.733 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.48 HD21 ' CD2' ' A' ' 39' ' ' PHE . 28.5 mt -100.26 -0.67 38.12 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.373 -1.075 . . . . 1.83 109.076 179.692 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -102.18 -44.56 5.4 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.519 -0.738 . . . . 2.34 109.565 -179.681 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 18.1 ptt180 -176.81 172.58 2.05 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.006 -1.059 . . . . 3.77 110.119 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -143.45 174.72 23.84 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 107.842 -2.103 . . . . 1.57 107.842 179.272 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 35.2 t -134.05 149.79 30.7 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.092 0 O-C-N 121.1 -1.235 . . . . 1.83 110.375 -179.842 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.544 ' HB2' ' HD3' ' A' ' 82' ' ' PRO . . . -41.47 114.17 0.48 Allowed 'General case' 0 N--CA 1.498 1.933 0 CA-C-O 121.804 0.812 . . . . 1.64 112.593 -179.128 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 57.18 47.3 88.74 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 111.552 -0.619 . . . . 1.73 111.552 176.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 25.5 t -127.23 113.53 21.54 Favored Pre-proline 0 N--CA 1.498 1.966 0 O-C-N 121.458 -1.024 . . . . 2.19 108.756 179.116 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -59.93 126.51 20.57 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 N-CA-C 109.944 -0.829 . . . . 1.96 109.944 -179.756 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.409 ' HB3' ' CZ ' ' A' ' 77' ' ' TYR . . . -127.58 174.56 8.96 Favored 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 108.182 -1.044 . . . . 1.69 108.182 179.597 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -163.09 171.28 16.63 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.838 -1.164 . . . . 2.23 110.961 -179.789 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.63 ' CE2' HD11 ' A' ' 41' ' ' ILE . 5.8 p90 -155.9 167.75 29.4 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 107.707 -1.22 . . . . 1.54 107.707 178.568 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 14.6 m -101.67 150.14 23.42 Favored 'General case' 0 N--CA 1.495 1.821 0 CA-C-O 121.803 0.811 . . . . 2.37 111.147 -178.1 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.657 HD12 HG21 ' A' ' 75' ' ' VAL . 11.8 mt -141.12 88.55 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 N-CA-C 108.436 -0.95 . . . . 1.65 108.436 178.774 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.459 ' HE1' ' CG ' ' A' ' 44' ' ' ARG . 5.6 t90 -90.77 132.99 35.52 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.105 -0.997 . . . . 3.68 108.788 -179.804 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.502 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.8 OUTLIER -160.94 128.53 4.28 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.22 -0.925 . . . . 2.89 109.949 -179.436 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 44' ' ' ARG . . . . . 0.459 ' CG ' ' HE1' ' A' ' 42' ' ' TRP . 1.8 ptp180 -178.39 77.27 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.278 -0.889 . . . . 4.63 109.612 179.6 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.469 ' H ' ' HZ3' ' A' ' 20' ' ' LYS . 26.0 tt0 -158.6 -52.32 0.06 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.187 -0.946 . . . . 2.89 109.498 179.796 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -60.79 -49.99 75.24 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.04 -1.038 . . . . 1.74 109.008 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 148.85 160.92 9.36 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.448 -1.461 . . . . 1.6 109.448 179.807 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.79 161.23 1.18 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.196 -1.179 . . . . 1.4 109.386 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -174.42 -128.88 1.12 Allowed Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.827 -1.309 . . . . 1.04 109.827 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -157.69 126.22 1.69 Allowed Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.58 -1.408 . . . . 1.06 109.58 -179.828 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 11.7 tp -97.97 100.53 11.87 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.294 -1.121 . . . . 1.1 109.078 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' SER . . . . . 0.403 ' HA ' ' CD2' ' B' ' 14' ' ' PHE . 2.0 t -88.36 142.72 27.5 Favored 'General case' 0 C--O 1.211 -0.947 0 N-CA-C 108.667 -0.864 . . . . 1.56 108.667 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.522 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 93.5 mt -134.08 106.97 9.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 O-C-N 121.025 -1.047 . . . . 0.65 109.764 -179.568 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -96.34 106.06 18.23 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.315 -0.995 . . . . 0.69 108.315 179.183 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.429 HG23 ' CB ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -94.52 144.57 9.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.421 -0.799 . . . . 0.91 109.676 -179.445 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 16.6 tt0 -141.1 145.16 35.44 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 107.529 -1.286 . . . . 1.8 107.529 178.738 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.428 ' O ' ' O ' ' B' ' 9' ' ' VAL . . . 163.14 -171.08 38.81 Favored Glycine 0 N--CA 1.489 2.196 0 C-N-CA 119.554 -1.308 . . . . 0.49 109.854 -179.065 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -62.68 -29.85 77.96 Favored 'Trans proline' 0 C--N 1.318 -1.063 0 C-N-CA 122.224 1.949 . . . . 0.66 112.386 -179.289 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 8.7 t -142.36 160.0 41.12 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 120.891 -1.131 . . . . 1.55 110.138 -179.643 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 80.5 mttt -78.33 109.53 12.55 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.498 -0.751 . . . . 2.53 109.204 179.796 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -76.46 142.37 41.01 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.258 -0.902 . . . . 0.82 109.588 -179.829 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.847 ' C ' HD12 ' A' ' 63' ' ' ILE . 20.6 tt0 -81.39 172.62 13.33 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.319 -0.863 . . . . 2.3 108.78 179.778 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.847 HD12 ' C ' ' A' ' 62' ' ' GLU . 3.2 mp -140.17 154.4 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 N-CA-C 108.309 -0.997 . . . . 1.4 108.309 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.55 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -151.07 114.88 4.95 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.758 -1.214 . . . . 1.36 109.538 -179.845 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.528 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 44.0 p90 -93.55 120.21 33.55 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.19 -0.944 . . . . 1.47 109.469 179.724 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 54.2 tt0 -141.51 103.22 4.35 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.234 -0.916 . . . . 2.51 109.611 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.431 ' OD1' ' N ' ' A' ' 67' ' ' ASP . 20.6 p-10 -85.39 102.61 13.57 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.238 -0.914 . . . . 2.07 109.149 179.696 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 2.5 ptp180 -101.46 5.96 42.21 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.335 -0.853 . . . . 4.63 109.537 -179.725 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.489 ' HB2' ' H ' ' A' ' 72' ' ' SER . 64.5 mmtt -118.25 -3.24 11.04 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.42 -0.8 . . . . 3.49 109.095 179.581 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 4.7 t70 68.56 3.3 3.77 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.351 -0.843 . . . . 3.06 109.406 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -150.61 -34.34 0.04 OUTLIER Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.919 -1.272 . . . . 2.16 109.919 -178.931 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.489 ' H ' ' HB2' ' A' ' 69' ' ' LYS . 5.8 m -95.39 125.36 39.95 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.235 -1.156 . . . . 2.2 108.85 179.58 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 15.1 t -88.02 126.63 35.18 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.151 -0.968 . . . . 2.05 109.773 -179.521 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -105.13 118.34 5.84 Favored Glycine 0 N--CA 1.498 2.831 0 N-CA-C 109.576 -1.41 . . . . 1.39 109.576 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.657 HG21 HD12 ' A' ' 41' ' ' ILE . 21.9 t -105.88 106.08 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.141 0 O-C-N 121.476 -1.014 . . . . 1.57 109.423 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.55 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.3 OUTLIER -96.17 139.21 32.66 Favored 'General case' 0 N--CA 1.493 1.676 0 N-CA-C 108.988 -0.745 . . . . 1.85 108.988 179.828 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.409 ' CZ ' ' HB3' ' A' ' 37' ' ' ALA . 41.9 p90 -138.07 173.3 11.77 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.294 -0.879 . . . . 1.54 109.262 -179.636 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.552 ' O ' HG13 ' A' ' 78' ' ' VAL . 8.9 p -138.69 120.01 16.53 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.246 0 O-C-N 121.372 -0.83 . . . . 1.9 109.969 179.56 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.441 HG22 ' H ' ' A' ' 79' ' ' VAL . 5.7 m -89.57 163.08 2.43 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.387 -0.82 . . . . 1.27 108.984 179.72 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 7.0 tp-100 -104.4 -47.6 4.06 Favored 'General case' 0 N--CA 1.501 2.077 0 O-C-N 121.199 -0.938 . . . . 2.48 111.103 -178.929 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -156.52 153.27 24.49 Favored Pre-proline 0 N--CA 1.503 2.194 0 O-C-N 120.641 -1.287 . . . . 1.92 111.106 -178.799 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.641 ' HG3' ' N ' ' A' ' 107' ' ' SER . 73.0 Cg_exo -37.63 158.68 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 123.267 2.644 . . . . 1.3 113.609 179.268 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 148.15 -163.45 28.9 Favored Glycine 0 N--CA 1.493 2.441 0 N-CA-C 109.662 -1.375 . . . . 1.02 109.662 179.606 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 46.6 m-20 -110.66 88.63 2.82 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.615 -0.932 . . . . 2.13 108.984 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.508 ' O ' ' N ' ' A' ' 103' ' ' VAL . 2.8 m-85 -76.16 129.69 37.14 Favored 'General case' 0 C--N 1.303 -1.414 0 N-CA-C 107.998 -1.112 . . . . 0.92 107.998 179.708 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -109.23 128.01 54.71 Favored 'General case' 0 N--CA 1.5 2.069 0 N-CA-C 108.35 -0.981 . . . . 1.53 108.35 -179.52 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 9.9 p -123.91 133.56 68.93 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.713 -0.617 . . . . 1.0 109.767 -179.295 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 6.6 m -123.84 95.05 4.42 Favored 'General case' 0 N--CA 1.497 1.886 0 CA-C-O 121.393 0.616 . . . . 1.59 109.54 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.415 ' H ' ' HB3' ' A' ' 99' ' ' SER . 1.2 pt -101.26 134.48 41.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.643 -0.661 . . . . 1.29 109.797 -179.775 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 90' ' ' LYS . . . . . 0.468 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.1 OUTLIER -140.32 121.98 15.28 Favored 'General case' 0 N--CA 1.485 1.296 0 N-CA-C 108.712 -0.847 . . . . 1.58 108.712 179.746 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 79.9 t80 -81.09 100.03 8.81 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 107.665 -1.235 . . . . 1.34 107.665 178.514 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' ASN . . . . . 0.438 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 26.8 t30 69.81 36.42 2.07 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.448 -0.782 . . . . 2.32 109.362 -178.809 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.438 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 0.7 OUTLIER 79.92 14.32 0.92 Allowed 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.688 -0.633 . . . . 1.92 111.554 179.42 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 94' ' ' GLU . . . . . 0.871 ' OE1' ' HB2' ' A' ' 18' ' ' ALA . 0.5 OUTLIER -100.94 95.53 6.66 Favored 'General case' 0 N--CA 1.499 1.98 0 N-CA-C 107.239 -1.393 . . . . 2.25 107.239 177.892 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 95' ' ' HIS . . . . . 0.461 ' O ' ' CG ' ' A' ' 95' ' ' HIS . 0.0 OUTLIER -66.58 110.55 3.22 Favored 'General case' 0 N--CA 1.488 1.466 0 CA-C-O 121.697 0.76 . . . . 2.88 111.177 -177.773 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 96' ' ' ILE . . . . . 0.536 ' O ' ' N ' ' A' ' 98' ' ' ASP . 5.5 mm -50.61 137.22 24.34 Favored Pre-proline 0 N--CA 1.492 1.671 0 N-CA-C 107.621 -1.251 . . . . 2.35 107.621 178.576 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -44.39 -16.75 0.12 Allowed 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 120.68 0.92 . . . . 2.48 109.844 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 96' ' ' ILE . 42.9 m-20 -76.92 -66.56 0.8 Allowed 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 108.517 -0.92 . . . . 2.65 108.517 178.277 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.415 ' HB3' ' H ' ' A' ' 89' ' ' ILE . 0.2 OUTLIER -57.34 144.02 72.09 Favored Pre-proline 0 C--N 1.297 -1.702 0 O-C-N 121.622 -0.674 . . . . 2.0 109.801 -178.106 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -83.82 110.36 1.79 Allowed 'Cis proline' 0 N--CA 1.491 1.339 0 N-CA-C 109.71 -0.919 . . . . 1.79 109.71 -2.129 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 47.3 p90 -108.87 166.98 10.41 Favored 'General case' 0 N--CA 1.515 2.794 0 O-C-N 120.51 -1.369 . . . . 2.19 110.035 179.109 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.3 p -94.39 153.13 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.518 -0.739 . . . . 1.44 110.758 -178.777 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.508 ' N ' ' O ' ' A' ' 85' ' ' TYR . 70.3 t -127.62 86.21 58.96 Favored Pre-proline 0 N--CA 1.499 1.986 0 N-CA-C 107.863 -1.162 . . . . 1.19 107.863 179.395 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -62.4 113.45 1.93 Allowed 'Trans proline' 0 C--N 1.318 -1.036 0 C-N-CA 121.288 1.325 . . . . 1.49 111.979 -177.82 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 42.7 t -90.4 141.68 14.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 N-CA-C 106.88 -1.526 . . . . 1.35 106.88 177.766 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.726 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -121.65 127.67 51.06 Favored 'General case' 0 N--CA 1.505 2.322 0 CA-C-O 121.664 0.745 . . . . 1.67 111.607 -177.033 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.641 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 7.8 t -88.69 77.76 7.84 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 120.365 -1.459 . . . . 2.04 107.484 178.97 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 108' ' ' LEU . . . . . 0.442 ' CB ' ' O ' ' A' ' 107' ' ' SER . 0.9 OUTLIER 72.66 -7.81 1.35 Allowed 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 107.307 -1.368 . . . . 3.2 107.307 -178.288 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.503 ' H ' ' C ' ' A' ' 107' ' ' SER . 3.0 m -78.11 -21.59 50.18 Favored 'General case' 0 N--CA 1.486 1.335 0 N-CA-C 108.602 -0.888 . . . . 2.09 108.602 178.993 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 110' ' ' ASP . . . . . 0.726 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 1.4 m-20 50.93 10.42 0.07 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.359 -0.838 . . . . 2.85 109.23 179.353 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.489 ' N ' ' C ' ' A' ' 109' ' ' SER . 0.8 OUTLIER -177.99 -21.47 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.482 -0.761 . . . . 2.46 110.438 -179.85 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.491 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 51.56 75.23 0.21 Allowed 'General case' 0 N--CA 1.496 1.871 0 O-C-N 120.373 -1.454 . . . . 2.08 108.631 -179.311 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 113' ' ' ARG . . . . . 0.433 ' O ' ' O ' ' A' ' 112' ' ' ALA . 1.0 OUTLIER -53.26 -170.72 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.374 -0.829 . . . . 5.93 110.04 -178.909 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.525 HH11 ' HG2' ' A' ' 114' ' ' ARG . 2.4 ttt-85 -132.36 2.52 3.87 Favored 'General case' 0 N--CA 1.492 1.659 0 N-CA-C 107.86 -1.163 . . . . 5.61 107.86 179.514 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 34.8 mt -128.49 -27.71 2.61 Favored 'General case' 0 N--CA 1.501 2.082 0 N-CA-C 109.188 -0.671 . . . . 4.39 109.188 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.504 ' C ' ' H ' ' A' ' 118' ' ' THR . 1.1 p -103.27 -80.37 0.52 Allowed 'General case' 0 N--CA 1.492 1.636 0 N-CA-C 106.859 -1.534 . . . . 4.09 106.859 179.082 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.44 ' O ' HG12 ' A' ' 117' ' ' VAL . 56.0 t -61.19 -8.81 2.19 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.718 0 N-CA-C 106.156 -1.794 . . . . 2.9 106.156 176.858 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 118' ' ' THR . . . . . 0.504 ' H ' ' C ' ' A' ' 116' ' ' THR . 4.5 t 36.54 61.01 0.87 Allowed 'General case' 0 N--CA 1.487 1.387 0 CA-C-O 122.019 0.914 . . . . 3.36 110.775 179.656 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 119' ' ' SER . . . . . 0.443 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.6 p . . . . . 0 C--N 1.303 -1.436 0 CA-C-O 117.954 -1.022 . . . . 3.39 109.577 179.349 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 21.7 mmt . . . . . 0 N--CA 1.49 1.57 0 N-CA-C 109.523 -0.547 . . . . 8.49 109.523 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -58.37 120.96 9.69 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.315 -0.866 . . . . 5.53 109.52 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 3' ' ' SER . . . . . . . . . . . . . 51.3 m -160.59 -52.17 0.05 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.233 -0.917 . . . . 5.43 109.412 179.858 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 4' ' ' LYS . . . . . . . . . . . . . 16.7 pttm -173.83 66.71 0.32 Allowed Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.21 -0.931 . . . . 6.87 109.756 179.885 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 5' ' ' PRO . . . . . . . . . . . . . 2.3 Cg_endo -61.99 100.12 0.2 Allowed 'Trans proline' 0 C--N 1.318 -1.041 0 C-N-CA 121.315 1.344 . . . . 5.16 109.658 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 6' ' ' GLU . . . . . 0.443 ' O ' ' C ' ' B' ' 7' ' ' LYS . 19.1 mt-10 -84.31 -153.46 0.15 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.307 -0.871 . . . . 4.78 109.935 -179.685 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 7' ' ' LYS . . . . . 0.443 ' C ' ' O ' ' B' ' 6' ' ' GLU . 13.4 pttm 31.86 79.36 0.03 OUTLIER 'General case' 0 N--CA 1.501 2.087 0 CA-C-O 121.268 0.556 . . . . 4.09 111.433 179.836 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.531 ' CG ' HH11 ' B' ' 8' ' ' ARG . 2.2 mtt-85 -86.78 157.95 19.49 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.003 -1.11 . . . . 3.04 108.003 178.897 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 9' ' ' VAL . . . . . 0.428 ' O ' ' O ' ' A' ' 57' ' ' GLY . 22.9 t -48.3 159.3 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.021 -1.049 . . . . 0.67 108.671 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -123.89 153.74 40.69 Favored 'General case' 0 N--CA 1.501 2.111 0 O-C-N 121.369 -0.832 . . . . 0.58 110.257 -178.89 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 11' ' ' SER . . . . . 0.429 ' CB ' HG23 ' A' ' 55' ' ' VAL . 2.7 t -148.66 147.12 28.56 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.498 -0.751 . . . . 1.19 109.235 179.773 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 28.5 p -145.89 126.77 14.47 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.164 -0.96 . . . . 1.38 110.064 -179.628 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 0.656 HG22 ' N ' ' B' ' 14' ' ' PHE . 7.2 p -172.18 174.8 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 N-CA-C 108.497 -0.927 . . . . 0.42 108.497 179.731 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 14' ' ' PHE . . . . . 0.656 ' N ' HG22 ' B' ' 13' ' ' VAL . 0.1 OUTLIER 174.41 -166.23 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.563 0 C-N-CA 118.779 -1.168 . . . . 1.79 111.864 -179.979 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 5.8 pt -137.58 139.49 43.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 N-CA-C 108.981 -0.748 . . . . 1.25 108.981 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 80.7 p -94.26 131.19 40.12 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.101 -0.999 . . . . 1.61 109.785 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.597 HD22 ' N ' ' B' ' 17' ' ' LEU . 3.5 mm? -92.98 107.31 19.12 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.294 -0.879 . . . . 1.32 108.891 179.615 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -155.45 89.1 3.01 Favored Pre-proline 0 N--CA 1.492 1.667 0 O-C-N 121.34 -0.85 . . . . 1.45 109.227 -179.49 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -59.38 166.49 7.56 Favored 'Trans proline' 0 CA--C 1.543 0.974 0 C-N-CA 120.954 1.103 . . . . 1.5 109.83 -179.176 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 20' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -59.67 -80.49 0.01 OUTLIER 'Trans proline' 0 C--N 1.319 -0.975 0 C-N-CA 121.56 1.506 . . . . 2.86 110.303 -179.72 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 21' ' ' ARG . . . . . 0.421 ' HD3' ' H ' ' B' ' 21' ' ' ARG . 0.0 OUTLIER -59.28 166.95 1.99 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.194 -0.941 . . . . 6.12 109.846 -179.439 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 22' ' ' ARG . . . . . 0.436 ' HG3' HH11 ' B' ' 22' ' ' ARG . 15.2 mmm-85 -69.79 -122.51 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.416 -0.803 . . . . 6.29 109.15 179.87 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 23' ' ' ASP . . . . . 0.434 ' CG ' ' H ' ' B' ' 24' ' ' VAL . 1.2 p-10 -144.74 -89.31 0.11 Allowed 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.02 -1.05 . . . . 5.62 109.397 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 24' ' ' VAL . . . . . 0.434 ' H ' ' CG ' ' B' ' 23' ' ' ASP . 13.3 t . . . . . 0 N--CA 1.489 1.516 0 CA-C-O 118.002 -0.999 . . . . 6.48 109.485 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.531 4.99 0 N-CA-C 119.758 2.663 . . . . 6.64 119.758 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.614 HG23 ' O ' ' A' ' 2' ' ' ILE . 3.6 tp -171.36 49.98 0.13 Allowed Pre-proline 0 C--N 1.306 -1.314 0 O-C-N 121.336 -1.097 . . . . 7.08 108.249 179.537 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.824 ' C ' ' H ' ' A' ' 5' ' ' PHE . 2.7 Cg_endo -51.74 -77.8 0.02 OUTLIER 'Trans proline' 0 C--N 1.319 -1.021 0 N-CA-C 109.02 -1.185 . . . . 5.5 109.02 179.488 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.513 ' C ' ' H ' ' A' ' 6' ' ' PHE . 0.3 OUTLIER 73.7 -16.23 0.52 Allowed 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 104.234 -2.506 . . . . 6.75 104.234 -175.732 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 5' ' ' PHE . . . . . 0.824 ' H ' ' C ' ' A' ' 3' ' ' PRO . 3.3 m-85 -89.78 17.74 6.3 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 103.822 -2.659 . . . . 6.07 103.822 176.817 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.531 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 42.8 p90 45.88 -155.76 0.04 OUTLIER 'General case' 0 C--N 1.306 -1.288 0 CA-C-N 114.17 -1.377 . . . . 4.72 109.686 -177.677 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.522 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 28.7 tp60 84.02 -8.74 1.0 Allowed 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 104.927 -2.249 . . . . 4.4 104.927 -177.09 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.45 ' H ' ' C ' ' A' ' 6' ' ' PHE . 66.8 t80 -154.83 -37.01 0.09 Allowed 'General case' 0 C--N 1.304 -1.376 0 CA-C-N 114.512 -1.222 . . . . 5.15 107.912 178.439 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.404 ' O ' ' C ' ' A' ' 10' ' ' VAL . 15.0 m -91.11 2.28 56.46 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 106.009 -1.849 . . . . 5.13 106.009 177.355 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.434 HG13 ' N ' ' A' ' 11' ' ' GLY . 7.2 p -41.11 -37.6 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 CA-C-O 121.773 0.796 . . . . 4.38 109.507 -179.828 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.659 ' O ' HD23 ' A' ' 13' ' ' LEU . . . 144.93 -86.58 0.18 Allowed Glycine 0 N--CA 1.496 2.685 0 N-CA-C 109.0 -1.64 . . . . 4.22 109.0 179.511 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.467 ' O ' ' N ' ' A' ' 14' ' ' GLY . 13.3 Cg_endo -68.93 36.18 0.2 Allowed 'Trans proline' 0 N--CA 1.482 0.82 0 C-N-CA 121.546 1.497 . . . . 3.85 109.225 178.666 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.874 ' N ' HD23 ' A' ' 13' ' ' LEU . 0.0 OUTLIER 43.1 24.17 0.04 OUTLIER 'General case' 0 N--CA 1.5 2.028 0 CA-C-O 121.846 0.831 . . . . 3.67 108.836 -178.823 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.612 ' O ' ' HB3' ' A' ' 18' ' ' ALA . . . 69.94 -39.08 0.41 Allowed Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.273 -1.531 . . . . 2.97 109.273 -179.831 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.521 ' H ' ' C ' ' A' ' 13' ' ' LEU . 24.7 tt0 47.77 15.08 0.05 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.352 -1.087 . . . . 2.97 108.83 -179.394 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.507 ' N ' ' O ' ' A' ' 14' ' ' GLY . . . 65.76 115.19 0.01 OUTLIER Glycine 0 N--CA 1.487 2.047 0 N-CA-C 110.082 -1.207 . . . . 2.44 110.082 179.695 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.567 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 91.88 -53.38 2.95 Favored Glycine 0 N--CA 1.494 2.542 0 N-CA-C 110.213 -1.155 . . . . 1.81 110.213 179.444 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.632 ' HB2' ' OE1' ' A' ' 94' ' ' GLU . . . -41.49 -18.22 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.84 -0.8 . . . . 2.21 110.463 -178.993 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' HIS . . . . . 0.567 ' N ' ' O ' ' A' ' 17' ' ' GLY . 11.0 t60 -85.39 -40.69 16.19 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.281 -0.887 . . . . 2.87 109.99 -179.456 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.599 ' HG2' ' HB2' ' A' ' 46' ' ' ALA . 0.0 OUTLIER -99.78 -29.04 12.85 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.099 -1.001 . . . . 2.02 110.584 -179.173 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 84.0 t -51.58 112.1 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.004 -1.06 . . . . 2.07 109.869 -179.608 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 3.9 tpt180 -119.15 136.43 54.18 Favored 'General case' 0 N--CA 1.495 1.792 0 N-CA-C 109.284 -0.635 . . . . 3.5 109.284 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -144.58 113.87 7.01 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.461 -0.775 . . . . 1.83 108.933 179.677 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -149.25 123.83 1.69 Allowed Glycine 0 N--CA 1.495 2.586 0 N-CA-C 110.137 -1.185 . . . . 1.9 110.137 -179.424 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.81 177.77 48.27 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.904 -1.279 . . . . 1.85 109.904 179.567 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 11.0 m -76.81 -12.62 60.0 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.291 -1.123 . . . . 2.31 109.958 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -67.68 -16.68 68.16 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 108.417 -1.873 . . . . 1.64 108.417 179.599 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.434 HD21 ' CD2' ' A' ' 39' ' ' PHE . 18.1 mt -92.92 -10.31 36.96 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.783 -0.833 . . . . 1.83 109.022 179.722 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 47.3 mm-40 -83.61 -55.23 4.4 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.491 -0.755 . . . . 2.34 110.056 -179.264 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 4.9 ptp180 -176.36 -177.59 0.87 Allowed 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.036 -1.04 . . . . 3.77 109.879 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -145.13 174.53 25.14 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 108.649 -1.78 . . . . 1.57 108.649 179.664 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 30.3 t -134.39 149.73 30.18 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.947 0 O-C-N 121.285 -1.126 . . . . 1.83 110.159 -179.779 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.516 ' HB2' ' HD3' ' A' ' 82' ' ' PRO . . . -40.5 112.19 0.26 Allowed 'General case' 0 N--CA 1.496 1.83 0 CA-C-O 121.499 0.666 . . . . 1.64 112.515 -178.887 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 58.82 47.16 91.9 Favored Glycine 0 N--CA 1.492 2.391 0 O-C-N 121.514 -0.741 . . . . 1.73 111.569 177.117 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 23.6 t -127.45 124.84 23.74 Favored Pre-proline 0 N--CA 1.499 1.988 0 O-C-N 121.417 -1.049 . . . . 2.19 108.417 179.031 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_exo -58.39 114.77 2.13 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 N-CA-C 109.99 -0.811 . . . . 1.96 109.99 -179.828 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.423 ' HB3' ' CE2' ' A' ' 77' ' ' TYR . . . -107.64 155.45 20.14 Favored 'General case' 0 N--CA 1.495 1.789 0 N-CA-C 107.803 -1.184 . . . . 1.69 107.803 179.176 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -164.51 169.85 16.63 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 118.431 -1.308 . . . . 2.23 111.41 -179.405 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.61 ' CE2' HD11 ' A' ' 41' ' ' ILE . 4.6 p90 -154.66 171.03 20.16 Favored 'General case' 0 C--N 1.298 -1.669 0 N-CA-C 107.705 -1.22 . . . . 1.54 107.705 178.008 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 83.6 p -100.59 150.99 22.13 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.575 -0.703 . . . . 2.37 110.599 -178.389 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.61 HD11 ' CE2' ' A' ' 39' ' ' PHE . 11.6 mt -143.6 104.71 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 N-CA-C 108.712 -0.847 . . . . 1.65 108.712 178.937 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.526 ' CG ' ' N ' ' A' ' 43' ' ' THR . 0.7 OUTLIER -102.62 166.45 10.5 Favored 'General case' 0 N--CA 1.497 1.911 0 N-CA-C 108.33 -0.989 . . . . 3.68 108.33 179.854 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.526 ' N ' ' CG ' ' A' ' 42' ' ' TRP . 35.0 p -153.6 131.49 11.68 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.146 -0.971 . . . . 2.89 109.827 -179.616 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' ARG . . . . . 0.475 ' H ' ' HB2' ' A' ' 20' ' ' LYS . 32.5 ttm180 -72.58 -86.3 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.243 -0.91 . . . . 4.63 109.43 179.847 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 24.9 tt0 -172.17 63.35 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.809 -1.182 . . . . 2.89 110.935 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.599 ' HB2' ' HG2' ' A' ' 20' ' ' LYS . . . -71.24 -52.0 21.45 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 120.73 -1.231 . . . . 1.74 108.584 178.823 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 155.39 169.62 20.02 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.487 -1.445 . . . . 1.6 109.487 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.8 143.98 19.53 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.215 -1.168 . . . . 1.4 109.371 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -163.72 -168.35 25.6 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.522 -1.431 . . . . 1.04 109.522 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -137.68 117.37 1.48 Allowed Glycine 0 N--CA 1.496 2.666 0 N-CA-C 109.261 -1.536 . . . . 1.06 109.261 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.463 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 9.7 tp -87.53 99.23 11.88 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.283 -1.128 . . . . 1.1 108.597 179.758 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 12.8 m -84.01 141.13 31.42 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 108.834 -0.802 . . . . 1.56 108.834 -179.887 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.512 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 72.6 mt -130.37 111.5 21.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.357 -0.839 . . . . 0.65 109.36 -179.891 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -100.85 106.98 18.41 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.374 -0.829 . . . . 0.69 108.938 179.724 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.428 ' O ' ' O ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -103.93 135.44 41.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 121.573 -0.704 . . . . 0.91 109.323 -179.771 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 27.3 tt0 -137.96 140.53 40.28 Favored 'General case' 0 N--CA 1.494 1.736 0 N-CA-C 108.024 -1.102 . . . . 1.8 108.024 179.092 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 168.47 -172.15 42.88 Favored Glycine 0 N--CA 1.487 2.092 0 N-CA-C 109.407 -1.477 . . . . 0.49 109.407 -179.271 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -62.87 -30.9 77.8 Favored 'Trans proline' 0 C--N 1.316 -1.16 0 C-N-CA 121.873 1.715 . . . . 0.66 111.584 -179.621 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.8 t -137.64 157.24 46.93 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.153 -0.967 . . . . 1.55 110.278 -179.488 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.436 ' O ' ' OE2' ' A' ' 62' ' ' GLU . 31.5 mtpt -80.65 123.37 28.11 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 109.09 -0.707 . . . . 2.53 109.09 179.728 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -85.79 144.29 27.82 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.162 -0.961 . . . . 0.82 109.318 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.482 ' CD ' ' N ' ' A' ' 62' ' ' GLU . 9.0 mp0 -96.76 100.52 12.07 Favored 'General case' 0 N--CA 1.502 2.137 0 O-C-N 121.048 -1.032 . . . . 2.3 110.619 -179.476 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.47 HD12 ' N ' ' A' ' 63' ' ' ILE . 1.7 mp -62.51 156.12 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 N-CA-C 108.673 -0.862 . . . . 1.4 108.673 178.721 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.524 ' HB3' ' OG ' ' A' ' 76' ' ' SER . . . -140.97 175.01 9.97 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.122 -0.987 . . . . 1.36 109.237 179.782 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.513 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 32.3 p90 -147.08 116.25 6.94 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.317 -0.864 . . . . 1.47 109.407 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 69.8 tt0 -141.38 127.6 19.72 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.287 -0.883 . . . . 2.51 109.515 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.468 ' N ' ' OD1' ' A' ' 67' ' ' ASP . 22.2 p-10 -81.69 120.1 24.67 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.263 -0.898 . . . . 2.07 109.402 179.903 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.599 ' CG ' HH11 ' A' ' 68' ' ' ARG . 0.1 OUTLIER -100.09 -23.24 14.92 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.303 -0.873 . . . . 4.63 109.748 -179.828 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.514 ' C ' ' H ' ' A' ' 71' ' ' GLY . 23.3 mmtp -125.15 7.9 7.91 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.511 -0.743 . . . . 3.49 109.283 -179.669 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.428 ' CB ' ' O ' ' A' ' 69' ' ' LYS . 1.5 t70 70.83 -12.68 0.54 Allowed 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.371 -0.831 . . . . 3.06 108.797 -179.439 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' GLY . . . . . 0.514 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -127.01 -26.79 1.07 Allowed Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.406 -1.478 . . . . 2.16 109.406 -179.341 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 28.9 t -95.58 134.37 38.53 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.237 -1.155 . . . . 2.2 108.782 179.465 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 37.9 t -93.39 126.42 38.52 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.148 -0.97 . . . . 2.05 109.644 -179.708 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -102.35 120.48 6.84 Favored Glycine 0 N--CA 1.497 2.755 0 N-CA-C 109.855 -1.298 . . . . 1.39 109.855 -179.795 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.414 ' CG2' HD12 ' A' ' 41' ' ' ILE . 41.3 t -104.59 119.34 53.35 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.959 0 O-C-N 121.464 -1.021 . . . . 1.57 108.814 179.603 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.524 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 0.4 OUTLIER -113.39 124.35 52.23 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.69 -0.631 . . . . 1.85 109.387 -179.836 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.423 ' CE2' ' HB3' ' A' ' 37' ' ' ALA . 51.7 p90 -122.97 131.62 53.79 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 108.358 -0.979 . . . . 1.54 108.358 179.316 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.625 ' O ' HG13 ' A' ' 78' ' ' VAL . 8.9 p -106.63 117.54 52.61 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.243 0 O-C-N 121.293 -0.879 . . . . 1.9 109.603 -179.378 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 1.2 m -90.07 161.8 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 O-C-N 121.282 -0.887 . . . . 1.27 108.978 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 12.6 tp60 -97.62 -51.33 4.15 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.122 -0.986 . . . . 2.48 110.787 -179.158 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.429 ' O ' ' O ' ' A' ' 82' ' ' PRO . 77.2 mm-40 -145.47 150.31 43.66 Favored Pre-proline 0 N--CA 1.504 2.259 0 O-C-N 120.872 -1.142 . . . . 1.92 111.718 -178.125 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.599 ' HG3' ' N ' ' A' ' 107' ' ' SER . 88.7 Cg_exo -36.73 166.38 0.01 OUTLIER 'Trans proline' 0 C--O 1.216 -0.616 0 C-N-CA 123.142 2.561 . . . . 1.3 113.381 178.391 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 142.7 -178.53 21.04 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.183 -1.567 . . . . 1.02 109.183 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' ASP . . . . . 0.717 ' H ' ' NH1' ' B' ' 8' ' ' ARG . 31.7 m-20 -97.22 85.9 3.8 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 107.79 -1.189 . . . . 2.13 107.79 179.213 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -70.16 132.54 45.96 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 108.128 -1.064 . . . . 0.92 108.128 -179.502 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -105.36 115.67 30.65 Favored 'General case' 0 N--CA 1.496 1.872 0 N-CA-C 108.255 -1.017 . . . . 1.53 108.255 -179.067 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.4 p -115.83 143.03 26.73 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 O-C-N 121.604 -0.685 . . . . 1.0 110.12 -179.29 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 2.9 m -138.87 97.06 3.24 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.507 -0.745 . . . . 1.59 109.588 179.661 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.539 HG13 HD11 ' A' ' 96' ' ' ILE . 1.1 pt -104.38 132.84 50.04 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 N-CA-C 109.332 -0.618 . . . . 1.29 109.332 -179.888 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 90' ' ' LYS . . . . . 0.435 ' HG3' ' H ' ' A' ' 93' ' ' ASP . 0.0 OUTLIER -148.09 132.76 17.85 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.106 -0.996 . . . . 1.58 109.855 -179.481 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 43.5 t80 -83.05 94.62 7.83 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.642 -1.286 . . . . 1.34 108.591 178.721 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' ASN . . . . . 0.479 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 38.7 t30 67.22 38.13 3.45 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.492 -0.929 . . . . 2.32 108.492 -179.088 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.479 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 0.6 OUTLIER 86.45 12.31 0.16 Allowed 'General case' 0 N--CA 1.503 2.181 0 CA-C-N 116.399 -0.364 . . . . 1.92 111.467 179.629 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 94' ' ' GLU . . . . . 0.632 ' OE1' ' HB2' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -90.51 90.14 7.88 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 107.191 -1.411 . . . . 2.25 107.191 177.984 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 95' ' ' HIS . . . . . 0.507 ' H ' ' CD2' ' A' ' 95' ' ' HIS . 9.7 p80 -72.19 98.13 2.09 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 119.759 -1.838 . . . . 2.88 109.848 -179.142 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 96' ' ' ILE . . . . . 0.906 ' H ' HD13 ' A' ' 96' ' ' ILE . 0.0 OUTLIER -48.74 158.93 0.59 Allowed Pre-proline 0 N--CA 1.504 2.269 0 N-CA-C 107.31 -1.367 . . . . 2.35 107.31 179.218 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -60.42 65.5 0.08 OUTLIER 'Trans proline' 0 N--CA 1.481 0.736 0 C-N-CA 121.504 1.469 . . . . 2.48 109.469 -179.87 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.593 ' N ' ' O ' ' A' ' 96' ' ' ILE . 8.8 m-20 -164.9 -57.56 0.03 OUTLIER 'General case' 0 C--N 1.298 -1.634 0 N-CA-C 108.167 -1.049 . . . . 2.65 108.167 -179.514 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.423 ' HB3' ' H ' ' A' ' 89' ' ' ILE . 3.3 p -68.8 137.29 90.16 Favored Pre-proline 0 C--N 1.296 -1.755 0 C-N-CA 119.489 -0.884 . . . . 2.0 109.754 -179.179 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 27.2 Cg_endo -89.54 119.87 4.28 Favored 'Cis proline' 0 N--CA 1.493 1.462 0 N-CA-C 110.017 -0.801 . . . . 1.79 110.017 -2.644 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 30.4 p90 -124.55 166.42 16.09 Favored 'General case' 0 N--CA 1.516 2.844 0 O-C-N 120.571 -1.33 . . . . 2.19 109.74 178.153 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.3 p -88.44 146.49 6.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.551 -0.718 . . . . 1.44 110.521 -178.532 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 71.4 t -119.63 86.66 35.34 Favored Pre-proline 0 N--CA 1.495 1.803 0 N-CA-C 107.82 -1.178 . . . . 1.19 107.82 179.157 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -61.96 112.92 1.65 Allowed 'Trans proline' 0 C--N 1.322 -0.866 0 C-N-CA 121.423 1.416 . . . . 1.49 112.121 -177.724 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 60.3 t -98.93 143.19 13.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 N-CA-C 106.15 -1.796 . . . . 1.35 106.15 177.719 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.658 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -136.48 135.15 38.36 Favored 'General case' 0 N--CA 1.51 2.56 0 O-C-N 120.972 -1.08 . . . . 1.67 112.089 -176.932 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.599 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 9.2 t -86.39 73.02 10.22 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 107.713 -1.218 . . . . 2.04 107.713 179.158 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER 68.11 -1.26 1.83 Allowed 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 107.363 -1.347 . . . . 3.2 107.363 -178.505 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.674 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 22.9 t -83.54 -21.96 32.55 Favored 'General case' 0 N--CA 1.486 1.344 0 N-CA-C 108.864 -0.791 . . . . 2.09 108.864 179.249 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 110' ' ' ASP . . . . . 0.658 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 1.8 m-20 52.34 12.23 0.22 Allowed 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 108.135 -1.061 . . . . 2.85 108.135 -179.344 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.492 ' H ' ' C ' ' A' ' 109' ' ' SER . 5.0 m-20 -169.02 -29.26 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 108.877 -0.786 . . . . 2.46 108.877 -179.702 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.674 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 53.92 84.92 0.06 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.823 -1.173 . . . . 2.08 109.429 -179.779 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 113' ' ' ARG . . . . . 0.415 ' O ' ' O ' ' A' ' 112' ' ' ALA . 10.5 mpt_? -55.48 -169.36 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.208 -0.932 . . . . 5.93 109.19 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 9.8 tpt180 -138.34 2.0 2.24 Favored 'General case' 0 N--CA 1.495 1.78 0 N-CA-C 108.749 -0.834 . . . . 5.61 108.749 -179.832 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 39.9 mt -129.36 -26.41 2.55 Favored 'General case' 0 N--CA 1.503 2.198 0 O-C-N 121.542 -0.723 . . . . 4.39 109.244 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.488 ' C ' ' N ' ' A' ' 118' ' ' THR . 1.3 p -103.89 -81.08 0.52 Allowed 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 106.857 -1.534 . . . . 4.09 106.857 179.066 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.444 ' O ' HG12 ' A' ' 117' ' ' VAL . 54.9 t -61.06 -8.87 2.1 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.63 0 N-CA-C 106.144 -1.798 . . . . 2.9 106.144 176.826 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 118' ' ' THR . . . . . 0.488 ' N ' ' C ' ' A' ' 116' ' ' THR . 4.2 t 36.84 61.45 0.87 Allowed 'General case' 0 N--CA 1.486 1.375 0 CA-C-O 121.999 0.904 . . . . 3.36 110.742 179.913 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 119' ' ' SER . . . . . 0.468 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.6 p . . . . . 0 C--N 1.305 -1.365 0 CA-C-O 117.998 -1.001 . . . . 3.39 109.635 179.291 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 28.1 ttt . . . . . 0 N--CA 1.49 1.554 0 N-CA-C 109.45 -0.574 . . . . 8.49 109.45 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -56.69 -37.33 70.72 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.227 -0.921 . . . . 5.53 109.432 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 3' ' ' SER . . . . . . . . . . . . . 40.5 m -160.69 28.96 0.15 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.226 -0.921 . . . . 5.43 109.378 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 4' ' ' LYS . . . . . . . . . . . . . 27.3 tttp 56.28 67.32 2.86 Favored Pre-proline 0 N--CA 1.489 1.507 0 O-C-N 121.329 -0.857 . . . . 6.87 109.35 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 5' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_endo -61.77 -162.1 0.03 OUTLIER 'Trans proline' 0 C--N 1.318 -1.027 0 C-N-CA 121.475 1.45 . . . . 5.16 110.1 -179.384 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 6' ' ' GLU . . . . . . . . . . . . . 53.9 mt-10 -150.84 56.57 0.91 Allowed 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.287 -0.883 . . . . 4.78 109.326 -179.908 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 38.7 mttm 55.05 174.68 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.267 -0.896 . . . . 4.09 109.695 179.806 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.717 ' NH1' ' H ' ' A' ' 84' ' ' ASP . 5.6 mtt180 -88.37 173.63 8.62 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.277 -0.889 . . . . 3.04 109.393 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 9' ' ' VAL . . . . . 0.408 ' CG1' ' N ' ' B' ' 10' ' ' ALA . 5.2 t -51.08 160.48 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 N-CA-C 108.226 -1.027 . . . . 0.67 108.226 179.375 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 0.408 ' N ' ' CG1' ' B' ' 9' ' ' VAL . . . -114.59 148.3 38.26 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.47 -0.768 . . . . 0.58 110.053 -179.158 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 11' ' ' SER . . . . . 0.428 ' O ' ' O ' ' A' ' 55' ' ' VAL . 31.3 t -150.02 133.06 16.2 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.517 -0.74 . . . . 1.19 109.2 179.634 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 34.1 p -144.55 120.54 10.69 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.117 -0.989 . . . . 1.38 109.809 -179.695 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 0.613 HG22 ' N ' ' B' ' 14' ' ' PHE . 4.1 p -164.04 168.4 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.436 -0.79 . . . . 0.42 109.07 179.858 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 14' ' ' PHE . . . . . 0.613 ' N ' HG22 ' B' ' 13' ' ' VAL . 10.7 p90 -176.38 -165.58 0.14 Allowed 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 119.172 -1.011 . . . . 1.79 112.265 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.7 pt -150.93 168.63 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.291 0 N-CA-C 108.598 -0.89 . . . . 1.25 108.598 179.873 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 3.8 t -145.17 157.41 44.09 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 120.965 -1.084 . . . . 1.61 109.367 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -131.47 150.63 52.08 Favored 'General case' 0 N--CA 1.5 2.062 0 O-C-N 121.397 -0.815 . . . . 1.32 109.533 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -150.89 81.13 6.43 Favored Pre-proline 0 N--CA 1.492 1.674 0 N-CA-C 108.726 -0.842 . . . . 1.45 108.726 -179.804 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 19' ' ' PRO . . . . . 0.439 ' O ' ' O ' ' B' ' 20' ' ' PRO . 5.5 Cg_exo -59.82 169.4 4.56 Favored 'Trans proline' 0 CA--C 1.545 1.042 0 C-N-CA 121.206 1.271 . . . . 1.5 109.977 -178.73 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 20' ' ' PRO . . . . . 0.439 ' O ' ' O ' ' B' ' 19' ' ' PRO . 3.9 Cg_exo -57.11 -146.81 0.0 OUTLIER 'Trans proline' 0 CA--C 1.542 0.91 0 C-N-CA 121.623 1.549 . . . . 2.86 110.239 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 35.3 mtp180 61.91 65.95 0.87 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.211 -0.931 . . . . 6.12 109.476 -179.813 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 22' ' ' ARG . . . . . 0.611 HH11 ' CG ' ' B' ' 22' ' ' ARG . 0.0 OUTLIER -169.89 -134.96 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.381 -0.824 . . . . 6.29 109.323 179.837 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 62.5 m-20 -88.4 129.02 35.52 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.157 -0.964 . . . . 5.62 109.447 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 39.3 t . . . . . 0 N--CA 1.49 1.533 0 CA-C-O 117.973 -1.013 . . . . 6.48 109.517 179.913 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.489 ' O ' HG23 ' A' ' 2' ' ' ILE . . . . . . . . 1 N--CA 1.53 4.904 0 N-CA-C 119.879 2.712 . . . . 6.64 119.879 . . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.627 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 1.1 pp -160.74 45.69 0.19 Allowed Pre-proline 0 C--N 1.308 -1.234 0 N-CA-C 107.767 -1.198 . . . . 7.08 107.767 179.038 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.814 ' C ' ' H ' ' A' ' 5' ' ' PHE . 1.2 Cg_endo -53.81 -79.33 0.02 OUTLIER 'Trans proline' 0 C--N 1.32 -0.942 0 N-CA-C 108.904 -1.229 . . . . 5.5 108.904 179.774 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.499 ' C ' ' H ' ' A' ' 6' ' ' PHE . 9.4 tt0 73.18 -18.15 0.38 Allowed 'General case' 0 N--CA 1.495 1.783 0 N-CA-C 104.373 -2.454 . . . . 6.75 104.373 -175.729 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' PHE . . . . . 0.814 ' H ' ' C ' ' A' ' 3' ' ' PRO . 4.6 m-85 -88.83 17.41 5.66 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 103.912 -2.625 . . . . 6.07 103.912 176.654 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.535 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 39.6 p90 46.08 -153.49 0.05 Allowed 'General case' 0 C--N 1.308 -1.233 0 CA-C-N 114.308 -1.314 . . . . 4.72 109.366 -177.553 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.523 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 16.8 tt0 82.89 -8.67 1.15 Allowed 'General case' 0 N--CA 1.49 1.543 0 N-CA-C 104.929 -2.248 . . . . 4.4 104.929 -177.112 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.489 ' H ' ' C ' ' A' ' 6' ' ' PHE . 35.1 t80 -150.53 -38.19 0.14 Allowed 'General case' 0 C--N 1.307 -1.252 0 N-CA-C 107.761 -1.199 . . . . 5.15 107.761 178.409 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.416 HG22 ' O ' ' A' ' 9' ' ' THR . 45.3 m -91.98 2.36 56.6 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 105.662 -1.977 . . . . 5.13 105.662 177.147 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.403 HG13 ' N ' ' A' ' 11' ' ' GLY . 7.1 p -46.37 -38.04 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.27 0 CA-C-N 115.268 -0.878 . . . . 4.38 109.479 -179.641 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.579 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 140.23 -83.25 0.23 Allowed Glycine 0 N--CA 1.5 2.915 0 N-CA-C 108.58 -1.808 . . . . 4.22 108.58 179.704 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.542 ' O ' ' N ' ' A' ' 14' ' ' GLY . 13.6 Cg_endo -66.6 40.95 0.16 Allowed 'Trans proline' 0 C--N 1.32 -0.964 0 C-N-CA 121.911 1.74 . . . . 3.85 108.798 177.954 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.579 ' H ' ' C ' ' A' ' 11' ' ' GLY . 0.2 OUTLIER 30.52 34.27 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.22 0 CA-C-O 121.518 0.675 . . . . 3.67 110.835 -179.277 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.546 ' C ' ' H ' ' A' ' 16' ' ' GLY . . . 67.25 -35.47 0.2 Allowed Glycine 0 N--CA 1.49 2.244 0 N-CA-C 110.159 -1.176 . . . . 2.97 110.159 179.427 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.537 ' H ' ' C ' ' A' ' 13' ' ' LEU . 6.4 tp10 58.47 1.58 0.18 Allowed 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.313 -1.11 . . . . 2.97 108.921 -179.332 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.546 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 70.22 112.34 0.03 OUTLIER Glycine 0 N--CA 1.487 2.099 0 C-N-CA 120.34 -0.933 . . . . 2.44 110.772 179.197 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.539 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 78.7 -52.6 3.91 Favored Glycine 0 N--CA 1.492 2.43 0 O-C-N 121.47 -1.018 . . . . 1.81 111.089 178.69 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.599 ' HB2' ' OE1' ' A' ' 94' ' ' GLU . . . -50.27 -6.68 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.081 -1.247 . . . . 2.21 110.162 -179.29 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' HIS . . . . . 0.539 ' N ' ' O ' ' A' ' 17' ' ' GLY . 29.5 t-80 -98.97 -6.31 28.91 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.092 -1.005 . . . . 2.87 110.717 -179.171 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.502 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.0 OUTLIER -137.7 2.38 2.42 Favored 'General case' 0 N--CA 1.502 2.164 0 O-C-N 120.959 -1.088 . . . . 2.02 110.258 -179.664 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 71.3 t -87.85 114.22 26.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 120.982 -1.074 . . . . 2.07 109.25 179.489 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 13.3 tpp180 -113.61 138.54 50.03 Favored 'General case' 0 N--CA 1.492 1.635 0 N-CA-C 108.83 -0.804 . . . . 3.5 108.83 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -147.13 113.57 5.95 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.434 -0.791 . . . . 1.83 108.987 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -152.0 130.33 3.07 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.677 -1.369 . . . . 1.9 109.677 -179.759 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.98 -178.79 48.47 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.603 -1.399 . . . . 1.85 109.603 179.87 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 6.6 p -78.93 -26.59 43.67 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.183 -1.186 . . . . 2.31 108.99 179.648 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -66.88 -18.25 68.36 Favored Glycine 0 N--CA 1.486 2.015 0 N-CA-C 108.283 -1.927 . . . . 1.64 108.283 179.482 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 57.1 mt -89.64 29.55 1.13 Allowed 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.527 -0.916 . . . . 1.83 108.527 179.395 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 27.5 mt-10 -140.09 -63.84 0.49 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.528 -0.733 . . . . 2.34 109.623 -179.557 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 41.2 mtt180 -148.45 168.57 22.34 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.168 -0.958 . . . . 3.77 110.293 -179.573 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -144.38 173.33 25.09 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 107.415 -2.274 . . . . 1.57 107.415 178.73 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 39.7 t -133.79 150.99 32.18 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.15 0 O-C-N 120.999 -1.295 . . . . 1.83 110.884 -179.365 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.434 ' HB2' ' HD3' ' A' ' 82' ' ' PRO . . . -42.34 114.81 0.61 Allowed 'General case' 0 N--CA 1.497 1.887 0 CA-C-O 121.893 0.854 . . . . 1.64 112.314 -179.299 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 55.8 48.2 73.69 Favored Glycine 0 N--CA 1.488 2.159 0 N-CA-C 111.497 -0.641 . . . . 1.73 111.497 177.119 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 t -127.45 123.8 23.32 Favored Pre-proline 0 N--CA 1.499 1.986 0 O-C-N 121.451 -1.029 . . . . 2.19 108.866 179.075 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -60.64 112.21 1.27 Allowed 'Trans proline' 0 C--O 1.215 -0.652 0 N-CA-C 109.949 -0.827 . . . . 1.96 109.949 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -110.87 158.96 18.13 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 108.401 -0.963 . . . . 1.69 108.401 179.445 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -160.64 170.46 20.79 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.767 -1.208 . . . . 2.23 111.496 -179.768 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.602 ' CE2' HD11 ' A' ' 41' ' ' ILE . 6.2 p90 -155.62 177.37 11.45 Favored 'General case' 0 C--N 1.296 -1.729 0 N-CA-C 107.217 -1.401 . . . . 1.54 107.217 178.473 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 27.5 m -105.17 152.32 22.97 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.344 -0.848 . . . . 2.37 110.619 -178.502 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.649 HD12 HG21 ' A' ' 75' ' ' VAL . 10.0 mt -143.64 89.53 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 N-CA-C 108.714 -0.847 . . . . 1.65 108.714 178.854 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.529 ' CD1' ' N ' ' A' ' 43' ' ' THR . 7.4 t90 -91.33 141.29 28.93 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.172 -0.955 . . . . 3.68 108.924 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.531 ' OG1' ' N ' ' A' ' 44' ' ' ARG . 1.7 t -162.34 -124.2 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.177 -0.952 . . . . 2.89 109.486 -179.845 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' ARG . . . . . 0.531 ' N ' ' OG1' ' A' ' 43' ' ' THR . 5.3 ttt-85 54.49 91.81 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.347 -0.845 . . . . 4.63 110.074 179.748 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -170.97 -50.23 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.285 -0.884 . . . . 2.89 109.304 179.457 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -61.14 -50.29 73.8 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.09 -1.006 . . . . 1.74 108.937 179.665 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 155.2 -178.81 31.65 Favored Glycine 0 N--CA 1.487 2.044 0 N-CA-C 109.536 -1.426 . . . . 1.6 109.536 179.813 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.68 156.92 2.45 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.169 -1.195 . . . . 1.4 109.263 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -179.65 -160.51 25.38 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.712 -1.355 . . . . 1.04 109.712 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -144.05 123.38 2.01 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 109.663 -1.375 . . . . 1.06 109.663 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 60.2 tp -96.82 104.99 17.04 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.34 -1.094 . . . . 1.1 108.651 179.571 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' SER . . . . . 0.406 ' HA ' ' CD2' ' B' ' 14' ' ' PHE . 2.0 t -93.23 144.66 25.08 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 108.93 -0.767 . . . . 1.56 108.93 179.736 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.507 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 80.0 mt -132.97 105.74 8.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 O-C-N 121.305 -0.872 . . . . 0.65 109.79 -179.378 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -95.76 107.86 20.13 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 107.726 -1.213 . . . . 0.69 107.726 178.841 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.41 ' O ' ' O ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -105.33 146.73 11.99 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 CA-C-O 121.772 0.796 . . . . 0.91 110.693 -178.421 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.408 ' OE2' ' O ' ' B' ' 9' ' ' VAL . 39.9 tp10 -139.23 129.41 25.31 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 107.248 -1.39 . . . . 1.8 107.248 177.954 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -175.82 163.59 33.3 Favored Glycine 0 N--CA 1.487 2.068 0 N-CA-C 108.386 -1.886 . . . . 0.49 108.386 -179.702 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_exo -46.37 -23.44 2.08 Favored 'Trans proline' 0 C--N 1.317 -1.13 0 C-N-CA 121.91 1.74 . . . . 0.66 111.714 -178.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 30.3 t -141.74 167.49 22.01 Favored 'General case' 0 N--CA 1.501 2.101 0 O-C-N 121.473 -0.767 . . . . 1.55 110.681 -179.274 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 29.3 tttm -91.4 92.05 8.4 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.666 -0.646 . . . . 2.53 109.535 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -52.05 145.13 10.78 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.341 -0.85 . . . . 0.82 109.308 179.889 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.426 ' OE2' ' O ' ' A' ' 63' ' ' ILE . 0.2 OUTLIER -93.78 87.63 5.5 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.234 -0.916 . . . . 2.3 109.561 -179.843 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.426 ' O ' ' OE2' ' A' ' 62' ' ' GLU . 25.0 mt -60.23 150.17 6.69 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 N-CA-C 109.263 -0.643 . . . . 1.4 109.263 179.574 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -151.09 114.83 4.93 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 120.725 -1.234 . . . . 1.36 109.939 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.492 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 40.1 p90 -86.85 124.17 32.79 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.222 -0.924 . . . . 1.47 109.198 179.531 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 62.9 tt0 -141.2 125.1 17.07 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.254 -0.904 . . . . 2.51 109.43 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -88.69 93.93 9.73 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.351 -0.843 . . . . 2.07 109.695 -179.906 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.616 ' CG ' HH11 ' A' ' 68' ' ' ARG . 0.0 OUTLIER -115.92 10.68 15.27 Favored 'General case' 0 N--CA 1.499 2.019 0 N-CA-C 108.3 -1.0 . . . . 4.63 108.3 179.53 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.455 ' HB2' ' H ' ' A' ' 72' ' ' SER . 28.3 mmtp -115.19 -8.71 12.34 Favored 'General case' 0 N--CA 1.496 1.845 0 N-CA-C 109.141 -0.689 . . . . 3.49 109.141 -179.492 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 3.0 t70 67.85 6.03 4.86 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.46 -0.775 . . . . 3.06 109.769 179.529 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -163.43 -41.92 0.02 OUTLIER Glycine 0 N--CA 1.487 2.048 0 C-N-CA 119.489 -1.338 . . . . 2.16 109.785 -179.428 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.455 ' H ' ' HB2' ' A' ' 69' ' ' LYS . 4.3 t -95.28 130.92 41.87 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.32 -1.106 . . . . 2.2 108.983 179.865 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 24.5 m -78.23 129.33 34.96 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.19 -0.944 . . . . 2.05 109.356 -179.844 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -101.14 116.5 5.59 Favored Glycine 0 N--CA 1.497 2.747 0 N-CA-C 110.111 -1.196 . . . . 1.39 110.111 -179.637 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.649 HG21 HD12 ' A' ' 41' ' ' ILE . 71.8 t -105.36 106.85 21.28 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.098 0 O-C-N 121.537 -0.978 . . . . 1.57 109.284 179.571 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 4.0 t -100.11 126.39 46.34 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.549 -0.719 . . . . 1.85 109.474 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.401 ' N ' ' CD1' ' A' ' 77' ' ' TYR . 12.0 p90 -125.36 131.69 52.94 Favored 'General case' 0 N--CA 1.497 1.882 0 N-CA-C 108.758 -0.831 . . . . 1.54 108.758 179.746 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.627 ' O ' HG13 ' A' ' 78' ' ' VAL . 9.9 p -98.73 114.35 36.17 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.294 -0.879 . . . . 1.9 109.255 -179.501 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.406 HG22 ' H ' ' A' ' 79' ' ' VAL . 15.5 m -81.79 161.83 3.57 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 O-C-N 121.041 -1.037 . . . . 1.27 109.027 -179.707 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -101.44 -48.54 4.32 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.227 -0.92 . . . . 2.48 110.781 -178.825 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -156.67 153.13 23.91 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 120.554 -1.341 . . . . 1.92 111.108 -179.506 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.648 ' HG3' ' N ' ' A' ' 107' ' ' SER . 76.4 Cg_exo -37.08 158.08 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.646 0 C-N-CA 123.363 2.709 . . . . 1.3 113.875 179.231 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 150.77 -167.49 30.46 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.359 -1.496 . . . . 1.02 109.359 179.765 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' ASP . . . . . 0.521 ' OD2' ' NH2' ' B' ' 8' ' ' ARG . 10.7 m-20 -109.3 91.58 3.7 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.532 -0.981 . . . . 2.13 108.756 179.64 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 3.0 m-85 -78.25 136.19 37.72 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 108.049 -1.093 . . . . 0.92 108.049 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' GLU . . . . . 0.402 ' OE2' ' O ' ' A' ' 84' ' ' ASP . 0.0 OUTLIER -119.18 117.36 28.44 Favored 'General case' 0 N--CA 1.501 2.086 0 N-CA-C 108.121 -1.066 . . . . 1.53 108.121 -179.033 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.437 ' O ' HG13 ' A' ' 87' ' ' VAL . 14.6 p -117.11 133.91 62.36 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 121.622 -0.674 . . . . 1.0 110.408 -178.842 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 3.5 p -128.65 105.77 8.49 Favored 'General case' 0 N--CA 1.501 2.092 0 O-C-N 121.61 -0.682 . . . . 1.59 109.459 179.715 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.4 pt -107.95 138.22 35.53 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.897 0 CA-C-O 121.415 0.626 . . . . 1.29 109.839 -179.732 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' LYS . . . . . 0.458 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -145.08 122.63 11.74 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 108.659 -0.867 . . . . 1.58 108.659 179.928 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 78.7 t80 -80.33 100.95 8.66 Favored 'General case' 0 N--CA 1.491 1.588 0 C-N-CA 118.764 -1.174 . . . . 1.34 107.891 178.492 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' ASN . . . . . 0.407 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 2.0 t30 69.59 39.86 1.49 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.343 -0.848 . . . . 2.32 109.177 -178.908 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.407 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 1.5 m-20 75.61 13.93 2.88 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.678 -0.639 . . . . 1.92 111.62 179.483 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 94' ' ' GLU . . . . . 0.599 ' OE1' ' HB2' ' A' ' 18' ' ' ALA . 0.5 OUTLIER -98.44 94.44 6.72 Favored 'General case' 0 N--CA 1.498 1.97 0 N-CA-C 106.964 -1.495 . . . . 2.25 106.964 177.58 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 95' ' ' HIS . . . . . 0.508 ' O ' ' CG ' ' A' ' 95' ' ' HIS . 29.5 p-80 -71.57 112.69 7.9 Favored 'General case' 0 N--CA 1.487 1.384 0 CA-C-O 121.485 0.66 . . . . 2.88 109.748 -178.219 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 96' ' ' ILE . . . . . 0.557 ' O ' ' N ' ' A' ' 98' ' ' ASP . 6.3 pt -57.06 152.02 31.4 Favored Pre-proline 0 C--N 1.3 -1.579 0 N-CA-C 108.319 -0.993 . . . . 2.35 108.319 179.594 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -59.05 73.96 0.05 OUTLIER 'Trans proline' 0 CA--C 1.54 0.789 0 N-CA-C 109.234 -1.102 . . . . 2.48 109.234 179.364 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.557 ' N ' ' O ' ' A' ' 96' ' ' ILE . 0.9 OUTLIER -174.93 -51.87 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.077 -1.014 . . . . 2.65 109.38 -179.339 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 5.3 t -54.25 134.31 60.57 Favored Pre-proline 0 C--N 1.299 -1.626 0 O-C-N 121.321 -0.862 . . . . 2.0 109.926 -177.64 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_endo -89.94 116.25 2.91 Favored 'Cis proline' 0 N--CA 1.495 1.606 0 CA-C-N 118.995 0.677 . . . . 1.79 110.521 -1.98 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 101' ' ' PHE . . . . . 0.574 ' CD1' ' N ' ' A' ' 101' ' ' PHE . 0.1 OUTLIER -89.49 149.59 22.84 Favored 'General case' 0 N--CA 1.512 2.639 0 O-C-N 119.979 -1.701 . . . . 2.19 108.76 178.029 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 8.6 p -86.45 138.43 19.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.5 -0.75 . . . . 1.44 109.133 179.681 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 76.7 t -120.15 85.37 35.6 Favored Pre-proline 0 N--CA 1.498 1.936 0 N-CA-C 108.312 -0.996 . . . . 1.19 108.312 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -65.3 112.97 2.25 Favored 'Trans proline' 0 C--N 1.32 -0.953 0 C-N-CA 121.276 1.317 . . . . 1.49 111.556 -178.012 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 47.2 t -89.73 143.06 11.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 N-CA-C 106.667 -1.605 . . . . 1.35 106.667 177.853 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.702 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -127.92 131.28 49.37 Favored 'General case' 0 N--CA 1.507 2.406 0 CA-C-O 121.956 0.884 . . . . 1.67 111.788 -177.016 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.648 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 66.4 p -99.8 84.77 2.96 Favored 'General case' 0 N--CA 1.493 1.693 0 N-CA-C 107.229 -1.397 . . . . 2.04 107.229 178.783 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 13.3 mt 65.12 -0.69 1.02 Allowed 'General case' 0 C--N 1.292 -1.917 0 N-CA-C 108.081 -1.081 . . . . 3.2 108.081 -178.103 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.602 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 53.8 p -89.1 -22.89 22.66 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.982 -0.747 . . . . 2.09 108.982 179.068 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 110' ' ' ASP . . . . . 0.702 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 32.9 t70 50.24 13.4 0.11 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.139 -0.975 . . . . 2.85 108.586 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.503 ' N ' ' C ' ' A' ' 109' ' ' SER . 65.3 t0 -171.93 -28.74 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 109.375 -0.602 . . . . 2.46 109.375 -179.605 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.602 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 49.5 78.93 0.09 Allowed 'General case' 0 N--CA 1.494 1.752 0 O-C-N 120.784 -1.197 . . . . 2.08 109.189 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 61.9 mtm180 -50.16 160.75 0.33 Allowed 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.412 -0.805 . . . . 5.93 109.82 -179.55 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 18.3 ttm180 -103.22 5.74 37.81 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.568 -0.707 . . . . 5.61 109.382 -179.512 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 28.6 mt -123.2 -30.81 3.67 Favored 'General case' 0 N--CA 1.506 2.326 0 O-C-N 121.526 -0.733 . . . . 4.39 110.003 -179.391 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.508 ' C ' ' N ' ' A' ' 118' ' ' THR . 0.8 OUTLIER -105.26 -79.23 0.56 Allowed 'General case' 0 N--CA 1.493 1.721 0 N-CA-C 107.241 -1.392 . . . . 4.09 107.241 179.527 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.428 ' O ' HG12 ' A' ' 117' ' ' VAL . 55.0 t -60.21 -9.85 2.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 N-CA-C 106.215 -1.772 . . . . 2.9 106.215 177.043 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 118' ' ' THR . . . . . 0.508 ' N ' ' C ' ' A' ' 116' ' ' THR . 5.0 t 36.98 60.86 0.95 Allowed 'General case' 0 N--CA 1.485 1.287 0 CA-C-O 122.109 0.957 . . . . 3.36 110.88 179.718 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 119' ' ' SER . . . . . 0.452 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.5 p . . . . . 0 C--N 1.304 -1.408 0 CA-C-O 118.025 -0.988 . . . . 3.39 109.548 179.207 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 34.1 ttp . . . . . 0 N--CA 1.491 1.582 0 N-CA-C 109.467 -0.568 . . . . 8.49 109.467 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -73.79 -73.7 0.21 Allowed 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.241 -0.912 . . . . 5.53 109.185 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 3' ' ' SER . . . . . . . . . . . . . 13.0 p -175.32 -40.76 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.313 -0.867 . . . . 5.43 109.726 179.824 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 4' ' ' LYS . . . . . . . . . . . . . 59.4 tttm -170.96 76.99 0.55 Allowed Pre-proline 0 N--CA 1.489 1.493 0 O-C-N 121.201 -0.937 . . . . 6.87 109.626 -179.537 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 5' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -59.99 156.92 36.37 Favored 'Trans proline' 0 C--N 1.318 -1.071 0 C-N-CA 121.291 1.327 . . . . 5.16 110.055 -179.612 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 6' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -47.61 171.86 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.27 -0.894 . . . . 4.78 109.902 -179.724 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 49.0 mtpt -78.78 -154.99 0.08 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.398 -0.814 . . . . 4.09 109.385 179.822 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.521 ' NH2' ' OD2' ' A' ' 84' ' ' ASP . 3.8 mmt-85 -89.55 -170.87 2.99 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.148 -0.97 . . . . 3.04 109.358 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 9' ' ' VAL . . . . . 0.408 ' O ' ' OE2' ' A' ' 56' ' ' GLU . 2.6 t -68.47 161.23 4.22 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 N-CA-C 107.505 -1.294 . . . . 0.67 107.505 178.549 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -97.77 138.94 34.38 Favored 'General case' 0 N--CA 1.5 2.034 0 O-C-N 121.186 -0.947 . . . . 0.58 110.809 -178.636 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 11' ' ' SER . . . . . 0.41 ' O ' ' O ' ' A' ' 55' ' ' VAL . 35.7 t -143.07 130.73 21.34 Favored 'General case' 0 N--CA 1.493 1.72 0 N-CA-C 108.444 -0.947 . . . . 1.19 108.444 179.092 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 11.1 t -150.69 125.37 9.67 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.069 -1.019 . . . . 1.38 110.072 -179.369 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 0.731 HG22 ' H ' ' B' ' 14' ' ' PHE . 12.3 p -173.26 179.81 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 N-CA-C 108.263 -1.014 . . . . 0.42 108.263 179.649 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 14' ' ' PHE . . . . . 0.731 ' H ' HG22 ' B' ' 13' ' ' VAL . 0.1 OUTLIER 174.59 -167.65 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.504 0 C-N-CA 118.548 -1.261 . . . . 1.79 112.237 179.629 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -141.34 159.66 22.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 N-CA-C 108.097 -1.075 . . . . 1.25 108.097 -179.841 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 1.7 t -132.11 151.07 51.98 Favored 'General case' 0 N--CA 1.499 2.017 0 O-C-N 121.303 -0.873 . . . . 1.61 109.474 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 28.4 mt -112.13 141.39 45.86 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.487 -0.758 . . . . 1.32 109.576 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -158.89 117.23 1.7 Allowed Pre-proline 0 N--CA 1.492 1.654 0 N-CA-C 108.73 -0.841 . . . . 1.45 108.73 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_exo -59.74 164.63 11.28 Favored 'Trans proline' 0 CA--C 1.545 1.068 0 N-CA-C 109.992 -0.811 . . . . 1.5 109.992 -179.493 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 20' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_endo -63.15 124.14 13.4 Favored 'Trans proline' 0 C--N 1.321 -0.894 0 C-N-CA 121.626 1.551 . . . . 2.86 110.089 179.72 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 21' ' ' ARG . . . . . 0.557 HH11 ' CG ' ' B' ' 21' ' ' ARG . 0.3 OUTLIER 46.55 -127.25 1.49 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.241 -0.912 . . . . 6.12 109.708 179.304 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 22' ' ' ARG . . . . . 0.439 ' O ' ' O ' ' B' ' 23' ' ' ASP . 9.9 tpt180 -122.5 25.15 8.96 Favored 'General case' 0 N--CA 1.499 1.984 0 N-CA-C 108.932 -0.766 . . . . 6.29 108.932 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 23' ' ' ASP . . . . . 0.439 ' O ' ' O ' ' B' ' 22' ' ' ARG . 0.8 OUTLIER 60.45 142.55 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.42 -0.8 . . . . 5.62 109.736 -179.93 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 24' ' ' VAL . . . . . 0.442 ' H ' HG22 ' B' ' 24' ' ' VAL . 11.0 m . . . . . 0 N--CA 1.491 1.587 0 O-C-N 121.118 -0.988 . . . . 6.48 109.483 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.583 ' C ' HD12 ' A' ' 2' ' ' ILE . . . . . . . . 1 N--CA 1.531 4.972 0 N-CA-C 119.763 2.665 . . . . 6.64 119.763 . . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.66 HD12 ' N ' ' A' ' 2' ' ' ILE . 1.7 mp -149.11 43.99 0.31 Allowed Pre-proline 0 C--N 1.31 -1.143 0 N-CA-C 107.51 -1.293 . . . . 7.08 107.51 178.512 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.728 ' C ' ' H ' ' A' ' 5' ' ' PHE . 1.8 Cg_endo -51.97 -75.59 0.03 OUTLIER 'Trans proline' 0 C--N 1.319 -0.998 0 N-CA-C 109.016 -1.186 . . . . 5.5 109.016 -179.722 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.427 ' CB ' ' O ' ' A' ' 3' ' ' PRO . 13.9 tp10 70.32 -6.14 1.21 Allowed 'General case' 0 N--CA 1.495 1.801 0 N-CA-C 104.319 -2.474 . . . . 6.75 104.319 -175.705 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' PHE . . . . . 0.728 ' H ' ' C ' ' A' ' 3' ' ' PRO . 3.0 m-85 -102.06 15.21 29.77 Favored 'General case' 0 C--N 1.3 -1.558 0 N-CA-C 103.434 -2.802 . . . . 6.07 103.434 177.542 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.551 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 47.3 p90 50.83 -153.34 0.17 Allowed 'General case' 0 C--N 1.308 -1.235 0 CA-C-N 113.838 -1.528 . . . . 4.72 110.346 -177.886 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.421 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 13.4 mt-30 82.7 -9.22 1.14 Allowed 'General case' 0 N--CA 1.495 1.822 0 N-CA-C 105.233 -2.136 . . . . 4.4 105.233 -176.465 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.478 ' H ' ' C ' ' A' ' 6' ' ' PHE . 88.4 m-85 -149.46 -37.93 0.16 Allowed 'General case' 0 C--N 1.306 -1.307 0 N-CA-C 107.828 -1.175 . . . . 5.15 107.828 178.178 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 23.0 m -93.31 3.59 55.38 Favored 'General case' 0 C--N 1.295 -1.799 0 N-CA-C 105.679 -1.971 . . . . 5.13 105.679 177.21 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 1.1 p -46.59 -30.33 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.249 0 CA-C-N 115.34 -0.845 . . . . 4.38 109.639 -179.131 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.61 ' O ' HD23 ' A' ' 13' ' ' LEU . . . 164.01 -83.75 0.11 Allowed Glycine 0 N--CA 1.499 2.868 0 C-N-CA 119.81 -1.186 . . . . 4.22 110.377 179.039 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -64.57 37.95 0.11 Allowed 'Trans proline' 0 N--CA 1.484 0.934 0 C-N-CA 122.137 1.891 . . . . 3.85 109.677 179.561 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.887 ' N ' HD23 ' A' ' 13' ' ' LEU . 0.0 OUTLIER 45.59 27.46 0.42 Allowed 'General case' 0 N--CA 1.498 1.932 0 N-CA-C 108.474 -0.936 . . . . 3.67 108.474 -179.412 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.493 ' C ' ' N ' ' A' ' 16' ' ' GLY . . . 72.55 -41.71 0.82 Allowed Glycine 0 N--CA 1.487 2.052 0 N-CA-C 108.192 -1.963 . . . . 2.97 108.192 -179.088 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.514 ' H ' ' C ' ' A' ' 13' ' ' LEU . 22.9 tp10 50.0 14.3 0.13 Allowed 'General case' 0 N--CA 1.486 1.353 0 O-C-N 121.532 -0.981 . . . . 2.97 108.452 -179.841 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.493 ' N ' ' C ' ' A' ' 14' ' ' GLY . . . 70.81 -155.85 53.03 Favored Glycine 0 N--CA 1.486 2.003 0 N-CA-C 109.886 -1.286 . . . . 2.44 109.886 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.544 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -68.24 -15.55 67.89 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.881 -1.288 . . . . 1.81 109.881 -179.68 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.51 ' N ' ' OE1' ' A' ' 94' ' ' GLU . . . -43.8 -17.67 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.525 -0.985 . . . . 2.21 109.823 -179.679 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' HIS . . . . . 0.544 ' N ' ' O ' ' A' ' 17' ' ' GLY . 11.7 t-80 -100.25 -52.56 3.35 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.447 -0.783 . . . . 2.87 110.388 -179.146 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.545 ' HZ1' ' CB ' ' A' ' 43' ' ' THR . 0.0 OUTLIER -64.49 -17.89 64.29 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.962 -1.086 . . . . 2.02 109.874 -179.288 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.592 ' O ' HG13 ' A' ' 21' ' ' VAL . 9.7 p -72.22 114.31 10.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.046 -1.034 . . . . 2.07 108.829 179.503 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.405 ' HG2' ' HE1' ' A' ' 42' ' ' TRP . 5.9 tpp180 -109.84 134.61 51.86 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.452 -0.78 . . . . 3.5 110.108 -178.944 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -141.79 113.59 7.89 Favored 'General case' 0 N--CA 1.493 1.691 0 N-CA-C 108.392 -0.966 . . . . 1.83 108.392 179.15 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -150.93 132.07 3.76 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 109.94 -1.264 . . . . 1.9 109.94 -179.294 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.38 179.11 48.9 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 110.055 -1.218 . . . . 1.85 110.055 179.721 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 7.2 m -75.9 -19.9 58.46 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.47 -1.018 . . . . 2.31 109.674 179.922 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.449 ' O ' ' OH ' ' A' ' 77' ' ' TYR . . . -70.97 -24.76 76.8 Favored Glycine 0 N--CA 1.488 2.138 0 N-CA-C 108.767 -1.733 . . . . 1.64 108.767 179.844 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 29.6 mt -81.51 -11.21 59.27 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.555 -0.968 . . . . 1.83 108.946 179.633 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 33.2 mm-40 -84.67 -49.03 8.88 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.512 -0.743 . . . . 2.34 109.762 -179.494 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ARG . . . . . 0.504 ' NH1' ' OD1' ' A' ' 110' ' ' ASP . 9.4 ptp180 -174.92 173.69 2.66 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.221 -0.925 . . . . 3.77 109.407 179.809 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -138.71 170.91 23.78 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 108.196 -1.962 . . . . 1.57 108.196 179.475 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.4 ' HA ' ' O ' ' A' ' 106' ' ' ALA . 25.6 t -134.64 149.36 29.56 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 O-C-N 121.23 -1.159 . . . . 1.83 109.944 -179.526 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.44 ' HB2' ' HD3' ' A' ' 82' ' ' PRO . . . -38.51 113.03 0.26 Allowed 'General case' 0 N--CA 1.496 1.832 0 CA-C-O 121.712 0.767 . . . . 1.64 112.098 -179.306 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 63.48 40.67 99.04 Favored Glycine 0 N--CA 1.491 2.337 0 O-C-N 121.685 -0.635 . . . . 1.73 111.814 177.424 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 46.4 t -127.32 119.95 22.07 Favored Pre-proline 0 N--CA 1.502 2.146 0 O-C-N 121.289 -1.124 . . . . 2.19 108.536 178.924 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -59.37 113.89 1.8 Allowed 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 120.589 0.86 . . . . 1.96 110.541 -179.488 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.517 ' HB3' ' CZ ' ' A' ' 77' ' ' TYR . . . -86.39 90.67 8.27 Favored 'General case' 0 N--CA 1.492 1.665 0 N-CA-C 108.281 -1.007 . . . . 1.69 108.281 179.032 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -85.78 148.28 25.92 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.244 -0.91 . . . . 2.23 110.884 -178.513 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.674 ' CE2' HD11 ' A' ' 41' ' ' ILE . 5.2 p90 -153.25 159.03 42.52 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 107.148 -1.427 . . . . 1.54 107.148 177.825 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' SER . . . . . 0.426 ' OG ' ' OG ' ' A' ' 72' ' ' SER . 3.6 t -98.26 156.2 16.82 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.223 -0.923 . . . . 2.37 111.904 -177.093 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.674 HD11 ' CE2' ' A' ' 39' ' ' PHE . 13.3 mt -149.18 117.16 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 N-CA-C 108.368 -0.975 . . . . 1.65 108.368 178.713 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.519 ' O ' ' CD2' ' A' ' 42' ' ' TRP . 7.3 p-90 -122.07 129.12 52.12 Favored 'General case' 0 N--CA 1.503 2.182 0 O-C-N 121.256 -0.903 . . . . 3.68 109.031 179.718 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.545 ' CB ' ' HZ1' ' A' ' 20' ' ' LYS . 0.6 OUTLIER -149.02 142.11 24.9 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.229 -0.919 . . . . 2.89 109.605 -179.103 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 44' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -178.1 68.16 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.352 -0.842 . . . . 4.63 109.308 179.501 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 28.6 tt0 -153.47 -51.33 0.1 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.176 -0.953 . . . . 2.89 109.501 -179.919 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -61.57 -57.16 13.16 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.146 -0.971 . . . . 1.74 109.439 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 136.13 -177.56 19.46 Favored Glycine 0 N--CA 1.495 2.586 0 N-CA-C 108.683 -1.767 . . . . 1.6 108.683 -179.621 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.78 142.36 23.98 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.048 -1.266 . . . . 1.4 109.306 179.907 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -159.2 176.95 35.94 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.422 -1.471 . . . . 1.04 109.422 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -109.82 114.35 3.87 Favored Glycine 0 N--CA 1.498 2.785 0 N-CA-C 109.439 -1.464 . . . . 1.06 109.439 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.474 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 10.5 tp -94.43 96.75 9.71 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.216 -1.167 . . . . 1.1 108.353 179.386 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 22.3 p -84.68 141.16 30.8 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.627 -0.879 . . . . 1.56 108.627 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.537 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 87.3 mt -134.01 113.96 18.72 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.342 -0.848 . . . . 0.65 109.489 -179.838 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -105.28 108.52 20.08 Favored 'General case' 0 N--CA 1.495 1.784 0 N-CA-C 108.808 -0.812 . . . . 0.69 108.808 179.611 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.433 HG23 ' OG ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -100.27 142.58 15.27 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.494 -0.753 . . . . 0.91 109.412 -179.795 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 12.5 tt0 -141.89 144.12 33.65 Favored 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 108.046 -1.094 . . . . 1.8 108.046 178.999 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.429 ' O ' ' O ' ' B' ' 9' ' ' VAL . . . 163.79 -172.4 39.66 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.836 -1.306 . . . . 0.49 109.836 -179.498 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -63.34 -28.73 72.03 Favored 'Trans proline' 0 C--N 1.318 -1.053 0 C-N-CA 122.133 1.889 . . . . 0.66 112.136 -179.412 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -131.73 175.99 8.72 Favored 'General case' 0 N--CA 1.502 2.152 0 O-C-N 121.225 -0.922 . . . . 1.55 110.165 -179.575 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 47.0 mttp -93.09 120.21 33.14 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.518 -0.739 . . . . 2.53 109.523 -179.712 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.673 ' HB1' ' HB2' ' A' ' 77' ' ' TYR . . . -80.94 108.63 14.78 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.331 -0.856 . . . . 0.82 108.825 179.82 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 23.4 mt-10 -83.51 103.17 12.65 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.072 -1.018 . . . . 2.3 109.87 -179.592 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 7.6 mm -58.73 156.96 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.886 -0.509 . . . . 1.4 109.751 179.781 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.469 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -139.66 174.5 10.45 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.122 -0.986 . . . . 1.36 109.015 179.649 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.441 ' CD1' ' N ' ' A' ' 65' ' ' PHE . 13.9 p90 -139.64 117.18 11.43 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.412 -0.805 . . . . 1.47 109.536 -179.896 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -141.36 113.53 8.0 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.31 -0.869 . . . . 2.51 109.453 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -74.38 138.83 43.66 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.207 -0.933 . . . . 2.07 109.148 179.719 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 66.2 ttt180 -118.96 -47.74 2.48 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.475 -0.766 . . . . 4.63 109.505 -179.787 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.521 ' C ' ' H ' ' A' ' 71' ' ' GLY . 33.0 mttm -115.86 7.22 14.46 Favored 'General case' 0 N--CA 1.495 1.803 0 N-CA-C 108.379 -0.971 . . . . 3.49 108.379 179.645 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.409 ' CB ' ' O ' ' A' ' 69' ' ' LYS . 6.0 t70 70.73 -40.73 0.48 Allowed 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 108.432 -0.951 . . . . 3.06 108.432 -179.054 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' GLY . . . . . 0.521 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -91.35 27.84 8.95 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.363 -1.495 . . . . 2.16 109.363 179.766 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.426 ' OG ' ' OG ' ' A' ' 40' ' ' SER . 24.2 t -156.16 119.59 4.31 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.425 -1.044 . . . . 2.2 109.131 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' CYS . . . . . 0.51 ' N ' ' O ' ' A' ' 41' ' ' ILE . 20.5 m -77.26 110.89 12.36 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.233 -0.917 . . . . 2.05 109.582 -179.849 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -83.79 115.15 4.0 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.408 -1.477 . . . . 1.39 109.408 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.552 HG21 HD12 ' A' ' 41' ' ' ILE . 10.1 t -115.42 133.86 60.41 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.052 0 O-C-N 121.649 -0.912 . . . . 1.57 108.964 179.897 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.469 ' O ' ' N ' ' A' ' 64' ' ' ALA . 6.0 t -136.73 139.82 42.16 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.447 -0.783 . . . . 1.85 109.944 -179.827 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.673 ' HB2' ' HB1' ' A' ' 61' ' ' ALA . 6.9 p90 -120.16 139.2 52.97 Favored 'General case' 0 N--CA 1.495 1.79 0 N-CA-C 108.201 -1.037 . . . . 1.54 108.201 179.224 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.576 ' O ' HG13 ' A' ' 78' ' ' VAL . 9.7 p -108.87 120.78 60.88 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 O-C-N 121.332 -0.855 . . . . 1.9 109.741 -179.078 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.415 HG12 ' CZ ' ' A' ' 85' ' ' TYR . 3.6 m -101.12 168.4 1.93 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 N-CA-C 108.439 -0.949 . . . . 1.27 108.439 179.448 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 34.2 tp60 -101.5 -40.56 6.99 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.08 -1.013 . . . . 2.48 110.758 -179.486 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.429 ' O ' ' O ' ' A' ' 82' ' ' PRO . 0.0 OUTLIER -153.32 156.51 32.54 Favored Pre-proline 0 N--CA 1.504 2.248 0 O-C-N 120.539 -1.351 . . . . 1.92 111.209 -179.276 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.558 ' HG3' ' N ' ' A' ' 107' ' ' SER . 78.7 Cg_exo -37.73 169.12 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.654 0 C-N-CA 123.444 2.763 . . . . 1.3 113.239 179.016 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 142.82 179.02 19.25 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.659 -1.376 . . . . 1.02 109.659 179.559 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 84' ' ' ASP . . . . . 0.814 ' H ' HH12 ' B' ' 8' ' ' ARG . 3.0 m-20 -96.97 87.2 4.18 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 107.929 -1.137 . . . . 2.13 107.929 179.301 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.415 ' CZ ' HG12 ' A' ' 79' ' ' VAL . 2.9 m-85 -74.13 134.76 42.87 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 108.351 -0.981 . . . . 0.92 108.351 -179.345 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -111.22 121.58 45.65 Favored 'General case' 0 N--CA 1.497 1.91 0 N-CA-C 108.682 -0.858 . . . . 1.53 108.682 -179.058 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.1 p -119.65 140.58 43.16 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.891 0 O-C-N 121.552 -0.717 . . . . 1.0 109.546 -179.798 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 12.2 t -133.18 101.39 5.18 Favored 'General case' 0 N--CA 1.5 2.026 0 O-C-N 121.515 -0.741 . . . . 1.59 109.308 179.772 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.42 HG13 HD11 ' A' ' 96' ' ' ILE . 1.9 pt -108.51 137.51 39.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.721 -0.612 . . . . 1.29 110.37 -179.285 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 90' ' ' LYS . . . . . 0.44 ' HG3' ' H ' ' A' ' 93' ' ' ASP . 0.2 OUTLIER -146.91 125.87 12.79 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.857 -0.794 . . . . 1.58 108.857 179.367 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 48.4 t80 -81.69 93.89 6.86 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 120.785 -1.197 . . . . 1.34 108.492 179.42 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' ASN . . . . . 0.409 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 5.4 t30 69.93 43.24 0.94 Allowed 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 107.913 -1.143 . . . . 2.32 107.913 -178.591 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.44 ' H ' ' HG3' ' A' ' 90' ' ' LYS . 3.4 m-20 78.3 11.76 1.75 Allowed 'General case' 0 N--CA 1.495 1.789 0 CA-C-O 121.253 0.549 . . . . 1.92 109.96 -179.241 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 94' ' ' GLU . . . . . 0.51 ' OE1' ' N ' ' A' ' 18' ' ' ALA . 50.0 mt-10 -85.43 77.34 9.94 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 107.805 -1.183 . . . . 2.25 107.805 178.454 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 95' ' ' HIS . . . . . 0.401 ' O ' ' CG ' ' A' ' 95' ' ' HIS . 0.0 OUTLIER -67.97 106.41 2.33 Favored 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 120.03 -0.668 . . . . 2.88 109.752 -179.513 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 96' ' ' ILE . . . . . 0.775 ' H ' HD13 ' A' ' 96' ' ' ILE . 0.0 OUTLIER -68.96 156.1 92.15 Favored Pre-proline 0 N--CA 1.495 1.787 0 N-CA-C 107.709 -1.219 . . . . 2.35 107.709 179.606 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -48.9 -29.28 14.86 Favored 'Trans proline' 0 C--N 1.323 -0.806 0 C-N-CA 121.059 1.173 . . . . 2.48 109.144 -179.797 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 57.0 m-20 -58.83 -64.16 1.04 Allowed 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 108.963 -0.755 . . . . 2.65 108.963 178.952 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 3.1 m -70.78 139.7 86.06 Favored Pre-proline 0 C--N 1.296 -1.739 0 O-C-N 121.05 -1.031 . . . . 2.0 110.073 -178.681 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -87.08 119.46 5.07 Favored 'Cis proline' 0 N--CA 1.493 1.49 0 N-CA-C 110.025 -0.798 . . . . 1.79 110.025 -2.342 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 40.5 p90 -121.14 166.97 13.17 Favored 'General case' 0 N--CA 1.519 2.996 0 O-C-N 120.499 -1.376 . . . . 2.19 109.882 178.195 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.4 p -92.35 146.23 6.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 CA-C-O 121.642 0.734 . . . . 1.44 110.918 -178.28 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 79.8 t -119.83 86.46 35.94 Favored Pre-proline 0 N--CA 1.496 1.842 0 N-CA-C 107.799 -1.185 . . . . 1.19 107.799 178.888 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -63.96 114.28 2.54 Favored 'Trans proline' 0 C--N 1.32 -0.95 0 C-N-CA 121.36 1.373 . . . . 1.49 111.683 -178.028 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 75.2 t -98.88 144.09 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 N-CA-C 106.569 -1.641 . . . . 1.35 106.569 178.11 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.681 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -134.94 138.28 43.91 Favored 'General case' 0 N--CA 1.51 2.556 0 CA-C-O 122.055 0.931 . . . . 1.67 112.08 -177.174 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.558 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 20.3 m -92.2 63.77 4.37 Favored 'General case' 0 N--CA 1.496 1.856 0 N-CA-C 107.152 -1.425 . . . . 2.04 107.152 178.652 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 108' ' ' LEU . . . . . 0.49 ' CB ' ' O ' ' A' ' 107' ' ' SER . 3.2 tp 80.45 -13.56 0.92 Allowed 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 106.456 -1.683 . . . . 3.2 106.456 -177.416 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.54 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 5.2 m -68.54 -21.9 64.53 Favored 'General case' 0 C--N 1.306 -1.305 0 N-CA-C 108.732 -0.84 . . . . 2.09 108.732 178.785 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 110' ' ' ASP . . . . . 0.681 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 21.5 t70 47.57 18.82 0.12 Allowed 'General case' 0 N--CA 1.494 1.736 0 CA-C-O 121.937 0.875 . . . . 2.85 108.666 179.876 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.462 ' N ' ' O ' ' A' ' 109' ' ' SER . 12.6 t70 -173.88 -30.84 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 108.567 -0.901 . . . . 2.46 108.567 -179.643 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.54 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 48.29 92.81 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.123 -0.986 . . . . 2.08 109.509 179.661 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 113' ' ' ARG . . . . . 0.566 ' CG ' HH11 ' A' ' 113' ' ' ARG . 0.0 OUTLIER -62.44 -154.16 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.222 -0.924 . . . . 5.93 109.16 -179.797 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 57.5 ttt180 -145.28 2.4 0.99 Allowed 'General case' 0 N--CA 1.492 1.636 0 N-CA-C 107.883 -1.155 . . . . 5.61 107.883 179.456 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 36.2 mt -130.62 -27.64 2.12 Favored 'General case' 0 N--CA 1.5 2.039 0 N-CA-C 108.968 -0.752 . . . . 4.39 108.968 179.497 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.493 ' C ' ' N ' ' A' ' 118' ' ' THR . 1.6 p -98.77 -81.0 0.45 Allowed 'General case' 0 N--CA 1.489 1.52 0 N-CA-C 106.82 -1.548 . . . . 4.09 106.82 178.907 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.426 ' O ' HG12 ' A' ' 117' ' ' VAL . 51.6 t -60.94 -9.46 2.43 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.602 0 N-CA-C 105.967 -1.864 . . . . 2.9 105.967 176.684 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 118' ' ' THR . . . . . 0.493 ' N ' ' C ' ' A' ' 116' ' ' THR . 4.9 t 36.91 60.79 0.94 Allowed 'General case' 0 N--CA 1.487 1.384 0 CA-C-N 115.136 -0.938 . . . . 3.36 110.685 179.736 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 119' ' ' SER . . . . . 0.45 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.6 p . . . . . 0 C--N 1.303 -1.43 0 CA-C-O 117.952 -1.023 . . . . 3.39 109.607 179.303 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 82.7 mtp . . . . . 0 N--CA 1.491 1.599 0 N-CA-C 109.414 -0.587 . . . . 8.49 109.414 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . 50.9 -160.24 0.08 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.293 -0.879 . . . . 5.53 109.506 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 3' ' ' SER . . . . . . . . . . . . . 10.2 t 50.35 73.43 0.27 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.354 -0.841 . . . . 5.43 109.654 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 4' ' ' LYS . . . . . 0.634 ' N ' ' CD ' ' B' ' 5' ' ' PRO . 29.7 tttm -77.26 -35.97 1.43 Allowed Pre-proline 0 N--CA 1.489 1.487 0 O-C-N 121.164 -0.96 . . . . 6.87 111.313 179.831 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 5' ' ' PRO . . . . . 0.634 ' CD ' ' N ' ' B' ' 4' ' ' LYS . 4.1 Cg_endo -74.08 116.8 4.77 Favored 'Trans proline' 0 C--N 1.324 -0.757 0 C-N-CA 120.764 0.976 . . . . 5.16 109.633 -179.584 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 6' ' ' GLU . . . . . 0.541 ' OE1' ' N ' ' B' ' 6' ' ' GLU . 0.0 OUTLIER -158.13 135.17 9.96 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.032 -1.043 . . . . 4.78 109.928 179.627 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 7' ' ' LYS . . . . . 0.448 ' O ' ' O ' ' B' ' 6' ' ' GLU . 30.9 mmtp 54.4 108.03 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.405 -0.809 . . . . 4.09 110.044 179.696 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.814 HH12 ' H ' ' A' ' 84' ' ' ASP . 10.7 mtt180 -78.07 171.07 15.57 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.087 -1.079 . . . . 3.04 108.087 179.19 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 9' ' ' VAL . . . . . 0.429 ' O ' ' O ' ' A' ' 57' ' ' GLY . 38.6 t -51.74 155.79 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 120.921 -1.112 . . . . 0.67 108.215 179.404 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -119.66 149.87 41.28 Favored 'General case' 0 N--CA 1.501 2.078 0 O-C-N 121.402 -0.811 . . . . 0.58 110.142 -178.914 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 11' ' ' SER . . . . . 0.433 ' OG ' HG23 ' A' ' 55' ' ' VAL . 6.9 t -147.36 141.84 26.46 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.506 -0.746 . . . . 1.19 109.301 179.688 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 6.7 m -143.88 121.14 11.56 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.176 -0.952 . . . . 1.38 109.439 -179.846 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 0.631 HG22 ' N ' ' B' ' 14' ' ' PHE . 7.7 p -163.62 168.76 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.39 -0.819 . . . . 0.42 109.183 179.91 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 14' ' ' PHE . . . . . 0.631 ' N ' HG22 ' B' ' 13' ' ' VAL . 7.9 p90 -176.91 -168.05 0.2 Allowed 'General case' 0 N--CA 1.488 1.437 0 C-N-CA 119.402 -0.919 . . . . 1.79 111.928 179.7 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.6 pt -151.29 167.47 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.344 0 N-CA-C 109.091 -0.707 . . . . 1.25 109.091 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 16' ' ' THR . . . . . 0.428 ' O ' HG23 ' B' ' 16' ' ' THR . 7.3 t -122.53 128.92 51.38 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 121.463 -0.773 . . . . 1.61 109.009 179.661 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 12.1 mt -97.63 150.94 20.61 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.204 -0.935 . . . . 1.32 109.866 -179.617 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -168.41 151.72 5.51 Favored Pre-proline 0 N--CA 1.49 1.545 0 N-CA-C 108.606 -0.887 . . . . 1.45 108.606 179.584 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -60.62 140.78 92.83 Favored 'Trans proline' 0 CA--C 1.551 1.35 0 C-N-CA 120.911 1.074 . . . . 1.5 109.431 179.84 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 20' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_endo -62.16 -36.46 69.25 Favored 'Trans proline' 0 C--N 1.324 -0.719 0 N-CA-C 109.359 -1.054 . . . . 2.86 109.359 179.159 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 79.4 mtm180 -66.8 -163.28 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.469 -0.769 . . . . 6.12 109.718 -179.717 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 22' ' ' ARG . . . . . . . . . . . . . 21.1 mmm180 -130.95 -78.14 0.53 Allowed 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.532 -0.73 . . . . 6.29 109.098 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 -64.97 -132.68 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.295 -0.878 . . . . 5.62 109.454 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 97.6 t . . . . . 0 N--CA 1.493 1.716 0 CA-C-O 117.974 -1.013 . . . . 6.48 109.336 179.977 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.91 0 N-CA-C 119.722 2.649 . . . . 6.64 119.722 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.643 HG23 ' O ' ' A' ' 2' ' ' ILE . 3.8 tp -172.42 50.69 0.12 Allowed Pre-proline 0 C--N 1.307 -1.258 0 N-CA-C 108.194 -1.039 . . . . 7.08 108.194 179.647 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.73 ' C ' ' H ' ' A' ' 5' ' ' PHE . 4.1 Cg_exo -50.53 -76.23 0.03 OUTLIER 'Trans proline' 0 C--N 1.319 -0.989 0 C-N-CA 121.194 1.263 . . . . 5.5 109.218 179.601 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.441 ' CB ' ' O ' ' A' ' 3' ' ' PRO . 8.7 tt0 70.97 -5.63 1.46 Allowed 'General case' 0 N--CA 1.494 1.745 0 N-CA-C 104.215 -2.513 . . . . 6.75 104.215 -175.717 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' PHE . . . . . 0.73 ' H ' ' C ' ' A' ' 3' ' ' PRO . 4.3 m-85 -103.56 17.43 24.11 Favored 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 103.392 -2.818 . . . . 6.07 103.392 177.648 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.542 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 44.1 p90 46.23 -159.01 0.03 OUTLIER 'General case' 0 C--N 1.308 -1.212 0 CA-C-N 113.774 -1.557 . . . . 4.72 109.852 -177.665 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.529 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 32.3 tp60 87.0 -9.81 0.62 Allowed 'General case' 0 N--CA 1.493 1.717 0 N-CA-C 104.911 -2.255 . . . . 4.4 104.911 -177.016 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.456 ' CD2' ' O ' ' A' ' 7' ' ' GLN . 45.3 m-85 -158.06 -35.81 0.07 Allowed 'General case' 0 C--N 1.304 -1.412 0 CA-C-N 114.537 -1.211 . . . . 5.15 107.915 178.179 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.582 HG22 ' O ' ' A' ' 9' ' ' THR . 17.8 m -92.39 2.57 56.58 Favored 'General case' 0 C--N 1.298 -1.638 0 N-CA-C 106.008 -1.849 . . . . 5.13 106.008 177.373 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.462 HG13 ' N ' ' A' ' 11' ' ' GLY . 7.5 p -40.74 -38.29 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 CA-C-O 121.792 0.806 . . . . 4.38 109.401 179.838 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.688 ' O ' HD23 ' A' ' 13' ' ' LEU . . . 143.97 -86.87 0.18 Allowed Glycine 0 N--CA 1.496 2.691 0 N-CA-C 108.564 -1.814 . . . . 4.22 108.564 179.566 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.452 ' O ' ' N ' ' A' ' 14' ' ' GLY . 12.5 Cg_endo -69.34 34.98 0.2 Allowed 'Trans proline' 0 C--N 1.321 -0.915 0 C-N-CA 121.321 1.347 . . . . 3.85 108.974 178.243 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.871 ' N ' HD23 ' A' ' 13' ' ' LEU . 0.0 OUTLIER 40.56 28.51 0.05 OUTLIER 'General case' 0 N--CA 1.503 2.206 0 CA-C-O 121.925 0.869 . . . . 3.67 108.731 -178.734 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.597 ' C ' ' H ' ' A' ' 16' ' ' GLY . . . 72.37 -42.21 0.81 Allowed Glycine 0 N--CA 1.487 2.071 0 N-CA-C 108.375 -1.89 . . . . 2.97 108.375 -179.226 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.506 ' H ' ' C ' ' A' ' 13' ' ' LEU . 28.4 tt0 55.13 2.22 0.05 OUTLIER 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.669 -0.901 . . . . 2.97 108.978 -179.257 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.597 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 87.24 -149.21 21.85 Favored Glycine 0 N--CA 1.488 2.107 0 O-C-N 121.292 -0.88 . . . . 2.44 111.157 178.78 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.55 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -38.83 -23.39 0.02 OUTLIER Glycine 0 N--CA 1.497 2.702 0 O-C-N 121.819 -0.813 . . . . 1.81 111.59 -178.704 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.709 ' HB2' ' OE1' ' A' ' 94' ' ' GLU . . . -47.25 -11.57 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.861 0 O-C-N 120.857 -1.378 . . . . 2.21 110.145 -179.467 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' HIS . . . . . 0.55 ' N ' ' O ' ' A' ' 17' ' ' GLY . 1.8 t60 -97.24 -37.73 9.96 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.249 -0.907 . . . . 2.87 110.242 -179.372 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.515 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.0 OUTLIER -91.03 -14.48 31.29 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.008 -1.057 . . . . 2.02 110.497 -179.145 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.566 ' O ' HG13 ' A' ' 21' ' ' VAL . 4.7 p -78.96 114.4 19.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 120.838 -1.164 . . . . 2.07 109.712 -179.763 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 12.5 tpp180 -109.75 139.27 45.0 Favored 'General case' 0 N--CA 1.492 1.646 0 N-CA-C 108.92 -0.771 . . . . 3.5 108.92 -179.877 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -147.32 113.57 5.89 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.535 -0.728 . . . . 1.83 109.2 179.584 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -147.6 128.38 2.9 Favored Glycine 0 N--CA 1.496 2.662 0 N-CA-C 109.472 -1.451 . . . . 1.9 109.472 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.07 171.24 43.69 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.842 -1.303 . . . . 1.85 109.842 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 34.1 m -74.89 -23.6 58.4 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.329 -1.101 . . . . 2.31 109.266 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.426 ' C ' ' H ' ' A' ' 29' ' ' GLU . . . -68.61 -27.92 73.51 Favored Glycine 0 N--CA 1.485 1.925 0 N-CA-C 108.444 -1.862 . . . . 1.64 108.444 179.641 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 24.9 mt -81.06 26.92 0.41 Allowed 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 108.416 -0.957 . . . . 1.83 108.416 179.397 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.426 ' H ' ' C ' ' A' ' 27' ' ' GLY . 42.5 mt-10 -132.21 -50.56 0.94 Allowed 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.687 -0.633 . . . . 2.34 109.608 -179.621 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 29.0 ptt180 -168.17 177.8 5.32 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 120.89 -1.131 . . . . 3.77 110.602 -179.774 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -151.08 175.68 29.92 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 108.566 -1.814 . . . . 1.57 108.566 179.686 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 39.9 t -134.56 151.93 32.58 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.087 0 O-C-N 121.22 -1.165 . . . . 1.83 110.748 -179.702 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.574 ' HB2' ' HB2' ' A' ' 107' ' ' SER . . . -39.16 108.95 0.09 Allowed 'General case' 0 N--CA 1.5 2.029 0 CA-C-O 121.399 0.618 . . . . 1.64 112.494 -179.388 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 54.57 53.71 37.15 Favored Glycine 0 N--CA 1.491 2.323 0 O-C-N 121.393 -0.817 . . . . 1.73 111.626 176.899 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 24.0 t -127.23 124.28 23.68 Favored Pre-proline 0 N--CA 1.496 1.826 0 N-CA-C 108.205 -1.035 . . . . 2.19 108.205 178.663 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo -57.24 128.95 31.69 Favored 'Trans proline' 0 C--O 1.216 -0.615 0 N-CA-C 109.693 -0.926 . . . . 1.96 109.693 -179.581 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.554 ' HB3' ' CZ ' ' A' ' 77' ' ' TYR . . . -134.36 157.89 45.22 Favored 'General case' 0 N--CA 1.502 2.16 0 O-C-N 121.518 -0.739 . . . . 1.69 109.507 -179.634 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -160.14 164.08 33.23 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.121 -0.987 . . . . 2.23 110.976 -179.663 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.558 ' CD1' ' N ' ' A' ' 39' ' ' PHE . 0.7 OUTLIER -139.89 -179.03 5.71 Favored 'General case' 0 C--N 1.304 -1.391 0 N-CA-C 106.896 -1.52 . . . . 1.54 106.896 177.75 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 52.2 p -119.16 145.87 45.64 Favored 'General case' 0 N--CA 1.5 2.04 0 O-C-N 121.598 -0.688 . . . . 2.37 110.609 -178.816 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.537 ' O ' ' N ' ' A' ' 73' ' ' CYS . 42.8 mt -143.63 128.68 15.1 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 N-CA-C 108.58 -0.896 . . . . 1.65 108.58 179.213 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 5.5 p-90 -128.24 138.78 52.59 Favored 'General case' 0 N--CA 1.502 2.161 0 N-CA-C 108.853 -0.795 . . . . 3.68 108.853 179.423 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.515 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -162.42 139.22 7.9 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.171 -0.956 . . . . 2.89 109.896 -179.534 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 44' ' ' ARG . . . . . . . . . . . . . 61.7 ttt180 -171.84 68.38 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.414 -0.804 . . . . 4.63 109.226 179.732 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 11.1 tp10 -153.72 -51.79 0.1 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.244 -0.91 . . . . 2.89 109.568 -179.87 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.76 -50.08 73.33 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.201 -0.937 . . . . 1.74 108.946 179.795 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 116.14 -162.4 12.62 Favored Glycine 0 N--CA 1.497 2.745 0 N-CA-C 109.639 -1.384 . . . . 1.6 109.639 179.735 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.4 151.98 5.11 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.276 -1.132 . . . . 1.4 109.386 -179.841 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -176.49 -162.72 27.7 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.55 -1.42 . . . . 1.04 109.55 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -140.47 119.71 1.63 Allowed Glycine 0 N--CA 1.496 2.663 0 N-CA-C 109.528 -1.429 . . . . 1.06 109.528 -179.878 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.466 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 11.6 tp -99.43 99.04 9.9 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.357 -1.084 . . . . 1.1 108.691 179.685 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 4.1 m -84.8 142.33 29.85 Favored 'General case' 0 N--CA 1.496 1.84 0 N-CA-C 108.741 -0.837 . . . . 1.56 108.741 179.867 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.52 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 80.5 mt -132.36 116.6 29.21 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 O-C-N 121.01 -1.056 . . . . 0.65 109.889 -179.915 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -106.99 106.92 17.69 Favored 'General case' 0 N--CA 1.496 1.865 0 N-CA-C 108.562 -0.903 . . . . 0.69 108.562 179.328 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -106.23 137.55 35.96 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 121.388 -0.82 . . . . 0.91 109.941 -179.186 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.433 ' OE2' ' O ' ' B' ' 9' ' ' VAL . 40.7 tp10 -131.97 142.78 49.72 Favored 'General case' 0 N--CA 1.495 1.785 0 N-CA-C 107.896 -1.15 . . . . 1.8 107.896 178.36 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 172.95 -179.51 44.34 Favored Glycine 0 N--CA 1.488 2.132 0 N-CA-C 108.784 -1.726 . . . . 0.49 108.784 -179.635 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -63.43 -21.91 71.26 Favored 'Trans proline' 0 C--N 1.315 -1.231 0 C-N-CA 121.678 1.585 . . . . 0.66 110.732 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' SER . . . . . 0.423 ' O ' ' OH ' ' A' ' 85' ' ' TYR . 36.6 m -143.24 165.47 27.36 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.453 -0.78 . . . . 1.55 110.114 -179.62 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 38.2 mttp -86.97 104.96 16.78 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.507 -0.746 . . . . 2.53 109.396 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -67.06 113.06 4.74 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.337 -0.852 . . . . 0.82 109.535 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 24.5 mm-40 -53.72 171.76 0.09 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.282 -0.886 . . . . 2.3 109.225 179.84 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.4 HG22 ' N ' ' A' ' 64' ' ' ALA . 90.1 mt -142.32 155.59 18.83 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 N-CA-C 108.122 -1.066 . . . . 1.4 108.122 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.542 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -149.56 175.35 11.6 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 120.642 -1.286 . . . . 1.36 109.635 -179.802 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.522 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 54.6 p90 -138.88 124.77 19.84 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.448 -0.782 . . . . 1.47 109.124 179.846 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -141.46 123.63 15.58 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.273 -0.892 . . . . 2.51 109.579 -179.825 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -99.77 101.97 13.28 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.364 -0.835 . . . . 2.07 109.267 179.807 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 39.4 ttm180 -90.14 -15.55 31.34 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.198 -0.939 . . . . 4.63 109.763 -179.771 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.526 ' C ' ' H ' ' A' ' 71' ' ' GLY . 4.5 mmmm -127.56 5.12 6.18 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 121.442 -0.786 . . . . 3.49 109.44 -179.681 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.464 ' CB ' ' O ' ' A' ' 69' ' ' LYS . 4.5 t0 73.14 -17.21 0.43 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.198 -0.939 . . . . 3.06 108.739 -179.437 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' GLY . . . . . 0.526 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -124.97 -17.02 2.84 Favored Glycine 0 N--CA 1.495 2.593 0 N-CA-C 109.367 -1.493 . . . . 2.16 109.367 -179.671 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 40.3 t -95.85 100.37 12.08 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.258 -1.142 . . . . 2.2 109.176 179.785 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' CYS . . . . . 0.537 ' N ' ' O ' ' A' ' 41' ' ' ILE . 46.6 t -71.54 111.1 6.57 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.228 -0.92 . . . . 2.05 109.48 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -91.96 115.14 4.71 Favored Glycine 0 N--CA 1.493 2.477 0 N-CA-C 109.692 -1.363 . . . . 1.39 109.692 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 45.3 t -99.38 102.0 12.84 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 O-C-N 121.467 -1.019 . . . . 1.57 109.011 179.721 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.542 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.4 OUTLIER -92.0 137.09 32.65 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.338 -0.851 . . . . 1.85 109.111 -179.837 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.554 ' CZ ' ' HB3' ' A' ' 37' ' ' ALA . 8.5 p90 -136.34 166.04 24.38 Favored 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 108.674 -0.861 . . . . 1.54 108.674 -179.862 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 6.7 t -141.86 110.05 2.34 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.329 -0.857 . . . . 1.9 109.585 -179.669 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.464 ' H ' HG22 ' A' ' 79' ' ' VAL . 3.3 m -84.73 154.32 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.544 -0.723 . . . . 1.27 109.429 -179.915 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 4.3 tp-100 -93.26 -48.93 6.21 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.065 -1.022 . . . . 2.48 111.015 -178.96 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.431 ' O ' ' O ' ' A' ' 82' ' ' PRO . 81.5 mm-40 -148.57 149.92 32.39 Favored Pre-proline 0 N--CA 1.504 2.263 0 O-C-N 120.68 -1.262 . . . . 1.92 111.609 -178.427 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.637 ' HG3' ' N ' ' A' ' 107' ' ' SER . 83.1 Cg_exo -37.18 168.53 0.0 OUTLIER 'Trans proline' 0 C--O 1.216 -0.599 0 C-N-CA 123.15 2.567 . . . . 1.3 113.787 178.37 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 141.8 -173.8 23.4 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 108.651 -1.779 . . . . 1.02 108.651 -179.87 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 84' ' ' ASP . . . . . 0.717 ' H ' ' NH1' ' B' ' 8' ' ' ARG . 0.4 OUTLIER -103.18 90.41 3.72 Favored 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 107.866 -1.161 . . . . 2.13 107.866 179.217 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.423 ' OH ' ' O ' ' A' ' 59' ' ' SER . 3.0 m-85 -74.69 133.4 42.09 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 107.992 -1.114 . . . . 0.92 107.992 -179.574 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.36 116.38 28.85 Favored 'General case' 0 N--CA 1.5 2.034 0 N-CA-C 108.503 -0.925 . . . . 1.53 108.503 -178.791 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.429 HG11 ' CZ ' ' A' ' 101' ' ' PHE . 11.3 p -114.63 142.32 27.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 121.719 -0.613 . . . . 1.0 109.865 -179.66 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 32.9 t -136.11 106.07 6.28 Favored 'General case' 0 N--CA 1.494 1.756 0 N-CA-C 109.289 -0.634 . . . . 1.59 109.289 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.413 ' H ' ' HB3' ' A' ' 99' ' ' SER . 1.8 pt -111.4 136.85 46.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 CA-C-O 121.374 0.607 . . . . 1.29 110.148 -179.429 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 90' ' ' LYS . . . . . 0.458 ' HZ2' ' CD2' ' A' ' 95' ' ' HIS . 0.3 OUTLIER -138.99 121.27 15.92 Favored 'General case' 0 N--CA 1.486 1.355 0 N-CA-C 108.518 -0.919 . . . . 1.58 108.518 179.329 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 52.6 t80 -80.1 99.02 7.52 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 107.699 -1.223 . . . . 1.34 107.699 178.563 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 92' ' ' ASN . . . . . 0.442 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 3.6 t-20 69.8 37.79 1.76 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.503 -0.748 . . . . 2.32 109.284 -178.735 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.442 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 1.8 m-20 79.06 13.49 1.2 Allowed 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.625 -0.672 . . . . 1.92 111.629 179.313 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 94' ' ' GLU . . . . . 0.709 ' OE1' ' HB2' ' A' ' 18' ' ' ALA . 0.6 OUTLIER -99.29 97.88 8.9 Favored 'General case' 0 N--CA 1.5 2.059 0 N-CA-C 106.857 -1.534 . . . . 2.25 106.857 177.732 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 95' ' ' HIS . . . . . 0.458 ' CD2' ' HZ2' ' A' ' 90' ' ' LYS . 5.9 m80 -67.88 101.86 1.16 Allowed 'General case' 0 N--CA 1.487 1.421 0 CA-C-O 121.411 0.624 . . . . 2.88 110.924 -177.636 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 96' ' ' ILE . . . . . 0.428 HG23 ' H ' ' A' ' 99' ' ' SER . 2.1 tt -53.32 137.46 49.69 Favored Pre-proline 0 N--CA 1.49 1.566 0 N-CA-C 106.869 -1.53 . . . . 2.35 106.869 178.26 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_exo -40.76 -39.06 2.95 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 121.077 1.184 . . . . 2.48 111.194 -178.575 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.408 ' OD1' ' CD1' ' A' ' 96' ' ' ILE . 8.6 m-20 -50.12 -67.2 0.28 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.787 -1.196 . . . . 2.65 109.092 178.843 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.428 ' H ' HG23 ' A' ' 96' ' ' ILE . 2.8 p -57.53 142.03 77.77 Favored Pre-proline 0 C--N 1.296 -1.759 0 O-C-N 121.405 -0.81 . . . . 2.0 110.086 -178.236 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -85.15 114.92 3.22 Favored 'Cis proline' 0 N--CA 1.49 1.288 0 N-CA-C 108.739 -1.293 . . . . 1.79 108.739 -2.612 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 101' ' ' PHE . . . . . 0.429 ' CZ ' HG11 ' A' ' 87' ' ' VAL . 51.8 p90 -112.77 156.45 22.83 Favored 'General case' 0 N--CA 1.514 2.748 0 O-C-N 120.405 -1.434 . . . . 2.19 110.217 179.286 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.4 p -88.94 146.1 6.58 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 CA-C-O 121.556 0.693 . . . . 1.44 110.417 -178.595 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.414 ' O ' HG12 ' A' ' 103' ' ' VAL . 47.3 t -120.97 86.55 42.09 Favored Pre-proline 0 N--CA 1.494 1.768 0 N-CA-C 107.753 -1.203 . . . . 1.19 107.753 179.236 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo -65.07 111.08 1.65 Allowed 'Trans proline' 0 C--N 1.32 -0.935 0 C-N-CA 121.393 1.395 . . . . 1.49 111.74 -177.879 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.431 HG21 HG11 ' A' ' 79' ' ' VAL . 58.6 t -96.53 141.05 16.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 N-CA-C 106.148 -1.797 . . . . 1.35 106.148 177.828 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.69 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -133.89 133.72 41.83 Favored 'General case' 0 N--CA 1.51 2.53 0 CA-C-O 122.303 1.049 . . . . 1.67 112.131 -177.031 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.637 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 17.0 t -101.02 85.55 2.87 Favored 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 107.129 -1.434 . . . . 2.04 107.129 178.685 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 12.9 mt 64.76 0.51 1.18 Allowed 'General case' 0 C--N 1.296 -1.729 0 N-CA-C 108.035 -1.098 . . . . 3.2 108.035 -178.011 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.624 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 8.2 t -89.88 -24.95 21.23 Favored 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 109.011 -0.737 . . . . 2.09 109.011 179.061 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 110' ' ' ASP . . . . . 0.69 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 25.2 t70 54.32 10.65 0.33 Allowed 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 107.897 -1.149 . . . . 2.85 107.897 -178.969 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.491 ' H ' ' C ' ' A' ' 109' ' ' SER . 42.3 t0 -168.81 -34.01 0.02 OUTLIER 'General case' 0 C--N 1.305 -1.341 0 O-C-N 121.756 -0.59 . . . . 2.46 109.556 -179.73 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.624 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 34.66 78.02 0.03 OUTLIER 'General case' 0 N--CA 1.508 2.433 0 O-C-N 121.479 -0.763 . . . . 2.08 110.894 179.883 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 113' ' ' ARG . . . . . 0.401 ' H ' ' HB ' ' A' ' 117' ' ' VAL . 72.6 mtt180 -82.91 167.15 18.28 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.127 -0.983 . . . . 5.93 109.756 -179.475 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 28.2 ttp180 -110.52 5.4 21.2 Favored 'General case' 0 N--CA 1.498 1.929 0 N-CA-C 108.649 -0.871 . . . . 5.61 108.649 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 27.9 mt -125.65 -26.59 3.5 Favored 'General case' 0 N--CA 1.503 2.221 0 N-CA-C 109.157 -0.682 . . . . 4.39 109.157 -179.901 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.504 ' C ' ' H ' ' A' ' 118' ' ' THR . 99.8 m -107.93 -79.19 0.58 Allowed 'General case' 0 N--CA 1.497 1.914 0 N-CA-C 107.244 -1.391 . . . . 4.09 107.244 179.165 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.417 ' O ' HG12 ' A' ' 117' ' ' VAL . 46.1 t -60.8 -8.94 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.644 0 N-CA-C 106.053 -1.832 . . . . 2.9 106.053 176.803 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 118' ' ' THR . . . . . 0.504 ' H ' ' C ' ' A' ' 116' ' ' THR . 4.9 t 36.59 59.07 1.03 Allowed 'General case' 0 N--CA 1.486 1.35 0 CA-C-N 115.181 -0.918 . . . . 3.36 110.835 179.632 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 119' ' ' SER . . . . . 0.456 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.6 p . . . . . 0 C--N 1.303 -1.44 0 CA-C-O 117.984 -1.008 . . . . 3.39 109.492 179.383 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 1' ' ' MET . . . . . 0.556 ' SD ' ' N ' ' B' ' 1' ' ' MET . 1.8 mpp? . . . . . 0 N--CA 1.491 1.602 0 N-CA-C 109.421 -0.585 . . . . 8.49 109.421 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 2' ' ' ALA . . . . . 0.448 ' O ' ' O ' ' B' ' 3' ' ' SER . . . 59.02 113.25 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.396 -0.815 . . . . 5.53 109.652 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 3' ' ' SER . . . . . 0.448 ' O ' ' O ' ' B' ' 2' ' ' ALA . 17.1 p 47.96 98.45 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.441 -0.787 . . . . 5.43 109.857 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 4' ' ' LYS . . . . . 0.479 ' O ' ' O ' ' B' ' 5' ' ' PRO . 37.2 mtmt -46.77 155.01 0.64 Allowed Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.272 -0.892 . . . . 6.87 109.095 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 5' ' ' PRO . . . . . 0.49 ' O ' ' CB ' ' B' ' 6' ' ' GLU . 3.2 Cg_exo -55.8 -148.31 0.0 OUTLIER 'Trans proline' 0 CA--C 1.544 1.002 0 C-N-CA 121.479 1.453 . . . . 5.16 110.357 179.411 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 6' ' ' GLU . . . . . 0.49 ' CB ' ' O ' ' B' ' 5' ' ' PRO . 20.0 tt0 82.18 150.59 0.09 Allowed 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.41 -0.806 . . . . 4.78 109.25 -179.682 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 44.1 mtmt -78.38 -156.51 0.1 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.299 -0.875 . . . . 4.09 109.869 -179.597 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.717 ' NH1' ' H ' ' A' ' 84' ' ' ASP . 43.8 mtt180 -101.02 -176.47 3.17 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.395 -0.816 . . . . 3.04 109.325 -179.781 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 9' ' ' VAL . . . . . 0.433 ' O ' ' OE2' ' A' ' 56' ' ' GLU . 15.2 t -59.34 160.32 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 N-CA-C 107.718 -1.215 . . . . 0.67 107.718 178.719 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -116.99 142.94 46.31 Favored 'General case' 0 N--CA 1.503 2.189 0 O-C-N 121.287 -0.883 . . . . 0.58 110.433 -179.073 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 30.2 t -143.72 131.36 21.25 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.471 -0.768 . . . . 1.19 109.063 179.47 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 87.8 p -140.39 120.19 13.46 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.232 -0.918 . . . . 1.38 109.587 -179.727 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 0.603 HG22 ' N ' ' B' ' 14' ' ' PHE . 3.0 p -162.26 168.3 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.412 0 O-C-N 121.379 -0.826 . . . . 0.42 109.073 -179.948 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 14' ' ' PHE . . . . . 0.603 ' N ' HG22 ' B' ' 13' ' ' VAL . 6.6 p90 -177.1 -171.76 0.37 Allowed 'General case' 0 N--CA 1.487 1.4 0 C-N-CA 119.391 -0.923 . . . . 1.79 112.008 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -142.64 173.78 6.38 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.322 0 N-CA-C 108.335 -0.987 . . . . 1.25 108.335 179.597 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 32.3 p -146.65 139.82 25.54 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 120.929 -1.107 . . . . 1.61 109.817 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.4 mt -90.34 133.62 34.85 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.256 -0.902 . . . . 1.32 109.074 179.582 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -169.56 80.74 0.66 Allowed Pre-proline 0 N--CA 1.489 1.489 0 O-C-N 121.278 -0.889 . . . . 1.45 109.516 -179.436 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_exo -57.34 112.15 1.04 Allowed 'Trans proline' 0 CA--C 1.554 1.505 0 C-N-CA 121.357 1.371 . . . . 1.5 109.82 -179.385 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 20' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -66.3 -65.61 0.04 OUTLIER 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 120.761 0.974 . . . . 2.86 110.101 -179.661 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 7.0 tpt180 -48.51 145.53 3.46 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.295 -0.878 . . . . 6.12 109.54 -179.423 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 22' ' ' ARG . . . . . 0.417 HH11 ' CG ' ' B' ' 22' ' ' ARG . 0.2 OUTLIER -147.96 64.97 1.1 Allowed 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.274 -0.891 . . . . 6.29 109.251 179.941 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -71.43 161.04 31.68 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.237 -0.914 . . . . 5.62 109.297 179.828 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 16.7 m . . . . . 0 N--CA 1.49 1.571 0 CA-C-O 117.938 -1.03 . . . . 6.48 109.483 -179.869 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.531 4.97 0 N-CA-C 119.75 2.66 . . . . 6.64 119.75 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.69 HG23 ' O ' ' A' ' 2' ' ' ILE . 11.0 tp -171.86 50.16 0.12 Allowed Pre-proline 0 C--N 1.307 -1.268 0 N-CA-C 108.131 -1.063 . . . . 7.08 108.131 179.559 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.782 ' C ' ' H ' ' A' ' 5' ' ' PHE . 1.0 OUTLIER -53.96 -79.53 0.02 OUTLIER 'Trans proline' 0 C--N 1.319 -1.013 0 C-N-CA 121.133 1.222 . . . . 5.5 109.073 179.737 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.501 ' C ' ' H ' ' A' ' 6' ' ' PHE . 9.4 tt0 73.35 -16.78 0.46 Allowed 'General case' 0 N--CA 1.494 1.73 0 N-CA-C 104.39 -2.448 . . . . 6.75 104.39 -175.703 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' PHE . . . . . 0.782 ' H ' ' C ' ' A' ' 3' ' ' PRO . 3.7 m-85 -89.73 17.92 6.07 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 103.909 -2.626 . . . . 6.07 103.909 176.708 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.531 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 41.3 p90 45.58 -155.0 0.04 OUTLIER 'General case' 0 C--N 1.307 -1.246 0 CA-C-N 114.23 -1.35 . . . . 4.72 109.432 -177.642 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.531 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 18.8 tt0 83.67 -9.26 1.02 Allowed 'General case' 0 N--CA 1.492 1.638 0 N-CA-C 105.019 -2.215 . . . . 4.4 105.019 -177.226 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.479 ' H ' ' C ' ' A' ' 6' ' ' PHE . 85.1 t80 -154.19 -36.56 0.1 Allowed 'General case' 0 C--N 1.305 -1.361 0 CA-C-N 114.66 -1.155 . . . . 5.15 108.111 178.484 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.496 HG22 ' O ' ' A' ' 9' ' ' THR . 94.2 m -93.79 2.99 56.09 Favored 'General case' 0 C--N 1.298 -1.673 0 N-CA-C 105.815 -1.921 . . . . 5.13 105.815 177.25 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.4 HG13 ' N ' ' A' ' 11' ' ' GLY . 7.3 p -43.18 -36.3 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 CA-C-N 115.433 -0.803 . . . . 4.38 109.399 -179.918 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.59 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 141.22 -84.86 0.21 Allowed Glycine 0 N--CA 1.497 2.757 0 N-CA-C 108.311 -1.916 . . . . 4.22 108.311 179.802 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.492 ' O ' ' N ' ' A' ' 14' ' ' GLY . 14.0 Cg_endo -67.84 40.33 0.21 Allowed 'Trans proline' 0 C--N 1.319 -0.996 0 C-N-CA 121.619 1.546 . . . . 3.85 108.412 177.633 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.59 ' H ' ' C ' ' A' ' 11' ' ' GLY . 0.2 OUTLIER 29.08 39.51 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.238 0 CA-C-O 121.508 0.671 . . . . 3.67 110.73 -179.295 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.499 ' C ' ' H ' ' A' ' 16' ' ' GLY . . . 69.61 -37.26 0.36 Allowed Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.423 -1.471 . . . . 2.97 109.423 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.535 ' H ' ' C ' ' A' ' 13' ' ' LEU . 7.2 tp10 57.66 4.43 0.25 Allowed 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.352 -1.087 . . . . 2.97 108.888 -179.833 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.548 ' O ' ' N ' ' A' ' 18' ' ' ALA . . . 65.9 90.73 0.04 OUTLIER Glycine 0 N--CA 1.49 2.255 0 N-CA-C 110.643 -0.983 . . . . 2.44 110.643 179.213 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.583 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 64.21 -47.1 0.1 OUTLIER Glycine 0 N--CA 1.493 2.497 0 O-C-N 121.479 -1.012 . . . . 1.81 111.055 178.823 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.548 ' N ' ' O ' ' A' ' 16' ' ' GLY . . . -46.24 -11.13 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.871 0 O-C-N 120.959 -1.318 . . . . 2.21 110.05 -179.578 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' HIS . . . . . 0.583 ' N ' ' O ' ' A' ' 17' ' ' GLY . 34.0 t60 -84.64 -48.42 9.51 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 120.994 -1.066 . . . . 2.87 109.6 179.729 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.552 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.1 OUTLIER -83.18 -3.63 57.57 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.047 -1.033 . . . . 2.02 110.192 -179.617 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 66.6 t -77.86 113.24 16.8 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 120.944 -1.098 . . . . 2.07 109.537 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 20.9 tpt180 -100.14 138.93 36.53 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.633 -0.667 . . . . 3.5 109.571 -179.858 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -147.42 113.37 5.79 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 108.402 -0.962 . . . . 1.83 108.402 179.332 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -158.5 128.7 2.12 Favored Glycine 0 N--CA 1.491 2.339 0 C-N-CA 119.688 -1.244 . . . . 1.9 110.234 -179.199 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.3 -179.7 48.77 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.641 -1.383 . . . . 1.85 109.641 179.611 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 6.5 m -76.58 -21.86 55.03 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.168 -1.195 . . . . 2.31 109.24 179.759 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.9 -23.83 77.64 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 108.818 -1.713 . . . . 1.64 108.818 179.71 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 34.6 mt -85.1 28.79 0.69 Allowed 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.499 -1.001 . . . . 1.83 108.689 179.572 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 15.0 mt-10 -138.71 -64.24 0.52 Allowed 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.503 -0.748 . . . . 2.34 109.908 -179.655 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 80.8 mtm180 -150.64 165.42 33.44 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 120.895 -1.128 . . . . 3.77 110.222 -179.248 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -139.07 170.57 24.01 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 107.473 -2.251 . . . . 1.57 107.473 178.887 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 40.5 t -133.85 151.31 32.63 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.109 0 O-C-N 121.088 -1.243 . . . . 1.83 110.948 -179.029 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.499 ' HB2' ' HB2' ' A' ' 107' ' ' SER . . . -40.48 114.59 0.47 Allowed 'General case' 0 N--CA 1.497 1.902 0 CA-C-O 121.867 0.841 . . . . 1.64 112.428 -179.313 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 52.99 49.71 54.19 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 111.225 -0.75 . . . . 1.73 111.225 177.13 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 22.5 t -127.02 124.98 24.1 Favored Pre-proline 0 N--CA 1.496 1.843 0 O-C-N 121.497 -1.002 . . . . 2.19 108.46 179.143 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -58.41 109.86 0.57 Allowed 'Trans proline' 0 C--O 1.215 -0.637 0 N-CA-C 109.682 -0.93 . . . . 1.96 109.682 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -108.03 142.07 38.74 Favored 'General case' 0 N--CA 1.495 1.825 0 N-CA-C 107.929 -1.138 . . . . 1.69 107.929 179.408 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -150.92 169.52 21.53 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.871 -1.143 . . . . 2.23 111.244 -179.385 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.61 ' CE2' HD11 ' A' ' 41' ' ' ILE . 5.2 p90 -154.35 173.78 15.73 Favored 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 107.617 -1.253 . . . . 1.54 107.617 178.452 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 72.9 m -101.54 150.82 22.68 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.496 -0.753 . . . . 2.37 110.469 -178.652 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.61 HD11 ' CE2' ' A' ' 39' ' ' PHE . 11.3 mt -142.95 90.64 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 N-CA-C 108.748 -0.834 . . . . 1.65 108.748 178.981 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.517 ' CE3' ' O ' ' A' ' 71' ' ' GLY . 31.1 t-105 -92.93 120.01 32.81 Favored 'General case' 0 N--CA 1.493 1.704 0 N-CA-C 108.251 -1.018 . . . . 3.68 108.251 179.504 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.552 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -152.74 108.84 3.36 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.276 -0.89 . . . . 2.89 109.594 -179.148 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 44' ' ' ARG . . . . . 0.598 ' CG ' HH11 ' A' ' 44' ' ' ARG . 0.1 OUTLIER -171.57 82.12 0.07 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.225 -0.922 . . . . 4.63 109.599 -179.984 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 74.2 tt0 -159.5 -46.24 0.05 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.016 -1.053 . . . . 2.89 109.985 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.456 ' H ' ' HE2' ' A' ' 20' ' ' LYS . . . -64.15 -45.62 87.68 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.03 -1.044 . . . . 1.74 109.195 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 160.78 -153.03 23.83 Favored Glycine 0 N--CA 1.485 1.903 0 C-N-CA 119.403 -1.379 . . . . 1.6 110.175 179.786 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -96.66 158.57 15.37 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.558 -0.966 . . . . 1.4 109.174 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -179.09 173.0 45.2 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.392 -1.483 . . . . 1.04 109.392 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -105.11 121.09 6.76 Favored Glycine 0 N--CA 1.495 2.624 0 N-CA-C 109.501 -1.439 . . . . 1.06 109.501 -179.891 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.465 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 64.2 tp -91.01 108.79 20.09 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.222 -1.163 . . . . 1.1 107.897 179.153 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.7 t -91.23 142.37 27.8 Favored 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 108.663 -0.865 . . . . 1.56 108.663 179.89 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.544 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 22.5 mt -130.49 100.62 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 121.521 -0.737 . . . . 0.65 109.071 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.438 ' HB3' ' OG ' ' A' ' 88' ' ' SER . . . -93.86 106.41 18.38 Favored 'General case' 0 N--CA 1.489 1.506 0 N-CA-C 108.621 -0.881 . . . . 0.69 108.621 179.711 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.408 HG23 ' CB ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -101.48 143.28 14.7 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 CA-C-O 121.588 0.708 . . . . 0.91 109.582 -179.631 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 8.2 tt0 -141.52 145.57 35.33 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 107.479 -1.304 . . . . 1.8 107.479 178.868 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 165.56 -172.71 41.14 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.856 -1.298 . . . . 0.49 109.856 -179.095 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -63.18 -33.99 70.14 Favored 'Trans proline' 0 C--N 1.319 -0.988 0 C-N-CA 122.315 2.01 . . . . 0.66 112.514 -179.435 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' SER . . . . . 0.497 ' OG ' ' N ' ' A' ' 60' ' ' LYS . 5.9 t -132.36 177.76 7.34 Favored 'General case' 0 N--CA 1.504 2.239 0 O-C-N 120.944 -1.097 . . . . 1.55 110.49 -179.273 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' LYS . . . . . 0.497 ' N ' ' OG ' ' A' ' 59' ' ' SER . 45.8 tttm -93.82 96.18 9.59 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.689 -0.632 . . . . 2.53 109.713 -179.591 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -61.54 131.17 49.23 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.179 -0.951 . . . . 0.82 109.017 179.696 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 16.2 tp10 -88.54 95.05 10.08 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 120.964 -1.085 . . . . 2.3 110.174 -179.456 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.563 HD12 ' N ' ' A' ' 63' ' ' ILE . 1.7 mp -60.61 156.04 3.43 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 N-CA-C 109.207 -0.664 . . . . 1.4 109.207 179.335 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.534 ' HB3' ' HB3' ' A' ' 76' ' ' SER . . . -144.72 172.38 13.08 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.013 -1.054 . . . . 1.36 108.78 179.598 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.524 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 41.0 p90 -148.44 116.2 6.33 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.26 -0.9 . . . . 1.47 109.188 179.845 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 78.6 tt0 -141.78 105.05 4.63 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.161 -0.962 . . . . 2.51 109.821 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -81.91 107.17 14.41 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.232 -0.918 . . . . 2.07 108.935 179.452 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.537 ' CG ' HH11 ' A' ' 68' ' ' ARG . 0.0 OUTLIER -110.98 -9.43 14.42 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.532 -0.73 . . . . 4.63 109.096 -179.477 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.485 ' C ' ' H ' ' A' ' 71' ' ' GLY . 58.1 mmtt -109.73 -9.37 14.84 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.355 -0.841 . . . . 3.49 109.104 179.894 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 4.8 t70 64.79 -3.12 0.6 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.378 -0.826 . . . . 3.06 109.394 179.656 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' GLY . . . . . 0.517 ' O ' ' CE3' ' A' ' 42' ' ' TRP . . . -141.34 17.18 2.69 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.423 -1.471 . . . . 2.16 109.423 -179.009 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 19.8 t -156.36 114.96 3.38 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.457 -1.025 . . . . 2.2 108.827 179.673 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 8.6 t -76.69 129.14 35.93 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.103 -0.998 . . . . 2.05 109.103 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -103.68 114.68 4.87 Favored Glycine 0 N--CA 1.496 2.69 0 N-CA-C 110.064 -1.214 . . . . 1.39 110.064 -179.332 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.588 HG21 HD12 ' A' ' 41' ' ' ILE . 38.4 t -101.83 108.74 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.925 0 O-C-N 121.516 -0.99 . . . . 1.57 108.771 179.426 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.534 ' HB3' ' HB3' ' A' ' 64' ' ' ALA . 4.1 t -103.46 127.69 50.79 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.531 -0.731 . . . . 1.85 109.457 179.849 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 6.4 p90 -128.45 128.2 43.97 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 108.303 -0.999 . . . . 1.54 108.303 179.838 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -103.8 110.06 29.01 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.159 0 O-C-N 121.324 -0.86 . . . . 1.9 109.404 -178.859 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.47 ' H ' HG22 ' A' ' 79' ' ' VAL . 5.8 m -82.6 163.39 3.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.496 -0.753 . . . . 1.27 109.42 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 20.1 tt0 -95.78 -50.39 4.93 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.005 -1.059 . . . . 2.48 111.117 -179.163 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -152.29 155.55 33.17 Favored Pre-proline 0 N--CA 1.504 2.237 0 O-C-N 120.688 -1.257 . . . . 1.92 111.72 -178.594 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.572 ' HG3' ' N ' ' A' ' 107' ' ' SER . 75.9 Cg_exo -37.07 160.77 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 123.61 2.873 . . . . 1.3 113.636 179.285 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 148.19 -164.16 28.94 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.223 -1.551 . . . . 1.02 109.223 179.816 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 84' ' ' ASP . . . . . 0.431 ' HB2' ' HE ' ' B' ' 8' ' ' ARG . 65.0 m-20 -108.82 88.85 2.83 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.601 -0.94 . . . . 2.13 108.662 179.656 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.499 ' O ' ' N ' ' A' ' 103' ' ' VAL . 2.9 m-85 -76.27 129.52 36.8 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 108.165 -1.05 . . . . 0.92 108.165 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -107.85 128.33 54.51 Favored 'General case' 0 N--CA 1.497 1.914 0 N-CA-C 108.144 -1.058 . . . . 1.53 108.144 -179.446 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 9.4 p -126.12 140.27 49.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.525 -0.734 . . . . 1.0 109.972 -179.401 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' SER . . . . . 0.438 ' OG ' ' HB3' ' A' ' 54' ' ' ALA . 11.1 p -134.4 104.39 6.11 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.585 -0.697 . . . . 1.59 109.52 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.414 HD11 ' CD1' ' A' ' 96' ' ' ILE . 0.8 OUTLIER -112.33 129.58 67.6 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 CA-C-O 121.585 0.707 . . . . 1.29 109.492 -179.847 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 90' ' ' LYS . . . . . 0.469 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -139.71 124.2 18.17 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 108.232 -1.025 . . . . 1.58 108.232 179.661 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.408 ' O ' ' CB ' ' A' ' 92' ' ' ASN . 31.8 t80 -85.64 102.96 14.02 Favored 'General case' 0 N--CA 1.494 1.737 0 N-CA-C 107.546 -1.279 . . . . 1.34 107.546 178.783 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 92' ' ' ASN . . . . . 0.423 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 8.5 t30 72.48 35.84 1.09 Allowed 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.806 -0.813 . . . . 2.32 108.806 -178.235 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.423 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 1.7 m-20 76.4 15.24 2.25 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.676 -0.64 . . . . 1.92 111.409 179.692 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 94' ' ' GLU . . . . . 0.498 ' CG ' ' O ' ' A' ' 94' ' ' GLU . 7.2 pt-20 -98.53 100.43 11.68 Favored 'General case' 0 N--CA 1.493 1.717 0 N-CA-C 107.201 -1.407 . . . . 2.25 107.201 177.949 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 95' ' ' HIS . . . . . 0.427 ' CD2' ' O ' ' A' ' 95' ' ' HIS . 17.7 p-80 -71.67 106.52 4.11 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.215 -0.928 . . . . 2.88 109.534 -178.541 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 96' ' ' ILE . . . . . 0.561 ' O ' ' N ' ' A' ' 98' ' ' ASP . 10.1 pt -55.82 150.19 28.94 Favored Pre-proline 0 N--CA 1.491 1.611 0 C-N-CA 119.377 -0.929 . . . . 2.35 108.507 179.795 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.411 ' O ' ' CG ' ' A' ' 98' ' ' ASP . 4.6 Cg_exo -53.87 82.01 0.03 OUTLIER 'Trans proline' 0 C--O 1.213 -0.738 0 N-CA-C 109.202 -1.114 . . . . 2.48 109.202 179.415 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.561 ' N ' ' O ' ' A' ' 96' ' ' ILE . 1.9 m-20 175.05 -63.36 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 108.037 -1.097 . . . . 2.65 108.037 -178.949 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 5.1 m -59.03 139.08 87.68 Favored Pre-proline 0 C--N 1.298 -1.671 0 O-C-N 121.539 -0.725 . . . . 2.0 110.119 -178.134 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_endo -88.58 115.21 2.9 Favored 'Cis proline' 0 N--CA 1.493 1.474 0 N-CA-C 109.722 -0.915 . . . . 1.79 109.722 -2.597 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 45.6 p90 -112.53 168.45 9.64 Favored 'General case' 0 N--CA 1.516 2.868 0 O-C-N 120.556 -1.34 . . . . 2.19 110.027 178.828 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.4 p -94.38 152.28 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.474 -0.766 . . . . 1.44 110.735 -178.901 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.499 ' N ' ' O ' ' A' ' 85' ' ' TYR . 61.3 t -126.69 87.01 57.4 Favored Pre-proline 0 N--CA 1.499 1.992 0 N-CA-C 107.919 -1.141 . . . . 1.19 107.919 179.193 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -61.25 113.09 1.61 Allowed 'Trans proline' 0 C--N 1.32 -0.951 0 C-N-CA 121.376 1.384 . . . . 1.49 112.189 -177.787 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 53.8 t -94.16 145.08 8.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 N-CA-C 106.64 -1.615 . . . . 1.35 106.64 177.736 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.543 ' HB1' ' H ' ' A' ' 110' ' ' ASP . . . -136.73 137.33 39.81 Favored 'General case' 0 N--CA 1.506 2.328 0 CA-C-O 122.268 1.032 . . . . 1.67 111.995 -177.507 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.572 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 9.5 t -110.53 68.47 0.67 Allowed 'General case' 0 N--CA 1.495 1.808 0 N-CA-C 107.229 -1.397 . . . . 2.04 107.229 178.855 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 108' ' ' LEU . . . . . 0.496 ' CB ' ' O ' ' A' ' 107' ' ' SER . 2.6 tp 81.23 -3.53 1.7 Allowed 'General case' 0 N--CA 1.492 1.641 0 N-CA-C 106.603 -1.629 . . . . 3.2 106.603 -177.574 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.487 ' O ' ' N ' ' A' ' 111' ' ' ASP . 2.0 m -80.08 -27.09 39.36 Favored 'General case' 0 N--CA 1.486 1.348 0 N-CA-C 108.853 -0.795 . . . . 2.09 108.853 179.138 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 110' ' ' ASP . . . . . 0.543 ' H ' ' HB1' ' A' ' 106' ' ' ALA . 37.8 m-20 47.71 16.21 0.07 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.283 -0.886 . . . . 2.85 108.799 -179.71 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.487 ' N ' ' O ' ' A' ' 109' ' ' SER . 9.8 t70 -171.55 -29.14 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.695 -0.628 . . . . 2.46 109.401 -179.757 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.481 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 51.88 97.62 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.812 0 O-C-N 120.973 -1.079 . . . . 2.08 109.572 179.851 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 10.8 mmt180 -72.16 -159.12 0.05 OUTLIER 'General case' 0 N--CA 1.485 1.305 0 O-C-N 121.192 -0.942 . . . . 5.93 110.25 -179.601 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.463 ' HG3' HH11 ' A' ' 114' ' ' ARG . 2.4 ttm-85 -142.01 3.39 1.59 Allowed 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.368 -0.832 . . . . 5.61 109.124 -179.578 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.448 HD23 ' N ' ' A' ' 115' ' ' LEU . 0.1 OUTLIER -126.78 -26.01 3.27 Favored 'General case' 0 N--CA 1.504 2.233 0 O-C-N 121.49 -0.756 . . . . 4.39 109.108 -179.672 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.506 ' C ' ' H ' ' A' ' 118' ' ' THR . 57.5 m -108.58 -78.96 0.58 Allowed 'General case' 0 N--CA 1.497 1.9 0 N-CA-C 107.227 -1.397 . . . . 4.09 107.227 179.239 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.429 ' O ' HG12 ' A' ' 117' ' ' VAL . 53.5 t -61.74 -8.16 2.28 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.672 0 N-CA-C 106.096 -1.816 . . . . 2.9 106.096 176.865 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 118' ' ' THR . . . . . 0.506 ' H ' ' C ' ' A' ' 116' ' ' THR . 4.0 t 36.16 61.4 0.78 Allowed 'General case' 0 N--CA 1.486 1.366 0 CA-C-N 115.135 -0.939 . . . . 3.36 110.896 179.699 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 119' ' ' SER . . . . . 0.428 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.7 p . . . . . 0 C--N 1.303 -1.431 0 CA-C-O 118.015 -0.993 . . . . 3.39 109.632 179.236 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 66.9 mtm . . . . . 0 N--CA 1.49 1.557 0 N-CA-C 109.444 -0.576 . . . . 8.49 109.444 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' B' B ' 2' ' ' ALA . . . . . 0.431 ' O ' ' O ' ' B' ' 3' ' ' SER . . . -79.0 129.6 34.63 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.165 -0.96 . . . . 5.53 109.435 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 3' ' ' SER . . . . . 0.431 ' O ' ' O ' ' B' ' 2' ' ' ALA . 32.7 p 51.99 178.49 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.213 -0.93 . . . . 5.43 109.301 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 4' ' ' LYS . . . . . . . . . . . . . 21.7 mtpp -81.39 147.7 60.86 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.218 -0.926 . . . . 6.87 108.707 179.851 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 5' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -55.34 105.92 0.17 Allowed 'Trans proline' 0 C--N 1.323 -0.777 0 C-N-CA 120.887 1.058 . . . . 5.16 109.69 179.553 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 6' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.41 157.29 27.6 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.25 -0.906 . . . . 4.78 109.32 -179.907 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 30.7 mmtp -109.12 167.36 10.16 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.522 -0.737 . . . . 4.09 109.164 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.546 ' CG ' HH11 ' B' ' 8' ' ' ARG . 1.5 mtt-85 -89.95 162.31 15.47 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.23 -0.919 . . . . 3.04 108.694 179.643 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 9' ' ' VAL . . . . . . . . . . . . . 5.7 t -49.09 159.82 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.065 -1.022 . . . . 0.67 108.263 179.547 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -117.67 162.16 18.5 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.524 -0.735 . . . . 0.58 110.222 -178.769 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 11' ' ' SER . . . . . 0.408 ' CB ' HG23 ' A' ' 55' ' ' VAL . 32.4 m -153.59 141.24 19.94 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.585 -0.697 . . . . 1.19 109.13 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 41.7 m -145.05 112.27 6.06 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.113 -0.992 . . . . 1.38 110.021 -179.664 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 0.595 HG22 ' N ' ' B' ' 14' ' ' PHE . 3.2 p -159.93 167.48 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 N-CA-C 108.689 -0.856 . . . . 0.42 108.689 179.661 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 14' ' ' PHE . . . . . 0.896 ' O ' HD13 ' B' ' 15' ' ' ILE . 9.1 p90 -176.77 -169.07 0.25 Allowed 'General case' 0 N--CA 1.49 1.565 0 C-N-CA 119.162 -1.015 . . . . 1.79 112.179 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.896 HD13 ' O ' ' B' ' 14' ' ' PHE . 3.9 mm -142.12 165.14 17.68 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 N-CA-C 108.69 -0.856 . . . . 1.25 108.69 179.759 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 75.7 p -120.0 136.72 54.45 Favored 'General case' 0 N--CA 1.503 2.2 0 O-C-N 121.283 -0.886 . . . . 1.61 109.681 179.876 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 11.0 mt -103.67 141.78 35.47 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.369 -0.832 . . . . 1.32 109.975 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -166.79 139.03 2.89 Favored Pre-proline 0 N--CA 1.49 1.549 0 N-CA-C 108.765 -0.828 . . . . 1.45 108.765 179.2 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_endo -62.73 142.54 89.59 Favored 'Trans proline' 0 CA--C 1.55 1.285 0 N-CA-C 109.553 -0.98 . . . . 1.5 109.553 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 20' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_endo -62.68 -52.5 2.33 Favored 'Trans proline' 0 C--O 1.214 -0.686 0 N-CA-C 109.047 -1.174 . . . . 2.86 109.047 178.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 21' ' ' ARG . . . . . 0.435 ' HG3' HH11 ' B' ' 21' ' ' ARG . 25.9 mtm-85 -149.07 106.12 3.59 Favored 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 108.846 -0.798 . . . . 6.12 108.846 179.816 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 22' ' ' ARG . . . . . 0.455 ' NH1' ' O ' ' B' ' 23' ' ' ASP . 0.2 OUTLIER -78.33 6.99 7.13 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.162 -0.961 . . . . 6.29 109.622 -179.666 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 23' ' ' ASP . . . . . 0.455 ' O ' ' NH1' ' B' ' 22' ' ' ARG . 26.4 t0 53.47 -130.44 2.19 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.205 -0.935 . . . . 5.62 109.556 179.755 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 14.9 p . . . . . 0 N--CA 1.49 1.54 0 CA-C-O 118.002 -0.999 . . . . 6.48 109.507 -179.972 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.503 ' O ' HG23 ' A' ' 2' ' ' ILE . . . . . . . . 1 N--CA 1.53 4.945 0 N-CA-C 119.718 2.647 . . . . 6.64 119.718 . . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.631 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 1.1 pp -160.83 45.44 0.18 Allowed Pre-proline 0 C--N 1.307 -1.25 0 N-CA-C 107.933 -1.136 . . . . 7.08 107.933 179.057 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.783 ' C ' ' H ' ' A' ' 5' ' ' PHE . 1.4 Cg_endo -52.54 -79.3 0.02 OUTLIER 'Trans proline' 0 C--N 1.32 -0.939 0 N-CA-C 108.856 -1.248 . . . . 5.5 108.856 179.729 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.528 ' C ' ' H ' ' A' ' 6' ' ' PHE . 4.5 tp10 73.56 -18.53 0.38 Allowed 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 104.365 -2.457 . . . . 6.75 104.365 -175.844 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' PHE . . . . . 0.783 ' H ' ' C ' ' A' ' 3' ' ' PRO . 2.0 m-85 -87.96 16.44 5.96 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 104.02 -2.585 . . . . 6.07 104.02 176.741 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.533 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 40.6 p90 45.56 -154.02 0.04 OUTLIER 'General case' 0 C--N 1.307 -1.252 0 CA-C-N 114.344 -1.298 . . . . 4.72 109.44 -177.612 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.526 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 6.7 tt0 83.19 -9.59 1.06 Allowed 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 105.008 -2.219 . . . . 4.4 105.008 -177.339 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.472 ' H ' ' C ' ' A' ' 6' ' ' PHE . 26.7 t80 -152.12 -36.61 0.12 Allowed 'General case' 0 C--N 1.306 -1.301 0 CA-C-N 114.794 -1.094 . . . . 5.15 108.076 178.475 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.498 HG22 ' O ' ' A' ' 9' ' ' THR . 92.4 m -96.05 4.49 52.56 Favored 'General case' 0 C--N 1.296 -1.753 0 N-CA-C 105.759 -1.941 . . . . 5.13 105.759 177.288 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.534 HG13 ' N ' ' A' ' 11' ' ' GLY . 8.4 p -45.9 -45.95 5.32 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.357 0 CA-C-N 115.473 -0.785 . . . . 4.38 109.211 -179.572 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.555 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 127.18 -80.56 0.36 Allowed Glycine 0 N--CA 1.502 3.063 0 N-CA-C 109.394 -1.483 . . . . 4.22 109.394 179.111 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.509 ' O ' ' N ' ' A' ' 14' ' ' GLY . 12.3 Cg_endo -66.97 37.56 0.15 Allowed 'Trans proline' 0 C--N 1.318 -1.043 0 C-N-CA 121.753 1.636 . . . . 3.85 109.099 178.854 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.555 ' H ' ' C ' ' A' ' 11' ' ' GLY . 0.0 OUTLIER 40.67 26.04 0.02 OUTLIER 'General case' 0 N--CA 1.505 2.289 0 N-CA-C 108.333 -0.988 . . . . 3.67 108.333 -178.955 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.533 ' O ' ' N ' ' A' ' 16' ' ' GLY . . . 70.19 -44.57 0.57 Allowed Glycine 0 N--CA 1.486 2.028 0 N-CA-C 107.88 -2.088 . . . . 2.97 107.88 -178.137 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.611 ' HB3' ' HB3' ' A' ' 18' ' ' ALA . 7.1 tp10 48.4 12.33 0.04 OUTLIER 'General case' 0 N--CA 1.488 1.462 0 CA-C-O 121.978 0.894 . . . . 2.97 108.914 179.866 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.533 ' N ' ' O ' ' A' ' 14' ' ' GLY . . . 58.21 114.51 0.01 OUTLIER Glycine 0 N--CA 1.488 2.115 0 O-C-N 121.38 -0.825 . . . . 2.44 111.568 178.996 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.541 ' C ' ' H ' ' A' ' 19' ' ' HIS . . . 67.71 -49.03 0.33 Allowed Glycine 0 N--CA 1.495 2.61 0 O-C-N 121.577 -0.955 . . . . 1.81 111.662 178.092 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.796 ' HB2' ' OE1' ' A' ' 94' ' ' GLU . . . -51.3 -5.29 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.853 0 O-C-N 120.963 -1.316 . . . . 2.21 109.975 -179.201 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' HIS . . . . . 0.541 ' H ' ' C ' ' A' ' 17' ' ' GLY . 6.1 t60 -98.75 -7.13 28.13 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.135 -0.978 . . . . 2.87 110.503 -179.545 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.551 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.0 OUTLIER -137.8 6.0 2.65 Favored 'General case' 0 N--CA 1.501 2.106 0 O-C-N 120.968 -1.082 . . . . 2.02 110.34 -179.581 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 71.3 t -91.05 113.43 26.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 120.95 -1.094 . . . . 2.07 109.851 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 12.8 tpp180 -105.33 137.88 42.43 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 108.827 -0.805 . . . . 3.5 108.827 179.844 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -147.12 113.64 5.98 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.418 -0.801 . . . . 1.83 108.857 179.794 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -155.26 129.73 2.61 Favored Glycine 0 N--CA 1.493 2.471 0 N-CA-C 109.678 -1.369 . . . . 1.9 109.678 -179.655 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.54 -176.88 46.8 Favored Glycine 0 N--CA 1.491 2.304 0 C-N-CA 119.741 -1.219 . . . . 1.85 110.088 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 12.6 p -79.65 -25.53 41.34 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.353 -1.086 . . . . 2.31 109.343 179.877 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -68.94 -15.99 69.94 Favored Glycine 0 N--CA 1.485 1.934 0 N-CA-C 108.304 -1.918 . . . . 1.64 108.304 179.548 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 90.4 mt -93.35 30.41 1.71 Allowed 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 108.601 -0.889 . . . . 1.83 108.601 179.49 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 15.3 mt-10 -139.11 -48.72 0.49 Allowed 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.504 -0.747 . . . . 2.34 109.34 -179.834 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 5.4 ptp180 -174.69 177.12 2.15 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.153 -0.967 . . . . 3.77 110.192 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -149.43 174.58 28.93 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 108.495 -1.842 . . . . 1.57 108.495 179.717 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 39.5 t -134.42 149.87 30.26 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.075 0 O-C-N 121.203 -1.175 . . . . 1.83 110.567 -179.702 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.575 ' HB2' ' HB2' ' A' ' 107' ' ' SER . . . -37.38 113.98 0.3 Allowed 'General case' 0 N--CA 1.496 1.864 0 CA-C-O 121.745 0.783 . . . . 1.64 112.471 -179.232 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 51.68 51.42 38.74 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 111.24 -0.744 . . . . 1.73 111.24 177.097 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 24.4 t -126.82 121.67 23.18 Favored Pre-proline 0 N--CA 1.495 1.821 0 N-CA-C 108.198 -1.038 . . . . 2.19 108.198 178.834 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -57.87 140.22 93.04 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 120.483 0.789 . . . . 1.96 110.142 -179.422 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.418 ' HB3' ' CE1' ' A' ' 77' ' ' TYR . . . -145.33 158.0 43.92 Favored 'General case' 0 N--CA 1.493 1.716 0 N-CA-C 108.275 -1.009 . . . . 1.69 108.275 179.603 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -155.8 172.01 19.06 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.815 -1.178 . . . . 2.23 110.8 -179.543 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.609 ' CE2' HD11 ' A' ' 41' ' ' ILE . 5.9 p90 -156.27 166.64 32.85 Favored 'General case' 0 C--N 1.298 -1.646 0 N-CA-C 107.888 -1.153 . . . . 1.54 107.888 178.446 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 43.9 m -99.05 152.12 20.18 Favored 'General case' 0 N--CA 1.494 1.762 0 CA-C-O 121.782 0.801 . . . . 2.37 111.129 -178.146 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.609 HD11 ' CE2' ' A' ' 39' ' ' PHE . 10.8 mt -143.48 85.79 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 N-CA-C 108.416 -0.957 . . . . 1.65 108.416 178.91 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 31.5 t90 -91.61 147.36 23.06 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.053 -1.029 . . . . 3.68 109.284 -179.489 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.551 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.1 OUTLIER -161.76 -110.99 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.286 -0.883 . . . . 2.89 109.628 -179.731 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 44' ' ' ARG . . . . . 0.526 HH11 ' HG2' ' A' ' 44' ' ' ARG . 2.3 ttt-85 52.69 90.74 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.221 -0.924 . . . . 4.63 109.862 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -172.2 -60.68 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.245 -0.909 . . . . 2.89 109.365 179.265 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -57.04 -57.89 10.57 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.988 -1.07 . . . . 1.74 108.741 179.724 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 150.99 -160.46 28.64 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 110.029 -1.228 . . . . 1.6 110.029 179.488 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.01 149.17 9.55 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.403 -1.057 . . . . 1.4 109.778 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -176.26 173.65 46.42 Favored Glycine 0 N--CA 1.489 2.168 0 N-CA-C 109.487 -1.445 . . . . 1.04 109.487 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -126.76 122.63 4.4 Favored Glycine 0 N--CA 1.498 2.825 0 N-CA-C 109.143 -1.583 . . . . 1.06 109.143 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.47 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 11.3 tp -93.85 99.37 11.75 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.221 -1.164 . . . . 1.1 108.843 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 2.2 t -83.51 141.27 31.76 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 108.42 -0.956 . . . . 1.56 108.42 179.687 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.559 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 92.3 mt -134.73 115.58 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.217 -0.927 . . . . 0.65 109.33 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -104.65 106.86 17.52 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.364 -0.835 . . . . 0.69 109.008 179.778 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -101.45 135.07 39.72 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.115 0 O-C-N 121.477 -0.765 . . . . 0.91 109.516 -179.771 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.43 ' OE2' ' O ' ' B' ' 9' ' ' VAL . 30.9 tp10 -134.36 142.46 47.22 Favored 'General case' 0 N--CA 1.494 1.738 0 N-CA-C 107.399 -1.334 . . . . 1.8 107.399 178.324 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 171.51 -176.67 44.67 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.421 -1.472 . . . . 0.49 109.421 -179.362 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -61.62 -28.35 82.6 Favored 'Trans proline' 0 C--N 1.318 -1.06 0 C-N-CA 121.992 1.795 . . . . 0.66 111.856 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' SER . . . . . 0.413 ' O ' ' OH ' ' A' ' 85' ' ' TYR . 10.6 p -142.39 163.24 33.37 Favored 'General case' 0 N--CA 1.501 2.095 0 O-C-N 121.063 -1.023 . . . . 1.55 110.349 -179.564 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 19.4 mtpp -81.09 115.71 20.66 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.532 -0.73 . . . . 2.53 109.28 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -80.67 129.54 34.58 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.284 -0.885 . . . . 0.82 109.648 -179.817 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.455 ' CB ' HG12 ' A' ' 78' ' ' VAL . 18.2 tp10 -68.29 170.95 7.85 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.127 -0.983 . . . . 2.3 108.535 179.722 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.402 HD12 ' N ' ' A' ' 63' ' ' ILE . 3.8 mp -139.9 153.75 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 N-CA-C 108.417 -0.956 . . . . 1.4 108.417 -179.389 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.563 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -150.79 114.6 4.98 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 120.672 -1.267 . . . . 1.36 109.747 -179.565 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.505 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 43.0 p90 -92.77 122.56 35.28 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.27 -0.894 . . . . 1.47 109.19 179.615 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -141.19 120.54 13.09 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.266 -0.896 . . . . 2.51 109.51 -179.835 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 9.7 p-10 -86.91 118.62 26.41 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.307 -0.871 . . . . 2.07 109.328 179.884 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 41.0 ttm180 -99.52 -21.96 15.7 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.256 -0.902 . . . . 4.63 109.646 -179.846 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.533 ' C ' ' H ' ' A' ' 71' ' ' GLY . 14.3 mmmt -124.56 3.45 8.31 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.467 -0.771 . . . . 3.49 109.067 -179.779 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.462 ' CB ' ' O ' ' A' ' 69' ' ' LYS . 0.8 OUTLIER 73.96 -26.43 0.19 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.33 -0.856 . . . . 3.06 108.712 -179.146 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 71' ' ' GLY . . . . . 0.533 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -107.13 -34.59 2.92 Favored Glycine 0 N--CA 1.494 2.535 0 N-CA-C 109.446 -1.462 . . . . 2.16 109.446 -179.801 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 89.9 p -95.44 121.59 37.28 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.271 -1.134 . . . . 2.2 109.107 179.834 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 29.7 t -89.72 136.47 33.02 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.199 -0.938 . . . . 2.05 109.682 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -114.24 114.24 3.24 Favored Glycine 0 N--CA 1.5 2.937 0 N-CA-C 109.696 -1.362 . . . . 1.39 109.696 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.465 HG21 HD12 ' A' ' 41' ' ' ILE . 78.9 t -99.7 105.13 17.04 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.102 0 O-C-N 121.411 -1.052 . . . . 1.57 109.629 179.722 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.563 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.1 OUTLIER -95.26 134.5 37.95 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 109.018 -0.734 . . . . 1.85 109.018 179.84 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.418 ' CE1' ' HB3' ' A' ' 37' ' ' ALA . 45.7 p90 -135.32 172.73 12.59 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.205 -0.934 . . . . 1.54 109.079 -179.848 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.602 ' O ' HG13 ' A' ' 78' ' ' VAL . 9.8 p -140.34 118.09 9.96 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.082 0 O-C-N 121.256 -0.902 . . . . 1.9 110.033 179.758 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.456 HG11 HG21 ' A' ' 105' ' ' VAL . 13.4 m -86.64 151.97 3.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.391 -0.818 . . . . 1.27 108.922 179.548 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 4.0 tp-100 -94.51 -47.24 6.64 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.042 -1.036 . . . . 2.48 110.899 -179.039 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -153.37 152.37 27.48 Favored Pre-proline 0 N--CA 1.505 2.302 0 O-C-N 120.406 -1.434 . . . . 1.92 110.965 -179.497 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.64 ' HG3' ' N ' ' A' ' 107' ' ' SER . 78.4 Cg_exo -38.48 164.42 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 123.392 2.728 . . . . 1.3 113.778 178.833 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 145.08 -164.97 27.84 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.004 -1.639 . . . . 1.02 109.004 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 25.2 m-20 -109.01 90.88 3.43 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.61 -0.935 . . . . 2.13 108.641 179.581 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.413 ' OH ' ' O ' ' A' ' 59' ' ' SER . 3.7 m-85 -78.74 130.53 35.88 Favored 'General case' 0 N--CA 1.487 1.406 0 N-CA-C 108.003 -1.11 . . . . 0.92 108.003 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -115.35 128.49 56.12 Favored 'General case' 0 N--CA 1.502 2.146 0 N-CA-C 108.946 -0.761 . . . . 1.53 108.946 -178.503 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 10.0 p -125.36 140.46 48.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.75 -0.593 . . . . 1.0 109.925 -179.852 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 16.2 m -129.33 100.07 5.45 Favored 'General case' 0 N--CA 1.497 1.884 0 N-CA-C 108.922 -0.77 . . . . 1.59 108.922 179.477 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.447 ' N ' ' OG ' ' A' ' 99' ' ' SER . 1.6 pt -105.57 134.93 45.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 CA-C-O 121.482 0.658 . . . . 1.29 110.208 -179.301 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 90' ' ' LYS . . . . . 0.591 ' HB3' ' HZ2' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -144.3 122.35 12.11 Favored 'General case' 0 C--N 1.305 -1.339 0 N-CA-C 108.271 -1.011 . . . . 1.58 108.271 179.508 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 62.9 t80 -80.97 101.27 9.4 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.864 -1.147 . . . . 1.34 107.995 178.705 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 70.37 39.04 1.29 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.392 -0.817 . . . . 2.32 108.982 -178.809 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 74.57 15.03 3.41 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.705 -0.622 . . . . 1.92 111.293 179.653 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' GLU . . . . . 0.796 ' OE1' ' HB2' ' A' ' 18' ' ' ALA . 0.5 OUTLIER -98.29 96.22 7.91 Favored 'General case' 0 N--CA 1.498 1.974 0 N-CA-C 106.813 -1.551 . . . . 2.25 106.813 177.641 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 4.3 m80 -73.07 111.66 8.39 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.615 -0.678 . . . . 2.88 110.112 -177.926 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 96' ' ' ILE . . . . . 0.683 ' H ' HD13 ' A' ' 96' ' ' ILE . 0.0 OUTLIER -70.35 155.93 92.67 Favored Pre-proline 0 N--CA 1.494 1.734 0 N-CA-C 107.444 -1.317 . . . . 2.35 107.444 179.148 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_exo -46.54 -35.6 16.93 Favored 'Trans proline' 0 C--N 1.322 -0.861 0 C-N-CA 121.336 1.357 . . . . 2.48 109.942 -179.412 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -53.78 -63.65 1.08 Allowed 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.301 -0.875 . . . . 2.65 109.383 179.267 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.447 ' OG ' ' N ' ' A' ' 89' ' ' ILE . 3.6 m -70.45 141.21 87.92 Favored Pre-proline 0 C--N 1.295 -1.777 0 O-C-N 120.92 -1.112 . . . . 2.0 110.19 -178.467 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -86.8 119.02 4.96 Favored 'Cis proline' 0 N--CA 1.493 1.474 0 N-CA-C 109.967 -0.82 . . . . 1.79 109.967 -2.439 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 45.2 p90 -120.89 158.34 27.85 Favored 'General case' 0 N--CA 1.518 2.939 0 O-C-N 120.445 -1.41 . . . . 2.19 109.506 178.273 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.469 HG22 ' N ' ' A' ' 103' ' ' VAL . 7.3 p -92.17 157.26 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.429 -0.794 . . . . 1.44 110.887 -178.426 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.469 ' N ' HG22 ' A' ' 102' ' ' VAL . 56.9 t -128.26 86.25 58.41 Favored Pre-proline 0 N--CA 1.495 1.778 0 N-CA-C 107.85 -1.167 . . . . 1.19 107.85 179.341 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -64.04 112.71 1.93 Allowed 'Trans proline' 0 C--N 1.32 -0.966 0 C-N-CA 121.377 1.385 . . . . 1.49 111.624 -177.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.456 HG21 HG11 ' A' ' 79' ' ' VAL . 54.8 t -95.54 141.01 15.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 N-CA-C 106.771 -1.566 . . . . 1.35 106.771 177.978 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.635 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -130.6 131.79 45.15 Favored 'General case' 0 N--CA 1.51 2.551 0 CA-C-O 121.925 0.869 . . . . 1.67 112.064 -177.041 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.64 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 35.4 t -101.36 92.99 5.19 Favored 'General case' 0 N--CA 1.494 1.75 0 N-CA-C 107.993 -1.114 . . . . 2.04 107.993 179.274 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 20.5 mt 60.08 3.71 0.54 Allowed 'General case' 0 C--N 1.295 -1.774 0 N-CA-C 108.166 -1.05 . . . . 3.2 108.166 -178.574 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.64 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 8.3 t -94.83 -29.26 14.82 Favored 'General case' 0 N--CA 1.49 1.563 0 N-CA-C 109.03 -0.729 . . . . 2.09 109.03 179.391 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 110' ' ' ASP . . . . . 0.635 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 16.9 t70 57.52 6.28 0.39 Allowed 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 107.754 -1.202 . . . . 2.85 107.754 -178.843 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.542 ' H ' ' C ' ' A' ' 109' ' ' SER . 17.8 m-20 -159.92 -35.47 0.06 Allowed 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 108.697 -0.853 . . . . 2.46 108.697 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.64 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 40.29 65.82 0.7 Allowed 'General case' 0 N--CA 1.501 2.077 0 O-C-N 121.491 -0.756 . . . . 2.08 110.251 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 113' ' ' ARG . . . . . 0.493 HH11 ' HG2' ' A' ' 113' ' ' ARG . 6.3 mtt-85 -54.1 -172.15 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.148 -0.97 . . . . 5.93 109.506 -179.562 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.581 ' CG ' HH11 ' A' ' 114' ' ' ARG . 0.1 OUTLIER -132.03 4.29 4.11 Favored 'General case' 0 N--CA 1.497 1.897 0 N-CA-C 108.711 -0.848 . . . . 5.61 108.711 -179.621 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 30.0 mt -127.27 -24.02 3.45 Favored 'General case' 0 N--CA 1.503 2.218 0 O-C-N 121.645 -0.659 . . . . 4.39 109.405 -179.709 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.52 ' C ' ' H ' ' A' ' 118' ' ' THR . 85.3 m -110.73 -78.67 0.59 Allowed 'General case' 0 N--CA 1.498 1.94 0 N-CA-C 107.106 -1.442 . . . . 4.09 107.106 179.079 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.444 ' O ' HG12 ' A' ' 117' ' ' VAL . 45.9 t -62.13 -7.83 2.35 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.672 0 N-CA-C 106.016 -1.846 . . . . 2.9 106.016 176.783 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 118' ' ' THR . . . . . 0.52 ' H ' ' C ' ' A' ' 116' ' ' THR . 4.4 t 36.48 59.8 0.95 Allowed 'General case' 0 N--CA 1.488 1.445 0 CA-C-N 115.253 -0.885 . . . . 3.36 110.728 179.823 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 119' ' ' SER . . . . . 0.457 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.5 p . . . . . 0 C--N 1.303 -1.417 0 CA-C-O 118.023 -0.989 . . . . 3.39 109.574 179.401 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 1' ' ' MET . . . . . 0.474 ' SD ' ' N ' ' B' ' 1' ' ' MET . 4.3 mpp? . . . . . 0 N--CA 1.49 1.545 0 CA-C-O 121.312 0.577 . . . . 8.49 109.455 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -167.33 -100.63 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.249 -0.907 . . . . 5.53 109.331 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 3' ' ' SER . . . . . . . . . . . . . 54.6 p -72.45 60.1 0.45 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.252 -0.905 . . . . 5.43 109.382 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 4' ' ' LYS . . . . . . . . . . . . . 6.8 ttpm? -168.44 69.3 0.78 Allowed Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.247 -0.908 . . . . 6.87 109.518 -179.892 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 5' ' ' PRO . . . . . 0.431 ' O ' ' O ' ' B' ' 6' ' ' GLU . 6.0 Cg_exo -60.59 -29.34 88.3 Favored 'Trans proline' 0 C--N 1.317 -1.103 0 C-N-CA 121.442 1.428 . . . . 5.16 109.811 -179.785 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 6' ' ' GLU . . . . . 0.431 ' O ' ' O ' ' B' ' 5' ' ' PRO . 31.2 tt0 57.32 160.5 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.412 -0.805 . . . . 4.78 109.855 179.815 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 46.3 mtpt -63.2 159.98 16.51 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.248 -0.908 . . . . 4.09 109.298 179.904 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.618 ' CG ' HH11 ' B' ' 8' ' ' ARG . 0.0 OUTLIER -101.58 163.68 12.14 Favored 'General case' 0 N--CA 1.494 1.769 0 N-CA-C 108.061 -1.088 . . . . 3.04 108.061 179.798 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 9' ' ' VAL . . . . . 0.43 ' O ' ' OE2' ' A' ' 56' ' ' GLU . 36.3 t -51.61 155.48 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 O-C-N 120.963 -1.085 . . . . 0.67 108.508 179.519 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -107.7 158.84 16.94 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 121.484 -0.76 . . . . 0.58 110.443 -178.763 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 25.6 t -159.34 112.91 2.29 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.487 -0.758 . . . . 1.19 109.007 179.51 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 15.0 p -117.02 124.9 50.44 Favored 'General case' 0 N--CA 1.501 2.111 0 O-C-N 121.417 -0.802 . . . . 1.38 109.413 -179.771 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 0.608 HG22 ' N ' ' B' ' 14' ' ' PHE . 6.6 p -164.39 164.01 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.293 -0.879 . . . . 0.42 109.786 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 14' ' ' PHE . . . . . 0.608 ' N ' HG22 ' B' ' 13' ' ' VAL . 6.5 p90 -179.29 -175.21 0.35 Allowed 'General case' 0 N--CA 1.488 1.472 0 CA-C-O 121.784 0.802 . . . . 1.79 111.427 179.102 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -144.01 168.8 10.77 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.295 0 N-CA-C 109.28 -0.637 . . . . 1.25 109.28 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 74.1 p -133.81 156.13 48.59 Favored 'General case' 0 N--CA 1.499 2.021 0 N-CA-C 108.72 -0.844 . . . . 1.61 108.72 179.523 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -159.18 159.55 34.44 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.948 -1.095 . . . . 1.32 110.643 -179.307 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -174.39 149.29 1.36 Allowed Pre-proline 0 N--CA 1.488 1.454 0 N-CA-C 108.843 -0.799 . . . . 1.45 108.843 179.751 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -57.65 166.83 4.52 Favored 'Trans proline' 0 CA--C 1.543 0.966 0 C-N-CA 120.933 1.089 . . . . 1.5 109.748 179.712 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 20' ' ' PRO . . . . . . . . . . . . . 2.3 Cg_endo -61.11 169.3 6.29 Favored 'Trans proline' 0 C--N 1.319 -0.985 0 C-N-CA 121.538 1.492 . . . . 2.86 109.448 179.366 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 21' ' ' ARG . . . . . 0.429 ' HG3' HH11 ' B' ' 21' ' ' ARG . 3.8 ptm180 -79.81 137.55 37.0 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.171 -0.955 . . . . 6.12 109.246 179.677 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 22' ' ' ARG . . . . . 0.571 HH11 ' CG ' ' B' ' 22' ' ' ARG . 0.1 OUTLIER -90.66 147.18 23.46 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.183 -0.948 . . . . 6.29 109.349 -179.923 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 66.9 m-20 -66.01 135.83 55.2 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.217 -0.927 . . . . 5.62 109.442 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 21.2 t . . . . . 0 N--CA 1.49 1.537 0 CA-C-O 118.046 -0.978 . . . . 6.48 109.624 -179.889 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.929 0 N-CA-C 119.8 2.68 . . . . 6.64 119.8 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.646 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 7.3 mt -153.39 44.31 0.25 Allowed Pre-proline 0 C--N 1.311 -1.094 0 N-CA-C 107.8 -1.185 . . . . 7.08 107.8 178.711 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.646 ' CD ' ' N ' ' A' ' 2' ' ' ILE . 0.9 OUTLIER -53.79 -76.32 0.02 OUTLIER 'Trans proline' 0 C--N 1.32 -0.969 0 N-CA-C 109.149 -1.135 . . . . 5.5 109.149 -179.799 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.423 ' CB ' ' O ' ' A' ' 3' ' ' PRO . 8.9 tp10 72.14 -50.1 0.69 Allowed 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 103.13 -2.915 . . . . 6.75 103.13 -175.861 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' PHE . . . . . 0.61 ' H ' ' C ' ' A' ' 3' ' ' PRO . 7.3 m-85 -49.62 -27.38 4.53 Favored 'General case' 0 C--N 1.303 -1.423 0 N-CA-C 106.485 -1.672 . . . . 6.07 106.485 174.967 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.604 ' CG ' ' N ' ' A' ' 7' ' ' GLN . 0.0 OUTLIER 109.75 -150.93 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.217 0 CA-C-N 114.458 -1.246 . . . . 4.72 111.144 179.47 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.604 ' N ' ' CG ' ' A' ' 6' ' ' PHE . 4.3 tt0 83.48 -4.06 1.19 Allowed 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 105.418 -2.068 . . . . 4.4 105.418 -177.714 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 80.1 t80 -152.19 -40.14 0.11 Allowed 'General case' 0 C--N 1.303 -1.436 0 N-CA-C 107.395 -1.335 . . . . 5.15 107.395 178.632 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.402 ' O ' HG22 ' A' ' 9' ' ' THR . 30.0 m -88.98 2.97 53.12 Favored 'General case' 0 C--N 1.296 -1.741 0 N-CA-C 106.201 -1.777 . . . . 5.13 106.201 177.533 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.519 HG13 ' N ' ' A' ' 11' ' ' GLY . 7.7 p -42.7 -41.72 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 CA-C-O 121.765 0.793 . . . . 4.38 109.408 -179.804 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.71 ' O ' HD23 ' A' ' 13' ' ' LEU . . . 144.06 -86.49 0.18 Allowed Glycine 0 N--CA 1.496 2.689 0 N-CA-C 108.658 -1.777 . . . . 4.22 108.658 179.691 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.44 ' O ' ' N ' ' A' ' 14' ' ' GLY . 12.0 Cg_endo -68.19 34.89 0.17 Allowed 'Trans proline' 0 C--N 1.321 -0.875 0 C-N-CA 121.425 1.417 . . . . 3.85 109.263 178.275 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.855 ' N ' HD23 ' A' ' 13' ' ' LEU . 0.0 OUTLIER 39.68 29.88 0.05 OUTLIER 'General case' 0 N--CA 1.504 2.238 0 CA-C-O 121.855 0.836 . . . . 3.67 109.001 -178.877 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.503 ' C ' ' N ' ' A' ' 16' ' ' GLY . . . 72.37 -41.46 0.78 Allowed Glycine 0 N--CA 1.488 2.161 0 N-CA-C 108.613 -1.795 . . . . 2.97 108.613 -179.283 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.496 ' H ' ' C ' ' A' ' 13' ' ' LEU . 26.2 tt0 51.95 10.33 0.11 Allowed 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.552 -0.97 . . . . 2.97 108.618 -179.491 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.503 ' N ' ' C ' ' A' ' 14' ' ' GLY . . . 78.19 -165.6 52.08 Favored Glycine 0 N--CA 1.486 2.007 0 N-CA-C 110.009 -1.236 . . . . 2.44 110.009 179.841 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.553 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -42.72 -19.8 0.07 OUTLIER Glycine 0 N--CA 1.49 2.282 0 O-C-N 121.417 -1.049 . . . . 1.81 110.839 -179.325 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.502 ' N ' ' O ' ' A' ' 16' ' ' GLY . . . -47.26 -12.92 0.03 OUTLIER 'General case' 0 N--CA 1.495 1.8 0 O-C-N 120.448 -1.619 . . . . 2.21 109.297 179.413 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' HIS . . . . . 0.553 ' N ' ' O ' ' A' ' 17' ' ' GLY . 12.8 t-80 -93.36 -52.25 4.61 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.268 -0.895 . . . . 2.87 109.906 179.882 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.535 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.1 OUTLIER -69.75 -23.6 63.4 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.869 -1.144 . . . . 2.02 109.588 -179.69 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 76.1 t -63.33 112.62 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.161 -0.962 . . . . 2.07 109.5 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 20.6 tpt180 -97.34 138.32 34.99 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 108.695 -0.854 . . . . 3.5 108.695 179.666 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -142.64 113.46 7.5 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.287 -0.883 . . . . 1.83 109.279 -179.88 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -154.08 130.85 3.03 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 109.518 -1.433 . . . . 1.9 109.518 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -177.94 171.17 43.67 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.703 -1.359 . . . . 1.85 109.703 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 10.9 p -77.97 -28.87 49.53 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.302 -1.117 . . . . 2.31 109.405 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -67.72 -16.88 68.51 Favored Glycine 0 N--CA 1.487 2.038 0 N-CA-C 108.42 -1.872 . . . . 1.64 108.42 179.606 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 49.0 mt -85.85 22.68 1.61 Allowed 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 108.506 -0.924 . . . . 1.83 108.506 179.356 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 11.5 mt-10 -133.47 -50.38 0.85 Allowed 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.62 -0.675 . . . . 2.34 109.398 -179.673 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 11.3 ptt180 -163.31 -176.71 4.92 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.069 -1.019 . . . . 3.77 109.936 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -157.18 -178.42 31.23 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 108.761 -1.735 . . . . 1.57 108.761 -179.799 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 38.4 t -134.71 151.8 32.09 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.153 0 O-C-N 121.154 -1.203 . . . . 1.83 110.663 -179.777 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.556 ' HB2' ' HD3' ' A' ' 82' ' ' PRO . . . -45.77 115.22 0.91 Allowed 'General case' 0 N--CA 1.498 1.936 0 CA-C-O 121.815 0.817 . . . . 1.64 112.443 -179.34 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 57.82 46.55 92.22 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 111.562 -0.615 . . . . 1.73 111.562 177.062 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 25.2 t -127.38 120.49 22.16 Favored Pre-proline 0 N--CA 1.499 1.98 0 O-C-N 121.37 -1.076 . . . . 2.19 108.818 179.178 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -60.09 113.02 1.48 Allowed 'Trans proline' 0 C--O 1.215 -0.657 0 N-CA-C 109.676 -0.932 . . . . 1.96 109.676 179.871 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -113.04 156.12 23.64 Favored 'General case' 0 N--CA 1.498 1.949 0 N-CA-C 108.268 -1.012 . . . . 1.69 108.268 179.617 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -158.03 163.68 37.49 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.718 -1.239 . . . . 2.23 111.403 -179.779 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.575 ' CD1' ' N ' ' A' ' 39' ' ' PHE . 0.8 OUTLIER -139.93 -173.17 3.57 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 107.228 -1.397 . . . . 1.54 107.228 178.513 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 24.4 m -121.83 149.11 43.82 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.535 -0.728 . . . . 2.37 110.307 -179.234 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 34.9 mt -144.48 102.05 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 N-CA-C 107.962 -1.125 . . . . 1.65 107.962 178.982 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.458 ' CD1' ' C ' ' A' ' 42' ' ' TRP . 0.1 OUTLIER -89.59 139.6 30.38 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.259 -0.901 . . . . 3.68 108.927 -179.635 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.535 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.1 OUTLIER -152.79 120.03 5.89 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.42 -0.8 . . . . 2.89 109.214 -179.733 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 44' ' ' ARG . . . . . . . . . . . . . 28.9 ttt-85 -170.28 62.87 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.201 -0.937 . . . . 4.63 109.848 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 25.4 tt0 -157.06 -56.6 0.08 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.14 -0.975 . . . . 2.89 109.534 179.65 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.423 ' H ' ' HE2' ' A' ' 20' ' ' LYS . . . -57.88 -57.4 12.93 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.092 -1.005 . . . . 1.74 108.88 179.883 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 142.03 -179.2 20.17 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.263 -1.535 . . . . 1.6 109.263 179.845 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -55.9 159.14 3.35 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.127 -1.22 . . . . 1.4 109.345 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -176.83 176.12 47.88 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.595 -1.402 . . . . 1.04 109.595 -179.877 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -106.94 123.26 7.24 Favored Glycine 0 N--CA 1.497 2.743 0 N-CA-C 109.427 -1.469 . . . . 1.06 109.427 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.453 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 12.3 tp -99.8 100.55 11.51 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.295 -1.12 . . . . 1.1 108.452 179.663 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 3.9 m -85.51 144.13 28.12 Favored 'General case' 0 N--CA 1.491 1.616 0 N-CA-C 108.662 -0.866 . . . . 1.56 108.662 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.525 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 78.5 mt -134.71 106.69 7.68 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 O-C-N 121.224 -0.922 . . . . 0.65 109.614 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -95.65 106.26 18.34 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.377 -0.971 . . . . 0.69 108.377 179.272 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.437 HG23 ' OG ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -97.45 145.29 9.47 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 121.421 -0.799 . . . . 0.91 109.933 -179.339 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 20.2 tt0 -141.56 145.06 34.65 Favored 'General case' 0 N--CA 1.491 1.61 0 N-CA-C 107.536 -1.283 . . . . 1.8 107.536 178.708 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 161.64 -171.04 37.52 Favored Glycine 0 N--CA 1.488 2.13 0 N-CA-C 109.644 -1.382 . . . . 0.49 109.644 -179.069 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -64.32 -30.31 63.46 Favored 'Trans proline' 0 C--N 1.316 -1.142 0 C-N-CA 122.047 1.831 . . . . 0.66 111.652 -179.598 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 24.3 t -142.1 164.96 28.76 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.039 -1.038 . . . . 1.55 110.129 -179.877 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 58.4 mttt -84.44 107.48 16.72 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.527 -0.733 . . . . 2.53 109.56 -179.8 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -67.08 143.39 56.71 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.222 -0.924 . . . . 0.82 109.4 179.932 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 23.3 tt0 -93.2 91.36 7.24 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.225 -0.922 . . . . 2.3 109.537 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.621 HD12 ' N ' ' A' ' 63' ' ' ILE . 2.2 mp -60.54 156.61 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 N-CA-C 109.138 -0.689 . . . . 1.4 109.138 179.602 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.559 ' HB3' ' HB3' ' A' ' 76' ' ' SER . . . -145.99 174.85 10.91 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.981 -1.074 . . . . 1.36 108.595 179.621 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.487 ' CG ' ' O ' ' A' ' 65' ' ' PHE . 28.8 p90 -147.87 115.87 6.47 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.093 -1.005 . . . . 1.47 109.647 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -141.96 118.74 11.12 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.209 -0.932 . . . . 2.51 109.485 179.791 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -84.93 119.77 25.74 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.143 -0.973 . . . . 2.07 109.415 179.865 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 8.0 mmm180 -110.49 -5.7 15.08 Favored 'General case' 0 N--CA 1.5 2.062 0 O-C-N 121.545 -0.722 . . . . 4.63 109.298 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.489 ' HB2' ' H ' ' A' ' 72' ' ' SER . 20.4 mmmt -125.19 2.4 7.87 Favored 'General case' 0 N--CA 1.5 2.051 0 O-C-N 121.416 -0.803 . . . . 3.49 109.379 -179.781 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.7 t70 67.3 -4.86 0.8 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.247 -0.908 . . . . 3.06 109.105 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' GLY . . . . . 0.47 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -139.7 -32.16 0.17 Allowed Glycine 0 N--CA 1.493 2.478 0 N-CA-C 109.924 -1.27 . . . . 2.16 109.924 -179.077 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.489 ' H ' ' HB2' ' A' ' 69' ' ' LYS . 5.5 p -95.84 116.14 28.46 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.195 -1.179 . . . . 2.2 109.085 179.829 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 7.7 t -75.42 146.58 40.64 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.214 -0.929 . . . . 2.05 109.622 -179.814 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -120.25 111.58 2.01 Favored Glycine 0 N--CA 1.499 2.851 0 N-CA-C 109.32 -1.512 . . . . 1.39 109.32 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 22.5 t -99.32 106.22 18.64 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 O-C-N 121.542 -0.975 . . . . 1.57 109.109 179.807 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.559 ' HB3' ' HB3' ' A' ' 64' ' ' ALA . 5.9 t -100.04 135.67 41.11 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.537 -0.727 . . . . 1.85 109.895 -179.687 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 4.9 p90 -133.59 131.4 39.61 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 108.801 -0.815 . . . . 1.54 108.801 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.587 ' O ' HG13 ' A' ' 78' ' ' VAL . 8.0 p -100.37 115.79 42.42 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.955 0 O-C-N 121.276 -0.89 . . . . 1.9 109.183 -179.668 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 26.9 m -84.73 164.5 2.53 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 121.187 -0.946 . . . . 1.27 109.142 -179.681 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 36.3 tt0 -102.54 -49.08 3.94 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.276 -0.89 . . . . 2.48 110.324 -179.689 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -157.15 153.99 25.04 Favored Pre-proline 0 N--CA 1.502 2.132 0 O-C-N 120.907 -1.121 . . . . 1.92 111.161 -179.147 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.588 ' HG3' ' N ' ' A' ' 107' ' ' SER . 89.1 Cg_exo -35.55 156.99 0.02 OUTLIER 'Trans proline' 0 C--O 1.214 -0.683 0 C-N-CA 123.394 2.729 . . . . 1.3 113.745 179.354 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 148.51 -170.3 29.02 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 108.556 -1.818 . . . . 1.02 108.556 -179.675 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 84' ' ' ASP . . . . . 0.571 ' CG ' ' HE ' ' B' ' 8' ' ' ARG . 4.5 p-10 -107.24 93.71 4.7 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.378 -1.072 . . . . 2.13 108.452 179.368 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.426 ' O ' ' N ' ' A' ' 103' ' ' VAL . 2.4 m-85 -77.38 131.63 38.15 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 108.398 -0.964 . . . . 0.92 108.398 -179.784 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -112.82 126.82 55.85 Favored 'General case' 0 N--CA 1.501 2.081 0 N-CA-C 108.465 -0.939 . . . . 1.53 108.465 -179.292 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.466 ' CG1' ' CE2' ' A' ' 101' ' ' PHE . 5.5 p -126.29 133.96 67.55 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 O-C-N 121.525 -0.734 . . . . 1.0 109.782 -179.703 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 88' ' ' SER . . . . . 0.407 ' O ' ' OG ' ' A' ' 88' ' ' SER . 19.0 p -124.58 104.82 8.92 Favored 'General case' 0 N--CA 1.499 1.986 0 N-CA-C 109.171 -0.678 . . . . 1.59 109.171 179.835 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.405 ' N ' ' OG ' ' A' ' 99' ' ' SER . 1.5 pt -108.37 133.18 54.13 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 CA-C-O 121.54 0.686 . . . . 1.29 110.37 -179.245 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 90' ' ' LYS . . . . . 0.456 ' O ' ' CG ' ' A' ' 90' ' ' LYS . 0.3 OUTLIER -138.08 122.51 18.36 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 107.927 -1.138 . . . . 1.58 107.927 179.257 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.412 ' O ' ' CB ' ' A' ' 92' ' ' ASN . 81.4 t80 -82.84 99.99 10.06 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 120.443 -1.411 . . . . 1.34 107.924 179.21 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 92' ' ' ASN . . . . . 0.446 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 14.2 t30 72.28 34.85 1.3 Allowed 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.266 -0.896 . . . . 2.32 108.983 -178.627 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.446 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 1.6 m-20 80.47 13.81 0.83 Allowed 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.725 -0.609 . . . . 1.92 111.662 179.336 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 94' ' ' GLU . . . . . 0.494 ' HB2' ' HB2' ' A' ' 18' ' ' ALA . 5.4 pt-20 -100.71 98.84 9.34 Favored 'General case' 0 N--CA 1.499 2.023 0 N-CA-C 107.459 -1.312 . . . . 2.25 107.459 177.843 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 95' ' ' HIS . . . . . 0.416 ' O ' ' OE2' ' A' ' 15' ' ' GLU . 26.6 p-80 -65.3 99.59 0.41 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.686 -0.634 . . . . 2.88 110.243 -178.251 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 96' ' ' ILE . . . . . 0.523 ' O ' ' N ' ' A' ' 98' ' ' ASP . 4.0 tt -50.82 136.09 26.77 Favored Pre-proline 0 N--CA 1.489 1.524 0 N-CA-C 107.988 -1.116 . . . . 2.35 107.988 179.089 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.433 ' O ' ' CB ' ' A' ' 98' ' ' ASP . 9.4 Cg_exo -47.88 90.35 0.02 OUTLIER 'Trans proline' 0 C--O 1.213 -0.727 0 C-N-CA 120.547 0.832 . . . . 2.48 110.006 -179.627 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.523 ' N ' ' O ' ' A' ' 96' ' ' ILE . 0.9 OUTLIER 166.5 -57.87 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.749 0 N-CA-C 108.445 -0.946 . . . . 2.65 108.445 -179.569 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.405 ' OG ' ' N ' ' A' ' 89' ' ' ILE . 3.3 m -55.55 137.75 69.7 Favored Pre-proline 0 C--N 1.296 -1.72 0 O-C-N 121.246 -0.909 . . . . 2.0 109.6 -178.185 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo -90.0 114.96 2.59 Favored 'Cis proline' 0 N--CA 1.494 1.513 0 N-CA-C 110.249 -0.712 . . . . 1.79 110.249 -2.33 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 101' ' ' PHE . . . . . 0.466 ' CE2' ' CG1' ' A' ' 87' ' ' VAL . 1.6 p90 -97.18 163.26 12.99 Favored 'General case' 0 N--CA 1.515 2.802 0 O-C-N 120.217 -1.552 . . . . 2.19 109.568 178.456 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.9 p -95.31 148.96 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.594 -0.691 . . . . 1.44 109.822 -179.703 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.426 ' N ' ' O ' ' A' ' 85' ' ' TYR . 64.5 t -128.53 86.41 57.79 Favored Pre-proline 0 N--CA 1.499 2.002 0 N-CA-C 108.432 -0.951 . . . . 1.19 108.432 179.89 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -63.92 112.16 1.76 Allowed 'Trans proline' 0 C--N 1.321 -0.88 0 C-N-CA 121.429 1.419 . . . . 1.49 111.821 -178.133 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 52.5 t -91.39 147.36 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.514 -1.291 . . . . 1.35 107.514 178.268 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.677 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -135.77 134.3 38.85 Favored 'General case' 0 N--CA 1.508 2.467 0 O-C-N 121.373 -0.829 . . . . 1.67 110.911 -178.074 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.588 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 16.5 t -87.69 67.75 9.29 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.571 -1.331 . . . . 2.04 108.095 179.799 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 108' ' ' LEU . . . . . 0.434 ' CB ' ' O ' ' A' ' 107' ' ' SER . 1.0 OUTLIER 71.53 -2.6 2.38 Favored 'General case' 0 C--N 1.295 -1.79 0 N-CA-C 106.921 -1.511 . . . . 3.2 106.921 -178.439 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.694 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 82.6 p -82.73 -21.63 34.7 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 109.165 -0.679 . . . . 2.09 109.165 179.422 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 110' ' ' ASP . . . . . 0.677 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 62.2 t0 48.62 17.35 0.14 Allowed 'General case' 0 N--CA 1.494 1.753 0 N-CA-C 108.312 -0.996 . . . . 2.85 108.312 -179.456 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.493 ' N ' ' C ' ' A' ' 109' ' ' SER . 58.3 t0 -175.41 -23.8 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.523 0 CA-C-N 115.819 -0.628 . . . . 2.46 109.469 -179.321 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.694 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 61.16 96.7 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.887 -1.133 . . . . 2.08 109.491 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 113' ' ' ARG . . . . . 0.586 ' CG ' HH11 ' A' ' 113' ' ' ARG . 2.1 mtt-85 -60.52 -165.15 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.314 0 O-C-N 121.282 -0.886 . . . . 5.93 109.49 -179.923 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.42 ' CG ' HH11 ' A' ' 114' ' ' ARG . 0.0 OUTLIER -149.63 4.88 0.59 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.036 -1.04 . . . . 5.61 109.914 -178.628 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.456 HD23 ' N ' ' A' ' 115' ' ' LEU . 0.1 OUTLIER -124.63 -29.26 3.47 Favored 'General case' 0 N--CA 1.507 2.424 0 O-C-N 121.236 -0.915 . . . . 4.39 109.876 -179.412 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.507 ' C ' ' H ' ' A' ' 118' ' ' THR . 0.6 OUTLIER -108.2 -79.1 0.58 Allowed 'General case' 0 N--CA 1.497 1.882 0 N-CA-C 107.093 -1.447 . . . . 4.09 107.093 179.558 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.437 ' O ' HG12 ' A' ' 117' ' ' VAL . 54.7 t -60.22 -9.18 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.703 0 N-CA-C 106.157 -1.794 . . . . 2.9 106.157 176.918 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 118' ' ' THR . . . . . 0.507 ' H ' ' C ' ' A' ' 116' ' ' THR . 4.9 t 36.88 60.68 0.94 Allowed 'General case' 0 N--CA 1.486 1.362 0 CA-C-O 122.071 0.939 . . . . 3.36 110.744 179.687 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 119' ' ' SER . . . . . 0.477 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.5 p . . . . . 0 C--N 1.304 -1.378 0 CA-C-O 117.982 -1.009 . . . . 3.39 109.634 179.299 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 44.7 mtm . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.543 -0.54 . . . . 8.49 109.543 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -67.09 141.17 57.55 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.212 -0.93 . . . . 5.53 109.526 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 3' ' ' SER . . . . . . . . . . . . . 34.3 t -89.95 -98.69 0.1 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.282 -0.886 . . . . 5.43 109.668 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 4' ' ' LYS . . . . . . . . . . . . . 83.8 tttt -171.83 85.46 0.46 Allowed Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.306 -0.872 . . . . 6.87 109.69 -179.577 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 5' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_exo -55.1 142.81 76.56 Favored 'Trans proline' 0 C--N 1.321 -0.902 0 C-N-CA 120.9 1.067 . . . . 5.16 109.714 -179.71 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 6' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -91.06 119.81 31.52 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.303 -0.873 . . . . 4.78 110.331 -178.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 7.0 mtpm? 41.77 -160.91 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.725 0 CA-C-O 121.622 0.725 . . . . 4.09 110.763 179.18 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.571 ' HE ' ' CG ' ' A' ' 84' ' ' ASP . 2.2 mtt-85 -138.55 164.05 30.44 Favored 'General case' 0 N--CA 1.494 1.742 0 N-CA-C 108.715 -0.846 . . . . 3.04 108.715 -179.728 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 9' ' ' VAL . . . . . . . . . . . . . 19.4 t -51.41 158.2 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.141 -0.975 . . . . 0.67 108.61 179.717 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -121.54 146.88 46.5 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.627 -0.67 . . . . 0.58 109.645 -179.339 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 11' ' ' SER . . . . . 0.437 ' OG ' HG23 ' A' ' 55' ' ' VAL . 4.9 t -140.62 143.77 35.39 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.387 -0.821 . . . . 1.19 109.436 179.878 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 46.8 t -141.39 116.54 9.98 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.319 -0.863 . . . . 1.38 109.689 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 0.645 HG22 ' N ' ' B' ' 14' ' ' PHE . 6.6 p -165.04 170.41 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.342 -0.849 . . . . 0.42 109.029 179.899 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 14' ' ' PHE . . . . . 0.645 ' N ' HG22 ' B' ' 13' ' ' VAL . 9.6 p90 -175.92 -163.14 0.1 Allowed 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 119.285 -0.966 . . . . 1.79 112.144 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.9 pt -150.47 165.55 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.339 0 N-CA-C 108.965 -0.754 . . . . 1.25 108.965 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 17.9 m -125.27 128.82 48.87 Favored 'General case' 0 N--CA 1.502 2.132 0 O-C-N 121.385 -0.822 . . . . 1.61 109.437 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 9.3 mt -99.07 138.72 35.76 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.267 -0.896 . . . . 1.32 109.922 -179.715 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -169.17 150.57 4.35 Favored Pre-proline 0 N--CA 1.49 1.538 0 N-CA-C 108.765 -0.828 . . . . 1.45 108.765 179.259 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -59.15 167.8 5.43 Favored 'Trans proline' 0 CA--C 1.542 0.89 0 C-N-CA 121.051 1.167 . . . . 1.5 109.507 179.836 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 20' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_endo -61.95 -61.45 0.16 Allowed 'Trans proline' 0 C--N 1.317 -1.085 0 C-N-CA 121.371 1.381 . . . . 2.86 109.455 179.348 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 11.6 ptp180 -72.36 162.89 28.86 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.427 -0.796 . . . . 6.12 109.619 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 22' ' ' ARG . . . . . 0.485 ' N ' ' CD ' ' B' ' 22' ' ' ARG . 11.0 mpt_? -83.24 -164.71 0.93 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.298 -0.876 . . . . 6.29 109.107 179.865 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -159.82 124.11 3.82 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.129 -0.982 . . . . 5.62 109.622 179.891 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 11.8 t . . . . . 0 N--CA 1.491 1.586 0 CA-C-O 117.921 -1.038 . . . . 6.48 109.478 179.947 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.59 ' O ' HG23 ' A' ' 2' ' ' ILE . . . . . . . . 1 N--CA 1.531 4.988 0 N-CA-C 119.72 2.648 . . . . 6.64 119.72 . . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.604 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 13.7 pt -162.6 47.06 0.2 Allowed Pre-proline 0 C--N 1.307 -1.282 0 N-CA-C 107.946 -1.131 . . . . 7.08 107.946 179.004 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.838 ' C ' ' H ' ' A' ' 5' ' ' PHE . 3.4 Cg_endo -56.51 -80.45 0.01 OUTLIER 'Trans proline' 0 C--N 1.318 -1.037 0 N-CA-C 109.042 -1.176 . . . . 5.5 109.042 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.492 ' C ' ' H ' ' A' ' 6' ' ' PHE . 1.8 tm-20 73.76 -18.04 0.41 Allowed 'General case' 0 N--CA 1.494 1.769 0 N-CA-C 104.217 -2.512 . . . . 6.75 104.217 -175.487 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' PHE . . . . . 0.838 ' H ' ' C ' ' A' ' 3' ' ' PRO . 3.8 m-85 -90.24 19.51 5.04 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 103.855 -2.646 . . . . 6.07 103.855 176.733 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.534 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 38.4 p90 47.59 -150.61 0.12 Allowed 'General case' 0 C--N 1.307 -1.267 0 CA-C-N 114.366 -1.288 . . . . 4.72 109.585 -177.581 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 7.0 mm-40 81.16 -8.28 1.42 Allowed 'General case' 0 N--CA 1.5 2.027 0 N-CA-C 105.241 -2.133 . . . . 4.4 105.241 -176.723 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.479 ' H ' ' C ' ' A' ' 6' ' ' PHE . 47.6 t80 -151.59 -37.22 0.12 Allowed 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 107.864 -1.162 . . . . 5.15 107.864 178.454 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 12.6 m -91.54 2.62 56.31 Favored 'General case' 0 C--N 1.297 -1.681 0 N-CA-C 105.867 -1.901 . . . . 5.13 105.867 177.326 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 10.0 p -41.58 -36.88 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.381 0 CA-C-N 115.255 -0.884 . . . . 4.38 109.518 -179.74 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.56 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 134.11 -81.46 0.31 Allowed Glycine 0 N--CA 1.505 3.242 0 N-CA-C 109.344 -1.502 . . . . 4.22 109.344 179.187 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.464 ' O ' ' C ' ' A' ' 13' ' ' LEU . 16.6 Cg_endo -66.49 42.15 0.17 Allowed 'Trans proline' 0 C--N 1.319 -0.994 0 C-N-CA 122.033 1.822 . . . . 3.85 108.533 178.462 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.56 ' H ' ' C ' ' A' ' 11' ' ' GLY . 0.2 OUTLIER 30.36 94.03 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.148 0 CA-C-O 121.355 0.598 . . . . 3.67 110.412 -178.806 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.506 ' C ' ' H ' ' A' ' 16' ' ' GLY . . . -35.69 -30.64 0.02 OUTLIER Glycine 0 N--CA 1.499 2.854 0 N-CA-C 110.02 -1.232 . . . . 2.97 110.02 -179.654 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.517 ' N ' ' O ' ' A' ' 13' ' ' LEU . 48.6 tt0 57.42 8.14 0.58 Allowed 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 108.287 -1.005 . . . . 2.97 108.287 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.506 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 95.02 -144.95 17.49 Favored Glycine 0 N--CA 1.488 2.122 0 N-CA-C 111.204 -0.758 . . . . 2.44 111.204 178.462 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.558 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -43.2 -23.65 0.26 Allowed Glycine 0 N--CA 1.49 2.271 0 O-C-N 121.715 -0.874 . . . . 1.81 111.489 -178.265 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.493 ' N ' ' OE1' ' A' ' 94' ' ' GLU . . . -43.01 -17.94 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.042 -1.27 . . . . 2.21 110.047 -179.715 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' HIS . . . . . 0.558 ' N ' ' O ' ' A' ' 17' ' ' GLY . 8.9 t-80 -95.3 -52.06 4.33 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.33 -0.856 . . . . 2.87 109.731 179.884 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.536 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.0 OUTLIER -67.21 -14.71 63.17 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.996 -1.065 . . . . 2.02 109.551 -179.602 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.414 HG23 ' O ' ' A' ' 17' ' ' GLY . 71.2 t -76.93 113.4 15.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.181 -0.95 . . . . 2.07 108.813 179.308 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 20.7 tpt180 -110.4 136.31 49.76 Favored 'General case' 0 N--CA 1.494 1.774 0 CA-C-O 121.567 0.698 . . . . 3.5 110.18 -179.015 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.474 ' HA ' HD13 ' A' ' 41' ' ' ILE . . . -140.05 113.61 8.61 Favored 'General case' 0 N--CA 1.491 1.603 0 N-CA-C 108.645 -0.872 . . . . 1.83 108.645 179.569 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -146.38 126.51 2.5 Favored Glycine 0 N--CA 1.496 2.638 0 N-CA-C 109.625 -1.39 . . . . 1.9 109.625 -179.647 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.32 177.93 48.5 Favored Glycine 0 N--CA 1.488 2.139 0 N-CA-C 109.743 -1.343 . . . . 1.85 109.743 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 41.7 p -79.63 -24.62 41.79 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.249 -1.148 . . . . 2.31 109.461 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -68.56 -14.1 66.6 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 108.387 -1.885 . . . . 1.64 108.387 179.492 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 33.6 mt -100.35 35.25 2.15 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.688 -0.856 . . . . 1.83 108.688 179.76 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 -144.32 -46.01 0.25 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.377 -0.827 . . . . 2.34 109.516 -179.742 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 29.2 ptt180 -172.36 171.95 4.58 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 120.98 -1.075 . . . . 3.77 110.093 -179.874 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -147.76 174.4 27.51 Favored Glycine 0 N--CA 1.493 2.439 0 N-CA-C 108.598 -1.801 . . . . 1.57 108.598 179.622 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 37.6 t -134.68 152.52 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.088 0 O-C-N 121.136 -1.214 . . . . 1.83 110.576 -179.635 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.563 ' HB2' ' HB2' ' A' ' 107' ' ' SER . . . -40.78 112.29 0.28 Allowed 'General case' 0 N--CA 1.499 1.999 0 CA-C-O 121.586 0.708 . . . . 1.64 112.321 -179.268 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 53.72 51.82 46.32 Favored Glycine 0 N--CA 1.49 2.253 0 O-C-N 121.57 -0.706 . . . . 1.73 111.377 177.049 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 24.7 t -127.29 98.38 29.68 Favored Pre-proline 0 N--CA 1.495 1.787 0 O-C-N 121.451 -1.029 . . . . 2.19 108.453 178.895 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_exo -57.85 138.71 87.37 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 120.67 0.913 . . . . 1.96 109.854 -179.25 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -146.79 -167.76 2.85 Favored 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 108.491 -0.929 . . . . 1.69 108.491 -179.839 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -169.26 170.75 8.38 Favored 'General case' 0 C--N 1.303 -1.415 0 C-N-CA 118.745 -1.182 . . . . 2.23 111.04 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.53 ' CD1' ' N ' ' A' ' 39' ' ' PHE . 1.2 p90 -142.3 -178.26 5.65 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 107.49 -1.3 . . . . 1.54 107.49 178.274 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 88.9 p -124.43 138.37 54.36 Favored 'General case' 0 N--CA 1.501 2.088 0 CA-C-O 122.118 0.961 . . . . 2.37 111.219 -178.515 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.474 HD13 ' HA ' ' A' ' 23' ' ' ALA . 33.3 mm -130.58 126.59 60.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 N-CA-C 108.238 -1.023 . . . . 1.65 108.238 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.504 ' CD1' ' C ' ' A' ' 42' ' ' TRP . 0.6 OUTLIER -138.28 142.13 39.83 Favored 'General case' 0 N--CA 1.503 2.221 0 O-C-N 120.898 -1.126 . . . . 3.68 109.539 179.357 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.536 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.2 OUTLIER -156.44 151.94 26.83 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.553 -0.717 . . . . 2.89 109.605 -179.076 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 44' ' ' ARG . . . . . 0.508 HH11 ' HG2' ' A' ' 44' ' ' ARG . 0.0 OUTLIER -168.38 62.47 0.06 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.481 -0.762 . . . . 4.63 109.069 179.596 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -155.43 -60.09 0.11 Allowed 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.106 -0.996 . . . . 2.89 110.016 -179.748 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.449 ' HB3' ' NZ ' ' A' ' 20' ' ' LYS . . . -59.7 -32.75 70.8 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.886 -1.134 . . . . 1.74 109.333 -179.734 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 94.94 -157.36 22.14 Favored Glycine 0 N--CA 1.495 2.603 0 N-CA-C 109.996 -1.242 . . . . 1.6 109.996 179.72 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.65 163.19 0.71 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.398 -1.06 . . . . 1.4 110.101 -179.605 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 175.56 -165.85 36.91 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.264 -1.534 . . . . 1.04 109.264 179.844 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.4 ' O ' ' N ' ' A' ' 92' ' ' ASN . . . -132.6 119.62 2.49 Favored Glycine 0 N--CA 1.498 2.816 0 N-CA-C 108.985 -1.646 . . . . 1.06 108.985 179.867 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.461 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 31.6 tp -100.44 104.53 15.94 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.328 -1.101 . . . . 1.1 109.014 -179.873 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 13.8 t -91.14 142.73 27.43 Favored 'General case' 0 N--CA 1.495 1.824 0 N-CA-C 108.703 -0.851 . . . . 1.56 108.703 179.575 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.533 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 66.0 mt -132.47 103.58 6.54 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.986 0 O-C-N 121.119 -0.988 . . . . 0.65 109.571 -179.922 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -93.76 106.23 18.21 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.641 -0.874 . . . . 0.69 108.641 179.479 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.429 ' O ' ' O ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -98.91 141.7 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.564 -0.71 . . . . 0.91 109.478 -179.622 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 21.0 tt0 -141.28 144.2 34.52 Favored 'General case' 0 N--CA 1.492 1.639 0 N-CA-C 107.535 -1.283 . . . . 1.8 107.535 178.678 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 164.07 -173.3 40.08 Favored Glycine 0 N--CA 1.488 2.134 0 N-CA-C 109.489 -1.444 . . . . 0.49 109.489 -178.913 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -64.01 -33.46 62.54 Favored 'Trans proline' 0 C--N 1.319 -1.015 0 C-N-CA 122.114 1.876 . . . . 0.66 112.154 -179.567 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 33.0 m -135.22 155.77 50.1 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.072 -1.017 . . . . 1.55 109.947 -179.307 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 77.3 tttt -73.7 96.35 2.49 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.621 -0.674 . . . . 2.53 109.609 -179.834 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -61.05 123.9 18.98 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.342 -0.849 . . . . 0.82 109.341 179.894 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.456 ' CB ' HG12 ' A' ' 78' ' ' VAL . 19.6 tt0 -70.94 171.03 11.48 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.238 -0.914 . . . . 2.3 109.214 -179.82 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 72.4 mt -140.92 152.08 20.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 N-CA-C 107.663 -1.236 . . . . 1.4 107.663 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.54 ' HB3' ' HB2' ' A' ' 76' ' ' SER . . . -150.09 113.45 4.93 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.537 -1.352 . . . . 1.36 109.356 179.816 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.461 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 47.0 p90 -87.24 125.14 34.01 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.35 -0.844 . . . . 1.47 109.71 179.874 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 59.5 tt0 -141.31 100.07 3.71 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.386 -0.821 . . . . 2.51 109.233 179.808 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.421 ' OD1' ' O ' ' A' ' 67' ' ' ASP . 1.3 p30 -74.16 128.54 35.81 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.251 -0.906 . . . . 2.07 109.53 -179.86 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 84.6 mtm180 -101.81 -33.85 9.65 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.401 -0.812 . . . . 4.63 109.699 -179.885 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.542 ' C ' ' H ' ' A' ' 71' ' ' GLY . 29.6 mtmt -122.66 11.23 9.78 Favored 'General case' 0 N--CA 1.495 1.813 0 N-CA-C 109.006 -0.739 . . . . 3.49 109.006 -179.937 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.457 ' CB ' ' O ' ' A' ' 69' ' ' LYS . 1.0 OUTLIER 72.92 -34.98 0.31 Allowed 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 108.577 -0.897 . . . . 3.06 108.577 -179.206 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 71' ' ' GLY . . . . . 0.542 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -89.6 -37.34 7.0 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.941 -1.264 . . . . 2.16 109.941 -179.76 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 45.5 t -95.54 113.45 25.11 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.22 -1.165 . . . . 2.2 109.612 -179.769 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' CYS . . . . . 0.409 ' N ' ' O ' ' A' ' 41' ' ' ILE . 42.6 m -87.91 114.15 24.24 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.293 -0.879 . . . . 2.05 109.548 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -93.9 118.21 5.68 Favored Glycine 0 N--CA 1.494 2.524 0 N-CA-C 109.15 -1.58 . . . . 1.39 109.15 179.815 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -106.92 106.14 20.08 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.298 0 O-C-N 121.53 -0.982 . . . . 1.57 109.011 -179.868 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.54 ' HB2' ' HB3' ' A' ' 64' ' ' ALA . 1.4 m -89.73 150.81 22.14 Favored 'General case' 0 N--CA 1.49 1.568 0 N-CA-C 108.523 -0.917 . . . . 1.85 108.523 179.273 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 11.7 p90 -145.89 174.27 11.4 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.212 -0.93 . . . . 1.54 109.348 -179.106 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.592 ' O ' HG13 ' A' ' 78' ' ' VAL . 4.8 p -145.79 116.71 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.503 2.192 0 O-C-N 120.991 -1.068 . . . . 1.9 110.66 179.47 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.457 HG11 HG21 ' A' ' 105' ' ' VAL . 10.3 m -90.96 151.41 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 O-C-N 121.144 -0.972 . . . . 1.27 108.745 179.295 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 80' ' ' GLN . . . . . 0.42 ' O ' ' OE2' ' A' ' 81' ' ' GLU . 7.2 tp-100 -94.76 -46.91 6.7 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.011 -1.056 . . . . 2.48 110.819 -179.06 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.42 ' OE2' ' O ' ' A' ' 80' ' ' GLN . 78.1 mm-40 -153.8 150.06 22.23 Favored Pre-proline 0 N--CA 1.503 2.185 0 O-C-N 120.68 -1.262 . . . . 1.92 111.02 -178.651 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.635 ' HG3' ' N ' ' A' ' 107' ' ' SER . 84.9 Cg_exo -36.76 163.45 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.645 0 C-N-CA 122.918 2.412 . . . . 1.3 113.529 178.177 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 148.16 -165.29 28.97 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.28 -1.528 . . . . 1.02 109.28 179.838 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -106.95 88.25 2.7 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.599 -0.942 . . . . 2.13 108.665 179.697 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.457 ' O ' ' N ' ' A' ' 103' ' ' VAL . 3.4 m-85 -76.64 129.55 36.55 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.283 -1.006 . . . . 0.92 108.283 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -110.21 121.49 45.41 Favored 'General case' 0 N--CA 1.498 1.933 0 N-CA-C 108.372 -0.973 . . . . 1.53 108.372 -179.101 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.417 ' O ' HG13 ' A' ' 87' ' ' VAL . 8.4 p -120.28 133.41 67.09 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.593 -0.692 . . . . 1.0 109.705 -179.607 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 11.6 t -128.24 101.64 6.33 Favored 'General case' 0 N--CA 1.498 1.958 0 N-CA-C 109.609 -0.515 . . . . 1.59 109.609 -179.831 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.472 ' H ' ' CB ' ' A' ' 99' ' ' SER . 0.8 OUTLIER -108.0 130.85 59.78 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.875 0 O-C-N 121.567 -0.708 . . . . 1.29 109.6 -179.806 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 90' ' ' LYS . . . . . 0.426 ' HG3' ' H ' ' A' ' 93' ' ' ASP . 0.1 OUTLIER -139.9 128.77 23.38 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.413 -0.804 . . . . 1.58 109.05 -179.979 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 44.7 t80 -84.69 95.63 8.98 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 120.527 -1.358 . . . . 1.34 108.387 179.296 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' ASN . . . . . 0.457 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 12.5 t-20 68.58 39.72 2.03 Favored 'General case' 0 N--CA 1.488 1.435 0 N-CA-C 107.893 -1.151 . . . . 2.32 107.893 -178.532 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.457 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 3.4 m-20 82.6 14.07 0.45 Allowed 'General case' 0 N--CA 1.499 1.992 0 CA-C-O 121.188 0.518 . . . . 1.92 110.23 -179.434 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 94' ' ' GLU . . . . . 0.493 ' OE1' ' N ' ' A' ' 18' ' ' ALA . 55.2 mt-10 -87.91 78.73 8.24 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.431 -0.951 . . . . 2.25 108.431 178.916 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 42.2 m80 -55.75 109.67 0.6 Allowed 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.529 -0.732 . . . . 2.88 110.602 -179.17 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 96' ' ' ILE . . . . . 0.426 ' O ' ' O ' ' A' ' 99' ' ' SER . 1.5 mp -66.55 136.48 94.88 Favored Pre-proline 0 N--CA 1.492 1.637 0 N-CA-C 107.476 -1.305 . . . . 2.35 107.476 179.034 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_exo -41.17 -41.21 4.51 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 120.997 1.131 . . . . 2.48 110.575 -179.633 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.506 ' N ' ' OD1' ' A' ' 98' ' ' ASP . 1.3 m-20 -56.9 -65.61 0.59 Allowed 'General case' 0 N--CA 1.488 1.434 0 O-C-N 120.83 -1.169 . . . . 2.65 108.026 178.191 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.472 ' CB ' ' H ' ' A' ' 89' ' ' ILE . 0.1 OUTLIER -68.71 145.02 96.68 Favored Pre-proline 0 C--N 1.293 -1.882 0 O-C-N 121.173 -0.955 . . . . 2.0 109.564 -179.448 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -85.22 113.01 2.71 Favored 'Cis proline' 0 CA--C 1.549 1.271 0 O-C-N 122.636 0.808 . . . . 1.79 110.154 -1.864 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 31.3 p90 -121.82 164.23 17.84 Favored 'General case' 0 N--CA 1.521 3.088 0 O-C-N 120.497 -1.377 . . . . 2.19 109.921 178.402 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.3 p -87.43 144.41 9.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.462 -0.774 . . . . 1.44 110.643 -178.129 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.457 ' N ' ' O ' ' A' ' 85' ' ' TYR . 71.7 t -117.24 89.54 31.26 Favored Pre-proline 0 N--CA 1.498 1.949 0 N-CA-C 108.503 -0.925 . . . . 1.19 108.503 179.354 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -62.93 113.99 2.24 Favored 'Trans proline' 0 C--N 1.319 -0.989 0 C-N-CA 121.142 1.228 . . . . 1.49 111.916 -178.266 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.457 HG21 HG11 ' A' ' 79' ' ' VAL . 55.4 t -96.41 140.4 17.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 N-CA-C 105.926 -1.879 . . . . 1.35 105.926 177.446 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.684 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -131.89 133.53 44.7 Favored 'General case' 0 N--CA 1.512 2.671 0 CA-C-O 122.067 0.937 . . . . 1.67 112.059 -176.889 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.635 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 23.2 t -101.06 86.77 3.11 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 107.928 -1.138 . . . . 2.04 107.928 179.177 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 13.3 mt 60.24 6.07 0.94 Allowed 'General case' 0 C--N 1.297 -1.708 0 N-CA-C 107.718 -1.216 . . . . 3.2 107.718 -178.323 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.599 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 52.0 p -97.77 -23.39 15.92 Favored 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 109.206 -0.664 . . . . 2.09 109.206 179.657 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 110' ' ' ASP . . . . . 0.684 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 34.4 t70 52.78 11.41 0.2 Allowed 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.131 -0.981 . . . . 2.85 108.436 -179.587 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.492 ' N ' ' C ' ' A' ' 109' ' ' SER . 30.8 t70 -171.57 -30.13 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.711 -0.618 . . . . 2.46 109.567 -179.736 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.599 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 41.88 83.9 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.074 0 O-C-N 121.25 -0.906 . . . . 2.08 110.1 179.884 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 113' ' ' ARG . . . . . 0.523 ' CG ' HH11 ' A' ' 113' ' ' ARG . 0.0 OUTLIER -71.46 149.19 46.1 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.167 -0.958 . . . . 5.93 109.268 -179.677 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.585 ' CG ' HH11 ' A' ' 114' ' ' ARG . 0.2 OUTLIER -93.59 6.26 48.87 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.513 -0.742 . . . . 5.61 109.156 -179.933 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 34.2 mt -128.0 -21.77 3.59 Favored 'General case' 0 N--CA 1.505 2.305 0 O-C-N 121.649 -0.657 . . . . 4.39 109.677 -179.507 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.497 ' C ' ' H ' ' A' ' 118' ' ' THR . 91.6 m -112.03 -77.22 0.59 Allowed 'General case' 0 N--CA 1.498 1.95 0 N-CA-C 107.087 -1.449 . . . . 4.09 107.087 179.049 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.463 ' O ' HG12 ' A' ' 117' ' ' VAL . 44.7 t -64.74 -6.2 2.87 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.749 0 N-CA-C 105.911 -1.885 . . . . 2.9 105.911 176.799 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 118' ' ' THR . . . . . 0.497 ' H ' ' C ' ' A' ' 116' ' ' THR . 4.5 t 35.99 59.07 0.92 Allowed 'General case' 0 N--CA 1.488 1.455 0 CA-C-N 115.026 -0.988 . . . . 3.36 110.797 179.902 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 119' ' ' SER . . . . . 0.46 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.5 p . . . . . 0 N--CA 1.488 1.434 0 CA-C-O 117.977 -1.011 . . . . 3.39 109.582 179.345 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 27.2 ttt . . . . . 0 N--CA 1.49 1.533 0 CA-C-O 121.277 0.561 . . . . 8.49 109.525 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -80.31 149.35 30.34 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.217 -0.927 . . . . 5.53 109.779 -179.818 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 3' ' ' SER . . . . . 0.439 ' H ' ' H ' ' B' ' 4' ' ' LYS . 21.6 p -171.34 -6.8 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.281 -0.887 . . . . 5.43 109.086 179.85 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 4' ' ' LYS . . . . . 0.651 ' N ' ' CD ' ' B' ' 5' ' ' PRO . 25.7 ttpt -81.19 -33.55 0.69 Allowed Pre-proline 0 N--CA 1.488 1.451 0 O-C-N 121.418 -0.801 . . . . 6.87 111.826 179.964 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 5' ' ' PRO . . . . . 0.651 ' CD ' ' N ' ' B' ' 4' ' ' LYS . 6.2 Cg_exo -65.08 -169.77 0.14 Allowed 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 120.606 0.871 . . . . 5.16 110.002 -178.977 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 6' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -77.54 35.18 0.18 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.234 -0.916 . . . . 4.78 109.764 -179.711 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 7' ' ' LYS . . . . . 0.407 ' H ' ' C ' ' B' ' 5' ' ' PRO . 91.4 mttt 45.6 -114.04 0.43 Allowed 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.317 -0.864 . . . . 4.09 109.847 179.89 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.456 HH11 ' HG2' ' B' ' 8' ' ' ARG . 11.7 mtt-85 -91.1 168.2 11.8 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.19 -0.944 . . . . 3.04 109.078 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 9' ' ' VAL . . . . . 0.403 ' CG1' ' N ' ' B' ' 10' ' ' ALA . 3.1 t -48.72 159.69 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.135 -0.978 . . . . 0.67 108.515 179.747 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 0.403 ' N ' ' CG1' ' B' ' 9' ' ' VAL . . . -116.44 150.84 37.18 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.655 -0.653 . . . . 0.58 109.482 -179.344 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 11' ' ' SER . . . . . 0.429 ' O ' ' O ' ' A' ' 55' ' ' VAL . 58.2 m -153.19 139.88 18.92 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.283 -0.886 . . . . 1.19 109.865 -179.832 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 51.6 p -148.36 112.51 5.21 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.197 -0.939 . . . . 1.38 109.562 -179.697 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 0.58 HG22 ' N ' ' B' ' 14' ' ' PHE . 2.5 p -154.61 167.58 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 N-CA-C 108.624 -0.88 . . . . 0.42 108.624 179.811 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 14' ' ' PHE . . . . . 0.58 ' N ' HG22 ' B' ' 13' ' ' VAL . 7.8 p90 -176.55 -167.18 0.18 Allowed 'General case' 0 N--CA 1.488 1.435 0 C-N-CA 119.132 -1.027 . . . . 1.79 112.069 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -143.45 146.26 21.49 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.226 0 N-CA-C 108.883 -0.784 . . . . 1.25 108.883 179.871 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 46.1 m -113.03 128.3 56.46 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.353 -0.842 . . . . 1.61 109.293 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 16.8 mt -97.95 142.51 29.59 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.174 -0.954 . . . . 1.32 109.562 179.939 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -171.75 66.97 0.42 Allowed Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.256 -0.903 . . . . 1.45 109.527 179.696 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -65.42 141.12 66.48 Favored 'Trans proline' 0 CA--C 1.551 1.363 0 C-N-CA 121.36 1.373 . . . . 1.5 109.32 -179.776 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 20' ' ' PRO . . . . . 0.426 ' O ' ' O ' ' B' ' 21' ' ' ARG . 4.6 Cg_endo -62.38 -36.2 68.32 Favored 'Trans proline' 0 CA--C 1.538 0.691 0 C-N-CA 120.872 1.048 . . . . 2.86 109.699 179.394 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 21' ' ' ARG . . . . . 0.426 ' O ' ' O ' ' B' ' 20' ' ' PRO . 50.9 mtp180 -55.79 -164.96 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.442 -0.786 . . . . 6.12 110.013 -179.579 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 22' ' ' ARG . . . . . . . . . . . . . 1.5 tmm_? 54.95 92.2 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.314 -0.866 . . . . 6.29 109.158 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 23' ' ' ASP . . . . . 0.409 ' H ' ' H ' ' B' ' 24' ' ' VAL . 14.8 m-20 -157.78 -13.4 0.08 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.331 -0.856 . . . . 5.62 109.442 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 24' ' ' VAL . . . . . 0.409 ' H ' ' H ' ' B' ' 23' ' ' ASP . 14.2 t . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 118.022 -0.989 . . . . 6.48 109.573 -179.834 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.964 0 N-CA-C 119.799 2.68 . . . . 6.64 119.799 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.525 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 2.8 tt -174.98 52.22 0.1 Allowed Pre-proline 0 C--N 1.309 -1.174 0 N-CA-C 107.972 -1.121 . . . . 7.08 107.972 179.578 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.721 ' C ' ' H ' ' A' ' 5' ' ' PHE . 1.3 Cg_endo -56.7 -80.92 0.01 OUTLIER 'Trans proline' 0 C--N 1.319 -0.996 0 N-CA-C 108.217 -1.494 . . . . 5.5 108.217 179.852 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 64.32 2.68 1.58 Allowed 'General case' 0 N--CA 1.499 2.024 0 N-CA-C 105.003 -2.221 . . . . 6.75 105.003 -176.61 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' PHE . . . . . 0.721 ' H ' ' C ' ' A' ' 3' ' ' PRO . 5.2 m-85 -114.6 18.42 16.71 Favored 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 102.46 -3.163 . . . . 6.07 102.46 177.58 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.541 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 36.0 p90 48.14 -151.09 0.13 Allowed 'General case' 0 C--N 1.308 -1.209 0 CA-C-N 113.302 -1.772 . . . . 4.72 109.532 -177.315 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.404 ' HB2' ' O ' ' A' ' 6' ' ' PHE . 66.4 mt-30 81.61 -9.53 1.25 Allowed 'General case' 0 N--CA 1.497 1.88 0 N-CA-C 105.139 -2.171 . . . . 4.4 105.139 -176.697 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.5 ' H ' ' C ' ' A' ' 6' ' ' PHE . 28.4 t80 -150.37 -36.66 0.15 Allowed 'General case' 0 N--CA 1.486 1.333 0 N-CA-C 107.983 -1.117 . . . . 5.15 107.983 178.24 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.422 HG22 ' O ' ' A' ' 9' ' ' THR . 39.1 m -94.91 4.57 53.66 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 105.704 -1.961 . . . . 5.13 105.704 177.456 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.536 HG13 ' N ' ' A' ' 11' ' ' GLY . 13.0 p -45.69 -46.23 4.81 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.296 0 CA-C-N 115.272 -0.876 . . . . 4.38 109.398 -179.535 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.576 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 131.03 -78.58 0.37 Allowed Glycine 0 N--CA 1.503 3.142 0 N-CA-C 109.132 -1.587 . . . . 4.22 109.132 179.393 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.446 ' O ' ' C ' ' A' ' 13' ' ' LEU . 11.8 Cg_endo -65.24 40.22 0.12 Allowed 'Trans proline' 0 C--N 1.32 -0.958 0 C-N-CA 122.186 1.924 . . . . 3.85 109.176 178.409 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.576 ' H ' ' C ' ' A' ' 11' ' ' GLY . 0.2 OUTLIER 28.17 46.05 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.157 0 CA-C-O 121.504 0.669 . . . . 3.67 111.062 -179.848 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.483 ' C ' ' N ' ' A' ' 16' ' ' GLY . . . 69.06 -36.89 0.3 Allowed Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.567 -1.413 . . . . 2.97 109.567 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.521 ' H ' ' C ' ' A' ' 13' ' ' LEU . 6.9 tp10 51.76 16.81 0.53 Allowed 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.115 -1.226 . . . . 2.97 107.798 -179.132 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.483 ' N ' ' C ' ' A' ' 14' ' ' GLY . . . 82.09 -166.08 45.99 Favored Glycine 0 N--CA 1.485 1.92 0 N-CA-C 109.48 -1.448 . . . . 2.44 109.48 -179.854 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.503 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -43.97 -19.76 0.13 Allowed Glycine 0 N--CA 1.488 2.159 0 O-C-N 121.387 -1.067 . . . . 1.81 110.579 -179.457 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.774 ' HB2' ' OE1' ' A' ' 94' ' ' GLU . . . -51.07 -9.9 0.06 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.826 -1.397 . . . . 2.21 109.204 -179.829 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' HIS . . . . . 0.503 ' N ' ' O ' ' A' ' 17' ' ' GLY . 22.0 t60 -103.01 -4.59 24.42 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.404 -0.81 . . . . 2.87 110.175 -179.738 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.594 ' HZ2' HG23 ' A' ' 21' ' ' VAL . 1.9 pptp? -135.81 0.6 2.69 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.1 -1.0 . . . . 2.02 110.261 -179.559 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.594 HG23 ' HZ2' ' A' ' 20' ' ' LYS . 55.3 t -88.8 113.47 25.55 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.003 -1.06 . . . . 2.07 109.751 179.665 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 21.0 tpt180 -108.97 135.85 49.47 Favored 'General case' 0 N--CA 1.495 1.79 0 N-CA-C 109.308 -0.627 . . . . 3.5 109.308 179.647 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -143.31 113.81 7.46 Favored 'General case' 0 N--CA 1.492 1.674 0 N-CA-C 108.566 -0.902 . . . . 1.83 108.566 179.467 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -152.6 130.95 3.2 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.671 -1.371 . . . . 1.9 109.671 -179.367 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -177.55 167.58 38.67 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.801 -1.32 . . . . 1.85 109.801 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.49 ' C ' ' H ' ' A' ' 28' ' ' LEU . 0.5 OUTLIER -80.5 -27.53 37.72 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.318 -1.107 . . . . 2.31 109.864 -179.698 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -64.21 -1.36 5.46 Favored Glycine 0 N--CA 1.483 1.78 0 N-CA-C 107.938 -2.065 . . . . 1.64 107.938 179.193 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.49 ' H ' ' C ' ' A' ' 26' ' ' THR . 60.9 mt -108.45 -10.56 15.27 Favored 'General case' 0 N--CA 1.493 1.712 0 N-CA-C 108.643 -0.873 . . . . 1.83 108.643 179.748 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 20.3 mm-40 -85.74 -54.16 4.7 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.568 -0.708 . . . . 2.34 109.561 -179.586 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' ARG . . . . . 0.584 ' CG ' HH11 ' A' ' 30' ' ' ARG . 3.2 mtt-85 -156.83 161.94 39.72 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.125 -0.984 . . . . 3.77 109.76 179.918 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -140.73 172.17 23.74 Favored Glycine 0 N--CA 1.493 2.499 0 N-CA-C 108.102 -1.999 . . . . 1.57 108.102 179.205 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 36.0 t -134.37 150.93 31.2 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.03 0 O-C-N 121.189 -1.183 . . . . 1.83 110.398 -179.338 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -38.83 113.89 0.34 Allowed 'General case' 0 N--CA 1.495 1.784 0 CA-C-O 121.862 0.839 . . . . 1.64 112.844 -179.184 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 53.99 49.77 57.64 Favored Glycine 0 N--CA 1.489 2.167 0 N-CA-C 111.238 -0.745 . . . . 1.73 111.238 177.378 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 25.3 t -126.98 99.41 28.88 Favored Pre-proline 0 N--CA 1.497 1.9 0 O-C-N 121.531 -0.982 . . . . 2.19 108.396 179.052 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -56.75 143.44 90.27 Favored 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 120.946 1.097 . . . . 1.96 110.588 -178.906 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.473 ' HB3' ' CE1' ' A' ' 77' ' ' TYR . . . -150.23 -169.06 3.28 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.563 -0.903 . . . . 1.69 108.563 179.869 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -169.38 162.23 10.22 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.958 -1.089 . . . . 2.23 111.03 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.575 ' CD1' ' N ' ' A' ' 39' ' ' PHE . 0.2 OUTLIER -134.8 -176.37 4.21 Favored 'General case' 0 N--CA 1.485 1.303 0 N-CA-C 106.638 -1.615 . . . . 1.54 106.638 178.355 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 18.3 t -121.35 145.97 47.34 Favored 'General case' 0 N--CA 1.501 2.1 0 CA-C-O 121.72 0.771 . . . . 2.37 111.07 -178.633 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.523 ' O ' ' N ' ' A' ' 73' ' ' CYS . 62.6 mt -143.19 118.69 4.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 N-CA-C 108.547 -0.908 . . . . 1.65 108.547 179.222 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.533 ' O ' ' CD2' ' A' ' 42' ' ' TRP . 5.9 p-90 -118.1 127.19 53.54 Favored 'General case' 0 N--CA 1.502 2.135 0 O-C-N 121.219 -0.926 . . . . 3.68 108.549 179.109 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.52 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -150.92 128.4 11.41 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.224 -0.923 . . . . 2.89 109.926 -178.828 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 44' ' ' ARG . . . . . . . . . . . . . 24.8 ttm180 -172.48 79.35 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.442 -0.786 . . . . 4.63 109.092 179.663 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 2.3 tm-20 -159.69 -55.04 0.06 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.188 -0.945 . . . . 2.89 109.881 -179.676 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -53.43 -55.29 26.38 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 120.911 -1.118 . . . . 1.74 108.672 -179.821 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 140.58 -170.37 24.47 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.163 -1.575 . . . . 1.6 109.163 179.678 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.67 148.28 10.05 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.14 -1.212 . . . . 1.4 109.202 179.832 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -171.66 -170.06 35.23 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.762 -1.335 . . . . 1.04 109.762 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -133.05 122.71 3.24 Favored Glycine 0 N--CA 1.497 2.727 0 N-CA-C 109.403 -1.479 . . . . 1.06 109.403 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 11.3 tp -97.65 97.98 9.49 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.303 -1.116 . . . . 1.1 108.69 179.651 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' SER . . . . . 0.409 ' HA ' ' CD2' ' B' ' 14' ' ' PHE . 0.3 OUTLIER -84.52 145.63 27.99 Favored 'General case' 0 C--N 1.312 -1.035 0 N-CA-C 108.026 -1.102 . . . . 1.56 108.026 179.695 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.445 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 65.4 mt -134.98 118.68 25.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.217 -0.927 . . . . 0.65 110.048 -179.315 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -106.63 106.85 17.57 Favored 'General case' 0 N--CA 1.495 1.824 0 N-CA-C 108.431 -0.952 . . . . 0.69 108.431 179.072 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 2.4 t -97.59 146.36 7.88 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.266 -0.897 . . . . 0.91 109.639 -179.436 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 22.8 tt0 -139.5 131.21 27.38 Favored 'General case' 0 N--CA 1.488 1.448 0 N-CA-C 107.616 -1.253 . . . . 1.8 107.616 178.835 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -178.41 172.31 44.71 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.159 -1.576 . . . . 0.49 109.159 -179.498 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_exo -52.06 -28.61 33.25 Favored 'Trans proline' 0 C--N 1.318 -1.076 0 C-N-CA 121.808 1.672 . . . . 0.66 110.859 -179.501 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.2 t -140.79 157.18 45.77 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.439 -0.788 . . . . 1.55 109.839 -179.527 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 49.3 mttp -77.78 104.75 8.52 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.421 -0.799 . . . . 2.53 109.169 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -74.15 136.95 42.89 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.272 -0.892 . . . . 0.82 109.549 -179.728 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.679 ' O ' HD13 ' A' ' 63' ' ' ILE . 46.9 mt-10 -75.33 175.54 8.29 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.141 -0.974 . . . . 2.3 109.629 -179.829 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.679 HD13 ' O ' ' A' ' 62' ' ' GLU . 4.8 mm -140.51 156.46 23.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 N-CA-C 108.033 -1.099 . . . . 1.4 108.033 -179.656 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.433 ' HB3' ' CB ' ' A' ' 76' ' ' SER . . . -144.45 174.63 10.77 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 120.551 -1.343 . . . . 1.36 108.999 179.749 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.51 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 37.7 p90 -147.25 116.36 6.9 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.308 -0.87 . . . . 1.47 109.46 -179.919 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 76.2 tt0 -141.57 111.0 6.4 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.317 -0.864 . . . . 2.51 109.241 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.428 ' OD1' ' O ' ' A' ' 67' ' ' ASP . 1.2 p30 -74.71 117.84 16.99 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.2 -0.938 . . . . 2.07 109.541 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 29.9 ttp180 -102.15 -24.12 13.97 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.371 -0.831 . . . . 4.63 109.46 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.511 ' C ' ' H ' ' A' ' 71' ' ' GLY . 40.1 mttp -121.29 1.56 10.23 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.55 -0.719 . . . . 3.49 109.079 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.463 ' CB ' ' O ' ' A' ' 69' ' ' LYS . 1.5 t70 74.0 -26.11 0.19 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.498 -0.751 . . . . 3.06 109.11 -179.628 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 71' ' ' GLY . . . . . 0.511 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -108.54 -30.34 3.84 Favored Glycine 0 N--CA 1.495 2.58 0 N-CA-C 109.894 -1.282 . . . . 2.16 109.894 -179.484 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 60.6 p -95.7 113.58 25.23 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.157 -1.202 . . . . 2.2 109.666 -179.783 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' CYS . . . . . 0.523 ' N ' ' O ' ' A' ' 41' ' ' ILE . 17.0 t -75.77 112.23 11.93 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.306 -0.871 . . . . 2.05 109.361 179.789 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -91.77 117.99 5.37 Favored Glycine 0 N--CA 1.493 2.439 0 N-CA-C 109.394 -1.482 . . . . 1.39 109.394 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 1.9 m -109.28 114.68 47.57 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.097 0 O-C-N 121.611 -0.935 . . . . 1.57 109.502 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.433 ' CB ' ' HB3' ' A' ' 64' ' ' ALA . 0.9 OUTLIER -92.55 167.84 11.66 Favored 'General case' 0 N--CA 1.491 1.62 0 N-CA-C 108.341 -0.985 . . . . 1.85 108.341 179.537 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.473 ' CE1' ' HB3' ' A' ' 37' ' ' ALA . 5.9 p90 -163.77 168.15 20.03 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.356 -0.84 . . . . 1.54 109.095 -179.338 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.577 ' O ' HG13 ' A' ' 78' ' ' VAL . 5.0 p -143.11 115.31 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.369 0 O-C-N 121.0 -1.062 . . . . 1.9 110.448 179.418 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.418 HG22 ' H ' ' A' ' 79' ' ' VAL . 14.3 m -88.82 152.38 3.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.244 -0.91 . . . . 1.27 109.233 179.741 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 28.4 tt0 -88.92 -50.33 6.26 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.092 -1.005 . . . . 2.48 110.764 -179.043 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -153.31 156.92 32.85 Favored Pre-proline 0 N--CA 1.504 2.271 0 O-C-N 120.722 -1.236 . . . . 1.92 110.766 -179.015 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.615 ' HG3' ' N ' ' A' ' 107' ' ' SER . 71.0 Cg_exo -37.67 163.55 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 123.293 2.662 . . . . 1.3 113.452 179.17 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 145.35 -177.37 23.82 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.138 -1.585 . . . . 1.02 109.138 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 84' ' ' ASP . . . . . 0.528 ' OD1' ' NH2' ' B' ' 8' ' ' ARG . 0.4 OUTLIER -99.81 90.93 4.61 Favored 'General case' 0 N--CA 1.493 1.715 0 N-CA-C 107.962 -1.125 . . . . 2.13 107.962 179.289 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -76.25 132.05 39.64 Favored 'General case' 0 C--N 1.296 -1.721 0 N-CA-C 108.245 -1.02 . . . . 0.92 108.245 -179.747 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.66 115.56 27.31 Favored 'General case' 0 N--CA 1.501 2.082 0 N-CA-C 108.337 -0.986 . . . . 1.53 108.337 -179.351 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.556 ' CG1' ' CE2' ' A' ' 101' ' ' PHE . 4.5 p -112.85 132.78 60.69 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.676 -0.64 . . . . 1.0 109.421 -179.779 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 3.0 m -121.85 139.53 53.51 Favored 'General case' 0 N--CA 1.497 1.886 0 N-CA-C 108.536 -0.912 . . . . 1.59 108.536 179.635 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.3 pt -141.1 130.68 25.34 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.181 0 O-C-N 121.076 -1.015 . . . . 1.29 109.845 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -136.89 123.61 21.14 Favored 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 107.72 -1.215 . . . . 1.58 107.72 178.191 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 83.5 t80 -83.7 102.2 12.09 Favored 'General case' 0 C--N 1.295 -1.77 0 N-CA-C 107.985 -1.117 . . . . 1.34 107.985 179.326 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 92' ' ' ASN . . . . . 0.442 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 1.3 t30 69.33 34.83 2.79 Favored 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 108.788 -0.819 . . . . 2.32 108.788 -178.651 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.442 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 2.7 m-20 79.34 16.66 0.89 Allowed 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.827 -0.546 . . . . 1.92 111.505 179.473 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 94' ' ' GLU . . . . . 0.774 ' OE1' ' HB2' ' A' ' 18' ' ' ALA . 0.6 OUTLIER -101.1 100.23 10.77 Favored 'General case' 0 N--CA 1.499 2.005 0 N-CA-C 107.407 -1.331 . . . . 2.25 107.407 178.188 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 4.1 m80 -73.97 110.92 8.64 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.117 -0.99 . . . . 2.88 110.632 -177.844 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 96' ' ' ILE . . . . . 0.465 ' O ' ' N ' ' A' ' 98' ' ' ASP . 3.4 tp -63.95 134.62 95.99 Favored Pre-proline 0 N--CA 1.488 1.455 0 N-CA-C 107.554 -1.276 . . . . 2.35 107.554 178.868 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.417 ' HD2' HD12 ' A' ' 96' ' ' ILE . 7.2 Cg_exo -49.56 92.5 0.03 OUTLIER 'Trans proline' 0 C--O 1.214 -0.721 0 N-CA-C 109.839 -0.87 . . . . 2.48 109.839 -179.824 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.465 ' N ' ' O ' ' A' ' 96' ' ' ILE . 0.9 OUTLIER 169.76 -54.05 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 108.756 -0.831 . . . . 2.65 108.756 -179.574 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 6.2 m -55.3 136.95 68.73 Favored Pre-proline 0 C--N 1.298 -1.636 0 O-C-N 121.231 -0.918 . . . . 2.0 109.588 -178.261 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_endo -88.36 113.58 2.43 Favored 'Cis proline' 0 N--CA 1.494 1.539 0 N-CA-C 110.328 -0.681 . . . . 1.79 110.328 -1.862 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 101' ' ' PHE . . . . . 0.598 ' CD1' ' N ' ' A' ' 101' ' ' PHE . 0.0 OUTLIER -80.71 155.08 26.93 Favored 'General case' 0 N--CA 1.509 2.522 0 O-C-N 119.727 -1.858 . . . . 2.19 108.66 178.346 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 10.5 p -89.21 144.5 8.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.483 -0.761 . . . . 1.44 109.158 179.653 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 76.9 t -128.04 85.87 59.52 Favored Pre-proline 0 N--CA 1.499 1.997 0 N-CA-C 108.133 -1.062 . . . . 1.19 108.133 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -64.91 112.53 2.04 Favored 'Trans proline' 0 C--N 1.321 -0.878 0 C-N-CA 121.433 1.422 . . . . 1.49 111.851 -177.867 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 54.5 t -96.36 143.89 11.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 N-CA-C 106.172 -1.788 . . . . 1.35 106.172 177.667 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.673 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -136.36 135.23 38.65 Favored 'General case' 0 N--CA 1.509 2.489 0 O-C-N 121.151 -0.968 . . . . 1.67 112.133 -176.985 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.615 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 11.0 t -89.67 76.27 7.31 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 107.413 -1.329 . . . . 2.04 107.413 178.982 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 13.6 mt 65.87 -0.06 1.42 Allowed 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 107.748 -1.204 . . . . 3.2 107.748 -177.861 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.67 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 22.9 t -84.67 -22.14 29.94 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.74 -0.837 . . . . 2.09 108.74 178.873 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 110' ' ' ASP . . . . . 0.673 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 5.5 m-20 57.17 6.93 0.4 Allowed 'General case' 0 N--CA 1.487 1.423 0 N-CA-C 107.984 -1.117 . . . . 2.85 107.984 -179.141 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.519 ' H ' ' C ' ' A' ' 109' ' ' SER . 22.4 m-20 -164.79 -33.5 0.03 OUTLIER 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 108.714 -0.847 . . . . 2.46 108.714 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.67 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 41.56 84.49 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.332 -0.855 . . . . 2.08 110.569 179.711 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 113' ' ' ARG . . . . . 0.446 ' NH1' ' CB ' ' A' ' 111' ' ' ASP . 10.3 mpt_? -61.63 -169.54 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.906 -1.121 . . . . 5.93 108.574 179.681 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.68 HH12 ' NE ' ' B' ' 8' ' ' ARG . 50.3 ttt180 -147.39 4.1 0.79 Allowed 'General case' 0 N--CA 1.493 1.721 0 N-CA-C 108.548 -0.908 . . . . 5.61 108.548 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 2.5 mp -129.8 -24.47 2.69 Favored 'General case' 0 N--CA 1.502 2.146 0 N-CA-C 109.458 -0.571 . . . . 4.39 109.458 179.778 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.488 ' C ' ' H ' ' A' ' 118' ' ' THR . 54.9 m -105.33 -79.44 0.56 Allowed 'General case' 0 N--CA 1.496 1.836 0 N-CA-C 106.955 -1.498 . . . . 4.09 106.955 178.8 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.44 ' O ' HG12 ' A' ' 117' ' ' VAL . 49.5 t -62.56 -8.2 2.88 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.702 0 N-CA-C 105.955 -1.869 . . . . 2.9 105.955 176.724 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 118' ' ' THR . . . . . 0.488 ' H ' ' C ' ' A' ' 116' ' ' THR . 4.4 t 36.47 60.2 0.92 Allowed 'General case' 0 N--CA 1.488 1.437 0 CA-C-N 115.2 -0.909 . . . . 3.36 110.729 179.967 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 119' ' ' SER . . . . . 0.463 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.6 p . . . . . 0 C--N 1.304 -1.404 0 CA-C-O 118.0 -1.0 . . . . 3.39 109.611 179.364 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 1' ' ' MET . . . . . 0.538 ' O ' ' N ' ' B' ' 3' ' ' SER . 6.5 ptm . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.467 -0.568 . . . . 8.49 109.467 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . 59.89 -76.95 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.461 -0.774 . . . . 5.53 109.75 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 3' ' ' SER . . . . . 0.538 ' N ' ' O ' ' B' ' 1' ' ' MET . 41.2 t -73.61 -144.71 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.131 -0.98 . . . . 5.43 109.503 -179.952 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 4' ' ' LYS . . . . . 0.488 ' N ' ' OG ' ' B' ' 3' ' ' SER . 79.8 tttt -164.37 68.3 1.47 Allowed Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.278 -0.888 . . . . 6.87 109.648 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 5' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_exo -61.24 169.82 5.86 Favored 'Trans proline' 0 C--N 1.318 -1.071 0 C-N-CA 121.392 1.394 . . . . 5.16 109.828 -179.819 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 6' ' ' GLU . . . . . . . . . . . . . 26.0 mt-10 -77.23 45.4 0.45 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.279 -0.888 . . . . 4.78 109.569 -179.912 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 68.9 mttm 48.85 -115.66 0.77 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.161 -0.962 . . . . 4.09 109.37 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.68 ' NE ' HH12 ' A' ' 114' ' ' ARG . 16.5 mmt-85 -90.41 173.79 7.91 Favored 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 108.435 -0.95 . . . . 3.04 108.435 179.561 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 9' ' ' VAL . . . . . . . . . . . . . 3.0 t -57.66 161.48 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 N-CA-C 106.924 -1.51 . . . . 0.67 106.924 178.746 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -115.07 148.52 38.8 Favored 'General case' 0 N--CA 1.504 2.267 0 O-C-N 121.267 -0.896 . . . . 0.58 111.151 -178.06 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 1.3 t -141.11 150.86 43.42 Favored 'General case' 0 N--CA 1.497 1.906 0 N-CA-C 109.232 -0.655 . . . . 1.19 109.232 179.39 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 28.5 p -149.09 131.47 15.64 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.053 -1.029 . . . . 1.38 110.224 -179.836 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 0.664 HG22 ' N ' ' B' ' 14' ' ' PHE . 7.5 p -173.6 174.39 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 N-CA-C 108.345 -0.983 . . . . 0.42 108.345 179.777 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 14' ' ' PHE . . . . . 0.664 ' N ' HG22 ' B' ' 13' ' ' VAL . 0.1 OUTLIER 173.05 -171.97 0.04 OUTLIER 'General case' 0 N--CA 1.493 1.702 0 C-N-CA 118.797 -1.161 . . . . 1.79 112.201 179.483 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -143.85 -179.4 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.339 0 N-CA-C 108.898 -0.779 . . . . 1.25 108.898 179.903 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 9.0 t -141.31 142.91 33.82 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.154 -0.966 . . . . 1.61 109.291 179.59 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.3 mt -101.86 147.26 26.72 Favored 'General case' 0 N--CA 1.499 2.019 0 O-C-N 121.261 -0.9 . . . . 1.32 110.108 -179.55 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -155.14 152.92 26.2 Favored Pre-proline 0 N--CA 1.492 1.649 0 N-CA-C 108.111 -1.07 . . . . 1.45 108.111 179.396 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -58.82 165.7 7.83 Favored 'Trans proline' 0 CA--C 1.544 0.992 0 C-N-CA 120.862 1.041 . . . . 1.5 109.625 -179.956 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 20' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_endo -63.3 -159.33 0.03 OUTLIER 'Trans proline' 0 C--N 1.319 -0.989 0 C-N-CA 121.497 1.465 . . . . 2.86 109.534 179.528 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 30.4 ptt180 -71.3 143.76 50.2 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.293 -0.879 . . . . 6.12 109.016 179.426 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 22' ' ' ARG . . . . . . . . . . . . . 42.4 mtp180 -67.87 109.44 3.41 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.151 -0.968 . . . . 6.29 109.511 -179.868 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 23' ' ' ASP . . . . . 0.431 ' O ' ' OXT' ' B' ' 24' ' ' VAL . 22.8 t0 -124.26 -34.77 2.88 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.583 -0.698 . . . . 5.62 109.225 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 24' ' ' VAL . . . . . 0.431 ' OXT' ' O ' ' B' ' 23' ' ' ASP . 3.9 t . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 117.973 -1.013 . . . . 6.48 109.62 179.884 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.531 5.016 0 N-CA-C 119.75 2.66 . . . . 6.64 119.75 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.726 HG23 ' O ' ' A' ' 2' ' ' ILE . 0.2 OUTLIER -170.46 49.85 0.14 Allowed Pre-proline 0 C--N 1.307 -1.257 0 N-CA-C 107.56 -1.274 . . . . 7.08 107.56 179.513 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.793 ' C ' ' H ' ' A' ' 5' ' ' PHE . 3.2 Cg_endo -56.42 -80.75 0.01 OUTLIER 'Trans proline' 0 C--N 1.32 -0.935 0 N-CA-C 108.996 -1.194 . . . . 5.5 108.996 179.559 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.493 ' C ' ' H ' ' A' ' 6' ' ' PHE . 7.3 tp10 73.62 -16.06 0.52 Allowed 'General case' 0 N--CA 1.495 1.788 0 N-CA-C 104.376 -2.454 . . . . 6.75 104.376 -175.746 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' PHE . . . . . 0.793 ' H ' ' C ' ' A' ' 3' ' ' PRO . 2.2 m-85 -91.45 18.65 6.98 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 103.84 -2.652 . . . . 6.07 103.84 176.906 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.531 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 37.2 p90 45.45 -153.84 0.04 OUTLIER 'General case' 0 C--N 1.306 -1.301 0 CA-C-N 114.174 -1.375 . . . . 4.72 109.496 -177.56 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.524 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 17.6 tt0 83.63 -9.13 1.03 Allowed 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 104.975 -2.232 . . . . 4.4 104.975 -177.131 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.467 ' H ' ' C ' ' A' ' 6' ' ' PHE . 49.6 t80 -151.6 -37.92 0.12 Allowed 'General case' 0 C--N 1.305 -1.353 0 N-CA-C 107.794 -1.188 . . . . 5.15 107.794 178.506 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 22.1 m -91.38 2.84 56.11 Favored 'General case' 0 C--N 1.297 -1.679 0 N-CA-C 105.895 -1.891 . . . . 5.13 105.895 177.386 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.407 HG13 ' N ' ' A' ' 11' ' ' GLY . 7.9 p -43.29 -38.15 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.337 0 CA-C-N 115.311 -0.859 . . . . 4.38 109.62 -179.654 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.582 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 138.88 -83.16 0.24 Allowed Glycine 0 N--CA 1.502 3.034 0 N-CA-C 109.157 -1.577 . . . . 4.22 109.157 179.493 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.456 ' O ' ' C ' ' A' ' 13' ' ' LEU . 12.2 Cg_endo -65.85 40.18 0.14 Allowed 'Trans proline' 0 C--N 1.321 -0.914 0 C-N-CA 121.926 1.75 . . . . 3.85 109.159 178.535 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.582 ' H ' ' C ' ' A' ' 11' ' ' GLY . 0.2 OUTLIER 29.04 44.45 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.219 0 CA-C-O 121.607 0.718 . . . . 3.67 110.983 -179.655 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.475 ' C ' ' N ' ' A' ' 16' ' ' GLY . . . 70.36 -37.96 0.45 Allowed Glycine 0 N--CA 1.486 2.032 0 N-CA-C 109.671 -1.371 . . . . 2.97 109.671 179.604 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.479 ' H ' ' C ' ' A' ' 13' ' ' LEU . 15.8 tp10 50.27 19.0 0.46 Allowed 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 107.776 -1.194 . . . . 2.97 107.776 -179.033 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.475 ' N ' ' C ' ' A' ' 14' ' ' GLY . . . 76.89 -162.5 51.84 Favored Glycine 0 N--CA 1.482 1.766 0 N-CA-C 108.52 -1.832 . . . . 2.44 108.52 -178.94 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.518 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -72.65 -4.81 62.42 Favored Glycine 0 N--CA 1.486 2.025 0 N-CA-C 109.717 -1.353 . . . . 1.81 109.717 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -49.03 -12.39 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.729 -1.453 . . . . 2.21 109.236 179.832 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' HIS . . . . . 0.518 ' N ' ' O ' ' A' ' 17' ' ' GLY . 10.6 t-160 -97.15 -41.15 8.46 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.39 -0.819 . . . . 2.87 109.445 179.651 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.719 ' HZ2' ' N ' ' A' ' 44' ' ' ARG . 0.0 OUTLIER -82.32 -25.37 33.99 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.141 -0.974 . . . . 2.02 109.722 -179.879 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 77.9 t -60.93 112.32 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.045 -1.034 . . . . 2.07 109.081 179.635 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 5.9 tpp180 -104.11 131.14 51.69 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.629 -0.669 . . . . 3.5 109.628 -179.648 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -136.7 113.64 10.47 Favored 'General case' 0 N--CA 1.493 1.723 0 N-CA-C 108.577 -0.898 . . . . 1.83 108.577 179.519 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -155.89 134.66 4.21 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.73 -1.348 . . . . 1.9 109.73 -179.463 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.1 -176.44 46.07 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.99 -1.244 . . . . 1.85 109.99 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 8.6 p -79.49 -25.82 41.74 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.335 -1.097 . . . . 2.31 109.538 -179.862 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.428 ' CA ' ' OH ' ' A' ' 77' ' ' TYR . . . -69.46 -15.44 70.54 Favored Glycine 0 N--CA 1.486 1.992 0 N-CA-C 108.506 -1.838 . . . . 1.64 108.506 179.676 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 65.8 mt -93.36 33.02 1.26 Allowed 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 108.487 -0.931 . . . . 1.83 108.487 179.454 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -144.3 -55.41 0.35 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.373 -0.829 . . . . 2.34 109.796 -179.545 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' ARG . . . . . 0.528 ' NH1' ' OD1' ' A' ' 110' ' ' ASP . 31.9 mtm180 -156.53 153.69 29.1 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 120.984 -1.073 . . . . 3.77 110.345 -179.441 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.55 ' C ' HG13 ' A' ' 105' ' ' VAL . . . -140.42 171.76 23.84 Favored Glycine 0 N--CA 1.495 2.61 0 N-CA-C 108.244 -1.942 . . . . 1.57 108.244 179.003 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.468 ' H ' ' CG1' ' A' ' 35' ' ' VAL . 28.1 t -135.54 148.32 28.4 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.008 0 O-C-N 121.173 -1.192 . . . . 1.83 110.448 -179.553 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.625 ' HB2' ' HD3' ' A' ' 82' ' ' PRO . . . -38.73 105.79 0.04 OUTLIER 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.916 -0.49 . . . . 1.64 111.688 -179.859 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 64.34 57.0 14.45 Favored Glycine 0 N--CA 1.489 2.23 0 O-C-N 121.089 -1.007 . . . . 1.73 111.864 177.353 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.468 ' CG1' ' H ' ' A' ' 32' ' ' VAL . 4.5 p -125.82 133.92 25.38 Favored Pre-proline 0 N--CA 1.503 2.208 0 O-C-N 121.279 -1.13 . . . . 2.19 108.949 178.72 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_endo -58.47 114.69 2.09 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 N-CA-C 108.547 -1.366 . . . . 1.96 108.547 178.739 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -127.0 148.61 50.1 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.344 -0.847 . . . . 1.69 109.494 -179.352 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.3 pt-20 -157.13 174.01 16.12 Favored 'General case' 0 N--CA 1.488 1.474 0 CA-C-O 122.22 1.01 . . . . 2.23 110.759 -179.886 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.603 ' CE2' HD11 ' A' ' 41' ' ' ILE . 5.0 p90 -159.52 167.07 29.49 Favored 'General case' 0 C--N 1.296 -1.753 0 N-CA-C 107.819 -1.178 . . . . 1.54 107.819 178.67 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 6.4 t -98.04 150.96 20.84 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.462 -0.774 . . . . 2.37 110.715 -178.409 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.603 HD11 ' CE2' ' A' ' 39' ' ' PHE . 10.7 mt -142.09 89.72 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 N-CA-C 108.757 -0.831 . . . . 1.65 108.757 179.117 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.458 ' CD1' ' C ' ' A' ' 42' ' ' TRP . 0.8 OUTLIER -85.28 142.35 29.44 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.115 -0.991 . . . . 3.68 108.815 -179.907 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.487 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -171.98 117.51 0.39 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.39 -0.818 . . . . 2.89 109.298 -179.688 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 44' ' ' ARG . . . . . 0.719 ' N ' ' HZ2' ' A' ' 20' ' ' LYS . 1.5 tpt180 -164.99 -12.24 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.171 -0.956 . . . . 4.63 109.696 -179.832 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.409 ' H ' ' HD3' ' A' ' 20' ' ' LYS . 0.4 OUTLIER -68.55 -47.53 66.63 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.0 -1.062 . . . . 2.89 109.763 -179.621 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -60.23 -59.76 4.89 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.098 -1.001 . . . . 1.74 109.299 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 142.94 -151.76 23.42 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.585 -1.406 . . . . 1.6 109.585 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -80.64 163.11 23.86 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.479 -1.012 . . . . 1.4 109.531 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 174.02 -143.49 7.05 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.666 -1.373 . . . . 1.04 109.666 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -148.48 127.64 2.6 Favored Glycine 0 N--CA 1.495 2.586 0 N-CA-C 109.554 -1.418 . . . . 1.06 109.554 -179.913 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.465 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 46.8 tp -102.65 107.03 17.79 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.367 -1.078 . . . . 1.1 108.843 179.833 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.4 t -90.62 141.44 28.77 Favored 'General case' 0 N--CA 1.494 1.75 0 N-CA-C 108.616 -0.883 . . . . 1.56 108.616 179.504 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.515 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 63.3 mt -132.06 102.35 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.923 0 O-C-N 121.214 -0.929 . . . . 0.65 109.469 -179.843 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -93.31 105.85 17.88 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 108.497 -0.927 . . . . 0.69 108.497 179.395 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.44 HG23 ' CB ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -95.42 145.07 8.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.521 -0.737 . . . . 0.91 109.254 -179.738 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -141.47 144.17 34.25 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 108.026 -1.101 . . . . 1.8 108.026 179.22 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.415 ' O ' ' O ' ' B' ' 9' ' ' VAL . . . 162.13 -172.95 38.37 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.768 -1.333 . . . . 0.49 109.768 -179.215 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -61.77 -31.88 85.87 Favored 'Trans proline' 0 C--N 1.319 -0.979 0 C-N-CA 122.302 2.001 . . . . 0.66 112.046 -179.666 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 8.0 t -139.0 169.95 16.86 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 120.949 -1.094 . . . . 1.55 110.549 -179.169 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 38.5 mtpt -87.1 106.86 18.16 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 109.003 -0.74 . . . . 2.53 109.003 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -73.48 127.42 32.67 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.165 -0.959 . . . . 0.82 109.776 -179.711 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 24.4 tt0 -65.42 170.44 4.87 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.288 -0.882 . . . . 2.3 109.028 179.732 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.414 HD12 HG13 ' B' ' 13' ' ' VAL . 20.1 mt -143.52 155.11 16.37 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 N-CA-C 108.345 -0.983 . . . . 1.4 108.345 -179.9 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.532 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -143.12 174.91 10.28 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 120.685 -1.259 . . . . 1.36 109.21 -179.775 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.449 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 51.7 p90 -142.29 128.49 19.82 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.363 -0.835 . . . . 1.47 109.172 179.9 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -141.38 113.08 7.7 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.296 -0.878 . . . . 2.51 109.987 -179.782 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.441 ' OD1' ' N ' ' A' ' 67' ' ' ASP . 4.2 p-10 -95.52 67.69 2.89 Favored 'General case' 0 N--CA 1.491 1.602 0 N-CA-C 108.155 -1.054 . . . . 2.07 108.155 178.493 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 50.4 mtp180 -121.96 29.46 7.07 Favored 'General case' 0 N--CA 1.5 2.042 0 N-CA-C 109.231 -0.655 . . . . 4.63 109.231 -179.55 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.427 ' O ' ' CB ' ' A' ' 70' ' ' ASP . 66.3 mmtt -108.21 3.32 23.54 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 107.882 -1.155 . . . . 3.49 107.882 179.405 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.427 ' CB ' ' O ' ' A' ' 69' ' ' LYS . 4.0 t0 72.49 12.79 5.52 Favored 'General case' 0 N--CA 1.487 1.388 0 N-CA-C 109.586 -0.524 . . . . 3.06 109.586 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 163.32 -30.84 0.27 Allowed Glycine 0 N--CA 1.49 2.247 0 C-N-CA 119.017 -1.564 . . . . 2.16 110.787 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.402 ' H ' ' HB2' ' A' ' 69' ' ' LYS . 5.0 t -95.11 143.15 26.78 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 120.964 -1.315 . . . . 2.2 109.764 -179.498 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 36.9 t -88.04 139.47 30.48 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.329 -0.857 . . . . 2.05 109.347 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -112.4 114.02 3.4 Favored Glycine 0 N--CA 1.5 2.948 0 N-CA-C 109.985 -1.246 . . . . 1.39 109.985 -179.761 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.502 HG21 HD12 ' A' ' 41' ' ' ILE . 77.9 t -100.97 116.15 43.97 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.948 0 O-C-N 121.467 -1.019 . . . . 1.57 108.912 179.291 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.532 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.6 OUTLIER -103.81 136.75 42.91 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.579 -0.7 . . . . 1.85 109.196 -179.846 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.428 ' OH ' ' CA ' ' A' ' 27' ' ' GLY . 11.3 p90 -134.65 166.69 22.34 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.508 -0.745 . . . . 1.54 109.671 -179.769 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 8.4 t -139.86 113.54 6.3 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 N-CA-C 108.887 -0.783 . . . . 1.9 108.887 -179.729 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.594 ' CG1' ' CE2' ' A' ' 85' ' ' TYR . 0.2 OUTLIER -79.75 168.57 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 N-CA-C 108.499 -0.926 . . . . 1.27 108.499 179.552 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 10.5 tt0 -109.3 -36.79 5.93 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.441 -0.787 . . . . 2.48 109.417 179.323 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.428 ' O ' ' O ' ' A' ' 82' ' ' PRO . 75.2 mm-40 -158.85 149.6 16.01 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.278 -0.888 . . . . 1.92 110.679 -179.308 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.625 ' HD3' ' HB2' ' A' ' 33' ' ' ALA . 82.1 Cg_exo -39.08 169.38 0.01 OUTLIER 'Trans proline' 0 C--O 1.213 -0.727 0 C-N-CA 122.761 2.307 . . . . 1.3 112.756 177.696 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 141.69 177.33 16.74 Favored Glycine 0 N--CA 1.493 2.451 0 N-CA-C 109.726 -1.35 . . . . 1.02 109.726 179.226 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -93.16 89.57 6.5 Favored 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 107.741 -1.207 . . . . 2.13 107.741 179.149 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.594 ' CE2' ' CG1' ' A' ' 79' ' ' VAL . 3.7 m-85 -78.04 132.15 37.64 Favored 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.458 -0.776 . . . . 0.92 108.912 -179.014 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -112.81 128.79 56.54 Favored 'General case' 0 N--CA 1.498 1.947 0 N-CA-C 108.588 -0.893 . . . . 1.53 108.588 -179.079 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.411 ' CG1' ' CE2' ' A' ' 101' ' ' PHE . 5.8 p -126.13 133.64 68.4 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 121.568 -0.708 . . . . 1.0 109.471 -179.865 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.1 t -123.64 103.96 8.73 Favored 'General case' 0 N--CA 1.498 1.933 0 N-CA-C 109.445 -0.576 . . . . 1.59 109.445 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.2 pt -107.7 130.29 60.29 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 CA-C-O 121.64 0.734 . . . . 1.29 110.045 -179.573 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' LYS . . . . . 0.47 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.98 122.68 17.52 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 107.9 -1.148 . . . . 1.58 107.9 179.593 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.412 ' O ' ' CB ' ' A' ' 92' ' ' ASN . 71.2 t80 -83.08 100.57 10.59 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 120.515 -1.365 . . . . 1.34 108.029 179.351 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 92' ' ' ASN . . . . . 0.429 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 2.2 t30 72.31 35.48 1.19 Allowed 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.196 -0.94 . . . . 2.32 108.809 -178.646 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.429 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 0.9 OUTLIER 78.2 14.77 1.44 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.879 -0.513 . . . . 1.92 111.609 179.53 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 94' ' ' GLU . . . . . 0.489 ' OE2' ' CA ' ' A' ' 17' ' ' GLY . 5.7 pt-20 -100.54 99.22 9.78 Favored 'General case' 0 N--CA 1.496 1.843 0 N-CA-C 107.145 -1.428 . . . . 2.25 107.145 177.964 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 95' ' ' HIS . . . . . 0.462 ' O ' ' CG ' ' A' ' 95' ' ' HIS . 46.2 p-80 -66.96 105.46 1.63 Allowed 'General case' 0 N--CA 1.487 1.389 0 CA-C-O 121.472 0.653 . . . . 2.88 110.453 -177.928 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 96' ' ' ILE . . . . . 0.523 ' O ' ' N ' ' A' ' 98' ' ' ASP . 4.0 tt -56.56 136.33 77.23 Favored Pre-proline 0 C--N 1.3 -1.548 0 N-CA-C 107.81 -1.182 . . . . 2.35 107.81 178.983 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.44 ' O ' ' CB ' ' A' ' 98' ' ' ASP . 11.6 Cg_exo -47.15 90.98 0.02 OUTLIER 'Trans proline' 0 C--O 1.213 -0.729 0 N-CA-C 109.886 -0.852 . . . . 2.48 109.886 -179.755 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.523 ' N ' ' O ' ' A' ' 96' ' ' ILE . 0.9 OUTLIER 165.61 -60.43 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 108.235 -1.024 . . . . 2.65 108.235 -179.418 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 1.3 t -55.8 139.08 70.18 Favored Pre-proline 0 C--N 1.296 -1.727 0 O-C-N 121.299 -0.875 . . . . 2.0 109.796 -178.306 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_endo -88.36 113.72 2.47 Favored 'Cis proline' 0 N--CA 1.494 1.521 0 N-CA-C 110.024 -0.798 . . . . 1.79 110.024 -2.393 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 101' ' ' PHE . . . . . 0.411 ' CE2' ' CG1' ' A' ' 87' ' ' VAL . 2.6 p90 -97.74 169.15 9.88 Favored 'General case' 0 N--CA 1.518 2.944 0 O-C-N 120.236 -1.54 . . . . 2.19 109.779 178.625 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.3 p -96.78 150.45 4.44 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.643 -0.66 . . . . 1.44 109.982 -179.635 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.446 ' N ' ' O ' ' A' ' 85' ' ' TYR . 87.0 t -128.3 87.03 56.36 Favored Pre-proline 0 N--CA 1.498 1.965 0 N-CA-C 108.379 -0.971 . . . . 1.19 108.379 179.675 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo -65.11 114.9 3.01 Favored 'Trans proline' 0 C--N 1.322 -0.856 0 C-N-CA 121.571 1.514 . . . . 1.49 111.8 -178.27 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.55 HG13 ' C ' ' A' ' 31' ' ' GLY . 84.3 t -106.59 143.54 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 N-CA-C 106.342 -1.725 . . . . 1.35 106.342 178.365 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.671 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -133.24 138.51 46.53 Favored 'General case' 0 N--CA 1.512 2.666 0 CA-C-O 122.272 1.034 . . . . 1.67 112.516 -176.719 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.623 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 59.8 p -94.29 78.21 3.95 Favored 'General case' 0 N--CA 1.494 1.725 0 N-CA-C 107.608 -1.256 . . . . 2.04 107.608 179.097 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 16.8 mt 63.15 3.33 1.27 Allowed 'General case' 0 C--N 1.295 -1.766 0 N-CA-C 107.438 -1.319 . . . . 3.2 107.438 -177.835 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.683 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 18.5 t -89.84 -23.18 21.74 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 108.813 -0.81 . . . . 2.09 108.813 179.328 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 110' ' ' ASP . . . . . 0.671 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 50.5 t0 54.83 11.33 0.46 Allowed 'General case' 0 N--CA 1.487 1.382 0 N-CA-C 107.822 -1.177 . . . . 2.85 107.822 -179.196 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.486 ' OD1' ' N ' ' A' ' 112' ' ' ALA . 2.8 p30 -169.33 -31.85 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 109.185 -0.672 . . . . 2.46 109.185 -179.7 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.683 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 43.75 88.75 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.208 -0.932 . . . . 2.08 109.783 179.915 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 13.9 ttt180 -58.03 -163.95 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.217 -0.927 . . . . 5.93 109.652 -179.436 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 44.9 ttt180 -136.03 0.16 2.59 Favored 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 108.002 -1.11 . . . . 5.61 108.002 179.684 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 2.5 mp -132.31 -23.71 2.12 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.709 -0.62 . . . . 4.39 109.616 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.484 ' C ' ' N ' ' A' ' 118' ' ' THR . 90.3 m -104.1 -78.13 0.56 Allowed 'General case' 0 N--CA 1.495 1.818 0 N-CA-C 106.691 -1.596 . . . . 4.09 106.691 178.768 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.45 ' O ' HG12 ' A' ' 117' ' ' VAL . 48.9 t -64.03 -7.66 3.65 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.742 0 N-CA-C 105.807 -1.923 . . . . 2.9 105.807 176.631 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 118' ' ' THR . . . . . 0.484 ' N ' ' C ' ' A' ' 116' ' ' THR . 4.4 t 36.2 60.33 0.87 Allowed 'General case' 0 N--CA 1.488 1.468 0 CA-C-N 115.164 -0.925 . . . . 3.36 110.638 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 119' ' ' SER . . . . . 0.474 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.5 p . . . . . 0 N--CA 1.487 1.38 0 CA-C-O 118.043 -0.979 . . . . 3.39 109.549 179.503 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 1' ' ' MET . . . . . 0.611 ' SD ' ' N ' ' B' ' 2' ' ' ALA . 14.6 tmm? . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.36 -0.607 . . . . 8.49 109.36 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 2' ' ' ALA . . . . . 0.611 ' N ' ' SD ' ' B' ' 1' ' ' MET . . . 45.67 91.85 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.188 -0.945 . . . . 5.53 109.766 -179.95 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 3' ' ' SER . . . . . . . . . . . . . 35.1 t -155.26 126.62 7.27 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.197 -0.939 . . . . 5.43 109.466 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 4' ' ' LYS . . . . . . . . . . . . . 22.4 mtpp -60.35 131.26 90.19 Favored Pre-proline 0 N--CA 1.487 1.422 0 O-C-N 121.187 -0.946 . . . . 6.87 108.794 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 5' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -59.75 -172.27 0.06 OUTLIER 'Trans proline' 0 C--O 1.216 -0.618 0 N-CA-C 109.837 -0.87 . . . . 5.16 109.837 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 6' ' ' GLU . . . . . 0.441 ' O ' ' O ' ' B' ' 7' ' ' LYS . 34.6 mt-10 -155.28 39.71 0.41 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.313 -0.867 . . . . 4.78 108.872 179.745 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 7' ' ' LYS . . . . . 0.441 ' O ' ' O ' ' B' ' 6' ' ' GLU . 32.9 mtmm 55.02 165.46 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.657 -0.652 . . . . 4.09 109.645 -179.868 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.563 ' CG ' HH11 ' B' ' 8' ' ' ARG . 1.4 mtt-85 -89.83 159.14 17.15 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.113 -0.992 . . . . 3.04 108.542 179.877 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 9' ' ' VAL . . . . . 0.415 ' O ' ' O ' ' A' ' 57' ' ' GLY . 11.2 t -49.89 159.85 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 120.973 -1.079 . . . . 0.67 108.311 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 0.4 ' N ' ' CG1' ' B' ' 9' ' ' VAL . . . -124.67 144.13 50.37 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.526 -0.734 . . . . 0.58 110.173 -178.887 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 11' ' ' SER . . . . . 0.44 ' CB ' HG23 ' A' ' 55' ' ' VAL . 2.8 t -134.7 145.88 48.93 Favored 'General case' 0 N--CA 1.495 1.817 0 N-CA-C 108.636 -0.876 . . . . 1.19 108.636 179.446 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 17.7 m -142.46 114.66 8.31 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.223 -0.923 . . . . 1.38 109.69 -179.491 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 0.57 HG22 ' N ' ' B' ' 14' ' ' PHE . 2.7 p -160.03 166.67 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 O-C-N 121.367 -0.833 . . . . 0.42 109.014 179.83 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 14' ' ' PHE . . . . . 0.57 ' N ' HG22 ' B' ' 13' ' ' VAL . 8.3 p90 -177.16 -166.88 0.15 Allowed 'General case' 0 N--CA 1.488 1.429 0 CA-C-O 122.077 0.941 . . . . 1.79 111.926 179.85 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.413 ' N ' HD13 ' B' ' 15' ' ' ILE . 0.0 OUTLIER -140.02 152.98 22.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 N-CA-C 108.271 -1.011 . . . . 1.25 108.271 179.721 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 7.2 m -123.66 131.14 53.54 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.317 -0.865 . . . . 1.61 109.921 -179.666 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 13.8 mt -99.3 117.93 34.85 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.327 -0.858 . . . . 1.32 109.01 179.609 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -146.33 78.52 11.11 Favored Pre-proline 0 N--CA 1.494 1.768 0 O-C-N 121.259 -0.901 . . . . 1.45 109.636 -179.566 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo -60.2 169.67 4.75 Favored 'Trans proline' 0 C--N 1.319 -1.012 0 C-N-CA 121.218 1.279 . . . . 1.5 109.417 -179.78 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 20' ' ' PRO . . . . . . . . . . . . . 4.1 Cg_exo -53.82 133.46 54.57 Favored 'Trans proline' 0 C--N 1.319 -1.007 0 C-N-CA 121.344 1.363 . . . . 2.86 110.281 -179.605 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 21' ' ' ARG . . . . . 0.506 ' HG2' HH11 ' B' ' 21' ' ' ARG . 0.0 OUTLIER -96.56 136.06 37.61 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.354 -0.841 . . . . 6.12 109.352 -179.927 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 22' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -158.7 52.66 0.41 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.245 -0.909 . . . . 6.29 109.454 179.756 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 18.6 m-20 -158.7 48.44 0.35 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.242 -0.911 . . . . 5.62 109.458 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 12.1 p . . . . . 0 N--CA 1.491 1.596 0 CA-C-O 118.034 -0.984 . . . . 6.48 109.462 -179.985 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.822 ' O ' HD13 ' A' ' 2' ' ' ILE . . . . . . . . 1 N--CA 1.531 4.976 0 N-CA-C 119.88 2.712 . . . . 6.64 119.88 . . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.822 HD13 ' O ' ' A' ' 1' ' ' GLY . 6.8 mm -149.28 43.7 0.3 Allowed Pre-proline 0 C--N 1.311 -1.081 0 N-CA-C 107.546 -1.279 . . . . 7.08 107.546 178.533 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.644 ' CD ' ' N ' ' A' ' 2' ' ' ILE . 1.8 Cg_endo -52.12 -74.45 0.03 OUTLIER 'Trans proline' 0 C--N 1.319 -0.978 0 N-CA-C 109.343 -1.06 . . . . 5.5 109.343 -179.804 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.436 ' CB ' ' O ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER 71.96 -49.83 0.69 Allowed 'General case' 0 N--CA 1.494 1.727 0 N-CA-C 103.11 -2.922 . . . . 6.75 103.11 -175.615 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 5' ' ' PHE . . . . . 0.631 ' H ' ' C ' ' A' ' 3' ' ' PRO . 5.3 m-85 -50.15 -28.09 6.84 Favored 'General case' 0 C--N 1.303 -1.414 0 N-CA-C 106.481 -1.674 . . . . 6.07 106.481 174.954 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.599 ' CG ' ' N ' ' A' ' 7' ' ' GLN . 0.0 OUTLIER 110.8 -150.84 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.217 0 CA-C-N 114.511 -1.222 . . . . 4.72 111.221 179.445 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.599 ' N ' ' CG ' ' A' ' 6' ' ' PHE . 18.5 tt0 81.74 -3.64 1.58 Allowed 'General case' 0 N--CA 1.493 1.702 0 N-CA-C 105.306 -2.109 . . . . 4.4 105.306 -177.469 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.405 ' H ' ' C ' ' A' ' 6' ' ' PHE . 38.3 t80 -152.96 -40.4 0.1 Allowed 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 107.202 -1.407 . . . . 5.15 107.202 178.623 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 12.1 m -86.19 1.44 50.7 Favored 'General case' 0 C--N 1.296 -1.722 0 N-CA-C 106.086 -1.82 . . . . 5.13 106.086 177.287 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.8 p -40.51 -33.57 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 CA-C-N 115.47 -0.786 . . . . 4.38 109.839 -179.77 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.555 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 146.71 -79.12 0.23 Allowed Glycine 0 N--CA 1.5 2.947 0 N-CA-C 109.172 -1.571 . . . . 4.22 109.172 179.626 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.452 ' O ' ' C ' ' A' ' 13' ' ' LEU . 14.5 Cg_endo -66.35 43.79 0.19 Allowed 'Trans proline' 0 C--N 1.321 -0.917 0 C-N-CA 122.148 1.899 . . . . 3.85 108.849 178.339 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.568 ' C ' ' H ' ' A' ' 15' ' ' GLU . 0.2 OUTLIER 29.17 46.78 0.02 OUTLIER 'General case' 0 N--CA 1.501 2.103 0 CA-C-N 115.692 -0.686 . . . . 3.67 111.094 -179.746 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.518 ' C ' ' H ' ' A' ' 16' ' ' GLY . . . 68.17 -36.43 0.25 Allowed Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.325 -1.51 . . . . 2.97 109.325 -179.884 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.568 ' H ' ' C ' ' A' ' 13' ' ' LEU . 24.6 tt0 55.31 6.59 0.17 Allowed 'General case' 0 N--CA 1.486 1.337 0 O-C-N 121.426 -1.043 . . . . 2.97 108.518 -179.159 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.519 ' O ' ' N ' ' A' ' 18' ' ' ALA . . . 87.45 -164.72 34.93 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 110.851 -0.899 . . . . 2.44 110.851 178.743 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.55 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -46.28 -12.33 0.05 OUTLIER Glycine 0 N--CA 1.491 2.333 0 N-CA-C 110.603 -0.999 . . . . 1.81 110.603 -179.2 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.519 ' N ' ' O ' ' A' ' 16' ' ' GLY . . . -47.64 -10.41 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.145 -1.209 . . . . 2.21 110.093 -179.924 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' HIS . . . . . 0.55 ' N ' ' O ' ' A' ' 17' ' ' GLY . 80.2 t60 -104.81 -31.36 9.34 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.188 -0.945 . . . . 2.87 110.444 -179.38 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -101.6 -14.72 17.32 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 120.997 -1.064 . . . . 2.02 110.848 -178.979 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.614 ' O ' HG13 ' A' ' 21' ' ' VAL . 9.0 p -70.85 114.39 8.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 120.819 -1.175 . . . . 2.07 109.818 -179.606 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 20.6 tpt180 -104.08 140.38 37.85 Favored 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 109.008 -0.738 . . . . 3.5 109.008 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -144.45 113.28 6.75 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.247 -0.908 . . . . 1.83 109.37 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -156.49 129.05 2.33 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.788 -1.325 . . . . 1.9 109.788 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.11 -177.59 47.72 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.666 -1.374 . . . . 1.85 109.666 179.805 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 12.3 p -78.36 -26.12 46.56 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.25 -1.147 . . . . 2.31 109.396 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -71.06 -12.13 71.23 Favored Glycine 0 N--CA 1.488 2.132 0 N-CA-C 109.301 -1.52 . . . . 1.64 109.301 -179.831 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 12.8 mt -91.36 -6.13 53.46 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.364 -1.08 . . . . 1.83 108.914 179.875 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -96.27 -51.03 4.55 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.336 -0.853 . . . . 2.34 109.748 -179.708 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 23.0 ptt180 -175.28 -173.65 0.67 Allowed 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.017 -1.052 . . . . 3.77 110.16 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -152.4 177.58 30.08 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 108.358 -1.897 . . . . 1.57 108.358 179.583 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 41.5 t -134.84 151.05 30.6 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.045 0 O-C-N 121.143 -1.21 . . . . 1.83 110.481 -179.683 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.589 ' HB2' ' HB3' ' A' ' 107' ' ' SER . . . -37.05 112.2 0.19 Allowed 'General case' 0 N--CA 1.5 2.072 0 CA-C-O 121.737 0.78 . . . . 1.64 112.406 -179.293 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 54.59 49.88 59.42 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 111.371 -0.692 . . . . 1.73 111.371 177.249 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 40.5 t -127.38 98.22 29.71 Favored Pre-proline 0 N--CA 1.496 1.826 0 O-C-N 121.511 -0.994 . . . . 2.19 108.512 178.95 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -56.89 149.05 63.43 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 120.955 1.103 . . . . 1.96 110.445 -178.86 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.403 ' HB3' ' CZ ' ' A' ' 77' ' ' TYR . . . -157.49 -167.73 2.37 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.4 -0.813 . . . . 1.69 109.018 -179.812 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -170.54 168.48 7.68 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.148 -0.97 . . . . 2.23 110.873 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.568 ' CE2' HD11 ' A' ' 41' ' ' ILE . 1.1 p90 -144.95 -178.68 6.16 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 107.161 -1.422 . . . . 1.54 107.161 178.345 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 12.0 m -109.42 150.99 27.27 Favored 'General case' 0 N--CA 1.5 2.049 0 O-C-N 121.359 -0.838 . . . . 2.37 110.99 -178.345 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.686 HD12 HG21 ' A' ' 75' ' ' VAL . 11.3 mt -147.8 94.55 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 N-CA-C 108.749 -0.834 . . . . 1.65 108.749 179.048 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.49 ' CD1' ' C ' ' A' ' 42' ' ' TRP . 0.6 OUTLIER -86.99 138.07 31.82 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 120.946 -1.096 . . . . 3.68 108.563 179.837 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -167.61 114.85 0.75 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.282 -0.886 . . . . 2.89 109.523 -179.678 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 44' ' ' ARG . . . . . 0.436 ' C ' ' CD ' ' A' ' 44' ' ' ARG . 1.7 ppt_? -169.47 -12.33 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.19 -0.944 . . . . 4.63 109.7 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -65.04 -46.15 82.46 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.213 -0.929 . . . . 2.89 109.469 -179.735 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.58 -50.4 72.07 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.153 -0.967 . . . . 1.74 108.856 179.695 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 139.76 -153.58 23.24 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.249 -1.54 . . . . 1.6 109.249 179.777 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -86.11 155.97 20.56 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.446 -1.032 . . . . 1.4 108.924 179.547 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 179.35 -140.28 4.28 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.563 -1.415 . . . . 1.04 109.563 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.47 ' O ' ' N ' ' A' ' 92' ' ' ASN . . . -138.88 167.64 25.04 Favored Glycine 0 N--CA 1.495 2.611 0 N-CA-C 109.283 -1.527 . . . . 1.06 109.283 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.445 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 46.4 tp -142.56 106.48 4.7 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.381 -1.07 . . . . 1.1 108.434 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.4 m -90.43 143.54 26.65 Favored 'General case' 0 N--CA 1.495 1.787 0 N-CA-C 108.557 -0.905 . . . . 1.56 108.557 179.863 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.548 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 53.6 mt -135.36 105.1 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.266 -0.897 . . . . 0.65 109.176 179.84 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -97.97 106.62 18.94 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.283 -0.886 . . . . 0.69 108.786 179.755 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.437 ' O ' ' O ' ' B' ' 11' ' ' SER . 0.2 OUTLIER -96.79 142.34 14.17 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.501 -0.749 . . . . 0.91 109.555 -179.745 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -141.78 142.7 33.22 Favored 'General case' 0 N--CA 1.491 1.61 0 N-CA-C 108.21 -1.033 . . . . 1.8 108.21 178.846 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 164.92 -173.9 40.83 Favored Glycine 0 N--CA 1.489 2.167 0 N-CA-C 109.448 -1.461 . . . . 0.49 109.448 -179.104 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -59.46 -26.0 80.51 Favored 'Trans proline' 0 C--N 1.315 -1.199 0 C-N-CA 121.93 1.753 . . . . 0.66 112.103 -179.299 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' SER . . . . . 0.435 ' O ' ' OH ' ' A' ' 85' ' ' TYR . 22.9 t -142.54 169.24 17.95 Favored 'General case' 0 N--CA 1.502 2.168 0 O-C-N 121.015 -1.053 . . . . 1.55 110.364 179.947 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 60.7 mttt -81.09 95.31 6.81 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.497 -0.752 . . . . 2.53 109.763 -179.608 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -63.54 117.29 6.55 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.173 -0.954 . . . . 0.82 109.511 179.854 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.453 ' CB ' HG12 ' A' ' 78' ' ' VAL . 26.0 tt0 -66.27 168.39 8.79 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.154 -0.966 . . . . 2.3 109.148 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.458 HD12 HG13 ' B' ' 13' ' ' VAL . 28.1 mt -141.0 155.61 21.76 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 N-CA-C 108.642 -0.873 . . . . 1.4 108.642 -179.79 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.542 ' HB3' ' OG ' ' A' ' 76' ' ' SER . . . -144.87 170.75 15.52 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 120.627 -1.295 . . . . 1.36 109.156 179.978 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.46 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 31.3 p90 -147.16 117.88 7.57 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.28 -0.887 . . . . 1.47 109.472 -179.962 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -141.44 102.6 4.24 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.364 -0.835 . . . . 2.51 109.546 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.519 ' N ' ' OD1' ' A' ' 67' ' ' ASP . 17.5 p-10 -73.85 95.43 2.43 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.213 -0.929 . . . . 2.07 109.18 179.848 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 54.6 ttt180 -90.08 -7.6 53.41 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.274 -0.891 . . . . 4.63 109.732 -179.662 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.48 ' C ' ' H ' ' A' ' 71' ' ' GLY . 31.3 mmtp -122.42 1.66 9.6 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.504 -0.747 . . . . 3.49 109.451 -179.839 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 4.1 t70 65.78 -4.01 0.66 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.258 -0.902 . . . . 3.06 109.272 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' GLY . . . . . 0.48 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -138.98 -33.36 0.18 Allowed Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.874 -1.29 . . . . 2.16 109.874 -178.907 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.477 ' H ' ' HB2' ' A' ' 69' ' ' LYS . 14.0 p -95.52 109.61 21.8 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.23 -1.159 . . . . 2.2 108.76 179.487 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 3.3 m -78.81 115.22 18.36 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.15 -0.969 . . . . 2.05 109.521 -179.585 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -93.72 114.68 4.78 Favored Glycine 0 N--CA 1.494 2.543 0 N-CA-C 109.919 -1.273 . . . . 1.39 109.919 -179.716 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.686 HG21 HD12 ' A' ' 41' ' ' ILE . 94.0 t -98.39 108.5 22.15 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 121.409 -1.053 . . . . 1.57 109.465 179.695 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.542 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 0.7 OUTLIER -89.55 166.64 13.53 Favored 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 108.268 -1.012 . . . . 1.85 108.268 179.331 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.406 ' CD1' ' N ' ' A' ' 77' ' ' TYR . 14.1 p90 -164.14 172.36 13.81 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.216 -0.928 . . . . 1.54 109.659 -179.36 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.533 ' O ' HG13 ' A' ' 78' ' ' VAL . 3.7 p -142.17 119.25 7.11 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.254 0 O-C-N 121.104 -0.998 . . . . 1.9 110.391 179.61 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.51 HG11 HG21 ' A' ' 105' ' ' VAL . 8.5 m -94.98 147.06 6.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.186 -0.946 . . . . 1.27 109.164 179.674 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 29.5 tt0 -90.16 -47.44 7.8 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.082 -1.011 . . . . 2.48 110.582 -179.254 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -155.9 155.59 29.52 Favored Pre-proline 0 N--CA 1.504 2.231 0 O-C-N 120.695 -1.253 . . . . 1.92 110.902 -179.347 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.663 ' HG3' ' N ' ' A' ' 107' ' ' SER . 87.2 Cg_exo -36.19 152.77 0.03 OUTLIER 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 123.279 2.653 . . . . 1.3 113.287 179.03 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 152.31 158.04 8.26 Favored Glycine 0 N--CA 1.487 2.052 0 N-CA-C 109.251 -1.54 . . . . 1.02 109.251 -179.926 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 84' ' ' ASP . . . . . 0.781 ' H ' HH12 ' B' ' 8' ' ' ARG . 0.3 OUTLIER -83.39 90.38 7.16 Favored 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 107.648 -1.242 . . . . 2.13 107.648 179.077 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.435 ' OH ' ' O ' ' A' ' 59' ' ' SER . 1.4 m-85 -73.28 156.11 38.8 Favored 'General case' 0 C--N 1.294 -1.843 0 N-CA-C 108.266 -1.012 . . . . 0.92 108.266 -179.267 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 86' ' ' GLU . . . . . 0.42 ' OE1' ' O ' ' A' ' 84' ' ' ASP . 0.0 OUTLIER -138.48 120.83 15.95 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.461 -0.774 . . . . 1.53 109.287 -179.369 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.7 p -120.89 147.17 24.87 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.532 -0.73 . . . . 1.0 109.54 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 82.6 p -129.98 107.25 9.21 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.437 -0.79 . . . . 1.59 109.328 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.6 pt -106.29 130.75 57.48 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.658 -0.651 . . . . 1.29 109.946 -179.568 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' LYS . . . . . 0.466 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.6 OUTLIER -136.55 122.63 20.29 Favored 'General case' 0 N--CA 1.492 1.627 0 N-CA-C 108.837 -0.801 . . . . 1.58 108.837 179.341 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.56 ' O ' ' ND2' ' A' ' 92' ' ' ASN . 60.0 t80 -80.16 107.0 12.61 Favored 'General case' 0 C--N 1.299 -1.603 0 C-N-CA 118.716 -1.193 . . . . 1.34 107.819 178.37 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 92' ' ' ASN . . . . . 0.56 ' ND2' ' O ' ' A' ' 91' ' ' PHE . 2.9 p30 61.71 32.79 18.26 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.448 -0.783 . . . . 2.32 109.94 -178.584 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.472 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 2.5 m-20 86.21 16.97 0.11 Allowed 'General case' 0 N--CA 1.506 2.363 0 O-C-N 121.593 -0.692 . . . . 1.92 112.24 178.171 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 94' ' ' GLU . . . . . 0.489 ' O ' ' OE1' ' A' ' 94' ' ' GLU . 0.3 OUTLIER -102.4 98.64 8.71 Favored 'General case' 0 N--CA 1.499 1.98 0 N-CA-C 107.039 -1.467 . . . . 2.25 107.039 177.503 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 95' ' ' HIS . . . . . 0.502 ' O ' ' CG ' ' A' ' 95' ' ' HIS . 52.1 p-80 -68.64 106.48 2.63 Favored 'General case' 0 N--CA 1.487 1.417 0 N-CA-C 109.14 -0.689 . . . . 2.88 109.14 -178.838 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 96' ' ' ILE . . . . . 0.897 ' O ' HD13 ' A' ' 96' ' ' ILE . 0.0 OUTLIER -58.91 155.07 34.28 Favored Pre-proline 0 N--CA 1.491 1.602 0 N-CA-C 108.557 -0.905 . . . . 2.35 108.557 -179.614 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_endo -63.47 77.24 0.13 Allowed 'Trans proline' 0 CA--C 1.539 0.768 0 C-N-CA 121.23 1.287 . . . . 2.48 109.892 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.507 ' CG ' ' CE2' ' A' ' 101' ' ' PHE . 0.4 OUTLIER 179.81 -28.72 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.857 0 O-C-N 120.968 -1.082 . . . . 2.65 109.054 -179.649 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 29.4 m -78.02 136.69 61.77 Favored Pre-proline 0 C--N 1.298 -1.674 0 N-CA-C 107.313 -1.366 . . . . 2.0 107.313 178.448 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -76.64 116.95 4.66 Favored 'Cis proline' 0 CA--C 1.547 1.174 0 C-N-CA 125.165 -0.765 . . . . 1.79 111.09 -0.099 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 101' ' ' PHE . . . . . 0.507 ' CE2' ' CG ' ' A' ' 98' ' ' ASP . 0.1 OUTLIER -70.54 164.77 24.11 Favored 'General case' 0 N--CA 1.494 1.736 0 N-CA-C 107.793 -1.188 . . . . 2.19 107.793 178.566 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.485 HG13 ' O ' ' A' ' 102' ' ' VAL . 8.6 p -123.4 127.93 74.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 N-CA-C 108.43 -0.952 . . . . 1.44 108.43 179.068 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 94.9 t -121.47 83.56 40.96 Favored Pre-proline 0 N--CA 1.503 2.18 0 O-C-N 121.406 -0.809 . . . . 1.19 109.535 -179.223 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -66.85 110.64 1.97 Allowed 'Trans proline' 0 C--N 1.32 -0.967 0 C-N-CA 121.252 1.301 . . . . 1.49 110.742 -179.131 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.51 HG21 HG11 ' A' ' 79' ' ' VAL . 54.2 t -89.06 146.15 6.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 N-CA-C 107.28 -1.378 . . . . 1.35 107.28 178.54 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.553 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -133.64 130.43 38.27 Favored 'General case' 0 N--CA 1.508 2.46 0 O-C-N 121.289 -0.882 . . . . 1.67 111.746 -177.085 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.663 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 94.6 p -106.05 93.4 4.6 Favored 'General case' 0 N--CA 1.494 1.752 0 N-CA-C 106.854 -1.536 . . . . 2.04 106.854 178.578 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 108' ' ' LEU . . . . . 0.491 HD12 ' N ' ' A' ' 108' ' ' LEU . 11.1 mp 57.38 7.47 0.49 Allowed 'General case' 0 C--N 1.293 -1.858 0 N-CA-C 107.839 -1.171 . . . . 3.2 107.839 -177.696 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.532 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 6.1 t -92.99 -29.42 15.85 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 108.506 -0.924 . . . . 2.09 108.506 178.989 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 110' ' ' ASP . . . . . 0.553 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 26.8 m-20 52.39 12.28 0.22 Allowed 'General case' 0 N--CA 1.488 1.432 0 N-CA-C 108.061 -1.089 . . . . 2.85 108.061 -178.994 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.537 ' O ' ' C ' ' A' ' 112' ' ' ALA . 17.5 t0 -167.22 -35.13 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.311 0 O-C-N 121.72 -0.613 . . . . 2.46 109.748 -179.704 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.537 ' C ' ' O ' ' A' ' 111' ' ' ASP . . . 22.07 66.84 0.03 OUTLIER 'General case' 0 N--CA 1.515 2.816 0 CA-C-O 121.067 0.46 . . . . 2.08 111.53 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 113' ' ' ARG . . . . . 0.584 ' CG ' HH11 ' A' ' 113' ' ' ARG . 0.0 OUTLIER -71.91 -165.53 0.17 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.096 -1.003 . . . . 5.93 109.891 -179.206 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 7.6 ttm180 -134.08 1.1 3.22 Favored 'General case' 0 N--CA 1.494 1.764 0 N-CA-C 108.045 -1.095 . . . . 5.61 108.045 179.535 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 2.4 mp -131.32 -23.67 2.37 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.808 -0.558 . . . . 4.39 109.495 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.488 ' C ' ' H ' ' A' ' 118' ' ' THR . 0.8 OUTLIER -105.41 -78.23 0.57 Allowed 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 106.558 -1.645 . . . . 4.09 106.558 178.768 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.448 ' O ' HG12 ' A' ' 117' ' ' VAL . 42.7 t -63.89 -7.12 2.97 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.702 0 N-CA-C 105.859 -1.904 . . . . 2.9 105.859 176.726 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 118' ' ' THR . . . . . 0.488 ' H ' ' C ' ' A' ' 116' ' ' THR . 3.0 t 36.16 68.64 0.23 Allowed 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.058 -0.974 . . . . 3.36 110.831 179.798 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 119' ' ' SER . . . . . 0.403 ' OXT' ' O ' ' A' ' 118' ' ' THR . 0.9 OUTLIER . . . . . 0 C--N 1.303 -1.449 0 CA-C-O 117.978 -1.01 . . . . 3.39 109.49 179.242 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 5.0 ptt? . . . . . 0 N--CA 1.491 1.617 0 N-CA-C 109.402 -0.592 . . . . 8.49 109.402 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' B' B ' 2' ' ' ALA . . . . . 0.414 ' O ' ' OG ' ' B' ' 3' ' ' SER . . . -165.9 131.76 2.52 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.108 -0.995 . . . . 5.53 109.74 -179.852 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 3' ' ' SER . . . . . 0.499 ' OG ' ' N ' ' B' ' 4' ' ' LYS . 19.5 p 54.98 -136.46 1.28 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.385 -0.822 . . . . 5.43 109.86 179.869 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 4' ' ' LYS . . . . . 0.499 ' N ' ' OG ' ' B' ' 3' ' ' SER . 13.8 pttp -169.12 74.6 0.74 Allowed Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.363 -0.836 . . . . 6.87 109.27 -179.666 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 5' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -59.69 128.53 27.3 Favored 'Trans proline' 0 C--N 1.317 -1.086 0 C-N-CA 121.28 1.32 . . . . 5.16 109.797 -179.548 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 6' ' ' GLU . . . . . . . . . . . . . 41.6 tp10 -78.22 83.76 4.47 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.274 -0.891 . . . . 4.78 109.881 -179.591 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 86.6 mttt 46.9 -163.54 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.248 -0.908 . . . . 4.09 109.691 179.647 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.781 HH12 ' H ' ' A' ' 84' ' ' ASP . 3.9 mtt180 -100.51 175.3 5.73 Favored 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 108.562 -0.903 . . . . 3.04 108.562 -179.78 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 9' ' ' VAL . . . . . . . . . . . . . 20.8 t -56.82 159.34 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 N-CA-C 107.632 -1.247 . . . . 0.67 107.632 179.041 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -125.84 150.1 48.12 Favored 'General case' 0 N--CA 1.502 2.133 0 O-C-N 121.328 -0.857 . . . . 0.58 109.968 -179.136 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 11' ' ' SER . . . . . 0.437 ' O ' ' O ' ' A' ' 55' ' ' VAL . 6.2 m -148.77 145.14 27.46 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.389 -0.819 . . . . 1.19 109.44 179.911 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 14.8 t -142.08 118.57 10.93 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.205 -0.934 . . . . 1.38 109.553 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 0.56 HG22 ' N ' ' B' ' 14' ' ' PHE . 2.4 p -157.61 167.04 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 121.365 -0.834 . . . . 0.42 108.804 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 14' ' ' PHE . . . . . 0.56 ' N ' HG22 ' B' ' 13' ' ' VAL . 5.4 p90 -176.69 -167.13 0.18 Allowed 'General case' 0 N--CA 1.488 1.47 0 C-N-CA 119.298 -0.961 . . . . 1.79 112.082 -179.859 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.9 pt -146.63 176.94 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 N-CA-C 108.419 -0.956 . . . . 1.25 108.419 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 16.1 m -140.2 142.09 35.91 Favored 'General case' 0 N--CA 1.5 2.041 0 O-C-N 120.921 -1.112 . . . . 1.61 110.096 -179.703 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 18.5 mt -104.86 120.27 41.02 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.532 -0.73 . . . . 1.32 109.084 179.531 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -159.23 107.06 1.53 Allowed Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.256 -0.903 . . . . 1.45 109.272 -179.661 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 19' ' ' PRO . . . . . 0.44 ' C ' ' H ' ' B' ' 21' ' ' ARG . 5.4 Cg_exo -60.12 114.31 2.04 Favored 'Trans proline' 0 CA--C 1.553 1.472 0 N-CA-C 109.394 -1.041 . . . . 1.5 109.394 -179.677 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 20' ' ' PRO . . . . . . . . . . . . . 1.6 Cg_endo -62.8 0.76 1.36 Allowed 'Trans proline' 0 C--O 1.215 -0.64 0 N-CA-C 109.782 -0.891 . . . . 2.86 109.782 -179.588 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 21' ' ' ARG . . . . . 0.44 ' H ' ' C ' ' B' ' 19' ' ' PRO . 77.2 mtt180 -65.93 -67.66 0.43 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.235 -0.916 . . . . 6.12 109.455 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 22' ' ' ARG . . . . . . . . . . . . . 97.5 mtt180 50.67 -146.23 0.44 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.175 -0.953 . . . . 6.29 109.512 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 26.4 t70 50.5 42.16 26.17 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.337 -0.852 . . . . 5.62 109.343 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 14.0 m . . . . . 0 N--CA 1.49 1.538 0 CA-C-O 118.038 -0.982 . . . . 6.48 109.495 179.986 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.531 5.013 0 N-CA-C 119.762 2.665 . . . . 6.64 119.762 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.567 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 12.3 tt -171.34 50.18 0.13 Allowed Pre-proline 0 C--N 1.307 -1.264 0 O-C-N 121.311 -1.111 . . . . 7.08 108.137 179.438 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.809 ' C ' ' H ' ' A' ' 5' ' ' PHE . 1.6 Cg_endo -52.81 -78.52 0.02 OUTLIER 'Trans proline' 0 C--N 1.319 -0.987 0 C-N-CA 121.117 1.212 . . . . 5.5 109.063 179.504 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.486 ' C ' ' H ' ' A' ' 6' ' ' PHE . 8.9 tt0 73.5 -16.48 0.49 Allowed 'General case' 0 N--CA 1.495 1.789 0 N-CA-C 104.237 -2.505 . . . . 6.75 104.237 -175.612 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' PHE . . . . . 0.809 ' H ' ' C ' ' A' ' 3' ' ' PRO . 4.2 t80 -90.03 17.11 7.23 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 103.788 -2.671 . . . . 6.07 103.788 176.82 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.545 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 42.3 p90 46.6 -155.94 0.04 OUTLIER 'General case' 0 C--N 1.307 -1.254 0 CA-C-N 114.08 -1.418 . . . . 4.72 109.759 -177.988 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.539 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 16.1 tt0 86.43 -10.56 0.66 Allowed 'General case' 0 N--CA 1.493 1.72 0 N-CA-C 105.081 -2.192 . . . . 4.4 105.081 -177.112 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' PHE . . . . . 0.441 ' H ' ' C ' ' A' ' 6' ' ' PHE . 70.2 t80 -154.27 -36.31 0.1 Allowed 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 114.717 -1.129 . . . . 5.15 108.029 178.358 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.497 HG22 ' O ' ' A' ' 9' ' ' THR . 88.1 m -94.3 4.16 54.25 Favored 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 105.941 -1.874 . . . . 5.13 105.941 177.383 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.546 HG13 ' N ' ' A' ' 11' ' ' GLY . 12.7 p -44.29 -45.22 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.388 0 CA-C-N 115.374 -0.83 . . . . 4.38 109.281 -179.693 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.608 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 130.83 -79.17 0.36 Allowed Glycine 0 N--CA 1.503 3.112 0 N-CA-C 108.791 -1.724 . . . . 4.22 108.791 179.343 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.459 ' O ' ' C ' ' A' ' 13' ' ' LEU . 11.6 Cg_endo -65.74 39.05 0.13 Allowed 'Trans proline' 0 C--N 1.318 -1.044 0 C-N-CA 121.91 1.74 . . . . 3.85 108.884 178.007 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.608 ' H ' ' C ' ' A' ' 11' ' ' GLY . 0.2 OUTLIER 28.08 46.1 0.01 OUTLIER 'General case' 0 N--CA 1.505 2.28 0 CA-C-O 121.477 0.656 . . . . 3.67 110.78 -179.611 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.514 ' C ' ' H ' ' A' ' 16' ' ' GLY . . . 67.77 -35.57 0.23 Allowed Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.399 -1.48 . . . . 2.97 109.399 -179.622 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.55 ' H ' ' C ' ' A' ' 13' ' ' LEU . 60.1 tt0 57.19 4.04 0.18 Allowed 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.316 -1.108 . . . . 2.97 109.235 -179.862 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.514 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 64.94 112.05 0.01 OUTLIER Glycine 0 N--CA 1.49 2.291 0 O-C-N 121.503 -0.748 . . . . 2.44 111.779 178.165 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.588 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 63.79 -49.83 0.08 OUTLIER Glycine 0 N--CA 1.493 2.475 0 O-C-N 121.759 -0.848 . . . . 1.81 111.669 177.968 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.512 ' N ' ' OE2' ' A' ' 94' ' ' GLU . . . -45.33 -12.08 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.111 -1.229 . . . . 2.21 109.935 -179.276 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' HIS . . . . . 0.588 ' N ' ' O ' ' A' ' 17' ' ' GLY . 1.5 t60 -83.65 -40.64 18.72 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.142 -0.974 . . . . 2.87 109.557 179.207 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.527 ' HZ2' HG23 ' A' ' 21' ' ' VAL . 0.9 OUTLIER -93.93 4.17 54.3 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 120.874 -1.141 . . . . 2.02 110.5 -179.508 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.527 HG23 ' HZ2' ' A' ' 20' ' ' LYS . 64.6 t -83.06 113.51 22.36 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 120.811 -1.18 . . . . 2.07 109.25 179.721 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 20.3 tpt180 -111.03 137.27 48.87 Favored 'General case' 0 N--CA 1.496 1.83 0 CA-C-O 121.408 0.623 . . . . 3.5 109.63 -179.634 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -144.21 113.55 6.98 Favored 'General case' 0 N--CA 1.493 1.701 0 N-CA-C 108.744 -0.836 . . . . 1.83 108.744 179.417 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -153.17 128.53 2.47 Favored Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.924 -1.27 . . . . 1.9 109.924 -179.465 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 179.84 -173.92 45.5 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.926 -1.269 . . . . 1.85 109.926 179.721 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 16.7 p -78.92 -25.76 43.7 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.358 -1.083 . . . . 2.31 109.235 179.554 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.485 ' N ' ' O ' ' A' ' 38' ' ' GLU . . . -65.9 -17.78 65.7 Favored Glycine 0 N--CA 1.488 2.131 0 N-CA-C 108.388 -1.885 . . . . 1.64 108.388 179.58 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 14.1 mt -94.12 32.46 1.5 Allowed 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 108.477 -0.935 . . . . 1.83 108.477 179.439 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -140.33 -50.91 0.47 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.445 -0.784 . . . . 2.34 109.615 -179.58 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' ARG . . . . . 0.519 ' NH1' ' OD1' ' A' ' 110' ' ' ASP . 30.8 ptt180 -172.27 173.75 4.13 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.953 -1.092 . . . . 3.77 110.573 -179.79 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -150.24 176.4 28.88 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 107.878 -2.089 . . . . 1.57 107.878 179.437 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 37.5 t -134.09 153.13 35.44 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.137 0 O-C-N 120.992 -1.299 . . . . 1.83 110.755 -179.629 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.813 ' HB2' ' OG ' ' A' ' 107' ' ' SER . . . -40.37 114.1 0.42 Allowed 'General case' 0 N--CA 1.497 1.891 0 CA-C-O 121.587 0.708 . . . . 1.64 112.092 -179.334 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 56.46 46.04 88.38 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 111.397 -0.681 . . . . 1.73 111.397 177.05 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 37.1 t -126.92 122.54 23.33 Favored Pre-proline 0 N--CA 1.497 1.909 0 O-C-N 121.443 -1.033 . . . . 2.19 108.23 178.933 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 2.3 Cg_endo -59.47 120.52 8.41 Favored 'Trans proline' 0 C--O 1.216 -0.622 0 C-N-CA 120.474 0.783 . . . . 1.96 110.27 -179.38 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.47 ' HB3' ' CE1' ' A' ' 77' ' ' TYR . . . -116.81 161.21 19.65 Favored 'General case' 0 N--CA 1.497 1.904 0 N-CA-C 107.814 -1.18 . . . . 1.69 107.814 179.167 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' GLU . . . . . 0.485 ' O ' ' N ' ' A' ' 27' ' ' GLY . 7.0 pt-20 -163.8 173.01 13.31 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 120.642 -1.286 . . . . 2.23 111.519 -179.455 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.675 ' CE2' HD11 ' A' ' 41' ' ' ILE . 5.6 p90 -157.99 165.24 35.63 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 107.647 -1.242 . . . . 1.54 107.647 178.504 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 58.0 m -99.96 148.96 23.93 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.404 -0.81 . . . . 2.37 110.843 -178.099 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.795 HD12 HG21 ' A' ' 75' ' ' VAL . 95.5 mt -137.84 102.64 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 N-CA-C 108.353 -0.98 . . . . 1.65 108.353 178.963 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 3.0 t-105 -100.04 132.77 45.21 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.314 -0.866 . . . . 3.68 108.683 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.547 ' OG1' ' N ' ' A' ' 44' ' ' ARG . 1.6 t -162.25 -126.16 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.405 -0.809 . . . . 2.89 109.503 -179.641 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' ARG . . . . . 0.547 ' N ' ' OG1' ' A' ' 43' ' ' THR . 25.9 mtm180 60.61 80.22 0.22 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.285 -0.885 . . . . 4.63 109.954 179.885 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 12.5 tp10 -159.45 -46.82 0.05 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.282 -0.886 . . . . 2.89 109.134 179.383 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -60.34 -59.96 4.58 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.086 -1.009 . . . . 1.74 109.066 179.715 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 163.59 -175.88 39.76 Favored Glycine 0 N--CA 1.484 1.856 0 C-N-CA 119.385 -1.388 . . . . 1.6 110.464 179.62 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.6 163.47 0.65 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.535 -0.98 . . . . 1.4 109.853 -179.686 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 172.72 -163.2 35.04 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.68 -1.368 . . . . 1.04 109.68 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -142.77 130.45 4.2 Favored Glycine 0 N--CA 1.496 2.634 0 N-CA-C 109.245 -1.542 . . . . 1.06 109.245 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.475 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 12.2 tp -103.07 100.62 10.56 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.425 -1.044 . . . . 1.1 109.042 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 3.9 m -88.77 139.76 30.14 Favored 'General case' 0 N--CA 1.497 1.92 0 N-CA-C 108.723 -0.843 . . . . 1.56 108.723 179.476 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.507 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 82.6 mt -128.15 113.28 29.78 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.111 0 O-C-N 121.088 -1.008 . . . . 0.65 109.916 -179.811 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -102.48 106.04 16.7 Favored 'General case' 0 N--CA 1.494 1.736 0 N-CA-C 108.718 -0.845 . . . . 0.69 108.718 179.251 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.44 HG23 ' OG ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -102.84 143.7 14.78 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 O-C-N 121.471 -0.768 . . . . 0.91 109.326 -179.697 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 -141.95 144.03 33.54 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 108.181 -1.044 . . . . 1.8 108.181 178.743 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 168.71 -172.59 43.17 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 109.179 -1.569 . . . . 0.49 109.179 -179.031 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -63.73 -27.6 68.37 Favored 'Trans proline' 0 C--N 1.316 -1.133 0 C-N-CA 121.888 1.725 . . . . 0.66 111.461 -179.696 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' SER . . . . . 0.421 ' O ' ' OH ' ' A' ' 85' ' ' TYR . 16.0 m -140.4 168.12 20.55 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.257 -0.902 . . . . 1.55 109.754 -179.77 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 37.1 mtpt -91.13 126.44 36.22 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.376 -0.828 . . . . 2.53 109.517 -179.713 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -86.83 135.12 33.45 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.242 -0.911 . . . . 0.82 109.358 179.861 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 20.0 tt0 -90.19 94.53 9.8 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.129 -0.982 . . . . 2.3 109.97 -179.658 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.602 HD12 ' N ' ' A' ' 63' ' ' ILE . 1.8 mp -60.34 153.74 4.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 N-CA-C 109.118 -0.697 . . . . 1.4 109.118 179.415 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.547 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -151.3 123.8 8.41 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.037 -1.039 . . . . 1.36 109.24 179.778 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.47 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 47.5 p90 -89.0 124.59 34.42 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.204 -0.935 . . . . 1.47 109.376 179.787 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 75.9 tt0 -141.58 111.16 6.49 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.222 -0.924 . . . . 2.51 109.772 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -79.78 127.81 32.67 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.202 -0.936 . . . . 2.07 108.687 179.273 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 56.0 ttt180 -118.16 -27.1 6.16 Favored 'General case' 0 N--CA 1.501 2.08 0 O-C-N 121.466 -0.771 . . . . 4.63 109.487 -179.583 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.541 ' C ' ' H ' ' A' ' 71' ' ' GLY . 39.5 mttp -116.66 -3.19 11.79 Favored 'General case' 0 N--CA 1.496 1.858 0 N-CA-C 108.691 -0.855 . . . . 3.49 108.691 179.829 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.444 ' CB ' ' O ' ' A' ' 69' ' ' LYS . 1.6 t70 72.15 -30.08 0.21 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.571 -0.706 . . . . 3.06 109.111 -179.56 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 71' ' ' GLY . . . . . 0.541 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -103.17 19.4 46.21 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.436 -1.466 . . . . 2.16 109.436 -179.765 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 3.3 t -153.85 129.65 10.13 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.351 -1.087 . . . . 2.2 109.092 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 76.4 m -86.23 113.39 22.21 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.126 -0.984 . . . . 2.05 109.428 -179.927 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -87.62 115.46 4.34 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.703 -1.359 . . . . 1.39 109.703 -179.717 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.795 HG21 HD12 ' A' ' 41' ' ' ILE . 22.0 t -107.03 104.46 17.1 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.995 0 O-C-N 121.605 -0.938 . . . . 1.57 109.012 179.79 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.547 ' O ' ' N ' ' A' ' 64' ' ' ALA . 37.3 m -99.4 131.84 45.14 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.558 -0.714 . . . . 1.85 110.06 -179.45 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.511 ' CD1' ' O ' ' A' ' 77' ' ' TYR . 44.3 p90 -128.01 134.96 49.29 Favored 'General case' 0 N--CA 1.497 1.915 0 N-CA-C 108.875 -0.787 . . . . 1.54 108.875 179.882 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.64 ' O ' HG13 ' A' ' 78' ' ' VAL . 9.7 p -104.52 114.2 43.51 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.099 0 O-C-N 121.324 -0.86 . . . . 1.9 109.582 -179.576 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.476 HG11 HG21 ' A' ' 105' ' ' VAL . 2.0 m -88.64 158.96 2.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.096 -1.002 . . . . 1.27 109.031 -179.865 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 35.1 tt0 -97.28 -49.47 4.93 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.079 -1.013 . . . . 2.48 110.758 -179.133 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 76.5 mm-40 -147.15 150.74 39.15 Favored Pre-proline 0 N--CA 1.504 2.242 0 O-C-N 120.794 -1.191 . . . . 1.92 111.661 -178.314 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.653 ' HG3' ' N ' ' A' ' 107' ' ' SER . 77.3 Cg_exo -36.85 164.27 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 123.248 2.632 . . . . 1.3 113.346 178.409 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 145.03 175.21 17.99 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.543 -1.423 . . . . 1.02 109.543 179.676 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 84' ' ' ASP . . . . . 0.837 ' H ' HH12 ' B' ' 8' ' ' ARG . 0.9 OUTLIER -94.26 83.97 4.33 Favored 'General case' 0 N--CA 1.49 1.549 0 N-CA-C 107.959 -1.126 . . . . 2.13 107.959 179.277 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 85' ' ' TYR . . . . . 0.421 ' OH ' ' O ' ' A' ' 59' ' ' SER . 2.7 m-85 -68.89 135.25 50.76 Favored 'General case' 0 C--N 1.299 -1.606 0 N-CA-C 107.84 -1.171 . . . . 0.92 107.84 -179.712 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 86' ' ' GLU . . . . . 0.442 ' OE2' ' O ' ' A' ' 84' ' ' ASP . 0.8 OUTLIER -116.31 121.04 40.8 Favored 'General case' 0 N--CA 1.499 1.996 0 N-CA-C 108.768 -0.827 . . . . 1.53 108.768 -179.37 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 10.6 p -116.46 145.35 22.33 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 121.592 -0.693 . . . . 1.0 110.194 -179.375 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' SER . . . . . 0.783 ' HB2' ' HE1' ' A' ' 95' ' ' HIS . 9.4 p -136.47 110.35 8.19 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 108.699 -0.852 . . . . 1.59 108.699 179.596 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.8 pt -116.89 135.75 56.23 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.949 0 O-C-N 121.577 -0.702 . . . . 1.29 110.632 -178.886 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' LYS . . . . . 0.461 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.3 OUTLIER -136.03 121.31 19.14 Favored 'General case' 0 N--CA 1.486 1.339 0 N-CA-C 107.923 -1.14 . . . . 1.58 107.923 178.625 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.409 ' O ' ' OE1' ' A' ' 94' ' ' GLU . 52.7 t80 -85.15 101.65 12.64 Favored 'General case' 0 N--CA 1.491 1.621 0 N-CA-C 107.196 -1.409 . . . . 1.34 107.196 178.632 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 92' ' ' ASN . . . . . 0.454 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 21.3 t30 72.09 34.36 1.45 Allowed 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 109.214 -0.661 . . . . 2.32 109.214 -178.266 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.454 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 1.4 m-20 80.22 14.4 0.84 Allowed 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.614 -0.679 . . . . 1.92 111.437 179.393 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 94' ' ' GLU . . . . . 0.512 ' OE2' ' N ' ' A' ' 18' ' ' ALA . 6.5 pt-20 -99.39 98.68 9.58 Favored 'General case' 0 N--CA 1.497 1.908 0 N-CA-C 107.09 -1.448 . . . . 2.25 107.09 177.898 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 95' ' ' HIS . . . . . 0.783 ' HE1' ' HB2' ' A' ' 88' ' ' SER . 0.7 OUTLIER -67.19 98.54 0.61 Allowed 'General case' 0 N--CA 1.491 1.578 0 CA-C-O 121.586 0.708 . . . . 2.88 110.022 -177.845 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 96' ' ' ILE . . . . . 0.467 HD13 ' HD2' ' A' ' 97' ' ' PRO . 0.1 OUTLIER -54.86 137.29 64.99 Favored Pre-proline 0 N--CA 1.489 1.503 0 N-CA-C 107.429 -1.322 . . . . 2.35 107.429 179.351 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.467 ' HD2' HD13 ' A' ' 96' ' ' ILE . 24.6 Cg_exo -39.37 -44.78 3.03 Favored 'Trans proline' 0 CA--C 1.537 0.657 0 C-N-CA 121.234 1.289 . . . . 2.48 111.791 -178.809 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.455 ' N ' ' OD1' ' A' ' 98' ' ' ASP . 1.2 m-20 -47.05 -65.72 0.52 Allowed 'General case' 0 N--CA 1.498 1.949 0 O-C-N 120.747 -1.221 . . . . 2.65 109.174 179.325 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.507 ' HB3' ' CE1' ' A' ' 95' ' ' HIS . 3.8 m -57.06 138.89 79.54 Favored Pre-proline 0 C--N 1.297 -1.705 0 O-C-N 121.26 -0.9 . . . . 2.0 109.204 -178.912 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -88.31 115.32 2.97 Favored 'Cis proline' 0 N--CA 1.49 1.271 0 N-CA-C 109.055 -1.171 . . . . 1.79 109.055 -1.669 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 52.5 p90 -114.5 162.96 16.03 Favored 'General case' 0 N--CA 1.517 2.918 0 O-C-N 120.546 -1.347 . . . . 2.19 110.335 179.117 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.1 p -91.79 151.92 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 CA-C-O 121.713 0.768 . . . . 1.44 110.749 -178.34 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 55.8 t -128.24 86.42 58.0 Favored Pre-proline 0 N--CA 1.494 1.766 0 N-CA-C 107.679 -1.23 . . . . 1.19 107.679 179.158 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -66.47 110.59 1.87 Allowed 'Trans proline' 0 C--N 1.321 -0.89 0 C-N-CA 121.623 1.549 . . . . 1.49 112.194 -177.563 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.476 HG21 HG11 ' A' ' 79' ' ' VAL . 55.5 t -94.51 142.52 13.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 N-CA-C 106.488 -1.671 . . . . 1.35 106.488 177.465 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.712 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -129.55 132.32 46.8 Favored 'General case' 0 N--CA 1.512 2.652 0 CA-C-O 122.173 0.987 . . . . 1.67 112.516 -176.59 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.813 ' OG ' ' HB2' ' A' ' 33' ' ' ALA . 35.7 m -94.53 81.33 3.91 Favored 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 107.117 -1.438 . . . . 2.04 107.117 178.515 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 23.9 mt 62.63 1.02 0.72 Allowed 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 107.795 -1.187 . . . . 3.2 107.795 -177.723 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.576 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 60.8 p -87.72 -21.39 25.22 Favored 'General case' 0 N--CA 1.488 1.444 0 N-CA-C 108.471 -0.937 . . . . 2.09 108.471 178.859 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 110' ' ' ASP . . . . . 0.712 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 36.0 t0 52.03 11.91 0.18 Allowed 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.512 -0.922 . . . . 2.85 108.512 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.517 ' OD1' ' N ' ' A' ' 112' ' ' ALA . 4.0 p30 -172.39 -30.16 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.693 -0.629 . . . . 2.46 109.482 -179.773 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.576 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 42.86 57.07 3.74 Favored 'General case' 0 N--CA 1.502 2.129 0 O-C-N 121.162 -0.961 . . . . 2.08 109.71 179.95 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 113' ' ' ARG . . . . . 0.611 ' CG ' HH11 ' A' ' 113' ' ' ARG . 0.0 OUTLIER -44.21 146.26 0.68 Allowed 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.343 -0.848 . . . . 5.93 110.028 -179.101 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 46.3 ttt180 -103.86 4.04 34.45 Favored 'General case' 0 N--CA 1.496 1.826 0 N-CA-C 108.848 -0.797 . . . . 5.61 108.848 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 33.9 mt -127.85 -25.0 3.14 Favored 'General case' 0 N--CA 1.504 2.235 0 O-C-N 121.712 -0.618 . . . . 4.39 109.386 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.508 ' C ' ' H ' ' A' ' 118' ' ' THR . 55.2 m -108.17 -78.21 0.59 Allowed 'General case' 0 N--CA 1.498 1.956 0 N-CA-C 107.172 -1.418 . . . . 4.09 107.172 179.056 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.454 ' O ' HG12 ' A' ' 117' ' ' VAL . 51.3 t -62.84 -8.04 2.96 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.715 0 N-CA-C 105.911 -1.885 . . . . 2.9 105.911 176.801 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 118' ' ' THR . . . . . 0.508 ' H ' ' C ' ' A' ' 116' ' ' THR . 4.1 t 36.13 60.58 0.83 Allowed 'General case' 0 N--CA 1.488 1.446 0 CA-C-N 115.221 -0.9 . . . . 3.36 110.636 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 119' ' ' SER . . . . . 0.472 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.6 p . . . . . 0 N--CA 1.487 1.38 0 CA-C-O 117.988 -1.006 . . . . 3.39 109.59 179.461 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 25.9 ttt . . . . . 0 N--CA 1.491 1.599 0 N-CA-C 109.364 -0.606 . . . . 8.49 109.364 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -164.04 176.51 9.27 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.271 -0.893 . . . . 5.53 109.442 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 3' ' ' SER . . . . . 0.477 ' O ' ' C ' ' B' ' 4' ' ' LYS . 18.0 m -160.01 107.44 1.65 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.253 -0.904 . . . . 5.43 109.292 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 4' ' ' LYS . . . . . 0.477 ' C ' ' O ' ' B' ' 3' ' ' SER . 66.5 mmtt -26.68 92.6 0.05 OUTLIER Pre-proline 0 N--CA 1.506 2.362 0 CA-C-O 119.523 -0.275 . . . . 6.87 111.317 -179.786 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 5' ' ' PRO . . . . . 0.417 ' N ' ' O ' ' B' ' 3' ' ' SER . 2.2 Cg_endo -69.39 -81.06 0.01 OUTLIER 'Trans proline' 0 C--N 1.324 -0.756 0 C-N-CA 121.135 1.223 . . . . 5.16 109.793 -179.437 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 6' ' ' GLU . . . . . 0.462 ' N ' ' CD ' ' B' ' 6' ' ' GLU . 0.6 OUTLIER 51.82 50.6 18.3 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.241 -0.912 . . . . 4.78 109.618 -179.8 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 7.1 ptmm? -159.96 146.49 16.01 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.225 -0.922 . . . . 4.09 109.482 179.768 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 8' ' ' ARG . . . . . 0.837 HH12 ' H ' ' A' ' 84' ' ' ASP . 39.0 mtt180 -140.53 168.13 20.53 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.301 -0.874 . . . . 3.04 108.847 179.903 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 9' ' ' VAL . . . . . . . . . . . . . 14.7 t -50.9 159.72 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 N-CA-C 108.059 -1.089 . . . . 0.67 108.059 179.24 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -122.66 144.26 49.25 Favored 'General case' 0 N--CA 1.501 2.092 0 O-C-N 121.372 -0.83 . . . . 0.58 110.092 -178.961 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 11' ' ' SER . . . . . 0.44 ' OG ' HG23 ' A' ' 55' ' ' VAL . 4.1 t -137.17 145.15 43.4 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.59 -0.693 . . . . 1.19 109.246 179.712 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 17.7 m -148.64 115.48 6.02 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.28 -0.888 . . . . 1.38 109.752 -179.797 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 0.596 HG22 ' N ' ' B' ' 14' ' ' PHE . 2.9 p -157.86 166.81 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 N-CA-C 108.694 -0.854 . . . . 0.42 108.694 179.624 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 14' ' ' PHE . . . . . 0.596 ' N ' HG22 ' B' ' 13' ' ' VAL . 6.9 p90 -177.33 -167.02 0.15 Allowed 'General case' 0 N--CA 1.489 1.509 0 C-N-CA 119.168 -1.013 . . . . 1.79 112.403 -179.811 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 3.2 pt -146.62 168.73 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 N-CA-C 108.437 -0.949 . . . . 1.25 108.437 179.819 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 49.5 m -138.69 142.08 38.97 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 120.999 -1.063 . . . . 1.61 110.178 -179.599 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 16.5 mt -103.32 129.86 50.44 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.52 -0.738 . . . . 1.32 109.162 179.545 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -141.94 77.9 18.04 Favored Pre-proline 0 N--CA 1.497 1.879 0 O-C-N 121.351 -0.843 . . . . 1.45 109.635 -179.658 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -60.15 169.13 5.23 Favored 'Trans proline' 0 CA--C 1.545 1.056 0 C-N-CA 121.321 1.347 . . . . 1.5 109.593 -179.754 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 20' ' ' PRO . . . . . 0.437 ' O ' ' O ' ' B' ' 21' ' ' ARG . 2.5 Cg_endo -57.42 88.95 0.05 OUTLIER 'Trans proline' 0 C--N 1.32 -0.957 0 C-N-CA 121.416 1.41 . . . . 2.86 110.367 -179.582 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 21' ' ' ARG . . . . . 0.437 ' O ' ' O ' ' B' ' 20' ' ' PRO . 2.6 tpm_? 58.16 158.03 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.231 -0.918 . . . . 6.12 109.796 179.536 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 22' ' ' ARG . . . . . 0.454 ' O ' ' N ' ' B' ' 24' ' ' VAL . 72.7 mtm180 -79.63 101.91 8.62 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.193 -0.942 . . . . 6.29 109.368 179.824 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -49.69 95.19 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.202 -0.936 . . . . 5.62 109.511 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 24' ' ' VAL . . . . . 0.454 ' N ' ' O ' ' B' ' 22' ' ' ARG . 12.4 t . . . . . 0 N--CA 1.49 1.543 0 CA-C-O 117.993 -1.003 . . . . 6.48 109.529 179.903 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.512 ' O ' ' N ' ' A' ' 18' ' ' ALA . . . . . . . . 0 N--CA 1.491 2.356 0 N-CA-C 110.809 -0.916 . . . . 2.44 110.809 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.536 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -46.59 -11.5 0.05 OUTLIER Glycine 0 N--CA 1.492 2.402 0 O-C-N 121.635 -0.921 . . . . 1.81 111.068 -178.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.512 ' N ' ' O ' ' A' ' 16' ' ' GLY . . . -45.93 -15.87 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.991 -1.299 . . . . 2.21 109.661 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' HIS . . . . . 0.536 ' N ' ' O ' ' A' ' 17' ' ' GLY . 10.7 t60 -94.48 -48.88 5.92 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.443 -0.786 . . . . 2.87 109.779 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.51 -14.4 62.1 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.891 -1.13 . . . . 2.02 109.435 -179.872 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 37.9 t -68.43 108.82 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.134 -0.979 . . . . 2.07 108.629 179.387 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.416 ' CG ' HH11 ' A' ' 22' ' ' ARG . 0.0 OUTLIER -113.83 138.49 50.21 Favored 'General case' 0 N--CA 1.491 1.609 0 N-CA-C 109.131 -0.692 . . . . 3.5 109.131 -179.515 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -147.72 113.36 5.68 Favored 'General case' 0 N--CA 1.491 1.603 0 N-CA-C 108.776 -0.824 . . . . 1.83 108.776 179.553 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -151.96 131.68 3.51 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.461 -1.456 . . . . 1.9 109.461 -179.597 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.0 -177.1 46.51 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.502 -1.439 . . . . 1.85 109.502 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.471 HG23 ' N ' ' A' ' 27' ' ' GLY . 13.5 t -79.59 -38.58 33.66 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.252 -1.146 . . . . 2.31 109.16 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.471 ' N ' HG23 ' A' ' 26' ' ' THR . . . -60.28 -6.94 6.37 Favored Glycine 0 N--CA 1.483 1.811 0 N-CA-C 107.864 -2.094 . . . . 1.64 107.864 179.222 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.451 ' H ' ' C ' ' A' ' 26' ' ' THR . 12.3 mt -99.3 24.29 8.2 Favored 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 108.247 -1.02 . . . . 1.83 108.247 179.38 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 18.2 mt-10 -136.81 -37.66 0.66 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.515 -0.741 . . . . 2.34 109.152 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . 0.514 HH11 ' HG2' ' A' ' 30' ' ' ARG . 2.5 ptt-85 -174.78 168.7 3.61 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.098 -1.001 . . . . 3.77 110.204 179.843 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -148.59 177.44 26.83 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 107.643 -2.183 . . . . 1.57 107.643 179.558 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 44.1 t -134.41 151.0 31.2 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.12 0 O-C-N 121.056 -1.261 . . . . 1.83 111.043 -179.528 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.515 ' HB2' ' HB3' ' A' ' 107' ' ' SER . . . -40.05 111.35 0.19 Allowed 'General case' 0 N--CA 1.498 1.937 0 CA-C-O 121.501 0.667 . . . . 1.64 112.418 -179.233 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 55.63 50.21 61.63 Favored Glycine 0 N--CA 1.492 2.395 0 O-C-N 121.589 -0.694 . . . . 1.73 111.427 176.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 31.5 t -127.35 124.19 23.55 Favored Pre-proline 0 N--CA 1.496 1.851 0 N-CA-C 108.312 -0.996 . . . . 2.19 108.312 178.827 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -57.3 131.98 48.23 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 N-CA-C 110.034 -0.795 . . . . 1.96 110.034 -179.527 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.527 ' HB3' ' CE1' ' A' ' 77' ' ' TYR . . . -136.04 160.31 39.04 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.46 -0.775 . . . . 1.69 109.004 179.81 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -155.32 171.47 19.8 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.012 -1.055 . . . . 2.23 111.213 -179.486 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 0.627 ' CE2' HD11 ' A' ' 41' ' ' ILE . 5.9 p90 -156.58 164.6 38.0 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 107.259 -1.386 . . . . 1.54 107.259 178.372 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 80.5 p -96.52 155.1 16.91 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.208 -0.933 . . . . 2.37 111.279 -177.806 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.878 HD12 HG21 ' A' ' 75' ' ' VAL . 46.6 mt -146.42 97.71 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 N-CA-C 107.516 -1.29 . . . . 1.65 107.516 178.767 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.4 ' CD1' ' C ' ' A' ' 42' ' ' TRP . 0.7 OUTLIER -84.88 146.96 27.03 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.113 -0.992 . . . . 3.68 109.125 -179.407 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.556 ' OG1' ' N ' ' A' ' 44' ' ' ARG . 1.4 t -154.31 -130.35 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.525 0 N-CA-C 109.138 -0.689 . . . . 2.89 109.138 -179.414 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' ARG . . . . . 0.556 ' N ' ' OG1' ' A' ' 43' ' ' THR . 39.6 ttp180 54.18 73.98 0.36 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.172 -0.955 . . . . 4.63 109.985 179.842 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 15.7 tt0 -165.14 -60.86 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.31 -0.869 . . . . 2.89 108.875 179.357 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.63 -54.56 44.64 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.059 -1.026 . . . . 1.74 108.71 179.286 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 145.58 179.63 21.97 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.292 -1.523 . . . . 1.6 109.292 179.848 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.73 162.74 0.82 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.134 -1.216 . . . . 1.4 109.598 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 168.89 -151.98 19.11 Favored Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.537 -1.425 . . . . 1.04 109.537 -179.881 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.538 ' O ' ' N ' ' A' ' 92' ' ' ASN . . . -133.87 159.12 23.61 Favored Glycine 0 N--CA 1.497 2.743 0 N-CA-C 109.413 -1.475 . . . . 1.06 109.413 -179.855 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.436 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 9.8 tp -134.14 100.5 4.73 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.529 -0.983 . . . . 1.1 108.424 179.767 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 3.8 m -83.93 144.13 29.38 Favored 'General case' 0 N--CA 1.491 1.58 0 N-CA-C 108.527 -0.916 . . . . 1.56 108.527 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.542 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 7.5 mt -135.71 100.94 2.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.354 -0.841 . . . . 0.65 109.203 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -98.19 106.22 18.48 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.306 -0.871 . . . . 0.69 108.986 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.44 ' O ' ' O ' ' B' ' 11' ' ' SER . 0.2 OUTLIER -97.64 144.42 11.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.499 -0.751 . . . . 0.91 109.403 -179.87 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 3.1 tt0 -141.11 142.09 34.14 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 107.909 -1.145 . . . . 1.8 107.909 179.059 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.432 ' O ' ' O ' ' B' ' 9' ' ' VAL . . . 169.03 176.89 39.44 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.173 -1.571 . . . . 0.49 109.173 -178.811 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -56.48 -17.99 23.76 Favored 'Trans proline' 0 C--N 1.317 -1.123 0 C-N-CA 121.94 1.76 . . . . 0.66 111.274 -179.482 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.4 p -150.22 159.93 44.07 Favored 'General case' 0 C--N 1.292 -1.922 0 O-C-N 121.284 -0.885 . . . . 1.55 110.154 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 68.2 mttt -78.86 108.2 12.14 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.498 -0.752 . . . . 2.53 109.558 -179.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -74.18 148.43 41.68 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.232 -0.918 . . . . 0.82 109.481 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.834 ' C ' HD12 ' A' ' 63' ' ' ILE . 5.0 tp10 -85.14 172.3 11.33 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.322 -0.861 . . . . 2.3 108.786 179.889 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.834 HD12 ' C ' ' A' ' 62' ' ' GLU . 3.7 mp -142.79 144.98 23.65 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.926 0 N-CA-C 108.259 -1.015 . . . . 1.4 108.259 179.809 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.521 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -150.53 114.47 5.04 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 120.6 -1.312 . . . . 1.36 109.923 -179.779 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 54.7 p90 -86.74 138.86 31.27 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.327 -0.858 . . . . 1.47 109.572 179.73 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 . . . . . 0 N--CA 1.496 1.871 0 O-C-N 121.22 -0.925 . . . . 2.51 109.711 -179.992 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 37.5 m . . . . . 0 N--CA 1.499 2.009 0 CA-C-O 121.418 0.628 . . . . 2.2 109.788 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 5.9 t -83.97 125.81 32.41 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.2 -0.938 . . . . 2.05 109.108 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -97.65 109.87 3.91 Favored Glycine 0 N--CA 1.495 2.616 0 N-CA-C 110.139 -1.184 . . . . 1.39 110.139 -179.572 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.878 HG21 HD12 ' A' ' 41' ' ' ILE . 32.1 t -99.23 100.86 11.26 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.929 0 O-C-N 121.583 -0.951 . . . . 1.57 108.757 179.13 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.521 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.1 OUTLIER -89.53 126.14 35.48 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.675 -0.64 . . . . 1.85 109.353 -179.551 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.527 ' CE1' ' HB3' ' A' ' 37' ' ' ALA . 52.0 p90 -123.52 173.89 7.75 Favored 'General case' 0 N--CA 1.495 1.811 0 N-CA-C 108.591 -0.892 . . . . 1.54 108.591 179.619 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 15.4 t -142.18 120.51 8.6 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.936 0 O-C-N 121.321 -0.862 . . . . 1.9 109.769 -179.628 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.526 HG11 HG21 ' A' ' 105' ' ' VAL . 8.1 m -90.82 154.98 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.435 -0.791 . . . . 1.27 109.314 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . 0.429 ' O ' ' OE2' ' A' ' 81' ' ' GLU . 33.5 tt0 -100.43 -45.85 5.43 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.192 -0.942 . . . . 2.48 110.746 -179.18 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.429 ' OE2' ' O ' ' A' ' 80' ' ' GLN . 79.6 mm-40 -152.39 149.12 22.11 Favored Pre-proline 0 N--CA 1.504 2.251 0 O-C-N 120.458 -1.401 . . . . 1.92 111.399 -179.151 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.678 ' HG3' ' N ' ' A' ' 107' ' ' SER . 84.6 Cg_exo -36.86 162.19 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 123.117 2.544 . . . . 1.3 113.637 178.232 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 143.42 -163.82 27.44 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 108.673 -1.771 . . . . 1.02 108.673 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . 0.422 ' O ' ' OE1' ' A' ' 86' ' ' GLU . 3.0 m-20 -111.82 93.77 4.62 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.502 -0.999 . . . . 2.13 108.353 179.354 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -78.59 146.19 34.32 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 108.206 -1.035 . . . . 0.92 108.206 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . 0.422 ' OE1' ' O ' ' A' ' 84' ' ' ASP . 0.0 OUTLIER -134.64 129.75 35.35 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.682 -0.636 . . . . 1.53 109.298 -178.98 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.8 p -124.99 146.79 30.05 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.554 -0.716 . . . . 1.0 109.762 -179.807 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 53.6 p -128.59 101.61 6.23 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.442 -0.786 . . . . 1.59 109.106 179.642 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.2 pt -102.4 130.64 51.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.615 -0.678 . . . . 1.29 109.577 -179.573 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' LYS . . . . . 0.435 ' HG3' ' H ' ' A' ' 93' ' ' ASP . 0.5 OUTLIER -138.62 124.85 20.29 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.244 -0.91 . . . . 1.58 109.238 179.721 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 36.5 t80 -83.13 95.16 8.0 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 120.992 -1.067 . . . . 1.34 108.599 179.391 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . 0.538 ' N ' ' O ' ' A' ' 50' ' ' GLY . 2.3 t-20 70.15 38.71 1.44 Allowed 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 107.925 -1.139 . . . . 2.32 107.925 -178.69 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.456 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 3.2 m-20 82.78 12.79 0.48 Allowed 'General case' 0 N--CA 1.498 1.943 0 CA-C-O 121.26 0.553 . . . . 1.92 110.005 -179.222 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . 0.405 ' HG2' ' H ' ' A' ' 18' ' ' ALA . 4.1 mt-10 -88.88 70.7 8.64 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 107.576 -1.268 . . . . 2.25 107.576 178.192 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' HIS . . . . . 0.462 ' H ' ' CD2' ' A' ' 95' ' ' HIS . 11.4 p80 -67.5 113.44 5.35 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-O 121.309 0.576 . . . . 2.88 109.953 -179.133 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' ILE . . . . . 0.406 HG12 ' H ' ' A' ' 96' ' ' ILE . 2.0 pt -62.64 153.78 76.73 Favored Pre-proline 0 N--CA 1.491 1.61 0 N-CA-C 108.295 -1.002 . . . . 2.35 108.295 179.444 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_exo -50.86 -44.69 40.08 Favored 'Trans proline' 0 C--N 1.321 -0.914 0 C-N-CA 121.051 1.167 . . . . 2.48 109.987 179.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.564 ' CB ' ' CE2' ' A' ' 101' ' ' PHE . 3.4 m-20 -51.33 -48.43 62.4 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.146 -0.972 . . . . 2.65 109.85 179.67 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 2.4 t -56.45 126.13 68.46 Favored Pre-proline 0 C--N 1.298 -1.655 0 N-CA-C 107.752 -1.203 . . . . 2.0 107.752 179.545 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 8.3 Cg_endo -72.24 117.55 3.94 Favored 'Cis proline' 0 CA--C 1.548 1.188 0 CA-C-N 119.317 0.792 . . . . 1.79 111.48 0.328 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . 0.564 ' CE2' ' CB ' ' A' ' 98' ' ' ASP . 0.1 OUTLIER -73.3 170.97 13.92 Favored 'General case' 0 N--CA 1.494 1.757 0 N-CA-C 107.251 -1.389 . . . . 2.19 107.251 178.273 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.403 ' O ' HG13 ' A' ' 102' ' ' VAL . 7.6 p -126.77 133.27 68.91 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 121.358 -0.838 . . . . 1.44 109.16 179.79 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 86.5 t -128.93 83.08 67.31 Favored Pre-proline 0 N--CA 1.502 2.161 0 O-C-N 121.454 -0.779 . . . . 1.19 109.63 -179.513 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -64.77 114.45 2.76 Favored 'Trans proline' 0 C--N 1.32 -0.932 0 C-N-CA 121.302 1.334 . . . . 1.49 110.477 -179.506 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.526 HG21 HG11 ' A' ' 79' ' ' VAL . 53.1 t -93.91 146.15 6.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 N-CA-C 108.292 -1.003 . . . . 1.35 108.292 179.484 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.65 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -131.92 130.28 41.38 Favored 'General case' 0 N--CA 1.507 2.401 0 CA-C-O 121.932 0.872 . . . . 1.67 111.941 -177.291 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . 0.678 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 76.2 p -98.65 98.3 9.46 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.733 -1.23 . . . . 2.04 107.788 179.184 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' LEU . . . . . 0.514 HD12 ' N ' ' A' ' 108' ' ' LEU . 8.9 mp 54.62 9.3 0.26 Allowed 'General case' 0 C--N 1.293 -1.872 0 N-CA-C 108.278 -1.008 . . . . 3.2 108.278 -178.585 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.48 ' H ' ' C ' ' A' ' 107' ' ' SER . 8.3 t -101.05 -28.57 12.64 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.604 -0.685 . . . . 2.09 109.16 179.503 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . 0.65 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 13.8 t70 . . . . . 0 N--CA 1.489 1.493 0 N-CA-C 107.776 -1.194 . . . . 2.85 107.776 -179.528 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . 0.592 ' CG ' HH11 ' B' ' 8' ' ' ARG . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.769 0 N-CA-C 107.349 -1.352 . . . . 3.04 107.349 . . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 9' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' A' ' 57' ' ' GLY . 34.8 t -71.94 160.0 5.47 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 120.75 -1.219 . . . . 0.67 108.422 179.611 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 0.4 ' N ' HG12 ' B' ' 9' ' ' VAL . . . -123.71 156.71 35.45 Favored 'General case' 0 N--CA 1.5 2.066 0 O-C-N 121.418 -0.801 . . . . 0.58 110.015 -179.26 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 11' ' ' SER . . . . . 0.44 ' O ' ' O ' ' A' ' 55' ' ' VAL . 3.2 t -149.56 144.03 25.97 Favored 'General case' 0 N--CA 1.492 1.641 0 N-CA-C 108.869 -0.789 . . . . 1.19 108.869 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 47.2 t -143.48 120.12 11.12 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 120.976 -1.078 . . . . 1.38 109.99 -179.666 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 0.582 HG22 ' N ' ' B' ' 14' ' ' PHE . 3.1 p -157.92 165.77 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 N-CA-C 108.722 -0.844 . . . . 0.42 108.722 179.542 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 14' ' ' PHE . . . . . 0.582 ' N ' HG22 ' B' ' 13' ' ' VAL . 4.9 p90 -177.99 -170.35 0.24 Allowed 'General case' 0 N--CA 1.49 1.563 0 C-N-CA 119.38 -0.928 . . . . 1.79 112.158 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 3.1 pt -149.87 -163.66 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.341 0 N-CA-C 108.273 -1.01 . . . . 1.25 108.273 179.831 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -161.09 146.55 14.22 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 120.724 -1.235 . . . . 1.61 109.911 179.769 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 13.4 mt . . . . . 0 N--CA 1.495 1.785 0 O-C-N 121.219 -0.926 . . . . 1.32 109.376 179.696 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.407 ' O ' ' CB ' ' A' ' 94' ' ' GLU . . . . . . . . 0 N--CA 1.49 2.24 0 N-CA-C 111.635 -0.586 . . . . 2.44 111.635 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.558 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 72.36 -52.34 1.45 Allowed Glycine 0 N--CA 1.493 2.487 0 O-C-N 121.458 -1.024 . . . . 1.81 111.127 178.296 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.749 ' HB2' ' OE1' ' A' ' 94' ' ' GLU . . . -49.45 -6.95 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.098 -1.236 . . . . 2.21 110.169 -179.308 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' HIS . . . . . 0.558 ' N ' ' O ' ' A' ' 17' ' ' GLY . 29.2 t-80 -94.97 -12.09 27.34 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.067 -1.021 . . . . 2.87 110.295 -179.801 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.424 ' NZ ' HG23 ' A' ' 21' ' ' VAL . 2.3 pptp? -132.6 11.64 4.44 Favored 'General case' 0 N--CA 1.504 2.235 0 O-C-N 121.031 -1.043 . . . . 2.02 110.457 -179.759 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.424 HG23 ' NZ ' ' A' ' 20' ' ' LYS . 53.2 t -94.29 113.19 28.38 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 120.976 -1.078 . . . . 2.07 109.257 179.491 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 20.3 tpt180 -113.08 121.33 44.24 Favored 'General case' 0 N--CA 1.496 1.846 0 N-CA-C 108.98 -0.748 . . . . 3.5 108.98 179.843 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -128.16 114.07 16.53 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 108.878 -0.786 . . . . 1.83 108.878 179.735 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -151.24 130.6 3.22 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 109.509 -1.436 . . . . 1.9 109.509 -179.616 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.29 171.08 43.42 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.739 -1.344 . . . . 1.85 109.739 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 13.2 p -78.51 -27.13 46.06 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.343 -1.092 . . . . 2.31 109.373 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.68 -12.55 70.57 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 109.11 -1.596 . . . . 1.64 109.11 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 12.1 mt -87.68 -15.53 36.9 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.437 -1.037 . . . . 1.83 108.852 179.679 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 42.2 mt-10 -87.66 -62.07 1.58 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.412 -0.805 . . . . 2.34 109.726 -179.793 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 72.5 mtt180 -148.14 178.48 8.51 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.114 -0.991 . . . . 3.77 110.058 -179.678 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -150.11 175.21 29.3 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 107.786 -2.125 . . . . 1.57 107.786 179.317 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 40.7 t -133.54 151.7 33.82 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.15 0 O-C-N 121.084 -1.245 . . . . 1.83 110.744 -179.57 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.457 ' HB2' ' HD3' ' A' ' 82' ' ' PRO . . . -43.56 111.01 0.23 Allowed 'General case' 0 N--CA 1.5 2.04 0 CA-C-O 121.57 0.7 . . . . 1.64 112.428 -178.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 55.87 52.8 46.37 Favored Glycine 0 N--CA 1.491 2.315 0 O-C-N 121.515 -0.741 . . . . 1.73 111.52 176.884 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 8.5 t -127.83 126.97 23.99 Favored Pre-proline 0 N--CA 1.497 1.911 0 O-C-N 121.502 -0.999 . . . . 2.19 108.373 178.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -57.77 117.8 4.57 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 N-CA-C 109.33 -1.065 . . . . 1.96 109.33 179.711 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -127.43 149.99 49.84 Favored 'General case' 0 N--CA 1.501 2.089 0 N-CA-C 108.873 -0.788 . . . . 1.69 108.873 -179.827 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -155.33 162.41 40.85 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.937 -1.102 . . . . 2.23 111.172 -179.448 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 0.58 ' CD1' ' N ' ' A' ' 39' ' ' PHE . 0.5 OUTLIER -137.98 -176.77 4.55 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 106.831 -1.544 . . . . 1.54 106.831 178.163 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 72.6 p -121.04 145.49 47.71 Favored 'General case' 0 N--CA 1.499 1.981 0 CA-C-O 121.5 0.667 . . . . 2.37 110.121 -179.222 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.444 ' O ' ' N ' ' A' ' 73' ' ' CYS . 48.5 mt -142.2 117.02 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 N-CA-C 108.515 -0.921 . . . . 1.65 108.515 179.32 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.434 ' CD1' ' C ' ' A' ' 42' ' ' TRP . 0.2 OUTLIER -113.74 129.62 56.55 Favored 'General case' 0 N--CA 1.497 1.878 0 N-CA-C 108.432 -0.951 . . . . 3.68 108.432 179.923 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.524 ' OG1' ' N ' ' A' ' 44' ' ' ARG . 9.2 p -144.73 -127.51 0.08 Allowed 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.343 -0.848 . . . . 2.89 109.16 -179.667 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' ARG . . . . . 0.524 ' N ' ' OG1' ' A' ' 43' ' ' THR . 1.6 ttt-85 56.89 79.85 0.17 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.363 -0.836 . . . . 4.63 110.059 179.646 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -156.27 -52.26 0.08 Allowed 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 108.543 -0.91 . . . . 2.89 108.543 179.146 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -60.78 -48.14 83.15 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.214 -0.929 . . . . 1.74 108.779 179.326 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 151.98 -174.48 30.99 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 109.514 -1.435 . . . . 1.6 109.514 179.809 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.33 161.44 0.94 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.252 -1.146 . . . . 1.4 109.047 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 176.17 -158.32 24.8 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.69 -1.364 . . . . 1.04 109.69 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -145.86 124.75 2.13 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 109.826 -1.31 . . . . 1.06 109.826 -179.806 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.468 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 10.4 tp -100.2 100.89 11.79 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.456 -1.026 . . . . 1.1 108.557 179.461 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 25.0 p -86.19 141.34 29.4 Favored 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 108.567 -0.901 . . . . 1.56 108.567 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.515 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 72.7 mt -130.44 114.25 27.96 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 O-C-N 121.235 -0.915 . . . . 0.65 109.552 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -105.36 107.94 19.2 Favored 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 108.777 -0.823 . . . . 0.69 108.777 179.677 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.412 HG23 ' CB ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -101.37 142.95 15.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 O-C-N 121.528 -0.733 . . . . 0.91 109.25 -179.857 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 8.7 tt0 -141.88 145.39 34.56 Favored 'General case' 0 N--CA 1.49 1.575 0 N-CA-C 107.685 -1.228 . . . . 1.8 107.685 178.755 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.43 ' O ' ' O ' ' B' ' 9' ' ' VAL . . . 164.58 -172.97 40.47 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.79 -1.324 . . . . 0.49 109.79 -179.296 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -67.71 -30.6 34.16 Favored 'Trans proline' 0 C--N 1.318 -1.06 0 C-N-CA 122.139 1.893 . . . . 0.66 112.09 -179.361 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . 0.424 ' CB ' ' OH ' ' A' ' 85' ' ' TYR . 0.3 OUTLIER -128.55 179.7 5.53 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 121.162 -0.962 . . . . 1.55 110.226 -179.126 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 62.7 mmtt -92.0 114.53 27.09 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.607 -0.683 . . . . 2.53 109.241 -179.817 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.598 ' O ' HD12 ' A' ' 63' ' ' ILE . . . -66.15 103.74 1.03 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.023 -1.048 . . . . 0.82 109.231 179.701 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 30.3 mt-10 -65.19 72.17 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.141 -0.974 . . . . 2.3 109.635 -179.738 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.598 HD12 ' O ' ' A' ' 61' ' ' ALA . 3.4 mp -58.14 149.35 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.613 -0.68 . . . . 1.4 109.295 179.852 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.54 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -150.4 127.6 11.29 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.996 -1.065 . . . . 1.36 109.453 -179.859 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.458 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 50.3 p90 -87.01 130.85 34.28 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.179 -0.951 . . . . 1.47 109.488 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 . . . . . 0 N--CA 1.497 1.891 0 O-C-N 121.286 -0.884 . . . . 2.51 109.338 179.821 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 16.1 t . . . . . 0 N--CA 1.495 1.785 0 N-CA-C 109.011 -0.736 . . . . 2.2 109.011 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' CYS . . . . . 0.444 ' N ' ' O ' ' A' ' 41' ' ' ILE . 33.7 m -83.31 105.17 14.05 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.202 -0.937 . . . . 2.05 109.825 -179.515 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -85.28 116.25 4.29 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.168 -1.573 . . . . 1.39 109.168 179.594 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 49.8 t -107.09 99.64 9.0 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.072 0 O-C-N 121.58 -0.953 . . . . 1.57 109.597 -179.674 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.54 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.5 OUTLIER -89.71 131.39 35.71 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.396 -0.815 . . . . 1.85 109.258 179.775 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.426 ' O ' ' CG ' ' A' ' 77' ' ' TYR . 2.3 p90 -133.07 126.81 32.65 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.379 -0.826 . . . . 1.54 109.825 -179.837 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 3.0 t -107.74 103.8 16.05 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 O-C-N 121.674 -0.641 . . . . 1.9 109.876 -179.665 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.463 ' H ' HG22 ' A' ' 79' ' ' VAL . 2.4 m -80.23 167.66 2.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.296 -0.877 . . . . 1.27 108.72 179.423 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 41.7 tp60 -102.26 -46.33 4.85 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.213 -0.929 . . . . 2.48 110.732 -179.298 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.448 ' OE2' ' HB1' ' A' ' 33' ' ' ALA . 71.8 mm-40 -147.61 151.02 38.4 Favored Pre-proline 0 N--CA 1.506 2.37 0 O-C-N 120.754 -1.216 . . . . 1.92 112.161 -178.254 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.638 ' HG3' ' N ' ' A' ' 107' ' ' SER . 86.0 Cg_exo -36.5 168.12 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 123.389 2.726 . . . . 1.3 113.734 178.113 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 140.9 -176.11 21.75 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.678 -1.369 . . . . 1.02 109.678 179.374 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . 0.528 ' OD2' ' NE ' ' B' ' 8' ' ' ARG . 2.4 p-10 -99.8 86.55 3.32 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.512 -0.993 . . . . 2.13 108.349 179.419 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.498 ' O ' ' N ' ' A' ' 103' ' ' VAL . 2.7 m-85 -72.87 130.72 41.05 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 108.044 -1.095 . . . . 0.92 108.044 -179.789 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . 0.428 ' H ' ' HG2' ' A' ' 86' ' ' GLU . 0.0 OUTLIER -107.24 129.12 54.91 Favored 'General case' 0 N--CA 1.496 1.87 0 N-CA-C 108.474 -0.936 . . . . 1.53 108.474 -179.196 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.446 ' CG1' ' CZ ' ' A' ' 101' ' ' PHE . 5.7 p -126.18 141.99 44.14 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 N-CA-C 109.17 -0.678 . . . . 1.0 109.17 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 13.5 p -138.65 107.15 5.84 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.264 -0.898 . . . . 1.59 109.795 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.8 pt -112.57 136.46 48.75 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.92 0 CA-C-O 121.414 0.626 . . . . 1.29 110.097 -179.738 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' LYS . . . . . 0.457 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.2 OUTLIER -143.05 122.41 13.08 Favored 'General case' 0 N--CA 1.486 1.333 0 O-C-N 121.383 -0.823 . . . . 1.58 108.785 179.447 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 55.3 t80 -79.67 99.74 7.53 Favored 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 107.716 -1.216 . . . . 1.34 107.716 178.458 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . 0.416 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 13.9 t-20 69.56 39.9 1.49 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.492 -0.755 . . . . 2.32 109.404 -178.885 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.422 ' H ' ' HG3' ' A' ' 90' ' ' LYS . 0.9 OUTLIER 76.7 13.27 2.32 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.665 -0.647 . . . . 1.92 111.585 179.442 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . 0.749 ' OE1' ' HB2' ' A' ' 18' ' ' ALA . 0.6 OUTLIER -98.27 94.9 7.03 Favored 'General case' 0 N--CA 1.499 1.978 0 N-CA-C 106.919 -1.511 . . . . 2.25 106.919 177.649 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' HIS . . . . . 0.653 ' H ' ' CD2' ' A' ' 95' ' ' HIS . 0.1 OUTLIER -71.12 106.99 3.94 Favored 'General case' 0 N--CA 1.488 1.431 0 CA-C-O 121.586 0.707 . . . . 2.88 109.839 -178.16 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' ILE . . . . . 0.574 ' O ' ' N ' ' A' ' 98' ' ' ASP . 10.6 pt -52.8 150.4 9.86 Favored Pre-proline 0 C--N 1.299 -1.6 0 N-CA-C 108.579 -0.897 . . . . 2.35 108.579 179.634 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.413 ' O ' ' CG ' ' A' ' 98' ' ' ASP . 1.0 OUTLIER -57.48 75.56 0.04 OUTLIER 'Trans proline' 0 C--O 1.214 -0.7 0 C-N-CA 121.146 1.231 . . . . 2.48 109.195 179.362 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.574 ' N ' ' O ' ' A' ' 96' ' ' ILE . 1.9 m-20 -177.62 -59.82 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.485 0 N-CA-C 108.278 -1.008 . . . . 2.65 108.278 -178.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 9.5 m -57.44 138.79 81.13 Favored Pre-proline 0 C--N 1.299 -1.627 0 O-C-N 121.414 -0.804 . . . . 2.0 110.031 -178.216 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_endo -89.78 114.28 2.41 Favored 'Cis proline' 0 N--CA 1.493 1.458 0 N-CA-C 109.707 -0.92 . . . . 1.79 109.707 -2.724 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . 0.446 ' CZ ' ' CG1' ' A' ' 87' ' ' VAL . 15.3 p90 -104.9 170.86 7.63 Favored 'General case' 0 N--CA 1.515 2.79 0 O-C-N 120.425 -1.422 . . . . 2.19 110.01 178.87 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.5 p -95.49 153.79 3.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.602 -0.686 . . . . 1.44 110.095 -179.467 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.498 ' N ' ' O ' ' A' ' 85' ' ' TYR . 69.2 t -128.66 86.37 57.78 Favored Pre-proline 0 N--CA 1.498 1.948 0 N-CA-C 107.868 -1.16 . . . . 1.19 107.868 179.316 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -60.99 113.85 1.91 Allowed 'Trans proline' 0 C--N 1.323 -0.792 0 C-N-CA 121.497 1.465 . . . . 1.49 112.256 -177.56 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 55.3 t -96.1 138.12 22.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 N-CA-C 106.784 -1.561 . . . . 1.35 106.784 177.724 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.549 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -119.0 126.56 52.02 Favored 'General case' 0 N--CA 1.511 2.582 0 N-CA-C 113.161 0.801 . . . . 1.67 113.161 -175.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . 0.638 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 23.8 t -94.84 97.89 10.35 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 120.3 -1.5 . . . . 2.04 107.586 178.09 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 13.7 mt 66.35 -21.04 0.1 Allowed 'General case' 0 C--N 1.289 -2.058 0 N-CA-C 109.22 -0.659 . . . . 3.2 109.22 -178.767 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.596 ' H ' ' C ' ' A' ' 107' ' ' SER . 9.6 t -70.93 -29.17 65.12 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.084 -1.01 . . . . 2.09 108.908 179.027 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . 0.549 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 9.1 m-20 . . . . . 0 N--CA 1.491 1.583 0 N-CA-C 107.874 -1.158 . . . . 2.85 107.874 179.83 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . 0.576 ' CG ' HH11 ' B' ' 8' ' ' ARG . 2.5 mtt-85 . . . . . 0 N--CA 1.489 1.511 0 N-CA-C 108.286 -1.005 . . . . 3.04 108.286 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 9' ' ' VAL . . . . . 0.43 ' O ' ' O ' ' A' ' 57' ' ' GLY . 24.6 t -50.81 158.72 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 N-CA-C 107.785 -1.191 . . . . 0.67 107.785 179.137 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -128.98 149.14 50.94 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.227 -0.921 . . . . 0.58 110.563 -178.585 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 11' ' ' SER . . . . . 0.412 ' CB ' HG23 ' A' ' 55' ' ' VAL . 4.1 t -139.58 146.35 39.73 Favored 'General case' 0 N--CA 1.495 1.789 0 N-CA-C 108.763 -0.829 . . . . 1.19 108.763 179.498 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 42.9 m -147.41 121.91 9.74 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.07 -1.019 . . . . 1.38 109.927 -179.589 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 0.645 HG22 ' N ' ' B' ' 14' ' ' PHE . 7.7 p -169.85 170.52 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 N-CA-C 108.883 -0.784 . . . . 0.42 108.883 179.759 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 14' ' ' PHE . . . . . 0.645 ' N ' HG22 ' B' ' 13' ' ' VAL . 9.1 p90 -176.6 -163.47 0.1 Allowed 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 119.226 -0.99 . . . . 1.79 112.084 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.3 pt -147.49 160.95 8.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 N-CA-C 108.518 -0.919 . . . . 1.25 108.518 179.82 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 17.9 m -131.18 141.73 50.11 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.273 -0.892 . . . . 1.61 109.892 -179.734 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.0 mt . . . . . 0 N--CA 1.498 1.926 0 O-C-N 121.418 -0.802 . . . . 1.32 109.36 179.712 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.988 0 N-CA-C 110.003 -1.239 . . . . 2.44 110.003 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.514 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 95.02 -57.99 1.76 Allowed Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.761 -1.336 . . . . 1.81 109.761 179.707 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.693 ' HB2' ' OE1' ' A' ' 94' ' ' GLU . . . -47.86 -12.32 0.03 OUTLIER 'General case' 0 C--N 1.297 -1.68 0 O-C-N 121.64 -0.917 . . . . 2.21 110.067 -179.121 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' HIS . . . . . 0.514 ' N ' ' O ' ' A' ' 17' ' ' GLY . 29.1 t-80 -98.46 -7.11 29.1 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.245 -0.909 . . . . 2.87 110.684 -178.745 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.498 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.4 OUTLIER -145.98 5.58 1.0 Allowed 'General case' 0 N--CA 1.496 1.851 0 O-C-N 120.854 -1.153 . . . . 2.02 110.252 -179.491 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.577 ' O ' HG13 ' A' ' 21' ' ' VAL . 7.4 p -77.35 115.56 19.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.022 -1.049 . . . . 2.07 108.51 179.116 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 12.7 tpp180 -109.92 139.27 45.2 Favored 'General case' 0 N--CA 1.49 1.574 0 CA-C-O 121.509 0.671 . . . . 3.5 109.566 -178.745 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -148.18 113.27 5.51 Favored 'General case' 0 N--CA 1.491 1.599 0 N-CA-C 108.609 -0.885 . . . . 1.83 108.609 179.424 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -147.85 132.1 4.11 Favored Glycine 0 N--CA 1.495 2.614 0 N-CA-C 109.523 -1.431 . . . . 1.9 109.523 -179.624 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.27 174.13 46.08 Favored Glycine 0 N--CA 1.488 2.115 0 C-N-CA 119.598 -1.287 . . . . 1.85 110.013 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 8.5 p -79.85 -22.04 43.42 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.338 -1.095 . . . . 2.31 108.985 179.479 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -68.67 -16.47 69.94 Favored Glycine 0 N--CA 1.487 2.034 0 N-CA-C 108.62 -1.792 . . . . 1.64 108.62 179.637 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.53 HD21 ' CG ' ' A' ' 39' ' ' PHE . 7.0 mt -93.04 30.28 1.66 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.625 -0.927 . . . . 1.83 108.799 179.783 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 13.5 mt-10 -141.91 -43.44 0.35 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.396 -0.815 . . . . 2.34 109.62 -179.375 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 11.8 ptm180 -175.65 172.11 2.63 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.007 -1.058 . . . . 3.77 109.991 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -150.77 176.51 29.3 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 108.335 -1.906 . . . . 1.57 108.335 179.665 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 39.2 t -134.23 151.54 32.41 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.031 0 O-C-N 121.186 -1.185 . . . . 1.83 110.529 -179.733 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.566 ' HB2' ' HD3' ' A' ' 82' ' ' PRO . . . -44.91 115.47 0.89 Allowed 'General case' 0 N--CA 1.497 1.88 0 CA-C-O 121.869 0.842 . . . . 1.64 112.477 -179.195 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 54.03 50.81 53.7 Favored Glycine 0 N--CA 1.488 2.143 0 N-CA-C 111.245 -0.742 . . . . 1.73 111.245 177.264 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 5.0 t -127.03 127.11 24.41 Favored Pre-proline 0 N--CA 1.496 1.871 0 N-CA-C 108.232 -1.025 . . . . 2.19 108.232 179.14 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -55.51 121.17 9.47 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 N-CA-C 109.918 -0.839 . . . . 1.96 109.918 -179.845 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -128.78 145.42 51.19 Favored 'General case' 0 N--CA 1.497 1.922 0 N-CA-C 108.488 -0.93 . . . . 1.69 108.488 179.736 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -152.16 164.05 38.11 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.995 -1.066 . . . . 2.23 110.765 -179.512 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 0.549 ' CD1' ' N ' ' A' ' 39' ' ' PHE . 0.7 OUTLIER -139.71 178.43 7.24 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 107.007 -1.479 . . . . 1.54 107.007 177.907 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 58.7 m -121.32 141.27 51.08 Favored 'General case' 0 N--CA 1.496 1.857 0 CA-C-O 121.573 0.702 . . . . 2.37 110.382 -178.83 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.508 ' O ' ' N ' ' A' ' 73' ' ' CYS . 68.3 mt -138.14 124.08 25.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 N-CA-C 108.307 -0.997 . . . . 1.65 108.307 179.106 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.556 ' HE1' ' CG ' ' A' ' 44' ' ' ARG . 3.1 t90 -128.08 125.46 39.31 Favored 'General case' 0 N--CA 1.496 1.858 0 N-CA-C 108.615 -0.884 . . . . 3.68 108.615 -179.549 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.498 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -151.21 118.23 5.89 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.321 -0.862 . . . . 2.89 109.269 -179.672 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' ARG . . . . . 0.556 ' CG ' ' HE1' ' A' ' 42' ' ' TRP . 10.6 ptm180 -171.09 72.19 0.05 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.172 -0.955 . . . . 4.63 109.72 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 21.3 tt0 -154.32 -45.19 0.09 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.306 -0.871 . . . . 2.89 109.083 179.579 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.99 -55.66 13.5 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.117 -0.989 . . . . 1.74 109.196 179.686 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 154.96 156.36 7.71 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.608 -1.397 . . . . 1.6 109.608 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.49 156.92 2.29 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.232 -1.158 . . . . 1.4 109.511 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -170.48 -111.34 0.25 Allowed Glycine 0 N--CA 1.488 2.16 0 N-CA-C 108.965 -1.654 . . . . 1.04 108.965 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.544 ' O ' ' N ' ' A' ' 92' ' ' ASN . . . -157.7 161.87 31.68 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.463 -1.455 . . . . 1.06 109.463 179.684 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.458 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 10.2 tp -140.55 97.0 3.12 Favored 'General case' 0 N--CA 1.493 1.703 0 N-CA-C 107.839 -1.171 . . . . 1.1 107.839 179.513 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 13.7 m -87.69 142.81 27.54 Favored 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 108.846 -0.798 . . . . 1.56 108.846 -179.586 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.54 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 6.7 mt -136.71 100.42 2.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.366 -0.834 . . . . 0.65 108.859 179.721 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -98.8 106.42 18.69 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.258 -0.902 . . . . 0.69 108.907 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -97.87 146.14 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 O-C-N 121.434 -0.791 . . . . 0.91 109.33 -179.814 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 35.4 tp10 -141.13 138.04 33.18 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 107.385 -1.339 . . . . 1.8 107.385 178.531 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.532 ' O ' ' N ' ' B' ' 9' ' ' VAL . . . 173.37 -173.0 45.58 Favored Glycine 0 N--CA 1.493 2.44 0 C-N-CA 119.271 -1.442 . . . . 0.49 110.033 -178.72 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -62.76 -35.1 70.54 Favored 'Trans proline' 0 C--N 1.318 -1.038 0 C-N-CA 122.127 1.885 . . . . 0.66 111.568 -179.596 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . 0.421 ' O ' ' OH ' ' A' ' 85' ' ' TYR . 10.7 m -139.57 162.34 35.31 Favored 'General case' 0 N--CA 1.5 2.025 0 O-C-N 121.072 -1.017 . . . . 1.55 110.057 -179.036 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 23.0 mttp -85.29 95.57 9.24 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.435 -0.791 . . . . 2.53 109.495 -179.844 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -50.59 135.32 23.15 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.336 -0.853 . . . . 0.82 109.315 179.83 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.47 ' CD ' ' N ' ' A' ' 62' ' ' GLU . 15.9 mp0 -71.09 85.38 0.73 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.247 -0.908 . . . . 2.3 109.582 -179.873 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 19.2 tt -58.88 150.21 5.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 N-CA-C 108.963 -0.755 . . . . 1.4 108.963 179.611 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.547 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -150.61 114.51 5.02 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 120.691 -1.255 . . . . 1.36 109.744 -179.715 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 17.7 p90 -90.33 125.08 35.41 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.284 -0.885 . . . . 1.47 109.388 179.612 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 . . . . . 0 N--CA 1.496 1.841 0 O-C-N 121.256 -0.902 . . . . 2.51 109.545 -179.893 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 10.6 t . . . . . 0 N--CA 1.494 1.765 0 N-CA-C 108.88 -0.785 . . . . 2.2 108.88 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' CYS . . . . . 0.508 ' N ' ' O ' ' A' ' 41' ' ' ILE . 49.8 t -80.05 104.81 10.87 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.222 -0.924 . . . . 2.05 109.845 -179.451 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -91.82 116.33 4.97 Favored Glycine 0 N--CA 1.493 2.5 0 N-CA-C 109.123 -1.591 . . . . 1.39 109.123 179.65 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 96.4 t -105.82 102.16 13.46 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.135 0 O-C-N 121.486 -1.008 . . . . 1.57 109.684 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.547 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.1 OUTLIER -88.42 130.08 35.26 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.376 -0.828 . . . . 1.85 108.936 179.649 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.426 ' O ' ' CG ' ' A' ' 77' ' ' TYR . 2.8 p90 -132.42 125.48 30.88 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.479 -0.763 . . . . 1.54 109.053 -179.824 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 5.9 t -99.86 103.72 15.14 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.392 -0.817 . . . . 1.9 109.37 -179.478 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 25.9 m -69.77 160.32 5.03 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 O-C-N 121.22 -0.925 . . . . 1.27 109.31 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 24.0 tp60 -100.72 -48.62 4.44 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.235 -0.915 . . . . 2.48 110.586 -179.416 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -155.25 152.77 25.66 Favored Pre-proline 0 N--CA 1.501 2.106 0 O-C-N 120.806 -1.184 . . . . 1.92 110.995 -178.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.617 ' HG3' ' N ' ' A' ' 107' ' ' SER . 75.1 Cg_exo -38.31 163.2 0.02 OUTLIER 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 123.176 2.584 . . . . 1.3 113.659 179.36 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 147.13 -162.36 28.59 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.156 -1.578 . . . . 1.02 109.156 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 33.5 m-20 -111.39 89.78 3.15 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.653 -0.91 . . . . 2.13 108.937 179.761 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.45 ' O ' ' N ' ' A' ' 103' ' ' VAL . 3.3 m-85 -77.64 128.94 34.93 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 108.004 -1.11 . . . . 0.92 108.004 179.687 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -112.63 129.74 56.28 Favored 'General case' 0 N--CA 1.5 2.042 0 N-CA-C 108.406 -0.961 . . . . 1.53 108.406 -179.088 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 8.6 p -124.84 137.63 56.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 CA-C-O 121.486 0.66 . . . . 1.0 110.002 -179.522 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 29.5 t -126.12 103.25 7.61 Favored 'General case' 0 N--CA 1.497 1.907 0 N-CA-C 109.405 -0.591 . . . . 1.59 109.405 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.413 ' H ' ' CB ' ' A' ' 99' ' ' SER . 0.8 OUTLIER -111.18 132.78 58.76 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.023 0 O-C-N 121.519 -0.738 . . . . 1.29 110.226 -179.39 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' LYS . . . . . 0.446 ' HG3' ' H ' ' A' ' 93' ' ' ASP . 0.4 OUTLIER -140.91 127.06 19.56 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.369 -0.832 . . . . 1.58 109.909 179.658 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.443 ' H ' ' HG3' ' A' ' 94' ' ' GLU . 54.5 t80 -82.3 94.39 7.33 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.12 -0.987 . . . . 1.34 108.457 178.855 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . 0.544 ' N ' ' O ' ' A' ' 50' ' ' GLY . 6.7 t30 69.22 37.08 2.19 Favored 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 108.074 -1.084 . . . . 2.32 108.074 -179.017 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.463 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 2.6 m-20 83.4 14.7 0.34 Allowed 'General case' 0 N--CA 1.499 1.981 0 CA-C-N 116.485 -0.325 . . . . 1.92 110.905 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . 0.693 ' OE1' ' HB2' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -91.17 90.83 7.97 Favored 'General case' 0 N--CA 1.496 1.827 0 N-CA-C 106.862 -1.533 . . . . 2.25 106.862 178.119 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' HIS . . . . . 0.509 ' O ' ' CG ' ' A' ' 95' ' ' HIS . 9.0 p80 -68.15 88.8 0.3 Allowed 'General case' 0 C--N 1.299 -1.615 0 O-C-N 119.94 -1.725 . . . . 2.88 110.359 -177.816 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 2.3 tt -48.3 137.13 11.73 Favored Pre-proline 0 N--CA 1.496 1.846 0 N-CA-C 107.635 -1.246 . . . . 2.35 107.635 178.675 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -40.51 -39.55 2.89 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 121.307 1.338 . . . . 2.48 111.747 -178.42 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 18.8 m-20 -49.18 -66.49 0.39 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 120.689 -1.257 . . . . 2.65 109.237 179.356 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.413 ' CB ' ' H ' ' A' ' 89' ' ' ILE . 0.1 OUTLIER -69.31 147.94 97.26 Favored Pre-proline 0 C--N 1.293 -1.875 0 O-C-N 121.151 -0.968 . . . . 2.0 110.067 -178.917 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -84.44 112.02 2.36 Favored 'Cis proline' 0 N--CA 1.491 1.343 0 N-CA-C 109.538 -0.986 . . . . 1.79 109.538 -2.238 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 43.1 p90 -116.21 166.86 11.55 Favored 'General case' 0 N--CA 1.522 3.162 0 O-C-N 120.509 -1.37 . . . . 2.19 110.445 178.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.2 p -95.49 148.19 5.35 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.903 0 CA-C-O 121.752 0.787 . . . . 1.44 111.549 -177.703 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.45 ' N ' ' O ' ' A' ' 85' ' ' TYR . 79.4 t -121.8 86.38 45.59 Favored Pre-proline 0 N--CA 1.498 1.926 0 N-CA-C 108.279 -1.008 . . . . 1.19 108.279 179.238 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_exo -62.81 114.14 2.28 Favored 'Trans proline' 0 C--N 1.319 -1.021 0 C-N-CA 121.351 1.367 . . . . 1.49 112.09 -178.011 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 55.2 t -95.27 144.34 10.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 N-CA-C 106.938 -1.504 . . . . 1.35 106.938 177.865 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.691 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -134.76 136.24 42.47 Favored 'General case' 0 N--CA 1.51 2.536 0 CA-C-O 122.079 0.942 . . . . 1.67 111.748 -177.457 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . 0.617 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 80.6 p -92.17 76.41 5.35 Favored 'General case' 0 N--CA 1.492 1.674 0 N-CA-C 107.472 -1.307 . . . . 2.04 107.472 179.278 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 23.6 mt 61.72 6.36 1.57 Allowed 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 107.103 -1.443 . . . . 3.2 107.103 -177.735 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.497 ' H ' ' C ' ' A' ' 107' ' ' SER . 14.0 t -92.27 -20.83 20.73 Favored 'General case' 0 N--CA 1.486 1.338 0 N-CA-C 109.205 -0.665 . . . . 2.09 109.205 179.588 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . 0.691 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 2.6 p30 . . . . . 0 N--CA 1.498 1.939 0 N-CA-C 108.417 -0.957 . . . . 2.85 108.417 -179.052 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . 0.412 ' NH1' ' HG3' ' B' ' 8' ' ' ARG . 23.4 mtm-85 . . . . . 0 N--CA 1.489 1.503 0 N-CA-C 108.287 -1.005 . . . . 3.04 108.287 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 9' ' ' VAL . . . . . 0.532 ' N ' ' O ' ' A' ' 57' ' ' GLY . 0.4 OUTLIER -122.48 170.85 12.22 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.069 0 N-CA-C 108.139 -1.06 . . . . 0.67 108.139 178.989 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 0.436 ' N ' HG13 ' B' ' 9' ' ' VAL . . . -114.81 136.24 53.31 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.717 -0.615 . . . . 0.58 110.07 -179.41 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 9.4 m -149.28 82.88 1.43 Allowed 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.376 -0.828 . . . . 1.19 109.44 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 12.8 t -101.04 116.72 33.52 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.363 -0.836 . . . . 1.38 109.434 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 0.579 HG22 ' N ' ' B' ' 14' ' ' PHE . 3.2 p -156.66 164.45 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.265 -0.897 . . . . 0.42 109.177 179.823 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 14' ' ' PHE . . . . . 0.579 ' N ' HG22 ' B' ' 13' ' ' VAL . 6.5 p90 -178.99 -164.7 0.07 Allowed 'General case' 0 N--CA 1.49 1.555 0 CA-C-O 122.1 0.953 . . . . 1.79 111.924 179.575 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.875 ' N ' HD13 ' B' ' 15' ' ' ILE . 0.1 OUTLIER -145.72 155.49 13.0 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.094 0 N-CA-C 108.635 -0.876 . . . . 1.25 108.635 179.811 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 16' ' ' THR . . . . . 0.478 HG22 ' N ' ' B' ' 17' ' ' LEU . 97.0 m -109.11 158.9 17.33 Favored 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.214 -0.929 . . . . 1.61 109.781 -179.799 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.478 ' N ' HG22 ' B' ' 16' ' ' THR . 34.3 mt . . . . . 0 N--CA 1.499 2.019 0 O-C-N 121.475 -0.766 . . . . 1.32 109.167 179.821 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.214 0 N-CA-C 110.735 -0.946 . . . . 2.44 110.735 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.559 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -67.71 -6.18 41.9 Favored Glycine 0 N--CA 1.491 2.338 0 O-C-N 121.42 -1.047 . . . . 1.81 111.063 -178.855 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.426 ' HB2' ' HB2' ' A' ' 94' ' ' GLU . . . -47.94 -11.99 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.465 -1.609 . . . . 2.21 109.452 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' HIS . . . . . 0.559 ' N ' ' O ' ' A' ' 17' ' ' GLY . 39.7 t-80 -96.92 -41.73 8.27 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.203 -0.935 . . . . 2.87 109.729 179.577 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.77 -24.43 41.52 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 120.92 -1.112 . . . . 2.02 109.95 -179.64 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.533 ' O ' HG13 ' A' ' 21' ' ' VAL . 4.1 p -68.07 115.27 5.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 120.924 -1.11 . . . . 2.07 108.927 179.87 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 12.0 tpp180 -98.07 136.05 38.88 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.625 -0.672 . . . . 3.5 109.445 -179.155 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -147.55 113.42 5.76 Favored 'General case' 0 N--CA 1.492 1.639 0 N-CA-C 108.69 -0.855 . . . . 1.83 108.69 179.486 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -162.62 136.5 4.36 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.584 -1.406 . . . . 1.9 109.584 -179.579 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.1 173.7 46.16 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.667 -1.373 . . . . 1.85 109.667 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 19.1 m -77.19 -18.43 57.77 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.352 -1.087 . . . . 2.31 109.604 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -73.34 -20.26 79.85 Favored Glycine 0 N--CA 1.487 2.05 0 N-CA-C 109.304 -1.518 . . . . 1.64 109.304 -179.884 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.572 HD21 ' CD2' ' A' ' 39' ' ' PHE . 55.7 mt -88.8 -13.97 38.14 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.433 -1.039 . . . . 1.83 109.341 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 56.9 mt-10 -84.06 -62.74 1.49 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.292 -0.88 . . . . 2.34 110.053 -179.519 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 79.3 mtt180 -149.0 165.2 32.34 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.014 -1.054 . . . . 3.77 110.342 -179.589 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -142.5 169.6 25.43 Favored Glycine 0 N--CA 1.495 2.591 0 N-CA-C 107.708 -2.157 . . . . 1.57 107.708 179.019 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 40.9 t -134.04 150.57 31.4 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.202 0 O-C-N 121.051 -1.264 . . . . 1.83 110.971 -179.326 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -37.5 113.1 0.24 Allowed 'General case' 0 N--CA 1.501 2.08 0 CA-C-O 121.809 0.814 . . . . 1.64 112.242 -179.533 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 52.29 50.54 46.36 Favored Glycine 0 N--CA 1.488 2.124 0 N-CA-C 111.244 -0.743 . . . . 1.73 111.244 177.162 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 24.1 t -126.6 103.3 25.05 Favored Pre-proline 0 N--CA 1.494 1.757 0 N-CA-C 108.061 -1.088 . . . . 2.19 108.061 178.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -55.69 139.83 83.66 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 120.749 0.966 . . . . 1.96 110.574 -178.713 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.479 ' HB3' ' CE1' ' A' ' 77' ' ' TYR . . . -146.97 175.04 10.97 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.449 -0.782 . . . . 1.69 109.458 -179.923 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -154.52 165.37 36.67 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.958 -1.089 . . . . 2.23 111.297 -179.378 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 0.572 ' CD2' HD21 ' A' ' 28' ' ' LEU . 0.7 OUTLIER -143.43 -174.25 4.17 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 107.066 -1.457 . . . . 1.54 107.066 177.464 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 44.7 m -120.63 151.58 39.28 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 121.238 -0.914 . . . . 2.37 111.512 -177.937 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 85.5 mt -141.97 91.68 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 N-CA-C 108.332 -0.988 . . . . 1.65 108.332 178.531 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.414 ' CD1' ' N ' ' A' ' 43' ' ' THR . 9.6 t90 -96.02 141.03 29.91 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.165 -0.959 . . . . 3.68 108.69 179.887 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.414 ' N ' ' CD1' ' A' ' 42' ' ' TRP . 0.0 OUTLIER -161.83 130.26 4.26 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.247 -0.908 . . . . 2.89 109.748 -179.577 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' ARG . . . . . . . . . . . . . 66.6 ttt180 -172.02 77.33 0.05 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.324 -0.86 . . . . 4.63 109.728 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 6.8 tp10 -165.18 -55.26 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.099 -1.001 . . . . 2.89 109.735 179.631 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -58.33 -58.66 7.49 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.125 -0.984 . . . . 1.74 109.018 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 142.27 -160.53 27.24 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.231 -1.548 . . . . 1.6 109.231 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -64.28 163.79 12.28 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.288 -1.125 . . . . 1.4 109.38 179.717 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 174.29 178.79 44.46 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.724 -1.351 . . . . 1.04 109.724 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -117.12 125.47 6.54 Favored Glycine 0 N--CA 1.499 2.856 0 N-CA-C 109.682 -1.367 . . . . 1.06 109.682 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.458 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 11.8 tp -99.53 101.17 12.31 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.283 -1.128 . . . . 1.1 108.642 179.63 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 19.1 m -88.79 140.51 29.37 Favored 'General case' 0 N--CA 1.493 1.694 0 N-CA-C 108.696 -0.854 . . . . 1.56 108.696 179.854 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.514 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 90.8 mt -132.28 108.03 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 O-C-N 121.288 -0.883 . . . . 0.65 109.347 -179.819 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -98.63 106.35 18.61 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.304 -0.872 . . . . 0.69 108.928 179.706 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.429 HG23 ' OG ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -99.34 141.94 15.89 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.53 -0.731 . . . . 0.91 109.408 -179.826 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 10.1 tt0 -141.97 143.92 33.45 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.279 -1.008 . . . . 1.8 108.279 178.793 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 165.55 -174.12 41.29 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.614 -1.394 . . . . 0.49 109.614 -179.289 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -58.18 -26.34 75.76 Favored 'Trans proline' 0 C--N 1.317 -1.122 0 C-N-CA 121.998 1.799 . . . . 0.66 111.971 -179.513 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 2.1 m -143.61 170.62 15.49 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.063 -1.023 . . . . 1.55 110.291 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 29.1 mtpt -90.31 100.28 13.14 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.387 -0.82 . . . . 2.53 109.373 -179.878 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -63.38 142.82 58.25 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.182 -0.949 . . . . 0.82 109.603 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 24.9 tt0 -80.66 172.0 14.31 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.283 -0.886 . . . . 2.3 109.281 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 14.0 mt -149.65 141.31 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.906 0 N-CA-C 108.006 -1.109 . . . . 1.4 108.006 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -150.67 112.47 4.51 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 120.449 -1.407 . . . . 1.36 110.251 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.519 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 51.3 p90 -85.92 123.51 31.35 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.562 -0.711 . . . . 1.47 110.205 179.795 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 42.8 tt0 . . . . . 0 N--CA 1.494 1.763 0 O-C-N 121.488 -0.757 . . . . 2.51 109.056 179.555 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 14.0 m . . . . . 0 N--CA 1.495 1.775 0 N-CA-C 109.271 -0.641 . . . . 2.2 109.271 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 11.3 t -82.48 120.29 25.3 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.217 -0.927 . . . . 2.05 109.463 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -99.51 117.22 5.8 Favored Glycine 0 N--CA 1.496 2.694 0 N-CA-C 109.657 -1.377 . . . . 1.39 109.657 -179.832 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -105.32 105.11 18.04 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.075 0 O-C-N 121.54 -0.977 . . . . 1.57 109.647 179.85 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 3.9 t -84.14 124.8 31.53 Favored 'General case' 0 N--CA 1.485 1.31 0 N-CA-C 108.148 -1.056 . . . . 1.85 108.148 178.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.479 ' CE1' ' HB3' ' A' ' 37' ' ' ALA . 1.9 p90 -123.0 171.84 8.95 Favored 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 108.57 -0.9 . . . . 1.54 108.57 -179.078 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 41.4 t -141.79 141.67 29.28 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.929 0 O-C-N 121.169 -0.957 . . . . 1.9 109.804 -179.581 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 30.7 m -109.53 150.69 12.07 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.095 0 O-C-N 121.439 -0.788 . . . . 1.27 109.254 179.646 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 6.6 tp-100 -96.7 -45.27 6.75 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.219 -0.925 . . . . 2.48 110.305 -179.717 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -159.28 152.33 18.39 Favored Pre-proline 0 N--CA 1.502 2.161 0 O-C-N 120.768 -1.208 . . . . 1.92 110.857 -179.26 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.686 ' HG3' ' N ' ' A' ' 107' ' ' SER . 85.5 Cg_exo -37.54 158.55 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 123.248 2.632 . . . . 1.3 113.369 179.032 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 147.92 166.99 13.08 Favored Glycine 0 N--CA 1.488 2.109 0 N-CA-C 109.477 -1.449 . . . . 1.02 109.477 179.823 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . 0.887 ' H ' HH12 ' B' ' 8' ' ' ARG . 66.9 m-20 -87.65 84.55 7.08 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 107.666 -1.235 . . . . 2.13 107.666 179.117 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -69.93 134.16 48.09 Favored 'General case' 0 C--N 1.297 -1.709 0 N-CA-C 107.966 -1.124 . . . . 0.92 107.966 -179.526 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . 0.419 ' OE1' ' O ' ' A' ' 84' ' ' ASP . 0.0 OUTLIER -112.27 127.63 56.03 Favored 'General case' 0 N--CA 1.501 2.105 0 N-CA-C 108.667 -0.864 . . . . 1.53 108.667 -179.413 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 9.6 p -123.88 141.06 45.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.712 -0.618 . . . . 1.0 109.794 -179.633 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 3.8 m -130.29 97.82 4.53 Favored 'General case' 0 N--CA 1.498 1.952 0 CA-C-O 121.539 0.685 . . . . 1.59 109.38 179.781 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.413 ' H ' ' HB3' ' A' ' 99' ' ' SER . 1.6 pt -104.88 133.32 49.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 CA-C-O 121.471 0.653 . . . . 1.29 109.846 -179.741 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' LYS . . . . . 0.458 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -144.42 127.39 16.45 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 108.027 -1.101 . . . . 1.58 108.027 179.946 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.421 ' O ' ' CB ' ' A' ' 92' ' ' ASN . 76.5 t80 -85.47 102.22 13.29 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.63 -1.294 . . . . 1.34 108.462 179.16 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . 0.431 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 13.0 t30 72.38 33.87 1.41 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.068 -1.02 . . . . 2.32 108.748 -178.679 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.431 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 0.8 OUTLIER 80.21 14.04 0.87 Allowed 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.891 -0.505 . . . . 1.92 111.698 179.509 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . 0.462 ' CG ' ' O ' ' A' ' 94' ' ' GLU . 5.0 pt-20 -99.84 94.44 6.32 Favored 'General case' 0 N--CA 1.495 1.806 0 N-CA-C 107.029 -1.471 . . . . 2.25 107.029 177.573 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' HIS . . . . . 0.618 ' H ' ' CD2' ' A' ' 95' ' ' HIS . 7.0 p80 -74.7 112.41 10.87 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-O 121.542 0.687 . . . . 2.88 110.281 -178.071 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' ILE . . . . . 0.796 ' H ' HD13 ' A' ' 96' ' ' ILE . 0.0 OUTLIER -60.49 155.76 46.83 Favored Pre-proline 0 N--CA 1.497 1.918 0 N-CA-C 107.257 -1.386 . . . . 2.35 107.257 178.994 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -49.47 -25.78 11.12 Favored 'Trans proline' 0 C--N 1.321 -0.879 0 N-CA-C 108.968 -1.204 . . . . 2.48 108.968 179.847 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.471 ' N ' ' OD1' ' A' ' 98' ' ' ASP . 0.9 OUTLIER -59.52 -64.69 0.85 Allowed 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 108.873 -0.788 . . . . 2.65 108.873 178.852 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.413 ' HB3' ' H ' ' A' ' 89' ' ' ILE . 2.4 p -66.83 141.01 96.52 Favored Pre-proline 0 C--N 1.297 -1.7 0 O-C-N 121.308 -0.87 . . . . 2.0 110.04 -178.42 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -85.91 116.99 4.11 Favored 'Cis proline' 0 N--CA 1.492 1.405 0 N-CA-C 109.563 -0.976 . . . . 1.79 109.563 -2.389 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 53.3 p90 -117.03 163.62 15.96 Favored 'General case' 0 N--CA 1.518 2.945 0 O-C-N 120.532 -1.355 . . . . 2.19 110.003 178.687 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.5 p -93.23 152.89 3.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 CA-C-O 121.666 0.746 . . . . 1.44 111.008 -178.144 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 65.1 t -125.92 86.84 57.04 Favored Pre-proline 0 N--CA 1.497 1.888 0 N-CA-C 107.917 -1.142 . . . . 1.19 107.917 179.024 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -63.71 113.29 2.08 Favored 'Trans proline' 0 C--N 1.319 -0.999 0 C-N-CA 121.418 1.412 . . . . 1.49 112.264 -177.743 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 54.3 t -97.72 142.18 14.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 N-CA-C 106.302 -1.74 . . . . 1.35 106.302 177.496 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.661 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -130.23 132.84 46.15 Favored 'General case' 0 N--CA 1.511 2.606 0 CA-C-O 122.109 0.956 . . . . 1.67 111.82 -177.18 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . 0.686 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 36.3 p -94.98 90.91 6.14 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.759 -1.213 . . . . 2.04 107.748 179.577 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' LEU . . . . . 0.569 HD12 ' N ' ' A' ' 108' ' ' LEU . 8.0 mp 54.65 10.49 0.36 Allowed 'General case' 0 C--N 1.294 -1.816 0 N-CA-C 107.848 -1.167 . . . . 3.2 107.848 -178.2 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.482 ' N ' ' C ' ' A' ' 107' ' ' SER . 9.0 t -98.88 -27.09 14.06 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 109.255 -0.646 . . . . 2.09 109.255 179.712 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . 0.661 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 1.8 m-20 . . . . . 0 N--CA 1.489 1.483 0 N-CA-C 107.941 -1.133 . . . . 2.85 107.941 -179.275 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . 0.887 HH12 ' H ' ' A' ' 84' ' ' ASP . 5.8 mtt180 . . . . . 0 N--CA 1.494 1.767 0 N-CA-C 108.638 -0.875 . . . . 3.04 108.638 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 9' ' ' VAL . . . . . . . . . . . . . 17.1 t -53.8 159.55 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 108.017 -1.105 . . . . 0.67 108.017 179.307 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -123.18 150.28 43.55 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.464 -0.773 . . . . 0.58 110.002 -179.115 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 11' ' ' SER . . . . . 0.429 ' OG ' HG23 ' A' ' 55' ' ' VAL . 4.2 t -144.57 139.54 28.21 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.454 -0.779 . . . . 1.19 109.017 179.695 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 16.7 m -140.4 116.03 10.17 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.328 -0.857 . . . . 1.38 109.465 -179.714 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 0.579 HG22 ' N ' ' B' ' 14' ' ' PHE . 2.9 p -160.15 166.29 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 O-C-N 121.34 -0.85 . . . . 0.42 109.234 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 14' ' ' PHE . . . . . 0.579 ' N ' HG22 ' B' ' 13' ' ' VAL . 7.4 p90 -177.54 -165.85 0.12 Allowed 'General case' 0 N--CA 1.487 1.425 0 CA-C-O 122.108 0.956 . . . . 1.79 112.083 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.7 pt -149.51 169.92 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.318 0 N-CA-C 108.387 -0.968 . . . . 1.25 108.387 179.851 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 65.9 p -135.54 128.64 31.68 Favored 'General case' 0 N--CA 1.5 2.049 0 O-C-N 121.184 -0.947 . . . . 1.61 109.784 -179.803 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.6 mt . . . . . 0 N--CA 1.492 1.671 0 O-C-N 121.349 -0.844 . . . . 1.32 109.167 179.651 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.404 ' O ' ' CB ' ' A' ' 94' ' ' GLU . . . . . . . . 0 N--CA 1.489 2.224 0 N-CA-C 110.912 -0.875 . . . . 2.44 110.912 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.531 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 71.35 -53.94 1.14 Allowed Glycine 0 N--CA 1.491 2.351 0 N-CA-C 110.416 -1.073 . . . . 1.81 110.416 179.066 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.461 ' HB2' ' OE1' ' A' ' 94' ' ' GLU . . . -46.79 -12.53 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.543 -0.975 . . . . 2.21 110.14 -179.439 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' HIS . . . . . 0.531 ' N ' ' O ' ' A' ' 17' ' ' GLY . 10.0 t-80 -89.77 -42.79 11.09 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.123 -0.985 . . . . 2.87 110.299 -179.168 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.84 -9.08 38.57 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 120.928 -1.108 . . . . 2.02 110.682 -179.006 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 74.2 t -83.4 112.14 20.54 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 120.865 -1.147 . . . . 2.07 110.3 -179.383 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 20.9 tpt180 -103.07 139.91 38.0 Favored 'General case' 0 N--CA 1.491 1.615 0 N-CA-C 108.06 -1.089 . . . . 3.5 108.06 179.042 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -140.02 113.3 8.39 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.263 -0.898 . . . . 1.83 109.648 -179.599 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -155.78 130.59 2.8 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 109.352 -1.499 . . . . 1.9 109.352 179.71 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.3 167.14 37.57 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.816 -1.314 . . . . 1.85 109.816 -179.856 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 17.6 m -74.1 -28.16 61.23 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.297 -1.119 . . . . 2.31 109.486 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.6 -22.9 78.02 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 109.085 -1.606 . . . . 1.64 109.085 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 20.8 mt -77.0 -10.21 59.21 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.446 -1.032 . . . . 1.83 108.963 179.689 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 59.4 mt-10 -90.15 -51.91 5.22 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.372 -0.83 . . . . 2.34 109.478 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . 0.411 ' NH1' ' HG2' ' A' ' 30' ' ' ARG . 0.0 OUTLIER -169.05 -168.69 0.87 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.035 -1.04 . . . . 3.77 109.993 -179.992 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -153.92 178.76 30.65 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 108.508 -1.837 . . . . 1.57 108.508 179.876 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 42.0 t -134.37 151.09 31.42 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.041 0 O-C-N 121.165 -1.197 . . . . 1.83 110.635 -179.618 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.522 ' HB2' ' HB3' ' A' ' 107' ' ' SER . . . -38.79 111.68 0.19 Allowed 'General case' 0 N--CA 1.5 2.062 0 CA-C-O 121.544 0.688 . . . . 1.64 112.39 -179.154 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 53.43 51.42 47.8 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 111.302 -0.719 . . . . 1.73 111.302 176.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 31.4 t -127.59 103.04 22.32 Favored Pre-proline 0 N--CA 1.495 1.78 0 O-C-N 121.513 -0.993 . . . . 2.19 109.016 179.203 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -58.55 133.07 52.03 Favored 'Trans proline' 0 C--O 1.215 -0.636 0 N-CA-C 109.51 -0.996 . . . . 1.96 109.51 -179.88 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.405 ' HB3' ' CZ ' ' A' ' 77' ' ' TYR . . . -142.18 -169.62 2.98 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.338 -0.851 . . . . 1.69 108.803 -179.825 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -169.45 165.23 10.54 Favored 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 118.931 -1.107 . . . . 2.23 111.228 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 0.57 ' CD1' ' N ' ' A' ' 39' ' ' PHE . 0.7 OUTLIER -138.32 -176.28 4.4 Favored 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 106.758 -1.571 . . . . 1.54 106.758 178.033 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 43.8 t -122.28 147.12 46.62 Favored 'General case' 0 N--CA 1.498 1.969 0 CA-C-O 121.596 0.712 . . . . 2.37 110.298 -179.103 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 49.6 mt -142.73 97.24 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 N-CA-C 107.986 -1.116 . . . . 1.65 107.986 179.033 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.46 ' CD1' ' C ' ' A' ' 42' ' ' TRP . 0.4 OUTLIER -86.68 144.96 26.88 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.355 -0.841 . . . . 3.68 108.864 -179.493 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.534 ' OG1' ' N ' ' A' ' 44' ' ' ARG . 1.7 t -168.16 -124.85 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.322 -0.861 . . . . 2.89 109.355 -179.898 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' ARG . . . . . 0.534 ' N ' ' OG1' ' A' ' 43' ' ' THR . 61.2 ttt180 57.62 77.67 0.27 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.277 -0.889 . . . . 4.63 109.754 179.804 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 26.1 tt0 -160.62 -45.93 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.289 -0.882 . . . . 2.89 109.127 179.642 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -61.82 -56.16 22.33 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.257 -0.902 . . . . 1.74 109.1 179.658 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 155.64 178.27 29.69 Favored Glycine 0 N--CA 1.489 2.167 0 N-CA-C 109.459 -1.457 . . . . 1.6 109.459 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.7 145.01 16.46 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.173 -1.192 . . . . 1.4 109.152 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -164.33 -164.24 19.13 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.667 -1.373 . . . . 1.04 109.667 -179.828 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -137.97 116.57 1.34 Allowed Glycine 0 N--CA 1.496 2.69 0 N-CA-C 109.546 -1.422 . . . . 1.06 109.546 -179.828 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.464 HD12 ' O ' ' A' ' 90' ' ' LYS . 64.3 tp -91.57 109.39 20.69 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.274 -1.133 . . . . 1.1 108.422 179.383 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 28.3 m -92.96 141.61 28.22 Favored 'General case' 0 N--CA 1.498 1.969 0 N-CA-C 108.598 -0.89 . . . . 1.56 108.598 179.616 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.581 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 93.9 mt -134.34 116.99 23.35 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.945 0 O-C-N 121.165 -0.959 . . . . 0.65 110.148 -179.304 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -107.47 109.66 21.41 Favored 'General case' 0 N--CA 1.495 1.799 0 N-CA-C 108.133 -1.062 . . . . 0.69 108.133 178.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -101.41 143.19 14.8 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.43 -0.794 . . . . 0.91 110.228 -178.862 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 23.4 tp10 -139.02 143.12 38.31 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 106.765 -1.569 . . . . 1.8 106.765 178.396 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.433 ' O ' ' N ' ' B' ' 9' ' ' VAL . . . 171.68 -173.98 45.07 Favored Glycine 0 N--CA 1.491 2.301 0 C-N-CA 119.131 -1.509 . . . . 0.49 109.654 -178.667 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -64.96 -32.68 53.92 Favored 'Trans proline' 0 C--N 1.316 -1.183 0 C-N-CA 121.748 1.632 . . . . 0.66 110.317 179.811 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . 0.413 ' O ' ' OH ' ' A' ' 85' ' ' TYR . 58.4 m -137.86 158.89 43.42 Favored 'General case' 0 N--CA 1.5 2.035 0 O-C-N 121.319 -0.863 . . . . 1.55 109.931 -179.323 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 34.5 mttp -76.03 93.14 3.24 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.363 -0.836 . . . . 2.53 109.483 -179.842 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -63.89 136.42 57.36 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.278 -0.888 . . . . 0.82 109.426 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.537 ' C ' HD12 ' A' ' 63' ' ' ILE . 55.1 mm-40 -79.49 172.54 13.65 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.126 -0.984 . . . . 2.3 109.539 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.537 HD12 ' C ' ' A' ' 62' ' ' GLU . 4.4 mp -140.22 151.01 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 N-CA-C 108.325 -0.991 . . . . 1.4 108.325 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -151.04 120.02 6.67 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 120.603 -1.31 . . . . 1.36 109.468 -179.712 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 54.4 p90 -86.19 139.13 31.34 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.276 -0.89 . . . . 1.47 109.764 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.487 ' N ' ' O ' ' A' ' 74' ' ' GLY . 43.7 tt0 . . . . . 0 N--CA 1.496 1.846 0 O-C-N 121.395 -0.816 . . . . 2.51 109.149 179.886 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 9.6 t . . . . . 0 N--CA 1.496 1.834 0 N-CA-C 109.107 -0.701 . . . . 2.2 109.107 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 10.4 t -78.06 153.12 32.56 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.248 -0.908 . . . . 2.05 109.438 -179.858 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.487 ' O ' ' N ' ' A' ' 66' ' ' GLU . . . -126.45 111.95 1.51 Allowed Glycine 0 N--CA 1.498 2.793 0 N-CA-C 109.352 -1.499 . . . . 1.39 109.352 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 27.4 t -100.52 99.93 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.011 0 O-C-N 121.56 -0.965 . . . . 1.57 109.399 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -84.79 165.3 17.89 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 108.293 -1.003 . . . . 1.85 108.293 179.399 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.405 ' CZ ' ' HB3' ' A' ' 37' ' ' ALA . 12.5 p90 -165.36 169.9 15.24 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.275 -0.891 . . . . 1.54 109.238 -179.329 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.577 ' O ' HG13 ' A' ' 78' ' ' VAL . 5.0 p -142.18 116.32 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.215 0 O-C-N 121.122 -0.986 . . . . 1.9 110.211 179.35 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.511 HG11 HG21 ' A' ' 105' ' ' VAL . 6.5 m -89.97 153.3 3.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.276 -0.89 . . . . 1.27 108.863 179.708 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . 0.407 ' O ' ' OE2' ' A' ' 81' ' ' GLU . 20.6 tt0 -94.57 -48.02 6.28 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.994 -1.066 . . . . 2.48 110.84 -178.892 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.407 ' OE2' ' O ' ' A' ' 80' ' ' GLN . 78.3 mm-40 -153.88 150.05 22.09 Favored Pre-proline 0 N--CA 1.503 2.198 0 O-C-N 120.613 -1.304 . . . . 1.92 111.218 -178.455 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.669 ' HG3' ' N ' ' A' ' 107' ' ' SER . 87.8 Cg_exo -36.76 157.9 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.944 2.429 . . . . 1.3 113.368 178.24 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 150.07 -156.92 26.98 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 108.893 -1.683 . . . . 1.02 108.893 -179.911 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 37.5 m-20 -116.38 92.4 3.87 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.52 -0.988 . . . . 2.13 109.408 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.53 ' O ' ' N ' ' A' ' 103' ' ' VAL . 2.7 m-85 -78.98 129.76 34.82 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 107.977 -1.12 . . . . 0.92 107.977 179.343 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.37 128.41 56.45 Favored 'General case' 0 N--CA 1.502 2.131 0 N-CA-C 108.675 -0.861 . . . . 1.53 108.675 -178.847 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 6.3 p -126.6 138.53 54.46 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.681 -0.637 . . . . 1.0 109.928 -179.667 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . 0.407 ' O ' ' OG ' ' A' ' 88' ' ' SER . 44.7 p -127.83 96.69 4.58 Favored 'General case' 0 N--CA 1.499 1.987 0 N-CA-C 109.358 -0.608 . . . . 1.59 109.358 179.792 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.421 HD11 ' CD1' ' A' ' 96' ' ' ILE . 1.0 OUTLIER -106.3 134.78 46.91 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 CA-C-O 121.479 0.657 . . . . 1.29 109.938 -179.469 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' LYS . . . . . 0.464 ' O ' HD12 ' A' ' 51' ' ' LEU . 0.0 OUTLIER -142.97 123.72 14.18 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.454 -0.779 . . . . 1.58 109.073 -179.882 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 57.2 t80 -80.05 101.11 8.51 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.011 -1.056 . . . . 1.34 108.199 178.661 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . 0.411 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 16.8 t-20 69.2 37.68 2.07 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.13 -0.982 . . . . 2.32 109.149 -179.014 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.411 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 1.5 m-20 77.87 14.87 1.57 Allowed 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.836 -0.54 . . . . 1.92 111.928 179.337 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . 0.493 ' O ' ' OE1' ' A' ' 94' ' ' GLU . 0.3 OUTLIER -100.6 99.81 10.44 Favored 'General case' 0 N--CA 1.501 2.106 0 N-CA-C 107.462 -1.31 . . . . 2.25 107.462 177.707 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 29.9 m-70 -70.16 105.12 2.82 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.553 -0.717 . . . . 2.88 109.779 -178.613 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' ILE . . . . . 0.639 ' O ' ' N ' ' A' ' 98' ' ' ASP . 9.9 pt -51.21 152.9 3.75 Favored Pre-proline 0 N--CA 1.493 1.681 0 N-CA-C 108.587 -0.894 . . . . 2.35 108.587 179.667 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -59.1 61.74 0.06 OUTLIER 'Trans proline' 0 N--CA 1.484 0.945 0 C-N-CA 121.457 1.438 . . . . 2.48 109.582 179.255 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.639 ' N ' ' O ' ' A' ' 96' ' ' ILE . 31.4 m-20 -162.17 -58.42 0.05 OUTLIER 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 108.386 -0.968 . . . . 2.65 108.386 -179.536 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 1.1 t -65.43 141.31 97.98 Favored Pre-proline 0 C--N 1.297 -1.705 0 C-N-CA 119.868 -0.733 . . . . 2.0 110.085 -177.895 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -85.99 114.56 3.03 Favored 'Cis proline' 0 N--CA 1.492 1.396 0 N-CA-C 109.585 -0.967 . . . . 1.79 109.585 -2.103 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 46.4 p90 -110.32 160.27 16.7 Favored 'General case' 0 N--CA 1.517 2.896 0 O-C-N 120.501 -1.375 . . . . 2.19 110.261 178.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.3 p -92.62 148.98 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 CA-C-O 121.517 0.675 . . . . 1.44 110.206 -179.152 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.53 ' N ' ' O ' ' A' ' 85' ' ' TYR . 70.8 t -124.11 85.6 54.62 Favored Pre-proline 0 N--CA 1.498 1.946 0 N-CA-C 107.858 -1.164 . . . . 1.19 107.858 179.511 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -63.45 113.08 1.94 Allowed 'Trans proline' 0 C--N 1.32 -0.968 0 C-N-CA 121.339 1.359 . . . . 1.49 112.021 -177.605 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.511 HG21 HG11 ' A' ' 79' ' ' VAL . 54.1 t -90.22 143.97 10.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 N-CA-C 106.682 -1.599 . . . . 1.35 106.682 177.71 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.686 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -131.78 130.29 41.65 Favored 'General case' 0 N--CA 1.508 2.462 0 O-C-N 121.217 -0.927 . . . . 1.67 111.629 -177.167 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . 0.669 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 60.3 p -95.45 90.61 5.84 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.71 -1.244 . . . . 2.04 107.873 179.36 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' LEU . . . . . 0.553 HD12 ' N ' ' A' ' 108' ' ' LEU . 9.2 mp 54.83 10.38 0.37 Allowed 'General case' 0 C--N 1.295 -1.774 0 N-CA-C 107.949 -1.13 . . . . 3.2 107.949 -178.434 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.483 ' H ' ' C ' ' A' ' 107' ' ' SER . 50.4 p -100.24 -24.97 14.41 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 109.32 -0.622 . . . . 2.09 109.32 179.563 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . 0.686 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 15.9 t70 . . . . . 0 N--CA 1.493 1.684 0 O-C-N 121.079 -1.013 . . . . 2.85 108.392 -179.604 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . 0.609 ' CG ' HH11 ' B' ' 8' ' ' ARG . 0.3 OUTLIER . . . . . 0 N--CA 1.494 1.766 0 N-CA-C 107.833 -1.173 . . . . 3.04 107.833 . . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 9' ' ' VAL . . . . . 0.433 ' N ' ' O ' ' A' ' 57' ' ' GLY . 0.5 OUTLIER -176.23 168.83 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 N-CA-C 107.612 -1.255 . . . . 0.67 107.612 177.936 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 0.422 ' N ' HG13 ' B' ' 9' ' ' VAL . . . -120.81 136.01 55.01 Favored 'General case' 0 N--CA 1.502 2.133 0 CA-C-O 121.487 0.66 . . . . 0.58 110.514 -178.971 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 18.4 m -149.65 138.45 21.0 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.468 -0.77 . . . . 1.19 109.265 179.395 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 27.8 p -145.94 126.08 13.79 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.089 -1.007 . . . . 1.38 109.984 -179.682 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 0.645 HG22 ' N ' ' B' ' 14' ' ' PHE . 6.8 p -167.11 170.81 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 N-CA-C 108.678 -0.86 . . . . 0.42 108.678 179.735 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 14' ' ' PHE . . . . . 0.883 ' O ' HD13 ' B' ' 15' ' ' ILE . 6.4 p90 -177.03 -171.45 0.36 Allowed 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 119.046 -1.061 . . . . 1.79 112.458 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.883 HD13 ' O ' ' B' ' 14' ' ' PHE . 4.0 mm -142.96 172.45 7.77 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 N-CA-C 108.213 -1.032 . . . . 1.25 108.213 179.85 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 16' ' ' THR . . . . . 0.419 ' H ' HG22 ' B' ' 15' ' ' ILE . 0.1 OUTLIER -144.05 144.58 31.7 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 120.89 -1.131 . . . . 1.61 109.567 179.645 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 21.7 mt . . . . . 0 N--CA 1.498 1.964 0 O-C-N 121.26 -0.9 . . . . 1.32 109.589 -179.886 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.438 ' O ' ' N ' ' A' ' 18' ' ' ALA . . . . . . . . 0 N--CA 1.489 2.232 0 N-CA-C 111.095 -0.802 . . . . 2.44 111.095 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.562 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 68.73 -53.63 0.51 Allowed Glycine 0 N--CA 1.492 2.405 0 O-C-N 121.499 -1.0 . . . . 1.81 110.668 178.733 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.67 ' HB2' ' OE1' ' A' ' 94' ' ' GLU . . . -42.66 -16.3 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.882 -0.775 . . . . 2.21 110.673 -178.598 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' HIS . . . . . 0.562 ' N ' ' O ' ' A' ' 17' ' ' GLY . 10.8 t-80 -93.82 -43.51 8.56 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.174 -0.954 . . . . 2.87 110.879 -178.409 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -91.29 -35.99 14.14 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 120.966 -1.084 . . . . 2.02 111.022 -178.486 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.609 ' O ' HG13 ' A' ' 21' ' ' VAL . 6.6 p -46.66 111.28 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 120.989 -1.069 . . . . 2.07 110.061 -178.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.414 ' HG2' ' HE1' ' A' ' 42' ' ' TRP . 19.5 tpt180 -118.43 124.84 48.63 Favored 'General case' 0 N--CA 1.497 1.878 0 N-CA-C 108.89 -0.781 . . . . 3.5 108.89 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -128.05 116.48 20.08 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.489 -0.757 . . . . 1.83 109.26 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -148.2 128.78 2.95 Favored Glycine 0 N--CA 1.495 2.571 0 N-CA-C 109.403 -1.479 . . . . 1.9 109.403 -179.879 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.11 169.19 40.38 Favored Glycine 0 N--CA 1.489 2.206 0 C-N-CA 119.574 -1.298 . . . . 1.85 110.062 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 43.3 p -74.06 -11.94 60.47 Favored 'General case' 0 N--CA 1.486 1.34 0 O-C-N 121.349 -1.089 . . . . 2.31 109.771 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -67.37 -17.06 68.03 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 108.205 -1.958 . . . . 1.64 108.205 179.46 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 28.2 mt -89.86 -11.65 41.32 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 108.467 -0.938 . . . . 1.83 108.467 179.437 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 19.9 mm-40 -82.68 -60.35 2.21 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.596 -0.69 . . . . 2.34 109.858 -179.47 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 26.6 ptt180 -172.96 178.79 2.45 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.032 -1.043 . . . . 3.77 109.992 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -148.85 178.0 26.71 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 108.446 -1.861 . . . . 1.57 108.446 179.765 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 27.3 t -134.8 148.33 29.31 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.015 0 O-C-N 121.205 -1.174 . . . . 1.83 110.145 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.641 ' HB2' ' HD3' ' A' ' 82' ' ' PRO . . . -41.56 113.95 0.47 Allowed 'General case' 0 N--CA 1.495 1.792 0 CA-C-O 121.567 0.699 . . . . 1.64 112.388 -179.155 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 59.87 46.44 94.1 Favored Glycine 0 N--CA 1.492 2.424 0 O-C-N 121.658 -0.651 . . . . 1.73 111.687 177.113 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 13.9 t -127.36 126.03 24.06 Favored Pre-proline 0 N--CA 1.499 2.009 0 N-CA-C 108.019 -1.104 . . . . 2.19 108.019 178.827 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -55.12 121.38 9.81 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 120.487 0.791 . . . . 1.96 110.441 -179.362 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -119.92 151.5 38.81 Favored 'General case' 0 N--CA 1.499 1.992 0 N-CA-C 108.235 -1.024 . . . . 1.69 108.235 179.319 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 8.6 pt-20 -160.16 166.24 30.1 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.727 -1.233 . . . . 2.23 111.334 -179.445 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 0.55 ' CD1' ' N ' ' A' ' 39' ' ' PHE . 0.9 OUTLIER -140.48 -178.08 5.34 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 107.046 -1.464 . . . . 1.54 107.046 177.428 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 15.5 m -128.31 134.83 48.98 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.678 -0.639 . . . . 2.37 110.084 -179.161 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.532 ' O ' ' N ' ' A' ' 73' ' ' CYS . 73.0 mt -124.61 145.79 31.26 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 N-CA-C 107.683 -1.228 . . . . 1.65 107.683 179.13 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.522 ' CD2' ' OG1' ' A' ' 43' ' ' THR . 14.5 p-90 -154.82 -176.99 6.2 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.678 -1.264 . . . . 3.68 110.445 -179.653 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.522 ' OG1' ' CD2' ' A' ' 42' ' ' TRP . 0.2 OUTLIER 81.85 109.9 0.07 Allowed 'General case' 0 N--CA 1.495 1.806 0 N-CA-C 109.356 -0.609 . . . . 2.89 109.356 -179.883 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' ARG . . . . . 0.59 ' CG ' HH11 ' A' ' 44' ' ' ARG . 0.0 OUTLIER -132.16 56.94 1.8 Allowed 'General case' 0 N--CA 1.499 1.976 0 N-CA-C 108.982 -0.747 . . . . 4.63 108.982 -179.864 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 27.3 tt0 -90.3 -15.91 30.29 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.264 -0.897 . . . . 2.89 109.976 -179.583 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.39 -66.88 0.5 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.04 -1.038 . . . . 1.74 109.179 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 138.21 -162.83 25.71 Favored Glycine 0 N--CA 1.495 2.633 0 N-CA-C 109.672 -1.371 . . . . 1.6 109.672 179.812 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.86 147.37 12.14 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.278 -1.131 . . . . 1.4 109.33 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.414 ' HA2' HD22 ' A' ' 92' ' ' ASN . . . -173.19 -168.96 35.1 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.538 -1.425 . . . . 1.04 109.538 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -137.49 114.29 1.09 Allowed Glycine 0 N--CA 1.496 2.663 0 N-CA-C 109.114 -1.594 . . . . 1.06 109.114 179.848 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.431 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 10.1 tp -93.74 97.58 10.53 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.251 -1.146 . . . . 1.1 108.582 179.79 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 4.2 m -83.78 142.16 30.87 Favored 'General case' 0 N--CA 1.494 1.738 0 N-CA-C 108.485 -0.932 . . . . 1.56 108.485 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.555 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 61.0 mt -133.65 123.22 45.29 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.083 -1.011 . . . . 0.65 109.674 -179.688 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -116.07 111.71 20.69 Favored 'General case' 0 N--CA 1.497 1.89 0 N-CA-C 108.325 -0.991 . . . . 0.69 108.325 179.236 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 1.1 t -102.94 149.14 7.32 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.977 0 O-C-N 121.449 -0.782 . . . . 0.91 110.052 -179.277 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . 0.42 ' OE2' ' O ' ' B' ' 9' ' ' VAL . 50.9 tp10 -140.65 138.39 34.3 Favored 'General case' 0 N--CA 1.486 1.374 0 N-CA-C 108.441 -0.948 . . . . 1.8 108.441 178.285 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 174.3 -177.51 46.47 Favored Glycine 0 N--CA 1.487 2.075 0 N-CA-C 108.719 -1.752 . . . . 0.49 108.719 -179.607 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_exo -62.74 -18.54 64.81 Favored 'Trans proline' 0 C--N 1.313 -1.32 0 C-N-CA 121.802 1.668 . . . . 0.66 110.957 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . 0.402 ' O ' ' OH ' ' A' ' 85' ' ' TYR . 1.1 p -149.77 166.36 29.68 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.349 -0.844 . . . . 1.55 110.411 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 46.1 mttt -89.92 125.74 35.47 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.607 -0.683 . . . . 2.53 109.502 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -81.8 142.86 32.21 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.278 -0.889 . . . . 0.82 109.325 179.766 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 10.0 tp10 -86.61 90.55 8.29 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.24 -0.913 . . . . 2.3 109.766 -179.808 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 6.3 mm -58.5 155.62 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 121.574 -0.704 . . . . 1.4 109.133 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.552 ' HB3' ' HB3' ' A' ' 76' ' ' SER . . . -149.68 114.43 5.33 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.804 -1.185 . . . . 1.36 109.503 179.577 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.463 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 16.5 p90 -88.85 119.11 29.05 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.164 -0.96 . . . . 1.47 109.041 179.476 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 . . . . . 0 N--CA 1.496 1.864 0 O-C-N 121.252 -0.905 . . . . 2.51 109.902 -179.633 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 74.8 m . . . . . 0 N--CA 1.493 1.703 0 N-CA-C 109.395 -0.594 . . . . 2.2 109.395 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' CYS . . . . . 0.532 ' N ' ' O ' ' A' ' 41' ' ' ILE . 28.2 m -80.18 119.89 23.55 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.225 -0.922 . . . . 2.05 109.295 179.801 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -98.26 123.58 7.9 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.42 -1.472 . . . . 1.39 109.42 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 40.2 t -114.85 102.68 14.19 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.089 0 O-C-N 121.632 -0.923 . . . . 1.57 109.05 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.552 ' HB3' ' HB3' ' A' ' 64' ' ' ALA . 3.3 t -94.01 130.4 40.16 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.34 -0.85 . . . . 1.85 110.136 -179.598 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 8.5 p90 -126.46 129.85 49.51 Favored 'General case' 0 N--CA 1.492 1.646 0 N-CA-C 108.158 -1.052 . . . . 1.54 108.158 179.455 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 11.3 t -100.56 111.29 29.78 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.181 -0.949 . . . . 1.9 109.453 -179.155 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.542 HG11 HG21 ' A' ' 105' ' ' VAL . 13.2 m -77.94 157.71 5.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 O-C-N 121.287 -0.883 . . . . 1.27 109.329 -179.866 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 30.1 tt0 -101.87 -47.92 4.43 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.173 -0.955 . . . . 2.48 110.303 -179.499 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.404 ' O ' ' O ' ' A' ' 82' ' ' PRO . 75.5 mm-40 -149.98 150.03 29.01 Favored Pre-proline 0 N--CA 1.502 2.143 0 O-C-N 120.829 -1.169 . . . . 1.92 111.253 -178.623 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.641 ' HD3' ' HB2' ' A' ' 33' ' ' ALA . 77.8 Cg_exo -37.43 165.49 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.679 0 C-N-CA 122.825 2.35 . . . . 1.3 113.296 178.551 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 142.37 -178.89 20.61 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 108.989 -1.644 . . . . 1.02 108.989 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . 0.552 ' O ' ' NH1' ' B' ' 8' ' ' ARG . 29.6 m-20 -98.69 89.74 4.47 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 107.835 -1.172 . . . . 2.13 107.835 179.224 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.402 ' OH ' ' O ' ' A' ' 59' ' ' SER . 2.9 m-85 -74.7 133.67 42.04 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 108.347 -0.983 . . . . 0.92 108.347 -179.366 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . 0.488 ' OE2' ' NH1' ' B' ' 8' ' ' ARG . 0.0 OUTLIER -117.65 125.05 50.04 Favored 'General case' 0 N--CA 1.498 1.949 0 N-CA-C 108.305 -0.998 . . . . 1.53 108.305 -179.098 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.556 ' CG1' ' CE2' ' A' ' 101' ' ' PHE . 7.5 p -122.94 137.38 56.6 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.986 0 O-C-N 121.624 -0.673 . . . . 1.0 109.401 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 99.8 p -131.55 113.87 14.18 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.596 -0.69 . . . . 1.59 109.797 -179.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 2.9 pt -111.83 143.13 22.24 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.735 -0.603 . . . . 1.29 109.917 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -140.4 123.52 16.67 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.236 -0.915 . . . . 1.58 109.273 178.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 25.1 t80 -78.67 92.99 4.82 Favored 'General case' 0 N--CA 1.494 1.744 0 C-N-CA 119.026 -1.069 . . . . 1.34 108.325 179.449 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . 0.486 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 5.8 t-20 65.82 37.62 5.52 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 108.236 -1.024 . . . . 2.32 108.236 -178.809 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.486 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 2.2 m-20 88.76 10.97 0.09 Allowed 'General case' 0 N--CA 1.503 2.192 0 CA-C-N 116.605 -0.27 . . . . 1.92 111.381 179.658 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . 0.711 ' OE2' HD13 ' A' ' 96' ' ' ILE . 0.0 OUTLIER -86.33 86.97 7.35 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 106.091 -1.818 . . . . 2.25 106.091 177.687 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' HIS . . . . . 0.445 ' O ' ' C ' ' A' ' 96' ' ' ILE . 2.3 t-80 -68.12 94.36 0.5 Allowed 'General case' 0 C--N 1.296 -1.735 0 O-C-N 120.4 -1.437 . . . . 2.88 110.948 -177.845 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' ILE . . . . . 0.711 HD13 ' OE2' ' A' ' 94' ' ' GLU . 4.7 mm -38.38 135.81 0.88 Allowed Pre-proline 0 N--CA 1.504 2.271 0 O-C-N 121.497 -0.752 . . . . 2.35 109.281 179.084 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -54.52 -7.36 0.8 Allowed 'Trans proline' 0 C--N 1.325 -0.7 0 N-CA-C 109.239 -1.1 . . . . 2.48 109.239 179.131 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.48 ' H ' ' C ' ' A' ' 96' ' ' ILE . 55.0 m-20 -86.87 -47.32 9.12 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.481 -0.762 . . . . 2.65 109.729 179.765 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 6.4 p -54.71 136.32 64.16 Favored Pre-proline 0 C--N 1.298 -1.661 0 O-C-N 121.191 -0.943 . . . . 2.0 109.835 -177.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -89.3 113.81 2.34 Favored 'Cis proline' 0 N--CA 1.494 1.554 0 CA-C-N 118.935 0.655 . . . . 1.79 110.44 -1.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . 0.609 ' CD1' ' N ' ' A' ' 101' ' ' PHE . 0.1 OUTLIER -81.42 158.58 24.55 Favored 'General case' 0 N--CA 1.509 2.522 0 O-C-N 119.674 -1.891 . . . . 2.19 108.785 178.476 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 10.4 p -97.93 138.04 23.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.404 -0.81 . . . . 1.44 109.388 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 60.6 t -121.03 85.53 40.95 Favored Pre-proline 0 N--CA 1.499 2.019 0 N-CA-C 108.623 -0.88 . . . . 1.19 108.623 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -65.63 111.32 1.85 Allowed 'Trans proline' 0 C--N 1.321 -0.899 0 C-N-CA 121.443 1.428 . . . . 1.49 111.467 -178.336 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.542 HG21 HG11 ' A' ' 79' ' ' VAL . 54.6 t -95.49 146.32 7.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.775 0 N-CA-C 107.1 -1.444 . . . . 1.35 107.1 178.34 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.656 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -138.71 135.65 34.98 Favored 'General case' 0 N--CA 1.509 2.523 0 O-C-N 121.092 -1.005 . . . . 1.67 111.799 -177.541 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . 0.542 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 9.9 m -86.71 58.73 5.23 Favored 'General case' 0 N--CA 1.494 1.752 0 N-CA-C 107.42 -1.326 . . . . 2.04 107.42 178.808 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' LEU . . . . . 0.508 ' CB ' ' O ' ' A' ' 107' ' ' SER . 3.4 tp 83.8 -11.35 0.89 Allowed 'General case' 0 N--CA 1.495 1.814 0 N-CA-C 106.972 -1.492 . . . . 3.2 106.972 -177.843 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.409 ' O ' ' CG ' ' A' ' 110' ' ' ASP . 24.1 t -71.18 -19.28 62.42 Favored 'General case' 0 C--N 1.305 -1.333 0 N-CA-C 108.878 -0.786 . . . . 2.09 108.878 178.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . 0.656 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 1.1 p30 . . . . . 0 N--CA 1.496 1.833 0 N-CA-C 108.285 -1.006 . . . . 2.85 108.285 -178.822 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . 0.552 ' NH1' ' O ' ' A' ' 84' ' ' ASP . 68.3 mtt180 . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 108.429 -0.952 . . . . 3.04 108.429 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 9' ' ' VAL . . . . . 0.42 ' O ' ' OE2' ' A' ' 56' ' ' GLU . 21.0 t -53.99 158.71 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 N-CA-C 108.162 -1.051 . . . . 0.67 108.162 178.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -117.83 141.72 48.11 Favored 'General case' 0 N--CA 1.502 2.166 0 O-C-N 121.489 -0.757 . . . . 0.58 109.981 -179.337 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 18.4 t -143.0 137.68 29.49 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.368 -0.832 . . . . 1.19 109.319 179.581 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 8.7 t -141.13 128.31 20.9 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.308 -0.87 . . . . 1.38 109.584 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 0.622 HG22 ' N ' ' B' ' 14' ' ' PHE . 6.1 p -169.44 167.89 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.484 -0.76 . . . . 0.42 109.205 -179.874 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 14' ' ' PHE . . . . . 0.622 ' N ' HG22 ' B' ' 13' ' ' VAL . 6.7 p90 -177.61 -167.67 0.16 Allowed 'General case' 0 N--CA 1.49 1.552 0 CA-C-O 122.202 1.001 . . . . 1.79 112.537 179.65 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.4 pt -150.71 172.07 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.31 0 N-CA-C 108.322 -0.992 . . . . 1.25 108.322 179.818 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 31.7 p -144.96 147.12 32.33 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 120.865 -1.147 . . . . 1.61 109.9 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.4 mt . . . . . 0 N--CA 1.494 1.774 0 O-C-N 121.349 -0.845 . . . . 1.32 109.178 179.715 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.899 0 N-CA-C 109.447 -1.461 . . . . 2.44 109.447 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.534 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -69.58 -5.93 52.67 Favored Glycine 0 N--CA 1.487 2.083 0 N-CA-C 110.054 -1.219 . . . . 1.81 110.054 -179.664 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -48.3 -13.39 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.675 0 O-C-N 120.663 -1.492 . . . . 2.21 109.228 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' HIS . . . . . 0.534 ' N ' ' O ' ' A' ' 17' ' ' GLY . 1.6 t60 -95.48 -45.17 7.2 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.384 -0.823 . . . . 2.87 109.181 179.38 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.52 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.0 OUTLIER -79.83 -26.08 40.59 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.112 -0.993 . . . . 2.02 109.332 179.894 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.417 HG11 HD11 ' A' ' 96' ' ' ILE . 69.2 t -62.98 112.66 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.115 -0.991 . . . . 2.07 109.051 179.497 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 12.9 tpp180 -100.93 137.52 39.19 Favored 'General case' 0 C--N 1.301 -1.535 0 CA-C-O 121.475 0.655 . . . . 3.5 109.263 -179.72 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -148.37 113.28 5.45 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.604 -0.887 . . . . 1.83 108.604 179.415 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -150.76 133.23 4.21 Favored Glycine 0 N--CA 1.496 2.68 0 N-CA-C 109.74 -1.344 . . . . 1.9 109.74 -179.616 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.46 175.36 47.37 Favored Glycine 0 N--CA 1.487 2.067 0 C-N-CA 119.628 -1.272 . . . . 1.85 110.268 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 18.0 m -77.44 -17.95 57.62 Favored 'General case' 0 N--CA 1.486 1.363 0 O-C-N 121.457 -1.025 . . . . 2.31 109.77 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -68.34 -22.75 74.87 Favored Glycine 0 N--CA 1.487 2.036 0 N-CA-C 108.761 -1.736 . . . . 1.64 108.761 179.757 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.5 mt -84.39 -7.15 59.39 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.623 -0.927 . . . . 1.83 108.963 179.853 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 27.0 mm-40 -88.45 -56.69 3.21 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.47 -0.769 . . . . 2.34 109.993 -179.341 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 26.1 ptt180 -175.05 -176.74 0.99 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.126 -0.984 . . . . 3.77 109.666 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -149.27 177.47 27.45 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 108.917 -1.673 . . . . 1.57 108.917 179.857 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.465 ' H ' ' CG1' ' A' ' 35' ' ' VAL . 25.8 t -134.91 148.03 29.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.425 -1.044 . . . . 1.83 109.803 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.464 ' HB2' ' HD3' ' A' ' 82' ' ' PRO . . . -37.84 106.65 0.05 Allowed 'General case' 0 N--CA 1.496 1.866 0 CA-C-O 121.341 0.591 . . . . 1.64 112.085 -179.142 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 62.49 57.51 16.23 Favored Glycine 0 N--CA 1.49 2.268 0 O-C-N 121.249 -0.907 . . . . 1.73 111.541 177.558 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.465 ' CG1' ' H ' ' A' ' 32' ' ' VAL . 2.8 p -126.09 129.2 24.31 Favored Pre-proline 0 N--CA 1.502 2.167 0 O-C-N 121.311 -1.111 . . . . 2.19 109.133 178.84 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -63.5 125.64 16.0 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 N-CA-C 108.24 -1.485 . . . . 1.96 108.24 178.473 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.598 ' HB3' ' CZ ' ' A' ' 77' ' ' TYR . . . -134.47 160.91 36.55 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.212 -0.93 . . . . 1.69 109.294 -179.367 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -162.36 167.22 24.08 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 121.161 -0.962 . . . . 2.23 110.758 -179.634 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 0.527 ' CD1' ' N ' ' A' ' 39' ' ' PHE . 0.7 OUTLIER -141.61 -179.98 6.48 Favored 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 107.059 -1.46 . . . . 1.54 107.059 177.627 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 6.1 m -124.12 138.05 54.48 Favored 'General case' 0 N--CA 1.498 1.941 0 CA-C-O 121.405 0.622 . . . . 2.37 110.178 -178.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.479 ' O ' ' N ' ' A' ' 73' ' ' CYS . 74.3 mt -136.7 119.38 20.99 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.556 -0.715 . . . . 1.65 109.269 179.645 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 6.2 p-90 -119.52 137.35 53.87 Favored 'General case' 0 N--CA 1.503 2.2 0 N-CA-C 108.905 -0.776 . . . . 3.68 108.905 179.201 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.52 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.1 OUTLIER -148.83 137.77 21.46 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.199 -0.938 . . . . 2.89 109.694 -179.581 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' ARG . . . . . . . . . . . . . 59.7 ttt180 -171.87 66.3 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.344 -0.848 . . . . 4.63 109.743 179.665 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.485 ' H ' ' HZ3' ' A' ' 20' ' ' LYS . 6.4 tp10 -157.84 -53.81 0.07 Allowed 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.078 -1.014 . . . . 2.89 109.43 179.553 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -58.46 -58.75 7.16 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.2 -0.937 . . . . 1.74 109.148 179.769 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 138.62 176.49 14.62 Favored Glycine 0 N--CA 1.494 2.502 0 N-CA-C 108.928 -1.669 . . . . 1.6 108.928 -179.938 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.39 163.51 0.6 Allowed 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.088 -1.243 . . . . 1.4 109.386 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 179.8 -148.78 8.2 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.868 -1.293 . . . . 1.04 109.868 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -144.13 126.98 2.85 Favored Glycine 0 N--CA 1.495 2.606 0 N-CA-C 109.618 -1.393 . . . . 1.06 109.618 -179.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.423 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 10.8 tp -102.93 102.15 12.21 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.399 -1.059 . . . . 1.1 109.027 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 3.2 t -85.97 142.11 29.03 Favored 'General case' 0 N--CA 1.494 1.767 0 N-CA-C 108.221 -1.029 . . . . 1.56 108.221 179.295 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.555 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 89.5 mt -133.54 120.14 36.85 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.987 0 O-C-N 121.087 -1.008 . . . . 0.65 109.896 -179.709 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.435 ' HB3' ' OG ' ' A' ' 88' ' ' SER . . . -109.44 106.86 16.8 Favored 'General case' 0 N--CA 1.496 1.874 0 N-CA-C 108.772 -0.825 . . . . 0.69 108.772 179.376 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.43 HG23 ' OG ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -97.84 143.19 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 O-C-N 121.245 -0.91 . . . . 0.91 109.25 -179.844 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 12.5 tt0 -141.61 142.87 33.44 Favored 'General case' 0 N--CA 1.491 1.624 0 N-CA-C 107.882 -1.155 . . . . 1.8 107.882 179.336 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 166.04 -172.88 41.54 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.502 -1.439 . . . . 0.49 109.502 -179.239 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -64.21 -30.18 64.54 Favored 'Trans proline' 0 C--N 1.318 -1.056 0 C-N-CA 121.993 1.795 . . . . 0.66 111.412 -179.218 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . 0.403 ' O ' ' OH ' ' A' ' 85' ' ' TYR . 6.0 m -141.4 152.26 44.16 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.075 -1.016 . . . . 1.55 109.827 -179.801 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 16.1 ptmt -74.56 107.68 6.84 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.261 -0.899 . . . . 2.53 109.024 179.829 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -72.67 136.43 45.63 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.014 -1.054 . . . . 0.82 109.401 -179.602 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -71.92 173.35 8.45 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.099 -1.0 . . . . 2.3 109.236 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 42.9 mt -142.52 152.52 17.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 N-CA-C 107.799 -1.185 . . . . 1.4 107.799 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.55 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -150.13 114.64 5.23 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 120.653 -1.279 . . . . 1.36 110.202 -179.45 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 45.1 p90 -86.76 129.07 35.02 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.248 -0.907 . . . . 1.47 109.157 179.393 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 54.0 tt0 . . . . . 0 N--CA 1.496 1.863 0 O-C-N 121.238 -0.914 . . . . 2.51 109.602 -179.756 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 94.0 p . . . . . 0 N--CA 1.495 1.812 0 N-CA-C 109.466 -0.568 . . . . 2.2 109.466 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' CYS . . . . . 0.479 ' N ' ' O ' ' A' ' 41' ' ' ILE . 32.3 m -85.31 117.27 24.14 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.232 -0.917 . . . . 2.05 109.633 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -99.95 119.8 6.64 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 109.294 -1.522 . . . . 1.39 109.294 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 17.9 t -109.74 103.09 14.94 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.153 0 O-C-N 121.524 -0.986 . . . . 1.57 109.818 -179.756 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.55 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.0 OUTLIER -91.76 142.94 27.04 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.326 -0.859 . . . . 1.85 108.851 179.687 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.598 ' CZ ' ' HB3' ' A' ' 37' ' ' ALA . 11.6 p90 -142.82 171.92 13.4 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.281 -0.887 . . . . 1.54 109.189 -179.421 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.556 ' O ' HG13 ' A' ' 78' ' ' VAL . 4.4 p -142.2 119.98 7.92 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.211 0 O-C-N 121.105 -0.997 . . . . 1.9 110.288 179.529 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.515 HG11 HG21 ' A' ' 105' ' ' VAL . 11.5 m -87.15 153.97 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.309 -0.87 . . . . 1.27 108.677 179.251 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 38.3 tt0 -96.6 -47.0 6.1 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.008 -1.057 . . . . 2.48 110.657 -179.156 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 80.2 mm-40 -152.16 150.48 25.66 Favored Pre-proline 0 N--CA 1.502 2.129 0 O-C-N 120.646 -1.284 . . . . 1.92 111.056 -178.625 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.576 ' HG3' ' N ' ' A' ' 107' ' ' SER . 75.7 Cg_exo -37.68 164.72 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.67 0 C-N-CA 122.8 2.333 . . . . 1.3 113.099 178.398 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 144.24 -163.88 27.71 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.122 -1.591 . . . . 1.02 109.122 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 20.0 m-20 -108.97 91.13 3.52 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.639 -0.918 . . . . 2.13 108.797 179.652 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.473 ' O ' ' N ' ' A' ' 103' ' ' VAL . 3.1 m-85 -78.81 130.69 36.0 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 108.091 -1.077 . . . . 0.92 108.091 179.896 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . 0.409 ' OE2' ' NH2' ' B' ' 8' ' ' ARG . 0.0 OUTLIER -115.62 129.23 56.43 Favored 'General case' 0 N--CA 1.501 2.1 0 N-CA-C 108.89 -0.781 . . . . 1.53 108.89 -179.041 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 9.9 p -124.12 140.19 48.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.712 -0.617 . . . . 1.0 109.361 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . 0.435 ' OG ' ' HB3' ' A' ' 54' ' ' ALA . 22.2 p -131.98 101.9 5.61 Favored 'General case' 0 N--CA 1.498 1.944 0 N-CA-C 109.184 -0.673 . . . . 1.59 109.184 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.418 ' H ' ' HB3' ' A' ' 99' ' ' SER . 1.5 pt -111.84 136.11 49.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 CA-C-O 121.599 0.714 . . . . 1.29 110.479 -179.084 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' LYS . . . . . 0.459 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.2 OUTLIER -140.95 122.77 15.35 Favored 'General case' 0 N--CA 1.486 1.329 0 N-CA-C 108.001 -1.111 . . . . 1.58 108.001 179.449 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.413 ' O ' ' OE1' ' A' ' 94' ' ' GLU . 84.7 t80 -82.15 100.29 9.73 Favored 'General case' 0 C--N 1.3 -1.569 0 C-N-CA 118.347 -1.341 . . . . 1.34 107.927 179.041 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . 0.438 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 0.3 OUTLIER 71.42 36.48 1.31 Allowed 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.25 -0.906 . . . . 2.32 109.158 -178.665 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.438 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 1.8 m-20 79.6 12.9 1.11 Allowed 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.703 -0.623 . . . . 1.92 111.903 179.232 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . 0.483 ' OE2' ' CA ' ' A' ' 17' ' ' GLY . 5.2 pt-20 -99.98 96.59 7.64 Favored 'General case' 0 N--CA 1.498 1.97 0 N-CA-C 106.958 -1.497 . . . . 2.25 106.958 177.617 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' HIS . . . . . 0.513 ' O ' ' ND1' ' A' ' 95' ' ' HIS . 0.0 OUTLIER -70.44 111.37 5.94 Favored 'General case' 0 N--CA 1.488 1.452 0 CA-C-O 121.595 0.712 . . . . 2.88 110.884 -177.577 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' ILE . . . . . 0.479 ' O ' ' N ' ' A' ' 98' ' ' ASP . 32.4 mt -57.66 137.39 82.54 Favored Pre-proline 0 C--N 1.3 -1.557 0 N-CA-C 107.826 -1.176 . . . . 2.35 107.826 178.651 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_exo -42.91 -21.75 0.23 Allowed 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 120.823 1.015 . . . . 2.48 110.184 -179.694 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.479 ' N ' ' O ' ' A' ' 96' ' ' ILE . 87.2 m-20 -67.58 -68.08 0.41 Allowed 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 108.478 -0.934 . . . . 2.65 108.478 178.266 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.418 ' HB3' ' H ' ' A' ' 89' ' ' ILE . 0.3 OUTLIER -60.65 143.65 90.3 Favored Pre-proline 0 C--N 1.295 -1.762 0 O-C-N 121.595 -0.69 . . . . 2.0 109.901 -178.389 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -84.41 112.62 2.6 Favored 'Cis proline' 0 N--CA 1.491 1.337 0 N-CA-C 109.456 -1.017 . . . . 1.79 109.456 -2.318 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 53.6 p90 -112.11 161.96 15.95 Favored 'General case' 0 N--CA 1.517 2.887 0 O-C-N 120.543 -1.348 . . . . 2.19 110.196 179.107 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.414 HG22 ' N ' ' A' ' 103' ' ' VAL . 7.2 p -93.66 154.42 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.528 -0.732 . . . . 1.44 110.928 -178.421 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.473 ' N ' ' O ' ' A' ' 85' ' ' TYR . 64.4 t -128.65 86.96 56.23 Favored Pre-proline 0 N--CA 1.498 1.934 0 N-CA-C 108.233 -1.025 . . . . 1.19 108.233 179.41 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 4.1 Cg_exo -63.54 113.12 1.97 Allowed 'Trans proline' 0 C--N 1.319 -1.008 0 C-N-CA 121.333 1.355 . . . . 1.49 111.963 -178.081 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.515 HG21 HG11 ' A' ' 79' ' ' VAL . 53.4 t -96.17 143.76 11.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 N-CA-C 106.713 -1.588 . . . . 1.35 106.713 177.862 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.649 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -136.65 133.63 36.43 Favored 'General case' 0 N--CA 1.51 2.539 0 O-C-N 121.14 -0.975 . . . . 1.67 111.863 -177.3 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . 0.576 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 38.7 p -85.27 63.73 8.26 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.796 -1.19 . . . . 2.04 107.819 179.12 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' LEU . . . . . 0.485 ' CB ' ' O ' ' A' ' 107' ' ' SER . 2.8 tp 79.9 -14.89 0.8 Allowed 'General case' 0 C--N 1.298 -1.648 0 N-CA-C 106.927 -1.509 . . . . 3.2 106.927 -177.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.481 ' H ' ' C ' ' A' ' 107' ' ' SER . 21.7 t -66.89 -23.46 66.0 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 108.762 -0.829 . . . . 2.09 108.762 178.769 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . 0.649 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 42.9 m-20 . . . . . 0 N--CA 1.493 1.685 0 N-CA-C 108.079 -1.082 . . . . 2.85 108.079 -179.46 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . 0.409 ' NH2' ' OE2' ' A' ' 86' ' ' GLU . 18.2 mtm-85 . . . . . 0 N--CA 1.491 1.594 0 N-CA-C 108.129 -1.063 . . . . 3.04 108.129 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 9' ' ' VAL . . . . . . . . . . . . . 20.4 t -52.96 159.54 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 120.916 -1.115 . . . . 0.67 108.21 179.617 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -120.64 149.11 42.99 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.404 -0.81 . . . . 0.58 110.422 -178.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 11' ' ' SER . . . . . 0.43 ' OG ' HG23 ' A' ' 55' ' ' VAL . 7.4 t -143.2 142.69 31.5 Favored 'General case' 0 N--CA 1.495 1.785 0 N-CA-C 108.814 -0.81 . . . . 1.19 108.814 179.365 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 23.6 p -145.38 127.92 16.05 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.987 -1.07 . . . . 1.38 110.121 -179.639 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 0.655 HG22 ' N ' ' B' ' 14' ' ' PHE . 7.2 p -172.44 171.46 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 N-CA-C 108.826 -0.805 . . . . 0.42 108.826 179.69 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 14' ' ' PHE . . . . . 0.655 ' N ' HG22 ' B' ' 13' ' ' VAL . 6.8 p90 -177.48 -167.95 0.17 Allowed 'General case' 0 N--CA 1.489 1.522 0 CA-C-O 122.234 1.016 . . . . 1.79 112.282 179.793 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.8 pt -148.95 172.64 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.29 0 N-CA-C 107.897 -1.149 . . . . 1.25 107.897 179.709 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 2.4 t -146.6 148.44 32.12 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 120.756 -1.215 . . . . 1.61 110.195 -179.842 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.2 mt . . . . . 0 N--CA 1.495 1.823 0 O-C-N 121.51 -0.744 . . . . 1.32 109.146 179.785 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.217 0 N-CA-C 111.605 -0.598 . . . . 2.44 111.605 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.523 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 74.05 -56.06 2.27 Favored Glycine 0 N--CA 1.493 2.451 0 N-CA-C 110.487 -1.045 . . . . 1.81 110.487 178.614 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.871 ' HB2' ' OE1' ' A' ' 94' ' ' GLU . . . -49.82 -9.22 0.04 OUTLIER 'General case' 0 C--N 1.294 -1.828 0 O-C-N 121.243 -1.151 . . . . 2.21 109.6 -179.624 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' HIS . . . . . 0.523 ' N ' ' O ' ' A' ' 17' ' ' GLY . 15.2 t-80 -94.91 -8.9 35.79 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.085 -1.009 . . . . 2.87 110.475 -179.456 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.502 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.0 OUTLIER -134.24 1.79 3.24 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.078 -1.014 . . . . 2.02 110.2 -179.685 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 68.7 t -88.07 113.43 25.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 120.92 -1.113 . . . . 2.07 109.637 179.767 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 6.2 tpt180 -97.8 132.9 42.99 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.577 -0.702 . . . . 3.5 109.126 179.808 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -139.28 113.92 9.18 Favored 'General case' 0 N--CA 1.494 1.751 0 N-CA-C 108.582 -0.896 . . . . 1.83 108.582 179.771 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -156.64 129.22 2.37 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.849 -1.3 . . . . 1.9 109.849 -179.448 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.94 -179.82 48.73 Favored Glycine 0 N--CA 1.488 2.127 0 C-N-CA 119.512 -1.328 . . . . 1.85 110.052 179.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 10.9 p -80.61 -15.96 55.29 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.397 -1.061 . . . . 2.31 109.451 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -76.89 -8.42 86.64 Favored Glycine 0 N--CA 1.487 2.074 0 N-CA-C 109.532 -1.427 . . . . 1.64 109.532 -179.733 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.48 HD21 ' CD2' ' A' ' 39' ' ' PHE . 28.5 mt -100.26 -0.67 38.12 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.373 -1.075 . . . . 1.83 109.076 179.692 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -102.18 -44.56 5.4 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.519 -0.738 . . . . 2.34 109.565 -179.681 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 18.1 ptt180 -176.81 172.58 2.05 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.006 -1.059 . . . . 3.77 110.119 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -143.45 174.72 23.84 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 107.842 -2.103 . . . . 1.57 107.842 179.272 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 35.2 t -134.05 149.79 30.7 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.092 0 O-C-N 121.1 -1.235 . . . . 1.83 110.375 -179.842 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.544 ' HB2' ' HD3' ' A' ' 82' ' ' PRO . . . -41.47 114.17 0.48 Allowed 'General case' 0 N--CA 1.498 1.933 0 CA-C-O 121.804 0.812 . . . . 1.64 112.593 -179.128 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 57.18 47.3 88.74 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 111.552 -0.619 . . . . 1.73 111.552 176.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 25.5 t -127.23 113.53 21.54 Favored Pre-proline 0 N--CA 1.498 1.966 0 O-C-N 121.458 -1.024 . . . . 2.19 108.756 179.116 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -59.93 126.51 20.57 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 N-CA-C 109.944 -0.829 . . . . 1.96 109.944 -179.756 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.409 ' HB3' ' CZ ' ' A' ' 77' ' ' TYR . . . -127.58 174.56 8.96 Favored 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 108.182 -1.044 . . . . 1.69 108.182 179.597 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -163.09 171.28 16.63 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.838 -1.164 . . . . 2.23 110.961 -179.789 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 0.63 ' CE2' HD11 ' A' ' 41' ' ' ILE . 5.8 p90 -155.9 167.75 29.4 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 107.707 -1.22 . . . . 1.54 107.707 178.568 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 14.6 m -101.67 150.14 23.42 Favored 'General case' 0 N--CA 1.495 1.821 0 CA-C-O 121.803 0.811 . . . . 2.37 111.147 -178.1 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.657 HD12 HG21 ' A' ' 75' ' ' VAL . 11.8 mt -141.12 88.55 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 N-CA-C 108.436 -0.95 . . . . 1.65 108.436 178.774 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.459 ' HE1' ' CG ' ' A' ' 44' ' ' ARG . 5.6 t90 -90.77 132.99 35.52 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.105 -0.997 . . . . 3.68 108.788 -179.804 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.502 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.8 OUTLIER -160.94 128.53 4.28 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.22 -0.925 . . . . 2.89 109.949 -179.436 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' ARG . . . . . 0.459 ' CG ' ' HE1' ' A' ' 42' ' ' TRP . 1.8 ptp180 -178.39 77.27 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.278 -0.889 . . . . 4.63 109.612 179.6 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.469 ' H ' ' HZ3' ' A' ' 20' ' ' LYS . 26.0 tt0 -158.6 -52.32 0.06 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.187 -0.946 . . . . 2.89 109.498 179.796 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -60.79 -49.99 75.24 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.04 -1.038 . . . . 1.74 109.008 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 148.85 160.92 9.36 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.448 -1.461 . . . . 1.6 109.448 179.807 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.79 161.23 1.18 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.196 -1.179 . . . . 1.4 109.386 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -174.42 -128.88 1.12 Allowed Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.827 -1.309 . . . . 1.04 109.827 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -157.69 126.22 1.69 Allowed Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.58 -1.408 . . . . 1.06 109.58 -179.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 11.7 tp -97.97 100.53 11.87 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.294 -1.121 . . . . 1.1 109.078 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . 0.403 ' HA ' ' CD2' ' B' ' 14' ' ' PHE . 2.0 t -88.36 142.72 27.5 Favored 'General case' 0 C--O 1.211 -0.947 0 N-CA-C 108.667 -0.864 . . . . 1.56 108.667 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.522 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 93.5 mt -134.08 106.97 9.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 O-C-N 121.025 -1.047 . . . . 0.65 109.764 -179.568 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -96.34 106.06 18.23 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.315 -0.995 . . . . 0.69 108.315 179.183 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.429 HG23 ' CB ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -94.52 144.57 9.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.421 -0.799 . . . . 0.91 109.676 -179.445 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 16.6 tt0 -141.1 145.16 35.44 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 107.529 -1.286 . . . . 1.8 107.529 178.738 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.428 ' O ' ' O ' ' B' ' 9' ' ' VAL . . . 163.14 -171.08 38.81 Favored Glycine 0 N--CA 1.489 2.196 0 C-N-CA 119.554 -1.308 . . . . 0.49 109.854 -179.065 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -62.68 -29.85 77.96 Favored 'Trans proline' 0 C--N 1.318 -1.063 0 C-N-CA 122.224 1.949 . . . . 0.66 112.386 -179.289 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 8.7 t -142.36 160.0 41.12 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 120.891 -1.131 . . . . 1.55 110.138 -179.643 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 80.5 mttt -78.33 109.53 12.55 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.498 -0.751 . . . . 2.53 109.204 179.796 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -76.46 142.37 41.01 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.258 -0.902 . . . . 0.82 109.588 -179.829 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.847 ' C ' HD12 ' A' ' 63' ' ' ILE . 20.6 tt0 -81.39 172.62 13.33 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.319 -0.863 . . . . 2.3 108.78 179.778 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.847 HD12 ' C ' ' A' ' 62' ' ' GLU . 3.2 mp -140.17 154.4 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 N-CA-C 108.309 -0.997 . . . . 1.4 108.309 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.55 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -151.07 114.88 4.95 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.758 -1.214 . . . . 1.36 109.538 -179.845 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.528 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 44.0 p90 -93.55 120.21 33.55 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.19 -0.944 . . . . 1.47 109.469 179.724 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 54.2 tt0 . . . . . 0 N--CA 1.497 1.91 0 O-C-N 121.234 -0.916 . . . . 2.51 109.611 -179.883 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.8 m . . . . . 0 N--CA 1.495 1.781 0 N-CA-C 108.85 -0.796 . . . . 2.2 108.85 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 15.1 t -88.02 126.63 35.18 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.151 -0.968 . . . . 2.05 109.773 -179.521 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -105.13 118.34 5.84 Favored Glycine 0 N--CA 1.498 2.831 0 N-CA-C 109.576 -1.41 . . . . 1.39 109.576 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.657 HG21 HD12 ' A' ' 41' ' ' ILE . 21.9 t -105.88 106.08 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.141 0 O-C-N 121.476 -1.014 . . . . 1.57 109.423 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.55 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.3 OUTLIER -96.17 139.21 32.66 Favored 'General case' 0 N--CA 1.493 1.676 0 N-CA-C 108.988 -0.745 . . . . 1.85 108.988 179.828 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.409 ' CZ ' ' HB3' ' A' ' 37' ' ' ALA . 41.9 p90 -138.07 173.3 11.77 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.294 -0.879 . . . . 1.54 109.262 -179.636 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.552 ' O ' HG13 ' A' ' 78' ' ' VAL . 8.9 p -138.69 120.01 16.53 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.246 0 O-C-N 121.372 -0.83 . . . . 1.9 109.969 179.56 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.441 HG22 ' H ' ' A' ' 79' ' ' VAL . 5.7 m -89.57 163.08 2.43 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.387 -0.82 . . . . 1.27 108.984 179.72 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 7.0 tp-100 -104.4 -47.6 4.06 Favored 'General case' 0 N--CA 1.501 2.077 0 O-C-N 121.199 -0.938 . . . . 2.48 111.103 -178.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -156.52 153.27 24.49 Favored Pre-proline 0 N--CA 1.503 2.194 0 O-C-N 120.641 -1.287 . . . . 1.92 111.106 -178.799 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.641 ' HG3' ' N ' ' A' ' 107' ' ' SER . 73.0 Cg_exo -37.63 158.68 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 123.267 2.644 . . . . 1.3 113.609 179.268 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 148.15 -163.45 28.9 Favored Glycine 0 N--CA 1.493 2.441 0 N-CA-C 109.662 -1.375 . . . . 1.02 109.662 179.606 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 46.6 m-20 -110.66 88.63 2.82 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.615 -0.932 . . . . 2.13 108.984 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.508 ' O ' ' N ' ' A' ' 103' ' ' VAL . 2.8 m-85 -76.16 129.69 37.14 Favored 'General case' 0 C--N 1.303 -1.414 0 N-CA-C 107.998 -1.112 . . . . 0.92 107.998 179.708 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -109.23 128.01 54.71 Favored 'General case' 0 N--CA 1.5 2.069 0 N-CA-C 108.35 -0.981 . . . . 1.53 108.35 -179.52 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 9.9 p -123.91 133.56 68.93 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.713 -0.617 . . . . 1.0 109.767 -179.295 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 6.6 m -123.84 95.05 4.42 Favored 'General case' 0 N--CA 1.497 1.886 0 CA-C-O 121.393 0.616 . . . . 1.59 109.54 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.415 ' H ' ' HB3' ' A' ' 99' ' ' SER . 1.2 pt -101.26 134.48 41.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.643 -0.661 . . . . 1.29 109.797 -179.775 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' LYS . . . . . 0.468 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.1 OUTLIER -140.32 121.98 15.28 Favored 'General case' 0 N--CA 1.485 1.296 0 N-CA-C 108.712 -0.847 . . . . 1.58 108.712 179.746 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 79.9 t80 -81.09 100.03 8.81 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 107.665 -1.235 . . . . 1.34 107.665 178.514 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . 0.438 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 26.8 t30 69.81 36.42 2.07 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.448 -0.782 . . . . 2.32 109.362 -178.809 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.438 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 0.7 OUTLIER 79.92 14.32 0.92 Allowed 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.688 -0.633 . . . . 1.92 111.554 179.42 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . 0.871 ' OE1' ' HB2' ' A' ' 18' ' ' ALA . 0.5 OUTLIER -100.94 95.53 6.66 Favored 'General case' 0 N--CA 1.499 1.98 0 N-CA-C 107.239 -1.393 . . . . 2.25 107.239 177.892 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' HIS . . . . . 0.53 ' CD2' ' O ' ' A' ' 95' ' ' HIS . 0.4 OUTLIER -66.58 110.55 3.22 Favored 'General case' 0 N--CA 1.488 1.466 0 CA-C-O 121.697 0.76 . . . . 2.88 111.177 -177.773 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' ILE . . . . . 0.536 ' O ' ' N ' ' A' ' 98' ' ' ASP . 5.5 mm -50.61 137.22 24.34 Favored Pre-proline 0 N--CA 1.492 1.671 0 N-CA-C 107.621 -1.251 . . . . 2.35 107.621 178.576 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -44.39 -16.75 0.12 Allowed 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 120.68 0.92 . . . . 2.48 109.844 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 96' ' ' ILE . 42.9 m-20 -76.92 -66.56 0.8 Allowed 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 108.517 -0.92 . . . . 2.65 108.517 178.277 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.415 ' HB3' ' H ' ' A' ' 89' ' ' ILE . 0.2 OUTLIER -57.34 144.02 72.09 Favored Pre-proline 0 C--N 1.297 -1.702 0 O-C-N 121.622 -0.674 . . . . 2.0 109.801 -178.106 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -83.82 110.36 1.79 Allowed 'Cis proline' 0 N--CA 1.491 1.339 0 N-CA-C 109.71 -0.919 . . . . 1.79 109.71 -2.129 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 47.3 p90 -108.87 166.98 10.41 Favored 'General case' 0 N--CA 1.515 2.794 0 O-C-N 120.51 -1.369 . . . . 2.19 110.035 179.109 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.3 p -94.39 153.13 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.518 -0.739 . . . . 1.44 110.758 -178.777 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.508 ' N ' ' O ' ' A' ' 85' ' ' TYR . 70.3 t -127.62 86.21 58.96 Favored Pre-proline 0 N--CA 1.499 1.986 0 N-CA-C 107.863 -1.162 . . . . 1.19 107.863 179.395 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -62.4 113.45 1.93 Allowed 'Trans proline' 0 C--N 1.318 -1.036 0 C-N-CA 121.288 1.325 . . . . 1.49 111.979 -177.82 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 42.7 t -90.4 141.68 14.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 N-CA-C 106.88 -1.526 . . . . 1.35 106.88 177.766 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.726 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -121.65 127.67 51.06 Favored 'General case' 0 N--CA 1.505 2.322 0 CA-C-O 121.664 0.745 . . . . 1.67 111.607 -177.033 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . 0.641 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 7.8 t -88.69 77.76 7.84 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 120.365 -1.459 . . . . 2.04 107.484 178.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' LEU . . . . . 0.442 ' CB ' ' O ' ' A' ' 107' ' ' SER . 0.9 OUTLIER 72.66 -7.81 1.35 Allowed 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 107.307 -1.368 . . . . 3.2 107.307 -178.288 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.503 ' H ' ' C ' ' A' ' 107' ' ' SER . 3.0 m -78.11 -21.59 50.18 Favored 'General case' 0 N--CA 1.486 1.335 0 N-CA-C 108.602 -0.888 . . . . 2.09 108.602 178.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . 0.726 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 1.4 m-20 . . . . . 0 N--CA 1.491 1.586 0 O-C-N 121.359 -0.838 . . . . 2.85 109.23 179.353 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . 0.531 ' CG ' HH11 ' B' ' 8' ' ' ARG . 2.2 mtt-85 . . . . . 0 N--CA 1.489 1.487 0 N-CA-C 108.003 -1.11 . . . . 3.04 108.003 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 9' ' ' VAL . . . . . 0.428 ' O ' ' O ' ' A' ' 57' ' ' GLY . 22.9 t -48.3 159.3 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.021 -1.049 . . . . 0.67 108.671 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -123.89 153.74 40.69 Favored 'General case' 0 N--CA 1.501 2.111 0 O-C-N 121.369 -0.832 . . . . 0.58 110.257 -178.89 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 11' ' ' SER . . . . . 0.429 ' CB ' HG23 ' A' ' 55' ' ' VAL . 2.7 t -148.66 147.12 28.56 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.498 -0.751 . . . . 1.19 109.235 179.773 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 28.5 p -145.89 126.77 14.47 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.164 -0.96 . . . . 1.38 110.064 -179.628 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 0.656 HG22 ' N ' ' B' ' 14' ' ' PHE . 7.2 p -172.18 174.8 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 N-CA-C 108.497 -0.927 . . . . 0.42 108.497 179.731 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 14' ' ' PHE . . . . . 0.656 ' N ' HG22 ' B' ' 13' ' ' VAL . 0.1 OUTLIER 174.41 -166.23 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.563 0 C-N-CA 118.779 -1.168 . . . . 1.79 111.864 -179.979 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 5.8 pt -137.58 139.49 43.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 N-CA-C 108.981 -0.748 . . . . 1.25 108.981 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 80.7 p -94.26 131.19 40.12 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.101 -0.999 . . . . 1.61 109.785 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.597 HD22 ' N ' ' B' ' 17' ' ' LEU . 3.5 mm? . . . . . 0 N--CA 1.494 1.756 0 O-C-N 121.294 -0.879 . . . . 1.32 108.891 179.615 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.047 0 N-CA-C 110.082 -1.207 . . . . 2.44 110.082 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.567 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 91.88 -53.38 2.95 Favored Glycine 0 N--CA 1.494 2.542 0 N-CA-C 110.213 -1.155 . . . . 1.81 110.213 179.444 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.632 ' HB2' ' OE1' ' A' ' 94' ' ' GLU . . . -41.49 -18.22 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.84 -0.8 . . . . 2.21 110.463 -178.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' HIS . . . . . 0.567 ' N ' ' O ' ' A' ' 17' ' ' GLY . 11.0 t60 -85.39 -40.69 16.19 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.281 -0.887 . . . . 2.87 109.99 -179.456 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.599 ' HG2' ' HB2' ' A' ' 46' ' ' ALA . 0.0 OUTLIER -99.78 -29.04 12.85 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.099 -1.001 . . . . 2.02 110.584 -179.173 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 84.0 t -51.58 112.1 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.004 -1.06 . . . . 2.07 109.869 -179.608 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 3.9 tpt180 -119.15 136.43 54.18 Favored 'General case' 0 N--CA 1.495 1.792 0 N-CA-C 109.284 -0.635 . . . . 3.5 109.284 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -144.58 113.87 7.01 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.461 -0.775 . . . . 1.83 108.933 179.677 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -149.25 123.83 1.69 Allowed Glycine 0 N--CA 1.495 2.586 0 N-CA-C 110.137 -1.185 . . . . 1.9 110.137 -179.424 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.81 177.77 48.27 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.904 -1.279 . . . . 1.85 109.904 179.567 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 11.0 m -76.81 -12.62 60.0 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.291 -1.123 . . . . 2.31 109.958 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -67.68 -16.68 68.16 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 108.417 -1.873 . . . . 1.64 108.417 179.599 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.434 HD21 ' CD2' ' A' ' 39' ' ' PHE . 18.1 mt -92.92 -10.31 36.96 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.783 -0.833 . . . . 1.83 109.022 179.722 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 47.3 mm-40 -83.61 -55.23 4.4 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.491 -0.755 . . . . 2.34 110.056 -179.264 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 4.9 ptp180 -176.36 -177.59 0.87 Allowed 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.036 -1.04 . . . . 3.77 109.879 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -145.13 174.53 25.14 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 108.649 -1.78 . . . . 1.57 108.649 179.664 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 30.3 t -134.39 149.73 30.18 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.947 0 O-C-N 121.285 -1.126 . . . . 1.83 110.159 -179.779 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.516 ' HB2' ' HD3' ' A' ' 82' ' ' PRO . . . -40.5 112.19 0.26 Allowed 'General case' 0 N--CA 1.496 1.83 0 CA-C-O 121.499 0.666 . . . . 1.64 112.515 -178.887 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 58.82 47.16 91.9 Favored Glycine 0 N--CA 1.492 2.391 0 O-C-N 121.514 -0.741 . . . . 1.73 111.569 177.117 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 23.6 t -127.45 124.84 23.74 Favored Pre-proline 0 N--CA 1.499 1.988 0 O-C-N 121.417 -1.049 . . . . 2.19 108.417 179.031 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_exo -58.39 114.77 2.13 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 N-CA-C 109.99 -0.811 . . . . 1.96 109.99 -179.828 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.423 ' HB3' ' CE2' ' A' ' 77' ' ' TYR . . . -107.64 155.45 20.14 Favored 'General case' 0 N--CA 1.495 1.789 0 N-CA-C 107.803 -1.184 . . . . 1.69 107.803 179.176 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -164.51 169.85 16.63 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 118.431 -1.308 . . . . 2.23 111.41 -179.405 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 0.61 ' CE2' HD11 ' A' ' 41' ' ' ILE . 4.6 p90 -154.66 171.03 20.16 Favored 'General case' 0 C--N 1.298 -1.669 0 N-CA-C 107.705 -1.22 . . . . 1.54 107.705 178.008 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 83.6 p -100.59 150.99 22.13 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.575 -0.703 . . . . 2.37 110.599 -178.389 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.61 HD11 ' CE2' ' A' ' 39' ' ' PHE . 11.6 mt -143.6 104.71 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 N-CA-C 108.712 -0.847 . . . . 1.65 108.712 178.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.526 ' CG ' ' N ' ' A' ' 43' ' ' THR . 0.7 OUTLIER -102.62 166.45 10.5 Favored 'General case' 0 N--CA 1.497 1.911 0 N-CA-C 108.33 -0.989 . . . . 3.68 108.33 179.854 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.526 ' N ' ' CG ' ' A' ' 42' ' ' TRP . 35.0 p -153.6 131.49 11.68 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.146 -0.971 . . . . 2.89 109.827 -179.616 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' ARG . . . . . 0.475 ' H ' ' HB2' ' A' ' 20' ' ' LYS . 32.5 ttm180 -72.58 -86.3 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.243 -0.91 . . . . 4.63 109.43 179.847 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 24.9 tt0 -172.17 63.35 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.809 -1.182 . . . . 2.89 110.935 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.599 ' HB2' ' HG2' ' A' ' 20' ' ' LYS . . . -71.24 -52.0 21.45 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 120.73 -1.231 . . . . 1.74 108.584 178.823 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 155.39 169.62 20.02 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.487 -1.445 . . . . 1.6 109.487 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.8 143.98 19.53 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.215 -1.168 . . . . 1.4 109.371 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -163.72 -168.35 25.6 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.522 -1.431 . . . . 1.04 109.522 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -137.68 117.37 1.48 Allowed Glycine 0 N--CA 1.496 2.666 0 N-CA-C 109.261 -1.536 . . . . 1.06 109.261 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.463 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 9.7 tp -87.53 99.23 11.88 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.283 -1.128 . . . . 1.1 108.597 179.758 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 12.8 m -84.01 141.13 31.42 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 108.834 -0.802 . . . . 1.56 108.834 -179.887 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.512 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 72.6 mt -130.37 111.5 21.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.357 -0.839 . . . . 0.65 109.36 -179.891 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -100.85 106.98 18.41 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.374 -0.829 . . . . 0.69 108.938 179.724 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.428 ' O ' ' O ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -103.93 135.44 41.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 121.573 -0.704 . . . . 0.91 109.323 -179.771 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 27.3 tt0 -137.96 140.53 40.28 Favored 'General case' 0 N--CA 1.494 1.736 0 N-CA-C 108.024 -1.102 . . . . 1.8 108.024 179.092 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 168.47 -172.15 42.88 Favored Glycine 0 N--CA 1.487 2.092 0 N-CA-C 109.407 -1.477 . . . . 0.49 109.407 -179.271 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -62.87 -30.9 77.8 Favored 'Trans proline' 0 C--N 1.316 -1.16 0 C-N-CA 121.873 1.715 . . . . 0.66 111.584 -179.621 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.8 t -137.64 157.24 46.93 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.153 -0.967 . . . . 1.55 110.278 -179.488 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.436 ' O ' ' OE2' ' A' ' 62' ' ' GLU . 31.5 mtpt -80.65 123.37 28.11 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 109.09 -0.707 . . . . 2.53 109.09 179.728 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -85.79 144.29 27.82 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.162 -0.961 . . . . 0.82 109.318 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.482 ' CD ' ' N ' ' A' ' 62' ' ' GLU . 9.0 mp0 -96.76 100.52 12.07 Favored 'General case' 0 N--CA 1.502 2.137 0 O-C-N 121.048 -1.032 . . . . 2.3 110.619 -179.476 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.47 HD12 ' N ' ' A' ' 63' ' ' ILE . 1.7 mp -62.51 156.12 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 N-CA-C 108.673 -0.862 . . . . 1.4 108.673 178.721 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.524 ' HB3' ' OG ' ' A' ' 76' ' ' SER . . . -140.97 175.01 9.97 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.122 -0.987 . . . . 1.36 109.237 179.782 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.513 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 32.3 p90 -147.08 116.25 6.94 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.317 -0.864 . . . . 1.47 109.407 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 69.8 tt0 . . . . . 0 N--CA 1.495 1.821 0 O-C-N 121.287 -0.883 . . . . 2.51 109.515 -179.977 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 28.9 t . . . . . 0 N--CA 1.494 1.754 0 N-CA-C 108.782 -0.821 . . . . 2.2 108.782 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 37.9 t -93.39 126.42 38.52 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.148 -0.97 . . . . 2.05 109.644 -179.708 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -102.35 120.48 6.84 Favored Glycine 0 N--CA 1.497 2.755 0 N-CA-C 109.855 -1.298 . . . . 1.39 109.855 -179.795 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.414 ' CG2' HD12 ' A' ' 41' ' ' ILE . 41.3 t -104.59 119.34 53.35 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.959 0 O-C-N 121.464 -1.021 . . . . 1.57 108.814 179.603 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.524 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 0.4 OUTLIER -113.39 124.35 52.23 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.69 -0.631 . . . . 1.85 109.387 -179.836 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.423 ' CE2' ' HB3' ' A' ' 37' ' ' ALA . 51.7 p90 -122.97 131.62 53.79 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 108.358 -0.979 . . . . 1.54 108.358 179.316 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.625 ' O ' HG13 ' A' ' 78' ' ' VAL . 8.9 p -106.63 117.54 52.61 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.243 0 O-C-N 121.293 -0.879 . . . . 1.9 109.603 -179.378 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 1.2 m -90.07 161.8 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 O-C-N 121.282 -0.887 . . . . 1.27 108.978 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 1.2 tp-100 -97.62 -51.33 4.15 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.122 -0.986 . . . . 2.48 110.787 -179.158 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.429 ' O ' ' O ' ' A' ' 82' ' ' PRO . 77.2 mm-40 -145.47 150.31 43.66 Favored Pre-proline 0 N--CA 1.504 2.259 0 O-C-N 120.872 -1.142 . . . . 1.92 111.718 -178.125 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.599 ' HG3' ' N ' ' A' ' 107' ' ' SER . 88.7 Cg_exo -36.73 166.38 0.01 OUTLIER 'Trans proline' 0 C--O 1.216 -0.616 0 C-N-CA 123.142 2.561 . . . . 1.3 113.381 178.391 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 142.7 -178.53 21.04 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.183 -1.567 . . . . 1.02 109.183 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . 0.717 ' H ' ' NH1' ' B' ' 8' ' ' ARG . 31.7 m-20 -97.22 85.9 3.8 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 107.79 -1.189 . . . . 2.13 107.79 179.213 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -70.16 132.54 45.96 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 108.128 -1.064 . . . . 0.92 108.128 -179.502 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -105.36 115.67 30.65 Favored 'General case' 0 N--CA 1.496 1.872 0 N-CA-C 108.255 -1.017 . . . . 1.53 108.255 -179.067 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.4 p -115.83 143.03 26.73 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 O-C-N 121.604 -0.685 . . . . 1.0 110.12 -179.29 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 2.9 m -138.87 97.06 3.24 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.507 -0.745 . . . . 1.59 109.588 179.661 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.539 HG13 HD11 ' A' ' 96' ' ' ILE . 1.1 pt -104.38 132.84 50.04 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 N-CA-C 109.332 -0.618 . . . . 1.29 109.332 -179.888 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' LYS . . . . . 0.435 ' HG3' ' H ' ' A' ' 93' ' ' ASP . 0.0 OUTLIER -148.09 132.76 17.85 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.106 -0.996 . . . . 1.58 109.855 -179.481 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 43.5 t80 -83.05 94.62 7.83 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.642 -1.286 . . . . 1.34 108.591 178.721 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . 0.479 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 38.7 t30 67.22 38.13 3.45 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.492 -0.929 . . . . 2.32 108.492 -179.088 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.479 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 0.6 OUTLIER 86.45 12.31 0.16 Allowed 'General case' 0 N--CA 1.503 2.181 0 CA-C-N 116.399 -0.364 . . . . 1.92 111.467 179.629 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . 0.632 ' OE1' ' HB2' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -90.51 90.14 7.88 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 107.191 -1.411 . . . . 2.25 107.191 177.984 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' HIS . . . . . 0.507 ' H ' ' CD2' ' A' ' 95' ' ' HIS . 9.7 p80 -72.19 98.13 2.09 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 119.759 -1.838 . . . . 2.88 109.848 -179.142 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' ILE . . . . . 0.906 ' H ' HD13 ' A' ' 96' ' ' ILE . 0.0 OUTLIER -48.74 158.93 0.59 Allowed Pre-proline 0 N--CA 1.504 2.269 0 N-CA-C 107.31 -1.367 . . . . 2.35 107.31 179.218 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -60.42 65.5 0.08 OUTLIER 'Trans proline' 0 N--CA 1.481 0.736 0 C-N-CA 121.504 1.469 . . . . 2.48 109.469 -179.87 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.593 ' N ' ' O ' ' A' ' 96' ' ' ILE . 8.8 m-20 -164.9 -57.56 0.03 OUTLIER 'General case' 0 C--N 1.298 -1.634 0 N-CA-C 108.167 -1.049 . . . . 2.65 108.167 -179.514 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.423 ' HB3' ' H ' ' A' ' 89' ' ' ILE . 3.3 p -68.8 137.29 90.16 Favored Pre-proline 0 C--N 1.296 -1.755 0 C-N-CA 119.489 -0.884 . . . . 2.0 109.754 -179.179 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 27.2 Cg_endo -89.54 119.87 4.28 Favored 'Cis proline' 0 N--CA 1.493 1.462 0 N-CA-C 110.017 -0.801 . . . . 1.79 110.017 -2.644 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 30.4 p90 -124.55 166.42 16.09 Favored 'General case' 0 N--CA 1.516 2.844 0 O-C-N 120.571 -1.33 . . . . 2.19 109.74 178.153 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.3 p -88.44 146.49 6.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.551 -0.718 . . . . 1.44 110.521 -178.532 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 71.4 t -119.63 86.66 35.34 Favored Pre-proline 0 N--CA 1.495 1.803 0 N-CA-C 107.82 -1.178 . . . . 1.19 107.82 179.157 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -61.96 112.92 1.65 Allowed 'Trans proline' 0 C--N 1.322 -0.866 0 C-N-CA 121.423 1.416 . . . . 1.49 112.121 -177.724 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 60.3 t -98.93 143.19 13.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 N-CA-C 106.15 -1.796 . . . . 1.35 106.15 177.719 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.658 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -136.48 135.15 38.36 Favored 'General case' 0 N--CA 1.51 2.56 0 O-C-N 120.972 -1.08 . . . . 1.67 112.089 -176.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . 0.599 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 9.2 t -86.39 73.02 10.22 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 107.713 -1.218 . . . . 2.04 107.713 179.158 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER 68.11 -1.26 1.83 Allowed 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 107.363 -1.347 . . . . 3.2 107.363 -178.505 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.493 ' H ' ' C ' ' A' ' 107' ' ' SER . 22.9 t -83.54 -21.96 32.55 Favored 'General case' 0 N--CA 1.486 1.344 0 N-CA-C 108.864 -0.791 . . . . 2.09 108.864 179.249 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . 0.658 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 1.8 m-20 . . . . . 0 N--CA 1.492 1.673 0 N-CA-C 108.135 -1.061 . . . . 2.85 108.135 -179.344 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . 0.717 ' NH1' ' H ' ' A' ' 84' ' ' ASP . 5.6 mtt180 . . . . . 0 N--CA 1.493 1.699 0 N-CA-C 109.393 -0.595 . . . . 3.04 109.393 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 9' ' ' VAL . . . . . 0.408 ' CG1' ' N ' ' B' ' 10' ' ' ALA . 5.2 t -51.08 160.48 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 N-CA-C 108.226 -1.027 . . . . 0.67 108.226 179.375 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 0.408 ' N ' ' CG1' ' B' ' 9' ' ' VAL . . . -114.59 148.3 38.26 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.47 -0.768 . . . . 0.58 110.053 -179.158 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 11' ' ' SER . . . . . 0.428 ' O ' ' O ' ' A' ' 55' ' ' VAL . 31.3 t -150.02 133.06 16.2 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.517 -0.74 . . . . 1.19 109.2 179.634 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 34.1 p -144.55 120.54 10.69 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.117 -0.989 . . . . 1.38 109.809 -179.695 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 0.613 HG22 ' N ' ' B' ' 14' ' ' PHE . 4.1 p -164.04 168.4 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.436 -0.79 . . . . 0.42 109.07 179.858 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 14' ' ' PHE . . . . . 0.613 ' N ' HG22 ' B' ' 13' ' ' VAL . 10.7 p90 -176.38 -165.58 0.14 Allowed 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 119.172 -1.011 . . . . 1.79 112.265 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.7 pt -150.93 168.63 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.291 0 N-CA-C 108.598 -0.89 . . . . 1.25 108.598 179.873 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 3.8 t -145.17 157.41 44.09 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 120.965 -1.084 . . . . 1.61 109.367 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.5 2.062 0 O-C-N 121.397 -0.815 . . . . 1.32 109.533 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.099 0 N-CA-C 110.772 -0.931 . . . . 2.44 110.772 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.539 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 78.7 -52.6 3.91 Favored Glycine 0 N--CA 1.492 2.43 0 O-C-N 121.47 -1.018 . . . . 1.81 111.089 178.69 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.599 ' HB2' ' OE1' ' A' ' 94' ' ' GLU . . . -50.27 -6.68 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.081 -1.247 . . . . 2.21 110.162 -179.29 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' HIS . . . . . 0.539 ' N ' ' O ' ' A' ' 17' ' ' GLY . 29.5 t-80 -98.97 -6.31 28.91 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.092 -1.005 . . . . 2.87 110.717 -179.171 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.502 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.0 OUTLIER -137.7 2.38 2.42 Favored 'General case' 0 N--CA 1.502 2.164 0 O-C-N 120.959 -1.088 . . . . 2.02 110.258 -179.664 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 71.3 t -87.85 114.22 26.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 120.982 -1.074 . . . . 2.07 109.25 179.489 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 13.3 tpp180 -113.61 138.54 50.03 Favored 'General case' 0 N--CA 1.492 1.635 0 N-CA-C 108.83 -0.804 . . . . 3.5 108.83 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -147.13 113.57 5.95 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.434 -0.791 . . . . 1.83 108.987 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -152.0 130.33 3.07 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.677 -1.369 . . . . 1.9 109.677 -179.759 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.98 -178.79 48.47 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.603 -1.399 . . . . 1.85 109.603 179.87 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 6.6 p -78.93 -26.59 43.67 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.183 -1.186 . . . . 2.31 108.99 179.648 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -66.88 -18.25 68.36 Favored Glycine 0 N--CA 1.486 2.015 0 N-CA-C 108.283 -1.927 . . . . 1.64 108.283 179.482 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 57.1 mt -89.64 29.55 1.13 Allowed 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.527 -0.916 . . . . 1.83 108.527 179.395 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 27.5 mt-10 -140.09 -63.84 0.49 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.528 -0.733 . . . . 2.34 109.623 -179.557 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 41.2 mtt180 -148.45 168.57 22.34 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.168 -0.958 . . . . 3.77 110.293 -179.573 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -144.38 173.33 25.09 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 107.415 -2.274 . . . . 1.57 107.415 178.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 39.7 t -133.79 150.99 32.18 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.15 0 O-C-N 120.999 -1.295 . . . . 1.83 110.884 -179.365 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.434 ' HB2' ' HD3' ' A' ' 82' ' ' PRO . . . -42.34 114.81 0.61 Allowed 'General case' 0 N--CA 1.497 1.887 0 CA-C-O 121.893 0.854 . . . . 1.64 112.314 -179.299 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 55.8 48.2 73.69 Favored Glycine 0 N--CA 1.488 2.159 0 N-CA-C 111.497 -0.641 . . . . 1.73 111.497 177.119 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 t -127.45 123.8 23.32 Favored Pre-proline 0 N--CA 1.499 1.986 0 O-C-N 121.451 -1.029 . . . . 2.19 108.866 179.075 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -60.64 112.21 1.27 Allowed 'Trans proline' 0 C--O 1.215 -0.652 0 N-CA-C 109.949 -0.827 . . . . 1.96 109.949 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -110.87 158.96 18.13 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 108.401 -0.963 . . . . 1.69 108.401 179.445 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -160.64 170.46 20.79 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.767 -1.208 . . . . 2.23 111.496 -179.768 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 0.602 ' CE2' HD11 ' A' ' 41' ' ' ILE . 6.2 p90 -155.62 177.37 11.45 Favored 'General case' 0 C--N 1.296 -1.729 0 N-CA-C 107.217 -1.401 . . . . 1.54 107.217 178.473 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 27.5 m -105.17 152.32 22.97 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.344 -0.848 . . . . 2.37 110.619 -178.502 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.649 HD12 HG21 ' A' ' 75' ' ' VAL . 10.0 mt -143.64 89.53 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 N-CA-C 108.714 -0.847 . . . . 1.65 108.714 178.854 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.529 ' CD1' ' N ' ' A' ' 43' ' ' THR . 7.4 t90 -91.33 141.29 28.93 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.172 -0.955 . . . . 3.68 108.924 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.531 ' OG1' ' N ' ' A' ' 44' ' ' ARG . 1.7 t -162.34 -124.2 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.177 -0.952 . . . . 2.89 109.486 -179.845 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' ARG . . . . . 0.531 ' N ' ' OG1' ' A' ' 43' ' ' THR . 5.3 ttt-85 54.49 91.81 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.347 -0.845 . . . . 4.63 110.074 179.748 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -170.97 -50.23 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.285 -0.884 . . . . 2.89 109.304 179.457 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -61.14 -50.29 73.8 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.09 -1.006 . . . . 1.74 108.937 179.665 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 155.2 -178.81 31.65 Favored Glycine 0 N--CA 1.487 2.044 0 N-CA-C 109.536 -1.426 . . . . 1.6 109.536 179.813 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.68 156.92 2.45 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.169 -1.195 . . . . 1.4 109.263 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -179.65 -160.51 25.38 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.712 -1.355 . . . . 1.04 109.712 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -144.05 123.38 2.01 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 109.663 -1.375 . . . . 1.06 109.663 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 60.2 tp -96.82 104.99 17.04 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.34 -1.094 . . . . 1.1 108.651 179.571 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . 0.406 ' HA ' ' CD2' ' B' ' 14' ' ' PHE . 2.0 t -93.23 144.66 25.08 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 108.93 -0.767 . . . . 1.56 108.93 179.736 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.507 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 80.0 mt -132.97 105.74 8.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 O-C-N 121.305 -0.872 . . . . 0.65 109.79 -179.378 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -95.76 107.86 20.13 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 107.726 -1.213 . . . . 0.69 107.726 178.841 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.41 ' O ' ' O ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -105.33 146.73 11.99 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 CA-C-O 121.772 0.796 . . . . 0.91 110.693 -178.421 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . 0.408 ' OE2' ' O ' ' B' ' 9' ' ' VAL . 39.9 tp10 -139.23 129.41 25.31 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 107.248 -1.39 . . . . 1.8 107.248 177.954 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -175.82 163.59 33.3 Favored Glycine 0 N--CA 1.487 2.068 0 N-CA-C 108.386 -1.886 . . . . 0.49 108.386 -179.702 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_exo -46.37 -23.44 2.08 Favored 'Trans proline' 0 C--N 1.317 -1.13 0 C-N-CA 121.91 1.74 . . . . 0.66 111.714 -178.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 30.3 t -141.74 167.49 22.01 Favored 'General case' 0 N--CA 1.501 2.101 0 O-C-N 121.473 -0.767 . . . . 1.55 110.681 -179.274 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 29.3 tttm -91.4 92.05 8.4 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.666 -0.646 . . . . 2.53 109.535 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -52.05 145.13 10.78 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.341 -0.85 . . . . 0.82 109.308 179.889 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.426 ' OE2' ' O ' ' A' ' 63' ' ' ILE . 0.2 OUTLIER -93.78 87.63 5.5 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.234 -0.916 . . . . 2.3 109.561 -179.843 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.426 ' O ' ' OE2' ' A' ' 62' ' ' GLU . 25.0 mt -60.23 150.17 6.69 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 N-CA-C 109.263 -0.643 . . . . 1.4 109.263 179.574 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -151.09 114.83 4.93 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 120.725 -1.234 . . . . 1.36 109.939 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.492 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 40.1 p90 -86.85 124.17 32.79 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.222 -0.924 . . . . 1.47 109.198 179.531 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 62.9 tt0 . . . . . 0 N--CA 1.497 1.915 0 O-C-N 121.254 -0.904 . . . . 2.51 109.43 179.971 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 4.3 t . . . . . 0 N--CA 1.492 1.671 0 N-CA-C 108.983 -0.747 . . . . 2.2 108.983 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 24.5 m -78.23 129.33 34.96 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.19 -0.944 . . . . 2.05 109.356 -179.844 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -101.14 116.5 5.59 Favored Glycine 0 N--CA 1.497 2.747 0 N-CA-C 110.111 -1.196 . . . . 1.39 110.111 -179.637 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.649 HG21 HD12 ' A' ' 41' ' ' ILE . 71.8 t -105.36 106.85 21.28 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.098 0 O-C-N 121.537 -0.978 . . . . 1.57 109.284 179.571 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 4.0 t -100.11 126.39 46.34 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.549 -0.719 . . . . 1.85 109.474 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.401 ' N ' ' CD1' ' A' ' 77' ' ' TYR . 12.0 p90 -125.36 131.69 52.94 Favored 'General case' 0 N--CA 1.497 1.882 0 N-CA-C 108.758 -0.831 . . . . 1.54 108.758 179.746 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.627 ' O ' HG13 ' A' ' 78' ' ' VAL . 9.9 p -98.73 114.35 36.17 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.294 -0.879 . . . . 1.9 109.255 -179.501 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.406 HG22 ' H ' ' A' ' 79' ' ' VAL . 15.5 m -81.79 161.83 3.57 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 O-C-N 121.041 -1.037 . . . . 1.27 109.027 -179.707 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . 0.531 ' O ' ' NE2' ' A' ' 80' ' ' GLN . 0.0 OUTLIER -101.44 -48.54 4.32 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.227 -0.92 . . . . 2.48 110.781 -178.825 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -156.67 153.13 23.91 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 120.554 -1.341 . . . . 1.92 111.108 -179.506 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.648 ' HG3' ' N ' ' A' ' 107' ' ' SER . 76.4 Cg_exo -37.08 158.08 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.646 0 C-N-CA 123.363 2.709 . . . . 1.3 113.875 179.231 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 150.77 -167.49 30.46 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.359 -1.496 . . . . 1.02 109.359 179.765 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . 0.521 ' OD2' ' NH2' ' B' ' 8' ' ' ARG . 10.7 m-20 -109.3 91.58 3.7 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.532 -0.981 . . . . 2.13 108.756 179.64 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 3.0 m-85 -78.25 136.19 37.72 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 108.049 -1.093 . . . . 0.92 108.049 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . 0.402 ' OE2' ' O ' ' A' ' 84' ' ' ASP . 0.0 OUTLIER -119.18 117.36 28.44 Favored 'General case' 0 N--CA 1.501 2.086 0 N-CA-C 108.121 -1.066 . . . . 1.53 108.121 -179.033 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.437 ' O ' HG13 ' A' ' 87' ' ' VAL . 14.6 p -117.11 133.91 62.36 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 121.622 -0.674 . . . . 1.0 110.408 -178.842 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 3.5 p -128.65 105.77 8.49 Favored 'General case' 0 N--CA 1.501 2.092 0 O-C-N 121.61 -0.682 . . . . 1.59 109.459 179.715 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.4 pt -107.95 138.22 35.53 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.897 0 CA-C-O 121.415 0.626 . . . . 1.29 109.839 -179.732 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' LYS . . . . . 0.458 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -145.08 122.63 11.74 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 108.659 -0.867 . . . . 1.58 108.659 179.928 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 78.7 t80 -80.33 100.95 8.66 Favored 'General case' 0 N--CA 1.491 1.588 0 C-N-CA 118.764 -1.174 . . . . 1.34 107.891 178.492 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . 0.407 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 2.0 t30 69.59 39.86 1.49 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.343 -0.848 . . . . 2.32 109.177 -178.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.407 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 1.5 m-20 75.61 13.93 2.88 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.678 -0.639 . . . . 1.92 111.62 179.483 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . 0.599 ' OE1' ' HB2' ' A' ' 18' ' ' ALA . 0.5 OUTLIER -98.44 94.44 6.72 Favored 'General case' 0 N--CA 1.498 1.97 0 N-CA-C 106.964 -1.495 . . . . 2.25 106.964 177.58 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' HIS . . . . . 0.508 ' O ' ' CG ' ' A' ' 95' ' ' HIS . 6.5 p80 -71.57 112.69 7.9 Favored 'General case' 0 N--CA 1.487 1.384 0 CA-C-O 121.485 0.66 . . . . 2.88 109.748 -178.219 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' ILE . . . . . 0.557 ' O ' ' N ' ' A' ' 98' ' ' ASP . 6.3 pt -57.06 152.02 31.4 Favored Pre-proline 0 C--N 1.3 -1.579 0 N-CA-C 108.319 -0.993 . . . . 2.35 108.319 179.594 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -59.05 73.96 0.05 OUTLIER 'Trans proline' 0 CA--C 1.54 0.789 0 N-CA-C 109.234 -1.102 . . . . 2.48 109.234 179.364 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.557 ' N ' ' O ' ' A' ' 96' ' ' ILE . 0.9 OUTLIER -174.93 -51.87 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.077 -1.014 . . . . 2.65 109.38 -179.339 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 5.3 t -54.25 134.31 60.57 Favored Pre-proline 0 C--N 1.299 -1.626 0 O-C-N 121.321 -0.862 . . . . 2.0 109.926 -177.64 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_endo -89.94 116.25 2.91 Favored 'Cis proline' 0 N--CA 1.495 1.606 0 CA-C-N 118.995 0.677 . . . . 1.79 110.521 -1.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . 0.574 ' CD1' ' N ' ' A' ' 101' ' ' PHE . 0.1 OUTLIER -89.49 149.59 22.84 Favored 'General case' 0 N--CA 1.512 2.639 0 O-C-N 119.979 -1.701 . . . . 2.19 108.76 178.029 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 8.6 p -86.45 138.43 19.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.5 -0.75 . . . . 1.44 109.133 179.681 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 76.7 t -120.15 85.37 35.6 Favored Pre-proline 0 N--CA 1.498 1.936 0 N-CA-C 108.312 -0.996 . . . . 1.19 108.312 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -65.3 112.97 2.25 Favored 'Trans proline' 0 C--N 1.32 -0.953 0 C-N-CA 121.276 1.317 . . . . 1.49 111.556 -178.012 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 47.2 t -89.73 143.06 11.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 N-CA-C 106.667 -1.605 . . . . 1.35 106.667 177.853 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.702 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -127.92 131.28 49.37 Favored 'General case' 0 N--CA 1.507 2.406 0 CA-C-O 121.956 0.884 . . . . 1.67 111.788 -177.016 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . 0.648 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 66.4 p -99.8 84.77 2.96 Favored 'General case' 0 N--CA 1.493 1.693 0 N-CA-C 107.229 -1.397 . . . . 2.04 107.229 178.783 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 13.3 mt 65.12 -0.69 1.02 Allowed 'General case' 0 C--N 1.292 -1.917 0 N-CA-C 108.081 -1.081 . . . . 3.2 108.081 -178.103 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.484 ' H ' ' C ' ' A' ' 107' ' ' SER . 53.8 p -89.1 -22.89 22.66 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.982 -0.747 . . . . 2.09 108.982 179.068 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . 0.702 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 32.9 t70 . . . . . 0 N--CA 1.493 1.676 0 O-C-N 121.139 -0.975 . . . . 2.85 108.586 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . 0.521 ' NH2' ' OD2' ' A' ' 84' ' ' ASP . 3.8 mmt-85 . . . . . 0 N--CA 1.492 1.67 0 CA-C-O 121.472 0.654 . . . . 3.04 109.358 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 9' ' ' VAL . . . . . 0.408 ' O ' ' OE2' ' A' ' 56' ' ' GLU . 2.6 t -68.47 161.23 4.22 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 N-CA-C 107.505 -1.294 . . . . 0.67 107.505 178.549 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -97.77 138.94 34.38 Favored 'General case' 0 N--CA 1.5 2.034 0 O-C-N 121.186 -0.947 . . . . 0.58 110.809 -178.636 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 11' ' ' SER . . . . . 0.41 ' O ' ' O ' ' A' ' 55' ' ' VAL . 35.7 t -143.07 130.73 21.34 Favored 'General case' 0 N--CA 1.493 1.72 0 N-CA-C 108.444 -0.947 . . . . 1.19 108.444 179.092 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 11.1 t -150.69 125.37 9.67 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.069 -1.019 . . . . 1.38 110.072 -179.369 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 0.731 HG22 ' H ' ' B' ' 14' ' ' PHE . 12.3 p -173.26 179.81 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 N-CA-C 108.263 -1.014 . . . . 0.42 108.263 179.649 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 14' ' ' PHE . . . . . 0.731 ' H ' HG22 ' B' ' 13' ' ' VAL . 0.1 OUTLIER 174.59 -167.65 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.504 0 C-N-CA 118.548 -1.261 . . . . 1.79 112.237 179.629 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -141.34 159.66 22.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 N-CA-C 108.097 -1.075 . . . . 1.25 108.097 -179.841 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 1.7 t -132.11 151.07 51.98 Favored 'General case' 0 N--CA 1.499 2.017 0 O-C-N 121.303 -0.873 . . . . 1.61 109.474 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 28.4 mt . . . . . 0 N--CA 1.5 2.047 0 O-C-N 121.487 -0.758 . . . . 1.32 109.576 -179.899 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 2.003 0 N-CA-C 109.886 -1.286 . . . . 2.44 109.886 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.544 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -68.24 -15.55 67.89 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.881 -1.288 . . . . 1.81 109.881 -179.68 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.51 ' N ' ' OE1' ' A' ' 94' ' ' GLU . . . -43.8 -17.67 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.525 -0.985 . . . . 2.21 109.823 -179.679 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' HIS . . . . . 0.544 ' N ' ' O ' ' A' ' 17' ' ' GLY . 11.7 t-80 -100.25 -52.56 3.35 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.447 -0.783 . . . . 2.87 110.388 -179.146 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.545 ' HZ1' ' CB ' ' A' ' 43' ' ' THR . 0.0 OUTLIER -64.49 -17.89 64.29 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.962 -1.086 . . . . 2.02 109.874 -179.288 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.592 ' O ' HG13 ' A' ' 21' ' ' VAL . 9.7 p -72.22 114.31 10.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.046 -1.034 . . . . 2.07 108.829 179.503 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.405 ' HG2' ' HE1' ' A' ' 42' ' ' TRP . 5.9 tpp180 -109.84 134.61 51.86 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.452 -0.78 . . . . 3.5 110.108 -178.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -141.79 113.59 7.89 Favored 'General case' 0 N--CA 1.493 1.691 0 N-CA-C 108.392 -0.966 . . . . 1.83 108.392 179.15 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -150.93 132.07 3.76 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 109.94 -1.264 . . . . 1.9 109.94 -179.294 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.38 179.11 48.9 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 110.055 -1.218 . . . . 1.85 110.055 179.721 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 7.2 m -75.9 -19.9 58.46 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.47 -1.018 . . . . 2.31 109.674 179.922 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.449 ' O ' ' OH ' ' A' ' 77' ' ' TYR . . . -70.97 -24.76 76.8 Favored Glycine 0 N--CA 1.488 2.138 0 N-CA-C 108.767 -1.733 . . . . 1.64 108.767 179.844 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 29.6 mt -81.51 -11.21 59.27 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.555 -0.968 . . . . 1.83 108.946 179.633 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 33.2 mm-40 -84.67 -49.03 8.88 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.512 -0.743 . . . . 2.34 109.762 -179.494 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . 0.504 ' NH1' ' OD1' ' A' ' 110' ' ' ASP . 9.4 ptp180 -174.92 173.69 2.66 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.221 -0.925 . . . . 3.77 109.407 179.809 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -138.71 170.91 23.78 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 108.196 -1.962 . . . . 1.57 108.196 179.475 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.4 ' HA ' ' O ' ' A' ' 106' ' ' ALA . 25.6 t -134.64 149.36 29.56 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 O-C-N 121.23 -1.159 . . . . 1.83 109.944 -179.526 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.44 ' HB2' ' HD3' ' A' ' 82' ' ' PRO . . . -38.51 113.03 0.26 Allowed 'General case' 0 N--CA 1.496 1.832 0 CA-C-O 121.712 0.767 . . . . 1.64 112.098 -179.306 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 63.48 40.67 99.04 Favored Glycine 0 N--CA 1.491 2.337 0 O-C-N 121.685 -0.635 . . . . 1.73 111.814 177.424 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 46.4 t -127.32 119.95 22.07 Favored Pre-proline 0 N--CA 1.502 2.146 0 O-C-N 121.289 -1.124 . . . . 2.19 108.536 178.924 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -59.37 113.89 1.8 Allowed 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 120.589 0.86 . . . . 1.96 110.541 -179.488 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.517 ' HB3' ' CZ ' ' A' ' 77' ' ' TYR . . . -86.39 90.67 8.27 Favored 'General case' 0 N--CA 1.492 1.665 0 N-CA-C 108.281 -1.007 . . . . 1.69 108.281 179.032 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -85.78 148.28 25.92 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.244 -0.91 . . . . 2.23 110.884 -178.513 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 0.674 ' CE2' HD11 ' A' ' 41' ' ' ILE . 5.2 p90 -153.25 159.03 42.52 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 107.148 -1.427 . . . . 1.54 107.148 177.825 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . 0.426 ' OG ' ' OG ' ' A' ' 72' ' ' SER . 3.6 t -98.26 156.2 16.82 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.223 -0.923 . . . . 2.37 111.904 -177.093 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.674 HD11 ' CE2' ' A' ' 39' ' ' PHE . 13.3 mt -149.18 117.16 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 N-CA-C 108.368 -0.975 . . . . 1.65 108.368 178.713 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.519 ' O ' ' CD2' ' A' ' 42' ' ' TRP . 7.3 p-90 -122.07 129.12 52.12 Favored 'General case' 0 N--CA 1.503 2.182 0 O-C-N 121.256 -0.903 . . . . 3.68 109.031 179.718 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.545 ' CB ' ' HZ1' ' A' ' 20' ' ' LYS . 0.6 OUTLIER -149.02 142.11 24.9 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.229 -0.919 . . . . 2.89 109.605 -179.103 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -178.1 68.16 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.352 -0.842 . . . . 4.63 109.308 179.501 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 28.6 tt0 -153.47 -51.33 0.1 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.176 -0.953 . . . . 2.89 109.501 -179.919 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -61.57 -57.16 13.16 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.146 -0.971 . . . . 1.74 109.439 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 136.13 -177.56 19.46 Favored Glycine 0 N--CA 1.495 2.586 0 N-CA-C 108.683 -1.767 . . . . 1.6 108.683 -179.621 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.78 142.36 23.98 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.048 -1.266 . . . . 1.4 109.306 179.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -159.2 176.95 35.94 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.422 -1.471 . . . . 1.04 109.422 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -109.82 114.35 3.87 Favored Glycine 0 N--CA 1.498 2.785 0 N-CA-C 109.439 -1.464 . . . . 1.06 109.439 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.474 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 10.5 tp -94.43 96.75 9.71 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.216 -1.167 . . . . 1.1 108.353 179.386 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 22.3 p -84.68 141.16 30.8 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.627 -0.879 . . . . 1.56 108.627 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.537 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 87.3 mt -134.01 113.96 18.72 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.342 -0.848 . . . . 0.65 109.489 -179.838 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -105.28 108.52 20.08 Favored 'General case' 0 N--CA 1.495 1.784 0 N-CA-C 108.808 -0.812 . . . . 0.69 108.808 179.611 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.433 HG23 ' OG ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -100.27 142.58 15.27 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.494 -0.753 . . . . 0.91 109.412 -179.795 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 12.5 tt0 -141.89 144.12 33.65 Favored 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 108.046 -1.094 . . . . 1.8 108.046 178.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.429 ' O ' ' O ' ' B' ' 9' ' ' VAL . . . 163.79 -172.4 39.66 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.836 -1.306 . . . . 0.49 109.836 -179.498 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -63.34 -28.73 72.03 Favored 'Trans proline' 0 C--N 1.318 -1.053 0 C-N-CA 122.133 1.889 . . . . 0.66 112.136 -179.412 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -131.73 175.99 8.72 Favored 'General case' 0 N--CA 1.502 2.152 0 O-C-N 121.225 -0.922 . . . . 1.55 110.165 -179.575 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 47.0 mttp -93.09 120.21 33.14 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.518 -0.739 . . . . 2.53 109.523 -179.712 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.673 ' HB1' ' HB2' ' A' ' 77' ' ' TYR . . . -80.94 108.63 14.78 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.331 -0.856 . . . . 0.82 108.825 179.82 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 23.4 mt-10 -83.51 103.17 12.65 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.072 -1.018 . . . . 2.3 109.87 -179.592 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 7.6 mm -58.73 156.96 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.886 -0.509 . . . . 1.4 109.751 179.781 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.469 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -139.66 174.5 10.45 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.122 -0.986 . . . . 1.36 109.015 179.649 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.441 ' CD1' ' N ' ' A' ' 65' ' ' PHE . 13.9 p90 -139.64 117.18 11.43 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.412 -0.805 . . . . 1.47 109.536 -179.896 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 . . . . . 0 N--CA 1.495 1.818 0 O-C-N 121.31 -0.869 . . . . 2.51 109.453 179.93 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.426 ' OG ' ' OG ' ' A' ' 40' ' ' SER . 24.2 t . . . . . 0 N--CA 1.49 1.561 0 N-CA-C 109.131 -0.692 . . . . 2.2 109.131 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' CYS . . . . . 0.51 ' N ' ' O ' ' A' ' 41' ' ' ILE . 20.5 m -77.26 110.89 12.36 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.233 -0.917 . . . . 2.05 109.582 -179.849 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -83.79 115.15 4.0 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.408 -1.477 . . . . 1.39 109.408 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.552 HG21 HD12 ' A' ' 41' ' ' ILE . 10.1 t -115.42 133.86 60.41 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.052 0 O-C-N 121.649 -0.912 . . . . 1.57 108.964 179.897 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.469 ' O ' ' N ' ' A' ' 64' ' ' ALA . 6.0 t -136.73 139.82 42.16 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.447 -0.783 . . . . 1.85 109.944 -179.827 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.673 ' HB2' ' HB1' ' A' ' 61' ' ' ALA . 6.9 p90 -120.16 139.2 52.97 Favored 'General case' 0 N--CA 1.495 1.79 0 N-CA-C 108.201 -1.037 . . . . 1.54 108.201 179.224 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.576 ' O ' HG13 ' A' ' 78' ' ' VAL . 9.7 p -108.87 120.78 60.88 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 O-C-N 121.332 -0.855 . . . . 1.9 109.741 -179.078 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.415 HG12 ' CZ ' ' A' ' 85' ' ' TYR . 3.6 m -101.12 168.4 1.93 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 N-CA-C 108.439 -0.949 . . . . 1.27 108.439 179.448 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 34.2 tp60 -101.5 -40.56 6.99 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.08 -1.013 . . . . 2.48 110.758 -179.486 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.429 ' O ' ' O ' ' A' ' 82' ' ' PRO . 0.0 OUTLIER -153.32 156.51 32.54 Favored Pre-proline 0 N--CA 1.504 2.248 0 O-C-N 120.539 -1.351 . . . . 1.92 111.209 -179.276 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.558 ' HG3' ' N ' ' A' ' 107' ' ' SER . 78.7 Cg_exo -37.73 169.12 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.654 0 C-N-CA 123.444 2.763 . . . . 1.3 113.239 179.016 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 142.82 179.02 19.25 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.659 -1.376 . . . . 1.02 109.659 179.559 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . 0.814 ' H ' HH12 ' B' ' 8' ' ' ARG . 3.0 m-20 -96.97 87.2 4.18 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 107.929 -1.137 . . . . 2.13 107.929 179.301 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.415 ' CZ ' HG12 ' A' ' 79' ' ' VAL . 2.9 m-85 -74.13 134.76 42.87 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 108.351 -0.981 . . . . 0.92 108.351 -179.345 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -111.22 121.58 45.65 Favored 'General case' 0 N--CA 1.497 1.91 0 N-CA-C 108.682 -0.858 . . . . 1.53 108.682 -179.058 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.1 p -119.65 140.58 43.16 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.891 0 O-C-N 121.552 -0.717 . . . . 1.0 109.546 -179.798 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 12.2 t -133.18 101.39 5.18 Favored 'General case' 0 N--CA 1.5 2.026 0 O-C-N 121.515 -0.741 . . . . 1.59 109.308 179.772 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.42 HG13 HD11 ' A' ' 96' ' ' ILE . 1.9 pt -108.51 137.51 39.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.721 -0.612 . . . . 1.29 110.37 -179.285 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' LYS . . . . . 0.44 ' HG3' ' H ' ' A' ' 93' ' ' ASP . 0.2 OUTLIER -146.91 125.87 12.79 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.857 -0.794 . . . . 1.58 108.857 179.367 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 48.4 t80 -81.69 93.89 6.86 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 120.785 -1.197 . . . . 1.34 108.492 179.42 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . 0.409 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 5.4 t30 69.93 43.24 0.94 Allowed 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 107.913 -1.143 . . . . 2.32 107.913 -178.591 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.44 ' H ' ' HG3' ' A' ' 90' ' ' LYS . 3.4 m-20 78.3 11.76 1.75 Allowed 'General case' 0 N--CA 1.495 1.789 0 CA-C-O 121.253 0.549 . . . . 1.92 109.96 -179.241 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . 0.51 ' OE1' ' N ' ' A' ' 18' ' ' ALA . 50.0 mt-10 -85.43 77.34 9.94 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 107.805 -1.183 . . . . 2.25 107.805 178.454 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' HIS . . . . . 0.546 ' CD2' ' O ' ' A' ' 95' ' ' HIS . 0.4 OUTLIER -67.97 106.41 2.33 Favored 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 120.03 -0.668 . . . . 2.88 109.752 -179.513 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' ILE . . . . . 0.775 ' H ' HD13 ' A' ' 96' ' ' ILE . 0.0 OUTLIER -68.96 156.1 92.15 Favored Pre-proline 0 N--CA 1.495 1.787 0 N-CA-C 107.709 -1.219 . . . . 2.35 107.709 179.606 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -48.9 -29.28 14.86 Favored 'Trans proline' 0 C--N 1.323 -0.806 0 C-N-CA 121.059 1.173 . . . . 2.48 109.144 -179.797 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 57.0 m-20 -58.83 -64.16 1.04 Allowed 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 108.963 -0.755 . . . . 2.65 108.963 178.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 3.1 m -70.78 139.7 86.06 Favored Pre-proline 0 C--N 1.296 -1.739 0 O-C-N 121.05 -1.031 . . . . 2.0 110.073 -178.681 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -87.08 119.46 5.07 Favored 'Cis proline' 0 N--CA 1.493 1.49 0 N-CA-C 110.025 -0.798 . . . . 1.79 110.025 -2.342 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 40.5 p90 -121.14 166.97 13.17 Favored 'General case' 0 N--CA 1.519 2.996 0 O-C-N 120.499 -1.376 . . . . 2.19 109.882 178.195 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.4 p -92.35 146.23 6.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 CA-C-O 121.642 0.734 . . . . 1.44 110.918 -178.28 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 79.8 t -119.83 86.46 35.94 Favored Pre-proline 0 N--CA 1.496 1.842 0 N-CA-C 107.799 -1.185 . . . . 1.19 107.799 178.888 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -63.96 114.28 2.54 Favored 'Trans proline' 0 C--N 1.32 -0.95 0 C-N-CA 121.36 1.373 . . . . 1.49 111.683 -178.028 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 75.2 t -98.88 144.09 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 N-CA-C 106.569 -1.641 . . . . 1.35 106.569 178.11 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.681 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -134.94 138.28 43.91 Favored 'General case' 0 N--CA 1.51 2.556 0 CA-C-O 122.055 0.931 . . . . 1.67 112.08 -177.174 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . 0.558 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 20.3 m -92.2 63.77 4.37 Favored 'General case' 0 N--CA 1.496 1.856 0 N-CA-C 107.152 -1.425 . . . . 2.04 107.152 178.652 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' LEU . . . . . 0.49 ' CB ' ' O ' ' A' ' 107' ' ' SER . 3.2 tp 80.45 -13.56 0.92 Allowed 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 106.456 -1.683 . . . . 3.2 106.456 -177.416 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.478 ' H ' ' C ' ' A' ' 107' ' ' SER . 5.2 m -68.54 -21.9 64.53 Favored 'General case' 0 C--N 1.306 -1.305 0 N-CA-C 108.732 -0.84 . . . . 2.09 108.732 178.785 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . 0.681 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 21.5 t70 . . . . . 0 N--CA 1.494 1.736 0 CA-C-O 121.937 0.875 . . . . 2.85 108.666 179.876 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . 0.814 HH12 ' H ' ' A' ' 84' ' ' ASP . 10.7 mtt180 . . . . . 0 N--CA 1.489 1.497 0 N-CA-C 108.087 -1.079 . . . . 3.04 108.087 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 9' ' ' VAL . . . . . 0.429 ' O ' ' O ' ' A' ' 57' ' ' GLY . 38.6 t -51.74 155.79 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 120.921 -1.112 . . . . 0.67 108.215 179.404 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -119.66 149.87 41.28 Favored 'General case' 0 N--CA 1.501 2.078 0 O-C-N 121.402 -0.811 . . . . 0.58 110.142 -178.914 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 11' ' ' SER . . . . . 0.433 ' OG ' HG23 ' A' ' 55' ' ' VAL . 6.9 t -147.36 141.84 26.46 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.506 -0.746 . . . . 1.19 109.301 179.688 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 6.7 m -143.88 121.14 11.56 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.176 -0.952 . . . . 1.38 109.439 -179.846 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 0.631 HG22 ' N ' ' B' ' 14' ' ' PHE . 7.7 p -163.62 168.76 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.39 -0.819 . . . . 0.42 109.183 179.91 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 14' ' ' PHE . . . . . 0.631 ' N ' HG22 ' B' ' 13' ' ' VAL . 7.9 p90 -176.91 -168.05 0.2 Allowed 'General case' 0 N--CA 1.488 1.437 0 C-N-CA 119.402 -0.919 . . . . 1.79 111.928 179.7 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.6 pt -151.29 167.47 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.344 0 N-CA-C 109.091 -0.707 . . . . 1.25 109.091 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 16' ' ' THR . . . . . 0.428 ' O ' HG23 ' B' ' 16' ' ' THR . 7.3 t -122.53 128.92 51.38 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 121.463 -0.773 . . . . 1.61 109.009 179.661 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 12.1 mt . . . . . 0 N--CA 1.497 1.901 0 O-C-N 121.204 -0.935 . . . . 1.32 109.866 -179.617 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.509 ' O ' ' N ' ' A' ' 18' ' ' ALA . . . . . . . . 0 N--CA 1.488 2.107 0 N-CA-C 111.157 -0.777 . . . . 2.44 111.157 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.55 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -38.83 -23.39 0.02 OUTLIER Glycine 0 N--CA 1.497 2.702 0 O-C-N 121.819 -0.813 . . . . 1.81 111.59 -178.704 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.709 ' HB2' ' OE1' ' A' ' 94' ' ' GLU . . . -47.25 -11.57 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.861 0 O-C-N 120.857 -1.378 . . . . 2.21 110.145 -179.467 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' HIS . . . . . 0.55 ' N ' ' O ' ' A' ' 17' ' ' GLY . 1.8 t60 -97.24 -37.73 9.96 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.249 -0.907 . . . . 2.87 110.242 -179.372 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.515 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.0 OUTLIER -91.03 -14.48 31.29 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.008 -1.057 . . . . 2.02 110.497 -179.145 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.566 ' O ' HG13 ' A' ' 21' ' ' VAL . 4.7 p -78.96 114.4 19.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 120.838 -1.164 . . . . 2.07 109.712 -179.763 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 12.5 tpp180 -109.75 139.27 45.0 Favored 'General case' 0 N--CA 1.492 1.646 0 N-CA-C 108.92 -0.771 . . . . 3.5 108.92 -179.877 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -147.32 113.57 5.89 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.535 -0.728 . . . . 1.83 109.2 179.584 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -147.6 128.38 2.9 Favored Glycine 0 N--CA 1.496 2.662 0 N-CA-C 109.472 -1.451 . . . . 1.9 109.472 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.07 171.24 43.69 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.842 -1.303 . . . . 1.85 109.842 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 34.1 m -74.89 -23.6 58.4 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.329 -1.101 . . . . 2.31 109.266 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.426 ' C ' ' H ' ' A' ' 29' ' ' GLU . . . -68.61 -27.92 73.51 Favored Glycine 0 N--CA 1.485 1.925 0 N-CA-C 108.444 -1.862 . . . . 1.64 108.444 179.641 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 24.9 mt -81.06 26.92 0.41 Allowed 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 108.416 -0.957 . . . . 1.83 108.416 179.397 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.426 ' H ' ' C ' ' A' ' 27' ' ' GLY . 42.5 mt-10 -132.21 -50.56 0.94 Allowed 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.687 -0.633 . . . . 2.34 109.608 -179.621 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 29.0 ptt180 -168.17 177.8 5.32 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 120.89 -1.131 . . . . 3.77 110.602 -179.774 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -151.08 175.68 29.92 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 108.566 -1.814 . . . . 1.57 108.566 179.686 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 39.9 t -134.56 151.93 32.58 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.087 0 O-C-N 121.22 -1.165 . . . . 1.83 110.748 -179.702 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.574 ' HB2' ' HB2' ' A' ' 107' ' ' SER . . . -39.16 108.95 0.09 Allowed 'General case' 0 N--CA 1.5 2.029 0 CA-C-O 121.399 0.618 . . . . 1.64 112.494 -179.388 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 54.57 53.71 37.15 Favored Glycine 0 N--CA 1.491 2.323 0 O-C-N 121.393 -0.817 . . . . 1.73 111.626 176.899 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 24.0 t -127.23 124.28 23.68 Favored Pre-proline 0 N--CA 1.496 1.826 0 N-CA-C 108.205 -1.035 . . . . 2.19 108.205 178.663 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo -57.24 128.95 31.69 Favored 'Trans proline' 0 C--O 1.216 -0.615 0 N-CA-C 109.693 -0.926 . . . . 1.96 109.693 -179.581 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.554 ' HB3' ' CZ ' ' A' ' 77' ' ' TYR . . . -134.36 157.89 45.22 Favored 'General case' 0 N--CA 1.502 2.16 0 O-C-N 121.518 -0.739 . . . . 1.69 109.507 -179.634 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -160.14 164.08 33.23 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.121 -0.987 . . . . 2.23 110.976 -179.663 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 0.558 ' CD1' ' N ' ' A' ' 39' ' ' PHE . 0.7 OUTLIER -139.89 -179.03 5.71 Favored 'General case' 0 C--N 1.304 -1.391 0 N-CA-C 106.896 -1.52 . . . . 1.54 106.896 177.75 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 52.2 p -119.16 145.87 45.64 Favored 'General case' 0 N--CA 1.5 2.04 0 O-C-N 121.598 -0.688 . . . . 2.37 110.609 -178.816 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.537 ' O ' ' N ' ' A' ' 73' ' ' CYS . 42.8 mt -143.63 128.68 15.1 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 N-CA-C 108.58 -0.896 . . . . 1.65 108.58 179.213 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 5.5 p-90 -128.24 138.78 52.59 Favored 'General case' 0 N--CA 1.502 2.161 0 N-CA-C 108.853 -0.795 . . . . 3.68 108.853 179.423 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.515 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -162.42 139.22 7.9 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.171 -0.956 . . . . 2.89 109.896 -179.534 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' ARG . . . . . . . . . . . . . 61.7 ttt180 -171.84 68.38 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.414 -0.804 . . . . 4.63 109.226 179.732 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 11.1 tp10 -153.72 -51.79 0.1 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.244 -0.91 . . . . 2.89 109.568 -179.87 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.76 -50.08 73.33 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.201 -0.937 . . . . 1.74 108.946 179.795 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 116.14 -162.4 12.62 Favored Glycine 0 N--CA 1.497 2.745 0 N-CA-C 109.639 -1.384 . . . . 1.6 109.639 179.735 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.4 151.98 5.11 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.276 -1.132 . . . . 1.4 109.386 -179.841 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -176.49 -162.72 27.7 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.55 -1.42 . . . . 1.04 109.55 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -140.47 119.71 1.63 Allowed Glycine 0 N--CA 1.496 2.663 0 N-CA-C 109.528 -1.429 . . . . 1.06 109.528 -179.878 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.466 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 11.6 tp -99.43 99.04 9.9 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.357 -1.084 . . . . 1.1 108.691 179.685 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 4.1 m -84.8 142.33 29.85 Favored 'General case' 0 N--CA 1.496 1.84 0 N-CA-C 108.741 -0.837 . . . . 1.56 108.741 179.867 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.52 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 80.5 mt -132.36 116.6 29.21 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 O-C-N 121.01 -1.056 . . . . 0.65 109.889 -179.915 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -106.99 106.92 17.69 Favored 'General case' 0 N--CA 1.496 1.865 0 N-CA-C 108.562 -0.903 . . . . 0.69 108.562 179.328 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -106.23 137.55 35.96 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 121.388 -0.82 . . . . 0.91 109.941 -179.186 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . 0.433 ' OE2' ' O ' ' B' ' 9' ' ' VAL . 40.7 tp10 -131.97 142.78 49.72 Favored 'General case' 0 N--CA 1.495 1.785 0 N-CA-C 107.896 -1.15 . . . . 1.8 107.896 178.36 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 172.95 -179.51 44.34 Favored Glycine 0 N--CA 1.488 2.132 0 N-CA-C 108.784 -1.726 . . . . 0.49 108.784 -179.635 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -63.43 -21.91 71.26 Favored 'Trans proline' 0 C--N 1.315 -1.231 0 C-N-CA 121.678 1.585 . . . . 0.66 110.732 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . 0.423 ' O ' ' OH ' ' A' ' 85' ' ' TYR . 36.6 m -143.24 165.47 27.36 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.453 -0.78 . . . . 1.55 110.114 -179.62 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 38.2 mttp -86.97 104.96 16.78 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.507 -0.746 . . . . 2.53 109.396 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -67.06 113.06 4.74 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.337 -0.852 . . . . 0.82 109.535 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 24.5 mm-40 -53.72 171.76 0.09 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.282 -0.886 . . . . 2.3 109.225 179.84 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.4 HG22 ' N ' ' A' ' 64' ' ' ALA . 90.1 mt -142.32 155.59 18.83 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 N-CA-C 108.122 -1.066 . . . . 1.4 108.122 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.542 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -149.56 175.35 11.6 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 120.642 -1.286 . . . . 1.36 109.635 -179.802 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.522 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 54.6 p90 -138.88 124.77 19.84 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.448 -0.782 . . . . 1.47 109.124 179.846 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 . . . . . 0 N--CA 1.495 1.821 0 O-C-N 121.273 -0.892 . . . . 2.51 109.579 -179.825 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 40.3 t . . . . . 0 N--CA 1.494 1.762 0 N-CA-C 109.176 -0.675 . . . . 2.2 109.176 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' CYS . . . . . 0.537 ' N ' ' O ' ' A' ' 41' ' ' ILE . 46.6 t -71.54 111.1 6.57 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.228 -0.92 . . . . 2.05 109.48 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -91.96 115.14 4.71 Favored Glycine 0 N--CA 1.493 2.477 0 N-CA-C 109.692 -1.363 . . . . 1.39 109.692 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 45.3 t -99.38 102.0 12.84 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 O-C-N 121.467 -1.019 . . . . 1.57 109.011 179.721 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.542 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.4 OUTLIER -92.0 137.09 32.65 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.338 -0.851 . . . . 1.85 109.111 -179.837 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.554 ' CZ ' ' HB3' ' A' ' 37' ' ' ALA . 8.5 p90 -136.34 166.04 24.38 Favored 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 108.674 -0.861 . . . . 1.54 108.674 -179.862 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 6.7 t -141.86 110.05 2.34 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.329 -0.857 . . . . 1.9 109.585 -179.669 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.464 ' H ' HG22 ' A' ' 79' ' ' VAL . 3.3 m -84.73 154.32 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.544 -0.723 . . . . 1.27 109.429 -179.915 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 4.3 tp-100 -93.26 -48.93 6.21 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.065 -1.022 . . . . 2.48 111.015 -178.96 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.431 ' O ' ' O ' ' A' ' 82' ' ' PRO . 81.5 mm-40 -148.57 149.92 32.39 Favored Pre-proline 0 N--CA 1.504 2.263 0 O-C-N 120.68 -1.262 . . . . 1.92 111.609 -178.427 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.637 ' HG3' ' N ' ' A' ' 107' ' ' SER . 83.1 Cg_exo -37.18 168.53 0.0 OUTLIER 'Trans proline' 0 C--O 1.216 -0.599 0 C-N-CA 123.15 2.567 . . . . 1.3 113.787 178.37 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 141.8 -173.8 23.4 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 108.651 -1.779 . . . . 1.02 108.651 -179.87 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . 0.717 ' H ' ' NH1' ' B' ' 8' ' ' ARG . 0.4 OUTLIER -103.18 90.41 3.72 Favored 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 107.866 -1.161 . . . . 2.13 107.866 179.217 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.423 ' OH ' ' O ' ' A' ' 59' ' ' SER . 3.0 m-85 -74.69 133.4 42.09 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 107.992 -1.114 . . . . 0.92 107.992 -179.574 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.36 116.38 28.85 Favored 'General case' 0 N--CA 1.5 2.034 0 N-CA-C 108.503 -0.925 . . . . 1.53 108.503 -178.791 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.429 HG11 ' CZ ' ' A' ' 101' ' ' PHE . 11.3 p -114.63 142.32 27.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 121.719 -0.613 . . . . 1.0 109.865 -179.66 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 32.9 t -136.11 106.07 6.28 Favored 'General case' 0 N--CA 1.494 1.756 0 N-CA-C 109.289 -0.634 . . . . 1.59 109.289 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.413 ' H ' ' HB3' ' A' ' 99' ' ' SER . 1.8 pt -111.4 136.85 46.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 CA-C-O 121.374 0.607 . . . . 1.29 110.148 -179.429 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' LYS . . . . . 0.458 ' HZ2' ' CD2' ' A' ' 95' ' ' HIS . 0.3 OUTLIER -138.99 121.27 15.92 Favored 'General case' 0 N--CA 1.486 1.355 0 N-CA-C 108.518 -0.919 . . . . 1.58 108.518 179.329 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 52.6 t80 -80.1 99.02 7.52 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 107.699 -1.223 . . . . 1.34 107.699 178.563 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . 0.442 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 3.6 t-20 69.8 37.79 1.76 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.503 -0.748 . . . . 2.32 109.284 -178.735 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.442 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 1.8 m-20 79.06 13.49 1.2 Allowed 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.625 -0.672 . . . . 1.92 111.629 179.313 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . 0.709 ' OE1' ' HB2' ' A' ' 18' ' ' ALA . 0.6 OUTLIER -99.29 97.88 8.9 Favored 'General case' 0 N--CA 1.5 2.059 0 N-CA-C 106.857 -1.534 . . . . 2.25 106.857 177.732 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' HIS . . . . . 0.458 ' CD2' ' HZ2' ' A' ' 90' ' ' LYS . 5.9 m80 -67.88 101.86 1.16 Allowed 'General case' 0 N--CA 1.487 1.421 0 CA-C-O 121.411 0.624 . . . . 2.88 110.924 -177.636 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' ILE . . . . . 0.428 HG23 ' H ' ' A' ' 99' ' ' SER . 2.1 tt -53.32 137.46 49.69 Favored Pre-proline 0 N--CA 1.49 1.566 0 N-CA-C 106.869 -1.53 . . . . 2.35 106.869 178.26 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_exo -40.76 -39.06 2.95 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 121.077 1.184 . . . . 2.48 111.194 -178.575 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.408 ' OD1' ' CD1' ' A' ' 96' ' ' ILE . 8.6 m-20 -50.12 -67.2 0.28 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.787 -1.196 . . . . 2.65 109.092 178.843 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.428 ' H ' HG23 ' A' ' 96' ' ' ILE . 2.8 p -57.53 142.03 77.77 Favored Pre-proline 0 C--N 1.296 -1.759 0 O-C-N 121.405 -0.81 . . . . 2.0 110.086 -178.236 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -85.15 114.92 3.22 Favored 'Cis proline' 0 N--CA 1.49 1.288 0 N-CA-C 108.739 -1.293 . . . . 1.79 108.739 -2.612 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . 0.429 ' CZ ' HG11 ' A' ' 87' ' ' VAL . 51.8 p90 -112.77 156.45 22.83 Favored 'General case' 0 N--CA 1.514 2.748 0 O-C-N 120.405 -1.434 . . . . 2.19 110.217 179.286 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.4 p -88.94 146.1 6.58 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 CA-C-O 121.556 0.693 . . . . 1.44 110.417 -178.595 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.414 ' O ' HG12 ' A' ' 103' ' ' VAL . 47.3 t -120.97 86.55 42.09 Favored Pre-proline 0 N--CA 1.494 1.768 0 N-CA-C 107.753 -1.203 . . . . 1.19 107.753 179.236 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo -65.07 111.08 1.65 Allowed 'Trans proline' 0 C--N 1.32 -0.935 0 C-N-CA 121.393 1.395 . . . . 1.49 111.74 -177.879 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.431 HG21 HG11 ' A' ' 79' ' ' VAL . 58.6 t -96.53 141.05 16.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 N-CA-C 106.148 -1.797 . . . . 1.35 106.148 177.828 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.69 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -133.89 133.72 41.83 Favored 'General case' 0 N--CA 1.51 2.53 0 CA-C-O 122.303 1.049 . . . . 1.67 112.131 -177.031 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . 0.637 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 17.0 t -101.02 85.55 2.87 Favored 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 107.129 -1.434 . . . . 2.04 107.129 178.685 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 12.9 mt 64.76 0.51 1.18 Allowed 'General case' 0 C--N 1.296 -1.729 0 N-CA-C 108.035 -1.098 . . . . 3.2 108.035 -178.011 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.489 ' H ' ' C ' ' A' ' 107' ' ' SER . 8.2 t -89.88 -24.95 21.23 Favored 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 109.011 -0.737 . . . . 2.09 109.011 179.061 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . 0.69 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 25.2 t70 . . . . . 0 N--CA 1.488 1.436 0 N-CA-C 107.897 -1.149 . . . . 2.85 107.897 -178.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . 0.717 ' NH1' ' H ' ' A' ' 84' ' ' ASP . 43.8 mtt180 . . . . . 0 N--CA 1.493 1.7 0 N-CA-C 109.325 -0.62 . . . . 3.04 109.325 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 9' ' ' VAL . . . . . 0.433 ' O ' ' OE2' ' A' ' 56' ' ' GLU . 15.2 t -59.34 160.32 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 N-CA-C 107.718 -1.215 . . . . 0.67 107.718 178.719 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -116.99 142.94 46.31 Favored 'General case' 0 N--CA 1.503 2.189 0 O-C-N 121.287 -0.883 . . . . 0.58 110.433 -179.073 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 30.2 t -143.72 131.36 21.25 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.471 -0.768 . . . . 1.19 109.063 179.47 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 87.8 p -140.39 120.19 13.46 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.232 -0.918 . . . . 1.38 109.587 -179.727 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 0.603 HG22 ' N ' ' B' ' 14' ' ' PHE . 3.0 p -162.26 168.3 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.412 0 O-C-N 121.379 -0.826 . . . . 0.42 109.073 -179.948 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 14' ' ' PHE . . . . . 0.603 ' N ' HG22 ' B' ' 13' ' ' VAL . 6.6 p90 -177.1 -171.76 0.37 Allowed 'General case' 0 N--CA 1.487 1.4 0 C-N-CA 119.391 -0.923 . . . . 1.79 112.008 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -142.64 173.78 6.38 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.322 0 N-CA-C 108.335 -0.987 . . . . 1.25 108.335 179.597 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 32.3 p -146.65 139.82 25.54 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 120.929 -1.107 . . . . 1.61 109.817 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.4 mt . . . . . 0 N--CA 1.494 1.737 0 O-C-N 121.256 -0.902 . . . . 1.32 109.074 179.582 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.548 ' O ' ' N ' ' A' ' 18' ' ' ALA . . . . . . . . 0 N--CA 1.49 2.255 0 N-CA-C 110.643 -0.983 . . . . 2.44 110.643 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.583 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 64.21 -47.1 0.1 OUTLIER Glycine 0 N--CA 1.493 2.497 0 O-C-N 121.479 -1.012 . . . . 1.81 111.055 178.823 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.548 ' N ' ' O ' ' A' ' 16' ' ' GLY . . . -46.24 -11.13 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.871 0 O-C-N 120.959 -1.318 . . . . 2.21 110.05 -179.578 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' HIS . . . . . 0.583 ' N ' ' O ' ' A' ' 17' ' ' GLY . 34.0 t60 -84.64 -48.42 9.51 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 120.994 -1.066 . . . . 2.87 109.6 179.729 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.552 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.1 OUTLIER -83.18 -3.63 57.57 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.047 -1.033 . . . . 2.02 110.192 -179.617 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 66.6 t -77.86 113.24 16.8 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 120.944 -1.098 . . . . 2.07 109.537 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 20.9 tpt180 -100.14 138.93 36.53 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.633 -0.667 . . . . 3.5 109.571 -179.858 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -147.42 113.37 5.79 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 108.402 -0.962 . . . . 1.83 108.402 179.332 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -158.5 128.7 2.12 Favored Glycine 0 N--CA 1.491 2.339 0 C-N-CA 119.688 -1.244 . . . . 1.9 110.234 -179.199 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.3 -179.7 48.77 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.641 -1.383 . . . . 1.85 109.641 179.611 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 6.5 m -76.58 -21.86 55.03 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.168 -1.195 . . . . 2.31 109.24 179.759 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.9 -23.83 77.64 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 108.818 -1.713 . . . . 1.64 108.818 179.71 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 34.6 mt -85.1 28.79 0.69 Allowed 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.499 -1.001 . . . . 1.83 108.689 179.572 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 15.0 mt-10 -138.71 -64.24 0.52 Allowed 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.503 -0.748 . . . . 2.34 109.908 -179.655 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 80.8 mtm180 -150.64 165.42 33.44 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 120.895 -1.128 . . . . 3.77 110.222 -179.248 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -139.07 170.57 24.01 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 107.473 -2.251 . . . . 1.57 107.473 178.887 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 40.5 t -133.85 151.31 32.63 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.109 0 O-C-N 121.088 -1.243 . . . . 1.83 110.948 -179.029 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.499 ' HB2' ' HB2' ' A' ' 107' ' ' SER . . . -40.48 114.59 0.47 Allowed 'General case' 0 N--CA 1.497 1.902 0 CA-C-O 121.867 0.841 . . . . 1.64 112.428 -179.313 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 52.99 49.71 54.19 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 111.225 -0.75 . . . . 1.73 111.225 177.13 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 22.5 t -127.02 124.98 24.1 Favored Pre-proline 0 N--CA 1.496 1.843 0 O-C-N 121.497 -1.002 . . . . 2.19 108.46 179.143 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -58.41 109.86 0.57 Allowed 'Trans proline' 0 C--O 1.215 -0.637 0 N-CA-C 109.682 -0.93 . . . . 1.96 109.682 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -108.03 142.07 38.74 Favored 'General case' 0 N--CA 1.495 1.825 0 N-CA-C 107.929 -1.138 . . . . 1.69 107.929 179.408 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -150.92 169.52 21.53 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.871 -1.143 . . . . 2.23 111.244 -179.385 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 0.61 ' CE2' HD11 ' A' ' 41' ' ' ILE . 5.2 p90 -154.35 173.78 15.73 Favored 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 107.617 -1.253 . . . . 1.54 107.617 178.452 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 72.9 m -101.54 150.82 22.68 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.496 -0.753 . . . . 2.37 110.469 -178.652 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.61 HD11 ' CE2' ' A' ' 39' ' ' PHE . 11.3 mt -142.95 90.64 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 N-CA-C 108.748 -0.834 . . . . 1.65 108.748 178.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 31.1 t-105 -92.93 120.01 32.81 Favored 'General case' 0 N--CA 1.493 1.704 0 N-CA-C 108.251 -1.018 . . . . 3.68 108.251 179.504 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.552 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -152.74 108.84 3.36 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.276 -0.89 . . . . 2.89 109.594 -179.148 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' ARG . . . . . 0.598 ' CG ' HH11 ' A' ' 44' ' ' ARG . 0.1 OUTLIER -171.57 82.12 0.07 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.225 -0.922 . . . . 4.63 109.599 -179.984 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 74.2 tt0 -159.5 -46.24 0.05 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.016 -1.053 . . . . 2.89 109.985 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.456 ' H ' ' HE2' ' A' ' 20' ' ' LYS . . . -64.15 -45.62 87.68 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.03 -1.044 . . . . 1.74 109.195 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 160.78 -153.03 23.83 Favored Glycine 0 N--CA 1.485 1.903 0 C-N-CA 119.403 -1.379 . . . . 1.6 110.175 179.786 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -96.66 158.57 15.37 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.558 -0.966 . . . . 1.4 109.174 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -179.09 173.0 45.2 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.392 -1.483 . . . . 1.04 109.392 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -105.11 121.09 6.76 Favored Glycine 0 N--CA 1.495 2.624 0 N-CA-C 109.501 -1.439 . . . . 1.06 109.501 -179.891 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.465 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 64.2 tp -91.01 108.79 20.09 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.222 -1.163 . . . . 1.1 107.897 179.153 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.7 t -91.23 142.37 27.8 Favored 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 108.663 -0.865 . . . . 1.56 108.663 179.89 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.544 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 22.5 mt -130.49 100.62 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 121.521 -0.737 . . . . 0.65 109.071 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.438 ' HB3' ' OG ' ' A' ' 88' ' ' SER . . . -93.86 106.41 18.38 Favored 'General case' 0 N--CA 1.489 1.506 0 N-CA-C 108.621 -0.881 . . . . 0.69 108.621 179.711 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.408 HG23 ' CB ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -101.48 143.28 14.7 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 CA-C-O 121.588 0.708 . . . . 0.91 109.582 -179.631 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 8.2 tt0 -141.52 145.57 35.33 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 107.479 -1.304 . . . . 1.8 107.479 178.868 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 165.56 -172.71 41.14 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.856 -1.298 . . . . 0.49 109.856 -179.095 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -63.18 -33.99 70.14 Favored 'Trans proline' 0 C--N 1.319 -0.988 0 C-N-CA 122.315 2.01 . . . . 0.66 112.514 -179.435 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . 0.497 ' OG ' ' N ' ' A' ' 60' ' ' LYS . 5.9 t -132.36 177.76 7.34 Favored 'General case' 0 N--CA 1.504 2.239 0 O-C-N 120.944 -1.097 . . . . 1.55 110.49 -179.273 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . 0.497 ' N ' ' OG ' ' A' ' 59' ' ' SER . 45.8 tttm -93.82 96.18 9.59 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.689 -0.632 . . . . 2.53 109.713 -179.591 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -61.54 131.17 49.23 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.179 -0.951 . . . . 0.82 109.017 179.696 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 16.2 tp10 -88.54 95.05 10.08 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 120.964 -1.085 . . . . 2.3 110.174 -179.456 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.563 HD12 ' N ' ' A' ' 63' ' ' ILE . 1.7 mp -60.61 156.04 3.43 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 N-CA-C 109.207 -0.664 . . . . 1.4 109.207 179.335 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.534 ' HB3' ' HB3' ' A' ' 76' ' ' SER . . . -144.72 172.38 13.08 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.013 -1.054 . . . . 1.36 108.78 179.598 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.524 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 41.0 p90 -148.44 116.2 6.33 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.26 -0.9 . . . . 1.47 109.188 179.845 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 78.6 tt0 . . . . . 0 N--CA 1.498 1.964 0 O-C-N 121.161 -0.962 . . . . 2.51 109.821 -179.884 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 19.8 t . . . . . 0 N--CA 1.488 1.467 0 N-CA-C 108.827 -0.805 . . . . 2.2 108.827 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 8.6 t -76.69 129.14 35.93 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.103 -0.998 . . . . 2.05 109.103 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -103.68 114.68 4.87 Favored Glycine 0 N--CA 1.496 2.69 0 N-CA-C 110.064 -1.214 . . . . 1.39 110.064 -179.332 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.588 HG21 HD12 ' A' ' 41' ' ' ILE . 38.4 t -101.83 108.74 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.925 0 O-C-N 121.516 -0.99 . . . . 1.57 108.771 179.426 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.534 ' HB3' ' HB3' ' A' ' 64' ' ' ALA . 4.1 t -103.46 127.69 50.79 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.531 -0.731 . . . . 1.85 109.457 179.849 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 6.4 p90 -128.45 128.2 43.97 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 108.303 -0.999 . . . . 1.54 108.303 179.838 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -103.8 110.06 29.01 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.159 0 O-C-N 121.324 -0.86 . . . . 1.9 109.404 -178.859 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.47 ' H ' HG22 ' A' ' 79' ' ' VAL . 5.8 m -82.6 163.39 3.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.496 -0.753 . . . . 1.27 109.42 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 20.1 tt0 -95.78 -50.39 4.93 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.005 -1.059 . . . . 2.48 111.117 -179.163 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -152.29 155.55 33.17 Favored Pre-proline 0 N--CA 1.504 2.237 0 O-C-N 120.688 -1.257 . . . . 1.92 111.72 -178.594 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.572 ' HG3' ' N ' ' A' ' 107' ' ' SER . 75.9 Cg_exo -37.07 160.77 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 123.61 2.873 . . . . 1.3 113.636 179.285 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 148.19 -164.16 28.94 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.223 -1.551 . . . . 1.02 109.223 179.816 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . 0.431 ' HB2' ' HE ' ' B' ' 8' ' ' ARG . 65.0 m-20 -108.82 88.85 2.83 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.601 -0.94 . . . . 2.13 108.662 179.656 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.499 ' O ' ' N ' ' A' ' 103' ' ' VAL . 2.9 m-85 -76.27 129.52 36.8 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 108.165 -1.05 . . . . 0.92 108.165 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -107.85 128.33 54.51 Favored 'General case' 0 N--CA 1.497 1.914 0 N-CA-C 108.144 -1.058 . . . . 1.53 108.144 -179.446 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 9.4 p -126.12 140.27 49.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.525 -0.734 . . . . 1.0 109.972 -179.401 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . 0.438 ' OG ' ' HB3' ' A' ' 54' ' ' ALA . 11.1 p -134.4 104.39 6.11 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.585 -0.697 . . . . 1.59 109.52 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.414 HD11 ' CD1' ' A' ' 96' ' ' ILE . 0.8 OUTLIER -112.33 129.58 67.6 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 CA-C-O 121.585 0.707 . . . . 1.29 109.492 -179.847 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' LYS . . . . . 0.469 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -139.71 124.2 18.17 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 108.232 -1.025 . . . . 1.58 108.232 179.661 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.408 ' O ' ' CB ' ' A' ' 92' ' ' ASN . 31.8 t80 -85.64 102.96 14.02 Favored 'General case' 0 N--CA 1.494 1.737 0 N-CA-C 107.546 -1.279 . . . . 1.34 107.546 178.783 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . 0.423 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 8.5 t30 72.48 35.84 1.09 Allowed 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.806 -0.813 . . . . 2.32 108.806 -178.235 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.423 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 1.7 m-20 76.4 15.24 2.25 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.676 -0.64 . . . . 1.92 111.409 179.692 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . 0.498 ' CG ' ' O ' ' A' ' 94' ' ' GLU . 7.2 pt-20 -98.53 100.43 11.68 Favored 'General case' 0 N--CA 1.493 1.717 0 N-CA-C 107.201 -1.407 . . . . 2.25 107.201 177.949 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' HIS . . . . . 0.631 ' H ' ' CD2' ' A' ' 95' ' ' HIS . 7.0 p80 -71.67 106.52 4.11 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.215 -0.928 . . . . 2.88 109.534 -178.541 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' ILE . . . . . 0.561 ' O ' ' N ' ' A' ' 98' ' ' ASP . 10.1 pt -55.82 150.19 28.94 Favored Pre-proline 0 N--CA 1.491 1.611 0 C-N-CA 119.377 -0.929 . . . . 2.35 108.507 179.795 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.411 ' O ' ' CG ' ' A' ' 98' ' ' ASP . 4.6 Cg_exo -53.87 82.01 0.03 OUTLIER 'Trans proline' 0 C--O 1.213 -0.738 0 N-CA-C 109.202 -1.114 . . . . 2.48 109.202 179.415 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.561 ' N ' ' O ' ' A' ' 96' ' ' ILE . 1.9 m-20 175.05 -63.36 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 108.037 -1.097 . . . . 2.65 108.037 -178.949 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 5.1 m -59.03 139.08 87.68 Favored Pre-proline 0 C--N 1.298 -1.671 0 O-C-N 121.539 -0.725 . . . . 2.0 110.119 -178.134 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_endo -88.58 115.21 2.9 Favored 'Cis proline' 0 N--CA 1.493 1.474 0 N-CA-C 109.722 -0.915 . . . . 1.79 109.722 -2.597 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 45.6 p90 -112.53 168.45 9.64 Favored 'General case' 0 N--CA 1.516 2.868 0 O-C-N 120.556 -1.34 . . . . 2.19 110.027 178.828 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.4 p -94.38 152.28 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.474 -0.766 . . . . 1.44 110.735 -178.901 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.499 ' N ' ' O ' ' A' ' 85' ' ' TYR . 61.3 t -126.69 87.01 57.4 Favored Pre-proline 0 N--CA 1.499 1.992 0 N-CA-C 107.919 -1.141 . . . . 1.19 107.919 179.193 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -61.25 113.09 1.61 Allowed 'Trans proline' 0 C--N 1.32 -0.951 0 C-N-CA 121.376 1.384 . . . . 1.49 112.189 -177.787 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 53.8 t -94.16 145.08 8.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 N-CA-C 106.64 -1.615 . . . . 1.35 106.64 177.736 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.543 ' HB1' ' H ' ' A' ' 110' ' ' ASP . . . -136.73 137.33 39.81 Favored 'General case' 0 N--CA 1.506 2.328 0 CA-C-O 122.268 1.032 . . . . 1.67 111.995 -177.507 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . 0.572 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 9.5 t -110.53 68.47 0.67 Allowed 'General case' 0 N--CA 1.495 1.808 0 N-CA-C 107.229 -1.397 . . . . 2.04 107.229 178.855 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' LEU . . . . . 0.496 ' CB ' ' O ' ' A' ' 107' ' ' SER . 2.6 tp 81.23 -3.53 1.7 Allowed 'General case' 0 N--CA 1.492 1.641 0 N-CA-C 106.603 -1.629 . . . . 3.2 106.603 -177.574 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 2.0 m -80.08 -27.09 39.36 Favored 'General case' 0 N--CA 1.486 1.348 0 N-CA-C 108.853 -0.795 . . . . 2.09 108.853 179.138 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . 0.543 ' H ' ' HB1' ' A' ' 106' ' ' ALA . 37.8 m-20 . . . . . 0 N--CA 1.492 1.659 0 O-C-N 121.283 -0.886 . . . . 2.85 108.799 -179.71 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . 0.546 ' CG ' HH11 ' B' ' 8' ' ' ARG . 1.5 mtt-85 . . . . . 0 N--CA 1.491 1.605 0 N-CA-C 108.694 -0.854 . . . . 3.04 108.694 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 9' ' ' VAL . . . . . . . . . . . . . 5.7 t -49.09 159.82 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.065 -1.022 . . . . 0.67 108.263 179.547 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -117.67 162.16 18.5 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.524 -0.735 . . . . 0.58 110.222 -178.769 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 11' ' ' SER . . . . . 0.408 ' CB ' HG23 ' A' ' 55' ' ' VAL . 32.4 m -153.59 141.24 19.94 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.585 -0.697 . . . . 1.19 109.13 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 41.7 m -145.05 112.27 6.06 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.113 -0.992 . . . . 1.38 110.021 -179.664 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 0.595 HG22 ' N ' ' B' ' 14' ' ' PHE . 3.2 p -159.93 167.48 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 N-CA-C 108.689 -0.856 . . . . 0.42 108.689 179.661 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 14' ' ' PHE . . . . . 0.896 ' O ' HD13 ' B' ' 15' ' ' ILE . 9.1 p90 -176.77 -169.07 0.25 Allowed 'General case' 0 N--CA 1.49 1.565 0 C-N-CA 119.162 -1.015 . . . . 1.79 112.179 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.896 HD13 ' O ' ' B' ' 14' ' ' PHE . 3.9 mm -142.12 165.14 17.68 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 N-CA-C 108.69 -0.856 . . . . 1.25 108.69 179.759 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 75.7 p -120.0 136.72 54.45 Favored 'General case' 0 N--CA 1.503 2.2 0 O-C-N 121.283 -0.886 . . . . 1.61 109.681 179.876 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 11.0 mt . . . . . 0 N--CA 1.5 2.058 0 O-C-N 121.369 -0.832 . . . . 1.32 109.975 -179.836 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.472 ' O ' ' CB ' ' A' ' 94' ' ' GLU . . . . . . . . 0 N--CA 1.488 2.115 0 N-CA-C 111.568 -0.613 . . . . 2.44 111.568 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.541 ' C ' ' H ' ' A' ' 19' ' ' HIS . . . 67.71 -49.03 0.33 Allowed Glycine 0 N--CA 1.495 2.61 0 O-C-N 121.577 -0.955 . . . . 1.81 111.662 178.092 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.796 ' HB2' ' OE1' ' A' ' 94' ' ' GLU . . . -51.3 -5.29 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.853 0 O-C-N 120.963 -1.316 . . . . 2.21 109.975 -179.201 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' HIS . . . . . 0.541 ' H ' ' C ' ' A' ' 17' ' ' GLY . 6.1 t60 -98.75 -7.13 28.13 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.135 -0.978 . . . . 2.87 110.503 -179.545 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.551 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.0 OUTLIER -137.8 6.0 2.65 Favored 'General case' 0 N--CA 1.501 2.106 0 O-C-N 120.968 -1.082 . . . . 2.02 110.34 -179.581 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 71.3 t -91.05 113.43 26.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 120.95 -1.094 . . . . 2.07 109.851 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 12.8 tpp180 -105.33 137.88 42.43 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 108.827 -0.805 . . . . 3.5 108.827 179.844 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -147.12 113.64 5.98 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.418 -0.801 . . . . 1.83 108.857 179.794 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -155.26 129.73 2.61 Favored Glycine 0 N--CA 1.493 2.471 0 N-CA-C 109.678 -1.369 . . . . 1.9 109.678 -179.655 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.54 -176.88 46.8 Favored Glycine 0 N--CA 1.491 2.304 0 C-N-CA 119.741 -1.219 . . . . 1.85 110.088 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 12.6 p -79.65 -25.53 41.34 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.353 -1.086 . . . . 2.31 109.343 179.877 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -68.94 -15.99 69.94 Favored Glycine 0 N--CA 1.485 1.934 0 N-CA-C 108.304 -1.918 . . . . 1.64 108.304 179.548 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 90.4 mt -93.35 30.41 1.71 Allowed 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 108.601 -0.889 . . . . 1.83 108.601 179.49 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 15.3 mt-10 -139.11 -48.72 0.49 Allowed 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.504 -0.747 . . . . 2.34 109.34 -179.834 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 5.4 ptp180 -174.69 177.12 2.15 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.153 -0.967 . . . . 3.77 110.192 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -149.43 174.58 28.93 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 108.495 -1.842 . . . . 1.57 108.495 179.717 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 39.5 t -134.42 149.87 30.26 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.075 0 O-C-N 121.203 -1.175 . . . . 1.83 110.567 -179.702 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.575 ' HB2' ' HB2' ' A' ' 107' ' ' SER . . . -37.38 113.98 0.3 Allowed 'General case' 0 N--CA 1.496 1.864 0 CA-C-O 121.745 0.783 . . . . 1.64 112.471 -179.232 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 51.68 51.42 38.74 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 111.24 -0.744 . . . . 1.73 111.24 177.097 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 24.4 t -126.82 121.67 23.18 Favored Pre-proline 0 N--CA 1.495 1.821 0 N-CA-C 108.198 -1.038 . . . . 2.19 108.198 178.834 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -57.87 140.22 93.04 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 120.483 0.789 . . . . 1.96 110.142 -179.422 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.418 ' HB3' ' CE1' ' A' ' 77' ' ' TYR . . . -145.33 158.0 43.92 Favored 'General case' 0 N--CA 1.493 1.716 0 N-CA-C 108.275 -1.009 . . . . 1.69 108.275 179.603 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -155.8 172.01 19.06 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.815 -1.178 . . . . 2.23 110.8 -179.543 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 0.609 ' CE2' HD11 ' A' ' 41' ' ' ILE . 5.9 p90 -156.27 166.64 32.85 Favored 'General case' 0 C--N 1.298 -1.646 0 N-CA-C 107.888 -1.153 . . . . 1.54 107.888 178.446 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 43.9 m -99.05 152.12 20.18 Favored 'General case' 0 N--CA 1.494 1.762 0 CA-C-O 121.782 0.801 . . . . 2.37 111.129 -178.146 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.609 HD11 ' CE2' ' A' ' 39' ' ' PHE . 10.8 mt -143.48 85.79 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 N-CA-C 108.416 -0.957 . . . . 1.65 108.416 178.91 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 31.5 t90 -91.61 147.36 23.06 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.053 -1.029 . . . . 3.68 109.284 -179.489 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.551 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.1 OUTLIER -161.76 -110.99 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.286 -0.883 . . . . 2.89 109.628 -179.731 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' ARG . . . . . 0.526 HH11 ' HG2' ' A' ' 44' ' ' ARG . 2.3 ttt-85 52.69 90.74 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.221 -0.924 . . . . 4.63 109.862 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -172.2 -60.68 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.245 -0.909 . . . . 2.89 109.365 179.265 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -57.04 -57.89 10.57 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.988 -1.07 . . . . 1.74 108.741 179.724 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 150.99 -160.46 28.64 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 110.029 -1.228 . . . . 1.6 110.029 179.488 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.01 149.17 9.55 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.403 -1.057 . . . . 1.4 109.778 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -176.26 173.65 46.42 Favored Glycine 0 N--CA 1.489 2.168 0 N-CA-C 109.487 -1.445 . . . . 1.04 109.487 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -126.76 122.63 4.4 Favored Glycine 0 N--CA 1.498 2.825 0 N-CA-C 109.143 -1.583 . . . . 1.06 109.143 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.47 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 11.3 tp -93.85 99.37 11.75 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.221 -1.164 . . . . 1.1 108.843 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 2.2 t -83.51 141.27 31.76 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 108.42 -0.956 . . . . 1.56 108.42 179.687 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.559 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 92.3 mt -134.73 115.58 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.217 -0.927 . . . . 0.65 109.33 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -104.65 106.86 17.52 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.364 -0.835 . . . . 0.69 109.008 179.778 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -101.45 135.07 39.72 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.115 0 O-C-N 121.477 -0.765 . . . . 0.91 109.516 -179.771 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . 0.43 ' OE2' ' O ' ' B' ' 9' ' ' VAL . 30.9 tp10 -134.36 142.46 47.22 Favored 'General case' 0 N--CA 1.494 1.738 0 N-CA-C 107.399 -1.334 . . . . 1.8 107.399 178.324 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 171.51 -176.67 44.67 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.421 -1.472 . . . . 0.49 109.421 -179.362 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -61.62 -28.35 82.6 Favored 'Trans proline' 0 C--N 1.318 -1.06 0 C-N-CA 121.992 1.795 . . . . 0.66 111.856 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . 0.413 ' O ' ' OH ' ' A' ' 85' ' ' TYR . 10.6 p -142.39 163.24 33.37 Favored 'General case' 0 N--CA 1.501 2.095 0 O-C-N 121.063 -1.023 . . . . 1.55 110.349 -179.564 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 19.4 mtpp -81.09 115.71 20.66 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.532 -0.73 . . . . 2.53 109.28 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -80.67 129.54 34.58 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.284 -0.885 . . . . 0.82 109.648 -179.817 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.455 ' CB ' HG12 ' A' ' 78' ' ' VAL . 18.2 tp10 -68.29 170.95 7.85 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.127 -0.983 . . . . 2.3 108.535 179.722 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.402 HD12 ' N ' ' A' ' 63' ' ' ILE . 3.8 mp -139.9 153.75 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 N-CA-C 108.417 -0.956 . . . . 1.4 108.417 -179.389 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.563 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -150.79 114.6 4.98 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 120.672 -1.267 . . . . 1.36 109.747 -179.565 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.505 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 43.0 p90 -92.77 122.56 35.28 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.27 -0.894 . . . . 1.47 109.19 179.615 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 . . . . . 0 N--CA 1.496 1.858 0 O-C-N 121.266 -0.896 . . . . 2.51 109.51 -179.835 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 89.9 p . . . . . 0 N--CA 1.495 1.78 0 N-CA-C 109.107 -0.701 . . . . 2.2 109.107 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 29.7 t -89.72 136.47 33.02 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.199 -0.938 . . . . 2.05 109.682 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -114.24 114.24 3.24 Favored Glycine 0 N--CA 1.5 2.937 0 N-CA-C 109.696 -1.362 . . . . 1.39 109.696 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.465 HG21 HD12 ' A' ' 41' ' ' ILE . 78.9 t -99.7 105.13 17.04 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.102 0 O-C-N 121.411 -1.052 . . . . 1.57 109.629 179.722 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.563 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.1 OUTLIER -95.26 134.5 37.95 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 109.018 -0.734 . . . . 1.85 109.018 179.84 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.418 ' CE1' ' HB3' ' A' ' 37' ' ' ALA . 45.7 p90 -135.32 172.73 12.59 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.205 -0.934 . . . . 1.54 109.079 -179.848 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.602 ' O ' HG13 ' A' ' 78' ' ' VAL . 9.8 p -140.34 118.09 9.96 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.082 0 O-C-N 121.256 -0.902 . . . . 1.9 110.033 179.758 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.456 HG11 HG21 ' A' ' 105' ' ' VAL . 13.4 m -86.64 151.97 3.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.391 -0.818 . . . . 1.27 108.922 179.548 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 4.0 tp-100 -94.51 -47.24 6.64 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.042 -1.036 . . . . 2.48 110.899 -179.039 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -153.37 152.37 27.48 Favored Pre-proline 0 N--CA 1.505 2.302 0 O-C-N 120.406 -1.434 . . . . 1.92 110.965 -179.497 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.64 ' HG3' ' N ' ' A' ' 107' ' ' SER . 78.4 Cg_exo -38.48 164.42 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 123.392 2.728 . . . . 1.3 113.778 178.833 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 145.08 -164.97 27.84 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.004 -1.639 . . . . 1.02 109.004 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 25.2 m-20 -109.01 90.88 3.43 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.61 -0.935 . . . . 2.13 108.641 179.581 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.413 ' OH ' ' O ' ' A' ' 59' ' ' SER . 3.7 m-85 -78.74 130.53 35.88 Favored 'General case' 0 N--CA 1.487 1.406 0 N-CA-C 108.003 -1.11 . . . . 0.92 108.003 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -115.35 128.49 56.12 Favored 'General case' 0 N--CA 1.502 2.146 0 N-CA-C 108.946 -0.761 . . . . 1.53 108.946 -178.503 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 10.0 p -125.36 140.46 48.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.75 -0.593 . . . . 1.0 109.925 -179.852 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 16.2 m -129.33 100.07 5.45 Favored 'General case' 0 N--CA 1.497 1.884 0 N-CA-C 108.922 -0.77 . . . . 1.59 108.922 179.477 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.447 ' N ' ' OG ' ' A' ' 99' ' ' SER . 1.6 pt -105.57 134.93 45.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 CA-C-O 121.482 0.658 . . . . 1.29 110.208 -179.301 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' LYS . . . . . 0.466 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -144.3 122.35 12.11 Favored 'General case' 0 C--N 1.305 -1.339 0 N-CA-C 108.271 -1.011 . . . . 1.58 108.271 179.508 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 62.9 t80 -80.97 101.27 9.4 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.864 -1.147 . . . . 1.34 107.995 178.705 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 70.37 39.04 1.29 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.392 -0.817 . . . . 2.32 108.982 -178.809 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 74.57 15.03 3.41 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.705 -0.622 . . . . 1.92 111.293 179.653 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . 0.796 ' OE1' ' HB2' ' A' ' 18' ' ' ALA . 0.5 OUTLIER -98.29 96.22 7.91 Favored 'General case' 0 N--CA 1.498 1.974 0 N-CA-C 106.813 -1.551 . . . . 2.25 106.813 177.641 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' HIS . . . . . 0.602 ' H ' ' CD2' ' A' ' 95' ' ' HIS . 5.8 m-70 -73.07 111.66 8.39 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.615 -0.678 . . . . 2.88 110.112 -177.926 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' ILE . . . . . 0.683 ' H ' HD13 ' A' ' 96' ' ' ILE . 0.0 OUTLIER -70.35 155.93 92.67 Favored Pre-proline 0 N--CA 1.494 1.734 0 N-CA-C 107.444 -1.317 . . . . 2.35 107.444 179.148 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_exo -46.54 -35.6 16.93 Favored 'Trans proline' 0 C--N 1.322 -0.861 0 C-N-CA 121.336 1.357 . . . . 2.48 109.942 -179.412 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -53.78 -63.65 1.08 Allowed 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.301 -0.875 . . . . 2.65 109.383 179.267 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.447 ' OG ' ' N ' ' A' ' 89' ' ' ILE . 3.6 m -70.45 141.21 87.92 Favored Pre-proline 0 C--N 1.295 -1.777 0 O-C-N 120.92 -1.112 . . . . 2.0 110.19 -178.467 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -86.8 119.02 4.96 Favored 'Cis proline' 0 N--CA 1.493 1.474 0 N-CA-C 109.967 -0.82 . . . . 1.79 109.967 -2.439 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 45.2 p90 -120.89 158.34 27.85 Favored 'General case' 0 N--CA 1.518 2.939 0 O-C-N 120.445 -1.41 . . . . 2.19 109.506 178.273 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.469 HG22 ' N ' ' A' ' 103' ' ' VAL . 7.3 p -92.17 157.26 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.429 -0.794 . . . . 1.44 110.887 -178.426 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.469 ' N ' HG22 ' A' ' 102' ' ' VAL . 56.9 t -128.26 86.25 58.41 Favored Pre-proline 0 N--CA 1.495 1.778 0 N-CA-C 107.85 -1.167 . . . . 1.19 107.85 179.341 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -64.04 112.71 1.93 Allowed 'Trans proline' 0 C--N 1.32 -0.966 0 C-N-CA 121.377 1.385 . . . . 1.49 111.624 -177.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.456 HG21 HG11 ' A' ' 79' ' ' VAL . 54.8 t -95.54 141.01 15.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 N-CA-C 106.771 -1.566 . . . . 1.35 106.771 177.978 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.635 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -130.6 131.79 45.15 Favored 'General case' 0 N--CA 1.51 2.551 0 CA-C-O 121.925 0.869 . . . . 1.67 112.064 -177.041 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . 0.64 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 35.4 t -101.36 92.99 5.19 Favored 'General case' 0 N--CA 1.494 1.75 0 N-CA-C 107.993 -1.114 . . . . 2.04 107.993 179.274 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 20.5 mt 60.08 3.71 0.54 Allowed 'General case' 0 C--N 1.295 -1.774 0 N-CA-C 108.166 -1.05 . . . . 3.2 108.166 -178.574 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.501 ' H ' ' C ' ' A' ' 107' ' ' SER . 8.3 t -94.83 -29.26 14.82 Favored 'General case' 0 N--CA 1.49 1.563 0 N-CA-C 109.03 -0.729 . . . . 2.09 109.03 179.391 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . 0.635 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 16.9 t70 . . . . . 0 N--CA 1.489 1.496 0 N-CA-C 107.754 -1.202 . . . . 2.85 107.754 -178.843 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . 0.618 ' CG ' HH11 ' B' ' 8' ' ' ARG . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.769 0 N-CA-C 108.061 -1.088 . . . . 3.04 108.061 . . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 9' ' ' VAL . . . . . 0.43 ' O ' ' OE2' ' A' ' 56' ' ' GLU . 36.3 t -51.61 155.48 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 O-C-N 120.963 -1.085 . . . . 0.67 108.508 179.519 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -107.7 158.84 16.94 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 121.484 -0.76 . . . . 0.58 110.443 -178.763 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 25.6 t -159.34 112.91 2.29 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.487 -0.758 . . . . 1.19 109.007 179.51 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 15.0 p -117.02 124.9 50.44 Favored 'General case' 0 N--CA 1.501 2.111 0 O-C-N 121.417 -0.802 . . . . 1.38 109.413 -179.771 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 0.608 HG22 ' N ' ' B' ' 14' ' ' PHE . 6.6 p -164.39 164.01 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.293 -0.879 . . . . 0.42 109.786 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 14' ' ' PHE . . . . . 0.608 ' N ' HG22 ' B' ' 13' ' ' VAL . 6.5 p90 -179.29 -175.21 0.35 Allowed 'General case' 0 N--CA 1.488 1.472 0 CA-C-O 121.784 0.802 . . . . 1.79 111.427 179.102 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -144.01 168.8 10.77 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.295 0 N-CA-C 109.28 -0.637 . . . . 1.25 109.28 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 74.1 p -133.81 156.13 48.59 Favored 'General case' 0 N--CA 1.499 2.021 0 N-CA-C 108.72 -0.844 . . . . 1.61 108.72 179.523 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.491 1.615 0 O-C-N 120.948 -1.095 . . . . 1.32 110.643 -179.307 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.502 ' O ' ' N ' ' A' ' 18' ' ' ALA . . . . . . . . 0 N--CA 1.486 2.007 0 N-CA-C 110.009 -1.236 . . . . 2.44 110.009 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.553 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -42.72 -19.8 0.07 OUTLIER Glycine 0 N--CA 1.49 2.282 0 O-C-N 121.417 -1.049 . . . . 1.81 110.839 -179.325 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.502 ' N ' ' O ' ' A' ' 16' ' ' GLY . . . -47.26 -12.92 0.03 OUTLIER 'General case' 0 N--CA 1.495 1.8 0 O-C-N 120.448 -1.619 . . . . 2.21 109.297 179.413 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' HIS . . . . . 0.553 ' N ' ' O ' ' A' ' 17' ' ' GLY . 12.8 t-80 -93.36 -52.25 4.61 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.268 -0.895 . . . . 2.87 109.906 179.882 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.535 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.1 OUTLIER -69.75 -23.6 63.4 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.869 -1.144 . . . . 2.02 109.588 -179.69 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 76.1 t -63.33 112.62 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.161 -0.962 . . . . 2.07 109.5 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 20.6 tpt180 -97.34 138.32 34.99 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 108.695 -0.854 . . . . 3.5 108.695 179.666 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -142.64 113.46 7.5 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.287 -0.883 . . . . 1.83 109.279 -179.88 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -154.08 130.85 3.03 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 109.518 -1.433 . . . . 1.9 109.518 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -177.94 171.17 43.67 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.703 -1.359 . . . . 1.85 109.703 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 10.9 p -77.97 -28.87 49.53 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.302 -1.117 . . . . 2.31 109.405 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -67.72 -16.88 68.51 Favored Glycine 0 N--CA 1.487 2.038 0 N-CA-C 108.42 -1.872 . . . . 1.64 108.42 179.606 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 49.0 mt -85.85 22.68 1.61 Allowed 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 108.506 -0.924 . . . . 1.83 108.506 179.356 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 11.5 mt-10 -133.47 -50.38 0.85 Allowed 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.62 -0.675 . . . . 2.34 109.398 -179.673 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 11.3 ptt180 -163.31 -176.71 4.92 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.069 -1.019 . . . . 3.77 109.936 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -157.18 -178.42 31.23 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 108.761 -1.735 . . . . 1.57 108.761 -179.799 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 38.4 t -134.71 151.8 32.09 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.153 0 O-C-N 121.154 -1.203 . . . . 1.83 110.663 -179.777 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.556 ' HB2' ' HD3' ' A' ' 82' ' ' PRO . . . -45.77 115.22 0.91 Allowed 'General case' 0 N--CA 1.498 1.936 0 CA-C-O 121.815 0.817 . . . . 1.64 112.443 -179.34 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 57.82 46.55 92.22 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 111.562 -0.615 . . . . 1.73 111.562 177.062 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 25.2 t -127.38 120.49 22.16 Favored Pre-proline 0 N--CA 1.499 1.98 0 O-C-N 121.37 -1.076 . . . . 2.19 108.818 179.178 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -60.09 113.02 1.48 Allowed 'Trans proline' 0 C--O 1.215 -0.657 0 N-CA-C 109.676 -0.932 . . . . 1.96 109.676 179.871 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -113.04 156.12 23.64 Favored 'General case' 0 N--CA 1.498 1.949 0 N-CA-C 108.268 -1.012 . . . . 1.69 108.268 179.617 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -158.03 163.68 37.49 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.718 -1.239 . . . . 2.23 111.403 -179.779 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 0.575 ' CD1' ' N ' ' A' ' 39' ' ' PHE . 0.8 OUTLIER -139.93 -173.17 3.57 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 107.228 -1.397 . . . . 1.54 107.228 178.513 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 24.4 m -121.83 149.11 43.82 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.535 -0.728 . . . . 2.37 110.307 -179.234 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 34.9 mt -144.48 102.05 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 N-CA-C 107.962 -1.125 . . . . 1.65 107.962 178.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.458 ' CD1' ' C ' ' A' ' 42' ' ' TRP . 0.1 OUTLIER -89.59 139.6 30.38 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.259 -0.901 . . . . 3.68 108.927 -179.635 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.535 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.1 OUTLIER -152.79 120.03 5.89 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.42 -0.8 . . . . 2.89 109.214 -179.733 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' ARG . . . . . . . . . . . . . 28.9 ttt-85 -170.28 62.87 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.201 -0.937 . . . . 4.63 109.848 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 25.4 tt0 -157.06 -56.6 0.08 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.14 -0.975 . . . . 2.89 109.534 179.65 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.423 ' H ' ' HE2' ' A' ' 20' ' ' LYS . . . -57.88 -57.4 12.93 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.092 -1.005 . . . . 1.74 108.88 179.883 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 142.03 -179.2 20.17 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.263 -1.535 . . . . 1.6 109.263 179.845 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -55.9 159.14 3.35 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.127 -1.22 . . . . 1.4 109.345 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -176.83 176.12 47.88 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.595 -1.402 . . . . 1.04 109.595 -179.877 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.405 ' H ' HD22 ' A' ' 92' ' ' ASN . . . -106.94 123.26 7.24 Favored Glycine 0 N--CA 1.497 2.743 0 N-CA-C 109.427 -1.469 . . . . 1.06 109.427 179.933 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.453 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 12.3 tp -99.8 100.55 11.51 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.295 -1.12 . . . . 1.1 108.452 179.663 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 3.9 m -85.51 144.13 28.12 Favored 'General case' 0 N--CA 1.491 1.616 0 N-CA-C 108.662 -0.866 . . . . 1.56 108.662 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.525 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 78.5 mt -134.71 106.69 7.68 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 O-C-N 121.224 -0.922 . . . . 0.65 109.614 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -95.65 106.26 18.34 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.377 -0.971 . . . . 0.69 108.377 179.272 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.437 HG23 ' OG ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -97.45 145.29 9.47 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 121.421 -0.799 . . . . 0.91 109.933 -179.339 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 20.2 tt0 -141.56 145.06 34.65 Favored 'General case' 0 N--CA 1.491 1.61 0 N-CA-C 107.536 -1.283 . . . . 1.8 107.536 178.708 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 161.64 -171.04 37.52 Favored Glycine 0 N--CA 1.488 2.13 0 N-CA-C 109.644 -1.382 . . . . 0.49 109.644 -179.069 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -64.32 -30.31 63.46 Favored 'Trans proline' 0 C--N 1.316 -1.142 0 C-N-CA 122.047 1.831 . . . . 0.66 111.652 -179.598 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 24.3 t -142.1 164.96 28.76 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.039 -1.038 . . . . 1.55 110.129 -179.877 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 58.4 mttt -84.44 107.48 16.72 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.527 -0.733 . . . . 2.53 109.56 -179.8 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -67.08 143.39 56.71 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.222 -0.924 . . . . 0.82 109.4 179.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 23.3 tt0 -93.2 91.36 7.24 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.225 -0.922 . . . . 2.3 109.537 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.621 HD12 ' N ' ' A' ' 63' ' ' ILE . 2.2 mp -60.54 156.61 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 N-CA-C 109.138 -0.689 . . . . 1.4 109.138 179.602 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.559 ' HB3' ' HB3' ' A' ' 76' ' ' SER . . . -145.99 174.85 10.91 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.981 -1.074 . . . . 1.36 108.595 179.621 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.487 ' CG ' ' O ' ' A' ' 65' ' ' PHE . 28.8 p90 -147.87 115.87 6.47 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.093 -1.005 . . . . 1.47 109.647 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 . . . . . 0 N--CA 1.497 1.883 0 O-C-N 121.209 -0.932 . . . . 2.51 109.485 179.791 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.5 p . . . . . 0 N--CA 1.495 1.791 0 N-CA-C 109.085 -0.709 . . . . 2.2 109.085 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 7.7 t -75.42 146.58 40.64 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.214 -0.929 . . . . 2.05 109.622 -179.814 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -120.25 111.58 2.01 Favored Glycine 0 N--CA 1.499 2.851 0 N-CA-C 109.32 -1.512 . . . . 1.39 109.32 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 22.5 t -99.32 106.22 18.64 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 O-C-N 121.542 -0.975 . . . . 1.57 109.109 179.807 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.559 ' HB3' ' HB3' ' A' ' 64' ' ' ALA . 5.9 t -100.04 135.67 41.11 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.537 -0.727 . . . . 1.85 109.895 -179.687 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 4.9 p90 -133.59 131.4 39.61 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 108.801 -0.815 . . . . 1.54 108.801 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.587 ' O ' HG13 ' A' ' 78' ' ' VAL . 8.0 p -100.37 115.79 42.42 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.955 0 O-C-N 121.276 -0.89 . . . . 1.9 109.183 -179.668 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 26.9 m -84.73 164.5 2.53 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 121.187 -0.946 . . . . 1.27 109.142 -179.681 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 36.3 tt0 -102.54 -49.08 3.94 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.276 -0.89 . . . . 2.48 110.324 -179.689 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -157.15 153.99 25.04 Favored Pre-proline 0 N--CA 1.502 2.132 0 O-C-N 120.907 -1.121 . . . . 1.92 111.161 -179.147 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.588 ' HG3' ' N ' ' A' ' 107' ' ' SER . 89.1 Cg_exo -35.55 156.99 0.02 OUTLIER 'Trans proline' 0 C--O 1.214 -0.683 0 C-N-CA 123.394 2.729 . . . . 1.3 113.745 179.354 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 148.51 -170.3 29.02 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 108.556 -1.818 . . . . 1.02 108.556 -179.675 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . 0.571 ' CG ' ' HE ' ' B' ' 8' ' ' ARG . 4.5 p-10 -107.24 93.71 4.7 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.378 -1.072 . . . . 2.13 108.452 179.368 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.426 ' O ' ' N ' ' A' ' 103' ' ' VAL . 2.4 m-85 -77.38 131.63 38.15 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 108.398 -0.964 . . . . 0.92 108.398 -179.784 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -112.82 126.82 55.85 Favored 'General case' 0 N--CA 1.501 2.081 0 N-CA-C 108.465 -0.939 . . . . 1.53 108.465 -179.292 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.466 ' CG1' ' CE2' ' A' ' 101' ' ' PHE . 5.5 p -126.29 133.96 67.55 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 O-C-N 121.525 -0.734 . . . . 1.0 109.782 -179.703 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . 0.407 ' O ' ' OG ' ' A' ' 88' ' ' SER . 19.0 p -124.58 104.82 8.92 Favored 'General case' 0 N--CA 1.499 1.986 0 N-CA-C 109.171 -0.678 . . . . 1.59 109.171 179.835 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.405 ' N ' ' OG ' ' A' ' 99' ' ' SER . 1.5 pt -108.37 133.18 54.13 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 CA-C-O 121.54 0.686 . . . . 1.29 110.37 -179.245 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' LYS . . . . . 0.456 ' O ' ' CG ' ' A' ' 90' ' ' LYS . 0.3 OUTLIER -138.08 122.51 18.36 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 107.927 -1.138 . . . . 1.58 107.927 179.257 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.412 ' O ' ' CB ' ' A' ' 92' ' ' ASN . 81.4 t80 -82.84 99.99 10.06 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 120.443 -1.411 . . . . 1.34 107.924 179.21 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . 0.446 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 3.2 t-20 72.28 34.85 1.3 Allowed 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.266 -0.896 . . . . 2.32 108.983 -178.627 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.446 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 1.6 m-20 80.47 13.81 0.83 Allowed 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.725 -0.609 . . . . 1.92 111.662 179.336 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . 0.494 ' HB2' ' HB2' ' A' ' 18' ' ' ALA . 5.4 pt-20 -100.71 98.84 9.34 Favored 'General case' 0 N--CA 1.499 2.023 0 N-CA-C 107.459 -1.312 . . . . 2.25 107.459 177.843 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 26.6 p-80 -65.3 99.59 0.41 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.686 -0.634 . . . . 2.88 110.243 -178.251 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' ILE . . . . . 0.523 ' O ' ' N ' ' A' ' 98' ' ' ASP . 4.0 tt -50.82 136.09 26.77 Favored Pre-proline 0 N--CA 1.489 1.524 0 N-CA-C 107.988 -1.116 . . . . 2.35 107.988 179.089 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.433 ' O ' ' CB ' ' A' ' 98' ' ' ASP . 9.4 Cg_exo -47.88 90.35 0.02 OUTLIER 'Trans proline' 0 C--O 1.213 -0.727 0 C-N-CA 120.547 0.832 . . . . 2.48 110.006 -179.627 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.523 ' N ' ' O ' ' A' ' 96' ' ' ILE . 0.9 OUTLIER 166.5 -57.87 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.749 0 N-CA-C 108.445 -0.946 . . . . 2.65 108.445 -179.569 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.405 ' OG ' ' N ' ' A' ' 89' ' ' ILE . 3.3 m -55.55 137.75 69.7 Favored Pre-proline 0 C--N 1.296 -1.72 0 O-C-N 121.246 -0.909 . . . . 2.0 109.6 -178.185 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo -90.0 114.96 2.59 Favored 'Cis proline' 0 N--CA 1.494 1.513 0 N-CA-C 110.249 -0.712 . . . . 1.79 110.249 -2.33 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . 0.466 ' CE2' ' CG1' ' A' ' 87' ' ' VAL . 1.6 p90 -97.18 163.26 12.99 Favored 'General case' 0 N--CA 1.515 2.802 0 O-C-N 120.217 -1.552 . . . . 2.19 109.568 178.456 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.9 p -95.31 148.96 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.594 -0.691 . . . . 1.44 109.822 -179.703 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.426 ' N ' ' O ' ' A' ' 85' ' ' TYR . 64.5 t -128.53 86.41 57.79 Favored Pre-proline 0 N--CA 1.499 2.002 0 N-CA-C 108.432 -0.951 . . . . 1.19 108.432 179.89 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -63.92 112.16 1.76 Allowed 'Trans proline' 0 C--N 1.321 -0.88 0 C-N-CA 121.429 1.419 . . . . 1.49 111.821 -178.133 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 52.5 t -91.39 147.36 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.514 -1.291 . . . . 1.35 107.514 178.268 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.677 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -135.77 134.3 38.85 Favored 'General case' 0 N--CA 1.508 2.467 0 O-C-N 121.373 -0.829 . . . . 1.67 110.911 -178.074 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . 0.588 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 16.5 t -87.69 67.75 9.29 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.571 -1.331 . . . . 2.04 108.095 179.799 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' LEU . . . . . 0.434 ' CB ' ' O ' ' A' ' 107' ' ' SER . 1.0 OUTLIER 71.53 -2.6 2.38 Favored 'General case' 0 C--N 1.295 -1.79 0 N-CA-C 106.921 -1.511 . . . . 3.2 106.921 -178.439 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.501 ' H ' ' C ' ' A' ' 107' ' ' SER . 82.6 p -82.73 -21.63 34.7 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 109.165 -0.679 . . . . 2.09 109.165 179.422 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . 0.677 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 62.2 t0 . . . . . 0 N--CA 1.494 1.753 0 N-CA-C 108.312 -0.996 . . . . 2.85 108.312 -179.456 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . 0.571 ' HE ' ' CG ' ' A' ' 84' ' ' ASP . 2.2 mtt-85 . . . . . 0 N--CA 1.494 1.742 0 N-CA-C 108.715 -0.846 . . . . 3.04 108.715 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 9' ' ' VAL . . . . . . . . . . . . . 19.4 t -51.41 158.2 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.141 -0.975 . . . . 0.67 108.61 179.717 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -121.54 146.88 46.5 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.627 -0.67 . . . . 0.58 109.645 -179.339 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 11' ' ' SER . . . . . 0.437 ' OG ' HG23 ' A' ' 55' ' ' VAL . 4.9 t -140.62 143.77 35.39 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.387 -0.821 . . . . 1.19 109.436 179.878 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 46.8 t -141.39 116.54 9.98 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.319 -0.863 . . . . 1.38 109.689 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 0.645 HG22 ' N ' ' B' ' 14' ' ' PHE . 6.6 p -165.04 170.41 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.342 -0.849 . . . . 0.42 109.029 179.899 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 14' ' ' PHE . . . . . 0.645 ' N ' HG22 ' B' ' 13' ' ' VAL . 9.6 p90 -175.92 -163.14 0.1 Allowed 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 119.285 -0.966 . . . . 1.79 112.144 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.9 pt -150.47 165.55 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.339 0 N-CA-C 108.965 -0.754 . . . . 1.25 108.965 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 17.9 m -125.27 128.82 48.87 Favored 'General case' 0 N--CA 1.502 2.132 0 O-C-N 121.385 -0.822 . . . . 1.61 109.437 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 9.3 mt . . . . . 0 N--CA 1.497 1.898 0 O-C-N 121.267 -0.896 . . . . 1.32 109.922 -179.715 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.122 0 N-CA-C 111.204 -0.758 . . . . 2.44 111.204 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.558 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -43.2 -23.65 0.26 Allowed Glycine 0 N--CA 1.49 2.271 0 O-C-N 121.715 -0.874 . . . . 1.81 111.489 -178.265 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.493 ' N ' ' OE1' ' A' ' 94' ' ' GLU . . . -43.01 -17.94 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.042 -1.27 . . . . 2.21 110.047 -179.715 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' HIS . . . . . 0.558 ' N ' ' O ' ' A' ' 17' ' ' GLY . 8.9 t-80 -95.3 -52.06 4.33 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.33 -0.856 . . . . 2.87 109.731 179.884 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.536 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.0 OUTLIER -67.21 -14.71 63.17 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.996 -1.065 . . . . 2.02 109.551 -179.602 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.414 HG23 ' O ' ' A' ' 17' ' ' GLY . 71.2 t -76.93 113.4 15.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.181 -0.95 . . . . 2.07 108.813 179.308 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 20.7 tpt180 -110.4 136.31 49.76 Favored 'General case' 0 N--CA 1.494 1.774 0 CA-C-O 121.567 0.698 . . . . 3.5 110.18 -179.015 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.474 ' HA ' HD13 ' A' ' 41' ' ' ILE . . . -140.05 113.61 8.61 Favored 'General case' 0 N--CA 1.491 1.603 0 N-CA-C 108.645 -0.872 . . . . 1.83 108.645 179.569 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -146.38 126.51 2.5 Favored Glycine 0 N--CA 1.496 2.638 0 N-CA-C 109.625 -1.39 . . . . 1.9 109.625 -179.647 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.32 177.93 48.5 Favored Glycine 0 N--CA 1.488 2.139 0 N-CA-C 109.743 -1.343 . . . . 1.85 109.743 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 41.7 p -79.63 -24.62 41.79 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.249 -1.148 . . . . 2.31 109.461 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -68.56 -14.1 66.6 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 108.387 -1.885 . . . . 1.64 108.387 179.492 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 33.6 mt -100.35 35.25 2.15 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.688 -0.856 . . . . 1.83 108.688 179.76 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 -144.32 -46.01 0.25 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.377 -0.827 . . . . 2.34 109.516 -179.742 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 29.2 ptt180 -172.36 171.95 4.58 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 120.98 -1.075 . . . . 3.77 110.093 -179.874 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -147.76 174.4 27.51 Favored Glycine 0 N--CA 1.493 2.439 0 N-CA-C 108.598 -1.801 . . . . 1.57 108.598 179.622 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 37.6 t -134.68 152.52 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.088 0 O-C-N 121.136 -1.214 . . . . 1.83 110.576 -179.635 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.563 ' HB2' ' HB2' ' A' ' 107' ' ' SER . . . -40.78 112.29 0.28 Allowed 'General case' 0 N--CA 1.499 1.999 0 CA-C-O 121.586 0.708 . . . . 1.64 112.321 -179.268 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 53.72 51.82 46.32 Favored Glycine 0 N--CA 1.49 2.253 0 O-C-N 121.57 -0.706 . . . . 1.73 111.377 177.049 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 24.7 t -127.29 98.38 29.68 Favored Pre-proline 0 N--CA 1.495 1.787 0 O-C-N 121.451 -1.029 . . . . 2.19 108.453 178.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_exo -57.85 138.71 87.37 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 120.67 0.913 . . . . 1.96 109.854 -179.25 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -146.79 -167.76 2.85 Favored 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 108.491 -0.929 . . . . 1.69 108.491 -179.839 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -169.26 170.75 8.38 Favored 'General case' 0 C--N 1.303 -1.415 0 C-N-CA 118.745 -1.182 . . . . 2.23 111.04 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 0.53 ' CD1' ' N ' ' A' ' 39' ' ' PHE . 1.2 p90 -142.3 -178.26 5.65 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 107.49 -1.3 . . . . 1.54 107.49 178.274 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 88.9 p -124.43 138.37 54.36 Favored 'General case' 0 N--CA 1.501 2.088 0 CA-C-O 122.118 0.961 . . . . 2.37 111.219 -178.515 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.474 HD13 ' HA ' ' A' ' 23' ' ' ALA . 33.3 mm -130.58 126.59 60.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 N-CA-C 108.238 -1.023 . . . . 1.65 108.238 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.504 ' CD1' ' C ' ' A' ' 42' ' ' TRP . 0.6 OUTLIER -138.28 142.13 39.83 Favored 'General case' 0 N--CA 1.503 2.221 0 O-C-N 120.898 -1.126 . . . . 3.68 109.539 179.357 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.536 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.2 OUTLIER -156.44 151.94 26.83 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.553 -0.717 . . . . 2.89 109.605 -179.076 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' ARG . . . . . 0.508 HH11 ' HG2' ' A' ' 44' ' ' ARG . 0.0 OUTLIER -168.38 62.47 0.06 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.481 -0.762 . . . . 4.63 109.069 179.596 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -155.43 -60.09 0.11 Allowed 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.106 -0.996 . . . . 2.89 110.016 -179.748 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.449 ' HB3' ' NZ ' ' A' ' 20' ' ' LYS . . . -59.7 -32.75 70.8 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.886 -1.134 . . . . 1.74 109.333 -179.734 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 94.94 -157.36 22.14 Favored Glycine 0 N--CA 1.495 2.603 0 N-CA-C 109.996 -1.242 . . . . 1.6 109.996 179.72 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.65 163.19 0.71 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.398 -1.06 . . . . 1.4 110.101 -179.605 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 175.56 -165.85 36.91 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.264 -1.534 . . . . 1.04 109.264 179.844 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.4 ' O ' ' N ' ' A' ' 92' ' ' ASN . . . -132.6 119.62 2.49 Favored Glycine 0 N--CA 1.498 2.816 0 N-CA-C 108.985 -1.646 . . . . 1.06 108.985 179.867 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.461 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 31.6 tp -100.44 104.53 15.94 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.328 -1.101 . . . . 1.1 109.014 -179.873 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 13.8 t -91.14 142.73 27.43 Favored 'General case' 0 N--CA 1.495 1.824 0 N-CA-C 108.703 -0.851 . . . . 1.56 108.703 179.575 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.533 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 66.0 mt -132.47 103.58 6.54 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.986 0 O-C-N 121.119 -0.988 . . . . 0.65 109.571 -179.922 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -93.76 106.23 18.21 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.641 -0.874 . . . . 0.69 108.641 179.479 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.429 ' O ' ' O ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -98.91 141.7 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.564 -0.71 . . . . 0.91 109.478 -179.622 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 21.0 tt0 -141.28 144.2 34.52 Favored 'General case' 0 N--CA 1.492 1.639 0 N-CA-C 107.535 -1.283 . . . . 1.8 107.535 178.678 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 164.07 -173.3 40.08 Favored Glycine 0 N--CA 1.488 2.134 0 N-CA-C 109.489 -1.444 . . . . 0.49 109.489 -178.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -64.01 -33.46 62.54 Favored 'Trans proline' 0 C--N 1.319 -1.015 0 C-N-CA 122.114 1.876 . . . . 0.66 112.154 -179.567 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 33.0 m -135.22 155.77 50.1 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.072 -1.017 . . . . 1.55 109.947 -179.307 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 77.3 tttt -73.7 96.35 2.49 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.621 -0.674 . . . . 2.53 109.609 -179.834 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -61.05 123.9 18.98 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.342 -0.849 . . . . 0.82 109.341 179.894 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.456 ' CB ' HG12 ' A' ' 78' ' ' VAL . 19.6 tt0 -70.94 171.03 11.48 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.238 -0.914 . . . . 2.3 109.214 -179.82 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 72.4 mt -140.92 152.08 20.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 N-CA-C 107.663 -1.236 . . . . 1.4 107.663 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.54 ' HB3' ' HB2' ' A' ' 76' ' ' SER . . . -150.09 113.45 4.93 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.537 -1.352 . . . . 1.36 109.356 179.816 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.461 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 47.0 p90 -87.24 125.14 34.01 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.35 -0.844 . . . . 1.47 109.71 179.874 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 59.5 tt0 . . . . . 0 N--CA 1.496 1.837 0 O-C-N 121.386 -0.821 . . . . 2.51 109.233 179.808 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 45.5 t . . . . . 0 N--CA 1.496 1.871 0 CA-C-O 121.242 0.544 . . . . 2.2 109.612 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' CYS . . . . . 0.409 ' N ' ' O ' ' A' ' 41' ' ' ILE . 42.6 m -87.91 114.15 24.24 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.293 -0.879 . . . . 2.05 109.548 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -93.9 118.21 5.68 Favored Glycine 0 N--CA 1.494 2.524 0 N-CA-C 109.15 -1.58 . . . . 1.39 109.15 179.815 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -106.92 106.14 20.08 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.298 0 O-C-N 121.53 -0.982 . . . . 1.57 109.011 -179.868 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.54 ' HB2' ' HB3' ' A' ' 64' ' ' ALA . 1.4 m -89.73 150.81 22.14 Favored 'General case' 0 N--CA 1.49 1.568 0 N-CA-C 108.523 -0.917 . . . . 1.85 108.523 179.273 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 11.7 p90 -145.89 174.27 11.4 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.212 -0.93 . . . . 1.54 109.348 -179.106 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.592 ' O ' HG13 ' A' ' 78' ' ' VAL . 4.8 p -145.79 116.71 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.503 2.192 0 O-C-N 120.991 -1.068 . . . . 1.9 110.66 179.47 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.457 HG11 HG21 ' A' ' 105' ' ' VAL . 10.3 m -90.96 151.41 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 O-C-N 121.144 -0.972 . . . . 1.27 108.745 179.295 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . 0.42 ' O ' ' OE2' ' A' ' 81' ' ' GLU . 7.2 tp-100 -94.76 -46.91 6.7 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.011 -1.056 . . . . 2.48 110.819 -179.06 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.42 ' OE2' ' O ' ' A' ' 80' ' ' GLN . 78.1 mm-40 -153.8 150.06 22.23 Favored Pre-proline 0 N--CA 1.503 2.185 0 O-C-N 120.68 -1.262 . . . . 1.92 111.02 -178.651 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.635 ' HG3' ' N ' ' A' ' 107' ' ' SER . 84.9 Cg_exo -36.76 163.45 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.645 0 C-N-CA 122.918 2.412 . . . . 1.3 113.529 178.177 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 148.16 -165.29 28.97 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.28 -1.528 . . . . 1.02 109.28 179.838 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -106.95 88.25 2.7 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.599 -0.942 . . . . 2.13 108.665 179.697 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.457 ' O ' ' N ' ' A' ' 103' ' ' VAL . 3.4 m-85 -76.64 129.55 36.55 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.283 -1.006 . . . . 0.92 108.283 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -110.21 121.49 45.41 Favored 'General case' 0 N--CA 1.498 1.933 0 N-CA-C 108.372 -0.973 . . . . 1.53 108.372 -179.101 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.417 ' O ' HG13 ' A' ' 87' ' ' VAL . 8.4 p -120.28 133.41 67.09 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.593 -0.692 . . . . 1.0 109.705 -179.607 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 11.6 t -128.24 101.64 6.33 Favored 'General case' 0 N--CA 1.498 1.958 0 N-CA-C 109.609 -0.515 . . . . 1.59 109.609 -179.831 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.472 ' H ' ' CB ' ' A' ' 99' ' ' SER . 0.8 OUTLIER -108.0 130.85 59.78 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.875 0 O-C-N 121.567 -0.708 . . . . 1.29 109.6 -179.806 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' LYS . . . . . 0.426 ' HG3' ' H ' ' A' ' 93' ' ' ASP . 0.1 OUTLIER -139.9 128.77 23.38 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.413 -0.804 . . . . 1.58 109.05 -179.979 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 44.7 t80 -84.69 95.63 8.98 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 120.527 -1.358 . . . . 1.34 108.387 179.296 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . 0.457 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 0.2 OUTLIER 68.58 39.72 2.03 Favored 'General case' 0 N--CA 1.488 1.435 0 N-CA-C 107.893 -1.151 . . . . 2.32 107.893 -178.532 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.457 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 3.4 m-20 82.6 14.07 0.45 Allowed 'General case' 0 N--CA 1.499 1.992 0 CA-C-O 121.188 0.518 . . . . 1.92 110.23 -179.434 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . 0.493 ' OE1' ' N ' ' A' ' 18' ' ' ALA . 55.2 mt-10 -87.91 78.73 8.24 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.431 -0.951 . . . . 2.25 108.431 178.916 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' HIS . . . . . 0.462 ' H ' ' CD2' ' A' ' 95' ' ' HIS . 44.2 m-70 -55.75 109.67 0.6 Allowed 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.529 -0.732 . . . . 2.88 110.602 -179.17 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' ILE . . . . . 0.426 ' O ' ' O ' ' A' ' 99' ' ' SER . 1.5 mp -66.55 136.48 94.88 Favored Pre-proline 0 N--CA 1.492 1.637 0 N-CA-C 107.476 -1.305 . . . . 2.35 107.476 179.034 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_exo -41.17 -41.21 4.51 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 120.997 1.131 . . . . 2.48 110.575 -179.633 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.506 ' N ' ' OD1' ' A' ' 98' ' ' ASP . 1.3 m-20 -56.9 -65.61 0.59 Allowed 'General case' 0 N--CA 1.488 1.434 0 O-C-N 120.83 -1.169 . . . . 2.65 108.026 178.191 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.472 ' CB ' ' H ' ' A' ' 89' ' ' ILE . 0.1 OUTLIER -68.71 145.02 96.68 Favored Pre-proline 0 C--N 1.293 -1.882 0 O-C-N 121.173 -0.955 . . . . 2.0 109.564 -179.448 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -85.22 113.01 2.71 Favored 'Cis proline' 0 CA--C 1.549 1.271 0 O-C-N 122.636 0.808 . . . . 1.79 110.154 -1.864 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 31.3 p90 -121.82 164.23 17.84 Favored 'General case' 0 N--CA 1.521 3.088 0 O-C-N 120.497 -1.377 . . . . 2.19 109.921 178.402 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.3 p -87.43 144.41 9.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.462 -0.774 . . . . 1.44 110.643 -178.129 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.457 ' N ' ' O ' ' A' ' 85' ' ' TYR . 71.7 t -117.24 89.54 31.26 Favored Pre-proline 0 N--CA 1.498 1.949 0 N-CA-C 108.503 -0.925 . . . . 1.19 108.503 179.354 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -62.93 113.99 2.24 Favored 'Trans proline' 0 C--N 1.319 -0.989 0 C-N-CA 121.142 1.228 . . . . 1.49 111.916 -178.266 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.457 HG21 HG11 ' A' ' 79' ' ' VAL . 55.4 t -96.41 140.4 17.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 N-CA-C 105.926 -1.879 . . . . 1.35 105.926 177.446 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.684 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -131.89 133.53 44.7 Favored 'General case' 0 N--CA 1.512 2.671 0 CA-C-O 122.067 0.937 . . . . 1.67 112.059 -176.889 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . 0.635 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 23.2 t -101.06 86.77 3.11 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 107.928 -1.138 . . . . 2.04 107.928 179.177 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 13.3 mt 60.24 6.07 0.94 Allowed 'General case' 0 C--N 1.297 -1.708 0 N-CA-C 107.718 -1.216 . . . . 3.2 107.718 -178.323 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.488 ' H ' ' C ' ' A' ' 107' ' ' SER . 52.0 p -97.77 -23.39 15.92 Favored 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 109.206 -0.664 . . . . 2.09 109.206 179.657 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . 0.684 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 34.4 t70 . . . . . 0 N--CA 1.489 1.484 0 O-C-N 121.131 -0.981 . . . . 2.85 108.436 -179.587 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . 0.456 HH11 ' HG2' ' B' ' 8' ' ' ARG . 11.7 mtt-85 . . . . . 0 N--CA 1.492 1.641 0 N-CA-C 109.078 -0.712 . . . . 3.04 109.078 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 9' ' ' VAL . . . . . 0.403 ' CG1' ' N ' ' B' ' 10' ' ' ALA . 3.1 t -48.72 159.69 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.135 -0.978 . . . . 0.67 108.515 179.747 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 0.403 ' N ' ' CG1' ' B' ' 9' ' ' VAL . . . -116.44 150.84 37.18 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.655 -0.653 . . . . 0.58 109.482 -179.344 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 11' ' ' SER . . . . . 0.429 ' O ' ' O ' ' A' ' 55' ' ' VAL . 58.2 m -153.19 139.88 18.92 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.283 -0.886 . . . . 1.19 109.865 -179.832 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 51.6 p -148.36 112.51 5.21 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.197 -0.939 . . . . 1.38 109.562 -179.697 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 0.58 HG22 ' N ' ' B' ' 14' ' ' PHE . 2.5 p -154.61 167.58 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 N-CA-C 108.624 -0.88 . . . . 0.42 108.624 179.811 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 14' ' ' PHE . . . . . 0.58 ' N ' HG22 ' B' ' 13' ' ' VAL . 7.8 p90 -176.55 -167.18 0.18 Allowed 'General case' 0 N--CA 1.488 1.435 0 C-N-CA 119.132 -1.027 . . . . 1.79 112.069 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -143.45 146.26 21.49 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.226 0 N-CA-C 108.883 -0.784 . . . . 1.25 108.883 179.871 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 46.1 m -113.03 128.3 56.46 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.353 -0.842 . . . . 1.61 109.293 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 16.8 mt . . . . . 0 N--CA 1.497 1.913 0 O-C-N 121.174 -0.954 . . . . 1.32 109.562 179.939 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.482 ' O ' ' N ' ' A' ' 18' ' ' ALA . . . . . . . . 0 N--CA 1.485 1.92 0 N-CA-C 109.48 -1.448 . . . . 2.44 109.48 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.503 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -43.97 -19.76 0.13 Allowed Glycine 0 N--CA 1.488 2.159 0 O-C-N 121.387 -1.067 . . . . 1.81 110.579 -179.457 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.774 ' HB2' ' OE1' ' A' ' 94' ' ' GLU . . . -51.07 -9.9 0.06 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.826 -1.397 . . . . 2.21 109.204 -179.829 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' HIS . . . . . 0.503 ' N ' ' O ' ' A' ' 17' ' ' GLY . 22.0 t60 -103.01 -4.59 24.42 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.404 -0.81 . . . . 2.87 110.175 -179.738 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.612 ' HZ2' HG23 ' A' ' 21' ' ' VAL . 1.9 pptp? -135.81 0.6 2.69 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.1 -1.0 . . . . 2.02 110.261 -179.559 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.612 HG23 ' HZ2' ' A' ' 20' ' ' LYS . 55.3 t -88.8 113.47 25.55 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.003 -1.06 . . . . 2.07 109.751 179.665 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 21.0 tpt180 -108.97 135.85 49.47 Favored 'General case' 0 N--CA 1.495 1.79 0 N-CA-C 109.308 -0.627 . . . . 3.5 109.308 179.647 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -143.31 113.81 7.46 Favored 'General case' 0 N--CA 1.492 1.674 0 N-CA-C 108.566 -0.902 . . . . 1.83 108.566 179.467 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -152.6 130.95 3.2 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.671 -1.371 . . . . 1.9 109.671 -179.367 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -177.55 167.58 38.67 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.801 -1.32 . . . . 1.85 109.801 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.49 ' C ' ' H ' ' A' ' 28' ' ' LEU . 0.5 OUTLIER -80.5 -27.53 37.72 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.318 -1.107 . . . . 2.31 109.864 -179.698 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -64.21 -1.36 5.46 Favored Glycine 0 N--CA 1.483 1.78 0 N-CA-C 107.938 -2.065 . . . . 1.64 107.938 179.193 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.49 ' H ' ' C ' ' A' ' 26' ' ' THR . 60.9 mt -108.45 -10.56 15.27 Favored 'General case' 0 N--CA 1.493 1.712 0 N-CA-C 108.643 -0.873 . . . . 1.83 108.643 179.748 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 20.3 mm-40 -85.74 -54.16 4.7 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.568 -0.708 . . . . 2.34 109.561 -179.586 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . 0.584 ' CG ' HH11 ' A' ' 30' ' ' ARG . 3.2 mtt-85 -156.83 161.94 39.72 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.125 -0.984 . . . . 3.77 109.76 179.918 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -140.73 172.17 23.74 Favored Glycine 0 N--CA 1.493 2.499 0 N-CA-C 108.102 -1.999 . . . . 1.57 108.102 179.205 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 36.0 t -134.37 150.93 31.2 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.03 0 O-C-N 121.189 -1.183 . . . . 1.83 110.398 -179.338 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -38.83 113.89 0.34 Allowed 'General case' 0 N--CA 1.495 1.784 0 CA-C-O 121.862 0.839 . . . . 1.64 112.844 -179.184 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 53.99 49.77 57.64 Favored Glycine 0 N--CA 1.489 2.167 0 N-CA-C 111.238 -0.745 . . . . 1.73 111.238 177.378 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 25.3 t -126.98 99.41 28.88 Favored Pre-proline 0 N--CA 1.497 1.9 0 O-C-N 121.531 -0.982 . . . . 2.19 108.396 179.052 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -56.75 143.44 90.27 Favored 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 120.946 1.097 . . . . 1.96 110.588 -178.906 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.473 ' HB3' ' CE1' ' A' ' 77' ' ' TYR . . . -150.23 -169.06 3.28 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.563 -0.903 . . . . 1.69 108.563 179.869 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -169.38 162.23 10.22 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.958 -1.089 . . . . 2.23 111.03 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 0.575 ' CD1' ' N ' ' A' ' 39' ' ' PHE . 0.2 OUTLIER -134.8 -176.37 4.21 Favored 'General case' 0 N--CA 1.485 1.303 0 N-CA-C 106.638 -1.615 . . . . 1.54 106.638 178.355 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 18.3 t -121.35 145.97 47.34 Favored 'General case' 0 N--CA 1.501 2.1 0 CA-C-O 121.72 0.771 . . . . 2.37 111.07 -178.633 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.523 ' O ' ' N ' ' A' ' 73' ' ' CYS . 62.6 mt -143.19 118.69 4.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 N-CA-C 108.547 -0.908 . . . . 1.65 108.547 179.222 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.533 ' O ' ' CD2' ' A' ' 42' ' ' TRP . 5.9 p-90 -118.1 127.19 53.54 Favored 'General case' 0 N--CA 1.502 2.135 0 O-C-N 121.219 -0.926 . . . . 3.68 108.549 179.109 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.52 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -150.92 128.4 11.41 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.224 -0.923 . . . . 2.89 109.926 -178.828 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' ARG . . . . . . . . . . . . . 24.8 ttm180 -172.48 79.35 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.442 -0.786 . . . . 4.63 109.092 179.663 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 2.3 tm-20 -159.69 -55.04 0.06 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.188 -0.945 . . . . 2.89 109.881 -179.676 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -53.43 -55.29 26.38 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 120.911 -1.118 . . . . 1.74 108.672 -179.821 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 140.58 -170.37 24.47 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.163 -1.575 . . . . 1.6 109.163 179.678 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.67 148.28 10.05 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.14 -1.212 . . . . 1.4 109.202 179.832 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -171.66 -170.06 35.23 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.762 -1.335 . . . . 1.04 109.762 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -133.05 122.71 3.24 Favored Glycine 0 N--CA 1.497 2.727 0 N-CA-C 109.403 -1.479 . . . . 1.06 109.403 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 11.3 tp -97.65 97.98 9.49 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.303 -1.116 . . . . 1.1 108.69 179.651 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . 0.409 ' HA ' ' CD2' ' B' ' 14' ' ' PHE . 0.3 OUTLIER -84.52 145.63 27.99 Favored 'General case' 0 C--N 1.312 -1.035 0 N-CA-C 108.026 -1.102 . . . . 1.56 108.026 179.695 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.445 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 65.4 mt -134.98 118.68 25.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.217 -0.927 . . . . 0.65 110.048 -179.315 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -106.63 106.85 17.57 Favored 'General case' 0 N--CA 1.495 1.824 0 N-CA-C 108.431 -0.952 . . . . 0.69 108.431 179.072 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 2.4 t -97.59 146.36 7.88 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.266 -0.897 . . . . 0.91 109.639 -179.436 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 22.8 tt0 -139.5 131.21 27.38 Favored 'General case' 0 N--CA 1.488 1.448 0 N-CA-C 107.616 -1.253 . . . . 1.8 107.616 178.835 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -178.41 172.31 44.71 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.159 -1.576 . . . . 0.49 109.159 -179.498 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_exo -52.06 -28.61 33.25 Favored 'Trans proline' 0 C--N 1.318 -1.076 0 C-N-CA 121.808 1.672 . . . . 0.66 110.859 -179.501 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.2 t -140.79 157.18 45.77 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.439 -0.788 . . . . 1.55 109.839 -179.527 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 49.3 mttp -77.78 104.75 8.52 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.421 -0.799 . . . . 2.53 109.169 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -74.15 136.95 42.89 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.272 -0.892 . . . . 0.82 109.549 -179.728 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.679 ' O ' HD13 ' A' ' 63' ' ' ILE . 46.9 mt-10 -75.33 175.54 8.29 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.141 -0.974 . . . . 2.3 109.629 -179.829 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.679 HD13 ' O ' ' A' ' 62' ' ' GLU . 4.8 mm -140.51 156.46 23.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 N-CA-C 108.033 -1.099 . . . . 1.4 108.033 -179.656 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.433 ' HB3' ' CB ' ' A' ' 76' ' ' SER . . . -144.45 174.63 10.77 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 120.551 -1.343 . . . . 1.36 108.999 179.749 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.51 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 37.7 p90 -147.25 116.36 6.9 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.308 -0.87 . . . . 1.47 109.46 -179.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 76.2 tt0 . . . . . 0 N--CA 1.496 1.849 0 O-C-N 121.317 -0.864 . . . . 2.51 109.241 179.989 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 60.6 p . . . . . 0 N--CA 1.495 1.807 0 CA-C-O 121.313 0.578 . . . . 2.2 109.666 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' CYS . . . . . 0.523 ' N ' ' O ' ' A' ' 41' ' ' ILE . 17.0 t -75.77 112.23 11.93 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.306 -0.871 . . . . 2.05 109.361 179.789 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -91.77 117.99 5.37 Favored Glycine 0 N--CA 1.493 2.439 0 N-CA-C 109.394 -1.482 . . . . 1.39 109.394 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 1.9 m -109.28 114.68 47.57 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.097 0 O-C-N 121.611 -0.935 . . . . 1.57 109.502 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.433 ' CB ' ' HB3' ' A' ' 64' ' ' ALA . 0.9 OUTLIER -92.55 167.84 11.66 Favored 'General case' 0 N--CA 1.491 1.62 0 N-CA-C 108.341 -0.985 . . . . 1.85 108.341 179.537 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.473 ' CE1' ' HB3' ' A' ' 37' ' ' ALA . 5.9 p90 -163.77 168.15 20.03 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.356 -0.84 . . . . 1.54 109.095 -179.338 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.577 ' O ' HG13 ' A' ' 78' ' ' VAL . 5.0 p -143.11 115.31 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.369 0 O-C-N 121.0 -1.062 . . . . 1.9 110.448 179.418 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.418 HG22 ' H ' ' A' ' 79' ' ' VAL . 14.3 m -88.82 152.38 3.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.244 -0.91 . . . . 1.27 109.233 179.741 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 6.8 tt0 -88.92 -50.33 6.26 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.092 -1.005 . . . . 2.48 110.764 -179.043 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -153.31 156.92 32.85 Favored Pre-proline 0 N--CA 1.504 2.271 0 O-C-N 120.722 -1.236 . . . . 1.92 110.766 -179.015 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.615 ' HG3' ' N ' ' A' ' 107' ' ' SER . 71.0 Cg_exo -37.67 163.55 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 123.293 2.662 . . . . 1.3 113.452 179.17 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 145.35 -177.37 23.82 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.138 -1.585 . . . . 1.02 109.138 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . 0.528 ' OD1' ' NH2' ' B' ' 8' ' ' ARG . 0.4 OUTLIER -99.81 90.93 4.61 Favored 'General case' 0 N--CA 1.493 1.715 0 N-CA-C 107.962 -1.125 . . . . 2.13 107.962 179.289 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -76.25 132.05 39.64 Favored 'General case' 0 C--N 1.296 -1.721 0 N-CA-C 108.245 -1.02 . . . . 0.92 108.245 -179.747 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.66 115.56 27.31 Favored 'General case' 0 N--CA 1.501 2.082 0 N-CA-C 108.337 -0.986 . . . . 1.53 108.337 -179.351 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.556 ' CG1' ' CE2' ' A' ' 101' ' ' PHE . 4.5 p -112.85 132.78 60.69 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.676 -0.64 . . . . 1.0 109.421 -179.779 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 3.0 m -121.85 139.53 53.51 Favored 'General case' 0 N--CA 1.497 1.886 0 N-CA-C 108.536 -0.912 . . . . 1.59 108.536 179.635 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.3 pt -141.1 130.68 25.34 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.181 0 O-C-N 121.076 -1.015 . . . . 1.29 109.845 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -136.89 123.61 21.14 Favored 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 107.72 -1.215 . . . . 1.58 107.72 178.191 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 83.5 t80 -83.7 102.2 12.09 Favored 'General case' 0 C--N 1.295 -1.77 0 N-CA-C 107.985 -1.117 . . . . 1.34 107.985 179.326 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . 0.442 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 1.3 t30 69.33 34.83 2.79 Favored 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 108.788 -0.819 . . . . 2.32 108.788 -178.651 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.442 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 2.7 m-20 79.34 16.66 0.89 Allowed 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.827 -0.546 . . . . 1.92 111.505 179.473 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . 0.774 ' OE1' ' HB2' ' A' ' 18' ' ' ALA . 0.6 OUTLIER -101.1 100.23 10.77 Favored 'General case' 0 N--CA 1.499 2.005 0 N-CA-C 107.407 -1.331 . . . . 2.25 107.407 178.188 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 11.9 m-70 -73.97 110.92 8.64 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.117 -0.99 . . . . 2.88 110.632 -177.844 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' ILE . . . . . 0.465 ' O ' ' N ' ' A' ' 98' ' ' ASP . 3.4 tp -63.95 134.62 95.99 Favored Pre-proline 0 N--CA 1.488 1.455 0 N-CA-C 107.554 -1.276 . . . . 2.35 107.554 178.868 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.417 ' HD2' HD12 ' A' ' 96' ' ' ILE . 7.2 Cg_exo -49.56 92.5 0.03 OUTLIER 'Trans proline' 0 C--O 1.214 -0.721 0 N-CA-C 109.839 -0.87 . . . . 2.48 109.839 -179.824 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.465 ' N ' ' O ' ' A' ' 96' ' ' ILE . 0.9 OUTLIER 169.76 -54.05 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 108.756 -0.831 . . . . 2.65 108.756 -179.574 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 6.2 m -55.3 136.95 68.73 Favored Pre-proline 0 C--N 1.298 -1.636 0 O-C-N 121.231 -0.918 . . . . 2.0 109.588 -178.261 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_endo -88.36 113.58 2.43 Favored 'Cis proline' 0 N--CA 1.494 1.539 0 N-CA-C 110.328 -0.681 . . . . 1.79 110.328 -1.862 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . 0.598 ' CD1' ' N ' ' A' ' 101' ' ' PHE . 0.0 OUTLIER -80.71 155.08 26.93 Favored 'General case' 0 N--CA 1.509 2.522 0 O-C-N 119.727 -1.858 . . . . 2.19 108.66 178.346 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 10.5 p -89.21 144.5 8.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.483 -0.761 . . . . 1.44 109.158 179.653 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 76.9 t -128.04 85.87 59.52 Favored Pre-proline 0 N--CA 1.499 1.997 0 N-CA-C 108.133 -1.062 . . . . 1.19 108.133 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -64.91 112.53 2.04 Favored 'Trans proline' 0 C--N 1.321 -0.878 0 C-N-CA 121.433 1.422 . . . . 1.49 111.851 -177.867 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 54.5 t -96.36 143.89 11.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 N-CA-C 106.172 -1.788 . . . . 1.35 106.172 177.667 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.673 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -136.36 135.23 38.65 Favored 'General case' 0 N--CA 1.509 2.489 0 O-C-N 121.151 -0.968 . . . . 1.67 112.133 -176.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . 0.615 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 11.0 t -89.67 76.27 7.31 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 107.413 -1.329 . . . . 2.04 107.413 178.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 13.6 mt 65.87 -0.06 1.42 Allowed 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 107.748 -1.204 . . . . 3.2 107.748 -177.861 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.502 ' H ' ' C ' ' A' ' 107' ' ' SER . 22.9 t -84.67 -22.14 29.94 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.74 -0.837 . . . . 2.09 108.74 178.873 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . 0.673 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 5.5 m-20 . . . . . 0 N--CA 1.487 1.423 0 N-CA-C 107.984 -1.117 . . . . 2.85 107.984 -179.141 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . 0.528 ' NH2' ' OD1' ' A' ' 84' ' ' ASP . 16.5 mmt-85 . . . . . 0 N--CA 1.491 1.606 0 N-CA-C 108.435 -0.95 . . . . 3.04 108.435 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 9' ' ' VAL . . . . . . . . . . . . . 3.0 t -57.66 161.48 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 N-CA-C 106.924 -1.51 . . . . 0.67 106.924 178.746 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -115.07 148.52 38.8 Favored 'General case' 0 N--CA 1.504 2.267 0 O-C-N 121.267 -0.896 . . . . 0.58 111.151 -178.06 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 1.3 t -141.11 150.86 43.42 Favored 'General case' 0 N--CA 1.497 1.906 0 N-CA-C 109.232 -0.655 . . . . 1.19 109.232 179.39 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 28.5 p -149.09 131.47 15.64 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.053 -1.029 . . . . 1.38 110.224 -179.836 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 0.664 HG22 ' N ' ' B' ' 14' ' ' PHE . 7.5 p -173.6 174.39 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 N-CA-C 108.345 -0.983 . . . . 0.42 108.345 179.777 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 14' ' ' PHE . . . . . 0.664 ' N ' HG22 ' B' ' 13' ' ' VAL . 0.1 OUTLIER 173.05 -171.97 0.04 OUTLIER 'General case' 0 N--CA 1.493 1.702 0 C-N-CA 118.797 -1.161 . . . . 1.79 112.201 179.483 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -143.85 -179.4 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.339 0 N-CA-C 108.898 -0.779 . . . . 1.25 108.898 179.903 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 9.0 t -141.31 142.91 33.82 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.154 -0.966 . . . . 1.61 109.291 179.59 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.3 mt . . . . . 0 N--CA 1.499 2.019 0 O-C-N 121.261 -0.9 . . . . 1.32 110.108 -179.55 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.766 0 N-CA-C 108.52 -1.832 . . . . 2.44 108.52 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.518 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -72.65 -4.81 62.42 Favored Glycine 0 N--CA 1.486 2.025 0 N-CA-C 109.717 -1.353 . . . . 1.81 109.717 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -49.03 -12.39 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.729 -1.453 . . . . 2.21 109.236 179.832 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' HIS . . . . . 0.518 ' N ' ' O ' ' A' ' 17' ' ' GLY . 10.6 t-160 -97.15 -41.15 8.46 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.39 -0.819 . . . . 2.87 109.445 179.651 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.719 ' HZ2' ' N ' ' A' ' 44' ' ' ARG . 0.0 OUTLIER -82.32 -25.37 33.99 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.141 -0.974 . . . . 2.02 109.722 -179.879 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 77.9 t -60.93 112.32 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.045 -1.034 . . . . 2.07 109.081 179.635 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 5.9 tpp180 -104.11 131.14 51.69 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.629 -0.669 . . . . 3.5 109.628 -179.648 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -136.7 113.64 10.47 Favored 'General case' 0 N--CA 1.493 1.723 0 N-CA-C 108.577 -0.898 . . . . 1.83 108.577 179.519 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -155.89 134.66 4.21 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.73 -1.348 . . . . 1.9 109.73 -179.463 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.1 -176.44 46.07 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.99 -1.244 . . . . 1.85 109.99 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 8.6 p -79.49 -25.82 41.74 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.335 -1.097 . . . . 2.31 109.538 -179.862 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.428 ' CA ' ' OH ' ' A' ' 77' ' ' TYR . . . -69.46 -15.44 70.54 Favored Glycine 0 N--CA 1.486 1.992 0 N-CA-C 108.506 -1.838 . . . . 1.64 108.506 179.676 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 65.8 mt -93.36 33.02 1.26 Allowed 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 108.487 -0.931 . . . . 1.83 108.487 179.454 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -144.3 -55.41 0.35 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.373 -0.829 . . . . 2.34 109.796 -179.545 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . 0.528 ' NH1' ' OD1' ' A' ' 110' ' ' ASP . 31.9 mtm180 -156.53 153.69 29.1 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 120.984 -1.073 . . . . 3.77 110.345 -179.441 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.55 ' C ' HG13 ' A' ' 105' ' ' VAL . . . -140.42 171.76 23.84 Favored Glycine 0 N--CA 1.495 2.61 0 N-CA-C 108.244 -1.942 . . . . 1.57 108.244 179.003 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.468 ' H ' ' CG1' ' A' ' 35' ' ' VAL . 28.1 t -135.54 148.32 28.4 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.008 0 O-C-N 121.173 -1.192 . . . . 1.83 110.448 -179.553 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.625 ' HB2' ' HD3' ' A' ' 82' ' ' PRO . . . -38.73 105.79 0.04 OUTLIER 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.916 -0.49 . . . . 1.64 111.688 -179.859 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 64.34 57.0 14.45 Favored Glycine 0 N--CA 1.489 2.23 0 O-C-N 121.089 -1.007 . . . . 1.73 111.864 177.353 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.468 ' CG1' ' H ' ' A' ' 32' ' ' VAL . 4.5 p -125.82 133.92 25.38 Favored Pre-proline 0 N--CA 1.503 2.208 0 O-C-N 121.279 -1.13 . . . . 2.19 108.949 178.72 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_endo -58.47 114.69 2.09 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 N-CA-C 108.547 -1.366 . . . . 1.96 108.547 178.739 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -127.0 148.61 50.1 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.344 -0.847 . . . . 1.69 109.494 -179.352 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.3 pt-20 -157.13 174.01 16.12 Favored 'General case' 0 N--CA 1.488 1.474 0 CA-C-O 122.22 1.01 . . . . 2.23 110.759 -179.886 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 0.603 ' CE2' HD11 ' A' ' 41' ' ' ILE . 5.0 p90 -159.52 167.07 29.49 Favored 'General case' 0 C--N 1.296 -1.753 0 N-CA-C 107.819 -1.178 . . . . 1.54 107.819 178.67 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 6.4 t -98.04 150.96 20.84 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.462 -0.774 . . . . 2.37 110.715 -178.409 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.603 HD11 ' CE2' ' A' ' 39' ' ' PHE . 10.7 mt -142.09 89.72 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 N-CA-C 108.757 -0.831 . . . . 1.65 108.757 179.117 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.458 ' CD1' ' C ' ' A' ' 42' ' ' TRP . 0.8 OUTLIER -85.28 142.35 29.44 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.115 -0.991 . . . . 3.68 108.815 -179.907 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.487 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -171.98 117.51 0.39 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.39 -0.818 . . . . 2.89 109.298 -179.688 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' ARG . . . . . 0.719 ' N ' ' HZ2' ' A' ' 20' ' ' LYS . 1.5 tpt180 -164.99 -12.24 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.171 -0.956 . . . . 4.63 109.696 -179.832 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.409 ' H ' ' HD3' ' A' ' 20' ' ' LYS . 0.4 OUTLIER -68.55 -47.53 66.63 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.0 -1.062 . . . . 2.89 109.763 -179.621 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -60.23 -59.76 4.89 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.098 -1.001 . . . . 1.74 109.299 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 142.94 -151.76 23.42 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.585 -1.406 . . . . 1.6 109.585 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -80.64 163.11 23.86 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.479 -1.012 . . . . 1.4 109.531 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 174.02 -143.49 7.05 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.666 -1.373 . . . . 1.04 109.666 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -148.48 127.64 2.6 Favored Glycine 0 N--CA 1.495 2.586 0 N-CA-C 109.554 -1.418 . . . . 1.06 109.554 -179.913 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.465 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 46.8 tp -102.65 107.03 17.79 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.367 -1.078 . . . . 1.1 108.843 179.833 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.4 t -90.62 141.44 28.77 Favored 'General case' 0 N--CA 1.494 1.75 0 N-CA-C 108.616 -0.883 . . . . 1.56 108.616 179.504 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.515 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 63.3 mt -132.06 102.35 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.923 0 O-C-N 121.214 -0.929 . . . . 0.65 109.469 -179.843 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -93.31 105.85 17.88 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 108.497 -0.927 . . . . 0.69 108.497 179.395 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.44 HG23 ' CB ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -95.42 145.07 8.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.521 -0.737 . . . . 0.91 109.254 -179.738 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -141.47 144.17 34.25 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 108.026 -1.101 . . . . 1.8 108.026 179.22 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.415 ' O ' ' O ' ' B' ' 9' ' ' VAL . . . 162.13 -172.95 38.37 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.768 -1.333 . . . . 0.49 109.768 -179.215 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -61.77 -31.88 85.87 Favored 'Trans proline' 0 C--N 1.319 -0.979 0 C-N-CA 122.302 2.001 . . . . 0.66 112.046 -179.666 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 8.0 t -139.0 169.95 16.86 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 120.949 -1.094 . . . . 1.55 110.549 -179.169 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 38.5 mtpt -87.1 106.86 18.16 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 109.003 -0.74 . . . . 2.53 109.003 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -73.48 127.42 32.67 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.165 -0.959 . . . . 0.82 109.776 -179.711 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 24.4 tt0 -65.42 170.44 4.87 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.288 -0.882 . . . . 2.3 109.028 179.732 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.414 HD12 HG13 ' B' ' 13' ' ' VAL . 20.1 mt -143.52 155.11 16.37 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 N-CA-C 108.345 -0.983 . . . . 1.4 108.345 -179.9 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.532 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -143.12 174.91 10.28 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 120.685 -1.259 . . . . 1.36 109.21 -179.775 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.449 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 51.7 p90 -142.29 128.49 19.82 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.363 -0.835 . . . . 1.47 109.172 179.9 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 . . . . . 0 N--CA 1.497 1.892 0 O-C-N 121.296 -0.878 . . . . 2.51 109.987 -179.782 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.0 t . . . . . 0 N--CA 1.497 1.88 0 CA-C-O 121.428 0.632 . . . . 2.2 109.764 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 36.9 t -88.04 139.47 30.48 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.329 -0.857 . . . . 2.05 109.347 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -112.4 114.02 3.4 Favored Glycine 0 N--CA 1.5 2.948 0 N-CA-C 109.985 -1.246 . . . . 1.39 109.985 -179.761 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.502 HG21 HD12 ' A' ' 41' ' ' ILE . 77.9 t -100.97 116.15 43.97 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.948 0 O-C-N 121.467 -1.019 . . . . 1.57 108.912 179.291 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.532 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.6 OUTLIER -103.81 136.75 42.91 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.579 -0.7 . . . . 1.85 109.196 -179.846 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.428 ' OH ' ' CA ' ' A' ' 27' ' ' GLY . 11.3 p90 -134.65 166.69 22.34 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.508 -0.745 . . . . 1.54 109.671 -179.769 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 8.4 t -139.86 113.54 6.3 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 N-CA-C 108.887 -0.783 . . . . 1.9 108.887 -179.729 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.594 ' CG1' ' CE2' ' A' ' 85' ' ' TYR . 0.2 OUTLIER -79.75 168.57 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 N-CA-C 108.499 -0.926 . . . . 1.27 108.499 179.552 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 10.5 tt0 -109.3 -36.79 5.93 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.441 -0.787 . . . . 2.48 109.417 179.323 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.428 ' O ' ' O ' ' A' ' 82' ' ' PRO . 75.2 mm-40 -158.85 149.6 16.01 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.278 -0.888 . . . . 1.92 110.679 -179.308 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.625 ' HD3' ' HB2' ' A' ' 33' ' ' ALA . 82.1 Cg_exo -39.08 169.38 0.01 OUTLIER 'Trans proline' 0 C--O 1.213 -0.727 0 C-N-CA 122.761 2.307 . . . . 1.3 112.756 177.696 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 141.69 177.33 16.74 Favored Glycine 0 N--CA 1.493 2.451 0 N-CA-C 109.726 -1.35 . . . . 1.02 109.726 179.226 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -93.16 89.57 6.5 Favored 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 107.741 -1.207 . . . . 2.13 107.741 179.149 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.594 ' CE2' ' CG1' ' A' ' 79' ' ' VAL . 3.7 m-85 -78.04 132.15 37.64 Favored 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.458 -0.776 . . . . 0.92 108.912 -179.014 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -112.81 128.79 56.54 Favored 'General case' 0 N--CA 1.498 1.947 0 N-CA-C 108.588 -0.893 . . . . 1.53 108.588 -179.079 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.411 ' CG1' ' CE2' ' A' ' 101' ' ' PHE . 5.8 p -126.13 133.64 68.4 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 121.568 -0.708 . . . . 1.0 109.471 -179.865 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.1 t -123.64 103.96 8.73 Favored 'General case' 0 N--CA 1.498 1.933 0 N-CA-C 109.445 -0.576 . . . . 1.59 109.445 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.2 pt -107.7 130.29 60.29 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 CA-C-O 121.64 0.734 . . . . 1.29 110.045 -179.573 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' LYS . . . . . 0.47 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.98 122.68 17.52 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 107.9 -1.148 . . . . 1.58 107.9 179.593 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.412 ' O ' ' CB ' ' A' ' 92' ' ' ASN . 71.2 t80 -83.08 100.57 10.59 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 120.515 -1.365 . . . . 1.34 108.029 179.351 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . 0.429 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 2.2 t30 72.31 35.48 1.19 Allowed 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.196 -0.94 . . . . 2.32 108.809 -178.646 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.429 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 0.9 OUTLIER 78.2 14.77 1.44 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.879 -0.513 . . . . 1.92 111.609 179.53 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . 0.489 ' OE2' ' CA ' ' A' ' 17' ' ' GLY . 5.7 pt-20 -100.54 99.22 9.78 Favored 'General case' 0 N--CA 1.496 1.843 0 N-CA-C 107.145 -1.428 . . . . 2.25 107.145 177.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' HIS . . . . . 0.462 ' O ' ' CG ' ' A' ' 95' ' ' HIS . 46.2 p-80 -66.96 105.46 1.63 Allowed 'General case' 0 N--CA 1.487 1.389 0 CA-C-O 121.472 0.653 . . . . 2.88 110.453 -177.928 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' ILE . . . . . 0.523 ' O ' ' N ' ' A' ' 98' ' ' ASP . 4.0 tt -56.56 136.33 77.23 Favored Pre-proline 0 C--N 1.3 -1.548 0 N-CA-C 107.81 -1.182 . . . . 2.35 107.81 178.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.44 ' O ' ' CB ' ' A' ' 98' ' ' ASP . 11.6 Cg_exo -47.15 90.98 0.02 OUTLIER 'Trans proline' 0 C--O 1.213 -0.729 0 N-CA-C 109.886 -0.852 . . . . 2.48 109.886 -179.755 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.523 ' N ' ' O ' ' A' ' 96' ' ' ILE . 0.9 OUTLIER 165.61 -60.43 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 108.235 -1.024 . . . . 2.65 108.235 -179.418 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 1.3 t -55.8 139.08 70.18 Favored Pre-proline 0 C--N 1.296 -1.727 0 O-C-N 121.299 -0.875 . . . . 2.0 109.796 -178.306 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_endo -88.36 113.72 2.47 Favored 'Cis proline' 0 N--CA 1.494 1.521 0 N-CA-C 110.024 -0.798 . . . . 1.79 110.024 -2.393 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . 0.411 ' CE2' ' CG1' ' A' ' 87' ' ' VAL . 2.6 p90 -97.74 169.15 9.88 Favored 'General case' 0 N--CA 1.518 2.944 0 O-C-N 120.236 -1.54 . . . . 2.19 109.779 178.625 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.3 p -96.78 150.45 4.44 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.643 -0.66 . . . . 1.44 109.982 -179.635 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.446 ' N ' ' O ' ' A' ' 85' ' ' TYR . 87.0 t -128.3 87.03 56.36 Favored Pre-proline 0 N--CA 1.498 1.965 0 N-CA-C 108.379 -0.971 . . . . 1.19 108.379 179.675 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo -65.11 114.9 3.01 Favored 'Trans proline' 0 C--N 1.322 -0.856 0 C-N-CA 121.571 1.514 . . . . 1.49 111.8 -178.27 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.55 HG13 ' C ' ' A' ' 31' ' ' GLY . 84.3 t -106.59 143.54 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 N-CA-C 106.342 -1.725 . . . . 1.35 106.342 178.365 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.671 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -133.24 138.51 46.53 Favored 'General case' 0 N--CA 1.512 2.666 0 CA-C-O 122.272 1.034 . . . . 1.67 112.516 -176.719 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . 0.623 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 59.8 p -94.29 78.21 3.95 Favored 'General case' 0 N--CA 1.494 1.725 0 N-CA-C 107.608 -1.256 . . . . 2.04 107.608 179.097 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 16.8 mt 63.15 3.33 1.27 Allowed 'General case' 0 C--N 1.295 -1.766 0 N-CA-C 107.438 -1.319 . . . . 3.2 107.438 -177.835 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.502 ' H ' ' C ' ' A' ' 107' ' ' SER . 18.5 t -89.84 -23.18 21.74 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 108.813 -0.81 . . . . 2.09 108.813 179.328 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . 0.671 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 50.5 t0 . . . . . 0 N--CA 1.487 1.382 0 N-CA-C 107.822 -1.177 . . . . 2.85 107.822 -179.196 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . 0.563 ' CG ' HH11 ' B' ' 8' ' ' ARG . 1.4 mtt-85 . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 108.542 -0.91 . . . . 3.04 108.542 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 9' ' ' VAL . . . . . 0.415 ' O ' ' O ' ' A' ' 57' ' ' GLY . 11.2 t -49.89 159.85 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 120.973 -1.079 . . . . 0.67 108.311 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 0.4 ' N ' ' CG1' ' B' ' 9' ' ' VAL . . . -124.67 144.13 50.37 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.526 -0.734 . . . . 0.58 110.173 -178.887 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 11' ' ' SER . . . . . 0.44 ' CB ' HG23 ' A' ' 55' ' ' VAL . 2.8 t -134.7 145.88 48.93 Favored 'General case' 0 N--CA 1.495 1.817 0 N-CA-C 108.636 -0.876 . . . . 1.19 108.636 179.446 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 17.7 m -142.46 114.66 8.31 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.223 -0.923 . . . . 1.38 109.69 -179.491 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 0.57 HG22 ' N ' ' B' ' 14' ' ' PHE . 2.7 p -160.03 166.67 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 O-C-N 121.367 -0.833 . . . . 0.42 109.014 179.83 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 14' ' ' PHE . . . . . 0.57 ' N ' HG22 ' B' ' 13' ' ' VAL . 8.3 p90 -177.16 -166.88 0.15 Allowed 'General case' 0 N--CA 1.488 1.429 0 CA-C-O 122.077 0.941 . . . . 1.79 111.926 179.85 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.413 ' N ' HD13 ' B' ' 15' ' ' ILE . 0.0 OUTLIER -140.02 152.98 22.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 N-CA-C 108.271 -1.011 . . . . 1.25 108.271 179.721 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 7.2 m -123.66 131.14 53.54 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.317 -0.865 . . . . 1.61 109.921 -179.666 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 13.8 mt . . . . . 0 N--CA 1.496 1.843 0 O-C-N 121.327 -0.858 . . . . 1.32 109.01 179.609 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.519 ' O ' ' N ' ' A' ' 18' ' ' ALA . . . . . . . . 0 N--CA 1.49 2.284 0 N-CA-C 110.851 -0.899 . . . . 2.44 110.851 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.55 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -46.28 -12.33 0.05 OUTLIER Glycine 0 N--CA 1.491 2.333 0 N-CA-C 110.603 -0.999 . . . . 1.81 110.603 -179.2 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.519 ' N ' ' O ' ' A' ' 16' ' ' GLY . . . -47.64 -10.41 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.145 -1.209 . . . . 2.21 110.093 -179.924 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' HIS . . . . . 0.55 ' N ' ' O ' ' A' ' 17' ' ' GLY . 80.2 t60 -104.81 -31.36 9.34 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.188 -0.945 . . . . 2.87 110.444 -179.38 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -101.6 -14.72 17.32 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 120.997 -1.064 . . . . 2.02 110.848 -178.979 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.614 ' O ' HG13 ' A' ' 21' ' ' VAL . 9.0 p -70.85 114.39 8.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 120.819 -1.175 . . . . 2.07 109.818 -179.606 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 20.6 tpt180 -104.08 140.38 37.85 Favored 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 109.008 -0.738 . . . . 3.5 109.008 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -144.45 113.28 6.75 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.247 -0.908 . . . . 1.83 109.37 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -156.49 129.05 2.33 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.788 -1.325 . . . . 1.9 109.788 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.11 -177.59 47.72 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.666 -1.374 . . . . 1.85 109.666 179.805 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 12.3 p -78.36 -26.12 46.56 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.25 -1.147 . . . . 2.31 109.396 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -71.06 -12.13 71.23 Favored Glycine 0 N--CA 1.488 2.132 0 N-CA-C 109.301 -1.52 . . . . 1.64 109.301 -179.831 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 12.8 mt -91.36 -6.13 53.46 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.364 -1.08 . . . . 1.83 108.914 179.875 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -96.27 -51.03 4.55 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.336 -0.853 . . . . 2.34 109.748 -179.708 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 23.0 ptt180 -175.28 -173.65 0.67 Allowed 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.017 -1.052 . . . . 3.77 110.16 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -152.4 177.58 30.08 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 108.358 -1.897 . . . . 1.57 108.358 179.583 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 41.5 t -134.84 151.05 30.6 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.045 0 O-C-N 121.143 -1.21 . . . . 1.83 110.481 -179.683 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.589 ' HB2' ' HB3' ' A' ' 107' ' ' SER . . . -37.05 112.2 0.19 Allowed 'General case' 0 N--CA 1.5 2.072 0 CA-C-O 121.737 0.78 . . . . 1.64 112.406 -179.293 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 54.59 49.88 59.42 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 111.371 -0.692 . . . . 1.73 111.371 177.249 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 40.5 t -127.38 98.22 29.71 Favored Pre-proline 0 N--CA 1.496 1.826 0 O-C-N 121.511 -0.994 . . . . 2.19 108.512 178.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -56.89 149.05 63.43 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 120.955 1.103 . . . . 1.96 110.445 -178.86 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.403 ' HB3' ' CZ ' ' A' ' 77' ' ' TYR . . . -157.49 -167.73 2.37 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.4 -0.813 . . . . 1.69 109.018 -179.812 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -170.54 168.48 7.68 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.148 -0.97 . . . . 2.23 110.873 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 0.568 ' CE2' HD11 ' A' ' 41' ' ' ILE . 1.1 p90 -144.95 -178.68 6.16 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 107.161 -1.422 . . . . 1.54 107.161 178.345 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 12.0 m -109.42 150.99 27.27 Favored 'General case' 0 N--CA 1.5 2.049 0 O-C-N 121.359 -0.838 . . . . 2.37 110.99 -178.345 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.686 HD12 HG21 ' A' ' 75' ' ' VAL . 11.3 mt -147.8 94.55 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 N-CA-C 108.749 -0.834 . . . . 1.65 108.749 179.048 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.49 ' CD1' ' C ' ' A' ' 42' ' ' TRP . 0.6 OUTLIER -86.99 138.07 31.82 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 120.946 -1.096 . . . . 3.68 108.563 179.837 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -167.61 114.85 0.75 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.282 -0.886 . . . . 2.89 109.523 -179.678 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' ARG . . . . . 0.436 ' C ' ' CD ' ' A' ' 44' ' ' ARG . 1.7 ppt_? -169.47 -12.33 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.19 -0.944 . . . . 4.63 109.7 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -65.04 -46.15 82.46 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.213 -0.929 . . . . 2.89 109.469 -179.735 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.58 -50.4 72.07 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.153 -0.967 . . . . 1.74 108.856 179.695 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 139.76 -153.58 23.24 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.249 -1.54 . . . . 1.6 109.249 179.777 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -86.11 155.97 20.56 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.446 -1.032 . . . . 1.4 108.924 179.547 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 179.35 -140.28 4.28 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.563 -1.415 . . . . 1.04 109.563 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.47 ' O ' ' N ' ' A' ' 92' ' ' ASN . . . -138.88 167.64 25.04 Favored Glycine 0 N--CA 1.495 2.611 0 N-CA-C 109.283 -1.527 . . . . 1.06 109.283 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.445 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 46.4 tp -142.56 106.48 4.7 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.381 -1.07 . . . . 1.1 108.434 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.4 m -90.43 143.54 26.65 Favored 'General case' 0 N--CA 1.495 1.787 0 N-CA-C 108.557 -0.905 . . . . 1.56 108.557 179.863 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.548 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 53.6 mt -135.36 105.1 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.266 -0.897 . . . . 0.65 109.176 179.84 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -97.97 106.62 18.94 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.283 -0.886 . . . . 0.69 108.786 179.755 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.437 ' O ' ' O ' ' B' ' 11' ' ' SER . 0.2 OUTLIER -96.79 142.34 14.17 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.501 -0.749 . . . . 0.91 109.555 -179.745 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -141.78 142.7 33.22 Favored 'General case' 0 N--CA 1.491 1.61 0 N-CA-C 108.21 -1.033 . . . . 1.8 108.21 178.846 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 164.92 -173.9 40.83 Favored Glycine 0 N--CA 1.489 2.167 0 N-CA-C 109.448 -1.461 . . . . 0.49 109.448 -179.104 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -59.46 -26.0 80.51 Favored 'Trans proline' 0 C--N 1.315 -1.199 0 C-N-CA 121.93 1.753 . . . . 0.66 112.103 -179.299 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . 0.435 ' O ' ' OH ' ' A' ' 85' ' ' TYR . 22.9 t -142.54 169.24 17.95 Favored 'General case' 0 N--CA 1.502 2.168 0 O-C-N 121.015 -1.053 . . . . 1.55 110.364 179.947 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 60.7 mttt -81.09 95.31 6.81 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.497 -0.752 . . . . 2.53 109.763 -179.608 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -63.54 117.29 6.55 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.173 -0.954 . . . . 0.82 109.511 179.854 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . 0.453 ' CB ' HG12 ' A' ' 78' ' ' VAL . 26.0 tt0 -66.27 168.39 8.79 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.154 -0.966 . . . . 2.3 109.148 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.458 HD12 HG13 ' B' ' 13' ' ' VAL . 28.1 mt -141.0 155.61 21.76 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 N-CA-C 108.642 -0.873 . . . . 1.4 108.642 -179.79 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.542 ' HB3' ' OG ' ' A' ' 76' ' ' SER . . . -144.87 170.75 15.52 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 120.627 -1.295 . . . . 1.36 109.156 179.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.46 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 31.3 p90 -147.16 117.88 7.57 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.28 -0.887 . . . . 1.47 109.472 -179.962 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 . . . . . 0 N--CA 1.495 1.81 0 O-C-N 121.364 -0.835 . . . . 2.51 109.546 -179.998 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 14.0 p . . . . . 0 N--CA 1.495 1.779 0 N-CA-C 108.76 -0.83 . . . . 2.2 108.76 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 3.3 m -78.81 115.22 18.36 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.15 -0.969 . . . . 2.05 109.521 -179.585 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -93.72 114.68 4.78 Favored Glycine 0 N--CA 1.494 2.543 0 N-CA-C 109.919 -1.273 . . . . 1.39 109.919 -179.716 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.686 HG21 HD12 ' A' ' 41' ' ' ILE . 94.0 t -98.39 108.5 22.15 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 121.409 -1.053 . . . . 1.57 109.465 179.695 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.542 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 0.7 OUTLIER -89.55 166.64 13.53 Favored 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 108.268 -1.012 . . . . 1.85 108.268 179.331 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.406 ' CD1' ' N ' ' A' ' 77' ' ' TYR . 14.1 p90 -164.14 172.36 13.81 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.216 -0.928 . . . . 1.54 109.659 -179.36 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.533 ' O ' HG13 ' A' ' 78' ' ' VAL . 3.7 p -142.17 119.25 7.11 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.254 0 O-C-N 121.104 -0.998 . . . . 1.9 110.391 179.61 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.51 HG11 HG21 ' A' ' 105' ' ' VAL . 8.5 m -94.98 147.06 6.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.186 -0.946 . . . . 1.27 109.164 179.674 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 29.5 tt0 -90.16 -47.44 7.8 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.082 -1.011 . . . . 2.48 110.582 -179.254 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -155.9 155.59 29.52 Favored Pre-proline 0 N--CA 1.504 2.231 0 O-C-N 120.695 -1.253 . . . . 1.92 110.902 -179.347 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.663 ' HG3' ' N ' ' A' ' 107' ' ' SER . 87.2 Cg_exo -36.19 152.77 0.03 OUTLIER 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 123.279 2.653 . . . . 1.3 113.287 179.03 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 152.31 158.04 8.26 Favored Glycine 0 N--CA 1.487 2.052 0 N-CA-C 109.251 -1.54 . . . . 1.02 109.251 -179.926 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . 0.781 ' H ' HH12 ' B' ' 8' ' ' ARG . 0.3 OUTLIER -83.39 90.38 7.16 Favored 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 107.648 -1.242 . . . . 2.13 107.648 179.077 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.435 ' OH ' ' O ' ' A' ' 59' ' ' SER . 1.4 m-85 -73.28 156.11 38.8 Favored 'General case' 0 C--N 1.294 -1.843 0 N-CA-C 108.266 -1.012 . . . . 0.92 108.266 -179.267 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . 0.42 ' OE1' ' O ' ' A' ' 84' ' ' ASP . 0.0 OUTLIER -138.48 120.83 15.95 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.461 -0.774 . . . . 1.53 109.287 -179.369 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.7 p -120.89 147.17 24.87 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.532 -0.73 . . . . 1.0 109.54 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 82.6 p -129.98 107.25 9.21 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.437 -0.79 . . . . 1.59 109.328 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.6 pt -106.29 130.75 57.48 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.658 -0.651 . . . . 1.29 109.946 -179.568 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' LYS . . . . . 0.466 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.6 OUTLIER -136.55 122.63 20.29 Favored 'General case' 0 N--CA 1.492 1.627 0 N-CA-C 108.837 -0.801 . . . . 1.58 108.837 179.341 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.56 ' O ' ' ND2' ' A' ' 92' ' ' ASN . 60.0 t80 -80.16 107.0 12.61 Favored 'General case' 0 C--N 1.299 -1.603 0 C-N-CA 118.716 -1.193 . . . . 1.34 107.819 178.37 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . 0.56 ' ND2' ' O ' ' A' ' 91' ' ' PHE . 2.9 p30 61.71 32.79 18.26 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.448 -0.783 . . . . 2.32 109.94 -178.584 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.472 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 2.5 m-20 86.21 16.97 0.11 Allowed 'General case' 0 N--CA 1.506 2.363 0 O-C-N 121.593 -0.692 . . . . 1.92 112.24 178.171 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . 0.489 ' O ' ' OE1' ' A' ' 94' ' ' GLU . 0.3 OUTLIER -102.4 98.64 8.71 Favored 'General case' 0 N--CA 1.499 1.98 0 N-CA-C 107.039 -1.467 . . . . 2.25 107.039 177.503 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' HIS . . . . . 0.502 ' O ' ' CG ' ' A' ' 95' ' ' HIS . 52.1 p-80 -68.64 106.48 2.63 Favored 'General case' 0 N--CA 1.487 1.417 0 N-CA-C 109.14 -0.689 . . . . 2.88 109.14 -178.838 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' ILE . . . . . 0.897 ' O ' HD13 ' A' ' 96' ' ' ILE . 0.0 OUTLIER -58.91 155.07 34.28 Favored Pre-proline 0 N--CA 1.491 1.602 0 N-CA-C 108.557 -0.905 . . . . 2.35 108.557 -179.614 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_endo -63.47 77.24 0.13 Allowed 'Trans proline' 0 CA--C 1.539 0.768 0 C-N-CA 121.23 1.287 . . . . 2.48 109.892 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.507 ' CG ' ' CE2' ' A' ' 101' ' ' PHE . 0.4 OUTLIER 179.81 -28.72 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.857 0 O-C-N 120.968 -1.082 . . . . 2.65 109.054 -179.649 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 29.4 m -78.02 136.69 61.77 Favored Pre-proline 0 C--N 1.298 -1.674 0 N-CA-C 107.313 -1.366 . . . . 2.0 107.313 178.448 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -76.64 116.95 4.66 Favored 'Cis proline' 0 CA--C 1.547 1.174 0 C-N-CA 125.165 -0.765 . . . . 1.79 111.09 -0.099 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . 0.507 ' CE2' ' CG ' ' A' ' 98' ' ' ASP . 0.1 OUTLIER -70.54 164.77 24.11 Favored 'General case' 0 N--CA 1.494 1.736 0 N-CA-C 107.793 -1.188 . . . . 2.19 107.793 178.566 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.485 HG13 ' O ' ' A' ' 102' ' ' VAL . 8.6 p -123.4 127.93 74.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 N-CA-C 108.43 -0.952 . . . . 1.44 108.43 179.068 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 94.9 t -121.47 83.56 40.96 Favored Pre-proline 0 N--CA 1.503 2.18 0 O-C-N 121.406 -0.809 . . . . 1.19 109.535 -179.223 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -66.85 110.64 1.97 Allowed 'Trans proline' 0 C--N 1.32 -0.967 0 C-N-CA 121.252 1.301 . . . . 1.49 110.742 -179.131 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.51 HG21 HG11 ' A' ' 79' ' ' VAL . 54.2 t -89.06 146.15 6.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 N-CA-C 107.28 -1.378 . . . . 1.35 107.28 178.54 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.553 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -133.64 130.43 38.27 Favored 'General case' 0 N--CA 1.508 2.46 0 O-C-N 121.289 -0.882 . . . . 1.67 111.746 -177.085 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . 0.663 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 94.6 p -106.05 93.4 4.6 Favored 'General case' 0 N--CA 1.494 1.752 0 N-CA-C 106.854 -1.536 . . . . 2.04 106.854 178.578 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' LEU . . . . . 0.491 HD12 ' N ' ' A' ' 108' ' ' LEU . 11.1 mp 57.38 7.47 0.49 Allowed 'General case' 0 C--N 1.293 -1.858 0 N-CA-C 107.839 -1.171 . . . . 3.2 107.839 -177.696 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.513 ' H ' ' C ' ' A' ' 107' ' ' SER . 6.1 t -92.99 -29.42 15.85 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 108.506 -0.924 . . . . 2.09 108.506 178.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . 0.553 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 26.8 m-20 . . . . . 0 N--CA 1.488 1.432 0 N-CA-C 108.061 -1.089 . . . . 2.85 108.061 -178.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . 0.781 HH12 ' H ' ' A' ' 84' ' ' ASP . 3.9 mtt180 . . . . . 0 N--CA 1.496 1.862 0 N-CA-C 108.562 -0.903 . . . . 3.04 108.562 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 9' ' ' VAL . . . . . . . . . . . . . 20.8 t -56.82 159.34 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 N-CA-C 107.632 -1.247 . . . . 0.67 107.632 179.041 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -125.84 150.1 48.12 Favored 'General case' 0 N--CA 1.502 2.133 0 O-C-N 121.328 -0.857 . . . . 0.58 109.968 -179.136 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 11' ' ' SER . . . . . 0.437 ' O ' ' O ' ' A' ' 55' ' ' VAL . 6.2 m -148.77 145.14 27.46 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.389 -0.819 . . . . 1.19 109.44 179.911 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 14.8 t -142.08 118.57 10.93 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.205 -0.934 . . . . 1.38 109.553 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 0.56 HG22 ' N ' ' B' ' 14' ' ' PHE . 2.4 p -157.61 167.04 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 121.365 -0.834 . . . . 0.42 108.804 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 14' ' ' PHE . . . . . 0.56 ' N ' HG22 ' B' ' 13' ' ' VAL . 5.4 p90 -176.69 -167.13 0.18 Allowed 'General case' 0 N--CA 1.488 1.47 0 C-N-CA 119.298 -0.961 . . . . 1.79 112.082 -179.859 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.9 pt -146.63 176.94 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 N-CA-C 108.419 -0.956 . . . . 1.25 108.419 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 16.1 m -140.2 142.09 35.91 Favored 'General case' 0 N--CA 1.5 2.041 0 O-C-N 120.921 -1.112 . . . . 1.61 110.096 -179.703 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 18.5 mt . . . . . 0 N--CA 1.497 1.917 0 O-C-N 121.532 -0.73 . . . . 1.32 109.084 179.531 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.477 ' O ' ' N ' ' A' ' 18' ' ' ALA . . . . . . . . 0 N--CA 1.49 2.291 0 N-CA-C 111.779 -0.529 . . . . 2.44 111.779 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.588 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 63.79 -49.83 0.08 OUTLIER Glycine 0 N--CA 1.493 2.475 0 O-C-N 121.759 -0.848 . . . . 1.81 111.669 177.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.512 ' N ' ' OE2' ' A' ' 94' ' ' GLU . . . -45.33 -12.08 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.111 -1.229 . . . . 2.21 109.935 -179.276 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' HIS . . . . . 0.588 ' N ' ' O ' ' A' ' 17' ' ' GLY . 1.5 t60 -83.65 -40.64 18.72 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.142 -0.974 . . . . 2.87 109.557 179.207 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.527 ' HZ2' HG23 ' A' ' 21' ' ' VAL . 0.9 OUTLIER -93.93 4.17 54.3 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 120.874 -1.141 . . . . 2.02 110.5 -179.508 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.527 HG23 ' HZ2' ' A' ' 20' ' ' LYS . 64.6 t -83.06 113.51 22.36 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 120.811 -1.18 . . . . 2.07 109.25 179.721 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 20.3 tpt180 -111.03 137.27 48.87 Favored 'General case' 0 N--CA 1.496 1.83 0 CA-C-O 121.408 0.623 . . . . 3.5 109.63 -179.634 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -144.21 113.55 6.98 Favored 'General case' 0 N--CA 1.493 1.701 0 N-CA-C 108.744 -0.836 . . . . 1.83 108.744 179.417 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -153.17 128.53 2.47 Favored Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.924 -1.27 . . . . 1.9 109.924 -179.465 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 179.84 -173.92 45.5 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.926 -1.269 . . . . 1.85 109.926 179.721 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 16.7 p -78.92 -25.76 43.7 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.358 -1.083 . . . . 2.31 109.235 179.554 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.485 ' N ' ' O ' ' A' ' 38' ' ' GLU . . . -65.9 -17.78 65.7 Favored Glycine 0 N--CA 1.488 2.131 0 N-CA-C 108.388 -1.885 . . . . 1.64 108.388 179.58 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 14.1 mt -94.12 32.46 1.5 Allowed 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 108.477 -0.935 . . . . 1.83 108.477 179.439 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -140.33 -50.91 0.47 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.445 -0.784 . . . . 2.34 109.615 -179.58 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . 0.519 ' NH1' ' OD1' ' A' ' 110' ' ' ASP . 30.8 ptt180 -172.27 173.75 4.13 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.953 -1.092 . . . . 3.77 110.573 -179.79 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -150.24 176.4 28.88 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 107.878 -2.089 . . . . 1.57 107.878 179.437 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 37.5 t -134.09 153.13 35.44 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.137 0 O-C-N 120.992 -1.299 . . . . 1.83 110.755 -179.629 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.813 ' HB2' ' OG ' ' A' ' 107' ' ' SER . . . -40.37 114.1 0.42 Allowed 'General case' 0 N--CA 1.497 1.891 0 CA-C-O 121.587 0.708 . . . . 1.64 112.092 -179.334 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 56.46 46.04 88.38 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 111.397 -0.681 . . . . 1.73 111.397 177.05 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 37.1 t -126.92 122.54 23.33 Favored Pre-proline 0 N--CA 1.497 1.909 0 O-C-N 121.443 -1.033 . . . . 2.19 108.23 178.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 2.3 Cg_endo -59.47 120.52 8.41 Favored 'Trans proline' 0 C--O 1.216 -0.622 0 C-N-CA 120.474 0.783 . . . . 1.96 110.27 -179.38 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.47 ' HB3' ' CE1' ' A' ' 77' ' ' TYR . . . -116.81 161.21 19.65 Favored 'General case' 0 N--CA 1.497 1.904 0 N-CA-C 107.814 -1.18 . . . . 1.69 107.814 179.167 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . 0.485 ' O ' ' N ' ' A' ' 27' ' ' GLY . 7.0 pt-20 -163.8 173.01 13.31 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 120.642 -1.286 . . . . 2.23 111.519 -179.455 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 0.675 ' CE2' HD11 ' A' ' 41' ' ' ILE . 5.6 p90 -157.99 165.24 35.63 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 107.647 -1.242 . . . . 1.54 107.647 178.504 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 58.0 m -99.96 148.96 23.93 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.404 -0.81 . . . . 2.37 110.843 -178.099 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.795 HD12 HG21 ' A' ' 75' ' ' VAL . 95.5 mt -137.84 102.64 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 N-CA-C 108.353 -0.98 . . . . 1.65 108.353 178.963 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 3.0 t-105 -100.04 132.77 45.21 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.314 -0.866 . . . . 3.68 108.683 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.547 ' OG1' ' N ' ' A' ' 44' ' ' ARG . 1.6 t -162.25 -126.16 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.405 -0.809 . . . . 2.89 109.503 -179.641 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' ARG . . . . . 0.547 ' N ' ' OG1' ' A' ' 43' ' ' THR . 25.9 mtm180 60.61 80.22 0.22 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.285 -0.885 . . . . 4.63 109.954 179.885 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 12.5 tp10 -159.45 -46.82 0.05 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.282 -0.886 . . . . 2.89 109.134 179.383 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -60.34 -59.96 4.58 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.086 -1.009 . . . . 1.74 109.066 179.715 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 163.59 -175.88 39.76 Favored Glycine 0 N--CA 1.484 1.856 0 C-N-CA 119.385 -1.388 . . . . 1.6 110.464 179.62 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.6 163.47 0.65 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.535 -0.98 . . . . 1.4 109.853 -179.686 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 172.72 -163.2 35.04 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.68 -1.368 . . . . 1.04 109.68 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -142.77 130.45 4.2 Favored Glycine 0 N--CA 1.496 2.634 0 N-CA-C 109.245 -1.542 . . . . 1.06 109.245 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.475 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 12.2 tp -103.07 100.62 10.56 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.425 -1.044 . . . . 1.1 109.042 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 3.9 m -88.77 139.76 30.14 Favored 'General case' 0 N--CA 1.497 1.92 0 N-CA-C 108.723 -0.843 . . . . 1.56 108.723 179.476 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.507 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 82.6 mt -128.15 113.28 29.78 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.111 0 O-C-N 121.088 -1.008 . . . . 0.65 109.916 -179.811 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -102.48 106.04 16.7 Favored 'General case' 0 N--CA 1.494 1.736 0 N-CA-C 108.718 -0.845 . . . . 0.69 108.718 179.251 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.44 HG23 ' OG ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -102.84 143.7 14.78 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 O-C-N 121.471 -0.768 . . . . 0.91 109.326 -179.697 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 -141.95 144.03 33.54 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 108.181 -1.044 . . . . 1.8 108.181 178.743 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 168.71 -172.59 43.17 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 109.179 -1.569 . . . . 0.49 109.179 -179.031 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -63.73 -27.6 68.37 Favored 'Trans proline' 0 C--N 1.316 -1.133 0 C-N-CA 121.888 1.725 . . . . 0.66 111.461 -179.696 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . 0.421 ' O ' ' OH ' ' A' ' 85' ' ' TYR . 16.0 m -140.4 168.12 20.55 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.257 -0.902 . . . . 1.55 109.754 -179.77 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 37.1 mtpt -91.13 126.44 36.22 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.376 -0.828 . . . . 2.53 109.517 -179.713 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -86.83 135.12 33.45 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.242 -0.911 . . . . 0.82 109.358 179.861 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 20.0 tt0 -90.19 94.53 9.8 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.129 -0.982 . . . . 2.3 109.97 -179.658 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.602 HD12 ' N ' ' A' ' 63' ' ' ILE . 1.8 mp -60.34 153.74 4.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 N-CA-C 109.118 -0.697 . . . . 1.4 109.118 179.415 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.547 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -151.3 123.8 8.41 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.037 -1.039 . . . . 1.36 109.24 179.778 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.47 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 47.5 p90 -89.0 124.59 34.42 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.204 -0.935 . . . . 1.47 109.376 179.787 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 75.9 tt0 . . . . . 0 N--CA 1.497 1.887 0 O-C-N 121.222 -0.924 . . . . 2.51 109.772 -179.96 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 3.3 t . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 109.092 -0.707 . . . . 2.2 109.092 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 76.4 m -86.23 113.39 22.21 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.126 -0.984 . . . . 2.05 109.428 -179.927 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -87.62 115.46 4.34 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.703 -1.359 . . . . 1.39 109.703 -179.717 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.795 HG21 HD12 ' A' ' 41' ' ' ILE . 22.0 t -107.03 104.46 17.1 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.995 0 O-C-N 121.605 -0.938 . . . . 1.57 109.012 179.79 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.547 ' O ' ' N ' ' A' ' 64' ' ' ALA . 37.3 m -99.4 131.84 45.14 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.558 -0.714 . . . . 1.85 110.06 -179.45 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.511 ' CD1' ' O ' ' A' ' 77' ' ' TYR . 44.3 p90 -128.01 134.96 49.29 Favored 'General case' 0 N--CA 1.497 1.915 0 N-CA-C 108.875 -0.787 . . . . 1.54 108.875 179.882 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.64 ' O ' HG13 ' A' ' 78' ' ' VAL . 9.7 p -104.52 114.2 43.51 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.099 0 O-C-N 121.324 -0.86 . . . . 1.9 109.582 -179.576 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.476 HG11 HG21 ' A' ' 105' ' ' VAL . 2.0 m -88.64 158.96 2.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.096 -1.002 . . . . 1.27 109.031 -179.865 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 35.1 tt0 -97.28 -49.47 4.93 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.079 -1.013 . . . . 2.48 110.758 -179.133 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 76.5 mm-40 -147.15 150.74 39.15 Favored Pre-proline 0 N--CA 1.504 2.242 0 O-C-N 120.794 -1.191 . . . . 1.92 111.661 -178.314 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.653 ' HG3' ' N ' ' A' ' 107' ' ' SER . 77.3 Cg_exo -36.85 164.27 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 123.248 2.632 . . . . 1.3 113.346 178.409 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 145.03 175.21 17.99 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.543 -1.423 . . . . 1.02 109.543 179.676 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . 0.837 ' H ' HH12 ' B' ' 8' ' ' ARG . 0.9 OUTLIER -94.26 83.97 4.33 Favored 'General case' 0 N--CA 1.49 1.549 0 N-CA-C 107.959 -1.126 . . . . 2.13 107.959 179.277 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' TYR . . . . . 0.421 ' OH ' ' O ' ' A' ' 59' ' ' SER . 2.7 m-85 -68.89 135.25 50.76 Favored 'General case' 0 C--N 1.299 -1.606 0 N-CA-C 107.84 -1.171 . . . . 0.92 107.84 -179.712 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . 0.442 ' OE2' ' O ' ' A' ' 84' ' ' ASP . 0.8 OUTLIER -116.31 121.04 40.8 Favored 'General case' 0 N--CA 1.499 1.996 0 N-CA-C 108.768 -0.827 . . . . 1.53 108.768 -179.37 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 10.6 p -116.46 145.35 22.33 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 121.592 -0.693 . . . . 1.0 110.194 -179.375 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 9.4 p -136.47 110.35 8.19 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 108.699 -0.852 . . . . 1.59 108.699 179.596 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.8 pt -116.89 135.75 56.23 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.949 0 O-C-N 121.577 -0.702 . . . . 1.29 110.632 -178.886 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' LYS . . . . . 0.511 ' HZ3' ' HB3' ' A' ' 90' ' ' LYS . 0.3 OUTLIER -136.03 121.31 19.14 Favored 'General case' 0 N--CA 1.486 1.339 0 N-CA-C 107.923 -1.14 . . . . 1.58 107.923 178.625 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.409 ' O ' ' OE1' ' A' ' 94' ' ' GLU . 52.7 t80 -85.15 101.65 12.64 Favored 'General case' 0 N--CA 1.491 1.621 0 N-CA-C 107.196 -1.409 . . . . 1.34 107.196 178.632 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' ASN . . . . . 0.454 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 21.3 t30 72.09 34.36 1.45 Allowed 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 109.214 -0.661 . . . . 2.32 109.214 -178.266 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.454 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 1.4 m-20 80.22 14.4 0.84 Allowed 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.614 -0.679 . . . . 1.92 111.437 179.393 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . 0.512 ' OE2' ' N ' ' A' ' 18' ' ' ALA . 6.5 pt-20 -99.39 98.68 9.58 Favored 'General case' 0 N--CA 1.497 1.908 0 N-CA-C 107.09 -1.448 . . . . 2.25 107.09 177.898 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' HIS . . . . . 0.452 ' CD2' ' HZ1' ' A' ' 90' ' ' LYS . 0.2 OUTLIER -67.19 98.54 0.61 Allowed 'General case' 0 N--CA 1.491 1.578 0 CA-C-O 121.586 0.708 . . . . 2.88 110.022 -177.845 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' ILE . . . . . 0.467 HD13 ' HD2' ' A' ' 97' ' ' PRO . 0.1 OUTLIER -54.86 137.29 64.99 Favored Pre-proline 0 N--CA 1.489 1.503 0 N-CA-C 107.429 -1.322 . . . . 2.35 107.429 179.351 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.467 ' HD2' HD13 ' A' ' 96' ' ' ILE . 24.6 Cg_exo -39.37 -44.78 3.03 Favored 'Trans proline' 0 CA--C 1.537 0.657 0 C-N-CA 121.234 1.289 . . . . 2.48 111.791 -178.809 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.455 ' N ' ' OD1' ' A' ' 98' ' ' ASP . 1.2 m-20 -47.05 -65.72 0.52 Allowed 'General case' 0 N--CA 1.498 1.949 0 O-C-N 120.747 -1.221 . . . . 2.65 109.174 179.325 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 3.8 m -57.06 138.89 79.54 Favored Pre-proline 0 C--N 1.297 -1.705 0 O-C-N 121.26 -0.9 . . . . 2.0 109.204 -178.912 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -88.31 115.32 2.97 Favored 'Cis proline' 0 N--CA 1.49 1.271 0 N-CA-C 109.055 -1.171 . . . . 1.79 109.055 -1.669 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 52.5 p90 -114.5 162.96 16.03 Favored 'General case' 0 N--CA 1.517 2.918 0 O-C-N 120.546 -1.347 . . . . 2.19 110.335 179.117 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.1 p -91.79 151.92 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 CA-C-O 121.713 0.768 . . . . 1.44 110.749 -178.34 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 55.8 t -128.24 86.42 58.0 Favored Pre-proline 0 N--CA 1.494 1.766 0 N-CA-C 107.679 -1.23 . . . . 1.19 107.679 179.158 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -66.47 110.59 1.87 Allowed 'Trans proline' 0 C--N 1.321 -0.89 0 C-N-CA 121.623 1.549 . . . . 1.49 112.194 -177.563 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.476 HG21 HG11 ' A' ' 79' ' ' VAL . 55.5 t -94.51 142.52 13.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 N-CA-C 106.488 -1.671 . . . . 1.35 106.488 177.465 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.712 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -129.55 132.32 46.8 Favored 'General case' 0 N--CA 1.512 2.652 0 CA-C-O 122.173 0.987 . . . . 1.67 112.516 -176.59 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . 0.813 ' OG ' ' HB2' ' A' ' 33' ' ' ALA . 35.7 m -94.53 81.33 3.91 Favored 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 107.117 -1.438 . . . . 2.04 107.117 178.515 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 23.9 mt 62.63 1.02 0.72 Allowed 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 107.795 -1.187 . . . . 3.2 107.795 -177.723 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 109' ' ' SER . . . . . 0.544 ' H ' ' C ' ' A' ' 107' ' ' SER . 60.8 p -87.72 -21.39 25.22 Favored 'General case' 0 N--CA 1.488 1.444 0 N-CA-C 108.471 -0.937 . . . . 2.09 108.471 178.859 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . 0.712 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 36.0 t0 . . . . . 0 N--CA 1.489 1.511 0 N-CA-C 108.512 -0.922 . . . . 2.85 108.512 -179.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 8' ' ' ARG . . . . . 0.837 HH12 ' H ' ' A' ' 84' ' ' ASP . 39.0 mtt180 . . . . . 0 N--CA 1.494 1.757 0 N-CA-C 108.847 -0.797 . . . . 3.04 108.847 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 9' ' ' VAL . . . . . . . . . . . . . 14.7 t -50.9 159.72 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 N-CA-C 108.059 -1.089 . . . . 0.67 108.059 179.24 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -122.66 144.26 49.25 Favored 'General case' 0 N--CA 1.501 2.092 0 O-C-N 121.372 -0.83 . . . . 0.58 110.092 -178.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 11' ' ' SER . . . . . 0.44 ' OG ' HG23 ' A' ' 55' ' ' VAL . 4.1 t -137.17 145.15 43.4 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.59 -0.693 . . . . 1.19 109.246 179.712 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 17.7 m -148.64 115.48 6.02 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.28 -0.888 . . . . 1.38 109.752 -179.797 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 0.596 HG22 ' N ' ' B' ' 14' ' ' PHE . 2.9 p -157.86 166.81 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 N-CA-C 108.694 -0.854 . . . . 0.42 108.694 179.624 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 14' ' ' PHE . . . . . 0.596 ' N ' HG22 ' B' ' 13' ' ' VAL . 6.9 p90 -177.33 -167.02 0.15 Allowed 'General case' 0 N--CA 1.489 1.509 0 C-N-CA 119.168 -1.013 . . . . 1.79 112.403 -179.811 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 3.2 pt -146.62 168.73 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 N-CA-C 108.437 -0.949 . . . . 1.25 108.437 179.819 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 49.5 m -138.69 142.08 38.97 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 120.999 -1.063 . . . . 1.61 110.178 -179.599 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 16.5 mt . . . . . 0 N--CA 1.497 1.899 0 O-C-N 121.52 -0.738 . . . . 1.32 109.162 179.545 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.955 0 N-CA-C 119.786 2.674 . . . . 6.64 119.786 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.559 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 14.5 tt -172.18 50.63 0.12 Allowed Pre-proline 0 C--N 1.306 -1.32 0 N-CA-C 107.8 -1.185 . . . . 7.08 107.8 179.421 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.749 ' C ' ' H ' ' A' ' 5' ' ' PHE . 5.5 Cg_endo -58.13 -82.22 0.01 OUTLIER 'Trans proline' 0 C--N 1.32 -0.962 0 N-CA-C 108.534 -1.372 . . . . 5.5 108.534 179.713 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 66.68 -3.83 0.84 Allowed 'General case' 0 N--CA 1.5 2.065 0 N-CA-C 105.101 -2.185 . . . . 6.75 105.101 -176.206 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . 0.749 ' H ' ' C ' ' A' ' 3' ' ' PRO . 5.4 m-85 -105.11 18.55 22.15 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 102.705 -3.072 . . . . 6.07 102.705 176.876 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.522 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 35.0 p90 46.16 -152.13 0.07 Allowed 'General case' 0 C--N 1.309 -1.169 0 CA-C-N 113.588 -1.642 . . . . 4.72 109.204 -177.176 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.506 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 5.1 tt0 82.99 -8.9 1.13 Allowed 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 104.819 -2.289 . . . . 4.4 104.819 -177.028 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.469 ' H ' ' C ' ' A' ' 6' ' ' PHE . 79.9 m-85 -146.98 -39.0 0.2 Allowed 'General case' 0 N--CA 1.484 1.268 0 N-CA-C 107.932 -1.136 . . . . 5.15 107.932 178.339 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.421 HG22 ' O ' ' A' ' 9' ' ' THR . 43.5 m -93.06 3.28 56.01 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 105.652 -1.981 . . . . 5.13 105.652 177.249 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.483 HG13 ' N ' ' A' ' 11' ' ' GLY . 9.7 p -46.76 -42.36 5.73 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 CA-C-N 115.278 -0.874 . . . . 4.38 109.544 -179.504 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.596 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 141.25 -83.18 0.22 Allowed Glycine 0 N--CA 1.499 2.889 0 N-CA-C 108.154 -1.978 . . . . 4.22 108.154 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.515 ' O ' ' N ' ' A' ' 14' ' ' GLY . 12.2 Cg_endo -66.35 40.57 0.15 Allowed 'Trans proline' 0 C--N 1.321 -0.901 0 C-N-CA 121.866 1.71 . . . . 3.85 108.779 177.463 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.596 ' H ' ' C ' ' A' ' 11' ' ' GLY . 0.2 OUTLIER 28.65 37.39 0.0 OUTLIER 'General case' 0 N--CA 1.505 2.276 0 CA-C-O 121.265 0.555 . . . . 3.67 110.997 -179.634 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.62 ' C ' ' H ' ' A' ' 16' ' ' GLY . . . 66.91 -35.08 0.18 Allowed Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.556 -1.418 . . . . 2.97 109.556 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.594 ' H ' ' C ' ' A' ' 13' ' ' LEU . 6.8 tp10 62.99 -9.31 0.11 Allowed 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.552 -0.969 . . . . 2.97 108.897 -178.856 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.62 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 102.87 -151.34 18.03 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 110.809 -0.916 . . . . 2.44 110.809 178.429 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.536 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -46.59 -11.5 0.05 OUTLIER Glycine 0 N--CA 1.492 2.402 0 O-C-N 121.635 -0.921 . . . . 1.81 111.068 -178.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.512 ' N ' ' O ' ' A' ' 16' ' ' GLY . . . -45.93 -15.87 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.991 -1.299 . . . . 2.21 109.661 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . 0.536 ' N ' ' O ' ' A' ' 17' ' ' GLY . 10.7 t60 -94.48 -48.88 5.92 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.443 -0.786 . . . . 2.87 109.779 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.51 -14.4 62.1 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.891 -1.13 . . . . 2.02 109.435 -179.872 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 37.9 t -68.43 108.82 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.134 -0.979 . . . . 2.07 108.629 179.387 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.416 ' CG ' HH11 ' A' ' 22' ' ' ARG . 0.0 OUTLIER -113.83 138.49 50.21 Favored 'General case' 0 N--CA 1.491 1.609 0 N-CA-C 109.131 -0.692 . . . . 3.5 109.131 -179.515 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -147.72 113.36 5.68 Favored 'General case' 0 N--CA 1.491 1.603 0 N-CA-C 108.776 -0.824 . . . . 1.83 108.776 179.553 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -151.96 131.68 3.51 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.461 -1.456 . . . . 1.9 109.461 -179.597 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.0 -177.1 46.51 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.502 -1.439 . . . . 1.85 109.502 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.471 HG23 ' N ' ' A' ' 27' ' ' GLY . 13.5 t -79.59 -38.58 33.66 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.252 -1.146 . . . . 2.31 109.16 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.471 ' N ' HG23 ' A' ' 26' ' ' THR . . . -60.28 -6.94 6.37 Favored Glycine 0 N--CA 1.483 1.811 0 N-CA-C 107.864 -2.094 . . . . 1.64 107.864 179.222 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.451 ' H ' ' C ' ' A' ' 26' ' ' THR . 12.3 mt -99.3 24.29 8.2 Favored 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 108.247 -1.02 . . . . 1.83 108.247 179.38 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 18.2 mt-10 -136.81 -37.66 0.66 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.515 -0.741 . . . . 2.34 109.152 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . 0.514 HH11 ' HG2' ' A' ' 30' ' ' ARG . 2.5 ptt-85 -174.78 168.7 3.61 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.098 -1.001 . . . . 3.77 110.204 179.843 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -148.59 177.44 26.83 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 107.643 -2.183 . . . . 1.57 107.643 179.558 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 44.1 t -134.41 151.0 31.2 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.12 0 O-C-N 121.056 -1.261 . . . . 1.83 111.043 -179.528 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.515 ' HB2' ' HB3' ' A' ' 107' ' ' SER . . . -40.05 111.35 0.19 Allowed 'General case' 0 N--CA 1.498 1.937 0 CA-C-O 121.501 0.667 . . . . 1.64 112.418 -179.233 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 55.63 50.21 61.63 Favored Glycine 0 N--CA 1.492 2.395 0 O-C-N 121.589 -0.694 . . . . 1.73 111.427 176.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 31.5 t -127.35 124.19 23.55 Favored Pre-proline 0 N--CA 1.496 1.851 0 N-CA-C 108.312 -0.996 . . . . 2.19 108.312 178.827 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -57.3 131.98 48.23 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 N-CA-C 110.034 -0.795 . . . . 1.96 110.034 -179.527 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.527 ' HB3' ' CE1' ' A' ' 77' ' ' TYR . . . -136.04 160.31 39.04 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.46 -0.775 . . . . 1.69 109.004 179.81 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -155.32 171.47 19.8 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.012 -1.055 . . . . 2.23 111.213 -179.486 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.627 ' CE2' HD11 ' A' ' 41' ' ' ILE . 5.9 p90 -156.58 164.6 38.0 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 107.259 -1.386 . . . . 1.54 107.259 178.372 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 80.5 p -96.52 155.1 16.91 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.208 -0.933 . . . . 2.37 111.279 -177.806 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.878 HD12 HG21 ' A' ' 75' ' ' VAL . 46.6 mt -146.42 97.71 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 N-CA-C 107.516 -1.29 . . . . 1.65 107.516 178.767 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.4 ' CD1' ' C ' ' A' ' 42' ' ' TRP . 0.7 OUTLIER -84.88 146.96 27.03 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.113 -0.992 . . . . 3.68 109.125 -179.407 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.556 ' OG1' ' N ' ' A' ' 44' ' ' ARG . 1.4 t -154.31 -130.35 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.525 0 N-CA-C 109.138 -0.689 . . . . 2.89 109.138 -179.414 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ARG . . . . . 0.556 ' N ' ' OG1' ' A' ' 43' ' ' THR . 39.6 ttp180 54.18 73.98 0.36 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.172 -0.955 . . . . 4.63 109.985 179.842 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 15.7 tt0 -165.14 -60.86 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.31 -0.869 . . . . 2.89 108.875 179.357 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.63 -54.56 44.64 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.059 -1.026 . . . . 1.74 108.71 179.286 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 145.58 179.63 21.97 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.292 -1.523 . . . . 1.6 109.292 179.848 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.73 162.74 0.82 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.134 -1.216 . . . . 1.4 109.598 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 168.89 -151.98 19.11 Favored Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.537 -1.425 . . . . 1.04 109.537 -179.881 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.538 ' O ' ' N ' ' A' ' 92' ' ' ASN . . . -133.87 159.12 23.61 Favored Glycine 0 N--CA 1.497 2.743 0 N-CA-C 109.413 -1.475 . . . . 1.06 109.413 -179.855 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.436 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 9.8 tp -134.14 100.5 4.73 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.529 -0.983 . . . . 1.1 108.424 179.767 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 3.8 m -83.93 144.13 29.38 Favored 'General case' 0 N--CA 1.491 1.58 0 N-CA-C 108.527 -0.916 . . . . 1.56 108.527 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.542 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 7.5 mt -135.71 100.94 2.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.354 -0.841 . . . . 0.65 109.203 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -98.19 106.22 18.48 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.306 -0.871 . . . . 0.69 108.986 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.44 ' O ' ' O ' ' B' ' 11' ' ' SER . 0.2 OUTLIER -97.64 144.42 11.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.499 -0.751 . . . . 0.91 109.403 -179.87 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 3.1 tt0 -141.11 142.09 34.14 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 107.909 -1.145 . . . . 1.8 107.909 179.059 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.432 ' O ' ' O ' ' B' ' 9' ' ' VAL . . . 169.03 176.89 39.44 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.173 -1.571 . . . . 0.49 109.173 -178.811 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -56.48 -17.99 23.76 Favored 'Trans proline' 0 C--N 1.317 -1.123 0 C-N-CA 121.94 1.76 . . . . 0.66 111.274 -179.482 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.4 p -150.22 159.93 44.07 Favored 'General case' 0 C--N 1.292 -1.922 0 O-C-N 121.284 -0.885 . . . . 1.55 110.154 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 68.2 mttt -78.86 108.2 12.14 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.498 -0.752 . . . . 2.53 109.558 -179.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -74.18 148.43 41.68 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.232 -0.918 . . . . 0.82 109.481 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.834 ' C ' HD12 ' A' ' 63' ' ' ILE . 5.0 tp10 -85.14 172.3 11.33 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.322 -0.861 . . . . 2.3 108.786 179.889 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.834 HD12 ' C ' ' A' ' 62' ' ' GLU . 3.7 mp -142.79 144.98 23.65 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.926 0 N-CA-C 108.259 -1.015 . . . . 1.4 108.259 179.809 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.521 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -150.53 114.47 5.04 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 120.6 -1.312 . . . . 1.36 109.923 -179.779 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 54.7 p90 -86.74 138.86 31.27 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.327 -0.858 . . . . 1.47 109.572 179.73 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 -141.4 105.61 4.81 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.22 -0.925 . . . . 2.51 109.711 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.427 ' OD1' ' O ' ' A' ' 67' ' ' ASP . 7.2 p30 -79.18 76.65 5.71 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 108.315 -0.995 . . . . 2.07 108.315 178.834 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.424 HH11 ' HG2' ' A' ' 68' ' ' ARG . 25.3 ttt-85 -137.55 59.62 1.66 Allowed 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.433 -0.792 . . . . 4.63 109.366 -179.39 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.467 ' O ' ' CB ' ' A' ' 70' ' ' ASP . 26.8 mttp -146.12 3.25 0.91 Allowed 'General case' 0 C--N 1.305 -1.338 0 O-C-N 121.217 -0.927 . . . . 3.49 108.732 179.837 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.467 ' CB ' ' O ' ' A' ' 69' ' ' LYS . 2.5 t70 77.15 4.11 3.25 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.833 -0.542 . . . . 3.06 109.66 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 166.7 -25.52 0.15 Allowed Glycine 0 N--CA 1.49 2.245 0 C-N-CA 118.719 -1.705 . . . . 2.16 111.472 179.703 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 37.5 m -95.11 135.15 37.01 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 120.844 -1.386 . . . . 2.2 109.788 -179.464 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 5.9 t -83.97 125.81 32.41 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.2 -0.938 . . . . 2.05 109.108 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -97.65 109.87 3.91 Favored Glycine 0 N--CA 1.495 2.616 0 N-CA-C 110.139 -1.184 . . . . 1.39 110.139 -179.572 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.878 HG21 HD12 ' A' ' 41' ' ' ILE . 32.1 t -99.23 100.86 11.26 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.929 0 O-C-N 121.583 -0.951 . . . . 1.57 108.757 179.13 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.521 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.1 OUTLIER -89.53 126.14 35.48 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.675 -0.64 . . . . 1.85 109.353 -179.551 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.527 ' CE1' ' HB3' ' A' ' 37' ' ' ALA . 52.0 p90 -123.52 173.89 7.75 Favored 'General case' 0 N--CA 1.495 1.811 0 N-CA-C 108.591 -0.892 . . . . 1.54 108.591 179.619 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 15.4 t -142.18 120.51 8.6 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.936 0 O-C-N 121.321 -0.862 . . . . 1.9 109.769 -179.628 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.526 HG11 HG21 ' A' ' 105' ' ' VAL . 8.1 m -90.82 154.98 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.435 -0.791 . . . . 1.27 109.314 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . 0.429 ' O ' ' OE2' ' A' ' 81' ' ' GLU . 33.5 tt0 -100.43 -45.85 5.43 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.192 -0.942 . . . . 2.48 110.746 -179.18 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.429 ' OE2' ' O ' ' A' ' 80' ' ' GLN . 79.6 mm-40 -152.39 149.12 22.11 Favored Pre-proline 0 N--CA 1.504 2.251 0 O-C-N 120.458 -1.401 . . . . 1.92 111.399 -179.151 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.678 ' HG3' ' N ' ' A' ' 107' ' ' SER . 84.6 Cg_exo -36.86 162.19 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 123.117 2.544 . . . . 1.3 113.637 178.232 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 143.42 -163.82 27.44 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 108.673 -1.771 . . . . 1.02 108.673 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . 0.422 ' O ' ' OE1' ' A' ' 86' ' ' GLU . 3.0 m-20 -111.82 93.77 4.62 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.502 -0.999 . . . . 2.13 108.353 179.354 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -78.59 146.19 34.32 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 108.206 -1.035 . . . . 0.92 108.206 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . 0.422 ' OE1' ' O ' ' A' ' 84' ' ' ASP . 0.0 OUTLIER -134.64 129.75 35.35 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.682 -0.636 . . . . 1.53 109.298 -178.98 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.8 p -124.99 146.79 30.05 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.554 -0.716 . . . . 1.0 109.762 -179.807 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 53.6 p -128.59 101.61 6.23 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.442 -0.786 . . . . 1.59 109.106 179.642 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.2 pt -102.4 130.64 51.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.615 -0.678 . . . . 1.29 109.577 -179.573 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . 0.435 ' HG3' ' H ' ' A' ' 93' ' ' ASP . 0.5 OUTLIER -138.62 124.85 20.29 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.244 -0.91 . . . . 1.58 109.238 179.721 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 36.5 t80 -83.13 95.16 8.0 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 120.992 -1.067 . . . . 1.34 108.599 179.391 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . 0.538 ' N ' ' O ' ' A' ' 50' ' ' GLY . 2.3 t-20 70.15 38.71 1.44 Allowed 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 107.925 -1.139 . . . . 2.32 107.925 -178.69 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.456 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 3.2 m-20 82.78 12.79 0.48 Allowed 'General case' 0 N--CA 1.498 1.943 0 CA-C-O 121.26 0.553 . . . . 1.92 110.005 -179.222 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . 0.405 ' HG2' ' H ' ' A' ' 18' ' ' ALA . 4.1 mt-10 -88.88 70.7 8.64 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 107.576 -1.268 . . . . 2.25 107.576 178.192 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . 0.462 ' H ' ' CD2' ' A' ' 95' ' ' HIS . 11.4 p80 -67.5 113.44 5.35 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-O 121.309 0.576 . . . . 2.88 109.953 -179.133 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . 0.406 HG12 ' H ' ' A' ' 96' ' ' ILE . 2.0 pt -62.64 153.78 76.73 Favored Pre-proline 0 N--CA 1.491 1.61 0 N-CA-C 108.295 -1.002 . . . . 2.35 108.295 179.444 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_exo -50.86 -44.69 40.08 Favored 'Trans proline' 0 C--N 1.321 -0.914 0 C-N-CA 121.051 1.167 . . . . 2.48 109.987 179.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.564 ' CB ' ' CE2' ' A' ' 101' ' ' PHE . 3.4 m-20 -51.33 -48.43 62.4 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.146 -0.972 . . . . 2.65 109.85 179.67 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 2.4 t -56.45 126.13 68.46 Favored Pre-proline 0 C--N 1.298 -1.655 0 N-CA-C 107.752 -1.203 . . . . 2.0 107.752 179.545 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 8.3 Cg_endo -72.24 117.55 3.94 Favored 'Cis proline' 0 CA--C 1.548 1.188 0 CA-C-N 119.317 0.792 . . . . 1.79 111.48 0.328 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . 0.564 ' CE2' ' CB ' ' A' ' 98' ' ' ASP . 0.1 OUTLIER -73.3 170.97 13.92 Favored 'General case' 0 N--CA 1.494 1.757 0 N-CA-C 107.251 -1.389 . . . . 2.19 107.251 178.273 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.403 ' O ' HG13 ' A' ' 102' ' ' VAL . 7.6 p -126.77 133.27 68.91 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 121.358 -0.838 . . . . 1.44 109.16 179.79 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 86.5 t -128.93 83.08 67.31 Favored Pre-proline 0 N--CA 1.502 2.161 0 O-C-N 121.454 -0.779 . . . . 1.19 109.63 -179.513 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -64.77 114.45 2.76 Favored 'Trans proline' 0 C--N 1.32 -0.932 0 C-N-CA 121.302 1.334 . . . . 1.49 110.477 -179.506 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.526 HG21 HG11 ' A' ' 79' ' ' VAL . 53.1 t -93.91 146.15 6.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 N-CA-C 108.292 -1.003 . . . . 1.35 108.292 179.484 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.65 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -131.92 130.28 41.38 Favored 'General case' 0 N--CA 1.507 2.401 0 CA-C-O 121.932 0.872 . . . . 1.67 111.941 -177.291 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.678 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 76.2 p -98.65 98.3 9.46 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.733 -1.23 . . . . 2.04 107.788 179.184 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . 0.514 HD12 ' N ' ' A' ' 108' ' ' LEU . 8.9 mp 54.62 9.3 0.26 Allowed 'General case' 0 C--N 1.293 -1.872 0 N-CA-C 108.278 -1.008 . . . . 3.2 108.278 -178.585 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.656 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 8.3 t -101.05 -28.57 12.64 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.604 -0.685 . . . . 2.09 109.16 179.503 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . 0.65 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 13.8 t70 55.04 11.12 0.46 Allowed 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 107.776 -1.194 . . . . 2.85 107.776 -179.528 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.478 ' H ' ' C ' ' A' ' 109' ' ' SER . 1.8 p30 -168.28 -30.53 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 109.484 -0.561 . . . . 2.46 109.484 -179.602 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.656 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 49.25 75.24 0.16 Allowed 'General case' 0 N--CA 1.497 1.883 0 O-C-N 120.79 -1.193 . . . . 2.08 108.821 -179.576 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . 0.501 ' C ' ' H ' ' A' ' 115' ' ' LEU . 0.0 OUTLIER -82.82 149.54 27.12 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.323 -0.861 . . . . 5.93 110.292 -178.785 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 22.6 ttp180 -73.9 12.49 0.67 Allowed 'General case' 0 N--CA 1.494 1.733 0 N-CA-C 108.664 -0.865 . . . . 5.61 108.664 179.239 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.501 ' H ' ' C ' ' A' ' 113' ' ' ARG . 31.0 mt -127.83 -29.83 2.56 Favored 'General case' 0 N--CA 1.503 2.183 0 N-CA-C 109.116 -0.698 . . . . 4.39 109.116 -179.906 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.503 ' C ' ' N ' ' A' ' 118' ' ' THR . 33.9 m -91.48 -80.01 0.36 Allowed 'General case' 0 N--CA 1.494 1.755 0 N-CA-C 106.893 -1.521 . . . . 4.09 106.893 178.847 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.403 ' O ' HG12 ' A' ' 117' ' ' VAL . 32.0 t -61.36 -10.04 3.34 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 N-CA-C 105.579 -2.008 . . . . 2.9 105.579 176.384 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' THR . . . . . 0.503 ' N ' ' C ' ' A' ' 116' ' ' THR . 5.1 t 36.6 58.22 1.08 Allowed 'General case' 0 N--CA 1.484 1.267 0 CA-C-N 114.851 -1.068 . . . . 3.36 110.742 179.88 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' SER . . . . . 0.463 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.7 p . . . . . 0 C--N 1.304 -1.404 0 CA-C-O 118.021 -0.99 . . . . 3.39 109.569 179.384 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 19.3 mmt . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.463 -0.569 . . . . 8.49 109.463 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . 50.97 90.41 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.213 -0.93 . . . . 5.53 109.435 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 3' ' ' SER . . . . . . . . . . . . . 36.4 t -53.31 107.66 0.26 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.26 -0.9 . . . . 5.43 109.454 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 4' ' ' LYS . . . . . 0.541 ' N ' ' CD ' ' B' ' 5' ' ' PRO . 6.3 tttp -60.9 -47.28 96.06 Favored Pre-proline 0 N--CA 1.488 1.465 0 O-C-N 121.346 -0.846 . . . . 6.87 110.296 -179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 5' ' ' PRO . . . . . 0.541 ' CD ' ' N ' ' B' ' 4' ' ' LYS . 6.1 Cg_exo -63.48 129.99 26.92 Favored 'Trans proline' 0 C--N 1.321 -0.872 0 C-N-CA 120.879 1.052 . . . . 5.16 109.852 -179.345 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 6' ' ' GLU . . . . . 0.422 ' HG2' ' H ' ' B' ' 6' ' ' GLU . 3.0 pt-20 -63.97 115.87 5.31 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.369 -0.832 . . . . 4.78 109.59 -179.766 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 67.2 mttt 48.64 -165.43 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.234 -0.916 . . . . 4.09 109.471 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.592 ' CG ' HH11 ' B' ' 8' ' ' ARG . 0.0 OUTLIER -101.53 -163.28 1.0 Allowed 'General case' 0 N--CA 1.494 1.769 0 N-CA-C 107.349 -1.352 . . . . 3.04 107.349 179.559 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 9' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' A' ' 57' ' ' GLY . 34.8 t -71.94 160.0 5.47 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 120.75 -1.219 . . . . 0.67 108.422 179.611 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 0.4 ' N ' HG12 ' B' ' 9' ' ' VAL . . . -123.71 156.71 35.45 Favored 'General case' 0 N--CA 1.5 2.066 0 O-C-N 121.418 -0.801 . . . . 0.58 110.015 -179.26 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 11' ' ' SER . . . . . 0.44 ' O ' ' O ' ' A' ' 55' ' ' VAL . 3.2 t -149.56 144.03 25.97 Favored 'General case' 0 N--CA 1.492 1.641 0 N-CA-C 108.869 -0.789 . . . . 1.19 108.869 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 47.2 t -143.48 120.12 11.12 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 120.976 -1.078 . . . . 1.38 109.99 -179.666 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 0.582 HG22 ' N ' ' B' ' 14' ' ' PHE . 3.1 p -157.92 165.77 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 N-CA-C 108.722 -0.844 . . . . 0.42 108.722 179.542 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 14' ' ' PHE . . . . . 0.582 ' N ' HG22 ' B' ' 13' ' ' VAL . 4.9 p90 -177.99 -170.35 0.24 Allowed 'General case' 0 N--CA 1.49 1.563 0 C-N-CA 119.38 -0.928 . . . . 1.79 112.158 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 3.1 pt -149.87 -163.66 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.341 0 N-CA-C 108.273 -1.01 . . . . 1.25 108.273 179.831 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -161.09 146.55 14.22 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 120.724 -1.235 . . . . 1.61 109.911 179.769 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 13.4 mt -91.66 108.6 20.02 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.219 -0.926 . . . . 1.32 109.376 179.696 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -138.7 82.37 21.53 Favored Pre-proline 0 N--CA 1.495 1.776 0 N-CA-C 108.741 -0.837 . . . . 1.45 108.741 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_exo -59.58 166.43 8.03 Favored 'Trans proline' 0 C--N 1.32 -0.93 0 C-N-CA 121.046 1.164 . . . . 1.5 109.808 -178.846 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 20' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -54.11 -173.57 0.02 OUTLIER 'Trans proline' 0 C--N 1.319 -1.024 0 C-N-CA 121.457 1.438 . . . . 2.86 109.998 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 78.9 mtm180 -58.34 129.61 42.84 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.286 -0.884 . . . . 6.12 109.72 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 22' ' ' ARG . . . . . . . . . . . . . 66.8 mtm180 -59.32 137.46 57.98 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.239 -0.913 . . . . 6.29 109.33 179.756 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 42.8 t0 -160.93 12.7 0.1 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.125 -0.985 . . . . 5.62 109.751 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 33.7 m . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 118.033 -0.985 . . . . 6.48 109.405 -179.99 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.922 0 N-CA-C 119.671 2.628 . . . . 6.64 119.671 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.568 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 15.0 tt -172.27 50.28 0.12 Allowed Pre-proline 0 C--N 1.307 -1.255 0 N-CA-C 107.807 -1.182 . . . . 7.08 107.807 179.573 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.814 ' C ' ' H ' ' A' ' 5' ' ' PHE . 6.1 Cg_endo -57.94 -82.71 0.01 OUTLIER 'Trans proline' 0 C--N 1.318 -1.076 0 N-CA-C 108.583 -1.353 . . . . 5.5 108.583 179.827 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.483 ' CB ' ' O ' ' A' ' 3' ' ' PRO . 0.5 OUTLIER 74.11 -18.76 0.39 Allowed 'General case' 0 N--CA 1.496 1.831 0 N-CA-C 104.209 -2.515 . . . . 6.75 104.209 -175.851 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . 0.814 ' H ' ' C ' ' A' ' 3' ' ' PRO . 5.5 m-85 -90.03 19.48 4.91 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 103.966 -2.605 . . . . 6.07 103.966 176.718 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.542 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 39.5 p90 46.17 -152.49 0.06 Allowed 'General case' 0 C--N 1.307 -1.27 0 CA-C-N 114.421 -1.263 . . . . 4.72 109.38 -177.436 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.53 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 8.6 tt0 83.6 -8.12 1.08 Allowed 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 105.023 -2.214 . . . . 4.4 105.023 -177.205 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.458 ' H ' ' C ' ' A' ' 6' ' ' PHE . 48.0 m-85 -148.34 -39.42 0.17 Allowed 'General case' 0 C--N 1.307 -1.27 0 N-CA-C 107.66 -1.237 . . . . 5.15 107.66 178.383 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 25.6 m -91.07 2.45 56.31 Favored 'General case' 0 C--N 1.295 -1.762 0 N-CA-C 105.874 -1.899 . . . . 5.13 105.874 177.199 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.533 HG13 ' N ' ' A' ' 11' ' ' GLY . 8.7 p -45.51 -44.16 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.327 0 CA-C-N 115.513 -0.767 . . . . 4.38 109.439 -179.568 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.559 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 143.86 -84.86 0.19 Allowed Glycine 0 N--CA 1.497 2.735 0 N-CA-C 108.411 -1.876 . . . . 4.22 108.411 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.529 ' O ' ' N ' ' A' ' 14' ' ' GLY . 12.3 Cg_endo -68.57 35.84 0.18 Allowed 'Trans proline' 0 C--N 1.322 -0.859 0 C-N-CA 121.468 1.445 . . . . 3.85 109.074 177.964 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.559 ' H ' ' C ' ' A' ' 11' ' ' GLY . 0.1 OUTLIER 40.46 23.91 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.261 0 N-CA-C 108.877 -0.786 . . . . 3.67 108.877 -179.152 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.532 ' C ' ' H ' ' A' ' 16' ' ' GLY . . . 69.99 -45.67 0.57 Allowed Glycine 0 N--CA 1.486 1.995 0 N-CA-C 107.42 -2.272 . . . . 2.97 107.42 -178.243 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.534 ' H ' ' C ' ' A' ' 13' ' ' LEU . 7.1 tp10 49.13 10.93 0.03 OUTLIER 'General case' 0 C--N 1.305 -1.359 0 CA-C-O 121.948 0.88 . . . . 2.97 109.01 179.73 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.532 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 55.16 121.21 0.01 OUTLIER Glycine 0 N--CA 1.49 2.24 0 O-C-N 121.513 -0.742 . . . . 2.44 111.635 178.835 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.558 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 72.36 -52.34 1.45 Allowed Glycine 0 N--CA 1.493 2.487 0 O-C-N 121.458 -1.024 . . . . 1.81 111.127 178.296 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.749 ' HB2' ' OE1' ' A' ' 94' ' ' GLU . . . -49.45 -6.95 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.098 -1.236 . . . . 2.21 110.169 -179.308 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . 0.558 ' N ' ' O ' ' A' ' 17' ' ' GLY . 29.2 t-80 -94.97 -12.09 27.34 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.067 -1.021 . . . . 2.87 110.295 -179.801 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.424 ' NZ ' HG23 ' A' ' 21' ' ' VAL . 2.3 pptp? -132.6 11.64 4.44 Favored 'General case' 0 N--CA 1.504 2.235 0 O-C-N 121.031 -1.043 . . . . 2.02 110.457 -179.759 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.424 HG23 ' NZ ' ' A' ' 20' ' ' LYS . 53.2 t -94.29 113.19 28.38 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 120.976 -1.078 . . . . 2.07 109.257 179.491 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 20.3 tpt180 -113.08 121.33 44.24 Favored 'General case' 0 N--CA 1.496 1.846 0 N-CA-C 108.98 -0.748 . . . . 3.5 108.98 179.843 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -128.16 114.07 16.53 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 108.878 -0.786 . . . . 1.83 108.878 179.735 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -151.24 130.6 3.22 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 109.509 -1.436 . . . . 1.9 109.509 -179.616 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.29 171.08 43.42 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.739 -1.344 . . . . 1.85 109.739 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 13.2 p -78.51 -27.13 46.06 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.343 -1.092 . . . . 2.31 109.373 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.68 -12.55 70.57 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 109.11 -1.596 . . . . 1.64 109.11 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 12.1 mt -87.68 -15.53 36.9 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.437 -1.037 . . . . 1.83 108.852 179.679 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 42.2 mt-10 -87.66 -62.07 1.58 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.412 -0.805 . . . . 2.34 109.726 -179.793 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 72.5 mtt180 -148.14 178.48 8.51 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.114 -0.991 . . . . 3.77 110.058 -179.678 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -150.11 175.21 29.3 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 107.786 -2.125 . . . . 1.57 107.786 179.317 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 40.7 t -133.54 151.7 33.82 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.15 0 O-C-N 121.084 -1.245 . . . . 1.83 110.744 -179.57 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.457 ' HB2' ' HD3' ' A' ' 82' ' ' PRO . . . -43.56 111.01 0.23 Allowed 'General case' 0 N--CA 1.5 2.04 0 CA-C-O 121.57 0.7 . . . . 1.64 112.428 -178.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 55.87 52.8 46.37 Favored Glycine 0 N--CA 1.491 2.315 0 O-C-N 121.515 -0.741 . . . . 1.73 111.52 176.884 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 8.5 t -127.83 126.97 23.99 Favored Pre-proline 0 N--CA 1.497 1.911 0 O-C-N 121.502 -0.999 . . . . 2.19 108.373 178.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -57.77 117.8 4.57 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 N-CA-C 109.33 -1.065 . . . . 1.96 109.33 179.711 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -127.43 149.99 49.84 Favored 'General case' 0 N--CA 1.501 2.089 0 N-CA-C 108.873 -0.788 . . . . 1.69 108.873 -179.827 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -155.33 162.41 40.85 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.937 -1.102 . . . . 2.23 111.172 -179.448 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.58 ' CD1' ' N ' ' A' ' 39' ' ' PHE . 0.5 OUTLIER -137.98 -176.77 4.55 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 106.831 -1.544 . . . . 1.54 106.831 178.163 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 72.6 p -121.04 145.49 47.71 Favored 'General case' 0 N--CA 1.499 1.981 0 CA-C-O 121.5 0.667 . . . . 2.37 110.121 -179.222 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.444 ' O ' ' N ' ' A' ' 73' ' ' CYS . 48.5 mt -142.2 117.02 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 N-CA-C 108.515 -0.921 . . . . 1.65 108.515 179.32 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.434 ' CD1' ' C ' ' A' ' 42' ' ' TRP . 0.2 OUTLIER -113.74 129.62 56.55 Favored 'General case' 0 N--CA 1.497 1.878 0 N-CA-C 108.432 -0.951 . . . . 3.68 108.432 179.923 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.524 ' OG1' ' N ' ' A' ' 44' ' ' ARG . 9.2 p -144.73 -127.51 0.08 Allowed 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.343 -0.848 . . . . 2.89 109.16 -179.667 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' ARG . . . . . 0.524 ' N ' ' OG1' ' A' ' 43' ' ' THR . 1.6 ttt-85 56.89 79.85 0.17 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.363 -0.836 . . . . 4.63 110.059 179.646 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -156.27 -52.26 0.08 Allowed 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 108.543 -0.91 . . . . 2.89 108.543 179.146 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -60.78 -48.14 83.15 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.214 -0.929 . . . . 1.74 108.779 179.326 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 151.98 -174.48 30.99 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 109.514 -1.435 . . . . 1.6 109.514 179.809 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.33 161.44 0.94 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.252 -1.146 . . . . 1.4 109.047 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 176.17 -158.32 24.8 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.69 -1.364 . . . . 1.04 109.69 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -145.86 124.75 2.13 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 109.826 -1.31 . . . . 1.06 109.826 -179.806 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.468 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 10.4 tp -100.2 100.89 11.79 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.456 -1.026 . . . . 1.1 108.557 179.461 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 25.0 p -86.19 141.34 29.4 Favored 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 108.567 -0.901 . . . . 1.56 108.567 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.515 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 72.7 mt -130.44 114.25 27.96 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 O-C-N 121.235 -0.915 . . . . 0.65 109.552 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -105.36 107.94 19.2 Favored 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 108.777 -0.823 . . . . 0.69 108.777 179.677 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.412 HG23 ' CB ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -101.37 142.95 15.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 O-C-N 121.528 -0.733 . . . . 0.91 109.25 -179.857 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 8.7 tt0 -141.88 145.39 34.56 Favored 'General case' 0 N--CA 1.49 1.575 0 N-CA-C 107.685 -1.228 . . . . 1.8 107.685 178.755 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.43 ' O ' ' O ' ' B' ' 9' ' ' VAL . . . 164.58 -172.97 40.47 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.79 -1.324 . . . . 0.49 109.79 -179.296 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -67.71 -30.6 34.16 Favored 'Trans proline' 0 C--N 1.318 -1.06 0 C-N-CA 122.139 1.893 . . . . 0.66 112.09 -179.361 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . 0.424 ' CB ' ' OH ' ' A' ' 85' ' ' TYR . 0.3 OUTLIER -128.55 179.7 5.53 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 121.162 -0.962 . . . . 1.55 110.226 -179.126 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 62.7 mmtt -92.0 114.53 27.09 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.607 -0.683 . . . . 2.53 109.241 -179.817 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.598 ' O ' HD12 ' A' ' 63' ' ' ILE . . . -66.15 103.74 1.03 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.023 -1.048 . . . . 0.82 109.231 179.701 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 30.3 mt-10 -65.19 72.17 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.141 -0.974 . . . . 2.3 109.635 -179.738 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.598 HD12 ' O ' ' A' ' 61' ' ' ALA . 3.4 mp -58.14 149.35 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.613 -0.68 . . . . 1.4 109.295 179.852 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.54 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -150.4 127.6 11.29 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.996 -1.065 . . . . 1.36 109.453 -179.859 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.458 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 50.3 p90 -87.01 130.85 34.28 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.179 -0.951 . . . . 1.47 109.488 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -141.19 109.49 5.87 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.286 -0.884 . . . . 2.51 109.338 179.821 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.473 ' OD1' ' N ' ' A' ' 67' ' ' ASP . 18.2 p-10 -90.13 107.2 18.99 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.243 -0.911 . . . . 2.07 109.32 179.77 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 79.8 mtm180 -99.03 -17.38 18.3 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.305 -0.872 . . . . 4.63 109.272 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.51 ' C ' ' H ' ' A' ' 71' ' ' GLY . 78.9 mttt -122.09 -0.77 9.39 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.6 -0.687 . . . . 3.49 109.16 179.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.461 ' CB ' ' O ' ' A' ' 69' ' ' LYS . 3.0 t0 73.51 -21.28 0.27 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.375 -0.828 . . . . 3.06 109.06 -179.683 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . 0.51 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -115.31 -24.98 3.95 Favored Glycine 0 N--CA 1.495 2.609 0 N-CA-C 109.434 -1.466 . . . . 2.16 109.434 -179.545 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 16.1 t -95.43 121.16 36.81 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.318 -1.107 . . . . 2.2 109.011 179.696 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' CYS . . . . . 0.444 ' N ' ' O ' ' A' ' 41' ' ' ILE . 33.7 m -83.31 105.17 14.05 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.202 -0.937 . . . . 2.05 109.825 -179.515 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -85.28 116.25 4.29 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.168 -1.573 . . . . 1.39 109.168 179.594 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 49.8 t -107.09 99.64 9.0 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.072 0 O-C-N 121.58 -0.953 . . . . 1.57 109.597 -179.674 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.54 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.5 OUTLIER -89.71 131.39 35.71 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.396 -0.815 . . . . 1.85 109.258 179.775 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.426 ' O ' ' CG ' ' A' ' 77' ' ' TYR . 2.3 p90 -133.07 126.81 32.65 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.379 -0.826 . . . . 1.54 109.825 -179.837 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 3.0 t -107.74 103.8 16.05 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 O-C-N 121.674 -0.641 . . . . 1.9 109.876 -179.665 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.463 ' H ' HG22 ' A' ' 79' ' ' VAL . 2.4 m -80.23 167.66 2.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.296 -0.877 . . . . 1.27 108.72 179.423 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 41.7 tp60 -102.26 -46.33 4.85 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.213 -0.929 . . . . 2.48 110.732 -179.298 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.448 ' OE2' ' HB1' ' A' ' 33' ' ' ALA . 71.8 mm-40 -147.61 151.02 38.4 Favored Pre-proline 0 N--CA 1.506 2.37 0 O-C-N 120.754 -1.216 . . . . 1.92 112.161 -178.254 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.638 ' HG3' ' N ' ' A' ' 107' ' ' SER . 86.0 Cg_exo -36.5 168.12 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 123.389 2.726 . . . . 1.3 113.734 178.113 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 140.9 -176.11 21.75 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.678 -1.369 . . . . 1.02 109.678 179.374 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . 0.528 ' OD2' ' NE ' ' B' ' 8' ' ' ARG . 2.4 p-10 -99.8 86.55 3.32 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.512 -0.993 . . . . 2.13 108.349 179.419 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.498 ' O ' ' N ' ' A' ' 103' ' ' VAL . 2.7 m-85 -72.87 130.72 41.05 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 108.044 -1.095 . . . . 0.92 108.044 -179.789 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . 0.428 ' H ' ' HG2' ' A' ' 86' ' ' GLU . 0.0 OUTLIER -107.24 129.12 54.91 Favored 'General case' 0 N--CA 1.496 1.87 0 N-CA-C 108.474 -0.936 . . . . 1.53 108.474 -179.196 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.446 ' CG1' ' CZ ' ' A' ' 101' ' ' PHE . 5.7 p -126.18 141.99 44.14 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 N-CA-C 109.17 -0.678 . . . . 1.0 109.17 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 13.5 p -138.65 107.15 5.84 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.264 -0.898 . . . . 1.59 109.795 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.8 pt -112.57 136.46 48.75 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.92 0 CA-C-O 121.414 0.626 . . . . 1.29 110.097 -179.738 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . 0.457 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.2 OUTLIER -143.05 122.41 13.08 Favored 'General case' 0 N--CA 1.486 1.333 0 O-C-N 121.383 -0.823 . . . . 1.58 108.785 179.447 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 55.3 t80 -79.67 99.74 7.53 Favored 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 107.716 -1.216 . . . . 1.34 107.716 178.458 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . 0.416 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 13.9 t-20 69.56 39.9 1.49 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.492 -0.755 . . . . 2.32 109.404 -178.885 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.422 ' H ' ' HG3' ' A' ' 90' ' ' LYS . 0.9 OUTLIER 76.7 13.27 2.32 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.665 -0.647 . . . . 1.92 111.585 179.442 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . 0.749 ' OE1' ' HB2' ' A' ' 18' ' ' ALA . 0.6 OUTLIER -98.27 94.9 7.03 Favored 'General case' 0 N--CA 1.499 1.978 0 N-CA-C 106.919 -1.511 . . . . 2.25 106.919 177.649 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . 0.653 ' H ' ' CD2' ' A' ' 95' ' ' HIS . 0.1 OUTLIER -71.12 106.99 3.94 Favored 'General case' 0 N--CA 1.488 1.431 0 CA-C-O 121.586 0.707 . . . . 2.88 109.839 -178.16 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . 0.574 ' O ' ' N ' ' A' ' 98' ' ' ASP . 10.6 pt -52.8 150.4 9.86 Favored Pre-proline 0 C--N 1.299 -1.6 0 N-CA-C 108.579 -0.897 . . . . 2.35 108.579 179.634 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.413 ' O ' ' CG ' ' A' ' 98' ' ' ASP . 1.0 OUTLIER -57.48 75.56 0.04 OUTLIER 'Trans proline' 0 C--O 1.214 -0.7 0 C-N-CA 121.146 1.231 . . . . 2.48 109.195 179.362 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.574 ' N ' ' O ' ' A' ' 96' ' ' ILE . 1.9 m-20 -177.62 -59.82 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.485 0 N-CA-C 108.278 -1.008 . . . . 2.65 108.278 -178.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 9.5 m -57.44 138.79 81.13 Favored Pre-proline 0 C--N 1.299 -1.627 0 O-C-N 121.414 -0.804 . . . . 2.0 110.031 -178.216 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_endo -89.78 114.28 2.41 Favored 'Cis proline' 0 N--CA 1.493 1.458 0 N-CA-C 109.707 -0.92 . . . . 1.79 109.707 -2.724 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . 0.446 ' CZ ' ' CG1' ' A' ' 87' ' ' VAL . 15.3 p90 -104.9 170.86 7.63 Favored 'General case' 0 N--CA 1.515 2.79 0 O-C-N 120.425 -1.422 . . . . 2.19 110.01 178.87 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.5 p -95.49 153.79 3.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.602 -0.686 . . . . 1.44 110.095 -179.467 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.498 ' N ' ' O ' ' A' ' 85' ' ' TYR . 69.2 t -128.66 86.37 57.78 Favored Pre-proline 0 N--CA 1.498 1.948 0 N-CA-C 107.868 -1.16 . . . . 1.19 107.868 179.316 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -60.99 113.85 1.91 Allowed 'Trans proline' 0 C--N 1.323 -0.792 0 C-N-CA 121.497 1.465 . . . . 1.49 112.256 -177.56 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 55.3 t -96.1 138.12 22.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 N-CA-C 106.784 -1.561 . . . . 1.35 106.784 177.724 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.549 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -119.0 126.56 52.02 Favored 'General case' 0 N--CA 1.511 2.582 0 N-CA-C 113.161 0.801 . . . . 1.67 113.161 -175.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.638 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 23.8 t -94.84 97.89 10.35 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 120.3 -1.5 . . . . 2.04 107.586 178.09 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 13.7 mt 66.35 -21.04 0.1 Allowed 'General case' 0 C--N 1.289 -2.058 0 N-CA-C 109.22 -0.659 . . . . 3.2 109.22 -178.767 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.64 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 9.6 t -70.93 -29.17 65.12 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.084 -1.01 . . . . 2.09 108.908 179.027 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . 0.549 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 9.1 m-20 54.31 13.23 0.59 Allowed 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 107.874 -1.158 . . . . 2.85 107.874 179.83 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.472 ' N ' ' C ' ' A' ' 109' ' ' SER . 28.6 t0 -172.55 -24.92 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.574 0 CA-C-N 116.107 -0.497 . . . . 2.46 109.738 -179.54 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.64 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 56.08 170.86 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.6 -1.312 . . . . 2.08 108.624 -179.515 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . 0.434 ' HB3' ' H ' ' A' ' 116' ' ' THR . 56.4 mtm180 -83.14 111.22 18.72 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.105 -0.997 . . . . 5.93 109.671 -179.564 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.446 ' HG3' HH11 ' A' ' 114' ' ' ARG . 8.0 ttm-85 -76.17 8.46 3.27 Favored 'General case' 0 N--CA 1.493 1.721 0 CA-C-O 121.751 0.786 . . . . 5.61 109.178 179.879 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 37.6 mt -124.48 -28.71 3.58 Favored 'General case' 0 N--CA 1.503 2.22 0 O-C-N 121.734 -0.604 . . . . 4.39 109.477 -179.896 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.497 ' C ' ' H ' ' A' ' 118' ' ' THR . 14.2 m -103.84 -76.29 0.6 Allowed 'General case' 0 N--CA 1.499 2.007 0 N-CA-C 107.327 -1.36 . . . . 4.09 107.327 179.071 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.432 ' O ' ' OXT' ' A' ' 119' ' ' SER . 51.7 t -62.9 -9.07 3.86 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.69 0 N-CA-C 105.726 -1.953 . . . . 2.9 105.726 176.887 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' THR . . . . . 0.497 ' H ' ' C ' ' A' ' 116' ' ' THR . 4.9 t 35.67 59.21 0.85 Allowed 'General case' 0 N--CA 1.485 1.305 0 CA-C-N 114.883 -1.053 . . . . 3.36 111.121 179.572 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' SER . . . . . 0.432 ' OXT' ' O ' ' A' ' 117' ' ' VAL . 1.7 p . . . . . 0 C--N 1.303 -1.45 0 CA-C-O 118.023 -0.989 . . . . 3.39 109.635 179.162 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . 0.544 ' C ' ' H ' ' B' ' 3' ' ' SER . 72.8 mtm . . . . . 0 N--CA 1.49 1.574 0 N-CA-C 109.495 -0.557 . . . . 8.49 109.495 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 2' ' ' ALA . . . . . 0.421 ' HB3' ' O ' ' B' ' 1' ' ' MET . . . 63.09 -7.42 0.15 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.43 -0.794 . . . . 5.53 109.774 -179.779 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 3' ' ' SER . . . . . 0.544 ' H ' ' C ' ' B' ' 1' ' ' MET . 8.0 m 45.45 -147.36 0.12 Allowed 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.208 -0.933 . . . . 5.43 110.066 179.699 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 4' ' ' LYS . . . . . . . . . . . . . 59.3 mttp -152.51 95.91 3.05 Favored Pre-proline 0 N--CA 1.493 1.676 0 O-C-N 121.473 -0.767 . . . . 6.87 108.942 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 5' ' ' PRO . . . . . . . . . . . . . 3.8 Cg_exo -59.54 97.59 0.1 Allowed 'Trans proline' 0 C--N 1.325 -0.701 0 C-N-CA 120.845 1.03 . . . . 5.16 110.177 -179.16 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 6' ' ' GLU . . . . . . . . . . . . . 14.6 pt-20 -115.58 32.39 6.1 Favored 'General case' 0 N--CA 1.498 1.95 0 N-CA-C 109.141 -0.689 . . . . 4.78 109.141 179.71 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 28.9 mmtp 57.26 107.62 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.595 -0.69 . . . . 4.09 110.09 179.825 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.576 ' CG ' HH11 ' B' ' 8' ' ' ARG . 2.5 mtt-85 -67.76 170.23 8.29 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.286 -1.005 . . . . 3.04 108.286 179.008 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 9' ' ' VAL . . . . . 0.43 ' O ' ' O ' ' A' ' 57' ' ' GLY . 24.6 t -50.81 158.72 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 N-CA-C 107.785 -1.191 . . . . 0.67 107.785 179.137 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -128.98 149.14 50.94 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.227 -0.921 . . . . 0.58 110.563 -178.585 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 11' ' ' SER . . . . . 0.412 ' CB ' HG23 ' A' ' 55' ' ' VAL . 4.1 t -139.58 146.35 39.73 Favored 'General case' 0 N--CA 1.495 1.789 0 N-CA-C 108.763 -0.829 . . . . 1.19 108.763 179.498 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 42.9 m -147.41 121.91 9.74 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.07 -1.019 . . . . 1.38 109.927 -179.589 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 0.645 HG22 ' N ' ' B' ' 14' ' ' PHE . 7.7 p -169.85 170.52 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 N-CA-C 108.883 -0.784 . . . . 0.42 108.883 179.759 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 14' ' ' PHE . . . . . 0.645 ' N ' HG22 ' B' ' 13' ' ' VAL . 9.1 p90 -176.6 -163.47 0.1 Allowed 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 119.226 -0.99 . . . . 1.79 112.084 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.3 pt -147.49 160.95 8.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 N-CA-C 108.518 -0.919 . . . . 1.25 108.518 179.82 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 17.9 m -131.18 141.73 50.11 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.273 -0.892 . . . . 1.61 109.892 -179.734 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.0 mt -100.3 127.17 46.66 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.418 -0.802 . . . . 1.32 109.36 179.712 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -156.59 90.55 2.6 Favored Pre-proline 0 N--CA 1.493 1.689 0 N-CA-C 109.108 -0.701 . . . . 1.45 109.108 -179.719 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_exo -60.06 167.14 7.77 Favored 'Trans proline' 0 CA--C 1.546 1.088 0 C-N-CA 121.136 1.224 . . . . 1.5 110.117 -178.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 20' ' ' PRO . . . . . 0.429 ' O ' ' O ' ' B' ' 21' ' ' ARG . 1.8 Cg_endo -58.06 -18.71 37.41 Favored 'Trans proline' 0 C--N 1.321 -0.874 0 C-N-CA 121.692 1.594 . . . . 2.86 110.703 -179.675 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . 0.429 ' O ' ' O ' ' B' ' 20' ' ' PRO . 38.3 mtp180 -63.25 -129.87 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.954 -1.091 . . . . 6.12 109.451 -179.792 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 22' ' ' ARG . . . . . . . . . . . . . 44.1 ttt180 58.44 42.5 21.11 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.235 -0.916 . . . . 6.29 109.435 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . 0.402 ' CG ' ' H ' ' B' ' 24' ' ' VAL . 2.8 p-10 -84.04 -65.18 1.04 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.271 -0.893 . . . . 5.62 109.345 -179.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . 0.402 ' H ' ' CG ' ' B' ' 23' ' ' ASP . 13.9 p . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 118.014 -0.993 . . . . 6.48 109.448 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.528 ' O ' HG23 ' A' ' 2' ' ' ILE . . . . . . . . 1 N--CA 1.53 4.906 0 N-CA-C 119.658 2.623 . . . . 6.64 119.658 . . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.617 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 1.0 OUTLIER -162.23 46.09 0.17 Allowed Pre-proline 0 C--N 1.305 -1.331 0 N-CA-C 107.658 -1.238 . . . . 7.08 107.658 179.222 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.838 ' C ' ' H ' ' A' ' 5' ' ' PHE . 2.1 Cg_endo -54.46 -80.86 0.02 OUTLIER 'Trans proline' 0 C--N 1.318 -1.042 0 N-CA-C 108.777 -1.278 . . . . 5.5 108.777 179.78 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.505 ' C ' ' H ' ' A' ' 6' ' ' PHE . 4.2 tp10 73.01 -17.84 0.39 Allowed 'General case' 0 N--CA 1.496 1.827 0 N-CA-C 104.359 -2.46 . . . . 6.75 104.359 -175.834 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . 0.838 ' H ' ' C ' ' A' ' 3' ' ' PRO . 2.3 m-85 -90.71 19.73 5.23 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 103.778 -2.675 . . . . 6.07 103.778 176.751 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.547 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 37.6 p90 45.85 -154.29 0.04 OUTLIER 'General case' 0 C--N 1.307 -1.249 0 CA-C-N 114.298 -1.319 . . . . 4.72 109.359 -177.435 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.524 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 17.3 tt0 86.31 -9.87 0.69 Allowed 'General case' 0 N--CA 1.492 1.646 0 N-CA-C 105.169 -2.16 . . . . 4.4 105.169 -177.389 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.418 ' H ' ' C ' ' A' ' 6' ' ' PHE . 45.1 t80 -152.49 -37.48 0.11 Allowed 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 107.925 -1.139 . . . . 5.15 107.925 178.39 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.49 HG22 ' O ' ' A' ' 9' ' ' THR . 89.5 m -93.15 3.96 54.81 Favored 'General case' 0 C--N 1.295 -1.77 0 N-CA-C 105.97 -1.863 . . . . 5.13 105.97 177.479 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.542 HG13 ' N ' ' A' ' 11' ' ' GLY . 12.5 p -44.38 -45.52 2.39 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.317 0 CA-C-N 115.555 -0.748 . . . . 4.38 109.25 -179.668 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.668 ' O ' HD23 ' A' ' 13' ' ' LEU . . . 134.27 -83.04 0.29 Allowed Glycine 0 N--CA 1.501 2.983 0 N-CA-C 109.098 -1.601 . . . . 4.22 109.098 179.148 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.437 ' O ' ' N ' ' A' ' 14' ' ' GLY . 11.4 Cg_endo -67.21 35.13 0.14 Allowed 'Trans proline' 0 C--N 1.319 -1.019 0 C-N-CA 121.566 1.51 . . . . 3.85 109.212 178.691 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.849 ' N ' HD23 ' A' ' 13' ' ' LEU . 0.1 OUTLIER 38.65 32.02 0.05 OUTLIER 'General case' 0 N--CA 1.506 2.327 0 CA-C-O 122.016 0.912 . . . . 3.67 108.791 -178.613 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.508 ' C ' ' H ' ' A' ' 16' ' ' GLY . . . 72.41 -40.52 0.75 Allowed Glycine 0 N--CA 1.488 2.155 0 N-CA-C 108.595 -1.802 . . . . 2.97 108.595 -179.241 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.489 ' H ' ' C ' ' A' ' 13' ' ' LEU . 8.9 tp10 52.87 8.85 0.1 Allowed 'General case' 0 C--N 1.304 -1.396 0 O-C-N 121.486 -1.008 . . . . 2.97 108.924 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.508 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 59.1 118.33 0.01 OUTLIER Glycine 0 N--CA 1.486 1.988 0 N-CA-C 110.003 -1.239 . . . . 2.44 110.003 179.823 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.514 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 95.02 -57.99 1.76 Allowed Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.761 -1.336 . . . . 1.81 109.761 179.707 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.693 ' HB2' ' OE1' ' A' ' 94' ' ' GLU . . . -47.86 -12.32 0.03 OUTLIER 'General case' 0 C--N 1.297 -1.68 0 O-C-N 121.64 -0.917 . . . . 2.21 110.067 -179.121 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . 0.514 ' N ' ' O ' ' A' ' 17' ' ' GLY . 29.1 t-80 -98.46 -7.11 29.1 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.245 -0.909 . . . . 2.87 110.684 -178.745 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.498 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.4 OUTLIER -145.98 5.58 1.0 Allowed 'General case' 0 N--CA 1.496 1.851 0 O-C-N 120.854 -1.153 . . . . 2.02 110.252 -179.491 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.577 ' O ' HG13 ' A' ' 21' ' ' VAL . 7.4 p -77.35 115.56 19.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.022 -1.049 . . . . 2.07 108.51 179.116 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 12.7 tpp180 -109.92 139.27 45.2 Favored 'General case' 0 N--CA 1.49 1.574 0 CA-C-O 121.509 0.671 . . . . 3.5 109.566 -178.745 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -148.18 113.27 5.51 Favored 'General case' 0 N--CA 1.491 1.599 0 N-CA-C 108.609 -0.885 . . . . 1.83 108.609 179.424 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -147.85 132.1 4.11 Favored Glycine 0 N--CA 1.495 2.614 0 N-CA-C 109.523 -1.431 . . . . 1.9 109.523 -179.624 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.27 174.13 46.08 Favored Glycine 0 N--CA 1.488 2.115 0 C-N-CA 119.598 -1.287 . . . . 1.85 110.013 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 8.5 p -79.85 -22.04 43.42 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.338 -1.095 . . . . 2.31 108.985 179.479 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -68.67 -16.47 69.94 Favored Glycine 0 N--CA 1.487 2.034 0 N-CA-C 108.62 -1.792 . . . . 1.64 108.62 179.637 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.53 HD21 ' CG ' ' A' ' 39' ' ' PHE . 7.0 mt -93.04 30.28 1.66 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.625 -0.927 . . . . 1.83 108.799 179.783 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 13.5 mt-10 -141.91 -43.44 0.35 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.396 -0.815 . . . . 2.34 109.62 -179.375 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 11.8 ptm180 -175.65 172.11 2.63 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.007 -1.058 . . . . 3.77 109.991 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -150.77 176.51 29.3 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 108.335 -1.906 . . . . 1.57 108.335 179.665 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 39.2 t -134.23 151.54 32.41 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.031 0 O-C-N 121.186 -1.185 . . . . 1.83 110.529 -179.733 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.566 ' HB2' ' HD3' ' A' ' 82' ' ' PRO . . . -44.91 115.47 0.89 Allowed 'General case' 0 N--CA 1.497 1.88 0 CA-C-O 121.869 0.842 . . . . 1.64 112.477 -179.195 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 54.03 50.81 53.7 Favored Glycine 0 N--CA 1.488 2.143 0 N-CA-C 111.245 -0.742 . . . . 1.73 111.245 177.264 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 5.0 t -127.03 127.11 24.41 Favored Pre-proline 0 N--CA 1.496 1.871 0 N-CA-C 108.232 -1.025 . . . . 2.19 108.232 179.14 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -55.51 121.17 9.47 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 N-CA-C 109.918 -0.839 . . . . 1.96 109.918 -179.845 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -128.78 145.42 51.19 Favored 'General case' 0 N--CA 1.497 1.922 0 N-CA-C 108.488 -0.93 . . . . 1.69 108.488 179.736 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -152.16 164.05 38.11 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.995 -1.066 . . . . 2.23 110.765 -179.512 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.549 ' CD1' ' N ' ' A' ' 39' ' ' PHE . 0.7 OUTLIER -139.71 178.43 7.24 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 107.007 -1.479 . . . . 1.54 107.007 177.907 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 58.7 m -121.32 141.27 51.08 Favored 'General case' 0 N--CA 1.496 1.857 0 CA-C-O 121.573 0.702 . . . . 2.37 110.382 -178.83 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.508 ' O ' ' N ' ' A' ' 73' ' ' CYS . 68.3 mt -138.14 124.08 25.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 N-CA-C 108.307 -0.997 . . . . 1.65 108.307 179.106 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.556 ' HE1' ' CG ' ' A' ' 44' ' ' ARG . 3.1 t90 -128.08 125.46 39.31 Favored 'General case' 0 N--CA 1.496 1.858 0 N-CA-C 108.615 -0.884 . . . . 3.68 108.615 -179.549 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.498 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -151.21 118.23 5.89 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.321 -0.862 . . . . 2.89 109.269 -179.672 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' ARG . . . . . 0.556 ' CG ' ' HE1' ' A' ' 42' ' ' TRP . 10.6 ptm180 -171.09 72.19 0.05 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.172 -0.955 . . . . 4.63 109.72 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 21.3 tt0 -154.32 -45.19 0.09 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.306 -0.871 . . . . 2.89 109.083 179.579 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.99 -55.66 13.5 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.117 -0.989 . . . . 1.74 109.196 179.686 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 154.96 156.36 7.71 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.608 -1.397 . . . . 1.6 109.608 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.49 156.92 2.29 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.232 -1.158 . . . . 1.4 109.511 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -170.48 -111.34 0.25 Allowed Glycine 0 N--CA 1.488 2.16 0 N-CA-C 108.965 -1.654 . . . . 1.04 108.965 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.544 ' O ' ' N ' ' A' ' 92' ' ' ASN . . . -157.7 161.87 31.68 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.463 -1.455 . . . . 1.06 109.463 179.684 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.458 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 10.2 tp -140.55 97.0 3.12 Favored 'General case' 0 N--CA 1.493 1.703 0 N-CA-C 107.839 -1.171 . . . . 1.1 107.839 179.513 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 13.7 m -87.69 142.81 27.54 Favored 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 108.846 -0.798 . . . . 1.56 108.846 -179.586 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.54 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 6.7 mt -136.71 100.42 2.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.366 -0.834 . . . . 0.65 108.859 179.721 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -98.8 106.42 18.69 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.258 -0.902 . . . . 0.69 108.907 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -97.87 146.14 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 O-C-N 121.434 -0.791 . . . . 0.91 109.33 -179.814 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 35.4 tp10 -141.13 138.04 33.18 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 107.385 -1.339 . . . . 1.8 107.385 178.531 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.532 ' O ' ' N ' ' B' ' 9' ' ' VAL . . . 173.37 -173.0 45.58 Favored Glycine 0 N--CA 1.493 2.44 0 C-N-CA 119.271 -1.442 . . . . 0.49 110.033 -178.72 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -62.76 -35.1 70.54 Favored 'Trans proline' 0 C--N 1.318 -1.038 0 C-N-CA 122.127 1.885 . . . . 0.66 111.568 -179.596 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . 0.421 ' O ' ' OH ' ' A' ' 85' ' ' TYR . 10.7 m -139.57 162.34 35.31 Favored 'General case' 0 N--CA 1.5 2.025 0 O-C-N 121.072 -1.017 . . . . 1.55 110.057 -179.036 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 23.0 mttp -85.29 95.57 9.24 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.435 -0.791 . . . . 2.53 109.495 -179.844 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -50.59 135.32 23.15 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.336 -0.853 . . . . 0.82 109.315 179.83 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.47 ' CD ' ' N ' ' A' ' 62' ' ' GLU . 15.9 mp0 -71.09 85.38 0.73 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.247 -0.908 . . . . 2.3 109.582 -179.873 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 19.2 tt -58.88 150.21 5.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 N-CA-C 108.963 -0.755 . . . . 1.4 108.963 179.611 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.547 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -150.61 114.51 5.02 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 120.691 -1.255 . . . . 1.36 109.744 -179.715 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 17.7 p90 -90.33 125.08 35.41 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.284 -0.885 . . . . 1.47 109.388 179.612 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 -141.48 105.79 4.82 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.256 -0.902 . . . . 2.51 109.545 -179.893 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -83.92 100.39 10.98 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.273 -0.892 . . . . 2.07 109.243 179.804 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.606 ' CG ' HH11 ' A' ' 68' ' ' ARG . 0.0 OUTLIER -90.98 -9.54 45.65 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.186 -0.946 . . . . 4.63 109.504 -179.752 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.5 ' C ' ' H ' ' A' ' 71' ' ' GLY . 20.5 mmmt -124.93 -0.17 7.93 Favored 'General case' 0 N--CA 1.5 2.035 0 O-C-N 121.48 -0.762 . . . . 3.49 109.439 -179.768 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.446 ' CB ' ' O ' ' A' ' 69' ' ' LYS . 2.4 t70 70.97 -11.48 0.66 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.2 -0.938 . . . . 3.06 108.899 -179.603 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . 0.5 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -129.71 -25.63 0.91 Allowed Glycine 0 N--CA 1.493 2.489 0 N-CA-C 109.559 -1.416 . . . . 2.16 109.559 -179.303 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 10.6 t -95.5 109.36 21.58 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.235 -1.156 . . . . 2.2 108.88 179.532 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' CYS . . . . . 0.508 ' N ' ' O ' ' A' ' 41' ' ' ILE . 49.8 t -80.05 104.81 10.87 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.222 -0.924 . . . . 2.05 109.845 -179.451 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -91.82 116.33 4.97 Favored Glycine 0 N--CA 1.493 2.5 0 N-CA-C 109.123 -1.591 . . . . 1.39 109.123 179.65 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 96.4 t -105.82 102.16 13.46 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.135 0 O-C-N 121.486 -1.008 . . . . 1.57 109.684 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.547 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.1 OUTLIER -88.42 130.08 35.26 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.376 -0.828 . . . . 1.85 108.936 179.649 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.426 ' O ' ' CG ' ' A' ' 77' ' ' TYR . 2.8 p90 -132.42 125.48 30.88 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.479 -0.763 . . . . 1.54 109.053 -179.824 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 5.9 t -99.86 103.72 15.14 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.392 -0.817 . . . . 1.9 109.37 -179.478 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 25.9 m -69.77 160.32 5.03 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 O-C-N 121.22 -0.925 . . . . 1.27 109.31 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 24.0 tp60 -100.72 -48.62 4.44 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.235 -0.915 . . . . 2.48 110.586 -179.416 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -155.25 152.77 25.66 Favored Pre-proline 0 N--CA 1.501 2.106 0 O-C-N 120.806 -1.184 . . . . 1.92 110.995 -178.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.617 ' HG3' ' N ' ' A' ' 107' ' ' SER . 75.1 Cg_exo -38.31 163.2 0.02 OUTLIER 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 123.176 2.584 . . . . 1.3 113.659 179.36 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 147.13 -162.36 28.59 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.156 -1.578 . . . . 1.02 109.156 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 33.5 m-20 -111.39 89.78 3.15 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.653 -0.91 . . . . 2.13 108.937 179.761 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.45 ' O ' ' N ' ' A' ' 103' ' ' VAL . 3.3 m-85 -77.64 128.94 34.93 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 108.004 -1.11 . . . . 0.92 108.004 179.687 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -112.63 129.74 56.28 Favored 'General case' 0 N--CA 1.5 2.042 0 N-CA-C 108.406 -0.961 . . . . 1.53 108.406 -179.088 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 8.6 p -124.84 137.63 56.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 CA-C-O 121.486 0.66 . . . . 1.0 110.002 -179.522 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 29.5 t -126.12 103.25 7.61 Favored 'General case' 0 N--CA 1.497 1.907 0 N-CA-C 109.405 -0.591 . . . . 1.59 109.405 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.413 ' H ' ' CB ' ' A' ' 99' ' ' SER . 0.8 OUTLIER -111.18 132.78 58.76 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.023 0 O-C-N 121.519 -0.738 . . . . 1.29 110.226 -179.39 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . 0.446 ' HG3' ' H ' ' A' ' 93' ' ' ASP . 0.4 OUTLIER -140.91 127.06 19.56 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.369 -0.832 . . . . 1.58 109.909 179.658 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.443 ' H ' ' HG3' ' A' ' 94' ' ' GLU . 54.5 t80 -82.3 94.39 7.33 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.12 -0.987 . . . . 1.34 108.457 178.855 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . 0.544 ' N ' ' O ' ' A' ' 50' ' ' GLY . 6.7 t30 69.22 37.08 2.19 Favored 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 108.074 -1.084 . . . . 2.32 108.074 -179.017 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.463 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 2.6 m-20 83.4 14.7 0.34 Allowed 'General case' 0 N--CA 1.499 1.981 0 CA-C-N 116.485 -0.325 . . . . 1.92 110.905 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . 0.693 ' OE1' ' HB2' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -91.17 90.83 7.97 Favored 'General case' 0 N--CA 1.496 1.827 0 N-CA-C 106.862 -1.533 . . . . 2.25 106.862 178.119 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . 0.509 ' O ' ' CG ' ' A' ' 95' ' ' HIS . 9.0 p80 -68.15 88.8 0.3 Allowed 'General case' 0 C--N 1.299 -1.615 0 O-C-N 119.94 -1.725 . . . . 2.88 110.359 -177.816 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 2.3 tt -48.3 137.13 11.73 Favored Pre-proline 0 N--CA 1.496 1.846 0 N-CA-C 107.635 -1.246 . . . . 2.35 107.635 178.675 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -40.51 -39.55 2.89 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 121.307 1.338 . . . . 2.48 111.747 -178.42 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 18.8 m-20 -49.18 -66.49 0.39 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 120.689 -1.257 . . . . 2.65 109.237 179.356 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.413 ' CB ' ' H ' ' A' ' 89' ' ' ILE . 0.1 OUTLIER -69.31 147.94 97.26 Favored Pre-proline 0 C--N 1.293 -1.875 0 O-C-N 121.151 -0.968 . . . . 2.0 110.067 -178.917 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -84.44 112.02 2.36 Favored 'Cis proline' 0 N--CA 1.491 1.343 0 N-CA-C 109.538 -0.986 . . . . 1.79 109.538 -2.238 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 43.1 p90 -116.21 166.86 11.55 Favored 'General case' 0 N--CA 1.522 3.162 0 O-C-N 120.509 -1.37 . . . . 2.19 110.445 178.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.2 p -95.49 148.19 5.35 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.903 0 CA-C-O 121.752 0.787 . . . . 1.44 111.549 -177.703 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.45 ' N ' ' O ' ' A' ' 85' ' ' TYR . 79.4 t -121.8 86.38 45.59 Favored Pre-proline 0 N--CA 1.498 1.926 0 N-CA-C 108.279 -1.008 . . . . 1.19 108.279 179.238 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_exo -62.81 114.14 2.28 Favored 'Trans proline' 0 C--N 1.319 -1.021 0 C-N-CA 121.351 1.367 . . . . 1.49 112.09 -178.011 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 55.2 t -95.27 144.34 10.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 N-CA-C 106.938 -1.504 . . . . 1.35 106.938 177.865 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.691 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -134.76 136.24 42.47 Favored 'General case' 0 N--CA 1.51 2.536 0 CA-C-O 122.079 0.942 . . . . 1.67 111.748 -177.457 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.617 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 80.6 p -92.17 76.41 5.35 Favored 'General case' 0 N--CA 1.492 1.674 0 N-CA-C 107.472 -1.307 . . . . 2.04 107.472 179.278 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 23.6 mt 61.72 6.36 1.57 Allowed 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 107.103 -1.443 . . . . 3.2 107.103 -177.735 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.647 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 14.0 t -92.27 -20.83 20.73 Favored 'General case' 0 N--CA 1.486 1.338 0 N-CA-C 109.205 -0.665 . . . . 2.09 109.205 179.588 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . 0.691 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 2.6 p30 45.31 19.6 0.04 OUTLIER 'General case' 0 N--CA 1.498 1.939 0 N-CA-C 108.417 -0.957 . . . . 2.85 108.417 -179.052 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.513 ' N ' ' O ' ' A' ' 109' ' ' SER . 23.8 t0 -173.34 -29.07 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 109.003 -0.74 . . . . 2.46 109.003 -179.584 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.647 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 59.03 -173.29 0.1 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.974 -1.079 . . . . 2.08 109.198 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 1.7 tpt180 -159.53 -157.8 0.61 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.156 -0.965 . . . . 5.93 109.467 179.816 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.428 ' HG3' HH11 ' A' ' 114' ' ' ARG . 24.3 ttm-85 -144.27 1.39 1.08 Allowed 'General case' 0 N--CA 1.492 1.664 0 N-CA-C 107.856 -1.164 . . . . 5.61 107.856 179.638 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.435 HD23 ' N ' ' A' ' 115' ' ' LEU . 0.1 OUTLIER -127.95 -26.81 2.85 Favored 'General case' 0 N--CA 1.501 2.079 0 N-CA-C 108.758 -0.83 . . . . 4.39 108.758 179.483 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.502 ' C ' ' H ' ' A' ' 118' ' ' THR . 77.9 m -105.29 -79.14 0.56 Allowed 'General case' 0 N--CA 1.495 1.815 0 N-CA-C 107.209 -1.404 . . . . 4.09 107.209 179.142 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.428 ' O ' HG12 ' A' ' 117' ' ' VAL . 53.3 t -62.11 -8.53 2.78 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.698 0 N-CA-C 106.014 -1.847 . . . . 2.9 106.014 176.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' THR . . . . . 0.502 ' H ' ' C ' ' A' ' 116' ' ' THR . 4.2 t 36.07 60.62 0.82 Allowed 'General case' 0 N--CA 1.487 1.413 0 CA-C-N 115.2 -0.909 . . . . 3.36 110.723 179.855 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' SER . . . . . 0.446 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.6 p . . . . . 0 C--N 1.303 -1.455 0 CA-C-O 117.971 -1.014 . . . . 3.39 109.562 179.409 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 19.3 mtt . . . . . 0 N--CA 1.49 1.564 0 N-CA-C 109.468 -0.567 . . . . 8.49 109.468 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -67.0 -149.21 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.251 -0.906 . . . . 5.53 109.512 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 3' ' ' SER . . . . . . . . . . . . . 22.8 t -75.02 150.13 39.03 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.31 -0.869 . . . . 5.43 109.515 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 4' ' ' LYS . . . . . . . . . . . . . 59.3 tttm -160.51 68.03 2.67 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.299 -0.876 . . . . 6.87 109.572 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 5' ' ' PRO . . . . . 0.428 ' O ' ' O ' ' B' ' 6' ' ' GLU . 2.0 Cg_endo -63.15 101.18 0.28 Allowed 'Trans proline' 0 C--N 1.318 -1.048 0 C-N-CA 121.527 1.485 . . . . 5.16 110.198 -179.612 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 6' ' ' GLU . . . . . 0.428 ' O ' ' O ' ' B' ' 5' ' ' PRO . 23.1 tp10 58.72 156.53 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.274 -0.891 . . . . 4.78 109.721 179.544 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 7' ' ' LYS . . . . . 0.4 ' O ' ' O ' ' B' ' 6' ' ' GLU . 36.9 mttp -63.83 -130.38 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.216 -0.927 . . . . 4.09 109.38 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.412 ' NH1' ' HG3' ' B' ' 8' ' ' ARG . 23.4 mtm-85 -98.51 -117.75 0.14 Allowed 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.287 -1.005 . . . . 3.04 108.287 179.841 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 9' ' ' VAL . . . . . 0.532 ' N ' ' O ' ' A' ' 57' ' ' GLY . 0.4 OUTLIER -122.48 170.85 12.22 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.069 0 N-CA-C 108.139 -1.06 . . . . 0.67 108.139 178.989 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 0.436 ' N ' HG13 ' B' ' 9' ' ' VAL . . . -114.81 136.24 53.31 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.717 -0.615 . . . . 0.58 110.07 -179.41 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 9.4 m -149.28 82.88 1.43 Allowed 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.376 -0.828 . . . . 1.19 109.44 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 12.8 t -101.04 116.72 33.52 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.363 -0.836 . . . . 1.38 109.434 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 0.579 HG22 ' N ' ' B' ' 14' ' ' PHE . 3.2 p -156.66 164.45 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.265 -0.897 . . . . 0.42 109.177 179.823 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 14' ' ' PHE . . . . . 0.579 ' N ' HG22 ' B' ' 13' ' ' VAL . 6.5 p90 -178.99 -164.7 0.07 Allowed 'General case' 0 N--CA 1.49 1.555 0 CA-C-O 122.1 0.953 . . . . 1.79 111.924 179.575 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.875 ' N ' HD13 ' B' ' 15' ' ' ILE . 0.1 OUTLIER -145.72 155.49 13.0 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.094 0 N-CA-C 108.635 -0.876 . . . . 1.25 108.635 179.811 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 16' ' ' THR . . . . . 0.478 HG22 ' N ' ' B' ' 17' ' ' LEU . 97.0 m -109.11 158.9 17.33 Favored 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.214 -0.929 . . . . 1.61 109.781 -179.799 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.478 ' N ' HG22 ' B' ' 16' ' ' THR . 34.3 mt -132.8 104.99 6.88 Favored 'General case' 0 N--CA 1.499 2.019 0 O-C-N 121.475 -0.766 . . . . 1.32 109.167 179.821 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -158.81 76.86 3.26 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.295 -0.878 . . . . 1.45 109.342 -179.828 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -65.79 166.15 21.17 Favored 'Trans proline' 0 CA--C 1.544 1.006 0 C-N-CA 121.303 1.335 . . . . 1.5 109.733 -179.36 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 20' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_endo -62.47 84.26 0.1 Allowed 'Trans proline' 0 C--N 1.319 -1.023 0 C-N-CA 121.509 1.472 . . . . 2.86 109.77 179.611 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 34.8 ttp180 -100.11 90.62 4.44 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.146 -0.971 . . . . 6.12 109.401 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 22' ' ' ARG . . . . . 0.586 HH11 ' CG ' ' B' ' 22' ' ' ARG . 3.4 mtt-85 -64.73 -106.5 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.233 -0.917 . . . . 6.29 109.392 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . 0.49 ' OD1' ' N ' ' B' ' 24' ' ' VAL . 37.8 t0 -170.65 146.75 2.74 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.196 -0.94 . . . . 5.62 109.436 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . 0.49 ' N ' ' OD1' ' B' ' 23' ' ' ASP . 15.4 m . . . . . 0 N--CA 1.49 1.557 0 CA-C-O 118.006 -0.997 . . . . 6.48 109.384 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.531 4.968 0 N-CA-C 119.773 2.669 . . . . 6.64 119.773 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.571 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 12.7 tt -171.75 50.66 0.13 Allowed Pre-proline 0 C--N 1.306 -1.32 0 N-CA-C 107.949 -1.13 . . . . 7.08 107.949 179.523 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.635 ' C ' ' H ' ' A' ' 5' ' ' PHE . 4.3 Cg_endo -57.08 -79.19 0.02 OUTLIER 'Trans proline' 0 C--N 1.318 -1.047 0 C-N-CA 121.279 1.32 . . . . 5.5 109.3 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.434 ' CB ' ' O ' ' A' ' 3' ' ' PRO . 0.0 OUTLIER 72.54 -48.94 0.69 Allowed 'General case' 0 N--CA 1.493 1.684 0 N-CA-C 103.227 -2.879 . . . . 6.75 103.227 -175.684 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . 0.635 ' H ' ' C ' ' A' ' 3' ' ' PRO . 7.3 m-85 -51.4 -27.28 9.59 Favored 'General case' 0 C--N 1.305 -1.356 0 N-CA-C 106.552 -1.647 . . . . 6.07 106.552 175.167 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.541 ' CD1' ' O ' ' A' ' 5' ' ' PHE . 0.0 OUTLIER 112.35 -151.4 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.262 0 C-N-CA 124.675 1.19 . . . . 4.72 111.353 179.378 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.533 ' N ' ' CG ' ' A' ' 6' ' ' PHE . 21.2 tt0 82.78 -4.61 1.32 Allowed 'General case' 0 N--CA 1.494 1.728 0 N-CA-C 105.442 -2.059 . . . . 4.4 105.442 -177.562 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.408 ' H ' ' C ' ' A' ' 6' ' ' PHE . 25.1 t80 -153.06 -40.12 0.1 Allowed 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 107.233 -1.395 . . . . 5.15 107.233 178.801 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.45 ' O ' ' N ' ' A' ' 11' ' ' GLY . 8.6 m -83.5 1.68 40.61 Favored 'General case' 0 C--N 1.296 -1.745 0 N-CA-C 105.937 -1.875 . . . . 5.13 105.937 177.011 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.654 HG13 ' HD2' ' A' ' 12' ' ' PRO . 8.0 p -38.46 -30.24 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 CA-C-N 115.257 -0.883 . . . . 4.38 109.897 -179.827 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.552 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 137.02 -72.83 0.45 Allowed Glycine 0 N--CA 1.499 2.872 0 N-CA-C 108.709 -1.756 . . . . 4.22 108.709 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.654 ' HD2' HG13 ' A' ' 10' ' ' VAL . 15.5 Cg_endo -68.71 39.92 0.24 Allowed 'Trans proline' 0 C--N 1.318 -1.051 0 C-N-CA 122.026 1.817 . . . . 3.85 108.68 178.352 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.571 ' C ' ' H ' ' A' ' 15' ' ' GLU . 0.2 OUTLIER 28.36 38.66 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.248 0 CA-C-O 121.452 0.644 . . . . 3.67 110.903 -179.595 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.61 ' C ' ' H ' ' A' ' 16' ' ' GLY . . . 68.84 -37.46 0.29 Allowed Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.108 -1.597 . . . . 2.97 109.108 -179.606 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.571 ' H ' ' C ' ' A' ' 13' ' ' LEU . 41.1 tt0 63.24 -10.58 0.1 Allowed 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.742 -0.857 . . . . 2.97 109.239 -179.099 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.61 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 89.88 -147.24 19.22 Favored Glycine 0 N--CA 1.489 2.214 0 O-C-N 121.181 -0.949 . . . . 2.44 110.735 178.725 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.559 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -67.71 -6.18 41.9 Favored Glycine 0 N--CA 1.491 2.338 0 O-C-N 121.42 -1.047 . . . . 1.81 111.063 -178.855 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.426 ' HB2' ' HB2' ' A' ' 94' ' ' GLU . . . -47.94 -11.99 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.465 -1.609 . . . . 2.21 109.452 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . 0.559 ' N ' ' O ' ' A' ' 17' ' ' GLY . 39.7 t-80 -96.92 -41.73 8.27 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.203 -0.935 . . . . 2.87 109.729 179.577 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.77 -24.43 41.52 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 120.92 -1.112 . . . . 2.02 109.95 -179.64 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.533 ' O ' HG13 ' A' ' 21' ' ' VAL . 4.1 p -68.07 115.27 5.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 120.924 -1.11 . . . . 2.07 108.927 179.87 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 12.0 tpp180 -98.07 136.05 38.88 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.625 -0.672 . . . . 3.5 109.445 -179.155 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -147.55 113.42 5.76 Favored 'General case' 0 N--CA 1.492 1.639 0 N-CA-C 108.69 -0.855 . . . . 1.83 108.69 179.486 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -162.62 136.5 4.36 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.584 -1.406 . . . . 1.9 109.584 -179.579 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.1 173.7 46.16 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.667 -1.373 . . . . 1.85 109.667 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 19.1 m -77.19 -18.43 57.77 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.352 -1.087 . . . . 2.31 109.604 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -73.34 -20.26 79.85 Favored Glycine 0 N--CA 1.487 2.05 0 N-CA-C 109.304 -1.518 . . . . 1.64 109.304 -179.884 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.572 HD21 ' CD2' ' A' ' 39' ' ' PHE . 55.7 mt -88.8 -13.97 38.14 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.433 -1.039 . . . . 1.83 109.341 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 56.9 mt-10 -84.06 -62.74 1.49 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.292 -0.88 . . . . 2.34 110.053 -179.519 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 79.3 mtt180 -149.0 165.2 32.34 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.014 -1.054 . . . . 3.77 110.342 -179.589 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -142.5 169.6 25.43 Favored Glycine 0 N--CA 1.495 2.591 0 N-CA-C 107.708 -2.157 . . . . 1.57 107.708 179.019 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 40.9 t -134.04 150.57 31.4 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.202 0 O-C-N 121.051 -1.264 . . . . 1.83 110.971 -179.326 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -37.5 113.1 0.24 Allowed 'General case' 0 N--CA 1.501 2.08 0 CA-C-O 121.809 0.814 . . . . 1.64 112.242 -179.533 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 52.29 50.54 46.36 Favored Glycine 0 N--CA 1.488 2.124 0 N-CA-C 111.244 -0.743 . . . . 1.73 111.244 177.162 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 24.1 t -126.6 103.3 25.05 Favored Pre-proline 0 N--CA 1.494 1.757 0 N-CA-C 108.061 -1.088 . . . . 2.19 108.061 178.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -55.69 139.83 83.66 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 120.749 0.966 . . . . 1.96 110.574 -178.713 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.479 ' HB3' ' CE1' ' A' ' 77' ' ' TYR . . . -146.97 175.04 10.97 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.449 -0.782 . . . . 1.69 109.458 -179.923 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -154.52 165.37 36.67 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.958 -1.089 . . . . 2.23 111.297 -179.378 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.572 ' CD2' HD21 ' A' ' 28' ' ' LEU . 0.7 OUTLIER -143.43 -174.25 4.17 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 107.066 -1.457 . . . . 1.54 107.066 177.464 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 44.7 m -120.63 151.58 39.28 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 121.238 -0.914 . . . . 2.37 111.512 -177.937 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 85.5 mt -141.97 91.68 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 N-CA-C 108.332 -0.988 . . . . 1.65 108.332 178.531 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.414 ' CD1' ' N ' ' A' ' 43' ' ' THR . 9.6 t90 -96.02 141.03 29.91 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.165 -0.959 . . . . 3.68 108.69 179.887 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.414 ' N ' ' CD1' ' A' ' 42' ' ' TRP . 0.0 OUTLIER -161.83 130.26 4.26 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.247 -0.908 . . . . 2.89 109.748 -179.577 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' ARG . . . . . . . . . . . . . 66.6 ttt180 -172.02 77.33 0.05 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.324 -0.86 . . . . 4.63 109.728 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 6.8 tp10 -165.18 -55.26 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.099 -1.001 . . . . 2.89 109.735 179.631 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -58.33 -58.66 7.49 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.125 -0.984 . . . . 1.74 109.018 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 142.27 -160.53 27.24 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.231 -1.548 . . . . 1.6 109.231 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -64.28 163.79 12.28 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.288 -1.125 . . . . 1.4 109.38 179.717 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 174.29 178.79 44.46 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.724 -1.351 . . . . 1.04 109.724 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -117.12 125.47 6.54 Favored Glycine 0 N--CA 1.499 2.856 0 N-CA-C 109.682 -1.367 . . . . 1.06 109.682 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.458 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 11.8 tp -99.53 101.17 12.31 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.283 -1.128 . . . . 1.1 108.642 179.63 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 19.1 m -88.79 140.51 29.37 Favored 'General case' 0 N--CA 1.493 1.694 0 N-CA-C 108.696 -0.854 . . . . 1.56 108.696 179.854 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.514 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 90.8 mt -132.28 108.03 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 O-C-N 121.288 -0.883 . . . . 0.65 109.347 -179.819 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -98.63 106.35 18.61 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.304 -0.872 . . . . 0.69 108.928 179.706 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.429 HG23 ' OG ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -99.34 141.94 15.89 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.53 -0.731 . . . . 0.91 109.408 -179.826 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 10.1 tt0 -141.97 143.92 33.45 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.279 -1.008 . . . . 1.8 108.279 178.793 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 165.55 -174.12 41.29 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.614 -1.394 . . . . 0.49 109.614 -179.289 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -58.18 -26.34 75.76 Favored 'Trans proline' 0 C--N 1.317 -1.122 0 C-N-CA 121.998 1.799 . . . . 0.66 111.971 -179.513 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 2.1 m -143.61 170.62 15.49 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.063 -1.023 . . . . 1.55 110.291 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 29.1 mtpt -90.31 100.28 13.14 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.387 -0.82 . . . . 2.53 109.373 -179.878 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -63.38 142.82 58.25 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.182 -0.949 . . . . 0.82 109.603 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 24.9 tt0 -80.66 172.0 14.31 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.283 -0.886 . . . . 2.3 109.281 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 14.0 mt -149.65 141.31 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.906 0 N-CA-C 108.006 -1.109 . . . . 1.4 108.006 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -150.67 112.47 4.51 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 120.449 -1.407 . . . . 1.36 110.251 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.519 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 51.3 p90 -85.92 123.51 31.35 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.562 -0.711 . . . . 1.47 110.205 179.795 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 42.8 tt0 -141.48 119.75 12.21 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.488 -0.757 . . . . 2.51 109.056 179.555 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -73.73 114.0 11.51 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.181 -0.949 . . . . 2.07 109.613 -179.733 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 38.6 ttp180 -108.67 -13.37 14.81 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.454 -0.779 . . . . 4.63 109.473 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.507 ' C ' ' H ' ' A' ' 71' ' ' GLY . 16.7 mtpp -122.62 -3.39 8.79 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.467 -0.77 . . . . 3.49 109.389 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.466 ' CB ' ' O ' ' A' ' 69' ' ' LYS . 1.4 t70 73.48 -19.18 0.34 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.391 -0.818 . . . . 3.06 109.214 -179.757 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . 0.507 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -119.39 -41.04 0.59 Allowed Glycine 0 N--CA 1.495 2.589 0 N-CA-C 109.725 -1.35 . . . . 2.16 109.725 -179.416 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.44 ' H ' ' HB2' ' A' ' 69' ' ' LYS . 14.0 m -95.37 126.28 40.57 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.175 -1.191 . . . . 2.2 109.271 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 11.3 t -82.48 120.29 25.3 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.217 -0.927 . . . . 2.05 109.463 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -99.51 117.22 5.8 Favored Glycine 0 N--CA 1.496 2.694 0 N-CA-C 109.657 -1.377 . . . . 1.39 109.657 -179.832 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -105.32 105.11 18.04 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.075 0 O-C-N 121.54 -0.977 . . . . 1.57 109.647 179.85 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 3.9 t -84.14 124.8 31.53 Favored 'General case' 0 N--CA 1.485 1.31 0 N-CA-C 108.148 -1.056 . . . . 1.85 108.148 178.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.479 ' CE1' ' HB3' ' A' ' 37' ' ' ALA . 1.9 p90 -123.0 171.84 8.95 Favored 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 108.57 -0.9 . . . . 1.54 108.57 -179.078 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 41.4 t -141.79 141.67 29.28 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.929 0 O-C-N 121.169 -0.957 . . . . 1.9 109.804 -179.581 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 30.7 m -109.53 150.69 12.07 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.095 0 O-C-N 121.439 -0.788 . . . . 1.27 109.254 179.646 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 6.6 tp-100 -96.7 -45.27 6.75 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.219 -0.925 . . . . 2.48 110.305 -179.717 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -159.28 152.33 18.39 Favored Pre-proline 0 N--CA 1.502 2.161 0 O-C-N 120.768 -1.208 . . . . 1.92 110.857 -179.26 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.686 ' HG3' ' N ' ' A' ' 107' ' ' SER . 85.5 Cg_exo -37.54 158.55 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 123.248 2.632 . . . . 1.3 113.369 179.032 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 147.92 166.99 13.08 Favored Glycine 0 N--CA 1.488 2.109 0 N-CA-C 109.477 -1.449 . . . . 1.02 109.477 179.823 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . 0.887 ' H ' HH12 ' B' ' 8' ' ' ARG . 66.9 m-20 -87.65 84.55 7.08 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 107.666 -1.235 . . . . 2.13 107.666 179.117 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -69.93 134.16 48.09 Favored 'General case' 0 C--N 1.297 -1.709 0 N-CA-C 107.966 -1.124 . . . . 0.92 107.966 -179.526 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . 0.419 ' OE1' ' O ' ' A' ' 84' ' ' ASP . 0.0 OUTLIER -112.27 127.63 56.03 Favored 'General case' 0 N--CA 1.501 2.105 0 N-CA-C 108.667 -0.864 . . . . 1.53 108.667 -179.413 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 9.6 p -123.88 141.06 45.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.712 -0.618 . . . . 1.0 109.794 -179.633 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 3.8 m -130.29 97.82 4.53 Favored 'General case' 0 N--CA 1.498 1.952 0 CA-C-O 121.539 0.685 . . . . 1.59 109.38 179.781 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.413 ' H ' ' HB3' ' A' ' 99' ' ' SER . 1.6 pt -104.88 133.32 49.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 CA-C-O 121.471 0.653 . . . . 1.29 109.846 -179.741 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . 0.458 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -144.42 127.39 16.45 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 108.027 -1.101 . . . . 1.58 108.027 179.946 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.421 ' O ' ' CB ' ' A' ' 92' ' ' ASN . 76.5 t80 -85.47 102.22 13.29 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.63 -1.294 . . . . 1.34 108.462 179.16 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . 0.431 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 13.0 t30 72.38 33.87 1.41 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.068 -1.02 . . . . 2.32 108.748 -178.679 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.431 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 0.8 OUTLIER 80.21 14.04 0.87 Allowed 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.891 -0.505 . . . . 1.92 111.698 179.509 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . 0.462 ' CG ' ' O ' ' A' ' 94' ' ' GLU . 5.0 pt-20 -99.84 94.44 6.32 Favored 'General case' 0 N--CA 1.495 1.806 0 N-CA-C 107.029 -1.471 . . . . 2.25 107.029 177.573 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . 0.618 ' H ' ' CD2' ' A' ' 95' ' ' HIS . 7.0 p80 -74.7 112.41 10.87 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-O 121.542 0.687 . . . . 2.88 110.281 -178.071 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . 0.796 ' H ' HD13 ' A' ' 96' ' ' ILE . 0.0 OUTLIER -60.49 155.76 46.83 Favored Pre-proline 0 N--CA 1.497 1.918 0 N-CA-C 107.257 -1.386 . . . . 2.35 107.257 178.994 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -49.47 -25.78 11.12 Favored 'Trans proline' 0 C--N 1.321 -0.879 0 N-CA-C 108.968 -1.204 . . . . 2.48 108.968 179.847 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.471 ' N ' ' OD1' ' A' ' 98' ' ' ASP . 0.9 OUTLIER -59.52 -64.69 0.85 Allowed 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 108.873 -0.788 . . . . 2.65 108.873 178.852 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.413 ' HB3' ' H ' ' A' ' 89' ' ' ILE . 2.4 p -66.83 141.01 96.52 Favored Pre-proline 0 C--N 1.297 -1.7 0 O-C-N 121.308 -0.87 . . . . 2.0 110.04 -178.42 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -85.91 116.99 4.11 Favored 'Cis proline' 0 N--CA 1.492 1.405 0 N-CA-C 109.563 -0.976 . . . . 1.79 109.563 -2.389 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 53.3 p90 -117.03 163.62 15.96 Favored 'General case' 0 N--CA 1.518 2.945 0 O-C-N 120.532 -1.355 . . . . 2.19 110.003 178.687 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.5 p -93.23 152.89 3.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 CA-C-O 121.666 0.746 . . . . 1.44 111.008 -178.144 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 65.1 t -125.92 86.84 57.04 Favored Pre-proline 0 N--CA 1.497 1.888 0 N-CA-C 107.917 -1.142 . . . . 1.19 107.917 179.024 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -63.71 113.29 2.08 Favored 'Trans proline' 0 C--N 1.319 -0.999 0 C-N-CA 121.418 1.412 . . . . 1.49 112.264 -177.743 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 54.3 t -97.72 142.18 14.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 N-CA-C 106.302 -1.74 . . . . 1.35 106.302 177.496 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.661 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -130.23 132.84 46.15 Favored 'General case' 0 N--CA 1.511 2.606 0 CA-C-O 122.109 0.956 . . . . 1.67 111.82 -177.18 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.686 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 36.3 p -94.98 90.91 6.14 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.759 -1.213 . . . . 2.04 107.748 179.577 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . 0.569 HD12 ' N ' ' A' ' 108' ' ' LEU . 8.0 mp 54.65 10.49 0.36 Allowed 'General case' 0 C--N 1.294 -1.816 0 N-CA-C 107.848 -1.167 . . . . 3.2 107.848 -178.2 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.664 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 9.0 t -98.88 -27.09 14.06 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 109.255 -0.646 . . . . 2.09 109.255 179.712 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . 0.661 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 1.8 m-20 53.93 12.23 0.42 Allowed 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 107.941 -1.133 . . . . 2.85 107.941 -179.275 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.492 ' N ' ' C ' ' A' ' 109' ' ' SER . 2.6 p30 -168.99 -30.13 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 109.348 -0.612 . . . . 2.46 109.348 -179.615 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.664 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 49.26 -171.3 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.81 0 O-C-N 120.825 -1.172 . . . . 2.08 109.198 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 15.7 ttt180 -159.2 -161.09 0.9 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.061 -1.025 . . . . 5.93 109.547 179.696 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 37.9 ttp180 -143.56 2.32 1.24 Allowed 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 107.578 -1.268 . . . . 5.61 107.578 179.442 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 32.1 mt -129.8 -26.93 2.38 Favored 'General case' 0 N--CA 1.499 2.022 0 N-CA-C 109.016 -0.735 . . . . 4.39 109.016 179.632 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.496 ' C ' ' H ' ' A' ' 118' ' ' THR . 98.5 m -102.13 -79.55 0.52 Allowed 'General case' 0 N--CA 1.495 1.793 0 N-CA-C 106.999 -1.482 . . . . 4.09 106.999 178.92 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.439 ' O ' HG12 ' A' ' 117' ' ' VAL . 50.7 t -61.88 -8.9 2.82 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 N-CA-C 105.967 -1.864 . . . . 2.9 105.967 176.715 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' THR . . . . . 0.496 ' H ' ' C ' ' A' ' 116' ' ' THR . 4.4 t 36.29 60.66 0.85 Allowed 'General case' 0 N--CA 1.487 1.422 0 CA-C-N 115.148 -0.933 . . . . 3.36 110.735 179.847 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' SER . . . . . 0.457 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.7 p . . . . . 0 C--N 1.303 -1.453 0 CA-C-O 117.973 -1.013 . . . . 3.39 109.569 179.363 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.595 0 N-CA-C 108.911 -0.774 . . . . 8.49 108.911 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -76.21 110.31 10.6 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.218 -0.926 . . . . 5.53 109.376 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 3' ' ' SER . . . . . . . . . . . . . 90.0 p -95.05 -137.05 0.22 Allowed 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.291 -0.881 . . . . 5.43 109.651 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 4' ' ' LYS . . . . . . . . . . . . . 19.8 tptp -172.4 70.17 0.42 Allowed Pre-proline 0 N--CA 1.491 1.619 0 O-C-N 121.317 -0.864 . . . . 6.87 109.287 -179.78 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 5' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_exo -60.8 -78.24 0.01 OUTLIER 'Trans proline' 0 C--N 1.317 -1.106 0 C-N-CA 121.458 1.438 . . . . 5.16 110.086 -179.497 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 6' ' ' GLU . . . . . . . . . . . . . 68.3 mt-10 -152.97 169.76 22.07 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.079 -1.013 . . . . 4.78 109.499 -179.858 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 78.0 mttt -77.9 179.61 6.62 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.334 -0.854 . . . . 4.09 109.35 179.864 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.887 HH12 ' H ' ' A' ' 84' ' ' ASP . 5.8 mtt180 -98.73 170.29 8.88 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.289 -0.882 . . . . 3.04 108.638 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 9' ' ' VAL . . . . . . . . . . . . . 17.1 t -53.8 159.55 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 108.017 -1.105 . . . . 0.67 108.017 179.307 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -123.18 150.28 43.55 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.464 -0.773 . . . . 0.58 110.002 -179.115 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 11' ' ' SER . . . . . 0.429 ' OG ' HG23 ' A' ' 55' ' ' VAL . 4.2 t -144.57 139.54 28.21 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.454 -0.779 . . . . 1.19 109.017 179.695 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 16.7 m -140.4 116.03 10.17 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.328 -0.857 . . . . 1.38 109.465 -179.714 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 0.579 HG22 ' N ' ' B' ' 14' ' ' PHE . 2.9 p -160.15 166.29 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 O-C-N 121.34 -0.85 . . . . 0.42 109.234 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 14' ' ' PHE . . . . . 0.579 ' N ' HG22 ' B' ' 13' ' ' VAL . 7.4 p90 -177.54 -165.85 0.12 Allowed 'General case' 0 N--CA 1.487 1.425 0 CA-C-O 122.108 0.956 . . . . 1.79 112.083 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.7 pt -149.51 169.92 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.318 0 N-CA-C 108.387 -0.968 . . . . 1.25 108.387 179.851 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 65.9 p -135.54 128.64 31.68 Favored 'General case' 0 N--CA 1.5 2.049 0 O-C-N 121.184 -0.947 . . . . 1.61 109.784 -179.803 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.6 mt -90.92 136.58 32.98 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.349 -0.844 . . . . 1.32 109.167 179.651 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -143.86 68.54 16.31 Favored Pre-proline 0 N--CA 1.495 1.796 0 O-C-N 121.302 -0.874 . . . . 1.45 109.49 -179.847 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -60.46 168.47 6.54 Favored 'Trans proline' 0 C--N 1.317 -1.098 0 C-N-CA 121.36 1.373 . . . . 1.5 109.504 -179.867 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 20' ' ' PRO . . . . . 0.471 ' O ' ' N ' ' B' ' 22' ' ' ARG . 3.1 Cg_exo -56.36 114.24 1.82 Allowed 'Trans proline' 0 C--N 1.319 -1.018 0 C-N-CA 121.346 1.364 . . . . 2.86 110.003 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 85.2 mtt180 -50.67 -11.23 0.08 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.307 -0.87 . . . . 6.12 109.399 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 22' ' ' ARG . . . . . 0.471 ' N ' ' O ' ' B' ' 20' ' ' PRO . 36.1 ttp180 52.39 -125.87 2.39 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.303 -0.873 . . . . 6.29 109.459 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 33.5 m-20 -91.42 175.86 6.77 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.089 -1.007 . . . . 5.62 109.614 -179.742 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 7.4 p . . . . . 0 N--CA 1.49 1.55 0 CA-C-O 117.988 -1.006 . . . . 6.48 109.399 179.938 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.954 0 N-CA-C 119.835 2.694 . . . . 6.64 119.835 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.647 HG23 ' O ' ' A' ' 2' ' ' ILE . 3.7 tp -172.62 50.61 0.12 Allowed Pre-proline 0 C--N 1.306 -1.292 0 N-CA-C 107.842 -1.17 . . . . 7.08 107.842 179.483 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.814 ' C ' ' H ' ' A' ' 5' ' ' PHE . 3.2 Cg_endo -56.18 -80.82 0.01 OUTLIER 'Trans proline' 0 C--N 1.318 -1.035 0 C-N-CA 121.13 1.22 . . . . 5.5 109.04 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.515 ' C ' ' H ' ' A' ' 6' ' ' PHE . 11.3 tt0 73.43 -18.34 0.38 Allowed 'General case' 0 N--CA 1.496 1.853 0 N-CA-C 104.349 -2.463 . . . . 6.75 104.349 -175.615 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . 0.814 ' H ' ' C ' ' A' ' 3' ' ' PRO . 10.4 t80 -89.83 18.66 5.41 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 103.892 -2.633 . . . . 6.07 103.892 176.841 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.539 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 41.5 p90 46.69 -154.73 0.05 Allowed 'General case' 0 C--N 1.307 -1.251 0 CA-C-N 114.159 -1.382 . . . . 4.72 109.53 -177.797 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.526 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 0.2 OUTLIER 85.42 -9.23 0.81 Allowed 'General case' 0 N--CA 1.492 1.644 0 N-CA-C 105.037 -2.209 . . . . 4.4 105.037 -177.143 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.404 ' H ' ' C ' ' A' ' 6' ' ' PHE . 52.0 t80 -153.2 -37.62 0.1 Allowed 'General case' 0 C--N 1.304 -1.383 0 N-CA-C 107.816 -1.179 . . . . 5.15 107.816 178.321 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 22.2 m -91.84 2.61 56.4 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 105.965 -1.865 . . . . 5.13 105.965 177.382 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.424 HG13 ' N ' ' A' ' 11' ' ' GLY . 7.5 p -43.25 -38.65 1.04 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 CA-C-N 115.481 -0.781 . . . . 4.38 109.618 -179.737 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.594 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 141.45 -84.8 0.21 Allowed Glycine 0 N--CA 1.498 2.786 0 N-CA-C 108.238 -1.945 . . . . 4.22 108.238 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.527 ' O ' ' N ' ' A' ' 14' ' ' GLY . 12.8 Cg_endo -67.35 39.57 0.18 Allowed 'Trans proline' 0 C--N 1.32 -0.964 0 C-N-CA 121.597 1.531 . . . . 3.85 108.496 177.541 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.594 ' H ' ' C ' ' A' ' 11' ' ' GLY . 0.2 OUTLIER 29.99 36.51 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.173 0 CA-C-O 121.607 0.718 . . . . 3.67 110.628 -179.168 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.533 ' C ' ' H ' ' A' ' 16' ' ' GLY . . . 68.49 -37.73 0.27 Allowed Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.586 -1.406 . . . . 2.97 109.586 179.812 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.532 ' H ' ' C ' ' A' ' 13' ' ' LEU . 31.2 tt0 56.24 4.46 0.14 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.359 -1.083 . . . . 2.97 109.136 -179.637 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.533 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 60.24 131.15 0.01 OUTLIER Glycine 0 N--CA 1.489 2.224 0 N-CA-C 110.912 -0.875 . . . . 2.44 110.912 179.084 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.531 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 71.35 -53.94 1.14 Allowed Glycine 0 N--CA 1.491 2.351 0 N-CA-C 110.416 -1.073 . . . . 1.81 110.416 179.066 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.461 ' HB2' ' OE1' ' A' ' 94' ' ' GLU . . . -46.79 -12.53 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.543 -0.975 . . . . 2.21 110.14 -179.439 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . 0.531 ' N ' ' O ' ' A' ' 17' ' ' GLY . 10.0 t-80 -89.77 -42.79 11.09 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.123 -0.985 . . . . 2.87 110.299 -179.168 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.84 -9.08 38.57 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 120.928 -1.108 . . . . 2.02 110.682 -179.006 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 74.2 t -83.4 112.14 20.54 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 120.865 -1.147 . . . . 2.07 110.3 -179.383 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 20.9 tpt180 -103.07 139.91 38.0 Favored 'General case' 0 N--CA 1.491 1.615 0 N-CA-C 108.06 -1.089 . . . . 3.5 108.06 179.042 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -140.02 113.3 8.39 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.263 -0.898 . . . . 1.83 109.648 -179.599 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -155.78 130.59 2.8 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 109.352 -1.499 . . . . 1.9 109.352 179.71 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.3 167.14 37.57 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.816 -1.314 . . . . 1.85 109.816 -179.856 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 17.6 m -74.1 -28.16 61.23 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.297 -1.119 . . . . 2.31 109.486 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.6 -22.9 78.02 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 109.085 -1.606 . . . . 1.64 109.085 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 20.8 mt -77.0 -10.21 59.21 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.446 -1.032 . . . . 1.83 108.963 179.689 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 59.4 mt-10 -90.15 -51.91 5.22 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.372 -0.83 . . . . 2.34 109.478 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . 0.411 ' NH1' ' HG2' ' A' ' 30' ' ' ARG . 0.0 OUTLIER -169.05 -168.69 0.87 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.035 -1.04 . . . . 3.77 109.993 -179.992 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -153.92 178.76 30.65 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 108.508 -1.837 . . . . 1.57 108.508 179.876 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 42.0 t -134.37 151.09 31.42 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.041 0 O-C-N 121.165 -1.197 . . . . 1.83 110.635 -179.618 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.522 ' HB2' ' HB3' ' A' ' 107' ' ' SER . . . -38.79 111.68 0.19 Allowed 'General case' 0 N--CA 1.5 2.062 0 CA-C-O 121.544 0.688 . . . . 1.64 112.39 -179.154 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 53.43 51.42 47.8 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 111.302 -0.719 . . . . 1.73 111.302 176.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 31.4 t -127.59 103.04 22.32 Favored Pre-proline 0 N--CA 1.495 1.78 0 O-C-N 121.513 -0.993 . . . . 2.19 109.016 179.203 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -58.55 133.07 52.03 Favored 'Trans proline' 0 C--O 1.215 -0.636 0 N-CA-C 109.51 -0.996 . . . . 1.96 109.51 -179.88 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.405 ' HB3' ' CZ ' ' A' ' 77' ' ' TYR . . . -142.18 -169.62 2.98 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.338 -0.851 . . . . 1.69 108.803 -179.825 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -169.45 165.23 10.54 Favored 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 118.931 -1.107 . . . . 2.23 111.228 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.57 ' CD1' ' N ' ' A' ' 39' ' ' PHE . 0.7 OUTLIER -138.32 -176.28 4.4 Favored 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 106.758 -1.571 . . . . 1.54 106.758 178.033 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 43.8 t -122.28 147.12 46.62 Favored 'General case' 0 N--CA 1.498 1.969 0 CA-C-O 121.596 0.712 . . . . 2.37 110.298 -179.103 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 49.6 mt -142.73 97.24 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 N-CA-C 107.986 -1.116 . . . . 1.65 107.986 179.033 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.46 ' CD1' ' C ' ' A' ' 42' ' ' TRP . 0.4 OUTLIER -86.68 144.96 26.88 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.355 -0.841 . . . . 3.68 108.864 -179.493 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.534 ' OG1' ' N ' ' A' ' 44' ' ' ARG . 1.7 t -168.16 -124.85 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.322 -0.861 . . . . 2.89 109.355 -179.898 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' ARG . . . . . 0.534 ' N ' ' OG1' ' A' ' 43' ' ' THR . 61.2 ttt180 57.62 77.67 0.27 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.277 -0.889 . . . . 4.63 109.754 179.804 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 26.1 tt0 -160.62 -45.93 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.289 -0.882 . . . . 2.89 109.127 179.642 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -61.82 -56.16 22.33 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.257 -0.902 . . . . 1.74 109.1 179.658 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 155.64 178.27 29.69 Favored Glycine 0 N--CA 1.489 2.167 0 N-CA-C 109.459 -1.457 . . . . 1.6 109.459 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.7 145.01 16.46 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.173 -1.192 . . . . 1.4 109.152 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -164.33 -164.24 19.13 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.667 -1.373 . . . . 1.04 109.667 -179.828 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -137.97 116.57 1.34 Allowed Glycine 0 N--CA 1.496 2.69 0 N-CA-C 109.546 -1.422 . . . . 1.06 109.546 -179.828 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.464 HD12 ' O ' ' A' ' 90' ' ' LYS . 64.3 tp -91.57 109.39 20.69 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.274 -1.133 . . . . 1.1 108.422 179.383 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 28.3 m -92.96 141.61 28.22 Favored 'General case' 0 N--CA 1.498 1.969 0 N-CA-C 108.598 -0.89 . . . . 1.56 108.598 179.616 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.581 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 93.9 mt -134.34 116.99 23.35 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.945 0 O-C-N 121.165 -0.959 . . . . 0.65 110.148 -179.304 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -107.47 109.66 21.41 Favored 'General case' 0 N--CA 1.495 1.799 0 N-CA-C 108.133 -1.062 . . . . 0.69 108.133 178.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -101.41 143.19 14.8 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.43 -0.794 . . . . 0.91 110.228 -178.862 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 23.4 tp10 -139.02 143.12 38.31 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 106.765 -1.569 . . . . 1.8 106.765 178.396 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.433 ' O ' ' N ' ' B' ' 9' ' ' VAL . . . 171.68 -173.98 45.07 Favored Glycine 0 N--CA 1.491 2.301 0 C-N-CA 119.131 -1.509 . . . . 0.49 109.654 -178.667 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -64.96 -32.68 53.92 Favored 'Trans proline' 0 C--N 1.316 -1.183 0 C-N-CA 121.748 1.632 . . . . 0.66 110.317 179.811 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . 0.413 ' O ' ' OH ' ' A' ' 85' ' ' TYR . 58.4 m -137.86 158.89 43.42 Favored 'General case' 0 N--CA 1.5 2.035 0 O-C-N 121.319 -0.863 . . . . 1.55 109.931 -179.323 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 34.5 mttp -76.03 93.14 3.24 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.363 -0.836 . . . . 2.53 109.483 -179.842 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -63.89 136.42 57.36 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.278 -0.888 . . . . 0.82 109.426 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.537 ' C ' HD12 ' A' ' 63' ' ' ILE . 55.1 mm-40 -79.49 172.54 13.65 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.126 -0.984 . . . . 2.3 109.539 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.537 HD12 ' C ' ' A' ' 62' ' ' GLU . 4.4 mp -140.22 151.01 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 N-CA-C 108.325 -0.991 . . . . 1.4 108.325 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -151.04 120.02 6.67 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 120.603 -1.31 . . . . 1.36 109.468 -179.712 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 54.4 p90 -86.19 139.13 31.34 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.276 -0.89 . . . . 1.47 109.764 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.487 ' N ' ' O ' ' A' ' 74' ' ' GLY . 43.7 tt0 -141.22 122.45 14.79 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.395 -0.816 . . . . 2.51 109.149 179.886 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.412 ' OD1' ' N ' ' A' ' 67' ' ' ASP . 15.1 p-10 -81.25 88.18 6.07 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.222 -0.924 . . . . 2.07 109.713 -179.812 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.408 ' C ' ' H ' ' A' ' 70' ' ' ASP . 16.6 mtm180 -98.81 162.4 13.12 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.286 -0.884 . . . . 4.63 108.965 179.606 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.478 ' C ' ' H ' ' A' ' 71' ' ' GLY . 19.5 mttm 60.77 7.09 1.32 Allowed 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.135 -0.978 . . . . 3.49 108.864 -179.884 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.408 ' H ' ' C ' ' A' ' 68' ' ' ARG . 7.5 t70 56.71 4.12 0.15 Allowed 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 119.928 -0.709 . . . . 3.06 110.063 178.514 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . 0.478 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -147.14 -30.73 0.07 OUTLIER Glycine 0 N--CA 1.485 1.933 0 N-CA-C 110.085 -1.206 . . . . 2.16 110.085 -178.522 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.435 ' H ' ' HB2' ' A' ' 69' ' ' LYS . 9.6 t -95.73 129.23 43.01 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.105 -1.233 . . . . 2.2 109.107 179.677 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 10.4 t -78.06 153.12 32.56 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.248 -0.908 . . . . 2.05 109.438 -179.858 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.487 ' O ' ' N ' ' A' ' 66' ' ' GLU . . . -126.45 111.95 1.51 Allowed Glycine 0 N--CA 1.498 2.793 0 N-CA-C 109.352 -1.499 . . . . 1.39 109.352 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 27.4 t -100.52 99.93 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.011 0 O-C-N 121.56 -0.965 . . . . 1.57 109.399 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -84.79 165.3 17.89 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 108.293 -1.003 . . . . 1.85 108.293 179.399 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.405 ' CZ ' ' HB3' ' A' ' 37' ' ' ALA . 12.5 p90 -165.36 169.9 15.24 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.275 -0.891 . . . . 1.54 109.238 -179.329 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.577 ' O ' HG13 ' A' ' 78' ' ' VAL . 5.0 p -142.18 116.32 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.215 0 O-C-N 121.122 -0.986 . . . . 1.9 110.211 179.35 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.511 HG11 HG21 ' A' ' 105' ' ' VAL . 6.5 m -89.97 153.3 3.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.276 -0.89 . . . . 1.27 108.863 179.708 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . 0.407 ' O ' ' OE2' ' A' ' 81' ' ' GLU . 20.6 tt0 -94.57 -48.02 6.28 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.994 -1.066 . . . . 2.48 110.84 -178.892 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.407 ' OE2' ' O ' ' A' ' 80' ' ' GLN . 78.3 mm-40 -153.88 150.05 22.09 Favored Pre-proline 0 N--CA 1.503 2.198 0 O-C-N 120.613 -1.304 . . . . 1.92 111.218 -178.455 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.669 ' HG3' ' N ' ' A' ' 107' ' ' SER . 87.8 Cg_exo -36.76 157.9 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.944 2.429 . . . . 1.3 113.368 178.24 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 150.07 -156.92 26.98 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 108.893 -1.683 . . . . 1.02 108.893 -179.911 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 37.5 m-20 -116.38 92.4 3.87 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.52 -0.988 . . . . 2.13 109.408 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.53 ' O ' ' N ' ' A' ' 103' ' ' VAL . 2.7 m-85 -78.98 129.76 34.82 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 107.977 -1.12 . . . . 0.92 107.977 179.343 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.37 128.41 56.45 Favored 'General case' 0 N--CA 1.502 2.131 0 N-CA-C 108.675 -0.861 . . . . 1.53 108.675 -178.847 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 6.3 p -126.6 138.53 54.46 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.681 -0.637 . . . . 1.0 109.928 -179.667 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . 0.407 ' O ' ' OG ' ' A' ' 88' ' ' SER . 44.7 p -127.83 96.69 4.58 Favored 'General case' 0 N--CA 1.499 1.987 0 N-CA-C 109.358 -0.608 . . . . 1.59 109.358 179.792 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.421 HD11 ' CD1' ' A' ' 96' ' ' ILE . 1.0 OUTLIER -106.3 134.78 46.91 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 CA-C-O 121.479 0.657 . . . . 1.29 109.938 -179.469 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . 0.464 ' O ' HD12 ' A' ' 51' ' ' LEU . 0.0 OUTLIER -142.97 123.72 14.18 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.454 -0.779 . . . . 1.58 109.073 -179.882 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 57.2 t80 -80.05 101.11 8.51 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.011 -1.056 . . . . 1.34 108.199 178.661 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . 0.411 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 16.8 t-20 69.2 37.68 2.07 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.13 -0.982 . . . . 2.32 109.149 -179.014 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.411 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 1.5 m-20 77.87 14.87 1.57 Allowed 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.836 -0.54 . . . . 1.92 111.928 179.337 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . 0.493 ' O ' ' OE1' ' A' ' 94' ' ' GLU . 0.3 OUTLIER -100.6 99.81 10.44 Favored 'General case' 0 N--CA 1.501 2.106 0 N-CA-C 107.462 -1.31 . . . . 2.25 107.462 177.707 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 29.9 m-70 -70.16 105.12 2.82 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.553 -0.717 . . . . 2.88 109.779 -178.613 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . 0.639 ' O ' ' N ' ' A' ' 98' ' ' ASP . 9.9 pt -51.21 152.9 3.75 Favored Pre-proline 0 N--CA 1.493 1.681 0 N-CA-C 108.587 -0.894 . . . . 2.35 108.587 179.667 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -59.1 61.74 0.06 OUTLIER 'Trans proline' 0 N--CA 1.484 0.945 0 C-N-CA 121.457 1.438 . . . . 2.48 109.582 179.255 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.639 ' N ' ' O ' ' A' ' 96' ' ' ILE . 31.4 m-20 -162.17 -58.42 0.05 OUTLIER 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 108.386 -0.968 . . . . 2.65 108.386 -179.536 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 1.1 t -65.43 141.31 97.98 Favored Pre-proline 0 C--N 1.297 -1.705 0 C-N-CA 119.868 -0.733 . . . . 2.0 110.085 -177.895 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -85.99 114.56 3.03 Favored 'Cis proline' 0 N--CA 1.492 1.396 0 N-CA-C 109.585 -0.967 . . . . 1.79 109.585 -2.103 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 46.4 p90 -110.32 160.27 16.7 Favored 'General case' 0 N--CA 1.517 2.896 0 O-C-N 120.501 -1.375 . . . . 2.19 110.261 178.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.3 p -92.62 148.98 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 CA-C-O 121.517 0.675 . . . . 1.44 110.206 -179.152 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.53 ' N ' ' O ' ' A' ' 85' ' ' TYR . 70.8 t -124.11 85.6 54.62 Favored Pre-proline 0 N--CA 1.498 1.946 0 N-CA-C 107.858 -1.164 . . . . 1.19 107.858 179.511 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -63.45 113.08 1.94 Allowed 'Trans proline' 0 C--N 1.32 -0.968 0 C-N-CA 121.339 1.359 . . . . 1.49 112.021 -177.605 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.511 HG21 HG11 ' A' ' 79' ' ' VAL . 54.1 t -90.22 143.97 10.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 N-CA-C 106.682 -1.599 . . . . 1.35 106.682 177.71 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.686 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -131.78 130.29 41.65 Favored 'General case' 0 N--CA 1.508 2.462 0 O-C-N 121.217 -0.927 . . . . 1.67 111.629 -177.167 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.669 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 60.3 p -95.45 90.61 5.84 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.71 -1.244 . . . . 2.04 107.873 179.36 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . 0.553 HD12 ' N ' ' A' ' 108' ' ' LEU . 9.2 mp 54.83 10.38 0.37 Allowed 'General case' 0 C--N 1.295 -1.774 0 N-CA-C 107.949 -1.13 . . . . 3.2 107.949 -178.434 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.638 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 50.4 p -100.24 -24.97 14.41 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 109.32 -0.622 . . . . 2.09 109.32 179.563 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . 0.686 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 15.9 t70 49.62 15.95 0.17 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.079 -1.013 . . . . 2.85 108.392 -179.604 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.482 ' N ' ' C ' ' A' ' 109' ' ' SER . 13.8 t0 -174.68 -25.07 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.896 -0.503 . . . . 2.46 109.724 -179.48 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.638 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 56.4 93.84 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.704 -1.248 . . . . 2.08 109.126 -179.742 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . 0.409 ' NH1' ' HG2' ' A' ' 113' ' ' ARG . 0.3 OUTLIER -57.18 -170.08 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.266 -0.896 . . . . 5.93 109.54 -179.743 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.45 ' HG3' HH11 ' A' ' 114' ' ' ARG . 7.5 ttm-85 -133.9 1.66 3.32 Favored 'General case' 0 N--CA 1.495 1.807 0 N-CA-C 108.511 -0.922 . . . . 5.61 108.511 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 30.3 mt -127.21 -25.47 3.24 Favored 'General case' 0 N--CA 1.502 2.139 0 N-CA-C 109.081 -0.711 . . . . 4.39 109.081 179.831 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.507 ' C ' ' H ' ' A' ' 118' ' ' THR . 97.9 m -107.88 -79.65 0.58 Allowed 'General case' 0 N--CA 1.497 1.903 0 N-CA-C 107.118 -1.438 . . . . 4.09 107.118 179.197 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.431 ' O ' HG12 ' A' ' 117' ' ' VAL . 50.9 t -61.29 -8.66 2.2 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.63 0 N-CA-C 106.032 -1.84 . . . . 2.9 106.032 176.842 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' THR . . . . . 0.507 ' H ' ' C ' ' A' ' 116' ' ' THR . 3.9 t 36.63 61.97 0.79 Allowed 'General case' 0 N--CA 1.487 1.417 0 CA-C-N 115.193 -0.912 . . . . 3.36 110.704 179.902 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' SER . . . . . 0.415 ' OG ' ' O ' ' A' ' 118' ' ' THR . 1.7 p . . . . . 0 C--N 1.302 -1.476 0 CA-C-O 118.034 -0.984 . . . . 3.39 109.624 179.299 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 67.7 mtm . . . . . 0 N--CA 1.49 1.572 0 N-CA-C 109.564 -0.532 . . . . 8.49 109.564 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -73.04 5.05 3.63 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.264 -0.897 . . . . 5.53 109.232 179.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 3' ' ' SER . . . . . . . . . . . . . 61.6 p -163.77 -168.5 1.64 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.283 -0.886 . . . . 5.43 109.343 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 4' ' ' LYS . . . . . . . . . . . . . 37.5 mmtm 49.96 69.36 2.7 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.205 -0.934 . . . . 6.87 109.535 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 5' ' ' PRO . . . . . . . . . . . . . 2.1 Cg_endo -63.75 -154.33 0.02 OUTLIER 'Trans proline' 0 C--N 1.317 -1.112 0 C-N-CA 121.474 1.45 . . . . 5.16 109.672 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 6' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -131.5 79.64 1.89 Allowed 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.368 -0.833 . . . . 4.78 109.198 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 6.1 ptpp? -158.79 138.46 11.83 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.3 -0.875 . . . . 4.09 109.352 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.609 ' CG ' HH11 ' B' ' 8' ' ' ARG . 0.3 OUTLIER -114.46 -76.32 0.58 Allowed 'General case' 0 N--CA 1.494 1.766 0 N-CA-C 107.833 -1.173 . . . . 3.04 107.833 -179.904 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 9' ' ' VAL . . . . . 0.433 ' N ' ' O ' ' A' ' 57' ' ' GLY . 0.5 OUTLIER -176.23 168.83 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 N-CA-C 107.612 -1.255 . . . . 0.67 107.612 177.936 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 0.422 ' N ' HG13 ' B' ' 9' ' ' VAL . . . -120.81 136.01 55.01 Favored 'General case' 0 N--CA 1.502 2.133 0 CA-C-O 121.487 0.66 . . . . 0.58 110.514 -178.971 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 18.4 m -149.65 138.45 21.0 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.468 -0.77 . . . . 1.19 109.265 179.395 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 27.8 p -145.94 126.08 13.79 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.089 -1.007 . . . . 1.38 109.984 -179.682 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 0.645 HG22 ' N ' ' B' ' 14' ' ' PHE . 6.8 p -167.11 170.81 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 N-CA-C 108.678 -0.86 . . . . 0.42 108.678 179.735 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 14' ' ' PHE . . . . . 0.883 ' O ' HD13 ' B' ' 15' ' ' ILE . 6.4 p90 -177.03 -171.45 0.36 Allowed 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 119.046 -1.061 . . . . 1.79 112.458 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.883 HD13 ' O ' ' B' ' 14' ' ' PHE . 4.0 mm -142.96 172.45 7.77 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 N-CA-C 108.213 -1.032 . . . . 1.25 108.213 179.85 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 16' ' ' THR . . . . . 0.419 ' H ' HG22 ' B' ' 15' ' ' ILE . 0.1 OUTLIER -144.05 144.58 31.7 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 120.89 -1.131 . . . . 1.61 109.567 179.645 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 21.7 mt -97.66 138.26 35.32 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.26 -0.9 . . . . 1.32 109.589 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -166.09 79.65 1.12 Allowed Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.478 -0.764 . . . . 1.45 109.056 -179.776 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -60.07 167.28 7.6 Favored 'Trans proline' 0 CA--C 1.544 1.001 0 C-N-CA 121.241 1.294 . . . . 1.5 109.972 -179.104 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 20' ' ' PRO . . . . . . . . . . . . . 1.1 Cg_endo -58.99 -58.78 0.57 Allowed 'Trans proline' 0 C--N 1.319 -0.996 0 C-N-CA 121.556 1.504 . . . . 2.86 110.281 -179.778 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . 0.432 ' O ' ' O ' ' B' ' 22' ' ' ARG . 25.0 ttm-85 -137.03 161.61 35.59 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.377 -0.827 . . . . 6.12 109.421 -179.533 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 22' ' ' ARG . . . . . 0.432 ' O ' ' O ' ' B' ' 21' ' ' ARG . 51.4 mtp180 -57.16 -163.53 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.379 -0.826 . . . . 6.29 109.461 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . 0.527 ' OD2' ' N ' ' B' ' 24' ' ' VAL . 5.6 p-10 41.58 -136.19 0.24 Allowed 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.667 -0.646 . . . . 5.62 110.059 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . 0.527 ' N ' ' OD2' ' B' ' 23' ' ' ASP . 63.3 t . . . . . 0 N--CA 1.494 1.731 0 CA-C-O 118.009 -0.996 . . . . 6.48 109.361 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.963 0 N-CA-C 119.62 2.608 . . . . 6.64 119.62 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.571 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 14.1 tt -172.08 50.0 0.12 Allowed Pre-proline 0 C--N 1.307 -1.282 0 N-CA-C 107.94 -1.134 . . . . 7.08 107.94 179.594 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.798 ' C ' ' H ' ' A' ' 5' ' ' PHE . 5.2 Cg_endo -57.41 -82.75 0.01 OUTLIER 'Trans proline' 0 C--N 1.318 -1.072 0 N-CA-C 108.512 -1.38 . . . . 5.5 108.512 179.632 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.516 ' C ' ' H ' ' A' ' 6' ' ' PHE . 11.9 tt0 73.52 -19.25 0.34 Allowed 'General case' 0 N--CA 1.496 1.839 0 N-CA-C 104.395 -2.446 . . . . 6.75 104.395 -176.029 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . 0.798 ' H ' ' C ' ' A' ' 3' ' ' PRO . 2.5 m-85 -88.68 17.5 5.46 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 104.055 -2.572 . . . . 6.07 104.055 176.777 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.526 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 38.6 p90 45.35 -153.24 0.04 OUTLIER 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 114.389 -1.278 . . . . 4.72 109.428 -177.616 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.505 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 2.1 tm0? 83.14 -9.76 1.05 Allowed 'General case' 0 N--CA 1.489 1.506 0 N-CA-C 105.007 -2.22 . . . . 4.4 105.007 -177.222 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.493 ' H ' ' C ' ' A' ' 6' ' ' PHE . 87.6 t80 -149.95 -37.57 0.15 Allowed 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 107.955 -1.128 . . . . 5.15 107.955 178.296 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.464 HG22 ' O ' ' A' ' 9' ' ' THR . 61.1 m -94.07 4.2 54.23 Favored 'General case' 0 C--N 1.297 -1.713 0 N-CA-C 105.922 -1.881 . . . . 5.13 105.922 177.349 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.553 HG13 ' N ' ' A' ' 11' ' ' GLY . 11.6 p -45.38 -46.2 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.324 0 CA-C-N 115.529 -0.759 . . . . 4.38 109.196 -179.507 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.576 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 132.07 -81.64 0.32 Allowed Glycine 0 N--CA 1.501 2.967 0 N-CA-C 108.64 -1.784 . . . . 4.22 108.64 179.413 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.498 ' O ' ' N ' ' A' ' 14' ' ' GLY . 13.6 Cg_endo -68.36 38.4 0.2 Allowed 'Trans proline' 0 C--N 1.319 -1.019 0 C-N-CA 121.562 1.508 . . . . 3.85 108.567 178.147 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.714 ' N ' HD23 ' A' ' 13' ' ' LEU . 0.2 OUTLIER 32.55 36.0 0.01 OUTLIER 'General case' 0 N--CA 1.505 2.323 0 CA-C-O 121.972 0.891 . . . . 3.67 109.781 -178.7 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.552 ' C ' ' H ' ' A' ' 16' ' ' GLY . . . 69.94 -39.37 0.42 Allowed Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.382 -1.487 . . . . 2.97 109.382 -179.806 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.51 ' H ' ' C ' ' A' ' 13' ' ' LEU . 21.6 tt0 52.2 6.58 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.478 -1.013 . . . . 2.97 109.386 -179.544 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.552 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 59.34 130.69 0.01 OUTLIER Glycine 0 N--CA 1.489 2.232 0 O-C-N 121.329 -0.857 . . . . 2.44 111.095 178.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.562 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 68.73 -53.63 0.51 Allowed Glycine 0 N--CA 1.492 2.405 0 O-C-N 121.499 -1.0 . . . . 1.81 110.668 178.733 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.67 ' HB2' ' OE1' ' A' ' 94' ' ' GLU . . . -42.66 -16.3 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.882 -0.775 . . . . 2.21 110.673 -178.598 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . 0.562 ' N ' ' O ' ' A' ' 17' ' ' GLY . 10.8 t-80 -93.82 -43.51 8.56 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.174 -0.954 . . . . 2.87 110.879 -178.409 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -91.29 -35.99 14.14 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 120.966 -1.084 . . . . 2.02 111.022 -178.486 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.609 ' O ' HG13 ' A' ' 21' ' ' VAL . 6.6 p -46.66 111.28 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 120.989 -1.069 . . . . 2.07 110.061 -178.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.414 ' HG2' ' HE1' ' A' ' 42' ' ' TRP . 19.5 tpt180 -118.43 124.84 48.63 Favored 'General case' 0 N--CA 1.497 1.878 0 N-CA-C 108.89 -0.781 . . . . 3.5 108.89 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -128.05 116.48 20.08 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.489 -0.757 . . . . 1.83 109.26 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -148.2 128.78 2.95 Favored Glycine 0 N--CA 1.495 2.571 0 N-CA-C 109.403 -1.479 . . . . 1.9 109.403 -179.879 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.11 169.19 40.38 Favored Glycine 0 N--CA 1.489 2.206 0 C-N-CA 119.574 -1.298 . . . . 1.85 110.062 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 43.3 p -74.06 -11.94 60.47 Favored 'General case' 0 N--CA 1.486 1.34 0 O-C-N 121.349 -1.089 . . . . 2.31 109.771 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -67.37 -17.06 68.03 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 108.205 -1.958 . . . . 1.64 108.205 179.46 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 28.2 mt -89.86 -11.65 41.32 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 108.467 -0.938 . . . . 1.83 108.467 179.437 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 19.9 mm-40 -82.68 -60.35 2.21 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.596 -0.69 . . . . 2.34 109.858 -179.47 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 26.6 ptt180 -172.96 178.79 2.45 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.032 -1.043 . . . . 3.77 109.992 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -148.85 178.0 26.71 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 108.446 -1.861 . . . . 1.57 108.446 179.765 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 27.3 t -134.8 148.33 29.31 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.015 0 O-C-N 121.205 -1.174 . . . . 1.83 110.145 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.641 ' HB2' ' HD3' ' A' ' 82' ' ' PRO . . . -41.56 113.95 0.47 Allowed 'General case' 0 N--CA 1.495 1.792 0 CA-C-O 121.567 0.699 . . . . 1.64 112.388 -179.155 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 59.87 46.44 94.1 Favored Glycine 0 N--CA 1.492 2.424 0 O-C-N 121.658 -0.651 . . . . 1.73 111.687 177.113 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 13.9 t -127.36 126.03 24.06 Favored Pre-proline 0 N--CA 1.499 2.009 0 N-CA-C 108.019 -1.104 . . . . 2.19 108.019 178.827 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -55.12 121.38 9.81 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 120.487 0.791 . . . . 1.96 110.441 -179.362 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -119.92 151.5 38.81 Favored 'General case' 0 N--CA 1.499 1.992 0 N-CA-C 108.235 -1.024 . . . . 1.69 108.235 179.319 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 8.6 pt-20 -160.16 166.24 30.1 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.727 -1.233 . . . . 2.23 111.334 -179.445 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.55 ' CD1' ' N ' ' A' ' 39' ' ' PHE . 0.9 OUTLIER -140.48 -178.08 5.34 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 107.046 -1.464 . . . . 1.54 107.046 177.428 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 15.5 m -128.31 134.83 48.98 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.678 -0.639 . . . . 2.37 110.084 -179.161 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.532 ' O ' ' N ' ' A' ' 73' ' ' CYS . 73.0 mt -124.61 145.79 31.26 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 N-CA-C 107.683 -1.228 . . . . 1.65 107.683 179.13 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.522 ' CD2' ' OG1' ' A' ' 43' ' ' THR . 14.5 p-90 -154.82 -176.99 6.2 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.678 -1.264 . . . . 3.68 110.445 -179.653 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.522 ' OG1' ' CD2' ' A' ' 42' ' ' TRP . 0.2 OUTLIER 81.85 109.9 0.07 Allowed 'General case' 0 N--CA 1.495 1.806 0 N-CA-C 109.356 -0.609 . . . . 2.89 109.356 -179.883 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' ARG . . . . . 0.59 ' CG ' HH11 ' A' ' 44' ' ' ARG . 0.0 OUTLIER -132.16 56.94 1.8 Allowed 'General case' 0 N--CA 1.499 1.976 0 N-CA-C 108.982 -0.747 . . . . 4.63 108.982 -179.864 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 27.3 tt0 -90.3 -15.91 30.29 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.264 -0.897 . . . . 2.89 109.976 -179.583 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.39 -66.88 0.5 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.04 -1.038 . . . . 1.74 109.179 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 138.21 -162.83 25.71 Favored Glycine 0 N--CA 1.495 2.633 0 N-CA-C 109.672 -1.371 . . . . 1.6 109.672 179.812 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.86 147.37 12.14 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.278 -1.131 . . . . 1.4 109.33 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.414 ' HA2' HD22 ' A' ' 92' ' ' ASN . . . -173.19 -168.96 35.1 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.538 -1.425 . . . . 1.04 109.538 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -137.49 114.29 1.09 Allowed Glycine 0 N--CA 1.496 2.663 0 N-CA-C 109.114 -1.594 . . . . 1.06 109.114 179.848 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.431 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 10.1 tp -93.74 97.58 10.53 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.251 -1.146 . . . . 1.1 108.582 179.79 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 4.2 m -83.78 142.16 30.87 Favored 'General case' 0 N--CA 1.494 1.738 0 N-CA-C 108.485 -0.932 . . . . 1.56 108.485 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.555 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 61.0 mt -133.65 123.22 45.29 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.083 -1.011 . . . . 0.65 109.674 -179.688 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -116.07 111.71 20.69 Favored 'General case' 0 N--CA 1.497 1.89 0 N-CA-C 108.325 -0.991 . . . . 0.69 108.325 179.236 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 1.1 t -102.94 149.14 7.32 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.977 0 O-C-N 121.449 -0.782 . . . . 0.91 110.052 -179.277 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.42 ' OE2' ' O ' ' B' ' 9' ' ' VAL . 50.9 tp10 -140.65 138.39 34.3 Favored 'General case' 0 N--CA 1.486 1.374 0 N-CA-C 108.441 -0.948 . . . . 1.8 108.441 178.285 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 174.3 -177.51 46.47 Favored Glycine 0 N--CA 1.487 2.075 0 N-CA-C 108.719 -1.752 . . . . 0.49 108.719 -179.607 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_exo -62.74 -18.54 64.81 Favored 'Trans proline' 0 C--N 1.313 -1.32 0 C-N-CA 121.802 1.668 . . . . 0.66 110.957 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . 0.402 ' O ' ' OH ' ' A' ' 85' ' ' TYR . 1.1 p -149.77 166.36 29.68 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.349 -0.844 . . . . 1.55 110.411 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 46.1 mttt -89.92 125.74 35.47 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.607 -0.683 . . . . 2.53 109.502 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -81.8 142.86 32.21 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.278 -0.889 . . . . 0.82 109.325 179.766 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 10.0 tp10 -86.61 90.55 8.29 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.24 -0.913 . . . . 2.3 109.766 -179.808 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 6.3 mm -58.5 155.62 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 121.574 -0.704 . . . . 1.4 109.133 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.552 ' HB3' ' HB3' ' A' ' 76' ' ' SER . . . -149.68 114.43 5.33 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.804 -1.185 . . . . 1.36 109.503 179.577 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.463 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 16.5 p90 -88.85 119.11 29.05 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.164 -0.96 . . . . 1.47 109.041 179.476 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -141.29 106.91 5.08 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.252 -0.905 . . . . 2.51 109.902 -179.633 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 11.2 p-10 -79.94 127.13 31.9 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.247 -0.908 . . . . 2.07 108.9 179.354 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 84.1 mtm180 -110.96 -34.11 6.31 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.407 -0.808 . . . . 4.63 109.574 -179.607 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.537 ' C ' ' H ' ' A' ' 71' ' ' GLY . 28.5 mmtp -117.41 3.49 12.51 Favored 'General case' 0 N--CA 1.496 1.843 0 N-CA-C 108.631 -0.878 . . . . 3.49 108.631 179.8 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.437 ' CB ' ' O ' ' A' ' 69' ' ' LYS . 1.3 t70 72.99 -34.64 0.3 Allowed 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 108.684 -0.858 . . . . 3.06 108.684 -179.2 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . 0.537 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -93.76 -35.17 6.23 Favored Glycine 0 N--CA 1.489 2.171 0 N-CA-C 109.443 -1.463 . . . . 2.16 109.443 -179.864 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 74.8 m -95.76 107.56 19.8 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.317 -1.108 . . . . 2.2 109.395 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' CYS . . . . . 0.532 ' N ' ' O ' ' A' ' 41' ' ' ILE . 28.2 m -80.18 119.89 23.55 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.225 -0.922 . . . . 2.05 109.295 179.801 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -98.26 123.58 7.9 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.42 -1.472 . . . . 1.39 109.42 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 40.2 t -114.85 102.68 14.19 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.089 0 O-C-N 121.632 -0.923 . . . . 1.57 109.05 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.552 ' HB3' ' HB3' ' A' ' 64' ' ' ALA . 3.3 t -94.01 130.4 40.16 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.34 -0.85 . . . . 1.85 110.136 -179.598 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 8.5 p90 -126.46 129.85 49.51 Favored 'General case' 0 N--CA 1.492 1.646 0 N-CA-C 108.158 -1.052 . . . . 1.54 108.158 179.455 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 11.3 t -100.56 111.29 29.78 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.181 -0.949 . . . . 1.9 109.453 -179.155 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.542 HG11 HG21 ' A' ' 105' ' ' VAL . 13.2 m -77.94 157.71 5.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 O-C-N 121.287 -0.883 . . . . 1.27 109.329 -179.866 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 30.1 tt0 -101.87 -47.92 4.43 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.173 -0.955 . . . . 2.48 110.303 -179.499 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.404 ' O ' ' O ' ' A' ' 82' ' ' PRO . 75.5 mm-40 -149.98 150.03 29.01 Favored Pre-proline 0 N--CA 1.502 2.143 0 O-C-N 120.829 -1.169 . . . . 1.92 111.253 -178.623 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.641 ' HD3' ' HB2' ' A' ' 33' ' ' ALA . 77.8 Cg_exo -37.43 165.49 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.679 0 C-N-CA 122.825 2.35 . . . . 1.3 113.296 178.551 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 142.37 -178.89 20.61 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 108.989 -1.644 . . . . 1.02 108.989 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . 0.552 ' O ' ' NH1' ' B' ' 8' ' ' ARG . 29.6 m-20 -98.69 89.74 4.47 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 107.835 -1.172 . . . . 2.13 107.835 179.224 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.402 ' OH ' ' O ' ' A' ' 59' ' ' SER . 2.9 m-85 -74.7 133.67 42.04 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 108.347 -0.983 . . . . 0.92 108.347 -179.366 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . 0.488 ' OE2' ' NH1' ' B' ' 8' ' ' ARG . 0.0 OUTLIER -117.65 125.05 50.04 Favored 'General case' 0 N--CA 1.498 1.949 0 N-CA-C 108.305 -0.998 . . . . 1.53 108.305 -179.098 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.556 ' CG1' ' CE2' ' A' ' 101' ' ' PHE . 7.5 p -122.94 137.38 56.6 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.986 0 O-C-N 121.624 -0.673 . . . . 1.0 109.401 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 99.8 p -131.55 113.87 14.18 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.596 -0.69 . . . . 1.59 109.797 -179.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 2.9 pt -111.83 143.13 22.24 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.735 -0.603 . . . . 1.29 109.917 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -140.4 123.52 16.67 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.236 -0.915 . . . . 1.58 109.273 178.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 25.1 t80 -78.67 92.99 4.82 Favored 'General case' 0 N--CA 1.494 1.744 0 C-N-CA 119.026 -1.069 . . . . 1.34 108.325 179.449 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . 0.486 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 5.8 t-20 65.82 37.62 5.52 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 108.236 -1.024 . . . . 2.32 108.236 -178.809 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.486 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 2.2 m-20 88.76 10.97 0.09 Allowed 'General case' 0 N--CA 1.503 2.192 0 CA-C-N 116.605 -0.27 . . . . 1.92 111.381 179.658 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . 0.711 ' OE2' HD13 ' A' ' 96' ' ' ILE . 0.0 OUTLIER -86.33 86.97 7.35 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 106.091 -1.818 . . . . 2.25 106.091 177.687 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . 0.445 ' O ' ' C ' ' A' ' 96' ' ' ILE . 2.3 t-80 -68.12 94.36 0.5 Allowed 'General case' 0 C--N 1.296 -1.735 0 O-C-N 120.4 -1.437 . . . . 2.88 110.948 -177.845 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . 0.711 HD13 ' OE2' ' A' ' 94' ' ' GLU . 4.7 mm -38.38 135.81 0.88 Allowed Pre-proline 0 N--CA 1.504 2.271 0 O-C-N 121.497 -0.752 . . . . 2.35 109.281 179.084 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -54.52 -7.36 0.8 Allowed 'Trans proline' 0 C--N 1.325 -0.7 0 N-CA-C 109.239 -1.1 . . . . 2.48 109.239 179.131 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.48 ' H ' ' C ' ' A' ' 96' ' ' ILE . 55.0 m-20 -86.87 -47.32 9.12 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.481 -0.762 . . . . 2.65 109.729 179.765 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 6.4 p -54.71 136.32 64.16 Favored Pre-proline 0 C--N 1.298 -1.661 0 O-C-N 121.191 -0.943 . . . . 2.0 109.835 -177.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -89.3 113.81 2.34 Favored 'Cis proline' 0 N--CA 1.494 1.554 0 CA-C-N 118.935 0.655 . . . . 1.79 110.44 -1.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . 0.609 ' CD1' ' N ' ' A' ' 101' ' ' PHE . 0.1 OUTLIER -81.42 158.58 24.55 Favored 'General case' 0 N--CA 1.509 2.522 0 O-C-N 119.674 -1.891 . . . . 2.19 108.785 178.476 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 10.4 p -97.93 138.04 23.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.404 -0.81 . . . . 1.44 109.388 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 60.6 t -121.03 85.53 40.95 Favored Pre-proline 0 N--CA 1.499 2.019 0 N-CA-C 108.623 -0.88 . . . . 1.19 108.623 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -65.63 111.32 1.85 Allowed 'Trans proline' 0 C--N 1.321 -0.899 0 C-N-CA 121.443 1.428 . . . . 1.49 111.467 -178.336 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.542 HG21 HG11 ' A' ' 79' ' ' VAL . 54.6 t -95.49 146.32 7.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.775 0 N-CA-C 107.1 -1.444 . . . . 1.35 107.1 178.34 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.656 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -138.71 135.65 34.98 Favored 'General case' 0 N--CA 1.509 2.523 0 O-C-N 121.092 -1.005 . . . . 1.67 111.799 -177.541 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.542 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 9.9 m -86.71 58.73 5.23 Favored 'General case' 0 N--CA 1.494 1.752 0 N-CA-C 107.42 -1.326 . . . . 2.04 107.42 178.808 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . 0.508 ' CB ' ' O ' ' A' ' 107' ' ' SER . 3.4 tp 83.8 -11.35 0.89 Allowed 'General case' 0 N--CA 1.495 1.814 0 N-CA-C 106.972 -1.492 . . . . 3.2 106.972 -177.843 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.681 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 24.1 t -71.18 -19.28 62.42 Favored 'General case' 0 C--N 1.305 -1.333 0 N-CA-C 108.878 -0.786 . . . . 2.09 108.878 178.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . 0.656 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 1.1 p30 48.44 15.06 0.07 Allowed 'General case' 0 N--CA 1.496 1.833 0 N-CA-C 108.285 -1.006 . . . . 2.85 108.285 -178.822 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.515 ' N ' ' C ' ' A' ' 109' ' ' SER . 29.9 m-20 -166.64 -34.16 0.03 OUTLIER 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 108.173 -1.047 . . . . 2.46 108.173 -179.759 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.681 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 39.16 83.41 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.604 -0.685 . . . . 2.08 110.585 179.765 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . 0.429 ' O ' ' N ' ' A' ' 118' ' ' THR . 82.5 mtt180 -76.77 138.77 40.1 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.164 -0.96 . . . . 5.93 109.222 179.875 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 57.8 ttt180 -90.18 5.64 46.09 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.438 -0.789 . . . . 5.61 109.121 -179.794 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 2.2 mp -125.84 -25.49 3.62 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.577 -0.702 . . . . 4.39 110.061 -179.401 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.511 ' C ' ' H ' ' A' ' 118' ' ' THR . 61.5 m -110.75 -77.83 0.59 Allowed 'General case' 0 N--CA 1.499 1.997 0 N-CA-C 107.252 -1.388 . . . . 4.09 107.252 179.177 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.439 ' O ' HG12 ' A' ' 117' ' ' VAL . 42.5 t -62.32 -7.61 2.32 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.656 0 N-CA-C 105.994 -1.854 . . . . 2.9 105.994 176.72 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' THR . . . . . 0.511 ' H ' ' C ' ' A' ' 116' ' ' THR . 4.2 t 36.19 59.39 0.93 Allowed 'General case' 0 N--CA 1.487 1.391 0 CA-C-N 115.12 -0.945 . . . . 3.36 110.687 179.743 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' SER . . . . . 0.452 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.5 p . . . . . 0 C--N 1.304 -1.398 0 CA-C-O 118.021 -0.99 . . . . 3.39 109.673 179.43 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 11.8 ptt? . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 109.468 -0.567 . . . . 8.49 109.468 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -172.74 145.79 1.54 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.216 -0.927 . . . . 5.53 109.405 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 3' ' ' SER . . . . . . . . . . . . . 60.7 p 49.79 75.29 0.17 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.257 -0.902 . . . . 5.43 109.361 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 4' ' ' LYS . . . . . 0.429 ' O ' ' O ' ' B' ' 5' ' ' PRO . 43.5 mttm -63.83 148.17 95.07 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.254 -0.904 . . . . 6.87 108.941 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 5' ' ' PRO . . . . . 0.429 ' O ' ' O ' ' B' ' 4' ' ' LYS . 1.9 Cg_endo -57.2 -158.02 0.01 OUTLIER 'Trans proline' 0 C--N 1.324 -0.727 0 C-N-CA 120.914 1.076 . . . . 5.16 109.766 179.544 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 6' ' ' GLU . . . . . . . . . . . . . 15.5 tt0 67.55 179.69 0.23 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.244 -0.91 . . . . 4.78 108.973 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 53.53 62.82 2.45 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.218 -0.926 . . . . 4.09 109.592 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.552 ' NH1' ' O ' ' A' ' 84' ' ' ASP . 68.3 mtt180 -98.82 176.63 5.54 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 108.429 -0.952 . . . . 3.04 108.429 179.606 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 9' ' ' VAL . . . . . 0.42 ' O ' ' OE2' ' A' ' 56' ' ' GLU . 21.0 t -53.99 158.71 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 N-CA-C 108.162 -1.051 . . . . 0.67 108.162 178.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -117.83 141.72 48.11 Favored 'General case' 0 N--CA 1.502 2.166 0 O-C-N 121.489 -0.757 . . . . 0.58 109.981 -179.337 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 18.4 t -143.0 137.68 29.49 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.368 -0.832 . . . . 1.19 109.319 179.581 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 8.7 t -141.13 128.31 20.9 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.308 -0.87 . . . . 1.38 109.584 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 0.622 HG22 ' N ' ' B' ' 14' ' ' PHE . 6.1 p -169.44 167.89 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.484 -0.76 . . . . 0.42 109.205 -179.874 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 14' ' ' PHE . . . . . 0.622 ' N ' HG22 ' B' ' 13' ' ' VAL . 6.7 p90 -177.61 -167.67 0.16 Allowed 'General case' 0 N--CA 1.49 1.552 0 CA-C-O 122.202 1.001 . . . . 1.79 112.537 179.65 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.4 pt -150.71 172.07 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.31 0 N-CA-C 108.322 -0.992 . . . . 1.25 108.322 179.818 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 31.7 p -144.96 147.12 32.33 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 120.865 -1.147 . . . . 1.61 109.9 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.4 mt -97.58 132.63 43.08 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.349 -0.845 . . . . 1.32 109.178 179.715 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -150.91 68.63 8.23 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.227 -0.921 . . . . 1.45 109.652 -179.862 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . 0.427 ' O ' ' O ' ' B' ' 20' ' ' PRO . 6.3 Cg_exo -60.45 170.4 4.29 Favored 'Trans proline' 0 C--N 1.317 -1.096 0 C-N-CA 121.3 1.334 . . . . 1.5 109.307 -179.911 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 20' ' ' PRO . . . . . 0.427 ' O ' ' O ' ' B' ' 19' ' ' PRO . 4.7 Cg_exo -56.6 -158.05 0.01 OUTLIER 'Trans proline' 0 C--N 1.318 -1.066 0 C-N-CA 121.259 1.306 . . . . 2.86 109.862 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -144.0 -163.53 1.69 Allowed 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.188 -0.945 . . . . 6.12 109.312 -179.934 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 22' ' ' ARG . . . . . . . . . . . . . 8.4 ptm180 -152.24 121.58 6.78 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.204 -0.935 . . . . 6.29 109.368 -179.866 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . 0.513 ' N ' ' OD1' ' B' ' 23' ' ' ASP . 8.5 p-10 -175.22 122.87 0.22 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.206 -0.934 . . . . 5.62 109.455 -179.895 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 15.0 p . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 117.959 -1.019 . . . . 6.48 109.443 179.978 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.531 4.997 0 N-CA-C 119.799 2.68 . . . . 6.64 119.799 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.562 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 11.4 tt -172.88 50.77 0.11 Allowed Pre-proline 0 C--N 1.308 -1.231 0 N-CA-C 107.784 -1.191 . . . . 7.08 107.784 179.53 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.803 ' C ' ' H ' ' A' ' 5' ' ' PHE . 6.5 Cg_endo -58.76 -82.79 0.01 OUTLIER 'Trans proline' 0 C--N 1.318 -1.042 0 N-CA-C 108.73 -1.296 . . . . 5.5 108.73 179.829 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.506 ' C ' ' H ' ' A' ' 6' ' ' PHE . 11.6 tt0 73.83 -19.13 0.36 Allowed 'General case' 0 N--CA 1.495 1.796 0 N-CA-C 104.373 -2.454 . . . . 6.75 104.373 -175.819 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . 0.803 ' H ' ' C ' ' A' ' 3' ' ' PRO . 6.4 m-85 -89.68 20.21 4.18 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 103.996 -2.594 . . . . 6.07 103.996 176.732 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.549 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 37.2 p90 46.33 -153.69 0.06 Allowed 'General case' 0 C--N 1.307 -1.275 0 CA-C-N 114.314 -1.312 . . . . 4.72 109.394 -177.466 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.537 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 22.0 tt0 86.8 -10.27 0.63 Allowed 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 105.282 -2.118 . . . . 4.4 105.282 -177.318 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.412 ' H ' ' C ' ' A' ' 6' ' ' PHE . 35.5 t80 -151.77 -37.25 0.12 Allowed 'General case' 0 C--N 1.305 -1.347 0 N-CA-C 107.955 -1.128 . . . . 5.15 107.955 178.485 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.415 HG22 ' O ' ' A' ' 9' ' ' THR . 39.9 m -93.58 3.74 55.04 Favored 'General case' 0 C--N 1.296 -1.72 0 N-CA-C 105.96 -1.867 . . . . 5.13 105.96 177.363 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.519 HG13 ' N ' ' A' ' 11' ' ' GLY . 9.8 p -44.35 -42.91 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 CA-C-N 115.457 -0.792 . . . . 4.38 109.867 -179.474 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.519 ' N ' HG13 ' A' ' 10' ' ' VAL . . . -114.64 -172.06 17.34 Favored Glycine 0 N--CA 1.494 2.54 0 N-CA-C 109.705 -1.358 . . . . 4.22 109.705 -179.039 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.48 ' C ' ' HG ' ' A' ' 13' ' ' LEU . 10.1 Cg_endo -69.46 -0.16 6.26 Favored 'Trans proline' 0 C--N 1.316 -1.171 0 C-N-CA 121.847 1.698 . . . . 3.85 109.514 -179.702 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.521 HD12 ' H ' ' A' ' 15' ' ' GLU . 0.3 OUTLIER 168.54 24.74 0.0 OUTLIER 'General case' 0 C--N 1.278 -2.523 0 CA-C-N 114.453 -1.249 . . . . 3.67 108.256 -177.698 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.458 ' C ' ' N ' ' A' ' 16' ' ' GLY . . . 77.45 -42.19 1.93 Allowed Glycine 0 N--CA 1.49 2.277 0 N-CA-C 108.732 -1.747 . . . . 2.97 108.732 -179.654 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.521 ' H ' HD12 ' A' ' 13' ' ' LEU . 25.3 tt0 53.24 13.89 0.46 Allowed 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 108.137 -1.06 . . . . 2.97 108.137 -179.685 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.458 ' N ' ' C ' ' A' ' 14' ' ' GLY . . . 73.67 -164.09 54.77 Favored Glycine 0 N--CA 1.484 1.899 0 N-CA-C 109.447 -1.461 . . . . 2.44 109.447 -179.892 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.534 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -69.58 -5.93 52.67 Favored Glycine 0 N--CA 1.487 2.083 0 N-CA-C 110.054 -1.219 . . . . 1.81 110.054 -179.664 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -48.3 -13.39 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.675 0 O-C-N 120.663 -1.492 . . . . 2.21 109.228 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . 0.534 ' N ' ' O ' ' A' ' 17' ' ' GLY . 1.6 t60 -95.48 -45.17 7.2 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.384 -0.823 . . . . 2.87 109.181 179.38 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.52 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.0 OUTLIER -79.83 -26.08 40.59 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.112 -0.993 . . . . 2.02 109.332 179.894 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.417 HG11 HD11 ' A' ' 96' ' ' ILE . 69.2 t -62.98 112.66 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.115 -0.991 . . . . 2.07 109.051 179.497 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 12.9 tpp180 -100.93 137.52 39.19 Favored 'General case' 0 C--N 1.301 -1.535 0 CA-C-O 121.475 0.655 . . . . 3.5 109.263 -179.72 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -148.37 113.28 5.45 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.604 -0.887 . . . . 1.83 108.604 179.415 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -150.76 133.23 4.21 Favored Glycine 0 N--CA 1.496 2.68 0 N-CA-C 109.74 -1.344 . . . . 1.9 109.74 -179.616 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.46 175.36 47.37 Favored Glycine 0 N--CA 1.487 2.067 0 C-N-CA 119.628 -1.272 . . . . 1.85 110.268 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 18.0 m -77.44 -17.95 57.62 Favored 'General case' 0 N--CA 1.486 1.363 0 O-C-N 121.457 -1.025 . . . . 2.31 109.77 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -68.34 -22.75 74.87 Favored Glycine 0 N--CA 1.487 2.036 0 N-CA-C 108.761 -1.736 . . . . 1.64 108.761 179.757 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.5 mt -84.39 -7.15 59.39 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.623 -0.927 . . . . 1.83 108.963 179.853 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 27.0 mm-40 -88.45 -56.69 3.21 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.47 -0.769 . . . . 2.34 109.993 -179.341 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 26.1 ptt180 -175.05 -176.74 0.99 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.126 -0.984 . . . . 3.77 109.666 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -149.27 177.47 27.45 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 108.917 -1.673 . . . . 1.57 108.917 179.857 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.465 ' H ' ' CG1' ' A' ' 35' ' ' VAL . 25.8 t -134.91 148.03 29.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.425 -1.044 . . . . 1.83 109.803 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.464 ' HB2' ' HD3' ' A' ' 82' ' ' PRO . . . -37.84 106.65 0.05 Allowed 'General case' 0 N--CA 1.496 1.866 0 CA-C-O 121.341 0.591 . . . . 1.64 112.085 -179.142 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 62.49 57.51 16.23 Favored Glycine 0 N--CA 1.49 2.268 0 O-C-N 121.249 -0.907 . . . . 1.73 111.541 177.558 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.465 ' CG1' ' H ' ' A' ' 32' ' ' VAL . 2.8 p -126.09 129.2 24.31 Favored Pre-proline 0 N--CA 1.502 2.167 0 O-C-N 121.311 -1.111 . . . . 2.19 109.133 178.84 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -63.5 125.64 16.0 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 N-CA-C 108.24 -1.485 . . . . 1.96 108.24 178.473 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.598 ' HB3' ' CZ ' ' A' ' 77' ' ' TYR . . . -134.47 160.91 36.55 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.212 -0.93 . . . . 1.69 109.294 -179.367 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -162.36 167.22 24.08 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 121.161 -0.962 . . . . 2.23 110.758 -179.634 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.527 ' CD1' ' N ' ' A' ' 39' ' ' PHE . 0.7 OUTLIER -141.61 -179.98 6.48 Favored 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 107.059 -1.46 . . . . 1.54 107.059 177.627 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 6.1 m -124.12 138.05 54.48 Favored 'General case' 0 N--CA 1.498 1.941 0 CA-C-O 121.405 0.622 . . . . 2.37 110.178 -178.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.479 ' O ' ' N ' ' A' ' 73' ' ' CYS . 74.3 mt -136.7 119.38 20.99 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.556 -0.715 . . . . 1.65 109.269 179.645 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 6.2 p-90 -119.52 137.35 53.87 Favored 'General case' 0 N--CA 1.503 2.2 0 N-CA-C 108.905 -0.776 . . . . 3.68 108.905 179.201 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.52 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.1 OUTLIER -148.83 137.77 21.46 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.199 -0.938 . . . . 2.89 109.694 -179.581 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' ARG . . . . . . . . . . . . . 59.7 ttt180 -171.87 66.3 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.344 -0.848 . . . . 4.63 109.743 179.665 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.485 ' H ' ' HZ3' ' A' ' 20' ' ' LYS . 6.4 tp10 -157.84 -53.81 0.07 Allowed 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.078 -1.014 . . . . 2.89 109.43 179.553 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -58.46 -58.75 7.16 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.2 -0.937 . . . . 1.74 109.148 179.769 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 138.62 176.49 14.62 Favored Glycine 0 N--CA 1.494 2.502 0 N-CA-C 108.928 -1.669 . . . . 1.6 108.928 -179.938 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.39 163.51 0.6 Allowed 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.088 -1.243 . . . . 1.4 109.386 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 179.8 -148.78 8.2 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.868 -1.293 . . . . 1.04 109.868 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -144.13 126.98 2.85 Favored Glycine 0 N--CA 1.495 2.606 0 N-CA-C 109.618 -1.393 . . . . 1.06 109.618 -179.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.423 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 10.8 tp -102.93 102.15 12.21 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.399 -1.059 . . . . 1.1 109.027 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 3.2 t -85.97 142.11 29.03 Favored 'General case' 0 N--CA 1.494 1.767 0 N-CA-C 108.221 -1.029 . . . . 1.56 108.221 179.295 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.555 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 89.5 mt -133.54 120.14 36.85 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.987 0 O-C-N 121.087 -1.008 . . . . 0.65 109.896 -179.709 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.435 ' HB3' ' OG ' ' A' ' 88' ' ' SER . . . -109.44 106.86 16.8 Favored 'General case' 0 N--CA 1.496 1.874 0 N-CA-C 108.772 -0.825 . . . . 0.69 108.772 179.376 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.43 HG23 ' OG ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -97.84 143.19 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 O-C-N 121.245 -0.91 . . . . 0.91 109.25 -179.844 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 12.5 tt0 -141.61 142.87 33.44 Favored 'General case' 0 N--CA 1.491 1.624 0 N-CA-C 107.882 -1.155 . . . . 1.8 107.882 179.336 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 166.04 -172.88 41.54 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.502 -1.439 . . . . 0.49 109.502 -179.239 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -64.21 -30.18 64.54 Favored 'Trans proline' 0 C--N 1.318 -1.056 0 C-N-CA 121.993 1.795 . . . . 0.66 111.412 -179.218 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . 0.403 ' O ' ' OH ' ' A' ' 85' ' ' TYR . 6.0 m -141.4 152.26 44.16 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.075 -1.016 . . . . 1.55 109.827 -179.801 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 16.1 ptmt -74.56 107.68 6.84 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.261 -0.899 . . . . 2.53 109.024 179.829 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -72.67 136.43 45.63 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.014 -1.054 . . . . 0.82 109.401 -179.602 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -71.92 173.35 8.45 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.099 -1.0 . . . . 2.3 109.236 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 42.9 mt -142.52 152.52 17.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 N-CA-C 107.799 -1.185 . . . . 1.4 107.799 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.55 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -150.13 114.64 5.23 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 120.653 -1.279 . . . . 1.36 110.202 -179.45 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 45.1 p90 -86.76 129.07 35.02 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.248 -0.907 . . . . 1.47 109.157 179.393 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 54.0 tt0 -141.26 123.78 15.91 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.238 -0.914 . . . . 2.51 109.602 -179.756 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.415 ' OD1' ' N ' ' A' ' 67' ' ' ASP . 2.3 p-10 -84.76 119.24 25.06 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.35 -0.844 . . . . 2.07 109.371 179.833 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.597 ' CG ' HH11 ' A' ' 68' ' ' ARG . 0.3 OUTLIER -96.06 -39.99 9.46 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.221 -0.924 . . . . 4.63 109.638 -179.926 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.528 ' C ' ' H ' ' A' ' 71' ' ' GLY . 20.4 mtpp -122.35 13.11 10.25 Favored 'General case' 0 N--CA 1.496 1.826 0 N-CA-C 108.663 -0.866 . . . . 3.49 108.663 179.853 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.473 ' CB ' ' O ' ' A' ' 69' ' ' LYS . 4.4 t0 74.04 -29.52 0.2 Allowed 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 108.476 -0.935 . . . . 3.06 108.476 -178.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . 0.528 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -103.63 -24.92 7.53 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.613 -1.395 . . . . 2.16 109.613 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 94.0 p -95.81 115.66 27.76 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.17 -1.194 . . . . 2.2 109.466 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' CYS . . . . . 0.479 ' N ' ' O ' ' A' ' 41' ' ' ILE . 32.3 m -85.31 117.27 24.14 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.232 -0.917 . . . . 2.05 109.633 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -99.95 119.8 6.64 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 109.294 -1.522 . . . . 1.39 109.294 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 17.9 t -109.74 103.09 14.94 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.153 0 O-C-N 121.524 -0.986 . . . . 1.57 109.818 -179.756 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.55 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.0 OUTLIER -91.76 142.94 27.04 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.326 -0.859 . . . . 1.85 108.851 179.687 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.598 ' CZ ' ' HB3' ' A' ' 37' ' ' ALA . 11.6 p90 -142.82 171.92 13.4 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.281 -0.887 . . . . 1.54 109.189 -179.421 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.556 ' O ' HG13 ' A' ' 78' ' ' VAL . 4.4 p -142.2 119.98 7.92 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.211 0 O-C-N 121.105 -0.997 . . . . 1.9 110.288 179.529 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.515 HG11 HG21 ' A' ' 105' ' ' VAL . 11.5 m -87.15 153.97 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.309 -0.87 . . . . 1.27 108.677 179.251 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 38.3 tt0 -96.6 -47.0 6.1 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.008 -1.057 . . . . 2.48 110.657 -179.156 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 80.2 mm-40 -152.16 150.48 25.66 Favored Pre-proline 0 N--CA 1.502 2.129 0 O-C-N 120.646 -1.284 . . . . 1.92 111.056 -178.625 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.576 ' HG3' ' N ' ' A' ' 107' ' ' SER . 75.7 Cg_exo -37.68 164.72 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.67 0 C-N-CA 122.8 2.333 . . . . 1.3 113.099 178.398 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 144.24 -163.88 27.71 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.122 -1.591 . . . . 1.02 109.122 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 20.0 m-20 -108.97 91.13 3.52 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.639 -0.918 . . . . 2.13 108.797 179.652 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.473 ' O ' ' N ' ' A' ' 103' ' ' VAL . 3.1 m-85 -78.81 130.69 36.0 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 108.091 -1.077 . . . . 0.92 108.091 179.896 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . 0.409 ' OE2' ' NH2' ' B' ' 8' ' ' ARG . 0.0 OUTLIER -115.62 129.23 56.43 Favored 'General case' 0 N--CA 1.501 2.1 0 N-CA-C 108.89 -0.781 . . . . 1.53 108.89 -179.041 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 9.9 p -124.12 140.19 48.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.712 -0.617 . . . . 1.0 109.361 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . 0.435 ' OG ' ' HB3' ' A' ' 54' ' ' ALA . 22.2 p -131.98 101.9 5.61 Favored 'General case' 0 N--CA 1.498 1.944 0 N-CA-C 109.184 -0.673 . . . . 1.59 109.184 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.418 ' H ' ' HB3' ' A' ' 99' ' ' SER . 1.5 pt -111.84 136.11 49.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 CA-C-O 121.599 0.714 . . . . 1.29 110.479 -179.084 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . 0.459 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.2 OUTLIER -140.95 122.77 15.35 Favored 'General case' 0 N--CA 1.486 1.329 0 N-CA-C 108.001 -1.111 . . . . 1.58 108.001 179.449 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.413 ' O ' ' OE1' ' A' ' 94' ' ' GLU . 84.7 t80 -82.15 100.29 9.73 Favored 'General case' 0 C--N 1.3 -1.569 0 C-N-CA 118.347 -1.341 . . . . 1.34 107.927 179.041 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . 0.438 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 0.3 OUTLIER 71.42 36.48 1.31 Allowed 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.25 -0.906 . . . . 2.32 109.158 -178.665 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.438 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 1.8 m-20 79.6 12.9 1.11 Allowed 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.703 -0.623 . . . . 1.92 111.903 179.232 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . 0.483 ' OE2' ' CA ' ' A' ' 17' ' ' GLY . 5.2 pt-20 -99.98 96.59 7.64 Favored 'General case' 0 N--CA 1.498 1.97 0 N-CA-C 106.958 -1.497 . . . . 2.25 106.958 177.617 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . 0.513 ' O ' ' ND1' ' A' ' 95' ' ' HIS . 0.0 OUTLIER -70.44 111.37 5.94 Favored 'General case' 0 N--CA 1.488 1.452 0 CA-C-O 121.595 0.712 . . . . 2.88 110.884 -177.577 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . 0.479 ' O ' ' N ' ' A' ' 98' ' ' ASP . 32.4 mt -57.66 137.39 82.54 Favored Pre-proline 0 C--N 1.3 -1.557 0 N-CA-C 107.826 -1.176 . . . . 2.35 107.826 178.651 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_exo -42.91 -21.75 0.23 Allowed 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 120.823 1.015 . . . . 2.48 110.184 -179.694 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.479 ' N ' ' O ' ' A' ' 96' ' ' ILE . 87.2 m-20 -67.58 -68.08 0.41 Allowed 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 108.478 -0.934 . . . . 2.65 108.478 178.266 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.418 ' HB3' ' H ' ' A' ' 89' ' ' ILE . 0.3 OUTLIER -60.65 143.65 90.3 Favored Pre-proline 0 C--N 1.295 -1.762 0 O-C-N 121.595 -0.69 . . . . 2.0 109.901 -178.389 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -84.41 112.62 2.6 Favored 'Cis proline' 0 N--CA 1.491 1.337 0 N-CA-C 109.456 -1.017 . . . . 1.79 109.456 -2.318 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 53.6 p90 -112.11 161.96 15.95 Favored 'General case' 0 N--CA 1.517 2.887 0 O-C-N 120.543 -1.348 . . . . 2.19 110.196 179.107 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.414 HG22 ' N ' ' A' ' 103' ' ' VAL . 7.2 p -93.66 154.42 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.528 -0.732 . . . . 1.44 110.928 -178.421 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.473 ' N ' ' O ' ' A' ' 85' ' ' TYR . 64.4 t -128.65 86.96 56.23 Favored Pre-proline 0 N--CA 1.498 1.934 0 N-CA-C 108.233 -1.025 . . . . 1.19 108.233 179.41 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 4.1 Cg_exo -63.54 113.12 1.97 Allowed 'Trans proline' 0 C--N 1.319 -1.008 0 C-N-CA 121.333 1.355 . . . . 1.49 111.963 -178.081 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.515 HG21 HG11 ' A' ' 79' ' ' VAL . 53.4 t -96.17 143.76 11.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 N-CA-C 106.713 -1.588 . . . . 1.35 106.713 177.862 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.649 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -136.65 133.63 36.43 Favored 'General case' 0 N--CA 1.51 2.539 0 O-C-N 121.14 -0.975 . . . . 1.67 111.863 -177.3 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.576 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 38.7 p -85.27 63.73 8.26 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.796 -1.19 . . . . 2.04 107.819 179.12 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . 0.485 ' CB ' ' O ' ' A' ' 107' ' ' SER . 2.8 tp 79.9 -14.89 0.8 Allowed 'General case' 0 C--N 1.298 -1.648 0 N-CA-C 106.927 -1.509 . . . . 3.2 106.927 -177.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.676 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 21.7 t -66.89 -23.46 66.0 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 108.762 -0.829 . . . . 2.09 108.762 178.769 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . 0.649 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 42.9 m-20 52.71 12.04 0.23 Allowed 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 108.079 -1.082 . . . . 2.85 108.079 -179.46 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.503 ' H ' ' C ' ' A' ' 109' ' ' SER . 4.5 m-20 -167.04 -30.43 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 108.663 -0.865 . . . . 2.46 108.663 -179.671 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.676 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 54.89 81.09 0.11 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.005 -1.059 . . . . 2.08 109.415 -179.898 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . 0.517 HH11 ' HG2' ' A' ' 113' ' ' ARG . 5.1 mtt-85 -65.17 -167.94 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.218 -0.927 . . . . 5.93 109.23 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 33.8 ttm180 -139.62 4.39 2.14 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.4 -0.813 . . . . 5.61 108.89 -179.597 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 32.3 mt -126.56 -27.57 3.12 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.607 -0.683 . . . . 4.39 109.216 179.799 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.541 ' C ' ' H ' ' A' ' 118' ' ' THR . 58.8 m -106.85 -75.62 0.63 Allowed 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 107.347 -1.353 . . . . 4.09 107.347 179.152 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.51 ' O ' HG12 ' A' ' 117' ' ' VAL . 47.9 t -65.11 -3.64 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 N-CA-C 106.201 -1.777 . . . . 2.9 106.201 176.981 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' THR . . . . . 0.677 ' O ' HG23 ' A' ' 118' ' ' THR . 6.7 t 29.54 69.39 0.08 Allowed 'General case' 0 N--CA 1.489 1.489 0 CA-C-O 122.277 1.037 . . . . 3.36 111.064 -179.698 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' SER . . . . . 0.405 ' O ' ' O ' ' A' ' 118' ' ' THR . 0.5 OUTLIER . . . . . 0 C--N 1.302 -1.462 0 CA-C-O 117.996 -1.002 . . . . 3.39 109.502 179.564 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 19.2 ttt . . . . . 0 N--CA 1.489 1.51 0 CA-C-O 121.244 0.545 . . . . 8.49 109.606 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -158.27 143.22 16.39 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.224 -0.923 . . . . 5.53 109.625 -179.821 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 3' ' ' SER . . . . . . . . . . . . . 9.5 p -66.19 81.25 0.08 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.268 -0.895 . . . . 5.43 109.211 179.84 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 4' ' ' LYS . . . . . . . . . . . . . 14.0 pttt -75.45 154.26 85.83 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.263 -0.898 . . . . 6.87 109.051 -179.745 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 5' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_exo -54.6 -175.38 0.03 OUTLIER 'Trans proline' 0 C--N 1.323 -0.8 0 C-N-CA 121.111 1.207 . . . . 5.16 109.745 179.386 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 6' ' ' GLU . . . . . . . . . . . . . 30.7 tt0 -151.34 129.56 11.95 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.275 -0.89 . . . . 4.78 109.355 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 9.2 ptmm? -57.87 139.93 53.08 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.292 -0.88 . . . . 4.09 109.425 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.409 ' NH2' ' OE2' ' A' ' 86' ' ' GLU . 18.2 mtm-85 -96.43 167.59 11.07 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 108.129 -1.063 . . . . 3.04 108.129 179.547 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 9' ' ' VAL . . . . . . . . . . . . . 20.4 t -52.96 159.54 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 120.916 -1.115 . . . . 0.67 108.21 179.617 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -120.64 149.11 42.99 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.404 -0.81 . . . . 0.58 110.422 -178.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 11' ' ' SER . . . . . 0.43 ' OG ' HG23 ' A' ' 55' ' ' VAL . 7.4 t -143.2 142.69 31.5 Favored 'General case' 0 N--CA 1.495 1.785 0 N-CA-C 108.814 -0.81 . . . . 1.19 108.814 179.365 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 23.6 p -145.38 127.92 16.05 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.987 -1.07 . . . . 1.38 110.121 -179.639 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 0.655 HG22 ' N ' ' B' ' 14' ' ' PHE . 7.2 p -172.44 171.46 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 N-CA-C 108.826 -0.805 . . . . 0.42 108.826 179.69 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 14' ' ' PHE . . . . . 0.655 ' N ' HG22 ' B' ' 13' ' ' VAL . 6.8 p90 -177.48 -167.95 0.17 Allowed 'General case' 0 N--CA 1.489 1.522 0 CA-C-O 122.234 1.016 . . . . 1.79 112.282 179.793 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.8 pt -148.95 172.64 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.29 0 N-CA-C 107.897 -1.149 . . . . 1.25 107.897 179.709 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 2.4 t -146.6 148.44 32.12 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 120.756 -1.215 . . . . 1.61 110.195 -179.842 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.2 mt -101.17 127.28 47.8 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.51 -0.744 . . . . 1.32 109.146 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -156.96 74.54 4.47 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.317 -0.864 . . . . 1.45 109.224 -179.685 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -62.44 166.93 12.19 Favored 'Trans proline' 0 C--N 1.318 -1.049 0 C-N-CA 121.269 1.313 . . . . 1.5 109.747 -179.264 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 20' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -58.46 150.21 69.78 Favored 'Trans proline' 0 C--N 1.318 -1.053 0 C-N-CA 121.517 1.478 . . . . 2.86 109.917 179.834 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . 0.417 ' HG2' HH11 ' B' ' 21' ' ' ARG . 0.3 OUTLIER -82.21 84.88 6.93 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.27 -0.894 . . . . 6.12 108.693 179.782 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 22' ' ' ARG . . . . . 0.417 HH11 ' CG ' ' B' ' 22' ' ' ARG . 0.5 OUTLIER -46.88 -51.89 15.67 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.302 -0.874 . . . . 6.29 109.707 -179.859 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 48.4 t0 52.61 -115.91 0.98 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.213 -0.929 . . . . 5.62 109.471 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 35.9 m . . . . . 0 N--CA 1.49 1.552 0 CA-C-O 118.025 -0.988 . . . . 6.48 109.435 179.993 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.595 ' C ' HD12 ' A' ' 2' ' ' ILE . . . . . . . . 1 N--CA 1.53 4.928 0 N-CA-C 119.763 2.665 . . . . 6.64 119.763 . . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.679 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 1.5 mp -149.45 41.33 0.23 Allowed Pre-proline 0 C--N 1.311 -1.105 0 N-CA-C 107.751 -1.203 . . . . 7.08 107.751 178.382 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.847 ' C ' ' H ' ' A' ' 5' ' ' PHE . 1.3 Cg_endo -54.63 -79.54 0.02 OUTLIER 'Trans proline' 0 C--N 1.32 -0.956 0 N-CA-C 108.449 -1.404 . . . . 5.5 108.449 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.527 ' C ' ' H ' ' A' ' 6' ' ' PHE . 6.6 tt0 73.56 -20.65 0.29 Allowed 'General case' 0 N--CA 1.496 1.832 0 N-CA-C 104.379 -2.452 . . . . 6.75 104.379 -176.106 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . 0.847 ' H ' ' C ' ' A' ' 3' ' ' PRO . 5.7 m-85 -87.54 17.66 4.44 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 104.298 -2.482 . . . . 6.07 104.298 176.718 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.534 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 38.7 p90 45.6 -153.15 0.05 OUTLIER 'General case' 0 C--N 1.308 -1.218 0 CA-C-N 114.513 -1.221 . . . . 4.72 109.478 -177.684 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.443 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 0.1 OUTLIER 82.97 -9.8 1.07 Allowed 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 104.973 -2.232 . . . . 4.4 104.973 -177.221 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.496 ' H ' ' C ' ' A' ' 6' ' ' PHE . 68.8 t80 -150.24 -37.59 0.15 Allowed 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 107.858 -1.164 . . . . 5.15 107.858 178.226 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.402 HG22 ' O ' ' A' ' 9' ' ' THR . 38.2 m -93.63 3.26 55.78 Favored 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 105.731 -1.951 . . . . 5.13 105.731 177.256 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.556 HG13 ' N ' ' A' ' 11' ' ' GLY . 13.0 p -46.44 -45.34 6.57 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.31 0 CA-C-N 115.508 -0.769 . . . . 4.38 109.32 -179.555 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.654 ' O ' HD23 ' A' ' 13' ' ' LEU . . . 135.7 -84.65 0.26 Allowed Glycine 0 N--CA 1.497 2.746 0 N-CA-C 108.92 -1.672 . . . . 4.22 108.92 179.616 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.431 ' O ' ' N ' ' A' ' 14' ' ' GLY . 13.3 Cg_endo -69.05 35.8 0.2 Allowed 'Trans proline' 0 C--N 1.321 -0.883 0 C-N-CA 121.587 1.525 . . . . 3.85 109.178 178.538 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.886 ' N ' HD23 ' A' ' 13' ' ' LEU . 0.0 OUTLIER 42.36 27.48 0.08 Allowed 'General case' 0 N--CA 1.501 2.109 0 N-CA-C 108.596 -0.89 . . . . 3.67 108.596 -178.731 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.536 ' C ' ' H ' ' A' ' 16' ' ' GLY . . . 71.95 -42.6 0.76 Allowed Glycine 0 N--CA 1.488 2.157 0 N-CA-C 108.622 -1.791 . . . . 2.97 108.622 -179.386 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.596 ' HB3' ' HB3' ' A' ' 18' ' ' ALA . 18.6 tp10 52.2 7.49 0.06 Allowed 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.579 -0.954 . . . . 2.97 109.237 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.536 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 55.99 118.29 0.01 OUTLIER Glycine 0 N--CA 1.489 2.217 0 O-C-N 121.3 -0.875 . . . . 2.44 111.605 178.899 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.523 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 74.05 -56.06 2.27 Favored Glycine 0 N--CA 1.493 2.451 0 N-CA-C 110.487 -1.045 . . . . 1.81 110.487 178.614 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.871 ' HB2' ' OE1' ' A' ' 94' ' ' GLU . . . -49.82 -9.22 0.04 OUTLIER 'General case' 0 C--N 1.294 -1.828 0 O-C-N 121.243 -1.151 . . . . 2.21 109.6 -179.624 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . 0.523 ' N ' ' O ' ' A' ' 17' ' ' GLY . 15.2 t-80 -94.91 -8.9 35.79 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.085 -1.009 . . . . 2.87 110.475 -179.456 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.502 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.0 OUTLIER -134.24 1.79 3.24 Favored 'General case' 0 N--CA 1.502 2.151 0 O-C-N 121.078 -1.014 . . . . 2.02 110.2 -179.685 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 68.7 t -88.07 113.43 25.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 120.92 -1.113 . . . . 2.07 109.637 179.767 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 6.2 tpt180 -97.8 132.9 42.99 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.577 -0.702 . . . . 3.5 109.126 179.808 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -139.28 113.92 9.18 Favored 'General case' 0 N--CA 1.494 1.751 0 N-CA-C 108.582 -0.896 . . . . 1.83 108.582 179.771 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -156.64 129.22 2.37 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.849 -1.3 . . . . 1.9 109.849 -179.448 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.94 -179.82 48.73 Favored Glycine 0 N--CA 1.488 2.127 0 C-N-CA 119.512 -1.328 . . . . 1.85 110.052 179.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 10.9 p -80.61 -15.96 55.29 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.397 -1.061 . . . . 2.31 109.451 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -76.89 -8.42 86.64 Favored Glycine 0 N--CA 1.487 2.074 0 N-CA-C 109.532 -1.427 . . . . 1.64 109.532 -179.733 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.48 HD21 ' CD2' ' A' ' 39' ' ' PHE . 28.5 mt -100.26 -0.67 38.12 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.373 -1.075 . . . . 1.83 109.076 179.692 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -102.18 -44.56 5.4 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.519 -0.738 . . . . 2.34 109.565 -179.681 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 18.1 ptt180 -176.81 172.58 2.05 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.006 -1.059 . . . . 3.77 110.119 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -143.45 174.72 23.84 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 107.842 -2.103 . . . . 1.57 107.842 179.272 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 35.2 t -134.05 149.79 30.7 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.092 0 O-C-N 121.1 -1.235 . . . . 1.83 110.375 -179.842 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.544 ' HB2' ' HD3' ' A' ' 82' ' ' PRO . . . -41.47 114.17 0.48 Allowed 'General case' 0 N--CA 1.498 1.933 0 CA-C-O 121.804 0.812 . . . . 1.64 112.593 -179.128 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 57.18 47.3 88.74 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 111.552 -0.619 . . . . 1.73 111.552 176.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 25.5 t -127.23 113.53 21.54 Favored Pre-proline 0 N--CA 1.498 1.966 0 O-C-N 121.458 -1.024 . . . . 2.19 108.756 179.116 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -59.93 126.51 20.57 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 N-CA-C 109.944 -0.829 . . . . 1.96 109.944 -179.756 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.409 ' HB3' ' CZ ' ' A' ' 77' ' ' TYR . . . -127.58 174.56 8.96 Favored 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 108.182 -1.044 . . . . 1.69 108.182 179.597 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -163.09 171.28 16.63 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.838 -1.164 . . . . 2.23 110.961 -179.789 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.63 ' CE2' HD11 ' A' ' 41' ' ' ILE . 5.8 p90 -155.9 167.75 29.4 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 107.707 -1.22 . . . . 1.54 107.707 178.568 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 14.6 m -101.67 150.14 23.42 Favored 'General case' 0 N--CA 1.495 1.821 0 CA-C-O 121.803 0.811 . . . . 2.37 111.147 -178.1 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.657 HD12 HG21 ' A' ' 75' ' ' VAL . 11.8 mt -141.12 88.55 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 N-CA-C 108.436 -0.95 . . . . 1.65 108.436 178.774 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.459 ' HE1' ' CG ' ' A' ' 44' ' ' ARG . 5.6 t90 -90.77 132.99 35.52 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.105 -0.997 . . . . 3.68 108.788 -179.804 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.502 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.8 OUTLIER -160.94 128.53 4.28 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.22 -0.925 . . . . 2.89 109.949 -179.436 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' ARG . . . . . 0.459 ' CG ' ' HE1' ' A' ' 42' ' ' TRP . 1.8 ptp180 -178.39 77.27 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.278 -0.889 . . . . 4.63 109.612 179.6 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.469 ' H ' ' HZ3' ' A' ' 20' ' ' LYS . 26.0 tt0 -158.6 -52.32 0.06 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.187 -0.946 . . . . 2.89 109.498 179.796 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -60.79 -49.99 75.24 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.04 -1.038 . . . . 1.74 109.008 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 148.85 160.92 9.36 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.448 -1.461 . . . . 1.6 109.448 179.807 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.79 161.23 1.18 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.196 -1.179 . . . . 1.4 109.386 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -174.42 -128.88 1.12 Allowed Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.827 -1.309 . . . . 1.04 109.827 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -157.69 126.22 1.69 Allowed Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.58 -1.408 . . . . 1.06 109.58 -179.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 11.7 tp -97.97 100.53 11.87 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.294 -1.121 . . . . 1.1 109.078 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . 0.403 ' HA ' ' CD2' ' B' ' 14' ' ' PHE . 2.0 t -88.36 142.72 27.5 Favored 'General case' 0 C--O 1.211 -0.947 0 N-CA-C 108.667 -0.864 . . . . 1.56 108.667 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.522 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 93.5 mt -134.08 106.97 9.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 O-C-N 121.025 -1.047 . . . . 0.65 109.764 -179.568 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -96.34 106.06 18.23 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.315 -0.995 . . . . 0.69 108.315 179.183 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.429 HG23 ' CB ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -94.52 144.57 9.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.421 -0.799 . . . . 0.91 109.676 -179.445 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 16.6 tt0 -141.1 145.16 35.44 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 107.529 -1.286 . . . . 1.8 107.529 178.738 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.428 ' O ' ' O ' ' B' ' 9' ' ' VAL . . . 163.14 -171.08 38.81 Favored Glycine 0 N--CA 1.489 2.196 0 C-N-CA 119.554 -1.308 . . . . 0.49 109.854 -179.065 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -62.68 -29.85 77.96 Favored 'Trans proline' 0 C--N 1.318 -1.063 0 C-N-CA 122.224 1.949 . . . . 0.66 112.386 -179.289 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 8.7 t -142.36 160.0 41.12 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 120.891 -1.131 . . . . 1.55 110.138 -179.643 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 80.5 mttt -78.33 109.53 12.55 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.498 -0.751 . . . . 2.53 109.204 179.796 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -76.46 142.37 41.01 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.258 -0.902 . . . . 0.82 109.588 -179.829 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.847 ' C ' HD12 ' A' ' 63' ' ' ILE . 20.6 tt0 -81.39 172.62 13.33 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.319 -0.863 . . . . 2.3 108.78 179.778 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.847 HD12 ' C ' ' A' ' 62' ' ' GLU . 3.2 mp -140.17 154.4 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 N-CA-C 108.309 -0.997 . . . . 1.4 108.309 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.55 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -151.07 114.88 4.95 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.758 -1.214 . . . . 1.36 109.538 -179.845 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.528 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 44.0 p90 -93.55 120.21 33.55 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.19 -0.944 . . . . 1.47 109.469 179.724 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 54.2 tt0 -141.51 103.22 4.35 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.234 -0.916 . . . . 2.51 109.611 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.431 ' OD1' ' N ' ' A' ' 67' ' ' ASP . 20.6 p-10 -85.39 102.61 13.57 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.238 -0.914 . . . . 2.07 109.149 179.696 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 2.5 ptp180 -101.46 5.96 42.21 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.335 -0.853 . . . . 4.63 109.537 -179.725 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.489 ' HB2' ' H ' ' A' ' 72' ' ' SER . 64.5 mmtt -118.25 -3.24 11.04 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.42 -0.8 . . . . 3.49 109.095 179.581 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 4.7 t70 68.56 3.3 3.77 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.351 -0.843 . . . . 3.06 109.406 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -150.61 -34.34 0.04 OUTLIER Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.919 -1.272 . . . . 2.16 109.919 -178.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.489 ' H ' ' HB2' ' A' ' 69' ' ' LYS . 5.8 m -95.39 125.36 39.95 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.235 -1.156 . . . . 2.2 108.85 179.58 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 15.1 t -88.02 126.63 35.18 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.151 -0.968 . . . . 2.05 109.773 -179.521 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -105.13 118.34 5.84 Favored Glycine 0 N--CA 1.498 2.831 0 N-CA-C 109.576 -1.41 . . . . 1.39 109.576 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.657 HG21 HD12 ' A' ' 41' ' ' ILE . 21.9 t -105.88 106.08 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.141 0 O-C-N 121.476 -1.014 . . . . 1.57 109.423 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.55 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.3 OUTLIER -96.17 139.21 32.66 Favored 'General case' 0 N--CA 1.493 1.676 0 N-CA-C 108.988 -0.745 . . . . 1.85 108.988 179.828 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.409 ' CZ ' ' HB3' ' A' ' 37' ' ' ALA . 41.9 p90 -138.07 173.3 11.77 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.294 -0.879 . . . . 1.54 109.262 -179.636 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.552 ' O ' HG13 ' A' ' 78' ' ' VAL . 8.9 p -138.69 120.01 16.53 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.246 0 O-C-N 121.372 -0.83 . . . . 1.9 109.969 179.56 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.441 HG22 ' H ' ' A' ' 79' ' ' VAL . 5.7 m -89.57 163.08 2.43 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.387 -0.82 . . . . 1.27 108.984 179.72 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 7.0 tp-100 -104.4 -47.6 4.06 Favored 'General case' 0 N--CA 1.501 2.077 0 O-C-N 121.199 -0.938 . . . . 2.48 111.103 -178.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -156.52 153.27 24.49 Favored Pre-proline 0 N--CA 1.503 2.194 0 O-C-N 120.641 -1.287 . . . . 1.92 111.106 -178.799 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.641 ' HG3' ' N ' ' A' ' 107' ' ' SER . 73.0 Cg_exo -37.63 158.68 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 123.267 2.644 . . . . 1.3 113.609 179.268 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 148.15 -163.45 28.9 Favored Glycine 0 N--CA 1.493 2.441 0 N-CA-C 109.662 -1.375 . . . . 1.02 109.662 179.606 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 46.6 m-20 -110.66 88.63 2.82 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.615 -0.932 . . . . 2.13 108.984 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.508 ' O ' ' N ' ' A' ' 103' ' ' VAL . 2.8 m-85 -76.16 129.69 37.14 Favored 'General case' 0 C--N 1.303 -1.414 0 N-CA-C 107.998 -1.112 . . . . 0.92 107.998 179.708 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -109.23 128.01 54.71 Favored 'General case' 0 N--CA 1.5 2.069 0 N-CA-C 108.35 -0.981 . . . . 1.53 108.35 -179.52 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 9.9 p -123.91 133.56 68.93 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.713 -0.617 . . . . 1.0 109.767 -179.295 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 6.6 m -123.84 95.05 4.42 Favored 'General case' 0 N--CA 1.497 1.886 0 CA-C-O 121.393 0.616 . . . . 1.59 109.54 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.415 ' H ' ' HB3' ' A' ' 99' ' ' SER . 1.2 pt -101.26 134.48 41.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.643 -0.661 . . . . 1.29 109.797 -179.775 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . 0.468 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.1 OUTLIER -140.32 121.98 15.28 Favored 'General case' 0 N--CA 1.485 1.296 0 N-CA-C 108.712 -0.847 . . . . 1.58 108.712 179.746 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 79.9 t80 -81.09 100.03 8.81 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 107.665 -1.235 . . . . 1.34 107.665 178.514 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . 0.438 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 26.8 t30 69.81 36.42 2.07 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.448 -0.782 . . . . 2.32 109.362 -178.809 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.438 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 0.7 OUTLIER 79.92 14.32 0.92 Allowed 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.688 -0.633 . . . . 1.92 111.554 179.42 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . 0.871 ' OE1' ' HB2' ' A' ' 18' ' ' ALA . 0.5 OUTLIER -100.94 95.53 6.66 Favored 'General case' 0 N--CA 1.499 1.98 0 N-CA-C 107.239 -1.393 . . . . 2.25 107.239 177.892 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . 0.53 ' CD2' ' O ' ' A' ' 95' ' ' HIS . 0.4 OUTLIER -66.58 110.55 3.22 Favored 'General case' 0 N--CA 1.488 1.466 0 CA-C-O 121.697 0.76 . . . . 2.88 111.177 -177.773 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . 0.536 ' O ' ' N ' ' A' ' 98' ' ' ASP . 5.5 mm -50.61 137.22 24.34 Favored Pre-proline 0 N--CA 1.492 1.671 0 N-CA-C 107.621 -1.251 . . . . 2.35 107.621 178.576 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -44.39 -16.75 0.12 Allowed 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 120.68 0.92 . . . . 2.48 109.844 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 96' ' ' ILE . 42.9 m-20 -76.92 -66.56 0.8 Allowed 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 108.517 -0.92 . . . . 2.65 108.517 178.277 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.415 ' HB3' ' H ' ' A' ' 89' ' ' ILE . 0.2 OUTLIER -57.34 144.02 72.09 Favored Pre-proline 0 C--N 1.297 -1.702 0 O-C-N 121.622 -0.674 . . . . 2.0 109.801 -178.106 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -83.82 110.36 1.79 Allowed 'Cis proline' 0 N--CA 1.491 1.339 0 N-CA-C 109.71 -0.919 . . . . 1.79 109.71 -2.129 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 47.3 p90 -108.87 166.98 10.41 Favored 'General case' 0 N--CA 1.515 2.794 0 O-C-N 120.51 -1.369 . . . . 2.19 110.035 179.109 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.3 p -94.39 153.13 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.518 -0.739 . . . . 1.44 110.758 -178.777 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.508 ' N ' ' O ' ' A' ' 85' ' ' TYR . 70.3 t -127.62 86.21 58.96 Favored Pre-proline 0 N--CA 1.499 1.986 0 N-CA-C 107.863 -1.162 . . . . 1.19 107.863 179.395 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -62.4 113.45 1.93 Allowed 'Trans proline' 0 C--N 1.318 -1.036 0 C-N-CA 121.288 1.325 . . . . 1.49 111.979 -177.82 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 42.7 t -90.4 141.68 14.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 N-CA-C 106.88 -1.526 . . . . 1.35 106.88 177.766 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.726 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -121.65 127.67 51.06 Favored 'General case' 0 N--CA 1.505 2.322 0 CA-C-O 121.664 0.745 . . . . 1.67 111.607 -177.033 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.641 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 7.8 t -88.69 77.76 7.84 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 120.365 -1.459 . . . . 2.04 107.484 178.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . 0.442 ' CB ' ' O ' ' A' ' 107' ' ' SER . 0.9 OUTLIER 72.66 -7.81 1.35 Allowed 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 107.307 -1.368 . . . . 3.2 107.307 -178.288 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.503 ' H ' ' C ' ' A' ' 107' ' ' SER . 3.0 m -78.11 -21.59 50.18 Favored 'General case' 0 N--CA 1.486 1.335 0 N-CA-C 108.602 -0.888 . . . . 2.09 108.602 178.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . 0.726 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 1.4 m-20 50.93 10.42 0.07 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.359 -0.838 . . . . 2.85 109.23 179.353 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.489 ' N ' ' C ' ' A' ' 109' ' ' SER . 0.8 OUTLIER -177.99 -21.47 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.482 -0.761 . . . . 2.46 110.438 -179.85 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.491 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 51.56 75.23 0.21 Allowed 'General case' 0 N--CA 1.496 1.871 0 O-C-N 120.373 -1.454 . . . . 2.08 108.631 -179.311 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . 0.433 ' O ' ' O ' ' A' ' 112' ' ' ALA . 1.0 OUTLIER -53.26 -170.72 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.374 -0.829 . . . . 5.93 110.04 -178.909 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.525 HH11 ' HG2' ' A' ' 114' ' ' ARG . 2.4 ttt-85 -132.36 2.52 3.87 Favored 'General case' 0 N--CA 1.492 1.659 0 N-CA-C 107.86 -1.163 . . . . 5.61 107.86 179.514 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 34.8 mt -128.49 -27.71 2.61 Favored 'General case' 0 N--CA 1.501 2.082 0 N-CA-C 109.188 -0.671 . . . . 4.39 109.188 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.504 ' C ' ' H ' ' A' ' 118' ' ' THR . 1.1 p -103.27 -80.37 0.52 Allowed 'General case' 0 N--CA 1.492 1.636 0 N-CA-C 106.859 -1.534 . . . . 4.09 106.859 179.082 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.44 ' O ' HG12 ' A' ' 117' ' ' VAL . 56.0 t -61.19 -8.81 2.19 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.718 0 N-CA-C 106.156 -1.794 . . . . 2.9 106.156 176.858 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' THR . . . . . 0.504 ' H ' ' C ' ' A' ' 116' ' ' THR . 4.5 t 36.54 61.01 0.87 Allowed 'General case' 0 N--CA 1.487 1.387 0 CA-C-O 122.019 0.914 . . . . 3.36 110.775 179.656 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' SER . . . . . 0.443 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.6 p . . . . . 0 C--N 1.303 -1.436 0 CA-C-O 117.954 -1.022 . . . . 3.39 109.577 179.349 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 21.7 mmt . . . . . 0 N--CA 1.49 1.57 0 N-CA-C 109.523 -0.547 . . . . 8.49 109.523 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -58.37 120.96 9.69 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.315 -0.866 . . . . 5.53 109.52 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 3' ' ' SER . . . . . . . . . . . . . 51.3 m -160.59 -52.17 0.05 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.233 -0.917 . . . . 5.43 109.412 179.858 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 4' ' ' LYS . . . . . . . . . . . . . 16.7 pttm -173.83 66.71 0.32 Allowed Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.21 -0.931 . . . . 6.87 109.756 179.885 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 5' ' ' PRO . . . . . . . . . . . . . 2.3 Cg_endo -61.99 100.12 0.2 Allowed 'Trans proline' 0 C--N 1.318 -1.041 0 C-N-CA 121.315 1.344 . . . . 5.16 109.658 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 6' ' ' GLU . . . . . 0.443 ' O ' ' C ' ' B' ' 7' ' ' LYS . 19.1 mt-10 -84.31 -153.46 0.15 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.307 -0.871 . . . . 4.78 109.935 -179.685 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 7' ' ' LYS . . . . . 0.443 ' C ' ' O ' ' B' ' 6' ' ' GLU . 13.4 pttm 31.86 79.36 0.03 OUTLIER 'General case' 0 N--CA 1.501 2.087 0 CA-C-O 121.268 0.556 . . . . 4.09 111.433 179.836 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.531 ' CG ' HH11 ' B' ' 8' ' ' ARG . 2.2 mtt-85 -86.78 157.95 19.49 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.003 -1.11 . . . . 3.04 108.003 178.897 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 9' ' ' VAL . . . . . 0.428 ' O ' ' O ' ' A' ' 57' ' ' GLY . 22.9 t -48.3 159.3 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.021 -1.049 . . . . 0.67 108.671 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -123.89 153.74 40.69 Favored 'General case' 0 N--CA 1.501 2.111 0 O-C-N 121.369 -0.832 . . . . 0.58 110.257 -178.89 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 11' ' ' SER . . . . . 0.429 ' CB ' HG23 ' A' ' 55' ' ' VAL . 2.7 t -148.66 147.12 28.56 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.498 -0.751 . . . . 1.19 109.235 179.773 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 28.5 p -145.89 126.77 14.47 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.164 -0.96 . . . . 1.38 110.064 -179.628 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 0.656 HG22 ' N ' ' B' ' 14' ' ' PHE . 7.2 p -172.18 174.8 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 N-CA-C 108.497 -0.927 . . . . 0.42 108.497 179.731 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 14' ' ' PHE . . . . . 0.656 ' N ' HG22 ' B' ' 13' ' ' VAL . 0.1 OUTLIER 174.41 -166.23 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.563 0 C-N-CA 118.779 -1.168 . . . . 1.79 111.864 -179.979 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 5.8 pt -137.58 139.49 43.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 N-CA-C 108.981 -0.748 . . . . 1.25 108.981 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 80.7 p -94.26 131.19 40.12 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.101 -0.999 . . . . 1.61 109.785 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.597 HD22 ' N ' ' B' ' 17' ' ' LEU . 3.5 mm? -92.98 107.31 19.12 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.294 -0.879 . . . . 1.32 108.891 179.615 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -155.45 89.1 3.01 Favored Pre-proline 0 N--CA 1.492 1.667 0 O-C-N 121.34 -0.85 . . . . 1.45 109.227 -179.49 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -59.38 166.49 7.56 Favored 'Trans proline' 0 CA--C 1.543 0.974 0 C-N-CA 120.954 1.103 . . . . 1.5 109.83 -179.176 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 20' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -59.67 -80.49 0.01 OUTLIER 'Trans proline' 0 C--N 1.319 -0.975 0 C-N-CA 121.56 1.506 . . . . 2.86 110.303 -179.72 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . 0.421 ' HD3' ' H ' ' B' ' 21' ' ' ARG . 0.0 OUTLIER -59.28 166.95 1.99 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.194 -0.941 . . . . 6.12 109.846 -179.439 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 22' ' ' ARG . . . . . 0.436 ' HG3' HH11 ' B' ' 22' ' ' ARG . 15.2 mmm-85 -69.79 -122.51 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.416 -0.803 . . . . 6.29 109.15 179.87 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . 0.434 ' CG ' ' H ' ' B' ' 24' ' ' VAL . 1.2 p-10 -144.74 -89.31 0.11 Allowed 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.02 -1.05 . . . . 5.62 109.397 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . 0.434 ' H ' ' CG ' ' B' ' 23' ' ' ASP . 13.3 t . . . . . 0 N--CA 1.489 1.516 0 CA-C-O 118.002 -0.999 . . . . 6.48 109.485 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.531 4.99 0 N-CA-C 119.758 2.663 . . . . 6.64 119.758 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.614 HG23 ' O ' ' A' ' 2' ' ' ILE . 3.6 tp -171.36 49.98 0.13 Allowed Pre-proline 0 C--N 1.306 -1.314 0 O-C-N 121.336 -1.097 . . . . 7.08 108.249 179.537 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.824 ' C ' ' H ' ' A' ' 5' ' ' PHE . 2.7 Cg_endo -51.74 -77.8 0.02 OUTLIER 'Trans proline' 0 C--N 1.319 -1.021 0 N-CA-C 109.02 -1.185 . . . . 5.5 109.02 179.488 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.513 ' C ' ' H ' ' A' ' 6' ' ' PHE . 0.3 OUTLIER 73.7 -16.23 0.52 Allowed 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 104.234 -2.506 . . . . 6.75 104.234 -175.732 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . 0.824 ' H ' ' C ' ' A' ' 3' ' ' PRO . 3.3 m-85 -89.78 17.74 6.3 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 103.822 -2.659 . . . . 6.07 103.822 176.817 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.531 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 42.8 p90 45.88 -155.76 0.04 OUTLIER 'General case' 0 C--N 1.306 -1.288 0 CA-C-N 114.17 -1.377 . . . . 4.72 109.686 -177.677 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.522 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 5.1 tp-100 84.02 -8.74 1.0 Allowed 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 104.927 -2.249 . . . . 4.4 104.927 -177.09 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.45 ' H ' ' C ' ' A' ' 6' ' ' PHE . 66.8 t80 -154.83 -37.01 0.09 Allowed 'General case' 0 C--N 1.304 -1.376 0 CA-C-N 114.512 -1.222 . . . . 5.15 107.912 178.439 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.404 ' O ' ' C ' ' A' ' 10' ' ' VAL . 15.0 m -91.11 2.28 56.46 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 106.009 -1.849 . . . . 5.13 106.009 177.355 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.434 HG13 ' N ' ' A' ' 11' ' ' GLY . 7.2 p -41.11 -37.6 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 CA-C-O 121.773 0.796 . . . . 4.38 109.507 -179.828 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.659 ' O ' HD23 ' A' ' 13' ' ' LEU . . . 144.93 -86.58 0.18 Allowed Glycine 0 N--CA 1.496 2.685 0 N-CA-C 109.0 -1.64 . . . . 4.22 109.0 179.511 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.467 ' O ' ' N ' ' A' ' 14' ' ' GLY . 13.3 Cg_endo -68.93 36.18 0.2 Allowed 'Trans proline' 0 N--CA 1.482 0.82 0 C-N-CA 121.546 1.497 . . . . 3.85 109.225 178.666 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.874 ' N ' HD23 ' A' ' 13' ' ' LEU . 0.0 OUTLIER 43.1 24.17 0.04 OUTLIER 'General case' 0 N--CA 1.5 2.028 0 CA-C-O 121.846 0.831 . . . . 3.67 108.836 -178.823 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.612 ' O ' ' HB3' ' A' ' 18' ' ' ALA . . . 69.94 -39.08 0.41 Allowed Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.273 -1.531 . . . . 2.97 109.273 -179.831 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.521 ' H ' ' C ' ' A' ' 13' ' ' LEU . 24.7 tt0 47.77 15.08 0.05 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.352 -1.087 . . . . 2.97 108.83 -179.394 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.507 ' N ' ' O ' ' A' ' 14' ' ' GLY . . . 65.76 115.19 0.01 OUTLIER Glycine 0 N--CA 1.487 2.047 0 N-CA-C 110.082 -1.207 . . . . 2.44 110.082 179.695 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.567 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 91.88 -53.38 2.95 Favored Glycine 0 N--CA 1.494 2.542 0 N-CA-C 110.213 -1.155 . . . . 1.81 110.213 179.444 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.632 ' HB2' ' OE1' ' A' ' 94' ' ' GLU . . . -41.49 -18.22 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.84 -0.8 . . . . 2.21 110.463 -178.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . 0.567 ' N ' ' O ' ' A' ' 17' ' ' GLY . 11.0 t60 -85.39 -40.69 16.19 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.281 -0.887 . . . . 2.87 109.99 -179.456 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.599 ' HG2' ' HB2' ' A' ' 46' ' ' ALA . 0.0 OUTLIER -99.78 -29.04 12.85 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.099 -1.001 . . . . 2.02 110.584 -179.173 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 84.0 t -51.58 112.1 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.004 -1.06 . . . . 2.07 109.869 -179.608 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 3.9 tpt180 -119.15 136.43 54.18 Favored 'General case' 0 N--CA 1.495 1.792 0 N-CA-C 109.284 -0.635 . . . . 3.5 109.284 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -144.58 113.87 7.01 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.461 -0.775 . . . . 1.83 108.933 179.677 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -149.25 123.83 1.69 Allowed Glycine 0 N--CA 1.495 2.586 0 N-CA-C 110.137 -1.185 . . . . 1.9 110.137 -179.424 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.81 177.77 48.27 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.904 -1.279 . . . . 1.85 109.904 179.567 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 11.0 m -76.81 -12.62 60.0 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.291 -1.123 . . . . 2.31 109.958 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -67.68 -16.68 68.16 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 108.417 -1.873 . . . . 1.64 108.417 179.599 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.434 HD21 ' CD2' ' A' ' 39' ' ' PHE . 18.1 mt -92.92 -10.31 36.96 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.783 -0.833 . . . . 1.83 109.022 179.722 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 47.3 mm-40 -83.61 -55.23 4.4 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.491 -0.755 . . . . 2.34 110.056 -179.264 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 4.9 ptp180 -176.36 -177.59 0.87 Allowed 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.036 -1.04 . . . . 3.77 109.879 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -145.13 174.53 25.14 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 108.649 -1.78 . . . . 1.57 108.649 179.664 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 30.3 t -134.39 149.73 30.18 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.947 0 O-C-N 121.285 -1.126 . . . . 1.83 110.159 -179.779 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.516 ' HB2' ' HD3' ' A' ' 82' ' ' PRO . . . -40.5 112.19 0.26 Allowed 'General case' 0 N--CA 1.496 1.83 0 CA-C-O 121.499 0.666 . . . . 1.64 112.515 -178.887 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 58.82 47.16 91.9 Favored Glycine 0 N--CA 1.492 2.391 0 O-C-N 121.514 -0.741 . . . . 1.73 111.569 177.117 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 23.6 t -127.45 124.84 23.74 Favored Pre-proline 0 N--CA 1.499 1.988 0 O-C-N 121.417 -1.049 . . . . 2.19 108.417 179.031 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_exo -58.39 114.77 2.13 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 N-CA-C 109.99 -0.811 . . . . 1.96 109.99 -179.828 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.423 ' HB3' ' CE2' ' A' ' 77' ' ' TYR . . . -107.64 155.45 20.14 Favored 'General case' 0 N--CA 1.495 1.789 0 N-CA-C 107.803 -1.184 . . . . 1.69 107.803 179.176 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -164.51 169.85 16.63 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 118.431 -1.308 . . . . 2.23 111.41 -179.405 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.61 ' CE2' HD11 ' A' ' 41' ' ' ILE . 4.6 p90 -154.66 171.03 20.16 Favored 'General case' 0 C--N 1.298 -1.669 0 N-CA-C 107.705 -1.22 . . . . 1.54 107.705 178.008 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 83.6 p -100.59 150.99 22.13 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.575 -0.703 . . . . 2.37 110.599 -178.389 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.61 HD11 ' CE2' ' A' ' 39' ' ' PHE . 11.6 mt -143.6 104.71 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 N-CA-C 108.712 -0.847 . . . . 1.65 108.712 178.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.526 ' CG ' ' N ' ' A' ' 43' ' ' THR . 0.7 OUTLIER -102.62 166.45 10.5 Favored 'General case' 0 N--CA 1.497 1.911 0 N-CA-C 108.33 -0.989 . . . . 3.68 108.33 179.854 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.526 ' N ' ' CG ' ' A' ' 42' ' ' TRP . 35.0 p -153.6 131.49 11.68 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.146 -0.971 . . . . 2.89 109.827 -179.616 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' ARG . . . . . 0.475 ' H ' ' HB2' ' A' ' 20' ' ' LYS . 32.5 ttm180 -72.58 -86.3 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.243 -0.91 . . . . 4.63 109.43 179.847 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 24.9 tt0 -172.17 63.35 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.809 -1.182 . . . . 2.89 110.935 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.599 ' HB2' ' HG2' ' A' ' 20' ' ' LYS . . . -71.24 -52.0 21.45 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 120.73 -1.231 . . . . 1.74 108.584 178.823 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 155.39 169.62 20.02 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.487 -1.445 . . . . 1.6 109.487 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.8 143.98 19.53 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.215 -1.168 . . . . 1.4 109.371 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -163.72 -168.35 25.6 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.522 -1.431 . . . . 1.04 109.522 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -137.68 117.37 1.48 Allowed Glycine 0 N--CA 1.496 2.666 0 N-CA-C 109.261 -1.536 . . . . 1.06 109.261 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.463 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 9.7 tp -87.53 99.23 11.88 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.283 -1.128 . . . . 1.1 108.597 179.758 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 12.8 m -84.01 141.13 31.42 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 108.834 -0.802 . . . . 1.56 108.834 -179.887 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.512 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 72.6 mt -130.37 111.5 21.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.357 -0.839 . . . . 0.65 109.36 -179.891 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -100.85 106.98 18.41 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.374 -0.829 . . . . 0.69 108.938 179.724 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.428 ' O ' ' O ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -103.93 135.44 41.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 121.573 -0.704 . . . . 0.91 109.323 -179.771 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 27.3 tt0 -137.96 140.53 40.28 Favored 'General case' 0 N--CA 1.494 1.736 0 N-CA-C 108.024 -1.102 . . . . 1.8 108.024 179.092 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 168.47 -172.15 42.88 Favored Glycine 0 N--CA 1.487 2.092 0 N-CA-C 109.407 -1.477 . . . . 0.49 109.407 -179.271 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -62.87 -30.9 77.8 Favored 'Trans proline' 0 C--N 1.316 -1.16 0 C-N-CA 121.873 1.715 . . . . 0.66 111.584 -179.621 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.8 t -137.64 157.24 46.93 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.153 -0.967 . . . . 1.55 110.278 -179.488 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.436 ' O ' ' OE2' ' A' ' 62' ' ' GLU . 31.5 mtpt -80.65 123.37 28.11 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 109.09 -0.707 . . . . 2.53 109.09 179.728 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -85.79 144.29 27.82 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.162 -0.961 . . . . 0.82 109.318 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.482 ' CD ' ' N ' ' A' ' 62' ' ' GLU . 9.0 mp0 -96.76 100.52 12.07 Favored 'General case' 0 N--CA 1.502 2.137 0 O-C-N 121.048 -1.032 . . . . 2.3 110.619 -179.476 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.47 HD12 ' N ' ' A' ' 63' ' ' ILE . 1.7 mp -62.51 156.12 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 N-CA-C 108.673 -0.862 . . . . 1.4 108.673 178.721 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.524 ' HB3' ' OG ' ' A' ' 76' ' ' SER . . . -140.97 175.01 9.97 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.122 -0.987 . . . . 1.36 109.237 179.782 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.513 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 32.3 p90 -147.08 116.25 6.94 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.317 -0.864 . . . . 1.47 109.407 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 69.8 tt0 -141.38 127.6 19.72 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.287 -0.883 . . . . 2.51 109.515 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.468 ' N ' ' OD1' ' A' ' 67' ' ' ASP . 22.2 p-10 -81.69 120.1 24.67 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.263 -0.898 . . . . 2.07 109.402 179.903 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.599 ' CG ' HH11 ' A' ' 68' ' ' ARG . 0.1 OUTLIER -100.09 -23.24 14.92 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.303 -0.873 . . . . 4.63 109.748 -179.828 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.514 ' C ' ' H ' ' A' ' 71' ' ' GLY . 23.3 mmtp -125.15 7.9 7.91 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.511 -0.743 . . . . 3.49 109.283 -179.669 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.428 ' CB ' ' O ' ' A' ' 69' ' ' LYS . 1.5 t70 70.83 -12.68 0.54 Allowed 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.371 -0.831 . . . . 3.06 108.797 -179.439 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . 0.514 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -127.01 -26.79 1.07 Allowed Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.406 -1.478 . . . . 2.16 109.406 -179.341 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 28.9 t -95.58 134.37 38.53 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.237 -1.155 . . . . 2.2 108.782 179.465 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 37.9 t -93.39 126.42 38.52 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.148 -0.97 . . . . 2.05 109.644 -179.708 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -102.35 120.48 6.84 Favored Glycine 0 N--CA 1.497 2.755 0 N-CA-C 109.855 -1.298 . . . . 1.39 109.855 -179.795 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.414 ' CG2' HD12 ' A' ' 41' ' ' ILE . 41.3 t -104.59 119.34 53.35 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.959 0 O-C-N 121.464 -1.021 . . . . 1.57 108.814 179.603 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.524 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 0.4 OUTLIER -113.39 124.35 52.23 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.69 -0.631 . . . . 1.85 109.387 -179.836 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.423 ' CE2' ' HB3' ' A' ' 37' ' ' ALA . 51.7 p90 -122.97 131.62 53.79 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 108.358 -0.979 . . . . 1.54 108.358 179.316 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.625 ' O ' HG13 ' A' ' 78' ' ' VAL . 8.9 p -106.63 117.54 52.61 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.243 0 O-C-N 121.293 -0.879 . . . . 1.9 109.603 -179.378 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 1.2 m -90.07 161.8 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 O-C-N 121.282 -0.887 . . . . 1.27 108.978 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 1.2 tp-100 -97.62 -51.33 4.15 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.122 -0.986 . . . . 2.48 110.787 -179.158 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.429 ' O ' ' O ' ' A' ' 82' ' ' PRO . 77.2 mm-40 -145.47 150.31 43.66 Favored Pre-proline 0 N--CA 1.504 2.259 0 O-C-N 120.872 -1.142 . . . . 1.92 111.718 -178.125 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.599 ' HG3' ' N ' ' A' ' 107' ' ' SER . 88.7 Cg_exo -36.73 166.38 0.01 OUTLIER 'Trans proline' 0 C--O 1.216 -0.616 0 C-N-CA 123.142 2.561 . . . . 1.3 113.381 178.391 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 142.7 -178.53 21.04 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.183 -1.567 . . . . 1.02 109.183 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . 0.717 ' H ' ' NH1' ' B' ' 8' ' ' ARG . 31.7 m-20 -97.22 85.9 3.8 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 107.79 -1.189 . . . . 2.13 107.79 179.213 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -70.16 132.54 45.96 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 108.128 -1.064 . . . . 0.92 108.128 -179.502 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -105.36 115.67 30.65 Favored 'General case' 0 N--CA 1.496 1.872 0 N-CA-C 108.255 -1.017 . . . . 1.53 108.255 -179.067 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.4 p -115.83 143.03 26.73 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 O-C-N 121.604 -0.685 . . . . 1.0 110.12 -179.29 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 2.9 m -138.87 97.06 3.24 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.507 -0.745 . . . . 1.59 109.588 179.661 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.539 HG13 HD11 ' A' ' 96' ' ' ILE . 1.1 pt -104.38 132.84 50.04 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 N-CA-C 109.332 -0.618 . . . . 1.29 109.332 -179.888 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . 0.435 ' HG3' ' H ' ' A' ' 93' ' ' ASP . 0.0 OUTLIER -148.09 132.76 17.85 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.106 -0.996 . . . . 1.58 109.855 -179.481 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 43.5 t80 -83.05 94.62 7.83 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.642 -1.286 . . . . 1.34 108.591 178.721 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . 0.479 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 38.7 t30 67.22 38.13 3.45 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.492 -0.929 . . . . 2.32 108.492 -179.088 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.479 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 0.6 OUTLIER 86.45 12.31 0.16 Allowed 'General case' 0 N--CA 1.503 2.181 0 CA-C-N 116.399 -0.364 . . . . 1.92 111.467 179.629 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . 0.632 ' OE1' ' HB2' ' A' ' 18' ' ' ALA . 0.0 OUTLIER -90.51 90.14 7.88 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 107.191 -1.411 . . . . 2.25 107.191 177.984 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . 0.507 ' H ' ' CD2' ' A' ' 95' ' ' HIS . 9.7 p80 -72.19 98.13 2.09 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 119.759 -1.838 . . . . 2.88 109.848 -179.142 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . 0.906 ' H ' HD13 ' A' ' 96' ' ' ILE . 0.0 OUTLIER -48.74 158.93 0.59 Allowed Pre-proline 0 N--CA 1.504 2.269 0 N-CA-C 107.31 -1.367 . . . . 2.35 107.31 179.218 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -60.42 65.5 0.08 OUTLIER 'Trans proline' 0 N--CA 1.481 0.736 0 C-N-CA 121.504 1.469 . . . . 2.48 109.469 -179.87 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.593 ' N ' ' O ' ' A' ' 96' ' ' ILE . 8.8 m-20 -164.9 -57.56 0.03 OUTLIER 'General case' 0 C--N 1.298 -1.634 0 N-CA-C 108.167 -1.049 . . . . 2.65 108.167 -179.514 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.423 ' HB3' ' H ' ' A' ' 89' ' ' ILE . 3.3 p -68.8 137.29 90.16 Favored Pre-proline 0 C--N 1.296 -1.755 0 C-N-CA 119.489 -0.884 . . . . 2.0 109.754 -179.179 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 27.2 Cg_endo -89.54 119.87 4.28 Favored 'Cis proline' 0 N--CA 1.493 1.462 0 N-CA-C 110.017 -0.801 . . . . 1.79 110.017 -2.644 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 30.4 p90 -124.55 166.42 16.09 Favored 'General case' 0 N--CA 1.516 2.844 0 O-C-N 120.571 -1.33 . . . . 2.19 109.74 178.153 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.3 p -88.44 146.49 6.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.551 -0.718 . . . . 1.44 110.521 -178.532 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 71.4 t -119.63 86.66 35.34 Favored Pre-proline 0 N--CA 1.495 1.803 0 N-CA-C 107.82 -1.178 . . . . 1.19 107.82 179.157 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -61.96 112.92 1.65 Allowed 'Trans proline' 0 C--N 1.322 -0.866 0 C-N-CA 121.423 1.416 . . . . 1.49 112.121 -177.724 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 60.3 t -98.93 143.19 13.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 N-CA-C 106.15 -1.796 . . . . 1.35 106.15 177.719 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.658 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -136.48 135.15 38.36 Favored 'General case' 0 N--CA 1.51 2.56 0 O-C-N 120.972 -1.08 . . . . 1.67 112.089 -176.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.599 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 9.2 t -86.39 73.02 10.22 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 107.713 -1.218 . . . . 2.04 107.713 179.158 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER 68.11 -1.26 1.83 Allowed 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 107.363 -1.347 . . . . 3.2 107.363 -178.505 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.674 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 22.9 t -83.54 -21.96 32.55 Favored 'General case' 0 N--CA 1.486 1.344 0 N-CA-C 108.864 -0.791 . . . . 2.09 108.864 179.249 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . 0.658 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 1.8 m-20 52.34 12.23 0.22 Allowed 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 108.135 -1.061 . . . . 2.85 108.135 -179.344 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.492 ' H ' ' C ' ' A' ' 109' ' ' SER . 5.0 m-20 -169.02 -29.26 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 108.877 -0.786 . . . . 2.46 108.877 -179.702 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.674 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 53.92 84.92 0.06 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.823 -1.173 . . . . 2.08 109.429 -179.779 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . 0.415 ' O ' ' O ' ' A' ' 112' ' ' ALA . 10.5 mpt_? -55.48 -169.36 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.208 -0.932 . . . . 5.93 109.19 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 9.8 tpt180 -138.34 2.0 2.24 Favored 'General case' 0 N--CA 1.495 1.78 0 N-CA-C 108.749 -0.834 . . . . 5.61 108.749 -179.832 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 39.9 mt -129.36 -26.41 2.55 Favored 'General case' 0 N--CA 1.503 2.198 0 O-C-N 121.542 -0.723 . . . . 4.39 109.244 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.488 ' C ' ' N ' ' A' ' 118' ' ' THR . 1.3 p -103.89 -81.08 0.52 Allowed 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 106.857 -1.534 . . . . 4.09 106.857 179.066 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.444 ' O ' HG12 ' A' ' 117' ' ' VAL . 54.9 t -61.06 -8.87 2.1 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.63 0 N-CA-C 106.144 -1.798 . . . . 2.9 106.144 176.826 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' THR . . . . . 0.488 ' N ' ' C ' ' A' ' 116' ' ' THR . 4.2 t 36.84 61.45 0.87 Allowed 'General case' 0 N--CA 1.486 1.375 0 CA-C-O 121.999 0.904 . . . . 3.36 110.742 179.913 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' SER . . . . . 0.468 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.6 p . . . . . 0 C--N 1.305 -1.365 0 CA-C-O 117.998 -1.001 . . . . 3.39 109.635 179.291 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 28.1 ttt . . . . . 0 N--CA 1.49 1.554 0 N-CA-C 109.45 -0.574 . . . . 8.49 109.45 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -56.69 -37.33 70.72 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.227 -0.921 . . . . 5.53 109.432 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 3' ' ' SER . . . . . . . . . . . . . 40.5 m -160.69 28.96 0.15 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.226 -0.921 . . . . 5.43 109.378 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 4' ' ' LYS . . . . . . . . . . . . . 27.3 tttp 56.28 67.32 2.86 Favored Pre-proline 0 N--CA 1.489 1.507 0 O-C-N 121.329 -0.857 . . . . 6.87 109.35 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 5' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_endo -61.77 -162.1 0.03 OUTLIER 'Trans proline' 0 C--N 1.318 -1.027 0 C-N-CA 121.475 1.45 . . . . 5.16 110.1 -179.384 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 6' ' ' GLU . . . . . . . . . . . . . 53.9 mt-10 -150.84 56.57 0.91 Allowed 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.287 -0.883 . . . . 4.78 109.326 -179.908 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 38.7 mttm 55.05 174.68 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.267 -0.896 . . . . 4.09 109.695 179.806 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.717 ' NH1' ' H ' ' A' ' 84' ' ' ASP . 5.6 mtt180 -88.37 173.63 8.62 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.277 -0.889 . . . . 3.04 109.393 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 9' ' ' VAL . . . . . 0.408 ' CG1' ' N ' ' B' ' 10' ' ' ALA . 5.2 t -51.08 160.48 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 N-CA-C 108.226 -1.027 . . . . 0.67 108.226 179.375 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 0.408 ' N ' ' CG1' ' B' ' 9' ' ' VAL . . . -114.59 148.3 38.26 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.47 -0.768 . . . . 0.58 110.053 -179.158 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 11' ' ' SER . . . . . 0.428 ' O ' ' O ' ' A' ' 55' ' ' VAL . 31.3 t -150.02 133.06 16.2 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.517 -0.74 . . . . 1.19 109.2 179.634 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 34.1 p -144.55 120.54 10.69 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.117 -0.989 . . . . 1.38 109.809 -179.695 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 0.613 HG22 ' N ' ' B' ' 14' ' ' PHE . 4.1 p -164.04 168.4 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.436 -0.79 . . . . 0.42 109.07 179.858 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 14' ' ' PHE . . . . . 0.613 ' N ' HG22 ' B' ' 13' ' ' VAL . 10.7 p90 -176.38 -165.58 0.14 Allowed 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 119.172 -1.011 . . . . 1.79 112.265 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.7 pt -150.93 168.63 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.291 0 N-CA-C 108.598 -0.89 . . . . 1.25 108.598 179.873 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 3.8 t -145.17 157.41 44.09 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 120.965 -1.084 . . . . 1.61 109.367 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -131.47 150.63 52.08 Favored 'General case' 0 N--CA 1.5 2.062 0 O-C-N 121.397 -0.815 . . . . 1.32 109.533 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -150.89 81.13 6.43 Favored Pre-proline 0 N--CA 1.492 1.674 0 N-CA-C 108.726 -0.842 . . . . 1.45 108.726 -179.804 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . 0.439 ' O ' ' O ' ' B' ' 20' ' ' PRO . 5.5 Cg_exo -59.82 169.4 4.56 Favored 'Trans proline' 0 CA--C 1.545 1.042 0 C-N-CA 121.206 1.271 . . . . 1.5 109.977 -178.73 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 20' ' ' PRO . . . . . 0.439 ' O ' ' O ' ' B' ' 19' ' ' PRO . 3.9 Cg_exo -57.11 -146.81 0.0 OUTLIER 'Trans proline' 0 CA--C 1.542 0.91 0 C-N-CA 121.623 1.549 . . . . 2.86 110.239 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 35.3 mtp180 61.91 65.95 0.87 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.211 -0.931 . . . . 6.12 109.476 -179.813 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 22' ' ' ARG . . . . . 0.611 HH11 ' CG ' ' B' ' 22' ' ' ARG . 0.0 OUTLIER -169.89 -134.96 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.381 -0.824 . . . . 6.29 109.323 179.837 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 62.5 m-20 -88.4 129.02 35.52 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.157 -0.964 . . . . 5.62 109.447 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 39.3 t . . . . . 0 N--CA 1.49 1.533 0 CA-C-O 117.973 -1.013 . . . . 6.48 109.517 179.913 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.489 ' O ' HG23 ' A' ' 2' ' ' ILE . . . . . . . . 1 N--CA 1.53 4.904 0 N-CA-C 119.879 2.712 . . . . 6.64 119.879 . . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.627 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 1.1 pp -160.74 45.69 0.19 Allowed Pre-proline 0 C--N 1.308 -1.234 0 N-CA-C 107.767 -1.198 . . . . 7.08 107.767 179.038 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.814 ' C ' ' H ' ' A' ' 5' ' ' PHE . 1.2 Cg_endo -53.81 -79.33 0.02 OUTLIER 'Trans proline' 0 C--N 1.32 -0.942 0 N-CA-C 108.904 -1.229 . . . . 5.5 108.904 179.774 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.499 ' C ' ' H ' ' A' ' 6' ' ' PHE . 9.4 tt0 73.18 -18.15 0.38 Allowed 'General case' 0 N--CA 1.495 1.783 0 N-CA-C 104.373 -2.454 . . . . 6.75 104.373 -175.729 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . 0.814 ' H ' ' C ' ' A' ' 3' ' ' PRO . 4.6 m-85 -88.83 17.41 5.66 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 103.912 -2.625 . . . . 6.07 103.912 176.654 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.535 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 39.6 p90 46.08 -153.49 0.05 Allowed 'General case' 0 C--N 1.308 -1.233 0 CA-C-N 114.308 -1.314 . . . . 4.72 109.366 -177.553 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.523 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 16.8 tt0 82.89 -8.67 1.15 Allowed 'General case' 0 N--CA 1.49 1.543 0 N-CA-C 104.929 -2.248 . . . . 4.4 104.929 -177.112 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.489 ' H ' ' C ' ' A' ' 6' ' ' PHE . 35.1 t80 -150.53 -38.19 0.14 Allowed 'General case' 0 C--N 1.307 -1.252 0 N-CA-C 107.761 -1.199 . . . . 5.15 107.761 178.409 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.416 HG22 ' O ' ' A' ' 9' ' ' THR . 45.3 m -91.98 2.36 56.6 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 105.662 -1.977 . . . . 5.13 105.662 177.147 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.403 HG13 ' N ' ' A' ' 11' ' ' GLY . 7.1 p -46.37 -38.04 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.27 0 CA-C-N 115.268 -0.878 . . . . 4.38 109.479 -179.641 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.579 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 140.23 -83.25 0.23 Allowed Glycine 0 N--CA 1.5 2.915 0 N-CA-C 108.58 -1.808 . . . . 4.22 108.58 179.704 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.542 ' O ' ' N ' ' A' ' 14' ' ' GLY . 13.6 Cg_endo -66.6 40.95 0.16 Allowed 'Trans proline' 0 C--N 1.32 -0.964 0 C-N-CA 121.911 1.74 . . . . 3.85 108.798 177.954 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.579 ' H ' ' C ' ' A' ' 11' ' ' GLY . 0.2 OUTLIER 30.52 34.27 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.22 0 CA-C-O 121.518 0.675 . . . . 3.67 110.835 -179.277 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.546 ' C ' ' H ' ' A' ' 16' ' ' GLY . . . 67.25 -35.47 0.2 Allowed Glycine 0 N--CA 1.49 2.244 0 N-CA-C 110.159 -1.176 . . . . 2.97 110.159 179.427 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.537 ' H ' ' C ' ' A' ' 13' ' ' LEU . 6.4 tp10 58.47 1.58 0.18 Allowed 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.313 -1.11 . . . . 2.97 108.921 -179.332 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.546 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 70.22 112.34 0.03 OUTLIER Glycine 0 N--CA 1.487 2.099 0 C-N-CA 120.34 -0.933 . . . . 2.44 110.772 179.197 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.539 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 78.7 -52.6 3.91 Favored Glycine 0 N--CA 1.492 2.43 0 O-C-N 121.47 -1.018 . . . . 1.81 111.089 178.69 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.599 ' HB2' ' OE1' ' A' ' 94' ' ' GLU . . . -50.27 -6.68 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.081 -1.247 . . . . 2.21 110.162 -179.29 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . 0.539 ' N ' ' O ' ' A' ' 17' ' ' GLY . 29.5 t-80 -98.97 -6.31 28.91 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.092 -1.005 . . . . 2.87 110.717 -179.171 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.502 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.0 OUTLIER -137.7 2.38 2.42 Favored 'General case' 0 N--CA 1.502 2.164 0 O-C-N 120.959 -1.088 . . . . 2.02 110.258 -179.664 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 71.3 t -87.85 114.22 26.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 120.982 -1.074 . . . . 2.07 109.25 179.489 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 13.3 tpp180 -113.61 138.54 50.03 Favored 'General case' 0 N--CA 1.492 1.635 0 N-CA-C 108.83 -0.804 . . . . 3.5 108.83 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -147.13 113.57 5.95 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.434 -0.791 . . . . 1.83 108.987 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -152.0 130.33 3.07 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.677 -1.369 . . . . 1.9 109.677 -179.759 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.98 -178.79 48.47 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.603 -1.399 . . . . 1.85 109.603 179.87 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 6.6 p -78.93 -26.59 43.67 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.183 -1.186 . . . . 2.31 108.99 179.648 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -66.88 -18.25 68.36 Favored Glycine 0 N--CA 1.486 2.015 0 N-CA-C 108.283 -1.927 . . . . 1.64 108.283 179.482 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 57.1 mt -89.64 29.55 1.13 Allowed 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.527 -0.916 . . . . 1.83 108.527 179.395 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 27.5 mt-10 -140.09 -63.84 0.49 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.528 -0.733 . . . . 2.34 109.623 -179.557 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 41.2 mtt180 -148.45 168.57 22.34 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.168 -0.958 . . . . 3.77 110.293 -179.573 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -144.38 173.33 25.09 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 107.415 -2.274 . . . . 1.57 107.415 178.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 39.7 t -133.79 150.99 32.18 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.15 0 O-C-N 120.999 -1.295 . . . . 1.83 110.884 -179.365 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.434 ' HB2' ' HD3' ' A' ' 82' ' ' PRO . . . -42.34 114.81 0.61 Allowed 'General case' 0 N--CA 1.497 1.887 0 CA-C-O 121.893 0.854 . . . . 1.64 112.314 -179.299 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 55.8 48.2 73.69 Favored Glycine 0 N--CA 1.488 2.159 0 N-CA-C 111.497 -0.641 . . . . 1.73 111.497 177.119 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 t -127.45 123.8 23.32 Favored Pre-proline 0 N--CA 1.499 1.986 0 O-C-N 121.451 -1.029 . . . . 2.19 108.866 179.075 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -60.64 112.21 1.27 Allowed 'Trans proline' 0 C--O 1.215 -0.652 0 N-CA-C 109.949 -0.827 . . . . 1.96 109.949 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -110.87 158.96 18.13 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 108.401 -0.963 . . . . 1.69 108.401 179.445 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -160.64 170.46 20.79 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.767 -1.208 . . . . 2.23 111.496 -179.768 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.602 ' CE2' HD11 ' A' ' 41' ' ' ILE . 6.2 p90 -155.62 177.37 11.45 Favored 'General case' 0 C--N 1.296 -1.729 0 N-CA-C 107.217 -1.401 . . . . 1.54 107.217 178.473 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 27.5 m -105.17 152.32 22.97 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.344 -0.848 . . . . 2.37 110.619 -178.502 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.649 HD12 HG21 ' A' ' 75' ' ' VAL . 10.0 mt -143.64 89.53 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 N-CA-C 108.714 -0.847 . . . . 1.65 108.714 178.854 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.529 ' CD1' ' N ' ' A' ' 43' ' ' THR . 7.4 t90 -91.33 141.29 28.93 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.172 -0.955 . . . . 3.68 108.924 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.531 ' OG1' ' N ' ' A' ' 44' ' ' ARG . 1.7 t -162.34 -124.2 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.177 -0.952 . . . . 2.89 109.486 -179.845 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' ARG . . . . . 0.531 ' N ' ' OG1' ' A' ' 43' ' ' THR . 5.3 ttt-85 54.49 91.81 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.347 -0.845 . . . . 4.63 110.074 179.748 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -170.97 -50.23 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.285 -0.884 . . . . 2.89 109.304 179.457 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -61.14 -50.29 73.8 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.09 -1.006 . . . . 1.74 108.937 179.665 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 155.2 -178.81 31.65 Favored Glycine 0 N--CA 1.487 2.044 0 N-CA-C 109.536 -1.426 . . . . 1.6 109.536 179.813 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.68 156.92 2.45 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.169 -1.195 . . . . 1.4 109.263 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -179.65 -160.51 25.38 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.712 -1.355 . . . . 1.04 109.712 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -144.05 123.38 2.01 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 109.663 -1.375 . . . . 1.06 109.663 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 60.2 tp -96.82 104.99 17.04 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.34 -1.094 . . . . 1.1 108.651 179.571 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . 0.406 ' HA ' ' CD2' ' B' ' 14' ' ' PHE . 2.0 t -93.23 144.66 25.08 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 108.93 -0.767 . . . . 1.56 108.93 179.736 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.507 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 80.0 mt -132.97 105.74 8.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 O-C-N 121.305 -0.872 . . . . 0.65 109.79 -179.378 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -95.76 107.86 20.13 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 107.726 -1.213 . . . . 0.69 107.726 178.841 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.41 ' O ' ' O ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -105.33 146.73 11.99 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 CA-C-O 121.772 0.796 . . . . 0.91 110.693 -178.421 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.408 ' OE2' ' O ' ' B' ' 9' ' ' VAL . 39.9 tp10 -139.23 129.41 25.31 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 107.248 -1.39 . . . . 1.8 107.248 177.954 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -175.82 163.59 33.3 Favored Glycine 0 N--CA 1.487 2.068 0 N-CA-C 108.386 -1.886 . . . . 0.49 108.386 -179.702 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_exo -46.37 -23.44 2.08 Favored 'Trans proline' 0 C--N 1.317 -1.13 0 C-N-CA 121.91 1.74 . . . . 0.66 111.714 -178.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 30.3 t -141.74 167.49 22.01 Favored 'General case' 0 N--CA 1.501 2.101 0 O-C-N 121.473 -0.767 . . . . 1.55 110.681 -179.274 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 29.3 tttm -91.4 92.05 8.4 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.666 -0.646 . . . . 2.53 109.535 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -52.05 145.13 10.78 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.341 -0.85 . . . . 0.82 109.308 179.889 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.426 ' OE2' ' O ' ' A' ' 63' ' ' ILE . 0.2 OUTLIER -93.78 87.63 5.5 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.234 -0.916 . . . . 2.3 109.561 -179.843 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.426 ' O ' ' OE2' ' A' ' 62' ' ' GLU . 25.0 mt -60.23 150.17 6.69 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 N-CA-C 109.263 -0.643 . . . . 1.4 109.263 179.574 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -151.09 114.83 4.93 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 120.725 -1.234 . . . . 1.36 109.939 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.492 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 40.1 p90 -86.85 124.17 32.79 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.222 -0.924 . . . . 1.47 109.198 179.531 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 62.9 tt0 -141.2 125.1 17.07 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.254 -0.904 . . . . 2.51 109.43 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -88.69 93.93 9.73 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.351 -0.843 . . . . 2.07 109.695 -179.906 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.616 ' CG ' HH11 ' A' ' 68' ' ' ARG . 0.0 OUTLIER -115.92 10.68 15.27 Favored 'General case' 0 N--CA 1.499 2.019 0 N-CA-C 108.3 -1.0 . . . . 4.63 108.3 179.53 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.455 ' HB2' ' H ' ' A' ' 72' ' ' SER . 28.3 mmtp -115.19 -8.71 12.34 Favored 'General case' 0 N--CA 1.496 1.845 0 N-CA-C 109.141 -0.689 . . . . 3.49 109.141 -179.492 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 3.0 t70 67.85 6.03 4.86 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.46 -0.775 . . . . 3.06 109.769 179.529 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -163.43 -41.92 0.02 OUTLIER Glycine 0 N--CA 1.487 2.048 0 C-N-CA 119.489 -1.338 . . . . 2.16 109.785 -179.428 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.455 ' H ' ' HB2' ' A' ' 69' ' ' LYS . 4.3 t -95.28 130.92 41.87 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.32 -1.106 . . . . 2.2 108.983 179.865 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 24.5 m -78.23 129.33 34.96 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.19 -0.944 . . . . 2.05 109.356 -179.844 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -101.14 116.5 5.59 Favored Glycine 0 N--CA 1.497 2.747 0 N-CA-C 110.111 -1.196 . . . . 1.39 110.111 -179.637 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.649 HG21 HD12 ' A' ' 41' ' ' ILE . 71.8 t -105.36 106.85 21.28 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.098 0 O-C-N 121.537 -0.978 . . . . 1.57 109.284 179.571 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 4.0 t -100.11 126.39 46.34 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.549 -0.719 . . . . 1.85 109.474 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.401 ' N ' ' CD1' ' A' ' 77' ' ' TYR . 12.0 p90 -125.36 131.69 52.94 Favored 'General case' 0 N--CA 1.497 1.882 0 N-CA-C 108.758 -0.831 . . . . 1.54 108.758 179.746 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.627 ' O ' HG13 ' A' ' 78' ' ' VAL . 9.9 p -98.73 114.35 36.17 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.294 -0.879 . . . . 1.9 109.255 -179.501 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.406 HG22 ' H ' ' A' ' 79' ' ' VAL . 15.5 m -81.79 161.83 3.57 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 O-C-N 121.041 -1.037 . . . . 1.27 109.027 -179.707 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . 0.531 ' O ' ' NE2' ' A' ' 80' ' ' GLN . 0.0 OUTLIER -101.44 -48.54 4.32 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.227 -0.92 . . . . 2.48 110.781 -178.825 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -156.67 153.13 23.91 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 120.554 -1.341 . . . . 1.92 111.108 -179.506 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.648 ' HG3' ' N ' ' A' ' 107' ' ' SER . 76.4 Cg_exo -37.08 158.08 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.646 0 C-N-CA 123.363 2.709 . . . . 1.3 113.875 179.231 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 150.77 -167.49 30.46 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.359 -1.496 . . . . 1.02 109.359 179.765 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . 0.521 ' OD2' ' NH2' ' B' ' 8' ' ' ARG . 10.7 m-20 -109.3 91.58 3.7 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.532 -0.981 . . . . 2.13 108.756 179.64 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 3.0 m-85 -78.25 136.19 37.72 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 108.049 -1.093 . . . . 0.92 108.049 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . 0.402 ' OE2' ' O ' ' A' ' 84' ' ' ASP . 0.0 OUTLIER -119.18 117.36 28.44 Favored 'General case' 0 N--CA 1.501 2.086 0 N-CA-C 108.121 -1.066 . . . . 1.53 108.121 -179.033 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.437 ' O ' HG13 ' A' ' 87' ' ' VAL . 14.6 p -117.11 133.91 62.36 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 121.622 -0.674 . . . . 1.0 110.408 -178.842 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 3.5 p -128.65 105.77 8.49 Favored 'General case' 0 N--CA 1.501 2.092 0 O-C-N 121.61 -0.682 . . . . 1.59 109.459 179.715 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.4 pt -107.95 138.22 35.53 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.897 0 CA-C-O 121.415 0.626 . . . . 1.29 109.839 -179.732 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . 0.458 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -145.08 122.63 11.74 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 108.659 -0.867 . . . . 1.58 108.659 179.928 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 78.7 t80 -80.33 100.95 8.66 Favored 'General case' 0 N--CA 1.491 1.588 0 C-N-CA 118.764 -1.174 . . . . 1.34 107.891 178.492 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . 0.407 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 2.0 t30 69.59 39.86 1.49 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.343 -0.848 . . . . 2.32 109.177 -178.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.407 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 1.5 m-20 75.61 13.93 2.88 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.678 -0.639 . . . . 1.92 111.62 179.483 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . 0.599 ' OE1' ' HB2' ' A' ' 18' ' ' ALA . 0.5 OUTLIER -98.44 94.44 6.72 Favored 'General case' 0 N--CA 1.498 1.97 0 N-CA-C 106.964 -1.495 . . . . 2.25 106.964 177.58 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . 0.508 ' O ' ' CG ' ' A' ' 95' ' ' HIS . 6.5 p80 -71.57 112.69 7.9 Favored 'General case' 0 N--CA 1.487 1.384 0 CA-C-O 121.485 0.66 . . . . 2.88 109.748 -178.219 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . 0.557 ' O ' ' N ' ' A' ' 98' ' ' ASP . 6.3 pt -57.06 152.02 31.4 Favored Pre-proline 0 C--N 1.3 -1.579 0 N-CA-C 108.319 -0.993 . . . . 2.35 108.319 179.594 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -59.05 73.96 0.05 OUTLIER 'Trans proline' 0 CA--C 1.54 0.789 0 N-CA-C 109.234 -1.102 . . . . 2.48 109.234 179.364 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.557 ' N ' ' O ' ' A' ' 96' ' ' ILE . 0.9 OUTLIER -174.93 -51.87 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.077 -1.014 . . . . 2.65 109.38 -179.339 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 5.3 t -54.25 134.31 60.57 Favored Pre-proline 0 C--N 1.299 -1.626 0 O-C-N 121.321 -0.862 . . . . 2.0 109.926 -177.64 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_endo -89.94 116.25 2.91 Favored 'Cis proline' 0 N--CA 1.495 1.606 0 CA-C-N 118.995 0.677 . . . . 1.79 110.521 -1.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . 0.574 ' CD1' ' N ' ' A' ' 101' ' ' PHE . 0.1 OUTLIER -89.49 149.59 22.84 Favored 'General case' 0 N--CA 1.512 2.639 0 O-C-N 119.979 -1.701 . . . . 2.19 108.76 178.029 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 8.6 p -86.45 138.43 19.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.5 -0.75 . . . . 1.44 109.133 179.681 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 76.7 t -120.15 85.37 35.6 Favored Pre-proline 0 N--CA 1.498 1.936 0 N-CA-C 108.312 -0.996 . . . . 1.19 108.312 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -65.3 112.97 2.25 Favored 'Trans proline' 0 C--N 1.32 -0.953 0 C-N-CA 121.276 1.317 . . . . 1.49 111.556 -178.012 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 47.2 t -89.73 143.06 11.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 N-CA-C 106.667 -1.605 . . . . 1.35 106.667 177.853 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.702 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -127.92 131.28 49.37 Favored 'General case' 0 N--CA 1.507 2.406 0 CA-C-O 121.956 0.884 . . . . 1.67 111.788 -177.016 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.648 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 66.4 p -99.8 84.77 2.96 Favored 'General case' 0 N--CA 1.493 1.693 0 N-CA-C 107.229 -1.397 . . . . 2.04 107.229 178.783 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 13.3 mt 65.12 -0.69 1.02 Allowed 'General case' 0 C--N 1.292 -1.917 0 N-CA-C 108.081 -1.081 . . . . 3.2 108.081 -178.103 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.602 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 53.8 p -89.1 -22.89 22.66 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.982 -0.747 . . . . 2.09 108.982 179.068 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . 0.702 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 32.9 t70 50.24 13.4 0.11 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.139 -0.975 . . . . 2.85 108.586 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.503 ' N ' ' C ' ' A' ' 109' ' ' SER . 65.3 t0 -171.93 -28.74 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 109.375 -0.602 . . . . 2.46 109.375 -179.605 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.602 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 49.5 78.93 0.09 Allowed 'General case' 0 N--CA 1.494 1.752 0 O-C-N 120.784 -1.197 . . . . 2.08 109.189 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 61.9 mtm180 -50.16 160.75 0.33 Allowed 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.412 -0.805 . . . . 5.93 109.82 -179.55 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 18.3 ttm180 -103.22 5.74 37.81 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.568 -0.707 . . . . 5.61 109.382 -179.512 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 28.6 mt -123.2 -30.81 3.67 Favored 'General case' 0 N--CA 1.506 2.326 0 O-C-N 121.526 -0.733 . . . . 4.39 110.003 -179.391 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.508 ' C ' ' N ' ' A' ' 118' ' ' THR . 0.8 OUTLIER -105.26 -79.23 0.56 Allowed 'General case' 0 N--CA 1.493 1.721 0 N-CA-C 107.241 -1.392 . . . . 4.09 107.241 179.527 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.428 ' O ' HG12 ' A' ' 117' ' ' VAL . 55.0 t -60.21 -9.85 2.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 N-CA-C 106.215 -1.772 . . . . 2.9 106.215 177.043 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' THR . . . . . 0.508 ' N ' ' C ' ' A' ' 116' ' ' THR . 5.0 t 36.98 60.86 0.95 Allowed 'General case' 0 N--CA 1.485 1.287 0 CA-C-O 122.109 0.957 . . . . 3.36 110.88 179.718 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' SER . . . . . 0.452 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.5 p . . . . . 0 C--N 1.304 -1.408 0 CA-C-O 118.025 -0.988 . . . . 3.39 109.548 179.207 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 34.1 ttp . . . . . 0 N--CA 1.491 1.582 0 N-CA-C 109.467 -0.568 . . . . 8.49 109.467 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -73.79 -73.7 0.21 Allowed 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.241 -0.912 . . . . 5.53 109.185 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 3' ' ' SER . . . . . . . . . . . . . 13.0 p -175.32 -40.76 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.313 -0.867 . . . . 5.43 109.726 179.824 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 4' ' ' LYS . . . . . . . . . . . . . 59.4 tttm -170.96 76.99 0.55 Allowed Pre-proline 0 N--CA 1.489 1.493 0 O-C-N 121.201 -0.937 . . . . 6.87 109.626 -179.537 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 5' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -59.99 156.92 36.37 Favored 'Trans proline' 0 C--N 1.318 -1.071 0 C-N-CA 121.291 1.327 . . . . 5.16 110.055 -179.612 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 6' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -47.61 171.86 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.27 -0.894 . . . . 4.78 109.902 -179.724 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 49.0 mtpt -78.78 -154.99 0.08 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.398 -0.814 . . . . 4.09 109.385 179.822 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.521 ' NH2' ' OD2' ' A' ' 84' ' ' ASP . 3.8 mmt-85 -89.55 -170.87 2.99 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.148 -0.97 . . . . 3.04 109.358 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 9' ' ' VAL . . . . . 0.408 ' O ' ' OE2' ' A' ' 56' ' ' GLU . 2.6 t -68.47 161.23 4.22 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 N-CA-C 107.505 -1.294 . . . . 0.67 107.505 178.549 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -97.77 138.94 34.38 Favored 'General case' 0 N--CA 1.5 2.034 0 O-C-N 121.186 -0.947 . . . . 0.58 110.809 -178.636 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 11' ' ' SER . . . . . 0.41 ' O ' ' O ' ' A' ' 55' ' ' VAL . 35.7 t -143.07 130.73 21.34 Favored 'General case' 0 N--CA 1.493 1.72 0 N-CA-C 108.444 -0.947 . . . . 1.19 108.444 179.092 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 11.1 t -150.69 125.37 9.67 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.069 -1.019 . . . . 1.38 110.072 -179.369 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 0.731 HG22 ' H ' ' B' ' 14' ' ' PHE . 12.3 p -173.26 179.81 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 N-CA-C 108.263 -1.014 . . . . 0.42 108.263 179.649 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 14' ' ' PHE . . . . . 0.731 ' H ' HG22 ' B' ' 13' ' ' VAL . 0.1 OUTLIER 174.59 -167.65 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.504 0 C-N-CA 118.548 -1.261 . . . . 1.79 112.237 179.629 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -141.34 159.66 22.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 N-CA-C 108.097 -1.075 . . . . 1.25 108.097 -179.841 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 1.7 t -132.11 151.07 51.98 Favored 'General case' 0 N--CA 1.499 2.017 0 O-C-N 121.303 -0.873 . . . . 1.61 109.474 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 28.4 mt -112.13 141.39 45.86 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.487 -0.758 . . . . 1.32 109.576 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -158.89 117.23 1.7 Allowed Pre-proline 0 N--CA 1.492 1.654 0 N-CA-C 108.73 -0.841 . . . . 1.45 108.73 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_exo -59.74 164.63 11.28 Favored 'Trans proline' 0 CA--C 1.545 1.068 0 N-CA-C 109.992 -0.811 . . . . 1.5 109.992 -179.493 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 20' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_endo -63.15 124.14 13.4 Favored 'Trans proline' 0 C--N 1.321 -0.894 0 C-N-CA 121.626 1.551 . . . . 2.86 110.089 179.72 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . 0.557 HH11 ' CG ' ' B' ' 21' ' ' ARG . 0.3 OUTLIER 46.55 -127.25 1.49 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.241 -0.912 . . . . 6.12 109.708 179.304 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 22' ' ' ARG . . . . . 0.439 ' O ' ' O ' ' B' ' 23' ' ' ASP . 9.9 tpt180 -122.5 25.15 8.96 Favored 'General case' 0 N--CA 1.499 1.984 0 N-CA-C 108.932 -0.766 . . . . 6.29 108.932 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . 0.439 ' O ' ' O ' ' B' ' 22' ' ' ARG . 0.8 OUTLIER 60.45 142.55 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.42 -0.8 . . . . 5.62 109.736 -179.93 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . 0.442 ' H ' HG22 ' B' ' 24' ' ' VAL . 11.0 m . . . . . 0 N--CA 1.491 1.587 0 O-C-N 121.118 -0.988 . . . . 6.48 109.483 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.583 ' C ' HD12 ' A' ' 2' ' ' ILE . . . . . . . . 1 N--CA 1.531 4.972 0 N-CA-C 119.763 2.665 . . . . 6.64 119.763 . . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.66 HD12 ' N ' ' A' ' 2' ' ' ILE . 1.7 mp -149.11 43.99 0.31 Allowed Pre-proline 0 C--N 1.31 -1.143 0 N-CA-C 107.51 -1.293 . . . . 7.08 107.51 178.512 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.728 ' C ' ' H ' ' A' ' 5' ' ' PHE . 1.8 Cg_endo -51.97 -75.59 0.03 OUTLIER 'Trans proline' 0 C--N 1.319 -0.998 0 N-CA-C 109.016 -1.186 . . . . 5.5 109.016 -179.722 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.427 ' CB ' ' O ' ' A' ' 3' ' ' PRO . 13.9 tp10 70.32 -6.14 1.21 Allowed 'General case' 0 N--CA 1.495 1.801 0 N-CA-C 104.319 -2.474 . . . . 6.75 104.319 -175.705 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . 0.728 ' H ' ' C ' ' A' ' 3' ' ' PRO . 3.0 m-85 -102.06 15.21 29.77 Favored 'General case' 0 C--N 1.3 -1.558 0 N-CA-C 103.434 -2.802 . . . . 6.07 103.434 177.542 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.551 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 47.3 p90 50.83 -153.34 0.17 Allowed 'General case' 0 C--N 1.308 -1.235 0 CA-C-N 113.838 -1.528 . . . . 4.72 110.346 -177.886 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.421 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 13.4 mt-30 82.7 -9.22 1.14 Allowed 'General case' 0 N--CA 1.495 1.822 0 N-CA-C 105.233 -2.136 . . . . 4.4 105.233 -176.465 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.478 ' H ' ' C ' ' A' ' 6' ' ' PHE . 88.4 m-85 -149.46 -37.93 0.16 Allowed 'General case' 0 C--N 1.306 -1.307 0 N-CA-C 107.828 -1.175 . . . . 5.15 107.828 178.178 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 23.0 m -93.31 3.59 55.38 Favored 'General case' 0 C--N 1.295 -1.799 0 N-CA-C 105.679 -1.971 . . . . 5.13 105.679 177.21 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 1.1 p -46.59 -30.33 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.249 0 CA-C-N 115.34 -0.845 . . . . 4.38 109.639 -179.131 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.61 ' O ' HD23 ' A' ' 13' ' ' LEU . . . 164.01 -83.75 0.11 Allowed Glycine 0 N--CA 1.499 2.868 0 C-N-CA 119.81 -1.186 . . . . 4.22 110.377 179.039 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -64.57 37.95 0.11 Allowed 'Trans proline' 0 N--CA 1.484 0.934 0 C-N-CA 122.137 1.891 . . . . 3.85 109.677 179.561 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.887 ' N ' HD23 ' A' ' 13' ' ' LEU . 0.0 OUTLIER 45.59 27.46 0.42 Allowed 'General case' 0 N--CA 1.498 1.932 0 N-CA-C 108.474 -0.936 . . . . 3.67 108.474 -179.412 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.493 ' C ' ' N ' ' A' ' 16' ' ' GLY . . . 72.55 -41.71 0.82 Allowed Glycine 0 N--CA 1.487 2.052 0 N-CA-C 108.192 -1.963 . . . . 2.97 108.192 -179.088 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.514 ' H ' ' C ' ' A' ' 13' ' ' LEU . 22.9 tp10 50.0 14.3 0.13 Allowed 'General case' 0 N--CA 1.486 1.353 0 O-C-N 121.532 -0.981 . . . . 2.97 108.452 -179.841 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.493 ' N ' ' C ' ' A' ' 14' ' ' GLY . . . 70.81 -155.85 53.03 Favored Glycine 0 N--CA 1.486 2.003 0 N-CA-C 109.886 -1.286 . . . . 2.44 109.886 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.544 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -68.24 -15.55 67.89 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.881 -1.288 . . . . 1.81 109.881 -179.68 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.51 ' N ' ' OE1' ' A' ' 94' ' ' GLU . . . -43.8 -17.67 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.525 -0.985 . . . . 2.21 109.823 -179.679 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . 0.544 ' N ' ' O ' ' A' ' 17' ' ' GLY . 11.7 t-80 -100.25 -52.56 3.35 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.447 -0.783 . . . . 2.87 110.388 -179.146 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.545 ' HZ1' ' CB ' ' A' ' 43' ' ' THR . 0.0 OUTLIER -64.49 -17.89 64.29 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.962 -1.086 . . . . 2.02 109.874 -179.288 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.592 ' O ' HG13 ' A' ' 21' ' ' VAL . 9.7 p -72.22 114.31 10.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.046 -1.034 . . . . 2.07 108.829 179.503 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.405 ' HG2' ' HE1' ' A' ' 42' ' ' TRP . 5.9 tpp180 -109.84 134.61 51.86 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.452 -0.78 . . . . 3.5 110.108 -178.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -141.79 113.59 7.89 Favored 'General case' 0 N--CA 1.493 1.691 0 N-CA-C 108.392 -0.966 . . . . 1.83 108.392 179.15 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -150.93 132.07 3.76 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 109.94 -1.264 . . . . 1.9 109.94 -179.294 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.38 179.11 48.9 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 110.055 -1.218 . . . . 1.85 110.055 179.721 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 7.2 m -75.9 -19.9 58.46 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.47 -1.018 . . . . 2.31 109.674 179.922 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.449 ' O ' ' OH ' ' A' ' 77' ' ' TYR . . . -70.97 -24.76 76.8 Favored Glycine 0 N--CA 1.488 2.138 0 N-CA-C 108.767 -1.733 . . . . 1.64 108.767 179.844 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 29.6 mt -81.51 -11.21 59.27 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.555 -0.968 . . . . 1.83 108.946 179.633 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 33.2 mm-40 -84.67 -49.03 8.88 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.512 -0.743 . . . . 2.34 109.762 -179.494 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . 0.504 ' NH1' ' OD1' ' A' ' 110' ' ' ASP . 9.4 ptp180 -174.92 173.69 2.66 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.221 -0.925 . . . . 3.77 109.407 179.809 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -138.71 170.91 23.78 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 108.196 -1.962 . . . . 1.57 108.196 179.475 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.4 ' HA ' ' O ' ' A' ' 106' ' ' ALA . 25.6 t -134.64 149.36 29.56 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 O-C-N 121.23 -1.159 . . . . 1.83 109.944 -179.526 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.44 ' HB2' ' HD3' ' A' ' 82' ' ' PRO . . . -38.51 113.03 0.26 Allowed 'General case' 0 N--CA 1.496 1.832 0 CA-C-O 121.712 0.767 . . . . 1.64 112.098 -179.306 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 63.48 40.67 99.04 Favored Glycine 0 N--CA 1.491 2.337 0 O-C-N 121.685 -0.635 . . . . 1.73 111.814 177.424 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 46.4 t -127.32 119.95 22.07 Favored Pre-proline 0 N--CA 1.502 2.146 0 O-C-N 121.289 -1.124 . . . . 2.19 108.536 178.924 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -59.37 113.89 1.8 Allowed 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 120.589 0.86 . . . . 1.96 110.541 -179.488 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.517 ' HB3' ' CZ ' ' A' ' 77' ' ' TYR . . . -86.39 90.67 8.27 Favored 'General case' 0 N--CA 1.492 1.665 0 N-CA-C 108.281 -1.007 . . . . 1.69 108.281 179.032 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -85.78 148.28 25.92 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.244 -0.91 . . . . 2.23 110.884 -178.513 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.674 ' CE2' HD11 ' A' ' 41' ' ' ILE . 5.2 p90 -153.25 159.03 42.52 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 107.148 -1.427 . . . . 1.54 107.148 177.825 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . 0.426 ' OG ' ' OG ' ' A' ' 72' ' ' SER . 3.6 t -98.26 156.2 16.82 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.223 -0.923 . . . . 2.37 111.904 -177.093 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.674 HD11 ' CE2' ' A' ' 39' ' ' PHE . 13.3 mt -149.18 117.16 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 N-CA-C 108.368 -0.975 . . . . 1.65 108.368 178.713 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.519 ' O ' ' CD2' ' A' ' 42' ' ' TRP . 7.3 p-90 -122.07 129.12 52.12 Favored 'General case' 0 N--CA 1.503 2.182 0 O-C-N 121.256 -0.903 . . . . 3.68 109.031 179.718 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.545 ' CB ' ' HZ1' ' A' ' 20' ' ' LYS . 0.6 OUTLIER -149.02 142.11 24.9 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.229 -0.919 . . . . 2.89 109.605 -179.103 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -178.1 68.16 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.352 -0.842 . . . . 4.63 109.308 179.501 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 28.6 tt0 -153.47 -51.33 0.1 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.176 -0.953 . . . . 2.89 109.501 -179.919 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -61.57 -57.16 13.16 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.146 -0.971 . . . . 1.74 109.439 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 136.13 -177.56 19.46 Favored Glycine 0 N--CA 1.495 2.586 0 N-CA-C 108.683 -1.767 . . . . 1.6 108.683 -179.621 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.78 142.36 23.98 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.048 -1.266 . . . . 1.4 109.306 179.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -159.2 176.95 35.94 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.422 -1.471 . . . . 1.04 109.422 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -109.82 114.35 3.87 Favored Glycine 0 N--CA 1.498 2.785 0 N-CA-C 109.439 -1.464 . . . . 1.06 109.439 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.474 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 10.5 tp -94.43 96.75 9.71 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.216 -1.167 . . . . 1.1 108.353 179.386 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 22.3 p -84.68 141.16 30.8 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.627 -0.879 . . . . 1.56 108.627 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.537 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 87.3 mt -134.01 113.96 18.72 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.342 -0.848 . . . . 0.65 109.489 -179.838 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -105.28 108.52 20.08 Favored 'General case' 0 N--CA 1.495 1.784 0 N-CA-C 108.808 -0.812 . . . . 0.69 108.808 179.611 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.433 HG23 ' OG ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -100.27 142.58 15.27 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.494 -0.753 . . . . 0.91 109.412 -179.795 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 12.5 tt0 -141.89 144.12 33.65 Favored 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 108.046 -1.094 . . . . 1.8 108.046 178.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.429 ' O ' ' O ' ' B' ' 9' ' ' VAL . . . 163.79 -172.4 39.66 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.836 -1.306 . . . . 0.49 109.836 -179.498 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -63.34 -28.73 72.03 Favored 'Trans proline' 0 C--N 1.318 -1.053 0 C-N-CA 122.133 1.889 . . . . 0.66 112.136 -179.412 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -131.73 175.99 8.72 Favored 'General case' 0 N--CA 1.502 2.152 0 O-C-N 121.225 -0.922 . . . . 1.55 110.165 -179.575 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 47.0 mttp -93.09 120.21 33.14 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.518 -0.739 . . . . 2.53 109.523 -179.712 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.673 ' HB1' ' HB2' ' A' ' 77' ' ' TYR . . . -80.94 108.63 14.78 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.331 -0.856 . . . . 0.82 108.825 179.82 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 23.4 mt-10 -83.51 103.17 12.65 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.072 -1.018 . . . . 2.3 109.87 -179.592 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 7.6 mm -58.73 156.96 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.886 -0.509 . . . . 1.4 109.751 179.781 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.469 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -139.66 174.5 10.45 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.122 -0.986 . . . . 1.36 109.015 179.649 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.441 ' CD1' ' N ' ' A' ' 65' ' ' PHE . 13.9 p90 -139.64 117.18 11.43 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.412 -0.805 . . . . 1.47 109.536 -179.896 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -141.36 113.53 8.0 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.31 -0.869 . . . . 2.51 109.453 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -74.38 138.83 43.66 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.207 -0.933 . . . . 2.07 109.148 179.719 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 66.2 ttt180 -118.96 -47.74 2.48 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.475 -0.766 . . . . 4.63 109.505 -179.787 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.521 ' C ' ' H ' ' A' ' 71' ' ' GLY . 33.0 mttm -115.86 7.22 14.46 Favored 'General case' 0 N--CA 1.495 1.803 0 N-CA-C 108.379 -0.971 . . . . 3.49 108.379 179.645 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.409 ' CB ' ' O ' ' A' ' 69' ' ' LYS . 6.0 t70 70.73 -40.73 0.48 Allowed 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 108.432 -0.951 . . . . 3.06 108.432 -179.054 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . 0.521 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -91.35 27.84 8.95 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.363 -1.495 . . . . 2.16 109.363 179.766 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.426 ' OG ' ' OG ' ' A' ' 40' ' ' SER . 24.2 t -156.16 119.59 4.31 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.425 -1.044 . . . . 2.2 109.131 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' CYS . . . . . 0.51 ' N ' ' O ' ' A' ' 41' ' ' ILE . 20.5 m -77.26 110.89 12.36 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.233 -0.917 . . . . 2.05 109.582 -179.849 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -83.79 115.15 4.0 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.408 -1.477 . . . . 1.39 109.408 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.552 HG21 HD12 ' A' ' 41' ' ' ILE . 10.1 t -115.42 133.86 60.41 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.052 0 O-C-N 121.649 -0.912 . . . . 1.57 108.964 179.897 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.469 ' O ' ' N ' ' A' ' 64' ' ' ALA . 6.0 t -136.73 139.82 42.16 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.447 -0.783 . . . . 1.85 109.944 -179.827 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.673 ' HB2' ' HB1' ' A' ' 61' ' ' ALA . 6.9 p90 -120.16 139.2 52.97 Favored 'General case' 0 N--CA 1.495 1.79 0 N-CA-C 108.201 -1.037 . . . . 1.54 108.201 179.224 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.576 ' O ' HG13 ' A' ' 78' ' ' VAL . 9.7 p -108.87 120.78 60.88 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 O-C-N 121.332 -0.855 . . . . 1.9 109.741 -179.078 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.415 HG12 ' CZ ' ' A' ' 85' ' ' TYR . 3.6 m -101.12 168.4 1.93 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 N-CA-C 108.439 -0.949 . . . . 1.27 108.439 179.448 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 34.2 tp60 -101.5 -40.56 6.99 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.08 -1.013 . . . . 2.48 110.758 -179.486 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.429 ' O ' ' O ' ' A' ' 82' ' ' PRO . 0.0 OUTLIER -153.32 156.51 32.54 Favored Pre-proline 0 N--CA 1.504 2.248 0 O-C-N 120.539 -1.351 . . . . 1.92 111.209 -179.276 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.558 ' HG3' ' N ' ' A' ' 107' ' ' SER . 78.7 Cg_exo -37.73 169.12 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.654 0 C-N-CA 123.444 2.763 . . . . 1.3 113.239 179.016 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 142.82 179.02 19.25 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.659 -1.376 . . . . 1.02 109.659 179.559 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . 0.814 ' H ' HH12 ' B' ' 8' ' ' ARG . 3.0 m-20 -96.97 87.2 4.18 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 107.929 -1.137 . . . . 2.13 107.929 179.301 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.415 ' CZ ' HG12 ' A' ' 79' ' ' VAL . 2.9 m-85 -74.13 134.76 42.87 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 108.351 -0.981 . . . . 0.92 108.351 -179.345 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -111.22 121.58 45.65 Favored 'General case' 0 N--CA 1.497 1.91 0 N-CA-C 108.682 -0.858 . . . . 1.53 108.682 -179.058 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.1 p -119.65 140.58 43.16 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.891 0 O-C-N 121.552 -0.717 . . . . 1.0 109.546 -179.798 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 12.2 t -133.18 101.39 5.18 Favored 'General case' 0 N--CA 1.5 2.026 0 O-C-N 121.515 -0.741 . . . . 1.59 109.308 179.772 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.42 HG13 HD11 ' A' ' 96' ' ' ILE . 1.9 pt -108.51 137.51 39.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.721 -0.612 . . . . 1.29 110.37 -179.285 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . 0.44 ' HG3' ' H ' ' A' ' 93' ' ' ASP . 0.2 OUTLIER -146.91 125.87 12.79 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.857 -0.794 . . . . 1.58 108.857 179.367 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 48.4 t80 -81.69 93.89 6.86 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 120.785 -1.197 . . . . 1.34 108.492 179.42 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . 0.409 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 5.4 t30 69.93 43.24 0.94 Allowed 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 107.913 -1.143 . . . . 2.32 107.913 -178.591 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.44 ' H ' ' HG3' ' A' ' 90' ' ' LYS . 3.4 m-20 78.3 11.76 1.75 Allowed 'General case' 0 N--CA 1.495 1.789 0 CA-C-O 121.253 0.549 . . . . 1.92 109.96 -179.241 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . 0.51 ' OE1' ' N ' ' A' ' 18' ' ' ALA . 50.0 mt-10 -85.43 77.34 9.94 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 107.805 -1.183 . . . . 2.25 107.805 178.454 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . 0.546 ' CD2' ' O ' ' A' ' 95' ' ' HIS . 0.4 OUTLIER -67.97 106.41 2.33 Favored 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 120.03 -0.668 . . . . 2.88 109.752 -179.513 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . 0.775 ' H ' HD13 ' A' ' 96' ' ' ILE . 0.0 OUTLIER -68.96 156.1 92.15 Favored Pre-proline 0 N--CA 1.495 1.787 0 N-CA-C 107.709 -1.219 . . . . 2.35 107.709 179.606 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -48.9 -29.28 14.86 Favored 'Trans proline' 0 C--N 1.323 -0.806 0 C-N-CA 121.059 1.173 . . . . 2.48 109.144 -179.797 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 57.0 m-20 -58.83 -64.16 1.04 Allowed 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 108.963 -0.755 . . . . 2.65 108.963 178.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 3.1 m -70.78 139.7 86.06 Favored Pre-proline 0 C--N 1.296 -1.739 0 O-C-N 121.05 -1.031 . . . . 2.0 110.073 -178.681 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -87.08 119.46 5.07 Favored 'Cis proline' 0 N--CA 1.493 1.49 0 N-CA-C 110.025 -0.798 . . . . 1.79 110.025 -2.342 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 40.5 p90 -121.14 166.97 13.17 Favored 'General case' 0 N--CA 1.519 2.996 0 O-C-N 120.499 -1.376 . . . . 2.19 109.882 178.195 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.4 p -92.35 146.23 6.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 CA-C-O 121.642 0.734 . . . . 1.44 110.918 -178.28 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 79.8 t -119.83 86.46 35.94 Favored Pre-proline 0 N--CA 1.496 1.842 0 N-CA-C 107.799 -1.185 . . . . 1.19 107.799 178.888 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -63.96 114.28 2.54 Favored 'Trans proline' 0 C--N 1.32 -0.95 0 C-N-CA 121.36 1.373 . . . . 1.49 111.683 -178.028 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 75.2 t -98.88 144.09 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 N-CA-C 106.569 -1.641 . . . . 1.35 106.569 178.11 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.681 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -134.94 138.28 43.91 Favored 'General case' 0 N--CA 1.51 2.556 0 CA-C-O 122.055 0.931 . . . . 1.67 112.08 -177.174 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.558 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 20.3 m -92.2 63.77 4.37 Favored 'General case' 0 N--CA 1.496 1.856 0 N-CA-C 107.152 -1.425 . . . . 2.04 107.152 178.652 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . 0.49 ' CB ' ' O ' ' A' ' 107' ' ' SER . 3.2 tp 80.45 -13.56 0.92 Allowed 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 106.456 -1.683 . . . . 3.2 106.456 -177.416 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.54 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 5.2 m -68.54 -21.9 64.53 Favored 'General case' 0 C--N 1.306 -1.305 0 N-CA-C 108.732 -0.84 . . . . 2.09 108.732 178.785 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . 0.681 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 21.5 t70 47.57 18.82 0.12 Allowed 'General case' 0 N--CA 1.494 1.736 0 CA-C-O 121.937 0.875 . . . . 2.85 108.666 179.876 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.462 ' N ' ' O ' ' A' ' 109' ' ' SER . 12.6 t70 -173.88 -30.84 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 108.567 -0.901 . . . . 2.46 108.567 -179.643 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.54 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 48.29 92.81 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.123 -0.986 . . . . 2.08 109.509 179.661 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . 0.566 ' CG ' HH11 ' A' ' 113' ' ' ARG . 0.0 OUTLIER -62.44 -154.16 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.222 -0.924 . . . . 5.93 109.16 -179.797 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 57.5 ttt180 -145.28 2.4 0.99 Allowed 'General case' 0 N--CA 1.492 1.636 0 N-CA-C 107.883 -1.155 . . . . 5.61 107.883 179.456 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 36.2 mt -130.62 -27.64 2.12 Favored 'General case' 0 N--CA 1.5 2.039 0 N-CA-C 108.968 -0.752 . . . . 4.39 108.968 179.497 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.493 ' C ' ' N ' ' A' ' 118' ' ' THR . 1.6 p -98.77 -81.0 0.45 Allowed 'General case' 0 N--CA 1.489 1.52 0 N-CA-C 106.82 -1.548 . . . . 4.09 106.82 178.907 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.426 ' O ' HG12 ' A' ' 117' ' ' VAL . 51.6 t -60.94 -9.46 2.43 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.602 0 N-CA-C 105.967 -1.864 . . . . 2.9 105.967 176.684 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' THR . . . . . 0.493 ' N ' ' C ' ' A' ' 116' ' ' THR . 4.9 t 36.91 60.79 0.94 Allowed 'General case' 0 N--CA 1.487 1.384 0 CA-C-N 115.136 -0.938 . . . . 3.36 110.685 179.736 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' SER . . . . . 0.45 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.6 p . . . . . 0 C--N 1.303 -1.43 0 CA-C-O 117.952 -1.023 . . . . 3.39 109.607 179.303 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 82.7 mtp . . . . . 0 N--CA 1.491 1.599 0 N-CA-C 109.414 -0.587 . . . . 8.49 109.414 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . 50.9 -160.24 0.08 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.293 -0.879 . . . . 5.53 109.506 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 3' ' ' SER . . . . . . . . . . . . . 10.2 t 50.35 73.43 0.27 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.354 -0.841 . . . . 5.43 109.654 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 4' ' ' LYS . . . . . 0.634 ' N ' ' CD ' ' B' ' 5' ' ' PRO . 29.7 tttm -77.26 -35.97 1.43 Allowed Pre-proline 0 N--CA 1.489 1.487 0 O-C-N 121.164 -0.96 . . . . 6.87 111.313 179.831 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 5' ' ' PRO . . . . . 0.634 ' CD ' ' N ' ' B' ' 4' ' ' LYS . 4.1 Cg_endo -74.08 116.8 4.77 Favored 'Trans proline' 0 C--N 1.324 -0.757 0 C-N-CA 120.764 0.976 . . . . 5.16 109.633 -179.584 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 6' ' ' GLU . . . . . 0.541 ' OE1' ' N ' ' B' ' 6' ' ' GLU . 0.0 OUTLIER -158.13 135.17 9.96 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.032 -1.043 . . . . 4.78 109.928 179.627 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 7' ' ' LYS . . . . . 0.448 ' O ' ' O ' ' B' ' 6' ' ' GLU . 30.9 mmtp 54.4 108.03 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.405 -0.809 . . . . 4.09 110.044 179.696 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.814 HH12 ' H ' ' A' ' 84' ' ' ASP . 10.7 mtt180 -78.07 171.07 15.57 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.087 -1.079 . . . . 3.04 108.087 179.19 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 9' ' ' VAL . . . . . 0.429 ' O ' ' O ' ' A' ' 57' ' ' GLY . 38.6 t -51.74 155.79 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 120.921 -1.112 . . . . 0.67 108.215 179.404 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -119.66 149.87 41.28 Favored 'General case' 0 N--CA 1.501 2.078 0 O-C-N 121.402 -0.811 . . . . 0.58 110.142 -178.914 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 11' ' ' SER . . . . . 0.433 ' OG ' HG23 ' A' ' 55' ' ' VAL . 6.9 t -147.36 141.84 26.46 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.506 -0.746 . . . . 1.19 109.301 179.688 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 6.7 m -143.88 121.14 11.56 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.176 -0.952 . . . . 1.38 109.439 -179.846 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 0.631 HG22 ' N ' ' B' ' 14' ' ' PHE . 7.7 p -163.62 168.76 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.39 -0.819 . . . . 0.42 109.183 179.91 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 14' ' ' PHE . . . . . 0.631 ' N ' HG22 ' B' ' 13' ' ' VAL . 7.9 p90 -176.91 -168.05 0.2 Allowed 'General case' 0 N--CA 1.488 1.437 0 C-N-CA 119.402 -0.919 . . . . 1.79 111.928 179.7 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.6 pt -151.29 167.47 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.344 0 N-CA-C 109.091 -0.707 . . . . 1.25 109.091 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 16' ' ' THR . . . . . 0.428 ' O ' HG23 ' B' ' 16' ' ' THR . 7.3 t -122.53 128.92 51.38 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 121.463 -0.773 . . . . 1.61 109.009 179.661 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 12.1 mt -97.63 150.94 20.61 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.204 -0.935 . . . . 1.32 109.866 -179.617 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -168.41 151.72 5.51 Favored Pre-proline 0 N--CA 1.49 1.545 0 N-CA-C 108.606 -0.887 . . . . 1.45 108.606 179.584 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -60.62 140.78 92.83 Favored 'Trans proline' 0 CA--C 1.551 1.35 0 C-N-CA 120.911 1.074 . . . . 1.5 109.431 179.84 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 20' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_endo -62.16 -36.46 69.25 Favored 'Trans proline' 0 C--N 1.324 -0.719 0 N-CA-C 109.359 -1.054 . . . . 2.86 109.359 179.159 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 79.4 mtm180 -66.8 -163.28 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.469 -0.769 . . . . 6.12 109.718 -179.717 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 22' ' ' ARG . . . . . . . . . . . . . 21.1 mmm180 -130.95 -78.14 0.53 Allowed 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.532 -0.73 . . . . 6.29 109.098 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 -64.97 -132.68 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.295 -0.878 . . . . 5.62 109.454 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 97.6 t . . . . . 0 N--CA 1.493 1.716 0 CA-C-O 117.974 -1.013 . . . . 6.48 109.336 179.977 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.91 0 N-CA-C 119.722 2.649 . . . . 6.64 119.722 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.643 HG23 ' O ' ' A' ' 2' ' ' ILE . 3.8 tp -172.42 50.69 0.12 Allowed Pre-proline 0 C--N 1.307 -1.258 0 N-CA-C 108.194 -1.039 . . . . 7.08 108.194 179.647 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.73 ' C ' ' H ' ' A' ' 5' ' ' PHE . 4.1 Cg_exo -50.53 -76.23 0.03 OUTLIER 'Trans proline' 0 C--N 1.319 -0.989 0 C-N-CA 121.194 1.263 . . . . 5.5 109.218 179.601 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.441 ' CB ' ' O ' ' A' ' 3' ' ' PRO . 8.7 tt0 70.97 -5.63 1.46 Allowed 'General case' 0 N--CA 1.494 1.745 0 N-CA-C 104.215 -2.513 . . . . 6.75 104.215 -175.717 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . 0.73 ' H ' ' C ' ' A' ' 3' ' ' PRO . 4.3 m-85 -103.56 17.43 24.11 Favored 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 103.392 -2.818 . . . . 6.07 103.392 177.648 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.542 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 44.1 p90 46.23 -159.01 0.03 OUTLIER 'General case' 0 C--N 1.308 -1.212 0 CA-C-N 113.774 -1.557 . . . . 4.72 109.852 -177.665 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.529 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 32.3 tp60 87.0 -9.81 0.62 Allowed 'General case' 0 N--CA 1.493 1.717 0 N-CA-C 104.911 -2.255 . . . . 4.4 104.911 -177.016 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.456 ' CD2' ' O ' ' A' ' 7' ' ' GLN . 45.3 m-85 -158.06 -35.81 0.07 Allowed 'General case' 0 C--N 1.304 -1.412 0 CA-C-N 114.537 -1.211 . . . . 5.15 107.915 178.179 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.582 HG22 ' O ' ' A' ' 9' ' ' THR . 17.8 m -92.39 2.57 56.58 Favored 'General case' 0 C--N 1.298 -1.638 0 N-CA-C 106.008 -1.849 . . . . 5.13 106.008 177.373 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.462 HG13 ' N ' ' A' ' 11' ' ' GLY . 7.5 p -40.74 -38.29 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 CA-C-O 121.792 0.806 . . . . 4.38 109.401 179.838 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.688 ' O ' HD23 ' A' ' 13' ' ' LEU . . . 143.97 -86.87 0.18 Allowed Glycine 0 N--CA 1.496 2.691 0 N-CA-C 108.564 -1.814 . . . . 4.22 108.564 179.566 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.452 ' O ' ' N ' ' A' ' 14' ' ' GLY . 12.5 Cg_endo -69.34 34.98 0.2 Allowed 'Trans proline' 0 C--N 1.321 -0.915 0 C-N-CA 121.321 1.347 . . . . 3.85 108.974 178.243 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.871 ' N ' HD23 ' A' ' 13' ' ' LEU . 0.0 OUTLIER 40.56 28.51 0.05 OUTLIER 'General case' 0 N--CA 1.503 2.206 0 CA-C-O 121.925 0.869 . . . . 3.67 108.731 -178.734 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.597 ' C ' ' H ' ' A' ' 16' ' ' GLY . . . 72.37 -42.21 0.81 Allowed Glycine 0 N--CA 1.487 2.071 0 N-CA-C 108.375 -1.89 . . . . 2.97 108.375 -179.226 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.506 ' H ' ' C ' ' A' ' 13' ' ' LEU . 28.4 tt0 55.13 2.22 0.05 OUTLIER 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.669 -0.901 . . . . 2.97 108.978 -179.257 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.597 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 87.24 -149.21 21.85 Favored Glycine 0 N--CA 1.488 2.107 0 O-C-N 121.292 -0.88 . . . . 2.44 111.157 178.78 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.55 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -38.83 -23.39 0.02 OUTLIER Glycine 0 N--CA 1.497 2.702 0 O-C-N 121.819 -0.813 . . . . 1.81 111.59 -178.704 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.709 ' HB2' ' OE1' ' A' ' 94' ' ' GLU . . . -47.25 -11.57 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.861 0 O-C-N 120.857 -1.378 . . . . 2.21 110.145 -179.467 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . 0.55 ' N ' ' O ' ' A' ' 17' ' ' GLY . 1.8 t60 -97.24 -37.73 9.96 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.249 -0.907 . . . . 2.87 110.242 -179.372 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.515 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.0 OUTLIER -91.03 -14.48 31.29 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.008 -1.057 . . . . 2.02 110.497 -179.145 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.566 ' O ' HG13 ' A' ' 21' ' ' VAL . 4.7 p -78.96 114.4 19.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 120.838 -1.164 . . . . 2.07 109.712 -179.763 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 12.5 tpp180 -109.75 139.27 45.0 Favored 'General case' 0 N--CA 1.492 1.646 0 N-CA-C 108.92 -0.771 . . . . 3.5 108.92 -179.877 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -147.32 113.57 5.89 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.535 -0.728 . . . . 1.83 109.2 179.584 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -147.6 128.38 2.9 Favored Glycine 0 N--CA 1.496 2.662 0 N-CA-C 109.472 -1.451 . . . . 1.9 109.472 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.07 171.24 43.69 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.842 -1.303 . . . . 1.85 109.842 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 34.1 m -74.89 -23.6 58.4 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.329 -1.101 . . . . 2.31 109.266 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.426 ' C ' ' H ' ' A' ' 29' ' ' GLU . . . -68.61 -27.92 73.51 Favored Glycine 0 N--CA 1.485 1.925 0 N-CA-C 108.444 -1.862 . . . . 1.64 108.444 179.641 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 24.9 mt -81.06 26.92 0.41 Allowed 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 108.416 -0.957 . . . . 1.83 108.416 179.397 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.426 ' H ' ' C ' ' A' ' 27' ' ' GLY . 42.5 mt-10 -132.21 -50.56 0.94 Allowed 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.687 -0.633 . . . . 2.34 109.608 -179.621 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 29.0 ptt180 -168.17 177.8 5.32 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 120.89 -1.131 . . . . 3.77 110.602 -179.774 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -151.08 175.68 29.92 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 108.566 -1.814 . . . . 1.57 108.566 179.686 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 39.9 t -134.56 151.93 32.58 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.087 0 O-C-N 121.22 -1.165 . . . . 1.83 110.748 -179.702 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.574 ' HB2' ' HB2' ' A' ' 107' ' ' SER . . . -39.16 108.95 0.09 Allowed 'General case' 0 N--CA 1.5 2.029 0 CA-C-O 121.399 0.618 . . . . 1.64 112.494 -179.388 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 54.57 53.71 37.15 Favored Glycine 0 N--CA 1.491 2.323 0 O-C-N 121.393 -0.817 . . . . 1.73 111.626 176.899 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 24.0 t -127.23 124.28 23.68 Favored Pre-proline 0 N--CA 1.496 1.826 0 N-CA-C 108.205 -1.035 . . . . 2.19 108.205 178.663 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo -57.24 128.95 31.69 Favored 'Trans proline' 0 C--O 1.216 -0.615 0 N-CA-C 109.693 -0.926 . . . . 1.96 109.693 -179.581 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.554 ' HB3' ' CZ ' ' A' ' 77' ' ' TYR . . . -134.36 157.89 45.22 Favored 'General case' 0 N--CA 1.502 2.16 0 O-C-N 121.518 -0.739 . . . . 1.69 109.507 -179.634 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -160.14 164.08 33.23 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.121 -0.987 . . . . 2.23 110.976 -179.663 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.558 ' CD1' ' N ' ' A' ' 39' ' ' PHE . 0.7 OUTLIER -139.89 -179.03 5.71 Favored 'General case' 0 C--N 1.304 -1.391 0 N-CA-C 106.896 -1.52 . . . . 1.54 106.896 177.75 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 52.2 p -119.16 145.87 45.64 Favored 'General case' 0 N--CA 1.5 2.04 0 O-C-N 121.598 -0.688 . . . . 2.37 110.609 -178.816 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.537 ' O ' ' N ' ' A' ' 73' ' ' CYS . 42.8 mt -143.63 128.68 15.1 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 N-CA-C 108.58 -0.896 . . . . 1.65 108.58 179.213 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 5.5 p-90 -128.24 138.78 52.59 Favored 'General case' 0 N--CA 1.502 2.161 0 N-CA-C 108.853 -0.795 . . . . 3.68 108.853 179.423 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.515 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -162.42 139.22 7.9 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.171 -0.956 . . . . 2.89 109.896 -179.534 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' ARG . . . . . . . . . . . . . 61.7 ttt180 -171.84 68.38 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.414 -0.804 . . . . 4.63 109.226 179.732 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 11.1 tp10 -153.72 -51.79 0.1 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.244 -0.91 . . . . 2.89 109.568 -179.87 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.76 -50.08 73.33 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.201 -0.937 . . . . 1.74 108.946 179.795 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 116.14 -162.4 12.62 Favored Glycine 0 N--CA 1.497 2.745 0 N-CA-C 109.639 -1.384 . . . . 1.6 109.639 179.735 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.4 151.98 5.11 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.276 -1.132 . . . . 1.4 109.386 -179.841 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -176.49 -162.72 27.7 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.55 -1.42 . . . . 1.04 109.55 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -140.47 119.71 1.63 Allowed Glycine 0 N--CA 1.496 2.663 0 N-CA-C 109.528 -1.429 . . . . 1.06 109.528 -179.878 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.466 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 11.6 tp -99.43 99.04 9.9 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.357 -1.084 . . . . 1.1 108.691 179.685 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 4.1 m -84.8 142.33 29.85 Favored 'General case' 0 N--CA 1.496 1.84 0 N-CA-C 108.741 -0.837 . . . . 1.56 108.741 179.867 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.52 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 80.5 mt -132.36 116.6 29.21 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 O-C-N 121.01 -1.056 . . . . 0.65 109.889 -179.915 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -106.99 106.92 17.69 Favored 'General case' 0 N--CA 1.496 1.865 0 N-CA-C 108.562 -0.903 . . . . 0.69 108.562 179.328 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -106.23 137.55 35.96 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 121.388 -0.82 . . . . 0.91 109.941 -179.186 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.433 ' OE2' ' O ' ' B' ' 9' ' ' VAL . 40.7 tp10 -131.97 142.78 49.72 Favored 'General case' 0 N--CA 1.495 1.785 0 N-CA-C 107.896 -1.15 . . . . 1.8 107.896 178.36 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 172.95 -179.51 44.34 Favored Glycine 0 N--CA 1.488 2.132 0 N-CA-C 108.784 -1.726 . . . . 0.49 108.784 -179.635 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -63.43 -21.91 71.26 Favored 'Trans proline' 0 C--N 1.315 -1.231 0 C-N-CA 121.678 1.585 . . . . 0.66 110.732 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . 0.423 ' O ' ' OH ' ' A' ' 85' ' ' TYR . 36.6 m -143.24 165.47 27.36 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.453 -0.78 . . . . 1.55 110.114 -179.62 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 38.2 mttp -86.97 104.96 16.78 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.507 -0.746 . . . . 2.53 109.396 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -67.06 113.06 4.74 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.337 -0.852 . . . . 0.82 109.535 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 24.5 mm-40 -53.72 171.76 0.09 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.282 -0.886 . . . . 2.3 109.225 179.84 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.4 HG22 ' N ' ' A' ' 64' ' ' ALA . 90.1 mt -142.32 155.59 18.83 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 N-CA-C 108.122 -1.066 . . . . 1.4 108.122 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.542 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -149.56 175.35 11.6 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 120.642 -1.286 . . . . 1.36 109.635 -179.802 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.522 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 54.6 p90 -138.88 124.77 19.84 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.448 -0.782 . . . . 1.47 109.124 179.846 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -141.46 123.63 15.58 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.273 -0.892 . . . . 2.51 109.579 -179.825 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -99.77 101.97 13.28 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.364 -0.835 . . . . 2.07 109.267 179.807 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 39.4 ttm180 -90.14 -15.55 31.34 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.198 -0.939 . . . . 4.63 109.763 -179.771 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.526 ' C ' ' H ' ' A' ' 71' ' ' GLY . 4.5 mmmm -127.56 5.12 6.18 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 121.442 -0.786 . . . . 3.49 109.44 -179.681 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.464 ' CB ' ' O ' ' A' ' 69' ' ' LYS . 4.5 t0 73.14 -17.21 0.43 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.198 -0.939 . . . . 3.06 108.739 -179.437 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . 0.526 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -124.97 -17.02 2.84 Favored Glycine 0 N--CA 1.495 2.593 0 N-CA-C 109.367 -1.493 . . . . 2.16 109.367 -179.671 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 40.3 t -95.85 100.37 12.08 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.258 -1.142 . . . . 2.2 109.176 179.785 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' CYS . . . . . 0.537 ' N ' ' O ' ' A' ' 41' ' ' ILE . 46.6 t -71.54 111.1 6.57 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.228 -0.92 . . . . 2.05 109.48 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -91.96 115.14 4.71 Favored Glycine 0 N--CA 1.493 2.477 0 N-CA-C 109.692 -1.363 . . . . 1.39 109.692 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 45.3 t -99.38 102.0 12.84 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 O-C-N 121.467 -1.019 . . . . 1.57 109.011 179.721 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.542 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.4 OUTLIER -92.0 137.09 32.65 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.338 -0.851 . . . . 1.85 109.111 -179.837 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.554 ' CZ ' ' HB3' ' A' ' 37' ' ' ALA . 8.5 p90 -136.34 166.04 24.38 Favored 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 108.674 -0.861 . . . . 1.54 108.674 -179.862 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 6.7 t -141.86 110.05 2.34 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.329 -0.857 . . . . 1.9 109.585 -179.669 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.464 ' H ' HG22 ' A' ' 79' ' ' VAL . 3.3 m -84.73 154.32 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.544 -0.723 . . . . 1.27 109.429 -179.915 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 4.3 tp-100 -93.26 -48.93 6.21 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.065 -1.022 . . . . 2.48 111.015 -178.96 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.431 ' O ' ' O ' ' A' ' 82' ' ' PRO . 81.5 mm-40 -148.57 149.92 32.39 Favored Pre-proline 0 N--CA 1.504 2.263 0 O-C-N 120.68 -1.262 . . . . 1.92 111.609 -178.427 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.637 ' HG3' ' N ' ' A' ' 107' ' ' SER . 83.1 Cg_exo -37.18 168.53 0.0 OUTLIER 'Trans proline' 0 C--O 1.216 -0.599 0 C-N-CA 123.15 2.567 . . . . 1.3 113.787 178.37 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 141.8 -173.8 23.4 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 108.651 -1.779 . . . . 1.02 108.651 -179.87 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . 0.717 ' H ' ' NH1' ' B' ' 8' ' ' ARG . 0.4 OUTLIER -103.18 90.41 3.72 Favored 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 107.866 -1.161 . . . . 2.13 107.866 179.217 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.423 ' OH ' ' O ' ' A' ' 59' ' ' SER . 3.0 m-85 -74.69 133.4 42.09 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 107.992 -1.114 . . . . 0.92 107.992 -179.574 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.36 116.38 28.85 Favored 'General case' 0 N--CA 1.5 2.034 0 N-CA-C 108.503 -0.925 . . . . 1.53 108.503 -178.791 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.429 HG11 ' CZ ' ' A' ' 101' ' ' PHE . 11.3 p -114.63 142.32 27.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 121.719 -0.613 . . . . 1.0 109.865 -179.66 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 32.9 t -136.11 106.07 6.28 Favored 'General case' 0 N--CA 1.494 1.756 0 N-CA-C 109.289 -0.634 . . . . 1.59 109.289 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.413 ' H ' ' HB3' ' A' ' 99' ' ' SER . 1.8 pt -111.4 136.85 46.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 CA-C-O 121.374 0.607 . . . . 1.29 110.148 -179.429 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . 0.458 ' HZ2' ' CD2' ' A' ' 95' ' ' HIS . 0.3 OUTLIER -138.99 121.27 15.92 Favored 'General case' 0 N--CA 1.486 1.355 0 N-CA-C 108.518 -0.919 . . . . 1.58 108.518 179.329 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 52.6 t80 -80.1 99.02 7.52 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 107.699 -1.223 . . . . 1.34 107.699 178.563 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . 0.442 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 3.6 t-20 69.8 37.79 1.76 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.503 -0.748 . . . . 2.32 109.284 -178.735 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.442 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 1.8 m-20 79.06 13.49 1.2 Allowed 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.625 -0.672 . . . . 1.92 111.629 179.313 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . 0.709 ' OE1' ' HB2' ' A' ' 18' ' ' ALA . 0.6 OUTLIER -99.29 97.88 8.9 Favored 'General case' 0 N--CA 1.5 2.059 0 N-CA-C 106.857 -1.534 . . . . 2.25 106.857 177.732 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . 0.458 ' CD2' ' HZ2' ' A' ' 90' ' ' LYS . 5.9 m80 -67.88 101.86 1.16 Allowed 'General case' 0 N--CA 1.487 1.421 0 CA-C-O 121.411 0.624 . . . . 2.88 110.924 -177.636 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . 0.428 HG23 ' H ' ' A' ' 99' ' ' SER . 2.1 tt -53.32 137.46 49.69 Favored Pre-proline 0 N--CA 1.49 1.566 0 N-CA-C 106.869 -1.53 . . . . 2.35 106.869 178.26 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_exo -40.76 -39.06 2.95 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 121.077 1.184 . . . . 2.48 111.194 -178.575 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.408 ' OD1' ' CD1' ' A' ' 96' ' ' ILE . 8.6 m-20 -50.12 -67.2 0.28 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.787 -1.196 . . . . 2.65 109.092 178.843 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.428 ' H ' HG23 ' A' ' 96' ' ' ILE . 2.8 p -57.53 142.03 77.77 Favored Pre-proline 0 C--N 1.296 -1.759 0 O-C-N 121.405 -0.81 . . . . 2.0 110.086 -178.236 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -85.15 114.92 3.22 Favored 'Cis proline' 0 N--CA 1.49 1.288 0 N-CA-C 108.739 -1.293 . . . . 1.79 108.739 -2.612 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . 0.429 ' CZ ' HG11 ' A' ' 87' ' ' VAL . 51.8 p90 -112.77 156.45 22.83 Favored 'General case' 0 N--CA 1.514 2.748 0 O-C-N 120.405 -1.434 . . . . 2.19 110.217 179.286 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.4 p -88.94 146.1 6.58 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 CA-C-O 121.556 0.693 . . . . 1.44 110.417 -178.595 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.414 ' O ' HG12 ' A' ' 103' ' ' VAL . 47.3 t -120.97 86.55 42.09 Favored Pre-proline 0 N--CA 1.494 1.768 0 N-CA-C 107.753 -1.203 . . . . 1.19 107.753 179.236 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo -65.07 111.08 1.65 Allowed 'Trans proline' 0 C--N 1.32 -0.935 0 C-N-CA 121.393 1.395 . . . . 1.49 111.74 -177.879 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.431 HG21 HG11 ' A' ' 79' ' ' VAL . 58.6 t -96.53 141.05 16.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 N-CA-C 106.148 -1.797 . . . . 1.35 106.148 177.828 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.69 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -133.89 133.72 41.83 Favored 'General case' 0 N--CA 1.51 2.53 0 CA-C-O 122.303 1.049 . . . . 1.67 112.131 -177.031 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.637 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 17.0 t -101.02 85.55 2.87 Favored 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 107.129 -1.434 . . . . 2.04 107.129 178.685 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 12.9 mt 64.76 0.51 1.18 Allowed 'General case' 0 C--N 1.296 -1.729 0 N-CA-C 108.035 -1.098 . . . . 3.2 108.035 -178.011 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.624 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 8.2 t -89.88 -24.95 21.23 Favored 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 109.011 -0.737 . . . . 2.09 109.011 179.061 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . 0.69 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 25.2 t70 54.32 10.65 0.33 Allowed 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 107.897 -1.149 . . . . 2.85 107.897 -178.969 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.491 ' H ' ' C ' ' A' ' 109' ' ' SER . 42.3 t0 -168.81 -34.01 0.02 OUTLIER 'General case' 0 C--N 1.305 -1.341 0 O-C-N 121.756 -0.59 . . . . 2.46 109.556 -179.73 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.624 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 34.66 78.02 0.03 OUTLIER 'General case' 0 N--CA 1.508 2.433 0 O-C-N 121.479 -0.763 . . . . 2.08 110.894 179.883 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . 0.401 ' H ' ' HB ' ' A' ' 117' ' ' VAL . 72.6 mtt180 -82.91 167.15 18.28 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.127 -0.983 . . . . 5.93 109.756 -179.475 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 28.2 ttp180 -110.52 5.4 21.2 Favored 'General case' 0 N--CA 1.498 1.929 0 N-CA-C 108.649 -0.871 . . . . 5.61 108.649 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 27.9 mt -125.65 -26.59 3.5 Favored 'General case' 0 N--CA 1.503 2.221 0 N-CA-C 109.157 -0.682 . . . . 4.39 109.157 -179.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.504 ' C ' ' H ' ' A' ' 118' ' ' THR . 99.8 m -107.93 -79.19 0.58 Allowed 'General case' 0 N--CA 1.497 1.914 0 N-CA-C 107.244 -1.391 . . . . 4.09 107.244 179.165 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.417 ' O ' HG12 ' A' ' 117' ' ' VAL . 46.1 t -60.8 -8.94 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.644 0 N-CA-C 106.053 -1.832 . . . . 2.9 106.053 176.803 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' THR . . . . . 0.504 ' H ' ' C ' ' A' ' 116' ' ' THR . 4.9 t 36.59 59.07 1.03 Allowed 'General case' 0 N--CA 1.486 1.35 0 CA-C-N 115.181 -0.918 . . . . 3.36 110.835 179.632 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' SER . . . . . 0.456 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.6 p . . . . . 0 C--N 1.303 -1.44 0 CA-C-O 117.984 -1.008 . . . . 3.39 109.492 179.383 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . 0.556 ' SD ' ' N ' ' B' ' 1' ' ' MET . 1.8 mpp? . . . . . 0 N--CA 1.491 1.602 0 N-CA-C 109.421 -0.585 . . . . 8.49 109.421 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 2' ' ' ALA . . . . . 0.448 ' O ' ' O ' ' B' ' 3' ' ' SER . . . 59.02 113.25 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.396 -0.815 . . . . 5.53 109.652 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 3' ' ' SER . . . . . 0.448 ' O ' ' O ' ' B' ' 2' ' ' ALA . 17.1 p 47.96 98.45 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.441 -0.787 . . . . 5.43 109.857 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 4' ' ' LYS . . . . . 0.479 ' O ' ' O ' ' B' ' 5' ' ' PRO . 37.2 mtmt -46.77 155.01 0.64 Allowed Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.272 -0.892 . . . . 6.87 109.095 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 5' ' ' PRO . . . . . 0.49 ' O ' ' CB ' ' B' ' 6' ' ' GLU . 3.2 Cg_exo -55.8 -148.31 0.0 OUTLIER 'Trans proline' 0 CA--C 1.544 1.002 0 C-N-CA 121.479 1.453 . . . . 5.16 110.357 179.411 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 6' ' ' GLU . . . . . 0.49 ' CB ' ' O ' ' B' ' 5' ' ' PRO . 20.0 tt0 82.18 150.59 0.09 Allowed 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.41 -0.806 . . . . 4.78 109.25 -179.682 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 44.1 mtmt -78.38 -156.51 0.1 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.299 -0.875 . . . . 4.09 109.869 -179.597 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.717 ' NH1' ' H ' ' A' ' 84' ' ' ASP . 43.8 mtt180 -101.02 -176.47 3.17 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.395 -0.816 . . . . 3.04 109.325 -179.781 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 9' ' ' VAL . . . . . 0.433 ' O ' ' OE2' ' A' ' 56' ' ' GLU . 15.2 t -59.34 160.32 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 N-CA-C 107.718 -1.215 . . . . 0.67 107.718 178.719 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -116.99 142.94 46.31 Favored 'General case' 0 N--CA 1.503 2.189 0 O-C-N 121.287 -0.883 . . . . 0.58 110.433 -179.073 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 30.2 t -143.72 131.36 21.25 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.471 -0.768 . . . . 1.19 109.063 179.47 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 87.8 p -140.39 120.19 13.46 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.232 -0.918 . . . . 1.38 109.587 -179.727 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 0.603 HG22 ' N ' ' B' ' 14' ' ' PHE . 3.0 p -162.26 168.3 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.412 0 O-C-N 121.379 -0.826 . . . . 0.42 109.073 -179.948 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 14' ' ' PHE . . . . . 0.603 ' N ' HG22 ' B' ' 13' ' ' VAL . 6.6 p90 -177.1 -171.76 0.37 Allowed 'General case' 0 N--CA 1.487 1.4 0 C-N-CA 119.391 -0.923 . . . . 1.79 112.008 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -142.64 173.78 6.38 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.322 0 N-CA-C 108.335 -0.987 . . . . 1.25 108.335 179.597 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 32.3 p -146.65 139.82 25.54 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 120.929 -1.107 . . . . 1.61 109.817 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.4 mt -90.34 133.62 34.85 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.256 -0.902 . . . . 1.32 109.074 179.582 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -169.56 80.74 0.66 Allowed Pre-proline 0 N--CA 1.489 1.489 0 O-C-N 121.278 -0.889 . . . . 1.45 109.516 -179.436 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_exo -57.34 112.15 1.04 Allowed 'Trans proline' 0 CA--C 1.554 1.505 0 C-N-CA 121.357 1.371 . . . . 1.5 109.82 -179.385 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 20' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -66.3 -65.61 0.04 OUTLIER 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 120.761 0.974 . . . . 2.86 110.101 -179.661 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 7.0 tpt180 -48.51 145.53 3.46 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.295 -0.878 . . . . 6.12 109.54 -179.423 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 22' ' ' ARG . . . . . 0.417 HH11 ' CG ' ' B' ' 22' ' ' ARG . 0.2 OUTLIER -147.96 64.97 1.1 Allowed 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.274 -0.891 . . . . 6.29 109.251 179.941 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -71.43 161.04 31.68 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.237 -0.914 . . . . 5.62 109.297 179.828 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 16.7 m . . . . . 0 N--CA 1.49 1.571 0 CA-C-O 117.938 -1.03 . . . . 6.48 109.483 -179.869 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.531 4.97 0 N-CA-C 119.75 2.66 . . . . 6.64 119.75 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.69 HG23 ' O ' ' A' ' 2' ' ' ILE . 11.0 tp -171.86 50.16 0.12 Allowed Pre-proline 0 C--N 1.307 -1.268 0 N-CA-C 108.131 -1.063 . . . . 7.08 108.131 179.559 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.782 ' C ' ' H ' ' A' ' 5' ' ' PHE . 1.0 OUTLIER -53.96 -79.53 0.02 OUTLIER 'Trans proline' 0 C--N 1.319 -1.013 0 C-N-CA 121.133 1.222 . . . . 5.5 109.073 179.737 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.501 ' C ' ' H ' ' A' ' 6' ' ' PHE . 9.4 tt0 73.35 -16.78 0.46 Allowed 'General case' 0 N--CA 1.494 1.73 0 N-CA-C 104.39 -2.448 . . . . 6.75 104.39 -175.703 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . 0.782 ' H ' ' C ' ' A' ' 3' ' ' PRO . 3.7 m-85 -89.73 17.92 6.07 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 103.909 -2.626 . . . . 6.07 103.909 176.708 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.531 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 41.3 p90 45.58 -155.0 0.04 OUTLIER 'General case' 0 C--N 1.307 -1.246 0 CA-C-N 114.23 -1.35 . . . . 4.72 109.432 -177.642 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.531 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 18.8 tt0 83.67 -9.26 1.02 Allowed 'General case' 0 N--CA 1.492 1.638 0 N-CA-C 105.019 -2.215 . . . . 4.4 105.019 -177.226 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.479 ' H ' ' C ' ' A' ' 6' ' ' PHE . 85.1 t80 -154.19 -36.56 0.1 Allowed 'General case' 0 C--N 1.305 -1.361 0 CA-C-N 114.66 -1.155 . . . . 5.15 108.111 178.484 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.496 HG22 ' O ' ' A' ' 9' ' ' THR . 94.2 m -93.79 2.99 56.09 Favored 'General case' 0 C--N 1.298 -1.673 0 N-CA-C 105.815 -1.921 . . . . 5.13 105.815 177.25 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.4 HG13 ' N ' ' A' ' 11' ' ' GLY . 7.3 p -43.18 -36.3 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 CA-C-N 115.433 -0.803 . . . . 4.38 109.399 -179.918 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.59 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 141.22 -84.86 0.21 Allowed Glycine 0 N--CA 1.497 2.757 0 N-CA-C 108.311 -1.916 . . . . 4.22 108.311 179.802 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.492 ' O ' ' N ' ' A' ' 14' ' ' GLY . 14.0 Cg_endo -67.84 40.33 0.21 Allowed 'Trans proline' 0 C--N 1.319 -0.996 0 C-N-CA 121.619 1.546 . . . . 3.85 108.412 177.633 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.59 ' H ' ' C ' ' A' ' 11' ' ' GLY . 0.2 OUTLIER 29.08 39.51 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.238 0 CA-C-O 121.508 0.671 . . . . 3.67 110.73 -179.295 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.499 ' C ' ' H ' ' A' ' 16' ' ' GLY . . . 69.61 -37.26 0.36 Allowed Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.423 -1.471 . . . . 2.97 109.423 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.535 ' H ' ' C ' ' A' ' 13' ' ' LEU . 7.2 tp10 57.66 4.43 0.25 Allowed 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.352 -1.087 . . . . 2.97 108.888 -179.833 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.548 ' O ' ' N ' ' A' ' 18' ' ' ALA . . . 65.9 90.73 0.04 OUTLIER Glycine 0 N--CA 1.49 2.255 0 N-CA-C 110.643 -0.983 . . . . 2.44 110.643 179.213 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.583 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 64.21 -47.1 0.1 OUTLIER Glycine 0 N--CA 1.493 2.497 0 O-C-N 121.479 -1.012 . . . . 1.81 111.055 178.823 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.548 ' N ' ' O ' ' A' ' 16' ' ' GLY . . . -46.24 -11.13 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.871 0 O-C-N 120.959 -1.318 . . . . 2.21 110.05 -179.578 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . 0.583 ' N ' ' O ' ' A' ' 17' ' ' GLY . 34.0 t60 -84.64 -48.42 9.51 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 120.994 -1.066 . . . . 2.87 109.6 179.729 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.552 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.1 OUTLIER -83.18 -3.63 57.57 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.047 -1.033 . . . . 2.02 110.192 -179.617 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 66.6 t -77.86 113.24 16.8 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 120.944 -1.098 . . . . 2.07 109.537 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 20.9 tpt180 -100.14 138.93 36.53 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.633 -0.667 . . . . 3.5 109.571 -179.858 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -147.42 113.37 5.79 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 108.402 -0.962 . . . . 1.83 108.402 179.332 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -158.5 128.7 2.12 Favored Glycine 0 N--CA 1.491 2.339 0 C-N-CA 119.688 -1.244 . . . . 1.9 110.234 -179.199 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.3 -179.7 48.77 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.641 -1.383 . . . . 1.85 109.641 179.611 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 6.5 m -76.58 -21.86 55.03 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.168 -1.195 . . . . 2.31 109.24 179.759 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.9 -23.83 77.64 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 108.818 -1.713 . . . . 1.64 108.818 179.71 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 34.6 mt -85.1 28.79 0.69 Allowed 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.499 -1.001 . . . . 1.83 108.689 179.572 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 15.0 mt-10 -138.71 -64.24 0.52 Allowed 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.503 -0.748 . . . . 2.34 109.908 -179.655 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 80.8 mtm180 -150.64 165.42 33.44 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 120.895 -1.128 . . . . 3.77 110.222 -179.248 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -139.07 170.57 24.01 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 107.473 -2.251 . . . . 1.57 107.473 178.887 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 40.5 t -133.85 151.31 32.63 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.109 0 O-C-N 121.088 -1.243 . . . . 1.83 110.948 -179.029 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.499 ' HB2' ' HB2' ' A' ' 107' ' ' SER . . . -40.48 114.59 0.47 Allowed 'General case' 0 N--CA 1.497 1.902 0 CA-C-O 121.867 0.841 . . . . 1.64 112.428 -179.313 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 52.99 49.71 54.19 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 111.225 -0.75 . . . . 1.73 111.225 177.13 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 22.5 t -127.02 124.98 24.1 Favored Pre-proline 0 N--CA 1.496 1.843 0 O-C-N 121.497 -1.002 . . . . 2.19 108.46 179.143 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -58.41 109.86 0.57 Allowed 'Trans proline' 0 C--O 1.215 -0.637 0 N-CA-C 109.682 -0.93 . . . . 1.96 109.682 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -108.03 142.07 38.74 Favored 'General case' 0 N--CA 1.495 1.825 0 N-CA-C 107.929 -1.138 . . . . 1.69 107.929 179.408 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -150.92 169.52 21.53 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.871 -1.143 . . . . 2.23 111.244 -179.385 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.61 ' CE2' HD11 ' A' ' 41' ' ' ILE . 5.2 p90 -154.35 173.78 15.73 Favored 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 107.617 -1.253 . . . . 1.54 107.617 178.452 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 72.9 m -101.54 150.82 22.68 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.496 -0.753 . . . . 2.37 110.469 -178.652 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.61 HD11 ' CE2' ' A' ' 39' ' ' PHE . 11.3 mt -142.95 90.64 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 N-CA-C 108.748 -0.834 . . . . 1.65 108.748 178.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.517 ' CE3' ' O ' ' A' ' 71' ' ' GLY . 31.1 t-105 -92.93 120.01 32.81 Favored 'General case' 0 N--CA 1.493 1.704 0 N-CA-C 108.251 -1.018 . . . . 3.68 108.251 179.504 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.552 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -152.74 108.84 3.36 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.276 -0.89 . . . . 2.89 109.594 -179.148 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' ARG . . . . . 0.598 ' CG ' HH11 ' A' ' 44' ' ' ARG . 0.1 OUTLIER -171.57 82.12 0.07 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.225 -0.922 . . . . 4.63 109.599 -179.984 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 74.2 tt0 -159.5 -46.24 0.05 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.016 -1.053 . . . . 2.89 109.985 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.456 ' H ' ' HE2' ' A' ' 20' ' ' LYS . . . -64.15 -45.62 87.68 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.03 -1.044 . . . . 1.74 109.195 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 160.78 -153.03 23.83 Favored Glycine 0 N--CA 1.485 1.903 0 C-N-CA 119.403 -1.379 . . . . 1.6 110.175 179.786 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -96.66 158.57 15.37 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.558 -0.966 . . . . 1.4 109.174 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -179.09 173.0 45.2 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.392 -1.483 . . . . 1.04 109.392 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -105.11 121.09 6.76 Favored Glycine 0 N--CA 1.495 2.624 0 N-CA-C 109.501 -1.439 . . . . 1.06 109.501 -179.891 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.465 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 64.2 tp -91.01 108.79 20.09 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.222 -1.163 . . . . 1.1 107.897 179.153 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.7 t -91.23 142.37 27.8 Favored 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 108.663 -0.865 . . . . 1.56 108.663 179.89 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.544 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 22.5 mt -130.49 100.62 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 121.521 -0.737 . . . . 0.65 109.071 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.438 ' HB3' ' OG ' ' A' ' 88' ' ' SER . . . -93.86 106.41 18.38 Favored 'General case' 0 N--CA 1.489 1.506 0 N-CA-C 108.621 -0.881 . . . . 0.69 108.621 179.711 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.408 HG23 ' CB ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -101.48 143.28 14.7 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 CA-C-O 121.588 0.708 . . . . 0.91 109.582 -179.631 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 8.2 tt0 -141.52 145.57 35.33 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 107.479 -1.304 . . . . 1.8 107.479 178.868 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 165.56 -172.71 41.14 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.856 -1.298 . . . . 0.49 109.856 -179.095 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -63.18 -33.99 70.14 Favored 'Trans proline' 0 C--N 1.319 -0.988 0 C-N-CA 122.315 2.01 . . . . 0.66 112.514 -179.435 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . 0.497 ' OG ' ' N ' ' A' ' 60' ' ' LYS . 5.9 t -132.36 177.76 7.34 Favored 'General case' 0 N--CA 1.504 2.239 0 O-C-N 120.944 -1.097 . . . . 1.55 110.49 -179.273 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . 0.497 ' N ' ' OG ' ' A' ' 59' ' ' SER . 45.8 tttm -93.82 96.18 9.59 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.689 -0.632 . . . . 2.53 109.713 -179.591 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -61.54 131.17 49.23 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.179 -0.951 . . . . 0.82 109.017 179.696 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 16.2 tp10 -88.54 95.05 10.08 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 120.964 -1.085 . . . . 2.3 110.174 -179.456 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.563 HD12 ' N ' ' A' ' 63' ' ' ILE . 1.7 mp -60.61 156.04 3.43 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 N-CA-C 109.207 -0.664 . . . . 1.4 109.207 179.335 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.534 ' HB3' ' HB3' ' A' ' 76' ' ' SER . . . -144.72 172.38 13.08 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.013 -1.054 . . . . 1.36 108.78 179.598 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.524 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 41.0 p90 -148.44 116.2 6.33 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.26 -0.9 . . . . 1.47 109.188 179.845 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 78.6 tt0 -141.78 105.05 4.63 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.161 -0.962 . . . . 2.51 109.821 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -81.91 107.17 14.41 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.232 -0.918 . . . . 2.07 108.935 179.452 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.537 ' CG ' HH11 ' A' ' 68' ' ' ARG . 0.0 OUTLIER -110.98 -9.43 14.42 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.532 -0.73 . . . . 4.63 109.096 -179.477 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.485 ' C ' ' H ' ' A' ' 71' ' ' GLY . 58.1 mmtt -109.73 -9.37 14.84 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.355 -0.841 . . . . 3.49 109.104 179.894 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 4.8 t70 64.79 -3.12 0.6 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.378 -0.826 . . . . 3.06 109.394 179.656 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . 0.517 ' O ' ' CE3' ' A' ' 42' ' ' TRP . . . -141.34 17.18 2.69 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.423 -1.471 . . . . 2.16 109.423 -179.009 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 19.8 t -156.36 114.96 3.38 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.457 -1.025 . . . . 2.2 108.827 179.673 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 8.6 t -76.69 129.14 35.93 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.103 -0.998 . . . . 2.05 109.103 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -103.68 114.68 4.87 Favored Glycine 0 N--CA 1.496 2.69 0 N-CA-C 110.064 -1.214 . . . . 1.39 110.064 -179.332 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.588 HG21 HD12 ' A' ' 41' ' ' ILE . 38.4 t -101.83 108.74 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.925 0 O-C-N 121.516 -0.99 . . . . 1.57 108.771 179.426 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.534 ' HB3' ' HB3' ' A' ' 64' ' ' ALA . 4.1 t -103.46 127.69 50.79 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.531 -0.731 . . . . 1.85 109.457 179.849 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 6.4 p90 -128.45 128.2 43.97 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 108.303 -0.999 . . . . 1.54 108.303 179.838 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -103.8 110.06 29.01 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.159 0 O-C-N 121.324 -0.86 . . . . 1.9 109.404 -178.859 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.47 ' H ' HG22 ' A' ' 79' ' ' VAL . 5.8 m -82.6 163.39 3.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.496 -0.753 . . . . 1.27 109.42 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 20.1 tt0 -95.78 -50.39 4.93 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.005 -1.059 . . . . 2.48 111.117 -179.163 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -152.29 155.55 33.17 Favored Pre-proline 0 N--CA 1.504 2.237 0 O-C-N 120.688 -1.257 . . . . 1.92 111.72 -178.594 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.572 ' HG3' ' N ' ' A' ' 107' ' ' SER . 75.9 Cg_exo -37.07 160.77 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 123.61 2.873 . . . . 1.3 113.636 179.285 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 148.19 -164.16 28.94 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.223 -1.551 . . . . 1.02 109.223 179.816 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . 0.431 ' HB2' ' HE ' ' B' ' 8' ' ' ARG . 65.0 m-20 -108.82 88.85 2.83 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.601 -0.94 . . . . 2.13 108.662 179.656 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.499 ' O ' ' N ' ' A' ' 103' ' ' VAL . 2.9 m-85 -76.27 129.52 36.8 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 108.165 -1.05 . . . . 0.92 108.165 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -107.85 128.33 54.51 Favored 'General case' 0 N--CA 1.497 1.914 0 N-CA-C 108.144 -1.058 . . . . 1.53 108.144 -179.446 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 9.4 p -126.12 140.27 49.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.525 -0.734 . . . . 1.0 109.972 -179.401 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . 0.438 ' OG ' ' HB3' ' A' ' 54' ' ' ALA . 11.1 p -134.4 104.39 6.11 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.585 -0.697 . . . . 1.59 109.52 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.414 HD11 ' CD1' ' A' ' 96' ' ' ILE . 0.8 OUTLIER -112.33 129.58 67.6 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 CA-C-O 121.585 0.707 . . . . 1.29 109.492 -179.847 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . 0.469 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -139.71 124.2 18.17 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 108.232 -1.025 . . . . 1.58 108.232 179.661 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.408 ' O ' ' CB ' ' A' ' 92' ' ' ASN . 31.8 t80 -85.64 102.96 14.02 Favored 'General case' 0 N--CA 1.494 1.737 0 N-CA-C 107.546 -1.279 . . . . 1.34 107.546 178.783 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . 0.423 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 8.5 t30 72.48 35.84 1.09 Allowed 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.806 -0.813 . . . . 2.32 108.806 -178.235 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.423 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 1.7 m-20 76.4 15.24 2.25 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.676 -0.64 . . . . 1.92 111.409 179.692 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . 0.498 ' CG ' ' O ' ' A' ' 94' ' ' GLU . 7.2 pt-20 -98.53 100.43 11.68 Favored 'General case' 0 N--CA 1.493 1.717 0 N-CA-C 107.201 -1.407 . . . . 2.25 107.201 177.949 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . 0.631 ' H ' ' CD2' ' A' ' 95' ' ' HIS . 7.0 p80 -71.67 106.52 4.11 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.215 -0.928 . . . . 2.88 109.534 -178.541 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . 0.561 ' O ' ' N ' ' A' ' 98' ' ' ASP . 10.1 pt -55.82 150.19 28.94 Favored Pre-proline 0 N--CA 1.491 1.611 0 C-N-CA 119.377 -0.929 . . . . 2.35 108.507 179.795 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.411 ' O ' ' CG ' ' A' ' 98' ' ' ASP . 4.6 Cg_exo -53.87 82.01 0.03 OUTLIER 'Trans proline' 0 C--O 1.213 -0.738 0 N-CA-C 109.202 -1.114 . . . . 2.48 109.202 179.415 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.561 ' N ' ' O ' ' A' ' 96' ' ' ILE . 1.9 m-20 175.05 -63.36 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 108.037 -1.097 . . . . 2.65 108.037 -178.949 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 5.1 m -59.03 139.08 87.68 Favored Pre-proline 0 C--N 1.298 -1.671 0 O-C-N 121.539 -0.725 . . . . 2.0 110.119 -178.134 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_endo -88.58 115.21 2.9 Favored 'Cis proline' 0 N--CA 1.493 1.474 0 N-CA-C 109.722 -0.915 . . . . 1.79 109.722 -2.597 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 45.6 p90 -112.53 168.45 9.64 Favored 'General case' 0 N--CA 1.516 2.868 0 O-C-N 120.556 -1.34 . . . . 2.19 110.027 178.828 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.4 p -94.38 152.28 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.474 -0.766 . . . . 1.44 110.735 -178.901 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.499 ' N ' ' O ' ' A' ' 85' ' ' TYR . 61.3 t -126.69 87.01 57.4 Favored Pre-proline 0 N--CA 1.499 1.992 0 N-CA-C 107.919 -1.141 . . . . 1.19 107.919 179.193 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -61.25 113.09 1.61 Allowed 'Trans proline' 0 C--N 1.32 -0.951 0 C-N-CA 121.376 1.384 . . . . 1.49 112.189 -177.787 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 53.8 t -94.16 145.08 8.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 N-CA-C 106.64 -1.615 . . . . 1.35 106.64 177.736 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.543 ' HB1' ' H ' ' A' ' 110' ' ' ASP . . . -136.73 137.33 39.81 Favored 'General case' 0 N--CA 1.506 2.328 0 CA-C-O 122.268 1.032 . . . . 1.67 111.995 -177.507 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.572 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 9.5 t -110.53 68.47 0.67 Allowed 'General case' 0 N--CA 1.495 1.808 0 N-CA-C 107.229 -1.397 . . . . 2.04 107.229 178.855 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . 0.496 ' CB ' ' O ' ' A' ' 107' ' ' SER . 2.6 tp 81.23 -3.53 1.7 Allowed 'General case' 0 N--CA 1.492 1.641 0 N-CA-C 106.603 -1.629 . . . . 3.2 106.603 -177.574 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.487 ' O ' ' N ' ' A' ' 111' ' ' ASP . 2.0 m -80.08 -27.09 39.36 Favored 'General case' 0 N--CA 1.486 1.348 0 N-CA-C 108.853 -0.795 . . . . 2.09 108.853 179.138 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . 0.543 ' H ' ' HB1' ' A' ' 106' ' ' ALA . 37.8 m-20 47.71 16.21 0.07 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.283 -0.886 . . . . 2.85 108.799 -179.71 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.487 ' N ' ' O ' ' A' ' 109' ' ' SER . 9.8 t70 -171.55 -29.14 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.695 -0.628 . . . . 2.46 109.401 -179.757 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.481 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 51.88 97.62 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.812 0 O-C-N 120.973 -1.079 . . . . 2.08 109.572 179.851 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 10.8 mmt180 -72.16 -159.12 0.05 OUTLIER 'General case' 0 N--CA 1.485 1.305 0 O-C-N 121.192 -0.942 . . . . 5.93 110.25 -179.601 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.463 ' HG3' HH11 ' A' ' 114' ' ' ARG . 2.4 ttm-85 -142.01 3.39 1.59 Allowed 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.368 -0.832 . . . . 5.61 109.124 -179.578 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.448 HD23 ' N ' ' A' ' 115' ' ' LEU . 0.1 OUTLIER -126.78 -26.01 3.27 Favored 'General case' 0 N--CA 1.504 2.233 0 O-C-N 121.49 -0.756 . . . . 4.39 109.108 -179.672 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.506 ' C ' ' H ' ' A' ' 118' ' ' THR . 57.5 m -108.58 -78.96 0.58 Allowed 'General case' 0 N--CA 1.497 1.9 0 N-CA-C 107.227 -1.397 . . . . 4.09 107.227 179.239 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.429 ' O ' HG12 ' A' ' 117' ' ' VAL . 53.5 t -61.74 -8.16 2.28 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.672 0 N-CA-C 106.096 -1.816 . . . . 2.9 106.096 176.865 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' THR . . . . . 0.506 ' H ' ' C ' ' A' ' 116' ' ' THR . 4.0 t 36.16 61.4 0.78 Allowed 'General case' 0 N--CA 1.486 1.366 0 CA-C-N 115.135 -0.939 . . . . 3.36 110.896 179.699 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' SER . . . . . 0.428 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.7 p . . . . . 0 C--N 1.303 -1.431 0 CA-C-O 118.015 -0.993 . . . . 3.39 109.632 179.236 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 66.9 mtm . . . . . 0 N--CA 1.49 1.557 0 N-CA-C 109.444 -0.576 . . . . 8.49 109.444 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' B' B ' 2' ' ' ALA . . . . . 0.431 ' O ' ' O ' ' B' ' 3' ' ' SER . . . -79.0 129.6 34.63 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.165 -0.96 . . . . 5.53 109.435 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 3' ' ' SER . . . . . 0.431 ' O ' ' O ' ' B' ' 2' ' ' ALA . 32.7 p 51.99 178.49 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.213 -0.93 . . . . 5.43 109.301 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 4' ' ' LYS . . . . . . . . . . . . . 21.7 mtpp -81.39 147.7 60.86 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.218 -0.926 . . . . 6.87 108.707 179.851 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 5' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -55.34 105.92 0.17 Allowed 'Trans proline' 0 C--N 1.323 -0.777 0 C-N-CA 120.887 1.058 . . . . 5.16 109.69 179.553 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 6' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.41 157.29 27.6 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.25 -0.906 . . . . 4.78 109.32 -179.907 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 30.7 mmtp -109.12 167.36 10.16 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.522 -0.737 . . . . 4.09 109.164 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.546 ' CG ' HH11 ' B' ' 8' ' ' ARG . 1.5 mtt-85 -89.95 162.31 15.47 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.23 -0.919 . . . . 3.04 108.694 179.643 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 9' ' ' VAL . . . . . . . . . . . . . 5.7 t -49.09 159.82 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.065 -1.022 . . . . 0.67 108.263 179.547 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -117.67 162.16 18.5 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.524 -0.735 . . . . 0.58 110.222 -178.769 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 11' ' ' SER . . . . . 0.408 ' CB ' HG23 ' A' ' 55' ' ' VAL . 32.4 m -153.59 141.24 19.94 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.585 -0.697 . . . . 1.19 109.13 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 41.7 m -145.05 112.27 6.06 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.113 -0.992 . . . . 1.38 110.021 -179.664 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 0.595 HG22 ' N ' ' B' ' 14' ' ' PHE . 3.2 p -159.93 167.48 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 N-CA-C 108.689 -0.856 . . . . 0.42 108.689 179.661 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 14' ' ' PHE . . . . . 0.896 ' O ' HD13 ' B' ' 15' ' ' ILE . 9.1 p90 -176.77 -169.07 0.25 Allowed 'General case' 0 N--CA 1.49 1.565 0 C-N-CA 119.162 -1.015 . . . . 1.79 112.179 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.896 HD13 ' O ' ' B' ' 14' ' ' PHE . 3.9 mm -142.12 165.14 17.68 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 N-CA-C 108.69 -0.856 . . . . 1.25 108.69 179.759 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 75.7 p -120.0 136.72 54.45 Favored 'General case' 0 N--CA 1.503 2.2 0 O-C-N 121.283 -0.886 . . . . 1.61 109.681 179.876 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 11.0 mt -103.67 141.78 35.47 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.369 -0.832 . . . . 1.32 109.975 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -166.79 139.03 2.89 Favored Pre-proline 0 N--CA 1.49 1.549 0 N-CA-C 108.765 -0.828 . . . . 1.45 108.765 179.2 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_endo -62.73 142.54 89.59 Favored 'Trans proline' 0 CA--C 1.55 1.285 0 N-CA-C 109.553 -0.98 . . . . 1.5 109.553 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 20' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_endo -62.68 -52.5 2.33 Favored 'Trans proline' 0 C--O 1.214 -0.686 0 N-CA-C 109.047 -1.174 . . . . 2.86 109.047 178.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . 0.435 ' HG3' HH11 ' B' ' 21' ' ' ARG . 25.9 mtm-85 -149.07 106.12 3.59 Favored 'General case' 0 N--CA 1.493 1.682 0 N-CA-C 108.846 -0.798 . . . . 6.12 108.846 179.816 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 22' ' ' ARG . . . . . 0.455 ' NH1' ' O ' ' B' ' 23' ' ' ASP . 0.2 OUTLIER -78.33 6.99 7.13 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.162 -0.961 . . . . 6.29 109.622 -179.666 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . 0.455 ' O ' ' NH1' ' B' ' 22' ' ' ARG . 26.4 t0 53.47 -130.44 2.19 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.205 -0.935 . . . . 5.62 109.556 179.755 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 14.9 p . . . . . 0 N--CA 1.49 1.54 0 CA-C-O 118.002 -0.999 . . . . 6.48 109.507 -179.972 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.503 ' O ' HG23 ' A' ' 2' ' ' ILE . . . . . . . . 1 N--CA 1.53 4.945 0 N-CA-C 119.718 2.647 . . . . 6.64 119.718 . . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.631 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 1.1 pp -160.83 45.44 0.18 Allowed Pre-proline 0 C--N 1.307 -1.25 0 N-CA-C 107.933 -1.136 . . . . 7.08 107.933 179.057 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.783 ' C ' ' H ' ' A' ' 5' ' ' PHE . 1.4 Cg_endo -52.54 -79.3 0.02 OUTLIER 'Trans proline' 0 C--N 1.32 -0.939 0 N-CA-C 108.856 -1.248 . . . . 5.5 108.856 179.729 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.528 ' C ' ' H ' ' A' ' 6' ' ' PHE . 4.5 tp10 73.56 -18.53 0.38 Allowed 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 104.365 -2.457 . . . . 6.75 104.365 -175.844 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . 0.783 ' H ' ' C ' ' A' ' 3' ' ' PRO . 2.0 m-85 -87.96 16.44 5.96 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 104.02 -2.585 . . . . 6.07 104.02 176.741 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.533 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 40.6 p90 45.56 -154.02 0.04 OUTLIER 'General case' 0 C--N 1.307 -1.252 0 CA-C-N 114.344 -1.298 . . . . 4.72 109.44 -177.612 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.526 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 6.7 tt0 83.19 -9.59 1.06 Allowed 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 105.008 -2.219 . . . . 4.4 105.008 -177.339 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.472 ' H ' ' C ' ' A' ' 6' ' ' PHE . 26.7 t80 -152.12 -36.61 0.12 Allowed 'General case' 0 C--N 1.306 -1.301 0 CA-C-N 114.794 -1.094 . . . . 5.15 108.076 178.475 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.498 HG22 ' O ' ' A' ' 9' ' ' THR . 92.4 m -96.05 4.49 52.56 Favored 'General case' 0 C--N 1.296 -1.753 0 N-CA-C 105.759 -1.941 . . . . 5.13 105.759 177.288 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.534 HG13 ' N ' ' A' ' 11' ' ' GLY . 8.4 p -45.9 -45.95 5.32 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.357 0 CA-C-N 115.473 -0.785 . . . . 4.38 109.211 -179.572 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.555 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 127.18 -80.56 0.36 Allowed Glycine 0 N--CA 1.502 3.063 0 N-CA-C 109.394 -1.483 . . . . 4.22 109.394 179.111 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.509 ' O ' ' N ' ' A' ' 14' ' ' GLY . 12.3 Cg_endo -66.97 37.56 0.15 Allowed 'Trans proline' 0 C--N 1.318 -1.043 0 C-N-CA 121.753 1.636 . . . . 3.85 109.099 178.854 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.555 ' H ' ' C ' ' A' ' 11' ' ' GLY . 0.0 OUTLIER 40.67 26.04 0.02 OUTLIER 'General case' 0 N--CA 1.505 2.289 0 N-CA-C 108.333 -0.988 . . . . 3.67 108.333 -178.955 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.533 ' O ' ' N ' ' A' ' 16' ' ' GLY . . . 70.19 -44.57 0.57 Allowed Glycine 0 N--CA 1.486 2.028 0 N-CA-C 107.88 -2.088 . . . . 2.97 107.88 -178.137 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.611 ' HB3' ' HB3' ' A' ' 18' ' ' ALA . 7.1 tp10 48.4 12.33 0.04 OUTLIER 'General case' 0 N--CA 1.488 1.462 0 CA-C-O 121.978 0.894 . . . . 2.97 108.914 179.866 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.533 ' N ' ' O ' ' A' ' 14' ' ' GLY . . . 58.21 114.51 0.01 OUTLIER Glycine 0 N--CA 1.488 2.115 0 O-C-N 121.38 -0.825 . . . . 2.44 111.568 178.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.541 ' C ' ' H ' ' A' ' 19' ' ' HIS . . . 67.71 -49.03 0.33 Allowed Glycine 0 N--CA 1.495 2.61 0 O-C-N 121.577 -0.955 . . . . 1.81 111.662 178.092 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.796 ' HB2' ' OE1' ' A' ' 94' ' ' GLU . . . -51.3 -5.29 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.853 0 O-C-N 120.963 -1.316 . . . . 2.21 109.975 -179.201 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . 0.541 ' H ' ' C ' ' A' ' 17' ' ' GLY . 6.1 t60 -98.75 -7.13 28.13 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.135 -0.978 . . . . 2.87 110.503 -179.545 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.551 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.0 OUTLIER -137.8 6.0 2.65 Favored 'General case' 0 N--CA 1.501 2.106 0 O-C-N 120.968 -1.082 . . . . 2.02 110.34 -179.581 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 71.3 t -91.05 113.43 26.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 120.95 -1.094 . . . . 2.07 109.851 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 12.8 tpp180 -105.33 137.88 42.43 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 108.827 -0.805 . . . . 3.5 108.827 179.844 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -147.12 113.64 5.98 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.418 -0.801 . . . . 1.83 108.857 179.794 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -155.26 129.73 2.61 Favored Glycine 0 N--CA 1.493 2.471 0 N-CA-C 109.678 -1.369 . . . . 1.9 109.678 -179.655 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.54 -176.88 46.8 Favored Glycine 0 N--CA 1.491 2.304 0 C-N-CA 119.741 -1.219 . . . . 1.85 110.088 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 12.6 p -79.65 -25.53 41.34 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.353 -1.086 . . . . 2.31 109.343 179.877 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -68.94 -15.99 69.94 Favored Glycine 0 N--CA 1.485 1.934 0 N-CA-C 108.304 -1.918 . . . . 1.64 108.304 179.548 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 90.4 mt -93.35 30.41 1.71 Allowed 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 108.601 -0.889 . . . . 1.83 108.601 179.49 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 15.3 mt-10 -139.11 -48.72 0.49 Allowed 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.504 -0.747 . . . . 2.34 109.34 -179.834 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 5.4 ptp180 -174.69 177.12 2.15 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.153 -0.967 . . . . 3.77 110.192 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -149.43 174.58 28.93 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 108.495 -1.842 . . . . 1.57 108.495 179.717 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 39.5 t -134.42 149.87 30.26 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.075 0 O-C-N 121.203 -1.175 . . . . 1.83 110.567 -179.702 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.575 ' HB2' ' HB2' ' A' ' 107' ' ' SER . . . -37.38 113.98 0.3 Allowed 'General case' 0 N--CA 1.496 1.864 0 CA-C-O 121.745 0.783 . . . . 1.64 112.471 -179.232 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 51.68 51.42 38.74 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 111.24 -0.744 . . . . 1.73 111.24 177.097 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 24.4 t -126.82 121.67 23.18 Favored Pre-proline 0 N--CA 1.495 1.821 0 N-CA-C 108.198 -1.038 . . . . 2.19 108.198 178.834 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -57.87 140.22 93.04 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 120.483 0.789 . . . . 1.96 110.142 -179.422 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.418 ' HB3' ' CE1' ' A' ' 77' ' ' TYR . . . -145.33 158.0 43.92 Favored 'General case' 0 N--CA 1.493 1.716 0 N-CA-C 108.275 -1.009 . . . . 1.69 108.275 179.603 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -155.8 172.01 19.06 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.815 -1.178 . . . . 2.23 110.8 -179.543 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.609 ' CE2' HD11 ' A' ' 41' ' ' ILE . 5.9 p90 -156.27 166.64 32.85 Favored 'General case' 0 C--N 1.298 -1.646 0 N-CA-C 107.888 -1.153 . . . . 1.54 107.888 178.446 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 43.9 m -99.05 152.12 20.18 Favored 'General case' 0 N--CA 1.494 1.762 0 CA-C-O 121.782 0.801 . . . . 2.37 111.129 -178.146 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.609 HD11 ' CE2' ' A' ' 39' ' ' PHE . 10.8 mt -143.48 85.79 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 N-CA-C 108.416 -0.957 . . . . 1.65 108.416 178.91 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 31.5 t90 -91.61 147.36 23.06 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.053 -1.029 . . . . 3.68 109.284 -179.489 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.551 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.1 OUTLIER -161.76 -110.99 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.286 -0.883 . . . . 2.89 109.628 -179.731 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' ARG . . . . . 0.526 HH11 ' HG2' ' A' ' 44' ' ' ARG . 2.3 ttt-85 52.69 90.74 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.221 -0.924 . . . . 4.63 109.862 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -172.2 -60.68 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.245 -0.909 . . . . 2.89 109.365 179.265 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -57.04 -57.89 10.57 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.988 -1.07 . . . . 1.74 108.741 179.724 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 150.99 -160.46 28.64 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 110.029 -1.228 . . . . 1.6 110.029 179.488 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -54.01 149.17 9.55 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.403 -1.057 . . . . 1.4 109.778 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -176.26 173.65 46.42 Favored Glycine 0 N--CA 1.489 2.168 0 N-CA-C 109.487 -1.445 . . . . 1.04 109.487 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -126.76 122.63 4.4 Favored Glycine 0 N--CA 1.498 2.825 0 N-CA-C 109.143 -1.583 . . . . 1.06 109.143 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.47 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 11.3 tp -93.85 99.37 11.75 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.221 -1.164 . . . . 1.1 108.843 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 2.2 t -83.51 141.27 31.76 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 108.42 -0.956 . . . . 1.56 108.42 179.687 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.559 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 92.3 mt -134.73 115.58 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.217 -0.927 . . . . 0.65 109.33 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -104.65 106.86 17.52 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.364 -0.835 . . . . 0.69 109.008 179.778 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -101.45 135.07 39.72 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.115 0 O-C-N 121.477 -0.765 . . . . 0.91 109.516 -179.771 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.43 ' OE2' ' O ' ' B' ' 9' ' ' VAL . 30.9 tp10 -134.36 142.46 47.22 Favored 'General case' 0 N--CA 1.494 1.738 0 N-CA-C 107.399 -1.334 . . . . 1.8 107.399 178.324 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 171.51 -176.67 44.67 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.421 -1.472 . . . . 0.49 109.421 -179.362 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -61.62 -28.35 82.6 Favored 'Trans proline' 0 C--N 1.318 -1.06 0 C-N-CA 121.992 1.795 . . . . 0.66 111.856 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . 0.413 ' O ' ' OH ' ' A' ' 85' ' ' TYR . 10.6 p -142.39 163.24 33.37 Favored 'General case' 0 N--CA 1.501 2.095 0 O-C-N 121.063 -1.023 . . . . 1.55 110.349 -179.564 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 19.4 mtpp -81.09 115.71 20.66 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.532 -0.73 . . . . 2.53 109.28 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -80.67 129.54 34.58 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.284 -0.885 . . . . 0.82 109.648 -179.817 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.455 ' CB ' HG12 ' A' ' 78' ' ' VAL . 18.2 tp10 -68.29 170.95 7.85 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.127 -0.983 . . . . 2.3 108.535 179.722 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.402 HD12 ' N ' ' A' ' 63' ' ' ILE . 3.8 mp -139.9 153.75 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 N-CA-C 108.417 -0.956 . . . . 1.4 108.417 -179.389 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.563 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -150.79 114.6 4.98 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 120.672 -1.267 . . . . 1.36 109.747 -179.565 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.505 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 43.0 p90 -92.77 122.56 35.28 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.27 -0.894 . . . . 1.47 109.19 179.615 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -141.19 120.54 13.09 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.266 -0.896 . . . . 2.51 109.51 -179.835 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 9.7 p-10 -86.91 118.62 26.41 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.307 -0.871 . . . . 2.07 109.328 179.884 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 41.0 ttm180 -99.52 -21.96 15.7 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.256 -0.902 . . . . 4.63 109.646 -179.846 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.533 ' C ' ' H ' ' A' ' 71' ' ' GLY . 14.3 mmmt -124.56 3.45 8.31 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.467 -0.771 . . . . 3.49 109.067 -179.779 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.462 ' CB ' ' O ' ' A' ' 69' ' ' LYS . 0.8 OUTLIER 73.96 -26.43 0.19 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.33 -0.856 . . . . 3.06 108.712 -179.146 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . 0.533 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -107.13 -34.59 2.92 Favored Glycine 0 N--CA 1.494 2.535 0 N-CA-C 109.446 -1.462 . . . . 2.16 109.446 -179.801 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 89.9 p -95.44 121.59 37.28 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.271 -1.134 . . . . 2.2 109.107 179.834 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 29.7 t -89.72 136.47 33.02 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.199 -0.938 . . . . 2.05 109.682 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -114.24 114.24 3.24 Favored Glycine 0 N--CA 1.5 2.937 0 N-CA-C 109.696 -1.362 . . . . 1.39 109.696 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.465 HG21 HD12 ' A' ' 41' ' ' ILE . 78.9 t -99.7 105.13 17.04 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.102 0 O-C-N 121.411 -1.052 . . . . 1.57 109.629 179.722 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.563 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.1 OUTLIER -95.26 134.5 37.95 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 109.018 -0.734 . . . . 1.85 109.018 179.84 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.418 ' CE1' ' HB3' ' A' ' 37' ' ' ALA . 45.7 p90 -135.32 172.73 12.59 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.205 -0.934 . . . . 1.54 109.079 -179.848 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.602 ' O ' HG13 ' A' ' 78' ' ' VAL . 9.8 p -140.34 118.09 9.96 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.082 0 O-C-N 121.256 -0.902 . . . . 1.9 110.033 179.758 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.456 HG11 HG21 ' A' ' 105' ' ' VAL . 13.4 m -86.64 151.97 3.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.391 -0.818 . . . . 1.27 108.922 179.548 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 4.0 tp-100 -94.51 -47.24 6.64 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.042 -1.036 . . . . 2.48 110.899 -179.039 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -153.37 152.37 27.48 Favored Pre-proline 0 N--CA 1.505 2.302 0 O-C-N 120.406 -1.434 . . . . 1.92 110.965 -179.497 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.64 ' HG3' ' N ' ' A' ' 107' ' ' SER . 78.4 Cg_exo -38.48 164.42 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 123.392 2.728 . . . . 1.3 113.778 178.833 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 145.08 -164.97 27.84 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.004 -1.639 . . . . 1.02 109.004 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 25.2 m-20 -109.01 90.88 3.43 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.61 -0.935 . . . . 2.13 108.641 179.581 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.413 ' OH ' ' O ' ' A' ' 59' ' ' SER . 3.7 m-85 -78.74 130.53 35.88 Favored 'General case' 0 N--CA 1.487 1.406 0 N-CA-C 108.003 -1.11 . . . . 0.92 108.003 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -115.35 128.49 56.12 Favored 'General case' 0 N--CA 1.502 2.146 0 N-CA-C 108.946 -0.761 . . . . 1.53 108.946 -178.503 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 10.0 p -125.36 140.46 48.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.75 -0.593 . . . . 1.0 109.925 -179.852 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 16.2 m -129.33 100.07 5.45 Favored 'General case' 0 N--CA 1.497 1.884 0 N-CA-C 108.922 -0.77 . . . . 1.59 108.922 179.477 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.447 ' N ' ' OG ' ' A' ' 99' ' ' SER . 1.6 pt -105.57 134.93 45.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 CA-C-O 121.482 0.658 . . . . 1.29 110.208 -179.301 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . 0.466 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -144.3 122.35 12.11 Favored 'General case' 0 C--N 1.305 -1.339 0 N-CA-C 108.271 -1.011 . . . . 1.58 108.271 179.508 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 62.9 t80 -80.97 101.27 9.4 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.864 -1.147 . . . . 1.34 107.995 178.705 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 70.37 39.04 1.29 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.392 -0.817 . . . . 2.32 108.982 -178.809 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 74.57 15.03 3.41 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.705 -0.622 . . . . 1.92 111.293 179.653 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . 0.796 ' OE1' ' HB2' ' A' ' 18' ' ' ALA . 0.5 OUTLIER -98.29 96.22 7.91 Favored 'General case' 0 N--CA 1.498 1.974 0 N-CA-C 106.813 -1.551 . . . . 2.25 106.813 177.641 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . 0.602 ' H ' ' CD2' ' A' ' 95' ' ' HIS . 5.8 m-70 -73.07 111.66 8.39 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.615 -0.678 . . . . 2.88 110.112 -177.926 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . 0.683 ' H ' HD13 ' A' ' 96' ' ' ILE . 0.0 OUTLIER -70.35 155.93 92.67 Favored Pre-proline 0 N--CA 1.494 1.734 0 N-CA-C 107.444 -1.317 . . . . 2.35 107.444 179.148 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_exo -46.54 -35.6 16.93 Favored 'Trans proline' 0 C--N 1.322 -0.861 0 C-N-CA 121.336 1.357 . . . . 2.48 109.942 -179.412 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -53.78 -63.65 1.08 Allowed 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.301 -0.875 . . . . 2.65 109.383 179.267 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.447 ' OG ' ' N ' ' A' ' 89' ' ' ILE . 3.6 m -70.45 141.21 87.92 Favored Pre-proline 0 C--N 1.295 -1.777 0 O-C-N 120.92 -1.112 . . . . 2.0 110.19 -178.467 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -86.8 119.02 4.96 Favored 'Cis proline' 0 N--CA 1.493 1.474 0 N-CA-C 109.967 -0.82 . . . . 1.79 109.967 -2.439 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 45.2 p90 -120.89 158.34 27.85 Favored 'General case' 0 N--CA 1.518 2.939 0 O-C-N 120.445 -1.41 . . . . 2.19 109.506 178.273 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.469 HG22 ' N ' ' A' ' 103' ' ' VAL . 7.3 p -92.17 157.26 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.429 -0.794 . . . . 1.44 110.887 -178.426 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.469 ' N ' HG22 ' A' ' 102' ' ' VAL . 56.9 t -128.26 86.25 58.41 Favored Pre-proline 0 N--CA 1.495 1.778 0 N-CA-C 107.85 -1.167 . . . . 1.19 107.85 179.341 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -64.04 112.71 1.93 Allowed 'Trans proline' 0 C--N 1.32 -0.966 0 C-N-CA 121.377 1.385 . . . . 1.49 111.624 -177.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.456 HG21 HG11 ' A' ' 79' ' ' VAL . 54.8 t -95.54 141.01 15.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 N-CA-C 106.771 -1.566 . . . . 1.35 106.771 177.978 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.635 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -130.6 131.79 45.15 Favored 'General case' 0 N--CA 1.51 2.551 0 CA-C-O 121.925 0.869 . . . . 1.67 112.064 -177.041 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.64 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 35.4 t -101.36 92.99 5.19 Favored 'General case' 0 N--CA 1.494 1.75 0 N-CA-C 107.993 -1.114 . . . . 2.04 107.993 179.274 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 20.5 mt 60.08 3.71 0.54 Allowed 'General case' 0 C--N 1.295 -1.774 0 N-CA-C 108.166 -1.05 . . . . 3.2 108.166 -178.574 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.64 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 8.3 t -94.83 -29.26 14.82 Favored 'General case' 0 N--CA 1.49 1.563 0 N-CA-C 109.03 -0.729 . . . . 2.09 109.03 179.391 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . 0.635 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 16.9 t70 57.52 6.28 0.39 Allowed 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 107.754 -1.202 . . . . 2.85 107.754 -178.843 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.542 ' H ' ' C ' ' A' ' 109' ' ' SER . 17.8 m-20 -159.92 -35.47 0.06 Allowed 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 108.697 -0.853 . . . . 2.46 108.697 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.64 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 40.29 65.82 0.7 Allowed 'General case' 0 N--CA 1.501 2.077 0 O-C-N 121.491 -0.756 . . . . 2.08 110.251 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . 0.493 HH11 ' HG2' ' A' ' 113' ' ' ARG . 6.3 mtt-85 -54.1 -172.15 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.148 -0.97 . . . . 5.93 109.506 -179.562 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.581 ' CG ' HH11 ' A' ' 114' ' ' ARG . 0.1 OUTLIER -132.03 4.29 4.11 Favored 'General case' 0 N--CA 1.497 1.897 0 N-CA-C 108.711 -0.848 . . . . 5.61 108.711 -179.621 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 30.0 mt -127.27 -24.02 3.45 Favored 'General case' 0 N--CA 1.503 2.218 0 O-C-N 121.645 -0.659 . . . . 4.39 109.405 -179.709 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.52 ' C ' ' H ' ' A' ' 118' ' ' THR . 85.3 m -110.73 -78.67 0.59 Allowed 'General case' 0 N--CA 1.498 1.94 0 N-CA-C 107.106 -1.442 . . . . 4.09 107.106 179.079 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.444 ' O ' HG12 ' A' ' 117' ' ' VAL . 45.9 t -62.13 -7.83 2.35 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.672 0 N-CA-C 106.016 -1.846 . . . . 2.9 106.016 176.783 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' THR . . . . . 0.52 ' H ' ' C ' ' A' ' 116' ' ' THR . 4.4 t 36.48 59.8 0.95 Allowed 'General case' 0 N--CA 1.488 1.445 0 CA-C-N 115.253 -0.885 . . . . 3.36 110.728 179.823 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' SER . . . . . 0.457 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.5 p . . . . . 0 C--N 1.303 -1.417 0 CA-C-O 118.023 -0.989 . . . . 3.39 109.574 179.401 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . 0.474 ' SD ' ' N ' ' B' ' 1' ' ' MET . 4.3 mpp? . . . . . 0 N--CA 1.49 1.545 0 CA-C-O 121.312 0.577 . . . . 8.49 109.455 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -167.33 -100.63 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.249 -0.907 . . . . 5.53 109.331 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 3' ' ' SER . . . . . . . . . . . . . 54.6 p -72.45 60.1 0.45 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.252 -0.905 . . . . 5.43 109.382 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 4' ' ' LYS . . . . . . . . . . . . . 6.8 ttpm? -168.44 69.3 0.78 Allowed Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.247 -0.908 . . . . 6.87 109.518 -179.892 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 5' ' ' PRO . . . . . 0.431 ' O ' ' O ' ' B' ' 6' ' ' GLU . 6.0 Cg_exo -60.59 -29.34 88.3 Favored 'Trans proline' 0 C--N 1.317 -1.103 0 C-N-CA 121.442 1.428 . . . . 5.16 109.811 -179.785 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 6' ' ' GLU . . . . . 0.431 ' O ' ' O ' ' B' ' 5' ' ' PRO . 31.2 tt0 57.32 160.5 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.412 -0.805 . . . . 4.78 109.855 179.815 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 46.3 mtpt -63.2 159.98 16.51 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.248 -0.908 . . . . 4.09 109.298 179.904 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.618 ' CG ' HH11 ' B' ' 8' ' ' ARG . 0.0 OUTLIER -101.58 163.68 12.14 Favored 'General case' 0 N--CA 1.494 1.769 0 N-CA-C 108.061 -1.088 . . . . 3.04 108.061 179.798 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 9' ' ' VAL . . . . . 0.43 ' O ' ' OE2' ' A' ' 56' ' ' GLU . 36.3 t -51.61 155.48 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 O-C-N 120.963 -1.085 . . . . 0.67 108.508 179.519 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -107.7 158.84 16.94 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 121.484 -0.76 . . . . 0.58 110.443 -178.763 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 25.6 t -159.34 112.91 2.29 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.487 -0.758 . . . . 1.19 109.007 179.51 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 15.0 p -117.02 124.9 50.44 Favored 'General case' 0 N--CA 1.501 2.111 0 O-C-N 121.417 -0.802 . . . . 1.38 109.413 -179.771 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 0.608 HG22 ' N ' ' B' ' 14' ' ' PHE . 6.6 p -164.39 164.01 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.293 -0.879 . . . . 0.42 109.786 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 14' ' ' PHE . . . . . 0.608 ' N ' HG22 ' B' ' 13' ' ' VAL . 6.5 p90 -179.29 -175.21 0.35 Allowed 'General case' 0 N--CA 1.488 1.472 0 CA-C-O 121.784 0.802 . . . . 1.79 111.427 179.102 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -144.01 168.8 10.77 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.295 0 N-CA-C 109.28 -0.637 . . . . 1.25 109.28 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 74.1 p -133.81 156.13 48.59 Favored 'General case' 0 N--CA 1.499 2.021 0 N-CA-C 108.72 -0.844 . . . . 1.61 108.72 179.523 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -159.18 159.55 34.44 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.948 -1.095 . . . . 1.32 110.643 -179.307 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -174.39 149.29 1.36 Allowed Pre-proline 0 N--CA 1.488 1.454 0 N-CA-C 108.843 -0.799 . . . . 1.45 108.843 179.751 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -57.65 166.83 4.52 Favored 'Trans proline' 0 CA--C 1.543 0.966 0 C-N-CA 120.933 1.089 . . . . 1.5 109.748 179.712 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 20' ' ' PRO . . . . . . . . . . . . . 2.3 Cg_endo -61.11 169.3 6.29 Favored 'Trans proline' 0 C--N 1.319 -0.985 0 C-N-CA 121.538 1.492 . . . . 2.86 109.448 179.366 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . 0.429 ' HG3' HH11 ' B' ' 21' ' ' ARG . 3.8 ptm180 -79.81 137.55 37.0 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.171 -0.955 . . . . 6.12 109.246 179.677 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 22' ' ' ARG . . . . . 0.571 HH11 ' CG ' ' B' ' 22' ' ' ARG . 0.1 OUTLIER -90.66 147.18 23.46 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.183 -0.948 . . . . 6.29 109.349 -179.923 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 66.9 m-20 -66.01 135.83 55.2 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.217 -0.927 . . . . 5.62 109.442 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 21.2 t . . . . . 0 N--CA 1.49 1.537 0 CA-C-O 118.046 -0.978 . . . . 6.48 109.624 -179.889 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.929 0 N-CA-C 119.8 2.68 . . . . 6.64 119.8 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.646 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 7.3 mt -153.39 44.31 0.25 Allowed Pre-proline 0 C--N 1.311 -1.094 0 N-CA-C 107.8 -1.185 . . . . 7.08 107.8 178.711 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.646 ' CD ' ' N ' ' A' ' 2' ' ' ILE . 0.9 OUTLIER -53.79 -76.32 0.02 OUTLIER 'Trans proline' 0 C--N 1.32 -0.969 0 N-CA-C 109.149 -1.135 . . . . 5.5 109.149 -179.799 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.423 ' CB ' ' O ' ' A' ' 3' ' ' PRO . 8.9 tp10 72.14 -50.1 0.69 Allowed 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 103.13 -2.915 . . . . 6.75 103.13 -175.861 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . 0.61 ' H ' ' C ' ' A' ' 3' ' ' PRO . 7.3 m-85 -49.62 -27.38 4.53 Favored 'General case' 0 C--N 1.303 -1.423 0 N-CA-C 106.485 -1.672 . . . . 6.07 106.485 174.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.604 ' CG ' ' N ' ' A' ' 7' ' ' GLN . 0.0 OUTLIER 109.75 -150.93 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.217 0 CA-C-N 114.458 -1.246 . . . . 4.72 111.144 179.47 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.604 ' N ' ' CG ' ' A' ' 6' ' ' PHE . 4.3 tt0 83.48 -4.06 1.19 Allowed 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 105.418 -2.068 . . . . 4.4 105.418 -177.714 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 80.1 t80 -152.19 -40.14 0.11 Allowed 'General case' 0 C--N 1.303 -1.436 0 N-CA-C 107.395 -1.335 . . . . 5.15 107.395 178.632 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.402 ' O ' HG22 ' A' ' 9' ' ' THR . 30.0 m -88.98 2.97 53.12 Favored 'General case' 0 C--N 1.296 -1.741 0 N-CA-C 106.201 -1.777 . . . . 5.13 106.201 177.533 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.519 HG13 ' N ' ' A' ' 11' ' ' GLY . 7.7 p -42.7 -41.72 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 CA-C-O 121.765 0.793 . . . . 4.38 109.408 -179.804 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.71 ' O ' HD23 ' A' ' 13' ' ' LEU . . . 144.06 -86.49 0.18 Allowed Glycine 0 N--CA 1.496 2.689 0 N-CA-C 108.658 -1.777 . . . . 4.22 108.658 179.691 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.44 ' O ' ' N ' ' A' ' 14' ' ' GLY . 12.0 Cg_endo -68.19 34.89 0.17 Allowed 'Trans proline' 0 C--N 1.321 -0.875 0 C-N-CA 121.425 1.417 . . . . 3.85 109.263 178.275 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.855 ' N ' HD23 ' A' ' 13' ' ' LEU . 0.0 OUTLIER 39.68 29.88 0.05 OUTLIER 'General case' 0 N--CA 1.504 2.238 0 CA-C-O 121.855 0.836 . . . . 3.67 109.001 -178.877 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.503 ' C ' ' N ' ' A' ' 16' ' ' GLY . . . 72.37 -41.46 0.78 Allowed Glycine 0 N--CA 1.488 2.161 0 N-CA-C 108.613 -1.795 . . . . 2.97 108.613 -179.283 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.496 ' H ' ' C ' ' A' ' 13' ' ' LEU . 26.2 tt0 51.95 10.33 0.11 Allowed 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.552 -0.97 . . . . 2.97 108.618 -179.491 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.503 ' N ' ' C ' ' A' ' 14' ' ' GLY . . . 78.19 -165.6 52.08 Favored Glycine 0 N--CA 1.486 2.007 0 N-CA-C 110.009 -1.236 . . . . 2.44 110.009 179.841 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.553 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -42.72 -19.8 0.07 OUTLIER Glycine 0 N--CA 1.49 2.282 0 O-C-N 121.417 -1.049 . . . . 1.81 110.839 -179.325 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.502 ' N ' ' O ' ' A' ' 16' ' ' GLY . . . -47.26 -12.92 0.03 OUTLIER 'General case' 0 N--CA 1.495 1.8 0 O-C-N 120.448 -1.619 . . . . 2.21 109.297 179.413 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . 0.553 ' N ' ' O ' ' A' ' 17' ' ' GLY . 12.8 t-80 -93.36 -52.25 4.61 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.268 -0.895 . . . . 2.87 109.906 179.882 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.535 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.1 OUTLIER -69.75 -23.6 63.4 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.869 -1.144 . . . . 2.02 109.588 -179.69 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 76.1 t -63.33 112.62 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.161 -0.962 . . . . 2.07 109.5 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 20.6 tpt180 -97.34 138.32 34.99 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 108.695 -0.854 . . . . 3.5 108.695 179.666 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -142.64 113.46 7.5 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.287 -0.883 . . . . 1.83 109.279 -179.88 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -154.08 130.85 3.03 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 109.518 -1.433 . . . . 1.9 109.518 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -177.94 171.17 43.67 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.703 -1.359 . . . . 1.85 109.703 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 10.9 p -77.97 -28.87 49.53 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.302 -1.117 . . . . 2.31 109.405 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -67.72 -16.88 68.51 Favored Glycine 0 N--CA 1.487 2.038 0 N-CA-C 108.42 -1.872 . . . . 1.64 108.42 179.606 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 49.0 mt -85.85 22.68 1.61 Allowed 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 108.506 -0.924 . . . . 1.83 108.506 179.356 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 11.5 mt-10 -133.47 -50.38 0.85 Allowed 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.62 -0.675 . . . . 2.34 109.398 -179.673 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 11.3 ptt180 -163.31 -176.71 4.92 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.069 -1.019 . . . . 3.77 109.936 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -157.18 -178.42 31.23 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 108.761 -1.735 . . . . 1.57 108.761 -179.799 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 38.4 t -134.71 151.8 32.09 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.153 0 O-C-N 121.154 -1.203 . . . . 1.83 110.663 -179.777 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.556 ' HB2' ' HD3' ' A' ' 82' ' ' PRO . . . -45.77 115.22 0.91 Allowed 'General case' 0 N--CA 1.498 1.936 0 CA-C-O 121.815 0.817 . . . . 1.64 112.443 -179.34 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 57.82 46.55 92.22 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 111.562 -0.615 . . . . 1.73 111.562 177.062 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 25.2 t -127.38 120.49 22.16 Favored Pre-proline 0 N--CA 1.499 1.98 0 O-C-N 121.37 -1.076 . . . . 2.19 108.818 179.178 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -60.09 113.02 1.48 Allowed 'Trans proline' 0 C--O 1.215 -0.657 0 N-CA-C 109.676 -0.932 . . . . 1.96 109.676 179.871 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -113.04 156.12 23.64 Favored 'General case' 0 N--CA 1.498 1.949 0 N-CA-C 108.268 -1.012 . . . . 1.69 108.268 179.617 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -158.03 163.68 37.49 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.718 -1.239 . . . . 2.23 111.403 -179.779 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.575 ' CD1' ' N ' ' A' ' 39' ' ' PHE . 0.8 OUTLIER -139.93 -173.17 3.57 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 107.228 -1.397 . . . . 1.54 107.228 178.513 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 24.4 m -121.83 149.11 43.82 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.535 -0.728 . . . . 2.37 110.307 -179.234 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 34.9 mt -144.48 102.05 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 N-CA-C 107.962 -1.125 . . . . 1.65 107.962 178.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.458 ' CD1' ' C ' ' A' ' 42' ' ' TRP . 0.1 OUTLIER -89.59 139.6 30.38 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.259 -0.901 . . . . 3.68 108.927 -179.635 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.535 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.1 OUTLIER -152.79 120.03 5.89 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.42 -0.8 . . . . 2.89 109.214 -179.733 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' ARG . . . . . . . . . . . . . 28.9 ttt-85 -170.28 62.87 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.201 -0.937 . . . . 4.63 109.848 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 25.4 tt0 -157.06 -56.6 0.08 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.14 -0.975 . . . . 2.89 109.534 179.65 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.423 ' H ' ' HE2' ' A' ' 20' ' ' LYS . . . -57.88 -57.4 12.93 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.092 -1.005 . . . . 1.74 108.88 179.883 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 142.03 -179.2 20.17 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.263 -1.535 . . . . 1.6 109.263 179.845 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -55.9 159.14 3.35 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.127 -1.22 . . . . 1.4 109.345 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -176.83 176.12 47.88 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.595 -1.402 . . . . 1.04 109.595 -179.877 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.405 ' H ' HD22 ' A' ' 92' ' ' ASN . . . -106.94 123.26 7.24 Favored Glycine 0 N--CA 1.497 2.743 0 N-CA-C 109.427 -1.469 . . . . 1.06 109.427 179.933 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.453 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 12.3 tp -99.8 100.55 11.51 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.295 -1.12 . . . . 1.1 108.452 179.663 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 3.9 m -85.51 144.13 28.12 Favored 'General case' 0 N--CA 1.491 1.616 0 N-CA-C 108.662 -0.866 . . . . 1.56 108.662 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.525 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 78.5 mt -134.71 106.69 7.68 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 O-C-N 121.224 -0.922 . . . . 0.65 109.614 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -95.65 106.26 18.34 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.377 -0.971 . . . . 0.69 108.377 179.272 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.437 HG23 ' OG ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -97.45 145.29 9.47 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 121.421 -0.799 . . . . 0.91 109.933 -179.339 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 20.2 tt0 -141.56 145.06 34.65 Favored 'General case' 0 N--CA 1.491 1.61 0 N-CA-C 107.536 -1.283 . . . . 1.8 107.536 178.708 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 161.64 -171.04 37.52 Favored Glycine 0 N--CA 1.488 2.13 0 N-CA-C 109.644 -1.382 . . . . 0.49 109.644 -179.069 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -64.32 -30.31 63.46 Favored 'Trans proline' 0 C--N 1.316 -1.142 0 C-N-CA 122.047 1.831 . . . . 0.66 111.652 -179.598 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 24.3 t -142.1 164.96 28.76 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.039 -1.038 . . . . 1.55 110.129 -179.877 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 58.4 mttt -84.44 107.48 16.72 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.527 -0.733 . . . . 2.53 109.56 -179.8 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -67.08 143.39 56.71 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.222 -0.924 . . . . 0.82 109.4 179.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 23.3 tt0 -93.2 91.36 7.24 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.225 -0.922 . . . . 2.3 109.537 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.621 HD12 ' N ' ' A' ' 63' ' ' ILE . 2.2 mp -60.54 156.61 3.11 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 N-CA-C 109.138 -0.689 . . . . 1.4 109.138 179.602 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.559 ' HB3' ' HB3' ' A' ' 76' ' ' SER . . . -145.99 174.85 10.91 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.981 -1.074 . . . . 1.36 108.595 179.621 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.487 ' CG ' ' O ' ' A' ' 65' ' ' PHE . 28.8 p90 -147.87 115.87 6.47 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.093 -1.005 . . . . 1.47 109.647 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -141.96 118.74 11.12 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.209 -0.932 . . . . 2.51 109.485 179.791 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -84.93 119.77 25.74 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.143 -0.973 . . . . 2.07 109.415 179.865 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 8.0 mmm180 -110.49 -5.7 15.08 Favored 'General case' 0 N--CA 1.5 2.062 0 O-C-N 121.545 -0.722 . . . . 4.63 109.298 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.489 ' HB2' ' H ' ' A' ' 72' ' ' SER . 20.4 mmmt -125.19 2.4 7.87 Favored 'General case' 0 N--CA 1.5 2.051 0 O-C-N 121.416 -0.803 . . . . 3.49 109.379 -179.781 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.7 t70 67.3 -4.86 0.8 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.247 -0.908 . . . . 3.06 109.105 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . 0.47 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -139.7 -32.16 0.17 Allowed Glycine 0 N--CA 1.493 2.478 0 N-CA-C 109.924 -1.27 . . . . 2.16 109.924 -179.077 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.489 ' H ' ' HB2' ' A' ' 69' ' ' LYS . 5.5 p -95.84 116.14 28.46 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.195 -1.179 . . . . 2.2 109.085 179.829 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 7.7 t -75.42 146.58 40.64 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.214 -0.929 . . . . 2.05 109.622 -179.814 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -120.25 111.58 2.01 Favored Glycine 0 N--CA 1.499 2.851 0 N-CA-C 109.32 -1.512 . . . . 1.39 109.32 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 22.5 t -99.32 106.22 18.64 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.95 0 O-C-N 121.542 -0.975 . . . . 1.57 109.109 179.807 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.559 ' HB3' ' HB3' ' A' ' 64' ' ' ALA . 5.9 t -100.04 135.67 41.11 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.537 -0.727 . . . . 1.85 109.895 -179.687 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 4.9 p90 -133.59 131.4 39.61 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 108.801 -0.815 . . . . 1.54 108.801 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.587 ' O ' HG13 ' A' ' 78' ' ' VAL . 8.0 p -100.37 115.79 42.42 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.955 0 O-C-N 121.276 -0.89 . . . . 1.9 109.183 -179.668 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 26.9 m -84.73 164.5 2.53 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 121.187 -0.946 . . . . 1.27 109.142 -179.681 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 36.3 tt0 -102.54 -49.08 3.94 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.276 -0.89 . . . . 2.48 110.324 -179.689 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -157.15 153.99 25.04 Favored Pre-proline 0 N--CA 1.502 2.132 0 O-C-N 120.907 -1.121 . . . . 1.92 111.161 -179.147 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.588 ' HG3' ' N ' ' A' ' 107' ' ' SER . 89.1 Cg_exo -35.55 156.99 0.02 OUTLIER 'Trans proline' 0 C--O 1.214 -0.683 0 C-N-CA 123.394 2.729 . . . . 1.3 113.745 179.354 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 148.51 -170.3 29.02 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 108.556 -1.818 . . . . 1.02 108.556 -179.675 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . 0.571 ' CG ' ' HE ' ' B' ' 8' ' ' ARG . 4.5 p-10 -107.24 93.71 4.7 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.378 -1.072 . . . . 2.13 108.452 179.368 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.426 ' O ' ' N ' ' A' ' 103' ' ' VAL . 2.4 m-85 -77.38 131.63 38.15 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 108.398 -0.964 . . . . 0.92 108.398 -179.784 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -112.82 126.82 55.85 Favored 'General case' 0 N--CA 1.501 2.081 0 N-CA-C 108.465 -0.939 . . . . 1.53 108.465 -179.292 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.466 ' CG1' ' CE2' ' A' ' 101' ' ' PHE . 5.5 p -126.29 133.96 67.55 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 O-C-N 121.525 -0.734 . . . . 1.0 109.782 -179.703 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . 0.407 ' O ' ' OG ' ' A' ' 88' ' ' SER . 19.0 p -124.58 104.82 8.92 Favored 'General case' 0 N--CA 1.499 1.986 0 N-CA-C 109.171 -0.678 . . . . 1.59 109.171 179.835 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.405 ' N ' ' OG ' ' A' ' 99' ' ' SER . 1.5 pt -108.37 133.18 54.13 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 CA-C-O 121.54 0.686 . . . . 1.29 110.37 -179.245 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . 0.456 ' O ' ' CG ' ' A' ' 90' ' ' LYS . 0.3 OUTLIER -138.08 122.51 18.36 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 107.927 -1.138 . . . . 1.58 107.927 179.257 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.412 ' O ' ' CB ' ' A' ' 92' ' ' ASN . 81.4 t80 -82.84 99.99 10.06 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 120.443 -1.411 . . . . 1.34 107.924 179.21 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . 0.446 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 3.2 t-20 72.28 34.85 1.3 Allowed 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.266 -0.896 . . . . 2.32 108.983 -178.627 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.446 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 1.6 m-20 80.47 13.81 0.83 Allowed 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.725 -0.609 . . . . 1.92 111.662 179.336 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . 0.494 ' HB2' ' HB2' ' A' ' 18' ' ' ALA . 5.4 pt-20 -100.71 98.84 9.34 Favored 'General case' 0 N--CA 1.499 2.023 0 N-CA-C 107.459 -1.312 . . . . 2.25 107.459 177.843 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . 0.416 ' O ' ' OE2' ' A' ' 15' ' ' GLU . 26.6 p-80 -65.3 99.59 0.41 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.686 -0.634 . . . . 2.88 110.243 -178.251 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . 0.523 ' O ' ' N ' ' A' ' 98' ' ' ASP . 4.0 tt -50.82 136.09 26.77 Favored Pre-proline 0 N--CA 1.489 1.524 0 N-CA-C 107.988 -1.116 . . . . 2.35 107.988 179.089 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.433 ' O ' ' CB ' ' A' ' 98' ' ' ASP . 9.4 Cg_exo -47.88 90.35 0.02 OUTLIER 'Trans proline' 0 C--O 1.213 -0.727 0 C-N-CA 120.547 0.832 . . . . 2.48 110.006 -179.627 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.523 ' N ' ' O ' ' A' ' 96' ' ' ILE . 0.9 OUTLIER 166.5 -57.87 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.749 0 N-CA-C 108.445 -0.946 . . . . 2.65 108.445 -179.569 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.405 ' OG ' ' N ' ' A' ' 89' ' ' ILE . 3.3 m -55.55 137.75 69.7 Favored Pre-proline 0 C--N 1.296 -1.72 0 O-C-N 121.246 -0.909 . . . . 2.0 109.6 -178.185 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo -90.0 114.96 2.59 Favored 'Cis proline' 0 N--CA 1.494 1.513 0 N-CA-C 110.249 -0.712 . . . . 1.79 110.249 -2.33 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . 0.466 ' CE2' ' CG1' ' A' ' 87' ' ' VAL . 1.6 p90 -97.18 163.26 12.99 Favored 'General case' 0 N--CA 1.515 2.802 0 O-C-N 120.217 -1.552 . . . . 2.19 109.568 178.456 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.9 p -95.31 148.96 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.594 -0.691 . . . . 1.44 109.822 -179.703 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.426 ' N ' ' O ' ' A' ' 85' ' ' TYR . 64.5 t -128.53 86.41 57.79 Favored Pre-proline 0 N--CA 1.499 2.002 0 N-CA-C 108.432 -0.951 . . . . 1.19 108.432 179.89 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -63.92 112.16 1.76 Allowed 'Trans proline' 0 C--N 1.321 -0.88 0 C-N-CA 121.429 1.419 . . . . 1.49 111.821 -178.133 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 52.5 t -91.39 147.36 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.514 -1.291 . . . . 1.35 107.514 178.268 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.677 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -135.77 134.3 38.85 Favored 'General case' 0 N--CA 1.508 2.467 0 O-C-N 121.373 -0.829 . . . . 1.67 110.911 -178.074 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.588 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 16.5 t -87.69 67.75 9.29 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.571 -1.331 . . . . 2.04 108.095 179.799 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . 0.434 ' CB ' ' O ' ' A' ' 107' ' ' SER . 1.0 OUTLIER 71.53 -2.6 2.38 Favored 'General case' 0 C--N 1.295 -1.79 0 N-CA-C 106.921 -1.511 . . . . 3.2 106.921 -178.439 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.694 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 82.6 p -82.73 -21.63 34.7 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 109.165 -0.679 . . . . 2.09 109.165 179.422 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . 0.677 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 62.2 t0 48.62 17.35 0.14 Allowed 'General case' 0 N--CA 1.494 1.753 0 N-CA-C 108.312 -0.996 . . . . 2.85 108.312 -179.456 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.493 ' N ' ' C ' ' A' ' 109' ' ' SER . 58.3 t0 -175.41 -23.8 0.01 OUTLIER 'General case' 0 C--N 1.301 -1.523 0 CA-C-N 115.819 -0.628 . . . . 2.46 109.469 -179.321 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.694 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 61.16 96.7 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.887 -1.133 . . . . 2.08 109.491 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . 0.586 ' CG ' HH11 ' A' ' 113' ' ' ARG . 2.1 mtt-85 -60.52 -165.15 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.314 0 O-C-N 121.282 -0.886 . . . . 5.93 109.49 -179.923 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.42 ' CG ' HH11 ' A' ' 114' ' ' ARG . 0.0 OUTLIER -149.63 4.88 0.59 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.036 -1.04 . . . . 5.61 109.914 -178.628 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.456 HD23 ' N ' ' A' ' 115' ' ' LEU . 0.1 OUTLIER -124.63 -29.26 3.47 Favored 'General case' 0 N--CA 1.507 2.424 0 O-C-N 121.236 -0.915 . . . . 4.39 109.876 -179.412 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.507 ' C ' ' H ' ' A' ' 118' ' ' THR . 0.6 OUTLIER -108.2 -79.1 0.58 Allowed 'General case' 0 N--CA 1.497 1.882 0 N-CA-C 107.093 -1.447 . . . . 4.09 107.093 179.558 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.437 ' O ' HG12 ' A' ' 117' ' ' VAL . 54.7 t -60.22 -9.18 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.703 0 N-CA-C 106.157 -1.794 . . . . 2.9 106.157 176.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' THR . . . . . 0.507 ' H ' ' C ' ' A' ' 116' ' ' THR . 4.9 t 36.88 60.68 0.94 Allowed 'General case' 0 N--CA 1.486 1.362 0 CA-C-O 122.071 0.939 . . . . 3.36 110.744 179.687 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' SER . . . . . 0.477 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.5 p . . . . . 0 C--N 1.304 -1.378 0 CA-C-O 117.982 -1.009 . . . . 3.39 109.634 179.299 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 44.7 mtm . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.543 -0.54 . . . . 8.49 109.543 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -67.09 141.17 57.55 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.212 -0.93 . . . . 5.53 109.526 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 3' ' ' SER . . . . . . . . . . . . . 34.3 t -89.95 -98.69 0.1 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.282 -0.886 . . . . 5.43 109.668 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 4' ' ' LYS . . . . . . . . . . . . . 83.8 tttt -171.83 85.46 0.46 Allowed Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.306 -0.872 . . . . 6.87 109.69 -179.577 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 5' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_exo -55.1 142.81 76.56 Favored 'Trans proline' 0 C--N 1.321 -0.902 0 C-N-CA 120.9 1.067 . . . . 5.16 109.714 -179.71 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 6' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -91.06 119.81 31.52 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.303 -0.873 . . . . 4.78 110.331 -178.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 7.0 mtpm? 41.77 -160.91 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.725 0 CA-C-O 121.622 0.725 . . . . 4.09 110.763 179.18 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.571 ' HE ' ' CG ' ' A' ' 84' ' ' ASP . 2.2 mtt-85 -138.55 164.05 30.44 Favored 'General case' 0 N--CA 1.494 1.742 0 N-CA-C 108.715 -0.846 . . . . 3.04 108.715 -179.728 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 9' ' ' VAL . . . . . . . . . . . . . 19.4 t -51.41 158.2 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.141 -0.975 . . . . 0.67 108.61 179.717 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -121.54 146.88 46.5 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.627 -0.67 . . . . 0.58 109.645 -179.339 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 11' ' ' SER . . . . . 0.437 ' OG ' HG23 ' A' ' 55' ' ' VAL . 4.9 t -140.62 143.77 35.39 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.387 -0.821 . . . . 1.19 109.436 179.878 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 46.8 t -141.39 116.54 9.98 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.319 -0.863 . . . . 1.38 109.689 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 0.645 HG22 ' N ' ' B' ' 14' ' ' PHE . 6.6 p -165.04 170.41 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.342 -0.849 . . . . 0.42 109.029 179.899 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 14' ' ' PHE . . . . . 0.645 ' N ' HG22 ' B' ' 13' ' ' VAL . 9.6 p90 -175.92 -163.14 0.1 Allowed 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 119.285 -0.966 . . . . 1.79 112.144 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.9 pt -150.47 165.55 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.339 0 N-CA-C 108.965 -0.754 . . . . 1.25 108.965 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 17.9 m -125.27 128.82 48.87 Favored 'General case' 0 N--CA 1.502 2.132 0 O-C-N 121.385 -0.822 . . . . 1.61 109.437 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 9.3 mt -99.07 138.72 35.76 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.267 -0.896 . . . . 1.32 109.922 -179.715 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -169.17 150.57 4.35 Favored Pre-proline 0 N--CA 1.49 1.538 0 N-CA-C 108.765 -0.828 . . . . 1.45 108.765 179.259 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -59.15 167.8 5.43 Favored 'Trans proline' 0 CA--C 1.542 0.89 0 C-N-CA 121.051 1.167 . . . . 1.5 109.507 179.836 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 20' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_endo -61.95 -61.45 0.16 Allowed 'Trans proline' 0 C--N 1.317 -1.085 0 C-N-CA 121.371 1.381 . . . . 2.86 109.455 179.348 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 11.6 ptp180 -72.36 162.89 28.86 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.427 -0.796 . . . . 6.12 109.619 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 22' ' ' ARG . . . . . 0.485 ' N ' ' CD ' ' B' ' 22' ' ' ARG . 11.0 mpt_? -83.24 -164.71 0.93 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.298 -0.876 . . . . 6.29 109.107 179.865 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -159.82 124.11 3.82 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.129 -0.982 . . . . 5.62 109.622 179.891 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 11.8 t . . . . . 0 N--CA 1.491 1.586 0 CA-C-O 117.921 -1.038 . . . . 6.48 109.478 179.947 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.59 ' O ' HG23 ' A' ' 2' ' ' ILE . . . . . . . . 1 N--CA 1.531 4.988 0 N-CA-C 119.72 2.648 . . . . 6.64 119.72 . . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.604 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 13.7 pt -162.6 47.06 0.2 Allowed Pre-proline 0 C--N 1.307 -1.282 0 N-CA-C 107.946 -1.131 . . . . 7.08 107.946 179.004 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.838 ' C ' ' H ' ' A' ' 5' ' ' PHE . 3.4 Cg_endo -56.51 -80.45 0.01 OUTLIER 'Trans proline' 0 C--N 1.318 -1.037 0 N-CA-C 109.042 -1.176 . . . . 5.5 109.042 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.492 ' C ' ' H ' ' A' ' 6' ' ' PHE . 1.8 tm-20 73.76 -18.04 0.41 Allowed 'General case' 0 N--CA 1.494 1.769 0 N-CA-C 104.217 -2.512 . . . . 6.75 104.217 -175.487 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . 0.838 ' H ' ' C ' ' A' ' 3' ' ' PRO . 3.8 m-85 -90.24 19.51 5.04 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 103.855 -2.646 . . . . 6.07 103.855 176.733 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.534 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 38.4 p90 47.59 -150.61 0.12 Allowed 'General case' 0 C--N 1.307 -1.267 0 CA-C-N 114.366 -1.288 . . . . 4.72 109.585 -177.581 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 7.0 mm-40 81.16 -8.28 1.42 Allowed 'General case' 0 N--CA 1.5 2.027 0 N-CA-C 105.241 -2.133 . . . . 4.4 105.241 -176.723 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.479 ' H ' ' C ' ' A' ' 6' ' ' PHE . 47.6 t80 -151.59 -37.22 0.12 Allowed 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 107.864 -1.162 . . . . 5.15 107.864 178.454 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 12.6 m -91.54 2.62 56.31 Favored 'General case' 0 C--N 1.297 -1.681 0 N-CA-C 105.867 -1.901 . . . . 5.13 105.867 177.326 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 10.0 p -41.58 -36.88 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.381 0 CA-C-N 115.255 -0.884 . . . . 4.38 109.518 -179.74 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.56 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 134.11 -81.46 0.31 Allowed Glycine 0 N--CA 1.505 3.242 0 N-CA-C 109.344 -1.502 . . . . 4.22 109.344 179.187 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.464 ' O ' ' C ' ' A' ' 13' ' ' LEU . 16.6 Cg_endo -66.49 42.15 0.17 Allowed 'Trans proline' 0 C--N 1.319 -0.994 0 C-N-CA 122.033 1.822 . . . . 3.85 108.533 178.462 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.56 ' H ' ' C ' ' A' ' 11' ' ' GLY . 0.2 OUTLIER 30.36 94.03 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.148 0 CA-C-O 121.355 0.598 . . . . 3.67 110.412 -178.806 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.506 ' C ' ' H ' ' A' ' 16' ' ' GLY . . . -35.69 -30.64 0.02 OUTLIER Glycine 0 N--CA 1.499 2.854 0 N-CA-C 110.02 -1.232 . . . . 2.97 110.02 -179.654 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.517 ' N ' ' O ' ' A' ' 13' ' ' LEU . 48.6 tt0 57.42 8.14 0.58 Allowed 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 108.287 -1.005 . . . . 2.97 108.287 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.506 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 95.02 -144.95 17.49 Favored Glycine 0 N--CA 1.488 2.122 0 N-CA-C 111.204 -0.758 . . . . 2.44 111.204 178.462 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.558 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -43.2 -23.65 0.26 Allowed Glycine 0 N--CA 1.49 2.271 0 O-C-N 121.715 -0.874 . . . . 1.81 111.489 -178.265 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.493 ' N ' ' OE1' ' A' ' 94' ' ' GLU . . . -43.01 -17.94 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.042 -1.27 . . . . 2.21 110.047 -179.715 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . 0.558 ' N ' ' O ' ' A' ' 17' ' ' GLY . 8.9 t-80 -95.3 -52.06 4.33 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.33 -0.856 . . . . 2.87 109.731 179.884 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.536 ' NZ ' ' OG1' ' A' ' 43' ' ' THR . 0.0 OUTLIER -67.21 -14.71 63.17 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.996 -1.065 . . . . 2.02 109.551 -179.602 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.414 HG23 ' O ' ' A' ' 17' ' ' GLY . 71.2 t -76.93 113.4 15.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.181 -0.95 . . . . 2.07 108.813 179.308 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 20.7 tpt180 -110.4 136.31 49.76 Favored 'General case' 0 N--CA 1.494 1.774 0 CA-C-O 121.567 0.698 . . . . 3.5 110.18 -179.015 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.474 ' HA ' HD13 ' A' ' 41' ' ' ILE . . . -140.05 113.61 8.61 Favored 'General case' 0 N--CA 1.491 1.603 0 N-CA-C 108.645 -0.872 . . . . 1.83 108.645 179.569 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -146.38 126.51 2.5 Favored Glycine 0 N--CA 1.496 2.638 0 N-CA-C 109.625 -1.39 . . . . 1.9 109.625 -179.647 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.32 177.93 48.5 Favored Glycine 0 N--CA 1.488 2.139 0 N-CA-C 109.743 -1.343 . . . . 1.85 109.743 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 41.7 p -79.63 -24.62 41.79 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.249 -1.148 . . . . 2.31 109.461 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -68.56 -14.1 66.6 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 108.387 -1.885 . . . . 1.64 108.387 179.492 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 33.6 mt -100.35 35.25 2.15 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.688 -0.856 . . . . 1.83 108.688 179.76 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 -144.32 -46.01 0.25 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.377 -0.827 . . . . 2.34 109.516 -179.742 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 29.2 ptt180 -172.36 171.95 4.58 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 120.98 -1.075 . . . . 3.77 110.093 -179.874 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -147.76 174.4 27.51 Favored Glycine 0 N--CA 1.493 2.439 0 N-CA-C 108.598 -1.801 . . . . 1.57 108.598 179.622 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 37.6 t -134.68 152.52 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.088 0 O-C-N 121.136 -1.214 . . . . 1.83 110.576 -179.635 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.563 ' HB2' ' HB2' ' A' ' 107' ' ' SER . . . -40.78 112.29 0.28 Allowed 'General case' 0 N--CA 1.499 1.999 0 CA-C-O 121.586 0.708 . . . . 1.64 112.321 -179.268 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 53.72 51.82 46.32 Favored Glycine 0 N--CA 1.49 2.253 0 O-C-N 121.57 -0.706 . . . . 1.73 111.377 177.049 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 24.7 t -127.29 98.38 29.68 Favored Pre-proline 0 N--CA 1.495 1.787 0 O-C-N 121.451 -1.029 . . . . 2.19 108.453 178.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_exo -57.85 138.71 87.37 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 120.67 0.913 . . . . 1.96 109.854 -179.25 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -146.79 -167.76 2.85 Favored 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 108.491 -0.929 . . . . 1.69 108.491 -179.839 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -169.26 170.75 8.38 Favored 'General case' 0 C--N 1.303 -1.415 0 C-N-CA 118.745 -1.182 . . . . 2.23 111.04 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.53 ' CD1' ' N ' ' A' ' 39' ' ' PHE . 1.2 p90 -142.3 -178.26 5.65 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 107.49 -1.3 . . . . 1.54 107.49 178.274 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 88.9 p -124.43 138.37 54.36 Favored 'General case' 0 N--CA 1.501 2.088 0 CA-C-O 122.118 0.961 . . . . 2.37 111.219 -178.515 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.474 HD13 ' HA ' ' A' ' 23' ' ' ALA . 33.3 mm -130.58 126.59 60.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 N-CA-C 108.238 -1.023 . . . . 1.65 108.238 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.504 ' CD1' ' C ' ' A' ' 42' ' ' TRP . 0.6 OUTLIER -138.28 142.13 39.83 Favored 'General case' 0 N--CA 1.503 2.221 0 O-C-N 120.898 -1.126 . . . . 3.68 109.539 179.357 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.536 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.2 OUTLIER -156.44 151.94 26.83 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.553 -0.717 . . . . 2.89 109.605 -179.076 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' ARG . . . . . 0.508 HH11 ' HG2' ' A' ' 44' ' ' ARG . 0.0 OUTLIER -168.38 62.47 0.06 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.481 -0.762 . . . . 4.63 109.069 179.596 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -155.43 -60.09 0.11 Allowed 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.106 -0.996 . . . . 2.89 110.016 -179.748 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.449 ' HB3' ' NZ ' ' A' ' 20' ' ' LYS . . . -59.7 -32.75 70.8 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.886 -1.134 . . . . 1.74 109.333 -179.734 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 94.94 -157.36 22.14 Favored Glycine 0 N--CA 1.495 2.603 0 N-CA-C 109.996 -1.242 . . . . 1.6 109.996 179.72 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.65 163.19 0.71 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.398 -1.06 . . . . 1.4 110.101 -179.605 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 175.56 -165.85 36.91 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.264 -1.534 . . . . 1.04 109.264 179.844 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.4 ' O ' ' N ' ' A' ' 92' ' ' ASN . . . -132.6 119.62 2.49 Favored Glycine 0 N--CA 1.498 2.816 0 N-CA-C 108.985 -1.646 . . . . 1.06 108.985 179.867 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.461 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 31.6 tp -100.44 104.53 15.94 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.328 -1.101 . . . . 1.1 109.014 -179.873 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 13.8 t -91.14 142.73 27.43 Favored 'General case' 0 N--CA 1.495 1.824 0 N-CA-C 108.703 -0.851 . . . . 1.56 108.703 179.575 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.533 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 66.0 mt -132.47 103.58 6.54 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.986 0 O-C-N 121.119 -0.988 . . . . 0.65 109.571 -179.922 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -93.76 106.23 18.21 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.641 -0.874 . . . . 0.69 108.641 179.479 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.429 ' O ' ' O ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -98.91 141.7 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.564 -0.71 . . . . 0.91 109.478 -179.622 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 21.0 tt0 -141.28 144.2 34.52 Favored 'General case' 0 N--CA 1.492 1.639 0 N-CA-C 107.535 -1.283 . . . . 1.8 107.535 178.678 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 164.07 -173.3 40.08 Favored Glycine 0 N--CA 1.488 2.134 0 N-CA-C 109.489 -1.444 . . . . 0.49 109.489 -178.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -64.01 -33.46 62.54 Favored 'Trans proline' 0 C--N 1.319 -1.015 0 C-N-CA 122.114 1.876 . . . . 0.66 112.154 -179.567 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 33.0 m -135.22 155.77 50.1 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.072 -1.017 . . . . 1.55 109.947 -179.307 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 77.3 tttt -73.7 96.35 2.49 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.621 -0.674 . . . . 2.53 109.609 -179.834 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -61.05 123.9 18.98 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.342 -0.849 . . . . 0.82 109.341 179.894 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.456 ' CB ' HG12 ' A' ' 78' ' ' VAL . 19.6 tt0 -70.94 171.03 11.48 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.238 -0.914 . . . . 2.3 109.214 -179.82 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 72.4 mt -140.92 152.08 20.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 N-CA-C 107.663 -1.236 . . . . 1.4 107.663 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.54 ' HB3' ' HB2' ' A' ' 76' ' ' SER . . . -150.09 113.45 4.93 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.537 -1.352 . . . . 1.36 109.356 179.816 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.461 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 47.0 p90 -87.24 125.14 34.01 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.35 -0.844 . . . . 1.47 109.71 179.874 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 59.5 tt0 -141.31 100.07 3.71 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.386 -0.821 . . . . 2.51 109.233 179.808 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.421 ' OD1' ' O ' ' A' ' 67' ' ' ASP . 1.3 p30 -74.16 128.54 35.81 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.251 -0.906 . . . . 2.07 109.53 -179.86 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 84.6 mtm180 -101.81 -33.85 9.65 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.401 -0.812 . . . . 4.63 109.699 -179.885 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.542 ' C ' ' H ' ' A' ' 71' ' ' GLY . 29.6 mtmt -122.66 11.23 9.78 Favored 'General case' 0 N--CA 1.495 1.813 0 N-CA-C 109.006 -0.739 . . . . 3.49 109.006 -179.937 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.457 ' CB ' ' O ' ' A' ' 69' ' ' LYS . 1.0 OUTLIER 72.92 -34.98 0.31 Allowed 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 108.577 -0.897 . . . . 3.06 108.577 -179.206 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . 0.542 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -89.6 -37.34 7.0 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.941 -1.264 . . . . 2.16 109.941 -179.76 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 45.5 t -95.54 113.45 25.11 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.22 -1.165 . . . . 2.2 109.612 -179.769 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' CYS . . . . . 0.409 ' N ' ' O ' ' A' ' 41' ' ' ILE . 42.6 m -87.91 114.15 24.24 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.293 -0.879 . . . . 2.05 109.548 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -93.9 118.21 5.68 Favored Glycine 0 N--CA 1.494 2.524 0 N-CA-C 109.15 -1.58 . . . . 1.39 109.15 179.815 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -106.92 106.14 20.08 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.298 0 O-C-N 121.53 -0.982 . . . . 1.57 109.011 -179.868 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.54 ' HB2' ' HB3' ' A' ' 64' ' ' ALA . 1.4 m -89.73 150.81 22.14 Favored 'General case' 0 N--CA 1.49 1.568 0 N-CA-C 108.523 -0.917 . . . . 1.85 108.523 179.273 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 11.7 p90 -145.89 174.27 11.4 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.212 -0.93 . . . . 1.54 109.348 -179.106 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.592 ' O ' HG13 ' A' ' 78' ' ' VAL . 4.8 p -145.79 116.71 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.503 2.192 0 O-C-N 120.991 -1.068 . . . . 1.9 110.66 179.47 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.457 HG11 HG21 ' A' ' 105' ' ' VAL . 10.3 m -90.96 151.41 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 O-C-N 121.144 -0.972 . . . . 1.27 108.745 179.295 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . 0.42 ' O ' ' OE2' ' A' ' 81' ' ' GLU . 7.2 tp-100 -94.76 -46.91 6.7 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.011 -1.056 . . . . 2.48 110.819 -179.06 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.42 ' OE2' ' O ' ' A' ' 80' ' ' GLN . 78.1 mm-40 -153.8 150.06 22.23 Favored Pre-proline 0 N--CA 1.503 2.185 0 O-C-N 120.68 -1.262 . . . . 1.92 111.02 -178.651 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.635 ' HG3' ' N ' ' A' ' 107' ' ' SER . 84.9 Cg_exo -36.76 163.45 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.645 0 C-N-CA 122.918 2.412 . . . . 1.3 113.529 178.177 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 148.16 -165.29 28.97 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.28 -1.528 . . . . 1.02 109.28 179.838 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -106.95 88.25 2.7 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.599 -0.942 . . . . 2.13 108.665 179.697 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.457 ' O ' ' N ' ' A' ' 103' ' ' VAL . 3.4 m-85 -76.64 129.55 36.55 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.283 -1.006 . . . . 0.92 108.283 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -110.21 121.49 45.41 Favored 'General case' 0 N--CA 1.498 1.933 0 N-CA-C 108.372 -0.973 . . . . 1.53 108.372 -179.101 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.417 ' O ' HG13 ' A' ' 87' ' ' VAL . 8.4 p -120.28 133.41 67.09 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.593 -0.692 . . . . 1.0 109.705 -179.607 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 11.6 t -128.24 101.64 6.33 Favored 'General case' 0 N--CA 1.498 1.958 0 N-CA-C 109.609 -0.515 . . . . 1.59 109.609 -179.831 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.472 ' H ' ' CB ' ' A' ' 99' ' ' SER . 0.8 OUTLIER -108.0 130.85 59.78 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.875 0 O-C-N 121.567 -0.708 . . . . 1.29 109.6 -179.806 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . 0.426 ' HG3' ' H ' ' A' ' 93' ' ' ASP . 0.1 OUTLIER -139.9 128.77 23.38 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.413 -0.804 . . . . 1.58 109.05 -179.979 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 44.7 t80 -84.69 95.63 8.98 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 120.527 -1.358 . . . . 1.34 108.387 179.296 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . 0.457 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 0.2 OUTLIER 68.58 39.72 2.03 Favored 'General case' 0 N--CA 1.488 1.435 0 N-CA-C 107.893 -1.151 . . . . 2.32 107.893 -178.532 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.457 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 3.4 m-20 82.6 14.07 0.45 Allowed 'General case' 0 N--CA 1.499 1.992 0 CA-C-O 121.188 0.518 . . . . 1.92 110.23 -179.434 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . 0.493 ' OE1' ' N ' ' A' ' 18' ' ' ALA . 55.2 mt-10 -87.91 78.73 8.24 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.431 -0.951 . . . . 2.25 108.431 178.916 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . 0.462 ' H ' ' CD2' ' A' ' 95' ' ' HIS . 44.2 m-70 -55.75 109.67 0.6 Allowed 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.529 -0.732 . . . . 2.88 110.602 -179.17 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . 0.426 ' O ' ' O ' ' A' ' 99' ' ' SER . 1.5 mp -66.55 136.48 94.88 Favored Pre-proline 0 N--CA 1.492 1.637 0 N-CA-C 107.476 -1.305 . . . . 2.35 107.476 179.034 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_exo -41.17 -41.21 4.51 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 120.997 1.131 . . . . 2.48 110.575 -179.633 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.506 ' N ' ' OD1' ' A' ' 98' ' ' ASP . 1.3 m-20 -56.9 -65.61 0.59 Allowed 'General case' 0 N--CA 1.488 1.434 0 O-C-N 120.83 -1.169 . . . . 2.65 108.026 178.191 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.472 ' CB ' ' H ' ' A' ' 89' ' ' ILE . 0.1 OUTLIER -68.71 145.02 96.68 Favored Pre-proline 0 C--N 1.293 -1.882 0 O-C-N 121.173 -0.955 . . . . 2.0 109.564 -179.448 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -85.22 113.01 2.71 Favored 'Cis proline' 0 CA--C 1.549 1.271 0 O-C-N 122.636 0.808 . . . . 1.79 110.154 -1.864 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 31.3 p90 -121.82 164.23 17.84 Favored 'General case' 0 N--CA 1.521 3.088 0 O-C-N 120.497 -1.377 . . . . 2.19 109.921 178.402 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.3 p -87.43 144.41 9.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.462 -0.774 . . . . 1.44 110.643 -178.129 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.457 ' N ' ' O ' ' A' ' 85' ' ' TYR . 71.7 t -117.24 89.54 31.26 Favored Pre-proline 0 N--CA 1.498 1.949 0 N-CA-C 108.503 -0.925 . . . . 1.19 108.503 179.354 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -62.93 113.99 2.24 Favored 'Trans proline' 0 C--N 1.319 -0.989 0 C-N-CA 121.142 1.228 . . . . 1.49 111.916 -178.266 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.457 HG21 HG11 ' A' ' 79' ' ' VAL . 55.4 t -96.41 140.4 17.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 N-CA-C 105.926 -1.879 . . . . 1.35 105.926 177.446 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.684 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -131.89 133.53 44.7 Favored 'General case' 0 N--CA 1.512 2.671 0 CA-C-O 122.067 0.937 . . . . 1.67 112.059 -176.889 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.635 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 23.2 t -101.06 86.77 3.11 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 107.928 -1.138 . . . . 2.04 107.928 179.177 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 13.3 mt 60.24 6.07 0.94 Allowed 'General case' 0 C--N 1.297 -1.708 0 N-CA-C 107.718 -1.216 . . . . 3.2 107.718 -178.323 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.599 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 52.0 p -97.77 -23.39 15.92 Favored 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 109.206 -0.664 . . . . 2.09 109.206 179.657 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . 0.684 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 34.4 t70 52.78 11.41 0.2 Allowed 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.131 -0.981 . . . . 2.85 108.436 -179.587 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.492 ' N ' ' C ' ' A' ' 109' ' ' SER . 30.8 t70 -171.57 -30.13 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.711 -0.618 . . . . 2.46 109.567 -179.736 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.599 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 41.88 83.9 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.074 0 O-C-N 121.25 -0.906 . . . . 2.08 110.1 179.884 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . 0.523 ' CG ' HH11 ' A' ' 113' ' ' ARG . 0.0 OUTLIER -71.46 149.19 46.1 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.167 -0.958 . . . . 5.93 109.268 -179.677 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.585 ' CG ' HH11 ' A' ' 114' ' ' ARG . 0.2 OUTLIER -93.59 6.26 48.87 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.513 -0.742 . . . . 5.61 109.156 -179.933 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 34.2 mt -128.0 -21.77 3.59 Favored 'General case' 0 N--CA 1.505 2.305 0 O-C-N 121.649 -0.657 . . . . 4.39 109.677 -179.507 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.497 ' C ' ' H ' ' A' ' 118' ' ' THR . 91.6 m -112.03 -77.22 0.59 Allowed 'General case' 0 N--CA 1.498 1.95 0 N-CA-C 107.087 -1.449 . . . . 4.09 107.087 179.049 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.463 ' O ' HG12 ' A' ' 117' ' ' VAL . 44.7 t -64.74 -6.2 2.87 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.749 0 N-CA-C 105.911 -1.885 . . . . 2.9 105.911 176.799 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' THR . . . . . 0.497 ' H ' ' C ' ' A' ' 116' ' ' THR . 4.5 t 35.99 59.07 0.92 Allowed 'General case' 0 N--CA 1.488 1.455 0 CA-C-N 115.026 -0.988 . . . . 3.36 110.797 179.902 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' SER . . . . . 0.46 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.5 p . . . . . 0 N--CA 1.488 1.434 0 CA-C-O 117.977 -1.011 . . . . 3.39 109.582 179.345 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 27.2 ttt . . . . . 0 N--CA 1.49 1.533 0 CA-C-O 121.277 0.561 . . . . 8.49 109.525 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -80.31 149.35 30.34 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.217 -0.927 . . . . 5.53 109.779 -179.818 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 3' ' ' SER . . . . . 0.439 ' H ' ' H ' ' B' ' 4' ' ' LYS . 21.6 p -171.34 -6.8 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.281 -0.887 . . . . 5.43 109.086 179.85 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 4' ' ' LYS . . . . . 0.651 ' N ' ' CD ' ' B' ' 5' ' ' PRO . 25.7 ttpt -81.19 -33.55 0.69 Allowed Pre-proline 0 N--CA 1.488 1.451 0 O-C-N 121.418 -0.801 . . . . 6.87 111.826 179.964 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 5' ' ' PRO . . . . . 0.651 ' CD ' ' N ' ' B' ' 4' ' ' LYS . 6.2 Cg_exo -65.08 -169.77 0.14 Allowed 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 120.606 0.871 . . . . 5.16 110.002 -178.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 6' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -77.54 35.18 0.18 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.234 -0.916 . . . . 4.78 109.764 -179.711 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 7' ' ' LYS . . . . . 0.407 ' H ' ' C ' ' B' ' 5' ' ' PRO . 91.4 mttt 45.6 -114.04 0.43 Allowed 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.317 -0.864 . . . . 4.09 109.847 179.89 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.456 HH11 ' HG2' ' B' ' 8' ' ' ARG . 11.7 mtt-85 -91.1 168.2 11.8 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.19 -0.944 . . . . 3.04 109.078 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 9' ' ' VAL . . . . . 0.403 ' CG1' ' N ' ' B' ' 10' ' ' ALA . 3.1 t -48.72 159.69 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.135 -0.978 . . . . 0.67 108.515 179.747 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 0.403 ' N ' ' CG1' ' B' ' 9' ' ' VAL . . . -116.44 150.84 37.18 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.655 -0.653 . . . . 0.58 109.482 -179.344 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 11' ' ' SER . . . . . 0.429 ' O ' ' O ' ' A' ' 55' ' ' VAL . 58.2 m -153.19 139.88 18.92 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.283 -0.886 . . . . 1.19 109.865 -179.832 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 51.6 p -148.36 112.51 5.21 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.197 -0.939 . . . . 1.38 109.562 -179.697 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 0.58 HG22 ' N ' ' B' ' 14' ' ' PHE . 2.5 p -154.61 167.58 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 N-CA-C 108.624 -0.88 . . . . 0.42 108.624 179.811 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 14' ' ' PHE . . . . . 0.58 ' N ' HG22 ' B' ' 13' ' ' VAL . 7.8 p90 -176.55 -167.18 0.18 Allowed 'General case' 0 N--CA 1.488 1.435 0 C-N-CA 119.132 -1.027 . . . . 1.79 112.069 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -143.45 146.26 21.49 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.226 0 N-CA-C 108.883 -0.784 . . . . 1.25 108.883 179.871 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 46.1 m -113.03 128.3 56.46 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.353 -0.842 . . . . 1.61 109.293 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 16.8 mt -97.95 142.51 29.59 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.174 -0.954 . . . . 1.32 109.562 179.939 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -171.75 66.97 0.42 Allowed Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.256 -0.903 . . . . 1.45 109.527 179.696 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -65.42 141.12 66.48 Favored 'Trans proline' 0 CA--C 1.551 1.363 0 C-N-CA 121.36 1.373 . . . . 1.5 109.32 -179.776 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 20' ' ' PRO . . . . . 0.426 ' O ' ' O ' ' B' ' 21' ' ' ARG . 4.6 Cg_endo -62.38 -36.2 68.32 Favored 'Trans proline' 0 CA--C 1.538 0.691 0 C-N-CA 120.872 1.048 . . . . 2.86 109.699 179.394 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . 0.426 ' O ' ' O ' ' B' ' 20' ' ' PRO . 50.9 mtp180 -55.79 -164.96 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.442 -0.786 . . . . 6.12 110.013 -179.579 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 22' ' ' ARG . . . . . . . . . . . . . 1.5 tmm_? 54.95 92.2 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.314 -0.866 . . . . 6.29 109.158 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . 0.409 ' H ' ' H ' ' B' ' 24' ' ' VAL . 14.8 m-20 -157.78 -13.4 0.08 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.331 -0.856 . . . . 5.62 109.442 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . 0.409 ' H ' ' H ' ' B' ' 23' ' ' ASP . 14.2 t . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 118.022 -0.989 . . . . 6.48 109.573 -179.834 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.53 4.964 0 N-CA-C 119.799 2.68 . . . . 6.64 119.799 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.525 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 2.8 tt -174.98 52.22 0.1 Allowed Pre-proline 0 C--N 1.309 -1.174 0 N-CA-C 107.972 -1.121 . . . . 7.08 107.972 179.578 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.721 ' C ' ' H ' ' A' ' 5' ' ' PHE . 1.3 Cg_endo -56.7 -80.92 0.01 OUTLIER 'Trans proline' 0 C--N 1.319 -0.996 0 N-CA-C 108.217 -1.494 . . . . 5.5 108.217 179.852 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 64.32 2.68 1.58 Allowed 'General case' 0 N--CA 1.499 2.024 0 N-CA-C 105.003 -2.221 . . . . 6.75 105.003 -176.61 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . 0.721 ' H ' ' C ' ' A' ' 3' ' ' PRO . 5.2 m-85 -114.6 18.42 16.71 Favored 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 102.46 -3.163 . . . . 6.07 102.46 177.58 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.541 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 36.0 p90 48.14 -151.09 0.13 Allowed 'General case' 0 C--N 1.308 -1.209 0 CA-C-N 113.302 -1.772 . . . . 4.72 109.532 -177.315 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.404 ' HB2' ' O ' ' A' ' 6' ' ' PHE . 66.4 mt-30 81.61 -9.53 1.25 Allowed 'General case' 0 N--CA 1.497 1.88 0 N-CA-C 105.139 -2.171 . . . . 4.4 105.139 -176.697 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.5 ' H ' ' C ' ' A' ' 6' ' ' PHE . 28.4 t80 -150.37 -36.66 0.15 Allowed 'General case' 0 N--CA 1.486 1.333 0 N-CA-C 107.983 -1.117 . . . . 5.15 107.983 178.24 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.422 HG22 ' O ' ' A' ' 9' ' ' THR . 39.1 m -94.91 4.57 53.66 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 105.704 -1.961 . . . . 5.13 105.704 177.456 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.536 HG13 ' N ' ' A' ' 11' ' ' GLY . 13.0 p -45.69 -46.23 4.81 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.296 0 CA-C-N 115.272 -0.876 . . . . 4.38 109.398 -179.535 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.576 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 131.03 -78.58 0.37 Allowed Glycine 0 N--CA 1.503 3.142 0 N-CA-C 109.132 -1.587 . . . . 4.22 109.132 179.393 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.446 ' O ' ' C ' ' A' ' 13' ' ' LEU . 11.8 Cg_endo -65.24 40.22 0.12 Allowed 'Trans proline' 0 C--N 1.32 -0.958 0 C-N-CA 122.186 1.924 . . . . 3.85 109.176 178.409 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.576 ' H ' ' C ' ' A' ' 11' ' ' GLY . 0.2 OUTLIER 28.17 46.05 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.157 0 CA-C-O 121.504 0.669 . . . . 3.67 111.062 -179.848 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.483 ' C ' ' N ' ' A' ' 16' ' ' GLY . . . 69.06 -36.89 0.3 Allowed Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.567 -1.413 . . . . 2.97 109.567 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.521 ' H ' ' C ' ' A' ' 13' ' ' LEU . 6.9 tp10 51.76 16.81 0.53 Allowed 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.115 -1.226 . . . . 2.97 107.798 -179.132 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.483 ' N ' ' C ' ' A' ' 14' ' ' GLY . . . 82.09 -166.08 45.99 Favored Glycine 0 N--CA 1.485 1.92 0 N-CA-C 109.48 -1.448 . . . . 2.44 109.48 -179.854 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.503 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -43.97 -19.76 0.13 Allowed Glycine 0 N--CA 1.488 2.159 0 O-C-N 121.387 -1.067 . . . . 1.81 110.579 -179.457 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.774 ' HB2' ' OE1' ' A' ' 94' ' ' GLU . . . -51.07 -9.9 0.06 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.826 -1.397 . . . . 2.21 109.204 -179.829 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . 0.503 ' N ' ' O ' ' A' ' 17' ' ' GLY . 22.0 t60 -103.01 -4.59 24.42 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.404 -0.81 . . . . 2.87 110.175 -179.738 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.594 ' HZ2' HG23 ' A' ' 21' ' ' VAL . 1.9 pptp? -135.81 0.6 2.69 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.1 -1.0 . . . . 2.02 110.261 -179.559 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.594 HG23 ' HZ2' ' A' ' 20' ' ' LYS . 55.3 t -88.8 113.47 25.55 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.003 -1.06 . . . . 2.07 109.751 179.665 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 21.0 tpt180 -108.97 135.85 49.47 Favored 'General case' 0 N--CA 1.495 1.79 0 N-CA-C 109.308 -0.627 . . . . 3.5 109.308 179.647 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -143.31 113.81 7.46 Favored 'General case' 0 N--CA 1.492 1.674 0 N-CA-C 108.566 -0.902 . . . . 1.83 108.566 179.467 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -152.6 130.95 3.2 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.671 -1.371 . . . . 1.9 109.671 -179.367 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -177.55 167.58 38.67 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.801 -1.32 . . . . 1.85 109.801 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.49 ' C ' ' H ' ' A' ' 28' ' ' LEU . 0.5 OUTLIER -80.5 -27.53 37.72 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.318 -1.107 . . . . 2.31 109.864 -179.698 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -64.21 -1.36 5.46 Favored Glycine 0 N--CA 1.483 1.78 0 N-CA-C 107.938 -2.065 . . . . 1.64 107.938 179.193 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.49 ' H ' ' C ' ' A' ' 26' ' ' THR . 60.9 mt -108.45 -10.56 15.27 Favored 'General case' 0 N--CA 1.493 1.712 0 N-CA-C 108.643 -0.873 . . . . 1.83 108.643 179.748 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 20.3 mm-40 -85.74 -54.16 4.7 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.568 -0.708 . . . . 2.34 109.561 -179.586 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . 0.584 ' CG ' HH11 ' A' ' 30' ' ' ARG . 3.2 mtt-85 -156.83 161.94 39.72 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.125 -0.984 . . . . 3.77 109.76 179.918 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -140.73 172.17 23.74 Favored Glycine 0 N--CA 1.493 2.499 0 N-CA-C 108.102 -1.999 . . . . 1.57 108.102 179.205 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 36.0 t -134.37 150.93 31.2 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.03 0 O-C-N 121.189 -1.183 . . . . 1.83 110.398 -179.338 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -38.83 113.89 0.34 Allowed 'General case' 0 N--CA 1.495 1.784 0 CA-C-O 121.862 0.839 . . . . 1.64 112.844 -179.184 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 53.99 49.77 57.64 Favored Glycine 0 N--CA 1.489 2.167 0 N-CA-C 111.238 -0.745 . . . . 1.73 111.238 177.378 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 25.3 t -126.98 99.41 28.88 Favored Pre-proline 0 N--CA 1.497 1.9 0 O-C-N 121.531 -0.982 . . . . 2.19 108.396 179.052 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -56.75 143.44 90.27 Favored 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 120.946 1.097 . . . . 1.96 110.588 -178.906 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.473 ' HB3' ' CE1' ' A' ' 77' ' ' TYR . . . -150.23 -169.06 3.28 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.563 -0.903 . . . . 1.69 108.563 179.869 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -169.38 162.23 10.22 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.958 -1.089 . . . . 2.23 111.03 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.575 ' CD1' ' N ' ' A' ' 39' ' ' PHE . 0.2 OUTLIER -134.8 -176.37 4.21 Favored 'General case' 0 N--CA 1.485 1.303 0 N-CA-C 106.638 -1.615 . . . . 1.54 106.638 178.355 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 18.3 t -121.35 145.97 47.34 Favored 'General case' 0 N--CA 1.501 2.1 0 CA-C-O 121.72 0.771 . . . . 2.37 111.07 -178.633 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.523 ' O ' ' N ' ' A' ' 73' ' ' CYS . 62.6 mt -143.19 118.69 4.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 N-CA-C 108.547 -0.908 . . . . 1.65 108.547 179.222 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.533 ' O ' ' CD2' ' A' ' 42' ' ' TRP . 5.9 p-90 -118.1 127.19 53.54 Favored 'General case' 0 N--CA 1.502 2.135 0 O-C-N 121.219 -0.926 . . . . 3.68 108.549 179.109 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.52 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -150.92 128.4 11.41 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.224 -0.923 . . . . 2.89 109.926 -178.828 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' ARG . . . . . . . . . . . . . 24.8 ttm180 -172.48 79.35 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.442 -0.786 . . . . 4.63 109.092 179.663 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 2.3 tm-20 -159.69 -55.04 0.06 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.188 -0.945 . . . . 2.89 109.881 -179.676 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -53.43 -55.29 26.38 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 120.911 -1.118 . . . . 1.74 108.672 -179.821 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 140.58 -170.37 24.47 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.163 -1.575 . . . . 1.6 109.163 179.678 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.67 148.28 10.05 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.14 -1.212 . . . . 1.4 109.202 179.832 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -171.66 -170.06 35.23 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.762 -1.335 . . . . 1.04 109.762 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -133.05 122.71 3.24 Favored Glycine 0 N--CA 1.497 2.727 0 N-CA-C 109.403 -1.479 . . . . 1.06 109.403 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 11.3 tp -97.65 97.98 9.49 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.303 -1.116 . . . . 1.1 108.69 179.651 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . 0.409 ' HA ' ' CD2' ' B' ' 14' ' ' PHE . 0.3 OUTLIER -84.52 145.63 27.99 Favored 'General case' 0 C--N 1.312 -1.035 0 N-CA-C 108.026 -1.102 . . . . 1.56 108.026 179.695 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.445 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 65.4 mt -134.98 118.68 25.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.217 -0.927 . . . . 0.65 110.048 -179.315 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -106.63 106.85 17.57 Favored 'General case' 0 N--CA 1.495 1.824 0 N-CA-C 108.431 -0.952 . . . . 0.69 108.431 179.072 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 2.4 t -97.59 146.36 7.88 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.266 -0.897 . . . . 0.91 109.639 -179.436 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 22.8 tt0 -139.5 131.21 27.38 Favored 'General case' 0 N--CA 1.488 1.448 0 N-CA-C 107.616 -1.253 . . . . 1.8 107.616 178.835 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -178.41 172.31 44.71 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.159 -1.576 . . . . 0.49 109.159 -179.498 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_exo -52.06 -28.61 33.25 Favored 'Trans proline' 0 C--N 1.318 -1.076 0 C-N-CA 121.808 1.672 . . . . 0.66 110.859 -179.501 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.2 t -140.79 157.18 45.77 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.439 -0.788 . . . . 1.55 109.839 -179.527 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 49.3 mttp -77.78 104.75 8.52 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.421 -0.799 . . . . 2.53 109.169 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -74.15 136.95 42.89 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.272 -0.892 . . . . 0.82 109.549 -179.728 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.679 ' O ' HD13 ' A' ' 63' ' ' ILE . 46.9 mt-10 -75.33 175.54 8.29 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.141 -0.974 . . . . 2.3 109.629 -179.829 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.679 HD13 ' O ' ' A' ' 62' ' ' GLU . 4.8 mm -140.51 156.46 23.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 N-CA-C 108.033 -1.099 . . . . 1.4 108.033 -179.656 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.433 ' HB3' ' CB ' ' A' ' 76' ' ' SER . . . -144.45 174.63 10.77 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 120.551 -1.343 . . . . 1.36 108.999 179.749 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.51 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 37.7 p90 -147.25 116.36 6.9 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.308 -0.87 . . . . 1.47 109.46 -179.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 76.2 tt0 -141.57 111.0 6.4 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.317 -0.864 . . . . 2.51 109.241 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.428 ' OD1' ' O ' ' A' ' 67' ' ' ASP . 1.2 p30 -74.71 117.84 16.99 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.2 -0.938 . . . . 2.07 109.541 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 29.9 ttp180 -102.15 -24.12 13.97 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.371 -0.831 . . . . 4.63 109.46 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.511 ' C ' ' H ' ' A' ' 71' ' ' GLY . 40.1 mttp -121.29 1.56 10.23 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.55 -0.719 . . . . 3.49 109.079 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.463 ' CB ' ' O ' ' A' ' 69' ' ' LYS . 1.5 t70 74.0 -26.11 0.19 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.498 -0.751 . . . . 3.06 109.11 -179.628 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . 0.511 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -108.54 -30.34 3.84 Favored Glycine 0 N--CA 1.495 2.58 0 N-CA-C 109.894 -1.282 . . . . 2.16 109.894 -179.484 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 60.6 p -95.7 113.58 25.23 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.157 -1.202 . . . . 2.2 109.666 -179.783 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' CYS . . . . . 0.523 ' N ' ' O ' ' A' ' 41' ' ' ILE . 17.0 t -75.77 112.23 11.93 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.306 -0.871 . . . . 2.05 109.361 179.789 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -91.77 117.99 5.37 Favored Glycine 0 N--CA 1.493 2.439 0 N-CA-C 109.394 -1.482 . . . . 1.39 109.394 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 1.9 m -109.28 114.68 47.57 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.097 0 O-C-N 121.611 -0.935 . . . . 1.57 109.502 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.433 ' CB ' ' HB3' ' A' ' 64' ' ' ALA . 0.9 OUTLIER -92.55 167.84 11.66 Favored 'General case' 0 N--CA 1.491 1.62 0 N-CA-C 108.341 -0.985 . . . . 1.85 108.341 179.537 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.473 ' CE1' ' HB3' ' A' ' 37' ' ' ALA . 5.9 p90 -163.77 168.15 20.03 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.356 -0.84 . . . . 1.54 109.095 -179.338 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.577 ' O ' HG13 ' A' ' 78' ' ' VAL . 5.0 p -143.11 115.31 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.369 0 O-C-N 121.0 -1.062 . . . . 1.9 110.448 179.418 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.418 HG22 ' H ' ' A' ' 79' ' ' VAL . 14.3 m -88.82 152.38 3.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.244 -0.91 . . . . 1.27 109.233 179.741 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 6.8 tt0 -88.92 -50.33 6.26 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.092 -1.005 . . . . 2.48 110.764 -179.043 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -153.31 156.92 32.85 Favored Pre-proline 0 N--CA 1.504 2.271 0 O-C-N 120.722 -1.236 . . . . 1.92 110.766 -179.015 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.615 ' HG3' ' N ' ' A' ' 107' ' ' SER . 71.0 Cg_exo -37.67 163.55 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 123.293 2.662 . . . . 1.3 113.452 179.17 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 145.35 -177.37 23.82 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.138 -1.585 . . . . 1.02 109.138 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . 0.528 ' OD1' ' NH2' ' B' ' 8' ' ' ARG . 0.4 OUTLIER -99.81 90.93 4.61 Favored 'General case' 0 N--CA 1.493 1.715 0 N-CA-C 107.962 -1.125 . . . . 2.13 107.962 179.289 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -76.25 132.05 39.64 Favored 'General case' 0 C--N 1.296 -1.721 0 N-CA-C 108.245 -1.02 . . . . 0.92 108.245 -179.747 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.66 115.56 27.31 Favored 'General case' 0 N--CA 1.501 2.082 0 N-CA-C 108.337 -0.986 . . . . 1.53 108.337 -179.351 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.556 ' CG1' ' CE2' ' A' ' 101' ' ' PHE . 4.5 p -112.85 132.78 60.69 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.676 -0.64 . . . . 1.0 109.421 -179.779 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 3.0 m -121.85 139.53 53.51 Favored 'General case' 0 N--CA 1.497 1.886 0 N-CA-C 108.536 -0.912 . . . . 1.59 108.536 179.635 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.3 pt -141.1 130.68 25.34 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.181 0 O-C-N 121.076 -1.015 . . . . 1.29 109.845 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -136.89 123.61 21.14 Favored 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 107.72 -1.215 . . . . 1.58 107.72 178.191 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . . . . . . . . . 83.5 t80 -83.7 102.2 12.09 Favored 'General case' 0 C--N 1.295 -1.77 0 N-CA-C 107.985 -1.117 . . . . 1.34 107.985 179.326 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . 0.442 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 1.3 t30 69.33 34.83 2.79 Favored 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 108.788 -0.819 . . . . 2.32 108.788 -178.651 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.442 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 2.7 m-20 79.34 16.66 0.89 Allowed 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.827 -0.546 . . . . 1.92 111.505 179.473 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . 0.774 ' OE1' ' HB2' ' A' ' 18' ' ' ALA . 0.6 OUTLIER -101.1 100.23 10.77 Favored 'General case' 0 N--CA 1.499 2.005 0 N-CA-C 107.407 -1.331 . . . . 2.25 107.407 178.188 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 11.9 m-70 -73.97 110.92 8.64 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.117 -0.99 . . . . 2.88 110.632 -177.844 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . 0.465 ' O ' ' N ' ' A' ' 98' ' ' ASP . 3.4 tp -63.95 134.62 95.99 Favored Pre-proline 0 N--CA 1.488 1.455 0 N-CA-C 107.554 -1.276 . . . . 2.35 107.554 178.868 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.417 ' HD2' HD12 ' A' ' 96' ' ' ILE . 7.2 Cg_exo -49.56 92.5 0.03 OUTLIER 'Trans proline' 0 C--O 1.214 -0.721 0 N-CA-C 109.839 -0.87 . . . . 2.48 109.839 -179.824 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.465 ' N ' ' O ' ' A' ' 96' ' ' ILE . 0.9 OUTLIER 169.76 -54.05 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 108.756 -0.831 . . . . 2.65 108.756 -179.574 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 6.2 m -55.3 136.95 68.73 Favored Pre-proline 0 C--N 1.298 -1.636 0 O-C-N 121.231 -0.918 . . . . 2.0 109.588 -178.261 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_endo -88.36 113.58 2.43 Favored 'Cis proline' 0 N--CA 1.494 1.539 0 N-CA-C 110.328 -0.681 . . . . 1.79 110.328 -1.862 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . 0.598 ' CD1' ' N ' ' A' ' 101' ' ' PHE . 0.0 OUTLIER -80.71 155.08 26.93 Favored 'General case' 0 N--CA 1.509 2.522 0 O-C-N 119.727 -1.858 . . . . 2.19 108.66 178.346 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 10.5 p -89.21 144.5 8.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.483 -0.761 . . . . 1.44 109.158 179.653 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 76.9 t -128.04 85.87 59.52 Favored Pre-proline 0 N--CA 1.499 1.997 0 N-CA-C 108.133 -1.062 . . . . 1.19 108.133 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -64.91 112.53 2.04 Favored 'Trans proline' 0 C--N 1.321 -0.878 0 C-N-CA 121.433 1.422 . . . . 1.49 111.851 -177.867 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 54.5 t -96.36 143.89 11.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 N-CA-C 106.172 -1.788 . . . . 1.35 106.172 177.667 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.673 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -136.36 135.23 38.65 Favored 'General case' 0 N--CA 1.509 2.489 0 O-C-N 121.151 -0.968 . . . . 1.67 112.133 -176.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.615 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 11.0 t -89.67 76.27 7.31 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 107.413 -1.329 . . . . 2.04 107.413 178.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 13.6 mt 65.87 -0.06 1.42 Allowed 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 107.748 -1.204 . . . . 3.2 107.748 -177.861 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.67 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 22.9 t -84.67 -22.14 29.94 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.74 -0.837 . . . . 2.09 108.74 178.873 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . 0.673 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 5.5 m-20 57.17 6.93 0.4 Allowed 'General case' 0 N--CA 1.487 1.423 0 N-CA-C 107.984 -1.117 . . . . 2.85 107.984 -179.141 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.519 ' H ' ' C ' ' A' ' 109' ' ' SER . 22.4 m-20 -164.79 -33.5 0.03 OUTLIER 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 108.714 -0.847 . . . . 2.46 108.714 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.67 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 41.56 84.49 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.332 -0.855 . . . . 2.08 110.569 179.711 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . 0.446 ' NH1' ' CB ' ' A' ' 111' ' ' ASP . 10.3 mpt_? -61.63 -169.54 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.906 -1.121 . . . . 5.93 108.574 179.681 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.68 HH12 ' NE ' ' B' ' 8' ' ' ARG . 50.3 ttt180 -147.39 4.1 0.79 Allowed 'General case' 0 N--CA 1.493 1.721 0 N-CA-C 108.548 -0.908 . . . . 5.61 108.548 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 2.5 mp -129.8 -24.47 2.69 Favored 'General case' 0 N--CA 1.502 2.146 0 N-CA-C 109.458 -0.571 . . . . 4.39 109.458 179.778 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.488 ' C ' ' H ' ' A' ' 118' ' ' THR . 54.9 m -105.33 -79.44 0.56 Allowed 'General case' 0 N--CA 1.496 1.836 0 N-CA-C 106.955 -1.498 . . . . 4.09 106.955 178.8 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.44 ' O ' HG12 ' A' ' 117' ' ' VAL . 49.5 t -62.56 -8.2 2.88 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.702 0 N-CA-C 105.955 -1.869 . . . . 2.9 105.955 176.724 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' THR . . . . . 0.488 ' H ' ' C ' ' A' ' 116' ' ' THR . 4.4 t 36.47 60.2 0.92 Allowed 'General case' 0 N--CA 1.488 1.437 0 CA-C-N 115.2 -0.909 . . . . 3.36 110.729 179.967 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' SER . . . . . 0.463 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.6 p . . . . . 0 C--N 1.304 -1.404 0 CA-C-O 118.0 -1.0 . . . . 3.39 109.611 179.364 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . 0.538 ' O ' ' N ' ' B' ' 3' ' ' SER . 6.5 ptm . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.467 -0.568 . . . . 8.49 109.467 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . 59.89 -76.95 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.461 -0.774 . . . . 5.53 109.75 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 3' ' ' SER . . . . . 0.538 ' N ' ' O ' ' B' ' 1' ' ' MET . 41.2 t -73.61 -144.71 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.131 -0.98 . . . . 5.43 109.503 -179.952 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 4' ' ' LYS . . . . . 0.488 ' N ' ' OG ' ' B' ' 3' ' ' SER . 79.8 tttt -164.37 68.3 1.47 Allowed Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.278 -0.888 . . . . 6.87 109.648 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 5' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_exo -61.24 169.82 5.86 Favored 'Trans proline' 0 C--N 1.318 -1.071 0 C-N-CA 121.392 1.394 . . . . 5.16 109.828 -179.819 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 6' ' ' GLU . . . . . . . . . . . . . 26.0 mt-10 -77.23 45.4 0.45 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.279 -0.888 . . . . 4.78 109.569 -179.912 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 68.9 mttm 48.85 -115.66 0.77 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.161 -0.962 . . . . 4.09 109.37 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.68 ' NE ' HH12 ' A' ' 114' ' ' ARG . 16.5 mmt-85 -90.41 173.79 7.91 Favored 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 108.435 -0.95 . . . . 3.04 108.435 179.561 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 9' ' ' VAL . . . . . . . . . . . . . 3.0 t -57.66 161.48 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 N-CA-C 106.924 -1.51 . . . . 0.67 106.924 178.746 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -115.07 148.52 38.8 Favored 'General case' 0 N--CA 1.504 2.267 0 O-C-N 121.267 -0.896 . . . . 0.58 111.151 -178.06 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 1.3 t -141.11 150.86 43.42 Favored 'General case' 0 N--CA 1.497 1.906 0 N-CA-C 109.232 -0.655 . . . . 1.19 109.232 179.39 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 28.5 p -149.09 131.47 15.64 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.053 -1.029 . . . . 1.38 110.224 -179.836 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 0.664 HG22 ' N ' ' B' ' 14' ' ' PHE . 7.5 p -173.6 174.39 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 N-CA-C 108.345 -0.983 . . . . 0.42 108.345 179.777 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 14' ' ' PHE . . . . . 0.664 ' N ' HG22 ' B' ' 13' ' ' VAL . 0.1 OUTLIER 173.05 -171.97 0.04 OUTLIER 'General case' 0 N--CA 1.493 1.702 0 C-N-CA 118.797 -1.161 . . . . 1.79 112.201 179.483 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -143.85 -179.4 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.339 0 N-CA-C 108.898 -0.779 . . . . 1.25 108.898 179.903 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 9.0 t -141.31 142.91 33.82 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.154 -0.966 . . . . 1.61 109.291 179.59 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.3 mt -101.86 147.26 26.72 Favored 'General case' 0 N--CA 1.499 2.019 0 O-C-N 121.261 -0.9 . . . . 1.32 110.108 -179.55 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -155.14 152.92 26.2 Favored Pre-proline 0 N--CA 1.492 1.649 0 N-CA-C 108.111 -1.07 . . . . 1.45 108.111 179.396 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -58.82 165.7 7.83 Favored 'Trans proline' 0 CA--C 1.544 0.992 0 C-N-CA 120.862 1.041 . . . . 1.5 109.625 -179.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 20' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_endo -63.3 -159.33 0.03 OUTLIER 'Trans proline' 0 C--N 1.319 -0.989 0 C-N-CA 121.497 1.465 . . . . 2.86 109.534 179.528 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 30.4 ptt180 -71.3 143.76 50.2 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.293 -0.879 . . . . 6.12 109.016 179.426 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 22' ' ' ARG . . . . . . . . . . . . . 42.4 mtp180 -67.87 109.44 3.41 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.151 -0.968 . . . . 6.29 109.511 -179.868 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . 0.431 ' O ' ' OXT' ' B' ' 24' ' ' VAL . 22.8 t0 -124.26 -34.77 2.88 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.583 -0.698 . . . . 5.62 109.225 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . 0.431 ' OXT' ' O ' ' B' ' 23' ' ' ASP . 3.9 t . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 117.973 -1.013 . . . . 6.48 109.62 179.884 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.531 5.016 0 N-CA-C 119.75 2.66 . . . . 6.64 119.75 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.726 HG23 ' O ' ' A' ' 2' ' ' ILE . 0.2 OUTLIER -170.46 49.85 0.14 Allowed Pre-proline 0 C--N 1.307 -1.257 0 N-CA-C 107.56 -1.274 . . . . 7.08 107.56 179.513 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.793 ' C ' ' H ' ' A' ' 5' ' ' PHE . 3.2 Cg_endo -56.42 -80.75 0.01 OUTLIER 'Trans proline' 0 C--N 1.32 -0.935 0 N-CA-C 108.996 -1.194 . . . . 5.5 108.996 179.559 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.493 ' C ' ' H ' ' A' ' 6' ' ' PHE . 7.3 tp10 73.62 -16.06 0.52 Allowed 'General case' 0 N--CA 1.495 1.788 0 N-CA-C 104.376 -2.454 . . . . 6.75 104.376 -175.746 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . 0.793 ' H ' ' C ' ' A' ' 3' ' ' PRO . 2.2 m-85 -91.45 18.65 6.98 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 103.84 -2.652 . . . . 6.07 103.84 176.906 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.531 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 37.2 p90 45.45 -153.84 0.04 OUTLIER 'General case' 0 C--N 1.306 -1.301 0 CA-C-N 114.174 -1.375 . . . . 4.72 109.496 -177.56 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.524 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 3.4 tt0 83.63 -9.13 1.03 Allowed 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 104.975 -2.232 . . . . 4.4 104.975 -177.131 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.467 ' H ' ' C ' ' A' ' 6' ' ' PHE . 49.6 t80 -151.6 -37.92 0.12 Allowed 'General case' 0 C--N 1.305 -1.353 0 N-CA-C 107.794 -1.188 . . . . 5.15 107.794 178.506 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 22.1 m -91.38 2.84 56.11 Favored 'General case' 0 C--N 1.297 -1.679 0 N-CA-C 105.895 -1.891 . . . . 5.13 105.895 177.386 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.407 HG13 ' N ' ' A' ' 11' ' ' GLY . 7.9 p -43.29 -38.15 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.337 0 CA-C-N 115.311 -0.859 . . . . 4.38 109.62 -179.654 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.582 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 138.88 -83.16 0.24 Allowed Glycine 0 N--CA 1.502 3.034 0 N-CA-C 109.157 -1.577 . . . . 4.22 109.157 179.493 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.456 ' O ' ' C ' ' A' ' 13' ' ' LEU . 12.2 Cg_endo -65.85 40.18 0.14 Allowed 'Trans proline' 0 C--N 1.321 -0.914 0 C-N-CA 121.926 1.75 . . . . 3.85 109.159 178.535 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.582 ' H ' ' C ' ' A' ' 11' ' ' GLY . 0.2 OUTLIER 29.04 44.45 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.219 0 CA-C-O 121.607 0.718 . . . . 3.67 110.983 -179.655 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.475 ' C ' ' N ' ' A' ' 16' ' ' GLY . . . 70.36 -37.96 0.45 Allowed Glycine 0 N--CA 1.486 2.032 0 N-CA-C 109.671 -1.371 . . . . 2.97 109.671 179.604 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.479 ' H ' ' C ' ' A' ' 13' ' ' LEU . 15.8 tp10 50.27 19.0 0.46 Allowed 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 107.776 -1.194 . . . . 2.97 107.776 -179.033 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.475 ' N ' ' C ' ' A' ' 14' ' ' GLY . . . 76.89 -162.5 51.84 Favored Glycine 0 N--CA 1.482 1.766 0 N-CA-C 108.52 -1.832 . . . . 2.44 108.52 -178.94 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.518 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -72.65 -4.81 62.42 Favored Glycine 0 N--CA 1.486 2.025 0 N-CA-C 109.717 -1.353 . . . . 1.81 109.717 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -49.03 -12.39 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.729 -1.453 . . . . 2.21 109.236 179.832 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . 0.518 ' N ' ' O ' ' A' ' 17' ' ' GLY . 10.6 t-160 -97.15 -41.15 8.46 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.39 -0.819 . . . . 2.87 109.445 179.651 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.719 ' HZ2' ' N ' ' A' ' 44' ' ' ARG . 0.0 OUTLIER -82.32 -25.37 33.99 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.141 -0.974 . . . . 2.02 109.722 -179.879 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 77.9 t -60.93 112.32 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.045 -1.034 . . . . 2.07 109.081 179.635 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 5.9 tpp180 -104.11 131.14 51.69 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.629 -0.669 . . . . 3.5 109.628 -179.648 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -136.7 113.64 10.47 Favored 'General case' 0 N--CA 1.493 1.723 0 N-CA-C 108.577 -0.898 . . . . 1.83 108.577 179.519 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -155.89 134.66 4.21 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.73 -1.348 . . . . 1.9 109.73 -179.463 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.1 -176.44 46.07 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.99 -1.244 . . . . 1.85 109.99 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 8.6 p -79.49 -25.82 41.74 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.335 -1.097 . . . . 2.31 109.538 -179.862 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.428 ' CA ' ' OH ' ' A' ' 77' ' ' TYR . . . -69.46 -15.44 70.54 Favored Glycine 0 N--CA 1.486 1.992 0 N-CA-C 108.506 -1.838 . . . . 1.64 108.506 179.676 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 65.8 mt -93.36 33.02 1.26 Allowed 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 108.487 -0.931 . . . . 1.83 108.487 179.454 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -144.3 -55.41 0.35 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.373 -0.829 . . . . 2.34 109.796 -179.545 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . 0.528 ' NH1' ' OD1' ' A' ' 110' ' ' ASP . 31.9 mtm180 -156.53 153.69 29.1 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 120.984 -1.073 . . . . 3.77 110.345 -179.441 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.55 ' C ' HG13 ' A' ' 105' ' ' VAL . . . -140.42 171.76 23.84 Favored Glycine 0 N--CA 1.495 2.61 0 N-CA-C 108.244 -1.942 . . . . 1.57 108.244 179.003 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.468 ' H ' ' CG1' ' A' ' 35' ' ' VAL . 28.1 t -135.54 148.32 28.4 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.008 0 O-C-N 121.173 -1.192 . . . . 1.83 110.448 -179.553 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.625 ' HB2' ' HD3' ' A' ' 82' ' ' PRO . . . -38.73 105.79 0.04 OUTLIER 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.916 -0.49 . . . . 1.64 111.688 -179.859 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 64.34 57.0 14.45 Favored Glycine 0 N--CA 1.489 2.23 0 O-C-N 121.089 -1.007 . . . . 1.73 111.864 177.353 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.468 ' CG1' ' H ' ' A' ' 32' ' ' VAL . 4.5 p -125.82 133.92 25.38 Favored Pre-proline 0 N--CA 1.503 2.208 0 O-C-N 121.279 -1.13 . . . . 2.19 108.949 178.72 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_endo -58.47 114.69 2.09 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 N-CA-C 108.547 -1.366 . . . . 1.96 108.547 178.739 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -127.0 148.61 50.1 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.344 -0.847 . . . . 1.69 109.494 -179.352 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.3 pt-20 -157.13 174.01 16.12 Favored 'General case' 0 N--CA 1.488 1.474 0 CA-C-O 122.22 1.01 . . . . 2.23 110.759 -179.886 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.603 ' CE2' HD11 ' A' ' 41' ' ' ILE . 5.0 p90 -159.52 167.07 29.49 Favored 'General case' 0 C--N 1.296 -1.753 0 N-CA-C 107.819 -1.178 . . . . 1.54 107.819 178.67 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 6.4 t -98.04 150.96 20.84 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.462 -0.774 . . . . 2.37 110.715 -178.409 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.603 HD11 ' CE2' ' A' ' 39' ' ' PHE . 10.7 mt -142.09 89.72 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 N-CA-C 108.757 -0.831 . . . . 1.65 108.757 179.117 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.458 ' CD1' ' C ' ' A' ' 42' ' ' TRP . 0.8 OUTLIER -85.28 142.35 29.44 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.115 -0.991 . . . . 3.68 108.815 -179.907 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.487 ' OG1' ' NZ ' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -171.98 117.51 0.39 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.39 -0.818 . . . . 2.89 109.298 -179.688 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' ARG . . . . . 0.719 ' N ' ' HZ2' ' A' ' 20' ' ' LYS . 1.5 tpt180 -164.99 -12.24 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.171 -0.956 . . . . 4.63 109.696 -179.832 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.409 ' H ' ' HD3' ' A' ' 20' ' ' LYS . 0.4 OUTLIER -68.55 -47.53 66.63 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.0 -1.062 . . . . 2.89 109.763 -179.621 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -60.23 -59.76 4.89 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.098 -1.001 . . . . 1.74 109.299 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 142.94 -151.76 23.42 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.585 -1.406 . . . . 1.6 109.585 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -80.64 163.11 23.86 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.479 -1.012 . . . . 1.4 109.531 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 174.02 -143.49 7.05 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.666 -1.373 . . . . 1.04 109.666 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -148.48 127.64 2.6 Favored Glycine 0 N--CA 1.495 2.586 0 N-CA-C 109.554 -1.418 . . . . 1.06 109.554 -179.913 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.465 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 46.8 tp -102.65 107.03 17.79 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.367 -1.078 . . . . 1.1 108.843 179.833 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.4 t -90.62 141.44 28.77 Favored 'General case' 0 N--CA 1.494 1.75 0 N-CA-C 108.616 -0.883 . . . . 1.56 108.616 179.504 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.515 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 63.3 mt -132.06 102.35 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.923 0 O-C-N 121.214 -0.929 . . . . 0.65 109.469 -179.843 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -93.31 105.85 17.88 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 108.497 -0.927 . . . . 0.69 108.497 179.395 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.44 HG23 ' CB ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -95.42 145.07 8.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.521 -0.737 . . . . 0.91 109.254 -179.738 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -141.47 144.17 34.25 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 108.026 -1.101 . . . . 1.8 108.026 179.22 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.415 ' O ' ' O ' ' B' ' 9' ' ' VAL . . . 162.13 -172.95 38.37 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.768 -1.333 . . . . 0.49 109.768 -179.215 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -61.77 -31.88 85.87 Favored 'Trans proline' 0 C--N 1.319 -0.979 0 C-N-CA 122.302 2.001 . . . . 0.66 112.046 -179.666 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 8.0 t -139.0 169.95 16.86 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 120.949 -1.094 . . . . 1.55 110.549 -179.169 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 38.5 mtpt -87.1 106.86 18.16 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 109.003 -0.74 . . . . 2.53 109.003 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -73.48 127.42 32.67 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.165 -0.959 . . . . 0.82 109.776 -179.711 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 24.4 tt0 -65.42 170.44 4.87 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.288 -0.882 . . . . 2.3 109.028 179.732 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.414 HD12 HG13 ' B' ' 13' ' ' VAL . 20.1 mt -143.52 155.11 16.37 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 N-CA-C 108.345 -0.983 . . . . 1.4 108.345 -179.9 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.532 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -143.12 174.91 10.28 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 120.685 -1.259 . . . . 1.36 109.21 -179.775 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.449 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 51.7 p90 -142.29 128.49 19.82 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.363 -0.835 . . . . 1.47 109.172 179.9 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -141.38 113.08 7.7 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.296 -0.878 . . . . 2.51 109.987 -179.782 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.441 ' OD1' ' N ' ' A' ' 67' ' ' ASP . 4.2 p-10 -95.52 67.69 2.89 Favored 'General case' 0 N--CA 1.491 1.602 0 N-CA-C 108.155 -1.054 . . . . 2.07 108.155 178.493 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 50.4 mtp180 -121.96 29.46 7.07 Favored 'General case' 0 N--CA 1.5 2.042 0 N-CA-C 109.231 -0.655 . . . . 4.63 109.231 -179.55 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.427 ' O ' ' CB ' ' A' ' 70' ' ' ASP . 66.3 mmtt -108.21 3.32 23.54 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 107.882 -1.155 . . . . 3.49 107.882 179.405 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.427 ' CB ' ' O ' ' A' ' 69' ' ' LYS . 4.0 t0 72.49 12.79 5.52 Favored 'General case' 0 N--CA 1.487 1.388 0 N-CA-C 109.586 -0.524 . . . . 3.06 109.586 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 163.32 -30.84 0.27 Allowed Glycine 0 N--CA 1.49 2.247 0 C-N-CA 119.017 -1.564 . . . . 2.16 110.787 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.402 ' H ' ' HB2' ' A' ' 69' ' ' LYS . 5.0 t -95.11 143.15 26.78 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 120.964 -1.315 . . . . 2.2 109.764 -179.498 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 36.9 t -88.04 139.47 30.48 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.329 -0.857 . . . . 2.05 109.347 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -112.4 114.02 3.4 Favored Glycine 0 N--CA 1.5 2.948 0 N-CA-C 109.985 -1.246 . . . . 1.39 109.985 -179.761 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.502 HG21 HD12 ' A' ' 41' ' ' ILE . 77.9 t -100.97 116.15 43.97 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.948 0 O-C-N 121.467 -1.019 . . . . 1.57 108.912 179.291 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.532 ' O ' ' N ' ' A' ' 64' ' ' ALA . 0.6 OUTLIER -103.81 136.75 42.91 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.579 -0.7 . . . . 1.85 109.196 -179.846 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.428 ' OH ' ' CA ' ' A' ' 27' ' ' GLY . 11.3 p90 -134.65 166.69 22.34 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.508 -0.745 . . . . 1.54 109.671 -179.769 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 8.4 t -139.86 113.54 6.3 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 N-CA-C 108.887 -0.783 . . . . 1.9 108.887 -179.729 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.594 ' CG1' ' CE2' ' A' ' 85' ' ' TYR . 0.2 OUTLIER -79.75 168.57 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 N-CA-C 108.499 -0.926 . . . . 1.27 108.499 179.552 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 10.5 tt0 -109.3 -36.79 5.93 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.441 -0.787 . . . . 2.48 109.417 179.323 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.428 ' O ' ' O ' ' A' ' 82' ' ' PRO . 75.2 mm-40 -158.85 149.6 16.01 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.278 -0.888 . . . . 1.92 110.679 -179.308 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.625 ' HD3' ' HB2' ' A' ' 33' ' ' ALA . 82.1 Cg_exo -39.08 169.38 0.01 OUTLIER 'Trans proline' 0 C--O 1.213 -0.727 0 C-N-CA 122.761 2.307 . . . . 1.3 112.756 177.696 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 141.69 177.33 16.74 Favored Glycine 0 N--CA 1.493 2.451 0 N-CA-C 109.726 -1.35 . . . . 1.02 109.726 179.226 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -93.16 89.57 6.5 Favored 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 107.741 -1.207 . . . . 2.13 107.741 179.149 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.594 ' CE2' ' CG1' ' A' ' 79' ' ' VAL . 3.7 m-85 -78.04 132.15 37.64 Favored 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.458 -0.776 . . . . 0.92 108.912 -179.014 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -112.81 128.79 56.54 Favored 'General case' 0 N--CA 1.498 1.947 0 N-CA-C 108.588 -0.893 . . . . 1.53 108.588 -179.079 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.411 ' CG1' ' CE2' ' A' ' 101' ' ' PHE . 5.8 p -126.13 133.64 68.4 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 121.568 -0.708 . . . . 1.0 109.471 -179.865 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.1 t -123.64 103.96 8.73 Favored 'General case' 0 N--CA 1.498 1.933 0 N-CA-C 109.445 -0.576 . . . . 1.59 109.445 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.2 pt -107.7 130.29 60.29 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 CA-C-O 121.64 0.734 . . . . 1.29 110.045 -179.573 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . 0.47 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.98 122.68 17.52 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 107.9 -1.148 . . . . 1.58 107.9 179.593 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.412 ' O ' ' CB ' ' A' ' 92' ' ' ASN . 71.2 t80 -83.08 100.57 10.59 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 120.515 -1.365 . . . . 1.34 108.029 179.351 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . 0.429 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 2.2 t30 72.31 35.48 1.19 Allowed 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.196 -0.94 . . . . 2.32 108.809 -178.646 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.429 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 0.9 OUTLIER 78.2 14.77 1.44 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.879 -0.513 . . . . 1.92 111.609 179.53 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . 0.489 ' OE2' ' CA ' ' A' ' 17' ' ' GLY . 5.7 pt-20 -100.54 99.22 9.78 Favored 'General case' 0 N--CA 1.496 1.843 0 N-CA-C 107.145 -1.428 . . . . 2.25 107.145 177.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . 0.462 ' O ' ' CG ' ' A' ' 95' ' ' HIS . 46.2 p-80 -66.96 105.46 1.63 Allowed 'General case' 0 N--CA 1.487 1.389 0 CA-C-O 121.472 0.653 . . . . 2.88 110.453 -177.928 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . 0.523 ' O ' ' N ' ' A' ' 98' ' ' ASP . 4.0 tt -56.56 136.33 77.23 Favored Pre-proline 0 C--N 1.3 -1.548 0 N-CA-C 107.81 -1.182 . . . . 2.35 107.81 178.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.44 ' O ' ' CB ' ' A' ' 98' ' ' ASP . 11.6 Cg_exo -47.15 90.98 0.02 OUTLIER 'Trans proline' 0 C--O 1.213 -0.729 0 N-CA-C 109.886 -0.852 . . . . 2.48 109.886 -179.755 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.523 ' N ' ' O ' ' A' ' 96' ' ' ILE . 0.9 OUTLIER 165.61 -60.43 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 108.235 -1.024 . . . . 2.65 108.235 -179.418 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 1.3 t -55.8 139.08 70.18 Favored Pre-proline 0 C--N 1.296 -1.727 0 O-C-N 121.299 -0.875 . . . . 2.0 109.796 -178.306 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_endo -88.36 113.72 2.47 Favored 'Cis proline' 0 N--CA 1.494 1.521 0 N-CA-C 110.024 -0.798 . . . . 1.79 110.024 -2.393 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . 0.411 ' CE2' ' CG1' ' A' ' 87' ' ' VAL . 2.6 p90 -97.74 169.15 9.88 Favored 'General case' 0 N--CA 1.518 2.944 0 O-C-N 120.236 -1.54 . . . . 2.19 109.779 178.625 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.3 p -96.78 150.45 4.44 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.643 -0.66 . . . . 1.44 109.982 -179.635 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.446 ' N ' ' O ' ' A' ' 85' ' ' TYR . 87.0 t -128.3 87.03 56.36 Favored Pre-proline 0 N--CA 1.498 1.965 0 N-CA-C 108.379 -0.971 . . . . 1.19 108.379 179.675 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo -65.11 114.9 3.01 Favored 'Trans proline' 0 C--N 1.322 -0.856 0 C-N-CA 121.571 1.514 . . . . 1.49 111.8 -178.27 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.55 HG13 ' C ' ' A' ' 31' ' ' GLY . 84.3 t -106.59 143.54 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 N-CA-C 106.342 -1.725 . . . . 1.35 106.342 178.365 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.671 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -133.24 138.51 46.53 Favored 'General case' 0 N--CA 1.512 2.666 0 CA-C-O 122.272 1.034 . . . . 1.67 112.516 -176.719 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.623 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 59.8 p -94.29 78.21 3.95 Favored 'General case' 0 N--CA 1.494 1.725 0 N-CA-C 107.608 -1.256 . . . . 2.04 107.608 179.097 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 16.8 mt 63.15 3.33 1.27 Allowed 'General case' 0 C--N 1.295 -1.766 0 N-CA-C 107.438 -1.319 . . . . 3.2 107.438 -177.835 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.683 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 18.5 t -89.84 -23.18 21.74 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 108.813 -0.81 . . . . 2.09 108.813 179.328 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . 0.671 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 50.5 t0 54.83 11.33 0.46 Allowed 'General case' 0 N--CA 1.487 1.382 0 N-CA-C 107.822 -1.177 . . . . 2.85 107.822 -179.196 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.486 ' OD1' ' N ' ' A' ' 112' ' ' ALA . 2.8 p30 -169.33 -31.85 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 109.185 -0.672 . . . . 2.46 109.185 -179.7 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.683 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 43.75 88.75 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.059 0 O-C-N 121.208 -0.932 . . . . 2.08 109.783 179.915 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 13.9 ttt180 -58.03 -163.95 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.217 -0.927 . . . . 5.93 109.652 -179.436 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 44.9 ttt180 -136.03 0.16 2.59 Favored 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 108.002 -1.11 . . . . 5.61 108.002 179.684 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 2.5 mp -132.31 -23.71 2.12 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.709 -0.62 . . . . 4.39 109.616 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.484 ' C ' ' N ' ' A' ' 118' ' ' THR . 90.3 m -104.1 -78.13 0.56 Allowed 'General case' 0 N--CA 1.495 1.818 0 N-CA-C 106.691 -1.596 . . . . 4.09 106.691 178.768 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.45 ' O ' HG12 ' A' ' 117' ' ' VAL . 48.9 t -64.03 -7.66 3.65 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.742 0 N-CA-C 105.807 -1.923 . . . . 2.9 105.807 176.631 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' THR . . . . . 0.484 ' N ' ' C ' ' A' ' 116' ' ' THR . 4.4 t 36.2 60.33 0.87 Allowed 'General case' 0 N--CA 1.488 1.468 0 CA-C-N 115.164 -0.925 . . . . 3.36 110.638 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' SER . . . . . 0.474 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.5 p . . . . . 0 N--CA 1.487 1.38 0 CA-C-O 118.043 -0.979 . . . . 3.39 109.549 179.503 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . 0.611 ' SD ' ' N ' ' B' ' 2' ' ' ALA . 14.6 tmm? . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.36 -0.607 . . . . 8.49 109.36 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 2' ' ' ALA . . . . . 0.611 ' N ' ' SD ' ' B' ' 1' ' ' MET . . . 45.67 91.85 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.188 -0.945 . . . . 5.53 109.766 -179.95 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 3' ' ' SER . . . . . . . . . . . . . 35.1 t -155.26 126.62 7.27 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.197 -0.939 . . . . 5.43 109.466 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 4' ' ' LYS . . . . . . . . . . . . . 22.4 mtpp -60.35 131.26 90.19 Favored Pre-proline 0 N--CA 1.487 1.422 0 O-C-N 121.187 -0.946 . . . . 6.87 108.794 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 5' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -59.75 -172.27 0.06 OUTLIER 'Trans proline' 0 C--O 1.216 -0.618 0 N-CA-C 109.837 -0.87 . . . . 5.16 109.837 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 6' ' ' GLU . . . . . 0.441 ' O ' ' O ' ' B' ' 7' ' ' LYS . 34.6 mt-10 -155.28 39.71 0.41 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.313 -0.867 . . . . 4.78 108.872 179.745 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 7' ' ' LYS . . . . . 0.441 ' O ' ' O ' ' B' ' 6' ' ' GLU . 32.9 mtmm 55.02 165.46 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.657 -0.652 . . . . 4.09 109.645 -179.868 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.563 ' CG ' HH11 ' B' ' 8' ' ' ARG . 1.4 mtt-85 -89.83 159.14 17.15 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.113 -0.992 . . . . 3.04 108.542 179.877 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 9' ' ' VAL . . . . . 0.415 ' O ' ' O ' ' A' ' 57' ' ' GLY . 11.2 t -49.89 159.85 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 120.973 -1.079 . . . . 0.67 108.311 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 0.4 ' N ' ' CG1' ' B' ' 9' ' ' VAL . . . -124.67 144.13 50.37 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.526 -0.734 . . . . 0.58 110.173 -178.887 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 11' ' ' SER . . . . . 0.44 ' CB ' HG23 ' A' ' 55' ' ' VAL . 2.8 t -134.7 145.88 48.93 Favored 'General case' 0 N--CA 1.495 1.817 0 N-CA-C 108.636 -0.876 . . . . 1.19 108.636 179.446 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 17.7 m -142.46 114.66 8.31 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.223 -0.923 . . . . 1.38 109.69 -179.491 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 0.57 HG22 ' N ' ' B' ' 14' ' ' PHE . 2.7 p -160.03 166.67 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 O-C-N 121.367 -0.833 . . . . 0.42 109.014 179.83 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 14' ' ' PHE . . . . . 0.57 ' N ' HG22 ' B' ' 13' ' ' VAL . 8.3 p90 -177.16 -166.88 0.15 Allowed 'General case' 0 N--CA 1.488 1.429 0 CA-C-O 122.077 0.941 . . . . 1.79 111.926 179.85 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.413 ' N ' HD13 ' B' ' 15' ' ' ILE . 0.0 OUTLIER -140.02 152.98 22.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 N-CA-C 108.271 -1.011 . . . . 1.25 108.271 179.721 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 7.2 m -123.66 131.14 53.54 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.317 -0.865 . . . . 1.61 109.921 -179.666 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 13.8 mt -99.3 117.93 34.85 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.327 -0.858 . . . . 1.32 109.01 179.609 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -146.33 78.52 11.11 Favored Pre-proline 0 N--CA 1.494 1.768 0 O-C-N 121.259 -0.901 . . . . 1.45 109.636 -179.566 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo -60.2 169.67 4.75 Favored 'Trans proline' 0 C--N 1.319 -1.012 0 C-N-CA 121.218 1.279 . . . . 1.5 109.417 -179.78 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 20' ' ' PRO . . . . . . . . . . . . . 4.1 Cg_exo -53.82 133.46 54.57 Favored 'Trans proline' 0 C--N 1.319 -1.007 0 C-N-CA 121.344 1.363 . . . . 2.86 110.281 -179.605 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . 0.506 ' HG2' HH11 ' B' ' 21' ' ' ARG . 0.0 OUTLIER -96.56 136.06 37.61 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.354 -0.841 . . . . 6.12 109.352 -179.927 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 22' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -158.7 52.66 0.41 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.245 -0.909 . . . . 6.29 109.454 179.756 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 18.6 m-20 -158.7 48.44 0.35 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.242 -0.911 . . . . 5.62 109.458 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 12.1 p . . . . . 0 N--CA 1.491 1.596 0 CA-C-O 118.034 -0.984 . . . . 6.48 109.462 -179.985 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.822 ' O ' HD13 ' A' ' 2' ' ' ILE . . . . . . . . 1 N--CA 1.531 4.976 0 N-CA-C 119.88 2.712 . . . . 6.64 119.88 . . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.822 HD13 ' O ' ' A' ' 1' ' ' GLY . 6.8 mm -149.28 43.7 0.3 Allowed Pre-proline 0 C--N 1.311 -1.081 0 N-CA-C 107.546 -1.279 . . . . 7.08 107.546 178.533 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.644 ' CD ' ' N ' ' A' ' 2' ' ' ILE . 1.8 Cg_endo -52.12 -74.45 0.03 OUTLIER 'Trans proline' 0 C--N 1.319 -0.978 0 N-CA-C 109.343 -1.06 . . . . 5.5 109.343 -179.804 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.436 ' CB ' ' O ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER 71.96 -49.83 0.69 Allowed 'General case' 0 N--CA 1.494 1.727 0 N-CA-C 103.11 -2.922 . . . . 6.75 103.11 -175.615 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . 0.631 ' H ' ' C ' ' A' ' 3' ' ' PRO . 5.3 m-85 -50.15 -28.09 6.84 Favored 'General case' 0 C--N 1.303 -1.414 0 N-CA-C 106.481 -1.674 . . . . 6.07 106.481 174.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.599 ' CG ' ' N ' ' A' ' 7' ' ' GLN . 0.0 OUTLIER 110.8 -150.84 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.217 0 CA-C-N 114.511 -1.222 . . . . 4.72 111.221 179.445 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.599 ' N ' ' CG ' ' A' ' 6' ' ' PHE . 18.5 tt0 81.74 -3.64 1.58 Allowed 'General case' 0 N--CA 1.493 1.702 0 N-CA-C 105.306 -2.109 . . . . 4.4 105.306 -177.469 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.405 ' H ' ' C ' ' A' ' 6' ' ' PHE . 38.3 t80 -152.96 -40.4 0.1 Allowed 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 107.202 -1.407 . . . . 5.15 107.202 178.623 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 12.1 m -86.19 1.44 50.7 Favored 'General case' 0 C--N 1.296 -1.722 0 N-CA-C 106.086 -1.82 . . . . 5.13 106.086 177.287 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 3.8 p -40.51 -33.57 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 CA-C-N 115.47 -0.786 . . . . 4.38 109.839 -179.77 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.555 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 146.71 -79.12 0.23 Allowed Glycine 0 N--CA 1.5 2.947 0 N-CA-C 109.172 -1.571 . . . . 4.22 109.172 179.626 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.452 ' O ' ' C ' ' A' ' 13' ' ' LEU . 14.5 Cg_endo -66.35 43.79 0.19 Allowed 'Trans proline' 0 C--N 1.321 -0.917 0 C-N-CA 122.148 1.899 . . . . 3.85 108.849 178.339 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.568 ' C ' ' H ' ' A' ' 15' ' ' GLU . 0.2 OUTLIER 29.17 46.78 0.02 OUTLIER 'General case' 0 N--CA 1.501 2.103 0 CA-C-N 115.692 -0.686 . . . . 3.67 111.094 -179.746 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.518 ' C ' ' H ' ' A' ' 16' ' ' GLY . . . 68.17 -36.43 0.25 Allowed Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.325 -1.51 . . . . 2.97 109.325 -179.884 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.568 ' H ' ' C ' ' A' ' 13' ' ' LEU . 24.6 tt0 55.31 6.59 0.17 Allowed 'General case' 0 N--CA 1.486 1.337 0 O-C-N 121.426 -1.043 . . . . 2.97 108.518 -179.159 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.519 ' O ' ' N ' ' A' ' 18' ' ' ALA . . . 87.45 -164.72 34.93 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 110.851 -0.899 . . . . 2.44 110.851 178.743 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.55 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . -46.28 -12.33 0.05 OUTLIER Glycine 0 N--CA 1.491 2.333 0 N-CA-C 110.603 -0.999 . . . . 1.81 110.603 -179.2 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.519 ' N ' ' O ' ' A' ' 16' ' ' GLY . . . -47.64 -10.41 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.145 -1.209 . . . . 2.21 110.093 -179.924 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . 0.55 ' N ' ' O ' ' A' ' 17' ' ' GLY . 80.2 t60 -104.81 -31.36 9.34 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.188 -0.945 . . . . 2.87 110.444 -179.38 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -101.6 -14.72 17.32 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 120.997 -1.064 . . . . 2.02 110.848 -178.979 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.614 ' O ' HG13 ' A' ' 21' ' ' VAL . 9.0 p -70.85 114.39 8.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 120.819 -1.175 . . . . 2.07 109.818 -179.606 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 20.6 tpt180 -104.08 140.38 37.85 Favored 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 109.008 -0.738 . . . . 3.5 109.008 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -144.45 113.28 6.75 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.247 -0.908 . . . . 1.83 109.37 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -156.49 129.05 2.33 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.788 -1.325 . . . . 1.9 109.788 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.11 -177.59 47.72 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.666 -1.374 . . . . 1.85 109.666 179.805 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 12.3 p -78.36 -26.12 46.56 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.25 -1.147 . . . . 2.31 109.396 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -71.06 -12.13 71.23 Favored Glycine 0 N--CA 1.488 2.132 0 N-CA-C 109.301 -1.52 . . . . 1.64 109.301 -179.831 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 12.8 mt -91.36 -6.13 53.46 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.364 -1.08 . . . . 1.83 108.914 179.875 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -96.27 -51.03 4.55 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.336 -0.853 . . . . 2.34 109.748 -179.708 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 23.0 ptt180 -175.28 -173.65 0.67 Allowed 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.017 -1.052 . . . . 3.77 110.16 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -152.4 177.58 30.08 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 108.358 -1.897 . . . . 1.57 108.358 179.583 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 41.5 t -134.84 151.05 30.6 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.045 0 O-C-N 121.143 -1.21 . . . . 1.83 110.481 -179.683 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.589 ' HB2' ' HB3' ' A' ' 107' ' ' SER . . . -37.05 112.2 0.19 Allowed 'General case' 0 N--CA 1.5 2.072 0 CA-C-O 121.737 0.78 . . . . 1.64 112.406 -179.293 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 54.59 49.88 59.42 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 111.371 -0.692 . . . . 1.73 111.371 177.249 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 40.5 t -127.38 98.22 29.71 Favored Pre-proline 0 N--CA 1.496 1.826 0 O-C-N 121.511 -0.994 . . . . 2.19 108.512 178.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -56.89 149.05 63.43 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 120.955 1.103 . . . . 1.96 110.445 -178.86 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.403 ' HB3' ' CZ ' ' A' ' 77' ' ' TYR . . . -157.49 -167.73 2.37 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.4 -0.813 . . . . 1.69 109.018 -179.812 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -170.54 168.48 7.68 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.148 -0.97 . . . . 2.23 110.873 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.568 ' CE2' HD11 ' A' ' 41' ' ' ILE . 1.1 p90 -144.95 -178.68 6.16 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 107.161 -1.422 . . . . 1.54 107.161 178.345 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 12.0 m -109.42 150.99 27.27 Favored 'General case' 0 N--CA 1.5 2.049 0 O-C-N 121.359 -0.838 . . . . 2.37 110.99 -178.345 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.686 HD12 HG21 ' A' ' 75' ' ' VAL . 11.3 mt -147.8 94.55 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 N-CA-C 108.749 -0.834 . . . . 1.65 108.749 179.048 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.49 ' CD1' ' C ' ' A' ' 42' ' ' TRP . 0.6 OUTLIER -86.99 138.07 31.82 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 120.946 -1.096 . . . . 3.68 108.563 179.837 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -167.61 114.85 0.75 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.282 -0.886 . . . . 2.89 109.523 -179.678 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' ARG . . . . . 0.436 ' C ' ' CD ' ' A' ' 44' ' ' ARG . 1.7 ppt_? -169.47 -12.33 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.19 -0.944 . . . . 4.63 109.7 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -65.04 -46.15 82.46 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.213 -0.929 . . . . 2.89 109.469 -179.735 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.58 -50.4 72.07 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.153 -0.967 . . . . 1.74 108.856 179.695 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 139.76 -153.58 23.24 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.249 -1.54 . . . . 1.6 109.249 179.777 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -86.11 155.97 20.56 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.446 -1.032 . . . . 1.4 108.924 179.547 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 179.35 -140.28 4.28 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.563 -1.415 . . . . 1.04 109.563 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.47 ' O ' ' N ' ' A' ' 92' ' ' ASN . . . -138.88 167.64 25.04 Favored Glycine 0 N--CA 1.495 2.611 0 N-CA-C 109.283 -1.527 . . . . 1.06 109.283 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.445 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 46.4 tp -142.56 106.48 4.7 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.381 -1.07 . . . . 1.1 108.434 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.4 m -90.43 143.54 26.65 Favored 'General case' 0 N--CA 1.495 1.787 0 N-CA-C 108.557 -0.905 . . . . 1.56 108.557 179.863 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.548 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 53.6 mt -135.36 105.1 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.266 -0.897 . . . . 0.65 109.176 179.84 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -97.97 106.62 18.94 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.283 -0.886 . . . . 0.69 108.786 179.755 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.437 ' O ' ' O ' ' B' ' 11' ' ' SER . 0.2 OUTLIER -96.79 142.34 14.17 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.501 -0.749 . . . . 0.91 109.555 -179.745 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -141.78 142.7 33.22 Favored 'General case' 0 N--CA 1.491 1.61 0 N-CA-C 108.21 -1.033 . . . . 1.8 108.21 178.846 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 164.92 -173.9 40.83 Favored Glycine 0 N--CA 1.489 2.167 0 N-CA-C 109.448 -1.461 . . . . 0.49 109.448 -179.104 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -59.46 -26.0 80.51 Favored 'Trans proline' 0 C--N 1.315 -1.199 0 C-N-CA 121.93 1.753 . . . . 0.66 112.103 -179.299 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . 0.435 ' O ' ' OH ' ' A' ' 85' ' ' TYR . 22.9 t -142.54 169.24 17.95 Favored 'General case' 0 N--CA 1.502 2.168 0 O-C-N 121.015 -1.053 . . . . 1.55 110.364 179.947 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 60.7 mttt -81.09 95.31 6.81 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.497 -0.752 . . . . 2.53 109.763 -179.608 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -63.54 117.29 6.55 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.173 -0.954 . . . . 0.82 109.511 179.854 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.453 ' CB ' HG12 ' A' ' 78' ' ' VAL . 26.0 tt0 -66.27 168.39 8.79 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.154 -0.966 . . . . 2.3 109.148 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.458 HD12 HG13 ' B' ' 13' ' ' VAL . 28.1 mt -141.0 155.61 21.76 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 N-CA-C 108.642 -0.873 . . . . 1.4 108.642 -179.79 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.542 ' HB3' ' OG ' ' A' ' 76' ' ' SER . . . -144.87 170.75 15.52 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 120.627 -1.295 . . . . 1.36 109.156 179.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.46 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 31.3 p90 -147.16 117.88 7.57 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.28 -0.887 . . . . 1.47 109.472 -179.962 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -141.44 102.6 4.24 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.364 -0.835 . . . . 2.51 109.546 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.519 ' N ' ' OD1' ' A' ' 67' ' ' ASP . 17.5 p-10 -73.85 95.43 2.43 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.213 -0.929 . . . . 2.07 109.18 179.848 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 54.6 ttt180 -90.08 -7.6 53.41 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.274 -0.891 . . . . 4.63 109.732 -179.662 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.48 ' C ' ' H ' ' A' ' 71' ' ' GLY . 31.3 mmtp -122.42 1.66 9.6 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.504 -0.747 . . . . 3.49 109.451 -179.839 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 4.1 t70 65.78 -4.01 0.66 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.258 -0.902 . . . . 3.06 109.272 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . 0.48 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -138.98 -33.36 0.18 Allowed Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.874 -1.29 . . . . 2.16 109.874 -178.907 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.477 ' H ' ' HB2' ' A' ' 69' ' ' LYS . 14.0 p -95.52 109.61 21.8 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.23 -1.159 . . . . 2.2 108.76 179.487 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 3.3 m -78.81 115.22 18.36 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.15 -0.969 . . . . 2.05 109.521 -179.585 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -93.72 114.68 4.78 Favored Glycine 0 N--CA 1.494 2.543 0 N-CA-C 109.919 -1.273 . . . . 1.39 109.919 -179.716 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.686 HG21 HD12 ' A' ' 41' ' ' ILE . 94.0 t -98.39 108.5 22.15 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 121.409 -1.053 . . . . 1.57 109.465 179.695 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.542 ' OG ' ' HB3' ' A' ' 64' ' ' ALA . 0.7 OUTLIER -89.55 166.64 13.53 Favored 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 108.268 -1.012 . . . . 1.85 108.268 179.331 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.406 ' CD1' ' N ' ' A' ' 77' ' ' TYR . 14.1 p90 -164.14 172.36 13.81 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.216 -0.928 . . . . 1.54 109.659 -179.36 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.533 ' O ' HG13 ' A' ' 78' ' ' VAL . 3.7 p -142.17 119.25 7.11 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.254 0 O-C-N 121.104 -0.998 . . . . 1.9 110.391 179.61 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.51 HG11 HG21 ' A' ' 105' ' ' VAL . 8.5 m -94.98 147.06 6.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.186 -0.946 . . . . 1.27 109.164 179.674 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 29.5 tt0 -90.16 -47.44 7.8 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.082 -1.011 . . . . 2.48 110.582 -179.254 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -155.9 155.59 29.52 Favored Pre-proline 0 N--CA 1.504 2.231 0 O-C-N 120.695 -1.253 . . . . 1.92 110.902 -179.347 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.663 ' HG3' ' N ' ' A' ' 107' ' ' SER . 87.2 Cg_exo -36.19 152.77 0.03 OUTLIER 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 123.279 2.653 . . . . 1.3 113.287 179.03 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 152.31 158.04 8.26 Favored Glycine 0 N--CA 1.487 2.052 0 N-CA-C 109.251 -1.54 . . . . 1.02 109.251 -179.926 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . 0.781 ' H ' HH12 ' B' ' 8' ' ' ARG . 0.3 OUTLIER -83.39 90.38 7.16 Favored 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 107.648 -1.242 . . . . 2.13 107.648 179.077 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.435 ' OH ' ' O ' ' A' ' 59' ' ' SER . 1.4 m-85 -73.28 156.11 38.8 Favored 'General case' 0 C--N 1.294 -1.843 0 N-CA-C 108.266 -1.012 . . . . 0.92 108.266 -179.267 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . 0.42 ' OE1' ' O ' ' A' ' 84' ' ' ASP . 0.0 OUTLIER -138.48 120.83 15.95 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.461 -0.774 . . . . 1.53 109.287 -179.369 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.7 p -120.89 147.17 24.87 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.532 -0.73 . . . . 1.0 109.54 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 82.6 p -129.98 107.25 9.21 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.437 -0.79 . . . . 1.59 109.328 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.6 pt -106.29 130.75 57.48 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.658 -0.651 . . . . 1.29 109.946 -179.568 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . 0.466 ' CG ' ' O ' ' A' ' 90' ' ' LYS . 0.6 OUTLIER -136.55 122.63 20.29 Favored 'General case' 0 N--CA 1.492 1.627 0 N-CA-C 108.837 -0.801 . . . . 1.58 108.837 179.341 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.56 ' O ' ' ND2' ' A' ' 92' ' ' ASN . 60.0 t80 -80.16 107.0 12.61 Favored 'General case' 0 C--N 1.299 -1.603 0 C-N-CA 118.716 -1.193 . . . . 1.34 107.819 178.37 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . 0.56 ' ND2' ' O ' ' A' ' 91' ' ' PHE . 2.9 p30 61.71 32.79 18.26 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.448 -0.783 . . . . 2.32 109.94 -178.584 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.472 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 2.5 m-20 86.21 16.97 0.11 Allowed 'General case' 0 N--CA 1.506 2.363 0 O-C-N 121.593 -0.692 . . . . 1.92 112.24 178.171 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . 0.489 ' O ' ' OE1' ' A' ' 94' ' ' GLU . 0.3 OUTLIER -102.4 98.64 8.71 Favored 'General case' 0 N--CA 1.499 1.98 0 N-CA-C 107.039 -1.467 . . . . 2.25 107.039 177.503 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . 0.502 ' O ' ' CG ' ' A' ' 95' ' ' HIS . 52.1 p-80 -68.64 106.48 2.63 Favored 'General case' 0 N--CA 1.487 1.417 0 N-CA-C 109.14 -0.689 . . . . 2.88 109.14 -178.838 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . 0.897 ' O ' HD13 ' A' ' 96' ' ' ILE . 0.0 OUTLIER -58.91 155.07 34.28 Favored Pre-proline 0 N--CA 1.491 1.602 0 N-CA-C 108.557 -0.905 . . . . 2.35 108.557 -179.614 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_endo -63.47 77.24 0.13 Allowed 'Trans proline' 0 CA--C 1.539 0.768 0 C-N-CA 121.23 1.287 . . . . 2.48 109.892 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.507 ' CG ' ' CE2' ' A' ' 101' ' ' PHE . 0.4 OUTLIER 179.81 -28.72 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.857 0 O-C-N 120.968 -1.082 . . . . 2.65 109.054 -179.649 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 29.4 m -78.02 136.69 61.77 Favored Pre-proline 0 C--N 1.298 -1.674 0 N-CA-C 107.313 -1.366 . . . . 2.0 107.313 178.448 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -76.64 116.95 4.66 Favored 'Cis proline' 0 CA--C 1.547 1.174 0 C-N-CA 125.165 -0.765 . . . . 1.79 111.09 -0.099 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . 0.507 ' CE2' ' CG ' ' A' ' 98' ' ' ASP . 0.1 OUTLIER -70.54 164.77 24.11 Favored 'General case' 0 N--CA 1.494 1.736 0 N-CA-C 107.793 -1.188 . . . . 2.19 107.793 178.566 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.485 HG13 ' O ' ' A' ' 102' ' ' VAL . 8.6 p -123.4 127.93 74.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 N-CA-C 108.43 -0.952 . . . . 1.44 108.43 179.068 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 94.9 t -121.47 83.56 40.96 Favored Pre-proline 0 N--CA 1.503 2.18 0 O-C-N 121.406 -0.809 . . . . 1.19 109.535 -179.223 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -66.85 110.64 1.97 Allowed 'Trans proline' 0 C--N 1.32 -0.967 0 C-N-CA 121.252 1.301 . . . . 1.49 110.742 -179.131 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.51 HG21 HG11 ' A' ' 79' ' ' VAL . 54.2 t -89.06 146.15 6.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 N-CA-C 107.28 -1.378 . . . . 1.35 107.28 178.54 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.553 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -133.64 130.43 38.27 Favored 'General case' 0 N--CA 1.508 2.46 0 O-C-N 121.289 -0.882 . . . . 1.67 111.746 -177.085 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.663 ' N ' ' HG3' ' A' ' 82' ' ' PRO . 94.6 p -106.05 93.4 4.6 Favored 'General case' 0 N--CA 1.494 1.752 0 N-CA-C 106.854 -1.536 . . . . 2.04 106.854 178.578 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . 0.491 HD12 ' N ' ' A' ' 108' ' ' LEU . 11.1 mp 57.38 7.47 0.49 Allowed 'General case' 0 C--N 1.293 -1.858 0 N-CA-C 107.839 -1.171 . . . . 3.2 107.839 -177.696 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.532 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 6.1 t -92.99 -29.42 15.85 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 108.506 -0.924 . . . . 2.09 108.506 178.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . 0.553 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 26.8 m-20 52.39 12.28 0.22 Allowed 'General case' 0 N--CA 1.488 1.432 0 N-CA-C 108.061 -1.089 . . . . 2.85 108.061 -178.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.537 ' O ' ' C ' ' A' ' 112' ' ' ALA . 17.5 t0 -167.22 -35.13 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.311 0 O-C-N 121.72 -0.613 . . . . 2.46 109.748 -179.704 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.537 ' C ' ' O ' ' A' ' 111' ' ' ASP . . . 22.07 66.84 0.03 OUTLIER 'General case' 0 N--CA 1.515 2.816 0 CA-C-O 121.067 0.46 . . . . 2.08 111.53 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . 0.584 ' CG ' HH11 ' A' ' 113' ' ' ARG . 0.0 OUTLIER -71.91 -165.53 0.17 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.096 -1.003 . . . . 5.93 109.891 -179.206 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 7.6 ttm180 -134.08 1.1 3.22 Favored 'General case' 0 N--CA 1.494 1.764 0 N-CA-C 108.045 -1.095 . . . . 5.61 108.045 179.535 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 2.4 mp -131.32 -23.67 2.37 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.808 -0.558 . . . . 4.39 109.495 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.488 ' C ' ' H ' ' A' ' 118' ' ' THR . 0.8 OUTLIER -105.41 -78.23 0.57 Allowed 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 106.558 -1.645 . . . . 4.09 106.558 178.768 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.448 ' O ' HG12 ' A' ' 117' ' ' VAL . 42.7 t -63.89 -7.12 2.97 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.702 0 N-CA-C 105.859 -1.904 . . . . 2.9 105.859 176.726 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' THR . . . . . 0.488 ' H ' ' C ' ' A' ' 116' ' ' THR . 3.0 t 36.16 68.64 0.23 Allowed 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.058 -0.974 . . . . 3.36 110.831 179.798 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' SER . . . . . 0.403 ' OXT' ' O ' ' A' ' 118' ' ' THR . 0.9 OUTLIER . . . . . 0 C--N 1.303 -1.449 0 CA-C-O 117.978 -1.01 . . . . 3.39 109.49 179.242 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 5.0 ptt? . . . . . 0 N--CA 1.491 1.617 0 N-CA-C 109.402 -0.592 . . . . 8.49 109.402 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' B' B ' 2' ' ' ALA . . . . . 0.414 ' O ' ' OG ' ' B' ' 3' ' ' SER . . . -165.9 131.76 2.52 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.108 -0.995 . . . . 5.53 109.74 -179.852 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 3' ' ' SER . . . . . 0.499 ' OG ' ' N ' ' B' ' 4' ' ' LYS . 19.5 p 54.98 -136.46 1.28 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.385 -0.822 . . . . 5.43 109.86 179.869 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 4' ' ' LYS . . . . . 0.499 ' N ' ' OG ' ' B' ' 3' ' ' SER . 13.8 pttp -169.12 74.6 0.74 Allowed Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.363 -0.836 . . . . 6.87 109.27 -179.666 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 5' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -59.69 128.53 27.3 Favored 'Trans proline' 0 C--N 1.317 -1.086 0 C-N-CA 121.28 1.32 . . . . 5.16 109.797 -179.548 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 6' ' ' GLU . . . . . . . . . . . . . 41.6 tp10 -78.22 83.76 4.47 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.274 -0.891 . . . . 4.78 109.881 -179.591 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 86.6 mttt 46.9 -163.54 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.248 -0.908 . . . . 4.09 109.691 179.647 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.781 HH12 ' H ' ' A' ' 84' ' ' ASP . 3.9 mtt180 -100.51 175.3 5.73 Favored 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 108.562 -0.903 . . . . 3.04 108.562 -179.78 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 9' ' ' VAL . . . . . . . . . . . . . 20.8 t -56.82 159.34 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 N-CA-C 107.632 -1.247 . . . . 0.67 107.632 179.041 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -125.84 150.1 48.12 Favored 'General case' 0 N--CA 1.502 2.133 0 O-C-N 121.328 -0.857 . . . . 0.58 109.968 -179.136 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 11' ' ' SER . . . . . 0.437 ' O ' ' O ' ' A' ' 55' ' ' VAL . 6.2 m -148.77 145.14 27.46 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.389 -0.819 . . . . 1.19 109.44 179.911 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 14.8 t -142.08 118.57 10.93 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.205 -0.934 . . . . 1.38 109.553 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 0.56 HG22 ' N ' ' B' ' 14' ' ' PHE . 2.4 p -157.61 167.04 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 121.365 -0.834 . . . . 0.42 108.804 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 14' ' ' PHE . . . . . 0.56 ' N ' HG22 ' B' ' 13' ' ' VAL . 5.4 p90 -176.69 -167.13 0.18 Allowed 'General case' 0 N--CA 1.488 1.47 0 C-N-CA 119.298 -0.961 . . . . 1.79 112.082 -179.859 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 2.9 pt -146.63 176.94 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 N-CA-C 108.419 -0.956 . . . . 1.25 108.419 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 16.1 m -140.2 142.09 35.91 Favored 'General case' 0 N--CA 1.5 2.041 0 O-C-N 120.921 -1.112 . . . . 1.61 110.096 -179.703 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 18.5 mt -104.86 120.27 41.02 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.532 -0.73 . . . . 1.32 109.084 179.531 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -159.23 107.06 1.53 Allowed Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.256 -0.903 . . . . 1.45 109.272 -179.661 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . 0.44 ' C ' ' H ' ' B' ' 21' ' ' ARG . 5.4 Cg_exo -60.12 114.31 2.04 Favored 'Trans proline' 0 CA--C 1.553 1.472 0 N-CA-C 109.394 -1.041 . . . . 1.5 109.394 -179.677 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 20' ' ' PRO . . . . . . . . . . . . . 1.6 Cg_endo -62.8 0.76 1.36 Allowed 'Trans proline' 0 C--O 1.215 -0.64 0 N-CA-C 109.782 -0.891 . . . . 2.86 109.782 -179.588 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . 0.44 ' H ' ' C ' ' B' ' 19' ' ' PRO . 77.2 mtt180 -65.93 -67.66 0.43 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.235 -0.916 . . . . 6.12 109.455 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 22' ' ' ARG . . . . . . . . . . . . . 97.5 mtt180 50.67 -146.23 0.44 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.175 -0.953 . . . . 6.29 109.512 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 26.4 t70 50.5 42.16 26.17 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.337 -0.852 . . . . 5.62 109.343 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 14.0 m . . . . . 0 N--CA 1.49 1.538 0 CA-C-O 118.038 -0.982 . . . . 6.48 109.495 179.986 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 1 N--CA 1.531 5.013 0 N-CA-C 119.762 2.665 . . . . 6.64 119.762 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.567 ' N ' ' CD ' ' A' ' 3' ' ' PRO . 12.3 tt -171.34 50.18 0.13 Allowed Pre-proline 0 C--N 1.307 -1.264 0 O-C-N 121.311 -1.111 . . . . 7.08 108.137 179.438 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.809 ' C ' ' H ' ' A' ' 5' ' ' PHE . 1.6 Cg_endo -52.81 -78.52 0.02 OUTLIER 'Trans proline' 0 C--N 1.319 -0.987 0 C-N-CA 121.117 1.212 . . . . 5.5 109.063 179.504 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.486 ' C ' ' H ' ' A' ' 6' ' ' PHE . 8.9 tt0 73.5 -16.48 0.49 Allowed 'General case' 0 N--CA 1.495 1.789 0 N-CA-C 104.237 -2.505 . . . . 6.75 104.237 -175.612 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . 0.809 ' H ' ' C ' ' A' ' 3' ' ' PRO . 4.2 t80 -90.03 17.11 7.23 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 103.788 -2.671 . . . . 6.07 103.788 176.82 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.545 ' CG ' ' O ' ' A' ' 5' ' ' PHE . 42.3 p90 46.6 -155.94 0.04 OUTLIER 'General case' 0 C--N 1.307 -1.254 0 CA-C-N 114.08 -1.418 . . . . 4.72 109.759 -177.988 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.539 ' CB ' ' O ' ' A' ' 6' ' ' PHE . 16.1 tt0 86.43 -10.56 0.66 Allowed 'General case' 0 N--CA 1.493 1.72 0 N-CA-C 105.081 -2.192 . . . . 4.4 105.081 -177.112 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . 0.441 ' H ' ' C ' ' A' ' 6' ' ' PHE . 70.2 t80 -154.27 -36.31 0.1 Allowed 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 114.717 -1.129 . . . . 5.15 108.029 178.358 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.497 HG22 ' O ' ' A' ' 9' ' ' THR . 88.1 m -94.3 4.16 54.25 Favored 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 105.941 -1.874 . . . . 5.13 105.941 177.383 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.546 HG13 ' N ' ' A' ' 11' ' ' GLY . 12.7 p -44.29 -45.22 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.388 0 CA-C-N 115.374 -0.83 . . . . 4.38 109.281 -179.693 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.608 ' C ' ' H ' ' A' ' 13' ' ' LEU . . . 130.83 -79.17 0.36 Allowed Glycine 0 N--CA 1.503 3.112 0 N-CA-C 108.791 -1.724 . . . . 4.22 108.791 179.343 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.459 ' O ' ' C ' ' A' ' 13' ' ' LEU . 11.6 Cg_endo -65.74 39.05 0.13 Allowed 'Trans proline' 0 C--N 1.318 -1.044 0 C-N-CA 121.91 1.74 . . . . 3.85 108.884 178.007 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.608 ' H ' ' C ' ' A' ' 11' ' ' GLY . 0.2 OUTLIER 28.08 46.1 0.01 OUTLIER 'General case' 0 N--CA 1.505 2.28 0 CA-C-O 121.477 0.656 . . . . 3.67 110.78 -179.611 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.514 ' C ' ' H ' ' A' ' 16' ' ' GLY . . . 67.77 -35.57 0.23 Allowed Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.399 -1.48 . . . . 2.97 109.399 -179.622 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.55 ' H ' ' C ' ' A' ' 13' ' ' LEU . 60.1 tt0 57.19 4.04 0.18 Allowed 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.316 -1.108 . . . . 2.97 109.235 -179.862 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.514 ' H ' ' C ' ' A' ' 14' ' ' GLY . . . 64.94 112.05 0.01 OUTLIER Glycine 0 N--CA 1.49 2.291 0 O-C-N 121.503 -0.748 . . . . 2.44 111.779 178.165 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.588 ' O ' ' N ' ' A' ' 19' ' ' HIS . . . 63.79 -49.83 0.08 OUTLIER Glycine 0 N--CA 1.493 2.475 0 O-C-N 121.759 -0.848 . . . . 1.81 111.669 177.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.512 ' N ' ' OE2' ' A' ' 94' ' ' GLU . . . -45.33 -12.08 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.111 -1.229 . . . . 2.21 109.935 -179.276 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . 0.588 ' N ' ' O ' ' A' ' 17' ' ' GLY . 1.5 t60 -83.65 -40.64 18.72 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.142 -0.974 . . . . 2.87 109.557 179.207 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.527 ' HZ2' HG23 ' A' ' 21' ' ' VAL . 0.9 OUTLIER -93.93 4.17 54.3 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 120.874 -1.141 . . . . 2.02 110.5 -179.508 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.527 HG23 ' HZ2' ' A' ' 20' ' ' LYS . 64.6 t -83.06 113.51 22.36 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 120.811 -1.18 . . . . 2.07 109.25 179.721 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 20.3 tpt180 -111.03 137.27 48.87 Favored 'General case' 0 N--CA 1.496 1.83 0 CA-C-O 121.408 0.623 . . . . 3.5 109.63 -179.634 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -144.21 113.55 6.98 Favored 'General case' 0 N--CA 1.493 1.701 0 N-CA-C 108.744 -0.836 . . . . 1.83 108.744 179.417 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -153.17 128.53 2.47 Favored Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.924 -1.27 . . . . 1.9 109.924 -179.465 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 179.84 -173.92 45.5 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.926 -1.269 . . . . 1.85 109.926 179.721 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 16.7 p -78.92 -25.76 43.7 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.358 -1.083 . . . . 2.31 109.235 179.554 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.485 ' N ' ' O ' ' A' ' 38' ' ' GLU . . . -65.9 -17.78 65.7 Favored Glycine 0 N--CA 1.488 2.131 0 N-CA-C 108.388 -1.885 . . . . 1.64 108.388 179.58 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 14.1 mt -94.12 32.46 1.5 Allowed 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 108.477 -0.935 . . . . 1.83 108.477 179.439 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -140.33 -50.91 0.47 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.445 -0.784 . . . . 2.34 109.615 -179.58 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . 0.519 ' NH1' ' OD1' ' A' ' 110' ' ' ASP . 30.8 ptt180 -172.27 173.75 4.13 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.953 -1.092 . . . . 3.77 110.573 -179.79 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -150.24 176.4 28.88 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 107.878 -2.089 . . . . 1.57 107.878 179.437 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 37.5 t -134.09 153.13 35.44 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.137 0 O-C-N 120.992 -1.299 . . . . 1.83 110.755 -179.629 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.813 ' HB2' ' OG ' ' A' ' 107' ' ' SER . . . -40.37 114.1 0.42 Allowed 'General case' 0 N--CA 1.497 1.891 0 CA-C-O 121.587 0.708 . . . . 1.64 112.092 -179.334 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 56.46 46.04 88.38 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 111.397 -0.681 . . . . 1.73 111.397 177.05 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 37.1 t -126.92 122.54 23.33 Favored Pre-proline 0 N--CA 1.497 1.909 0 O-C-N 121.443 -1.033 . . . . 2.19 108.23 178.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 2.3 Cg_endo -59.47 120.52 8.41 Favored 'Trans proline' 0 C--O 1.216 -0.622 0 C-N-CA 120.474 0.783 . . . . 1.96 110.27 -179.38 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.47 ' HB3' ' CE1' ' A' ' 77' ' ' TYR . . . -116.81 161.21 19.65 Favored 'General case' 0 N--CA 1.497 1.904 0 N-CA-C 107.814 -1.18 . . . . 1.69 107.814 179.167 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . 0.485 ' O ' ' N ' ' A' ' 27' ' ' GLY . 7.0 pt-20 -163.8 173.01 13.31 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 120.642 -1.286 . . . . 2.23 111.519 -179.455 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.675 ' CE2' HD11 ' A' ' 41' ' ' ILE . 5.6 p90 -157.99 165.24 35.63 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 107.647 -1.242 . . . . 1.54 107.647 178.504 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 58.0 m -99.96 148.96 23.93 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.404 -0.81 . . . . 2.37 110.843 -178.099 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.795 HD12 HG21 ' A' ' 75' ' ' VAL . 95.5 mt -137.84 102.64 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 N-CA-C 108.353 -0.98 . . . . 1.65 108.353 178.963 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 3.0 t-105 -100.04 132.77 45.21 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.314 -0.866 . . . . 3.68 108.683 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.547 ' OG1' ' N ' ' A' ' 44' ' ' ARG . 1.6 t -162.25 -126.16 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.405 -0.809 . . . . 2.89 109.503 -179.641 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' ARG . . . . . 0.547 ' N ' ' OG1' ' A' ' 43' ' ' THR . 25.9 mtm180 60.61 80.22 0.22 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.285 -0.885 . . . . 4.63 109.954 179.885 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 12.5 tp10 -159.45 -46.82 0.05 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.282 -0.886 . . . . 2.89 109.134 179.383 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -60.34 -59.96 4.58 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.086 -1.009 . . . . 1.74 109.066 179.715 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 163.59 -175.88 39.76 Favored Glycine 0 N--CA 1.484 1.856 0 C-N-CA 119.385 -1.388 . . . . 1.6 110.464 179.62 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -53.6 163.47 0.65 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.535 -0.98 . . . . 1.4 109.853 -179.686 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 172.72 -163.2 35.04 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.68 -1.368 . . . . 1.04 109.68 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -142.77 130.45 4.2 Favored Glycine 0 N--CA 1.496 2.634 0 N-CA-C 109.245 -1.542 . . . . 1.06 109.245 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.475 ' O ' ' HB2' ' B' ' 14' ' ' PHE . 12.2 tp -103.07 100.62 10.56 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.425 -1.044 . . . . 1.1 109.042 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 3.9 m -88.77 139.76 30.14 Favored 'General case' 0 N--CA 1.497 1.92 0 N-CA-C 108.723 -0.843 . . . . 1.56 108.723 179.476 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.507 ' H ' ' HB3' ' B' ' 14' ' ' PHE . 82.6 mt -128.15 113.28 29.78 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.111 0 O-C-N 121.088 -1.008 . . . . 0.65 109.916 -179.811 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -102.48 106.04 16.7 Favored 'General case' 0 N--CA 1.494 1.736 0 N-CA-C 108.718 -0.845 . . . . 0.69 108.718 179.251 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.44 HG23 ' OG ' ' B' ' 11' ' ' SER . 0.0 OUTLIER -102.84 143.7 14.78 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.799 0 O-C-N 121.471 -0.768 . . . . 0.91 109.326 -179.697 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 -141.95 144.03 33.54 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 108.181 -1.044 . . . . 1.8 108.181 178.743 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 168.71 -172.59 43.17 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 109.179 -1.569 . . . . 0.49 109.179 -179.031 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -63.73 -27.6 68.37 Favored 'Trans proline' 0 C--N 1.316 -1.133 0 C-N-CA 121.888 1.725 . . . . 0.66 111.461 -179.696 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . 0.421 ' O ' ' OH ' ' A' ' 85' ' ' TYR . 16.0 m -140.4 168.12 20.55 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.257 -0.902 . . . . 1.55 109.754 -179.77 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 37.1 mtpt -91.13 126.44 36.22 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.376 -0.828 . . . . 2.53 109.517 -179.713 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -86.83 135.12 33.45 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.242 -0.911 . . . . 0.82 109.358 179.861 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 20.0 tt0 -90.19 94.53 9.8 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.129 -0.982 . . . . 2.3 109.97 -179.658 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.602 HD12 ' N ' ' A' ' 63' ' ' ILE . 1.8 mp -60.34 153.74 4.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 N-CA-C 109.118 -0.697 . . . . 1.4 109.118 179.415 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.547 ' N ' ' O ' ' A' ' 76' ' ' SER . . . -151.3 123.8 8.41 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.037 -1.039 . . . . 1.36 109.24 179.778 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.47 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 47.5 p90 -89.0 124.59 34.42 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.204 -0.935 . . . . 1.47 109.376 179.787 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 75.9 tt0 -141.58 111.16 6.49 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.222 -0.924 . . . . 2.51 109.772 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -79.78 127.81 32.67 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.202 -0.936 . . . . 2.07 108.687 179.273 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 56.0 ttt180 -118.16 -27.1 6.16 Favored 'General case' 0 N--CA 1.501 2.08 0 O-C-N 121.466 -0.771 . . . . 4.63 109.487 -179.583 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.541 ' C ' ' H ' ' A' ' 71' ' ' GLY . 39.5 mttp -116.66 -3.19 11.79 Favored 'General case' 0 N--CA 1.496 1.858 0 N-CA-C 108.691 -0.855 . . . . 3.49 108.691 179.829 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.444 ' CB ' ' O ' ' A' ' 69' ' ' LYS . 1.6 t70 72.15 -30.08 0.21 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.571 -0.706 . . . . 3.06 109.111 -179.56 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . 0.541 ' H ' ' C ' ' A' ' 69' ' ' LYS . . . -103.17 19.4 46.21 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.436 -1.466 . . . . 2.16 109.436 -179.765 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 3.3 t -153.85 129.65 10.13 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.351 -1.087 . . . . 2.2 109.092 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' CYS . . . . . . . . . . . . . 76.4 m -86.23 113.39 22.21 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.126 -0.984 . . . . 2.05 109.428 -179.927 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -87.62 115.46 4.34 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.703 -1.359 . . . . 1.39 109.703 -179.717 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.795 HG21 HD12 ' A' ' 41' ' ' ILE . 22.0 t -107.03 104.46 17.1 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.995 0 O-C-N 121.605 -0.938 . . . . 1.57 109.012 179.79 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.547 ' O ' ' N ' ' A' ' 64' ' ' ALA . 37.3 m -99.4 131.84 45.14 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.558 -0.714 . . . . 1.85 110.06 -179.45 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.511 ' CD1' ' O ' ' A' ' 77' ' ' TYR . 44.3 p90 -128.01 134.96 49.29 Favored 'General case' 0 N--CA 1.497 1.915 0 N-CA-C 108.875 -0.787 . . . . 1.54 108.875 179.882 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.64 ' O ' HG13 ' A' ' 78' ' ' VAL . 9.7 p -104.52 114.2 43.51 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.099 0 O-C-N 121.324 -0.86 . . . . 1.9 109.582 -179.576 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.476 HG11 HG21 ' A' ' 105' ' ' VAL . 2.0 m -88.64 158.96 2.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.096 -1.002 . . . . 1.27 109.031 -179.865 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 35.1 tt0 -97.28 -49.47 4.93 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.079 -1.013 . . . . 2.48 110.758 -179.133 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 76.5 mm-40 -147.15 150.74 39.15 Favored Pre-proline 0 N--CA 1.504 2.242 0 O-C-N 120.794 -1.191 . . . . 1.92 111.661 -178.314 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.653 ' HG3' ' N ' ' A' ' 107' ' ' SER . 77.3 Cg_exo -36.85 164.27 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 123.248 2.632 . . . . 1.3 113.346 178.409 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 145.03 175.21 17.99 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.543 -1.423 . . . . 1.02 109.543 179.676 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . 0.837 ' H ' HH12 ' B' ' 8' ' ' ARG . 0.9 OUTLIER -94.26 83.97 4.33 Favored 'General case' 0 N--CA 1.49 1.549 0 N-CA-C 107.959 -1.126 . . . . 2.13 107.959 179.277 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' TYR . . . . . 0.421 ' OH ' ' O ' ' A' ' 59' ' ' SER . 2.7 m-85 -68.89 135.25 50.76 Favored 'General case' 0 C--N 1.299 -1.606 0 N-CA-C 107.84 -1.171 . . . . 0.92 107.84 -179.712 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . 0.442 ' OE2' ' O ' ' A' ' 84' ' ' ASP . 0.8 OUTLIER -116.31 121.04 40.8 Favored 'General case' 0 N--CA 1.499 1.996 0 N-CA-C 108.768 -0.827 . . . . 1.53 108.768 -179.37 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 10.6 p -116.46 145.35 22.33 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 121.592 -0.693 . . . . 1.0 110.194 -179.375 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 9.4 p -136.47 110.35 8.19 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 108.699 -0.852 . . . . 1.59 108.699 179.596 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 1.8 pt -116.89 135.75 56.23 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.949 0 O-C-N 121.577 -0.702 . . . . 1.29 110.632 -178.886 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . 0.511 ' HZ3' ' HB3' ' A' ' 90' ' ' LYS . 0.3 OUTLIER -136.03 121.31 19.14 Favored 'General case' 0 N--CA 1.486 1.339 0 N-CA-C 107.923 -1.14 . . . . 1.58 107.923 178.625 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.409 ' O ' ' OE1' ' A' ' 94' ' ' GLU . 52.7 t80 -85.15 101.65 12.64 Favored 'General case' 0 N--CA 1.491 1.621 0 N-CA-C 107.196 -1.409 . . . . 1.34 107.196 178.632 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' ASN . . . . . 0.454 ' O ' ' CB ' ' A' ' 93' ' ' ASP . 21.3 t30 72.09 34.36 1.45 Allowed 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 109.214 -0.661 . . . . 2.32 109.214 -178.266 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.454 ' CB ' ' O ' ' A' ' 92' ' ' ASN . 1.4 m-20 80.22 14.4 0.84 Allowed 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.614 -0.679 . . . . 1.92 111.437 179.393 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . 0.512 ' OE2' ' N ' ' A' ' 18' ' ' ALA . 6.5 pt-20 -99.39 98.68 9.58 Favored 'General case' 0 N--CA 1.497 1.908 0 N-CA-C 107.09 -1.448 . . . . 2.25 107.09 177.898 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . 0.452 ' CD2' ' HZ1' ' A' ' 90' ' ' LYS . 0.2 OUTLIER -67.19 98.54 0.61 Allowed 'General case' 0 N--CA 1.491 1.578 0 CA-C-O 121.586 0.708 . . . . 2.88 110.022 -177.845 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . 0.467 HD13 ' HD2' ' A' ' 97' ' ' PRO . 0.1 OUTLIER -54.86 137.29 64.99 Favored Pre-proline 0 N--CA 1.489 1.503 0 N-CA-C 107.429 -1.322 . . . . 2.35 107.429 179.351 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.467 ' HD2' HD13 ' A' ' 96' ' ' ILE . 24.6 Cg_exo -39.37 -44.78 3.03 Favored 'Trans proline' 0 CA--C 1.537 0.657 0 C-N-CA 121.234 1.289 . . . . 2.48 111.791 -178.809 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.455 ' N ' ' OD1' ' A' ' 98' ' ' ASP . 1.2 m-20 -47.05 -65.72 0.52 Allowed 'General case' 0 N--CA 1.498 1.949 0 O-C-N 120.747 -1.221 . . . . 2.65 109.174 179.325 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 3.8 m -57.06 138.89 79.54 Favored Pre-proline 0 C--N 1.297 -1.705 0 O-C-N 121.26 -0.9 . . . . 2.0 109.204 -178.912 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -88.31 115.32 2.97 Favored 'Cis proline' 0 N--CA 1.49 1.271 0 N-CA-C 109.055 -1.171 . . . . 1.79 109.055 -1.669 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 52.5 p90 -114.5 162.96 16.03 Favored 'General case' 0 N--CA 1.517 2.918 0 O-C-N 120.546 -1.347 . . . . 2.19 110.335 179.117 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 7.1 p -91.79 151.92 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 CA-C-O 121.713 0.768 . . . . 1.44 110.749 -178.34 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 55.8 t -128.24 86.42 58.0 Favored Pre-proline 0 N--CA 1.494 1.766 0 N-CA-C 107.679 -1.23 . . . . 1.19 107.679 179.158 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -66.47 110.59 1.87 Allowed 'Trans proline' 0 C--N 1.321 -0.89 0 C-N-CA 121.623 1.549 . . . . 1.49 112.194 -177.563 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.476 HG21 HG11 ' A' ' 79' ' ' VAL . 55.5 t -94.51 142.52 13.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 N-CA-C 106.488 -1.671 . . . . 1.35 106.488 177.465 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.712 ' HB1' ' N ' ' A' ' 110' ' ' ASP . . . -129.55 132.32 46.8 Favored 'General case' 0 N--CA 1.512 2.652 0 CA-C-O 122.173 0.987 . . . . 1.67 112.516 -176.59 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.813 ' OG ' ' HB2' ' A' ' 33' ' ' ALA . 35.7 m -94.53 81.33 3.91 Favored 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 107.117 -1.438 . . . . 2.04 107.117 178.515 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 23.9 mt 62.63 1.02 0.72 Allowed 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 107.795 -1.187 . . . . 3.2 107.795 -177.723 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.576 ' CB ' ' H ' ' A' ' 112' ' ' ALA . 60.8 p -87.72 -21.39 25.22 Favored 'General case' 0 N--CA 1.488 1.444 0 N-CA-C 108.471 -0.937 . . . . 2.09 108.471 178.859 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . 0.712 ' N ' ' HB1' ' A' ' 106' ' ' ALA . 36.0 t0 52.03 11.91 0.18 Allowed 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.512 -0.922 . . . . 2.85 108.512 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.517 ' OD1' ' N ' ' A' ' 112' ' ' ALA . 4.0 p30 -172.39 -30.16 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.693 -0.629 . . . . 2.46 109.482 -179.773 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.576 ' H ' ' CB ' ' A' ' 109' ' ' SER . . . 42.86 57.07 3.74 Favored 'General case' 0 N--CA 1.502 2.129 0 O-C-N 121.162 -0.961 . . . . 2.08 109.71 179.95 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . 0.611 ' CG ' HH11 ' A' ' 113' ' ' ARG . 0.0 OUTLIER -44.21 146.26 0.68 Allowed 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.343 -0.848 . . . . 5.93 110.028 -179.101 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 46.3 ttt180 -103.86 4.04 34.45 Favored 'General case' 0 N--CA 1.496 1.826 0 N-CA-C 108.848 -0.797 . . . . 5.61 108.848 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 33.9 mt -127.85 -25.0 3.14 Favored 'General case' 0 N--CA 1.504 2.235 0 O-C-N 121.712 -0.618 . . . . 4.39 109.386 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.508 ' C ' ' H ' ' A' ' 118' ' ' THR . 55.2 m -108.17 -78.21 0.59 Allowed 'General case' 0 N--CA 1.498 1.956 0 N-CA-C 107.172 -1.418 . . . . 4.09 107.172 179.056 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.454 ' O ' HG12 ' A' ' 117' ' ' VAL . 51.3 t -62.84 -8.04 2.96 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.715 0 N-CA-C 105.911 -1.885 . . . . 2.9 105.911 176.801 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' THR . . . . . 0.508 ' H ' ' C ' ' A' ' 116' ' ' THR . 4.1 t 36.13 60.58 0.83 Allowed 'General case' 0 N--CA 1.488 1.446 0 CA-C-N 115.221 -0.9 . . . . 3.36 110.636 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' SER . . . . . 0.472 ' CB ' ' O ' ' A' ' 118' ' ' THR . 1.6 p . . . . . 0 N--CA 1.487 1.38 0 CA-C-O 117.988 -1.006 . . . . 3.39 109.59 179.461 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 25.9 ttt . . . . . 0 N--CA 1.491 1.599 0 N-CA-C 109.364 -0.606 . . . . 8.49 109.364 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -164.04 176.51 9.27 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.271 -0.893 . . . . 5.53 109.442 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 3' ' ' SER . . . . . 0.477 ' O ' ' C ' ' B' ' 4' ' ' LYS . 18.0 m -160.01 107.44 1.65 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.253 -0.904 . . . . 5.43 109.292 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 4' ' ' LYS . . . . . 0.477 ' C ' ' O ' ' B' ' 3' ' ' SER . 66.5 mmtt -26.68 92.6 0.05 OUTLIER Pre-proline 0 N--CA 1.506 2.362 0 CA-C-O 119.523 -0.275 . . . . 6.87 111.317 -179.786 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 5' ' ' PRO . . . . . 0.417 ' N ' ' O ' ' B' ' 3' ' ' SER . 2.2 Cg_endo -69.39 -81.06 0.01 OUTLIER 'Trans proline' 0 C--N 1.324 -0.756 0 C-N-CA 121.135 1.223 . . . . 5.16 109.793 -179.437 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 6' ' ' GLU . . . . . 0.462 ' N ' ' CD ' ' B' ' 6' ' ' GLU . 0.6 OUTLIER 51.82 50.6 18.3 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.241 -0.912 . . . . 4.78 109.618 -179.8 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 7' ' ' LYS . . . . . . . . . . . . . 7.1 ptmm? -159.96 146.49 16.01 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.225 -0.922 . . . . 4.09 109.482 179.768 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 8' ' ' ARG . . . . . 0.837 HH12 ' H ' ' A' ' 84' ' ' ASP . 39.0 mtt180 -140.53 168.13 20.53 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.301 -0.874 . . . . 3.04 108.847 179.903 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 9' ' ' VAL . . . . . . . . . . . . . 14.7 t -50.9 159.72 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 N-CA-C 108.059 -1.089 . . . . 0.67 108.059 179.24 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . . . . . . . . . . . -122.66 144.26 49.25 Favored 'General case' 0 N--CA 1.501 2.092 0 O-C-N 121.372 -0.83 . . . . 0.58 110.092 -178.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 11' ' ' SER . . . . . 0.44 ' OG ' HG23 ' A' ' 55' ' ' VAL . 4.1 t -137.17 145.15 43.4 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.59 -0.693 . . . . 1.19 109.246 179.712 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 12' ' ' SER . . . . . . . . . . . . . 17.7 m -148.64 115.48 6.02 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.28 -0.888 . . . . 1.38 109.752 -179.797 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 0.596 HG22 ' N ' ' B' ' 14' ' ' PHE . 2.9 p -157.86 166.81 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 N-CA-C 108.694 -0.854 . . . . 0.42 108.694 179.624 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 14' ' ' PHE . . . . . 0.596 ' N ' HG22 ' B' ' 13' ' ' VAL . 6.9 p90 -177.33 -167.02 0.15 Allowed 'General case' 0 N--CA 1.489 1.509 0 C-N-CA 119.168 -1.013 . . . . 1.79 112.403 -179.811 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . . . . . . . . . 3.2 pt -146.62 168.73 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 N-CA-C 108.437 -0.949 . . . . 1.25 108.437 179.819 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 49.5 m -138.69 142.08 38.97 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 120.999 -1.063 . . . . 1.61 110.178 -179.599 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 16.5 mt -103.32 129.86 50.44 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.52 -0.738 . . . . 1.32 109.162 179.545 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -141.94 77.9 18.04 Favored Pre-proline 0 N--CA 1.497 1.879 0 O-C-N 121.351 -0.843 . . . . 1.45 109.635 -179.658 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -60.15 169.13 5.23 Favored 'Trans proline' 0 CA--C 1.545 1.056 0 C-N-CA 121.321 1.347 . . . . 1.5 109.593 -179.754 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 20' ' ' PRO . . . . . 0.437 ' O ' ' O ' ' B' ' 21' ' ' ARG . 2.5 Cg_endo -57.42 88.95 0.05 OUTLIER 'Trans proline' 0 C--N 1.32 -0.957 0 C-N-CA 121.416 1.41 . . . . 2.86 110.367 -179.582 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . 0.437 ' O ' ' O ' ' B' ' 20' ' ' PRO . 2.6 tpm_? 58.16 158.03 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.231 -0.918 . . . . 6.12 109.796 179.536 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 22' ' ' ARG . . . . . 0.454 ' O ' ' N ' ' B' ' 24' ' ' VAL . 72.7 mtm180 -79.63 101.91 8.62 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.193 -0.942 . . . . 6.29 109.368 179.824 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -49.69 95.19 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.202 -0.936 . . . . 5.62 109.511 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . 0.454 ' N ' ' O ' ' B' ' 22' ' ' ARG . 12.4 t . . . . . 0 N--CA 1.49 1.543 0 CA-C-O 117.993 -1.003 . . . . 6.48 109.529 179.903 . . . . . . . . 1 1 . 1 stop_ save_